ID   1433B_HUMAN             Reviewed;         246 AA.
AC   P31946; A8K9K2; E1P616;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   09-JUL-2014, entry version 166.
DE   RecName: Full=14-3-3 protein beta/alpha;
DE   AltName: Full=Protein 1054;
DE   AltName: Full=Protein kinase C inhibitor protein 1;
DE            Short=KCIP-1;
DE   Contains:
DE     RecName: Full=14-3-3 protein beta/alpha, N-terminally processed;
GN   Name=YWHAB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Keratinocyte;
RX   PubMed=8515476; DOI=10.1006/jmbi.1993.1346;
RA   Leffers H., Madsen P., Rasmussen H.H., Honore B., Andersen A.H.,
RA   Walbum E., Vandekerckhove J., Celis J.E.;
RT   "Molecular cloning and expression of the transformation sensitive
RT   epithelial marker stratifin. A member of a protein family that has
RT   been involved in the protein kinase C signalling pathway.";
RL   J. Mol. Biol. 231:982-998(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-11; 14-57; 63-70; 106-117; 130-169 AND 215-246,
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma;
RA   Bienvenut W.V., Zebisch A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [7]
RP   PROTEIN SEQUENCE OF 3-20.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [8]
RP   INTERACTION WITH AANAT.
RX   PubMed=11427721; DOI=10.1073/pnas.141118798;
RA   Ganguly S., Gastel J.A., Weller J.L., Schwartz C., Jaffe H.,
RA   Namboodiri M.A., Coon S.L., Hickman A.B., Rollag M., Obsil T.,
RA   Beauverger P., Ferry G., Boutin J.A., Klein D.C.;
RT   "Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-
RT   3-3-binding switch in melatonin synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8083-8088(2001).
RN   [9]
RP   INTERACTION WITH CRTC2.
RX   PubMed=15454081; DOI=10.1016/j.cell.2004.09.015;
RA   Screaton R.A., Conkright M.D., Katoh Y., Best J.L., Canettieri G.,
RA   Jeffries S., Guzman E., Niessen S., Yates J.R. III, Takemori H.,
RA   Okamoto M., Montminy M.;
RT   "The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive
RT   coincidence detector.";
RL   Cell 119:61-74(2004).
RN   [10]
RP   INTERACTION WITH SSH1.
RX   PubMed=15159416; DOI=10.1083/jcb.200401136;
RA   Nagata-Ohashi K., Ohta Y., Goto K., Chiba S., Mori R., Nishita M.,
RA   Ohashi K., Kousaka K., Iwamatsu A., Niwa R., Uemura T., Mizuno K.;
RT   "A pathway of neuregulin-induced activation of cofilin-phosphatase
RT   Slingshot and cofilin in lamellipodia.";
RL   J. Cell Biol. 165:465-471(2004).
RN   [11]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [12]
RP   INTERACTION WITH YAP1.
RX   PubMed=17974916; DOI=10.1101/gad.1602907;
RA   Zhao B., Wei X., Li W., Udan R.S., Yang Q., Kim J., Xie J.,
RA   Ikenoue T., Yu J., Li L., Zheng P., Ye K., Chinnaiyan A., Halder G.,
RA   Lai Z.C., Guan K.L.;
RT   "Inactivation of YAP oncoprotein by the Hippo pathway is involved in
RT   cell contact inhibition and tissue growth control.";
RL   Genes Dev. 21:2747-2761(2007).
RN   [13]
RP   INTERACTION WITH ROR2, FUNCTION, PHOSPHORYLATION, DIMERIZATION, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17717073; DOI=10.1210/me.2007-0323;
RA   Liu Y., Ross J.F., Bodine P.V.N., Billiard J.;
RT   "Homodimerization of Ror2 tyrosine kinase receptor induces 14-3-
RT   3(beta) phosphorylation and promotes osteoblast differentiation and
RT   bone formation.";
RL   Mol. Endocrinol. 21:3050-3061(2007).
RN   [14]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D.,
RA   Guilhaus M., James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by
RT   the Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH SRPK2.
RX   PubMed=19592491; DOI=10.1074/jbc.M109.026237;
RA   Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.;
RT   "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell
RT   cycle and cell death in neurons.";
RL   J. Biol. Chem. 284:24512-24525(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-70 AND LYS-117, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 AND THR-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [20]
RP   INTERACTION WITH MYO1C.
RX   PubMed=24636949; DOI=10.1016/j.jmb.2014.03.004;
RA   Stefan Munnich M.H., Manstein D.J.;
RT   "Crystal structure of human myosin 1c - the motor in GLUT4 exocytosis:
RT   implications for Ca(2+)-regulation and 14-3-3 binding.";
RL   J. Mol. Biol. 426:2070-2081(2014).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-239, IDENTIFICATION BY MASS
RP   SPECTROMETRY, INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.
RX   PubMed=17085597; DOI=10.1073/pnas.0605779103;
RA   Yang X., Lee W.H., Sobott F., Papagrigoriou E., Robinson C.V.,
RA   Grossmann J.G., Sundstroem M., Doyle D.A., Elkins J.M.;
RT   "Structural basis for protein-protein interactions in the 14-3-3
RT   protein family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:17237-17242(2006).
RN   [22]
RP   VARIANT ILE-99.
RX   PubMed=21248752; DOI=10.1038/nature09639;
RA   Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P.,
RA   Davies H., Jones D., Lin M.L., Teague J., Bignell G., Butler A.,
RA   Cho J., Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C.,
RA   Jia M., Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A.,
RA   Mudie L., Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S.,
RA   Kahnoski R.J., Anema J., Tuveson D.A., Perez-Mancera P.A.,
RA   Mustonen V., Fischer A., Adams D.J., Rust A., Chan-On W., Subimerb C.,
RA   Dykema K., Furge K., Campbell P.J., Teh B.T., Stratton M.R.,
RA   Futreal P.A.;
RT   "Exome sequencing identifies frequent mutation of the SWI/SNF complex
RT   gene PBRM1 in renal carcinoma.";
RL   Nature 469:539-542(2011).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner. Negative
CC       regulator of osteogenesis. Blocks the nuclear translocation of the
CC       phosphorylated form (by AKT1) of SRPK2 and antagonizes its
CC       stimulatory effect on cyclin D1 expression resulting in blockage
CC       of neuronal apoptosis elicited by SRPK2.
CC   -!- SUBUNIT: Homodimer. Interacts with SAMSN1 and PRKCE (By
CC       similarity). Interacts with SSH1 and TORC2/CRTC2. Interacts with
CC       ABL1; the interaction results in cytoplasmic location of ABL1 and
CC       inhibition of cABL-mediated apoptosis. Interacts with ROR2
CC       (dimer); the interaction results in phosphorylation of YWHAB on
CC       tyrosine residues. Interacts with GAB2 and YAP1 (phosphorylated
CC       form). Interacts with the phosphorylated (by AKT1) form of SRPK2.
CC       Interacts with PKA-phosphorylated AANAT. Interacts with MYO1C.
CC   -!- INTERACTION:
CC       Q76353:- (xeno); NbExp=3; IntAct=EBI-359815, EBI-6248077;
CC       Q9P0K1-3:ADAM22; NbExp=2; IntAct=EBI-359815, EBI-1567267;
CC       P15056:BRAF; NbExp=3; IntAct=EBI-359815, EBI-365980;
CC       P22681:CBL; NbExp=3; IntAct=EBI-359815, EBI-518228;
CC       O00257:CBX4; NbExp=2; IntAct=EBI-359815, EBI-722425;
CC       P30304:CDC25A; NbExp=8; IntAct=EBI-359815, EBI-747671;
CC       P30305:CDC25B; NbExp=4; IntAct=EBI-359815, EBI-1051746;
CC       O94921:CDK14; NbExp=5; IntAct=EBI-359815, EBI-1043945;
CC       P67828:CSNK1A1 (xeno); NbExp=3; IntAct=EBI-359815, EBI-7540603;
CC       Q9NYF0:DACT1; NbExp=4; IntAct=EBI-359815, EBI-3951744;
CC       Q13627-2:DYRK1A; NbExp=3; IntAct=EBI-359815, EBI-1053621;
CC       Q9UQC2:GAB2; NbExp=4; IntAct=EBI-359815, EBI-975200;
CC       P55040:GEM; NbExp=3; IntAct=EBI-359815, EBI-744104;
CC       P55041:Gem (xeno); NbExp=3; IntAct=EBI-359815, EBI-7082069;
CC       P56524:HDAC4; NbExp=3; IntAct=EBI-359815, EBI-308629;
CC       Q11184:let-756 (xeno); NbExp=2; IntAct=EBI-359815, EBI-3843983;
CC       Q5S007:LRRK2; NbExp=3; IntAct=EBI-359815, EBI-5323863;
CC       Q99759:MAP3K3; NbExp=2; IntAct=EBI-359815, EBI-307281;
CC       Q99683:MAP3K5; NbExp=3; IntAct=EBI-359815, EBI-476263;
CC       Q7KZI7:MARK2; NbExp=3; IntAct=EBI-359815, EBI-516560;
CC       P27448:MARK3; NbExp=4; IntAct=EBI-359815, EBI-707595;
CC       P04049:RAF1; NbExp=17; IntAct=EBI-359815, EBI-365996;
CC       Q96TC7:RMDN3; NbExp=5; IntAct=EBI-359815, EBI-1056589;
CC       P61587:RND3; NbExp=2; IntAct=EBI-359815, EBI-1111534;
CC       P61588:Rnd3 (xeno); NbExp=5; IntAct=EBI-359815, EBI-6930266;
CC       P78362:SRPK2; NbExp=2; IntAct=EBI-359815, EBI-593303;
CC       Q8WYL5:SSH1; NbExp=3; IntAct=EBI-359815, EBI-1222387;
CC       Q91YE8:Synpo2 (xeno); NbExp=3; IntAct=EBI-359815, EBI-7623057;
CC       P49815:TSC2; NbExp=4; IntAct=EBI-359815, EBI-396587;
CC       P46937:YAP1; NbExp=5; IntAct=EBI-359815, EBI-1044059;
CC       P62258:YWHAE; NbExp=3; IntAct=EBI-359815, EBI-356498;
CC       P22893:Zfp36 (xeno); NbExp=5; IntAct=EBI-359815, EBI-647803;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Melanosome. Note=Identified by
CC       mass spectrometry in melanosome fractions from stage I to stage
CC       IV.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P31946-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P31946-2; Sequence=VSP_018632;
CC         Note=Contains a N-acetylmethionine at position 1 (By
CC         similarity);
CC   -!- PTM: The alpha, brain-specific form differs from the beta form in
CC       being phosphorylated (By similarity). Phosphorylated on Ser-60 by
CC       protein kinase C delta type catalytic subunit in a sphingosine-
CC       dependent fashion (By similarity).
CC   -!- PTM: Isoform Short contains a N-acetylmethionine at position 1 (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the 14-3-3 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X57346; CAA40621.1; -; mRNA.
DR   EMBL; AK292717; BAF85406.1; -; mRNA.
DR   EMBL; AL008725; CAA15497.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75893.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75894.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75896.1; -; Genomic_DNA.
DR   EMBL; BC001359; AAH01359.1; -; mRNA.
DR   CCDS; CCDS13339.1; -. [P31946-1]
DR   PIR; S34755; S34755.
DR   RefSeq; NP_003395.1; NM_003404.4. [P31946-1]
DR   RefSeq; NP_647539.1; NM_139323.3. [P31946-1]
DR   UniGene; Hs.643544; -.
DR   PDB; 2BQ0; X-ray; 2.50 A; A/B=2-239.
DR   PDB; 2C23; X-ray; 2.65 A; A=2-239.
DR   PDB; 4DNK; X-ray; 2.20 A; A/B=1-246.
DR   PDBsum; 2BQ0; -.
DR   PDBsum; 2C23; -.
DR   PDBsum; 4DNK; -.
DR   ProteinModelPortal; P31946; -.
DR   SMR; P31946; 1-234.
DR   BioGrid; 113361; 302.
DR   DIP; DIP-743N; -.
DR   IntAct; P31946; 240.
DR   MINT; MINT-99570; -.
DR   STRING; 9606.ENSP00000300161; -.
DR   PhosphoSite; P31946; -.
DR   DMDM; 1345590; -.
DR   OGP; P31946; -.
DR   REPRODUCTION-2DPAGE; IPI00216318; -.
DR   MaxQB; P31946; -.
DR   PaxDb; P31946; -.
DR   PRIDE; P31946; -.
DR   DNASU; 7529; -.
DR   Ensembl; ENST00000353703; ENSP00000300161; ENSG00000166913. [P31946-1]
DR   Ensembl; ENST00000372839; ENSP00000361930; ENSG00000166913. [P31946-1]
DR   GeneID; 7529; -.
DR   KEGG; hsa:7529; -.
DR   UCSC; uc002xmt.3; human. [P31946-1]
DR   CTD; 7529; -.
DR   GeneCards; GC20P043515; -.
DR   HGNC; HGNC:12849; YWHAB.
DR   HPA; CAB003759; -.
DR   HPA; HPA007925; -.
DR   HPA; HPA011212; -.
DR   MIM; 601289; gene.
DR   neXtProt; NX_P31946; -.
DR   PharmGKB; PA37438; -.
DR   eggNOG; COG5040; -.
DR   HOGENOM; HOG000240379; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; P31946; -.
DR   KO; K16197; -.
DR   OMA; MGREYRE; -.
DR   OrthoDB; EOG7HHWT3; -.
DR   PhylomeDB; P31946; -.
DR   TreeFam; TF102003; -.
DR   Reactome; REACT_111045; Developmental Biology.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_116125; Disease.
DR   Reactome; REACT_21257; Metabolism of RNA.
DR   Reactome; REACT_578; Apoptosis.
DR   Reactome; REACT_6900; Immune System.
DR   Reactome; REACT_71; Gene Expression.
DR   SignaLink; P31946; -.
DR   ChiTaRS; YWHAB; human.
DR   EvolutionaryTrace; P31946; -.
DR   GeneWiki; YWHAB; -.
DR   GenomeRNAi; 7529; -.
DR   NextBio; 29453; -.
DR   PRO; PR:P31946; -.
DR   ArrayExpress; P31946; -.
DR   Bgee; P31946; -.
DR   CleanEx; HS_YWHAB; -.
DR   Genevestigator; P31946; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0017053; C:transcriptional repressor complex; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:BHF-UCL.
DR   GO; GO:0051219; F:phosphoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0050815; F:phosphoserine binding; IPI:BHF-UCL.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:Ensembl.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0051220; P:cytoplasmic sequestering of protein; IDA:BHF-UCL.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0035329; P:hippo signaling; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0016071; P:mRNA metabolic process; TAS:Reactome.
DR   GO; GO:0035308; P:negative regulation of protein dephosphorylation; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0043085; P:positive regulation of catalytic activity; IDA:BHF-UCL.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0051291; P:protein heterooligomerization; IEA:Ensembl.
DR   GO; GO:0006605; P:protein targeting; IEA:Ensembl.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0016070; P:RNA metabolic process; TAS:Reactome.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   Gene3D; 1.20.190.20; -; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; SSF48445; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Nitration; Phosphoprotein;
KW   Polymorphism; Reference proteome.
FT   CHAIN         1    246       14-3-3 protein beta/alpha.
FT                                /FTId=PRO_0000367900.
FT   INIT_MET      1      1       Removed; alternate.
FT   CHAIN         2    246       14-3-3 protein beta/alpha, N-terminally
FT                                processed.
FT                                /FTId=PRO_0000000003.
FT   SITE         58     58       Interaction with phosphoserine on
FT                                interacting protein (By similarity).
FT   SITE        129    129       Interaction with phosphoserine on
FT                                interacting protein (By similarity).
FT   MOD_RES       1      1       N-acetylmethionine; in 14-3-3 protein
FT                                beta/alpha; alternate.
FT   MOD_RES       2      2       N-acetylthreonine; in 14-3-3 protein
FT                                beta/alpha, N-terminally processed.
FT   MOD_RES      60     60       Phosphoserine (By similarity).
FT   MOD_RES      70     70       N6-acetyllysine.
FT   MOD_RES      84     84       Nitrated tyrosine (By similarity).
FT   MOD_RES     106    106       Nitrated tyrosine (By similarity).
FT   MOD_RES     117    117       N6-acetyllysine.
FT   MOD_RES     186    186       Phosphoserine (By similarity).
FT   VAR_SEQ       1      2       Missing (in isoform Short).
FT                                /FTId=VSP_018632.
FT   VARIANT      99     99       V -> I (found in a renal cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_064762.
FT   HELIX         5     17
FT   HELIX        21     33
FT   HELIX        40     69
FT   HELIX        75    105
FT   HELIX       107    110
FT   HELIX       114    133
FT   HELIX       139    161
FT   HELIX       167    182
FT   HELIX       187    202
FT   HELIX       203    207
FT   TURN        210    212
FT   HELIX       213    232
SQ   SEQUENCE   246 AA;  28082 MW;  6BE1A9BF97468017 CRC64;
     MTMDKSELVQ KAKLAEQAER YDDMAAAMKA VTEQGHELSN EERNLLSVAY KNVVGARRSS
     WRVISSIEQK TERNEKKQQM GKEYREKIEA ELQDICNDVL ELLDKYLIPN ATQPESKVFY
     LKMKGDYFRY LSEVASGDNK QTTVSNSQQA YQEAFEISKK EMQPTHPIRL GLALNFSVFY
     YEILNSPEKA CSLAKTAFDE AIAELDTLNE ESYKDSTLIM QLLRDNLTLW TSENQGDEGD
     AGEGEN
//
ID   1433E_HUMAN             Reviewed;         255 AA.
AC   P62258; B3KY71; D3DTH5; P29360; P42655; Q4VJB6; Q53XZ5; Q63631;
AC   Q7M4R4;
DT   05-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   09-JUL-2014, entry version 124.
DE   RecName: Full=14-3-3 protein epsilon;
DE            Short=14-3-3E;
GN   Name=YWHAE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7644510; DOI=10.1073/pnas.92.17.7892;
RA   Conklin D.S., Galaktionov K., Beach D.;
RT   "14-3-3 proteins associate with cdc25 phosphatases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7892-7896(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=8858348; DOI=10.1101/gr.6.8.735;
RA   Chong S.S., Tanigami A., Roschke A.V., Ledbetter D.H.;
RT   "14-3-3 epsilon has no homology to LIS1 and lies telomeric to it on
RT   chromosome 17p13.3 outside the Miller-Dieker syndrome chromosome
RT   region.";
RL   Genome Res. 6:735-741(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8684458; DOI=10.1038/382308a0;
RA   Jin D.-Y., Lyu M.S., Kozak C.A., Jeang K.-T.;
RT   "Function of 14-3-3 proteins.";
RL   Nature 382:308-308(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SV), AND ALTERNATIVE SPLICING.
RC   TISSUE=Brain;
RX   PubMed=20417184; DOI=10.1016/j.bbrc.2010.04.104;
RA   Han D., Ye G., Liu T., Chen C., Yang X., Wan B., Pan Y., Yu L.;
RT   "Functional identification of a novel 14-3-3 epsilon splicing variant
RT   suggests dimerization is not necessary for 14-3-3 epsilon to inhibit
RT   UV-induced apoptosis.";
RL   Biochem. Biophys. Res. Commun. 396:401-406(2010).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Heart;
RA   Luk S.C.W., Lee C.Y., Waye M.M.Y.;
RT   "Sequence determination of human epsilon 14-3-3 protein.";
RL   Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Tanigami A., Chong S.S., Ledbetter D.H.;
RT   "14-3-3 epsilon genomic sequence.";
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND SV).
RC   TISSUE=Caudate nucleus, Heart, and Subthalamic nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 1-19.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [12]
RP   PROTEIN SEQUENCE OF 1-19; 30-50 AND 131-170, ACETYLATION AT MET-1, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (MAY-2005) to UniProtKB.
RN   [13]
RP   PROTEIN SEQUENCE OF 103-108; 120-123; 131-141 AND 143-153.
RC   TISSUE=Histiocytic lymphoma;
RX   PubMed=2026444;
RA   Demeter J., Medzihradszky D., Kha H., Goetzl E.J., Turck C.W.;
RT   "Isolation and partial characterization of the structures of
RT   fibroblast activating factor-related proteins from U937 cells.";
RL   Immunology 72:350-354(1991).
RN   [14]
RP   PROTEIN SEQUENCE OF 131-141 AND 154-190, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Afjehi-Sadat L.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [15]
RP   INTERACTION WITH HCV CORE PROTEIN.
RX   PubMed=10644344; DOI=10.1128/JVI.74.4.1736-1741.2000;
RA   Aoki H., Hayashi J., Moriyama M., Arakawa Y., Hino O.;
RT   "Hepatitis C virus core protein interacts with 14-3-3 protein and
RT   activates the kinase Raf-1.";
RL   J. Virol. 74:1736-1741(2000).
RN   [16]
RP   INTERACTION WITH AANAT.
RX   PubMed=11427721; DOI=10.1073/pnas.141118798;
RA   Ganguly S., Gastel J.A., Weller J.L., Schwartz C., Jaffe H.,
RA   Namboodiri M.A., Coon S.L., Hickman A.B., Rollag M., Obsil T.,
RA   Beauverger P., Ferry G., Boutin J.A., Klein D.C.;
RT   "Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-
RT   3-3-binding switch in melatonin synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8083-8088(2001).
RN   [17]
RP   INTERACTION WITH CDKN1B, AND SUBCELLULAR LOCATION.
RX   PubMed=12042314; DOI=10.1074/jbc.M203668200;
RA   Fujita N., Sato S., Katayama K., Tsuruo T.;
RT   "Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3
RT   and cytoplasmic localization.";
RL   J. Biol. Chem. 277:28706-28713(2002).
RN   [18]
RP   INTERACTION WITH GRB10.
RX   PubMed=15722337; DOI=10.1074/jbc.M501477200;
RA   Urschel S., Bassermann F., Bai R.Y., Munch S., Peschel C., Duyster J.;
RT   "Phosphorylation of grb10 regulates its interaction with 14-3-3.";
RL   J. Biol. Chem. 280:16987-16993(2005).
RN   [19]
RP   INTERACTION WITH ABL1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15696159; DOI=10.1038/ncb1228;
RA   Yoshida K., Yamaguchi T., Natsume T., Kufe D., Miki Y.;
RT   "JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of
RT   c-Abl in the apoptotic response to DNA damage.";
RL   Nat. Cell Biol. 7:278-285(2005).
RN   [20]
RP   INTERACTION WITH YWHAZ.
RX   PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024;
RA   Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.;
RT   "Protein kinase A phosphorylates and regulates dimerization of 14-3-3
RT   epsilon.";
RL   FEBS Lett. 580:305-310(2006).
RN   [21]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [22]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D.,
RA   Guilhaus M., James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by
RT   the Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [25]
RP   INTERACTION WITH SRPK2.
RX   PubMed=19592491; DOI=10.1074/jbc.M109.026237;
RA   Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.;
RT   "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell
RT   cycle and cell death in neurons.";
RL   J. Biol. Chem. 284:24512-24525(2009).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-50; LYS-69; LYS-118 AND
RP   LYS-123, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-210, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-210, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 1-233, IDENTIFICATION BY
RP   MASS SPECTROMETRY, INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.
RX   PubMed=17085597; DOI=10.1073/pnas.0605779103;
RA   Yang X., Lee W.H., Sobott F., Papagrigoriou E., Robinson C.V.,
RA   Grossmann J.G., Sundstroem M., Doyle D.A., Elkins J.M.;
RT   "Structural basis for protein-protein interactions in the 14-3-3
RT   protein family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:17237-17242(2006).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner.
CC   -!- SUBUNIT: Homodimer. Heterodimerizes with YWHAZ. Interacts with
CC       NDEL1, ARHGEF28 and TIAM2 (By similarity). Interacts with HCV core
CC       protein. Interacts with ABL1 (phosphorylated form); the
CC       interaction retains it in the cytoplasm. Weakly interacts with
CC       CDKN1B. Interacts with GAB2. Interacts with phosphorylated GRB10.
CC       Interacts with PKA-phosphorylated AANAT. Interacts with the
CC       phosphorylated (by AKT1) form of SRPK2.
CC   -!- INTERACTION:
CC       O92972:- (xeno); NbExp=5; IntAct=EBI-356498, EBI-9213553;
CC       O14727:APAF1; NbExp=2; IntAct=EBI-356498, EBI-446492;
CC       O00257-3:CBX4; NbExp=2; IntAct=EBI-356498, EBI-4392727;
CC       O94921:CDK14; NbExp=3; IntAct=EBI-356498, EBI-1043945;
CC       Q9UKT5:FBXO4; NbExp=5; IntAct=EBI-356498, EBI-960409;
CC       P56524:HDAC4; NbExp=4; IntAct=EBI-356498, EBI-308629;
CC       Q14678-2:KANK1; NbExp=3; IntAct=EBI-356498, EBI-6173812;
CC       Q5S007:LRRK2; NbExp=4; IntAct=EBI-356498, EBI-5323863;
CC       Q99759:MAP3K3; NbExp=3; IntAct=EBI-356498, EBI-307281;
CC       O15151:MDM4; NbExp=3; IntAct=EBI-356498, EBI-398437;
CC       P58340:MLF1; NbExp=3; IntAct=EBI-356498, EBI-721328;
CC       O35244:Prdx6 (xeno); NbExp=2; IntAct=EBI-356498, EBI-915490;
CC       P61588:Rnd3 (xeno); NbExp=2; IntAct=EBI-356498, EBI-6930266;
CC       Q99469:STAC; NbExp=2; IntAct=EBI-356498, EBI-2652799;
CC       Q9GZV5:WWTR1; NbExp=3; IntAct=EBI-356498, EBI-747743;
CC       P31946:YWHAB; NbExp=3; IntAct=EBI-356498, EBI-359815;
CC       P61981:YWHAG; NbExp=4; IntAct=EBI-356498, EBI-359832;
CC       P63104:YWHAZ; NbExp=5; IntAct=EBI-356498, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Melanosome.
CC       Note=Identified by mass spectrometry in melanosome fractions from
CC       stage I to stage IV.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P62258-1; Sequence=Displayed;
CC       Name=SV;
CC         IsoId=P62258-2; Sequence=VSP_040621;
CC         Note=Unable to dimerize with YWHAZ;
CC   -!- SIMILARITY: Belongs to the 14-3-3 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U20972; AAC50175.1; -; mRNA.
DR   EMBL; U54778; AAC50710.1; -; mRNA.
DR   EMBL; U43399; AAC50625.1; -; mRNA.
DR   EMBL; U43430; AAD00026.1; -; mRNA.
DR   EMBL; U28936; AAA75301.1; -; mRNA.
DR   EMBL; AB017103; BAA32538.1; -; Genomic_DNA.
DR   EMBL; AY883089; AAX68683.1; -; mRNA.
DR   EMBL; AK128785; BAG54733.1; -; mRNA.
DR   EMBL; AK295260; BAG58249.1; -; mRNA.
DR   EMBL; AK316185; BAH14556.1; -; mRNA.
DR   EMBL; BT007161; AAP35825.1; -; mRNA.
DR   EMBL; CH471108; EAW90628.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90629.1; -; Genomic_DNA.
DR   EMBL; BC000179; AAH00179.1; -; mRNA.
DR   EMBL; BC001440; AAH01440.1; -; mRNA.
DR   CCDS; CCDS11001.1; -. [P62258-1]
DR   PIR; A61235; A61235.
DR   PIR; I38947; I38947.
DR   RefSeq; NP_006752.1; NM_006761.4. [P62258-1]
DR   UniGene; Hs.513851; -.
DR   PDB; 2BR9; X-ray; 1.75 A; A=1-233.
DR   PDB; 3UAL; X-ray; 1.80 A; A=1-232.
DR   PDB; 3UBW; X-ray; 1.90 A; A=1-234.
DR   PDBsum; 2BR9; -.
DR   PDBsum; 3UAL; -.
DR   PDBsum; 3UBW; -.
DR   ProteinModelPortal; P62258; -.
DR   SMR; P62258; 3-232.
DR   BioGrid; 113363; 316.
DR   DIP; DIP-36676N; -.
DR   IntAct; P62258; 147.
DR   MINT; MINT-4998623; -.
DR   STRING; 9606.ENSP00000264335; -.
DR   PhosphoSite; P62258; -.
DR   DMDM; 51702210; -.
DR   OGP; P42655; -.
DR   UCD-2DPAGE; P62258; -.
DR   MaxQB; P62258; -.
DR   PaxDb; P62258; -.
DR   PeptideAtlas; P62258; -.
DR   PRIDE; P62258; -.
DR   DNASU; 7531; -.
DR   Ensembl; ENST00000264335; ENSP00000264335; ENSG00000108953. [P62258-1]
DR   Ensembl; ENST00000571732; ENSP00000461762; ENSG00000108953. [P62258-2]
DR   GeneID; 7531; -.
DR   KEGG; hsa:7531; -.
DR   UCSC; uc002fsj.3; human. [P62258-1]
DR   CTD; 7531; -.
DR   GeneCards; GC17M001148; -.
DR   H-InvDB; HIX0013751; -.
DR   H-InvDB; HIX0030006; -.
DR   HGNC; HGNC:12851; YWHAE.
DR   HPA; CAB016200; -.
DR   HPA; CAB021109; -.
DR   HPA; CAB047350; -.
DR   HPA; HPA008445; -.
DR   MIM; 605066; gene.
DR   neXtProt; NX_P62258; -.
DR   Orphanet; 217385; 17p13.3 microduplication syndrome.
DR   Orphanet; 261257; Distal 17p13.3 microdeletion syndrome.
DR   Orphanet; 531; Miller-Dieker syndrome.
DR   PharmGKB; PA37440; -.
DR   eggNOG; COG5040; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; P62258; -.
DR   KO; K06630; -.
DR   OMA; MQESDKP; -.
DR   OrthoDB; EOG7HHWT3; -.
DR   PhylomeDB; P62258; -.
DR   TreeFam; TF102003; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_115566; Cell Cycle.
DR   Reactome; REACT_120956; Cellular responses to stress.
DR   Reactome; REACT_578; Apoptosis.
DR   SignaLink; P62258; -.
DR   ChiTaRS; YWHAE; human.
DR   EvolutionaryTrace; P62258; -.
DR   GeneWiki; YWHAE; -.
DR   GenomeRNAi; 7531; -.
DR   NextBio; 29461; -.
DR   PMAP-CutDB; P62258; -.
DR   PRO; PR:P62258; -.
DR   ArrayExpress; P62258; -.
DR   Bgee; P62258; -.
DR   CleanEx; HS_YWHAE; -.
DR   Genevestigator; P62258; -.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProtKB.
DR   GO; GO:0005871; C:kinesin complex; IEA:Ensembl.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:BHF-UCL.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0023026; F:MHC class II protein complex binding; IDA:UniProt.
DR   GO; GO:0051219; F:phosphoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0050815; F:phosphoserine binding; IPI:BHF-UCL.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0015459; F:potassium channel regulator activity; IDA:BHF-UCL.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0035329; P:hippo signaling; TAS:Reactome.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0086013; P:membrane repolarization during cardiac muscle cell action potential; IC:BHF-UCL.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:Reactome.
DR   GO; GO:1902309; P:negative regulation of peptidyl-serine dephosphorylation; IDA:BHF-UCL.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0006605; P:protein targeting; IEA:Ensembl.
DR   GO; GO:0043281; P:regulation of cysteine-type endopeptidase activity involved in apoptotic process; TAS:Reactome.
DR   GO; GO:0086091; P:regulation of heart rate by cardiac conduction; IC:BHF-UCL.
DR   GO; GO:0003064; P:regulation of heart rate by hormone; NAS:BHF-UCL.
DR   GO; GO:0060306; P:regulation of membrane repolarization; IDA:BHF-UCL.
DR   GO; GO:1901016; P:regulation of potassium ion transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:0021762; P:substantia nigra development; IEP:UniProt.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 1.20.190.20; -; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; SSF48445; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Host-virus interaction;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN         1    255       14-3-3 protein epsilon.
FT                                /FTId=PRO_0000058618.
FT   SITE         57     57       Interaction with phosphoserine on
FT                                interacting protein.
FT   SITE        130    130       Interaction with phosphoserine on
FT                                interacting protein.
FT   MOD_RES       1      1       N-acetylmethionine.
FT   MOD_RES      50     50       N6-acetyllysine.
FT   MOD_RES      69     69       N6-acetyllysine.
FT   MOD_RES     118    118       N6-acetyllysine.
FT   MOD_RES     123    123       N6-acetyllysine.
FT   MOD_RES     210    210       Phosphoserine.
FT   VAR_SEQ       1     22       Missing (in isoform SV).
FT                                /FTId=VSP_040621.
FT   CONFLICT    106    107       KH -> NY (in Ref. 13; AA sequence).
FT   CONFLICT    143    143       E -> F (in Ref. 13; AA sequence).
FT   CONFLICT    148    148       S -> T (in Ref. 13; AA sequence).
FT   HELIX         4     17
FT   HELIX        20     31
FT   HELIX        39     73
FT   HELIX        76    106
FT   HELIX       108    111
FT   HELIX       115    135
FT   HELIX       138    162
FT   HELIX       168    183
FT   HELIX       188    204
FT   HELIX       205    208
FT   TURN        211    213
FT   HELIX       214    231
SQ   SEQUENCE   255 AA;  29174 MW;  07817CCBD1F75B26 CRC64;
     MDDREDLVYQ AKLAEQAERY DEMVESMKKV AGMDVELTVE ERNLLSVAYK NVIGARRASW
     RIISSIEQKE ENKGGEDKLK MIREYRQMVE TELKLICCDI LDVLDKHLIP AANTGESKVF
     YYKMKGDYHR YLAEFATGND RKEAAENSLV AYKAASDIAM TELPPTHPIR LGLALNFSVF
     YYEILNSPDR ACRLAKAAFD DAIAELDTLS EESYKDSTLI MQLLRDNLTL WTSDMQGDGE
     EQNKEALQDV EDENQ
//
ID   1433F_HUMAN             Reviewed;         246 AA.
AC   Q04917;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   09-JUL-2014, entry version 161.
DE   RecName: Full=14-3-3 protein eta;
DE   AltName: Full=Protein AS1;
GN   Name=YWHAH; Synonyms=YWHA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=8218406; DOI=10.1016/0167-4781(93)90053-G;
RA   Swanson K.D., Dhar M.S., Joshi J.G.;
RT   "The human and bovine 14-3-3 eta protein mRNAs are highly conserved in
RT   both their translated and untranslated regions.";
RL   Biochim. Biophys. Acta 1216:145-148(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Brain;
RX   PubMed=1578511; DOI=10.1002/jnr.490310403;
RA   Ichimura-Ohshima Y., Morii K., Ichimura T., Araki K., Takahashi Y.,
RA   Isobe T., Minoshima S., Fukuyama R., Shimizu N., Kuwano R.;
RT   "cDNA cloning and chromosome assignment of the gene for human brain
RT   14-3-3 protein eta chain.";
RL   J. Neurosci. Res. 31:600-605(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Leffers H., Tommerup N., Celis J.E.;
RL   Submitted (MAR-1994) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8561965; DOI=10.1007/BF02740697;
RA   Muratake T., Hayashi S., Ichimura Y., Morii K., Kuwano R.,
RA   Ichikawa T., Kumanishi T., Isobe T., Watanabe M., Kondo H.;
RT   "The effect on methamphetamine on the mRNA level for 14.3.3 eta chain
RT   in the human cultured cells.";
RL   Mol. Neurobiol. 11:223-230(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8812417; DOI=10.1006/geno.1996.0426;
RA   Muratake T., Hayashi S., Ichikawa T., Kumanishi T., Ichimura Y.,
RA   Kuwano R., Isobe T., Wang Y., Minoshima S., Shimizu N., Takahashi Y.;
RT   "Structural organization and chromosomal assignment of the human 14-3-
RT   3 eta chain gene (YWHAH).";
RL   Genomics 36:63-69(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 27-225.
RC   TISSUE=Keratinocyte;
RX   PubMed=8515476; DOI=10.1006/jmbi.1993.1346;
RA   Leffers H., Madsen P., Rasmussen H.H., Honore B., Andersen A.H.,
RA   Walbum E., Vandekerckhove J., Celis J.E.;
RT   "Molecular cloning and expression of the transformation sensitive
RT   epithelial marker stratifin. A member of a protein family that has
RT   been involved in the protein kinase C signalling pathway.";
RL   J. Mol. Biol. 231:982-998(1993).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-10.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-10; 29-50; 62-69; 126-132; 144-155; 163-172 AND
RP   218-227, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT GLY-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RA   Bienvenut W.V.;
RL   Submitted (AUG-2005) to UniProtKB.
RN   [12]
RP   INTERACTION WITH AR; ESR1; ESR2; MC2R; NRIP1; NR3C1; PPARBP AND THRA.
RX   PubMed=11266503; DOI=10.1210/me.15.4.501;
RA   Zilliacus J., Holter E., Wakui H., Tazawa H., Treuter E.,
RA   Gustafsson J.-A.;
RT   "Regulation of glucocorticoid receptor activity by 14-3-3-dependent
RT   intracellular relocalization of the corepressor RIP140.";
RL   Mol. Endocrinol. 15:501-511(2001).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH PDPK1.
RX   PubMed=12177059; DOI=10.1074/jbc.M205141200;
RA   Sato S., Fujita N., Tsuruo T.;
RT   "Regulation of kinase activity of 3-phosphoinositide-dependent protein
RT   kinase-1 by binding to 14-3-3.";
RL   J. Biol. Chem. 277:39360-39367(2002).
RN   [14]
RP   INTERACTION WITH CDKN1B.
RX   PubMed=14504289; DOI=10.1074/jbc.M306614200;
RA   Fujita N., Sato S., Tsuruo T.;
RT   "Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein
RT   S6 kinases promotes its binding to 14-3-3 and cytoplasmic
RT   localization.";
RL   J. Biol. Chem. 278:49254-49260(2003).
RN   [15]
RP   INTERACTION WITH ABL1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15696159; DOI=10.1038/ncb1228;
RA   Yoshida K., Yamaguchi T., Natsume T., Kufe D., Miki Y.;
RT   "JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of
RT   c-Abl in the apoptotic response to DNA damage.";
RL   Nat. Cell Biol. 7:278-285(2005).
RN   [16]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D.,
RA   Guilhaus M., James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by
RT   the Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-25, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS), IDENTIFICATION BY MASS
RP   SPECTROMETRY, INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.
RX   PubMed=17085597; DOI=10.1073/pnas.0605779103;
RA   Yang X., Lee W.H., Sobott F., Papagrigoriou E., Robinson C.V.,
RA   Grossmann J.G., Sundstroem M., Doyle D.A., Elkins J.M.;
RT   "Structural basis for protein-protein interactions in the 14-3-3
RT   protein family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:17237-17242(2006).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner.
CC       Negatively regulates the kinase activity of PDPK1.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with many nuclear
CC       hormone receptors and cofactors including AR, ESR1, ESR2, MC2R,
CC       NR3C1, NRIP1, PPARBP and THRA. Interacts with ABL1 (phosphorylated
CC       form); the interaction retains it in the cytoplasm. Interacts with
CC       ARHGEF28 and CDK16 (By similarity). Weakly interacts with CDKN1B.
CC       Interacts with GAB2. Interacts with KCNK18 in a phosphorylation-
CC       dependent manner. Interacts with SAMSN1 (By similarity). Interacts
CC       with the 'Ser-241' phosphorylated form of PDPK1.
CC   -!- INTERACTION:
CC       Q96B36:AKT1S1; NbExp=3; IntAct=EBI-306940, EBI-720593;
CC       Q8N5S9:CAMKK1; NbExp=5; IntAct=EBI-306940, EBI-6424030;
CC       P30305:CDC25B; NbExp=3; IntAct=EBI-306940, EBI-1051746;
CC       O94921:CDK14; NbExp=3; IntAct=EBI-306940, EBI-1043945;
CC       P67828:CSNK1A1 (xeno); NbExp=8; IntAct=EBI-306940, EBI-7540603;
CC       O60565:GREM1; NbExp=5; IntAct=EBI-306940, EBI-944395;
CC       P56524:HDAC4; NbExp=3; IntAct=EBI-306940, EBI-308629;
CC       Q14678-2:KANK1; NbExp=3; IntAct=EBI-306940, EBI-6173812;
CC       Q5S007:LRRK2; NbExp=3; IntAct=EBI-306940, EBI-5323863;
CC       Q7KZI7:MARK2; NbExp=8; IntAct=EBI-306940, EBI-516560;
CC       P27448:MARK3; NbExp=4; IntAct=EBI-306940, EBI-707595;
CC       Q96L34:MARK4; NbExp=6; IntAct=EBI-306940, EBI-302319;
CC       Q8TEW0:PARD3; NbExp=6; IntAct=EBI-306940, EBI-81968;
CC       Q9NPB6:PARD6A; NbExp=2; IntAct=EBI-306940, EBI-81876;
CC       Q9BYG5:PARD6B; NbExp=2; IntAct=EBI-306940, EBI-295391;
CC       Q9BYG4:PARD6G; NbExp=2; IntAct=EBI-306940, EBI-295417;
CC       P41743:PRKCI; NbExp=3; IntAct=EBI-306940, EBI-286199;
CC       P04049:RAF1; NbExp=3; IntAct=EBI-306940, EBI-365996;
CC       P61588:Rnd3 (xeno); NbExp=2; IntAct=EBI-306940, EBI-6930266;
CC   -!- TISSUE SPECIFICITY: Expressed mainly in the brain and present in
CC       other tissues albeit at lower levels.
CC   -!- PTM: Phosphorylated on Ser-59 by protein kinase C delta type
CC       catalytic subunit in a sphingosine-dependent fashion (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the 14-3-3 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L20422; AAA35483.1; -; mRNA.
DR   EMBL; X80536; CAA56676.1; -; Genomic_DNA.
DR   EMBL; X78138; CAA55017.1; -; mRNA.
DR   EMBL; X57345; CAA40620.1; -; mRNA.
DR   EMBL; D78577; BAA11418.1; -; Genomic_DNA.
DR   EMBL; S80794; AAB36036.1; -; mRNA.
DR   EMBL; CR456612; CAG30498.1; -; mRNA.
DR   EMBL; Z82248; CAB05112.1; -; Genomic_DNA.
DR   EMBL; BC003047; AAH03047.1; -; mRNA.
DR   CCDS; CCDS13901.1; -.
DR   PIR; S34756; S34756.
DR   PIR; S38509; S38509.
DR   PIR; S38532; S38532.
DR   RefSeq; NP_003396.1; NM_003405.3.
DR   UniGene; Hs.226755; -.
DR   PDB; 2C63; X-ray; 2.15 A; A/B/C/D=2-246.
DR   PDB; 2C74; X-ray; 2.70 A; A/B=2-246.
DR   PDBsum; 2C63; -.
DR   PDBsum; 2C74; -.
DR   ProteinModelPortal; Q04917; -.
DR   SMR; Q04917; 3-235.
DR   BioGrid; 113365; 121.
DR   DIP; DIP-27566N; -.
DR   IntAct; Q04917; 144.
DR   MINT; MINT-124456; -.
DR   STRING; 9606.ENSP00000248975; -.
DR   PhosphoSite; Q04917; -.
DR   DMDM; 1345593; -.
DR   MaxQB; Q04917; -.
DR   PaxDb; Q04917; -.
DR   PeptideAtlas; Q04917; -.
DR   PRIDE; Q04917; -.
DR   DNASU; 7533; -.
DR   Ensembl; ENST00000248975; ENSP00000248975; ENSG00000128245.
DR   GeneID; 7533; -.
DR   KEGG; hsa:7533; -.
DR   UCSC; uc003alz.3; human.
DR   CTD; 7533; -.
DR   GeneCards; GC22P032340; -.
DR   HGNC; HGNC:12853; YWHAH.
DR   HPA; CAB025918; -.
DR   MIM; 113508; gene.
DR   neXtProt; NX_Q04917; -.
DR   PharmGKB; PA37442; -.
DR   eggNOG; COG5040; -.
DR   HOGENOM; HOG000240379; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; Q04917; -.
DR   KO; K16198; -.
DR   OMA; ESSEAAY; -.
DR   OrthoDB; EOG7HHWT3; -.
DR   PhylomeDB; Q04917; -.
DR   TreeFam; TF102003; -.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_578; Apoptosis.
DR   SignaLink; Q04917; -.
DR   ChiTaRS; YWHAH; human.
DR   EvolutionaryTrace; Q04917; -.
DR   GeneWiki; YWHAH; -.
DR   GenomeRNAi; 7533; -.
DR   NextBio; 29471; -.
DR   PRO; PR:Q04917; -.
DR   ArrayExpress; Q04917; -.
DR   Bgee; Q04917; -.
DR   CleanEx; HS_YWHAH; -.
DR   Genevestigator; Q04917; -.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProtKB.
DR   GO; GO:0014704; C:intercalated disc; IC:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0035259; F:glucocorticoid receptor binding; IPI:UniProtKB.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; ISS:UniProtKB.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; ISS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0017080; F:sodium channel regulator activity; IDA:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0006713; P:glucocorticoid catabolic process; IDA:UniProtKB.
DR   GO; GO:0042921; P:glucocorticoid receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006886; P:intracellular protein transport; ISS:UniProtKB.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IDA:BHF-UCL.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0050774; P:negative regulation of dendrite morphogenesis; ISS:UniProtKB.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0045664; P:regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:2000649; P:regulation of sodium ion transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:0002028; P:regulation of sodium ion transport; IDA:BHF-UCL.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; ISS:UniProtKB.
DR   GO; GO:0021762; P:substantia nigra development; IEP:UniProt.
DR   Gene3D; 1.20.190.20; -; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; SSF48445; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome;
KW   Direct protein sequencing; Phosphoprotein; Reference proteome.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    246       14-3-3 protein eta.
FT                                /FTId=PRO_0000058623.
FT   SITE         57     57       Interaction with phosphoserine on
FT                                interacting protein.
FT   SITE        132    132       Interaction with phosphoserine on
FT                                interacting protein.
FT   MOD_RES       2      2       N-acetylglycine.
FT   MOD_RES      25     25       Phosphoserine.
FT   MOD_RES      59     59       Phosphoserine (By similarity).
FT   CONFLICT    144    144       N -> T (in Ref. 9; CAA40620).
FT   CONFLICT    157    157       A -> G (in Ref. 1; AAA35483).
FT   CONFLICT    237    237       Q -> L (in Ref. 1; AAA35483).
FT   HELIX         4     16
FT   HELIX        20     31
FT   HELIX        39     73
FT   HELIX        76    106
FT   TURN        107    111
FT   HELIX       117    137
FT   HELIX       140    164
FT   HELIX       170    185
FT   HELIX       190    206
FT   HELIX       207    210
FT   TURN        213    215
FT   HELIX       216    234
SQ   SEQUENCE   246 AA;  28219 MW;  D70FBC100C45D6E5 CRC64;
     MGDREQLLQR ARLAEQAERY DDMASAMKAV TELNEPLSNE DRNLLSVAYK NVVGARRSSW
     RVISSIEQKT MADGNEKKLE KVKAYREKIE KELETVCNDV LSLLDKFLIK NCNDFQYESK
     VFYLKMKGDY YRYLAEVASG EKKNSVVEAS EAAYKEAFEI SKEQMQPTHP IRLGLALNFS
     VFYYEIQNAP EQACLLAKQA FDDAIAELDT LNEDSYKDST LIMQLLRDNL TLWTSDQQDE
     EAGEGN
//
ID   1433G_HUMAN             Reviewed;         247 AA.
AC   P61981; O70457; P35214; Q6FH52; Q9UDP2; Q9UN99;
DT   07-JUN-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   09-JUL-2014, entry version 122.
DE   RecName: Full=14-3-3 protein gamma;
DE   AltName: Full=Protein kinase C inhibitor protein 1;
DE            Short=KCIP-1;
DE   Contains:
DE     RecName: Full=14-3-3 protein gamma, N-terminally processed;
GN   Name=YWHAG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PHOSPHORYLATION, AND INTERACTION WITH
RP   RAF1.
RC   TISSUE=Vascular smooth muscle;
RX   PubMed=10433554; DOI=10.1089/104454999315105;
RA   Autieri M.V., Carbone C.J.;
RT   "14-3-3gamma interacts with and is phosphorylated by multiple protein
RT   kinase C isoforms in PDGF-stimulated human vascular smooth muscle
RT   cells.";
RL   DNA Cell Biol. 18:555-564(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=10486217; DOI=10.1006/geno.1999.5887;
RA   Horie M., Suzuki M., Takahashi E., Tanigami A.;
RT   "Cloning, expression, and chromosomal mapping of the human 14-3-3gamma
RT   gene (YWHAG) to 7q11.23.";
RL   Genomics 60:241-243(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Endometrial tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-10; 13-56; 62-69; 133-172 AND 199-227, CLEAVAGE
RP   OF INITIATOR METHIONINE, ACETYLATION AT MET-1 AND VAL-2,
RP   PHOSPHORYLATION AT THR-145, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma, and Hepatoma;
RA   Bienvenut W.V., Boldt K., von Kriegsheim A.F., Zebisch A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [7]
RP   PROTEIN SEQUENCE OF 2-12.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-10; 13-19; 29-42; 62-69; 133-143 AND 218-227,
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT VAL-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RA   Bienvenut W.V., Claeys D.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [9]
RP   PROTEIN SEQUENCE OF 92-110; 199-217 AND 228-247, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [10]
RP   INTERACTION WITH AANAT.
RX   PubMed=11427721; DOI=10.1073/pnas.141118798;
RA   Ganguly S., Gastel J.A., Weller J.L., Schwartz C., Jaffe H.,
RA   Namboodiri M.A., Coon S.L., Hickman A.B., Rollag M., Obsil T.,
RA   Beauverger P., Ferry G., Boutin J.A., Klein D.C.;
RT   "Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-
RT   3-3-binding switch in melatonin synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8083-8088(2001).
RN   [11]
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT VAL-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=14534293; DOI=10.1074/jbc.M309039200;
RA   Towbin H., Bair K.W., DeCaprio J.A., Eck M.J., Kim S., Kinder F.R.,
RA   Morollo A., Mueller D.R., Schindler P., Song H.K., van Oostrum J.,
RA   Versace R.W., Voshol H., Wood J., Zabludoff S., Phillips P.E.;
RT   "Proteomics-based target identification: bengamides as a new class of
RT   methionine aminopeptidase inhibitors.";
RL   J. Biol. Chem. 278:52964-52971(2003).
RN   [12]
RP   INTERACTION WITH CRTC2.
RX   PubMed=15454081; DOI=10.1016/j.cell.2004.09.015;
RA   Screaton R.A., Conkright M.D., Katoh Y., Best J.L., Canettieri G.,
RA   Jeffries S., Guzman E., Niessen S., Yates J.R. III, Takemori H.,
RA   Okamoto M., Montminy M.;
RT   "The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive
RT   coincidence detector.";
RL   Cell 119:61-74(2004).
RN   [13]
RP   INTERACTION WITH SSH1.
RX   PubMed=15159416; DOI=10.1083/jcb.200401136;
RA   Nagata-Ohashi K., Ohta Y., Goto K., Chiba S., Mori R., Nishita M.,
RA   Ohashi K., Kousaka K., Iwamatsu A., Niwa R., Uemura T., Mizuno K.;
RT   "A pathway of neuregulin-induced activation of cofilin-phosphatase
RT   Slingshot and cofilin in lamellipodia.";
RL   J. Cell Biol. 165:465-471(2004).
RN   [14]
RP   INTERACTION WITH ABL1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15696159; DOI=10.1038/ncb1228;
RA   Yoshida K., Yamaguchi T., Natsume T., Kufe D., Miki Y.;
RT   "JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of
RT   c-Abl in the apoptotic response to DNA damage.";
RL   Nat. Cell Biol. 7:278-285(2005).
RN   [15]
RP   FUNCTION IN TP53 ACTIVATION, AND INTERACTION WITH MDM4.
RX   PubMed=16511572; DOI=10.1038/sj.emboj.7601010;
RA   Jin Y., Dai M.S., Lu S.Z., Xu Y., Luo Z., Zhao Y., Lu H.;
RT   "14-3-3gamma binds to MDMX that is phosphorylated by UV-activated
RT   Chk1, resulting in p53 activation.";
RL   EMBO J. 25:1207-1218(2006).
RN   [16]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D.,
RA   Guilhaus M., James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by
RT   the Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT VAL-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS), IDENTIFICATION BY MASS
RP   SPECTROMETRY, INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.
RX   PubMed=17085597; DOI=10.1073/pnas.0605779103;
RA   Yang X., Lee W.H., Sobott F., Papagrigoriou E., Robinson C.V.,
RA   Grossmann J.G., Sundstroem M., Doyle D.A., Elkins J.M.;
RT   "Structural basis for protein-protein interactions in the 14-3-3
RT   protein family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:17237-17242(2006).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner.
CC   -!- SUBUNIT: Homodimer. Interacts with SAMSN1 (By similarity).
CC       Interacts with RAF1, SSH1 and CRTC2/TORC2. Interacts with ABL1
CC       (phosphorylated form); the interaction retains it in the
CC       cytoplasm. Interacts with GAB2. Interacts with MDM4
CC       (phosphorylated); negatively regulates MDM4 activity toward TP53.
CC       Interacts with PKA-phosphorylated AANAT.
CC   -!- INTERACTION:
CC       O14757:CHEK1; NbExp=7; IntAct=EBI-359832, EBI-974488;
CC       P67828:CSNK1A1 (xeno); NbExp=3; IntAct=EBI-359832, EBI-7540603;
CC       P56524:HDAC4; NbExp=3; IntAct=EBI-359832, EBI-308629;
CC       Q14678-2:KANK1; NbExp=3; IntAct=EBI-359832, EBI-6173812;
CC       Q5S007:LRRK2; NbExp=3; IntAct=EBI-359832, EBI-5323863;
CC       Q7KZI7:MARK2; NbExp=2; IntAct=EBI-359832, EBI-516560;
CC       P27448:MARK3; NbExp=2; IntAct=EBI-359832, EBI-707595;
CC       O15151:MDM4; NbExp=7; IntAct=EBI-359832, EBI-398437;
CC       P61588:Rnd3 (xeno); NbExp=2; IntAct=EBI-359832, EBI-6930266;
CC       P04637:TP53; NbExp=5; IntAct=EBI-359832, EBI-366083;
CC       P62258:YWHAE; NbExp=4; IntAct=EBI-359832, EBI-356498;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity).
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain, skeletal muscle,
CC       and heart.
CC   -!- PTM: Phosphorylated by various PKC isozymes.
CC   -!- SIMILARITY: Belongs to the 14-3-3 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF142498; AAD48408.1; -; mRNA.
DR   EMBL; AB024334; BAA85184.1; -; mRNA.
DR   EMBL; CR541904; CAG46702.1; -; mRNA.
DR   EMBL; CR541925; CAG46723.1; -; mRNA.
DR   EMBL; AC006388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC020963; AAH20963.1; -; mRNA.
DR   CCDS; CCDS5584.1; -.
DR   RefSeq; NP_036611.2; NM_012479.3.
DR   UniGene; Hs.744840; -.
DR   PDB; 2B05; X-ray; 2.55 A; A/B/C/D/E/F=2-247.
DR   PDB; 3UZD; X-ray; 1.86 A; A=1-247.
DR   PDB; 4E2E; X-ray; 2.25 A; A=1-247.
DR   PDB; 4J6S; X-ray; 3.08 A; A/B/C/D=1-247.
DR   PDB; 4O46; X-ray; 2.90 A; A/B/C/D/E/F=1-247.
DR   PDBsum; 2B05; -.
DR   PDBsum; 3UZD; -.
DR   PDBsum; 4E2E; -.
DR   PDBsum; 4J6S; -.
DR   PDBsum; 4O46; -.
DR   ProteinModelPortal; P61981; -.
DR   SMR; P61981; 1-235.
DR   BioGrid; 113364; 255.
DR   IntAct; P61981; 101.
DR   MINT; MINT-248956; -.
DR   STRING; 9606.ENSP00000306330; -.
DR   BindingDB; P61981; -.
DR   ChEMBL; CHEMBL1293296; -.
DR   PhosphoSite; P61981; -.
DR   DMDM; 48428721; -.
DR   REPRODUCTION-2DPAGE; IPI00220642; -.
DR   MaxQB; P61981; -.
DR   PaxDb; P61981; -.
DR   PeptideAtlas; P61981; -.
DR   PRIDE; P61981; -.
DR   DNASU; 7532; -.
DR   Ensembl; ENST00000307630; ENSP00000306330; ENSG00000170027.
DR   GeneID; 7532; -.
DR   KEGG; hsa:7532; -.
DR   UCSC; uc011kgj.1; human.
DR   CTD; 7532; -.
DR   GeneCards; GC07M075956; -.
DR   HGNC; HGNC:12852; YWHAG.
DR   HPA; CAB013274; -.
DR   HPA; CAB018389; -.
DR   HPA; HPA026918; -.
DR   MIM; 605356; gene.
DR   neXtProt; NX_P61981; -.
DR   PharmGKB; PA37441; -.
DR   eggNOG; COG5040; -.
DR   HOGENOM; HOG000240379; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; P61981; -.
DR   KO; K16198; -.
DR   OMA; CSETQHE; -.
DR   OrthoDB; EOG7HHWT3; -.
DR   PhylomeDB; P61981; -.
DR   TreeFam; TF102003; -.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_115566; Cell Cycle.
DR   Reactome; REACT_578; Apoptosis.
DR   SignaLink; P61981; -.
DR   ChiTaRS; YWHAG; human.
DR   EvolutionaryTrace; P61981; -.
DR   GeneWiki; YWHAG; -.
DR   GenomeRNAi; 7532; -.
DR   NextBio; 29467; -.
DR   PRO; PR:P61981; -.
DR   ArrayExpress; P61981; -.
DR   Bgee; P61981; -.
DR   CleanEx; HS_YWHAG; -.
DR   Genevestigator; P61981; -.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProtKB.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB.
DR   GO; GO:0008426; F:protein kinase C inhibitor activity; NAS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; NAS:UniProtKB.
DR   GO; GO:0071901; P:negative regulation of protein serine/threonine kinase activity; NAS:GOC.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0006605; P:protein targeting; IEA:Ensembl.
DR   GO; GO:0045664; P:regulation of neuron differentiation; IMP:UniProtKB.
DR   GO; GO:0009966; P:regulation of signal transduction; NAS:UniProtKB.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; IMP:UniProtKB.
DR   Gene3D; 1.20.190.20; -; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; SSF48445; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Phosphoprotein; Reference proteome.
FT   CHAIN         1    247       14-3-3 protein gamma.
FT                                /FTId=PRO_0000367907.
FT   INIT_MET      1      1       Removed; alternate.
FT   CHAIN         2    247       14-3-3 protein gamma, N-terminally
FT                                processed.
FT                                /FTId=PRO_0000058606.
FT   SITE         57     57       Interaction with phosphoserine on
FT                                interacting protein.
FT   SITE        132    132       Interaction with phosphoserine on
FT                                interacting protein.
FT   MOD_RES       1      1       N-acetylmethionine; in 14-3-3 protein
FT                                gamma; alternate; partial.
FT   MOD_RES       2      2       N-acetylvaline; in 14-3-3 protein gamma,
FT                                N-terminally processed; partial.
FT   MOD_RES       2      2       N-acetylvaline; partial.
FT   MOD_RES     145    145       Phosphothreonine.
FT   CONFLICT      4      4       R -> P (in Ref. 1; AAD48408).
FT   CONFLICT     19     19       R -> G (in Ref. 1; AAD48408).
FT   CONFLICT     78     78       Missing (in Ref. 1; AAD48408).
FT   CONFLICT     89     89       I -> V (in Ref. 1; AAD48408).
FT   CONFLICT    104    104       L -> V (in Ref. 1; AAD48408).
FT   CONFLICT    109    109       I -> Y (in Ref. 1; AAD48408).
FT   CONFLICT    119    122       SKVF -> RKDL (in Ref. 1; AAD48408).
FT   CONFLICT    144    145       AT -> GD (in Ref. 1; AAD48408).
FT   CONFLICT    157    158       AH -> R (in Ref. 1; AAD48408).
FT   CONFLICT    200    202       AFD -> EFE (in Ref. 1; AAD48408).
FT   CONFLICT    214    214       D -> E (in Ref. 1; AAD48408).
FT   CONFLICT    240    240       D -> DH (in Ref. 1; AAD48408).
FT   HELIX         4     16
FT   HELIX        20     31
FT   HELIX        39     70
FT   HELIX        79    106
FT   HELIX       108    111
FT   HELIX       117    137
FT   HELIX       140    164
FT   HELIX       170    185
FT   HELIX       190    206
FT   HELIX       207    210
FT   TURN        213    215
FT   HELIX       216    233
SQ   SEQUENCE   247 AA;  28303 MW;  B0D16C6DE1F4455D CRC64;
     MVDREQLVQK ARLAEQAERY DDMAAAMKNV TELNEPLSNE ERNLLSVAYK NVVGARRSSW
     RVISSIEQKT SADGNEKKIE MVRAYREKIE KELEAVCQDV LSLLDNYLIK NCSETQYESK
     VFYLKMKGDY YRYLAEVATG EKRATVVESS EKAYSEAHEI SKEHMQPTHP IRLGLALNYS
     VFYYEIQNAP EQACHLAKTA FDDAIAELDT LNEDSYKDST LIMQLLRDNL TLWTSDQQDD
     DGGEGNN
//
ID   1433S_HUMAN             Reviewed;         248 AA.
AC   P31947; Q6FH30; Q6FH51; Q96DH0;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 1.
DT   09-JUL-2014, entry version 153.
DE   RecName: Full=14-3-3 protein sigma;
DE   AltName: Full=Epithelial cell marker protein 1;
DE   AltName: Full=Stratifin;
GN   Name=SFN; Synonyms=HME1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Epithelium;
RX   PubMed=1390337;
RA   Prasad G.L., Valverius E.M., McDuffie E., Cooper H.L.;
RT   "Complementary DNA cloning of a novel epithelial cell marker protein,
RT   HME1, that may be down-regulated in neoplastic mammary cells.";
RL   Cell Growth Differ. 3:507-513(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 19-25;
RP   42-49; 118-122; 130-139; 149-159; 161-181; 196-199; 225-229 AND
RP   231-239.
RC   TISSUE=Keratinocyte;
RX   PubMed=8515476; DOI=10.1006/jmbi.1993.1346;
RA   Leffers H., Madsen P., Rasmussen H.H., Honore B., Andersen A.H.,
RA   Walbum E., Vandekerckhove J., Celis J.E.;
RT   "Molecular cloning and expression of the transformation sensitive
RT   epithelial marker stratifin. A member of a protein family that has
RT   been involved in the protein kinase C signalling pathway.";
RL   J. Mol. Biol. 231:982-998(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=9659898; DOI=10.1016/S1097-2765(00)80002-7;
RA   Hermeking H., Lengauer C., Polyak K., He T.-C., Zhang L.,
RA   Thiagalingam S., Kinzler K.W., Vogelstein B.;
RT   "14-3-3 sigma is a p53-regulated inhibitor of G2/M progression.";
RL   Mol. Cell 1:3-11(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Cervix, Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 42-49 AND 118-122.
RC   TISSUE=Keratinocyte;
RX   PubMed=1286667; DOI=10.1002/elps.11501301199;
RA   Rasmussen H.H., van Damme J., Puype M., Gesser B., Celis J.E.,
RA   Vandekerckhove J.;
RT   "Microsequences of 145 proteins recorded in the two-dimensional gel
RT   protein database of normal human epidermal keratinocytes.";
RL   Electrophoresis 13:960-969(1992).
RN   [8]
RP   IDENTIFICATION IN A COMPLEX WITH XPO7; ARHGAP1; EIF4A1; VPS26A; VPS29
RP   AND VPS35.
RX   PubMed=15282546; DOI=10.1038/sj.emboj.7600338;
RA   Mingot J.-M., Bohnsack M.T., Jaekle U., Goerlich D.;
RT   "Exportin 7 defines a novel general nuclear export pathway.";
RL   EMBO J. 23:3227-3236(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-248, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [10]
RP   FUNCTION IN MDM2 UBIQUITINATION, AND UBIQUITINATION BY RFFL.
RX   PubMed=18382127;
RA   Yang W., Dicker D.T., Chen J., El-Deiry W.S.;
RT   "CARPs enhance p53 turnover by degrading 14-3-3sigma and stabilizing
RT   MDM2.";
RL   Cell Cycle 7:670-682(2008).
RN   [11]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D.,
RA   Guilhaus M., James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by
RT   the Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-248, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-248, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   INTERACTION WITH SRPK2.
RX   PubMed=19592491; DOI=10.1074/jbc.M109.026237;
RA   Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.;
RT   "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell
RT   cycle and cell death in neurons.";
RL   J. Biol. Chem. 284:24512-24525(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5 AND SER-248, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   INTERACTION WITH COPS6 AND RFWD2.
RX   PubMed=21625211; DOI=10.1038/onc.2011.192;
RA   Choi H.H., Gully C., Su C.H., Velazquez-Torres G., Chou P.C.,
RA   Tseng C., Zhao R., Phan L., Shaiken T., Chen J., Yeung S.C., Lee M.H.;
RT   "COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3
RT   ubiquitin ligase for 14-3-3sigma.";
RL   Oncogene 30:4791-4801(2011).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH PHOSPHOSERINE
RP   PEPTIDE.
RX   PubMed=15731107; DOI=10.1074/jbc.M500982200;
RA   Wilker E.W., Grant R.A., Artim S.C., Yaffe M.B.;
RT   "A structural basis for 14-3-3sigma functional specificity.";
RL   J. Biol. Chem. 280:18891-18898(2005).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-231 IN COMPLEX WITH PADI6
RP   PHOSPHOPEPTIDES.
RX   PubMed=22634725; DOI=10.1016/j.jsb.2012.05.010;
RA   Rose R., Rose M., Ottmann C.;
RT   "Identification and structural characterization of two 14-3-3 binding
RT   sites in the human peptidylarginine deiminase type VI.";
RL   J. Struct. Biol. 180:65-72(2012).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner. When
CC       bound to KRT17, regulates protein synthesis and epithelial cell
CC       growth by stimulating Akt/mTOR pathway. May also regulate MDM2
CC       autoubiquitination and degradation and thereby activate p53/TP53.
CC   -!- FUNCTION: p53-regulated inhibitor of G2/M progression.
CC   -!- SUBUNIT: Homodimer. Interacts with KRT17 and SAMSN1 (By
CC       similarity). Found in a complex with XPO7, EIF4A1, ARHGAP1,
CC       VPS26A, VPS29, VPS35 and SFN. Interacts with GAB2. Interacts with
CC       SRPK2. Interacts with COPS6. Interacts with RFWD2; this
CC       interaction leads to proteasomal degradation.
CC   -!- INTERACTION:
CC       P00519:ABL1; NbExp=2; IntAct=EBI-476295, EBI-375543;
CC       Q96IF1:AJUBA; NbExp=2; IntAct=EBI-476295, EBI-949782;
CC       Q92934:BAD; NbExp=4; IntAct=EBI-476295, EBI-700771;
CC       Q7L5N1:COPS6; NbExp=7; IntAct=EBI-476295, EBI-486838;
CC       Q9UJM3:ERRFI1; NbExp=3; IntAct=EBI-476295, EBI-2941912;
CC       O60269:GPRIN2; NbExp=2; IntAct=EBI-476295, EBI-740397;
CC       P56524:HDAC4; NbExp=4; IntAct=EBI-476295, EBI-308629;
CC       Q9UQL6:HDAC5; NbExp=3; IntAct=EBI-476295, EBI-715576;
CC       Q8WUI4:HDAC7; NbExp=3; IntAct=EBI-476295, EBI-1048378;
CC       Q14103-4:HNRNPD; NbExp=7; IntAct=EBI-476295, EBI-432545;
CC       P27448:MARK3; NbExp=2; IntAct=EBI-476295, EBI-707595;
CC       O00444:PLK4; NbExp=2; IntAct=EBI-476295, EBI-746202;
CC       P04049:RAF1; NbExp=2; IntAct=EBI-476295, EBI-365996;
CC       Q8NFH8-2:REPS2; NbExp=2; IntAct=EBI-476295, EBI-8029141;
CC       Q8NHY2:RFWD2; NbExp=6; IntAct=EBI-476295, EBI-1176214;
CC       P04637:TP53; NbExp=4; IntAct=EBI-476295, EBI-366083;
CC       P63104:YWHAZ; NbExp=2; IntAct=EBI-476295, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus (By similarity).
CC       Secreted. Note=May be secreted by a non-classical secretory
CC       pathway.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P31947-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P31947-2; Sequence=VSP_021768;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Present mainly in tissues enriched in
CC       stratified squamous keratinizing epithelium.
CC   -!- PTM: Ubiquitinated. Ubiquitination by RFFL induces proteasomal
CC       degradation and indirectly regulates p53/TP53 activation.
CC   -!- SIMILARITY: Belongs to the 14-3-3 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M93010; AAA59546.1; -; mRNA.
DR   EMBL; X57348; CAA40623.1; -; mRNA.
DR   EMBL; AF029081; AAC52029.1; -; Genomic_DNA.
DR   EMBL; AF029082; AAC52030.1; -; mRNA.
DR   EMBL; CR541905; CAG46703.1; -; mRNA.
DR   EMBL; CR541926; CAG46724.1; -; mRNA.
DR   EMBL; AL034380; CAB92118.1; -; Genomic_DNA.
DR   EMBL; BC000329; AAH00329.1; -; mRNA.
DR   EMBL; BC000995; AAH00995.1; -; mRNA.
DR   EMBL; BC001550; AAH01550.1; -; mRNA.
DR   EMBL; BC002995; AAH02995.1; -; mRNA.
DR   EMBL; BC023552; AAH23552.1; -; mRNA.
DR   CCDS; CCDS288.1; -. [P31947-1]
DR   PIR; S34753; S34753.
DR   PIR; S38956; S38956.
DR   RefSeq; NP_006133.1; NM_006142.3. [P31947-1]
DR   UniGene; Hs.523718; -.
DR   PDB; 1YWT; X-ray; 2.40 A; A/B=1-248.
DR   PDB; 1YZ5; X-ray; 2.80 A; A/B=1-248.
DR   PDB; 3IQJ; X-ray; 1.15 A; A=1-231.
DR   PDB; 3IQU; X-ray; 1.05 A; A=1-231.
DR   PDB; 3IQV; X-ray; 1.20 A; A=1-231.
DR   PDB; 3LW1; X-ray; 1.28 A; A=1-248.
DR   PDB; 3MHR; X-ray; 1.15 A; A=1-231.
DR   PDB; 3O8I; X-ray; 2.00 A; A=1-231.
DR   PDB; 3P1N; X-ray; 1.40 A; A=1-231.
DR   PDB; 3P1O; X-ray; 1.90 A; A=1-231.
DR   PDB; 3P1P; X-ray; 1.95 A; A=1-231.
DR   PDB; 3P1Q; X-ray; 1.70 A; A=1-231.
DR   PDB; 3P1R; X-ray; 1.70 A; A=1-231.
DR   PDB; 3P1S; X-ray; 1.65 A; A=1-231.
DR   PDB; 3SMK; X-ray; 2.10 A; A=1-231.
DR   PDB; 3SML; X-ray; 1.90 A; A=1-231.
DR   PDB; 3SMM; X-ray; 2.00 A; A=1-231.
DR   PDB; 3SMN; X-ray; 2.00 A; A=1-231.
DR   PDB; 3SMO; X-ray; 1.80 A; A=1-231.
DR   PDB; 3SPR; X-ray; 1.99 A; A=1-231.
DR   PDB; 3T0L; X-ray; 1.60 A; A=1-231.
DR   PDB; 3T0M; X-ray; 1.62 A; A=1-231.
DR   PDB; 3U9X; X-ray; 1.80 A; A=1-231.
DR   PDB; 3UX0; X-ray; 1.75 A; A=1-231.
DR   PDB; 4DAT; X-ray; 1.40 A; A=1-231.
DR   PDB; 4DAU; X-ray; 2.00 A; A=1-231.
DR   PDB; 4DHM; X-ray; 1.70 A; A=1-231.
DR   PDB; 4DHN; X-ray; 1.80 A; A=1-231.
DR   PDB; 4DHO; X-ray; 1.70 A; A=1-231.
DR   PDB; 4DHP; X-ray; 1.75 A; A=1-231.
DR   PDB; 4DHQ; X-ray; 1.75 A; A=1-231.
DR   PDB; 4DHR; X-ray; 1.40 A; A=1-231.
DR   PDB; 4DHS; X-ray; 1.74 A; A=1-231.
DR   PDB; 4DHT; X-ray; 1.80 A; A=1-231.
DR   PDB; 4DHU; X-ray; 1.67 A; A=1-231.
DR   PDB; 4FL5; X-ray; 1.90 A; A/B=1-231.
DR   PDB; 4FR3; X-ray; 1.90 A; A=1-231.
DR   PDB; 4HQW; X-ray; 2.35 A; A=1-231.
DR   PDB; 4HRU; X-ray; 3.15 A; A=1-231.
DR   PDB; 4IEA; X-ray; 1.70 A; A=1-231.
DR   PDB; 4JC3; X-ray; 2.05 A; A=1-231.
DR   PDB; 4JDD; X-ray; 2.10 A; A=1-231.
DR   PDBsum; 1YWT; -.
DR   PDBsum; 1YZ5; -.
DR   PDBsum; 3IQJ; -.
DR   PDBsum; 3IQU; -.
DR   PDBsum; 3IQV; -.
DR   PDBsum; 3LW1; -.
DR   PDBsum; 3MHR; -.
DR   PDBsum; 3O8I; -.
DR   PDBsum; 3P1N; -.
DR   PDBsum; 3P1O; -.
DR   PDBsum; 3P1P; -.
DR   PDBsum; 3P1Q; -.
DR   PDBsum; 3P1R; -.
DR   PDBsum; 3P1S; -.
DR   PDBsum; 3SMK; -.
DR   PDBsum; 3SML; -.
DR   PDBsum; 3SMM; -.
DR   PDBsum; 3SMN; -.
DR   PDBsum; 3SMO; -.
DR   PDBsum; 3SPR; -.
DR   PDBsum; 3T0L; -.
DR   PDBsum; 3T0M; -.
DR   PDBsum; 3U9X; -.
DR   PDBsum; 3UX0; -.
DR   PDBsum; 4DAT; -.
DR   PDBsum; 4DAU; -.
DR   PDBsum; 4DHM; -.
DR   PDBsum; 4DHN; -.
DR   PDBsum; 4DHO; -.
DR   PDBsum; 4DHP; -.
DR   PDBsum; 4DHQ; -.
DR   PDBsum; 4DHR; -.
DR   PDBsum; 4DHS; -.
DR   PDBsum; 4DHT; -.
DR   PDBsum; 4DHU; -.
DR   PDBsum; 4FL5; -.
DR   PDBsum; 4FR3; -.
DR   PDBsum; 4HQW; -.
DR   PDBsum; 4HRU; -.
DR   PDBsum; 4IEA; -.
DR   PDBsum; 4JC3; -.
DR   PDBsum; 4JDD; -.
DR   ProteinModelPortal; P31947; -.
DR   SMR; P31947; 1-231.
DR   BioGrid; 109072; 138.
DR   DIP; DIP-29861N; -.
DR   IntAct; P31947; 149.
DR   MINT; MINT-108060; -.
DR   STRING; 9606.ENSP00000340989; -.
DR   BindingDB; P31947; -.
DR   ChEMBL; CHEMBL1909482; -.
DR   PhosphoSite; P31947; -.
DR   DMDM; 398953; -.
DR   OGP; P31947; -.
DR   SWISS-2DPAGE; P31947; -.
DR   MaxQB; P31947; -.
DR   PaxDb; P31947; -.
DR   PeptideAtlas; P31947; -.
DR   PRIDE; P31947; -.
DR   DNASU; 2810; -.
DR   Ensembl; ENST00000339276; ENSP00000340989; ENSG00000175793. [P31947-1]
DR   GeneID; 2810; -.
DR   KEGG; hsa:2810; -.
DR   UCSC; uc001bnc.1; human. [P31947-1]
DR   CTD; 2810; -.
DR   GeneCards; GC01P027189; -.
DR   HGNC; HGNC:10773; SFN.
DR   HPA; CAB006268; -.
DR   HPA; CAB040552; -.
DR   HPA; HPA011105; -.
DR   MIM; 601290; gene.
DR   neXtProt; NX_P31947; -.
DR   PharmGKB; PA177; -.
DR   eggNOG; COG5040; -.
DR   HOGENOM; HOG000240379; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; P31947; -.
DR   KO; K06644; -.
DR   OMA; EQKGNEE; -.
DR   OrthoDB; EOG7HHWT3; -.
DR   PhylomeDB; P31947; -.
DR   TreeFam; TF102003; -.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_578; Apoptosis.
DR   SignaLink; P31947; -.
DR   EvolutionaryTrace; P31947; -.
DR   GeneWiki; Stratifin; -.
DR   GenomeRNAi; 2810; -.
DR   NextBio; 11071; -.
DR   PRO; PR:P31947; -.
DR   Bgee; P31947; -.
DR   CleanEx; HS_SFN; -.
DR   Genevestigator; P31947; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0008426; F:protein kinase C inhibitor activity; TAS:ProtInc.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0061436; P:establishment of skin barrier; ISS:UniProtKB.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:HGNC.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0043616; P:keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:HGNC.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; TAS:ProtInc.
DR   GO; GO:0071901; P:negative regulation of protein serine/threonine kinase activity; TAS:GOC.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0045606; P:positive regulation of epidermal cell differentiation; ISS:UniProtKB.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; IEA:Ensembl.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; IEA:Ensembl.
DR   GO; GO:0010482; P:regulation of epidermal cell division; ISS:UniProtKB.
DR   GO; GO:0001836; P:release of cytochrome c from mitochondria; IDA:HGNC.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 1.20.190.20; -; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; SSF48445; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Secreted; Ubl conjugation.
FT   CHAIN         1    248       14-3-3 protein sigma.
FT                                /FTId=PRO_0000058643.
FT   SITE         56     56       Interaction with phosphoserine on
FT                                interacting protein.
FT   SITE        129    129       Interaction with phosphoserine on
FT                                interacting protein.
FT   MOD_RES       5      5       Phosphoserine.
FT   MOD_RES     248    248       Phosphoserine.
FT   VAR_SEQ      85    116       Missing (in isoform 2).
FT                                /FTId=VSP_021768.
FT   VARIANT     155    155       M -> I (in dbSNP:rs11542705).
FT                                /FTId=VAR_048095.
FT   CONFLICT     77     77       K -> M (in Ref. 4; CAG46703).
FT   CONFLICT    120    120       Y -> H (in Ref. 2; AAA59546).
FT   CONFLICT    242    242       A -> V (in Ref. 2; AAA59546).
FT   HELIX         3     15
FT   HELIX        19     31
FT   HELIX        38     69
FT   HELIX        80    104
FT   HELIX       107    110
FT   HELIX       114    134
FT   STRAND      137    139
FT   HELIX       140    161
FT   HELIX       167    182
FT   HELIX       187    204
FT   HELIX       205    207
FT   HELIX       210    230
SQ   SEQUENCE   248 AA;  27774 MW;  7F4B44E3AA59ECE6 CRC64;
     MERASLIQKA KLAEQAERYE DMAAFMKGAV EKGEELSCEE RNLLSVAYKN VVGGQRAAWR
     VLSSIEQKSN EEGSEEKGPE VREYREKVET ELQGVCDTVL GLLDSHLIKE AGDAESRVFY
     LKMKGDYYRY LAEVATGDDK KRIIDSARSA YQEAMDISKK EMPPTNPIRL GLALNFSVFH
     YEIANSPEEA ISLAKTTFDE AMADLHTLSE DSYKDSTLIM QLLRDNLTLW TADNAGEEGG
     EAPQEPQS
//
ID   1433T_HUMAN             Reviewed;         245 AA.
AC   P27348; D6W4Z5; Q567U5; Q5TZU8; Q9UP48;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1992, sequence version 1.
DT   09-JUL-2014, entry version 158.
DE   RecName: Full=14-3-3 protein theta;
DE   AltName: Full=14-3-3 protein T-cell;
DE   AltName: Full=14-3-3 protein tau;
DE   AltName: Full=Protein HS1;
GN   Name=YWHAQ;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=T-cell;
RX   PubMed=2015305; DOI=10.1016/0167-4781(91)90136-A;
RA   Nielsen P.J.;
RT   "Primary structure of a human protein kinase regulator protein.";
RL   Biochim. Biophys. Acta 1088:425-428(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Keratinocyte;
RX   PubMed=8515476; DOI=10.1006/jmbi.1993.1346;
RA   Leffers H., Madsen P., Rasmussen H.H., Honore B., Andersen A.H.,
RA   Walbum E., Vandekerckhove J., Celis J.E.;
RT   "Molecular cloning and expression of the transformation sensitive
RT   epithelial marker stratifin. A member of a protein family that has
RT   been involved in the protein kinase C signalling pathway.";
RL   J. Mol. Biol. 231:982-998(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta, Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-18.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-9; 28-49; 61-68; 104-115; 139-167 AND 213-222,
RP   ACETYLATION AT MET-1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma, and Hepatoma;
RA   Bienvenut W.V., Dhillon A.S., Kolch W.;
RL   Submitted (FEB-2008) to UniProtKB.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 73-245.
RC   TISSUE=Brain;
RA   Yu W., Gibbs R.A.;
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   PHOSPHORYLATION AT SER-232, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=9360956; DOI=10.1074/jbc.272.46.28882;
RA   Dubois T., Rommel C., Howell S., Steinhussen U., Soneji Y.,
RA   Morrice N., Moelling K., Aitken A.;
RT   "14-3-3 is phosphorylated by casein kinase I on residue 233.
RT   Phosphorylation at this site in vivo regulates Raf/14-3-3
RT   interaction.";
RL   J. Biol. Chem. 272:28882-28888(1997).
RN   [10]
RP   TISSUE SPECIFICITY.
RX   PubMed=11080204; DOI=10.1046/j.1471-4159.2000.0752511.x;
RA   Malaspina A., Kaushik N., de Belleroche J.;
RT   "A 14-3-3 mRNA is up-regulated in amyotrophic lateral sclerosis spinal
RT   cord.";
RL   J. Neurochem. 75:2511-2520(2000).
RN   [11]
RP   INTERACTION WITH CDKN1B.
RX   PubMed=12042314; DOI=10.1074/jbc.M203668200;
RA   Fujita N., Sato S., Katayama K., Tsuruo T.;
RT   "Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3
RT   and cytoplasmic localization.";
RL   J. Biol. Chem. 277:28706-28713(2002).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH PDPK1.
RX   PubMed=12177059; DOI=10.1074/jbc.M205141200;
RA   Sato S., Fujita N., Tsuruo T.;
RT   "Regulation of kinase activity of 3-phosphoinositide-dependent protein
RT   kinase-1 by binding to 14-3-3.";
RL   J. Biol. Chem. 277:39360-39367(2002).
RN   [13]
RP   INTERACTION WITH SSH1.
RX   PubMed=15159416; DOI=10.1083/jcb.200401136;
RA   Nagata-Ohashi K., Ohta Y., Goto K., Chiba S., Mori R., Nishita M.,
RA   Ohashi K., Kousaka K., Iwamatsu A., Niwa R., Uemura T., Mizuno K.;
RT   "A pathway of neuregulin-induced activation of cofilin-phosphatase
RT   Slingshot and cofilin in lamellipodia.";
RL   J. Cell Biol. 165:465-471(2004).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D.,
RA   Guilhaus M., James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by
RT   the Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1; LYS-3; LYS-49; LYS-68 AND
RP   LYS-115, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS).
RX   PubMed=7603573; DOI=10.1038/376188a0;
RA   Xiao B., Smerdon S.J., Jones D.H., Dodson G.G., Soneji Y., Aitken A.,
RA   Gamblin S.J.;
RT   "Structure of a 14-3-3 protein and implications for coordination of
RT   multiple signalling pathways.";
RL   Nature 376:188-191(1995).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-234, IDENTIFICATION BY MASS
RP   SPECTROMETRY, INTERACTION WITH PHOSPHOSERINE MOTIFS, AND SUBUNIT.
RX   PubMed=17085597; DOI=10.1073/pnas.0605779103;
RA   Yang X., Lee W.H., Sobott F., Papagrigoriou E., Robinson C.V.,
RA   Grossmann J.G., Sundstroem M., Doyle D.A., Elkins J.M.;
RT   "Structural basis for protein-protein interactions in the 14-3-3
RT   protein family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:17237-17242(2006).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner.
CC       Negatively regulates the kinase activity of PDPK1.
CC   -!- SUBUNIT: Homodimer. Interacts with CDK16 (By similarity).
CC       Interacts with SSH1. Interacts with CDKN1B ('Thr-198'
CC       phosphorylated form); the interaction translocates CDKN1B to the
CC       cytoplasm. Interacts with GAB2. Interacts with the 'Ser-241'
CC       phosphorylated form of PDPK1.
CC   -!- INTERACTION:
CC       Q9P0K1-3:ADAM22; NbExp=2; IntAct=EBI-359854, EBI-1567267;
CC       P49407:ARRB1; NbExp=3; IntAct=EBI-359854, EBI-743313;
CC       P32121:ARRB2; NbExp=3; IntAct=EBI-359854, EBI-714559;
CC       P22681:CBL; NbExp=6; IntAct=EBI-359854, EBI-518228;
CC       O94921:CDK14; NbExp=3; IntAct=EBI-359854, EBI-1043945;
CC       P46527:CDKN1B; NbExp=4; IntAct=EBI-359854, EBI-519280;
CC       P67828:CSNK1A1 (xeno); NbExp=2; IntAct=EBI-359854, EBI-7540603;
CC       P00533:EGFR; NbExp=5; IntAct=EBI-359854, EBI-297353;
CC       P23945:FSHR; NbExp=4; IntAct=EBI-359854, EBI-848239;
CC       Q14678:KANK1; NbExp=2; IntAct=EBI-359854, EBI-2556221;
CC       Q14678-2:KANK1; NbExp=3; IntAct=EBI-359854, EBI-6173812;
CC       Q5S007:LRRK2; NbExp=7; IntAct=EBI-359854, EBI-5323863;
CC       P61588:Rnd3 (xeno); NbExp=2; IntAct=EBI-359854, EBI-6930266;
CC       Q8WYL5:SSH1; NbExp=2; IntAct=EBI-359854, EBI-1222387;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Note=In neurons, axonally
CC       transported to the nerve terminals.
CC   -!- TISSUE SPECIFICITY: Abundantly expressed in brain, heart and
CC       pancreas, and at lower levels in kidney and placenta. Up-regulated
CC       in the lumbar spinal cord from patients with sporadic amyotrophic
CC       lateral sclerosis (ALS) compared with controls, with highest
CC       levels of expression in individuals with predominant lower motor
CC       neuron involvement.
CC   -!- PTM: Ser-232 is probably phosphorylated by CK1.
CC   -!- SIMILARITY: Belongs to the 14-3-3 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X56468; CAA39840.1; -; mRNA.
DR   EMBL; X57347; CAA40622.1; -; mRNA.
DR   EMBL; BT020014; AAV38817.1; -; mRNA.
DR   EMBL; CH471053; EAX00977.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00979.1; -; Genomic_DNA.
DR   EMBL; BC050601; AAH50601.1; -; mRNA.
DR   EMBL; BC056867; AAH56867.1; -; mRNA.
DR   EMBL; BC093019; AAH93019.1; -; mRNA.
DR   EMBL; AF070556; AAC28640.1; -; mRNA.
DR   CCDS; CCDS1666.1; -.
DR   PIR; S15076; S15076.
DR   RefSeq; NP_006817.1; NM_006826.3.
DR   UniGene; Hs.74405; -.
DR   PDB; 2BTP; X-ray; 2.80 A; A/B=1-234.
DR   PDBsum; 2BTP; -.
DR   ProteinModelPortal; P27348; -.
DR   SMR; P27348; 1-230.
DR   BioGrid; 116168; 380.
DR   DIP; DIP-27584N; -.
DR   IntAct; P27348; 80.
DR   MINT; MINT-121282; -.
DR   STRING; 9606.ENSP00000238081; -.
DR   PhosphoSite; P27348; -.
DR   DMDM; 112690; -.
DR   OGP; P27348; -.
DR   REPRODUCTION-2DPAGE; IPI00018146; -.
DR   MaxQB; P27348; -.
DR   PaxDb; P27348; -.
DR   PeptideAtlas; P27348; -.
DR   PRIDE; P27348; -.
DR   DNASU; 10971; -.
DR   Ensembl; ENST00000238081; ENSP00000238081; ENSG00000134308.
DR   Ensembl; ENST00000381844; ENSP00000371267; ENSG00000134308.
DR   GeneID; 10971; -.
DR   KEGG; hsa:10971; -.
DR   UCSC; uc002qzx.3; human.
DR   CTD; 10971; -.
DR   GeneCards; GC02M009724; -.
DR   H-InvDB; HIX0077146; -.
DR   HGNC; HGNC:12854; YWHAQ.
DR   HPA; CAB010286; -.
DR   HPA; HPA007925; -.
DR   MIM; 609009; gene.
DR   neXtProt; NX_P27348; -.
DR   PharmGKB; PA37443; -.
DR   eggNOG; COG5040; -.
DR   HOGENOM; HOG000240379; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; P27348; -.
DR   KO; K16197; -.
DR   OMA; CELRSIC; -.
DR   OrthoDB; EOG7HHWT3; -.
DR   PhylomeDB; P27348; -.
DR   TreeFam; TF102002; -.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_578; Apoptosis.
DR   SignaLink; P27348; -.
DR   ChiTaRS; YWHAQ; human.
DR   EvolutionaryTrace; P27348; -.
DR   GeneWiki; YWHAQ; -.
DR   GenomeRNAi; 10971; -.
DR   NextBio; 41686; -.
DR   PMAP-CutDB; P27348; -.
DR   PRO; PR:P27348; -.
DR   ArrayExpress; P27348; -.
DR   Bgee; P27348; -.
DR   CleanEx; HS_YWHAQ; -.
DR   Genevestigator; P27348; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0006605; P:protein targeting; IEA:Ensembl.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IEA:Ensembl.
DR   GO; GO:0021762; P:substantia nigra development; IEP:UniProt.
DR   Gene3D; 1.20.190.20; -; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; SSF48445; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Phosphoprotein; Reference proteome.
FT   CHAIN         1    245       14-3-3 protein theta.
FT                                /FTId=PRO_0000058636.
FT   SITE         56     56       Interaction with phosphoserine on
FT                                interacting protein.
FT   SITE        127    127       Interaction with phosphoserine on
FT                                interacting protein.
FT   MOD_RES       1      1       N-acetylmethionine.
FT   MOD_RES       3      3       N6-acetyllysine.
FT   MOD_RES      49     49       N6-acetyllysine.
FT   MOD_RES      68     68       N6-acetyllysine.
FT   MOD_RES     115    115       N6-acetyllysine.
FT   MOD_RES     232    232       Phosphoserine.
FT   CONFLICT    136    136       D -> N (in Ref. 3; AAV38817).
FT   HELIX         3     15
FT   HELIX        19     31
FT   HELIX        38     68
FT   HELIX        75    103
FT   TURN        104    108
FT   HELIX       112    132
FT   HELIX       135    159
FT   HELIX       165    180
FT   HELIX       185    201
FT   TURN        202    205
FT   HELIX       208    227
SQ   SEQUENCE   245 AA;  27764 MW;  175534325E9E37C4 CRC64;
     MEKTELIQKA KLAEQAERYD DMATCMKAVT EQGAELSNEE RNLLSVAYKN VVGGRRSAWR
     VISSIEQKTD TSDKKLQLIK DYREKVESEL RSICTTVLEL LDKYLIANAT NPESKVFYLK
     MKGDYFRYLA EVACGDDRKQ TIDNSQGAYQ EAFDISKKEM QPTHPIRLGL ALNFSVFYYE
     ILNNPELACT LAKTAFDEAI AELDTLNEDS YKDSTLIMQL LRDNLTLWTS DSAGEECDAA
     EGAEN
//
ID   1433Z_HUMAN             Reviewed;         245 AA.
AC   P63104; A8K1N0; B7Z465; P29213; P29312; Q32P43; Q5XJ08; Q6GPI2;
AC   Q6IN74; Q6NUR9; Q6P3U9; Q86V33;
DT   13-SEP-2004, integrated into UniProtKB/Swiss-Prot.
DT   13-SEP-2004, sequence version 1.
DT   09-JUL-2014, entry version 129.
DE   RecName: Full=14-3-3 protein zeta/delta;
DE   AltName: Full=Protein kinase C inhibitor protein 1;
DE            Short=KCIP-1;
GN   Name=YWHAZ;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=1577711;
RA   Zupan L.A., Steffens D.L., Berry C.A., Landt M.L., Gross R.W.;
RT   "Cloning and expression of a human 14-3-3 protein mediating
RT   phospholipolysis. Identification of an arachidonoyl-enzyme
RT   intermediate during catalysis.";
RL   J. Biol. Chem. 267:8707-8710(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=9512661; DOI=10.1016/S0167-4781(97)00171-1;
RA   Seluja G.A., Pietromonaco S.F., Elias L.;
RT   "Two unique 5' untranslated regions in mRNAs encoding human 14-3-3
RT   zeta: differential expression in hemopoietic cells.";
RL   Biochim. Biophys. Acta 1395:281-287(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Hippocampus, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, Colon, Eye, Melanoma, PNS, Skin, Testis, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-18.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-9; 12-18; 28-49; 61-68; 86-91; 128-158 AND
RP   213-222, ACETYLATION AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=B-cell lymphoma, and Platelet;
RA   Bienvenut W.V., Potts A., Barblan J., Claeys D., Quadroni M.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [8]
RP   PROTEIN SEQUENCE OF 92-103; 140-157; 194-212 AND 223-245, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [9]
RP   PHOSPHORYLATION AT THR-232, INTERACTION WITH RAF1, AND FUNCTION.
RX   PubMed=9360956; DOI=10.1074/jbc.272.46.28882;
RA   Dubois T., Rommel C., Howell S., Steinhussen U., Soneji Y.,
RA   Morrice N., Moelling K., Aitken A.;
RT   "14-3-3 is phosphorylated by casein kinase I on residue 233.
RT   Phosphorylation at this site in vivo regulates Raf/14-3-3
RT   interaction.";
RL   J. Biol. Chem. 272:28882-28888(1997).
RN   [10]
RP   INTERACTION WITH TLK2.
RX   PubMed=10455159; DOI=10.1074/jbc.274.35.24865;
RA   Zhang S., Xing H., Muslin A.J.;
RT   "Nuclear localization of protein kinase U-alpha is regulated by 14-3-
RT   3.";
RL   J. Biol. Chem. 274:24865-24872(1999).
RN   [11]
RP   INTERACTION WITH AANAT.
RX   PubMed=11427721; DOI=10.1073/pnas.141118798;
RA   Ganguly S., Gastel J.A., Weller J.L., Schwartz C., Jaffe H.,
RA   Namboodiri M.A., Coon S.L., Hickman A.B., Rollag M., Obsil T.,
RA   Beauverger P., Ferry G., Boutin J.A., Klein D.C.;
RT   "Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-
RT   3-3-binding switch in melatonin synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8083-8088(2001).
RN   [12]
RP   PHOSPHORYLATION AT SER-58, AND INTERACTION WITH AKT1.
RX   PubMed=11956222; DOI=10.1074/jbc.M203167200;
RA   Powell D.W., Rane M.J., Chen Q., Singh S., McLeish K.R.;
RT   "Identification of 14-3-3zeta as a protein kinase B/Akt substrate.";
RL   J. Biol. Chem. 277:21639-21642(2002).
RN   [13]
RP   PHOSPHORYLATION AT SER-58, AND DIMERIZATION.
RX   PubMed=12865427; DOI=10.1074/jbc.M304689200;
RA   Woodcock J.M., Murphy J., Stomski F.C., Berndt M.C., Lopez A.F.;
RT   "The dimeric versus monomeric status of 14-3-3zeta is controlled by
RT   phosphorylation of Ser58 at the dimer interface.";
RL   J. Biol. Chem. 278:36323-36327(2003).
RN   [14]
RP   INTERACTION WITH AANAT, AND FUNCTION.
RX   PubMed=14578935; DOI=10.1038/nsb1005;
RA   Zheng W., Zhang Z., Ganguly S., Weller J.L., Klein D.C., Cole P.A.;
RT   "Cellular stabilization of the melatonin rhythm enzyme induced by
RT   nonhydrolyzable phosphonate incorporation.";
RL   Nat. Struct. Biol. 10:1054-1057(2003).
RN   [15]
RP   PHOSPHORYLATION AT SER-184, INTERACTION WITH BAX, FUNCTION, AND
RP   MUTAGENESIS OF SER-184.
RX   PubMed=15071501; DOI=10.1038/sj.emboj.7600194;
RA   Tsuruta F., Sunayama J., Mori Y., Hattori S., Shimizu S.,
RA   Tsujimoto Y., Yoshioka K., Masuyama N., Gotoh Y.;
RT   "JNK promotes Bax translocation to mitochondria through
RT   phosphorylation of 14-3-3 proteins.";
RL   EMBO J. 23:1889-1899(2004).
RN   [16]
RP   INTERACTION WITH SSH1.
RX   PubMed=15159416; DOI=10.1083/jcb.200401136;
RA   Nagata-Ohashi K., Ohta Y., Goto K., Chiba S., Mori R., Nishita M.,
RA   Ohashi K., Kousaka K., Iwamatsu A., Niwa R., Uemura T., Mizuno K.;
RT   "A pathway of neuregulin-induced activation of cofilin-phosphatase
RT   Slingshot and cofilin in lamellipodia.";
RL   J. Cell Biol. 165:465-471(2004).
RN   [17]
RP   INTERACTION WITH MLLT7.
RX   PubMed=16114898; DOI=10.1021/bi050618r;
RA   Obsilova V., Vecer J., Herman P., Pabianova A., Sulc M., Teisinger J.,
RA   Boura E., Obsil T.;
RT   "14-3-3 protein interacts with nuclear localization sequence of
RT   forkhead transcription factor FoxO4.";
RL   Biochemistry 44:11608-11617(2005).
RN   [18]
RP   INTERACTION WITH SSH1.
RX   PubMed=15660133; DOI=10.1038/sj.emboj.7600543;
RA   Soosairajah J., Maiti S., Wiggan O., Sarmiere P., Moussi N.,
RA   Sarcevic B., Sampath R., Bamburg J.R., Bernard O.;
RT   "Interplay between components of a novel LIM kinase-slingshot
RT   phosphatase complex regulates cofilin.";
RL   EMBO J. 24:473-486(2005).
RN   [19]
RP   PHOSPHORYLATION AT SER-58, AND MUTAGENESIS OF SER-58.
RX   PubMed=15883165; DOI=10.1074/jbc.M409081200;
RA   Ma Y., Pitson S., Hercus T., Murphy J., Lopez A., Woodcock J.;
RT   "Sphingosine activates protein kinase A type II by a novel cAMP-
RT   independent mechanism.";
RL   J. Biol. Chem. 280:26011-26017(2005).
RN   [20]
RP   INTERACTION WITH ABL1, IDENTIFICATION BY MASS SPECTROMETRY,
RP   PHOSPHORYLATION AT SER-184, AND MUTAGENESIS OF SER-184.
RX   PubMed=15696159; DOI=10.1038/ncb1228;
RA   Yoshida K., Yamaguchi T., Natsume T., Kufe D., Miki Y.;
RT   "JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of
RT   c-Abl in the apoptotic response to DNA damage.";
RL   Nat. Cell Biol. 7:278-285(2005).
RN   [21]
RP   INTERACTION WITH AANAT, AND FUNCTION.
RX   PubMed=15644438; DOI=10.1073/pnas.0406871102;
RA   Ganguly S., Weller J.L., Ho A., Chemineau P., Malpaux B., Klein D.C.;
RT   "Melatonin synthesis: 14-3-3-dependent activation and inhibition of
RT   arylalkylamine N-acetyltransferase mediated by phosphoserine-205.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1222-1227(2005).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [23]
RP   PHOSPHORYLATION AT SER-58, DIMERIZATION, INTERACTION WITH TP53 AND
RP   YWHAE, FUNCTION, AND MUTAGENESIS OF SER-58.
RX   PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024;
RA   Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.;
RT   "Protein kinase A phosphorylates and regulates dimerization of 14-3-3
RT   epsilon.";
RL   FEBS Lett. 580:305-310(2006).
RN   [24]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [25]
RP   INTERACTION WITH NOXA1, AND MUTAGENESIS OF LYS-49.
RX   PubMed=17913709; DOI=10.1074/jbc.M704754200;
RA   Kim J.-S., Diebold B.A., Babior B.M., Knaus U.G., Bokoch G.M.;
RT   "Regulation of Nox1 activity via PKA-mediated phosphorylation of NoxA1
RT   and 14-3-3 binding.";
RL   J. Biol. Chem. 282:34787-34800(2007).
RN   [26]
RP   INTERACTION WITH ARHGEF2.
RX   PubMed=14970201; DOI=10.1074/jbc.M400084200;
RA   Zenke F.T., Krendel M., DerMardirossian C., King C.C., Bohl B.P.,
RA   Bokoch G.M.;
RT   "p21-activated kinase 1 phosphorylates and regulates 14-3-3 binding to
RT   GEF-H1, a microtubule-localized Rho exchange factor.";
RL   J. Biol. Chem. 279:18392-18400(2004).
RN   [27]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D.,
RA   Guilhaus M., James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by
RT   the Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-207, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [31]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1; LYS-3 AND LYS-68, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-207 AND THR-232, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [35]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [36]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=10488331; DOI=10.1016/S1097-2765(00)80363-9;
RA   Rittinger K., Budman J., Xu J., Volinia S., Cantley L.C.,
RA   Smerdon S.J., Gamblin S.J., Yaffe M.B.;
RT   "Structural analysis of 14-3-3 phosphopeptide complexes identifies a
RT   dual role for the nuclear export signal of 14-3-3 in ligand binding.";
RL   Mol. Cell 4:153-166(1999).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEX WITH AANAT.
RX   PubMed=11336675; DOI=10.1016/S0092-8674(01)00316-6;
RA   Obsil T., Ghirlando R., Klein D.C., Ganguly S., Dyda F.;
RT   "Crystal structure of the 14-3-3zeta:serotonin N-acetyltransferase
RT   complex. a role for scaffolding in enzyme regulation.";
RL   Cell 105:257-267(2001).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITH HISTONE H3
RP   PHOSPHOPEPTIDE.
RX   PubMed=16246723; DOI=10.1016/j.molcel.2005.08.032;
RA   Macdonald N., Welburn J.P.I., Noble M.E.M., Nguyen A., Yaffe M.B.,
RA   Clynes D., Moggs J.G., Orphanides G., Thomson S., Edmunds J.W.,
RA   Clayton A.L., Endicott J.A., Mahadevan L.C.;
RT   "Molecular basis for the recognition of phosphorylated and
RT   phosphoacetylated histone h3 by 14-3-3.";
RL   Mol. Cell 20:199-211(2005).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 1-230 IN COMPLEX WITH
RP   PSEUDOMONAS AERUGINOSA EXOS.
RX   PubMed=17235285; DOI=10.1038/sj.emboj.7601530;
RA   Ottmann C., Yasmin L., Weyand M., Veesenmeyer J.L., Diaz M.H.,
RA   Palmer R.H., Francis M.S., Hauser A.R., Wittinghofer A., Hallberg B.;
RT   "Phosphorylation-independent interaction between 14-3-3 and exoenzyme
RT   S: from structure to pathogenesis.";
RL   EMBO J. 26:902-913(2007).
CC   -!- FUNCTION: Adapter protein implicated in the regulation of a large
CC       spectrum of both general and specialized signaling pathways. Binds
CC       to a large number of partners, usually by recognition of a
CC       phosphoserine or phosphothreonine motif. Binding generally results
CC       in the modulation of the activity of the binding partner.
CC   -!- SUBUNIT: Interacts with CDK16 and BSPRY (By similarity). Interacts
CC       with WEE1 (C-terminal). Interacts with SAMSN1 (By similarity).
CC       Interacts with MLF1 (phosphorylated form); the interaction retains
CC       it in the cytoplasm (By similarity). Interacts with Thr-
CC       phosphorylated ITGB2 (By similarity). Interacts with BCL2L11 (By
CC       similarity). Homodimer. Heterodimerizes with YWHAE. Homo- and
CC       hetero-dimerization is inhibited by phosphorylation on Ser-58.
CC       Interacts with FOXO4, NOXA1, SSH1 and ARHGEF2. Interacts with
CC       Pseudomonas aeruginosa exoS (unphosphorylated form). Interacts
CC       with BAX; the interaction occurs in the cytoplasm. Under stress
CC       conditions, MAPK8-mediated phosphorylation releases BAX to
CC       mitochondria. Interacts with phosphorylated RAF1; the interaction
CC       is inhibited when YWHAZ is phosphorylated on Thr-232. Interacts
CC       with TP53; the interaction enhances p53 transcriptional activity.
CC       The Ser-58 phosphorylated form inhibits this interaction and p53
CC       transcriptional activity. Interacts with ABL1 (phosphorylated
CC       form); the interaction retains ABL1 in the cytoplasm. Interacts
CC       with PKA-phosphorylated AANAT; the interaction modulates AANAT
CC       enzymatic activity by increasing affinity for arylalkylamines and
CC       acetyl-CoA and protecting the enzyme from dephosphorylation and
CC       proteasomal degradation. It may also prevent thiol-dependent
CC       inactivation. Interacts with AKT1; the interaction phosphorylates
CC       YWHAZ and modulates dimerization. Interacts with GAB2 and TLK2.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-347088, EBI-347088;
CC       Q29495:AANAT (xeno); NbExp=3; IntAct=EBI-347088, EBI-446413;
CC       P00519:ABL1; NbExp=2; IntAct=EBI-347088, EBI-375543;
CC       P60709:ACTB; NbExp=3; IntAct=EBI-347088, EBI-353944;
CC       Q9P0K1:ADAM22; NbExp=3; IntAct=EBI-347088, EBI-1567236;
CC       Q9P0K1-3:ADAM22; NbExp=3; IntAct=EBI-347088, EBI-1567267;
CC       P10398:ARAF; NbExp=3; IntAct=EBI-347088, EBI-365961;
CC       Q92974:ARHGEF2; NbExp=2; IntAct=EBI-347088, EBI-302405;
CC       P25705:ATP5A1; NbExp=3; IntAct=EBI-347088, EBI-351437;
CC       P06576:ATP5B; NbExp=2; IntAct=EBI-347088, EBI-356231;
CC       Q92934:BAD; NbExp=5; IntAct=EBI-347088, EBI-700771;
CC       Q61337:Bad (xeno); NbExp=3; IntAct=EBI-347088, EBI-400328;
CC       P15056:BRAF; NbExp=3; IntAct=EBI-347088, EBI-365980;
CC       P62158:CALM3; NbExp=2; IntAct=EBI-347088, EBI-397435;
CC       O00257-3:CBX4; NbExp=2; IntAct=EBI-347088, EBI-4392727;
CC       P30304:CDC25A; NbExp=2; IntAct=EBI-347088, EBI-747671;
CC       P30305:CDC25B; NbExp=4; IntAct=EBI-347088, EBI-1051746;
CC       Q00537:CDK17; NbExp=2; IntAct=EBI-347088, EBI-624648;
CC       Q07002:CDK18; NbExp=2; IntAct=EBI-347088, EBI-746238;
CC       P23528:CFL1; NbExp=3; IntAct=EBI-347088, EBI-352733;
CC       P31327:CPS1; NbExp=2; IntAct=EBI-347088, EBI-536811;
CC       P67828:CSNK1A1 (xeno); NbExp=4; IntAct=EBI-347088, EBI-7540603;
CC       P68104:EEF1A1; NbExp=2; IntAct=EBI-347088, EBI-352162;
CC       P00533:EGFR; NbExp=4; IntAct=EBI-347088, EBI-297353;
CC       P06733:ENO1; NbExp=2; IntAct=EBI-347088, EBI-353877;
CC       Q16658:FSCN1; NbExp=3; IntAct=EBI-347088, EBI-351076;
CC       P30793:GCH1; NbExp=4; IntAct=EBI-347088, EBI-958183;
CC       P49841:GSK3B; NbExp=4; IntAct=EBI-347088, EBI-373586;
CC       P56524:HDAC4; NbExp=5; IntAct=EBI-347088, EBI-308629;
CC       Q9UQL6:HDAC5; NbExp=2; IntAct=EBI-347088, EBI-715576;
CC       Q8WUI4:HDAC7; NbExp=3; IntAct=EBI-347088, EBI-1048378;
CC       P0C0S8:HIST1H2AM; NbExp=2; IntAct=EBI-347088, EBI-1390628;
CC       P68431:HIST1H3D; NbExp=3; IntAct=EBI-347088, EBI-79722;
CC       P62805:HIST2H4B; NbExp=3; IntAct=EBI-347088, EBI-302023;
CC       P07910:HNRNPC; NbExp=2; IntAct=EBI-347088, EBI-357966;
CC       P04792:HSPB1; NbExp=2; IntAct=EBI-347088, EBI-352682;
CC       Q02241:KIF23; NbExp=5; IntAct=EBI-347088, EBI-306852;
CC       P02545:LMNA; NbExp=2; IntAct=EBI-347088, EBI-351935;
CC       Q5S007:LRRK2; NbExp=7; IntAct=EBI-347088, EBI-5323863;
CC       Q99683:MAP3K5; NbExp=3; IntAct=EBI-347088, EBI-476263;
CC       P10636:MAPT; NbExp=8; IntAct=EBI-347088, EBI-366182;
CC       P10636-3:MAPT; NbExp=9; IntAct=EBI-347088, EBI-7145070;
CC       P29172:MAPT (xeno); NbExp=2; IntAct=EBI-347088, EBI-7291149;
CC       Q7KZI7:MARK2; NbExp=6; IntAct=EBI-347088, EBI-516560;
CC       P27448:MARK3; NbExp=9; IntAct=EBI-347088, EBI-707595;
CC       P19338:NCL; NbExp=2; IntAct=EBI-347088, EBI-346967;
CC       P06748:NPM1; NbExp=2; IntAct=EBI-347088, EBI-78579;
CC       Q8TEW0:PARD3; NbExp=4; IntAct=EBI-347088, EBI-81968;
CC       Q02156:PRKCE; NbExp=5; IntAct=EBI-347088, EBI-706254;
CC       O14744:PRMT5; NbExp=2; IntAct=EBI-347088, EBI-351098;
CC       P04049:RAF1; NbExp=12; IntAct=EBI-347088, EBI-365996;
CC       Q8NFH8-2:REPS2; NbExp=2; IntAct=EBI-347088, EBI-8029141;
CC       P61587:RND3; NbExp=11; IntAct=EBI-347088, EBI-1111534;
CC       P61588:Rnd3 (xeno); NbExp=3; IntAct=EBI-347088, EBI-6930266;
CC       P23396:RPS3; NbExp=2; IntAct=EBI-347088, EBI-351193;
CC       P31947:SFN; NbExp=2; IntAct=EBI-347088, EBI-476295;
CC       P57059:SIK1; NbExp=4; IntAct=EBI-347088, EBI-1181640;
CC       Q9Y2K2:SIK3; NbExp=5; IntAct=EBI-347088, EBI-1181460;
CC       O94875:SORBS2; NbExp=2; IntAct=EBI-347088, EBI-311323;
CC       Q15831:STK11; NbExp=6; IntAct=EBI-347088, EBI-306838;
CC       O00506:STK25; NbExp=2; IntAct=EBI-347088, EBI-618295;
CC       P36897:TGFBR1; NbExp=4; IntAct=EBI-347088, EBI-1027557;
CC       P04637:TP53; NbExp=2; IntAct=EBI-347088, EBI-366083;
CC       P49815:TSC2; NbExp=7; IntAct=EBI-347088, EBI-396587;
CC       P55072:VCP; NbExp=2; IntAct=EBI-347088, EBI-355164;
CC       P08670:VIM; NbExp=2; IntAct=EBI-347088, EBI-353844;
CC       P30291:WEE1; NbExp=3; IntAct=EBI-347088, EBI-914695;
CC       P46937:YAP1; NbExp=3; IntAct=EBI-347088, EBI-1044059;
CC       P62258:YWHAE; NbExp=5; IntAct=EBI-347088, EBI-356498;
CC       Q9NYL2:ZAK; NbExp=4; IntAct=EBI-347088, EBI-602273;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Melanosome. Note=Located to stage
CC       I to stage IV melanosomes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P63104-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P63104-2; Sequence=VSP_047505;
CC         Note=No experimental confirmation available;
CC   -!- PTM: The delta, brain-specific form differs from the zeta form in
CC       being phosphorylated (By similarity). Phosphorylation on Ser-184
CC       by MAPK8; promotes dissociation of BAX and translocation of BAX to
CC       mitochondria. Phosphorylation on Thr-232; inhibits binding of
CC       RAF1. Phosphorylated on Ser-58 by PKA and protein kinase C delta
CC       type catalytic subunit in a sphingosine-dependent fashion.
CC       Phosphorylation on Ser-58 by PKA; disrupts homodimerization and
CC       heterodimerization with YHAE and TP53.
CC   -!- SIMILARITY: Belongs to the 14-3-3 family.
CC   -!- CAUTION: Was originally (PubMed:1577711) thought to have
CC       phospholipase A2 activity.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH51814.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC       Sequence=AAH73141.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M86400; AAA36446.1; -; mRNA.
DR   EMBL; U28964; AAC52052.1; -; mRNA.
DR   EMBL; AK289945; BAF82634.1; -; mRNA.
DR   EMBL; AK296902; BAH12451.1; -; mRNA.
DR   EMBL; CH471060; EAW91823.1; -; Genomic_DNA.
DR   EMBL; BC003623; AAH03623.3; -; mRNA.
DR   EMBL; BC051814; AAH51814.1; ALT_INIT; mRNA.
DR   EMBL; BC063824; AAH63824.2; -; mRNA.
DR   EMBL; BC068456; AAH68456.2; -; mRNA.
DR   EMBL; BC072426; AAH72426.2; -; mRNA.
DR   EMBL; BC073141; AAH73141.1; ALT_INIT; mRNA.
DR   EMBL; BC083508; AAH83508.2; -; mRNA.
DR   EMBL; BC099904; AAH99904.1; -; mRNA.
DR   EMBL; BC101483; AAI01484.1; -; mRNA.
DR   EMBL; BC108281; AAI08282.1; -; mRNA.
DR   EMBL; BC111951; AAI11952.1; -; mRNA.
DR   CCDS; CCDS6290.1; -. [P63104-1]
DR   PIR; A38246; PSHUAM.
DR   RefSeq; NP_001129171.1; NM_001135699.1. [P63104-1]
DR   RefSeq; NP_001129172.1; NM_001135700.1. [P63104-1]
DR   RefSeq; NP_001129173.1; NM_001135701.1. [P63104-1]
DR   RefSeq; NP_001129174.1; NM_001135702.1. [P63104-1]
DR   RefSeq; NP_003397.1; NM_003406.3. [P63104-1]
DR   RefSeq; NP_663723.1; NM_145690.2. [P63104-1]
DR   RefSeq; XP_005251118.1; XM_005251061.1. [P63104-1]
DR   RefSeq; XP_005251119.1; XM_005251062.1. [P63104-1]
DR   RefSeq; XP_005251120.1; XM_005251063.1. [P63104-1]
DR   UniGene; Hs.492407; -.
DR   PDB; 1IB1; X-ray; 2.70 A; A/B/C/D=1-245.
DR   PDB; 1QJA; X-ray; 2.00 A; A/B=1-245.
DR   PDB; 1QJB; X-ray; 2.00 A; A/B=1-245.
DR   PDB; 2C1J; X-ray; 2.60 A; A/B=1-245.
DR   PDB; 2C1N; X-ray; 2.00 A; A/B=1-245.
DR   PDB; 2O02; X-ray; 1.50 A; A/B=1-230.
DR   PDB; 2WH0; X-ray; 2.25 A; A/B/C/D=1-245.
DR   PDB; 3CU8; X-ray; 2.40 A; A/B=1-245.
DR   PDB; 3NKX; X-ray; 2.40 A; A/B=1-245.
DR   PDB; 3RDH; X-ray; 2.39 A; A/B/C/D=1-245.
DR   PDB; 4BG6; X-ray; 2.30 A; A/B=1-245.
DR   PDB; 4FJ3; X-ray; 1.95 A; A/B=1-230.
DR   PDB; 4HKC; X-ray; 2.20 A; A=1-245.
DR   PDB; 4IHL; X-ray; 2.20 A; A/B=1-230.
DR   PDB; 4N7G; X-ray; 2.25 A; A=1-230.
DR   PDB; 4N7Y; X-ray; 2.16 A; A/B=1-230.
DR   PDB; 4N84; X-ray; 2.50 A; A/B=1-230.
DR   PDBsum; 1IB1; -.
DR   PDBsum; 1QJA; -.
DR   PDBsum; 1QJB; -.
DR   PDBsum; 2C1J; -.
DR   PDBsum; 2C1N; -.
DR   PDBsum; 2O02; -.
DR   PDBsum; 2WH0; -.
DR   PDBsum; 3CU8; -.
DR   PDBsum; 3NKX; -.
DR   PDBsum; 3RDH; -.
DR   PDBsum; 4BG6; -.
DR   PDBsum; 4FJ3; -.
DR   PDBsum; 4HKC; -.
DR   PDBsum; 4IHL; -.
DR   PDBsum; 4N7G; -.
DR   PDBsum; 4N7Y; -.
DR   PDBsum; 4N84; -.
DR   ProteinModelPortal; P63104; -.
DR   SMR; P63104; 1-230.
DR   BioGrid; 113366; 372.
DR   DIP; DIP-563N; -.
DR   IntAct; P63104; 513.
DR   MINT; MINT-89071; -.
DR   DrugBank; DB01381; Ginkgo biloba.
DR   PhosphoSite; P63104; -.
DR   DMDM; 52000887; -.
DR   DOSAC-COBS-2DPAGE; P63104; -.
DR   OGP; P63104; -.
DR   UCD-2DPAGE; P63104; -.
DR   MaxQB; P63104; -.
DR   PaxDb; P63104; -.
DR   PRIDE; P63104; -.
DR   DNASU; 7534; -.
DR   Ensembl; ENST00000353245; ENSP00000309503; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000395951; ENSP00000379281; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000395953; ENSP00000379283; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000395956; ENSP00000379286; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000395957; ENSP00000379287; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000395958; ENSP00000379288; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000419477; ENSP00000395114; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000457309; ENSP00000398599; ENSG00000164924. [P63104-1]
DR   Ensembl; ENST00000522542; ENSP00000430072; ENSG00000164924. [P63104-2]
DR   GeneID; 7534; -.
DR   KEGG; hsa:7534; -.
DR   UCSC; uc003yjv.2; human. [P63104-1]
DR   CTD; 7534; -.
DR   GeneCards; GC08M101930; -.
DR   HGNC; HGNC:12855; YWHAZ.
DR   HPA; CAB005065; -.
DR   MIM; 601288; gene.
DR   neXtProt; NX_P63104; -.
DR   PharmGKB; PA37444; -.
DR   eggNOG; COG5040; -.
DR   HOVERGEN; HBG050423; -.
DR   InParanoid; P63104; -.
DR   KO; K16197; -.
DR   OrthoDB; EOG7HHWT3; -.
DR   PhylomeDB; P63104; -.
DR   TreeFam; TF102003; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_21257; Metabolism of RNA.
DR   Reactome; REACT_578; Apoptosis.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6900; Immune System.
DR   Reactome; REACT_71; Gene Expression.
DR   SignaLink; P63104; -.
DR   ChiTaRS; YWHAZ; human.
DR   EvolutionaryTrace; P63104; -.
DR   GeneWiki; YWHAZ; -.
DR   GenomeRNAi; 7534; -.
DR   NextBio; 29475; -.
DR   PRO; PR:P63104; -.
DR   ArrayExpress; P63104; -.
DR   Bgee; P63104; -.
DR   Genevestigator; P63104; -.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProt.
DR   GO; GO:0031252; C:cell leading edge; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProt.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProtKB.
DR   GO; GO:0042629; C:mast cell granule; IEA:GOC.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProt.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0002553; P:histamine secretion by mast cell; IEA:Ensembl.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0016071; P:mRNA metabolic process; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0006626; P:protein targeting to mitochondrion; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0016070; P:RNA metabolic process; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 1.20.190.20; -; 1.
DR   InterPro; IPR000308; 14-3-3.
DR   InterPro; IPR023409; 14-3-3_CS.
DR   InterPro; IPR023410; 14-3-3_domain.
DR   PANTHER; PTHR18860; PTHR18860; 1.
DR   Pfam; PF00244; 14-3-3; 1.
DR   PIRSF; PIRSF000868; 14-3-3; 1.
DR   PRINTS; PR00305; 1433ZETA.
DR   SMART; SM00101; 14_3_3; 1.
DR   SUPFAM; SSF48445; SSF48445; 1.
DR   PROSITE; PS00796; 1433_1; 1.
DR   PROSITE; PS00797; 1433_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN         1    245       14-3-3 protein zeta/delta.
FT                                /FTId=PRO_0000058627.
FT   SITE         56     56       Interaction with phosphoserine on
FT                                interacting protein (By similarity).
FT   SITE        127    127       Interaction with phosphoserine on
FT                                interacting protein (By similarity).
FT   MOD_RES       1      1       N-acetylmethionine.
FT   MOD_RES       3      3       N6-acetyllysine.
FT   MOD_RES      58     58       Phosphoserine; by PKA and PKB/AKT1.
FT   MOD_RES      68     68       N6-acetyllysine.
FT   MOD_RES     184    184       Phosphoserine; by MAPK8.
FT   MOD_RES     207    207       Phosphoserine.
FT   MOD_RES     232    232       Phosphothreonine; by CK1.
FT   VAR_SEQ       1     98       MDKNELVQKAKLAEQAERYDDMAACMKSVTEQGAELSNEER
FT                                NLLSVAYKNVVGARRSSWRVVSSIEQKTEGAEKKQQMAREY
FT                                REKIETELRDICNDVL -> MSQPCRKLWRHNYETSSCIEF
FT                                LK (in isoform 2).
FT                                /FTId=VSP_047505.
FT   MUTAGEN      49     49       K->E: Loss of interaction with NOXA1.
FT   MUTAGEN      58     58       S->A: Loss of sphingosine-activated PKA
FT                                phosphorylation. Promotes
FT                                homodimerization and heterodimerization
FT                                with YWHAE. Enhanced transcriptional
FT                                activity of P53.
FT   MUTAGEN      58     58       S->E: Loss of homodimerization. Reduced
FT                                dimerization with YWHAE. Significantly
FT                                reduced interaction with P53. No
FT                                enhancement of P53 transcriptional
FT                                activity.
FT   MUTAGEN     184    184       S->A: On DNA damage, loss of MAPK8-
FT                                mediated phosphorylation. Loss of binding
FT                                ABL1. Attenuates ABL1-mediated apoptosis.
FT                                No loss of interaction with BAX under
FT                                stress conditions. Inhibits translocation
FT                                of BAX to mitochondria.
FT   CONFLICT     22     22       M -> V (in Ref. 5; AAH68456).
FT   CONFLICT    136    136       D -> G (in Ref. 3; BAH12451).
FT   HELIX         3     15
FT   HELIX        19     31
FT   HELIX        38     67
FT   TURN         69     71
FT   HELIX        76    103
FT   HELIX       105    108
FT   HELIX       112    131
FT   HELIX       135    159
FT   HELIX       165    180
FT   HELIX       185    200
FT   HELIX       201    205
FT   TURN        208    210
FT   HELIX       211    228
SQ   SEQUENCE   245 AA;  27745 MW;  D464DF2286BBFE60 CRC64;
     MDKNELVQKA KLAEQAERYD DMAACMKSVT EQGAELSNEE RNLLSVAYKN VVGARRSSWR
     VVSSIEQKTE GAEKKQQMAR EYREKIETEL RDICNDVLSL LEKFLIPNAS QAESKVFYLK
     MKGDYYRYLA EVAAGDDKKG IVDQSQQAYQ EAFEISKKEM QPTHPIRLGL ALNFSVFYYE
     ILNSPEKACS LAKTAFDEAI AELDTLSEES YKDSTLIMQL LRDNLTLWTS DTQGDEAEAG
     EGGEN
//
ID   1A01_HUMAN              Reviewed;         365 AA.
AC   P30443; O77964; O78171; Q9MYA3; Q9TP25; Q9TQP5;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   09-JUL-2014, entry version 131.
DE   RecName: Full=HLA class I histocompatibility antigen, A-1 alpha chain;
DE   AltName: Full=MHC class I antigen A*1;
DE   Flags: Precursor;
GN   Name=HLA-A; Synonyms=HLAA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*01:01).
RX   PubMed=3375250; DOI=10.1073/pnas.85.11.4005;
RA   Parham P., Lomen C.E., Lawlor D.A., Ways J.P., Holmes N., Coppin H.L.,
RA   Salter R.D., Wan A.M., Ennis P.D.;
RT   "Nature of polymorphism in HLA-A, -B, and -C molecules.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:4005-4009(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*01:01).
RX   PubMed=2715640;
RA   Parham P., Lawlor D.A., Lomen C.E., Ennis P.D.;
RT   "Diversity and diversification of HLA-A,B,C alleles.";
RL   J. Immunol. 142:3937-3950(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*01:01).
RA   Warren E.;
RL   Submitted (APR-1989) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*01:01).
RX   PubMed=2251137; DOI=10.1093/nar/18.22.6701;
RA   Girdlestone J.;
RT   "Nucleotide sequence of an HLA-A1 gene.";
RL   Nucleic Acids Res. 18:6701-6701(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*01:01).
RX   PubMed=9349617; DOI=10.1111/j.1399-0039.1997.tb02885.x;
RA   Laforet M., Froelich N., Parissiadis A., Pfeiffer B., Schell A.,
RA   Faller B., Woehl-Jaegle M.L., Cazenave J.-P., Tongio M.M.;
RT   "A nucleotide insertion in exon 4 is responsible for the absence of
RT   expression of an HLA-A*01 allele.";
RL   Tissue Antigens 50:347-350(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*01:01).
RA   Waller M.J., Robinson J., Marsh S.G.E.;
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE A*01:01).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*01:02).
RX   PubMed=7761977; DOI=10.1111/j.1399-0039.1995.tb02437.x;
RA   Browning M.J., Madrigal J.A., Krausa P., Kowalski H., Allsopp C.E.,
RA   Little A.-M., Turner S., Adams E.J., Arnett K.L., Bodmer W.F.,
RA   Parham P.;
RT   "The HLA-A,B,C genotype of the class I negative cell line Daudi
RT   reveals novel HLA-A and -B alleles.";
RL   Tissue Antigens 45:177-187(1995).
RN   [9]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*01:03).
RX   PubMed=9438203; DOI=10.1016/S0198-8859(97)00204-8;
RA   Sitha S., Scheltinga S.A., Johnston-Dow L.A., White C.B.,
RA   der van Zwan A.W., Bakema J.E., Rozemuller E.H., van der Tweel J.G.,
RA   Kronink M.N., Tilanus M.G.J.;
RT   "A generic sequencing based typing approach for the identification of
RT   HLA-A diversity.";
RL   Hum. Immunol. 57:120-128(1997).
RN   [10]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*01:03).
RC   TISSUE=Blood;
RX   PubMed=11182232; DOI=10.1016/S0198-8859(00)00238-X;
RA   Poland G.A., Sohni Y., Domanico M., Kroning C.M., DeGoey S.R.,
RA   Jimale M., Jacobson R.M., Moore S.B.;
RT   "High frequency of HLA-A*0103 allele in a Somali population.";
RL   Hum. Immunol. 62:197-200(2001).
RN   [11]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*01:06).
RX   PubMed=10852390; DOI=10.1034/j.1399-0039.2000.550412.x;
RA   Ellis J., Steiner N.K., Kosman C., Henson V., Mitton W., Koester R.,
RA   Ng J., Hartzman R.J., Hurley C.K.;
RT   "Seventeen more novel HLA-A locus alleles.";
RL   Tissue Antigens 55:369-373(2000).
RN   [12]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*01:07).
RA   Tamouza R., Fortier C., Mahfoudh N., Schaeffer V., Poirier J.C.,
RA   Marzais F., Gautreau C., Charron D.;
RT   "A new HLA-A*01 allele.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   SULFATION.
RX   PubMed=3121736;
RA   Sant A.J., Zacheis M., Rumbarger T., Giacoletto K.S., Schwartz B.D.;
RT   "Human Ia alpha- and beta-chains are sulfated.";
RL   J. Immunol. 140:155-160(1988).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 25-298 IN COMPLEX WITH MAGE
RP   ANTIGENIC PEPTIDE AND ANTIBODY, AND DISULFIDE BONDS.
RX   PubMed=15537658; DOI=10.1074/jbc.M411323200;
RA   Hulsmeyer M., Chames P., Hillig R.C., Stanfield R.L., Held G.,
RA   Coulie P.G., Alings C., Wille G., Saenger W., Uchanska-Ziegler B.,
RA   Hoogenboom H.R., Ziegler A.;
RT   "A major histocompatibility complex-peptide-restricted antibody and t
RT   cell receptor molecules recognize their target by distinct binding
RT   modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1
RT   in complex with FAB-HYB3.";
RL   J. Biol. Chem. 280:2972-2980(2005).
RN   [16]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-166, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Dimer of alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Sulfated.
CC   -!- PTM: Polyubiquitinated in a post ER compartment through
CC       interaction with human herpesvirus 8 MIR1 protein. This targets
CC       the protein for rapid degradation via the ubiquitin system (By
CC       similarity).
CC   -!- POLYMORPHISM: The following alleles of A-1 are known: A*01:01,
CC       A*01:02, A*01:03, A*01:06 and A*01:07. The sequence shown is that
CC       of A*01:01.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M24043; AAA59652.1; -; Genomic_DNA.
DR   EMBL; X55710; CAA39243.1; -; Genomic_DNA.
DR   EMBL; Z93949; CAB07989.1; -; Genomic_DNA.
DR   EMBL; AJ278305; CAB93537.1; -; Genomic_DNA.
DR   EMBL; BC003069; AAH03069.1; -; mRNA.
DR   EMBL; U07161; AAA80569.1; -; mRNA.
DR   EMBL; Y12469; CAA73072.1; -; Genomic_DNA.
DR   EMBL; Y12470; CAA73073.1; -; Genomic_DNA.
DR   EMBL; AH008863; AAF19525.1; -; Genomic_DNA.
DR   EMBL; AH007762; AAD33894.1; -; Genomic_DNA.
DR   EMBL; AH009407; AAF73862.1; -; Genomic_DNA.
DR   CCDS; CCDS34373.1; -.
DR   PIR; I38518; I38518.
DR   PIR; I61856; I61856.
DR   RefSeq; NP_001229687.1; NM_001242758.1.
DR   UniGene; Hs.181244; -.
DR   UniGene; Hs.713441; -.
DR   PDB; 1W72; X-ray; 2.15 A; A/D=25-298.
DR   PDB; 3BO8; X-ray; 1.80 A; A=25-298.
DR   PDB; 4NQV; X-ray; 2.39 A; A/C/E/G/I/K=25-298.
DR   PDB; 4NQX; X-ray; 2.00 A; A/C/E/G/I/K=25-308.
DR   PDBsum; 1W72; -.
DR   PDBsum; 3BO8; -.
DR   PDBsum; 4NQV; -.
DR   PDBsum; 4NQX; -.
DR   ProteinModelPortal; P30443; -.
DR   SMR; P30443; 25-298.
DR   BioGrid; 109350; 33.
DR   IntAct; P30443; 1.
DR   MINT; MINT-4655826; -.
DR   DMDM; 231347; -.
DR   PaxDb; P30443; -.
DR   PRIDE; P30443; -.
DR   DNASU; 3105; -.
DR   Ensembl; ENST00000431930; ENSP00000406366; ENSG00000229215.
DR   Ensembl; ENST00000443552; ENSP00000404678; ENSG00000224320.
DR   Ensembl; ENST00000549869; ENSP00000447635; ENSG00000224320.
DR   Ensembl; ENST00000552193; ENSP00000447614; ENSG00000229215.
DR   GeneID; 3105; -.
DR   KEGG; hsa:3105; -.
DR   UCSC; uc011ejp.2; human.
DR   CTD; 3105; -.
DR   GeneCards; GC06P029949; -.
DR   GeneCards; GC06Pi29846; -.
DR   GeneCards; GC06Pj29898; -.
DR   HGNC; HGNC:4931; HLA-A.
DR   MIM; 142800; gene.
DR   neXtProt; NX_P30443; -.
DR   Orphanet; 179; Chorioretinopathy, Birdshot type.
DR   eggNOG; NOG42056; -.
DR   HOVERGEN; HBG016709; -.
DR   KO; K06751; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-A; human.
DR   EvolutionaryTrace; P30443; -.
DR   GenomeRNAi; 3105; -.
DR   NextBio; 12319; -.
DR   CleanEx; HS_HLA-A; -.
DR   Genevestigator; P30443; -.
DR   GO; GO:0009986; C:cell surface; ISS:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0042612; C:MHC class I protein complex; ISS:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030881; F:beta-2-microglobulin binding; ISS:UniProt.
DR   GO; GO:0042605; F:peptide antigen binding; IBA:RefGenome.
DR   GO; GO:0005102; F:receptor binding; IBA:RefGenome.
DR   GO; GO:0046977; F:TAP binding; IDA:UniProt.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0016045; P:detection of bacterium; IMP:UniProtKB.
DR   GO; GO:0006955; P:immune response; IMP:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IDA:UniProt.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disulfide bond; Glycoprotein;
KW   Host-virus interaction; Immunity; Immunoglobulin domain; Membrane;
KW   MHC I; Polymorphism; Reference proteome; Signal; Sulfation;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    365       HLA class I histocompatibility antigen,
FT                                A-1 alpha chain.
FT                                /FTId=PRO_0000018813.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    332       Helical; (Potential).
FT   TOPO_DOM    333    365       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   MOD_RES      83     83       Sulfotyrosine (Potential).
FT   CARBOHYD    110    110       N-linked (GlcNAc...).
FT   DISULFID    125    188
FT   DISULFID    227    283
FT   VARIANT      33     33       F -> S (in allele A*01:02;
FT                                dbSNP:rs2075684).
FT                                /FTId=VAR_004332.
FT   VARIANT      41     41       R -> S (in allele A*01:02).
FT                                /FTId=VAR_004333.
FT   VARIANT      80     80       G -> R (in allele A*01:07).
FT                                /FTId=VAR_016719.
FT   VARIANT      89     89       R -> G (in dbSNP:rs1059459).
FT                                /FTId=VAR_056247.
FT   VARIANT      91     91       M -> V (in allele A*01:07).
FT                                /FTId=VAR_016720.
FT   VARIANT     100    100       A -> E (in allele A*01:07).
FT                                /FTId=VAR_016721.
FT   VARIANT     114    114       D -> A (in allele A*01:07).
FT                                /FTId=VAR_016722.
FT   VARIANT     121    121       I -> M (in allele A*01:03).
FT                                /FTId=VAR_016723.
FT   VARIANT     131    131       G -> W (in dbSNP:rs1136702).
FT                                /FTId=VAR_056248.
FT   VARIANT     133    133       F -> L (in dbSNP:rs1059488).
FT                                /FTId=VAR_056249.
FT   VARIANT     151    151       N -> K (in dbSNP:rs1059509).
FT                                /FTId=VAR_056250.
FT   VARIANT     166    166       I -> T (in dbSNP:rs1059516).
FT                                /FTId=VAR_056251.
FT   VARIANT     169    169       R -> H (in dbSNP:rs1059520).
FT                                /FTId=VAR_056252.
FT   VARIANT     180    180       R -> L (in allele A*01:06).
FT                                /FTId=VAR_016724.
FT   VARIANT     182    182       V -> A (in allele A*01:06).
FT                                /FTId=VAR_016725.
FT   VARIANT     205    205       R -> H (in dbSNP:rs17185861).
FT                                /FTId=VAR_056253.
FT   STRAND       27     36
FT   STRAND       41     43
FT   STRAND       45     52
FT   STRAND       55     61
FT   STRAND       64     66
FT   STRAND       70     73
FT   HELIX        74     76
FT   HELIX        81    109
FT   STRAND      113    115
FT   STRAND      118    127
FT   STRAND      133    142
FT   STRAND      145    150
FT   STRAND      157    159
FT   HELIX       162    173
FT   HELIX       176    185
FT   HELIX       187    198
FT   HELIX       200    203
FT   STRAND      210    217
FT   STRAND      219    235
FT   STRAND      238    243
FT   STRAND      246    248
FT   HELIX       249    251
FT   STRAND      252    254
FT   STRAND      261    263
FT   STRAND      265    274
FT   HELIX       278    280
FT   STRAND      281    286
FT   STRAND      290    292
FT   STRAND      294    296
SQ   SEQUENCE   365 AA;  40846 MW;  8667AFF3F06C4932 CRC64;
     MAVMAPRTLL LLLSGALALT QTWAGSHSMR YFFTSVSRPG RGEPRFIAVG YVDDTQFVRF
     DSDAASQKME PRAPWIEQEG PEYWDQETRN MKAHSQTDRA NLGTLRGYYN QSEDGSHTIQ
     IMYGCDVGPD GRFLRGYRQD AYDGKDYIAL NEDLRSWTAA DMAAQITKRK WEAVHAAEQR
     RVYLEGRCVD GLRRYLENGK ETLQRTDPPK THMTHHPISD HEATLRCWAL GFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDGTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEL
     SSQPTIPIVG IIAGLVLLGA VITGAVVAAV MWRRKSSDRK GGSYTQAASS DSAQGSDVSL
     TACKV
//
ID   1A02_HUMAN              Reviewed;         365 AA.
AC   P01892; O19619; P06338; P10313; P30444; P30445; P30446; P30514;
AC   Q29680; Q29837; Q29899; Q95352; Q95380; Q9TPX8; Q9TPX9; Q9TPY0;
AC   Q9TQH5; Q9TQI3;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   09-JUL-2014, entry version 168.
DE   RecName: Full=HLA class I histocompatibility antigen, A-2 alpha chain;
DE   AltName: Full=MHC class I antigen A*2;
DE   Flags: Precursor;
GN   Name=HLA-A; Synonyms=HLAA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*02:01).
RX   PubMed=2982951;
RA   Koller B.H., Orr H.T.;
RT   "Cloning and complete sequence of an HLA-A2 gene: analysis of two HLA-
RT   A alleles at the nucleotide level.";
RL   J. Immunol. 134:2727-2733(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:01).
RX   PubMed=2914713; DOI=10.1007/BF00395855;
RA   Cianetti L., Testa U., Scotto L., la Valle R., Simeone A., Boccoli G.,
RA   Giannella G., Peschle C., Boncinelli E.;
RT   "Three new class I HLA alleles: structure of mRNAs and alternative
RT   mechanisms of processing.";
RL   Immunogenetics 29:80-91(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:01).
RX   PubMed=2320591; DOI=10.1073/pnas.87.7.2833;
RA   Ennis P.D., Zemmour J., Salter R.D., Parham P.;
RT   "Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction:
RT   frequency and nature of errors produced in amplification.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:2833-2837(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 91-365.
RX   PubMed=3863816;
RA   Davidson W.F., Kress M., Khoury G., Jay G.;
RT   "Comparison of HLA class I gene sequences. Derivation of locus-
RT   specific oligonucleotide probes specific for HLA-A, HLA-B, and HLA-C
RT   genes.";
RL   J. Biol. Chem. 260:13414-13423(1985).
RN   [5]
RP   NUCLEOTIDE SEQUENCE (ALLELES A*02:01; A*02:11 AND A*02:12).
RX   PubMed=1317015; DOI=10.1038/357326a0;
RA   Belich M.P., Madrigal J.A., Hildebrand W.H., Zemmour J.,
RA   Williams R.C., Luz R., Petzl-Erler M.L., Parham P.;
RT   "Unusual HLA-B alleles in two tribes of Brazilian Indians.";
RL   Nature 357:326-329(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 39-365 (ALLELE A*02:01).
RX   PubMed=3874058;
RA   Krangel M.S.;
RT   "Unusual RNA splicing generates a secreted form of HLA-A2 in a
RT   mutagenized B lymphoblastoid cell line.";
RL   EMBO J. 4:1205-1210(1985).
RN   [7]
RP   PROTEIN SEQUENCE OF 25-295 (ALLELE A*02:01).
RX   PubMed=92029; DOI=10.1073/pnas.76.9.4395;
RA   Orr H.T., Lopez de Castro J.A., Parham P., Ploegh H.L.,
RA   Strominger J.L.;
RT   "Comparison of amino acid sequences of two human histocompatibility
RT   antigens, HLA-A2 and HLA-B7: location of putative alloantigenic
RT   sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:4395-4399(1979).
RN   [8]
RP   SEQUENCE REVISION (ALLELE A*02:01).
RX   PubMed=6179086; DOI=10.1073/pnas.79.12.3813;
RA   Lopez de Castro J.A., Strominger J.L., Strong D.M., Orr H.T.;
RT   "Structure of crossreactive human histocompatibility antigens HLA-A28
RT   and HLA-A2: possible implications for the generation of HLA
RT   polymorphism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:3813-3817(1982).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*02:01).
RC   TISSUE=Blood;
RX   PubMed=7836067; DOI=10.1016/0198-8859(94)90087-6;
RA   Balas A., Garcia-Sanchez F., Gomez-Reino F., Vicario J.L.;
RT   "HLA class I allele (HLA-A2) expression defect associated with a
RT   mutation in its enhancer B inverted CAT box in two families.";
RL   Hum. Immunol. 41:69-73(1994).
RN   [10]
RP   SEQUENCE REVISION.
RA   Balas A.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:01).
RA   Cox S.T.;
RT   "Confirmation of HLA-A*0201.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-298 (ALLELES A*02:02 AND
RP   A*02:03).
RX   PubMed=3497874; DOI=10.1007/BF00365911;
RA   Mattson D.H., Handy D.E., Bradley D.A., Coligan J.E., Cowan E.P.,
RA   Biddison W.E.;
RT   "DNA sequences of the genes that encode the CTL-defined HLA-A2
RT   variants M7 and DK1.";
RL   Immunogenetics 26:190-192(1987).
RN   [13]
RP   NUCLEOTIDE SEQUENCE (ALLELES A*02:03 AND A*02:05).
RX   PubMed=3496393;
RA   Holmes N., Ennis P., Wan A.M., Denney D.W., Parham P.;
RT   "Multiple genetic mechanisms have contributed to the generation of the
RT   HLA-A2/A28 family of class I MHC molecules.";
RL   J. Immunol. 139:936-941(1987).
RN   [14]
RP   NUCLEOTIDE SEQUENCE (ALLELES A*02:03 AND A*02:05).
RA   Domena J.D.;
RL   Submitted (NOV-1993) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9-365 (ALLELE A*02:04).
RX   PubMed=1937577; DOI=10.1007/BF00211991;
RA   Castano A.R., Lopez de Castro J.A.;
RT   "Structure of the HLA-A*0204 antigen, found in South American Indians.
RT   Spatial clustering of HLA-A2 subtype polymorphism.";
RL   Immunogenetics 34:281-285(1991).
RN   [16]
RP   NUCLEOTIDE SEQUENCE OF 9-365 (ALLELE A*02:04).
RX   PubMed=1589035; DOI=10.1038/357329a0;
RA   Watkins D.I., McAdam S.N., Liu X., Stang C.R., Milford E.L.,
RA   Levine C.G., Garber T.L., Dogon A.L., Lord C.I., Ghim S.H.,
RA   Troup G.M., Hughes A.L., Letvin N.L.;
RT   "New recombinant HLA-B alleles in a tribe of South American
RT   Amerindians indicate rapid evolution of MHC class I loci.";
RL   Nature 357:329-333(1992).
RN   [17]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:06).
RX   PubMed=2715640;
RA   Parham P., Lawlor D.A., Lomen C.E., Ennis P.D.;
RT   "Diversity and diversification of HLA-A,B,C alleles.";
RL   J. Immunol. 142:3937-3950(1989).
RN   [18]
RP   PARTIAL PROTEIN SEQUENCE (ALLELE A*02:06).
RX   PubMed=3489037;
RA   Ezquerra A., Domenech N., van der Poel J., Strominger J.L., Vega M.A.,
RA   Lopez de Castro J.A.;
RT   "Molecular analysis of an HLA-A2 functional variant CLA defined by
RT   cytolytic T lymphocytes.";
RL   J. Immunol. 137:1642-1649(1986).
RN   [19]
RP   PARTIAL PROTEIN SEQUENCE (ALLELE A*02:07).
RX   PubMed=2448239; DOI=10.1007/BF00346586;
RA   Domenech N., Ezquerra A., Castano R., Lopez de Castro J.A.;
RT   "Structural analysis of HLA-A2.4 functional variant KNE. Implications
RT   for the mapping of HLA-A2-specific T-cell epitopes.";
RL   Immunogenetics 27:196-202(1988).
RN   [20]
RP   PARTIAL PROTEIN SEQUENCE (ALLELE A*02:08).
RX   PubMed=2457548; DOI=10.1007/BF00375853;
RA   Domenech N., Castano R., Goulmy E., Lopez de Castro J.A.;
RT   "Molecular analysis of HLA-A2.4 functional variant KLO: close
RT   structural and evolutionary relatedness to the HLA-A2.2 subtype.";
RL   Immunogenetics 28:143-152(1988).
RN   [21]
RP   PARTIAL PROTEIN SEQUENCE (ALLELE A*02:09).
RX   PubMed=3258580; DOI=10.1007/BF00395130;
RA   Castano R., Ezquerra A., Domenech N., Lopez de Castro J.A.;
RT   "An HLA-A2 population variant with structural polymorphism in the
RT   alpha 3 region.";
RL   Immunogenetics 27:345-355(1988).
RN   [22]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:10).
RX   PubMed=2783680; DOI=10.1007/BF00395859;
RA   Epstein H., Kennedy L., Holmes N.;
RT   "An Oriental HLA-A2 subtype is closely related to a subset of
RT   Caucasoid HLA-A2 alleles.";
RL   Immunogenetics 29:112-116(1989).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9-365 (ALLELE A*02:11).
RX   PubMed=1559719; DOI=10.1007/BF00189898;
RA   Castano A.R., Lopez de Castro J.A.;
RT   "Structure of the HLA-A*0211 (A2.5) subtype: further evidence for
RT   selection-driven diversification of HLA-A2 antigens.";
RL   Immunogenetics 35:344-346(1992).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*02:13).
RX   PubMed=8168863; DOI=10.1007/BF00189243;
RA   Barber D.F., Fernandez J.M., Lopez de Castro J.A.;
RT   "Primary structure of a new HLA-A2 subtype: HLA-A*0213.";
RL   Immunogenetics 39:378-378(1994).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*02:16).
RX   PubMed=7759139; DOI=10.1007/BF00164000;
RA   Barouch D., Krausa P., Bodmer J., Browning M.J., McMichael A.J.;
RT   "Identification of a novel HLA-A2 subtype, HLA-A*0216.";
RL   Immunogenetics 41:388-388(1995).
RN   [26]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*02:17).
RC   TISSUE=Blood;
RX   PubMed=7652742; DOI=10.1111/j.1399-0039.1995.tb02464.x;
RA   Selvakumar A., Granja C.B., Salazar M., Alosco S.M., Yunis E.J.,
RA   Dupont B.;
RT   "A novel subtype of A2 (A*0217) isolated from the South American
RT   Indian B-cell line AMALA.";
RL   Tissue Antigens 45:343-347(1995).
RN   [27]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:18).
RC   TISSUE=Blood;
RA   Kashiwase K., Tokunaga K., Ishikawa Y., Oohashi H., Hashimoto M.,
RA   Akaza T., Tadokoro K., Juji T.;
RT   "A new A2 sequence HLA-A2K from Japanese.";
RL   Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.
RN   [28]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*02:20).
RC   TISSUE=Blood;
RX   PubMed=9008310; DOI=10.1111/j.1399-0039.1996.tb02691.x;
RA   Fleischhauer K., Zino E., Mazzi B., Severini G.M., Benazzi E.,
RA   Bordignon C.;
RT   "HLA-A*02 subtype distribution in Caucasians from northern Italy:
RT   identification of A*0220.";
RL   Tissue Antigens 48:673-679(1996).
RN   [29]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*02:21).
RC   TISSUE=Blood;
RA   Szmania S., Baxter-Lowe L.A.;
RT   "Nucleotide sequence of a novel HLA-A2 gene.";
RL   Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [30]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*02:31).
RX   PubMed=10689125; DOI=10.1016/S0198-8859(99)00155-X;
RA   Ellis J.M., Henson V., Slack R., Ng J., Hartzman R.J., Hurley C.K.;
RT   "Frequencies of HLA-A2 alleles in five U.S. population groups.
RT   Predominance Of A*02011 and identification of HLA-A*0231.";
RL   Hum. Immunol. 61:334-340(2000).
RN   [31]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-298 (ALLELE A*02:34).
RX   PubMed=10746792; DOI=10.1034/j.1399-0039.2000.550212.x;
RA   Moses J.H., Greville W.D., Downes J., McClenahan W., Kennedy A.,
RA   Dunckley H.;
RT   "A new HLA-A*02 allele, A*0234, detected by polymerase chain reaction
RT   using sequence-specific primers (PCR-SSP).";
RL   Tissue Antigens 55:175-177(2000).
RN   [32]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES A*02:35; A*02:36 AND A*02:37).
RX   PubMed=10852390; DOI=10.1034/j.1399-0039.2000.550412.x;
RA   Ellis J., Steiner N.K., Kosman C., Henson V., Mitton W., Koester R.,
RA   Ng J., Hartzman R.J., Hurley C.K.;
RT   "Seventeen more novel HLA-A locus alleles.";
RL   Tissue Antigens 55:369-373(2000).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-356, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [35]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF A*02:01.
RX   PubMed=3309677; DOI=10.1038/329506a0;
RA   Bjorkman P.J., Saper M.A., Samraoui B., Bennett W.S., Strominger J.L.,
RA   Wiley D.C.;
RT   "Structure of the human class I histocompatibility antigen, HLA-A2.";
RL   Nature 329:506-512(1987).
RN   [37]
RP   INTERACTION WITH HTLV-1 ACCESSORY PROTEIN P12I.
RX   PubMed=11390610; DOI=10.1128/JVI.75.13.6086-6094.2001;
RA   Johnson J.M., Nicot C., Fullen J., Ciminale V., Casareto L.,
RA   Mulloy J.C., Jacobson S., Franchini G.;
RT   "Free major histocompatibility complex class I heavy chain is
RT   preferentially targeted for degradation by human T-cell
RT   leukemia/lymphotropic virus type 1 p12(I) protein.";
RL   J. Virol. 75:6086-6094(2001).
RN   [38]
RP   INTERACTION WITH HUMAN HERPESVIRUS 8 MIR1 PROTEIN, AND UBIQUITINATION.
RX   PubMed=12006494; DOI=10.1093/emboj/21.10.2418;
RA   Hewitt E.W., Duncan L., Mufti D., Baker J., Stevenson P.G.,
RA   Lehner P.J.;
RT   "Ubiquitylation of MHC class I by the K3 viral protein signals
RT   internalization and TSG101-dependent degradation.";
RL   EMBO J. 21:2418-2429(2002).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 25-300 OF HLA-A/B2M
RP   HETERODIMER IN COMPLEX WITH TRAC AND TRBC1, AND DISULFIDE BONDS.
RX   PubMed=12796775; DOI=10.1038/ni942;
RA   Stewart-Jones G.B.E., McMichael A.J., Bell J.I., Stuart D.I.,
RA   Jones E.Y.;
RT   "A structural basis for immunodominant human T cell receptor
RT   recognition.";
RL   Nat. Immunol. 4:657-663(2003).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF A*02:01.
RX   PubMed=2038058; DOI=10.1016/0022-2836(91)90567-P;
RA   Saper M.A., Bjorkman P.J., Wiley D.C.;
RT   "Refined structure of the human histocompatibility antigen HLA-A2 at
RT   2.6-A resolution.";
RL   J. Mol. Biol. 219:277-319(1991).
RN   [41]
RP   VARIANT [LARGE SCALE ANALYSIS] GLU-176, VARIANT [LARGE SCALE ANALYSIS]
RP   TRP-180, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Dimer of alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein.
CC       Interacts with HTLV-1 accessory protein p12I.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment through
CC       interaction with human herpesvirus 8 MIR1 protein. This targets
CC       the protein for rapid degradation via the ubiquitin system.
CC   -!- POLYMORPHISM: The following alleles of A-2 are known: A*02:01,
CC       A*02:02, A*02:03, A*02:04, A*02:05, A*02:06 (A2.4A), A*02:07,
CC       A*02:08, A*02:09, A*02:10, A*02:11 (A2.5), A*02:12, A*02:13
CC       (A*02SLU), A*02:16, A*02:17, A*02:18 (A2K), A*02:19, A*02:20,
CC       A*02:21, A*02:31, A*02:34 (A*AAT), A*02:35, A*02:36 and A*02:37.
CC       The sequence shown is that of A*02:01.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA41022.1; Type=Miscellaneous discrepancy; Note=The sequence differs from that shown extensively;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K02883; AAA98727.1; -; Genomic_DNA.
DR   EMBL; M84379; AAA59606.1; -; mRNA.
DR   EMBL; X02457; CAA26297.1; -; mRNA.
DR   EMBL; M11887; AAA52656.1; -; mRNA.
DR   EMBL; M19670; AAA03683.2; -; Genomic_DNA.
DR   EMBL; AH003586; AAB02120.1; -; Genomic_DNA.
DR   EMBL; U03863; AAA03604.1; -; mRNA.
DR   EMBL; M86404; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X57954; CAA41022.1; ALT_SEQ; mRNA.
DR   EMBL; U02935; AAA76608.2; -; Genomic_DNA.
DR   EMBL; AJ555412; CAD87771.1; -; Genomic_DNA.
DR   EMBL; U03862; AAA03603.1; -; mRNA.
DR   EMBL; M24042; AAA59653.1; -; mRNA.
DR   EMBL; Z23071; CAA80612.1; -; mRNA.
DR   EMBL; M84377; AAA59603.1; -; mRNA.
DR   EMBL; X60764; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; M84378; AAA59604.1; -; mRNA.
DR   EMBL; Z27120; CAA81644.1; -; mRNA.
DR   EMBL; Z46633; CAA86602.1; -; mRNA.
DR   EMBL; U18930; AAA87076.1; -; mRNA.
DR   EMBL; D83515; BAA11935.1; -; mRNA.
DR   EMBL; X96724; CAA65501.1; -; mRNA.
DR   EMBL; U56825; AAB17465.1; -; mRNA.
DR   EMBL; AH007560; AAD23437.1; -; Genomic_DNA.
DR   EMBL; AH007704; AAD30272.1; -; Genomic_DNA.
DR   EMBL; AH008013; AAD45690.1; -; Genomic_DNA.
DR   EMBL; AH008012; AAD45689.1; -; Genomic_DNA.
DR   EMBL; AH008007; AAD45324.1; -; Genomic_DNA.
DR   PIR; B24512; HLHU10.
DR   PIR; I37470; I37470.
DR   PIR; I37542; I37542.
DR   PIR; I38418; I38418.
DR   PIR; I38442; I38442.
DR   PIR; I38443; I38443.
DR   PIR; I55948; HLHUA2.
DR   PIR; I61857; I61857.
DR   PIR; I61902; I61902.
DR   PIR; I84448; I84448.
DR   RefSeq; XP_006725814.1; XM_006725751.1.
DR   UniGene; Hs.181244; -.
DR   UniGene; Hs.713441; -.
DR   PDB; 1AKJ; X-ray; 2.65 A; A=25-300.
DR   PDB; 1AO7; X-ray; 2.60 A; A=25-299.
DR   PDB; 1AQD; X-ray; 2.45 A; C/F/I/L=127-141.
DR   PDB; 1B0G; X-ray; 2.50 A; A/D=25-299.
DR   PDB; 1B0R; X-ray; 2.90 A; A=25-299.
DR   PDB; 1BD2; X-ray; 2.50 A; A=25-299.
DR   PDB; 1DUY; X-ray; 2.15 A; A/D=25-299.
DR   PDB; 1DUZ; X-ray; 1.80 A; A/D=25-299.
DR   PDB; 1EEY; X-ray; 2.25 A; A/D=25-299.
DR   PDB; 1EEZ; X-ray; 2.30 A; A/D=25-299.
DR   PDB; 1HHG; X-ray; 2.60 A; A/D=25-299.
DR   PDB; 1HHH; X-ray; 3.00 A; A=25-299.
DR   PDB; 1HHI; X-ray; 2.50 A; A/D=25-299.
DR   PDB; 1HHJ; X-ray; 2.50 A; A/D=25-299.
DR   PDB; 1HHK; X-ray; 2.50 A; A/D=25-299.
DR   PDB; 1HLA; X-ray; 3.50 A; A=25-294.
DR   PDB; 1I1F; X-ray; 2.80 A; A/D=25-299.
DR   PDB; 1I1Y; X-ray; 2.20 A; A/D=25-299.
DR   PDB; 1I4F; X-ray; 1.40 A; A=25-299.
DR   PDB; 1I7R; X-ray; 2.20 A; A/D=25-299.
DR   PDB; 1I7T; X-ray; 2.80 A; A/D=25-299.
DR   PDB; 1I7U; X-ray; 1.80 A; A/D=25-299.
DR   PDB; 1IM3; X-ray; 2.20 A; A/E/I/M=25-299.
DR   PDB; 1JF1; X-ray; 1.85 A; A=25-299.
DR   PDB; 1JHT; X-ray; 2.15 A; A=25-299.
DR   PDB; 1LP9; X-ray; 2.00 A; A/H=25-299.
DR   PDB; 1OGA; X-ray; 1.40 A; A=25-300.
DR   PDB; 1P7Q; X-ray; 3.40 A; A=25-300.
DR   PDB; 1QEW; X-ray; 2.20 A; A=25-299.
DR   PDB; 1QR1; X-ray; 2.40 A; A/D=25-299.
DR   PDB; 1QRN; X-ray; 2.80 A; A=25-298.
DR   PDB; 1QSE; X-ray; 2.80 A; A=25-298.
DR   PDB; 1QSF; X-ray; 2.80 A; A=25-298.
DR   PDB; 1S8D; X-ray; 2.20 A; A=25-299.
DR   PDB; 1S9W; X-ray; 2.20 A; A=25-298.
DR   PDB; 1S9X; X-ray; 2.50 A; A=25-298.
DR   PDB; 1S9Y; X-ray; 2.30 A; A=25-298.
DR   PDB; 1T1W; X-ray; 2.20 A; A=25-299.
DR   PDB; 1T1X; X-ray; 2.20 A; A=25-299.
DR   PDB; 1T1Y; X-ray; 2.00 A; A=25-299.
DR   PDB; 1T1Z; X-ray; 1.90 A; A=25-299.
DR   PDB; 1T20; X-ray; 2.20 A; A=25-299.
DR   PDB; 1T21; X-ray; 2.19 A; A=25-299.
DR   PDB; 1T22; X-ray; 2.20 A; A=25-299.
DR   PDB; 1TVB; X-ray; 1.80 A; A/D=25-299.
DR   PDB; 1TVH; X-ray; 1.80 A; A/D=25-299.
DR   PDB; 1UR7; Model; -; A=25-299.
DR   PDB; 2AV1; X-ray; 1.95 A; A/D=25-299.
DR   PDB; 2AV7; X-ray; 2.05 A; A/D=25-299.
DR   PDB; 2BNQ; X-ray; 1.70 A; A=25-300.
DR   PDB; 2BNR; X-ray; 1.90 A; A=25-300.
DR   PDB; 2C7U; X-ray; 2.38 A; A/D=25-300.
DR   PDB; 2CLR; X-ray; 2.00 A; A/D=25-299.
DR   PDB; 2F53; X-ray; 2.10 A; A=25-299.
DR   PDB; 2F54; X-ray; 2.70 A; A/F=25-298.
DR   PDB; 2GIT; X-ray; 1.70 A; A/D=25-299.
DR   PDB; 2GJ6; X-ray; 2.56 A; A=25-299.
DR   PDB; 2GT9; X-ray; 1.75 A; A/D=25-299.
DR   PDB; 2GTW; X-ray; 1.55 A; A/D=25-299.
DR   PDB; 2GTZ; X-ray; 1.70 A; A/D=25-299.
DR   PDB; 2GUO; X-ray; 1.90 A; A/D=25-299.
DR   PDB; 2J8U; X-ray; 2.88 A; A/H=25-299.
DR   PDB; 2JCC; X-ray; 2.50 A; A/H=25-299.
DR   PDB; 2P5E; X-ray; 1.89 A; A=25-300.
DR   PDB; 2P5W; X-ray; 2.20 A; A=25-300.
DR   PDB; 2PYE; X-ray; 2.30 A; A=25-300.
DR   PDB; 2UWE; X-ray; 2.40 A; A/H=25-299.
DR   PDB; 2V2W; X-ray; 1.60 A; A/D=25-300.
DR   PDB; 2V2X; X-ray; 1.60 A; A/D=25-300.
DR   PDB; 2VLJ; X-ray; 2.40 A; A=25-300.
DR   PDB; 2VLK; X-ray; 2.50 A; A=25-300.
DR   PDB; 2VLL; X-ray; 1.60 A; A/D=25-300.
DR   PDB; 2VLR; X-ray; 2.30 A; A/F=25-300.
DR   PDB; 2X4N; X-ray; 2.34 A; A/D=25-299.
DR   PDB; 2X4O; X-ray; 2.30 A; A/D=25-299.
DR   PDB; 2X4P; X-ray; 2.30 A; A/D=25-299.
DR   PDB; 2X4Q; X-ray; 1.90 A; A/D=25-299.
DR   PDB; 2X4R; X-ray; 2.30 A; A/D=25-299.
DR   PDB; 2X4S; X-ray; 2.55 A; A/D=25-299.
DR   PDB; 2X4T; X-ray; 2.30 A; A/D=25-299.
DR   PDB; 2X4U; X-ray; 2.10 A; A/D=25-299.
DR   PDB; 2X70; X-ray; 2.00 A; A/D=25-299.
DR   PDB; 3BGM; X-ray; 1.60 A; A=25-298.
DR   PDB; 3BH8; X-ray; 1.65 A; A=25-298.
DR   PDB; 3BH9; X-ray; 1.70 A; A=25-299.
DR   PDB; 3BHB; X-ray; 2.20 A; A=25-298.
DR   PDB; 3D25; X-ray; 1.30 A; A=25-298.
DR   PDB; 3D39; X-ray; 2.81 A; A=25-299.
DR   PDB; 3D3V; X-ray; 2.80 A; A=25-299.
DR   PDB; 3FQN; X-ray; 1.65 A; A=25-299.
DR   PDB; 3FQR; X-ray; 1.70 A; A=25-299.
DR   PDB; 3FQT; X-ray; 1.80 A; A=25-299.
DR   PDB; 3FQU; X-ray; 1.80 A; A=25-299.
DR   PDB; 3FQW; X-ray; 1.93 A; A=25-299.
DR   PDB; 3FQX; X-ray; 1.70 A; A=25-299.
DR   PDB; 3FT2; X-ray; 1.80 A; A=25-299.
DR   PDB; 3FT3; X-ray; 1.95 A; A=25-299.
DR   PDB; 3FT4; X-ray; 1.90 A; A=25-299.
DR   PDB; 3GIV; X-ray; 2.00 A; A/D=25-299.
DR   PDB; 3GJF; X-ray; 1.90 A; A/D=25-300.
DR   PDB; 3GSN; X-ray; 2.80 A; H=25-298.
DR   PDB; 3GSO; X-ray; 1.60 A; A=25-298.
DR   PDB; 3GSQ; X-ray; 2.12 A; A=25-298.
DR   PDB; 3GSR; X-ray; 1.95 A; A=25-298.
DR   PDB; 3GSU; X-ray; 1.80 A; A=25-299.
DR   PDB; 3GSV; X-ray; 1.90 A; A=25-299.
DR   PDB; 3GSW; X-ray; 1.81 A; A=25-298.
DR   PDB; 3GSX; X-ray; 2.10 A; A=25-298.
DR   PDB; 3H7B; X-ray; 1.88 A; A/D=25-299.
DR   PDB; 3H9H; X-ray; 2.00 A; A/D=25-299.
DR   PDB; 3H9S; X-ray; 2.70 A; A=25-299.
DR   PDB; 3HAE; X-ray; 2.90 A; A/D/J/P=25-300.
DR   PDB; 3HLA; X-ray; 2.60 A; A=25-294.
DR   PDB; 3HPJ; X-ray; 2.00 A; A/D=25-299.
DR   PDB; 3I6G; X-ray; 2.20 A; A/D=25-299.
DR   PDB; 3I6K; X-ray; 2.80 A; A/E=25-299.
DR   PDB; 3IXA; X-ray; 2.10 A; A/D=25-299.
DR   PDB; 3KLA; X-ray; 1.65 A; A/D=25-299.
DR   PDB; 3MGO; X-ray; 2.30 A; A/D/G/J=25-299.
DR   PDB; 3MGT; X-ray; 2.20 A; A/D/G/J=25-299.
DR   PDB; 3MR9; X-ray; 1.93 A; A=25-300.
DR   PDB; 3MRB; X-ray; 1.40 A; A=25-300.
DR   PDB; 3MRC; X-ray; 1.80 A; A=25-300.
DR   PDB; 3MRD; X-ray; 1.70 A; A=25-300.
DR   PDB; 3MRE; X-ray; 1.10 A; A=25-300.
DR   PDB; 3MRF; X-ray; 2.30 A; A=25-300.
DR   PDB; 3MRG; X-ray; 1.30 A; A=25-300.
DR   PDB; 3MRH; X-ray; 2.40 A; A=25-300.
DR   PDB; 3MRI; X-ray; 2.10 A; A=25-300.
DR   PDB; 3MRJ; X-ray; 1.87 A; A=25-300.
DR   PDB; 3MRK; X-ray; 1.40 A; A=25-300.
DR   PDB; 3MRL; X-ray; 2.41 A; A=25-300.
DR   PDB; 3MRM; X-ray; 1.90 A; A=25-300.
DR   PDB; 3MRN; X-ray; 2.30 A; A=25-300.
DR   PDB; 3MRO; X-ray; 2.35 A; A=25-300.
DR   PDB; 3MRP; X-ray; 2.10 A; A=25-300.
DR   PDB; 3MRQ; X-ray; 2.20 A; A=25-300.
DR   PDB; 3MRR; X-ray; 1.60 A; A=25-300.
DR   PDB; 3MYJ; X-ray; 1.89 A; A/D=25-299.
DR   PDB; 3O3A; X-ray; 1.80 A; A/D=25-299.
DR   PDB; 3O3B; X-ray; 1.90 A; A/D=25-299.
DR   PDB; 3O3D; X-ray; 1.70 A; A/D=25-299.
DR   PDB; 3O3E; X-ray; 1.85 A; A/D=25-299.
DR   PDB; 3O4L; X-ray; 2.54 A; A=25-300.
DR   PDB; 3PWJ; X-ray; 1.70 A; A/D=25-299.
DR   PDB; 3PWL; X-ray; 1.65 A; A/D=25-299.
DR   PDB; 3PWN; X-ray; 1.60 A; A/D=25-299.
DR   PDB; 3PWP; X-ray; 2.69 A; A=25-299.
DR   PDB; 3QDG; X-ray; 2.69 A; A=25-299.
DR   PDB; 3QDJ; X-ray; 2.30 A; A=25-299.
DR   PDB; 3QDM; X-ray; 2.80 A; A=25-299.
DR   PDB; 3QEQ; X-ray; 2.59 A; A=25-299.
DR   PDB; 3QFD; X-ray; 1.68 A; A/D=25-299.
DR   PDB; 3QFJ; X-ray; 2.29 A; A=25-299.
DR   PDB; 3REW; X-ray; 1.90 A; A/D=25-299.
DR   PDB; 3TO2; X-ray; 2.60 A; A=25-299.
DR   PDB; 3UTQ; X-ray; 1.67 A; A=25-300.
DR   PDB; 3UTS; X-ray; 2.71 A; A/F=25-300.
DR   PDB; 3UTT; X-ray; 2.60 A; A/F=25-299.
DR   PDB; 3V5D; X-ray; 2.00 A; A/D=25-299.
DR   PDB; 3V5H; X-ray; 1.63 A; A/D=25-299.
DR   PDB; 3V5K; X-ray; 2.31 A; A/D=25-299.
DR   PDB; 4E5X; X-ray; 1.95 A; A/D=25-299.
DR   PDB; 4EMZ; X-ray; 2.90 A; D/E=338-365.
DR   PDB; 4EN2; X-ray; 2.58 A; D/E=338-365.
DR   PDB; 4EUP; X-ray; 2.88 A; A/D=25-299.
DR   PDB; 4EUQ; X-ray; 2.69 A; A/D=25-299.
DR   PDB; 4FTV; X-ray; 2.74 A; A=25-299.
DR   PDB; 4GKN; X-ray; 2.75 A; A/D=25-300.
DR   PDB; 4GKS; X-ray; 2.35 A; A/D=25-300.
DR   PDB; 4I4W; X-ray; 1.77 A; A=25-300.
DR   PDB; 4JFD; X-ray; 2.46 A; A=25-300.
DR   PDB; 4JFE; X-ray; 2.70 A; A=25-300.
DR   PDB; 4JFF; X-ray; 2.43 A; A=25-300.
DR   PDB; 4JFO; X-ray; 2.11 A; A/D=25-299.
DR   PDB; 4JFP; X-ray; 1.91 A; A/D=25-300.
DR   PDB; 4JFQ; X-ray; 1.90 A; A/D=25-300.
DR   PDB; 4K7F; X-ray; 2.00 A; A/D=25-299.
DR   PDB; 4L29; X-ray; 3.09 A; A/C/E/G/I/K/M/O/Q/S/U/W/Y/a=25-300.
DR   PDB; 4L3C; X-ray; 2.64 A; A/C/E/G/I/K/M/O/Q/S/U/W/Y/a=25-300.
DR   PDB; 4MNQ; X-ray; 2.74 A; A=25-300.
DR   PDBsum; 1AKJ; -.
DR   PDBsum; 1AO7; -.
DR   PDBsum; 1AQD; -.
DR   PDBsum; 1B0G; -.
DR   PDBsum; 1B0R; -.
DR   PDBsum; 1BD2; -.
DR   PDBsum; 1DUY; -.
DR   PDBsum; 1DUZ; -.
DR   PDBsum; 1EEY; -.
DR   PDBsum; 1EEZ; -.
DR   PDBsum; 1HHG; -.
DR   PDBsum; 1HHH; -.
DR   PDBsum; 1HHI; -.
DR   PDBsum; 1HHJ; -.
DR   PDBsum; 1HHK; -.
DR   PDBsum; 1HLA; -.
DR   PDBsum; 1I1F; -.
DR   PDBsum; 1I1Y; -.
DR   PDBsum; 1I4F; -.
DR   PDBsum; 1I7R; -.
DR   PDBsum; 1I7T; -.
DR   PDBsum; 1I7U; -.
DR   PDBsum; 1IM3; -.
DR   PDBsum; 1JF1; -.
DR   PDBsum; 1JHT; -.
DR   PDBsum; 1LP9; -.
DR   PDBsum; 1OGA; -.
DR   PDBsum; 1P7Q; -.
DR   PDBsum; 1QEW; -.
DR   PDBsum; 1QR1; -.
DR   PDBsum; 1QRN; -.
DR   PDBsum; 1QSE; -.
DR   PDBsum; 1QSF; -.
DR   PDBsum; 1S8D; -.
DR   PDBsum; 1S9W; -.
DR   PDBsum; 1S9X; -.
DR   PDBsum; 1S9Y; -.
DR   PDBsum; 1T1W; -.
DR   PDBsum; 1T1X; -.
DR   PDBsum; 1T1Y; -.
DR   PDBsum; 1T1Z; -.
DR   PDBsum; 1T20; -.
DR   PDBsum; 1T21; -.
DR   PDBsum; 1T22; -.
DR   PDBsum; 1TVB; -.
DR   PDBsum; 1TVH; -.
DR   PDBsum; 1UR7; -.
DR   PDBsum; 2AV1; -.
DR   PDBsum; 2AV7; -.
DR   PDBsum; 2BNQ; -.
DR   PDBsum; 2BNR; -.
DR   PDBsum; 2C7U; -.
DR   PDBsum; 2CLR; -.
DR   PDBsum; 2F53; -.
DR   PDBsum; 2F54; -.
DR   PDBsum; 2GIT; -.
DR   PDBsum; 2GJ6; -.
DR   PDBsum; 2GT9; -.
DR   PDBsum; 2GTW; -.
DR   PDBsum; 2GTZ; -.
DR   PDBsum; 2GUO; -.
DR   PDBsum; 2J8U; -.
DR   PDBsum; 2JCC; -.
DR   PDBsum; 2P5E; -.
DR   PDBsum; 2P5W; -.
DR   PDBsum; 2PYE; -.
DR   PDBsum; 2UWE; -.
DR   PDBsum; 2V2W; -.
DR   PDBsum; 2V2X; -.
DR   PDBsum; 2VLJ; -.
DR   PDBsum; 2VLK; -.
DR   PDBsum; 2VLL; -.
DR   PDBsum; 2VLR; -.
DR   PDBsum; 2X4N; -.
DR   PDBsum; 2X4O; -.
DR   PDBsum; 2X4P; -.
DR   PDBsum; 2X4Q; -.
DR   PDBsum; 2X4R; -.
DR   PDBsum; 2X4S; -.
DR   PDBsum; 2X4T; -.
DR   PDBsum; 2X4U; -.
DR   PDBsum; 2X70; -.
DR   PDBsum; 3BGM; -.
DR   PDBsum; 3BH8; -.
DR   PDBsum; 3BH9; -.
DR   PDBsum; 3BHB; -.
DR   PDBsum; 3D25; -.
DR   PDBsum; 3D39; -.
DR   PDBsum; 3D3V; -.
DR   PDBsum; 3FQN; -.
DR   PDBsum; 3FQR; -.
DR   PDBsum; 3FQT; -.
DR   PDBsum; 3FQU; -.
DR   PDBsum; 3FQW; -.
DR   PDBsum; 3FQX; -.
DR   PDBsum; 3FT2; -.
DR   PDBsum; 3FT3; -.
DR   PDBsum; 3FT4; -.
DR   PDBsum; 3GIV; -.
DR   PDBsum; 3GJF; -.
DR   PDBsum; 3GSN; -.
DR   PDBsum; 3GSO; -.
DR   PDBsum; 3GSQ; -.
DR   PDBsum; 3GSR; -.
DR   PDBsum; 3GSU; -.
DR   PDBsum; 3GSV; -.
DR   PDBsum; 3GSW; -.
DR   PDBsum; 3GSX; -.
DR   PDBsum; 3H7B; -.
DR   PDBsum; 3H9H; -.
DR   PDBsum; 3H9S; -.
DR   PDBsum; 3HAE; -.
DR   PDBsum; 3HLA; -.
DR   PDBsum; 3HPJ; -.
DR   PDBsum; 3I6G; -.
DR   PDBsum; 3I6K; -.
DR   PDBsum; 3IXA; -.
DR   PDBsum; 3KLA; -.
DR   PDBsum; 3MGO; -.
DR   PDBsum; 3MGT; -.
DR   PDBsum; 3MR9; -.
DR   PDBsum; 3MRB; -.
DR   PDBsum; 3MRC; -.
DR   PDBsum; 3MRD; -.
DR   PDBsum; 3MRE; -.
DR   PDBsum; 3MRF; -.
DR   PDBsum; 3MRG; -.
DR   PDBsum; 3MRH; -.
DR   PDBsum; 3MRI; -.
DR   PDBsum; 3MRJ; -.
DR   PDBsum; 3MRK; -.
DR   PDBsum; 3MRL; -.
DR   PDBsum; 3MRM; -.
DR   PDBsum; 3MRN; -.
DR   PDBsum; 3MRO; -.
DR   PDBsum; 3MRP; -.
DR   PDBsum; 3MRQ; -.
DR   PDBsum; 3MRR; -.
DR   PDBsum; 3MYJ; -.
DR   PDBsum; 3O3A; -.
DR   PDBsum; 3O3B; -.
DR   PDBsum; 3O3D; -.
DR   PDBsum; 3O3E; -.
DR   PDBsum; 3O4L; -.
DR   PDBsum; 3PWJ; -.
DR   PDBsum; 3PWL; -.
DR   PDBsum; 3PWN; -.
DR   PDBsum; 3PWP; -.
DR   PDBsum; 3QDG; -.
DR   PDBsum; 3QDJ; -.
DR   PDBsum; 3QDM; -.
DR   PDBsum; 3QEQ; -.
DR   PDBsum; 3QFD; -.
DR   PDBsum; 3QFJ; -.
DR   PDBsum; 3REW; -.
DR   PDBsum; 3TO2; -.
DR   PDBsum; 3UTQ; -.
DR   PDBsum; 3UTS; -.
DR   PDBsum; 3UTT; -.
DR   PDBsum; 3V5D; -.
DR   PDBsum; 3V5H; -.
DR   PDBsum; 3V5K; -.
DR   PDBsum; 4E5X; -.
DR   PDBsum; 4EMZ; -.
DR   PDBsum; 4EN2; -.
DR   PDBsum; 4EUP; -.
DR   PDBsum; 4EUQ; -.
DR   PDBsum; 4FTV; -.
DR   PDBsum; 4GKN; -.
DR   PDBsum; 4GKS; -.
DR   PDBsum; 4I4W; -.
DR   PDBsum; 4JFD; -.
DR   PDBsum; 4JFE; -.
DR   PDBsum; 4JFF; -.
DR   PDBsum; 4JFO; -.
DR   PDBsum; 4JFP; -.
DR   PDBsum; 4JFQ; -.
DR   PDBsum; 4K7F; -.
DR   PDBsum; 4L29; -.
DR   PDBsum; 4L3C; -.
DR   PDBsum; 4MNQ; -.
DR   ProteinModelPortal; P01892; -.
DR   SMR; P01892; 25-298.
DR   DIP; DIP-6085N; -.
DR   IntAct; P01892; 12.
DR   MINT; MINT-5000859; -.
DR   PhosphoSite; P01892; -.
DR   DMDM; 122138; -.
DR   MaxQB; P01892; -.
DR   PaxDb; P01892; -.
DR   PRIDE; P01892; -.
DR   Ensembl; ENST00000457879; ENSP00000403575; ENSG00000235657.
DR   Ensembl; ENST00000547271; ENSP00000447962; ENSG00000235657.
DR   GeneID; 3105; -.
DR   GeneCards; GC06P029949; -.
DR   GeneCards; GC06Pk29899; -.
DR   HGNC; HGNC:4931; HLA-A.
DR   MIM; 142800; gene.
DR   neXtProt; NX_P01892; -.
DR   eggNOG; NOG42056; -.
DR   HOVERGEN; HBG016709; -.
DR   Reactome; REACT_116125; Disease.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-A; human.
DR   EvolutionaryTrace; P01892; -.
DR   CleanEx; HS_HLA-A; -.
DR   Genevestigator; P01892; -.
DR   GO; GO:0009986; C:cell surface; IDA:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProt.
DR   GO; GO:0070971; C:endoplasmic reticulum exit site; IDA:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProt.
DR   GO; GO:0005797; C:Golgi medial cisterna; IDA:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0042612; C:MHC class I protein complex; IDA:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030881; F:beta-2-microglobulin binding; IDA:UniProt.
DR   GO; GO:0042605; F:peptide antigen binding; IDA:UniProt.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:BHF-UCL.
DR   GO; GO:0046977; F:TAP binding; IDA:UniProt.
DR   GO; GO:0002486; P:antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent; IDA:UniProt.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; IDA:UniProt.
DR   GO; GO:2000568; P:positive regulation of memory T cell activation; IDA:UniProt.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IDA:UniProt.
DR   GO; GO:0050690; P:regulation of defense response to virus by virus; TAS:Reactome.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Host-virus interaction; Immunity;
KW   Membrane; MHC I; Phosphoprotein; Polymorphism; Reference proteome;
KW   Signal; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    365       HLA class I histocompatibility antigen,
FT                                A-2 alpha chain.
FT                                /FTId=PRO_0000018814.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    332       Helical; (Potential).
FT   TOPO_DOM    333    365       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   MOD_RES     356    356       Phosphoserine.
FT   CARBOHYD    110    110       N-linked (GlcNAc...).
FT   DISULFID    125    188
FT   DISULFID    227    283
FT   VARIANT      33     33       F -> Y (in allele A*02:05, allele
FT                                A*02:06, allele A*02:08, allele A*02:10
FT                                and allele A*02:21).
FT                                /FTId=VAR_004334.
FT   VARIANT      54     54       D -> N (in allele A*02:21).
FT                                /FTId=VAR_004335.
FT   VARIANT      65     65       A -> G (in allele A*02:31).
FT                                /FTId=VAR_016726.
FT   VARIANT      67     67       Q -> R (in allele A*02:02, allele A*02:05
FT                                and allele A*02:08).
FT                                /FTId=VAR_004336.
FT   VARIANT      90     90       K -> N (in allele A*02:08 and allele
FT                                A*02:20).
FT                                /FTId=VAR_004337.
FT   VARIANT      94     94       H -> Q (in allele A*02:34 and allele
FT                                A*02:35).
FT                                /FTId=VAR_016727.
FT   VARIANT      97     97       T -> I (in allele A*02:11).
FT                                /FTId=VAR_004338.
FT   VARIANT      98     98       H -> D (in allele A*02:11 and allele
FT                                A*02:35).
FT                                /FTId=VAR_016728.
FT   VARIANT     119    119       V -> L (in allele A*02:02, allele
FT                                A*02:05, allele A*02:08 and allele
FT                                A*02:17).
FT                                /FTId=VAR_004339.
FT   VARIANT     121    121       R -> M (in allele A*02:04 and allele
FT                                A*02:17).
FT                                /FTId=VAR_004340.
FT   VARIANT     123    123       Y -> C (in allele A*02:07 and allele
FT                                A*02:18).
FT                                /FTId=VAR_004341.
FT   VARIANT     123    123       Y -> F (in allele A*02:10 and allele
FT                                A*02:17).
FT                                /FTId=VAR_004342.
FT   VARIANT     131    131       W -> G (in allele A*02:10).
FT                                /FTId=VAR_004343.
FT   VARIANT     162    162       M -> K (in allele A*02:18).
FT                                /FTId=VAR_004344.
FT   VARIANT     173    173       A -> T (in allele A*02:03).
FT                                /FTId=VAR_004345.
FT   VARIANT     176    176       V -> E (in allele A*02:03 and allele
FT                                A*02:13).
FT                                /FTId=VAR_004346.
FT   VARIANT     180    180       L -> Q (in allele A*02:12, allele A*02:13
FT                                and allele A*02:37).
FT                                /FTId=VAR_004348.
FT   VARIANT     180    180       L -> W (in allele A*02:02, allele
FT                                A*02:03, allele A*02:05 and allele
FT                                A*02:08).
FT                                /FTId=VAR_004347.
FT   VARIANT     187    187       T -> E (in allele A*02:16; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_004349.
FT   VARIANT     190    190       E -> D (in allele A*02:36 and allele
FT                                A*02:37).
FT                                /FTId=VAR_016729.
FT   VARIANT     191    191       W -> G (in allele A*02:36 and allele
FT                                A*02:37).
FT                                /FTId=VAR_016730.
FT   VARIANT     260    260       A -> E (in allele A*02:09).
FT                                /FTId=VAR_004350.
FT   CONFLICT    115    115       G -> V (in Ref. 4; AAA52656).
FT   CONFLICT    140    140       Y -> V (in Ref. 4; AAA52656).
FT   CONFLICT    277    277       Q -> E (in Ref. 4; AAA52656).
FT   CONFLICT    318    318       F -> L (in Ref. 4; AAA52656).
FT   STRAND       27     36
FT   STRAND       41     43
FT   STRAND       45     52
FT   STRAND       55     61
FT   STRAND       64     66
FT   STRAND       70     73
FT   HELIX        74     78
FT   HELIX        81    108
FT   STRAND      113    115
FT   STRAND      118    127
FT   STRAND      131    142
FT   STRAND      145    150
FT   STRAND      157    159
FT   HELIX       162    173
FT   HELIX       176    184
FT   HELIX       187    198
FT   HELIX       200    203
FT   STRAND      210    235
FT   STRAND      238    243
FT   STRAND      246    248
FT   HELIX       249    251
FT   STRAND      252    254
FT   STRAND      261    263
FT   STRAND      265    274
FT   STRAND      275    277
FT   HELIX       278    280
FT   STRAND      281    286
FT   STRAND      290    292
FT   STRAND      294    297
FT   STRAND      348    350
SQ   SEQUENCE   365 AA;  40922 MW;  B54A97B24B337C08 CRC64;
     MAVMAPRTLV LLLSGALALT QTWAGSHSMR YFFTSVSRPG RGEPRFIAVG YVDDTQFVRF
     DSDAASQRME PRAPWIEQEG PEYWDGETRK VKAHSQTHRV DLGTLRGYYN QSEAGSHTVQ
     RMYGCDVGSD WRFLRGYHQY AYDGKDYIAL KEDLRSWTAA DMAAQTTKHK WEAAHVAEQL
     RAYLEGTCVE WLRRYLENGK ETLQRTDAPK THMTHHAVSD HEATLRCWAL SFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDGTFQKWAA VVVPSGQEQR YTCHVQHEGL PKPLTLRWEP
     SSQPTIPIVG IIAGLVLFGA VITGAVVAAV MWRRKSSDRK GGSYSQAASS DSAQGSDVSL
     TACKV
//
ID   1A11_HUMAN              Reviewed;         365 AA.
AC   P13746; O19605; O19606; Q29747; Q29835; Q5S3G1; Q9BCN0; Q9MYI5;
AC   Q9TQE9; Q9TQP6; Q9TQP7;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1990, sequence version 1.
DT   09-JUL-2014, entry version 127.
DE   RecName: Full=HLA class I histocompatibility antigen, A-11 alpha chain;
DE   AltName: Full=MHC class I antigen A*11;
DE   Flags: Precursor;
GN   Name=HLA-A; Synonyms=HLAA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELES A*11:01 AND A*11:02).
RX   PubMed=2460344;
RA   Mayer W.E., Jonker M., Klein D., Ivanyi P., van Seventer G., Klein J.;
RT   "Nucleotide sequences of chimpanzee MHC class I alleles: evidence for
RT   trans-species mode of evolution.";
RL   EMBO J. 7:2765-2774(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELES A*11:01 AND A*11:02).
RX   PubMed=8016845; DOI=10.1111/j.1399-0039.1994.tb02304.x;
RA   Lin L., Tokunaga K., Ishikawa Y., Bannai M., Kashiwase K., Kuwata S.,
RA   Akaza T., Tadokoro K., Shibata Y., Juji T.;
RT   "Sequence analysis of serological HLA-A11 split antigens, A11.1 and
RT   A11.2.";
RL   Tissue Antigens 43:78-82(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*11:05).
RX   PubMed=10395112; DOI=10.1034/j.1399-0039.1999.530612.x;
RA   Morrell G., Whalley J., Stewart A., Day S., Lewis L., Makar Y.,
RA   Ross J., Dunn P.P.;
RT   "Identification of an HLA-A11 serological variant and its
RT   characterization by sequencing based typing.";
RL   Tissue Antigens 53:591-594(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*11:03).
RC   TISSUE=Blood;
RX   PubMed=10703613; DOI=10.1034/j.1399-0039.2000.550113.x;
RA   Tijssen H.J., Sistermans E.A., van den Beucken M.J.G., Krausa P.,
RA   Joosten I.;
RT   "Complete sequence analysis of the A*1103 allele.";
RL   Tissue Antigens 55:68-70(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*11:03).
RC   TISSUE=Blood;
RX   PubMed=10885562; DOI=10.1034/j.1399-0039.2000.550504.x;
RA   Tijssen H.J., Sistermans E.A., Joosten I.;
RT   "A unique second donor splice site in the intron 5 sequence of the
RT   HLA-A*11 alleles results in a class I transcript encoding a molecule
RT   with an elongated cytoplasmic domain.";
RL   Tissue Antigens 55:422-428(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE A*11:05).
RX   PubMed=10852390; DOI=10.1034/j.1399-0039.2000.550412.x;
RA   Ellis J., Steiner N.K., Kosman C., Henson V., Mitton W., Koester R.,
RA   Ng J., Hartzman R.J., Hurley C.K.;
RT   "Seventeen more novel HLA-A locus alleles.";
RL   Tissue Antigens 55:369-373(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*11:07).
RX   PubMed=11703829; DOI=10.1034/j.1399-0039.2001.580309.x;
RA   Pyo C.W., Choi H.B., Han H., Hong Y.S., Kim T.G.;
RT   "Identification of HLA-A*11 variant (A*1107) in the Korean
RT   population.";
RL   Tissue Antigens 58:190-192(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*11:04) (ISOFORM 2).
RX   PubMed=17092262; DOI=10.1111/j.1399-0039.2006.00687.x;
RA   Sun Y., Liu S., Luo Y., Liang F., Xi Y.;
RT   "Identification and frequency of a novel HLA-A allele, A*110104.";
RL   Tissue Antigens 68:453-454(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*11:04) (ISOFORM 2).
RA   Xu L.-H., Chi X.-Y., Jia Q.-T., Li F.-Y., Zha Q.-B., He X.-H.;
RT   "Cloning of high frequency HLA-B alleles from Chinese population.";
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*11:04).
RA   Bettinotti M.P.;
RL   Submitted (MAR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-365 (ALLELE A*11:01).
RX   PubMed=2437024; DOI=10.1007/BF00404694;
RA   Cowan E.P., Jelachich M.L., Biddison W.E., Coligan J.E.;
RT   "DNA sequence of HLA-A11: remarkable homology with HLA-A3 allows
RT   identification of residues involved in epitopes recognized by
RT   antibodies and T cells.";
RL   Immunogenetics 25:241-250(1987).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE A*11:04).
RA   Chandanayingyong D., Sirikong M., Luangtrakool K., Srinak D.,
RA   Rungroung E., Bejchandra S.;
RT   "A11 alleles (A*11O4).";
RL   Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-356, VARIANT [LARGE
RP   SCALE ANALYSIS] SER-345, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 25-299 (ALLELE A*11:01) IN
RP   COMPLEX WITH SARS NUCLEOCAPSID PEPTIDE, AND DISULFIDE BONDS.
RX   PubMed=16041067; DOI=10.1107/S0907444905013090;
RA   Blicher T., Kastrup J.S., Buus S., Gajhede M.;
RT   "High-resolution structure of HLA-A*1101 in complex with SARS
RT   nucleocapsid peptide.";
RL   Acta Crystallogr. D 61:1031-1040(2005).
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-345, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-166, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P13746-1; Sequence=Displayed;
CC       Name=2; Synonyms=Long;
CC         IsoId=P13746-2; Sequence=VSP_008099;
CC         Note=Only produced by allele A*1103;
CC   -!- PTM: Polyubiquitinated in a post ER compartment by interaction
CC       with human herpesvirus 8 MIR1 protein. This targets the protein
CC       for rapid degradation via the ubiquitin system (By similarity).
CC   -!- POLYMORPHISM: The following alleles of A-11 are known: A*11:01 (A-
CC       11E), A*11:02 (A-11K), A*11:03, A*11:04, A*11:05 and A*11:07. The
CC       sequence shown is that of A*11:01.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X13111; CAA31503.1; -; mRNA.
DR   EMBL; X13112; CAA31504.1; -; mRNA.
DR   EMBL; D16841; BAA04117.1; -; mRNA.
DR   EMBL; D16842; BAA04118.1; -; mRNA.
DR   EMBL; AJ306733; CAC37336.1; -; Genomic_DNA.
DR   EMBL; X91399; CAA62745.1; -; mRNA.
DR   EMBL; Y17224; CAB38056.1; -; mRNA.
DR   EMBL; Y17224; CAB38057.1; -; mRNA.
DR   EMBL; AH007763; AAD33991.1; -; Genomic_DNA.
DR   EMBL; AF165065; AAF25781.1; -; mRNA.
DR   EMBL; DQ336694; ABC59611.1; -; mRNA.
DR   EMBL; AY786586; AAV53344.1; -; mRNA.
DR   EMBL; AY786587; AAV53345.1; -; mRNA.
DR   EMBL; U50574; AAB60406.1; -; mRNA.
DR   EMBL; AH003070; AAA65449.1; -; Genomic_DNA.
DR   EMBL; AH005647; AAB87052.1; -; Genomic_DNA.
DR   EMBL; AH005646; AAB87051.1; -; Genomic_DNA.
DR   PIR; I83063; I83063.
DR   PIR; S03536; A47636.
DR   UniGene; Hs.181244; -.
DR   UniGene; Hs.713441; -.
DR   PDB; 1Q94; X-ray; 2.40 A; A/D=25-299.
DR   PDB; 1QVO; X-ray; 2.22 A; A/D=25-299.
DR   PDB; 1X7Q; X-ray; 1.45 A; A=25-299.
DR   PDB; 2HN7; X-ray; 1.60 A; A=25-299.
DR   PDB; 4BEO; X-ray; 2.43 A; A/C=25-299.
DR   PDB; 4N8V; X-ray; 2.50 A; A/D=25-298.
DR   PDBsum; 1Q94; -.
DR   PDBsum; 1QVO; -.
DR   PDBsum; 1X7Q; -.
DR   PDBsum; 2HN7; -.
DR   PDBsum; 4BEO; -.
DR   PDBsum; 4N8V; -.
DR   ProteinModelPortal; P13746; -.
DR   SMR; P13746; 25-299.
DR   DMDM; 122157; -.
DR   MaxQB; P13746; -.
DR   PRIDE; P13746; -.
DR   Ensembl; ENST00000376809; ENSP00000366005; ENSG00000206503.
DR   Ensembl; ENST00000396634; ENSP00000379873; ENSG00000206503.
DR   GeneCards; GC06P029949; -.
DR   HGNC; HGNC:4931; HLA-A.
DR   MIM; 142800; gene.
DR   neXtProt; NX_P13746; -.
DR   HOVERGEN; HBG016709; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-A; human.
DR   EvolutionaryTrace; P13746; -.
DR   PRO; PR:P13746; -.
DR   ArrayExpress; P13746; -.
DR   Bgee; P13746; -.
DR   CleanEx; HS_HLA-A; -.
DR   Genevestigator; P13746; -.
DR   GO; GO:0009986; C:cell surface; IDA:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0042612; C:MHC class I protein complex; ISS:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030881; F:beta-2-microglobulin binding; ISS:UniProt.
DR   GO; GO:0042605; F:peptide antigen binding; IDA:UniProt.
DR   GO; GO:0046977; F:TAP binding; IDA:UniProt.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:InterPro.
DR   GO; GO:0042270; P:protection from natural killer cell mediated cytotoxicity; IDA:UniProt.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Disulfide bond;
KW   Glycoprotein; Host-virus interaction; Immunity; Membrane; MHC I;
KW   Phosphoprotein; Polymorphism; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    365       HLA class I histocompatibility antigen,
FT                                A-11 alpha chain.
FT                                /FTId=PRO_0000018816.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    332       Helical; (Potential).
FT   TOPO_DOM    333    365       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   MOD_RES     356    356       Phosphoserine.
FT   CARBOHYD    110    110       N-linked (GlcNAc...) (By similarity).
FT   DISULFID    125    188
FT   DISULFID    227    283
FT   VAR_SEQ     337    337       S -> SGGEGVK (in isoform 2).
FT                                /FTId=VSP_008099.
FT   VARIANT      43     43       E -> K (in allele A*11:02).
FT                                /FTId=VAR_004353.
FT   VARIANT      89     89       R -> G (in dbSNP:rs1059459).
FT                                /FTId=VAR_056254.
FT   VARIANT      94     94       Q -> H (in dbSNP:rs1059463).
FT                                /FTId=VAR_056255.
FT   VARIANT     101    101       D -> N (in dbSNP:rs1136688).
FT                                /FTId=VAR_056256.
FT   VARIANT     131    131       G -> W (in dbSNP:rs1136702).
FT                                /FTId=VAR_056257.
FT   VARIANT     133    133       F -> L (in allele A*11:07;
FT                                dbSNP:rs1059488).
FT                                /FTId=VAR_016731.
FT   VARIANT     151    151       N -> K (in dbSNP:rs1059509).
FT                                /FTId=VAR_056258.
FT   VARIANT     166    166       I -> T (in dbSNP:rs1059516).
FT                                /FTId=VAR_056259.
FT   VARIANT     168    168       K -> E (in allele A*11:05).
FT                                /FTId=VAR_016732.
FT   VARIANT     169    169       R -> H (in dbSNP:rs1059520).
FT                                /FTId=VAR_056260.
FT   VARIANT     175    175       H -> R (in allele A*11:03).
FT                                /FTId=VAR_016733.
FT   VARIANT     176    176       A -> E (in allele A*11:03).
FT                                /FTId=VAR_016734.
FT   VARIANT     187    187       R -> T (in allele A*11:04).
FT                                /FTId=VAR_016735.
FT   VARIANT     205    205       R -> H (in dbSNP:rs17185861).
FT                                /FTId=VAR_056261.
FT   VARIANT     345    345       T -> S (in allele A*11:05).
FT                                /FTId=VAR_016736.
FT   STRAND       27     36
FT   STRAND       41     43
FT   STRAND       45     52
FT   STRAND       55     61
FT   STRAND       64     66
FT   HELIX        74     76
FT   HELIX        81    108
FT   STRAND      113    115
FT   STRAND      118    127
FT   STRAND      133    142
FT   STRAND      145    150
FT   STRAND      157    159
FT   HELIX       162    173
FT   HELIX       176    185
FT   HELIX       187    198
FT   HELIX       200    203
FT   STRAND      210    217
FT   STRAND      219    235
FT   STRAND      238    243
FT   STRAND      246    248
FT   STRAND      252    254
FT   STRAND      261    263
FT   STRAND      265    274
FT   HELIX       278    280
FT   STRAND      281    286
FT   STRAND      288    292
FT   STRAND      294    297
SQ   SEQUENCE   365 AA;  40937 MW;  FE449CE2D4BF6CC5 CRC64;
     MAVMAPRTLL LLLSGALALT QTWAGSHSMR YFYTSVSRPG RGEPRFIAVG YVDDTQFVRF
     DSDAASQRME PRAPWIEQEG PEYWDQETRN VKAQSQTDRV DLGTLRGYYN QSEDGSHTIQ
     IMYGCDVGPD GRFLRGYRQD AYDGKDYIAL NEDLRSWTAA DMAAQITKRK WEAAHAAEQQ
     RAYLEGRCVE WLRRYLENGK ETLQRTDPPK THMTHHPISD HEATLRCWAL GFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDGTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEL
     SSQPTIPIVG IIAGLVLLGA VITGAVVAAV MWRRKSSDRK GGSYTQAASS DSAQGSDVSL
     TACKV
//
ID   1A24_HUMAN              Reviewed;         365 AA.
AC   P05534; P30448; P30449; Q29908; Q29909; Q29910; Q95355;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   27-JUN-2003, sequence version 2.
DT   09-JUL-2014, entry version 147.
DE   RecName: Full=HLA class I histocompatibility antigen, A-24 alpha chain;
DE   AltName: Full=Aw-24;
DE   AltName: Full=HLA class I histocompatibility antigen, A-9 alpha chain;
DE   AltName: Full=MHC class I antigen A*24;
DE   Flags: Precursor;
GN   Name=HLA-A; Synonyms=HLAA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*2401).
RX   PubMed=2987115; DOI=10.1007/BF00430931;
RA   N'Guyen C., Sodoyer R., Trucy J., Strachan T., Jordan B.R.;
RT   "The HLA-AW24 gene: sequence, surroundings and comparison with the
RT   HLA-A2 and HLA-A3 genes.";
RL   Immunogenetics 21:479-489(1985).
RN   [2]
RP   SEQUENCE REVISION.
RA   Jordan B.R.;
RL   Submitted (JUL-1988) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ALLELES A*24:02 AND
RP   A*24:03).
RX   PubMed=1729171; DOI=10.1007/BF00216625;
RA   Little A.-M., Madrigal J.A., Parham P.;
RT   "Molecular definition of an elusive third HLA-A9 molecule: HLA-A9.3.";
RL   Immunogenetics 35:41-45(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*24:02).
RX   PubMed=1317015; DOI=10.1038/357326a0;
RA   Belich M.P., Madrigal J.A., Hildebrand W.H., Zemmour J.,
RA   Williams R.C., Luz R., Petzl-Erler M.L., Parham P.;
RT   "Unusual HLA-B alleles in two tribes of Brazilian Indians.";
RL   Nature 357:326-329(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*24:02).
RX   PubMed=9349616; DOI=10.1111/j.1399-0039.1997.tb02884.x;
RA   Laforet M., Froelich N., Parissiadis A., Bausinger H., Pfeiffer B.,
RA   Tongio M.M.;
RT   "An intronic mutation responsible for a low level of expression of an
RT   HLA-A*24 allele.";
RL   Tissue Antigens 50:340-346(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*24:08).
RC   TISSUE=Blood;
RA   Kashiwase K., Tokunaga K., Ishikawa Y., Qiu L., Furuya M.,
RA   Sawanaka K., Akaza T., Tadokoro K., Juji T.;
RT   "Sequence analysis of a serological subtype, HLA-A9HH, observed in
RT   Japanese and the confirmatory sequence of A*2408.";
RL   MHC 3:9-14(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-337 (ALLELE A*24:29).
RA   Dunn P.;
RT   "Confirmation of the sequence of HLA-A*2429 allele found in a
RT   potential bone marrow donor.";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE A*24:10).
RC   TISSUE=Blood;
RX   PubMed=9008316; DOI=10.1111/j.1399-0039.1996.tb02697.x;
RA   Gao X., Matheson B.;
RT   "A novel HLA-A*24 (A*2410) identified in a Javanese population.";
RL   Tissue Antigens 48:711-713(1996).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELES A*24:06; A*24:13
RP   AND A*24:14).
RC   TISSUE=Blood;
RX   PubMed=9271829; DOI=10.1111/j.1399-0039.1997.tb02858.x;
RA   Gao X., Lester S., Matheson B., Boettcher B., McCluskey J.;
RT   "Three newly identified A*24 alleles: A*2406, A*2413 and A*2414.";
RL   Tissue Antigens 50:192-196(1997).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-356, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.39 ANGSTROMS) OF 25-298 (ALLELE A*24:02) IN
RP   COMPLEX WITH B2M AND CD8, AND DISULFIDE BONDS.
RX   PubMed=21645925; DOI=10.1016/j.molimm.2011.05.009;
RA   Shi Y., Qi J., Iwamoto A., Gao G.F.;
RT   "Plasticity of human CD8alphaalpha binding to peptide-HLA-A*2402.";
RL   Mol. Immunol. 48:2198-2202(2011).
RN   [14]
RP   VARIANT [LARGE SCALE ANALYSIS] TRP-180, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment by interaction
CC       with human herpesvirus 8 MIR1 protein. This targets the protein
CC       for rapid degradation via the ubiquitin system (By similarity).
CC   -!- POLYMORPHISM: The following alleles of A-24 are known: A*2401,
CC       A*24:02, A*24:03, A*24:06, A*24:08 (A9HH), A*24:10 (A*24JV),
CC       A*24:13 (A*24YM), A*24:14 (A*24SA) and A*24:29. Allele A*24:02 is
CC       represented in all major racial groups. Allele A*24:06 and allele
CC       A*24:13 are found in the Australian Aboriginal population. Allele
CC       A*24:14 is found in individuals of South American descent. The
CC       sequence shown is that of A*24:02.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M15497; AAA59611.1; -; Genomic_DNA.
DR   EMBL; M64740; AAA59600.1; -; mRNA.
DR   EMBL; M64741; AAA59601.1; -; Genomic_DNA.
DR   EMBL; Z72422; CAA96532.1; -; Genomic_DNA.
DR   EMBL; D83516; BAA11936.1; -; mRNA.
DR   EMBL; U37111; AAA83264.1; -; Genomic_DNA.
DR   EMBL; U37110; AAA83264.1; JOINED; Genomic_DNA.
DR   EMBL; U37113; AAA83265.1; -; Genomic_DNA.
DR   EMBL; U37112; AAA83265.1; JOINED; Genomic_DNA.
DR   EMBL; AH004915; AAB40048.1; -; Genomic_DNA.
DR   EMBL; AH005378; AAB60651.1; -; Genomic_DNA.
DR   PIR; I54416; I54416.
DR   UniGene; Hs.181244; -.
DR   UniGene; Hs.713441; -.
DR   PDB; 2BCK; X-ray; 2.80 A; A/D=25-300.
DR   PDB; 3I6L; X-ray; 2.40 A; D=25-298.
DR   PDB; 3NFN; X-ray; 2.39 A; A=25-298.
DR   PDB; 3QZW; X-ray; 2.80 A; A/D=25-298.
DR   PDB; 3VXM; X-ray; 2.50 A; A=25-298.
DR   PDB; 3VXN; X-ray; 1.95 A; A=25-298.
DR   PDB; 3VXO; X-ray; 2.61 A; A/D=25-298.
DR   PDB; 3VXP; X-ray; 2.50 A; A/D=25-298.
DR   PDB; 3VXR; X-ray; 2.40 A; A=25-298.
DR   PDB; 3VXS; X-ray; 1.80 A; A=25-298.
DR   PDB; 3VXU; X-ray; 2.70 A; A/F=25-298.
DR   PDB; 3W0W; X-ray; 2.60 A; A=25-298.
DR   PDB; 4F7M; X-ray; 2.40 A; A/D=25-298.
DR   PDB; 4F7P; X-ray; 1.90 A; A=25-298.
DR   PDB; 4F7T; X-ray; 1.70 A; A/D=25-298.
DR   PDBsum; 2BCK; -.
DR   PDBsum; 3I6L; -.
DR   PDBsum; 3NFN; -.
DR   PDBsum; 3QZW; -.
DR   PDBsum; 3VXM; -.
DR   PDBsum; 3VXN; -.
DR   PDBsum; 3VXO; -.
DR   PDBsum; 3VXP; -.
DR   PDBsum; 3VXR; -.
DR   PDBsum; 3VXS; -.
DR   PDBsum; 3VXU; -.
DR   PDBsum; 3W0W; -.
DR   PDBsum; 4F7M; -.
DR   PDBsum; 4F7P; -.
DR   PDBsum; 4F7T; -.
DR   ProteinModelPortal; P05534; -.
DR   SMR; P05534; 25-298.
DR   DMDM; 32363482; -.
DR   MaxQB; P05534; -.
DR   PaxDb; P05534; -.
DR   PRIDE; P05534; -.
DR   Ensembl; ENST00000431930; ENSP00000406366; ENSG00000229215.
DR   Ensembl; ENST00000443552; ENSP00000404678; ENSG00000224320.
DR   GeneCards; GC06P029949; -.
DR   GeneCards; GC06Pi29846; -.
DR   GeneCards; GC06Pj29898; -.
DR   H-InvDB; HIX0165910; -.
DR   H-InvDB; HIX0165954; -.
DR   H-InvDB; HIX0166079; -.
DR   H-InvDB; HIX0166152; -.
DR   H-InvDB; HIX0166432; -.
DR   H-InvDB; HIX0166685; -.
DR   H-InvDB; HIX0166954; -.
DR   HGNC; HGNC:4931; HLA-A.
DR   MIM; 142800; gene.
DR   neXtProt; NX_P05534; -.
DR   eggNOG; NOG42056; -.
DR   HOVERGEN; HBG016709; -.
DR   PhylomeDB; P05534; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-A; human.
DR   EvolutionaryTrace; P05534; -.
DR   PRO; PR:P05534; -.
DR   CleanEx; HS_HLA-A; -.
DR   Genevestigator; P05534; -.
DR   GO; GO:0009986; C:cell surface; ISS:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0042612; C:MHC class I protein complex; ISS:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030881; F:beta-2-microglobulin binding; ISS:UniProt.
DR   GO; GO:0042605; F:peptide antigen binding; IEA:InterPro.
DR   GO; GO:0046977; F:TAP binding; IDA:UniProt.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:InterPro.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disulfide bond; Glycoprotein;
KW   Host-virus interaction; Immunity; Membrane; MHC I; Phosphoprotein;
KW   Polymorphism; Reference proteome; Signal; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    365       HLA class I histocompatibility antigen,
FT                                A-24 alpha chain.
FT                                /FTId=PRO_0000018818.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    332       Helical; (Potential).
FT   TOPO_DOM    333    365       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   MOD_RES     356    356       Phosphoserine.
FT   CARBOHYD    110    110       N-linked (GlcNAc...).
FT   DISULFID    125    188
FT   DISULFID    227    283
FT   VARIANT       5      5       A -> G (in allele A*2401).
FT                                /FTId=VAR_004354.
FT   VARIANT      27     27       H -> Q (in allele A*24:08;
FT                                dbSNP:rs41541319).
FT                                /FTId=VAR_004355.
FT   VARIANT      86     86       E -> G (in allele A*24:08).
FT                                /FTId=VAR_004356.
FT   VARIANT      89     89       G -> R (in allele A*24:08 and allele
FT                                A*24:29).
FT                                /FTId=VAR_004357.
FT   VARIANT     119    119       L -> V (in allele A*24:14).
FT                                /FTId=VAR_015765.
FT   VARIANT     121    121       M -> R (in allele A*24:14).
FT                                /FTId=VAR_015766.
FT   VARIANT     123    123       F -> Y (in allele A*24:14).
FT                                /FTId=VAR_015767.
FT   VARIANT     131    131       G -> W (in allele A*24:14).
FT                                /FTId=VAR_015768.
FT   VARIANT     180    180       Q -> L (in allele A*24:13).
FT                                /FTId=VAR_015769.
FT   VARIANT     180    180       Q -> W (in allele A*24:06; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_004358.
FT   VARIANT     187    187       T -> R (in allele A*24:10).
FT                                /FTId=VAR_015770.
FT   VARIANT     190    191       DG -> EW (in allele A*24:03 and allele
FT                                A*24:10).
FT                                /FTId=VAR_004359.
FT   VARIANT     205    205       R -> H (in dbSNP:rs17185861).
FT                                /FTId=VAR_056263.
FT   VARIANT     206    206       T -> A (in allele A*2401).
FT                                /FTId=VAR_004360.
FT   STRAND       27     36
FT   TURN         39     41
FT   STRAND       45     52
FT   STRAND       55     61
FT   STRAND       64     66
FT   STRAND       70     73
FT   HELIX        74     78
FT   HELIX        81    109
FT   STRAND      113    115
FT   STRAND      118    127
FT   STRAND      133    142
FT   STRAND      145    150
FT   STRAND      157    159
FT   HELIX       162    173
FT   HELIX       176    185
FT   HELIX       187    198
FT   HELIX       200    203
FT   STRAND      210    217
FT   STRAND      219    235
FT   STRAND      238    246
FT   HELIX       249    251
FT   STRAND      252    254
FT   STRAND      261    263
FT   STRAND      265    274
FT   STRAND      280    286
FT   STRAND      290    292
FT   STRAND      294    296
FT   STRAND      298    300
SQ   SEQUENCE   365 AA;  40689 MW;  D33684D126F98EC3 CRC64;
     MAVMAPRTLV LLLSGALALT QTWAGSHSMR YFSTSVSRPG RGEPRFIAVG YVDDTQFVRF
     DSDAASQRME PRAPWIEQEG PEYWDEETGK VKAHSQTDRE NLRIALRYYN QSEAGSHTLQ
     MMFGCDVGSD GRFLRGYHQY AYDGKDYIAL KEDLRSWTAA DMAAQITKRK WEAAHVAEQQ
     RAYLEGTCVD GLRRYLENGK ETLQRTDPPK THMTHHPISD HEATLRCWAL GFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDGTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP
     SSQPTVPIVG IIAGLVLLGA VITGAVVAAV MWRRNSSDRK GGSYSQAASS DSAQGSDVSL
     TACKV
//
ID   1A30_HUMAN              Reviewed;         365 AA.
AC   P16188; O19598; O62921; P30452; Q9UIP7;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   09-JUL-2014, entry version 120.
DE   RecName: Full=HLA class I histocompatibility antigen, A-30 alpha chain;
DE   AltName: Full=MHC class I antigen A*30;
DE   Flags: Precursor;
GN   Name=HLA-A; Synonyms=HLAA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*30:01).
RX   PubMed=2478623;
RA   Kato K., Trapani J.A., Allopenna J., Dupont B., Yang S.Y.;
RT   "Molecular analysis of the serologically defined HLA-Aw19 antigens. A
RT   genetically distinct family of HLA-A antigens comprising A29, A31,
RT   A32, and Aw33, but probably not A30.";
RL   J. Immunol. 143:3371-3378(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*30:01).
RX   PubMed=7871528; DOI=10.1111/j.1399-0039.1994.tb02393.x;
RA   Olerup O., Daniels T.J., Baxter-Lowe L.;
RT   "Correct sequence of the A*3001 allele obtained by PCR-SSP typing and
RT   automated nucleotide sequencing.";
RL   Tissue Antigens 44:265-267(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*30:02).
RX   PubMed=1431115;
RA   Madrigal J.A., Belich M.P., Hildebrand W.H., Benjamin R.J.,
RA   Little A.-M., Zemmour J., Ennis P.D., Ward F.E., Petzl-Erler M.L.,
RA   Martell R.W., du Toit E.D., Parham P.;
RT   "Distinctive HLA-A,B antigens of black populations formed by
RT   interallelic conversion.";
RL   J. Immunol. 149:3411-3415(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 25-279 (ALLELE A*30:03).
RX   PubMed=8458735; DOI=10.1016/0198-8859(93)90004-K;
RA   Choo S.Y., Starling G.C., Anasetti C., Hansen J.A.;
RT   "Selection of an unrelated donor for marrow transplantation
RT   facilitated by the molecular characterization of a novel HLA-A
RT   allele.";
RL   Hum. Immunol. 36:20-26(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*30:04).
RX   PubMed=8522453; DOI=10.1016/0198-8859(95)00046-7;
RA   Krausa P., Carcassi C., Orru S., Bodmer J.G., Browning M.J., Contu L.;
RT   "Defining the allelic variants of HLA-A30 in the Sardinian population
RT   using amplification refractory mutation system -- polymerase chain
RT   reaction.";
RL   Hum. Immunol. 44:35-42(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 26-206 (ALLELE A*30:04).
RX   PubMed=8838350; DOI=10.1111/j.1399-0039.1995.tb03133.x;
RA   Lienert K., Russ G., Bennett G., Gao X., McCluskey J.;
RT   "HLA-A*3004: a new A30 allele identified in an Australian Caucasoid
RT   population.";
RL   Tissue Antigens 46:394-397(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 28-205 (ALLELE A*30:04).
RX   PubMed=8560452; DOI=10.1111/j.1399-0039.1995.tb02500.x;
RA   Blasczyk R., Wehling J., Paessler M., Hahn U., Huhn D., Salama A.;
RT   "A novel HLA-A30 allele (A*3004) identified by single-strand
RT   conformation polymorphism analysis and confirmed by solid-phase
RT   sequencing.";
RL   Tissue Antigens 46:322-326(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*30:06).
RX   PubMed=11098929; DOI=10.1034/j.1399-0039.2000.560401.x;
RA   Ellis J.M., Mack S.J., Leke R.F.G., Quakyi I., Johnson A.H.,
RA   Hurley C.K.;
RT   "Diversity is demonstrated in class I HLA-A and HLA-B alleles in
RT   Cameroon, Africa: description of HLA-A*03012, *2612, *3006 and HLA-
RT   B*1403, *4016, *4703.";
RL   Tissue Antigens 56:291-302(2000).
RN   [9]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*30:07).
RX   PubMed=10852390; DOI=10.1034/j.1399-0039.2000.550412.x;
RA   Ellis J., Steiner N.K., Kosman C., Henson V., Mitton W., Koester R.,
RA   Ng J., Hartzman R.J., Hurley C.K.;
RT   "Seventeen more novel HLA-A locus alleles.";
RL   Tissue Antigens 55:369-373(2000).
RN   [10]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*30:08).
RX   PubMed=11169261; DOI=10.1034/j.1399-0039.2001.057001070.x;
RA   Cox S.T., Mcwhinnie A.J., Koester R.P., Heine U., Holman R.,
RA   Madrigal A.J., Little A.-M.;
RT   "Further diversity at HLA-A and -B loci identified in Afro-Caribbean
RT   potential bone marrow donors.";
RL   Tissue Antigens 57:70-72(2001).
RN   [11]
RP   VARIANT [LARGE SCALE ANALYSIS] GLY-80, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment by interaction
CC       with human herpesvirus 8 MIR1 protein. This targets the protein
CC       for rapid degradation via the ubiquitin system (By similarity).
CC   -!- POLYMORPHISM: The following alleles of A-30 are known: A*30:01
CC       (A30.3), A*30:02, A*30:03, A*30:04 (A30W7), A*30:06, A*30:07 and
CC       A*30:08. The sequence shown is that of A*30:01.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M30576; AAA59612.1; -; Genomic_DNA.
DR   EMBL; U07234; AAA70162.1; -; mRNA.
DR   EMBL; X61702; CAA43871.1; -; mRNA.
DR   EMBL; M93657; AAA58650.1; -; Genomic_DNA.
DR   EMBL; Z34921; CAA84401.1; -; Genomic_DNA.
DR   EMBL; AH005195; AAB53658.1; -; Genomic_DNA.
DR   EMBL; U24261; AAB50434.1; -; mRNA.
DR   EMBL; X83770; CAA58723.1; -; Genomic_DNA.
DR   EMBL; X83771; CAA58724.1; -; Genomic_DNA.
DR   EMBL; AH006045; AAC14191.1; -; Genomic_DNA.
DR   EMBL; AH006148; AAC18600.1; -; Genomic_DNA.
DR   EMBL; AJ249308; CAB57306.1; -; Genomic_DNA.
DR   EMBL; AJ249309; CAB57306.1; JOINED; Genomic_DNA.
DR   EMBL; AJ249310; CAB57306.1; JOINED; Genomic_DNA.
DR   EMBL; AJ249311; CAB57306.1; JOINED; Genomic_DNA.
DR   EMBL; AJ249312; CAB57306.1; JOINED; Genomic_DNA.
DR   EMBL; AJ249313; CAB57306.1; JOINED; Genomic_DNA.
DR   EMBL; AJ249314; CAB57306.1; JOINED; Genomic_DNA.
DR   EMBL; AJ249315; CAB57306.1; JOINED; Genomic_DNA.
DR   PIR; I38519; I38519.
DR   PIR; I54307; I54307.
DR   PIR; I56039; I56039.
DR   ProteinModelPortal; P16188; -.
DR   SMR; P16188; 25-298.
DR   DMDM; 1345596; -.
DR   MaxQB; P16188; -.
DR   PRIDE; P16188; -.
DR   Ensembl; ENST00000376809; ENSP00000366005; ENSG00000206503.
DR   Ensembl; ENST00000396634; ENSP00000379873; ENSG00000206503.
DR   GeneCards; GC06P029949; -.
DR   HGNC; HGNC:4931; HLA-A.
DR   MIM; 142800; gene.
DR   neXtProt; NX_P16188; -.
DR   HOVERGEN; HBG016709; -.
DR   TreeFam; TF336617; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-A; human.
DR   NextBio; 35537752; -.
DR   ArrayExpress; P16188; -.
DR   Bgee; P16188; -.
DR   CleanEx; HS_HLA-A; -.
DR   Genevestigator; P16188; -.
DR   GO; GO:0009986; C:cell surface; ISS:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0042612; C:MHC class I protein complex; ISS:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030881; F:beta-2-microglobulin binding; ISS:UniProt.
DR   GO; GO:0042605; F:peptide antigen binding; IEA:InterPro.
DR   GO; GO:0046977; F:TAP binding; IDA:UniProt.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:InterPro.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Disulfide bond; Glycoprotein;
KW   Host-virus interaction; Immunity; Membrane; MHC I; Phosphoprotein;
KW   Polymorphism; Reference proteome; Signal; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    365       HLA class I histocompatibility antigen,
FT                                A-30 alpha chain.
FT                                /FTId=PRO_0000018822.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    332       Helical; (Potential).
FT   TOPO_DOM    333    365       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   MOD_RES     356    356       Phosphoserine (By similarity).
FT   CARBOHYD    110    110       N-linked (GlcNAc...) (By similarity).
FT   DISULFID    125    188       By similarity.
FT   DISULFID    227    283       By similarity.
FT   VARIANT      21     21       H -> Q (in allele A*30:02, allele A*30:04
FT                                and allele A*30:08).
FT                                /FTId=VAR_004366.
FT   VARIANT      33     33       S -> Y (in allele A*30:08).
FT                                /FTId=VAR_010284.
FT   VARIANT      55     55       T -> A (in allele A*30:06).
FT                                /FTId=VAR_016653.
FT   VARIANT      80     80       R -> G (in allele A*30:03).
FT                                /FTId=VAR_004367.
FT   VARIANT      86     86       Q -> E (in allele A*30:07).
FT                                /FTId=VAR_016738.
FT   VARIANT      89     90       RN -> GK (in allele A*30:07).
FT                                /FTId=VAR_016739.
FT   VARIANT      89     89       R -> G (in dbSNP:rs1059459).
FT                                /FTId=VAR_056271.
FT   VARIANT      94     94       Q -> H (in allele A*30:02, allele
FT                                A*30:03, allele A*30:04, allele A*30:06
FT                                and allele A*30:07; dbSNP:rs1059463).
FT                                /FTId=VAR_004368.
FT   VARIANT     100    101       VD -> EN (in allele A*30:02, allele
FT                                A*30:03, allele A*30:04, allele A*30:06
FT                                and allele A*30:07).
FT                                /FTId=VAR_004369.
FT   VARIANT     101    101       D -> N (in dbSNP:rs1136688).
FT                                /FTId=VAR_056272.
FT   VARIANT     121    121       I -> M (in dbSNP:rs1136695).
FT                                /FTId=VAR_056273.
FT   VARIANT     129    129       S -> P (in dbSNP:rs1136700).
FT                                /FTId=VAR_056274.
FT   VARIANT     131    131       G -> W (in dbSNP:rs1136702).
FT                                /FTId=VAR_056275.
FT   VARIANT     133    133       F -> L (in dbSNP:rs1059488).
FT                                /FTId=VAR_056276.
FT   VARIANT     151    151       N -> K (in dbSNP:rs1059509).
FT                                /FTId=VAR_056277.
FT   VARIANT     166    166       I -> T (in dbSNP:rs1059516).
FT                                /FTId=VAR_056278.
FT   VARIANT     175    176       RW -> HV (in allele A*30:04 and allele
FT                                A*30:06).
FT                                /FTId=VAR_004370.
FT   VARIANT     176    176       W -> R (in allele A*30:02, allele A*30:03
FT                                and allele A*30:07).
FT                                /FTId=VAR_004371.
FT   VARIANT     180    180       L -> W (in allele A*30:04 and allele
FT                                A*30:06).
FT                                /FTId=VAR_004372.
FT   VARIANT     205    205       R -> H (in dbSNP:rs17185861).
FT                                /FTId=VAR_056279.
FT   CONFLICT     33     33       S -> F (in Ref. 1; AAA59612).
SQ   SEQUENCE   365 AA;  40905 MW;  521166D95FB1DC28 CRC64;
     MAVMAPRTLL LLLSGALALT HTWAGSHSMR YFSTSVSRPG SGEPRFIAVG YVDDTQFVRF
     DSDAASQRME PRAPWIEQER PEYWDQETRN VKAQSQTDRV DLGTLRGYYN QSEAGSHTIQ
     IMYGCDVGSD GRFLRGYEQH AYDGKDYIAL NEDLRSWTAA DMAAQITQRK WEAARWAEQL
     RAYLEGTCVE WLRRYLENGK ETLQRTDPPK THMTHHPISD HEATLRCWAL GFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDGTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEL
     SSQPTIPIVG IIAGLVLLGA VITGAVVAAV MWRRKSSDRK GGSYTQAASS DSAQGSDVSL
     TACKV
//
ID   1A68_HUMAN              Reviewed;         365 AA.
AC   P01891; O19673; O19695; O19794; O19795; O43907; O77938; O98010;
AC   P10315; P79505; Q9MYA5; Q9MYC4; Q9TQG7; Q9TQN5; Q9UIN2;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-FEB-2001, sequence version 4.
DT   09-JUL-2014, entry version 144.
DE   RecName: Full=HLA class I histocompatibility antigen, A-68 alpha chain;
DE   AltName: Full=Aw-68;
DE   AltName: Full=HLA class I histocompatibility antigen, A-28 alpha chain;
DE   AltName: Full=MHC class I antigen A*68;
DE   Flags: Precursor;
GN   Name=HLA-A; Synonyms=HLAA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*68:02).
RX   PubMed=3496393;
RA   Holmes N., Ennis P., Wan A.M., Denney D.W., Parham P.;
RT   "Multiple genetic mechanisms have contributed to the generation of the
RT   HLA-A2/A28 family of class I MHC molecules.";
RL   J. Immunol. 139:936-941(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*68:02).
RA   Domena J.D.;
RL   Submitted (NOV-1993) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE A*68:03).
RX   PubMed=8881043; DOI=10.1007/s002510050172;
RA   Ellexson M., Lau M., Terasaki P., Hildebrand W.H.;
RT   "Molecular characterization of HLA-A*6803.";
RL   Immunogenetics 45:78-79(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*68:08).
RX   PubMed=10395114; DOI=10.1034/j.1399-0039.1999.530614.x;
RA   Cox S.T., Arguello J.R., Marsh S.G.E., Boham E., Lau M., Kwan P.L.,
RA   Madrigal J.A., Little A.-M.;
RT   "Sequence of HLA-A*6808.";
RL   Tissue Antigens 53:597-600(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE (ALLELE A*68:011).
RC   TISSUE=Blood;
RA   Cox S.T.;
RT   "Confirmation of HLA-A*68011.";
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*68:17).
RX   PubMed=10885567; DOI=10.1034/j.1399-0039.2000.550509.x;
RA   Ramon D., Scott I., Cox S.T., Pesoa S., Vullo C., Little A.-M.,
RA   Madrigal J.A.;
RT   "HLA-A*6817, identified in the Kolla Amerindians of north-west
RT   Argentina possesses a novel nucleotide substitution.";
RL   Tissue Antigens 55:453-454(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*68:06).
RA   Bei M., Hurley C.K.;
RL   Submitted (FEB-1997) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE A*68:03).
RC   TISSUE=Blood;
RX   PubMed=9271640; DOI=10.1007/s002510050304;
RA   Vargas-Alarcon G., Martinez-Laso J., Gomez-Casado E., Perez-Blas M.,
RA   Granados J., Alegre R., Alvarez M., Zuniga J., Arnaiz-Villena A.;
RT   "Description of HLA-A*6803 and A*68N in Mazatecan Indians from
RT   Mexico.";
RL   Immunogenetics 46:446-447(1997).
RN   [9]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*68:03).
RC   TISSUE=Blood;
RA   Blasczyk R.;
RL   Submitted (AUG-1997) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE A*68:02).
RA   Edson S.M., Hurley C.K.;
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES A*68:09 AND A*68:10).
RX   PubMed=10852390; DOI=10.1034/j.1399-0039.2000.550412.x;
RA   Ellis J., Steiner N.K., Kosman C., Henson V., Mitton W., Koester R.,
RA   Ng J., Hartzman R.J., Hurley C.K.;
RT   "Seventeen more novel HLA-A locus alleles.";
RL   Tissue Antigens 55:369-373(2000).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3-206 (ALLELE A*68:16).
RX   PubMed=10803837; DOI=10.1007/s002510050618;
RA   Gomez-Casado E., Martinez-Laso J., Gonzalez-Hevilla M., Longas J.,
RA   Rubio I., Silvera-Redondo C., Garcia-Gomez A., Lowy E.,
RA   Arnaiz-Villena A.;
RT   "A novel HLA-A*6816 allele possible generated by a point mutation in a
RT   Chilean from Punta Arenas (Magellan Strait).";
RL   Immunogenetics 51:257-260(2000).
RN   [13]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES A*68:07 AND A*68:17).
RX   PubMed=11260503; DOI=10.1034/j.1399-0039.2001.057002095.x;
RA   Hickman H.D., Cavett J.W., Ellexson-Turner M.E., Sparkman J.N.,
RA   Bennett T.T., Turner S., Sidebottom D.A., Trachtenberg E.A.,
RA   Confer D.L., Hildebrand W.H.;
RT   "Non-conservative substitutions distinguish previously uncharacterized
RT   HLA-A molecules.";
RL   Tissue Antigens 57:95-102(2001).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-297 (ALLELE A*68:01).
RX   PubMed=3877632;
RA   Holmes N., Parham P.;
RT   "Exon shuffling in vivo can generate novel HLA class I molecules.";
RL   EMBO J. 4:2849-2854(1985).
RN   [15]
RP   PROTEIN SEQUENCE OF 25-294 (A*68:01).
RX   PubMed=6179086; DOI=10.1073/pnas.79.12.3813;
RA   Lopez de Castro J.A., Strominger J.L., Strong D.M., Orr H.T.;
RT   "Structure of crossreactive human histocompatibility antigens HLA-A28
RT   and HLA-A2: possible implications for the generation of HLA
RT   polymorphism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:3813-3817(1982).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-356, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 25-294 (A*68:01).
RX   PubMed=1448153; DOI=10.1038/360364a0;
RA   Guo H.-C., Jardetzky T.S., Garrett T.P.J., Lane W.S., Strominger J.L.,
RA   Wiley D.C.;
RT   "Different length peptides bind to HLA-Aw68 similarly at their ends
RT   but bulge out in the middle.";
RL   Nature 360:364-366(1992).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 25-294 (A*68:01).
RX   PubMed=1448154; DOI=10.1038/360367a0;
RA   Silver M.L., Guo H.-C., Strominger J.L., Wiley D.C.;
RT   "Atomic structure of a human MHC molecule presenting an influenza
RT   virus peptide.";
RL   Nature 360:367-369(1992).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 25-199 (A*68:01).
RX   PubMed=7862664; DOI=10.1073/pnas.92.4.1218;
RA   Collins E.J., Garboczi D.N., Karpusas M.N., Wiley D.C.;
RT   "The three-dimensional structure of a class I major histocompatibility
RT   complex molecule missing the alpha 3 domain of the heavy chain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:1218-1221(1995).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment by interaction
CC       with human herpesvirus 8 MIR1 protein. This targets the protein
CC       for rapid degradation via the ubiquitin system (By similarity).
CC   -!- POLYMORPHISM: The following alleles of A-68 are known: A*68:01
CC       (Aw68.1), A*68:02, A*68:03. A*68:04, A*68:05, A*68:06, A*68:07,
CC       A*68:08, A*68:09, A*68:10, A*68:16 and A*68:17. The sequence shown
CC       is that of A*68:01.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U03861; AAA03602.1; -; mRNA.
DR   EMBL; X03070; CAB56605.1; -; Genomic_DNA.
DR   EMBL; X03071; CAB56606.1; -; Genomic_DNA.
DR   EMBL; U41057; AAB41292.1; -; mRNA.
DR   EMBL; AJ315642; CAC44382.1; -; Genomic_DNA.
DR   EMBL; AF144013; AAF74211.1; -; Genomic_DNA.
DR   EMBL; AJ245567; CAB59722.1; -; Genomic_DNA.
DR   EMBL; AH005127; AAB50567.1; -; Genomic_DNA.
DR   EMBL; U89946; AAB82079.1; -; Genomic_DNA.
DR   EMBL; U89947; AAB82080.1; -; Genomic_DNA.
DR   EMBL; AJ001274; CAA04647.1; -; mRNA.
DR   EMBL; AH006296; AAC25782.1; -; Genomic_DNA.
DR   EMBL; AH007538; AAD22270.1; -; Genomic_DNA.
DR   EMBL; AH007605; AAD27539.1; -; Genomic_DNA.
DR   EMBL; AJ223972; CAA11708.1; -; Genomic_DNA.
DR   EMBL; AH007201; AAD02208.1; -; Genomic_DNA.
DR   EMBL; AH009406; AAF73477.1; -; Genomic_DNA.
DR   PIR; A02187; HLHU28.
DR   PIR; A24671; HLHUAW.
DR   PIR; I38441; I38441.
DR   UniGene; Hs.181244; -.
DR   UniGene; Hs.713441; -.
DR   PDB; 1HSB; X-ray; 1.90 A; A=25-294.
DR   PDB; 1TMC; X-ray; 2.30 A; A=25-199.
DR   PDB; 2HLA; X-ray; 2.60 A; A=25-294.
DR   PDB; 4HWZ; X-ray; 2.40 A; A=25-298.
DR   PDB; 4HX1; X-ray; 1.80 A; A=25-296.
DR   PDB; 4I48; X-ray; 2.80 A; A=25-296.
DR   PDBsum; 1HSB; -.
DR   PDBsum; 1TMC; -.
DR   PDBsum; 2HLA; -.
DR   PDBsum; 4HWZ; -.
DR   PDBsum; 4HX1; -.
DR   PDBsum; 4I48; -.
DR   ProteinModelPortal; P01891; -.
DR   SMR; P01891; 25-294.
DR   MINT; MINT-274751; -.
DR   DMDM; 13124681; -.
DR   MaxQB; P01891; -.
DR   PRIDE; P01891; -.
DR   Ensembl; ENST00000457879; ENSP00000403575; ENSG00000235657.
DR   GeneCards; GC06P029949; -.
DR   GeneCards; GC06Pk29899; -.
DR   HGNC; HGNC:4931; HLA-A.
DR   MIM; 142800; gene.
DR   neXtProt; NX_P01891; -.
DR   HOVERGEN; HBG016709; -.
DR   PhylomeDB; P01891; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-A; human.
DR   EvolutionaryTrace; P01891; -.
DR   CleanEx; HS_HLA-A; -.
DR   Genevestigator; P01891; -.
DR   GO; GO:0009986; C:cell surface; ISS:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0042612; C:MHC class I protein complex; ISS:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030881; F:beta-2-microglobulin binding; ISS:UniProt.
DR   GO; GO:0042605; F:peptide antigen binding; IEA:InterPro.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProt.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:InterPro.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Host-virus interaction; Immunity;
KW   Membrane; MHC I; Phosphoprotein; Polymorphism; Reference proteome;
KW   Signal; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    365       HLA class I histocompatibility antigen,
FT                                A-68 alpha chain.
FT                                /FTId=PRO_0000018830.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    332       Helical; (Potential).
FT   TOPO_DOM    333    365       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   MOD_RES     356    356       Phosphoserine.
FT   CARBOHYD    110    110       N-linked (GlcNAc...).
FT   DISULFID    125    188
FT   DISULFID    227    283
FT   VARIANT      36     36       V -> M (in allele A*68:02).
FT                                /FTId=VAR_004389.
FT   VARIANT      86     87       RN -> EE (in allele A*68:10).
FT                                /FTId=VAR_010362.
FT   VARIANT      89     89       R -> G (in dbSNP:rs1059459).
FT                                /FTId=VAR_056304.
FT   VARIANT      94     94       Q -> H (in allele A*68:03, allele A*68:04
FT                                and allele A*68:05; dbSNP:rs1059463).
FT                                /FTId=VAR_010363.
FT   VARIANT      97     97       T -> I (in allele A*68:04).
FT                                /FTId=VAR_010364.
FT   VARIANT      98     98       D -> H (in allele A*68:05).
FT                                /FTId=VAR_010365.
FT   VARIANT     101    101       D -> N (in dbSNP:rs1136688).
FT                                /FTId=VAR_056305.
FT   VARIANT     121    121       M -> R (in allele A*68:02).
FT                                /FTId=VAR_004390.
FT   VARIANT     129    129       S -> P (in allele A*68:02;
FT                                dbSNP:rs1136700).
FT                                /FTId=VAR_004391.
FT   VARIANT     133    133       F -> L (in dbSNP:rs1059488).
FT                                /FTId=VAR_056306.
FT   VARIANT     138    138       R -> E (in allele A*68:06; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_010366.
FT   VARIANT     138    138       R -> H (in allele A*68:02).
FT                                /FTId=VAR_004392.
FT   VARIANT     140    140       D -> H (in allele A*68:06 and allele
FT                                A*68:07).
FT                                /FTId=VAR_010367.
FT   VARIANT     140    140       D -> V (in allele A*68:17).
FT                                /FTId=VAR_010368.
FT   VARIANT     140    140       D -> Y (in allele A*68:02).
FT                                /FTId=VAR_004393.
FT   VARIANT     175    175       H -> L (in allele A*68:16).
FT                                /FTId=VAR_010369.
FT   VARIANT     180    180       W -> L (in allele A*68:08).
FT                                /FTId=VAR_010370.
FT   VARIANT     180    180       W -> Q (in allele A*68:09; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_010371.
FT   CONFLICT    206    206       T -> A (in Ref. 12; AAF74211).
FT   CONFLICT    231    231       S -> G (in Ref. 15; AA sequence).
FT   STRAND       27     36
FT   STRAND       41     43
FT   STRAND       45     52
FT   STRAND       55     61
FT   STRAND       64     66
FT   HELIX        74     76
FT   HELIX        81    108
FT   STRAND      113    115
FT   STRAND      118    127
FT   STRAND      133    142
FT   STRAND      145    150
FT   STRAND      154    161
FT   HELIX       162    173
FT   HELIX       176    185
FT   HELIX       187    198
FT   HELIX       200    203
FT   STRAND      210    217
FT   STRAND      219    235
FT   STRAND      238    243
FT   STRAND      246    248
FT   STRAND      252    254
FT   STRAND      261    263
FT   STRAND      265    274
FT   HELIX       278    280
FT   STRAND      281    286
FT   STRAND      290    292
FT   STRAND      294    296
SQ   SEQUENCE   365 AA;  40909 MW;  78539C59DB8B1DFC CRC64;
     MAVMAPRTLV LLLSGALALT QTWAGSHSMR YFYTSVSRPG RGEPRFIAVG YVDDTQFVRF
     DSDAASQRME PRAPWIEQEG PEYWDRNTRN VKAQSQTDRV DLGTLRGYYN QSEAGSHTIQ
     MMYGCDVGSD GRFLRGYRQD AYDGKDYIAL KEDLRSWTAA DMAAQTTKHK WEAAHVAEQW
     RAYLEGTCVE WLRRYLENGK ETLQRTDAPK THMTHHAVSD HEATLRCWAL SFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDGTFQKWVA VVVPSGQEQR YTCHVQHEGL PKPLTLRWEP
     SSQPTIPIVG IIAGLVLFGA VITGAVVAAV MWRRKSSDRK GGSYSQAASS DSAQGSDVSL
     TACKV
//
ID   1B07_HUMAN              Reviewed;         362 AA.
AC   P01889; Q29638; Q29681; Q29854; Q29861; Q31613; Q5SRJ2; Q9GIX1;
AC   Q9TP95;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 3.
DT   09-JUL-2014, entry version 151.
DE   RecName: Full=HLA class I histocompatibility antigen, B-7 alpha chain;
DE   AltName: Full=MHC class I antigen B*7;
DE   Flags: Precursor;
GN   Name=HLA-B; Synonyms=HLAB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:02).
RX   PubMed=2320591; DOI=10.1073/pnas.87.7.2833;
RA   Ennis P.D., Zemmour J., Salter R.D., Parham P.;
RT   "Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction:
RT   frequency and nature of errors produced in amplification.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:2833-2837(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*07:02).
RX   PubMed=2700944;
RA   Parham P., Benjamin R.J., Chen B.P., Clayberger C., Ennis P.D.,
RA   Krensky A.M., Lawlor D.A., Littman D.R., Norment A.M., Orr H.T.,
RA   Salter R.D., Zemmour J.;
RT   "Diversity of class I HLA molecules: functional and evolutionary
RT   interactions with T cells.";
RL   Cold Spring Harb. Symp. Quant. Biol. 54:529-543(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:02).
RX   PubMed=2993161; DOI=10.1007/BF00563508;
RA   Sood A.K., Pan J., Biro P.A., Pereira D., Srivastava R., Reddy V.B.,
RA   Duceman B.W., Weissman S.M.;
RT   "Structure and polymorphism of class I MHC antigen mRNA.";
RL   Immunogenetics 22:101-121(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*07:02).
RA   Ellexson M.E., Zhang L., Hildebrand W.H.;
RL   Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:03).
RX   PubMed=8106270; DOI=10.1016/0198-8859(93)90533-7;
RA   Bergmans A., Tijssen H., Lardy J., Reekers P.;
RT   "Complete nucleotide sequence of HLA-B*0703, a B7-variant (BPOT).";
RL   Hum. Immunol. 38:159-162(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:04).
RX   PubMed=7652739; DOI=10.1111/j.1399-0039.1995.tb02461.x;
RA   Kubens B.S., Arnett K.L., Adams E.J., Parham P., Grosse-Wilde H.;
RT   "Definition of a new HLA-B7 subtype (B*0704) by isoelectric focusing,
RT   family studies and DNA sequence analysis.";
RL   Tissue Antigens 45:322-327(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:05).
RX   PubMed=7878658; DOI=10.1111/j.1399-0039.1994.tb02402.x;
RA   Arnett K.L., Adams E.J., Domena J.D., Parham P.;
RT   "Structure of a novel subtype of B7 (B*0705) isolated from a Chinese
RT   individual.";
RL   Tissue Antigens 44:318-321(1994).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*07:03 AND B*07:05).
RX   PubMed=8537119;
RA   Smith K.D., Epperson D.F., Lutz C.T.;
RT   "Alloreactive cytotoxic T-lymphocyte-defined HLA-B7 subtypes differ in
RT   peptide antigen presentation.";
RL   Immunogenetics 43:27-37(1996).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:06).
RX   PubMed=8773323; DOI=10.1111/j.1399-0039.1996.tb02561.x;
RA   Sanz L., Vilches C., de Pablo R., Bunce M., Moreno M.E., Kreisler M.;
RT   "Haplotypic association of two new HLA class I alleles: Cw*15052 and
RT   B*0706: evolutionary relationships of HLA-Cw*15 alleles.";
RL   Tissue Antigens 47:329-332(1996).
RN   [10]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*07:18).
RA   Bettinotti M.P., Hadzikadic L., Dhillon G., Barracchini K.,
RA   Marincola F.M.;
RT   "A new HLA-B allele.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*07:02).
RA   Marsh S.G.E.;
RT   "Intron sequences of HLA class I.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*07:02).
RC   TISSUE=Blood;
RX   PubMed=12622774; DOI=10.1034/j.1399-0039.2003.610103.x;
RA   Cox S.T., McWhinnie A.J., Robinson J., Marsh S.G.E., Parham P.,
RA   Madrigal J.A., Little A.-M.;
RT   "Cloning and sequencing full-length HLA-B and -C genes.";
RL   Tissue Antigens 61:20-48(2003).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Subthalamic nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*07:24).
RC   TISSUE=Peripheral blood;
RX   PubMed=11556973; DOI=10.1034/j.1399-0039.2001.057005471.x;
RA   Middleton D., Curran M.D., Anholts J.D., Reilly E.R., Schreuder G.M.;
RT   "Characterisation of a new HLA-B allele, HLA-B*0724.";
RL   Tissue Antigens 57:471-473(2001).
RN   [16]
RP   PROTEIN SEQUENCE OF 25-295 (B*07:02).
RX   PubMed=518865; DOI=10.1021/bi00592a030;
RA   Orr H.T., Lopez de Castro J.A., Lancet D., Strominger J.L.;
RT   "Complete amino acid sequence of a papain-solubilized human
RT   histocompatibility antigen, HLA-B7. 2. Sequence determination and
RT   search for homologies.";
RL   Biochemistry 18:5711-5720(1979).
RN   [17]
RP   INTERACTION WITH HTLV-1 ACCESSORY PROTEIN P12I.
RX   PubMed=11390610; DOI=10.1128/JVI.75.13.6086-6094.2001;
RA   Johnson J.M., Nicot C., Fullen J., Ciminale V., Casareto L.,
RA   Mulloy J.C., Jacobson S., Franchini G.;
RT   "Free major histocompatibility complex class I heavy chain is
RT   preferentially targeted for degradation by human T-cell
RT   leukemia/lymphotropic virus type 1 p12(I) protein.";
RL   J. Virol. 75:6086-6094(2001).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [19]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-65, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity). Interacts with HTLV-1 accessory protein p12I.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment by interaction
CC       with human herpesvirus 8 MIR1 protein. This targets the protein
CC       for rapid degradation via the ubiquitin system (By similarity).
CC   -!- POLYMORPHISM: The following alleles of B-7 are known: B*07:02
CC       (B7.2), B*07:03 (BPOT), B*07:04, B*07:05, B*07:06 (B7_L79),
CC       B*07:18 and B*07:24. The sequence shown is B*07:02.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M32317; AAA36230.1; -; mRNA.
DR   EMBL; M16102; AAA59622.1; ALT_SEQ; mRNA.
DR   EMBL; U29057; AAA91229.1; -; mRNA.
DR   EMBL; X64454; CAA45785.1; -; mRNA.
DR   EMBL; U04245; AAA87398.1; -; mRNA.
DR   EMBL; L33922; AAA65639.1; -; mRNA.
DR   EMBL; U21052; AAA92563.1; -; mRNA.
DR   EMBL; U21053; AAA92564.1; -; mRNA.
DR   EMBL; X91749; CAA62864.1; -; mRNA.
DR   EMBL; AF189017; AAF01052.1; -; mRNA.
DR   EMBL; AJ309047; CAC35468.1; -; Genomic_DNA.
DR   EMBL; AJ292075; CAC33440.1; -; Genomic_DNA.
DR   EMBL; AL671883; CAI18148.1; -; Genomic_DNA.
DR   EMBL; AK313911; BAG36634.1; -; mRNA.
DR   EMBL; AJ401222; CAC10402.1; -; Genomic_DNA.
DR   CCDS; CCDS34394.1; -.
DR   PIR; B35997; HLHUB7.
DR   PIR; I54418; I54418.
DR   PIR; I59651; I59651.
DR   PIR; S60601; S60601.
DR   RefSeq; NP_005505.2; NM_005514.6.
DR   UniGene; Hs.654404; -.
DR   UniGene; Hs.77961; -.
DR   PDB; 3VCL; X-ray; 1.70 A; A=25-299.
DR   PDBsum; 3VCL; -.
DR   ProteinModelPortal; P01889; -.
DR   SMR; P01889; 25-299.
DR   BioGrid; 109351; 31.
DR   IntAct; P01889; 4.
DR   DMDM; 122162; -.
DR   MaxQB; P01889; -.
DR   PaxDb; P01889; -.
DR   PRIDE; P01889; -.
DR   Ensembl; ENST00000412585; ENSP00000399168; ENSG00000234745.
DR   GeneID; 3106; -.
DR   KEGG; hsa:3106; -.
DR   UCSC; uc003ntg.1; human.
DR   CTD; 3106; -.
DR   GeneCards; GC06M031321; -.
DR   HGNC; HGNC:4932; HLA-B.
DR   HPA; CAB015418; -.
DR   MIM; 142830; gene.
DR   neXtProt; NX_P01889; -.
DR   PharmGKB; PA35056; -.
DR   eggNOG; NOG42056; -.
DR   HOVERGEN; HBG016709; -.
DR   KO; K06751; -.
DR   OMA; FLANTRM; -.
DR   OrthoDB; EOG7JT6WQ; -.
DR   PhylomeDB; P01889; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-B; human.
DR   GeneWiki; HLA-B; -.
DR   GenomeRNAi; 3106; -.
DR   NextBio; 12323; -.
DR   PRO; PR:P01889; -.
DR   ArrayExpress; P01889; -.
DR   Bgee; P01889; -.
DR   CleanEx; HS_HLA-B; -.
DR   Genevestigator; P01889; -.
DR   GO; GO:0009986; C:cell surface; ISS:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0042612; C:MHC class I protein complex; ISS:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0042605; F:peptide antigen binding; ISS:UniProt.
DR   GO; GO:0005102; F:receptor binding; IPI:BHF-UCL.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:InterPro.
DR   GO; GO:2001198; P:regulation of dendritic cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0032655; P:regulation of interleukin-12 production; IMP:BHF-UCL.
DR   GO; GO:0032675; P:regulation of interleukin-6 production; IMP:BHF-UCL.
DR   GO; GO:0002667; P:regulation of T cell anergy; IMP:BHF-UCL.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Host-virus interaction; Immunity;
KW   Membrane; MHC I; Polymorphism; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    362       HLA class I histocompatibility antigen,
FT                                B-7 alpha chain.
FT                                /FTId=PRO_0000018833.
FT   TOPO_DOM     25    309       Extracellular (Potential).
FT   TRANSMEM    310    333       Helical; (Potential).
FT   TOPO_DOM    334    362       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    309       Connecting peptide.
FT   CARBOHYD    110    110       N-linked (GlcNAc...).
FT   DISULFID    125    188
FT   DISULFID    227    283
FT   VARIANT       4      4       M -> T (in dbSNP:rs1050458).
FT                                /FTId=VAR_050332.
FT   VARIANT       9      9       V -> L (in dbSNP:rs1050462).
FT                                /FTId=VAR_050333.
FT   VARIANT      17     17       L -> V (in dbSNP:rs1131165).
FT                                /FTId=VAR_050334.
FT   VARIANT      35     35       S -> A (in dbSNP:rs1131170).
FT                                /FTId=VAR_050335.
FT   VARIANT      36     36       V -> M (in dbSNP:rs1050486).
FT                                /FTId=VAR_050336.
FT   VARIANT      48     48       S -> A (in dbSNP:rs713031).
FT                                /FTId=VAR_061386.
FT   VARIANT      48     48       S -> P (in dbSNP:rs713031).
FT                                /FTId=VAR_061387.
FT   VARIANT      48     48       S -> T (in dbSNP:rs713031).
FT                                /FTId=VAR_061388.
FT   VARIANT      65     65       A -> T (in dbSNP:rs1050529).
FT                                /FTId=VAR_050337.
FT   VARIANT      87     87       N -> D (in dbSNP:rs1050570).
FT                                /FTId=VAR_050338.
FT   VARIANT      87     87       N -> K (in dbSNP:rs1065386).
FT                                /FTId=VAR_059467.
FT   VARIANT      93     95       AQA -> TNT (in allele B*07:03).
FT                                /FTId=VAR_016351.
FT   VARIANT      97     97       T -> A (in dbSNP:rs1050393).
FT                                /FTId=VAR_050339.
FT   VARIANT      98     98       D -> Y (in dbSNP:rs1131215).
FT                                /FTId=VAR_059468.
FT   VARIANT     101    101       S -> N (in dbSNP:rs1050388).
FT                                /FTId=VAR_050340.
FT   VARIANT     118    119       TL -> II (in allele B*07:18).
FT                                /FTId=VAR_016352.
FT   VARIANT     121    121       S -> R (in allele B*07:18).
FT                                /FTId=VAR_016353.
FT   VARIANT     137    137       H -> Y (in dbSNP:rs1050379).
FT                                /FTId=VAR_050341.
FT   VARIANT     138    138       D -> H (in dbSNP:rs709055).
FT                                /FTId=VAR_061389.
FT   VARIANT     138    138       D -> N (in allele B*07:05 and allele
FT                                B*07:06; dbSNP:rs709055).
FT                                /FTId=VAR_016354.
FT   VARIANT     155    155       R -> S (in dbSNP:rs1050654).
FT                                /FTId=VAR_050342.
FT   VARIANT     180    180       R -> D (in allele B*07:04; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016355.
FT   VARIANT     187    187       E -> A (in dbSNP:rs2308466).
FT                                /FTId=VAR_059469.
FT   VARIANT     187    187       E -> G (in dbSNP:rs2308466).
FT                                /FTId=VAR_059470.
FT   VARIANT     187    187       E -> K (in dbSNP:rs2523600).
FT                                /FTId=VAR_059471.
FT   VARIANT     187    187       E -> L (in allele B*07:24; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016616.
FT   VARIANT     187    187       E -> Q (in dbSNP:rs2523600).
FT                                /FTId=VAR_059472.
FT   VARIANT     187    187       E -> V (in dbSNP:rs2308466).
FT                                /FTId=VAR_059473.
FT   VARIANT     195    195       Y -> H (in dbSNP:rs1050696).
FT                                /FTId=VAR_050343.
FT   VARIANT     306    306       V -> I (in allele B*07:05;
FT                                dbSNP:rs1131500).
FT                                /FTId=VAR_016356.
FT   VARIANT     329    329       A -> T (in dbSNP:rs1051488).
FT                                /FTId=VAR_050344.
FT   VARIANT     349    349       C -> S (in dbSNP:rs2308655).
FT                                /FTId=VAR_061390.
FT   VARIANT     349    349       C -> Y (in dbSNP:rs2308655).
FT                                /FTId=VAR_061391.
FT   CONFLICT     15     18       AALA -> GPW (in Ref. 3; AAA59622).
FT   CONFLICT    266    266       Q -> E (in Ref. 16; AA sequence).
FT   CONFLICT    268    268       W -> S (in Ref. 3; AAA59622).
FT   CONFLICT    297    297       R -> G (in Ref. 3; AAA59622).
FT   CONFLICT    314    315       GL -> RP (in Ref. 3; AAA59622).
FT   STRAND       27     36
FT   STRAND       45     52
FT   STRAND       55     61
FT   STRAND       64     66
FT   HELIX        74     76
FT   HELIX        81    108
FT   STRAND      118    127
FT   STRAND      133    142
FT   STRAND      145    150
FT   STRAND      157    161
FT   HELIX       162    173
FT   HELIX       176    185
FT   HELIX       187    198
FT   HELIX       200    203
FT   STRAND      210    235
FT   STRAND      238    243
FT   HELIX       249    251
FT   STRAND      252    254
FT   STRAND      261    263
FT   STRAND      265    274
FT   HELIX       278    280
FT   STRAND      281    286
FT   STRAND      290    292
FT   STRAND      294    296
SQ   SEQUENCE   362 AA;  40460 MW;  5E5A7BDE031403D6 CRC64;
     MLVMAPRTVL LLLSAALALT ETWAGSHSMR YFYTSVSRPG RGEPRFISVG YVDDTQFVRF
     DSDAASPREE PRAPWIEQEG PEYWDRNTQI YKAQAQTDRE SLRNLRGYYN QSEAGSHTLQ
     SMYGCDVGPD GRLLRGHDQY AYDGKDYIAL NEDLRSWTAA DTAAQITQRK WEAAREAEQR
     RAYLEGECVE WLRRYLENGK DKLERADPPK THVTHHPISD HEATLRCWAL GFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDRTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP
     SSQSTVPIVG IVAGLAVLAV VVIGAVVAAV MCRRKSSGGK GGSYSQAACS DSAQGSDVSL
     TA
//
ID   1B15_HUMAN              Reviewed;         362 AA.
AC   P30464; B0V0B8; P30465; P30513; Q29633; Q29636; Q29829; Q29953;
AC   Q29982; Q95343; Q95344; Q9BD06;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   22-AUG-2003, sequence version 2.
DT   09-JUL-2014, entry version 128.
DE   RecName: Full=HLA class I histocompatibility antigen, B-15 alpha chain;
DE   AltName: Full=MHC class I antigen B*15;
DE   Flags: Precursor;
GN   Name=HLA-B; Synonyms=HLAB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*15:02).
RX   PubMed=1801311; DOI=10.1111/j.1399-0039.1991.tb01895.x;
RA   Little A.-M., Parham P.;
RT   "The HLA-Bw75 subtype of B15: molecular characterization and
RT   comparison with crossreacting antigens.";
RL   Tissue Antigens 38:186-190(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*15:01; B*15:11 AND B*15:19).
RX   PubMed=7521976; DOI=10.1111/j.1399-0039.1994.tb02327.x;
RA   Hildebrand W.H., Domena J.D., Shen S.Y., Lau M., Terasaki P.I.,
RA   Bunce M., Marsh S.G.E., Guttridge M.G., Bias W.B., Parham P.;
RT   "HLA-B15: a widespread and diverse family of HLA-B alleles.";
RL   Tissue Antigens 43:209-218(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*15:01; B*15:02 AND B*15:11).
RC   TISSUE=Blood;
RX   PubMed=8773315; DOI=10.1111/j.1399-0039.1996.tb02553.x;
RA   Lin L., Tokunaga K., Tanaka H., Nakajima F., Imanishi T.,
RA   Kashiwase K., Bannai M., Mizuno S., Akaza T., Tadokoro K., Shibata Y.,
RA   Juji T.;
RT   "Further molecular diversity in the HLA-B15 group.";
RL   Tissue Antigens 47:265-274(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*15:03).
RX   PubMed=1431115;
RA   Madrigal J.A., Belich M.P., Hildebrand W.H., Benjamin R.J.,
RA   Little A.-M., Zemmour J., Ennis P.D., Ward F.E., Petzl-Erler M.L.,
RA   Martell R.W., du Toit E.D., Parham P.;
RT   "Distinctive HLA-A,B antigens of black populations formed by
RT   interallelic conversion.";
RL   J. Immunol. 149:3411-3415(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*15:04).
RX   PubMed=1589035; DOI=10.1038/357329a0;
RA   Watkins D.I., McAdam S.N., Liu X., Stang C.R., Milford E.L.,
RA   Levine C.G., Garber T.L., Dogon A.L., Lord C.I., Ghim S.H.,
RA   Troup G.M., Hughes A.L., Letvin N.L.;
RT   "New recombinant HLA-B alleles in a tribe of South American
RT   Amerindians indicate rapid evolution of MHC class I loci.";
RL   Nature 357:329-333(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*15:04).
RC   TISSUE=Blood;
RA   Ramos M., Barber D.F., Layrisse Z., de Castro J.A.;
RL   Submitted (OCT-1996) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*15:01).
RC   TISSUE=Blood;
RX   PubMed=12622774; DOI=10.1034/j.1399-0039.2003.610103.x;
RA   Cox S.T., McWhinnie A.J., Robinson J., Marsh S.G.E., Parham P.,
RA   Madrigal J.A., Little A.-M.;
RT   "Cloning and sequencing full-length HLA-B and -C genes.";
RL   Tissue Antigens 61:20-48(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*15:66).
RX   PubMed=12144628; DOI=10.1034/j.1399-0039.2002.590511.x;
RA   Cox S.T., Prokupek B., Baker F., Holman R., Leung V.T., Wong A.S.,
RA   Madrigal J.A., Little A.-M.;
RT   "Identification of HLA-B*1566.";
RL   Tissue Antigens 59:424-425(2002).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 5-362 (ALLELE B*15:01).
RX   PubMed=2714852; DOI=10.1007/BF00352839;
RA   Pohla H., Kuon W., Tabaczewski P., Doerner C., Weiss E.H.;
RT   "Allelic variation in HLA-B and HLA-C sequences and the evolution of
RT   the HLA-B alleles.";
RL   Immunogenetics 29:297-307(1989).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 25-362 (ALLELE B*15:01).
RX   PubMed=8423049; DOI=10.1007/BF00216833;
RA   Choo S.Y., Fan L.A., Hansen J.A.;
RT   "Allelic variations clustered in the antigen binding sites of HLA-Bw62
RT   molecules.";
RL   Immunogenetics 37:108-113(1993).
RN   [12]
RP   ASSOCIATION OF ALLELE B*15:02 WITH STEVENS-JOHNSON SYNDROME.
RX   PubMed=15057820; DOI=10.1038/428486a;
RA   Chung W.-H., Hung S.-I., Hong H.-S., Hsih M.-S., Yang L.-C., Ho H.-C.,
RA   Wu J.-Y., Chen Y.-T.;
RT   "Medical genetics: a marker for Stevens-Johnson syndrome.";
RL   Nature 428:486-486(2004).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 25-300 (ALLELE B*15:01) IN
RP   COMPLEX WITH EBV NUCLEAR ANTIGEN AND UBE2 PEPTIDES, AND DISULFIDE
RP   BONDS.
RX   PubMed=17057332; DOI=10.1107/S0907444906027636;
RA   Roder G., Blicher T., Justesen S., Johannesen B., Kristensen O.,
RA   Kastrup J., Buus S., Gajhede M.;
RT   "Crystal structures of two peptide-HLA-B*1501 complexes; structural
RT   characterization of the HLA-B62 supertype.";
RL   Acta Crystallogr. D 62:1300-1310(2006).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment by interaction
CC       with human herpesvirus 8 MIR1 protein. This targets the protein
CC       for rapid degradation via the ubiquitin system (By similarity).
CC   -!- POLYMORPHISM: The following alleles of B-15 are known: B*15:01
CC       (Bw-62; B-62), B*15:02 (Bw-75, B-75), B*15:03 (Bw-72; B-72; B-70)
CC       B*15:04, B*15:11, B*15:19 and B*15:66. The sequence shown is that
CC       of B*15:01.
CC   -!- DISEASE: Stevens-Johnson syndrome (SJS) [MIM:608579]: A rare
CC       blistering mucocutaneous disease that share clinical and
CC       histopathologic features with toxic epidermal necrolysis. Both
CC       disorders are characterized by high fever, malaise, and a rapidly
CC       developing blistering exanthema of macules and target-like lesions
CC       accompanied by mucosal involvement. Stevens-Johnson syndrome is a
CC       milder disease characterized by destruction and detachment of the
CC       skin epithelium and mucous membranes involving less than 10% of
CC       the body surface area. Ocular symptoms include ulcerative
CC       conjunctivitis, keratitis, iritis, uveitis and sometimes
CC       blindness. It can be caused by a severe adverse reaction to
CC       particular types of medication, although Mycoplasma infections may
CC       induce some cases. Note=Disease susceptibility is associated with
CC       variations affecting the gene represented in this entry. Increased
CC       susceptibility to Stevens-Johnson syndrome is conferred by allele
CC       B*15:02.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M75138; AAA59630.1; -; mRNA.
DR   EMBL; U03859; AAA03601.1; -; mRNA.
DR   EMBL; U03027; AAA18902.1; -; mRNA.
DR   EMBL; L11604; AAA56836.1; -; mRNA.
DR   EMBL; D50292; BAA08823.1; -; mRNA.
DR   EMBL; D50293; BAA08824.1; -; mRNA.
DR   EMBL; D50294; BAA08825.1; -; mRNA.
DR   EMBL; X61709; CAA43878.1; -; mRNA.
DR   EMBL; M84382; AAA59632.1; -; mRNA.
DR   EMBL; U70528; AAB16918.1; -; mRNA.
DR   EMBL; AJ295140; CAC17462.1; -; Genomic_DNA.
DR   EMBL; AJ308399; CAC33441.1; -; Genomic_DNA.
DR   EMBL; CR759828; CAQ10738.1; -; Genomic_DNA.
DR   EMBL; M28203; AAA53258.1; -; mRNA.
DR   EMBL; M83193; AAA58628.1; -; mRNA.
DR   PIR; G01230; G01230.
DR   PIR; I38421; I38421.
DR   PIR; I62042; I62042.
DR   PIR; S16789; S16789.
DR   PIR; S24433; S24433.
DR   PIR; S77966; S77966.
DR   UniGene; Hs.654404; -.
DR   UniGene; Hs.77961; -.
DR   PDB; 1XR8; X-ray; 2.30 A; A=25-300.
DR   PDB; 1XR9; X-ray; 1.79 A; A=25-300.
DR   PDB; 3C9N; X-ray; 1.87 A; A=25-300.
DR   PDBsum; 1XR8; -.
DR   PDBsum; 1XR9; -.
DR   PDBsum; 3C9N; -.
DR   ProteinModelPortal; P30464; -.
DR   SMR; P30464; 25-300.
DR   IntAct; P30464; 1.
DR   DMDM; 34305703; -.
DR   MaxQB; P30464; -.
DR   PRIDE; P30464; -.
DR   Ensembl; ENST00000450871; ENSP00000388208; ENSG00000232126.
DR   UCSC; uc011hpo.2; human.
DR   GeneCards; GC06M031321; -.
DR   GeneCards; GC06Mm31398; -.
DR   HGNC; HGNC:4932; HLA-B.
DR   MIM; 142830; gene.
DR   MIM; 608579; phenotype.
DR   neXtProt; NX_P30464; -.
DR   Orphanet; 240841; Abacavir toxicity.
DR   Orphanet; 240845; Allopurinol toxicity.
DR   Orphanet; 825; Ankylosing spondylitis.
DR   Orphanet; 117; Behcet disease.
DR   Orphanet; 240871; Flucloxacilline toxicity.
DR   Orphanet; 240901; Fosphenytoin toxicity.
DR   Orphanet; 240899; Phenytoin toxicity.
DR   Orphanet; 275798; Pulmonary arterial hypertension associated with connective tissue disease.
DR   Orphanet; 36426; Stevens-Johnson syndrome.
DR   Orphanet; 241001; Susceptibility to hepatitis due to flucloxacilline treatment.
DR   Orphanet; 241005; Susceptibility to hypersensitivity syndrome due to abacavir treatment.
DR   Orphanet; 241035; Susceptibility to toxic epidermal necrolysis due to allopurinol treatment.
DR   Orphanet; 241037; Susceptibility to toxic epidermal necrolysis due to carbamazepine treatment.
DR   Orphanet; 241039; Susceptibility to toxic epidermal necrolysis due to phenytoin treatment.
DR   Orphanet; 241041; Susceptibility to toxic epidermal necrolysis due to phosphenytoin treatment.
DR   Orphanet; 3287; Takayasu arteritis.
DR   HOVERGEN; HBG016709; -.
DR   InParanoid; P30464; -.
DR   OMA; NTRISEN; -.
DR   PhylomeDB; P30464; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-B; human.
DR   EvolutionaryTrace; P30464; -.
DR   CleanEx; HS_HLA-B; -.
DR   Genevestigator; P30464; -.
DR   GO; GO:0009986; C:cell surface; ISS:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0042612; C:MHC class I protein complex; ISS:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0042605; F:peptide antigen binding; ISS:UniProt.
DR   GO; GO:0005102; F:receptor binding; IBA:RefGenome.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:InterPro.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disulfide bond; Glycoprotein;
KW   Host-virus interaction; Immunity; Membrane; MHC I; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    362       HLA class I histocompatibility antigen,
FT                                B-15 alpha chain.
FT                                /FTId=PRO_0000018837.
FT   TOPO_DOM     25    309       Extracellular (Potential).
FT   TRANSMEM    310    333       Helical; (Potential).
FT   TOPO_DOM    334    362       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    309       Connecting peptide.
FT   CARBOHYD    110    110       N-linked (GlcNAc...) (By similarity).
FT   DISULFID    125    188
FT   DISULFID    227    283
FT   VARIANT      48     48       A -> S (in allele B*15:03).
FT                                /FTId=VAR_016365.
FT   VARIANT      69     70       MA -> EE (in allele B*15:03).
FT                                /FTId=VAR_016366.
FT   VARIANT      87     87       E -> N (in allele B*15:02 and allele
FT                                B*15:11; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_016367.
FT   VARIANT      91     91       S -> C (in allele B*15:66).
FT                                /FTId=VAR_016368.
FT   VARIANT      91     91       S -> Y (in allele B*15:11).
FT                                /FTId=VAR_016369.
FT   VARIANT     118    119       TL -> II (in allele B*15:02).
FT                                /FTId=VAR_016370.
FT   VARIANT     119    119       L -> W (in allele B*15:04).
FT                                /FTId=VAR_016371.
FT   VARIANT     121    121       R -> T (in allele B*15:04).
FT                                /FTId=VAR_016372.
FT   VARIANT     137    137       H -> Y (in allele B*15:02).
FT                                /FTId=VAR_016373.
FT   VARIANT     180    180       W -> L (in allele B*15:02 and allele
FT                                B*15:03).
FT                                /FTId=VAR_016374.
FT   VARIANT     190    191       EW -> DG (in allele B*15:19).
FT                                /FTId=VAR_016375.
FT   VARIANT     274    274       P -> L (in allele B*15:19).
FT                                /FTId=VAR_016376.
FT   STRAND       27     36
FT   STRAND       41     43
FT   STRAND       45     52
FT   STRAND       55     61
FT   STRAND       64     66
FT   HELIX        74     76
FT   HELIX        81    108
FT   STRAND      118    127
FT   STRAND      133    142
FT   STRAND      145    150
FT   STRAND      157    161
FT   HELIX       162    173
FT   HELIX       176    185
FT   HELIX       187    198
FT   HELIX       200    203
FT   STRAND      210    217
FT   STRAND      219    235
FT   STRAND      238    243
FT   HELIX       249    251
FT   STRAND      261    263
FT   STRAND      265    274
FT   HELIX       278    280
FT   STRAND      281    286
FT   STRAND      290    292
FT   STRAND      294    296
SQ   SEQUENCE   362 AA;  40388 MW;  86E938087372EBE0 CRC64;
     MRVTAPRTVL LLLSGALALT ETWAGSHSMR YFYTAMSRPG RGEPRFIAVG YVDDTQFVRF
     DSDAASPRMA PRAPWIEQEG PEYWDRETQI SKTNTQTYRE SLRNLRGYYN QSEAGSHTLQ
     RMYGCDVGPD GRLLRGHDQS AYDGKDYIAL NEDLSSWTAA DTAAQITQRK WEAAREAEQW
     RAYLEGLCVE WLRRYLENGK ETLQRADPPK THVTHHPISD HEATLRCWAL GFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDRTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP
     SSQSTIPIVG IVAGLAVLAV VVIGAVVATV MCRRKSSGGK GGSYSQAASS DSAQGSDVSL
     TA
//
ID   1B27_HUMAN              Reviewed;         362 AA.
AC   P03989; O19692; P10317; P10318; P19373; P30467; Q08136; Q29693;
AC   Q29846; Q29961;
DT   23-OCT-1986, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 2.
DT   09-JUL-2014, entry version 151.
DE   RecName: Full=HLA class I histocompatibility antigen, B-27 alpha chain;
DE   AltName: Full=MHC class I antigen B*27;
DE   Flags: Precursor;
GN   Name=HLA-B; Synonyms=HLAB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*27:01).
RX   PubMed=3912316;
RA   Weiss E.H., Kuon W., Doerner C., Lang M., Riethmueller G.;
RT   "Organization, sequence and expression of the HLA-B27 gene: a
RT   molecular approach to analyze HLA and disease associations.";
RL   Immunobiology 170:367-380(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 25-361 (ALLELE B*27:01).
RX   PubMed=3485286; DOI=10.1073/pnas.83.5.1428;
RA   Szoets H., Riethmueller G., Weiss E., Meo T.;
RT   "Complete sequence of HLA-B27 cDNA identified through the
RT   characterization of structural markers unique to the HLA-A, -B, and -C
RT   allelic series.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:1428-1432(1986).
RN   [3]
RP   PROTEIN SEQUENCE OF 25-295 (B*27:01).
RX   PubMed=2408663; DOI=10.1021/bi00328a025;
RA   Ezquerra A., Bragado R., Vega M.A., Strominger J.L., Woody J.,
RA   Lopez de Castro J.A.;
RT   "Primary structure of papain-solubilized human histocompatibility
RT   antigen HLA-B27.";
RL   Biochemistry 24:1733-1741(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*27:01 AND B*27:02).
RX   PubMed=3011411;
RA   Seemann G.H.A., Rein R.S., Brown C.S., Ploegh H.L.;
RT   "Gene conversion-like mechanisms may generate polymorphism in human
RT   class I genes.";
RL   EMBO J. 5:547-552(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*27:02).
RX   PubMed=7482496; DOI=10.1111/j.1399-0039.1995.tb02475.x;
RA   Moses J.H., Marsh S.G.E., Arnett K.L., Adams E.J., Bodmer J.G.,
RA   Parham P.;
RT   "On the nucleotide sequences of B*2702 and B*2705.";
RL   Tissue Antigens 46:50-53(1995).
RN   [6]
RP   PROTEIN SEQUENCE OF 86-107 AND 171-181 (B*27:02).
RX   PubMed=2414775; DOI=10.1073/pnas.82.21.7394;
RA   Vega M.A., Ezquerra A., Rojo S., Aparicio P., Bragado R.,
RA   Lopez de Castro J.A.;
RT   "Structural analysis of an HLA-B27 functional variant: identification
RT   of residues that contribute to the specificity of recognition by
RT   cytolytic T lymphocytes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:7394-7398(1985).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*27:03).
RX   PubMed=3286582; DOI=10.1016/0198-8859(88)90072-9;
RA   Choo S.Y., St John T., Orr H.T., Hansen J.A.;
RT   "Molecular analysis of the variant alloantigen HLA-B27d (HLA-B*2703)
RT   identifies a unique single amino acid substitution.";
RL   Hum. Immunol. 21:209-219(1988).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*27:04 AND B*27:06).
RX   PubMed=8550101; DOI=10.1007/BF00176678;
RA   Rudwaleit M., Bowness P., Wordsworth P.;
RT   "The nucleotide sequence of HLA-B*2704 reveals a new amino acid
RT   substitution in exon 4 which is also present in HLA-B*2706.";
RL   Immunogenetics 43:160-162(1996).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 25-298 (ALLELE B*27:05).
RX   PubMed=3489755;
RA   Coppin H.L., McDevitt H.O.;
RT   "Absence of polymorphism between HLA-B27 genomic exon sequences
RT   isolated from normal donors and ankylosing spondylitis patients.";
RL   J. Immunol. 137:2168-2172(1986).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*27:06).
RX   PubMed=8276469; DOI=10.1007/BF00241265;
RA   Vilches C., de Pablo R., Kreisler M.;
RT   "Nucleotide sequence of HLA-B*2706.";
RL   Immunogenetics 39:219-219(1994).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*27:07).
RX   PubMed=1711072;
RA   Choo Y.S., Fan L.A., Hansen J.A.;
RT   "A novel HLA-B27 allele maps B27 allospecificity to the region around
RT   position 70 in the alpha 1 domain.";
RL   J. Immunol. 147:174-180(1991).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*27:08).
RX   PubMed=7974468; DOI=10.1111/j.1399-0039.1994.tb02356.x;
RA   Hildebrand W.H., Domena J.D., Shen S.Y., Marsh S.G.E., Bunce M.,
RA   Guttridge M.G., Darke C., Parham P.;
RT   "The HLA-B7Qui antigen is encoded by a new subtype of HLA-B27
RT   (B*2708).";
RL   Tissue Antigens 44:47-51(1994).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*27:09).
RC   TISSUE=Blood;
RX   PubMed=8089488;
RA   Del Porto P., D'Amato M., Fiorillo M.T., Tuosto L., Piccolella E.,
RA   Sorrentino R.;
RT   "Identification of a novel HLA-B27 subtype by restriction analysis of
RT   a cytotoxic gamma/delta T cell clone.";
RL   J. Immunol. 153:3093-3100(1994).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 25-300.
RX   PubMed=1525820; DOI=10.1016/0092-8674(92)90252-8;
RA   Madden D.R., Gorga J.C., Strominger J.L., Wiley D.C.;
RT   "The three-dimensional structure of HLA-B27 at 2.1-A resolution
RT   suggests a general mechanism for tight peptide binding to MHC.";
RL   Cell 70:1035-1048(1992).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 25-300.
RX   PubMed=1922337; DOI=10.1038/353321a0;
RA   Madden D.R., Gorga J.C., Strominger J.L., Wiley D.C.;
RT   "The structure of HLA-B27 reveals nonamer self-peptides bound in an
RT   extended conformation.";
RL   Nature 353:321-325(1991).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 25-300.
RX   PubMed=12244049; DOI=10.1074/jbc.M206392200;
RA   Hulsmeyer M., Hillig R.C., Volz A., Ruhl M., Schroder W., Saenger W.,
RA   Ziegler A., Uchanska-Ziegler B.;
RT   "HLA-B27 subtypes differentially associated with disease exhibit
RT   subtle structural alterations.";
RL   J. Biol. Chem. 277:47844-47853(2002).
RN   [18]
RP   3D-STRUCTURE MODELING OF 115-206.
RX   PubMed=7846047; DOI=10.1073/pnas.92.3.753;
RA   Rognan D., Scapozza L., Folkers G., Daser A.;
RT   "Rational design of nonnatural peptides as high-affinity ligands for
RT   the HLA-B*2705 human leukocyte antigen.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:753-757(1995).
RN   [19]
RP   DISEASE, AND POSSIBLE PROTECTIVE ROLE OF ALLELE B*27:07.
RX   PubMed=15603872; DOI=10.1016/j.humimm.2004.08.177;
RA   Varnavidou-Nicolaidou A., Karpasitou K., Georgiou D., Stylianou G.,
RA   Kokkofitou A., Michalis C., Constantina C., Gregoriadou C.,
RA   Kyriakides G.;
RT   "HLA-B27 in the Greek Cypriot population: distribution of subtypes in
RT   patients with ankylosing spondylitis and other HLA-B27-related
RT   diseases. The possible protective role of B*2707.";
RL   Hum. Immunol. 65:1451-1454(2004).
RN   [20]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-65, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment by interaction
CC       with human herpesvirus 8 MIR1 protein. This targets the protein
CC       for rapid degradation via the ubiquitin system (By similarity).
CC   -!- POLYMORPHISM: The following alleles of B-27 are known:
CC       B*27:01=B*27:05, B*27:02 (B27.2; B-27k; B27e), B*27:03 (B27d),
CC       B*27:04, B*27:06, B*27:07, B*27:08 (B7Qui) and B*27:09 (B27-ci).
CC       The sequence shown is that of B*27:01.
CC   -!- DISEASE: Spondyloarthropathy 1 (SPDA1) [MIM:106300]: A chronic
CC       rheumatic disease with multifactorial inheritance. It includes a
CC       spectrum of related disorders comprising ankylosing spondylitis, a
CC       subset of psoriatic arthritis, reactive arthritis (e.g. Reiter
CC       syndrome), arthritis associated with inflammatory bowel disease
CC       and undifferentiated spondyloarthropathy. These disorders may
CC       occur simultaneously or sequentially in the same patient, probably
CC       representing various phenotypic expressions of the same disease.
CC       Ankylosing spondylitis is the form of rheumatoid arthritis
CC       affecting the spine and is considered the prototype of
CC       seronegative spondyloarthropathies. It produces pain and stiffness
CC       as a result of inflammation of the sacroiliac, intervertebral, and
CC       costovertebral joints. Note=Disease susceptibility is associated
CC       with variations affecting the gene represented in this entry. A
CC       restricted number of HLA-B27 subtypes can be associated with
CC       ankylosing spondylitis and other B27-related diseases, and an
CC       elevated frequency of the B*2702 allele in ankylosing spondylitis
CC       patients is identified. The allele B*2707 seems to have a
CC       protective role some populations because it was found only in the
CC       healthy controls.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X03945; CAA27578.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; X03664; CAA27301.1; -; Genomic_DNA.
DR   EMBL; X03667; CAA27301.1; JOINED; Genomic_DNA.
DR   EMBL; L38504; AAA69724.1; -; mRNA.
DR   EMBL; M54883; AAA59616.1; -; Genomic_DNA.
DR   EMBL; X03665; CAA27302.1; -; Genomic_DNA.
DR   EMBL; X03666; CAA27302.1; JOINED; Genomic_DNA.
DR   EMBL; M12967; AAA36221.1; -; Genomic_DNA.
DR   EMBL; U27608; AAC50444.1; -; mRNA.
DR   EMBL; U35734; AAC50447.1; -; mRNA.
DR   EMBL; M14013; AAA59643.1; -; Genomic_DNA.
DR   EMBL; X73578; CAA51980.1; -; mRNA.
DR   EMBL; M62852; AAA59647.1; -; mRNA.
DR   EMBL; L19923; AAA59658.1; -; mRNA.
DR   EMBL; Z33453; CAA83876.1; -; mRNA.
DR   PIR; I37515; I37515.
DR   PIR; I56116; I56116.
DR   PIR; S07441; HLHUB2.
DR   UniGene; Hs.654404; -.
DR   UniGene; Hs.77961; -.
DR   PDB; 1HSA; X-ray; 2.10 A; A/D=25-300.
DR   PDB; 1JGD; X-ray; 1.90 A; A=25-300.
DR   PDB; 1JGE; X-ray; 2.10 A; A=25-300.
DR   PDB; 1K5N; X-ray; 1.09 A; A=25-300.
DR   PDB; 1OF2; X-ray; 2.20 A; A=25-300.
DR   PDB; 1OGT; X-ray; 1.47 A; A=25-300.
DR   PDB; 1ROG; Model; -; A=25-206.
DR   PDB; 1ROH; Model; -; A=25-206.
DR   PDB; 1ROI; Model; -; A=25-206.
DR   PDB; 1ROJ; Model; -; A=25-206.
DR   PDB; 1ROK; Model; -; A=25-206.
DR   PDB; 1ROL; Model; -; A=25-206.
DR   PDB; 1UXS; X-ray; 1.55 A; A=25-300.
DR   PDB; 1UXW; X-ray; 1.71 A; A=25-300.
DR   PDB; 1W0V; X-ray; 2.27 A; A=25-300.
DR   PDB; 1W0W; X-ray; 2.10 A; A=25-300.
DR   PDB; 2A83; X-ray; 1.40 A; A=25-300.
DR   PDB; 2BSR; X-ray; 2.30 A; A=25-300.
DR   PDB; 2BSS; X-ray; 2.00 A; A=25-300.
DR   PDB; 2BST; X-ray; 2.10 A; A=25-300.
DR   PDB; 3B3I; X-ray; 1.86 A; A=25-300.
DR   PDB; 3B6S; X-ray; 1.80 A; A=25-300.
DR   PDB; 3BP4; X-ray; 1.85 A; A=25-300.
DR   PDB; 3BP7; X-ray; 1.80 A; A=25-300.
DR   PDB; 3CZF; X-ray; 1.20 A; A=25-300.
DR   PDB; 3D18; X-ray; 1.74 A; A=25-300.
DR   PDB; 3DTX; X-ray; 2.10 A; A=25-300.
DR   PDB; 3HCV; X-ray; 1.95 A; A=25-300.
DR   PDB; 3LV3; X-ray; 1.94 A; A=25-300.
DR   PDB; 4G8G; X-ray; 2.40 A; A=25-300.
DR   PDB; 4G8I; X-ray; 1.60 A; A=25-300.
DR   PDB; 4G9D; X-ray; 1.60 A; A=25-300.
DR   PDB; 4G9F; X-ray; 1.90 A; A=25-300.
DR   PDBsum; 1HSA; -.
DR   PDBsum; 1JGD; -.
DR   PDBsum; 1JGE; -.
DR   PDBsum; 1K5N; -.
DR   PDBsum; 1OF2; -.
DR   PDBsum; 1OGT; -.
DR   PDBsum; 1ROG; -.
DR   PDBsum; 1ROH; -.
DR   PDBsum; 1ROI; -.
DR   PDBsum; 1ROJ; -.
DR   PDBsum; 1ROK; -.
DR   PDBsum; 1ROL; -.
DR   PDBsum; 1UXS; -.
DR   PDBsum; 1UXW; -.
DR   PDBsum; 1W0V; -.
DR   PDBsum; 1W0W; -.
DR   PDBsum; 2A83; -.
DR   PDBsum; 2BSR; -.
DR   PDBsum; 2BSS; -.
DR   PDBsum; 2BST; -.
DR   PDBsum; 3B3I; -.
DR   PDBsum; 3B6S; -.
DR   PDBsum; 3BP4; -.
DR   PDBsum; 3BP7; -.
DR   PDBsum; 3CZF; -.
DR   PDBsum; 3D18; -.
DR   PDBsum; 3DTX; -.
DR   PDBsum; 3HCV; -.
DR   PDBsum; 3LV3; -.
DR   PDBsum; 4G8G; -.
DR   PDBsum; 4G8I; -.
DR   PDBsum; 4G9D; -.
DR   PDBsum; 4G9F; -.
DR   ProteinModelPortal; P03989; -.
DR   SMR; P03989; 25-300.
DR   DIP; DIP-6188N; -.
DR   IntAct; P03989; 1.
DR   MINT; MINT-247525; -.
DR   DMDM; 34305677; -.
DR   PaxDb; P03989; -.
DR   PRIDE; P03989; -.
DR   Ensembl; ENST00000435618; ENSP00000405178; ENSG00000224608.
DR   GeneCards; GC06M031321; -.
DR   GeneCards; GC06Ml31364; -.
DR   HGNC; HGNC:4932; HLA-B.
DR   MIM; 106300; phenotype.
DR   MIM; 142830; gene.
DR   neXtProt; NX_P03989; -.
DR   eggNOG; NOG42056; -.
DR   HOVERGEN; HBG016709; -.
DR   InParanoid; P03989; -.
DR   PhylomeDB; P03989; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-B; human.
DR   EvolutionaryTrace; P03989; -.
DR   CleanEx; HS_HLA-B; -.
DR   Genevestigator; P03989; -.
DR   GO; GO:0009986; C:cell surface; IDA:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; TAS:UniProtKB.
DR   GO; GO:0042612; C:MHC class I protein complex; IDA:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0042605; F:peptide antigen binding; IDA:UniProt.
DR   GO; GO:0002486; P:antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent; IDA:UniProt.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006952; P:defense response; TAS:UniProtKB.
DR   GO; GO:0016045; P:detection of bacterium; IMP:UniProtKB.
DR   GO; GO:0006955; P:immune response; IMP:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:InterPro.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Host-virus interaction; Immunity;
KW   Membrane; MHC I; Polymorphism; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    362       HLA class I histocompatibility antigen,
FT                                B-27 alpha chain.
FT                                /FTId=PRO_0000018839.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    332       Helical; (Potential).
FT   TOPO_DOM    333    362       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   CARBOHYD    110    110       N-linked (GlcNAc...).
FT   DISULFID    125    188
FT   DISULFID    227    283
FT   VARIANT      65     65       A -> T (in dbSNP:rs1050529).
FT                                /FTId=VAR_056341.
FT   VARIANT      83     83       Y -> H (in allele B*27:03).
FT                                /FTId=VAR_016379.
FT   VARIANT     101    101       D -> N (in allele B*27:02).
FT                                /FTId=VAR_016380.
FT   VARIANT     101    101       D -> S (in allele B*27:04, allele B*27:06
FT                                and allele B*27:08; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_016381.
FT   VARIANT     104    105       TL -> IA (in allele B*27:02).
FT                                /FTId=VAR_016382.
FT   VARIANT     104    104       T -> N (in allele B*27:08).
FT                                /FTId=VAR_016383.
FT   VARIANT     106    107       LR -> RG (in allele B*27:08).
FT                                /FTId=VAR_016384.
FT   VARIANT     121    121       N -> S (in allele B*27:07).
FT                                /FTId=VAR_016385.
FT   VARIANT     137    138       YH -> HN (in allele B*27:07).
FT                                /FTId=VAR_016386.
FT   VARIANT     138    138       H -> D (in allele B*27:06).
FT                                /FTId=VAR_016387.
FT   VARIANT     140    140       D -> H (in allele B*27:09).
FT                                /FTId=VAR_016388.
FT   VARIANT     140    140       D -> Y (in allele B*27:06 and allele
FT                                B*27:07).
FT                                /FTId=VAR_016389.
FT   VARIANT     155    155       S -> R (in allele B*27:07).
FT                                /FTId=VAR_016390.
FT   VARIANT     176    176       V -> E (in allele B*27:04 and allele
FT                                B*27:06).
FT                                /FTId=VAR_016391.
FT   VARIANT     235    235       A -> G (in allele B*27:04 and allele
FT                                B*27:06).
FT                                /FTId=VAR_016392.
FT   VARIANT     306    306       V -> I (in dbSNP:rs1131500).
FT                                /FTId=VAR_056342.
FT   VARIANT     329    329       A -> T (in dbSNP:rs1051488).
FT                                /FTId=VAR_056343.
FT   VARIANT     349    349       C -> S (in dbSNP:rs2308655).
FT                                /FTId=VAR_061402.
FT   VARIANT     349    349       C -> Y (in dbSNP:rs2308655).
FT                                /FTId=VAR_061403.
FT   CONFLICT    206    206       A -> V (in Ref. 2).
FT   CONFLICT    266    266       Q -> E (in Ref. 3; AA sequence).
FT   STRAND       27     36
FT   STRAND       41     43
FT   STRAND       45     52
FT   STRAND       55     61
FT   STRAND       64     66
FT   HELIX        74     76
FT   HELIX        81    108
FT   STRAND      113    115
FT   STRAND      118    127
FT   STRAND      133    142
FT   STRAND      145    150
FT   STRAND      157    161
FT   HELIX       162    173
FT   HELIX       176    185
FT   HELIX       187    198
FT   TURN        199    204
FT   STRAND      210    219
FT   STRAND      222    235
FT   STRAND      238    243
FT   HELIX       249    251
FT   STRAND      252    254
FT   STRAND      261    263
FT   STRAND      265    274
FT   HELIX       278    280
FT   STRAND      281    286
FT   STRAND      290    292
FT   STRAND      294    296
SQ   SEQUENCE   362 AA;  40428 MW;  C8D2F154E3292031 CRC64;
     MRVTAPRTLL LLLWGAVALT ETWAGSHSMR YFHTSVSRPG RGEPRFITVG YVDDTLFVRF
     DSDAASPREE PRAPWIEQEG PEYWDRETQI CKAKAQTDRE DLRTLLRYYN QSEAGSHTLQ
     NMYGCDVGPD GRLLRGYHQD AYDGKDYIAL NEDLSSWTAA DTAAQITQRK WEAARVAEQL
     RAYLEGECVE WLRRYLENGK ETLQRADPPK THVTHHPISD HEATLRCWAL GFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDRTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP
     SSQSTVPIVG IVAGLAVLAV VVIGAVVAAV MCRRKSSGGK GGSYSQAACS DSAQGSDVSL
     TA
//
ID   1B35_HUMAN              Reviewed;         362 AA.
AC   P30685; O62919; P30468; P30469; P30470; P30471; P30472; P30473;
AC   P30474; Q9GJM7; Q9TPV2; Q9TQH3; Q9TQH9; Q9TQN4; Q9TQN6;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   09-JUL-2014, entry version 136.
DE   RecName: Full=HLA class I histocompatibility antigen, B-35 alpha chain;
DE   AltName: Full=MHC class I antigen B*35;
DE   Flags: Precursor;
GN   Name=HLA-B; Synonyms=HLAB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*35:01).
RX   PubMed=2788131; DOI=10.1007/BF02421534;
RA   Ooba T., Hayashi H., Karaki S., Tanabe M., Kano K., Takiguchi M.;
RT   "The structure of HLA-B35 suggests that it is derived from HLA-Bw58 by
RT   two genetic mechanisms.";
RL   Immunogenetics 30:76-80(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*35:02).
RX   PubMed=1890016; DOI=10.1016/0198-8859(91)90020-A;
RA   Chertkoff L.P., Herrera M., Fainboim L., Satz M.L.;
RT   "Complete nucleotide sequence of a genomic clone encoding HLA-B35
RT   isolated from a Caucasian individual of Hispanic origin.
RT   Identification of a new variant of HLA-B35.";
RL   Hum. Immunol. 31:153-158(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*35:03).
RX   PubMed=1541831;
RA   Zemmour J., Little A.-M., Schendel D.J., Parham P.;
RT   "The HLA-A,B 'negative' mutant cell line C1R expresses a novel HLA-B35
RT   allele, which also has a point mutation in the translation initiation
RT   codon.";
RL   J. Immunol. 148:1941-1948(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*35:03).
RC   TISSUE=Blood;
RX   PubMed=7759996; DOI=10.1084/jem.181.6.2037;
RA   Beck Y., Satz L., Takamiya Y., Nakayama S., Ling L., Ishikawa Y.,
RA   Nagao T., Uchida H., Tokunaga K., Mueller C., Juji T., Takiguchi M.;
RT   "Polymorphism of human minor histocompatibility antigens: T cell
RT   recognition of human minor histocompatibility peptides presented by
RT   HLA-B35 subtype molecules.";
RL   J. Exp. Med. 181:2037-2048(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE (ALLELES B*35:05 AND B*35:06).
RX   PubMed=1317015; DOI=10.1038/357326a0;
RA   Belich M.P., Madrigal J.A., Hildebrand W.H., Zemmour J.,
RA   Williams R.C., Luz R., Petzl-Erler M.L., Parham P.;
RT   "Unusual HLA-B alleles in two tribes of Brazilian Indians.";
RL   Nature 357:326-329(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*35:07 AND B*35:08).
RX   PubMed=8316945; DOI=10.1111/j.1399-0039.1993.tb01993.x;
RA   Theiler G., Pando M., Delfino J.M., Takiguchi M., Satz M.L.;
RT   "Isolation and characterization of two new functional subtypes of HLA-
RT   B35.";
RL   Tissue Antigens 41:143-147(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*35:08).
RX   PubMed=8138421; DOI=10.1016/0198-8859(93)90553-D;
RA   Steinle A., Reinhardt C., Noessner E., Uchanska-Ziegler B.,
RA   Ziegler A., Schendel D.J.;
RT   "Microheterogeneity in HLA-B35 alleles influences peptide-dependent
RT   allorecognition by cytotoxic T cells but not binding of a peptide-
RT   restricted monoclonal antibody.";
RL   Hum. Immunol. 38:261-269(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE OF 9-362 (ALLELE B*35:04).
RX   PubMed=1589035; DOI=10.1038/357329a0;
RA   Watkins D.I., McAdam S.N., Liu X., Stang C.R., Milford E.L.,
RA   Levine C.G., Garber T.L., Dogon A.L., Lord C.I., Ghim S.H.,
RA   Troup G.M., Hughes A.L., Letvin N.L.;
RT   "New recombinant HLA-B alleles in a tribe of South American
RT   Amerindians indicate rapid evolution of MHC class I loci.";
RL   Nature 357:329-333(1992).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELES B*35:29 AND
RP   B*35:32).
RX   PubMed=10777103; DOI=10.1034/j.1399-0039.2000.550311.x;
RA   Kennedy C.T., Dodd R., Le T., Wallace R., Ng G., Greville W.D.,
RA   Kennedy A., Taverniti A., Moses J.H., Clow N., Watson N., Dunckley H.;
RT   "Routine HLA-B genotyping with PCR-sequence-specific oligonucleotides
RT   (PCR-SSO) detects eight new alleles: B*0807, B*0809, B*1551, B*3529,
RT   B*3532, B*4025, B*5304 and B*5508.";
RL   Tissue Antigens 55:266-270(2000).
RN   [10]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELES B*35:25; B*35:28; B*35:29;
RP   B*35:30 AND B*35:36).
RX   PubMed=11556976; DOI=10.1034/j.1399-0039.2001.057005481.x;
RA   Steiner N.K., Kosman C., Jones P.F., Gans C.P., Rodriguez-Marino S.G.,
RA   Rizzuto G., Baldassarre L.A., Edson S., Koester R., Sese D.,
RA   Mitton W., Ng J., Hartzman R.J., Hurley C.K.;
RT   "Twenty-nine new HLA-B alleles associated with antigens in the 5C
RT   CREG.";
RL   Tissue Antigens 57:481-485(2001).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 25-300.
RX   PubMed=8624811; DOI=10.1016/S1074-7613(00)80429-X;
RA   Smith K.J., Reid S.W., Stuart D.I., McMichael A.J., Jones E.Y.,
RA   Bell J.I.;
RT   "An altered position of the alpha 2 helix of MHC class I is revealed
RT   by the crystal structure of HLA-B*3501.";
RL   Immunity 4:203-214(1996).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RX   PubMed=9878435; DOI=10.1006/jmbi.1998.2363;
RA   Menssen R., Orth P., Ziegler A., Saenger W.;
RT   "Decamer-like conformation of a nona-peptide bound to HLA-B*3501 due
RT   to non-standard positioning of the C-terminus.";
RL   J. Mol. Biol. 285:645-653(1999).
RN   [13]
RP   VARIANT [LARGE SCALE ANALYSIS] TYR-140, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment by interaction
CC       with human herpesvirus 8 MIR1 protein. This targets the protein
CC       for rapid degradation via the ubiquitin system (By similarity).
CC   -!- POLYMORPHISM: The following alleles of B-35 are known: B*35:01,
CC       B*35:02, B*35:03, B*35:04, B*35:05 (B35-G), B*35:06 (B35-K),
CC       B*35:07, B*35:08, B*35:25, B*35:28, B*35:29 (B*KG), B*35:30,
CC       B*35:32 (B*TMUL) and B*35:36. The sequence shown is that of
CC       B*35:01.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M28115; AAA59617.1; -; Genomic_DNA.
DR   EMBL; M28109; AAA59617.1; JOINED; Genomic_DNA.
DR   EMBL; M28110; AAA59617.1; JOINED; Genomic_DNA.
DR   EMBL; M28111; AAA59617.1; JOINED; Genomic_DNA.
DR   EMBL; M28112; AAA59617.1; JOINED; Genomic_DNA.
DR   EMBL; M28113; AAA59617.1; JOINED; Genomic_DNA.
DR   EMBL; M28114; AAA59617.1; JOINED; Genomic_DNA.
DR   EMBL; M63454; AAA59682.1; -; Genomic_DNA.
DR   EMBL; M81798; AAA59684.1; -; mRNA.
DR   EMBL; D50299; BAA08828.1; -; mRNA.
DR   EMBL; M84385; AAA59635.1; -; mRNA.
DR   EMBL; M84381; AAA59631.1; -; mRNA.
DR   EMBL; L04695; AAA59694.1; -; mRNA.
DR   EMBL; L04696; AAA52674.1; -; mRNA.
DR   EMBL; Z22651; CAA80366.1; -; mRNA.
DR   EMBL; M86403; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AH007565; AAD23460.1; -; Genomic_DNA.
DR   EMBL; AH007706; AAD30277.1; -; Genomic_DNA.
DR   EMBL; AH006372; AAC32570.1; -; Genomic_DNA.
DR   EMBL; AH007604; AAD27538.1; -; Genomic_DNA.
DR   EMBL; AH008126; AAD51745.1; -; Genomic_DNA.
DR   EMBL; AH007584; AAD26151.1; -; Genomic_DNA.
DR   EMBL; AH009759; AAG01819.1; -; Genomic_DNA.
DR   PIR; A45880; A45880.
DR   PIR; I54298; I54298.
DR   PIR; I56133; I56133.
DR   PIR; I61904; I61904.
DR   PIR; I61907; I61907.
DR   PIR; I81233; I81233.
DR   UniGene; Hs.654404; -.
DR   UniGene; Hs.77961; -.
DR   PDB; 1A1N; X-ray; 2.00 A; A=25-300.
DR   PDB; 1A9B; X-ray; 3.20 A; A/D=25-301.
DR   PDB; 1A9E; X-ray; 2.50 A; A=25-301.
DR   PDB; 1CG9; X-ray; 2.70 A; A=25-301.
DR   PDB; 1XH3; X-ray; 1.48 A; A=25-300.
DR   PDB; 1ZHK; X-ray; 1.60 A; A=25-300.
DR   PDB; 1ZHL; X-ray; 1.50 A; A=25-300.
DR   PDB; 1ZSD; X-ray; 1.70 A; A=25-300.
DR   PDB; 2AK4; X-ray; 2.50 A; A/F/K/Q=25-300.
DR   PDB; 2AXF; X-ray; 1.80 A; A=25-300.
DR   PDB; 2AXG; X-ray; 2.00 A; A=25-300.
DR   PDB; 2CIK; X-ray; 1.75 A; A=25-300.
DR   PDB; 2FYY; X-ray; 1.50 A; A=25-300.
DR   PDB; 2FZ3; X-ray; 1.90 A; A=25-300.
DR   PDB; 2H6P; X-ray; 1.90 A; A=25-300.
DR   PDB; 2NW3; X-ray; 1.70 A; A=25-300.
DR   PDB; 2NX5; X-ray; 2.70 A; A/F/K/Q=25-300.
DR   PDB; 3BW9; X-ray; 1.75 A; A=25-300.
DR   PDB; 3BWA; X-ray; 1.30 A; A=25-300.
DR   PDB; 3KWW; X-ray; 2.18 A; A=25-300.
DR   PDB; 3KXF; X-ray; 3.10 A; A/C/I/K=25-300.
DR   PDB; 3LKN; X-ray; 2.00 A; A=25-300.
DR   PDB; 3LKO; X-ray; 1.80 A; A=25-300.
DR   PDB; 3LKP; X-ray; 1.80 A; A=25-300.
DR   PDB; 3LKQ; X-ray; 1.80 A; A=25-300.
DR   PDB; 3LKR; X-ray; 2.00 A; A=25-300.
DR   PDB; 3LKS; X-ray; 1.90 A; A=25-300.
DR   PDB; 3MV7; X-ray; 2.00 A; A=25-300.
DR   PDB; 3MV8; X-ray; 2.10 A; A=25-300.
DR   PDB; 3MV9; X-ray; 2.70 A; A=25-300.
DR   PDB; 3VFS; X-ray; 1.85 A; A=25-300.
DR   PDB; 3VFT; X-ray; 1.95 A; A=25-300.
DR   PDB; 3VFU; X-ray; 1.65 A; A=25-300.
DR   PDB; 3VFV; X-ray; 1.55 A; A=25-300.
DR   PDB; 3VFW; X-ray; 2.30 A; A=25-300.
DR   PDB; 4PR5; X-ray; 1.80 A; A=25-300.
DR   PDB; 4PRN; X-ray; 1.65 A; A=25-300.
DR   PDBsum; 1A1N; -.
DR   PDBsum; 1A9B; -.
DR   PDBsum; 1A9E; -.
DR   PDBsum; 1CG9; -.
DR   PDBsum; 1XH3; -.
DR   PDBsum; 1ZHK; -.
DR   PDBsum; 1ZHL; -.
DR   PDBsum; 1ZSD; -.
DR   PDBsum; 2AK4; -.
DR   PDBsum; 2AXF; -.
DR   PDBsum; 2AXG; -.
DR   PDBsum; 2CIK; -.
DR   PDBsum; 2FYY; -.
DR   PDBsum; 2FZ3; -.
DR   PDBsum; 2H6P; -.
DR   PDBsum; 2NW3; -.
DR   PDBsum; 2NX5; -.
DR   PDBsum; 3BW9; -.
DR   PDBsum; 3BWA; -.
DR   PDBsum; 3KWW; -.
DR   PDBsum; 3KXF; -.
DR   PDBsum; 3LKN; -.
DR   PDBsum; 3LKO; -.
DR   PDBsum; 3LKP; -.
DR   PDBsum; 3LKQ; -.
DR   PDBsum; 3LKR; -.
DR   PDBsum; 3LKS; -.
DR   PDBsum; 3MV7; -.
DR   PDBsum; 3MV8; -.
DR   PDBsum; 3MV9; -.
DR   PDBsum; 3VFS; -.
DR   PDBsum; 3VFT; -.
DR   PDBsum; 3VFU; -.
DR   PDBsum; 3VFV; -.
DR   PDBsum; 3VFW; -.
DR   PDBsum; 4PR5; -.
DR   PDBsum; 4PRN; -.
DR   ProteinModelPortal; P30685; -.
DR   SMR; P30685; 25-300.
DR   IntAct; P30685; 1.
DR   MINT; MINT-1516663; -.
DR   DMDM; 231390; -.
DR   PRIDE; P30685; -.
DR   Ensembl; ENST00000359635; ENSP00000352656; ENSG00000206450.
DR   GeneCards; GC06M031321; -.
DR   GeneCards; GC06Mn31311; -.
DR   H-InvDB; HIX0167180; -.
DR   HGNC; HGNC:4932; HLA-B.
DR   MIM; 142830; gene.
DR   neXtProt; NX_P30685; -.
DR   HOVERGEN; HBG016709; -.
DR   InParanoid; P30685; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-B; human.
DR   EvolutionaryTrace; P30685; -.
DR   CleanEx; HS_HLA-B; -.
DR   Genevestigator; P30685; -.
DR   GO; GO:0009986; C:cell surface; ISS:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0042612; C:MHC class I protein complex; ISS:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0042605; F:peptide antigen binding; ISS:UniProt.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:InterPro.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disulfide bond; Glycoprotein;
KW   Host-virus interaction; Immunity; Membrane; MHC I; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    362       HLA class I histocompatibility antigen,
FT                                B-35 alpha chain.
FT                                /FTId=PRO_0000018840.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    332       Helical; (Potential).
FT   TOPO_DOM    333    362       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   CARBOHYD    110    110       N-linked (GlcNAc...) (By similarity).
FT   DISULFID    125    188
FT   DISULFID    227    283
FT   VARIANT      40     40       G -> V (in allele B*35:07).
FT                                /FTId=VAR_016393.
FT   VARIANT      48     48       A -> S (in allele B*35:25).
FT                                /FTId=VAR_016394.
FT   VARIANT      69     69       T -> E (in allele B*35:25; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016395.
FT   VARIANT      87     87       N -> E (in allele B*35:28; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016396.
FT   VARIANT      91     91       F -> S (in allele B*35:28).
FT                                /FTId=VAR_016397.
FT   VARIANT      98     98       Y -> D (in allele B*35:29).
FT                                /FTId=VAR_016398.
FT   VARIANT     107    107       G -> D (in allele B*35:36).
FT                                /FTId=VAR_016399.
FT   VARIANT     118    119       II -> TL (in allele B*35:05 and allele
FT                                B*35:32).
FT                                /FTId=VAR_016400.
FT   VARIANT     121    121       R -> S (in allele B*35:05 and allele
FT                                B*35:30).
FT                                /FTId=VAR_016401.
FT   VARIANT     127    127       L -> V (in allele B*35:32).
FT                                /FTId=VAR_016402.
FT   VARIANT     133    133       L -> F (in allele B*35:02).
FT                                /FTId=VAR_016403.
FT   VARIANT     138    138       D -> N (in allele B*35:02, allele B*35:04
FT                                and allele B*35:06).
FT                                /FTId=VAR_016404.
FT   VARIANT     140    140       S -> F (in allele B*35:06 and allele
FT                                B*35:36).
FT                                /FTId=VAR_016405.
FT   VARIANT     140    140       S -> Y (in allele B*35:02, allele B*35:03
FT                                and allele B*35:04).
FT                                /FTId=VAR_016406.
FT   VARIANT     180    180       L -> R (in allele B*35:08).
FT                                /FTId=VAR_016407.
FT   STRAND       27     36
FT   STRAND       41     43
FT   STRAND       45     52
FT   STRAND       55     61
FT   STRAND       64     66
FT   STRAND       69     71
FT   HELIX        74     76
FT   HELIX        81    108
FT   STRAND      113    115
FT   STRAND      118    127
FT   STRAND      133    142
FT   STRAND      145    150
FT   STRAND      157    161
FT   HELIX       162    173
FT   HELIX       176    185
FT   HELIX       187    198
FT   HELIX       200    203
FT   STRAND      210    217
FT   STRAND      219    235
FT   STRAND      238    243
FT   HELIX       249    251
FT   STRAND      252    254
FT   STRAND      261    263
FT   STRAND      265    274
FT   HELIX       278    280
FT   STRAND      281    286
FT   STRAND      290    292
FT   STRAND      294    296
SQ   SEQUENCE   362 AA;  40455 MW;  52906854FC43E7A6 CRC64;
     MRVTAPRTVL LLLWGAVALT ETWAGSHSMR YFYTAMSRPG RGEPRFIAVG YVDDTQFVRF
     DSDAASPRTE PRAPWIEQEG PEYWDRNTQI FKTNTQTYRE SLRNLRGYYN QSEAGSHIIQ
     RMYGCDLGPD GRLLRGHDQS AYDGKDYIAL NEDLSSWTAA DTAAQITQRK WEAARVAEQL
     RAYLEGLCVE WLRRYLENGK ETLQRADPPK THVTHHPVSD HEATLRCWAL GFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDRTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP
     SSQSTIPIVG IVAGLAVLAV VVIGAVVATV MCRRKSSGGK GGSYSQAASS DSAQGSDVSL
     TA
//
ID   1B39_HUMAN              Reviewed;         362 AA.
AC   P30475; O02960; O78217; P30476; P79504; Q29665; Q29697; Q29749;
AC   Q29847; Q29852; Q29858; Q8HWF0; Q9TPQ7;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   09-JUL-2014, entry version 121.
DE   RecName: Full=HLA class I histocompatibility antigen, B-39 alpha chain;
DE   AltName: Full=MHC class I antigen B*39;
DE   Flags: Precursor;
GN   Name=HLA-B; Synonyms=HLAB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*39:01 AND B*39:02).
RX   PubMed=8420828; DOI=10.1007/BF00191887;
RA   Kato N., Karaki S., Kashiwase K., Mueller C., Akaza T., Juji T.,
RA   Kano K., Takiguchi M.;
RT   "Molecular analysis of HLA-B39 subtypes.";
RL   Immunogenetics 37:212-216(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*39:02 AND B*39:05).
RX   PubMed=7725307; DOI=10.1111/j.1399-0039.1995.tb02410.x;
RA   Adams E.J., Martinez-Naves E., Arnett K.L., Little A.-M., Tyan D.B.,
RA   Parham P.;
RT   "HLA-B16 antigens: sequence of the ST-16 antigen, further definition
RT   of two B38 subtypes and evidence for convergent evolution of B*3902.";
RL   Tissue Antigens 45:18-26(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*39:04).
RC   TISSUE=Peripheral blood;
RX   PubMed=7533753; DOI=10.1016/0198-8859(94)90042-6;
RA   Ogawa A., Tokunaga K., Nakajima F., Kikuchi A., Karaki S.,
RA   Kashiwase K., Ge J., Hannestad K., Juji T., Takiguchi M.;
RT   "Identification of the gene encoding a novel HLA-B39 subtype. Two
RT   amino acid substitutions on the beta-sheet out of the peptide-binding
RT   floor form a novel serological epitope.";
RL   Hum. Immunol. 41:241-247(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*39:09).
RC   TISSUE=Blood;
RX   PubMed=8838352; DOI=10.1111/j.1399-0039.1995.tb03135.x;
RA   Ramos M., Postigo J.M., Vilches C., Layrisse Z., Lopez de Castro J.A.;
RT   "Primary structure of a novel HLA-B39 allele (B*3909) from the Warao
RT   Indians of Venezuela. Further evidence for local HLA-B diversification
RT   in South America.";
RL   Tissue Antigens 46:401-404(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*39:06).
RX   PubMed=8795147; DOI=10.1111/j.1399-0039.1996.tb02582.x;
RA   Zhao W., Fernandez-Vina M.A., Lazaro A.M., Araujo H.A., Miller S.,
RA   Stastny P.;
RT   "Full cDNA of a novel HLA-B39 subtype, B*39061.";
RL   Tissue Antigens 47:435-437(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*39:06).
RA   Zhang L., Ellexson M.E., Hildebrand W.H.;
RL   Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*39:10).
RX   PubMed=8988545; DOI=10.1111/j.1399-0039.1996.tb02676.x;
RA   Wells R.S., Parham P.;
RT   "A novel recombinant HLA-B*39 allele (B*3910) in a South African
RT   Zulu.";
RL   Tissue Antigens 48:595-597(1996).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*39:10).
RX   PubMed=9234488; DOI=10.1111/j.1399-0039.1997.tb02814.x;
RA   Vilches C., Bunce M., de Pablo R., Moreno M.E., Puente S., Sanz L.,
RA   Kreisler M.;
RT   "The novel HLA-Cw*1802 allele is associated with B*5703 in the Bubi
RT   population from Equatorial Guinea.";
RL   Tissue Antigens 49:644-648(1997).
RN   [9]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*39:01).
RA   Kashiwase K.;
RL   Submitted (SEP-2002) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*39:24).
RC   TISSUE=Peripheral blood;
RX   PubMed=12558815; DOI=10.1046/j.1365-2370.2003.00362.x;
RA   Estefania E., Gomez-Lozano N., de Pablo R., Moreno M.E., Vilches C.;
RT   "Complementary DNA sequence of the HLA-B*3924 allele.";
RL   Eur. J. Immunogenet. 30:11-12(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 10-362 (ALLELE B*39:08).
RX   PubMed=8838356; DOI=10.1111/j.1399-0039.1995.tb03139.x;
RA   Adams E.J., Little A.-M., Arnett K.L., McAuley J.E., Williams R.C.,
RA   Parham P.;
RT   "Three new HLA-B alleles found in Mexican-Americans.";
RL   Tissue Antigens 46:414-416(1995).
RN   [12]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*39:12).
RX   PubMed=10372543; DOI=10.1034/j.1399-0039.1999.530504.x;
RA   Marcos C.Y., Fernandez-Vina M.A., Lazaro A.M., Moraes M.E.,
RA   Moraes J.R., Stastny P.;
RT   "Novel HLA-A and HLA-B alleles in South American Indians.";
RL   Tissue Antigens 53:476-485(1999).
RN   [13]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*39:12).
RX   PubMed=10600013; DOI=10.1016/S0198-8859(99)00092-0;
RA   Lazaro A.M., Moraes M.E., Marcos C.Y., Moraes J.R.,
RA   Fernandez-Vina M.A., Stastny P.;
RT   "Evolution of HLA-class I compared to HLA-class II polymorphism in
RT   Terena, a South-American Indian tribe.";
RL   Hum. Immunol. 60:1138-1149(1999).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*39:23).
RX   PubMed=11260515; DOI=10.1034/j.1399-0039.2001.057002169.x;
RA   Akesaka T., Kashiwase K., Ishikawa Y., Tanaka H., Shimizu M.,
RA   Kawai S., Akaza T., Takahashi T., Juji T.;
RT   "Allele frequency of HLA-B39 in the Japanese population and
RT   identification of a novel B39 allele, B*3923.";
RL   Tissue Antigens 57:169-172(2001).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 60-196 (ALLELE B*39:07).
RX   PubMed=7797264; DOI=10.1007/BF00164983;
RA   Garber T.L., Butler L.M., Trachtenberg E.A., Erlich H.A., Rickards O.,
RA   De Stefano G., Watkins D.I.;
RT   "HLA-B alleles of the Cayapa of Ecuador: new B39 and B15 alleles.";
RL   Immunogenetics 42:19-27(1995).
RN   [16]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-65, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment by interaction
CC       with human herpesvirus 8 MIR1 protein. This targets the protein
CC       for rapid degradation via the ubiquitin system (By similarity).
CC   -!- POLYMORPHISM: The following alleles of B-39 are known: B*39:01
CC       (B39.1), B*39:02 (B9.2), B*39:03, B*39:04 (B39N), B*39:05 (ST-16),
CC       B*39:06 (B39G), B*39:07 (B39uw3), B*39:09, B*39:10, B*39:12
CC       (B3901v), B*39:23 (B39022v1) and B*39:24. The sequence shown is
CC       that of B*39:01.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M94052; AAA52658.1; -; Genomic_DNA.
DR   EMBL; M94051; AAA52660.1; -; Genomic_DNA.
DR   EMBL; M94053; AAA52659.1; -; Genomic_DNA.
DR   EMBL; U04243; AAA87396.1; -; mRNA.
DR   EMBL; L36318; AAA73942.1; -; mRNA.
DR   EMBL; L22649; AAA69861.1; -; Genomic_DNA.
DR   EMBL; U29480; AAC50392.1; -; mRNA.
DR   EMBL; L42024; AAB59484.1; -; mRNA.
DR   EMBL; U29083; AAC32741.1; -; mRNA.
DR   EMBL; U56246; AAB01985.1; -; Genomic_DNA.
DR   EMBL; Y09058; CAA70261.1; -; mRNA.
DR   EMBL; AB091216; BAC11810.1; -; Genomic_DNA.
DR   EMBL; AB091218; BAC11811.1; -; Genomic_DNA.
DR   EMBL; AF428252; AAN63555.1; -; mRNA.
DR   EMBL; L42280; AAB51452.1; -; Genomic_DNA.
DR   EMBL; AH004887; AAB39108.1; -; Genomic_DNA.
DR   EMBL; AB032097; BAA84116.1; -; Genomic_DNA.
DR   EMBL; U15640; AAA74047.1; -; Genomic_DNA.
DR   PIR; I38876; I38876.
DR   PIR; I54314; I54314.
DR   PIR; I54505; I54505.
DR   PIR; I68850; I68850.
DR   PIR; I84488; I84488.
DR   UniGene; Hs.654404; -.
DR   UniGene; Hs.77961; -.
DR   ProteinModelPortal; P30475; -.
DR   SMR; P30475; 25-300.
DR   DMDM; 231398; -.
DR   PRIDE; P30475; -.
DR   Ensembl; ENST00000425848; ENSP00000400842; ENSG00000223532.
DR   GeneCards; GC06M031321; -.
DR   GeneCards; GC06Mj31312; -.
DR   HGNC; HGNC:4932; HLA-B.
DR   MIM; 142830; gene.
DR   neXtProt; NX_P30475; -.
DR   HOVERGEN; HBG016709; -.
DR   InParanoid; P30475; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-B; human.
DR   CleanEx; HS_HLA-B; -.
DR   Genevestigator; P30475; -.
DR   GO; GO:0009986; C:cell surface; ISS:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0042612; C:MHC class I protein complex; ISS:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0042605; F:peptide antigen binding; ISS:UniProt.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:InterPro.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Disulfide bond; Glycoprotein;
KW   Host-virus interaction; Immunity; Membrane; MHC I; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    362       HLA class I histocompatibility antigen,
FT                                B-39 alpha chain.
FT                                /FTId=PRO_0000018843.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    332       Helical; (Potential).
FT   TOPO_DOM    333    362       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   CARBOHYD    110    110       N-linked (GlcNAc...) (By similarity).
FT   DISULFID    125    188       By similarity.
FT   DISULFID    227    283       By similarity.
FT   VARIANT       4      4       M -> T (in dbSNP:rs1050458).
FT                                /FTId=VAR_056355.
FT   VARIANT       9      9       V -> L (in dbSNP:rs1050462).
FT                                /FTId=VAR_056356.
FT   VARIANT      17     17       L -> V (in dbSNP:rs1131165).
FT                                /FTId=VAR_056357.
FT   VARIANT      33     33       Y -> D (in allele B*39:12).
FT                                /FTId=VAR_016659.
FT   VARIANT      35     35       S -> A (in allele B*39:04 and allele
FT                                B*39:12; dbSNP:rs1131170).
FT                                /FTId=VAR_016421.
FT   VARIANT      36     36       V -> M (in allele B*39:04;
FT                                dbSNP:rs1050486).
FT                                /FTId=VAR_016660.
FT   VARIANT      48     48       S -> A (in dbSNP:rs713031).
FT                                /FTId=VAR_061410.
FT   VARIANT      48     48       S -> P (in dbSNP:rs713031).
FT                                /FTId=VAR_061411.
FT   VARIANT      48     48       S -> T (in dbSNP:rs713031).
FT                                /FTId=VAR_061412.
FT   VARIANT      65     65       A -> T (in dbSNP:rs1050529).
FT                                /FTId=VAR_056358.
FT   VARIANT      87     87       N -> D (in dbSNP:rs1050570).
FT                                /FTId=VAR_056359.
FT   VARIANT      87     87       N -> E (in allele B*39:02, allele B*39:08
FT                                and allele B*39:23; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_016422.
FT   VARIANT      87     87       N -> K (in dbSNP:rs1065386).
FT                                /FTId=VAR_059479.
FT   VARIANT      91     91       C -> S (in allele B*39:02, allele B*39:08
FT                                and allele B*39:23).
FT                                /FTId=VAR_016423.
FT   VARIANT      91     91       C -> Y (in allele B*39:10).
FT                                /FTId=VAR_016424.
FT   VARIANT      97     97       T -> A (in dbSNP:rs1050393).
FT                                /FTId=VAR_056360.
FT   VARIANT      98     98       D -> Y (in allele B*39:05, allele B*39:07
FT                                and allele B*39:08; dbSNP:rs1131215).
FT                                /FTId=VAR_016425.
FT   VARIANT     119    119       L -> W (in allele B*39:06).
FT                                /FTId=VAR_016426.
FT   VARIANT     121    121       R -> S (in allele B*39:03 and allele
FT                                B*39:24).
FT                                /FTId=VAR_016427.
FT   VARIANT     121    121       R -> T (in allele B*39:06).
FT                                /FTId=VAR_016428.
FT   VARIANT     122    122       M -> T (in allele B*39:24).
FT                                /FTId=VAR_016429.
FT   VARIANT     123    123       Y -> S (in allele B*39:09).
FT                                /FTId=VAR_016430.
FT   VARIANT     138    138       N -> D (in allele B*39:07).
FT                                /FTId=VAR_016431.
FT   VARIANT     140    140       F -> S (in allele B*39:07).
FT                                /FTId=VAR_016432.
FT   VARIANT     168    168       Q -> R (in allele B*39:23).
FT                                /FTId=VAR_016433.
FT   VARIANT     180    180       L -> R (in allele B*39:08).
FT                                /FTId=VAR_016434.
FT   VARIANT     306    306       V -> I (in dbSNP:rs1131500).
FT                                /FTId=VAR_056361.
FT   VARIANT     329    329       A -> T (in dbSNP:rs1051488).
FT                                /FTId=VAR_056362.
SQ   SEQUENCE   362 AA;  40328 MW;  422698063DEAB039 CRC64;
     MLVMAPRTVL LLLSAALALT ETWAGSHSMR YFYTSVSRPG RGEPRFISVG YVDDTQFVRF
     DSDAASPREE PRAPWIEQEG PEYWDRNTQI CKTNTQTDRE SLRNLRGYYN QSEAGSHTLQ
     RMYGCDVGPD GRLLRGHNQF AYDGKDYIAL NEDLSSWTAA DTAAQITQRK WEAARVAEQL
     RTYLEGTCVE WLRRYLENGK ETLQRADPPK THVTHHPISD HEATLRCWAL GFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDRTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP
     SSQSTVPIVG IVAGLAVLAV VVIGAVVAAV MCRRKSSGGK GGSYSQAASS DSAQGSDVSL
     TA
//
ID   1B40_HUMAN              Reviewed;         362 AA.
AC   Q04826; O19556; O19651; P01890; P30477; P30478; Q29762; Q29842;
AC   Q29855; Q30173; Q31603; Q9TPT6;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   09-JUL-2014, entry version 126.
DE   RecName: Full=HLA class I histocompatibility antigen, B-40 alpha chain;
DE   AltName: Full=Bw-60;
DE   AltName: Full=MHC class I antigen B*40;
DE   Flags: Precursor;
GN   Name=HLA-B; Synonyms=HLAB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*40:01).
RX   PubMed=2437025; DOI=10.1007/BF00404425;
RA   Ways J.W., Lawlor D.A., Wan A.M., Parham P.;
RT   "A transposable epitope of HLA-B7, B40 molecules.";
RL   Immunogenetics 25:323-328(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*40:01).
RX   PubMed=7517584; DOI=10.1111/j.1399-0039.1994.tb02294.x;
RA   Little A.-M., Domena J.D., Hildebrand W.H., Shen S.Y., Barber L.D.,
RA   Marsh S.G.E., Bias W.B., Parham P.;
RT   "HLA-B67: a member of the HLA-B16 family that expresses the ME1
RT   epitope.";
RL   Tissue Antigens 43:38-43(1994).
RN   [3]
RP   PROTEIN SEQUENCE OF 25-295 (B*40:01).
RX   PubMed=6193808; DOI=10.1021/bi00285a036;
RA   Lopez de Castro J.A., Bragado R., Strong D.M., Strominger J.L.;
RT   "Primary structure of papain-solubilized human histocompatibility
RT   antigen HLA-B40 (-Bw60). An outline of alloantigenic determinants.";
RL   Biochemistry 22:3961-3969(1983).
RN   [4]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*40:02).
RX   PubMed=1362296; DOI=10.1111/j.1399-0039.1992.tb02053.x;
RA   Domena J.D., Johnston-Dow L., Parham P.;
RT   "The B*4002 allele encodes the B61 antigen: B40* is identical to
RT   B61.";
RL   Tissue Antigens 40:254-256(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE OF 13-318 (ALLELE B*40:02).
RC   TISSUE=Blood;
RX   PubMed=1481202; DOI=10.1111/j.1399-0039.1992.tb02054.x;
RA   Lin L., Watanabe Y., Tokunaga K., Kuwata S., Kohsaka T., Akaza T.;
RT   "A common Japanese haplotype HLA-A26-Cw3-B61-DR9-DQ3 carries HLA-
RT   B*4002.";
RL   Tissue Antigens 40:257-260(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE (ALLELES B*40:03 AND B*40:04).
RX   PubMed=1317015; DOI=10.1038/357326a0;
RA   Belich M.P., Madrigal J.A., Hildebrand W.H., Zemmour J.,
RA   Williams R.C., Luz R., Petzl-Erler M.L., Parham P.;
RT   "Unusual HLA-B alleles in two tribes of Brazilian Indians.";
RL   Nature 357:326-329(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*40:05).
RX   PubMed=1385528;
RA   Hildebrand W.H., Madrigal J.A., Belich M.P., Zemmour J., Ward F.E.,
RA   Williams R.C., Parham P.;
RT   "Serologic cross-reactivities poorly reflect allelic relationships in
RT   the HLA-B12 and HLA-B21 groups. Dominant epitopes of the alpha 2
RT   helix.";
RL   J. Immunol. 149:3563-3568(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*40:06).
RA   Herrero M.J.;
RL   Submitted (FEB-1995) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*40:06).
RC   TISSUE=Blood;
RX   PubMed=12622774; DOI=10.1034/j.1399-0039.2003.610103.x;
RA   Cox S.T., McWhinnie A.J., Robinson J., Marsh S.G.E., Parham P.,
RA   Madrigal J.A., Little A.-M.;
RT   "Cloning and sequencing full-length HLA-B and -C genes.";
RL   Tissue Antigens 61:20-48(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*40:08).
RX   PubMed=8525480; DOI=10.1111/j.1399-0039.1995.tb03120.x;
RA   Adams E.J., Little A.-M., Arnett K.L., Leushner J., Parham P.;
RT   "Identification of a novel HLA-B40 allele (B*4008) in a patient with
RT   leukemia.";
RL   Tissue Antigens 46:204-205(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 26-206 (ALLELE B*40:09).
RX   PubMed=10372543; DOI=10.1034/j.1399-0039.1999.530504.x;
RA   Marcos C.Y., Fernandez-Vina M.A., Lazaro A.M., Moraes M.E.,
RA   Moraes J.R., Stastny P.;
RT   "Novel HLA-A and HLA-B alleles in South American Indians.";
RL   Tissue Antigens 53:476-485(1999).
RN   [12]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*40:16).
RX   PubMed=11098929; DOI=10.1034/j.1399-0039.2000.560401.x;
RA   Ellis J.M., Mack S.J., Leke R.F.G., Quakyi I., Johnson A.H.,
RA   Hurley C.K.;
RT   "Diversity is demonstrated in class I HLA-A and HLA-B alleles in
RT   Cameroon, Africa: description of HLA-A*03012, *2612, *3006 and HLA-
RT   B*1403, *4016, *4703.";
RL   Tissue Antigens 56:291-302(2000).
RN   [13]
RP   NUCLEOTIDE SEQUENCE OF 26-206 (ALLELE B*40:27).
RA   Pimtanothai N., Hurley C.K.;
RT   "Novel HLA-B allele.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   VARIANT [LARGE SCALE ANALYSIS] ASP-138, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment by interaction
CC       with human herpesvirus 8 MIR1 protein. This targets the protein
CC       for rapid degradation via the ubiquitin system (By similarity).
CC   -!- POLYMORPHISM: The following alleles of B-40 are known: B*40:01,
CC       B*40:02, B*40:03 (B40-G1), B*40:04 (B40-G2), B*40:05 (BN21),
CC       B*40:06, B*40:08, B*40:09, B*40:16 and B*40:27. The sequence shown
CC       is that of B*40:02.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U03698; AAA03719.1; -; mRNA.
DR   EMBL; L41628; AAA65040.1; -; Genomic_DNA.
DR   EMBL; L09736; AAA36224.1; -; mRNA.
DR   EMBL; D14343; BAA03277.1; -; mRNA.
DR   EMBL; M84383; AAA59633.1; -; mRNA.
DR   EMBL; M84384; AAA59634.1; -; mRNA.
DR   EMBL; M84694; AAA03661.1; -; mRNA.
DR   EMBL; X84725; CAA59215.1; -; mRNA.
DR   EMBL; AJ300180; CAC15501.1; -; Genomic_DNA.
DR   EMBL; AJ292253; CAC29021.1; -; Genomic_DNA.
DR   EMBL; L41353; AAC41923.1; -; Genomic_DNA.
DR   EMBL; L76934; AAA96270.1; -; mRNA.
DR   EMBL; AH005563; AAB70252.1; -; Genomic_DNA.
DR   EMBL; AH008232; AAD56943.1; -; Genomic_DNA.
DR   PIR; I38437; HLHU40.
DR   PIR; I56149; I56149.
DR   PIR; I59655; I59655.
DR   PIR; I61905; I61905.
DR   PIR; I61906; I61906.
DR   PIR; S52486; S52486.
DR   UniGene; Hs.654404; -.
DR   UniGene; Hs.77961; -.
DR   ProteinModelPortal; Q04826; -.
DR   SMR; Q04826; 25-298.
DR   DMDM; 416557; -.
DR   PRIDE; Q04826; -.
DR   Ensembl; ENST00000359635; ENSP00000352656; ENSG00000206450.
DR   GeneCards; GC06M031321; -.
DR   GeneCards; GC06Mn31311; -.
DR   HGNC; HGNC:4932; HLA-B.
DR   MIM; 142830; gene.
DR   neXtProt; NX_Q04826; -.
DR   HOVERGEN; HBG016709; -.
DR   InParanoid; Q04826; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-B; human.
DR   CleanEx; HS_HLA-B; -.
DR   Genevestigator; Q04826; -.
DR   GO; GO:0009986; C:cell surface; ISS:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0042612; C:MHC class I protein complex; ISS:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0042605; F:peptide antigen binding; ISS:UniProt.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:InterPro.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Direct protein sequencing; Disulfide bond;
KW   Glycoprotein; Host-virus interaction; Immunity; Membrane; MHC I;
KW   Polymorphism; Reference proteome; Signal; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    362       HLA class I histocompatibility antigen,
FT                                B-40 alpha chain.
FT                                /FTId=PRO_0000018844.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    332       Helical; (Potential).
FT   TOPO_DOM    333    362       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   CARBOHYD    110    110       N-linked (GlcNAc...).
FT   DISULFID    125    188
FT   DISULFID    227    283
FT   VARIANT       9      9       L -> V (in allele B*40:01).
FT                                /FTId=VAR_016435.
FT   VARIANT      14     15       WG -> SA (in allele B*40:01).
FT                                /FTId=VAR_016436.
FT   VARIANT      17     17       V -> L (in allele B*40:01).
FT                                /FTId=VAR_016437.
FT   VARIANT      35     36       SV -> AM (in allele B*40:01 and allele
FT                                B*40:16).
FT                                /FTId=VAR_016438.
FT   VARIANT      87     87       E -> N (in allele B*40:08; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016439.
FT   VARIANT      91     91       S -> F (in allele B*40:08).
FT                                /FTId=VAR_016440.
FT   VARIANT     101    101       S -> N (in dbSNP:rs1050388).
FT                                /FTId=VAR_056363.
FT   VARIANT     118    119       TL -> II (in allele B*40:03).
FT                                /FTId=VAR_016441.
FT   VARIANT     119    119       L -> W (in allele B*40:06).
FT                                /FTId=VAR_016442.
FT   VARIANT     121    121       S -> R (in allele B*40:01 and allele
FT                                B*40:03).
FT                                /FTId=VAR_016443.
FT   VARIANT     121    121       S -> T (in allele B*40:06).
FT                                /FTId=VAR_016444.
FT   VARIANT     127    127       V -> L (in allele B*40:03).
FT                                /FTId=VAR_016445.
FT   VARIANT     137    137       H -> Y (in allele B*40:09;
FT                                dbSNP:rs1050379).
FT                                /FTId=VAR_016658.
FT   VARIANT     138    138       N -> D (in allele B*40:04 and allele
FT                                B*40:09).
FT                                /FTId=VAR_016446.
FT   VARIANT     140    140       Y -> N (in allele B*40:27).
FT                                /FTId=VAR_016447.
FT   VARIANT     140    140       Y -> S (in allele B*40:04).
FT                                /FTId=VAR_016448.
FT   VARIANT     155    155       R -> S (in dbSNP:rs1050654).
FT                                /FTId=VAR_056364.
FT   VARIANT     167    167       T -> S (in allele B*40:01).
FT                                /FTId=VAR_016449.
FT   VARIANT     171    171       W -> L (in allele B*40:01).
FT                                /FTId=VAR_016450.
FT   VARIANT     176    176       V -> E (in allele B*40:05 and allele
FT                                B*40:16).
FT                                /FTId=VAR_016451.
FT   VARIANT     180    180       L -> R (in allele B*40:16).
FT                                /FTId=VAR_016655.
FT   VARIANT     187    187       E -> L (in allele B*40:05; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016452.
FT   VARIANT     201    202       ET -> DK (in allele B*40:01 and allele
FT                                B*40:16).
FT                                /FTId=VAR_016453.
FT   VARIANT     204    204       Q -> E (in allele B*40:01 and allele
FT                                B*40:16).
FT                                /FTId=VAR_016454.
FT   VARIANT     306    306       V -> I (in dbSNP:rs1131500).
FT                                /FTId=VAR_056365.
FT   VARIANT     329    329       A -> T (in dbSNP:rs1051488).
FT                                /FTId=VAR_056366.
FT   VARIANT     349    349       C -> S (in dbSNP:rs2308655).
FT                                /FTId=VAR_061413.
FT   VARIANT     349    349       C -> Y (in dbSNP:rs2308655).
FT                                /FTId=VAR_061414.
FT   CONFLICT    167    167       Missing (in Ref. 3; AA sequence).
SQ   SEQUENCE   362 AA;  40505 MW;  7D66503ACD865152 CRC64;
     MRVTAPRTLL LLLWGAVALT ETWAGSHSMR YFHTSVSRPG RGEPRFITVG YVDDTLFVRF
     DSDATSPRKE PRAPWIEQEG PEYWDRETQI SKTNTQTYRE SLRNLRGYYN QSEAGSHTLQ
     SMYGCDVGPD GRLLRGHNQY AYDGKDYIAL NEDLRSWTAA DTAAQITQRK WEAARVAEQL
     RAYLEGECVE WLRRYLENGK ETLQRADPPK THVTHHPISD HEATLRCWAL GFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDRTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP
     SSQSTVPIVG IVAGLAVLAV VVIGAVVAAV MCRRKSSGGK GGSYSQAACS DSAQGSDVSL
     TA
//
ID   1B51_HUMAN              Reviewed;         362 AA.
AC   P18464; O19675; O78173; P30489; Q29851; Q29857; Q96IT9; Q9MY43;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   09-JUL-2014, entry version 132.
DE   RecName: Full=HLA class I histocompatibility antigen, B-51 alpha chain;
DE   AltName: Full=MHC class I antigen B*51;
DE   Flags: Precursor;
GN   Name=HLA-B; Synonyms=HLAB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*51:01).
RX   PubMed=2320591; DOI=10.1073/pnas.87.7.2833;
RA   Ennis P.D., Zemmour J., Salter R.D., Parham P.;
RT   "Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction:
RT   frequency and nature of errors produced in amplification.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:2833-2837(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*51:01).
RX   PubMed=2909619;
RA   Hayashi H., Ennis P.D., Ariga H., Salter R.D., Parham P., Kano K.,
RA   Takiguchi M.;
RT   "HLA-B51 and HLA-Bw52 differ by only two amino acids which are in the
RT   helical region of the alpha 1 domain.";
RL   J. Immunol. 142:306-311(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*51:01).
RX   PubMed=2714852; DOI=10.1007/BF00352839;
RA   Pohla H., Kuon W., Tabaczewski P., Doerner C., Weiss E.H.;
RT   "Allelic variation in HLA-B and HLA-C sequences and the evolution of
RT   the HLA-B alleles.";
RL   Immunogenetics 29:297-307(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*51:04).
RX   PubMed=1317015; DOI=10.1038/357326a0;
RA   Belich M.P., Madrigal J.A., Hildebrand W.H., Zemmour J.,
RA   Williams R.C., Luz R., Petzl-Erler M.L., Parham P.;
RT   "Unusual HLA-B alleles in two tribes of Brazilian Indians.";
RL   Nature 357:326-329(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*51:03).
RC   TISSUE=Peripheral blood;
RX   PubMed=8248893; DOI=10.1111/j.1399-0039.1993.tb02164.x;
RA   Kawaguchi G., Nakayama S., Nagao T., Takiguchi M.;
RT   "A single amino acid substitution at residue 167 forms a novel HLA-B51
RT   subtype.";
RL   Tissue Antigens 42:39-41(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*51:02).
RX   PubMed=8929712; DOI=10.1111/j.1399-0039.1996.tb02513.x;
RA   Prilliman K., Steiner N.K., Ellexson M., Stewart D., Lau M.,
RA   Terasaki P., Hurley C.K., Hildebrand W.H.;
RT   "Novel alleles HLA-B*7802 and B*51022: evidence for convergency in the
RT   HLA-B5 family.";
RL   Tissue Antigens 47:49-57(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*51:08).
RX   PubMed=9243753; DOI=10.1111/j.1399-0039.1997.tb02831.x;
RA   Vilches C., Bunce M., de Pablo R., Murray A.K., McIntyre C.A.,
RA   Kreisler M.;
RT   "Complete coding regions of two novel HLA-B alleles detected by
RT   phototyping (PCR-SSP) in the British Caucasoid population: B*5108 and
RT   B*5002.";
RL   Tissue Antigens 50:38-41(1997).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*51:01).
RX   PubMed=11696219; DOI=10.1034/j.1399-0039.2001.580202.x;
RA   Sano K., Yabuki K., Imagawa Y., Shiina T., Mizuki N., Ohno S.,
RA   Kulski J.K., Inoko H.;
RT   "The absence of disease-specific polymorphisms within the HLA-B51 gene
RT   that is the susceptible locus for Behcet's disease.";
RL   Tissue Antigens 58:77-82(2001).
RN   [9]
RP   NUCLEOTIDE SEQUENCE (ALLELE B*51:01).
RX   PubMed=12622774; DOI=10.1034/j.1399-0039.2003.610103.x;
RA   Cox S.T., McWhinnie A.J., Robinson J., Marsh S.G.E., Parham P.,
RA   Madrigal J.A., Little A.-M.;
RT   "Cloning and sequencing full-length HLA-B and -C genes.";
RL   Tissue Antigens 61:20-48(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-206 (ALLELE B*51:01).
RX   PubMed=7871529; DOI=10.1111/j.1399-0039.1994.tb02394.x;
RA   Steinle A., Schendel D.J.;
RT   "HLA class I alleles of LCL 721 and 174 x CEM.T2 (T2).";
RL   Tissue Antigens 44:268-270(1994).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3-362 (ALLELE B*51:01).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE B*51:24).
RC   TISSUE=Peripheral blood;
RX   PubMed=11580855; DOI=10.1034/j.1399-0039.2001.580107.x;
RA   Anholts J.D.H., Kemps-Mols B., Verduijn W., Oudshoorn M.,
RA   Schreuder G.M.T.;
RT   "Three newly identified HLA-B alleles: B*5124, B*5306, B*5307 and
RT   confirmation of B*0809 and B*5606.";
RL   Tissue Antigens 58:38-41(2001).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 25-300 (B*51:01).
RX   PubMed=10975842; DOI=10.4049/jimmunol.165.6.3260;
RA   Maenaka K., Maenaka T., Tomiyama H., Takiguchi M., Stuart D.I.,
RA   Jones E.Y.;
RT   "Nonstandard peptide binding revealed by crystal structures of HLA-
RT   B*5101 complexed with HIV immunodominant epitopes.";
RL   J. Immunol. 165:3260-3267(2000).
RN   [15]
RP   INVOLVEMENT IN BEHCET DISEASE.
RX   PubMed=15063364; DOI=10.1016/j.coph.2003.10.009;
RA   Arayssi T., Hamdan A.;
RT   "New insights into the pathogenesis and therapy of Behcet's disease.";
RL   Curr. Opin. Pharmacol. 4:183-188(2004).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment by interaction
CC       with human herpesvirus 8 MIR1 protein. This targets the protein
CC       for rapid degradation via the ubiquitin system (By similarity).
CC   -!- POLYMORPHISM: The following alleles of B-51 are known: B*51:01,
CC       B*51:03, B*51:04, B*51:08 and B*51:24. The sequence shown is that
CC       of B*51:01.
CC   -!- MISCELLANEOUS: There is evidence that HLA-B51 is associated with
CC       susceptibility to Behcet disease. However, it is not certain
CC       whether HLA-B51 itself or a closely linked gene is responsible for
CC       susceptibility. The world distribution of HLA-B51 in healthy
CC       people corresponds to the global distribution of Behcet disease;
CC       in Southern hemisphere countries (Africa, South Pacific, etc.) and
CC       in some parts of Europe, the prevalence of HLA-B51 in healthy
CC       people is low or null, corresponding to a low prevalence of Behcet
CC       disease. The wide variation that exists in the relative risk of
CC       HLA-B51 would support other nongenetic risk factors.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M32319; AAA36232.1; -; mRNA.
DR   EMBL; M22792; AAA59620.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; M22786; AAA59620.1; JOINED; Genomic_DNA.
DR   EMBL; M22787; AAA59620.1; JOINED; Genomic_DNA.
DR   EMBL; M22788; AAA59620.1; JOINED; Genomic_DNA.
DR   EMBL; M22789; AAA59620.1; JOINED; Genomic_DNA.
DR   EMBL; M22790; AAA59620.1; JOINED; Genomic_DNA.
DR   EMBL; M22791; AAA59620.1; JOINED; Genomic_DNA.
DR   EMBL; L41087; AAA64513.1; -; Genomic_DNA.
DR   EMBL; L41086; AAA64513.1; JOINED; Genomic_DNA.
DR   EMBL; Z15143; CAA78849.1; -; mRNA.
DR   EMBL; M80670; AAA52661.1; -; Genomic_DNA.
DR   EMBL; L41925; AAC41979.1; -; mRNA.
DR   EMBL; Y08994; CAA70198.1; -; mRNA.
DR   EMBL; AB056860; BAB64902.1; -; Genomic_DNA.
DR   EMBL; AB056862; BAB64904.1; -; Genomic_DNA.
DR   EMBL; AB056863; BAB64905.1; -; Genomic_DNA.
DR   EMBL; AB056864; BAB64906.1; -; Genomic_DNA.
DR   EMBL; AB056865; BAB64907.1; -; Genomic_DNA.
DR   EMBL; AJ278903; CAC05371.1; -; Genomic_DNA.
DR   EMBL; BC007243; AAH07243.1; -; mRNA.
DR   EMBL; AJ276995; CAB86196.1; -; Genomic_DNA.
DR   EMBL; Z46808; CAA86838.1; -; mRNA.
DR   PIR; A30345; A30345.
DR   PIR; I37120; I37120.
DR   UniGene; Hs.654404; -.
DR   UniGene; Hs.77961; -.
DR   PDB; 1E27; X-ray; 2.20 A; A=25-300.
DR   PDB; 1E28; X-ray; 3.00 A; A=25-300.
DR   PDBsum; 1E27; -.
DR   PDBsum; 1E28; -.
DR   ProteinModelPortal; P18464; -.
DR   SMR; P18464; 25-300.
DR   DIP; DIP-6150N; -.
DR   MINT; MINT-144207; -.
DR   DMDM; 122172; -.
DR   PRIDE; P18464; -.
DR   Ensembl; ENST00000359635; ENSP00000352656; ENSG00000206450.
DR   GeneCards; GC06M031321; -.
DR   GeneCards; GC06Mn31311; -.
DR   H-InvDB; HIX0005715; -.
DR   HGNC; HGNC:4932; HLA-B.
DR   MIM; 142830; gene.
DR   neXtProt; NX_P18464; -.
DR   HOVERGEN; HBG016709; -.
DR   InParanoid; P18464; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-B; human.
DR   EvolutionaryTrace; P18464; -.
DR   CleanEx; HS_HLA-B; -.
DR   Genevestigator; P18464; -.
DR   GO; GO:0009986; C:cell surface; IDA:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0042612; C:MHC class I protein complex; IDA:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0042605; F:peptide antigen binding; IDA:UniProt.
DR   GO; GO:0002486; P:antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent; IDA:UniProt.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:InterPro.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disulfide bond; Glycoprotein;
KW   Host-virus interaction; Immunity; Membrane; MHC I; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    362       HLA class I histocompatibility antigen,
FT                                B-51 alpha chain.
FT                                /FTId=PRO_0000018854.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    332       Helical; (Potential).
FT   TOPO_DOM    333    362       Cytoplasmic (Potential).
FT   DOMAIN      209    295       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   CARBOHYD    110    110       N-linked (GlcNAc...) (By similarity).
FT   DISULFID    125    188       By similarity.
FT   DISULFID    227    283       By similarity.
FT   VARIANT     118    121       TWQT -> IIQR (in allele B*51:04).
FT                                /FTId=VAR_016478.
FT   VARIANT     155    155       S -> R (in allele B*51:24).
FT                                /FTId=VAR_017442.
FT   VARIANT     176    176       E -> V (in allele B*51:08).
FT                                /FTId=VAR_016479.
FT   VARIANT     180    180       L -> D (in allele B*51:08; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016480.
FT   VARIANT     191    191       W -> G (in allele B*51:03).
FT                                /FTId=VAR_016481.
FT   VARIANT     195    195       H -> Y (in allele B*51:02).
FT                                /FTId=VAR_016482.
FT   STRAND       27     36
FT   STRAND       45     52
FT   STRAND       55     61
FT   STRAND       64     66
FT   HELIX        74     78
FT   HELIX        81    108
FT   STRAND      118    127
FT   STRAND      133    142
FT   STRAND      145    150
FT   STRAND      157    161
FT   HELIX       162    173
FT   HELIX       176    185
FT   HELIX       187    198
FT   HELIX       200    203
FT   STRAND      210    217
FT   STRAND      219    235
FT   STRAND      238    243
FT   HELIX       249    251
FT   STRAND      252    254
FT   STRAND      261    263
FT   STRAND      265    274
FT   HELIX       278    280
FT   STRAND      281    286
FT   STRAND      290    292
FT   STRAND      294    296
SQ   SEQUENCE   362 AA;  40566 MW;  D104163B4CC71F92 CRC64;
     MRVTAPRTVL LLLWGAVALT ETWAGSHSMR YFYTAMSRPG RGEPRFIAVG YVDDTQFVRF
     DSDAASPRTE PRAPWIEQEG PEYWDRNTQI FKTNTQTYRE NLRIALRYYN QSEAGSHTWQ
     TMYGCDVGPD GRLLRGHNQY AYDGKDYIAL NEDLSSWTAA DTAAQITQRK WEAAREAEQL
     RAYLEGLCVE WLRRHLENGK ETLQRADPPK THVTHHPVSD HEATLRCWAL GFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDRTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP
     SSQSTIPIVG IVAGLAVLAV VVIGAVVATV MCRRKSSGGK GGSYSQAASS DSAQGSDVSL
     TA
//
ID   1C07_HUMAN              Reviewed;         366 AA.
AC   P10321; O78061; O78083; Q29631; Q29652; Q29867; Q29990; Q95463;
AC   Q95603; Q9MY31; Q9TQP9;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   20-DEC-2005, sequence version 3.
DT   09-JUL-2014, entry version 139.
DE   RecName: Full=HLA class I histocompatibility antigen, Cw-7 alpha chain;
DE   AltName: Full=MHC class I antigen Cw*7;
DE   Flags: Precursor;
GN   Name=HLA-C; Synonyms=HLAC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*07:04).
RX   PubMed=7482492; DOI=10.1111/j.1399-0039.1995.tb02471.x;
RA   Vilches C., Bunce M., de Pablo R., Herrero M.J., Kreisler M.;
RT   "Anchored PCR cloning of the novel HLA-Cw*0704 allele detected by PCR-
RT   SSP.";
RL   Tissue Antigens 46:19-23(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELES CW*07:02 AND CW*07:04).
RC   TISSUE=Blood;
RX   PubMed=8655361; DOI=10.1016/0198-8859(95)00150-6;
RA   Wang H., Tokunaga K., Ishikawa Y., Asahina A., Kuwata S., Akaza T.,
RA   Tadokoro K., Shibata Y., Takiguchi M., Juji T.;
RT   "Identification and DNA typing of two Cw7 alleles (Cw*0702 and
RT   Cw*0704) in Japanese, with the corrected sequence of Cw*0702.";
RL   Hum. Immunol. 45:52-58(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*07:06).
RX   PubMed=9008313; DOI=10.1111/j.1399-0039.1996.tb02694.x;
RA   Vilches C., Bunce M., Sanz L., de Pablo R., Puente S., Kreisler M.;
RT   "Molecular cloning of two new HLA-C alleles: Cw*1801 and Cw*0706.";
RL   Tissue Antigens 48:698-702(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE CW*07:02).
RX   PubMed=9435339; DOI=10.1007/s002510050350;
RA   Cooper S.L., Adams E.J., Wells R.S., Walker C.M., Parham P.;
RT   "A major histocompatibility complex class I allele shared by two
RT   species of chimpanzee.";
RL   Immunogenetics 47:212-217(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*07:11).
RX   PubMed=10372547; DOI=10.1034/j.1399-0039.1999.530508.x;
RA   Baurain J.-F., Coulie P.G.;
RT   "Correction of HLA-Cw*0501 and identification of HLA-Cw*0711.";
RL   Tissue Antigens 53:510-512(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES CW*07:02 AND CW*07:04).
RC   TISSUE=Blood;
RX   PubMed=12622774; DOI=10.1034/j.1399-0039.2003.610103.x;
RA   Cox S.T., McWhinnie A.J., Robinson J., Marsh S.G.E., Parham P.,
RA   Madrigal J.A., Little A.-M.;
RT   "Cloning and sequencing full-length HLA-B and -C genes.";
RL   Tissue Antigens 61:20-48(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CW*07:04).
RC   TISSUE=Melanoma;
RA   Coulie P.G.;
RT   "Identification of a new HLA-Cw7 allele.";
RL   Submitted (MAY-1994) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-206 (ALLELE CW*07:01).
RX   PubMed=7871529; DOI=10.1111/j.1399-0039.1994.tb02394.x;
RA   Steinle A., Schendel D.J.;
RT   "HLA class I alleles of LCL 721 and 174 x CEM.T2 (T2).";
RL   Tissue Antigens 44:268-270(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 25-366 (ALLELE CW*07:03).
RX   PubMed=3863816;
RA   Davidson W.F., Kress M., Khoury G., Jay G.;
RT   "Comparison of HLA class I gene sequences. Derivation of locus-
RT   specific oligonucleotide probes specific for HLA-A, HLA-B, and HLA-C
RT   genes.";
RL   J. Biol. Chem. 260:13414-13423(1985).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-206 (ALLELE CW*07:09).
RX   PubMed=9686604;
RA   Turner S., Ellexson M.E., Hickman H.D., Sidebottom D.A.,
RA   Fernandez-Vina M., Confer D.L., Hildebrand W.H.;
RT   "Sequence-based typing provides a new look at HLA-C diversity.";
RL   J. Immunol. 161:1406-1413(1998).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 26-338 (ALLELE CW*07:01).
RX   PubMed=10488744; DOI=10.1034/j.1399-0039.1999.540208.x;
RA   van der Vlies S.A., Voorter C.E., van den Berg-Loonen E.M.;
RT   "There is more to HLA -C than exons 2 and 3: sequencing exons 1, 4 and
RT   5.";
RL   Tissue Antigens 54:169-177(1999).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 77-309 (ALLELE CW*07:01).
RX   PubMed=2714852; DOI=10.1007/BF00352839;
RA   Pohla H., Kuon W., Tabaczewski P., Doerner C., Weiss E.H.;
RT   "Allelic variation in HLA-B and HLA-C sequences and the evolution of
RT   the HLA-B alleles.";
RL   Immunogenetics 29:297-307(1989).
CC   -!- FUNCTION: Involved in the presentation of foreign antigens to the
CC       immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain (beta-2-
CC       microglobulin). Interacts with human herpesvirus 8 MIR1 protein
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Polyubiquitinated in a post ER compartment by interaction
CC       with human herpesvirus 8 MIR1 protein. This targets the protein
CC       for rapid degradation via the ubiquitin system (By similarity).
CC   -!- POLYMORPHISM: The following alleles of Cw-7 are known: Cw*07:01,
CC       Cw*07:02, Cw*07:03, Cw*07:04, Cw*07:06, Cw*07:09 and Cw*07:11. The
CC       sequence shown is that of Cw*07:02.
CC   -!- SIMILARITY: Belongs to the MHC class I family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X83394; CAA58313.1; -; mRNA.
DR   EMBL; D38526; BAA07531.1; -; mRNA.
DR   EMBL; D49819; BAA08625.1; -; mRNA.
DR   EMBL; D49552; BAA08500.1; -; mRNA.
DR   EMBL; X97321; CAA65986.1; -; mRNA.
DR   EMBL; AJ001977; CAA05125.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AJ010749; CAA09341.1; -; mRNA.
DR   EMBL; AJ293016; CAC04321.1; -; Genomic_DNA.
DR   EMBL; AJ293017; CAC04322.1; -; Genomic_DNA.
DR   EMBL; AJ291815; CAC19191.1; -; Genomic_DNA.
DR   EMBL; U09853; AAA50217.1; -; mRNA.
DR   EMBL; AL671883; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z46810; CAA86840.1; -; mRNA.
DR   EMBL; M11886; AAA52665.1; -; mRNA.
DR   EMBL; AH006132; AAC17722.1; -; Genomic_DNA.
DR   EMBL; Y18533; CAB71800.1; -; Genomic_DNA.
DR   EMBL; Y18534; CAB71800.1; JOINED; Genomic_DNA.
DR   EMBL; Y18535; CAB71800.1; JOINED; Genomic_DNA.
DR   EMBL; Y18536; CAB71800.1; JOINED; Genomic_DNA.
DR   EMBL; M28207; AAA53259.1; -; mRNA.
DR   CCDS; CCDS34393.1; -.
DR   PIR; A24512; HLHUC4.
DR   PIR; I37078; I37078.
DR   PIR; I37529; I37529.
DR   PIR; I68750; I68750.
DR   RefSeq; NP_002108.4; NM_002117.5.
DR   UniGene; Hs.656020; -.
DR   UniGene; Hs.743218; -.
DR   UniGene; Hs.77961; -.
DR   PDB; 3BZF; X-ray; 2.50 A; P/Q=3-11.
DR   PDBsum; 3BZF; -.
DR   ProteinModelPortal; P10321; -.
DR   SMR; P10321; 26-298.
DR   BioGrid; 109352; 22.
DR   DMDM; 84028168; -.
DR   MaxQB; P10321; -.
DR   PRIDE; P10321; -.
DR   DNASU; 3107; -.
DR   Ensembl; ENST00000376228; ENSP00000365402; ENSG00000204525.
DR   GeneID; 3107; -.
DR   KEGG; hsa:3107; -.
DR   UCSC; uc003nsy.3; human.
DR   CTD; 3107; -.
DR   GeneCards; GC06M031236; -.
DR   HGNC; HGNC:4933; HLA-C.
DR   MIM; 142840; gene.
DR   neXtProt; NX_P10321; -.
DR   PharmGKB; PA35057; -.
DR   HOVERGEN; HBG016709; -.
DR   KO; K06751; -.
DR   OrthoDB; EOG7JT6WQ; -.
DR   PhylomeDB; P10321; -.
DR   TreeFam; TF336617; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-C; human.
DR   EvolutionaryTrace; P10321; -.
DR   GeneWiki; HLA-C; -.
DR   GenomeRNAi; 3107; -.
DR   NextBio; 12327; -.
DR   ArrayExpress; P10321; -.
DR   Bgee; P10321; -.
DR   CleanEx; HS_HLA-C; -.
DR   Genevestigator; P10321; -.
DR   GO; GO:0009986; C:cell surface; IDA:UniProt.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProt.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0042612; C:MHC class I protein complex; ISS:UniProt.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0042605; F:peptide antigen binding; ISS:UniProt.
DR   GO; GO:0005102; F:receptor binding; IBA:RefGenome.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:InterPro.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   InterPro; IPR010579; MHC_I_a_C.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   Pfam; PF06623; MHC_I_C; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disulfide bond; Glycoprotein;
KW   Host-virus interaction; Immunity; Membrane; MHC I; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     24
FT   CHAIN        25    366       HLA class I histocompatibility antigen,
FT                                Cw-7 alpha chain.
FT                                /FTId=PRO_0000018874.
FT   TOPO_DOM     25    308       Extracellular (Potential).
FT   TRANSMEM    309    333       Helical; (Potential).
FT   TOPO_DOM    334    366       Cytoplasmic (Potential).
FT   DOMAIN      209    297       Ig-like C1-type.
FT   REGION       25    114       Alpha-1.
FT   REGION      115    206       Alpha-2.
FT   REGION      207    298       Alpha-3.
FT   REGION      299    308       Connecting peptide.
FT   CARBOHYD    110    110       N-linked (GlcNAc...) (By similarity).
FT   DISULFID    125    188       By similarity.
FT   DISULFID    227    283       By similarity.
FT   VARIANT      10     10       L -> I (in dbSNP:rs2308527).
FT                                /FTId=VAR_059506.
FT   VARIANT      43     43       E -> K (in dbSNP:rs1050438).
FT                                /FTId=VAR_050345.
FT   VARIANT      48     48       S -> A (in dbSNP:rs707911).
FT                                /FTId=VAR_061450.
FT   VARIANT      48     48       S -> P (in dbSNP:rs707911).
FT                                /FTId=VAR_061451.
FT   VARIANT      48     48       S -> T (in dbSNP:rs707911).
FT                                /FTId=VAR_061452.
FT   VARIANT      73     73       A -> E (in dbSNP:rs1050409).
FT                                /FTId=VAR_050346.
FT   VARIANT      76     76       V -> M (in dbSNP:rs1065382).
FT                                /FTId=VAR_050347.
FT   VARIANT      90     90       K -> N (in allele Cw*07:01;
FT                                dbSNP:rs28626310).
FT                                /FTId=VAR_016590.
FT   VARIANT      97     97       A -> T (in dbSNP:rs41543814).
FT                                /FTId=VAR_050348.
FT   VARIANT     101    101       S -> N (in allele Cw*07:09;
FT                                dbSNP:rs2308557).
FT                                /FTId=VAR_016591.
FT   VARIANT     104    104       N -> K (in allele Cw*07:09;
FT                                dbSNP:rs17408553).
FT                                /FTId=VAR_016592.
FT   VARIANT     119    119       L -> F (in allele Cw*07:04 and allele
FT                                Cw*07:11; dbSNP:rs1071649).
FT                                /FTId=VAR_016593.
FT   VARIANT     123    123       S -> C (in dbSNP:rs1131115).
FT                                /FTId=VAR_059507.
FT   VARIANT     123    123       S -> F (in dbSNP:rs1131115).
FT                                /FTId=VAR_059508.
FT   VARIANT     123    123       S -> Y (in allele Cw*07:01;
FT                                dbSNP:rs1131115).
FT                                /FTId=VAR_016594.
FT   VARIANT     137    137       Y -> H (in dbSNP:rs2308574).
FT                                /FTId=VAR_050349.
FT   VARIANT     140    140       S -> F (in allele Cw*07:04 and allele
FT                                Cw*07:11; dbSNP:rs713032).
FT                                /FTId=VAR_016595.
FT   VARIANT     171    171       L -> W (in allele Cw*07:03;
FT                                dbSNP:rs1050366).
FT                                /FTId=VAR_016646.
FT   VARIANT     180    180       L -> D (in allele Cw*07:04 and allele
FT                                Cw*07:11; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_016596.
FT   VARIANT     182    182       A -> V (in dbSNP:rs1059539).
FT                                /FTId=VAR_050350.
FT   VARIANT     187    187       T -> L (in allele Cw*07:03; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016647.
FT   VARIANT     201    201       E -> K (in allele Cw*07:04 and allele
FT                                Cw0711; dbSNP:rs1131103).
FT                                /FTId=VAR_016597.
FT   VARIANT     208    208       P -> H (in dbSNP:rs1131096).
FT                                /FTId=VAR_061453.
FT   VARIANT     208    208       P -> R (in dbSNP:rs1131096).
FT                                /FTId=VAR_061454.
FT   VARIANT     272    272       V -> M (in dbSNP:rs1050276).
FT                                /FTId=VAR_050351.
FT   VARIANT     328    328       V -> I (in dbSNP:rs1050118).
FT                                /FTId=VAR_050352.
FT   VARIANT     330    330       A -> V (in dbSNP:rs1050105).
FT                                /FTId=VAR_050353.
FT   VARIANT     331    331       M -> K (in allele Cw*07:06;
FT                                dbSNP:rs41542414).
FT                                /FTId=VAR_016598.
FT   VARIANT     331    331       M -> V (in dbSNP:rs1130935).
FT                                /FTId=VAR_050354.
FT   VARIANT     348    348       A -> V (in allele Cw*07:06;
FT                                dbSNP:rs41559915).
FT                                /FTId=VAR_016599.
FT   VARIANT     350    350       C -> S (in dbSNP:rs35708511).
FT                                /FTId=VAR_061455.
FT   VARIANT     363    363       T -> A (in allele Cw*07:11;
FT                                dbSNP:rs1130838).
FT                                /FTId=VAR_016600.
FT   CONFLICT     15     16       GG -> AA (in Ref. 7; AAA50217).
FT   CONFLICT     41     41       R -> A (in Ref. 10; AAA52665).
FT   CONFLICT    309    309       M -> V (in Ref. 13; AAA53259).
SQ   SEQUENCE   366 AA;  40649 MW;  59C23D95FD1D0BC8 CRC64;
     MRVMAPRALL LLLSGGLALT ETWACSHSMR YFDTAVSRPG RGEPRFISVG YVDDTQFVRF
     DSDAASPRGE PRAPWVEQEG PEYWDRETQK YKRQAQADRV SLRNLRGYYN QSEDGSHTLQ
     RMSGCDLGPD GRLLRGYDQS AYDGKDYIAL NEDLRSWTAA DTAAQITQRK LEAARAAEQL
     RAYLEGTCVE WLRRYLENGK ETLQRAEPPK THVTHHPLSD HEATLRCWAL GFYPAEITLT
     WQRDGEDQTQ DTELVETRPA GDGTFQKWAA VVVPSGQEQR YTCHMQHEGL QEPLTLSWEP
     SSQPTIPIMG IVAGLAVLVV LAVLGAVVTA MMCRRKSSGG KGGSCSQAAC SNSAQGSDES
     LITCKA
//
ID   2A5D_HUMAN              Reviewed;         602 AA.
AC   Q14738; A8K3I9; B5BUA6; O00494; O00696; Q15171; Q5TC39;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   09-JUL-2014, entry version 154.
DE   RecName: Full=Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform;
DE   AltName: Full=PP2A B subunit isoform B'-delta;
DE   AltName: Full=PP2A B subunit isoform B56-delta;
DE   AltName: Full=PP2A B subunit isoform PR61-delta;
DE   AltName: Full=PP2A B subunit isoform R5-delta;
GN   Name=PPP2R5D;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM DELTA-1).
RC   TISSUE=Fetal brain;
RX   PubMed=8703017; DOI=10.1074/jbc.271.36.22081;
RA   McCright B., Rivers A.M., Audlin S., Virshup D.M.;
RT   "The B56 family of protein phosphatase 2A (PP2A) regulatory subunits
RT   encodes differentiation-induced phosphoproteins that target PP2A to
RT   both nucleus and cytoplasm.";
RL   J. Biol. Chem. 271:22081-22089(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS DELTA-1 AND DELTA-3).
RC   TISSUE=Brain cortex;
RX   PubMed=9180267; DOI=10.1016/S0014-5793(97)00392-X;
RA   Tanabe O., Gomez G.A., Nishito Y., Usui H., Takeda M.;
RT   "Molecular heterogeneity of the cDNA encoding a 74-kDa regulatory
RT   subunit (B'' or delta) of human protein phosphatase 2A.";
RL   FEBS Lett. 408:52-56(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM DELTA-2), AND PROTEIN SEQUENCE OF
RP   501-508; 550-559; 573-580 AND 584-601 (DELTA-1).
RC   TISSUE=Bone marrow, and Brain cortex;
RX   PubMed=8566219; DOI=10.1016/0014-5793(95)01500-0;
RA   Tanabe O., Nagase T., Murakami T., Nozaki H., Usui H., Nishito Y.,
RA   Hayashi H., Kagamiyama H., Takeda M.;
RT   "Molecular cloning of a 74-kDa regulatory subunit (B'' or delta) of
RT   human protein phosphatase 2A.";
RL   FEBS Lett. 379:107-111(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM DELTA-2).
RC   TISSUE=Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM DELTA-1).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS DELTA-1 AND DELTA-2).
RC   TISSUE=Colon, Eye, and Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH SGOL1.
RX   PubMed=16541025; DOI=10.1038/nature04663;
RA   Kitajima T.S., Sakuno T., Ishiguro K., Iemura S., Natsume T.,
RA   Kawashima S.A., Watanabe Y.;
RT   "Shugoshin collaborates with protein phosphatase 2A to protect
RT   cohesin.";
RL   Nature 441:46-52(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-598, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [14]
RP   VARIANT SER-53.
RX   PubMed=23033978; DOI=10.1056/NEJMoa1206524;
RA   de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G.,
RA   Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P.,
RA   Gilissen C., del Rosario M., Hoischen A., Scheffer H., de Vries B.B.,
RA   Brunner H.G., Veltman J.A., Vissers L.E.;
RT   "Diagnostic exome sequencing in persons with severe intellectual
RT   disability.";
RL   N. Engl. J. Med. 367:1921-1929(2012).
CC   -!- FUNCTION: The B regulatory subunit might modulate substrate
CC       selectivity and catalytic activity, and also might direct the
CC       localization of the catalytic enzyme to a particular subcellular
CC       compartment.
CC   -!- SUBUNIT: PP2A consists of a common heterodimeric core enzyme,
CC       composed of a 36 kDa catalytic subunit (subunit C) and a 65 kDa
CC       constant regulatory subunit (PR65 or subunit A), that associates
CC       with a variety of regulatory subunits. Proteins that associate
CC       with the core dimer include three families of regulatory subunits
CC       B (the R2/B/PR55/B55, R3/B''/PR72/PR130/PR59 and R5/B'/B56
CC       families), the 48 kDa variable regulatory subunit, viral proteins,
CC       and cell signaling molecules. Interacts with SGOL1.
CC   -!- INTERACTION:
CC       O08785:Clock (xeno); NbExp=2; IntAct=EBI-396563, EBI-79859;
CC       Q13136:PPFIA1; NbExp=2; IntAct=EBI-396563, EBI-745426;
CC       P30153:PPP2R1A; NbExp=4; IntAct=EBI-396563, EBI-302388;
CC       P30154:PPP2R1B; NbExp=2; IntAct=EBI-396563, EBI-357094;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Nuclear in
CC       interphase, nuclear during mitosis.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Delta-1;
CC         IsoId=Q14738-1; Sequence=Displayed;
CC       Name=Delta-2;
CC         IsoId=Q14738-2; Sequence=VSP_005111;
CC       Name=Delta-3;
CC         IsoId=Q14738-3; Sequence=VSP_005110;
CC   -!- TISSUE SPECIFICITY: Isoform Delta-2 is widely expressed. Isoform
CC       Delta-1 is highly expressed in brain.
CC   -!- INDUCTION: By retinoic acid; in neuroblastoma cell lines.
CC   -!- SIMILARITY: Belongs to the phosphatase 2A regulatory subunit B56
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L76702; AAB69751.1; -; mRNA.
DR   EMBL; AB000634; BAA20381.1; -; mRNA.
DR   EMBL; AB000635; BAA20382.1; -; mRNA.
DR   EMBL; D78360; BAA11372.1; -; mRNA.
DR   EMBL; AK290604; BAF83293.1; -; mRNA.
DR   EMBL; AB451342; BAG70156.1; -; mRNA.
DR   EMBL; AB451357; BAG70171.1; -; mRNA.
DR   EMBL; AL136304; CAI19791.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX04133.1; -; Genomic_DNA.
DR   EMBL; BC010692; AAH10692.1; -; mRNA.
DR   EMBL; BC001095; AAH01095.1; -; mRNA.
DR   EMBL; BC001175; AAH01175.1; -; mRNA.
DR   CCDS; CCDS43464.1; -. [Q14738-3]
DR   CCDS; CCDS4878.1; -. [Q14738-1]
DR   CCDS; CCDS55002.1; -. [Q14738-2]
DR   PIR; S68686; S68686.
DR   RefSeq; NP_001257405.1; NM_001270476.1.
DR   RefSeq; NP_006236.1; NM_006245.3. [Q14738-1]
DR   RefSeq; NP_851307.1; NM_180976.2. [Q14738-2]
DR   RefSeq; NP_851308.1; NM_180977.2. [Q14738-3]
DR   UniGene; Hs.533308; -.
DR   ProteinModelPortal; Q14738; -.
DR   SMR; Q14738; 110-512.
DR   BioGrid; 111520; 32.
DR   DIP; DIP-29961N; -.
DR   IntAct; Q14738; 26.
DR   MINT; MINT-5006095; -.
DR   STRING; 9606.ENSP00000417963; -.
DR   PhosphoSite; Q14738; -.
DR   DMDM; 7387495; -.
DR   MaxQB; Q14738; -.
DR   PaxDb; Q14738; -.
DR   PRIDE; Q14738; -.
DR   DNASU; 5528; -.
DR   Ensembl; ENST00000394110; ENSP00000377669; ENSG00000112640. [Q14738-2]
DR   Ensembl; ENST00000461010; ENSP00000420674; ENSG00000112640. [Q14738-3]
DR   Ensembl; ENST00000485511; ENSP00000417963; ENSG00000112640. [Q14738-1]
DR   GeneID; 5528; -.
DR   KEGG; hsa:5528; -.
DR   UCSC; uc003oth.4; human. [Q14738-1]
DR   UCSC; uc010jyd.4; human. [Q14738-3]
DR   UCSC; uc021yzq.2; human. [Q14738-2]
DR   CTD; 5528; -.
DR   GeneCards; GC06P042952; -.
DR   HGNC; HGNC:9312; PPP2R5D.
DR   HPA; HPA029045; -.
DR   HPA; HPA029046; -.
DR   MIM; 601646; gene.
DR   neXtProt; NX_Q14738; -.
DR   PharmGKB; PA33676; -.
DR   eggNOG; NOG264925; -.
DR   HOVERGEN; HBG000009; -.
DR   InParanoid; Q14738; -.
DR   KO; K11584; -.
DR   OMA; GSGRAEM; -.
DR   OrthoDB; EOG7C2R2S; -.
DR   PhylomeDB; Q14738; -.
DR   TreeFam; TF105556; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_115566; Cell Cycle.
DR   Reactome; REACT_116125; Disease.
DR   Reactome; REACT_21300; Mitotic M-M/G1 phases.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6782; TRAF6 Mediated Induction of proinflammatory cytokines.
DR   Reactome; REACT_6900; Immune System.
DR   SignaLink; Q14738; -.
DR   GeneWiki; PPP2R5D; -.
DR   GenomeRNAi; 5528; -.
DR   NextBio; 21410; -.
DR   PRO; PR:Q14738; -.
DR   ArrayExpress; Q14738; -.
DR   Bgee; Q14738; -.
DR   CleanEx; HS_PPP2R5D; -.
DR   Genevestigator; Q14738; -.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0000159; C:protein phosphatase type 2A complex; IEA:InterPro.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0008601; F:protein phosphatase type 2A regulator activity; TAS:ProtInc.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; TAS:Reactome.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0016311; P:dephosphorylation; TAS:GOC.
DR   GO; GO:0006112; P:energy reserve metabolic process; TAS:Reactome.
DR   GO; GO:0006006; P:glucose metabolic process; TAS:Reactome.
DR   GO; GO:0006096; P:glycolytic process; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0002756; P:MyD88-independent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0050790; P:regulation of catalytic activity; TAS:GOC.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; TAS:Reactome.
DR   GO; GO:0034166; P:toll-like receptor 10 signaling pathway; TAS:Reactome.
DR   GO; GO:0034134; P:toll-like receptor 2 signaling pathway; TAS:Reactome.
DR   GO; GO:0034138; P:toll-like receptor 3 signaling pathway; TAS:Reactome.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; TAS:Reactome.
DR   GO; GO:0034146; P:toll-like receptor 5 signaling pathway; TAS:Reactome.
DR   GO; GO:0034162; P:toll-like receptor 9 signaling pathway; TAS:Reactome.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038123; P:toll-like receptor TLR1:TLR2 signaling pathway; TAS:Reactome.
DR   GO; GO:0038124; P:toll-like receptor TLR6:TLR2 signaling pathway; TAS:Reactome.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR002554; PP2A_B56.
DR   PANTHER; PTHR10257; PTHR10257; 1.
DR   Pfam; PF01603; B56; 1.
DR   PIRSF; PIRSF028043; PP2A_B56; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat.
FT   CHAIN         1    602       Serine/threonine-protein phosphatase 2A
FT                                56 kDa regulatory subunit delta isoform.
FT                                /FTId=PRO_0000071452.
FT   REPEAT       37     38       1.
FT   REPEAT       39     40       2.
FT   REPEAT       41     42       3.
FT   REPEAT       43     44       4.
FT   REPEAT       45     46       5.
FT   REPEAT       47     48       6; approximate.
FT   REPEAT       49     50       7; approximate.
FT   REPEAT       51     52       8.
FT   REGION       37     52       8 X 2 AA approximate tandem repeats of Q-
FT                                P.
FT   MOTIF       523    530       SH3-binding; class I (Potential).
FT   MOTIF       548    565       Nuclear localization signal (Potential).
FT   MOD_RES     573    573       Phosphoserine.
FT   MOD_RES     598    598       Phosphoserine.
FT   VAR_SEQ      11    116       Missing (in isoform Delta-3).
FT                                /FTId=VSP_005110.
FT   VAR_SEQ      85    116       Missing (in isoform Delta-2).
FT                                /FTId=VSP_005111.
FT   VARIANT      53     53       P -> S (found in a patient with delayed
FT                                psychomotor development, no speech and
FT                                cataracts).
FT                                /FTId=VAR_069414.
SQ   SEQUENCE   602 AA;  69992 MW;  F15F71AF4E565387 CRC64;
     MPYKLKKEKE PPKVAKCTAK PSSSGKDGGG ENTEEAQPQP QPQPQPQAQS QPPSSNKRPS
     NSTPPPTQLS KIKYSGGPQI VKKERRQSSS RFNLSKNREL QKLPALKDSP TQEREELFIQ
     KLRQCCVLFD FVSDPLSDLK FKEVKRAGLN EMVEYITHSR DVVTEAIYPE AVTMFSVNLF
     RTLPPSSNPT GAEFDPEEDE PTLEAAWPHL QLVYEFFLRF LESPDFQPNI AKKYIDQKFV
     LALLDLFDSE DPRERDFLKT ILHRIYGKFL GLRAYIRRQI NHIFYRFIYE TEHHNGIAEL
     LEILGSIING FALPLKEEHK MFLIRVLLPL HKVKSLSVYH PQLAYCVVQF LEKESSLTEP
     VIVGLLKFWP KTHSPKEVMF LNELEEILDV IEPSEFSKVM EPLFRQLAKC VSSPHFQVAE
     RALYYWNNEY IMSLISDNAA RVLPIMFPAL YRNSKSHWNK TIHGLIYNAL KLFMEMNQKL
     FDDCTQQYKA EKQKGRFRMK EREEMWQKIE ELARLNPQYP MFRAPPPLPP VYSMETETPT
     AEDIQLLKRT VETEAVQMLK DIKKEKVLLR RKSELPQDVY TIKALEAHKR AEEFLTASQE
     AL
//
ID   2A5G_HUMAN              Reviewed;         524 AA.
AC   Q13362; B4DYJ8; B5BUA5; F5GWP3; Q14391; Q15060; Q15174; Q6ZN33;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   09-JUL-2014, entry version 145.
DE   RecName: Full=Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform;
DE   AltName: Full=PP2A B subunit isoform B'-gamma;
DE   AltName: Full=PP2A B subunit isoform B56-gamma;
DE   AltName: Full=PP2A B subunit isoform PR61-gamma;
DE   AltName: Full=PP2A B subunit isoform R5-gamma;
DE   AltName: Full=Renal carcinoma antigen NY-REN-29;
GN   Name=PPP2R5C; Synonyms=KIAA0044;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GAMMA-3).
RC   TISSUE=Umbilical vein;
RX   PubMed=8617797; DOI=10.1074/jbc.271.9.5164;
RA   Tehrani M.A., Mumby M.C., Kamibayashi C.;
RT   "Identification of a novel protein phosphatase 2A regulatory subunit
RT   highly expressed in muscle.";
RL   J. Biol. Chem. 271:5164-5170(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GAMMA-1).
RC   TISSUE=Fetal retina;
RX   PubMed=8694763;
RA   Zolnierowicz S., van Hoof C., Andjelkovic N., Cron P., Stevens I.,
RA   Merlevede W., Goris J., Hemmings B.A.;
RT   "The variable subunit associated with protein phosphatase 2A0 defines
RT   a novel multimember family of regulatory subunits.";
RL   Biochem. J. 317:187-194(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND PARTIAL
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Hippocampus, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GAMMA-3).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-524 (ISOFORM GAMMA-2).
RC   TISSUE=Bone marrow;
RX   PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S.,
RA   Seki N., Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II.
RT   The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 11-524 (ISOFORM GAMMA-1).
RX   PubMed=7592815; DOI=10.1074/jbc.270.44.26123;
RA   McCright B., Virshup D.M.;
RT   "Identification of a new family of protein phosphatase 2A regulatory
RT   subunits.";
RL   J. Biol. Chem. 270:26123-26128(1995).
RN   [9]
RP   PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=8703017; DOI=10.1074/jbc.271.36.22081;
RA   McCright B., Rivers A.M., Audlin S., Virshup D.M.;
RT   "The B56 family of protein phosphatase 2A (PP2A) regulatory subunits
RT   encodes differentiation-induced phosphoproteins that target PP2A to
RT   both nucleus and cytoplasm.";
RL   J. Biol. Chem. 271:22081-22089(1996).
RN   [10]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH SGOL1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=16580887; DOI=10.1016/j.devcel.2006.03.010;
RA   Tang Z., Shu H., Qi W., Mahmood N.A., Mumby M.C., Yu H.;
RT   "PP2A is required for centromeric localization of Sgo1 and proper
RT   chromosome segregation.";
RL   Dev. Cell 10:575-585(2006).
RN   [12]
RP   FUNCTION, INTERACTION WITH IER3 AND ERK KINASES, AND PHOSPHORYLATION.
RX   PubMed=16456541; DOI=10.1038/sj.emboj.7600980;
RA   Letourneux C., Rocher G., Porteu F.;
RT   "B56-containing PP2A dephosphorylate ERK and their activity is
RT   controlled by the early gene IEX-1 and ERK.";
RL   EMBO J. 25:727-738(2006).
RN   [13]
RP   INTERACTION WITH SGOL1.
RX   PubMed=16541025; DOI=10.1038/nature04663;
RA   Kitajima T.S., Sakuno T., Ishiguro K., Iemura S., Natsume T.,
RA   Kawashima S.A., Watanabe Y.;
RT   "Shugoshin collaborates with protein phosphatase 2A to protect
RT   cohesin.";
RL   Nature 441:46-52(2006).
RN   [14]
RP   FUNCTION, INTERACTION WITH TP53, AND INDUCTION.
RX   PubMed=17245430; DOI=10.1038/sj.emboj.7601519;
RA   Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.;
RT   "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-
RT   induced dephosphorylation of p53 at Thr55.";
RL   EMBO J. 26:402-411(2007).
RN   [15]
RP   INTERACTION WITH TP53.
RX   PubMed=17967874; DOI=10.1128/MCB.00983-07;
RA   Shouse G.P., Cai X., Liu X.;
RT   "Serine 15 phosphorylation of p53 directs its interaction with
RT   B56gamma and the tumor suppressor activity of B56gamma-specific
RT   protein phosphatase 2A.";
RL   Mol. Cell. Biol. 28:448-456(2008).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (3.30 ANGSTROMS) OF 1-442 IN COMPLEX WITH PPP2CA
RP   AND PPP2R1A.
RX   PubMed=17174897; DOI=10.1016/j.cell.2006.11.033;
RA   Xu Y., Xing Y., Chen Y., Chao Y., Lin Z., Fan E., Yu J.W., Strack S.,
RA   Jeffrey P.D., Shi Y.;
RT   "Structure of the protein phosphatase 2A holoenzyme.";
RL   Cell 127:1239-1251(2006).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (3.50 ANGSTROMS) OF 30-436 IN COMPLEX WITH
RP   PPP2CA AND PPP2R1A.
RX   PubMed=17086192; DOI=10.1038/nature05351;
RA   Cho U.S., Xu W.;
RT   "Crystal structure of a protein phosphatase 2A heterotrimeric
RT   holoenzyme.";
RL   Nature 445:53-57(2007).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 34-436 IN COMPLEX WITH
RP   PPP2CA; PPP2R1A AND SGOL1.
RX   PubMed=19716788; DOI=10.1016/j.molcel.2009.06.031;
RA   Xu Z., Cetin B., Anger M., Cho U.S., Helmhart W., Nasmyth K., Xu W.;
RT   "Structure and function of the PP2A-shugoshin interaction.";
RL   Mol. Cell 35:426-441(2009).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 11-380.
RX   PubMed=18618707; DOI=10.1002/prot.22150;
RA   Magnusdottir A., Stenmark P., Flodin S., Nyman T., Kotenyova T.,
RA   Graeslund S., Ogg D., Nordlund P.;
RT   "The structure of the PP2A regulatory subunit B56 gamma: the remaining
RT   piece of the PP2A jigsaw puzzle.";
RL   Proteins 74:212-221(2009).
CC   -!- FUNCTION: The B regulatory subunit might modulate substrate
CC       selectivity and catalytic activity, and also might direct the
CC       localization of the catalytic enzyme to a particular subcellular
CC       compartment. The PP2A-PPP2R5C holoenzyme may specifically
CC       dephosphorylate and activate TP53 and play a role in DNA damage-
CC       induced inhibition of cell proliferation. PP2A-PPP2R5C may also
CC       regulate the ERK signaling pathway through ERK dephosphorylation.
CC   -!- SUBUNIT: PP2A consists of a common heterodimeric core enzyme,
CC       composed of PPP2CA a 36 kDa catalytic subunit (subunit C) and
CC       PPP2R1A a 65 kDa constant regulatory subunit (PR65 or subunit A),
CC       that associates with a variety of regulatory subunits. Proteins
CC       that associate with the core dimer include three families of
CC       regulatory subunits B (the R2/B/PR55/B55, R3/B''/PR72/PR130/PR59
CC       and R5/B'/B56 families), the 48 kDa variable regulatory subunit,
CC       viral proteins, and cell signaling molecules. Interacts with
CC       PPP2CA AND PPP2R1A; the interaction is direct. Interacts with
CC       SGOL1; the interaction is direct. Isoform 1 and isoform 2 interact
CC       with TP53 (phosphorylated at Ser-15 by ATM); increased upon DNA
CC       damage it drives PP2A-mediated dephosphorylation of TP53 at Thr-
CC       55. Interacts with IER3 and/or ERK kinases; regulates ERK
CC       dephosphorylation.
CC   -!- INTERACTION:
CC       O96017:CHEK2; NbExp=4; IntAct=EBI-1266176, EBI-1180783;
CC       P46695:IER3; NbExp=2; IntAct=EBI-1266156, EBI-1748945;
CC       Q00987:MDM2; NbExp=5; IntAct=EBI-1266156, EBI-389668;
CC       P67775:PPP2CA; NbExp=7; IntAct=EBI-1266156, EBI-712311;
CC       P30153:PPP2R1A; NbExp=6; IntAct=EBI-1266156, EBI-302388;
CC       P30154:PPP2R1B; NbExp=2; IntAct=EBI-1266156, EBI-357094;
CC       P04637:TP53; NbExp=3; IntAct=EBI-1266156, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome, centromere.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=Gamma-3;
CC         IsoId=Q13362-1; Sequence=Displayed;
CC       Name=Gamma-1;
CC         IsoId=Q13362-2; Sequence=VSP_005112;
CC       Name=Gamma-2;
CC         IsoId=Q13362-3; Sequence=VSP_005113;
CC       Name=4;
CC         IsoId=Q13362-4; Sequence=VSP_043645, VSP_005113;
CC         Note=No experimental confirmation available;
CC       Name=5;
CC         IsoId=Q13362-5; Sequence=VSP_046768;
CC         Note=Ref.3 (BAG63760) sequence is in conflict in position:
CC         3:N->K. No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Highest levels in heart, skeletal muscle and
CC       brain. Lower levels in pancreas, kidney, lung and placenta. Very
CC       low levels in liver.
CC   -!- INDUCTION: Up-regulated upon DNA damage.
CC   -!- PTM: Isoform Gamma-3 is phosphorylated on serine residues. Isoform
CC       Gamma-1 phosphorylation by ERK2 is IER3-dependent and inhibits ERK
CC       dephosphorylation by PP2A-PPP2R5C.
CC   -!- SIMILARITY: Belongs to the phosphatase 2A regulatory subunit B56
CC       family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC50387.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=BAG63760.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U37352; AAC50387.1; ALT_INIT; mRNA.
DR   EMBL; Z69030; CAA93154.1; -; mRNA.
DR   EMBL; AK131391; BAD18542.1; -; mRNA.
DR   EMBL; AK302470; BAG63760.1; ALT_INIT; mRNA.
DR   EMBL; AB451341; BAG70155.1; -; mRNA.
DR   EMBL; AL118558; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL137779; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471061; EAW81756.1; -; Genomic_DNA.
DR   EMBL; D26445; BAA05465.1; -; mRNA.
DR   EMBL; L42375; AAC37603.1; -; mRNA.
DR   CCDS; CCDS45163.1; -. [Q13362-2]
DR   CCDS; CCDS53911.1; -. [Q13362-4]
DR   CCDS; CCDS53912.1; -. [Q13362-5]
DR   CCDS; CCDS9964.1; -. [Q13362-1]
DR   CCDS; CCDS9965.1; -. [Q13362-3]
DR   RefSeq; NP_001155197.1; NM_001161725.1. [Q13362-5]
DR   RefSeq; NP_001155198.1; NM_001161726.1. [Q13362-4]
DR   RefSeq; NP_002710.2; NM_002719.3. [Q13362-1]
DR   RefSeq; NP_848701.1; NM_178586.2. [Q13362-3]
DR   RefSeq; NP_848702.1; NM_178587.2. [Q13362-2]
DR   RefSeq; XP_005267884.1; XM_005267827.1.
DR   UniGene; Hs.368264; -.
DR   PDB; 2IAE; X-ray; 3.50 A; B/E=30-436.
DR   PDB; 2JAK; X-ray; 2.60 A; A=11-380.
DR   PDB; 2NPP; X-ray; 3.30 A; B/E=1-442.
DR   PDB; 2NYL; X-ray; 3.80 A; B/E=38-425.
DR   PDB; 2NYM; X-ray; 3.60 A; B/E=38-425.
DR   PDB; 3FGA; X-ray; 2.70 A; B=34-436.
DR   PDBsum; 2IAE; -.
DR   PDBsum; 2JAK; -.
DR   PDBsum; 2NPP; -.
DR   PDBsum; 2NYL; -.
DR   PDBsum; 2NYM; -.
DR   PDBsum; 3FGA; -.
DR   ProteinModelPortal; Q13362; -.
DR   SMR; Q13362; 34-436.
DR   BioGrid; 111519; 26.
DR   DIP; DIP-39401N; -.
DR   IntAct; Q13362; 18.
DR   MINT; MINT-2835438; -.
DR   STRING; 9606.ENSP00000333905; -.
DR   PhosphoSite; Q13362; -.
DR   DMDM; 116241235; -.
DR   MaxQB; Q13362; -.
DR   PaxDb; Q13362; -.
DR   PRIDE; Q13362; -.
DR   DNASU; 5527; -.
DR   Ensembl; ENST00000328724; ENSP00000329009; ENSG00000078304. [Q13362-4]
DR   Ensembl; ENST00000334743; ENSP00000333905; ENSG00000078304. [Q13362-1]
DR   Ensembl; ENST00000350249; ENSP00000262239; ENSG00000078304. [Q13362-3]
DR   Ensembl; ENST00000422945; ENSP00000412324; ENSG00000078304. [Q13362-5]
DR   Ensembl; ENST00000445439; ENSP00000408389; ENSG00000078304. [Q13362-2]
DR   GeneID; 5527; -.
DR   KEGG; hsa:5527; -.
DR   UCSC; uc001ykk.3; human. [Q13362-4]
DR   UCSC; uc001ykn.3; human. [Q13362-2]
DR   UCSC; uc001yko.3; human. [Q13362-1]
DR   UCSC; uc001ykp.3; human. [Q13362-3]
DR   CTD; 5527; -.
DR   GeneCards; GC14P102228; -.
DR   HGNC; HGNC:9311; PPP2R5C.
DR   HPA; HPA027553; -.
DR   MIM; 601645; gene.
DR   neXtProt; NX_Q13362; -.
DR   PharmGKB; PA33674; -.
DR   eggNOG; NOG264925; -.
DR   HOGENOM; HOG000067326; -.
DR   HOVERGEN; HBG000009; -.
DR   KO; K11584; -.
DR   OMA; SERWEAD; -.
DR   PhylomeDB; Q13362; -.
DR   TreeFam; TF105556; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_115566; Cell Cycle.
DR   Reactome; REACT_21300; Mitotic M-M/G1 phases.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6900; Immune System.
DR   SignaLink; Q13362; -.
DR   ChiTaRS; PPP2R5C; human.
DR   EvolutionaryTrace; Q13362; -.
DR   GeneWiki; PPP2R5C; -.
DR   GenomeRNAi; 5527; -.
DR   NextBio; 21400; -.
DR   PMAP-CutDB; Q13362; -.
DR   PRO; PR:Q13362; -.
DR   ArrayExpress; Q13362; -.
DR   Bgee; Q13362; -.
DR   CleanEx; HS_PPP2R5C; -.
DR   Genevestigator; Q13362; -.
DR   GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000159; C:protein phosphatase type 2A complex; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0008601; F:protein phosphatase type 2A regulator activity; IDA:UniProtKB.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:MGI.
DR   GO; GO:0050790; P:regulation of catalytic activity; IDA:GOC.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR002554; PP2A_B56.
DR   PANTHER; PTHR10257; PTHR10257; 1.
DR   Pfam; PF01603; B56; 1.
DR   PIRSF; PIRSF028043; PP2A_B56; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Centromere;
KW   Chromosome; Complete proteome; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome.
FT   CHAIN         1    524       Serine/threonine-protein phosphatase 2A
FT                                56 kDa regulatory subunit gamma isoform.
FT                                /FTId=PRO_0000071457.
FT   MOTIF       416    422       Nuclear localization signal (Potential).
FT   MOD_RES       1      1       N-acetylmethionine.
FT   VAR_SEQ       1     31       MLTCNKAGSRMVVDAANSNGPFQPVVLLHIR -> MPNKNK
FT                                KEKESPKAGKSGKSSKEGQDTVESEQISVRKNSLVAVPSTV
FT                                SAKIKVPVSQPIVKKDKRQNSSRFSASNNRELQKLPSLK
FT                                (in isoform 4).
FT                                /FTId=VSP_043645.
FT   VAR_SEQ       1     30       MLTCNKAGSRMVVDAANSNGPFQPVVLLHI -> MPNKNKK
FT                                EKESPKAGKSGKSSKEGQDTVESEGTSPEEPSSPKVPPPLL
FT                                PELLVLIFGGLQG (in isoform 5).
FT                                /FTId=VSP_046768.
FT   VAR_SEQ     443    524       YTVYSQASTMSIPVAMETDGPLFEDVQMLRKTVKDEAHQAQ
FT                                KDPKKDRPLARRKSELPQDPHTKKALEAHCRADELASQDGR
FT                                -> VLKKRIT (in isoform Gamma-1).
FT                                /FTId=VSP_005112.
FT   VAR_SEQ     443    481       Missing (in isoform Gamma-2 and isoform
FT                                4).
FT                                /FTId=VSP_005113.
FT   VARIANT     515    515       A -> P (in dbSNP:rs3742424).
FT                                /FTId=VAR_051745.
FT   CONFLICT    494    494       R -> L (in Ref. 1; AAC50387).
FT   HELIX        40     48
FT   STRAND       55     58
FT   STRAND       59     62
FT   HELIX        63     80
FT   STRAND       83     85
FT   HELIX        91    103
FT   STRAND      115    118
FT   HELIX       120    122
FT   HELIX       131    146
FT   HELIX       152    155
FT   TURN        156    158
FT   HELIX       161    170
FT   HELIX       176    192
FT   HELIX       194    196
FT   HELIX       197    212
FT   TURN        213    215
FT   HELIX       221    233
FT   HELIX       241    249
FT   HELIX       252    255
FT   HELIX       258    262
FT   HELIX       264    277
FT   HELIX       279    281
FT   HELIX       282    291
FT   HELIX       301    313
FT   HELIX       317    335
FT   HELIX       340    347
FT   HELIX       348    351
FT   HELIX       353    361
FT   HELIX       363    366
FT   TURN        367    369
FT   TURN        372    377
FT   HELIX       384    398
FT   HELIX       409    430
SQ   SEQUENCE   524 AA;  61061 MW;  B9CBF54550D713F8 CRC64;
     MLTCNKAGSR MVVDAANSNG PFQPVVLLHI RDVPPADQEK LFIQKLRQCC VLFDFVSDPL
     SDLKWKEVKR AALSEMVEYI THNRNVITEP IYPEVVHMFA VNMFRTLPPS SNPTGAEFDP
     EEDEPTLEAA WPHLQLVYEF FLRFLESPDF QPNIAKKYID QKFVLQLLEL FDSEDPRERD
     FLKTTLHRIY GKFLGLRAYI RKQINNIFYR FIYETEHHNG IAELLEILGS IINGFALPLK
     EEHKIFLLKV LLPLHKVKSL SVYHPQLAYC VVQFLEKDST LTEPVVMALL KYWPKTHSPK
     EVMFLNELEE ILDVIEPSEF VKIMEPLFRQ LAKCVSSPHF QVAERALYYW NNEYIMSLIS
     DNAAKILPIM FPSLYRNSKT HWNKTIHGLI YNALKLFMEM NQKLFDDCTQ QFKAEKLKEK
     LKMKEREEAW VKIENLAKAN PQYTVYSQAS TMSIPVAMET DGPLFEDVQM LRKTVKDEAH
     QAQKDPKKDR PLARRKSELP QDPHTKKALE AHCRADELAS QDGR
//
ID   2AAA_HUMAN              Reviewed;         589 AA.
AC   P30153; Q13773; Q6ICQ3; Q96DH3;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 4.
DT   09-JUL-2014, entry version 150.
DE   RecName: Full=Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform;
DE   AltName: Full=Medium tumor antigen-associated 61 kDa protein;
DE   AltName: Full=PP2A subunit A isoform PR65-alpha;
DE   AltName: Full=PP2A subunit A isoform R1-alpha;
GN   Name=PPP2R1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 242-255.
RC   TISSUE=Placenta;
RX   PubMed=2554323; DOI=10.1073/pnas.86.22.8669;
RA   Walter G., Ferre F., Espiritu O., Carbone-Wiley A.;
RT   "Molecular cloning and sequence of cDNA encoding polyoma medium tumor
RT   antigen-associated 61-kDa protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:8669-8672(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2159327; DOI=10.1021/bi00465a002;
RA   Hemmings B.A., Adams-Pearson C., Maurer F., Mueller P., Goris J.,
RA   Merlevede W., Hofsteenge J., Stone S.R.;
RT   "Alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A
RT   have a similar 39 amino acid repeating structure.";
RL   Biochemistry 29:3166-3173(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 34-46, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Vishwanath V.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [6]
RP   PROTEIN SEQUENCE OF 204-214; 261-272 AND 521-527.
RX   PubMed=8694763;
RA   Zolnierowicz S., van Hoof C., Andjelkovic N., Cron P., Stevens I.,
RA   Merlevede W., Goris J., Hemmings B.A.;
RT   "The variable subunit associated with protein phosphatase 2A0 defines
RT   a novel multimember family of regulatory subunits.";
RL   Biochem. J. 317:187-194(1996).
RN   [7]
RP   BINDING DOMAINS.
RX   PubMed=8254721;
RA   Ruediger R., Hentz M., Fait J., Mumby M., Walter G.;
RT   "Molecular model of the A subunit of protein phosphatase 2A:
RT   interaction with other subunits and tumor antigens.";
RL   J. Virol. 68:123-129(1994).
RN   [8]
RP   INTERACTION WITH IPO9.
RX   PubMed=12670497; DOI=10.1016/S0006-291X(03)00434-0;
RA   Lubert E.J., Sarge K.D.;
RT   "Interaction between protein phosphatase 2A and members of the
RT   importin beta superfamily.";
RL   Biochem. Biophys. Res. Commun. 303:908-913(2003).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, SUBCELLULAR LOCATION,
RP   AND INTERACTION WITH SGOL1.
RX   PubMed=16580887; DOI=10.1016/j.devcel.2006.03.010;
RA   Tang Z., Shu H., Qi W., Mahmood N.A., Mumby M.C., Yu H.;
RT   "PP2A is required for centromeric localization of Sgo1 and proper
RT   chromosome segregation.";
RL   Dev. Cell 10:575-585(2006).
RN   [10]
RP   INTERACTION WITH TP53.
RX   PubMed=17245430; DOI=10.1038/sj.emboj.7601519;
RA   Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.;
RT   "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-
RT   induced dephosphorylation of p53 at Thr55.";
RL   EMBO J. 26:402-411(2007).
RN   [11]
RP   INTERACTION WITH PLA2G16.
RX   PubMed=17374643; DOI=10.1242/jcs.000018;
RA   Nazarenko I., Schafer R., Sers C.;
RT   "Mechanisms of the HRSL3 tumor suppressor function in ovarian
RT   carcinoma cells.";
RL   J. Cell Sci. 120:1393-1404(2007).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   INTERACTION WITH CTTNBP2NL.
RX   PubMed=18782753; DOI=10.1074/mcp.M800266-MCP200;
RA   Goudreault M., D'Ambrosio L.M., Kean M.J., Mullin M.J., Larsen B.G.,
RA   Sanchez A., Chaudhry S., Chen G.I., Sicheri F., Nesvizhskii A.I.,
RA   Aebersold R., Raught B., Gingras A.C.;
RT   "A PP2A phosphatase high density interaction network identifies a
RT   novel striatin-interacting phosphatase and kinase complex linked to
RT   the cerebral cavernous malformation 3 (CCM3) protein.";
RL   Mol. Cell. Proteomics 8:157-171(2009).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-280, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   PubMed=9989501; DOI=10.1016/S0092-8674(00)80963-0;
RA   Groves M.R., Hanlon N., Turowski P., Hemmings B.A., Barford D.;
RT   "The structure of the protein phosphatase 2A PR65/A subunit reveals
RT   the conformation of its 15 tandemly repeated HEAT motifs.";
RL   Cell 96:99-110(1999).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 9-589 IN COMPLEX WITH WITH
RP   PPP2CA AND PPME1.
RX   PubMed=18394995; DOI=10.1016/j.cell.2008.02.041;
RA   Xing Y., Li Z., Chen Y., Stock J.B., Jeffrey P.D., Shi Y.;
RT   "Structural mechanism of demethylation and inactivation of protein
RT   phosphatase 2A.";
RL   Cell 133:154-163(2008).
CC   -!- FUNCTION: The PR65 subunit of protein phosphatase 2A serves as a
CC       scaffolding molecule to coordinate the assembly of the catalytic
CC       subunit and a variable regulatory B subunit. Required for proper
CC       chromosome segregation and for centromeric localization of SGOL1
CC       in mitosis.
CC   -!- SUBUNIT: Found in a complex with at least ARL2, PPP2CB, PPP2R1A,
CC       PPP2R2A, PPP2R5E and TBCD. Interacts with FOXO1; the interaction
CC       dephosphorylates FOXO1 on AKT-mediated phosphoylation sites (By
CC       similarity). PP2A consists of a common heterodimeric core enzyme,
CC       composed of PPP2CA a 36 kDa catalytic subunit (subunit C) and
CC       PPP2R1A a 65 kDa constant regulatory subunit (PR65 or subunit A),
CC       that associates with a variety of regulatory subunits. Proteins
CC       that associate with the core dimer include three families of
CC       regulatory subunits B (the R2/B/PR55/B55, R3/B''/PR72/PR130/PR59
CC       and R5/B'/B56 families), the 48 kDa variable regulatory subunit,
CC       viral proteins, and cell signaling molecules. Interacts with IPO9.
CC       Interacts with TP53 and SGOL1. Interacts with PLA2G16; this
CC       interaction might decrease PP2A activity. Interacts with
CC       CTTNBP2NL.
CC   -!- INTERACTION:
CC       P03081:- (xeno); NbExp=3; IntAct=EBI-302388, EBI-1266256;
CC       P31749:AKT1; NbExp=2; IntAct=EBI-302388, EBI-296087;
CC       P03129:E7 (xeno); NbExp=3; IntAct=EBI-302388, EBI-866453;
CC       P04020:E7 (xeno); NbExp=2; IntAct=EBI-302388, EBI-7005254;
CC       Q8TCG1:KIAA1524; NbExp=4; IntAct=EBI-302388, EBI-1379376;
CC       P97346:Nxn (xeno); NbExp=2; IntAct=EBI-302388, EBI-309684;
CC       P53816:PLA2G16; NbExp=7; IntAct=EBI-302388, EBI-746318;
CC       P67775:PPP2CA; NbExp=14; IntAct=EBI-302388, EBI-712311;
CC       P63151:PPP2R2A; NbExp=8; IntAct=EBI-302388, EBI-1048931;
CC       Q00005:PPP2R2B; NbExp=5; IntAct=EBI-302388, EBI-1052159;
CC       Q15172:PPP2R5A; NbExp=3; IntAct=EBI-302388, EBI-641666;
CC       Q13362:PPP2R5C; NbExp=6; IntAct=EBI-302388, EBI-1266156;
CC       Q13362-1:PPP2R5C; NbExp=5; IntAct=EBI-302388, EBI-1266170;
CC       Q13362-2:PPP2R5C; NbExp=2; IntAct=EBI-302388, EBI-1266173;
CC       Q60996-3:Ppp2r5c (xeno); NbExp=2; IntAct=EBI-302388, EBI-1369292;
CC       Q14738:PPP2R5D; NbExp=4; IntAct=EBI-302388, EBI-396563;
CC       Q16537:PPP2R5E; NbExp=3; IntAct=EBI-302388, EBI-968374;
CC       P60510:PPP4C; NbExp=3; IntAct=EBI-302388, EBI-1046072;
CC       P53041:PPP5C; NbExp=3; IntAct=EBI-302388, EBI-716663;
CC       Q04206:RELA; NbExp=2; IntAct=EBI-302388, EBI-73886;
CC       O43815:STRN; NbExp=4; IntAct=EBI-302388, EBI-1046642;
CC       P04637:TP53; NbExp=2; IntAct=EBI-302388, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Chromosome,
CC       centromere. Note=Centromeric localization requires the presence of
CC       BUB1.
CC   -!- DOMAIN: Each HEAT repeat appears to consist of two alpha helices
CC       joined by a hydrophilic region, the intrarepeat loop. The repeat
CC       units may be arranged laterally to form a rod-like structure.
CC   -!- SIMILARITY: Belongs to the phosphatase 2A regulatory subunit A
CC       family.
CC   -!- SIMILARITY: Contains 15 HEAT repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M31786; AAA35531.1; -; mRNA.
DR   EMBL; J02902; AAA36399.1; -; mRNA.
DR   EMBL; CR450340; CAG29336.1; -; mRNA.
DR   EMBL; BC001537; AAH01537.1; -; mRNA.
DR   CCDS; CCDS12849.1; -.
DR   PIR; A34541; A34541.
DR   RefSeq; NP_055040.2; NM_014225.5.
DR   UniGene; Hs.467192; -.
DR   PDB; 1B3U; X-ray; 2.30 A; A/B=2-589.
DR   PDB; 2IE3; X-ray; 2.80 A; A=1-589.
DR   PDB; 2IE4; X-ray; 2.60 A; A=1-589.
DR   PDB; 2NPP; X-ray; 3.30 A; A/D=1-589.
DR   PDB; 2NYL; X-ray; 3.80 A; A/D=8-589.
DR   PDB; 2NYM; X-ray; 3.60 A; A/D=8-589.
DR   PDB; 2PKG; X-ray; 3.30 A; A/B=10-589.
DR   PDB; 3C5W; X-ray; 2.80 A; A=9-589.
DR   PDB; 3DW8; X-ray; 2.85 A; A/D=9-589.
DR   PDB; 3K7V; X-ray; 2.85 A; A=1-589.
DR   PDB; 3K7W; X-ray; 2.96 A; A=1-589.
DR   PDB; 4I5L; X-ray; 2.43 A; A/D=6-589.
DR   PDB; 4I5N; X-ray; 2.80 A; A/D=6-589.
DR   PDB; 4LAC; X-ray; 2.82 A; A=404-589.
DR   PDBsum; 1B3U; -.
DR   PDBsum; 2IE3; -.
DR   PDBsum; 2IE4; -.
DR   PDBsum; 2NPP; -.
DR   PDBsum; 2NYL; -.
DR   PDBsum; 2NYM; -.
DR   PDBsum; 2PKG; -.
DR   PDBsum; 3C5W; -.
DR   PDBsum; 3DW8; -.
DR   PDBsum; 3K7V; -.
DR   PDBsum; 3K7W; -.
DR   PDBsum; 4I5L; -.
DR   PDBsum; 4I5N; -.
DR   PDBsum; 4LAC; -.
DR   ProteinModelPortal; P30153; -.
DR   SMR; P30153; 2-589.
DR   BioGrid; 111510; 143.
DR   DIP; DIP-29394N; -.
DR   IntAct; P30153; 116.
DR   MINT; MINT-1141071; -.
DR   STRING; 9606.ENSP00000324804; -.
DR   PhosphoSite; P30153; -.
DR   DMDM; 143811355; -.
DR   OGP; P30153; -.
DR   REPRODUCTION-2DPAGE; IPI00554737; -.
DR   MaxQB; P30153; -.
DR   PaxDb; P30153; -.
DR   PRIDE; P30153; -.
DR   DNASU; 5518; -.
DR   Ensembl; ENST00000322088; ENSP00000324804; ENSG00000105568.
DR   GeneID; 5518; -.
DR   KEGG; hsa:5518; -.
DR   UCSC; uc002pyp.3; human.
DR   CTD; 5518; -.
DR   GeneCards; GC19P052693; -.
DR   HGNC; HGNC:9302; PPP2R1A.
DR   HPA; CAB018599; -.
DR   MIM; 605983; gene.
DR   neXtProt; NX_P30153; -.
DR   PharmGKB; PA33666; -.
DR   eggNOG; NOG247268; -.
DR   HOGENOM; HOG000078539; -.
DR   HOVERGEN; HBG000011; -.
DR   InParanoid; P30153; -.
DR   KO; K03456; -.
DR   OMA; RNLCQDD; -.
DR   OrthoDB; EOG764722; -.
DR   PhylomeDB; P30153; -.
DR   TreeFam; TF105552; -.
DR   BioCyc; MetaCyc:ENSG00000105568-MONOMER; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_115566; Cell Cycle.
DR   Reactome; REACT_116125; Disease.
DR   Reactome; REACT_21257; Metabolism of RNA.
DR   Reactome; REACT_21300; Mitotic M-M/G1 phases.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6782; TRAF6 Mediated Induction of proinflammatory cytokines.
DR   Reactome; REACT_6900; Immune System.
DR   Reactome; REACT_71; Gene Expression.
DR   SignaLink; P30153; -.
DR   EvolutionaryTrace; P30153; -.
DR   GeneWiki; PPP2R1A; -.
DR   GenomeRNAi; 5518; -.
DR   NextBio; 21342; -.
DR   PMAP-CutDB; P30153; -.
DR   PRO; PR:P30153; -.
DR   ArrayExpress; P30153; -.
DR   Bgee; P30153; -.
DR   CleanEx; HS_PPP2R1A; -.
DR   Genevestigator; P30153; -.
DR   GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; NAS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; NAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; NAS:UniProtKB.
DR   GO; GO:0000159; C:protein phosphatase type 2A complex; IDA:UniProtKB.
DR   GO; GO:0003823; F:antigen binding; IPI:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0008601; F:protein phosphatase type 2A regulator activity; TAS:UniProtKB.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0006672; P:ceramide metabolic process; NAS:UniProtKB.
DR   GO; GO:0007059; P:chromosome segregation; IDA:UniProtKB.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0000188; P:inactivation of MAPK activity; NAS:UniProtKB.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0007084; P:mitotic nuclear envelope reassembly; TAS:Reactome.
DR   GO; GO:0016071; P:mRNA metabolic process; TAS:Reactome.
DR   GO; GO:0030308; P:negative regulation of cell growth; NAS:UniProtKB.
DR   GO; GO:0042518; P:negative regulation of tyrosine phosphorylation of Stat3 protein; NAS:UniProtKB.
DR   GO; GO:0000184; P:nuclear-transcribed mRNA catabolic process, nonsense-mediated decay; TAS:Reactome.
DR   GO; GO:0070262; P:peptidyl-serine dephosphorylation; IEA:Ensembl.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0006461; P:protein complex assembly; TAS:UniProtKB.
DR   GO; GO:0006470; P:protein dephosphorylation; TAS:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; NAS:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; NAS:UniProtKB.
DR   GO; GO:0006275; P:regulation of DNA replication; NAS:UniProtKB.
DR   GO; GO:0040008; P:regulation of growth; NAS:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0030111; P:regulation of Wnt signaling pathway; NAS:UniProtKB.
DR   GO; GO:0010033; P:response to organic substance; NAS:UniProtKB.
DR   GO; GO:0016070; P:RNA metabolic process; TAS:Reactome.
DR   GO; GO:0008380; P:RNA splicing; NAS:UniProtKB.
DR   GO; GO:0019932; P:second-messenger-mediated signaling; NAS:UniProtKB.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000357; HEAT.
DR   InterPro; IPR021133; HEAT_type_2.
DR   Pfam; PF02985; HEAT; 2.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   PROSITE; PS50077; HEAT_REPEAT; 11.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Centromere; Chromosome;
KW   Chromosome partition; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Reference proteome; Repeat.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    589       Serine/threonine-protein phosphatase 2A
FT                                65 kDa regulatory subunit A alpha
FT                                isoform.
FT                                /FTId=PRO_0000071400.
FT   REPEAT        8     46       HEAT 1.
FT   REPEAT       47     84       HEAT 2.
FT   REPEAT       85    123       HEAT 3.
FT   REPEAT      124    161       HEAT 4.
FT   REPEAT      162    200       HEAT 5.
FT   REPEAT      201    239       HEAT 6.
FT   REPEAT      240    278       HEAT 7.
FT   REPEAT      279    321       HEAT 8.
FT   REPEAT      322    360       HEAT 9.
FT   REPEAT      361    399       HEAT 10.
FT   REPEAT      400    438       HEAT 11.
FT   REPEAT      439    477       HEAT 12.
FT   REPEAT      478    516       HEAT 13.
FT   REPEAT      517    555       HEAT 14.
FT   REPEAT      556    589       HEAT 15.
FT   REGION        8    399       PP2A subunit B binding.
FT   REGION       47    321       Polyoma small and medium T antigens
FT                                Binding.
FT   REGION       85    239       SV40 small T antigen binding.
FT   REGION      400    589       PP2A subunit C binding.
FT   MOD_RES       2      2       N-acetylalanine.
FT   MOD_RES     280    280       N6-acetyllysine.
FT   CONFLICT    130    130       P -> A (in Ref. 1; AAA35531).
FT   CONFLICT    258    258       R -> A (in Ref. 2; AAA36399).
FT   CONFLICT    272    272       K -> R (in Ref. 6; AA sequence).
FT   CONFLICT    551    551       L -> P (in Ref. 3; CAG29336).
FT   TURN          6      8
FT   HELIX        11     19
FT   HELIX        25     33
FT   HELIX        35     41
FT   HELIX        44     49
FT   HELIX        51     57
FT   HELIX        63     73
FT   HELIX        78     80
FT   HELIX        83     89
FT   HELIX        90     96
FT   STRAND       99    101
FT   HELIX       102    116
FT   HELIX       121    126
FT   HELIX       128    136
FT   STRAND      138    140
FT   HELIX       141    147
FT   HELIX       148    150
FT   HELIX       151    154
FT   TURN        155    157
FT   HELIX       160    174
FT   HELIX       179    194
FT   HELIX       198    203
FT   HELIX       205    213
FT   HELIX       218    221
FT   HELIX       224    234
FT   HELIX       237    239
FT   HELIX       240    243
FT   HELIX       245    252
FT   HELIX       257    265
FT   HELIX       267    274
FT   HELIX       276    281
FT   HELIX       283    291
FT   HELIX       296    311
FT   TURN        315    317
FT   HELIX       318    324
FT   HELIX       326    334
FT   HELIX       339    346
FT   HELIX       349    352
FT   HELIX       353    356
FT   HELIX       358    364
FT   HELIX       366    373
FT   HELIX       378    385
FT   HELIX       389    394
FT   HELIX       397    412
FT   HELIX       417    434
FT   HELIX       436    438
FT   HELIX       441    449
FT   HELIX       450    452
FT   HELIX       456    473
FT   HELIX       475    481
FT   HELIX       483    488
FT   TURN        489    491
FT   HELIX       495    520
FT   HELIX       522    527
FT   HELIX       528    530
FT   HELIX       534    547
FT   HELIX       548    550
FT   HELIX       553    567
FT   HELIX       573    585
SQ   SEQUENCE   589 AA;  65309 MW;  5174EBE94D537836 CRC64;
     MAAADGDDSL YPIAVLIDEL RNEDVQLRLN SIKKLSTIAL ALGVERTRSE LLPFLTDTIY
     DEDEVLLALA EQLGTFTTLV GGPEYVHCLL PPLESLATVE ETVVRDKAVE SLRAISHEHS
     PSDLEAHFVP LVKRLAGGDW FTSRTSACGL FSVCYPRVSS AVKAELRQYF RNLCSDDTPM
     VRRAAASKLG EFAKVLELDN VKSEIIPMFS NLASDEQDSV RLLAVEACVN IAQLLPQEDL
     EALVMPTLRQ AAEDKSWRVR YMVADKFTEL QKAVGPEITK TDLVPAFQNL MKDCEAEVRA
     AASHKVKEFC ENLSADCREN VIMSQILPCI KELVSDANQH VKSALASVIM GLSPILGKDN
     TIEHLLPLFL AQLKDECPEV RLNIISNLDC VNEVIGIRQL SQSLLPAIVE LAEDAKWRVR
     LAIIEYMPLL AGQLGVEFFD EKLNSLCMAW LVDHVYAIRE AATSNLKKLV EKFGKEWAHA
     TIIPKVLAMS GDPNYLHRMT TLFCINVLSE VCGQDITTKH MLPTVLRMAG DPVANVRFNV
     AKSLQKIGPI LDNSTLQSEV KPILEKLTQD QDVDVKYFAQ EALTVLSLA
//
ID   2AAB_HUMAN              Reviewed;         601 AA.
AC   P30154; A8MY67; B0YJ69; B4DGQ6; B4DK91; B4DWW5; F8W8G1; O75620;
AC   Q8NHV8;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   09-JUL-2014, entry version 140.
DE   RecName: Full=Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform;
DE   AltName: Full=PP2A subunit A isoform PR65-beta;
DE   AltName: Full=PP2A subunit A isoform R1-beta;
GN   Name=PPP2R1B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9795170; DOI=10.1016/S0378-1119(98)00350-3;
RA   Baysal B.E., Farr J.E., Goss J.R., Devlin B., Richard C.W. III;
RT   "Genomic organization and precise physical location of protein
RT   phosphatase 2A regulatory subunit A beta isoform gene on chromosome
RT   band 11q23.";
RL   Gene 217:107-116(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-8; SER-65;
RP   ASP-90; PRO-101; GLU-343; ALA-448; GLY-504 AND ALA-545.
RX   PubMed=9765152; DOI=10.1126/science.282.5387.284;
RA   Wang S.S., Esplin E.D., Li J.L., Huang L., Gazdar A., Minna J.,
RA   Evans G.A.;
RT   "Alterations of the PPP2R1B gene in human lung and colon cancer.";
RL   Science 282:284-287(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11313745; DOI=10.1038/sj/ejhg/5200585;
RA   Baysal B.E., Willett-Brozick J.E., Taschner P.E.M., Dauwerse J.G.,
RA   Devilee P., Devlin B.;
RT   "A high-resolution integrated map spanning the SDHD gene at 11q23: a
RT   1.1-Mb BAC contig, a partial transcript map and 15 new repeat
RT   polymorphisms in a tumour-suppressor region.";
RL   Eur. J. Hum. Genet. 9:121-129(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 4 AND 5).
RC   TISSUE=Brain, Testis, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 31-601 (ISOFORM 1).
RX   PubMed=2159327; DOI=10.1021/bi00465a002;
RA   Hemmings B.A., Adams-Pearson C., Maurer F., Mueller P., Goris J.,
RA   Merlevede W., Hofsteenge J., Stone S.R.;
RT   "Alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A
RT   have a similar 39 amino acid repeating structure.";
RL   Biochemistry 29:3166-3173(1990).
RN   [10]
RP   INTERACTION WITH RAF1.
RX   PubMed=10801873; DOI=10.1074/jbc.M003259200;
RA   Abraham D., Podar K., Pacher M., Kubicek M., Welzel N., Hemmings B.A.,
RA   Dilworth S.M., Mischak H., Kolch W., Baccarini M.;
RT   "Raf-1-associated protein phosphatase 2A as a positive regulator of
RT   kinase activation.";
RL   J. Biol. Chem. 275:22300-22304(2000).
RN   [11]
RP   INTERACTION WITH IPO9.
RX   PubMed=12670497; DOI=10.1016/S0006-291X(03)00434-0;
RA   Lubert E.J., Sarge K.D.;
RT   "Interaction between protein phosphatase 2A and members of the
RT   importin beta superfamily.";
RL   Biochem. Biophys. Res. Commun. 303:908-913(2003).
RN   [12]
RP   INTERACTION WITH SGOL1.
RX   PubMed=16541025; DOI=10.1038/nature04663;
RA   Kitajima T.S., Sakuno T., Ishiguro K., Iemura S., Natsume T.,
RA   Kawashima S.A., Watanabe Y.;
RT   "Shugoshin collaborates with protein phosphatase 2A to protect
RT   cohesin.";
RL   Nature 441:46-52(2006).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [15]
RP   VARIANT ASP-90.
RX   PubMed=10597236; DOI=10.1038/sj.onc.1203070;
RA   Campbell I.G., Manolitsas T.;
RT   "Absence of PPP2R1B gene alterations in primary ovarian cancers.";
RL   Oncogene 18:6367-6369(1999).
RN   [16]
RP   VARIANTS ALA-15; PRO-365; GLU-498; ILE-499 AND GLY-500.
RX   PubMed=10896920; DOI=10.1136/gut.47.2.268;
RA   Takagi Y., Futamura M., Yamaguchi K., Aoki S., Takahashi T., Saji S.;
RT   "Alterations of the PPP2R1B gene located at 11q23 in human colorectal
RT   cancers.";
RL   Gut 47:268-271(2000).
RN   [17]
RP   VARIANT ASP-90.
RX   PubMed=11996789; DOI=10.1016/S0165-4608(01)00597-0;
RA   Hemmer S., Wasenius V.M., Haglund C., Zhu Y., Knuutila S.,
RA   Franssila K., Joensuu H.;
RT   "Alterations in the suppressor gene PPP2R1B in parathyroid
RT   hyperplasias and adenomas.";
RL   Cancer Genet. Cytogenet. 134:13-17(2002).
CC   -!- FUNCTION: The PR65 subunit of protein phosphatase 2A serves as a
CC       scaffolding molecule to coordinate the assembly of the catalytic
CC       subunit and a variable regulatory B subunit.
CC   -!- SUBUNIT: PP2A consists of a common heterodimeric core enzyme,
CC       composed of a 36 kDa catalytic subunit (subunit C) and a 65 kDa
CC       constant regulatory subunit (PR65 or subunit A), that associates
CC       with a variety of regulatory subunits. Proteins that associate
CC       with the core dimer include three families of regulatory subunits
CC       B (the R2/B/PR55/B55, R3/B''/PR72/PR130/PR59 and R5/B'/B56
CC       families), the 48 kDa variable regulatory subunit, viral proteins,
CC       and cell signaling molecules. Interacts with IPO9. Interacts with
CC       SGOL1. Interacts with RAF1.
CC   -!- INTERACTION:
CC       O08785:Clock (xeno); NbExp=2; IntAct=EBI-357094, EBI-79859;
CC       P67775:PPP2CA; NbExp=7; IntAct=EBI-357094, EBI-712311;
CC       P63151:PPP2R2A; NbExp=2; IntAct=EBI-357094, EBI-1048931;
CC       Q15172:PPP2R5A; NbExp=2; IntAct=EBI-357094, EBI-641666;
CC       Q13362:PPP2R5C; NbExp=2; IntAct=EBI-357094, EBI-1266156;
CC       Q14738:PPP2R5D; NbExp=2; IntAct=EBI-357094, EBI-396563;
CC       Q16537:PPP2R5E; NbExp=3; IntAct=EBI-357094, EBI-968374;
CC       P11233:RALA; NbExp=6; IntAct=EBI-357094, EBI-1036803;
CC       O08722:Unc5b (xeno); NbExp=4; IntAct=EBI-357094, EBI-4404185;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=P30154-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P30154-2; Sequence=VSP_036460;
CC       Name=3;
CC         IsoId=P30154-3; Sequence=VSP_043379, VSP_036460;
CC         Note=No experimental confirmation available;
CC       Name=4;
CC         IsoId=P30154-4; Sequence=VSP_045275;
CC         Note=No experimental confirmation available;
CC       Name=5;
CC         IsoId=P30154-5; Sequence=VSP_046684;
CC   -!- DOMAIN: Each HEAT repeat appears to consist of two alpha helices
CC       joined by a hydrophilic region, the intrarepeat loop. The repeat
CC       units may be arranged laterally to form a rod-like structure.
CC   -!- SIMILARITY: Belongs to the phosphatase 2A regulatory subunit A
CC       family.
CC   -!- SIMILARITY: Contains 15 HEAT repeats.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA59983.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part;
CC       Sequence=BAG59103.1; Type=Frameshift; Positions=540;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF083439; AAC63525.1; -; Genomic_DNA.
DR   EMBL; AF083425; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083426; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083427; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083428; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083429; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083430; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083431; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083432; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083433; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083434; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083435; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083436; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083437; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083438; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF087438; AAC69624.1; -; mRNA.
DR   EMBL; AF163473; AAG39644.1; -; mRNA.
DR   EMBL; AK294716; BAG57867.1; -; mRNA.
DR   EMBL; AK296455; BAG59103.1; ALT_FRAME; mRNA.
DR   EMBL; AK301705; BAG63177.1; -; mRNA.
DR   EMBL; EF445011; ACA06046.1; -; Genomic_DNA.
DR   EMBL; EF445011; ACA06047.1; -; Genomic_DNA.
DR   EMBL; AP000925; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471065; EAW67150.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67151.1; -; Genomic_DNA.
DR   EMBL; BC027596; AAH27596.1; -; mRNA.
DR   EMBL; M65254; AAA59983.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS53706.1; -. [P30154-3]
DR   CCDS; CCDS53707.1; -. [P30154-5]
DR   CCDS; CCDS53708.1; -. [P30154-4]
DR   CCDS; CCDS8348.1; -. [P30154-2]
DR   CCDS; CCDS8349.1; -. [P30154-1]
DR   PIR; B34541; B34541.
DR   RefSeq; NP_001171033.1; NM_001177562.1. [P30154-4]
DR   RefSeq; NP_001171034.1; NM_001177563.1. [P30154-5]
DR   RefSeq; NP_002707.3; NM_002716.4. [P30154-1]
DR   RefSeq; NP_859050.1; NM_181699.2. [P30154-2]
DR   RefSeq; NP_859051.1; NM_181700.1. [P30154-3]
DR   UniGene; Hs.269128; -.
DR   UniGene; Hs.584790; -.
DR   ProteinModelPortal; P30154; -.
DR   SMR; P30154; 19-601.
DR   BioGrid; 111511; 56.
DR   IntAct; P30154; 64.
DR   MINT; MINT-1150161; -.
DR   STRING; 9606.ENSP00000311344; -.
DR   PhosphoSite; P30154; -.
DR   DMDM; 116241236; -.
DR   MaxQB; P30154; -.
DR   PaxDb; P30154; -.
DR   PRIDE; P30154; -.
DR   DNASU; 5519; -.
DR   Ensembl; ENST00000311129; ENSP00000311344; ENSG00000137713. [P30154-2]
DR   Ensembl; ENST00000341980; ENSP00000343317; ENSG00000137713. [P30154-4]
DR   Ensembl; ENST00000393055; ENSP00000376775; ENSG00000137713. [P30154-5]
DR   Ensembl; ENST00000426998; ENSP00000410671; ENSG00000137713. [P30154-3]
DR   Ensembl; ENST00000527614; ENSP00000437193; ENSG00000137713. [P30154-1]
DR   Ensembl; ENST00000571902; ENSP00000459644; ENSG00000262764. [P30154-3]
DR   Ensembl; ENST00000571959; ENSP00000459838; ENSG00000262764. [P30154-2]
DR   Ensembl; ENST00000573946; ENSP00000459456; ENSG00000262764. [P30154-5]
DR   Ensembl; ENST00000575443; ENSP00000459827; ENSG00000262764. [P30154-4]
DR   Ensembl; ENST00000576276; ENSP00000461254; ENSG00000262764. [P30154-1]
DR   GeneID; 5519; -.
DR   KEGG; hsa:5519; -.
DR   UCSC; uc001plw.1; human. [P30154-2]
DR   UCSC; uc001plx.1; human. [P30154-1]
DR   UCSC; uc010rwi.1; human. [P30154-3]
DR   CTD; 5519; -.
DR   GeneCards; GC11M111642; -.
DR   HGNC; HGNC:9303; PPP2R1B.
DR   HPA; CAB004034; -.
DR   HPA; HPA018908; -.
DR   MIM; 603113; gene.
DR   neXtProt; NX_P30154; -.
DR   PharmGKB; PA33667; -.
DR   eggNOG; NOG247268; -.
DR   HOGENOM; HOG000078539; -.
DR   HOVERGEN; HBG000011; -.
DR   KO; K03456; -.
DR   OMA; NREQIIM; -.
DR   OrthoDB; EOG764722; -.
DR   PhylomeDB; P30154; -.
DR   TreeFam; TF105552; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_115566; Cell Cycle.
DR   Reactome; REACT_116125; Disease.
DR   Reactome; REACT_21300; Mitotic M-M/G1 phases.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6782; TRAF6 Mediated Induction of proinflammatory cytokines.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; PPP2R1B; human.
DR   GeneWiki; PPP2R1B; -.
DR   GenomeRNAi; 5519; -.
DR   NextBio; 21346; -.
DR   PRO; PR:P30154; -.
DR   ArrayExpress; P30154; -.
DR   Bgee; P30154; -.
DR   CleanEx; HS_PPP2R1B; -.
DR   Genevestigator; P30154; -.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0060561; P:apoptotic process involved in morphogenesis; IMP:UniProtKB.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000357; HEAT.
DR   InterPro; IPR021133; HEAT_type_2.
DR   Pfam; PF02985; HEAT; 2.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   PROSITE; PS50077; HEAT_REPEAT; 12.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Complete proteome; Polymorphism;
KW   Reference proteome; Repeat.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    601       Serine/threonine-protein phosphatase 2A
FT                                65 kDa regulatory subunit A beta isoform.
FT                                /FTId=PRO_0000071403.
FT   REPEAT       20     58       HEAT 1.
FT   REPEAT       59     96       HEAT 2.
FT   REPEAT       97    135       HEAT 3.
FT   REPEAT      136    173       HEAT 4.
FT   REPEAT      174    212       HEAT 5.
FT   REPEAT      213    251       HEAT 6.
FT   REPEAT      252    290       HEAT 7.
FT   REPEAT      291    333       HEAT 8.
FT   REPEAT      334    372       HEAT 9.
FT   REPEAT      373    411       HEAT 10.
FT   REPEAT      412    450       HEAT 11.
FT   REPEAT      451    489       HEAT 12.
FT   REPEAT      490    528       HEAT 13.
FT   REPEAT      529    567       HEAT 14.
FT   REPEAT      568    601       HEAT 15.
FT   MOD_RES       2      2       N-acetylalanine.
FT   VAR_SEQ      39    102       Missing (in isoform 3).
FT                                /FTId=VSP_043379.
FT   VAR_SEQ     103    229       Missing (in isoform 5).
FT                                /FTId=VSP_046684.
FT   VAR_SEQ     344    388       Missing (in isoform 4).
FT                                /FTId=VSP_045275.
FT   VAR_SEQ     598    601       LALA -> VAQRLRKLEFPVKDSGEPSVPRADKNHFPRPTV
FT                                PGEDMGKGPVYQLRGDTRDTLAQLGIAELVHFSQSTD (in
FT                                isoform 2 and isoform 3).
FT                                /FTId=VSP_036460.
FT   VARIANT       8      8       G -> R (in a lung cancer patient;
FT                                dbSNP:rs142771326).
FT                                /FTId=VAR_022895.
FT   VARIANT      15     15       G -> A (in a colorectal cancer patient).
FT                                /FTId=VAR_022896.
FT   VARIANT      65     65       P -> S (in a lung cancer patient).
FT                                /FTId=VAR_022897.
FT   VARIANT      90     90       G -> D (in a lung cancer patient;
FT                                dbSNP:rs1805076).
FT                                /FTId=VAR_006384.
FT   VARIANT     101    101       L -> P (in a colon adenocarcinoma).
FT                                /FTId=VAR_022898.
FT   VARIANT     343    343       K -> E (in a lung cancer patient).
FT                                /FTId=VAR_022899.
FT   VARIANT     365    365       S -> P (in a colorectal cancer patient).
FT                                /FTId=VAR_022900.
FT   VARIANT     448    448       V -> A (in a colon adenocarcinoma).
FT                                /FTId=VAR_022901.
FT   VARIANT     498    498       V -> E (in a colorectal cancer patient).
FT                                /FTId=VAR_022902.
FT   VARIANT     499    499       L -> I (in a colorectal cancer patient).
FT                                /FTId=VAR_022903.
FT   VARIANT     500    500       V -> G (in a colorectal cancer patient).
FT                                /FTId=VAR_022904.
FT   VARIANT     504    504       D -> G (in a lung cancer patient).
FT                                /FTId=VAR_022905.
FT   VARIANT     545    545       V -> A (in a colon adenocarcinoma).
FT                                /FTId=VAR_022906.
FT   CONFLICT     74     74       E -> V (in Ref. 9; AAA59983).
FT   CONFLICT    178    178       I -> T (in Ref. 1; AAC63525, 3; AAG39644
FT                                and 9; AAA59983).
FT   CONFLICT    211    211       D -> G (in Ref. 4; BAG57867).
FT   CONFLICT    411    411       Q -> R (in Ref. 9; AAA59983).
FT   CONFLICT    503    503       N -> S (in Ref. 4; BAG57867).
SQ   SEQUENCE   601 AA;  66214 MW;  86AB20D7505210B0 CRC64;
     MAGASELGTG PGAAGGDGDD SLYPIAVLID ELRNEDVQLR LNSIKKLSTI ALALGVERTR
     SELLPFLTDT IYDEDEVLLA LAEQLGNFTG LVGGPDFAHC LLPPLENLAT VEETVVRDKA
     VESLRQISQE HTPVALEAYF VPLVKRLASG DWFTSRTSAC GLFSVCYPRA SNAVKAEIRQ
     QFRSLCSDDT PMVRRAAASK LGEFAKVLEL DSVKSEIVPL FTSLASDEQD SVRLLAVEAC
     VSIAQLLSQD DLETLVMPTL RQAAEDKSWR VRYMVADRFS ELQKAMGPKI TLNDLIPAFQ
     NLLKDCEAEV RAAAAHKVKE LGENLPIEDR ETIIMNQILP YIKELVSDTN QHVKSALASV
     IMGLSTILGK ENTIEHLLPL FLAQLKDECP DVRLNIISNL DCVNEVIGIR QLSQSLLPAI
     VELAEDAKWR VRLAIIEYMP LLAGQLGVEF FDEKLNSLCM AWLVDHVYAI REAATNNLMK
     LVQKFGTEWA QNTIVPKVLV MANDPNYLHR MTTLFCINAL SEACGQEITT KQMLPIVLKM
     AGDQVANVRF NVAKSLQKIG PILDTNALQG EVKPVLQKLG QDEDMDVKYF AQEAISVLAL
     A
//
ID   2B11_HUMAN              Reviewed;         266 AA.
AC   P04229; A4F5N0; A8K098; O62869; P13758; Q06662; Q30116; Q30117;
AC   Q5Y7E9; Q7M2H4; Q95461; Q9BCL7; Q9GIK5; Q9MXZ0; Q9MXZ5; Q9TQ91;
DT   20-MAR-1987, integrated into UniProtKB/Swiss-Prot.
DT   29-AUG-2003, sequence version 2.
DT   09-JUL-2014, entry version 143.
DE   RecName: Full=HLA class II histocompatibility antigen, DRB1-1 beta chain;
DE   AltName: Full=MHC class II antigen DRB1*1;
DE            Short=DR-1;
DE            Short=DR1;
DE   Flags: Precursor;
GN   Name=HLA-DRB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*01:01).
RX   PubMed=2998758;
RA   Tonnelle C., Demars R., Long E.O.;
RT   "DO beta: a new beta chain gene in HLA-D with a distinct regulation of
RT   expression.";
RL   EMBO J. 4:2839-2847(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*01:01).
RX   PubMed=3858829; DOI=10.1073/pnas.82.10.3405;
RA   Bell J.I., Estess P., St John T., Saiki R., Watling D.L., Erlich H.A.,
RA   McDevitt H.O.;
RT   "DNA sequence and characterization of human class II major
RT   histocompatibility complex beta chains from the DR1 haplotype.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:3405-3409(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*01:03).
RX   PubMed=1688595;
RA   Coppin H.L., Avoustin P., Fabron J., Huchenq A., Garnier J.-M.,
RA   Thomsen M., De Preval C.;
RT   "Evolution of the HLA-DR1 gene family. Structural and functional
RT   analysis of the new allele 'DR-BON'.";
RL   J. Immunol. 144:984-989(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=16140993; DOI=10.1101/gr.3554305;
RA   Raymond C.K., Kas A., Paddock M., Qiu R., Zhou Y., Subramanian S.,
RA   Chang J., Palmieri A., Haugen E., Kaul R., Olson M.V.;
RT   "Ancient haplotypes of the HLA Class II region.";
RL   Genome Res. 15:1250-1257(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE DRB1*01:01), AND VARIANT
RP   ARG-262.
RX   PubMed=17345114; DOI=10.1007/s00251-007-0196-8;
RA   von Salome J., Gyllensten U., Bergstroem T.F.;
RT   "Full-length sequence analysis of the HLA-DRB1 locus suggests a recent
RT   origin of alleles.";
RL   Immunogenetics 59:261-271(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29.
RC   TISSUE=B-cell;
RX   PubMed=8462990; DOI=10.1007/BF00216386;
RA   Louis P., Eliaou J.F., Kerlan-Candon S., Pinet V., Vincent R.,
RA   Clot J.;
RT   "Polymorphism in the regulatory region of HLA-DRB genes correlating
RT   with haplotype evolution.";
RL   Immunogenetics 38:21-26(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELE DRB1*01:04).
RA   Middleton D., Versluis L.F., Tilanus M.G.J.;
RL   Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   PROTEIN SEQUENCE OF 30-64.
RC   TISSUE=B-cell;
RX   PubMed=6600932; DOI=10.1021/bi00270a027;
RA   Walker L.E., Hewick R., Hunkapiller M.W., Hood L.E., Dreyer W.J.,
RA   Reisfeld R.A.;
RT   "N-terminal amino acid sequences of the alpha and beta chains of HLA-
RT   DR1 and HLA-DR2 antigens.";
RL   Biochemistry 22:185-188(1983).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*01:06).
RX   PubMed=10203026; DOI=10.1034/j.1399-0039.1999.530313.x;
RA   Palou E., Mongay L., Arias M.T., Isart F., Suarez B., Masso M.,
RA   Fabregat V., Martorell J., Gaya A.;
RT   "Identification of a novel DRB1-allele (DRB1*0106) by sequence-based
RT   typing.";
RL   Tissue Antigens 53:308-310(1999).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*01:07).
RX   PubMed=12753659; DOI=10.1034/j.1399-0039.2003.00034.x;
RA   Voorter C.E.M., Hepkema B.G., Lems S.P.M., van den Berg-Loonen E.M.;
RT   "Identification of three new DRB1 alleles, DRB1*0107, *0425 and *13012
RT   and confirmation of DRB4*01033.";
RL   Tissue Antigens 61:398-402(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*01:05).
RA   Kashiwase K., Akaza T., Juji T.;
RT   "HLA-DRB1 new alleles.";
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*01:07).
RA   Dormoy A., Froelich N., Leisenbach R., Tongio M.M.;
RT   "A new HLA-DRB1*01 allele.";
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-122 (ALLELE DRB1*01:02).
RC   TISSUE=Blood;
RA   Hashemi S., Couture C., Cole R., Buyse I.;
RT   "Identification and sequencing of a novel DRB1*01 allele.";
RL   Submitted (AUG-1995) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 37-266 (ALLELE DRB1*01:02).
RX   PubMed=2453563;
RA   Hurley C.K., Ziff B.L., Silver J., Gregersen P.K., Hartzman R.,
RA   Johnson A.H.;
RT   "Polymorphism of the HLA-DR1 haplotype in American blacks.
RT   Identification of a DR1 beta-chain determinant recognized in the mixed
RT   lymphocyte reaction.";
RL   J. Immunol. 140:4019-4023(1988).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 43-115 (ALLELES DRB1*01:01 AND
RP   DRB1*01:02).
RC   TISSUE=Blood;
RA   Arnaiz-Villena A.;
RT   "HLA class II polymorphism.";
RL   Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   DISEASE.
RX   PubMed=14508706; DOI=10.1086/378097;
RA   Rossman M.D., Thompson B., Frederick M., Maliarik M., Iannuzzi M.C.,
RA   Rybicki B.A., Pandey J.P., Newman L.S., Magira E., Beznik-Cizman B.,
RA   Monos D.;
RT   "HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks
RT   and whites.";
RL   Am. J. Hum. Genet. 73:720-735(2003).
RN   [18]
RP   REVIEW.
RX   PubMed=8598037; DOI=10.1016/S0092-8674(00)81025-9;
RA   Cresswell P.;
RT   "Invariant chain structure and MHC class II function.";
RL   Cell 84:505-507(1996).
RN   [19]
RP   REVIEW.
RX   PubMed=11684289; DOI=10.1016/S0161-5890(01)00069-4;
RA   Villadangos J.A.;
RT   "Presentation of antigens by MHC class II molecules: getting the most
RT   out of them.";
RL   Mol. Immunol. 38:329-346(2001).
RN   [20]
RP   REVIEW.
RX   PubMed=17241953; DOI=10.1016/j.immuni.2007.01.005;
RA   Menendez-Benito V., Neefjes J.;
RT   "Autophagy in MHC class II presentation: sampling from within.";
RL   Immunity 26:1-3(2007).
RN   [21]
RP   REVIEW.
RX   PubMed=18046453; DOI=10.1038/sj.emboj.7601945;
RA   Rocha N., Neefjes J.;
RT   "MHC class II molecules on the move for successful antigen
RT   presentation.";
RL   EMBO J. 27:1-5(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   UBIQUITINATION BY MARCH1, AND SUBCELLULAR LOCATION.
RX   PubMed=18305173; DOI=10.1073/pnas.0708874105;
RA   De Gassart A., Camosseto V., Thibodeau J., Ceppi M., Catalan N.,
RA   Pierre P., Gatti E.;
RT   "MHC class II stabilization at the surface of human dendritic cells is
RT   the result of maturation-dependent MARCH I down-regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3491-3496(2008).
RN   [24]
RP   REVIEW.
RX   PubMed=19092054; DOI=10.1242/jcs.035089;
RA   Berger A.C., Roche P.A.;
RT   "MHC class II transport at a glance.";
RL   J. Cell Sci. 122:1-4(2009).
RN   [25]
RP   REVIEW.
RX   PubMed=19533806; DOI=10.3748/wjg.15.2855;
RA   Beswick E.J., Reyes V.E.;
RT   "CD74 in antigen presentation, inflammation, and cancers of the
RT   gastrointestinal tract.";
RL   World J. Gastroenterol. 15:2855-2861(2009).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 32-219.
RX   PubMed=8316295; DOI=10.1038/364033a0;
RA   Brown J.H., Jardetzky T.S., Gorga J.C., Stern L.J., Urban R.G.,
RA   Strominger J.L., Wiley D.C.;
RT   "Three-dimensional structure of the human class II histocompatibility
RT   antigen HLA-DR1.";
RL   Nature 364:33-39(1993).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 32-219.
RX   PubMed=8145819; DOI=10.1038/368215a0;
RA   Stern L.J., Brown J.H., Jardetzky T.J., Gorga J.C., Urban R.G.,
RA   Strominger J.L., Wiley D.C.;
RT   "Crystal structure of the human class II MHC protein HLA-DR1 complexed
RT   with an influenza virus peptide.";
RL   Nature 368:215-221(1994).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF COMPLEX WITH SEB.
RX   PubMed=8152483; DOI=10.1038/368711a0;
RA   Jardetzky T.S., Brown J.H., Gorga J.C., Stern L.J., Urban R.G.,
RA   Chi Y.I., Stauffacher C., Strominger J.L., Wiley D.C.;
RT   "Three-dimensional structure of a human class II histocompatibility
RT   molecule complexed with superantigen.";
RL   Nature 368:711-718(1994).
CC   -!- FUNCTION: Binds peptides derived from antigens that access the
CC       endocytic route of antigen presenting cells (APC) and presents
CC       them on the cell surface for recognition by the CD4 T-cells. The
CC       peptide binding cleft accommodates peptides of 10-30 residues. The
CC       peptides presented by MHC class II molecules are generated mostly
CC       by degradation of proteins that access the endocytic route; where
CC       they are processed by lysosomal proteases and other hydrolases.
CC       Exogenous antigens that have been endocytosed by the APC are thus
CC       readily available for presentation via MHC II molecules; and for
CC       this reason this antigen presentation pathway is usually referred
CC       to as exogenous. As membrane proteins on their way to degradation
CC       in lysosomes as part of their normal turn-over are also contained
CC       in the endosomal/lysosomal compartments; exogenous antigens must
CC       compete with those derived from endogenous components. Autophagy
CC       is also a source of endogenous peptides; autophagosomes
CC       constitutively fuse with MHC class II loading compartments. In
CC       addition to APCs; other cells of the gastrointestinal tract; such
CC       as epithelial cells; express MHC class II molecules and CD74 and
CC       act as APCs; which is an unusual trait of the GI tract. To produce
CC       a MHC class II molecule that presents an antigen; three MHC class
CC       II molecules (heterodimers of an alpha and a beta chain) associate
CC       with a CD74 trimer in the ER to form a heterononamer. Soon after
CC       the entry of this complex into the endosomal/lysosomal system
CC       where antigen processing occurs; CD74 undergoes a sequential
CC       degradation by various proteases; including CTSS and CTSL; leaving
CC       a small fragment termed CLIP (class-II-associated invariant chain
CC       peptide). The removal of CLIP is facilitated by HLA-DM via direct
CC       binding to the alpha-beta-CLIP complex so that CLIP is released.
CC       HLA-DM stabilizes MHC class II molecules until primary high
CC       affinity antigenic peptides are bound. The MHC II molecule bound
CC       to a peptide is then transported to the cell membrane surface. In
CC       B-cells; the interaction between HLA-DM and MHC class II molecules
CC       is regulated by HLA-DO. Primary dendritic cells (DCs) also to
CC       express HLA-DO. Lysosomal microenvironment has been implicated in
CC       the regulation of antigen loading into MHC II molecules; increased
CC       acidification produces increased proteolysis and efficient peptide
CC       loading.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit; also referred
CC       as MHC class II molecule. In the endoplasmic reticulum (ER) it
CC       forms a heterononamer; 3 MHC class II molecules bind to a CD74
CC       homotrimer (also known as invariant chain or HLA class II
CC       histocompatibility antigen gamma chain). In the
CC       endosomal/lysosomal system; CD74 undergoes sequential degradation
CC       by various proteases; leaving a small fragment termed CLIP on each
CC       MHC class II molecule. MHC class II molecule interacts with
CC       HLA_DM, and HLA_DO in B-cells, in order to release CLIP and
CC       facilitate the binding of antigenic peptides.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane; Single-pass type I
CC       membrane protein. Golgi apparatus, trans-Golgi network membrane;
CC       Single-pass type I membrane protein. Endosome membrane; Single-
CC       pass type I membrane protein. Lysosome membrane; Single-pass type
CC       I membrane protein. Late endosome membrane; Single-pass type I
CC       membrane protein. Note=The MHC class II complex transits through a
CC       number of intracellular compartments in the endocytic pathway
CC       until it reaches the cell membrane for antigen presentation.
CC   -!- PTM: Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to
CC       sorting into the endosome system and down-regulation of MHC class
CC       II (Probable).
CC   -!- POLYMORPHISM: The following alleles of DRB1-1 are known:
CC       DRB1*01:01; DRB1*01:02; DRB1*01:03; DRB1*01:04; DRB1*01:05;
CC       DRB1*01:06; DRB1*01:07; DRB1*01:08; DRB1*01:09; DRB1*01:10;
CC       DRB1*01:11; DRB1*01:12; DRB1*01:13; DRB1*01:14; DRB1*01:15;
CC       DRB1*01:16; DRB1*01:17; DRB1*01:18; DRB1*01:19; DRB1*01:20 and
CC       DRB1*01:21. The sequence shown is that of DRB1*01:01.
CC   -!- DISEASE: Sarcoidosis 1 (SS1) [MIM:181000]: An idiopathic,
CC       systemic, inflammatory disease characterized by the formation of
CC       immune granulomas in involved organs. Granulomas predominantly
CC       invade the lungs and the lymphatic system, but also skin, liver,
CC       spleen, eyes and other organs may be involved. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the MHC class II family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X03069; CAA26873.1; -; mRNA.
DR   EMBL; M11161; AAA59781.1; -; mRNA.
DR   EMBL; M33600; AAA59782.1; -; mRNA.
DR   EMBL; AY663400; AAU87993.1; -; Genomic_DNA.
DR   EMBL; AM419948; CAL99240.1; -; Genomic_DNA.
DR   EMBL; AK289463; BAF82152.1; -; mRNA.
DR   EMBL; X64547; CAA45845.1; -; Genomic_DNA.
DR   EMBL; X99896; CAA68171.1; -; mRNA.
DR   EMBL; AF089723; AAD51131.1; -; Genomic_DNA.
DR   EMBL; AJ276206; CAC27123.1; -; Genomic_DNA.
DR   EMBL; AB015184; BAA28761.1; -; Genomic_DNA.
DR   EMBL; AJ303118; CAC19693.1; -; Genomic_DNA.
DR   EMBL; Z50871; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M21008; AAA59780.1; -; mRNA.
DR   EMBL; AF029288; AAF65497.1; -; Genomic_DNA.
DR   EMBL; AF029293; AAF65502.1; -; Genomic_DNA.
DR   PIR; A19197; A19197.
DR   PIR; D24669; HLHU1B.
DR   PIR; I56072; I56072.
DR   PIR; PH0147; PH0147.
DR   UniGene; Hs.534322; -.
DR   UniGene; Hs.696211; -.
DR   UniGene; Hs.736560; -.
DR   PDB; 1AQD; X-ray; 2.45 A; B/E/H/K=30-227.
DR   PDB; 1DLH; X-ray; 2.80 A; B/E=32-219.
DR   PDB; 1FYT; X-ray; 2.60 A; B=30-221.
DR   PDB; 1HXY; X-ray; 2.60 A; B=30-219.
DR   PDB; 1JWM; X-ray; 2.70 A; B=30-219.
DR   PDB; 1JWS; X-ray; 2.60 A; B=30-219.
DR   PDB; 1JWU; X-ray; 2.30 A; B=30-219.
DR   PDB; 1KG0; X-ray; 2.65 A; B=32-219.
DR   PDB; 1KLG; X-ray; 2.40 A; B=30-219.
DR   PDB; 1KLU; X-ray; 1.93 A; B=30-219.
DR   PDB; 1LO5; X-ray; 3.20 A; B=30-219.
DR   PDB; 1PYW; X-ray; 2.10 A; B=30-219.
DR   PDB; 1R5I; X-ray; 2.60 A; B/F=30-219.
DR   PDB; 1SEB; X-ray; 2.70 A; B/F=30-221.
DR   PDB; 1SJE; X-ray; 2.45 A; B=30-219.
DR   PDB; 1SJH; X-ray; 2.25 A; B=30-219.
DR   PDB; 1T5W; X-ray; 2.40 A; B/E=30-219.
DR   PDB; 1T5X; X-ray; 2.50 A; B=30-219.
DR   PDB; 2FSE; X-ray; 3.10 A; B/D=33-219.
DR   PDB; 2G9H; X-ray; 2.00 A; B=30-219.
DR   PDB; 2IAM; X-ray; 2.80 A; B=30-219.
DR   PDB; 2IAN; X-ray; 2.80 A; B/G/L/Q=30-219.
DR   PDB; 2ICW; X-ray; 2.41 A; B/E=30-219.
DR   PDB; 2IPK; X-ray; 2.30 A; B=30-219.
DR   PDB; 2OJE; X-ray; 3.00 A; B/F=30-219.
DR   PDB; 2XN9; X-ray; 2.30 A; E=30-219.
DR   PDB; 3L6F; X-ray; 2.10 A; B=30-221.
DR   PDB; 3PDO; X-ray; 1.95 A; B=30-227.
DR   PDB; 3PGC; X-ray; 2.66 A; B/E=30-227.
DR   PDB; 3PGD; X-ray; 2.72 A; B/E=30-227.
DR   PDB; 3QXA; X-ray; 2.71 A; B/E=30-219.
DR   PDB; 3QXD; X-ray; 2.30 A; B/E=30-219.
DR   PDB; 3S4S; X-ray; 2.40 A; B/E=30-221.
DR   PDB; 3S5L; X-ray; 2.10 A; B/E=30-221.
DR   PDB; 4AEN; X-ray; 2.20 A; B=30-227.
DR   PDB; 4AH2; X-ray; 2.36 A; B=30-227.
DR   PDB; 4E41; X-ray; 2.60 A; B/G=30-219.
DR   PDB; 4FQX; X-ray; 2.60 A; B=30-221.
DR   PDB; 4GBX; X-ray; 3.00 A; B=30-220.
DR   PDB; 4I5B; X-ray; 2.12 A; B/E=31-222.
DR   PDBsum; 1AQD; -.
DR   PDBsum; 1DLH; -.
DR   PDBsum; 1FYT; -.
DR   PDBsum; 1HXY; -.
DR   PDBsum; 1JWM; -.
DR   PDBsum; 1JWS; -.
DR   PDBsum; 1JWU; -.
DR   PDBsum; 1KG0; -.
DR   PDBsum; 1KLG; -.
DR   PDBsum; 1KLU; -.
DR   PDBsum; 1LO5; -.
DR   PDBsum; 1PYW; -.
DR   PDBsum; 1R5I; -.
DR   PDBsum; 1SEB; -.
DR   PDBsum; 1SJE; -.
DR   PDBsum; 1SJH; -.
DR   PDBsum; 1T5W; -.
DR   PDBsum; 1T5X; -.
DR   PDBsum; 2FSE; -.
DR   PDBsum; 2G9H; -.
DR   PDBsum; 2IAM; -.
DR   PDBsum; 2IAN; -.
DR   PDBsum; 2ICW; -.
DR   PDBsum; 2IPK; -.
DR   PDBsum; 2OJE; -.
DR   PDBsum; 2XN9; -.
DR   PDBsum; 3L6F; -.
DR   PDBsum; 3PDO; -.
DR   PDBsum; 3PGC; -.
DR   PDBsum; 3PGD; -.
DR   PDBsum; 3QXA; -.
DR   PDBsum; 3QXD; -.
DR   PDBsum; 3S4S; -.
DR   PDBsum; 3S5L; -.
DR   PDBsum; 4AEN; -.
DR   PDBsum; 4AH2; -.
DR   PDBsum; 4E41; -.
DR   PDBsum; 4FQX; -.
DR   PDBsum; 4GBX; -.
DR   PDBsum; 4I5B; -.
DR   ProteinModelPortal; P04229; -.
DR   SMR; P04229; 30-219.
DR   DIP; DIP-6143N; -.
DR   IntAct; P04229; 6.
DR   MINT; MINT-203282; -.
DR   BindingDB; P04229; -.
DR   ChEMBL; CHEMBL1943; -.
DR   DrugBank; DB05259; Glatiramer Acetate.
DR   PhosphoSite; P04229; -.
DR   DMDM; 34395916; -.
DR   PaxDb; P04229; -.
DR   PRIDE; P04229; -.
DR   Ensembl; ENST00000360004; ENSP00000353099; ENSG00000196126.
DR   GeneCards; GC06M032546; -.
DR   HGNC; HGNC:4948; HLA-DRB1.
DR   HPA; CAB015400; -.
DR   HPA; CAB034021; -.
DR   MIM; 142857; gene.
DR   MIM; 181000; phenotype.
DR   neXtProt; NX_P04229; -.
DR   Orphanet; 703; Bullous pemphigoid.
DR   Orphanet; 555; Celiac disease.
DR   Orphanet; 243377; Diabetes mellitus type 1.
DR   Orphanet; 220393; Diffuse cutaneous systemic sclerosis.
DR   Orphanet; 545; Follicular lymphoma.
DR   Orphanet; 220402; Limited cutaneous systemic sclerosis.
DR   Orphanet; 220407; Limited systemic sclerosis.
DR   Orphanet; 802; Multiple sclerosis.
DR   Orphanet; 83465; Narcolepsy without cataplexy.
DR   Orphanet; 2073; Narcolepsy-cataplexy.
DR   Orphanet; 284130; Rheumatoid arthritis.
DR   Orphanet; 797; Sarcoidosis.
DR   Orphanet; 536; Systemic lupus erythematosus.
DR   eggNOG; NOG68200; -.
DR   HOVERGEN; HBG012730; -.
DR   InParanoid; P04229; -.
DR   OrthoDB; EOG7PS1GV; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-DRB1; human.
DR   EvolutionaryTrace; P04229; -.
DR   PRO; PR:P04229; -.
DR   ArrayExpress; P04229; -.
DR   Bgee; P04229; -.
DR   CleanEx; HS_HLA-DRB1; -.
DR   Genevestigator; P04229; -.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031902; C:late endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0042613; C:MHC class II protein complex; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0030658; C:transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0023026; F:MHC class II protein complex binding; IDA:UniProt.
DR   GO; GO:0042605; F:peptide antigen binding; ISS:UniProtKB.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0016045; P:detection of bacterium; ISS:UniProtKB.
DR   GO; GO:0002455; P:humoral immune response mediated by circulating immunoglobulin; ISS:UniProtKB.
DR   GO; GO:0006955; P:immune response; ISS:UniProtKB.
DR   GO; GO:0002381; P:immunoglobulin production involved in immunoglobulin mediated immune response; ISS:UniProtKB.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; ISS:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; ISS:UniProtKB.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; ISS:UniProtKB.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; ISS:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; ISS:UniProtKB.
DR   GO; GO:2001179; P:regulation of interleukin-10 secretion; ISS:UniProtKB.
DR   GO; GO:0032673; P:regulation of interleukin-4 production; ISS:UniProtKB.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042088; P:T-helper 1 type immune response; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.320.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR014745; MHC_II_a/b_N.
DR   InterPro; IPR000353; MHC_II_b_N.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00969; MHC_II_beta; 1.
DR   ProDom; PD000328; MHC_II_b_N; 1.
DR   SMART; SM00407; IGc1; 1.
DR   SMART; SM00921; MHC_II_beta; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Endoplasmic reticulum;
KW   Endosome; Glycoprotein; Golgi apparatus; Immunity; Isopeptide bond;
KW   Lysosome; Membrane; MHC II; Polymorphism; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     29
FT   CHAIN        30    266       HLA class II histocompatibility antigen,
FT                                DRB1-1 beta chain.
FT                                /FTId=PRO_0000018949.
FT   TOPO_DOM     30    227       Extracellular (Potential).
FT   TRANSMEM    228    250       Helical; (Potential).
FT   TOPO_DOM    251    266       Cytoplasmic (Potential).
FT   DOMAIN      126    214       Ig-like C1-type.
FT   REGION       30    124       Beta-1.
FT   REGION      125    227       Beta-2.
FT   CARBOHYD     48     48       N-linked (GlcNAc...) (Potential).
FT   DISULFID     44    108       By similarity.
FT   DISULFID    146    202       By similarity.
FT   CROSSLNK    254    254       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VARIANT       5      5       K -> R (in dbSNP:rs9270305).
FT                                /FTId=VAR_056527.
FT   VARIANT      13     13       T -> A (in dbSNP:rs1059553).
FT                                /FTId=VAR_033377.
FT   VARIANT      29     29       A -> S (in dbSNP:rs9270299).
FT                                /FTId=VAR_033378.
FT   VARIANT      33     33       R -> K (in dbSNP:rs34716432).
FT                                /FTId=VAR_033379.
FT   VARIANT      33     33       R -> Q (in dbSNP:rs34716432).
FT                                /FTId=VAR_033380.
FT   VARIANT      39     39       Q -> E (in allele DRB1*01:07).
FT                                /FTId=VAR_016740.
FT   VARIANT      66     66       S -> Y (in dbSNP:rs16822820).
FT                                /FTId=VAR_033381.
FT   VARIANT      74     74       G -> R (in allele DRB1*01:05).
FT                                /FTId=VAR_016741.
FT   VARIANT      76     76       Y -> F (in dbSNP:rs1060346).
FT                                /FTId=VAR_033382.
FT   VARIANT      89     89       Y -> S (in dbSNP:rs36074728).
FT                                /FTId=VAR_033383.
FT   VARIANT      96     96       L -> I (in allele DRB1*01:03).
FT                                /FTId=VAR_016710.
FT   VARIANT      99     99       Q -> D (in allele DRB1*01:03; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016711.
FT   VARIANT      99     99       Q -> E (in dbSNP:rs17881965).
FT                                /FTId=VAR_033384.
FT   VARIANT      99     99       Q -> H (in dbSNP:rs17879599).
FT                                /FTId=VAR_033385.
FT   VARIANT     100    100       R -> A (in allele DRB1*01:06; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016742.
FT   VARIANT     100    100       R -> E (in allele DRB1*01:03; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016712.
FT   VARIANT     102    102       A -> G (in dbSNP:rs17878857).
FT                                /FTId=VAR_033386.
FT   VARIANT     103    103       A -> E (in dbSNP:rs16822805).
FT                                /FTId=VAR_033387.
FT   VARIANT     106    106       T -> N (in allele DRB1*01:04;
FT                                dbSNP:rs16822752).
FT                                /FTId=VAR_016713.
FT   VARIANT     107    107       Y -> H (in dbSNP:rs16822512).
FT                                /FTId=VAR_033388.
FT   VARIANT     114    114       V -> A (in allele DRB1*01:02;
FT                                dbSNP:rs17424145).
FT                                /FTId=VAR_016714.
FT   VARIANT     115    115       G -> V (in allele DRB1*01:02, allele
FT                                DRB1*01:04 and allele DRB1*01:06;
FT                                dbSNP:rs2230810).
FT                                /FTId=VAR_016715.
FT   VARIANT     164    164       G -> D (in dbSNP:rs1059633).
FT                                /FTId=VAR_033389.
FT   VARIANT     169    169       A -> T (in dbSNP:rs2308768).
FT                                /FTId=VAR_033390.
FT   VARIANT     171    171       V -> M (in dbSNP:rs701829).
FT                                /FTId=VAR_033391.
FT   VARIANT     178    178       Q -> H (in dbSNP:rs701830).
FT                                /FTId=VAR_033392.
FT   VARIANT     195    195       R -> Q (in dbSNP:rs3205588).
FT                                /FTId=VAR_033393.
FT   VARIANT     210    210       T -> I (in dbSNP:rs17423930).
FT                                /FTId=VAR_033394.
FT   VARIANT     236    236       V -> M (in dbSNP:rs2230816).
FT                                /FTId=VAR_033395.
FT   VARIANT     253    253       Q -> E (in allele DRB1*01:02).
FT                                /FTId=VAR_016716.
FT   VARIANT     262    262       T -> R (in dbSNP:rs9269744).
FT                                /FTId=VAR_056528.
FT   CONFLICT     25     25       P -> R (in Ref. 2; AAA59781).
FT   CONFLICT     36     36       F -> S (in Ref. 9; AA sequence).
FT   CONFLICT     58     59       RC -> LF (in Ref. 9; AA sequence).
FT   CONFLICT     80     80       T -> E (in Ref. 2; AAA59781).
FT   CONFLICT    100    103       RRAA -> KRGQ (in Ref. 2; AAA59781).
FT   CONFLICT    192    192       T -> I (in Ref. 2; AAA59781).
FT   STRAND       36     47
FT   TURN         48     51
FT   STRAND       52     63
FT   STRAND       65     70
FT   TURN         71     73
FT   STRAND       75     80
FT   HELIX        81     83
FT   HELIX        84     91
FT   HELIX        94    106
FT   HELIX       108    115
FT   HELIX       116    118
FT   TURN        119    121
FT   STRAND      127    132
FT   STRAND      135    139
FT   STRAND      142    154
FT   STRAND      157    162
FT   STRAND      165    167
FT   STRAND      169    173
FT   STRAND      180    182
FT   STRAND      184    192
FT   STRAND      199    205
FT   STRAND      213    218
SQ   SEQUENCE   266 AA;  29914 MW;  CC9CC7E2D0DD036C CRC64;
     MVCLKLPGGS CMTALTVTLM VLSSPLALAG DTRPRFLWQL KFECHFFNGT ERVRLLERCI
     YNQEESVRFD SDVGEYRAVT ELGRPDAEYW NSQKDLLEQR RAAVDTYCRH NYGVGESFTV
     QRRVEPKVTV YPSKTQPLQH HNLLVCSVSG FYPGSIEVRW FRNGQEEKAG VVSTGLIQNG
     DWTFQTLVML ETVPRSGEVY TCQVEHPSVT SPLTVEWRAR SESAQSKMLS GVGGFVLGLL
     FLGAGLFIYF RNQKGHSGLQ PTGFLS
//
ID   2B13_HUMAN              Reviewed;         266 AA.
AC   P01912;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   09-JUL-2014, entry version 130.
DE   RecName: Full=HLA class II histocompatibility antigen, DRB1-3 chain;
DE   AltName: Full=Clone P2-beta-3;
DE   AltName: Full=MHC class II antigen DRB1*3;
DE   Flags: Precursor;
GN   Name=HLA-DRB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*03:01).
RX   PubMed=6589154;
RA   Peterson P.A., Gustafsson K., Wiman K.G., Emmoth E., Larhammar D.,
RA   Boehme J., Hyldig-Nielsen J.J., Ronne H., Rask L.;
RT   "Mutations and selection in the generation of class II
RT   histocompatibility antigen polymorphism.";
RL   EMBO J. 3:1655-1660(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELE DRB1*03:01).
RX   PubMed=6415003; DOI=10.1016/0198-8859(83)90087-3;
RA   Larhammar D., Andersson G., Andersson M., Bill P., Boehme J.,
RA   Claesson L., Denaro M., Emmoth E., Gustafsson K., Hammarling U.,
RA   Heldin E., Hyldig-Nielsen J.-J., Lind P., Schenning L., Servenius B.,
RA   Widmark E., Rask L., Peterson P.A.;
RT   "Molecular analysis of human class II transplantation antigens and
RT   their genes.";
RL   Hum. Immunol. 8:95-103(1983).
RN   [3]
RP   REVIEW.
RX   PubMed=8598037; DOI=10.1016/S0092-8674(00)81025-9;
RA   Cresswell P.;
RT   "Invariant chain structure and MHC class II function.";
RL   Cell 84:505-507(1996).
RN   [4]
RP   REVIEW.
RX   PubMed=11684289; DOI=10.1016/S0161-5890(01)00069-4;
RA   Villadangos J.A.;
RT   "Presentation of antigens by MHC class II molecules: getting the most
RT   out of them.";
RL   Mol. Immunol. 38:329-346(2001).
RN   [5]
RP   REVIEW.
RX   PubMed=17241953; DOI=10.1016/j.immuni.2007.01.005;
RA   Menendez-Benito V., Neefjes J.;
RT   "Autophagy in MHC class II presentation: sampling from within.";
RL   Immunity 26:1-3(2007).
RN   [6]
RP   REVIEW.
RX   PubMed=18046453; DOI=10.1038/sj.emboj.7601945;
RA   Rocha N., Neefjes J.;
RT   "MHC class II molecules on the move for successful antigen
RT   presentation.";
RL   EMBO J. 27:1-5(2008).
RN   [7]
RP   UBIQUITINATION BY MARCH1, AND SUBCELLULAR LOCATION.
RX   PubMed=18305173; DOI=10.1073/pnas.0708874105;
RA   De Gassart A., Camosseto V., Thibodeau J., Ceppi M., Catalan N.,
RA   Pierre P., Gatti E.;
RT   "MHC class II stabilization at the surface of human dendritic cells is
RT   the result of maturation-dependent MARCH I down-regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3491-3496(2008).
RN   [8]
RP   REVIEW.
RX   PubMed=19092054; DOI=10.1242/jcs.035089;
RA   Berger A.C., Roche P.A.;
RT   "MHC class II transport at a glance.";
RL   J. Cell Sci. 122:1-4(2009).
RN   [9]
RP   REVIEW.
RX   PubMed=19533806; DOI=10.3748/wjg.15.2855;
RA   Beswick E.J., Reyes V.E.;
RT   "CD74 in antigen presentation, inflammation, and cancers of the
RT   gastrointestinal tract.";
RL   World J. Gastroenterol. 15:2855-2861(2009).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-48.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 34-220 OF HLA-DRA/HLA-DRB1
RP   HETERODIMER IN COMPLEX WITH CD74 PEPTIDE (CLIP), SUBUNIT, AND
RP   DISULFIDE BONDS.
RX   PubMed=7477400; DOI=10.1038/378457a0;
RA   Ghosh P., Amaya M., Mellins E., Wiley D.C.;
RT   "The structure of an intermediate in class II MHC maturation: CLIP
RT   bound to HLA-DR3.";
RL   Nature 378:457-462(1995).
CC   -!- FUNCTION: Binds peptides derived from antigens that access the
CC       endocytic route of antigen presenting cells (APC) and presents
CC       them on the cell surface for recognition by the CD4 T-cells. The
CC       peptide binding cleft accommodates peptides of 10-30 residues. The
CC       peptides presented by MHC class II molecules are generated mostly
CC       by degradation of proteins that access the endocytic route; where
CC       they are processed by lysosomal proteases and other hydrolases.
CC       Exogenous antigens that have been endocytosed by the APC are thus
CC       readily available for presentation via MHC II molecules; and for
CC       this reason this antigen presentation pathway is usually referred
CC       to as exogenous. As membrane proteins on their way to degradation
CC       in lysosomes as part of their normal turn-over are also contained
CC       in the endosomal/lysosomal compartments; exogenous antigens must
CC       compete with those derived from endogenous components. Autophagy
CC       is also a source of endogenous peptides; autophagosomes
CC       constitutively fuse with MHC class II loading compartments. In
CC       addition to APCs; other cells of the gastrointestinal tract; such
CC       as epithelial cells; express MHC class II molecules and CD74 and
CC       act as APCs; which is an unusual trait of the GI tract. To produce
CC       a MHC class II molecule that presents an antigen; three MHC class
CC       II molecules (heterodimers of an alpha and a beta chain) associate
CC       with a CD74 trimer in the ER to form a heterononamer. Soon after
CC       the entry of this complex into the endosomal/lysosomal system
CC       where antigen processing occurs; CD74 undergoes a sequential
CC       degradation by various proteases; including CTSS and CTSL; leaving
CC       a small fragment termed CLIP (class-II-associated invariant chain
CC       peptide). The removal of CLIP is facilitated by HLA-DM via direct
CC       binding to the alpha-beta-CLIP complex so that CLIP is released.
CC       HLA-DM stabilizes MHC class II molecules until primary high
CC       affinity antigenic peptides are bound. The MHC II molecule bound
CC       to a peptide is then transported to the cell membrane surface. In
CC       B-cells; the interaction between HLA-DM and MHC class II molecules
CC       is regulated by HLA-DO. Primary dendritic cells (DCs) also to
CC       express HLA-DO. Lysosomal microenvironment has been implicated in
CC       the regulation of antigen loading into MHC II molecules; increased
CC       acidification produces increased proteolysis and efficient peptide
CC       loading.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit; also referred
CC       as MHC class II molecule. In the endoplasmic reticulum (ER) it
CC       forms a heterononamer; 3 MHC class II molecules bind to a CD74
CC       homotrimer (also known as invariant chain or HLA class II
CC       histocompatibility antigen gamma chain). In the
CC       endosomal/lysosomal system; CD74 undergoes sequential degradation
CC       by various proteases; leaving a small fragment termed CLIP on each
CC       MHC class II molecule. MHC class II molecule interacts with
CC       HLA_DM, and HLA_DO in B-cells, in order to release CLIP and
CC       facilitate the binding of antigenic peptides.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane; Single-pass type I
CC       membrane protein. Golgi apparatus, trans-Golgi network membrane;
CC       Single-pass type I membrane protein. Endosome membrane; Single-
CC       pass type I membrane protein. Lysosome membrane; Single-pass type
CC       I membrane protein. Late endosome membrane; Single-pass type I
CC       membrane protein. Note=The MHC class II complex transits through a
CC       number of intracellular compartments in the endocytic pathway
CC       until it reaches the cell membrane for antigen presentation.
CC   -!- PTM: Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to
CC       sorting into the endosome system and down-regulation of MHC class
CC       II (Probable).
CC   -!- POLYMORPHISM: The following alleles of DRB1-3 are known:
CC       DRB1*03:01; DRB1*03:02; DRB1*03:03; DRB1*03:04; DRB1*03:05;
CC       DRB1*03:06; DRB1*03:07; DRB1*03:08; DRB1*03:09; DRB1*03:10;
CC       DRB1*03:11; DRB1*03:12; DRB1*03:13; DRB1*03:14; DRB1*03:15;
CC       DRB1*03:16; DRB1*03:17; DRB1*03:18; DRB1*03:19; DRB1*03:20;
CC       DRB1*03:21; DRB1*03:22; DRB1*03:23; DRB1*03:24; DRB1*03:25;
CC       DRB1*03:26; DRB1*03:27; DRB1*03:28; DRB1*03:29; DRB1*03:30;
CC       DRB1*03:31; DRB1*03:32; DRB1*03:33; DRB1*03:34; DRB1*03:35;
CC       DRB1*03:36; DRB1*03:37; DRB1*03:38; DRB1*03:39; DRB1*03:40 and
CC       DRB1*03:41. The sequence shown is that of DRB1*03:01.
CC   -!- SIMILARITY: Belongs to the MHC class II family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X00699; CAA25295.1; -; mRNA.
DR   PIR; I37546; HLHU3D.
DR   RefSeq; NP_001230894.1; NM_001243965.1.
DR   UniGene; Hs.534322; -.
DR   UniGene; Hs.696211; -.
DR   UniGene; Hs.736560; -.
DR   PDB; 1A6A; X-ray; 2.75 A; B=34-220.
DR   PDBsum; 1A6A; -.
DR   ProteinModelPortal; P01912; -.
DR   SMR; P01912; 34-220.
DR   BioGrid; 109368; 15.
DR   DIP; DIP-6064N; -.
DR   IntAct; P01912; 8.
DR   MINT; MINT-1505391; -.
DR   DMDM; 1708116; -.
DR   PRIDE; P01912; -.
DR   DNASU; 3123; -.
DR   Ensembl; ENST00000328980; ENSP00000331343; ENSG00000206306.
DR   Ensembl; ENST00000399450; ENSP00000382378; ENSG00000206240.
DR   GeneID; 3123; -.
DR   KEGG; hsa:3123; -.
DR   UCSC; uc011eri.2; human.
DR   CTD; 3123; -.
DR   GeneCards; GC06M032546; -.
DR   GeneCards; GC06Mj32477; -.
DR   GeneCards; GC06Mn32480; -.
DR   HGNC; HGNC:4948; HLA-DRB1.
DR   MIM; 142857; gene.
DR   neXtProt; NX_P01912; -.
DR   HOVERGEN; HBG012730; -.
DR   KO; K06752; -.
DR   OMA; NGMERVR; -.
DR   PhylomeDB; P01912; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-DRB1; human.
DR   EvolutionaryTrace; P01912; -.
DR   GenomeRNAi; 3123; -.
DR   NextBio; 12394; -.
DR   CleanEx; HS_HLA-DRB1; -.
DR   Genevestigator; P01912; -.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031902; C:late endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0042613; C:MHC class II protein complex; IDA:UniProt.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0030658; C:transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0042605; F:peptide antigen binding; IDA:UniProt.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0002455; P:humoral immune response mediated by circulating immunoglobulin; IDA:UniProtKB.
DR   GO; GO:0002381; P:immunoglobulin production involved in immunoglobulin mediated immune response; IDA:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0002503; P:peptide antigen assembly with MHC class II protein complex; IDA:UniProt.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.320.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR014745; MHC_II_a/b_N.
DR   InterPro; IPR000353; MHC_II_b_N.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00969; MHC_II_beta; 1.
DR   ProDom; PD000328; MHC_II_b_N; 1.
DR   SMART; SM00407; IGc1; 1.
DR   SMART; SM00921; MHC_II_beta; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Golgi apparatus;
KW   Immunity; Isopeptide bond; Lysosome; Membrane; MHC II; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     29
FT   CHAIN        30    266       HLA class II histocompatibility antigen,
FT                                DRB1-3 chain.
FT                                /FTId=PRO_0000018965.
FT   TOPO_DOM     30    227       Extracellular (Potential).
FT   TRANSMEM    228    250       Helical; (Potential).
FT   TOPO_DOM    251    266       Cytoplasmic (Potential).
FT   DOMAIN      126    214       Ig-like C1-type.
FT   REGION       30    123       Beta-1.
FT   REGION      124    217       Beta-2.
FT   REGION      218    227       Connecting peptide.
FT   CARBOHYD     48     48       N-linked (GlcNAc...).
FT   DISULFID     44    108
FT   DISULFID    146    202
FT   CROSSLNK    254    254       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VARIANT      55     55       Y -> F (in dbSNP:rs16822516).
FT                                /FTId=VAR_050371.
FT   VARIANT     106    106       N -> T (in dbSNP:rs9269941).
FT                                /FTId=VAR_050372.
FT   VARIANT     164    164       G -> S (in dbSNP:rs1059633).
FT                                /FTId=VAR_050373.
FT   VARIANT     169    169       T -> A (in dbSNP:rs2308768).
FT                                /FTId=VAR_050374.
FT   VARIANT     236    236       V -> M (in dbSNP:rs2230816).
FT                                /FTId=VAR_056545.
FT   STRAND       37     47
FT   TURN         48     51
FT   STRAND       52     61
FT   STRAND       64     70
FT   TURN         71     73
FT   STRAND       75     80
FT   HELIX        81     83
FT   HELIX        84     92
FT   HELIX        94    101
FT   HELIX       103    106
FT   HELIX       108    115
FT   TURN        116    121
FT   STRAND      127    134
FT   STRAND      138    140
FT   STRAND      143    150
FT   STRAND      152    154
FT   STRAND      157    162
FT   STRAND      180    182
FT   STRAND      184    187
FT   STRAND      189    191
FT   STRAND      199    205
FT   STRAND      213    218
SQ   SEQUENCE   266 AA;  30120 MW;  37329B097C6BEEB4 CRC64;
     MVCLRLPGGS CMAVLTVTLM VLSSPLALAG DTRPRFLEYS TSECHFFNGT ERVRYLDRYF
     HNQEENVRFD SDVGEFRAVT ELGRPDAEYW NSQKDLLEQK RGRVDNYCRH NYGVVESFTV
     QRRVHPKVTV YPSKTQPLQH HNLLVCSVSG FYPGSIEVRW FRNGQEEKTG VVSTGLIHNG
     DWTFQTLVML ETVPRSGEVY TCQVEHPSVT SPLTVEWRAR SESAQSKMLS GVGGFVLGLL
     FLGAGLFIYF RNQKGHSGLQ PRGFLS
//
ID   2B14_HUMAN              Reviewed;         266 AA.
AC   P13760; O19717; O19739; P13759; Q29875; Q30145; Q9GIX9; Q9GIY4;
AC   Q9MY13; Q9XRY5;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1990, sequence version 1.
DT   09-JUL-2014, entry version 142.
DE   RecName: Full=HLA class II histocompatibility antigen, DRB1-4 beta chain;
DE   AltName: Full=MHC class II antigen DRB1*4;
DE            Short=DR-4;
DE            Short=DR4;
DE   Flags: Precursor;
GN   Name=HLA-DRB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE DRB1*04:01).
RX   PubMed=3036826;
RA   Andersson G., Larhammar D., Widmark E., Servenius B., Peterson P.A.,
RA   Rask L.;
RT   "Class II genes of the human major histocompatibility complex.
RT   Organization and evolutionary relationship of the DR beta genes.";
RL   J. Biol. Chem. 262:8748-8758(1987).
RN   [2]
RP   ERRATUM, AND SEQUENCE REVISION.
RA   Andersson G., Larhammar D., Widmark E., Servenius B., Peterson P.A.,
RA   Rask L.;
RL   J. Biol. Chem. 263:8551-8551(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE DRB1*04:01).
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELE DRB1*04:01).
RX   PubMed=3476943; DOI=10.1073/pnas.84.17.6234;
RA   Bell J.I., Denney D. Jr., Foster L., Belt T.K., Todd J.A.,
RA   McDevitt H.O.;
RT   "Allelic variation in the DR subregion of the human major
RT   histocompatibility complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6234-6238(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*04:01).
RX   PubMed=3860851; DOI=10.1073/pnas.82.15.5165;
RA   Spies T., Sorrentino R., Boss J.M., Okada K., Strominger J.L.;
RT   "Structural organization of the DR subregion of the human major
RT   histocompatibility complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:5165-5169(1985).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*04:01).
RX   PubMed=9098937; DOI=10.1111/j.1399-0039.1997.tb02751.x;
RA   Thonnard J., Gervais T., Heusterpreute M., Mersch G., De Canck I.,
RA   De Greef C., Demanet C., Van Waeyenberge C.;
RT   "A new silent mutation at codon 35 in exon 2 yielding a DRB1*04012
RT   allele.";
RL   Tissue Antigens 49:274-276(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*04:02).
RX   PubMed=12358860; DOI=10.1046/j.1365-2370.2002.00354.x;
RA   Ramon D., Corell A., Cox S.T., Soteriou B., Madrigal J.A.,
RA   Marsh S.G.E.;
RT   "Complete cDNA sequences of the HLA-DRB1*0402 and DRB1*11041
RT   alleles.";
RL   Eur. J. Immunogenet. 29:453-455(2002).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 43-115 (ALLELE DRB1*04:03).
RC   TISSUE=Blood;
RA   Arnaiz-Villena A.;
RT   "HLA class II polymorphism.";
RL   Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-122 (ALLELE DRB1*04:03).
RA   Greville W.D., van Eijck A., Dunckley H.;
RT   "New HLA class II (DRB1) alleles detected by sequencing-based
RT   typing.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*04:03).
RA   Guttridge M.G., Hammond L.;
RT   "Confirmatory sequence of HLA-DRB1*04032.";
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*04:04).
RX   PubMed=3875800; DOI=10.1038/317166a0;
RA   Cairns J.S., Curtsinger J.M., Dahl C.A., Freeman S., Alter B.J.,
RA   Bach F.H.;
RT   "Sequence polymorphism of HLA DR beta 1 alleles relating to T-cell-
RT   recognized determinants.";
RL   Nature 317:166-168(1985).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 30-123 (ALLELE DRB1*04:04).
RX   PubMed=3458223; DOI=10.1073/pnas.83.8.2642;
RA   Gregersen P.K., Shen M., Song Q.-L., Merryman P., Degar S., Seki T.,
RA   Maccari J., Goldberg D., Murphy H., Schwenzer J., Wang C.Y.,
RA   Winchester R.J., Nepom G.T., Silver J.;
RT   "Molecular diversity of HLA-DR4 haplotypes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:2642-2646(1986).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*04:11).
RA   Zhao W., Fernandez-Vina M.A., Stastny P.;
RT   "Full cDNA sequence of HLA-DRB1*0411.";
RL   Submitted (MAY-1995) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   REVIEW.
RX   PubMed=8598037; DOI=10.1016/S0092-8674(00)81025-9;
RA   Cresswell P.;
RT   "Invariant chain structure and MHC class II function.";
RL   Cell 84:505-507(1996).
RN   [15]
RP   REVIEW.
RX   PubMed=11684289; DOI=10.1016/S0161-5890(01)00069-4;
RA   Villadangos J.A.;
RT   "Presentation of antigens by MHC class II molecules: getting the most
RT   out of them.";
RL   Mol. Immunol. 38:329-346(2001).
RN   [16]
RP   REVIEW.
RX   PubMed=17241953; DOI=10.1016/j.immuni.2007.01.005;
RA   Menendez-Benito V., Neefjes J.;
RT   "Autophagy in MHC class II presentation: sampling from within.";
RL   Immunity 26:1-3(2007).
RN   [17]
RP   REVIEW.
RX   PubMed=18046453; DOI=10.1038/sj.emboj.7601945;
RA   Rocha N., Neefjes J.;
RT   "MHC class II molecules on the move for successful antigen
RT   presentation.";
RL   EMBO J. 27:1-5(2008).
RN   [18]
RP   UBIQUITINATION BY MARCH1, AND SUBCELLULAR LOCATION.
RX   PubMed=18305173; DOI=10.1073/pnas.0708874105;
RA   De Gassart A., Camosseto V., Thibodeau J., Ceppi M., Catalan N.,
RA   Pierre P., Gatti E.;
RT   "MHC class II stabilization at the surface of human dendritic cells is
RT   the result of maturation-dependent MARCH I down-regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3491-3496(2008).
RN   [19]
RP   REVIEW.
RX   PubMed=19092054; DOI=10.1242/jcs.035089;
RA   Berger A.C., Roche P.A.;
RT   "MHC class II transport at a glance.";
RL   J. Cell Sci. 122:1-4(2009).
RN   [20]
RP   REVIEW.
RX   PubMed=19533806; DOI=10.3748/wjg.15.2855;
RA   Beswick E.J., Reyes V.E.;
RT   "CD74 in antigen presentation, inflammation, and cancers of the
RT   gastrointestinal tract.";
RL   World J. Gastroenterol. 15:2855-2861(2009).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF COMPLEX WITH A COLLAGEN
RP   PEPTIDE.
RX   PubMed=9354468; DOI=10.1016/S1074-7613(00)80369-6;
RA   Dessen A., Lawrence C.M., Cupo S., Zaller D.M., Wiley D.C.;
RT   "X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed
RT   with a peptide from human collagen II.";
RL   Immunity 7:473-481(1997).
CC   -!- FUNCTION: Binds peptides derived from antigens that access the
CC       endocytic route of antigen presenting cells (APC) and presents
CC       them on the cell surface for recognition by the CD4 T-cells. The
CC       peptide binding cleft accommodates peptides of 10-30 residues. The
CC       peptides presented by MHC class II molecules are generated mostly
CC       by degradation of proteins that access the endocytic route; where
CC       they are processed by lysosomal proteases and other hydrolases.
CC       Exogenous antigens that have been endocytosed by the APC are thus
CC       readily available for presentation via MHC II molecules; and for
CC       this reason this antigen presentation pathway is usually referred
CC       to as exogenous. As membrane proteins on their way to degradation
CC       in lysosomes as part of their normal turn-over are also contained
CC       in the endosomal/lysosomal compartments; exogenous antigens must
CC       compete with those derived from endogenous components. Autophagy
CC       is also a source of endogenous peptides; autophagosomes
CC       constitutively fuse with MHC class II loading compartments. In
CC       addition to APCs; other cells of the gastrointestinal tract; such
CC       as epithelial cells; express MHC class II molecules and CD74 and
CC       act as APCs; which is an unusual trait of the GI tract. To produce
CC       a MHC class II molecule that presents an antigen; three MHC class
CC       II molecules (heterodimers of an alpha and a beta chain) associate
CC       with a CD74 trimer in the ER to form a heterononamer. Soon after
CC       the entry of this complex into the endosomal/lysosomal system
CC       where antigen processing occurs; CD74 undergoes a sequential
CC       degradation by various proteases; including CTSS and CTSL; leaving
CC       a small fragment termed CLIP (class-II-associated invariant chain
CC       peptide). The removal of CLIP is facilitated by HLA-DM via direct
CC       binding to the alpha-beta-CLIP complex so that CLIP is released.
CC       HLA-DM stabilizes MHC class II molecules until primary high
CC       affinity antigenic peptides are bound. The MHC II molecule bound
CC       to a peptide is then transported to the cell membrane surface. In
CC       B-cells; the interaction between HLA-DM and MHC class II molecules
CC       is regulated by HLA-DO. Primary dendritic cells (DCs) also to
CC       express HLA-DO. Lysosomal microenvironment has been implicated in
CC       the regulation of antigen loading into MHC II molecules; increased
CC       acidification produces increased proteolysis and efficient peptide
CC       loading.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit; also referred
CC       as MHC class II molecule. In the endoplasmic reticulum (ER) it
CC       forms a heterononamer; 3 MHC class II molecules bind to a CD74
CC       homotrimer (also known as invariant chain or HLA class II
CC       histocompatibility antigen gamma chain). In the
CC       endosomal/lysosomal system; CD74 undergoes sequential degradation
CC       by various proteases; leaving a small fragment termed CLIP on each
CC       MHC class II molecule. MHC class II molecule interacts with
CC       HLA_DM, and HLA_DO in B-cells, in order to release CLIP and
CC       facilitate the binding of antigenic peptides.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane; Single-pass type I
CC       membrane protein. Golgi apparatus, trans-Golgi network membrane;
CC       Single-pass type I membrane protein. Endosome membrane; Single-
CC       pass type I membrane protein. Lysosome membrane; Single-pass type
CC       I membrane protein. Late endosome membrane; Single-pass type I
CC       membrane protein. Note=The MHC class II complex transits through a
CC       number of intracellular compartments in the endocytic pathway
CC       until it reaches the cell membrane for antigen presentation.
CC   -!- PTM: Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to
CC       sorting into the endosome system and down-regulation of MHC class
CC       II (Probable).
CC   -!- POLYMORPHISM: The following alleles of DRB1-4 are known:
CC       DRB1*04:01, DRB1*04:02, DRB1*04:03, DRB1*04:04, DRB1*04:05,
CC       DRB1*04:06, DRB1*04:07, DRB1*04:08, DRB1*04:09, DRB1*04:10,
CC       DRB1*04:11, DRB1*04:12, DRB1*04:13, DRB1*04:14, DRB1*04:15,
CC       DRB1*04:16, DRB1*04:17, DRB1*04:18, DRB1*04:19, DRB1*04:20,
CC       DRB1*04:21, DRB1*04:22, DRB1*04:23, DRB1*04:24, DRB1*04:25,
CC       DRB1*04:26, DRB1*04:27, DRB1*04:28, DRB1*04:29, DRB1*04:30,
CC       DRB1*04:31, DRB1*04:32, DRB1*04:33, DRB1*04:34, DRB1*04:35,
CC       DRB1*04:36, DRB1*04:37, DRB1*04:38, DRB1*04:39, DRB1*04:40,
CC       DRB1*04:41, DRB1*04:42, DRB1*04:43, DRB1*04:44, DRB1*04:45,
CC       DRB1*04:46, DRB1*04:47, DRB1*04:48, DRB1*04:49, DRB1*04:50,
CC       DRB1*04:51, DRB1*04:52, DRB1*04:53, DRB1*04:54, DRB1*04:55,
CC       DRB1*04:56, DRB1*04:57, DRB1*04:58, DRB1*04:59, DRB1*04:60,
CC       DRB1*04:61, DRB1*04:62, DRB1*04:63, DRB1*04:64, DRB1*04:65,
CC       DRB1*04:66, DRB1*04:67, DRB1*04:68, DRB1*04:69, DRB1*04:70,
CC       DRB1*04:71, DRB1*04:72, DRB1*04:73, DRB1*04:74, DRB1*04:75,
CC       DRB1*04:76, DRB1*04:77 and DRB1*04:78. The sequence shown is that
CC       of DRB1*04:01.
CC   -!- SIMILARITY: Belongs to the MHC class II family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M20548; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M20549; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M20550; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL137064; CAC19360.1; -; Genomic_DNA.
DR   EMBL; M17381; AAA59805.1; -; mRNA.
DR   EMBL; K02776; AAA59808.1; -; Genomic_DNA.
DR   EMBL; X96851; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AJ297586; CAC08826.2; -; mRNA.
DR   EMBL; AF029269; AAF65479.1; -; Genomic_DNA.
DR   EMBL; AF112876; AAD29581.1; -; Genomic_DNA.
DR   EMBL; AJ295845; CAC08181.1; -; Genomic_DNA.
DR   EMBL; X02902; CAA26660.1; -; mRNA.
DR   EMBL; M15069; AAA59809.1; -; mRNA.
DR   EMBL; L42143; AAA67104.1; -; mRNA.
DR   PIR; A94681; A29310.
DR   PIR; I79419; I79419.
DR   UniGene; Hs.534322; -.
DR   UniGene; Hs.696211; -.
DR   UniGene; Hs.716081; -.
DR   UniGene; Hs.723344; -.
DR   UniGene; Hs.736560; -.
DR   PDB; 1D5M; X-ray; 2.00 A; B=30-221.
DR   PDB; 1D5X; X-ray; 2.45 A; B=30-221.
DR   PDB; 1D5Z; X-ray; 2.00 A; B=30-221.
DR   PDB; 1D6E; X-ray; 2.45 A; B=30-221.
DR   PDB; 1J8H; X-ray; 2.40 A; B=30-221.
DR   PDB; 2SEB; X-ray; 2.50 A; B=30-221.
DR   PDB; 3O6F; X-ray; 2.80 A; B/F=31-221.
DR   PDB; 3T0E; X-ray; 4.00 A; B=30-221.
DR   PDB; 4IS6; X-ray; 2.50 A; B=30-221.
DR   PDB; 4MCY; X-ray; 2.30 A; B=30-219.
DR   PDB; 4MCZ; X-ray; 2.41 A; B=30-219.
DR   PDB; 4MD0; X-ray; 2.19 A; B=30-219.
DR   PDB; 4MD4; X-ray; 1.95 A; B=30-219.
DR   PDB; 4MD5; X-ray; 1.65 A; B=30-219.
DR   PDB; 4MDI; X-ray; 2.00 A; B=30-219.
DR   PDB; 4MDJ; X-ray; 1.70 A; B=30-219.
DR   PDBsum; 1D5M; -.
DR   PDBsum; 1D5X; -.
DR   PDBsum; 1D5Z; -.
DR   PDBsum; 1D6E; -.
DR   PDBsum; 1J8H; -.
DR   PDBsum; 2SEB; -.
DR   PDBsum; 3O6F; -.
DR   PDBsum; 3T0E; -.
DR   PDBsum; 4IS6; -.
DR   PDBsum; 4MCY; -.
DR   PDBsum; 4MCZ; -.
DR   PDBsum; 4MD0; -.
DR   PDBsum; 4MD4; -.
DR   PDBsum; 4MD5; -.
DR   PDBsum; 4MDI; -.
DR   PDBsum; 4MDJ; -.
DR   ProteinModelPortal; P13760; -.
DR   SMR; P13760; 31-219.
DR   IntAct; P13760; 6.
DR   PhosphoSite; P13760; -.
DR   DMDM; 122253; -.
DR   MaxQB; P13760; -.
DR   PaxDb; P13760; -.
DR   PRIDE; P13760; -.
DR   Ensembl; ENST00000419393; ENSP00000403458; ENSG00000228080.
DR   GeneCards; GC06M032546; -.
DR   GeneCards; GC06Mo32593; -.
DR   H-InvDB; HIX0207659; -.
DR   HGNC; HGNC:4948; HLA-DRB1.
DR   MIM; 142857; gene.
DR   neXtProt; NX_P13760; -.
DR   eggNOG; NOG68200; -.
DR   HOVERGEN; HBG012730; -.
DR   InParanoid; P13760; -.
DR   PhylomeDB; P13760; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-DRB1; human.
DR   EvolutionaryTrace; P13760; -.
DR   PRO; PR:P13760; -.
DR   CleanEx; HS_HLA-DRB1; -.
DR   Genevestigator; P13760; -.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:UniProtKB.
DR   GO; GO:0031902; C:late endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0042613; C:MHC class II protein complex; IDA:UniProt.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0030658; C:transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0032395; F:MHC class II receptor activity; TAS:UniProtKB.
DR   GO; GO:0042605; F:peptide antigen binding; ISS:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0016045; P:detection of bacterium; ISS:UniProtKB.
DR   GO; GO:0002455; P:humoral immune response mediated by circulating immunoglobulin; ISS:UniProtKB.
DR   GO; GO:0006955; P:immune response; ISS:UniProtKB.
DR   GO; GO:0002381; P:immunoglobulin production involved in immunoglobulin mediated immune response; ISS:UniProtKB.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IDA:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; IDA:UniProtKB.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; ISS:UniProtKB.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; ISS:UniProtKB.
DR   GO; GO:0002503; P:peptide antigen assembly with MHC class II protein complex; IDA:UniProt.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; ISS:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; ISS:UniProtKB.
DR   GO; GO:2001179; P:regulation of interleukin-10 secretion; ISS:UniProtKB.
DR   GO; GO:0032673; P:regulation of interleukin-4 production; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; NAS:ProtInc.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042088; P:T-helper 1 type immune response; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.320.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR014745; MHC_II_a/b_N.
DR   InterPro; IPR000353; MHC_II_b_N.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00969; MHC_II_beta; 1.
DR   ProDom; PD000328; MHC_II_b_N; 1.
DR   SMART; SM00407; IGc1; 1.
DR   SMART; SM00921; MHC_II_beta; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Golgi apparatus;
KW   Immunity; Isopeptide bond; Lysosome; Membrane; MHC II; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     29
FT   CHAIN        30    266       HLA class II histocompatibility antigen,
FT                                DRB1-4 beta chain.
FT                                /FTId=PRO_0000018950.
FT   TOPO_DOM     30    227       Extracellular (Potential).
FT   TRANSMEM    228    250       Helical; (Potential).
FT   TOPO_DOM    251    266       Cytoplasmic (Potential).
FT   DOMAIN      126    214       Ig-like C1-type.
FT   REGION       30    124       Beta-1.
FT   REGION      125    227       Beta-2.
FT   CARBOHYD     48     48       N-linked (GlcNAc...) (Potential).
FT   DISULFID     44    108       By similarity.
FT   DISULFID    146    202       By similarity.
FT   CROSSLNK    254    254       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VARIANT       5      5       K -> R (in dbSNP:rs9270305).
FT                                /FTId=VAR_056529.
FT   VARIANT      86     86       D -> S (in allele DRB1*04:11; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016673.
FT   VARIANT      96     96       L -> I (in allele DRB1*04:02).
FT                                /FTId=VAR_016674.
FT   VARIANT      99     99       Q -> D (in allele DRB1*04:02; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_016675.
FT   VARIANT     100    100       K -> E (in allele DRB1*04:02).
FT                                /FTId=VAR_016676.
FT   VARIANT     100    100       K -> R (in allele DRB1*04:03, allele
FT                                DRB1*04:04 and allele DRB1*04:11).
FT                                /FTId=VAR_016677.
FT   VARIANT     103    103       A -> E (in allele DRB1*04:03 and allele
FT                                DRB1*04:11).
FT                                /FTId=VAR_016678.
FT   VARIANT     115    115       G -> V (in allele DRB1*04:02, allele
FT                                DRB1*04:03, allele DRB1*04:04 and allele
FT                                DRB1*04:11).
FT                                /FTId=VAR_016679.
FT   VARIANT     236    236       V -> M (in dbSNP:rs2230816).
FT                                /FTId=VAR_056530.
FT   VARIANT     262    262       T -> R (in dbSNP:rs9269744).
FT                                /FTId=VAR_056531.
FT   CONFLICT    154    154       G -> A (in Ref. 4; AAA59805).
FT   STRAND       36     47
FT   TURN         48     51
FT   STRAND       52     61
FT   STRAND       64     70
FT   TURN         71     73
FT   STRAND       74     80
FT   HELIX        81     83
FT   HELIX        84     91
FT   HELIX        94    106
FT   HELIX       108    115
FT   HELIX       116    118
FT   TURN        119    121
FT   STRAND      127    133
FT   STRAND      143    154
FT   STRAND      157    162
FT   STRAND      165    167
FT   STRAND      171    173
FT   STRAND      180    182
FT   STRAND      184    191
FT   STRAND      199    205
FT   STRAND      213    218
SQ   SEQUENCE   266 AA;  30112 MW;  8116E91DA38294E5 CRC64;
     MVCLKFPGGS CMAALTVTLM VLSSPLALAG DTRPRFLEQV KHECHFFNGT ERVRFLDRYF
     YHQEEYVRFD SDVGEYRAVT ELGRPDAEYW NSQKDLLEQK RAAVDTYCRH NYGVGESFTV
     QRRVYPEVTV YPAKTQPLQH HNLLVCSVNG FYPGSIEVRW FRNGQEEKTG VVSTGLIQNG
     DWTFQTLVML ETVPRSGEVY TCQVEHPSLT SPLTVEWRAR SESAQSKMLS GVGGFVLGLL
     FLGAGLFIYF RNQKGHSGLQ PTGFLS
//
ID   2B18_HUMAN              Reviewed;         266 AA.
AC   Q30134; O19718; O19788; Q29968; Q30108; Q30115; Q9BCP0; Q9BCP1;
AC   Q9BCP2; Q9BD33; Q9TQ37; Q9UIM9;
DT   29-AUG-2003, integrated into UniProtKB/Swiss-Prot.
DT   29-AUG-2003, sequence version 2.
DT   16-APR-2014, entry version 108.
DE   RecName: Full=HLA class II histocompatibility antigen, DRB1-8 beta chain;
DE   AltName: Full=MHC class II antigen DRB1*8;
DE            Short=DR-8;
DE            Short=DR8;
DE            Short=DRw8;
DE   Flags: Precursor;
GN   Name=HLA-DRB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*08:02).
RX   PubMed=2497068; DOI=10.1007/BF00352840;
RA   Jonsson A.K., Andersson L., Rask L.;
RT   "A cellular and functional split in the DRw8 haplotype is due to a
RT   single amino acid replacement (DR beta ser 57- asp 57).";
RL   Immunogenetics 29:308-316(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-21.
RX   PubMed=8106268; DOI=10.1016/0198-8859(93)90531-5;
RA   Emery P., Mach B., Reith W.;
RT   "The different level of expression of HLA-DRB1 and -DRB3 genes is
RT   controlled by conserved isotypic differences in promoter sequence.";
RL   Hum. Immunol. 38:137-147(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 32-115 (ALLELE DRB1*08:01).
RX   PubMed=3476943; DOI=10.1073/pnas.84.17.6234;
RA   Bell J.I., Denney D. Jr., Foster L., Belt T.K., Todd J.A.,
RA   McDevitt H.O.;
RT   "Allelic variation in the DR subregion of the human major
RT   histocompatibility complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6234-6238(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123.
RX   PubMed=1979063;
RA   Van Kerckhove C., Melin-Aldana H., Elma M.S., Luyrink L., Donnelly P.,
RA   Taylor J., Maksymowych W.P., Lovell D.J., Choi E., Glass D.N.;
RT   "A distinct HLA-DRw8 haplotype characterizes patients with juvenile
RT   rheumatoid arthritis.";
RL   Immunogenetics 32:304-308(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*08:01).
RA   Dormoy A., Froelich N., Weschler B., Tongio M.M.;
RT   "A new DRB1*08 allele.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*08:04).
RC   TISSUE=Blood;
RA   Hurley C.K., Tang T., Li L.;
RT   "Human leukocyte antigen class II DRB1*0804 variant.";
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-208 (ALLELE DRB1*08:01).
RA   Greville W.D.;
RT   "SBT of DRB1*0801, exons two and three.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-115 (ALLELE DRB1*08:03).
RX   PubMed=2592019; DOI=10.1007/BF02421173;
RA   Abe A., Ito I., Ohkubo M., Kaneko T., Ito K., Kato H., Kashiwagi N.,
RA   Obata F.;
RT   "Two distinct subtypes of the HLA-DRw12 haplotypes in the Japanese
RT   population detected by nucleotide sequence analysis and
RT   oligonucleotide genotyping.";
RL   Immunogenetics 30:422-426(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 43-120 (ALLELE DRB1*08:01).
RA   Eberle M., Asu U., Taylor M., Hunter J.B., Fuller T.C., Maurer D.;
RT   "Identification of a putative DR8 founder haplotype containing a novel
RT   DRB1*08 allele.";
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 47-122 (ALLELE DRB1*08:04).
RC   TISSUE=Blood;
RX   PubMed=8023844;
RA   Titus-Trachtenberg E.A., Rickards O., De Stefano G.F., Erlich H.A.;
RT   "Analysis of HLA class II haplotypes in the Cayapa Indians of Ecuador:
RT   a novel DRB1 allele reveals evidence for convergent evolution and
RT   balancing selection at position 86.";
RL   Am. J. Hum. Genet. 55:160-167(1994).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 124-217.
RX   PubMed=2471740;
RA   Gorski J.;
RT   "HLA-DR beta-chain polymorphism. Second domain polymorphism reflects
RT   evolutionary relatedness of alleles and may explain public serologic
RT   epitopes.";
RL   J. Immunol. 143:329-333(1989).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 256-266.
RX   PubMed=3458223; DOI=10.1073/pnas.83.8.2642;
RA   Gregersen P.K., Shen M., Song Q.-L., Merryman P., Degar S., Seki T.,
RA   Maccari J., Goldberg D., Murphy H., Schwenzer J., Wang C.Y.,
RA   Winchester R.J., Nepom G.T., Silver J.;
RT   "Molecular diversity of HLA-DR4 haplotypes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:2642-2646(1986).
RN   [13]
RP   REVIEW.
RX   PubMed=8598037; DOI=10.1016/S0092-8674(00)81025-9;
RA   Cresswell P.;
RT   "Invariant chain structure and MHC class II function.";
RL   Cell 84:505-507(1996).
RN   [14]
RP   REVIEW.
RX   PubMed=11684289; DOI=10.1016/S0161-5890(01)00069-4;
RA   Villadangos J.A.;
RT   "Presentation of antigens by MHC class II molecules: getting the most
RT   out of them.";
RL   Mol. Immunol. 38:329-346(2001).
RN   [15]
RP   REVIEW.
RX   PubMed=17241953; DOI=10.1016/j.immuni.2007.01.005;
RA   Menendez-Benito V., Neefjes J.;
RT   "Autophagy in MHC class II presentation: sampling from within.";
RL   Immunity 26:1-3(2007).
RN   [16]
RP   REVIEW.
RX   PubMed=18046453; DOI=10.1038/sj.emboj.7601945;
RA   Rocha N., Neefjes J.;
RT   "MHC class II molecules on the move for successful antigen
RT   presentation.";
RL   EMBO J. 27:1-5(2008).
RN   [17]
RP   UBIQUITINATION BY MARCH1, AND SUBCELLULAR LOCATION.
RX   PubMed=18305173; DOI=10.1073/pnas.0708874105;
RA   De Gassart A., Camosseto V., Thibodeau J., Ceppi M., Catalan N.,
RA   Pierre P., Gatti E.;
RT   "MHC class II stabilization at the surface of human dendritic cells is
RT   the result of maturation-dependent MARCH I down-regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3491-3496(2008).
RN   [18]
RP   REVIEW.
RX   PubMed=19092054; DOI=10.1242/jcs.035089;
RA   Berger A.C., Roche P.A.;
RT   "MHC class II transport at a glance.";
RL   J. Cell Sci. 122:1-4(2009).
RN   [19]
RP   REVIEW.
RX   PubMed=19533806; DOI=10.3748/wjg.15.2855;
RA   Beswick E.J., Reyes V.E.;
RT   "CD74 in antigen presentation, inflammation, and cancers of the
RT   gastrointestinal tract.";
RL   World J. Gastroenterol. 15:2855-2861(2009).
CC   -!- FUNCTION: Binds peptides derived from antigens that access the
CC       endocytic route of antigen presenting cells (APC) and presents
CC       them on the cell surface for recognition by the CD4 T-cells. The
CC       peptide binding cleft accommodates peptides of 10-30 residues. The
CC       peptides presented by MHC class II molecules are generated mostly
CC       by degradation of proteins that access the endocytic route; where
CC       they are processed by lysosomal proteases and other hydrolases.
CC       Exogenous antigens that have been endocytosed by the APC are thus
CC       readily available for presentation via MHC II molecules; and for
CC       this reason this antigen presentation pathway is usually referred
CC       to as exogenous. As membrane proteins on their way to degradation
CC       in lysosomes as part of their normal turn-over are also contained
CC       in the endosomal/lysosomal compartments; exogenous antigens must
CC       compete with those derived from endogenous components. Autophagy
CC       is also a source of endogenous peptides; autophagosomes
CC       constitutively fuse with MHC class II loading compartments. In
CC       addition to APCs; other cells of the gastrointestinal tract; such
CC       as epithelial cells; express MHC class II molecules and CD74 and
CC       act as APCs; which is an unusual trait of the GI tract. To produce
CC       a MHC class II molecule that presents an antigen; three MHC class
CC       II molecules (heterodimers of an alpha and a beta chain) associate
CC       with a CD74 trimer in the ER to form a heterononamer. Soon after
CC       the entry of this complex into the endosomal/lysosomal system
CC       where antigen processing occurs; CD74 undergoes a sequential
CC       degradation by various proteases; including CTSS and CTSL; leaving
CC       a small fragment termed CLIP (class-II-associated invariant chain
CC       peptide). The removal of CLIP is facilitated by HLA-DM via direct
CC       binding to the alpha-beta-CLIP complex so that CLIP is released.
CC       HLA-DM stabilizes MHC class II molecules until primary high
CC       affinity antigenic peptides are bound. The MHC II molecule bound
CC       to a peptide is then transported to the cell membrane surface. In
CC       B-cells; the interaction between HLA-DM and MHC class II molecules
CC       is regulated by HLA-DO. Primary dendritic cells (DCs) also to
CC       express HLA-DO. Lysosomal microenvironment has been implicated in
CC       the regulation of antigen loading into MHC II molecules; increased
CC       acidification produces increased proteolysis and efficient peptide
CC       loading.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit; also referred
CC       as MHC class II molecule. In the endoplasmic reticulum (ER) it
CC       forms a heterononamer; 3 MHC class II molecules bind to a CD74
CC       homotrimer (also known as invariant chain or HLA class II
CC       histocompatibility antigen gamma chain). In the
CC       endosomal/lysosomal system; CD74 undergoes sequential degradation
CC       by various proteases; leaving a small fragment termed CLIP on each
CC       MHC class II molecule. MHC class II molecule interacts with
CC       HLA_DM, and HLA_DO in B-cells, in order to release CLIP and
CC       facilitate the binding of antigenic peptides.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane; Single-pass type I
CC       membrane protein. Golgi apparatus, trans-Golgi network membrane;
CC       Single-pass type I membrane protein. Endosome membrane; Single-
CC       pass type I membrane protein. Lysosome membrane; Single-pass type
CC       I membrane protein. Late endosome membrane; Single-pass type I
CC       membrane protein. Note=The MHC class II complex transits through a
CC       number of intracellular compartments in the endocytic pathway
CC       until it reaches the cell membrane for antigen presentation.
CC   -!- PTM: Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to
CC       sorting into the endosome system and down-regulation of MHC class
CC       II (Probable).
CC   -!- POLYMORPHISM: The following alleles of DRB1-8 are known:
CC       DRB1*08:01 (Dw8.1), DRB1*08:02 (Dw8.2; DRB1L), DRB1*08:03 (Dw8.3);
CC       DRB1*08:04; DRB1*08:05, DRB1*08:06, DRB1*08:07, DRB1*08:08,
CC       DRB1*08:09, DRB1*08:10, DRB1*08:11, DRB1*08:12, DRB1*08:13,
CC       DRB1*08:14, DRB1*08:15, DRB1*08:16, DRB1*08:17, DRB1*08:18,
CC       DRB1*08:19, DRB1*08:20, DRB1*08:21, DRB1*08:22, DRB1*08:23,
CC       DRB1*08:24, DRB1*08:25, DRB1*08:26, DRB1*08:27, DRB1*08:28,
CC       DRB1*08:29, DRB1*08:30, DRB1*08:31, DRB1*08:32, DRB1*08:33,
CC       DRB1*08:34, DRB1*08:35 and DRB1*08:36. The sequence shown is that
CC       of DRB1*08:01.
CC   -!- SIMILARITY: Belongs to the MHC class II family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M26038; AAA59794.1; -; mRNA.
DR   EMBL; S69987; AAD14052.1; -; Genomic_DNA.
DR   EMBL; M17386; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; M60216; AAA36298.1; -; Genomic_DNA.
DR   EMBL; AJ249626; CAB56284.1; -; Genomic_DNA.
DR   EMBL; AF330103; AAK08504.1; -; Genomic_DNA.
DR   EMBL; AH010612; AAK31608.1; -; Genomic_DNA.
DR   EMBL; AH010613; AAK31609.1; -; Genomic_DNA.
DR   EMBL; AH010614; AAK31610.1; -; Genomic_DNA.
DR   EMBL; M27511; AAA59817.1; -; Genomic_DNA.
DR   EMBL; AF144105; AAD38374.1; -; Genomic_DNA.
DR   EMBL; L10402; AAA51400.1; -; Genomic_DNA.
DR   EMBL; M15074; AAA59810.1; -; mRNA.
DR   PIR; A45856; A45856.
DR   PIR; F60748; F60748.
DR   PIR; I51875; I51875.
DR   PIR; I54473; I54473.
DR   PIR; I68778; I68778.
DR   PIR; PH0160; PH0160.
DR   PIR; PT0161; PT0161.
DR   UniGene; Hs.534322; -.
DR   UniGene; Hs.696211; -.
DR   UniGene; Hs.736560; -.
DR   ProteinModelPortal; Q30134; -.
DR   SMR; Q30134; 34-220.
DR   DMDM; 34395492; -.
DR   PaxDb; Q30134; -.
DR   PRIDE; Q30134; -.
DR   Ensembl; ENST00000328980; ENSP00000331343; ENSG00000206306.
DR   Ensembl; ENST00000399450; ENSP00000382378; ENSG00000206240.
DR   GeneCards; GC06M032546; -.
DR   GeneCards; GC06Mj32477; -.
DR   GeneCards; GC06Mn32480; -.
DR   HGNC; HGNC:4948; HLA-DRB1.
DR   MIM; 142857; gene.
DR   neXtProt; NX_Q30134; -.
DR   eggNOG; NOG68200; -.
DR   HOVERGEN; HBG012730; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-DRB1; human.
DR   PRO; PR:Q30134; -.
DR   CleanEx; HS_HLA-DRB1; -.
DR   Genevestigator; Q30134; -.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031902; C:late endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0042613; C:MHC class II protein complex; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0030658; C:transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.320.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR014745; MHC_II_a/b_N.
DR   InterPro; IPR000353; MHC_II_b_N.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00969; MHC_II_beta; 1.
DR   ProDom; PD000328; MHC_II_b_N; 1.
DR   SMART; SM00407; IGc1; 1.
DR   SMART; SM00921; MHC_II_beta; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Golgi apparatus;
KW   Immunity; Isopeptide bond; Lysosome; Membrane; MHC II; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     29
FT   CHAIN        30    266       HLA class II histocompatibility antigen,
FT                                DRB1-8 beta chain.
FT                                /FTId=PRO_0000018952.
FT   TOPO_DOM     30    227       Extracellular (Potential).
FT   TRANSMEM    228    250       Helical; (Potential).
FT   TOPO_DOM    251    266       Cytoplasmic (Potential).
FT   DOMAIN      126    214       Ig-like C1-type.
FT   REGION       30    124       Beta-1.
FT   REGION      125    227       Beta-2.
FT   CARBOHYD     48     48       N-linked (GlcNAc...) (Potential).
FT   DISULFID     44    108       By similarity.
FT   DISULFID    146    202       By similarity.
FT   CROSSLNK    254    254       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VARIANT      86     86       S -> D (in allele DRB1*08:02 and allele
FT                                DRB1*08:04; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_016683.
FT   VARIANT      96     96       F -> I (in allele DRB1*08:03).
FT                                /FTId=VAR_016684.
FT   VARIANT     115    115       G -> V (in allele DRB1*08:04).
FT                                /FTId=VAR_016685.
FT   VARIANT     236    236       V -> M (in dbSNP:rs2230816).
FT                                /FTId=VAR_056535.
FT   VARIANT     262    262       T -> R (in dbSNP:rs9269744).
FT                                /FTId=VAR_056536.
SQ   SEQUENCE   266 AA;  30004 MW;  D452D1C3A75CEA31 CRC64;
     MVCLRLPGGS CMAVLTVTLM VLSSPLALAG DTRPRFLEYS TGECYFFNGT ERVRFLDRYF
     YNQEEYVRFD SDVGEYRAVT ELGRPSAEYW NSQKDFLEDR RALVDTYCRH NYGVGESFTV
     QRRVHPKVTV YPSKTQPLQH HNLLVCSVSG FYPGSIEVRW FRNGQEEKTG VVSTGLIHNG
     DWTFQTLVML ETVPRSGEVY TCQVEHPSVT SPLTVEWSAR SESAQSKMLS GVGGFVLGLL
     FLGAGLFIYF RNQKGHSGLQ PTGFLS
//
ID   2B1C_HUMAN              Reviewed;         266 AA.
AC   Q95IE3; A7LA26; B0LUZ6; B6VCX2; B7UDB2; O19585; Q19AF2; Q29771;
AC   Q2L9H4; Q2MZ92; Q5EER6; Q5NDB9; Q5UT58; Q5Y7G0; Q768U4; Q7YP04;
AC   Q861H8; Q95IT6; Q9BD40;
DT   02-MAR-2010, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   16-APR-2014, entry version 94.
DE   RecName: Full=HLA class II histocompatibility antigen, DRB1-12 beta chain;
DE   AltName: Full=MHC class II antigen DRB1*12;
DE            Short=DR-12;
DE            Short=DR12;
DE   Flags: Precursor;
GN   Name=HLA-DRB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*12:01).
RX   PubMed=12028552; DOI=10.1034/j.1399-0039.2002.590221.x;
RA   Zanone R., Bettens F., Tiercy J.M.;
RT   "Sequence of a new DR12 allele with two silent mutations that affect
RT   PCR-SSP typing.";
RL   Tissue Antigens 59:165-167(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*12:10).
RX   PubMed=15361134; DOI=10.1111/j.1399-0039.2004.00309.x;
RA   Kim E., Lee E.J., Lim Y.H., Lee J.Y., Koh I.S., Kimm K., Ji G.E.,
RA   Kwack K.;
RT   "Identification of a novel HLA-DRB1*12 allele (DRB1*1210) in the
RT   Korean population.";
RL   Tissue Antigens 64:518-519(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*12:17).
RX   PubMed=19493243; DOI=10.1111/j.1399-0039.2009.01224.x;
RA   Park M.H., Kim Y., Lee J.Y.;
RT   "Identification of a novel HLA-DRB1 allele, HLA-DRB1*1217, in a Korean
RT   individual.";
RL   Tissue Antigens 73:627-628(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-262 (ALLELE DRB1*12:01).
RX   PubMed=16140993; DOI=10.1101/gr.3554305;
RA   Raymond C.K., Kas A., Paddock M., Qiu R., Zhou Y., Subramanian S.,
RA   Chang J., Palmieri A., Haugen E., Kaul R., Olson M.V.;
RT   "Ancient haplotypes of the HLA Class II region.";
RL   Genome Res. 15:1250-1257(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-208 (ALLELE DRB1*12:07).
RX   PubMed=12028551; DOI=10.1034/j.1399-0039.2002.590220.x;
RA   Dunckley H., Le T., Dodd R., Hogbin J.P., Strickland J., Chapman G.,
RA   Greville W.D.;
RT   "Description of a novel HLA-DRB1 allele, DRB1*1207.";
RL   Tissue Antigens 59:162-164(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:11).
RC   TISSUE=Peripheral blood;
RX   PubMed=16690413; DOI=10.1016/j.humimm.2005.05.002;
RA   Horn P.A., DeLuca D.S., Jindra P., Blasczyk R.;
RT   "The replacement mutation in HLA-DRB1*1211 affects a likely keystone
RT   position.";
RL   Hum. Immunol. 66:1254-1257(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:08).
RX   PubMed=12144630; DOI=10.1034/j.1399-0039.2002.590513.x;
RA   Sheldon M.H., Bunce M., Dunn P.P., Day S., Lee G.D., Park Y.J.,
RA   Bang B.K., Kim B.K., Oh E.J.;
RT   "Identification of two new alleles in a single Korean individual, HLA-
RT   B*1568 and HLA-DRB1*1208.";
RL   Tissue Antigens 59:430-432(2002).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:15).
RX   PubMed=19046299; DOI=10.1111/j.1744-313X.2008.00785.x;
RA   Lee H.L., Chu C.C., Trejaut J.A., Yang K.L., Lin M.;
RT   "Identification of two novel HLA-DRB1 alleles, HLA-DRB1*1214 and HLA-
RT   DRB1*1215, in two Taiwanese individuals.";
RL   Int. J. Immunogenet. 35:423-426(2008).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:19).
RX   PubMed=19624612; DOI=10.1111/j.1399-0039.2009.01316.x;
RA   Nie X.M., Fang Y.H., Zhang Y., He W.D., Zhu C.F.;
RT   "A novel HLA-DRB1 allele, DRB1*1219, was identified by sequence-based
RT   typing in a Chinese leukaemia family.";
RL   Tissue Antigens 74:352-354(2009).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:18).
RX   PubMed=19508407; DOI=10.1111/j.1399-0039.2009.01294.x;
RA   Gao S.Q., Deng Z.H., Xu Y.P.;
RT   "Identification of a novel HLA-DRB1*12 allele, DRB1*1218, in Chinese
RT   population.";
RL   Tissue Antigens 74:265-267(2009).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:05).
RA   Kashiwase K., Tokunaga K., Akaza T., Tadokoro K., Juji T.;
RT   "Sequence of new allele.";
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:09).
RA   Ono A.;
RT   "A new HLA-DR12V allele detected by PCR-RFLP.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:04).
RA   Gedil M.A., Steiner N.K., Hurley C.K.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:12).
RA   Zhu F., Lu Q., Zhang W.;
RT   "Identification a novel HLA-DRB1*12 in Chinese by sequence-based
RT   typed.";
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:13).
RA   Hur S.S., Lee M.N., Park S.Y., Kwon O.J.;
RT   "Novel HLA-DRB1*120201 variant allele.";
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:14).
RA   Chu C.-C.;
RT   "A novel HLA-DRB1 allele.";
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*12:16).
RA   Zhang C., Liu J.;
RL   Submitted (JUN-2007) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-122 (ALLELE DRB1*12:03).
RX   PubMed=8851733; DOI=10.1111/j.1399-0039.1996.tb02532.x;
RA   Hashemi S., Couture C., Buyse I., Cole R., Aye M.T.;
RT   "Sequence analysis of three novel HLA-DRB1 alleles: DRB1*1113,
RT   DRB1*1114 and DRB1*12032.";
RL   Tissue Antigens 47:155-158(1996).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-123 (ALLELE DRB1*12:02).
RA   Lo B.;
RT   "HLA class II DRB1*120201 confirmatory sequence.";
RL   Submitted (NOV-2002) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 88-197 (ALLELE DRB1*12:06).
RX   PubMed=10372549; DOI=10.1034/j.1399-0039.1999.530510.x;
RA   Maeng C.Y., Kim K.H., Kang J.H., Han H., Kim K.L.;
RT   "A novel HLA-DR12 allele (DRB1*1206) found in a Korean B-cell line.";
RL   Tissue Antigens 53:516-518(1999).
RN   [21]
RP   REVIEW.
RX   PubMed=8598037; DOI=10.1016/S0092-8674(00)81025-9;
RA   Cresswell P.;
RT   "Invariant chain structure and MHC class II function.";
RL   Cell 84:505-507(1996).
RN   [22]
RP   REVIEW.
RX   PubMed=11684289; DOI=10.1016/S0161-5890(01)00069-4;
RA   Villadangos J.A.;
RT   "Presentation of antigens by MHC class II molecules: getting the most
RT   out of them.";
RL   Mol. Immunol. 38:329-346(2001).
RN   [23]
RP   REVIEW.
RX   PubMed=17241953; DOI=10.1016/j.immuni.2007.01.005;
RA   Menendez-Benito V., Neefjes J.;
RT   "Autophagy in MHC class II presentation: sampling from within.";
RL   Immunity 26:1-3(2007).
RN   [24]
RP   REVIEW.
RX   PubMed=18046453; DOI=10.1038/sj.emboj.7601945;
RA   Rocha N., Neefjes J.;
RT   "MHC class II molecules on the move for successful antigen
RT   presentation.";
RL   EMBO J. 27:1-5(2008).
RN   [25]
RP   UBIQUITINATION BY MARCH1, AND SUBCELLULAR LOCATION.
RX   PubMed=18305173; DOI=10.1073/pnas.0708874105;
RA   De Gassart A., Camosseto V., Thibodeau J., Ceppi M., Catalan N.,
RA   Pierre P., Gatti E.;
RT   "MHC class II stabilization at the surface of human dendritic cells is
RT   the result of maturation-dependent MARCH I down-regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3491-3496(2008).
RN   [26]
RP   REVIEW.
RX   PubMed=19092054; DOI=10.1242/jcs.035089;
RA   Berger A.C., Roche P.A.;
RT   "MHC class II transport at a glance.";
RL   J. Cell Sci. 122:1-4(2009).
RN   [27]
RP   REVIEW.
RX   PubMed=19533806; DOI=10.3748/wjg.15.2855;
RA   Beswick E.J., Reyes V.E.;
RT   "CD74 in antigen presentation, inflammation, and cancers of the
RT   gastrointestinal tract.";
RL   World J. Gastroenterol. 15:2855-2861(2009).
CC   -!- FUNCTION: Binds peptides derived from antigens that access the
CC       endocytic route of antigen presenting cells (APC) and presents
CC       them on the cell surface for recognition by the CD4 T-cells. The
CC       peptide binding cleft accommodates peptides of 10-30 residues. The
CC       peptides presented by MHC class II molecules are generated mostly
CC       by degradation of proteins that access the endocytic route, where
CC       they are processed by lysosomal proteases and other hydrolases.
CC       Exogenous antigens that have been endocytosed by the APC are thus
CC       readily available for presentation via MHC II molecules, and for
CC       this reason this antigen presentation pathway is usually referred
CC       to as exogenous. As membrane proteins on their way to degradation
CC       in lysosomes as part of their normal turn-over are also contained
CC       in the endosomal/lysosomal compartments, exogenous antigens must
CC       compete with those derived from endogenous components. Autophagy
CC       is also a source of endogenous peptides, autophagosomes
CC       constitutively fuse with MHC class II loading compartments. In
CC       addition to APCs, other cells of the gastrointestinal tract, such
CC       as epithelial cells, express MHC class II molecules and CD74 and
CC       act as APCs, which is an unusual trait of the GI tract. To produce
CC       a MHC class II molecule that presents an antigen, three MHC class
CC       II molecules (heterodimers of an alpha and a beta chain) associate
CC       with a CD74 trimer in the ER to form a heterononamer. Soon after
CC       the entry of this complex into the endosomal/lysosomal system
CC       where antigen processing occurs, CD74 undergoes a sequential
CC       degradation by various proteases, including CTSS and CTSL, leaving
CC       a small fragment termed CLIP (class-II-associated invariant chain
CC       peptide). The removal of CLIP is facilitated by HLA-DM via direct
CC       binding to the alpha-beta-CLIP complex so that CLIP is released.
CC       HLA-DM stabilizes MHC class II molecules until primary high
CC       affinity antigenic peptides are bound. The MHC II molecule bound
CC       to a peptide is then transported to the cell membrane surface. In
CC       B-cells, the interaction between HLA-DM and MHC class II molecules
CC       is regulated by HLA-DO. Primary dendritic cells (DCs) also to
CC       express HLA-DO. Lysosomal microenvironment has been implicated in
CC       the regulation of antigen loading into MHC II molecules, increased
CC       acidification produces increased proteolysis and efficient peptide
CC       loading.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit; also referred
CC       as MHC class II molecule. In the endoplasmic reticulum (ER) it
CC       forms a heterononamer; 3 MHC class II molecules bind to a CD74
CC       homotrimer (also known as invariant chain or HLA class II
CC       histocompatibility antigen gamma chain). In the
CC       endosomal/lysosomal system; CD74 undergoes sequential degradation
CC       by various proteases; leaving a small fragment termed CLIP on each
CC       MHC class II molecule. MHC class II molecule interacts with
CC       HLA_DM, and HLA_DO in B-cells, in order to release CLIP and
CC       facilitate the binding of antigenic peptides.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane; Single-pass type I
CC       membrane protein. Golgi apparatus, trans-Golgi network membrane;
CC       Single-pass type I membrane protein. Endosome membrane; Single-
CC       pass type I membrane protein. Lysosome membrane; Single-pass type
CC       I membrane protein. Late endosome membrane; Single-pass type I
CC       membrane protein. Note=The MHC class II complex transits through a
CC       number of intracellular compartments in the endocytic pathway
CC       until it reaches the cell membrane for antigen presentation.
CC   -!- PTM: Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to
CC       sorting into the endosome system and down-regulation of MHC class
CC       II (Probable).
CC   -!- POLYMORPHISM: The following alleles of DRB1-12 are known:
CC       DRB1*12:01, DRB1*12:02, DRB1*12:03, DRB1*12:04, DRB1*12:05,
CC       DRB1*12:06, DRB1*12:07, DRB1*12:08, DRB1*12:09, DRB1*12:10,
CC       DRB1*12:11, DRB1*12:12, DRB1*12:13, DRB1*12:14, DRB1*12:15,
CC       DRB1*12:16, DRB1*12:17, DRB1*12:18 and DRB1*12:19. The sequence
CC       shown is that of DRB1*12:01.
CC   -!- SIMILARITY: Belongs to the MHC class II family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ302075; CAC44379.1; -; mRNA.
DR   EMBL; AY626551; AAV34808.1; -; mRNA.
DR   EMBL; EU375850; ABY78039.1; -; mRNA.
DR   EMBL; AY663396; AAU87983.1; -; Genomic_DNA.
DR   EMBL; AH010330; AAK07563.1; -; Genomic_DNA.
DR   EMBL; AJ870921; CAI35044.1; -; Genomic_DNA.
DR   EMBL; AY033428; AAK55114.1; -; Genomic_DNA.
DR   EMBL; DQ533486; ABF74752.1; -; Genomic_DNA.
DR   EMBL; FJ374889; ACJ09136.1; -; Genomic_DNA.
DR   EMBL; FJ481086; ACK77491.1; -; Genomic_DNA.
DR   EMBL; D86503; BAA13098.1; -; Genomic_DNA.
DR   EMBL; AB112911; BAD02942.1; -; Genomic_DNA.
DR   EMBL; AY339246; AAQ18913.1; -; Genomic_DNA.
DR   EMBL; AY899825; AAW82078.1; -; Genomic_DNA.
DR   EMBL; DQ250650; ABC59072.1; -; Genomic_DNA.
DR   EMBL; DQ343834; ABC70992.1; -; Genomic_DNA.
DR   EMBL; EF688603; ABS11697.1; -; Genomic_DNA.
DR   EMBL; X83455; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AY174091; AAO20088.1; -; Genomic_DNA.
DR   EMBL; AF017439; AAB70553.1; -; mRNA.
DR   PIR; C60748; C60748.
DR   PIR; F60748; F60748.
DR   PIR; PH0154; PH0154.
DR   UniGene; Hs.534322; -.
DR   UniGene; Hs.696211; -.
DR   UniGene; Hs.716081; -.
DR   UniGene; Hs.723344; -.
DR   UniGene; Hs.736560; -.
DR   ProteinModelPortal; Q95IE3; -.
DR   SMR; Q95IE3; 34-220.
DR   DMDM; 74760669; -.
DR   PRIDE; Q95IE3; -.
DR   Ensembl; ENST00000328980; ENSP00000331343; ENSG00000206306.
DR   Ensembl; ENST00000399450; ENSP00000382378; ENSG00000206240.
DR   Ensembl; ENST00000412634; ENSP00000408795; ENSG00000228080.
DR   Ensembl; ENST00000415796; ENSP00000412168; ENSG00000206306.
DR   Ensembl; ENST00000419393; ENSP00000403458; ENSG00000228080.
DR   Ensembl; ENST00000428566; ENSP00000392280; ENSG00000206240.
DR   GeneCards; GC06M032546; -.
DR   GeneCards; GC06Mj32477; -.
DR   GeneCards; GC06Mn32480; -.
DR   GeneCards; GC06Mo32593; -.
DR   HGNC; HGNC:4948; HLA-DRB1.
DR   neXtProt; NX_Q95IE3; -.
DR   HOVERGEN; HBG012730; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-DRB1; human.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031902; C:late endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0042613; C:MHC class II protein complex; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0030658; C:transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.320.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR014745; MHC_II_a/b_N.
DR   InterPro; IPR000353; MHC_II_b_N.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00969; MHC_II_beta; 1.
DR   ProDom; PD000328; MHC_II_b_N; 1.
DR   SMART; SM00407; IGc1; 1.
DR   SMART; SM00921; MHC_II_beta; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Golgi apparatus;
KW   Immunity; Isopeptide bond; Lysosome; Membrane; MHC II; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     29       Potential.
FT   CHAIN        30    266       HLA class II histocompatibility antigen,
FT                                DRB1-12 beta chain.
FT                                /FTId=PRO_0000391832.
FT   TRANSMEM    228    248       Helical; (Potential).
FT   DOMAIN      126    214       Ig-like C1-type.
FT   CARBOHYD     48     48       N-linked (GlcNAc...) (Potential).
FT   DISULFID    146    202       By similarity.
FT   CROSSLNK    254    254       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VARIANT       5      5       R -> K (in allele DRB1*12:17).
FT                                /FTId=VAR_062818.
FT   VARIANT      13     13       A -> T (in allele DRB1*12:17).
FT                                /FTId=VAR_062819.
FT   VARIANT      14     14       V -> A (in allele DRB1*12:17).
FT                                /FTId=VAR_062820.
FT   VARIANT      14     14       V -> I (in allele DRB1*12:10).
FT                                /FTId=VAR_062821.
FT   VARIANT      54     54       R -> L (in allele DRB1*12:13).
FT                                /FTId=VAR_062822.
FT   VARIANT      55     55       L -> F (in allele DRB1*12:08).
FT                                /FTId=VAR_062823.
FT   VARIANT      66     66       L -> F (in allele DRB1*12:05, allele
FT                                DRB1*12:14 and allele DRB1*12:15).
FT                                /FTId=VAR_062824.
FT   VARIANT      67     67       L -> V (in allele DRB1*12:14).
FT                                /FTId=VAR_062825.
FT   VARIANT      76     76       F -> L (in allele DRB1*12:11).
FT                                /FTId=VAR_062826.
FT   VARIANT      86     86       V -> D (in allele DRB1*12:04 and allele
FT                                DRB1*12:09).
FT                                /FTId=VAR_062827.
FT   VARIANT      87     87       A -> E (in allele DRB1*12:04).
FT                                /FTId=VAR_062828.
FT   VARIANT      88     88       E -> Q (in allele DRB1*12:18).
FT                                /FTId=VAR_062829.
FT   VARIANT      89     89       S -> Y (in allele DRB1*12:04 and allele
FT                                DRB1*12:09).
FT                                /FTId=VAR_062830.
FT   VARIANT      96     96       I -> F (in allele DRB1*12:02, allele
FT                                DRB1*12:13, allele DRB1*12:15, allele
FT                                DRB1*12:16, allele DRB1*12:18 and allele
FT                                DRB1*12:19).
FT                                /FTId=VAR_062831.
FT   VARIANT      96     96       I -> L (in allele DRB1*12:12).
FT                                /FTId=VAR_062832.
FT   VARIANT      98     98       E -> G (in allele DRB1*12:07).
FT                                /FTId=VAR_062833.
FT   VARIANT     114    114       A -> V (in allele DRB1*12:03, allele
FT                                DRB1*12:16 and allele DRB1*12:19).
FT                                /FTId=VAR_062834.
FT   VARIANT     115    115       V -> G (in allele DRB1*12:16).
FT                                /FTId=VAR_062835.
FT   VARIANT     125    125       H -> E (in allele DRB1*12:17; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_062836.
FT   VARIANT     169    169       T -> A (in allele DRB1*12:17).
FT                                /FTId=VAR_062837.
FT   VARIANT     178    178       H -> Q (in allele DRB1*12:06 and allele
FT                                DRB1*12:17).
FT                                /FTId=VAR_062838.
FT   VARIANT     262    262       R -> T (in allele DRB1*12:17;
FT                                dbSNP:rs9269744).
FT                                /FTId=VAR_062839.
SQ   SEQUENCE   266 AA;  29878 MW;  FFDD0001C2F0BAF9 CRC64;
     MVCLRLPGGS CMAVLTVTLM VLSSPLALAG DTRPRFLEYS TGECYFFNGT ERVRLLERHF
     HNQEELLRFD SDVGEFRAVT ELGRPVAESW NSQKDILEDR RAAVDTYCRH NYGAVESFTV
     QRRVHPKVTV YPSKTQPLQH HNLLVCSVSG FYPGSIEVRW FRNGQEEKTG VVSTGLIHNG
     DWTFQTLVML ETVPRSGEVY TCQVEHPSVT SPLTVEWRAR SESAQSKMLS GVGGFVLGLL
     FLGAGLFIYF RNQKGHSGLQ PRGFLS
//
ID   2B1D_HUMAN              Reviewed;         266 AA.
AC   Q5Y7A7; A0MWF2; A2ICT1; A4ZXA5; A4ZXA6; A7UHG2; A7X5K7; A8YQE9;
AC   B0BK85; B3VTQ3; B5A8Y2; B5A8Y3; B5B9V6; B5QSK8; C0LAB5; O02930;
AC   O62889; O78047; P79545; Q14280; Q14QT2; Q19K86; Q1G0Z9; Q1KLJ6;
AC   Q29673; Q29720; Q29722; Q29806; Q29833; Q29874; Q29886; Q2MF40;
AC   Q2YHQ2; Q30112; Q3LA93; Q3LA94; Q3LA95; Q3LA96; Q3LA97; Q3LA98;
AC   Q3LA99; Q3LAA0; Q3LAA1; Q3LAA2; Q3MQ60; Q53IG1; Q56FP2; Q56FP3;
AC   Q58F52; Q5K3W2; Q5UBA2; Q5W3L4; Q6REE2; Q6U387; Q701T1; Q70Q85;
AC   Q768U2; Q7YP03; Q7YQ26; Q7YQA3; Q860E5; Q860H8; Q860Z3; Q861G6;
AC   Q861H0; Q861H4; Q8HWQ6; Q8WMA0; Q95389; Q95HL1; Q96HZ9; Q9BCP5;
AC   Q9BD21; Q9GIP3; Q9GJ25; Q9GJ60; Q9GJF8; Q9GJF9; Q9GJG0; Q9MY45;
AC   Q9MY56; Q9TPW3; Q9TPW9; Q9TPX4; Q9UBY1; Q9UIN0; Q9XRX1; Q9Y453;
DT   23-MAR-2010, integrated into UniProtKB/Swiss-Prot.
DT   23-NOV-2004, sequence version 1.
DT   14-MAY-2014, entry version 86.
DE   RecName: Full=HLA class II histocompatibility antigen, DRB1-13 beta chain;
DE   AltName: Full=MHC class II antigen DRB1*13;
DE            Short=DR-13;
DE            Short=DR13;
DE   Flags: Precursor;
GN   Name=HLA-DRB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES DRB1*13:01 AND DRB1*13:02).
RX   PubMed=16140993; DOI=10.1101/gr.3554305;
RA   Raymond C.K., Kas A., Paddock M., Qiu R., Zhou Y., Subramanian S.,
RA   Chang J., Palmieri A., Haugen E., Kaul R., Olson M.V.;
RT   "Ancient haplotypes of the HLA Class II region.";
RL   Genome Res. 15:1250-1257(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*13:05).
RX   PubMed=15896200; DOI=10.1111/j.1399-0039.2005.00407.x;
RA   Vilches C., Sepulveda S., Balas A., Solis R., Aviles M.J.,
RA   Estefania E., Gomez-Lozano N., Vicario J.L., DePablo R.;
RT   "Complete coding sequences and haplotypic associations of HLA-B*0707,
RT   -B*1524, -B*4405, -B*4802, -DRB1*0409, -DRB1*0411, -DRB1*1115, -
RT   DRB1*1305, and the novel allele -DRB1*0709. Group-specific
RT   amplification of cDNA from DRB1 alleles associated to DRB3 and DRB4.";
RL   Tissue Antigens 65:529-538(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELES DRB1*13:27 AND DRB1*13:56).
RX   PubMed=17174751; DOI=10.1016/j.humimm.2006.09.002;
RA   Balas A., Vilches C., Rodriguez M.A., Fernandez B., Martinez M.P.,
RA   de Pablo R., Garcia-Sanchez F., Vicario J.L.;
RT   "Group-specific amplification of cDNA from DRB1 genes. Complete coding
RT   sequences of partially defined alleles and identification of the new
RT   alleles DRB1*040602, DRB1*111102, DRB1*080103, and DRB1*0113.";
RL   Hum. Immunol. 67:1008-1016(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*13:02).
RC   TISSUE=Blood;
RA   Arnaiz-Villena A., Martinez-Quiles N., De Juan-Echavarri D.,
RA   Martin-Villa M., Martinez-Laso J.;
RT   "New complete sequences of MHC-DR in Spanish family with systemic
RT   lupus erythematosus.";
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE DRB1*13:01).
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE DRB1*13:02).
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 5-148 (ALLELE DRB1*13:21).
RC   TISSUE=Leukocyte;
RA   Maurer D.H.;
RL   Submitted (MAY-1995) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 26-123 (ALLELE DRB1*13:19).
RC   TISSUE=Blood;
RX   PubMed=7652736; DOI=10.1111/j.1399-0039.1995.tb02458.x;
RA   Robbins F., Tang T., Yao H., Ng J., Hartzman R.J., Hurley C.K.;
RT   "Direct sequencing of SSP-PCR-amplified cDNA to identify new alleles
RT   in the DR52-associated DRB1 group: identification of DRB1*1115,
RT   DRB1*1117 and DRB1*1319.";
RL   Tissue Antigens 45:302-308(1995).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 30-130 (ALLELE DRB1*13:04).
RX   PubMed=2212675;
RA   Lee K.W., Johnson A.H., Hurley C.K.;
RT   "Two divergent routes of evolution gave rise to the DRw13
RT   haplotypes.";
RL   J. Immunol. 145:3119-3125(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-217 (ALLELE DRB1*13:87).
RA   Ogrzewalla K., Tillmann G., Scheibelhut N., Lauber J., Enczmann J.;
RT   "A novel HLA-DRB1*13 allele identified by sequence-based typing.";
RL   Submitted (JUL-2008) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-216 (ALLELES DRB1*13:03;
RP   DRB1*13:06; DRB1*13:08; DRB1*13:10; DRB1*13:11; DRB1*13:14;
RP   DRB1*13:17; DRB1*13:20; DRB1*13:29 AND DRB1*13:36).
RC   TISSUE=Peripheral blood;
RX   PubMed=17767557; DOI=10.1111/j.1399-0039.2007.00918.x;
RA   Horn P.A., Albis-Camps M., Verboom M., Bunce M., Yousaf K.,
RA   Williams S., Blasczyk R.;
RT   "The nature of diversity of HLA-DRB1 exon 3.";
RL   Tissue Antigens 70:335-337(2007).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-124 (ALLELE DRB1*13:12).
RA   Hu C.J.;
RT   "DR variant with a DR5-like-haplotype found in Taiwan.";
RL   Submitted (APR-1994) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:18).
RX   PubMed=8575826; DOI=10.1007/s002510050054;
RA   Dormoy A., Delbosc A., Galy-Floc'h M., Tongio M.M.;
RT   "A new HLA-DRB1(*)13 allele (DRB1(*)1318) with a short DRB1(*)08
RT   sequence.";
RL   Immunogenetics 43:240-241(1996).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:22).
RX   PubMed=9271638; DOI=10.1007/s002510050302;
RA   Duran K.J., Maeda H., Otten H.G., Vries R.D., Schreuder G.M.,
RA   Tilanus M.G.;
RT   "Two newly identified HLA-DRB1 alleles: DRB1*1322 and DRB1*1327.";
RL   Immunogenetics 46:442-443(1997).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*13:42 AND
RP   DRB1*13:43), NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-122 (ALLELES
RP   DRB1*13:35; DRB1*13:37 AND DRB1*13:49), AND NUCLEOTIDE SEQUENCE
RP   [GENOMIC DNA] OF 35-115 (ALLELE DRB1*13:38).
RX   PubMed=11972885; DOI=10.1034/j.1399-0039.2002.590115.x;
RA   Tang T.F., Lin Y.-S., Robbins F.M., Li L., Sintasath D.,
RA   Coquillard G., Huang A., Heine U., Ng J., Hartzman R.J., Hurley C.K.;
RT   "Description of fourteen new DRB alleles found in a stem cell donor
RT   registry.";
RL   Tissue Antigens 59:63-65(2002).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:46).
RX   PubMed=12028548; DOI=10.1034/j.1399-0039.2002.590217.x;
RA   Greville W.D., Chapman G., Hogbin J.-P., Kennedy A., Dunckley H.;
RT   "Novel HLA-DRB1 alleles discovered during routine sequencing based
RT   typing, DRB1*03052, DRB1*04032, DRB1*1139 and DRB1*1346.";
RL   Tissue Antigens 59:154-156(2002).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:44).
RX   PubMed=12028549; DOI=10.1034/j.1399-0039.2002.590218.x;
RA   Kennedy A., Le T., Chapman G., Greville W.D., Dunckley H.;
RT   "Identification of two new HLA-DRB1 alleles, DRB1*1138 and
RT   DRB1*1344.";
RL   Tissue Antigens 59:157-158(2002).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:60).
RX   PubMed=15140048; DOI=10.1111/j.0001-2815.2004.00226.x;
RA   Testa G.V., Bunce M., Sheldon M.H., Dunn P.P., Day S., Marques S.B.;
RT   "Identification of a new allele, HLA-DRB1*1360, on a DRB5 haplotype in
RT   a Brazilian individual.";
RL   Tissue Antigens 63:617-618(2004).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:57).
RX   PubMed=15245379; DOI=10.1111/j.1399-0039.2004.00261.x;
RA   Danzer M., Leitner D., Gangl E., Fae I., Fischer G.F., Gabriel C.;
RT   "A novel HLA-DRB1*13 allele (DRB1*1357) identified by polymerase chain
RT   reaction with sequence-specific primers and direct sequencing.";
RL   Tissue Antigens 64:213-214(2004).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:50).
RX   PubMed=15304013; DOI=10.1111/j.0001-2815.2004.00282.x;
RA   Chen Z.X., Tsan S.G., Dang C.W., Chu C.C., Lin M., Lee Y.J.;
RT   "Identification of two new HLA-DRB1 alleles: HLA-DRB1*1350 and
RT   DRB1*140502.";
RL   Tissue Antigens 64:300-303(2004).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:51).
RX   PubMed=15304015; DOI=10.1111/j.0001-2815.2004.00275.x;
RA   Chu C.C., Lee H.L., Hsieh N.K., Trejaut J., Lin M.;
RT   "Two novel HLA-DRB1 alleles identified using a sequence-based typing:
RT   HLA-DRB1*1443 and HLA-DRB1*1351*.";
RL   Tissue Antigens 64:308-310(2004).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:66).
RX   PubMed=15982265; DOI=10.1111/j.1399-0039.2005.00427.x;
RA   Milia S., Lai S., Valentini T., Testi M., Cappai L., Moscetti A.,
RA   Mariani M., Alba F., Carcassi C.;
RT   "Identification of a new allele, HLA-DRB1*1366*.";
RL   Tissue Antigens 66:69-71(2005).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:64).
RC   TISSUE=Peripheral blood;
RX   PubMed=16029439; DOI=10.1111/j.1399-0039.2005.00440.x;
RA   Czachurski D., Scollo A., Skambraks A., Perichon A.M., Scherer S.,
RA   Tran T.H., Opelz G., Grappiolo I., Mytilineos J.;
RT   "Description and characterization of two new HLA alleles, B*4051 and
RT   DRB1*1364, identified by sequence-based typing.";
RL   Tissue Antigens 66:151-155(2005).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:68).
RX   PubMed=16101838; DOI=10.1111/j.1399-0039.2005.00451.x;
RA   Caggiari L., Simula M.P., Marzotto A., Caragnano A., Luchetti M.,
RA   Gabrielli A., De Re V.;
RT   "Identification of a novel human DRB1*13 allele by sequence-based DRB
RT   typing.";
RL   Tissue Antigens 66:246-247(2005).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:70).
RC   TISSUE=Peripheral blood;
RX   PubMed=16634878; DOI=10.1111/j.1399-0039.2006.00580.x;
RA   Horn P.A., Zingsem J., Eckstein R., Blasczyk R.;
RT   "Novel HLA-DRB1*1370 allele identified in a cord blood donor and her
RT   mother.";
RL   Tissue Antigens 67:345-347(2006).
RN   [26]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:77).
RC   TISSUE=Blood;
RA   Tavoularis S., Conrod V., Ribeiro E.;
RT   "Identification of three novel DRB1 alleles.";
RL   Hum. Immunol. 68:S63-S63(2007).
RN   [27]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:75).
RX   PubMed=17257328; DOI=10.1111/j.1399-0039.2006.00750.x;
RA   Sanchez-Gordo F., Balas A., Ortiz M., Prat I., Vicario J.L.;
RT   "A new human leukocyte antigen DRB1 allele, HLA-DRB1*1375.";
RL   Tissue Antigens 69:204-205(2007).
RN   [28]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:71).
RX   PubMed=17493158; DOI=10.1111/j.1399-0039.2006.00753.x;
RA   McWhinnie A.J., Shah A., Peat J., Tavarozzi F., Little A.M.;
RT   "Description of HLA-DRB1*1371 allele, which has the 3' intron 1
RT   sequence and HLA-DQB1 association normally seen with a DRB1*0301
RT   allele.";
RL   Tissue Antigens 69:284-285(2007).
RN   [29]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:76).
RX   PubMed=17498272; DOI=10.1111/j.1399-0039.2007.00835.x;
RA   Abdeen H., McErlean C., Moraes M.E., Torres M., Campiotto S.,
RA   Galvao S., Gouvea C., Middleton D.;
RT   "Identification of three novel alleles of HLA-DRB1 and HLA-A in the
RT   Brazilian population.";
RL   Tissue Antigens 69:607-610(2007).
RN   [30]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:82).
RC   TISSUE=Blood;
RX   PubMed=19744147; DOI=10.1111/j.1399-0039.2009.01334.x;
RA   Anholts J.D., Aneq M., Dirks H.L., Tas A., Verduyn W., Oudshoorn M.;
RT   "Thirty-six novel HLA alleles: 7 HLA-A, 11 HLA-B, 15 HLA-C and 3 HLA-
RT   DRB1.";
RL   Tissue Antigens 74:424-428(2009).
RN   [31]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:32).
RC   TISSUE=Peripheral blood;
RA   Lester S., Laham N., Humphreys I., McCluskey J.;
RT   "A new DRB1*13 allele detected by PCR-SSOP and confirmed by
RT   sequencing.";
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [32]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:34).
RA   Erne G., Schmid C., Schwarz K., Woelpl A.;
RL   Submitted (FEB-1998) to the EMBL/GenBank/DDBJ databases.
RN   [33]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:39).
RA   Park M.H., Whang D.H., Kang S.J.;
RT   "A new HLA-DRB1*13 allele in a Korean individual.";
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [34]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:14).
RC   TISSUE=Peripheral blood;
RA   Guttridge M.G.;
RT   "Sequence confirmation of HLA-DRB1*1314.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [35]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:41).
RA   Bois M., Dormoy A., Alcalay D.;
RT   "Characterization of a new HLA-DRB1*13 class II allele.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [36]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:48).
RC   TISSUE=Peripheral blood;
RA   Moine A.;
RT   "A new HLA DRB1* allele close to DRB1*1304.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [37]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:47).
RA   Kashiwase K., Shimizu M., Juji T., Tanaka H., Ishikawa Y.;
RT   "HLA-DRB1-1307V for exon2.";
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [38]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:07).
RA   Tamouza R., Keyhani M., Poirier J.C., Schaeffer V., Fortier C.,
RA   Labie D., Charron D.;
RT   "New HLA-DRB1*13.";
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [39]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:01).
RA   Voorter C.E., van den Berg-Loonen E.M.;
RT   "New HLA DRB1*13 allele identified by sequence-based typing.";
RL   Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [40]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*13:01 AND
RP   DRB1*13:16).
RA   Rizzo M., Gedil M.A., Steiner N.K., Hurley C.K.;
RT   "Complete exon 2 sequence for HLA-DRB1*1316.";
RL   Submitted (NOV-2002) to the EMBL/GenBank/DDBJ databases.
RN   [41]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:69).
RA   Rodriguez-Marino S., Coquillard G.J.;
RT   "Novel HLA-DRB1*1301 Variant.";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [42]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:58).
RA   Chen D.-F., Dong L., Janzen M., Rabson A., Fraser P.;
RT   "Novel HLA-DRB1*13 alleles detected by PCR-SSOP and confirmed by
RT   single allele specific sequencing.";
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [43]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:54).
RA   Ono A.;
RT   "A new HLA-DR12V allele detected by PCR-RFLP.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [44]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:61).
RA   Lazaro A.M., Gedil M.A., Rizzo M., Hurley C.K.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [45]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*13:62 AND
RP   DRB1*13:63).
RA   Hirv K., Krauss A., Schwarz K.;
RT   "Characterization of a new HLA-DRB1 allele by direct sequencing.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [46]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:59).
RA   Bendukidze N.;
RT   "Rare DRB1*1359 alleles confirmatory testing.";
RL   Submitted (FEB-2004) to the EMBL/GenBank/DDBJ databases.
RN   [47]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:65).
RA   Czachurski D.;
RT   "Hochaufloesende Typisierung von HLA-Klasse I und Klasse II mittels
RT   Sequenzanalyse. Einfluss auf das Transplantatueberleben.";
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [48]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:67).
RC   TISSUE=Peripheral blood;
RA   Binder T.M.C., Mosebach M., Kuehnl P., Heim M.U., Blasczyk R.,
RA   Eiermann T.H.;
RT   "A new HLA-DRB1*13 variant similar to DRB1*130201 and DRB3*020101.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [49]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:74).
RC   TISSUE=Peripheral blood;
RA   Dunne C., Crowley J.;
RT   "Sequence of new HLA-DRB1*13 allele DRB1*13XX.";
RL   Submitted (JUL-2006) to the EMBL/GenBank/DDBJ databases.
RN   [50]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:79).
RC   TISSUE=Blood;
RA   Duignan P., Varney M., Holdsworth R.;
RT   "New DRB1*13 allele found in cord blood.";
RL   Submitted (MAR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [51]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:78).
RA   Moore J., Bowman S., Varney M., Tait B.;
RT   "New HLA DR13 sequence found in bone marrow donor.";
RL   Submitted (MAR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [52]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*13:83).
RA   Horn P.A., Blasczyk R.;
RT   "A novel HLA-DRB1*13 allele.";
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [53]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*13:31;
RP   DRB1*13:72; DRB1*13:73; DRB1*13:80; DRB1*13:81; DRB1*13:84;
RP   DRB1*13:85; DRB1*13:86 AND DRB1*13:88).
RA   Lazaro A.M., Xiao Y., Cao K., Shan X., Zhang B., Masaberg C.,
RA   Hurley C.K.;
RT   "Novel HLA-class II allele.";
RL   Submitted (MAY-2008) to the EMBL/GenBank/DDBJ databases.
RN   [54]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-122 (ALLELES DRB1*13:23 AND
RP   DRB1*13:24).
RX   PubMed=9243754; DOI=10.1111/j.1399-0039.1997.tb02832.x;
RA   Ellis J.M., Robbins F., Wang J., Tang T., Heine U., Mason J.M.,
RA   Sese D., Milford E., Hurley C.K.;
RT   "Identification of four new DR52-associated DRB1 alleles: DRB1*1424,
RT   *1425, *1323 and *1324.";
RL   Tissue Antigens 50:42-46(1997).
RN   [55]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-120 (ALLELE DRB1*13:13).
RC   TISSUE=Blood;
RA   Hurley C.K., Noreen H., Lin Y.S.;
RT   "DRB1*1313.";
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [56]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-120 (ALLELE DRB1*13:52).
RA   Rodriguez-Marino S., Coquillard G.;
RT   "Characterization of a new DRB1*13011 variant allele.";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [57]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-116 (ALLELE DRB1*13:25).
RX   PubMed=9008317; DOI=10.1111/j.1399-0039.1996.tb02698.x;
RA   Poli F., Bianchi P., Crespiatico L., Sirchia G.;
RT   "Identification of a new DRB1 allele (DRB1*1325) by PCR-SSP and DNA
RT   sequencing.";
RL   Tissue Antigens 48:714-716(1996).
RN   [58]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-115 (ALLELE DRB1*13:33).
RC   TISSUE=Blood;
RX   PubMed=9694360; DOI=10.1111/j.1399-0039.1998.tb03010.x;
RA   Buyse I.M., Ouellet S., Hashemi-Tavoularis S.;
RT   "Identification of novel DRB1*13 (DRB1*1333), DRB1*04 (DRB1*0426) and
RT   DRB5* (DRB5*0109) alleles.";
RL   Tissue Antigens 51:658-662(1998).
RN   [59]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-123 (ALLELE DRB1*13:40).
RC   TISSUE=Cervix;
RX   PubMed=11019927; DOI=10.1034/j.1399-0039.2000.560218.x;
RA   Maciag P.C., Junes K.S., Villa L.L., Petzl-Erler M.L.;
RT   "Identification of a novel allele, DRB1*1340, in two Brazilian
RT   individuals.";
RL   Tissue Antigens 56:194-196(2000).
RN   [60]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-123 (ALLELE DRB1*13:53).
RC   TISSUE=Peripheral blood;
RA   Poli F., Longhi E., Frison S.;
RT   "Identification of a new HLA DRB1*13 by SBT.";
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [61]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-123 (ALLELES DRB1*13:15 AND
RP   DRB1*13:55).
RA   Lo B.;
RT   "Confirmatory Sequence of HLA Class II DRB1*1315.";
RL   Submitted (NOV-2002) to the EMBL/GenBank/DDBJ databases.
RN   [62]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-120 (ALLELE DRB1*13:09).
RC   TISSUE=Blood;
RX   PubMed=8023320; DOI=10.1111/j.1399-0039.1994.tb02298.x;
RA   Yunis J.J., Kineke E., Yunis E.J.;
RT   "Characterization of a new DRB1 allele, DRB1*1309, by PCR-SSOP and
RT   sequencing.";
RL   Tissue Antigens 43:54-57(1994).
RN   [63]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-119 (ALLELE DRB1*13:30).
RA   Greville W.D., Bowman S.;
RT   "New HLA class II (DRB1) allele from Melbourne BTS.";
RL   Submitted (SEP-1996) to the EMBL/GenBank/DDBJ databases.
RN   [64]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-119 (ALLELE DRB1*13:28).
RA   Varney M.D., Tait B.D.;
RT   "Identification of a novel DPB allele.";
RL   Submitted (MAR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [65]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-116 (ALLELE DRB1*13:26).
RX   PubMed=9027974; DOI=10.1111/j.1399-0039.1997.tb02718.x;
RA   Voorter C.E.M., de Bruyn-Geraets D., Verduyn W., Schreuder G.M.T.,
RA   van den Berg-Loonen E.M.;
RT   "Identification of a new HLA-DRB1*13 allele (DRB1*1326) with a short
RT   DRB1*16 sequence.";
RL   Tissue Antigens 49:88-91(1997).
RN   [66]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-116 (ALLELE DRB1*13:45).
RX   PubMed=12028550; DOI=10.1034/j.1399-0039.2002.590219.x;
RA   Bengtsson M., Jansson I.E., Danielsson F., Henrysson H., Kallsten K.;
RT   "Identification of a novel HLA DRB1 exon 2 sequence, DRB1*1345.";
RL   Tissue Antigens 59:159-161(2002).
RN   [67]
RP   REVIEW.
RX   PubMed=8598037; DOI=10.1016/S0092-8674(00)81025-9;
RA   Cresswell P.;
RT   "Invariant chain structure and MHC class II function.";
RL   Cell 84:505-507(1996).
RN   [68]
RP   REVIEW.
RX   PubMed=11684289; DOI=10.1016/S0161-5890(01)00069-4;
RA   Villadangos J.A.;
RT   "Presentation of antigens by MHC class II molecules: getting the most
RT   out of them.";
RL   Mol. Immunol. 38:329-346(2001).
RN   [69]
RP   REVIEW.
RX   PubMed=17241953; DOI=10.1016/j.immuni.2007.01.005;
RA   Menendez-Benito V., Neefjes J.;
RT   "Autophagy in MHC class II presentation: sampling from within.";
RL   Immunity 26:1-3(2007).
RN   [70]
RP   REVIEW.
RX   PubMed=18046453; DOI=10.1038/sj.emboj.7601945;
RA   Rocha N., Neefjes J.;
RT   "MHC class II molecules on the move for successful antigen
RT   presentation.";
RL   EMBO J. 27:1-5(2008).
RN   [71]
RP   UBIQUITINATION BY MARCH1, AND SUBCELLULAR LOCATION.
RX   PubMed=18305173; DOI=10.1073/pnas.0708874105;
RA   De Gassart A., Camosseto V., Thibodeau J., Ceppi M., Catalan N.,
RA   Pierre P., Gatti E.;
RT   "MHC class II stabilization at the surface of human dendritic cells is
RT   the result of maturation-dependent MARCH I down-regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3491-3496(2008).
RN   [72]
RP   REVIEW.
RX   PubMed=19092054; DOI=10.1242/jcs.035089;
RA   Berger A.C., Roche P.A.;
RT   "MHC class II transport at a glance.";
RL   J. Cell Sci. 122:1-4(2009).
RN   [73]
RP   REVIEW.
RX   PubMed=19533806; DOI=10.3748/wjg.15.2855;
RA   Beswick E.J., Reyes V.E.;
RT   "CD74 in antigen presentation, inflammation, and cancers of the
RT   gastrointestinal tract.";
RL   World J. Gastroenterol. 15:2855-2861(2009).
CC   -!- FUNCTION: Binds peptides derived from antigens that access the
CC       endocytic route of antigen presenting cells (APC) and presents
CC       them on the cell surface for recognition by the CD4 T-cells. The
CC       peptide binding cleft accommodates peptides of 10-30 residues. The
CC       peptides presented by MHC class II molecules are generated mostly
CC       by degradation of proteins that access the endocytic route, where
CC       they are processed by lysosomal proteases and other hydrolases.
CC       Exogenous antigens that have been endocytosed by the APC are thus
CC       readily available for presentation via MHC II molecules, and for
CC       this reason this antigen presentation pathway is usually referred
CC       to as exogenous. As membrane proteins on their way to degradation
CC       in lysosomes as part of their normal turn-over are also contained
CC       in the endosomal/lysosomal compartments, exogenous antigens must
CC       compete with those derived from endogenous components. Autophagy
CC       is also a source of endogenous peptides, autophagosomes
CC       constitutively fuse with MHC class II loading compartments. In
CC       addition to APCs, other cells of the gastrointestinal tract, such
CC       as epithelial cells, express MHC class II molecules and CD74 and
CC       act as APCs, which is an unusual trait of the GI tract. To produce
CC       a MHC class II molecule that presents an antigen, three MHC class
CC       II molecules (heterodimers of an alpha and a beta chain) associate
CC       with a CD74 trimer in the ER to form a heterononamer. Soon after
CC       the entry of this complex into the endosomal/lysosomal system
CC       where antigen processing occurs, CD74 undergoes a sequential
CC       degradation by various proteases, including CTSS and CTSL, leaving
CC       a small fragment termed CLIP (class-II-associated invariant chain
CC       peptide). The removal of CLIP is facilitated by HLA-DM via direct
CC       binding to the alpha-beta-CLIP complex so that CLIP is released.
CC       HLA-DM stabilizes MHC class II molecules until primary high
CC       affinity antigenic peptides are bound. The MHC II molecule bound
CC       to a peptide is then transported to the cell membrane surface. In
CC       B-cells, the interaction between HLA-DM and MHC class II molecules
CC       is regulated by HLA-DO. Primary dendritic cells (DCs) also to
CC       express HLA-DO. Lysosomal microenvironment has been implicated in
CC       the regulation of antigen loading into MHC II molecules, increased
CC       acidification produces increased proteolysis and efficient peptide
CC       loading.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit; also referred
CC       as MHC class II molecule. In the endoplasmic reticulum (ER) it
CC       forms a heterononamer; 3 MHC class II molecules bind to a CD74
CC       homotrimer (also known as invariant chain or HLA class II
CC       histocompatibility antigen gamma chain). In the
CC       endosomal/lysosomal system; CD74 undergoes sequential degradation
CC       by various proteases; leaving a small fragment termed CLIP on each
CC       MHC class II molecule. MHC class II molecule interacts with
CC       HLA_DM, and HLA_DO in B-cells, in order to release CLIP and
CC       facilitate the binding of antigenic peptides.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane; Single-pass type I
CC       membrane protein. Golgi apparatus, trans-Golgi network membrane;
CC       Single-pass type I membrane protein. Endosome membrane; Single-
CC       pass type I membrane protein. Lysosome membrane; Single-pass type
CC       I membrane protein. Late endosome membrane; Single-pass type I
CC       membrane protein. Note=The MHC class II complex transits through a
CC       number of intracellular compartments in the endocytic pathway
CC       until it reaches the cell membrane for antigen presentation.
CC   -!- PTM: Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to
CC       sorting into the endosome system and down-regulation of MHC class
CC       II (Probable).
CC   -!- POLYMORPHISM: The following alleles of DRB1-13 are known:
CC       DRB1*13:01, DRB1*13:02, DRB1*13:03, DRB1*13:04, DRB1*13:05,
CC       DRB1*13:06, DRB1*13:07, DRB1*13:08, DRB1*13:09, DRB1*13:10,
CC       DRB1*13:11, DRB1*13:12, DRB1*13:13, DRB1*13:14, DRB1*13:15,
CC       DRB1*13:16, DRB1*13:17, DRB1*13:18, DRB1*13:19, DRB1*13:20,
CC       DRB1*13:21, DRB1*13:22, DRB1*13:23, DRB1*13:24, DRB1*13:25,
CC       DRB1*13:26, DRB1*13:27, DRB1*13:28, DRB1*13:29, DRB1*13:30,
CC       DRB1*13:31, DRB1*13:32, DRB1*13:33, DRB1*13:34, DRB1*13:35,
CC       DRB1*13:36, DRB1*13:37, DRB1*13:38, DRB1*13:39, DRB1*13:40,
CC       DRB1*13:41, DRB1*13:42, DRB1*13:43, DRB1*13:44, DRB1*13:45,
CC       DRB1*13:46, DRB1*13:47, DRB1*13:48, DRB1*13:49, DRB1*13:50,
CC       DRB1*13:51, DRB1*13:52, DRB1*13:53, DRB1*13:54, DRB1*13:55,
CC       DRB1*13:56, DRB1*13:57, DRB1*13:58, DRB1*13:59, DRB1*13:60,
CC       DRB1*13:61, DRB1*13:62, DRB1*13:63, DRB1*13:64, DRB1*13:65,
CC       DRB1*13:66, DRB1*13:67, DRB1*13:68, DRB1*13:69, DRB1*13:70,
CC       DRB1*13:71, DRB1*13:72, DRB1*13:73, DRB1*13:74, DRB1*13:75,
CC       DRB1*13:76, DRB1*13:77, DRB1*13:78, DRB1*13:79, DRB1*13:80,
CC       DRB1*13:81, DRB1*13:82, DRB1*13:83, DRB1*13:84, DRB1*13:85,
CC       DRB1*13:86, DRB1*13:87 and DRB1*13:88. The sequence shown is that
CC       of DRB1*13:01.
CC   -!- SIMILARITY: Belongs to the MHC class II family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAB40418.1; Type=Erroneous gene model prediction;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY663413; AAU88029.1; -; Genomic_DNA.
DR   EMBL; AY663415; AAU88035.1; -; Genomic_DNA.
DR   EMBL; AJ697893; CAG27026.1; -; mRNA.
DR   EMBL; AY961069; AAX63457.1; -; mRNA.
DR   EMBL; AY961070; AAX63458.2; -; mRNA.
DR   EMBL; L76133; AAL40069.1; -; mRNA.
DR   EMBL; AK293020; BAF85709.1; -; mRNA.
DR   EMBL; BC007920; AAH07920.1; -; mRNA.
DR   EMBL; L41992; AAA65914.1; -; Genomic_DNA.
DR   EMBL; U17381; AAC50167.1; -; mRNA.
DR   EMBL; M59803; AAA64237.1; -; mRNA.
DR   EMBL; FM196526; CAQ86517.1; -; Genomic_DNA.
DR   EMBL; AM109988; CAJ33595.1; -; Genomic_DNA.
DR   EMBL; AM109989; CAJ33596.1; -; Genomic_DNA.
DR   EMBL; AM109990; CAJ33597.1; -; Genomic_DNA.
DR   EMBL; AM109991; CAJ33598.1; -; Genomic_DNA.
DR   EMBL; AM109992; CAJ33599.1; -; Genomic_DNA.
DR   EMBL; AM109993; CAJ33600.1; -; Genomic_DNA.
DR   EMBL; AM109994; CAJ33601.1; -; Genomic_DNA.
DR   EMBL; AM109995; CAJ33602.1; -; Genomic_DNA.
DR   EMBL; AM109996; CAJ33603.1; -; Genomic_DNA.
DR   EMBL; AM109997; CAJ33604.1; -; Genomic_DNA.
DR   EMBL; D29836; BAA06216.1; -; Genomic_DNA.
DR   EMBL; Z48631; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X86326; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF136155; AAD27646.1; -; Genomic_DNA.
DR   EMBL; AF164346; AAD47814.1; -; Genomic_DNA.
DR   EMBL; AF169239; AAD51315.1; -; Genomic_DNA.
DR   EMBL; AF243537; AAG00414.1; -; Genomic_DNA.
DR   EMBL; AF243538; AAG00415.1; -; Genomic_DNA.
DR   EMBL; AF352295; AAK27712.1; -; Genomic_DNA.
DR   EMBL; AF306862; AAG42258.1; -; Genomic_DNA.
DR   EMBL; AF247533; AAF99607.1; -; Genomic_DNA.
DR   EMBL; AY178845; AAO18733.1; -; Genomic_DNA.
DR   EMBL; AJ555156; CAD87537.1; -; Genomic_DNA.
DR   EMBL; AY048687; AAL12226.1; -; Genomic_DNA.
DR   EMBL; AF441789; AAL35834.1; -; Genomic_DNA.
DR   EMBL; AY765349; AAV35213.1; -; Genomic_DNA.
DR   EMBL; AJ634529; CAG25408.1; -; Genomic_DNA.
DR   EMBL; AY963587; AAX51706.1; -; Genomic_DNA.
DR   EMBL; AM086025; CAJ30431.1; -; Genomic_DNA.
DR   EMBL; AM494414; CAM36736.1; -; Genomic_DNA.
DR   EMBL; EF053230; ABK33462.1; -; Genomic_DNA.
DR   EMBL; AM158254; CAJ43560.1; -; Genomic_DNA.
DR   EMBL; EF196873; ABM69041.1; -; Genomic_DNA.
DR   EMBL; AM904556; CAP17407.1; -; Genomic_DNA.
DR   EMBL; U97554; AAB58309.1; -; Genomic_DNA.
DR   EMBL; AF048688; AAC05271.1; -; Genomic_DNA.
DR   EMBL; AF170582; AAD50971.1; -; Genomic_DNA.
DR   EMBL; AJ245717; CAB53346.1; -; Genomic_DNA.
DR   EMBL; AJ249591; CAB56840.1; -; Genomic_DNA.
DR   EMBL; AJ401236; CAB96577.1; -; Genomic_DNA.
DR   EMBL; AB049459; BAB16298.1; -; Genomic_DNA.
DR   EMBL; AF305212; AAG22826.1; -; Genomic_DNA.
DR   EMBL; AJ271206; CAC27122.1; -; Genomic_DNA.
DR   EMBL; AY178184; AAO21939.1; -; Genomic_DNA.
DR   EMBL; AY277392; AAP34696.1; -; Genomic_DNA.
DR   EMBL; AY225520; AAO67727.1; -; Genomic_DNA.
DR   EMBL; AY259126; AAP21612.1; -; Genomic_DNA.
DR   EMBL; AB112913; BAD02944.1; -; Genomic_DNA.
DR   EMBL; AY339247; AAQ18914.1; -; Genomic_DNA.
DR   EMBL; AY379480; AAQ85128.1; -; Genomic_DNA.
DR   EMBL; AY502108; AAR89455.1; -; Genomic_DNA.
DR   EMBL; AJ627565; CAF28889.1; -; Genomic_DNA.
DR   EMBL; AJ783982; CAH04455.1; -; Genomic_DNA.
DR   EMBL; AJ853708; CAH68606.1; -; Genomic_DNA.
DR   EMBL; AM279417; CAK50561.1; -; Genomic_DNA.
DR   EMBL; EF493833; ABP68561.1; -; Genomic_DNA.
DR   EMBL; EF493832; ABP68560.1; -; Genomic_DNA.
DR   EMBL; AM931066; CAP62371.1; -; Genomic_DNA.
DR   EMBL; DQ473293; ABF18979.1; -; Genomic_DNA.
DR   EMBL; DQ514602; ABF60565.1; -; Genomic_DNA.
DR   EMBL; DQ525629; ABF74594.1; -; Genomic_DNA.
DR   EMBL; EU029803; ABU86862.1; -; Genomic_DNA.
DR   EMBL; EU071684; ABS87343.1; -; Genomic_DNA.
DR   EMBL; EU812541; ACE88700.1; -; Genomic_DNA.
DR   EMBL; EU826130; ACF36162.1; -; Genomic_DNA.
DR   EMBL; EU826129; ACF36161.1; -; Genomic_DNA.
DR   EMBL; FJ688163; ACN56340.1; -; Genomic_DNA.
DR   EMBL; U36827; AAC51629.1; -; Genomic_DNA.
DR   EMBL; U36825; AAC51628.1; -; Genomic_DNA.
DR   EMBL; U79025; AAB52235.1; -; Genomic_DNA.
DR   EMBL; AF499445; AAP68877.1; -; Genomic_DNA.
DR   EMBL; X93924; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AJ001254; CAA04628.1; -; Genomic_DNA.
DR   EMBL; AJ237964; CAB40418.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AJ488066; CAD32373.1; -; Genomic_DNA.
DR   EMBL; AY174182; AAO17054.1; -; Genomic_DNA.
DR   EMBL; AY179366; AAO23237.1; -; Genomic_DNA.
DR   EMBL; L23534; AAA62591.1; -; Genomic_DNA.
DR   EMBL; U72264; AAB17276.1; -; Genomic_DNA.
DR   EMBL; X97407; CAA66060.1; -; Genomic_DNA.
DR   EMBL; X96396; CAA65260.1; -; Genomic_DNA.
DR   EMBL; AJ276873; CAB82169.1; -; Genomic_DNA.
DR   PIR; D25239; D25239.
DR   PIR; I38899; I38899.
DR   PIR; I59647; I59647.
DR   PIR; I72484; I72484.
DR   PIR; PH0155; PH0155.
DR   PIR; S03439; S03439.
DR   UniGene; Hs.485130; -.
DR   UniGene; Hs.534322; -.
DR   UniGene; Hs.696211; -.
DR   UniGene; Hs.716081; -.
DR   UniGene; Hs.723344; -.
DR   UniGene; Hs.736560; -.
DR   ProteinModelPortal; Q5Y7A7; -.
DR   SMR; Q5Y7A7; 34-220.
DR   DMDM; 74757225; -.
DR   MaxQB; Q5Y7A7; -.
DR   PRIDE; Q5Y7A7; -.
DR   Ensembl; ENST00000328980; ENSP00000331343; ENSG00000206306.
DR   Ensembl; ENST00000399450; ENSP00000382378; ENSG00000206240.
DR   Ensembl; ENST00000415796; ENSP00000412168; ENSG00000206306.
DR   Ensembl; ENST00000428566; ENSP00000392280; ENSG00000206240.
DR   GeneCards; GC06M032546; -.
DR   GeneCards; GC06Mj32477; -.
DR   GeneCards; GC06Mn32480; -.
DR   HGNC; HGNC:4948; HLA-DRB1.
DR   MIM; 142857; gene.
DR   neXtProt; NX_Q5Y7A7; -.
DR   HOVERGEN; HBG012730; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-DRB1; human.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031902; C:late endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0042613; C:MHC class II protein complex; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0030658; C:transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.320.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR014745; MHC_II_a/b_N.
DR   InterPro; IPR000353; MHC_II_b_N.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00969; MHC_II_beta; 1.
DR   ProDom; PD000328; MHC_II_b_N; 1.
DR   SMART; SM00407; IGc1; 1.
DR   SMART; SM00921; MHC_II_beta; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Golgi apparatus;
KW   Immunity; Isopeptide bond; Lysosome; Membrane; MHC II; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     29       Potential.
FT   CHAIN        30    266       HLA class II histocompatibility antigen,
FT                                DRB1-13 beta chain.
FT                                /FTId=PRO_0000392290.
FT   TRANSMEM    228    248       Helical; (Potential).
FT   DOMAIN      126    214       Ig-like C1-type.
FT   CARBOHYD     48     48       N-linked (GlcNAc...) (Potential).
FT   DISULFID    146    202       By similarity.
FT   CROSSLNK    254    254       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VARIANT      39     39       Y -> L (in allele DRB1*13:67; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_062866.
FT   VARIANT      40     40       S -> L (in allele DRB1*13:67).
FT                                /FTId=VAR_062867.
FT   VARIANT      41     41       T -> K (in allele DRB1*13:67).
FT                                /FTId=VAR_062868.
FT   VARIANT      42     42       S -> G (in allele DRB1*13:17).
FT                                /FTId=VAR_062869.
FT   VARIANT      45     45       H -> Q (in allele DRB1*13:72).
FT                                /FTId=VAR_062871.
FT   VARIANT      45     45       H -> Y (in allele DRB1*13:17).
FT                                /FTId=VAR_062870.
FT   VARIANT      54     54       R -> L (in allele DRB1*13:73).
FT                                /FTId=VAR_062872.
FT   VARIANT      55     55       F -> Y (in allele DRB1*13:27, allele
FT                                DRB1*13:41 and allele DRB1*13:71).
FT                                /FTId=VAR_062873.
FT   VARIANT      56     56       L -> Q (in allele DRB1*13:59).
FT                                /FTId=VAR_062874.
FT   VARIANT      57     57       D -> E (in allele DRB1*13:15, allele
FT                                DRB1*13:19, allele DRB1*13:26, allele
FT                                DRB1*13:53, allele DRB1*13:57, allele
FT                                DRB1*13:85 and allele DRB1*13:86).
FT                                /FTId=VAR_062875.
FT   VARIANT      61     61       H -> Y (in allele DRB1*13:03, allele
FT                                DRB1*13:07, allele DRB1*13:04, allele
FT                                DRB1*13:11, allele DRB1*13:12, allele
FT                                DRB1*13:13, allele DRB1*13:14, allele
FT                                DRB1*13:17, allele DRB1*13:21, allele
FT                                DRB1*13:22, allele DRB1*13:23, allele
FT                                DRB1*13:24, allele DRB1*13:25, allele
FT                                DRB1*13:30, allele DRB1*13:33, allele
FT                                DRB1*13:37, allele DRB1*13:38, allele
FT                                DRB1*13:44, allele DRB1*13:45, allele
FT                                DRB1*13:46, allele DRB1*13:47, allele
FT                                DRB1*13:48, allele DRB1*13:49, allele
FT                                DRB1*13:50, allele DRB1*13:54, allele
FT                                DRB1*13:55, allele DRB1*13:58, allele
FT                                DRB1*13:60, allele DRB1*13:62, allele
FT                                DRB1*13:66, allele DRB1*13:69, allele
FT                                DRB1*13:70, allele DRB1*13:75, allele
FT                                DRB1*13:81, allele DRB1*13:82, allele
FT                                DRB1*13:86 and allele DRB1*13:88).
FT                                /FTId=VAR_062876.
FT   VARIANT      66     66       N -> D (in allele DRB1*13:62 and allele
FT                                DRB1*13:68).
FT                                /FTId=VAR_062880.
FT   VARIANT      66     66       N -> F (in allele DRB1*13:08, allele
FT                                DRB1*13:19, allele DRB1*13:57, allele
FT                                DRB1*13:64, allele DRB1*13:72, allele
FT                                DRB1*13:76 and allele DRB1*13:83;
FT                                requires 2 nucleotide substitutions).
FT                                /FTId=VAR_062878.
FT   VARIANT      66     66       N -> I (in allele DRB1*13:87).
FT                                /FTId=VAR_062881.
FT   VARIANT      66     66       N -> S (in allele DRB1*13:60 and allele
FT                                DRB1*13:84).
FT                                /FTId=VAR_062879.
FT   VARIANT      66     66       N -> Y (in allele DRB1*13:03, allele
FT                                DRB1*13:07, allele DRB1*13:04, allele
FT                                DRB1*13:11, allele DRB1*13:12, allele
FT                                DRB1*13:13, allele DRB1*13:14, allele
FT                                DRB1*13:17, allele DRB1*13:21, allele
FT                                DRB1*13:22, allele DRB1*13:23, allele
FT                                DRB1*13:24, allele DRB1*13:25, allele
FT                                DRB1*13:30, allele DRB1*13:33, allele
FT                                DRB1*13:37, allele DRB1*13:38, allele
FT                                DRB1*13:44, allele DRB1*13:45, allele
FT                                DRB1*13:46, allele DRB1*13:47, allele
FT                                DRB1*13:48, allele DRB1*13:49, allele
FT                                DRB1*13:52, allele DRB1*13:54, allele
FT                                DRB1*13:55, allele DRB1*13:58, allele
FT                                DRB1*13:66, allele DRB1*13:70, allele
FT                                DRB1*13:75, allele DRB1*13:81, allele
FT                                DRB1*13:82, allele DRB1*13:86 and allele
FT                                DRB1*13:88).
FT                                /FTId=VAR_062877.
FT   VARIANT      67     67       V -> L (in allele DRB1*13:34, allele
FT                                DRB1*13:62 and allele DRB1*13:64).
FT                                /FTId=VAR_062882.
FT   VARIANT      76     76       F -> Y (in allele DRB1*13:03, allele
FT                                DRB1*13:07, allele DRB1*13:08, allele
FT                                DRB1*13:12, allele DRB1*13:13, allele
FT                                DRB1*13:19, allele DRB1*13:26, allele
FT                                DRB1*13:32, allele DRB1*13:33, allele
FT                                DRB1*13:36, allele DRB1*13:37, allele
FT                                DRB1*13:38, allele DRB1*13:40, allele
FT                                DRB1*13:47, allele DRB1*13:48, allele
FT                                DRB1*13:49, allele DRB1*13:53, allele
FT                                DRB1*13:55, allele DRB1*13:58, allele
FT                                DRB1*13:60, allele DRB1*13:65, allele
FT                                DRB1*13:70, allele DRB1*13:72, allele
FT                                DRB1*13:76, allele DRB1*13:81, allele
FT                                DRB1*13:84, allele DRB1*13:85 and allele
FT                                DRB1*13:88).
FT                                /FTId=VAR_062883.
FT   VARIANT      77     77       R -> L (in allele DRB1*13:35).
FT                                /FTId=VAR_062884.
FT   VARIANT      77     77       R -> W (in allele DRB1*13:80).
FT                                /FTId=VAR_062885.
FT   VARIANT      79     79       V -> L (in allele DRB1*13:51).
FT                                /FTId=VAR_062886.
FT   VARIANT      86     86       D -> A (in allele DRB1*13:43 and allele
FT                                DRB1*13:45).
FT                                /FTId=VAR_062889.
FT   VARIANT      86     86       D -> S (in allele DRB1*13:03, allele
FT                                DRB1*13:04, allele DRB1*13:12, allele
FT                                DRB1*13:13, allele DRB1*13:21, allele
FT                                DRB1*13:30, allele DRB1*13:32, allele
FT                                DRB1*13:33, allele DRB1*13:38, allele
FT                                DRB1*13:48, allele DRB1*13:49, allele
FT                                DRB1*13:55, allele DRB1*13:58, allele
FT                                DRB1*13:65, allele DRB1*13:66, allele
FT                                DRB1*13:75, allele DRB1*13:81 and allele
FT                                DRB1*13:88; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062887.
FT   VARIANT      86     86       D -> V (in allele DRB1*13:31, allele
FT                                DRB1*13:46, allele DRB1*13:54 and allele
FT                                DRB1*13:77).
FT                                /FTId=VAR_062888.
FT   VARIANT      89     89       Y -> H (in allele DRB1*13:43 and allele
FT                                DRB1*13:45).
FT                                /FTId=VAR_062891.
FT   VARIANT      89     89       Y -> S (in allele DRB1*13:39, allele
FT                                DRB1*13:54, allele DRB1*13:77, allele
FT                                DRB1*13:78 and allele DRB1*13:79).
FT                                /FTId=VAR_062890.
FT   VARIANT      96     96       I -> F (in allele DRB1*13:07, allele
FT                                DRB1*13:05, allele DRB1*13:11, allele
FT                                DRB1*13:14, allele DRB1*13:18, allele
FT                                DRB1*13:21, allele DRB1*13:24, allele
FT                                DRB1*13:26, allele DRB1*13:42, allele
FT                                DRB1*13:46, allele DRB1*13:47, allele
FT                                DRB1*13:49, allele DRB1*13:50, allele
FT                                DRB1*13:54, allele DRB1*13:55, allele
FT                                DRB1*13:62, allele DRB1*13:63 and allele
FT                                DRB1*13:75).
FT                                /FTId=VAR_062892.
FT   VARIANT      96     96       I -> L (in allele DRB1*13:20, allele
FT                                DRB1*13:25, allele DRB1*13:29, allele
FT                                DRB1*13:43, allele DRB1*13:44, allele
FT                                DRB1*13:56, allele DRB1*13:60, allele
FT                                DRB1*13:71, allele DRB1*13:78, allele
FT                                DRB1*13:86 and allele DRB1*13:88).
FT                                /FTId=VAR_062893.
FT   VARIANT      97     97       L -> R (in allele DRB1*13:74).
FT                                /FTId=VAR_062894.
FT   VARIANT      99     99       D -> Q (in allele DRB1*13:09, allele
FT                                DRB1*13:44 and allele DRB1*13:86;
FT                                requires 2 nucleotide substitutions).
FT                                /FTId=VAR_062895.
FT   VARIANT     100    100       E -> A (in allele DRB1*13:09).
FT                                /FTId=VAR_062898.
FT   VARIANT     100    100       E -> K (in allele DRB1*13:03, allele
FT                                DRB1*13:10, allele DRB1*13:33, allele
FT                                DRB1*13:37, allele DRB1*13:66, allele
FT                                DRB1*13:81, allele DRB1*13:85 and allele
FT                                DRB1*13:88).
FT                                /FTId=VAR_062897.
FT   VARIANT     100    100       E -> R (in allele DRB1*13:07, allele
FT                                DRB1*13:05, allele DRB1*13:06, allele
FT                                DRB1*13:11, allele DRB1*13:12, allele
FT                                DRB1*13:13, allele DRB1*13:14, allele
FT                                DRB1*13:18, allele DRB1*13:21, allele
FT                                DRB1*13:25, allele DRB1*13:26, allele
FT                                DRB1*13:30, allele DRB1*13:42, allele
FT                                DRB1*13:44, allele DRB1*13:46, allele
FT                                DRB1*13:47, allele DRB1*13:49, allele
FT                                DRB1*13:50, allele DRB1*13:55, allele
FT                                DRB1*13:56, allele DRB1*13:58, allele
FT                                DRB1*13:60, allele DRB1*13:62, allele
FT                                DRB1*13:77, allele DRB1*13:82 and allele
FT                                DRB1*13:86; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062896.
FT   VARIANT     103    103       A -> E (in allele DRB1*13:76).
FT                                /FTId=VAR_062900.
FT   VARIANT     103    103       A -> L (in allele DRB1*13:13, allele
FT                                DRB1*13:18, allele DRB1*13:47 and allele
FT                                DRB1*13:55; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062899.
FT   VARIANT     106    106       T -> N (in allele DRB1*13:33 and allele
FT                                DRB1*13:61).
FT                                /FTId=VAR_062901.
FT   VARIANT     113    113       G -> R (in allele DRB1*13:28).
FT                                /FTId=VAR_062902.
FT   VARIANT     114    114       V -> A (in allele DRB1*13:58 and allele
FT                                DRB1*13:81).
FT                                /FTId=VAR_062903.
FT   VARIANT     115    115       V -> D (in allele DRB1*13:16).
FT                                /FTId=VAR_062905.
FT   VARIANT     115    115       V -> G (in allele DRB1*13:02, allele
FT                                DRB1*13:03, allele DRB1*13:07, allele
FT                                DRB1*13:05, allele DRB1*13:12, allele
FT                                DRB1*13:13, allele DRB1*13:14, allele
FT                                DRB1*13:21, allele DRB1*13:23, allele
FT                                DRB1*13:25, allele DRB1*13:26, allele
FT                                DRB1*13:29, allele DRB1*13:30, allele
FT                                DRB1*13:31, allele DRB1*13:33, allele
FT                                DRB1*13:34, allele DRB1*13:36, allele
FT                                DRB1*13:37, allele DRB1*13:38, allele
FT                                DRB1*13:39, allele DRB1*13:41, allele
FT                                DRB1*13:45, allele DRB1*13:46, allele
FT                                DRB1*13:47, allele DRB1*13:49, allele
FT                                DRB1*13:50, allele DRB1*13:55, allele
FT                                DRB1*13:56, allele DRB1*13:60, allele
FT                                DRB1*13:62, allele DRB1*13:63, allele
FT                                DRB1*13:65, allele DRB1*13:66, allele
FT                                DRB1*13:67, allele DRB1*13:73, allele
FT                                DRB1*13:74, allele DRB1*13:82, allele
FT                                DRB1*13:85, allele DRB1*13:86 and allele
FT                                DRB1*13:88).
FT                                /FTId=VAR_062904.
FT   CONFLICT    104    104       V -> L (in Ref. 46; CAA04628).
FT   CONFLICT    121    121       Q -> H (in Ref. 25; AAC05271).
FT   CONFLICT    124    124       V -> G (in Ref. 11; BAA06216).
SQ   SEQUENCE   266 AA;  30008 MW;  17731F784445CC39 CRC64;
     MVCLRLPGGS CMAVLTVTLM VLSSPLALAG DTRPRFLEYS TSECHFFNGT ERVRFLDRYF
     HNQEENVRFD SDVGEFRAVT ELGRPDAEYW NSQKDILEDE RAAVDTYCRH NYGVVESFTV
     QRRVHPKVTV YPSKTQPLQH HNLLVCSVSG FYPGSIEVRW FRNGQEEKTG VVSTGLIHNG
     DWTFQTLVML ETVPRSGEVY TCQVEHPSVT SPLTVEWRAR SESAQSKMLS GVGGFVLGLL
     FLGAGLFIYF RNQKGHSGLQ PRGFLS
//
ID   2B1E_HUMAN              Reviewed;         266 AA.
AC   Q9GIY3; A0N0W1; A2TGX3; A4ZY86; A5H000; A5HKN8; A7DZP9; A7X5B1;
AC   A7X5B7; A7X5E0; A7X5E6; A7X5H8; A9JPG0; B1GWE7; B2CR03; B2LVF9;
AC   B2NJ29; B2ZCY1; B3VTP8; B5B8U0; B5B9V5; B5LZ25; B6VEL9; B9VRA4;
AC   B9X248; O02876; O46793; O77969; O78210; Q0PQ39; Q155F7; Q1AP33;
AC   Q1JRP3; Q27PR6; Q27PR7; Q29734; Q29770; Q29772; Q29800; Q2A120;
AC   Q2HZE5; Q2LE76; Q2MJA6; Q2VQU1; Q307W5; Q31636; Q3LA87; Q3LA88;
AC   Q3LA89; Q3LA90; Q3LA91; Q3LA92; Q3T919; Q4PRC3; Q4PRC5; Q4VZY7;
AC   Q56FP1; Q5BM92; Q5U9W6; Q683P7; Q70GL2; Q7YNY9; Q7YQA5; Q860D8;
AC   Q860D9; Q860S0; Q861H5; Q861H7; Q8MH59; Q8MH60; Q8WLU3; Q95348;
AC   Q95HK1; Q95HL0; Q95IG2; Q9GIL5; Q9GIL6; Q9GIY0; Q9GIY1; Q9GIY2;
AC   Q9GJ56; Q9GJ57; Q9GJ58; Q9TPB6; Q9TPW1; Q9XRY4; Q9Y4H7;
DT   23-MAR-2010, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   16-APR-2014, entry version 96.
DE   RecName: Full=HLA class II histocompatibility antigen, DRB1-14 beta chain;
DE   AltName: Full=MHC class II antigen DRB1*14;
DE            Short=DR-14;
DE            Short=DR14;
DE   Flags: Precursor;
GN   Name=HLA-DRB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*14:05).
RX   PubMed=12652907; DOI=10.1080/1042517021000041822;
RA   Kohsaka H., Nasu K., Matsushita S., Miyasaka N.;
RT   "Complete cDNA coding sequence of the HLA-DRB1*1405 allele.";
RL   DNA Seq. 13:359-361(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES DRB1*14:01 AND DRB1*14:04),
RP   AND NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-264 (ALLELES DRB1*14:02 AND
RP   DRB1*14:03).
RX   PubMed=11972886; DOI=10.1034/j.1399-0039.2002.590116.x;
RA   Corell A., Cox S.T., Soteriou B., Ramon D., Madrigal J.A.,
RA   Marsh S.G.E.;
RT   "Complete cDNA sequences of the HLA-DRB1*14011, *1402, *1403 and *1404
RT   alleles.";
RL   Tissue Antigens 59:66-69(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE DRB1*14:05).
RX   PubMed=16140993; DOI=10.1101/gr.3554305;
RA   Raymond C.K., Kas A., Paddock M., Qiu R., Zhou Y., Subramanian S.,
RA   Chang J., Palmieri A., Haugen E., Kaul R., Olson M.V.;
RT   "Ancient haplotypes of the HLA Class II region.";
RL   Genome Res. 15:1250-1257(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*14:11), AND NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 1-265 (ALLELE DRB1*14:46).
RX   PubMed=17174751; DOI=10.1016/j.humimm.2006.09.002;
RA   Balas A., Vilches C., Rodriguez M.A., Fernandez B., Martinez M.P.,
RA   de Pablo R., Garcia-Sanchez F., Vicario J.L.;
RT   "Group-specific amplification of cDNA from DRB1 genes. Complete coding
RT   sequences of partially defined alleles and identification of the new
RT   alleles DRB1*040602, DRB1*111102, DRB1*080103, and DRB1*0113.";
RL   Hum. Immunol. 67:1008-1016(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-217 (ALLELE DRB1*14:57).
RX   PubMed=17026471; DOI=10.1111/j.1399-0039.2006.00669.x;
RA   Chen Q., Zou H., Xu X.H., Luo M., Wang J., Zuo Y.Q., Chen Y.H.,
RA   Chen X.H., Chen X.L., Yao Z.Q., Song N., Zeng J., Mi X.Y., Sun S.X.,
RA   Wang J.X., Zhao T.M.;
RT   "Characterization of HLA-B*5516, -B*1313, -B*9512, and -DRB1*1457
RT   alleles identified in a southwest Chinese population.";
RL   Tissue Antigens 68:339-343(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-208 (ALLELE DRB1*14:54).
RX   PubMed=19284446; DOI=10.1111/j.1744-313X.2008.00826.x;
RA   Yang K.L., Chen M.J., Lee S.K., Lin C.C., Tsai M.J., Chiu H.M.,
RA   Jiang S., Chao Y.C., Chen S.P., Lin S., Shyr M.H., Lin P.Y.;
RT   "New allele name of some HLA-DRB1*1401: HLA-DRB1*1454.";
RL   Int. J. Immunogenet. 36:119-120(2009).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 30-123 (ALLELE DRB1*14:19).
RX   PubMed=8560458; DOI=10.1111/j.1399-0039.1995.tb02506.x;
RA   Loeffler D., Woelpl A., Kern P., Eiermann T.H.;
RT   "A novel HLA-DR allele, DRB1*1419.";
RL   Tissue Antigens 46:343-344(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-217 (ALLELE DRB1*14:82).
RA   Ogrzewalla K., Tillmann G., Scheibelhut N., Lauber J., Enczmann J.;
RT   "A novel HLA-DRB1*14 allele identified by sequence-based typing.";
RL   Submitted (JUL-2008) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-216 (ALLELES DRB1*14:06;
RP   DRB1*14:07; DRB1*14:10; DRB1*14:13; DRB1*14:14 AND DRB1*14:21).
RC   TISSUE=Peripheral blood;
RX   PubMed=17767557; DOI=10.1111/j.1399-0039.2007.00918.x;
RA   Horn P.A., Albis-Camps M., Verboom M., Bunce M., Yousaf K.,
RA   Williams S., Blasczyk R.;
RT   "The nature of diversity of HLA-DRB1 exon 3.";
RL   Tissue Antigens 70:335-337(2007).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-124 (ALLELE DRB1*14:85).
RA   Maruya E., Matsushita M., Saji H., Ounuma T., Futagami T., Kojima H.,
RA   Tujino T., Hayashi K., Kusunoki Y., Yoshida T., Maekawajiri S.;
RT   "HLA-DR new allele related with DRB1*1403.";
RL   Submitted (FEB-2009) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:22).
RX   PubMed=8575830; DOI=10.1007/s002510050058;
RA   Adami N., Aubert V., Jeannet M., Tiercy J.M.;
RT   "Sequencing of a new HLA-DR14 allele (DRB1(*)1422).";
RL   Immunogenetics 43:248-249(1996).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:36).
RX   PubMed=10321590; DOI=10.1034/j.1399-0039.1999.530421.x;
RA   Bodmer J., Marsh S., Albert E., Bodmer W.;
RT   "Nomenclature for factors of the HLA system, 1998.";
RL   Tissue Antigens 53:407-446(1999).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:37).
RC   TISSUE=Blood;
RX   PubMed=11380954; DOI=10.1034/j.1399-0039.2001.057004384.x;
RA   Wu S., Shiao Y.M., Lai C.Y., Lai S.M., Chen S.P., Sidebottom D.A.,
RA   Hildebrand W.H., Tilanus M.G.J., Chou F.C., Tsai M.F.;
RT   "Polymorphism of human HLA-DRB1 antigens generated by genetic exchange
RT   between DR2 (DRB1*15011) and DR6 (DRB1*1405) alleles: a novel DRB1
RT   allele (DRB1*1437) identified in a Paiwan tribe member of Taiwan.";
RL   Tissue Antigens 57:384-387(2001).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:41), AND
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 35-123 (ALLELE DRB1*14:42).
RX   PubMed=12144619; DOI=10.1034/j.1399-0039.2002.590502.x;
RA   Gans C.P., Tang T.F., Slack R., Ng J., Hartzman R.J., Hurley C.K.;
RT   "DRB1*14 diversity and DRB3 associations in four major population
RT   groups in the United States.";
RL   Tissue Antigens 59:364-369(2002).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:43).
RX   PubMed=15304015; DOI=10.1111/j.0001-2815.2004.00275.x;
RA   Chu C.C., Lee H.L., Hsieh N.K., Trejaut J., Lin M.;
RT   "Two novel HLA-DRB1 alleles identified using a sequence-based typing:
RT   HLA-DRB1*1443 and HLA-DRB1*1351*.";
RL   Tissue Antigens 64:308-310(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*14:47 AND
RP   DRB1*14:48).
RX   PubMed=16185331; DOI=10.1111/j.1399-0039.2005.00459.x;
RA   Lazaro A.M., Steiner N.K., Moraes M.E., Moraes J.R., Ng J.,
RA   Hartzman R.J., Hurley C.K.;
RT   "Ten novel HLA-DRB1 alleles and one novel DRB3 allele.";
RL   Tissue Antigens 66:327-329(2005).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:50).
RC   TISSUE=Peripheral blood;
RX   PubMed=16185333; DOI=10.1111/j.1399-0039.2005.00472a.x;
RA   Tijssen H.J., Zeeuw van der S.C., Joosten I.;
RT   "Exon 2 sequence analysis of a novel HLA-DRB1 allele, DRB1*1450.";
RL   Tissue Antigens 66:332-333(2005).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:49).
RX   PubMed=16426240; DOI=10.1111/j.1744-313X.2005.00557.x;
RA   Miao K.R., Xue M., Zhou X.Y., Xu R., Fei X.M., Pan Q.Q., Zhang J.W.,
RA   Zhao X., Fan S., Kukuruga D., Xu A.L., Wang C.Y.;
RT   "Characterization of a novel DRB1*14 allele (DRB1*1449) in the Han-
RT   Chinese population.";
RL   Int. J. Immunogenet. 33:33-35(2006).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:56).
RX   PubMed=16774552; DOI=10.1111/j.1399-0039.2006.00612.x;
RA   Baek J.Y., Yun H.S., Hur S.S., Kwon O.J., Kwack K.;
RT   "Identification of a novel HLA-DRB1*14 allele, DRB1*1456, in the cord
RT   blood of a Korean baby.";
RL   Tissue Antigens 68:97-98(2006).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:60).
RC   TISSUE=Peripheral blood;
RX   PubMed=17026474; DOI=10.1111/j.1399-0039.2006.00675.x;
RA   Tijssen H.J., van den Dungen-Toet J.H.G., van Houwelingen K.P.,
RA   Allebes W.A., Joosten I.;
RT   "Exon 2 sequence analysis of a novel HLA-DRB1 allele, DRB1*1460.";
RL   Tissue Antigens 68:346-347(2006).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:65).
RX   PubMed=17498272; DOI=10.1111/j.1399-0039.2007.00835.x;
RA   Abdeen H., McErlean C., Moraes M.E., Torres M., Campiotto S.,
RA   Galvao S., Gouvea C., Middleton D.;
RT   "Identification of three novel alleles of HLA-DRB1 and HLA-A in the
RT   Brazilian population.";
RL   Tissue Antigens 69:607-610(2007).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:74).
RX   PubMed=18179646; DOI=10.1111/j.1399-0039.2007.00993.x;
RA   Rahal M., Kervaire B., Villard J., Tiercy J.M.;
RT   "DNA typing by microbead arrays and PCR-SSP: apparent false-negative
RT   or -positive hybridization or amplification signals disclose new HLA-B
RT   and -DRB1 alleles.";
RL   Tissue Antigens 71:238-241(2008).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:67).
RC   TISSUE=Blood;
RX   PubMed=18643964; DOI=10.1111/j.1399-0039.2008.01089.x;
RA   Yan L.N., Li S.Y., Dong Z., Dong L., Xie J.H., An S.P., Yuan Y.H.;
RT   "Sequence-based typing reveals the novel HLA-DRB1*1467 allele in a
RT   Chinese individual.";
RL   Tissue Antigens 72:409-410(2008).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:75).
RX   PubMed=18937796; DOI=10.1111/j.1399-0039.2008.01116.x;
RA   Schuett S., Geflitter A., von Baehr V.;
RT   "Sequence-based typing of a novel HLA-DRB1*14 allele, DRB1*1475, in a
RT   Caucasian woman.";
RL   Tissue Antigens 72:501-502(2008).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:61).
RX   PubMed=19000132; DOI=10.1111/j.1399-0039.2008.01135.x;
RA   Wang Z., Shan X., Zhang Z.;
RT   "Identification of a novel HLA-DRB allele, HLA-DRB1*1461.";
RL   Tissue Antigens 72:603-604(2008).
RN   [26]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:78).
RX   PubMed=19140840; DOI=10.1111/j.1399-0039.2008.01175.x;
RA   Han S.H., Jung S.M., Park S.R., Chung S.Y., Han H.;
RT   "Identification of a new HLA-DRB1*14 variant, HLA-DRB1*1478, in a
RT   Korean individual.";
RL   Tissue Antigens 73:81-83(2009).
RN   [27]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*14:26;
RP   DRB1*14:27 AND DRB1*14:29).
RA   Kashiwase K., Tokunaga K., Akaza T., Tadokoro K., Juji T.;
RT   "Sequence of new allele.";
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [28]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:32).
RA   Blasczyk R.;
RT   "A new HLA-DRB1*14 variant.";
RL   Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases.
RN   [29]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:34).
RA   Whidborne R.S., Sayer D.C., Christiansen F.T.;
RT   "Novel DRB1*14 and 15 alleles in the Western Australian population.";
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [30]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:17).
RA   Gervais T.G., Latinne D.;
RT   "Confirmatory sequence for HLA-DRB1*1417 gene obtained by sequence
RT   based typing.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [31]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:18).
RA   Rizzo M., Steiner N.K., Nichol L., Hurley C.K.;
RT   "Complete exon 2 sequence for HLA-DRB1*1418.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [32]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:15).
RA   Kervaire B., Villard J., Tiercy J.M.;
RT   "An unusual HLA-DR/DQ haplotype carrying a new DR8 variant and the
RT   DRB3*0202 allele.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [33]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:23).
RC   TISSUE=Blood;
RA   Velickovic Z.M.;
RT   "Novel HLA-DRB1*11 allele.";
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [34]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:12).
RA   Oh H.B., Byun E.K., Hong S.A., Lee M.N., Kwon O.J.;
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [35]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:01).
RA   Lee T.D.;
RT   "Identification of a novel HLA-DRB1*14 allele.";
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [36]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:53).
RA   Dormoy A.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [37]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:55).
RC   TISSUE=Leukocyte;
RA   Hirv K., Krauss A., Mytilineos J.;
RT   "Characterization of a new HLA-DRB1*14 allele.";
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [38]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:58).
RA   Karvunidis T., Jindra P., Fischer G., Koza V.;
RT   "Identification of a new HLA-DRB1*14 allele by sequence-based
RT   typing.";
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [39]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:59).
RA   Dormoy A., Weschler B., Leinsenbach R.;
RT   "A new DRB1*14 allele close to the DRB1*1418 allele is different for 3
RT   substitutions at nucleotide positions 84, 152 and 174 leading to the
RT   change of 2 amino acids at positions 28 and 51.";
RL   Submitted (MAR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [40]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:63).
RA   Ye S., Liu M., Qi J.;
RT   "Identification a novel HLA-DRB1*14 new allele.";
RL   Submitted (JUN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [41]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:30).
RA   Greville W.D., Dunckley H.;
RL   Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
RN   [42]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:76).
RC   TISSUE=Blood;
RA   Tavoularis S., Rebeiro E., Sayer D.;
RT   "Identification of a novel DRB1 allele.";
RL   Submitted (JAN-2008) to the EMBL/GenBank/DDBJ databases.
RN   [43]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:77).
RC   TISSUE=Blood;
RA   Yan L.N., An S.P., Li S.Y., Xie J.H., Dong L., Dong Z., Yuan Y.H.;
RT   "A new allele of HLA-DRB1*14 detected with SBT.";
RL   Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases.
RN   [44]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*14:38;
RP   DRB1*14:39; DRB1*14:40; DRB1*14:44; DRB1*14:45 AND DRB1*14:80).
RA   Juji T., Shimizu M., Kashiwase K., Nakajima F., Tadokoro K.,
RA   Tanaka H.;
RT   "HLA-DRB1*1401V1M, HLA-DRB1*1401V2, HLA-DRB1*1403V2, HLA-DRB1*1405V1,
RT   HLA-DRB1*1405V2, HLA-DRB1*1406V1.";
RL   Submitted (MAY-2008) to the EMBL/GenBank/DDBJ databases.
RN   [45]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELES DRB1*14:51;
RP   DRB1*14:52; DRB1*14:62; DRB1*14:64; DRB1*14:68; DRB1*14:69;
RP   DRB1*14:70; DRB1*14:71; DRB1*14:72; DRB1*14:73; DRB1*14:79; DRB1*14:81
RP   AND DRB1*14:83).
RA   Lazaro A.M., Cao K., Xiao Y., Lebeck L., Hurley C.K.;
RT   "Novel class II allele.";
RL   Submitted (JUL-2008) to the EMBL/GenBank/DDBJ databases.
RN   [46]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:24).
RA   Dormoy A., Weschler B.;
RT   "The HLA-DRB1*14New allele has 3 nucleotide changes from the DRB1*1402
RT   allele at positions 286, 298 and 299 of exon 2 where: C286->A286
RT   (codon 72 (CTC->ATC)) resulting in a change of amino acid: Leu->Ile
RT   A298->G298 + G299->C299 (codon 76 (AGG->GCG)) resulting in a change of
RT   amino acid: Arg->Ala.";
RL   Submitted (JUL-2008) to the EMBL/GenBank/DDBJ databases.
RN   [47]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*14:84).
RC   TISSUE=Peripheral blood;
RA   Lee T.-D., Chien W.-C.;
RT   "A new DR14-related DRB1 allele, identified by sequence-based
RT   typing.";
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [48]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-122 (ALLELE DRB1*14:35).
RX   PubMed=11532019; DOI=10.1046/j.1365-2370.2001.00243.x;
RA   Trejaut J., Kennedy A., Hobart D., Le T., Greville W.D., Ng G.,
RA   Taverniti A., Dunckley H.;
RT   "PCR-RFLP typing detects new HLA-DRB1 alleles: DRB1*13022, DRB1*1336
RT   and DRB1*1435.";
RL   Eur. J. Immunogenet. 28:441-447(2001).
RN   [49]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-115 (ALLELE DRB1*14:28).
RC   TISSUE=Blood;
RX   PubMed=9243765; DOI=10.1111/j.1399-0039.1997.tb02843.x;
RA   Hashemi-Tavoularis S., Couture C., Buyse I.M.;
RT   "Identification of new DRB1*01 (DRB1*01022), DRB1*14 (DRB1*1428) and
RT   DRB3* (DRB3*0206) alleles.";
RL   Tissue Antigens 50:89-93(1997).
RN   [50]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-115 (ALLELE DRB1*14:01).
RC   TISSUE=Peripheral blood;
RX   PubMed=15104685; DOI=10.1111/j.0001-2815.2004.00186.x;
RA   Tavoularis S., Couture C., Ribeiro-Barros E.;
RT   "Identification of three novel alleles: DRB3*0110, DRB1*1140, and
RT   DRB1*140102.";
RL   Tissue Antigens 63:496-500(2004).
RN   [51]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-123 (ALLELES DRB1*14:09 AND
RP   DRB1*14:25).
RA   Vayntrub T., Lo B.;
RT   "Confirmatory sequence of HLA class II DRB1*1409 and DRB1*1425.";
RL   Submitted (NOV-2002) to the EMBL/GenBank/DDBJ databases.
RN   [52]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-122 (ALLELE DRB1*14:08).
RC   TISSUE=Blood;
RX   PubMed=1644450; DOI=10.1007/BF00215663;
RA   Gao X., Veale A., Serjeantson S.W.;
RT   "HLA class II diversity in Australian aborigines: unusual HLA-DRB1
RT   alleles.";
RL   Immunogenetics 36:333-337(1992).
RN   [53]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-119 (ALLELE DRB1*14:31).
RX   PubMed=10599892; DOI=10.1034/j.1399-0039.1999.540510.x;
RA   Panigoro R., Greville W.D., Kennedy A., Trejaut J., Dunckley H.;
RT   "New HLA class II alleles in the Indonesian population.";
RL   Tissue Antigens 54:521-523(1999).
RN   [54]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-122 (ALLELE DRB1*14:33).
RA   Greville W.D., van Eijck A., Dunckley H.;
RT   "New HLA class II (DRB1) alleles detected by sequencing-based
RT   typing.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [55]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-116 (ALLELE DRB1*14:20).
RX   PubMed=8883296; DOI=10.1111/j.1399-0039.1996.tb02611.x;
RA   Verduyn W., Anholts J.D., Versluis L.F., Parlevliet J., Drabbels J.,
RA   De Meester J., Tilanus M.G., Doxiadis I.I., Giphart M.J.,
RA   Schreuder G.M.;
RT   "Six newly identified HLA-DRB alleles: DRB1*1121, *1419, *1420, *1421,
RT   DRB3*0203 and DRB5*0103.";
RL   Tissue Antigens 48:80-86(1996).
RN   [56]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 42-131 (ALLELE DRB1*14:24).
RC   TISSUE=B-cell;
RA   Hurley C.K.;
RL   Submitted (NOV-1995) to the EMBL/GenBank/DDBJ databases.
RN   [57]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 43-120 (ALLELE DRB1*14:16).
RA   Gervais T.G., Latinne D.;
RT   "Confirmatory typing for exon 2 of HLA-DRB1*1416 gene, obtained by
RT   sequence-based typing.";
RL   Submitted (SEP-2002) to the EMBL/GenBank/DDBJ databases.
RN   [58]
RP   REVIEW.
RX   PubMed=8598037; DOI=10.1016/S0092-8674(00)81025-9;
RA   Cresswell P.;
RT   "Invariant chain structure and MHC class II function.";
RL   Cell 84:505-507(1996).
RN   [59]
RP   REVIEW.
RX   PubMed=11684289; DOI=10.1016/S0161-5890(01)00069-4;
RA   Villadangos J.A.;
RT   "Presentation of antigens by MHC class II molecules: getting the most
RT   out of them.";
RL   Mol. Immunol. 38:329-346(2001).
RN   [60]
RP   REVIEW.
RX   PubMed=17241953; DOI=10.1016/j.immuni.2007.01.005;
RA   Menendez-Benito V., Neefjes J.;
RT   "Autophagy in MHC class II presentation: sampling from within.";
RL   Immunity 26:1-3(2007).
RN   [61]
RP   REVIEW.
RX   PubMed=18046453; DOI=10.1038/sj.emboj.7601945;
RA   Rocha N., Neefjes J.;
RT   "MHC class II molecules on the move for successful antigen
RT   presentation.";
RL   EMBO J. 27:1-5(2008).
RN   [62]
RP   UBIQUITINATION BY MARCH1, AND SUBCELLULAR LOCATION.
RX   PubMed=18305173; DOI=10.1073/pnas.0708874105;
RA   De Gassart A., Camosseto V., Thibodeau J., Ceppi M., Catalan N.,
RA   Pierre P., Gatti E.;
RT   "MHC class II stabilization at the surface of human dendritic cells is
RT   the result of maturation-dependent MARCH I down-regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3491-3496(2008).
RN   [63]
RP   REVIEW.
RX   PubMed=19092054; DOI=10.1242/jcs.035089;
RA   Berger A.C., Roche P.A.;
RT   "MHC class II transport at a glance.";
RL   J. Cell Sci. 122:1-4(2009).
RN   [64]
RP   REVIEW.
RX   PubMed=19533806; DOI=10.3748/wjg.15.2855;
RA   Beswick E.J., Reyes V.E.;
RT   "CD74 in antigen presentation, inflammation, and cancers of the
RT   gastrointestinal tract.";
RL   World J. Gastroenterol. 15:2855-2861(2009).
CC   -!- FUNCTION: Binds peptides derived from antigens that access the
CC       endocytic route of antigen presenting cells (APC) and presents
CC       them on the cell surface for recognition by the CD4 T-cells. The
CC       peptide binding cleft accommodates peptides of 10-30 residues. The
CC       peptides presented by MHC class II molecules are generated mostly
CC       by degradation of proteins that access the endocytic route, where
CC       they are processed by lysosomal proteases and other hydrolases.
CC       Exogenous antigens that have been endocytosed by the APC are thus
CC       readily available for presentation via MHC II molecules, and for
CC       this reason this antigen presentation pathway is usually referred
CC       to as exogenous. As membrane proteins on their way to degradation
CC       in lysosomes as part of their normal turn-over are also contained
CC       in the endosomal/lysosomal compartments, exogenous antigens must
CC       compete with those derived from endogenous components. Autophagy
CC       is also a source of endogenous peptides, autophagosomes
CC       constitutively fuse with MHC class II loading compartments. In
CC       addition to APCs, other cells of the gastrointestinal tract, such
CC       as epithelial cells, express MHC class II molecules and CD74 and
CC       act as APCs, which is an unusual trait of the GI tract. To produce
CC       a MHC class II molecule that presents an antigen, three MHC class
CC       II molecules (heterodimers of an alpha and a beta chain) associate
CC       with a CD74 trimer in the ER to form a heterononamer. Soon after
CC       the entry of this complex into the endosomal/lysosomal system
CC       where antigen processing occurs, CD74 undergoes a sequential
CC       degradation by various proteases, including CTSS and CTSL, leaving
CC       a small fragment termed CLIP (class-II-associated invariant chain
CC       peptide). The removal of CLIP is facilitated by HLA-DM via direct
CC       binding to the alpha-beta-CLIP complex so that CLIP is released.
CC       HLA-DM stabilizes MHC class II molecules until primary high
CC       affinity antigenic peptides are bound. The MHC II molecule bound
CC       to a peptide is then transported to the cell membrane surface. In
CC       B-cells, the interaction between HLA-DM and MHC class II molecules
CC       is regulated by HLA-DO. Primary dendritic cells (DCs) also to
CC       express HLA-DO. Lysosomal microenvironment has been implicated in
CC       the regulation of antigen loading into MHC II molecules, increased
CC       acidification produces increased proteolysis and efficient peptide
CC       loading.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit; also referred
CC       as MHC class II molecule. In the endoplasmic reticulum (ER) it
CC       forms a heterononamer; 3 MHC class II molecules bind to a CD74
CC       homotrimer (also known as invariant chain or HLA class II
CC       histocompatibility antigen gamma chain). In the
CC       endosomal/lysosomal system; CD74 undergoes sequential degradation
CC       by various proteases; leaving a small fragment termed CLIP on each
CC       MHC class II molecule. MHC class II molecule interacts with
CC       HLA_DM, and HLA_DO in B-cells, in order to release CLIP and
CC       facilitate the binding of antigenic peptides.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane; Single-pass type I
CC       membrane protein. Golgi apparatus, trans-Golgi network membrane;
CC       Single-pass type I membrane protein. Endosome membrane; Single-
CC       pass type I membrane protein. Lysosome membrane; Single-pass type
CC       I membrane protein. Late endosome membrane; Single-pass type I
CC       membrane protein. Note=The MHC class II complex transits through a
CC       number of intracellular compartments in the endocytic pathway
CC       until it reaches the cell membrane for antigen presentation.
CC   -!- PTM: Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to
CC       sorting into the endosome system and down-regulation of MHC class
CC       II (Probable).
CC   -!- POLYMORPHISM: The following alleles of DRB1-14 are known:
CC       DRB1*14:01, DRB1*14:02, DRB1*14:03, DRB1*14:04, DRB1*14:05,
CC       DRB1*14:06, DRB1*14:07, DRB1*14:08, DRB1*14:09, DRB1*14:10,
CC       DRB1*14:11, DRB1*14:12, DRB1*14:13, DRB1*14:14, DRB1*14:15,
CC       DRB1*14:16, DRB1*14:17, DRB1*14:18, DRB1*14:19, DRB1*14:20,
CC       DRB1*14:21, DRB1*14:22, DRB1*14:23, DRB1*14:24, DRB1*14:25,
CC       DRB1*14:26, DRB1*14:27, DRB1*14:28, DRB1*14:29, DRB1*14:30,
CC       DRB1*14:31, DRB1*14:32, DRB1*14:33, DRB1*14:34, DRB1*14:35,
CC       DRB1*14:36, DRB1*14:37, DRB1*14:38, DRB1*14:39, DRB1*14:40,
CC       DRB1*14:41, DRB1*14:42, DRB1*14:43, DRB1*14:44, DRB1*14:45,
CC       DRB1*14:46, DRB1*14:47, DRB1*14:48, DRB1*14:49, DRB1*14:50,
CC       DRB1*14:51, DRB1*14:52, DRB1*14:53, DRB1*14:54, DRB1*14:55,
CC       DRB1*14:56, DRB1*14:57, DRB1*14:58, DRB1*14:59, DRB1*14:60,
CC       DRB1*14:61, DRB1*14:62, DRB1*14:63, DRB1*14:64, DRB1*14:65,
CC       DRB1*14:67, DRB1*14:68, DRB1*14:69, DRB1*14:70, DRB1*14:71,
CC       DRB1*14:72, DRB1*14:73, DRB1*14:74, DRB1*14:75, DRB1*14:76,
CC       DRB1*14:77, DRB1*14:78, DRB1*14:79, DRB1*14:80, DRB1*14:81,
CC       DRB1*14:82, DRB1*14:83, DRB1*14:84 and DRB1*14:85. The sequence
CC       shown is that of DRB1*14:01.
CC   -!- SIMILARITY: Belongs to the MHC class II family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAB45249.1; Type=Erroneous gene model prediction;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB062112; BAB84521.2; -; mRNA.
DR   EMBL; AJ297582; CAC08822.1; -; mRNA.
DR   EMBL; AJ297583; CAC08823.1; -; mRNA.
DR   EMBL; AJ297584; CAC08824.1; -; mRNA.
DR   EMBL; AJ297585; CAC08825.1; -; mRNA.
DR   EMBL; AY663408; AAU88014.1; -; Genomic_DNA.
DR   EMBL; AY935719; AAX33315.1; -; mRNA.
DR   EMBL; AY961071; AAX63459.2; -; mRNA.
DR   EMBL; DQ235685; ABB52004.1; -; Genomic_DNA.
DR   EMBL; DQ390459; ABD60300.1; -; Genomic_DNA.
DR   EMBL; DQ390460; ABD60301.1; -; Genomic_DNA.
DR   EMBL; FJ379259; ACJ06537.1; -; Genomic_DNA.
DR   EMBL; Z38072; CAA86217.1; -; Genomic_DNA.
DR   EMBL; FM196525; CAQ86516.1; -; Genomic_DNA.
DR   EMBL; AM109998; CAJ33605.1; -; Genomic_DNA.
DR   EMBL; AM109999; CAJ33606.1; -; Genomic_DNA.
DR   EMBL; AM110000; CAJ33607.1; -; Genomic_DNA.
DR   EMBL; AM110001; CAJ33608.1; -; Genomic_DNA.
DR   EMBL; AM110002; CAJ33609.1; -; Genomic_DNA.
DR   EMBL; AM110003; CAJ33610.1; -; Genomic_DNA.
DR   EMBL; AB485773; BAH23562.1; -; Genomic_DNA.
DR   EMBL; Z50730; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AJ242985; CAB45249.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AJ251985; CAC19086.1; -; Genomic_DNA.
DR   EMBL; AY050186; AAL23547.1; -; Genomic_DNA.
DR   EMBL; AY054375; AAL15169.1; -; mRNA.
DR   EMBL; AF400066; AAK85431.1; -; Genomic_DNA.
DR   EMBL; AY267905; AAP32696.1; -; Genomic_DNA.
DR   EMBL; AY267906; AAP32697.1; -; Genomic_DNA.
DR   EMBL; AJ969417; CAI94542.1; -; Genomic_DNA.
DR   EMBL; AY912075; AAY17288.1; -; Genomic_DNA.
DR   EMBL; DQ333353; ABC59115.1; -; Genomic_DNA.
DR   EMBL; AM259285; CAJ90660.1; -; Genomic_DNA.
DR   EMBL; EF199810; ABM90423.1; -; Genomic_DNA.
DR   EMBL; AM774161; CAO81738.1; -; Genomic_DNA.
DR   EMBL; EF495154; ABP38039.1; -; Genomic_DNA.
DR   EMBL; AM922324; CAP58300.1; -; Genomic_DNA.
DR   EMBL; DQ494324; ABF50050.1; -; Genomic_DNA.
DR   EMBL; EU588391; ACB97664.1; -; Genomic_DNA.
DR   EMBL; D86502; BAA13097.1; -; Genomic_DNA.
DR   EMBL; D86504; BAA13099.1; -; Genomic_DNA.
DR   EMBL; D88310; BAA13587.1; -; Genomic_DNA.
DR   EMBL; AJ010982; CAA09450.1; -; Genomic_DNA.
DR   EMBL; AF172071; AAD51970.1; -; Genomic_DNA.
DR   EMBL; AJ543433; CAD65908.1; -; Genomic_DNA.
DR   EMBL; AY277390; AAP34694.1; -; Genomic_DNA.
DR   EMBL; AJ581744; CAE46451.1; -; Genomic_DNA.
DR   EMBL; AJ812566; CAH23708.1; -; Genomic_DNA.
DR   EMBL; AY770520; AAV37191.1; -; Genomic_DNA.
DR   EMBL; DQ021915; AAY85747.1; -; Genomic_DNA.
DR   EMBL; AM084908; CAJ29895.1; -; Genomic_DNA.
DR   EMBL; DQ327711; ABC59293.1; -; Genomic_DNA.
DR   EMBL; DQ358688; ABC84557.1; -; Genomic_DNA.
DR   EMBL; AM233907; CAJ80873.1; -; Genomic_DNA.
DR   EMBL; DQ643390; ABG25965.1; -; Genomic_DNA.
DR   EMBL; U95115; AAB58397.2; -; Genomic_DNA.
DR   EMBL; AM933133; CAP69806.1; -; Genomic_DNA.
DR   EMBL; EU545181; ACB30275.1; -; Genomic_DNA.
DR   EMBL; AB049830; BAB16682.1; -; Genomic_DNA.
DR   EMBL; AB049831; BAB16683.1; -; Genomic_DNA.
DR   EMBL; AB049832; BAB16684.1; -; Genomic_DNA.
DR   EMBL; AB087875; BAC02938.1; -; Genomic_DNA.
DR   EMBL; AB087876; BAC02939.1; -; Genomic_DNA.
DR   EMBL; AB436778; BAG32234.1; -; Genomic_DNA.
DR   EMBL; EF078986; ABK56696.1; -; Genomic_DNA.
DR   EMBL; EF536016; ABQ08747.1; -; Genomic_DNA.
DR   EMBL; EU029787; ABU86846.1; -; Genomic_DNA.
DR   EMBL; EU029788; ABU86847.1; -; Genomic_DNA.
DR   EMBL; EU029792; ABU86851.1; -; Genomic_DNA.
DR   EMBL; EU029793; ABU86852.1; -; Genomic_DNA.
DR   EMBL; EU029798; ABU86857.1; -; Genomic_DNA.
DR   EMBL; EU643616; ACD01094.1; -; Genomic_DNA.
DR   EMBL; EU812536; ACE88696.1; -; Genomic_DNA.
DR   EMBL; EU924810; ACH57405.1; -; Genomic_DNA.
DR   EMBL; DQ060439; AAY59541.1; -; Genomic_DNA.
DR   EMBL; DQ060441; AAY59543.1; -; Genomic_DNA.
DR   EMBL; DQ782331; ABG91054.1; -; Genomic_DNA.
DR   EMBL; FM179681; CAQ77159.1; -; Genomic_DNA.
DR   EMBL; FJ594768; ACM47962.1; -; Genomic_DNA.
DR   EMBL; AF177215; AAD53910.1; -; Genomic_DNA.
DR   EMBL; X99839; CAA68150.1; -; Genomic_DNA.
DR   EMBL; AJ289123; CAC19015.1; -; Genomic_DNA.
DR   EMBL; AY174092; AAO20089.1; -; Genomic_DNA.
DR   EMBL; AY174181; AAO17053.1; -; Genomic_DNA.
DR   EMBL; M77673; AAA73131.1; -; Genomic_DNA.
DR   EMBL; AF028010; AAB94612.1; -; Genomic_DNA.
DR   EMBL; AF112879; AAD29584.1; -; Genomic_DNA.
DR   EMBL; X86974; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U41489; AAA86242.1; -; Genomic_DNA.
DR   EMBL; AJ508388; CAD48196.1; -; Genomic_DNA.
DR   PIR; B33287; B33287.
DR   PIR; C33287; C33287.
DR   PIR; C60748; C60748.
DR   PIR; F60748; F60748.
DR   PIR; PH0157; PH0157.
DR   PIR; PH0158; PH0158.
DR   PIR; S03440; S03440.
DR   UniGene; Hs.485130; -.
DR   UniGene; Hs.534322; -.
DR   UniGene; Hs.696211; -.
DR   UniGene; Hs.716081; -.
DR   UniGene; Hs.723344; -.
DR   UniGene; Hs.736560; -.
DR   ProteinModelPortal; Q9GIY3; -.
DR   SMR; Q9GIY3; 34-220.
DR   IntAct; Q9GIY3; 1.
DR   DMDM; 74761361; -.
DR   PRIDE; Q9GIY3; -.
DR   Ensembl; ENST00000328980; ENSP00000331343; ENSG00000206306.
DR   Ensembl; ENST00000360004; ENSP00000353099; ENSG00000196126.
DR   Ensembl; ENST00000399450; ENSP00000382378; ENSG00000206240.
DR   Ensembl; ENST00000412634; ENSP00000408795; ENSG00000228080.
DR   Ensembl; ENST00000415796; ENSP00000412168; ENSG00000206306.
DR   Ensembl; ENST00000419393; ENSP00000403458; ENSG00000228080.
DR   Ensembl; ENST00000428566; ENSP00000392280; ENSG00000206240.
DR   GeneCards; GC06M032546; -.
DR   GeneCards; GC06Mj32477; -.
DR   GeneCards; GC06Mn32480; -.
DR   GeneCards; GC06Mo32593; -.
DR   HGNC; HGNC:4948; HLA-DRB1.
DR   HPA; CAB015400; -.
DR   HPA; CAB034021; -.
DR   MIM; 142857; gene.
DR   neXtProt; NX_Q9GIY3; -.
DR   HOVERGEN; HBG012730; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-DRB1; human.
DR   ArrayExpress; Q9GIY3; -.
DR   Bgee; Q9GIY3; -.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031902; C:late endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0042613; C:MHC class II protein complex; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0030658; C:transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.320.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR014745; MHC_II_a/b_N.
DR   InterPro; IPR000353; MHC_II_b_N.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00969; MHC_II_beta; 1.
DR   ProDom; PD000328; MHC_II_b_N; 1.
DR   SMART; SM00407; IGc1; 1.
DR   SMART; SM00921; MHC_II_beta; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Golgi apparatus;
KW   Immunity; Isopeptide bond; Lysosome; Membrane; MHC II; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     29       Potential.
FT   CHAIN        30    266       HLA class II histocompatibility antigen,
FT                                DRB1-14 beta chain.
FT                                /FTId=PRO_5000066676.
FT   TRANSMEM    228    248       Helical; (Potential).
FT   DOMAIN      126    214       Ig-like C1-type.
FT   CARBOHYD     48     48       N-linked (GlcNAc...) (Potential).
FT   DISULFID    146    202       By similarity.
FT   CROSSLNK    254    254       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VARIANT      39     39       Y -> L (in allele DRB1*14:46; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_062907.
FT   VARIANT      39     39       Y -> Q (in allele DRB1*14:10 and allele
FT                                DRB1*14:57; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062906.
FT   VARIANT      40     40       S -> P (in allele DRB1*14:39).
FT                                /FTId=VAR_062910.
FT   VARIANT      40     40       S -> R (in allele DRB1*14:46).
FT                                /FTId=VAR_062908.
FT   VARIANT      40     40       S -> V (in allele DRB1*14:10 and allele
FT                                DRB1*14:57; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062909.
FT   VARIANT      41     41       T -> K (in allele DRB1*14:10, allele
FT                                DRB1*14:46 and allele DRB1*14:57).
FT                                /FTId=VAR_062911.
FT   VARIANT      42     42       S -> G (in allele DRB1*14:04, allele
FT                                DRB1*14:11, allele DRB1*14:15, allele
FT                                DRB1*14:28, allele DRB1*14:31, allele
FT                                DRB1*14:50, allele DRB1*14:52, allele
FT                                DRB1*14:61, allele DRB1*14:68, allele
FT                                DRB1*14:71, allele DRB1*14:73, allele
FT                                DRB1*14:76 and allele DRB1*14:79).
FT                                /FTId=VAR_062913.
FT   VARIANT      42     42       S -> H (in allele DRB1*14:10 and allele
FT                                DRB1*14:57; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062912.
FT   VARIANT      45     45       H -> Q (in allele DRB1*14:05, allele
FT                                DRB1*14:37, allele DRB1*14:43, allele
FT                                DRB1*14:44, allele DRB1*14:45, allele
FT                                DRB1*14:56 and allele DRB1*14:84).
FT                                /FTId=VAR_062915.
FT   VARIANT      45     45       H -> Y (in allele DRB1*14:04, allele
FT                                DRB1*14:11, allele DRB1*14:15, allele
FT                                DRB1*14:28, allele DRB1*14:31, allele
FT                                DRB1*14:50, allele DRB1*14:52, allele
FT                                DRB1*14:68, allele DRB1*14:71, allele
FT                                DRB1*14:73, allele DRB1*14:76 and allele
FT                                DRB1*14:79).
FT                                /FTId=VAR_062914.
FT   VARIANT      54     54       R -> Q (in allele DRB1*14:26).
FT                                /FTId=VAR_062916.
FT   VARIANT      55     55       F -> Y (in allele DRB1*14:82).
FT                                /FTId=VAR_062917.
FT   VARIANT      56     56       L -> M (in allele DRB1*14:83).
FT                                /FTId=VAR_062918.
FT   VARIANT      57     57       D -> E (in allele DRB1*14:02, allele
FT                                DRB1*14:03, allele DRB1*14:06, allele
FT                                DRB1*14:12, allele DRB1*14:13, allele
FT                                DRB1*14:18, allele DRB1*14:19, allele
FT                                DRB1*14:20, allele DRB1*14:24, allele
FT                                DRB1*14:27, allele DRB1*14:29, allele
FT                                DRB1*14:40, allele DRB1*14:41, allele
FT                                DRB1*14:46, allele DRB1*14:47, allele
FT                                DRB1*14:48, allele DRB1*14:49, allele
FT                                DRB1*14:51, allele DRB1*14:52, allele
FT                                DRB1*14:63, allele DRB1*14:67, allele
FT                                DRB1*14:77, allele DRB1*14:78, allele
FT                                DRB1*14:81, allele DRB1*14:83 and allele
FT                                DRB1*14:85).
FT                                /FTId=VAR_062919.
FT   VARIANT      59     59       Y -> H (in allele DRB1*14:70).
FT                                /FTId=VAR_062920.
FT   VARIANT      61     61       H -> Y (in allele DRB1*14:25, allele
FT                                DRB1*14:42, allele DRB1*14:53, allele
FT                                DRB1*14:58 and allele DRB1*14:69).
FT                                /FTId=VAR_062921.
FT   VARIANT      66     66       F -> N (in allele DRB1*14:02, allele
FT                                DRB1*14:03, allele DRB1*14:06, allele
FT                                DRB1*14:09, allele DRB1*14:12, allele
FT                                DRB1*14:13, allele DRB1*14:17, allele
FT                                DRB1*14:18, allele DRB1*14:19, allele
FT                                DRB1*14:21, allele DRB1*14:24, allele
FT                                DRB1*14:27, allele DRB1*14:29, allele
FT                                DRB1*14:30, allele DRB1*14:33, allele
FT                                DRB1*14:46, allele DRB1*14:47, allele
FT                                DRB1*14:48, allele DRB1*14:51, allele
FT                                DRB1*14:52, allele DRB1*14:59, allele
FT                                DRB1*14:63, allele DRB1*14:64, allele
FT                                DRB1*14:67, allele DRB1*14:78, allele
FT                                DRB1*14:80, allele DRB1*14:81, allele
FT                                DRB1*14:83 and allele DRB1*14:85;
FT                                requires 2 nucleotide substitutions).
FT                                /FTId=VAR_062923.
FT   VARIANT      66     66       F -> Y (in allele DRB1*14:25, allele
FT                                DRB1*14:42, allele DRB1*14:53, allele
FT                                DRB1*14:58 and allele DRB1*14:69).
FT                                /FTId=VAR_062922.
FT   VARIANT      67     67       V -> L (in allele DRB1*14:41 and allele
FT                                DRB1*14:77).
FT                                /FTId=VAR_062924.
FT   VARIANT      74     74       G -> R (in allele DRB1*14:36 and allele
FT                                DRB1*14:60).
FT                                /FTId=VAR_062925.
FT   VARIANT      76     76       Y -> F (in allele DRB1*14:17, allele
FT                                DRB1*14:21, allele DRB1*14:30, allele
FT                                DRB1*14:33, allele DRB1*14:35, allele
FT                                DRB1*14:42, allele DRB1*14:53, allele
FT                                DRB1*14:64, allele DRB1*14:65 and allele
FT                                DRB1*14:72).
FT                                /FTId=VAR_062926.
FT   VARIANT      80     80       T -> R (in allele DRB1*14:59).
FT                                /FTId=VAR_062927.
FT   VARIANT      86     86       A -> D (in allele DRB1*14:02, allele
FT                                DRB1*14:03, allele DRB1*14:05, allele
FT                                DRB1*14:06, allele DRB1*14:08, allele
FT                                DRB1*14:09, allele DRB1*14:11, allele
FT                                DRB1*14:12, allele DRB1*14:14, allele
FT                                DRB1*14:15, allele DRB1*14:17, allele
FT                                DRB1*14:18, allele DRB1*14:19, allele
FT                                DRB1*14:20, allele DRB1*14:21, allele
FT                                DRB1*14:23, allele DRB1*14:24, allele
FT                                DRB1*14:27, allele DRB1*14:29, allele
FT                                DRB1*14:30, allele DRB1*14:33, allele
FT                                DRB1*14:34, allele DRB1*14:36, allele
FT                                DRB1*14:37, allele DRB1*14:40, allele
FT                                DRB1*14:41, allele DRB1*14:42, allele
FT                                DRB1*14:43, allele DRB1*14:44, allele
FT                                DRB1*14:45, allele DRB1*14:46, allele
FT                                DRB1*14:47, allele DRB1*14:51, allele
FT                                DRB1*14:52, allele DRB1*14:56, allele
FT                                DRB1*14:59, allele DRB1*14:64, allele
FT                                DRB1*14:67, allele DRB1*14:72, allele
FT                                DRB1*14:77, allele DRB1*14:80, allele
FT                                DRB1*14:81, allele DRB1*14:83 and allele
FT                                DRB1*14:84).
FT                                /FTId=VAR_062928.
FT   VARIANT      86     86       A -> S (in allele DRB1*14:13, allele
FT                                DRB1*14:63, allele DRB1*14:65, allele
FT                                DRB1*14:78 and allele DRB1*14:85).
FT                                /FTId=VAR_062929.
FT   VARIANT      86     86       A -> T (in allele DRB1*14:62).
FT                                /FTId=VAR_062930.
FT   VARIANT      86     86       A -> V (in allele DRB1*14:48).
FT                                /FTId=VAR_062931.
FT   VARIANT      87     87       A -> E (in allele DRB1*14:11).
FT                                /FTId=VAR_062932.
FT   VARIANT      89     89       H -> S (in allele DRB1*14:48 and allele
FT                                DRB1*14:64; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062934.
FT   VARIANT      89     89       H -> Y (in allele DRB1*14:02, allele
FT                                DRB1*14:03, allele DRB1*14:05, allele
FT                                DRB1*14:06, allele DRB1*14:09, allele
FT                                DRB1*14:11, allele DRB1*14:12, allele
FT                                DRB1*14:13, allele DRB1*14:14, allele
FT                                DRB1*14:15, allele DRB1*14:17, allele
FT                                DRB1*14:18, allele DRB1*14:19, allele
FT                                DRB1*14:20, allele DRB1*14:21, allele
FT                                DRB1*14:23, allele DRB1*14:24, allele
FT                                DRB1*14:27, allele DRB1*14:29, allele
FT                                DRB1*14:30, allele DRB1*14:33, allele
FT                                DRB1*14:36, allele DRB1*14:37, allele
FT                                DRB1*14:40, allele DRB1*14:41, allele
FT                                DRB1*14:42, allele DRB1*14:43, allele
FT                                DRB1*14:44, allele DRB1*14:45, allele
FT                                DRB1*14:46, allele DRB1*14:47, allele
FT                                DRB1*14:51, allele DRB1*14:52, allele
FT                                DRB1*14:56, allele DRB1*14:57, allele
FT                                DRB1*14:59, allele DRB1*14:63, allele
FT                                DRB1*14:65, allele DRB1*14:67, allele
FT                                DRB1*14:76, allele DRB1*14:77, allele
FT                                DRB1*14:78, allele DRB1*14:80, allele
FT                                DRB1*14:81, allele DRB1*14:83, allele
FT                                DRB1*14:84 and allele DRB1*14:85).
FT                                /FTId=VAR_062933.
FT   VARIANT      96     96       L -> F (in allele DRB1*14:15, allele
FT                                DRB1*14:22, allele DRB1*14:25, allele
FT                                DRB1*14:27, allele DRB1*14:53 and allele
FT                                DRB1*14:73).
FT                                /FTId=VAR_062935.
FT   VARIANT      96     96       L -> I (in allele DRB1*14:16, allele
FT                                DRB1*14:24, allele DRB1*14:37, allele
FT                                DRB1*14:45, allele DRB1*14:57, allele
FT                                DRB1*14:63, allele DRB1*14:67 and allele
FT                                DRB1*14:78).
FT                                /FTId=VAR_062936.
FT   VARIANT      99     99       R -> D (in allele DRB1*14:03, allele
FT                                DRB1*14:12, allele DRB1*14:15, allele
FT                                DRB1*14:16, allele DRB1*14:22, allele
FT                                DRB1*14:25, allele DRB1*14:27, allele
FT                                DRB1*14:40, allele DRB1*14:53, allele
FT                                DRB1*14:57, allele DRB1*14:63, allele
FT                                DRB1*14:67, allele DRB1*14:69, allele
FT                                DRB1*14:73, allele DRB1*14:74, allele
FT                                DRB1*14:77, allele DRB1*14:78, allele
FT                                DRB1*14:84 and allele DRB1*14:85;
FT                                requires 2 nucleotide substitutions).
FT                                /FTId=VAR_062938.
FT   VARIANT      99     99       R -> Q (in allele DRB1*14:02, allele
FT                                DRB1*14:06, allele DRB1*14:09, allele
FT                                DRB1*14:13, allele DRB1*14:17, allele
FT                                DRB1*14:19, allele DRB1*14:20, allele
FT                                DRB1*14:21, allele DRB1*14:24, allele
FT                                DRB1*14:29, allele DRB1*14:30, allele
FT                                DRB1*14:33, allele DRB1*14:37, allele
FT                                DRB1*14:41, allele DRB1*14:46, allele
FT                                DRB1*14:47, allele DRB1*14:48, allele
FT                                DRB1*14:49, allele DRB1*14:51, allele
FT                                DRB1*14:52, allele DRB1*14:76, allele
FT                                DRB1*14:79, allele DRB1*14:80 and allele
FT                                DRB1*14:83).
FT                                /FTId=VAR_062937.
FT   VARIANT     100    100       R -> A (in allele DRB1*14:24 and allele
FT                                DRB1*14:37; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062941.
FT   VARIANT     100    100       R -> E (in allele DRB1*14:16 and allele
FT                                DRB1*14:57; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062940.
FT   VARIANT     100    100       R -> K (in allele DRB1*14:19, allele
FT                                DRB1*14:21, allele DRB1*14:76 and allele
FT                                DRB1*14:79).
FT                                /FTId=VAR_062939.
FT   VARIANT     102    102       A -> G (in allele DRB1*14:76 and allele
FT                                DRB1*14:79).
FT                                /FTId=VAR_062943.
FT   VARIANT     102    102       A -> S (in allele DRB1*14:56).
FT                                /FTId=VAR_062942.
FT   VARIANT     103    103       E -> A (in allele DRB1*14:02, allele
FT                                DRB1*14:06, allele DRB1*14:09, allele
FT                                DRB1*14:13, allele DRB1*14:16, allele
FT                                DRB1*14:17, allele DRB1*14:19, allele
FT                                DRB1*14:20, allele DRB1*14:21, allele
FT                                DRB1*14:22, allele DRB1*14:24, allele
FT                                DRB1*14:25, allele DRB1*14:29, allele
FT                                DRB1*14:30, allele DRB1*14:31, allele
FT                                DRB1*14:32, allele DRB1*14:34, allele
FT                                DRB1*14:37, allele DRB1*14:41, allele
FT                                DRB1*14:46, allele DRB1*14:47, allele
FT                                DRB1*14:48, allele DRB1*14:49, allele
FT                                DRB1*14:52, allele DRB1*14:53, allele
FT                                DRB1*14:57, allele DRB1*14:65, allele
FT                                DRB1*14:69, allele DRB1*14:74, allele
FT                                DRB1*14:80, allele DRB1*14:81 and allele
FT                                DRB1*14:83).
FT                                /FTId=VAR_062944.
FT   VARIANT     103    103       E -> L (in allele DRB1*14:03, allele
FT                                DRB1*14:12, allele DRB1*14:15, allele
FT                                DRB1*14:27, allele DRB1*14:40, allele
FT                                DRB1*14:55, allele DRB1*14:63, allele
FT                                DRB1*14:67, allele DRB1*14:77, allele
FT                                DRB1*14:78, allele DRB1*14:84 and allele
FT                                DRB1*14:85; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062945.
FT   VARIANT     103    103       E -> R (in allele DRB1*14:76 and allele
FT                                DRB1*14:79; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062946.
FT   VARIANT     106    106       T -> A (in allele DRB1*14:43).
FT                                /FTId=VAR_062948.
FT   VARIANT     106    106       T -> N (in allele DRB1*14:38, allele
FT                                DRB1*14:47, allele DRB1*14:50, allele
FT                                DRB1*14:76 and allele DRB1*14:79).
FT                                /FTId=VAR_062947.
FT   VARIANT     110    110       H -> Y (in allele DRB1*14:75).
FT                                /FTId=VAR_062949.
FT   VARIANT     114    114       V -> A (in allele DRB1*14:28 and allele
FT                                DRB1*14:29).
FT                                /FTId=VAR_062950.
FT   VARIANT     115    115       V -> G (in allele DRB1*14:02, allele
FT                                DRB1*14:03, allele DRB1*14:07, allele
FT                                DRB1*14:09, allele DRB1*14:13, allele
FT                                DRB1*14:14, allele DRB1*14:19, allele
FT                                DRB1*14:22, allele DRB1*14:24, allele
FT                                DRB1*14:25, allele DRB1*14:27, allele
FT                                DRB1*14:30, allele DRB1*14:36, allele
FT                                DRB1*14:40, allele DRB1*14:41, allele
FT                                DRB1*14:42, allele DRB1*14:44, allele
FT                                DRB1*14:46, allele DRB1*14:47, allele
FT                                DRB1*14:48, allele DRB1*14:49, allele
FT                                DRB1*14:51, allele DRB1*14:53, allele
FT                                DRB1*14:63, allele DRB1*14:67, allele
FT                                DRB1*14:68, allele DRB1*14:69, allele
FT                                DRB1*14:77 and allele DRB1*14:85).
FT                                /FTId=VAR_062951.
FT   VARIANT     115    115       V -> M (in allele DRB1*14:71).
FT                                /FTId=VAR_062952.
FT   VARIANT     141    141       Y -> H (in allele DRB1*14:02, allele
FT                                DRB1*14:03, allele DRB1*14:04, allele
FT                                DRB1*14:05, allele DRB1*14:06, allele
FT                                DRB1*14:07, allele DRB1*14:10, allele
FT                                DRB1*14:11, allele DRB1*14:13, allele
FT                                DRB1*14:14, allele DRB1*14:21, allele
FT                                DRB1*14:46, allele DRB1*14:54, allele
FT                                DRB1*14:57 and allele DRB1*14:82).
FT                                /FTId=VAR_062953.
FT   CONFLICT    124    124       V -> G (in Ref. 10; BAH23562).
SQ   SEQUENCE   266 AA;  30139 MW;  FA4BE90DFAB4FA55 CRC64;
     MVCLRLPGGS CMAVLTVTLM VLSSPLALAG DTRPRFLEYS TSECHFFNGT ERVRFLDRYF
     HNQEEFVRFD SDVGEYRAVT ELGRPAAEHW NSQKDLLERR RAEVDTYCRH NYGVVESFTV
     QRRVHPKVTV YPSKTQPLQH YNLLVCSVSG FYPGSIEVRW FRNGQEEKTG VVSTGLIHNG
     DWTFQTLVML ETVPRSGEVY TCQVEHPSVT SPLTVEWRAR SESAQSKMLS GVGGFVLGLL
     FLGAGLFIYF RNQKGHSGLQ PRGFLS
//
ID   2B1F_HUMAN              Reviewed;         266 AA.
AC   P01911; Q29790; Q29975; Q30142; Q30166; Q32MY7; Q56FN9; Q5Y7B0;
AC   Q5Y7B9;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   15-JAN-2008, sequence version 2.
DT   09-JUL-2014, entry version 122.
DE   RecName: Full=HLA class II histocompatibility antigen, DRB1-15 beta chain;
DE   AltName: Full=DW2.2/DR2.2;
DE   AltName: Full=MHC class II antigen DRB1*15;
DE   Flags: Precursor;
GN   Name=HLA-DRB1; Synonyms=HLA-DRB2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*15:01).
RC   TISSUE=B-cell;
RX   PubMed=3259543; DOI=10.1007/BF00364432;
RA   Lock C.B., So A.K., Welsh K.I., Parkes J.D., Trowsdale J.;
RT   "MHC class II sequences of an HLA-DR2 narcoleptic.";
RL   Immunogenetics 27:449-455(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES DRB1*15:01; DRB1*15:02 AND
RP   DRB1*15:03).
RX   PubMed=16140993; DOI=10.1101/gr.3554305;
RA   Raymond C.K., Kas A., Paddock M., Qiu R., Zhou Y., Subramanian S.,
RA   Chang J., Palmieri A., Haugen E., Kaul R., Olson M.V.;
RT   "Ancient haplotypes of the HLA Class II region.";
RL   Genome Res. 15:1250-1257(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELES DRB1*15:03 AND DRB1*15:04).
RC   TISSUE=Blood;
RX   PubMed=17174751; DOI=10.1016/j.humimm.2006.09.002;
RA   Balas A., Vilches C., Rodriguez M.A., Fernandez B., Martinez M.P.,
RA   de Pablo R., Garcia-Sanchez F., Vicario J.L.;
RT   "Group-specific amplification of cDNA from DRB1 genes. Complete coding
RT   sequences of partially defined alleles and identification of the new
RT   alleles DRB1*040602, DRB1*111102, DRB1*080103, and DRB1*0113.";
RL   Hum. Immunol. 67:1008-1016(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE DRB1*15:01).
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELES DRB1*15:01 AND
RP   DRB1*15:02).
RC   TISSUE=Leukocyte;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 11-266 (ALLELE DRB1*15:02).
RC   TISSUE=Lymphoblast;
RX   PubMed=3571980;
RA   Wu S.K., Yabe T., Madden M., Saunders T.L., Bach F.H.;
RT   "cDNA cloning and sequencing reveals that the electrophoretically
RT   constant DR beta 2 molecules, as well as the variable DR beta 1
RT   molecules, from HLA-DR2 subtypes have different amino acid sequences
RT   including a hypervariable region for a functionally important
RT   epitope.";
RL   J. Immunol. 138:2953-2959(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELE DRB1*15:01).
RC   TISSUE=Lymphoblast;
RX   PubMed=2885840; DOI=10.1073/pnas.84.13.4591;
RA   Lee B.S.M., Rust N.A., McMichael A.J., McDevitt H.O.;
RT   "HLA-DR2 subtypes form an additional supertypic family of DR beta
RT   alleles.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4591-4595(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELE DRB1*15:01).
RC   TISSUE=Lymphoblast;
RX   PubMed=3476943; DOI=10.1073/pnas.84.17.6234;
RA   Bell J.I., Denney D. Jr., Foster L., Belt T.K., Todd J.A.,
RA   McDevitt H.O.;
RT   "Allelic variation in the DR subregion of the human major
RT   histocompatibility complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6234-6238(1987).
RN   [9]
RP   PROTEIN SEQUENCE OF 30-228.
RC   TISSUE=Lymphoblast;
RX   PubMed=6947956;
RA   Kratzin H., Yang C.-Y., Gotz H., Pauly E., Kolbel S., Egert G.,
RA   Thinnes F.P., Wernet P., Altevogt P., Hilschmann N.;
RT   "Primary structure of class II human histocompatibility antigens. 1st
RT   communication. Amino acid sequence of the N-terminal 198 residues of
RT   the beta chain of a HLA-Dw2,2;DR2,2-alloantigen.";
RL   Hoppe-Seyler's Z. Physiol. Chem. 362:1665-1669(1981).
RN   [10]
RP   PROTEIN SEQUENCE OF 30-64.
RC   TISSUE=B-cell;
RX   PubMed=6600932; DOI=10.1021/bi00270a027;
RA   Walker L.E., Hewick R., Hunkapiller M.W., Hood L.E., Dreyer W.J.,
RA   Reisfeld R.A.;
RT   "N-terminal amino acid sequences of the alpha and beta chains of HLA-
RT   DR1 and HLA-DR2 antigens.";
RL   Biochemistry 22:185-188(1983).
RN   [11]
RP   REVIEW.
RX   PubMed=8598037; DOI=10.1016/S0092-8674(00)81025-9;
RA   Cresswell P.;
RT   "Invariant chain structure and MHC class II function.";
RL   Cell 84:505-507(1996).
RN   [12]
RP   REVIEW.
RX   PubMed=11684289; DOI=10.1016/S0161-5890(01)00069-4;
RA   Villadangos J.A.;
RT   "Presentation of antigens by MHC class II molecules: getting the most
RT   out of them.";
RL   Mol. Immunol. 38:329-346(2001).
RN   [13]
RP   REVIEW.
RX   PubMed=17241953; DOI=10.1016/j.immuni.2007.01.005;
RA   Menendez-Benito V., Neefjes J.;
RT   "Autophagy in MHC class II presentation: sampling from within.";
RL   Immunity 26:1-3(2007).
RN   [14]
RP   REVIEW.
RX   PubMed=18046453; DOI=10.1038/sj.emboj.7601945;
RA   Rocha N., Neefjes J.;
RT   "MHC class II molecules on the move for successful antigen
RT   presentation.";
RL   EMBO J. 27:1-5(2008).
RN   [15]
RP   UBIQUITINATION BY MARCH1, AND SUBCELLULAR LOCATION.
RX   PubMed=18305173; DOI=10.1073/pnas.0708874105;
RA   De Gassart A., Camosseto V., Thibodeau J., Ceppi M., Catalan N.,
RA   Pierre P., Gatti E.;
RT   "MHC class II stabilization at the surface of human dendritic cells is
RT   the result of maturation-dependent MARCH I down-regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3491-3496(2008).
RN   [16]
RP   REVIEW.
RX   PubMed=19092054; DOI=10.1242/jcs.035089;
RA   Berger A.C., Roche P.A.;
RT   "MHC class II transport at a glance.";
RL   J. Cell Sci. 122:1-4(2009).
RN   [17]
RP   REVIEW.
RX   PubMed=19533806; DOI=10.3748/wjg.15.2855;
RA   Beswick E.J., Reyes V.E.;
RT   "CD74 in antigen presentation, inflammation, and cancers of the
RT   gastrointestinal tract.";
RL   World J. Gastroenterol. 15:2855-2861(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF 30-227.
RX   PubMed=15821740; DOI=10.1038/ni1187;
RA   Hahn M., Nicholson M.J., Pyrdol J., Wucherpfennig K.W.;
RT   "Unconventional topology of self peptide-major histocompatibility
RT   complex binding by a human autoimmune T cell receptor.";
RL   Nat. Immunol. 6:490-496(2005).
CC   -!- FUNCTION: Binds peptides derived from antigens that access the
CC       endocytic route of antigen presenting cells (APC) and presents
CC       them on the cell surface for recognition by the CD4 T-cells. The
CC       peptide binding cleft accommodates peptides of 10-30 residues. The
CC       peptides presented by MHC class II molecules are generated mostly
CC       by degradation of proteins that access the endocytic route, where
CC       they are processed by lysosomal proteases and other hydrolases.
CC       Exogenous antigens that have been endocytosed by the APC are thus
CC       readily available for presentation via MHC II molecules, and for
CC       this reason this antigen presentation pathway is usually referred
CC       to as exogenous. As membrane proteins on their way to degradation
CC       in lysosomes as part of their normal turn-over are also contained
CC       in the endosomal/lysosomal compartments, exogenous antigens must
CC       compete with those derived from endogenous components. Autophagy
CC       is also a source of endogenous peptides, autophagosomes
CC       constitutively fuse with MHC class II loading compartments. In
CC       addition to APCs, other cells of the gastrointestinal tract, such
CC       as epithelial cells, express MHC class II molecules and CD74 and
CC       act as APCs, which is an unusual trait of the GI tract. To produce
CC       a MHC class II molecule that presents an antigen, three MHC class
CC       II molecules (heterodimers of an alpha and a beta chain) associate
CC       with a CD74 trimer in the ER to form a heterononamer. Soon after
CC       the entry of this complex into the endosomal/lysosomal system
CC       where antigen processing occurs, CD74 undergoes a sequential
CC       degradation by various proteases, including CTSS and CTSL, leaving
CC       a small fragment termed CLIP (class-II-associated invariant chain
CC       peptide). The removal of CLIP is facilitated by HLA-DM via direct
CC       binding to the alpha-beta-CLIP complex so that CLIP is released.
CC       HLA-DM stabilizes MHC class II molecules until primary high
CC       affinity antigenic peptides are bound. The MHC II molecule bound
CC       to a peptide is then transported to the cell membrane surface. In
CC       B-cells, the interaction between HLA-DM and MHC class II molecules
CC       is regulated by HLA-DO. Primary dendritic cells (DCs) also to
CC       express HLA-DO. Lysosomal microenvironment has been implicated in
CC       the regulation of antigen loading into MHC II molecules, increased
CC       acidification produces increased proteolysis and efficient peptide
CC       loading.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit; also referred
CC       as MHC class II molecule. In the endoplasmic reticulum (ER) it
CC       forms a heterononamer; 3 MHC class II molecules bind to a CD74
CC       homotrimer (also known as invariant chain or HLA class II
CC       histocompatibility antigen gamma chain). In the
CC       endosomal/lysosomal system; CD74 undergoes sequential degradation
CC       by various proteases; leaving a small fragment termed CLIP on each
CC       MHC class II molecule. MHC class II molecule interacts with
CC       HLA_DM, and HLA_DO in B-cells, in order to release CLIP and
CC       facilitate the binding of antigenic peptides.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane; Single-pass type I
CC       membrane protein. Golgi apparatus, trans-Golgi network membrane;
CC       Single-pass type I membrane protein. Endosome membrane; Single-
CC       pass type I membrane protein. Lysosome membrane; Single-pass type
CC       I membrane protein. Late endosome membrane; Single-pass type I
CC       membrane protein. Note=The MHC class II complex transits through a
CC       number of intracellular compartments in the endocytic pathway
CC       until it reaches the cell membrane for antigen presentation.
CC   -!- PTM: Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to
CC       sorting into the endosome system and down-regulation of MHC class
CC       II (Probable).
CC   -!- POLYMORPHISM: The following alleles of DRB1-15 are known:
CC       DRB1*15:01, DRB1*15:02, DRB1*15:03, DRB1*15:04, DRB1*15:05,
CC       DRB1*15:06, DRB1*15:07, DRB1*15:08, DRB1*15:09, DRB1*15:10,
CC       DRB1*15:11, DRB1*15:12, DRB1*15:13, DRB1*15:14, DRB1*15:15,
CC       DRB1*15:16, DRB1*15:18, DRB1*15:19, DRB1*15:20, DRB1*15:21,
CC       DRB1*15:22, DRB1*15:23, DRB1*15:24, DRB1*15:25, DRB1*15:26,
CC       DRB1*15:27, DRB1*15:28, DRB1*15:29, DRB1*15:30, DRB1*15:31 and
CC       DRB1*15:32. The sequence shown is that of DRB1*15:01.
CC   -!- MISCELLANEOUS: The chain shown constituted about 70% of a pool of
CC       at least seven similar beta chains.
CC   -!- SIMILARITY: Belongs to the MHC class II family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M20430; AAA59831.1; -; mRNA.
DR   EMBL; AY663395; AAU87979.1; -; Genomic_DNA.
DR   EMBL; AY663406; AAU88008.1; -; Genomic_DNA.
DR   EMBL; AY663411; AAU88023.1; -; Genomic_DNA.
DR   EMBL; AY663414; AAU88033.1; -; Genomic_DNA.
DR   EMBL; AY961072; AAX63460.1; -; mRNA.
DR   EMBL; AY961073; AAX63461.1; -; mRNA.
DR   EMBL; AL713966; CAI18081.1; -; Genomic_DNA.
DR   EMBL; BC033827; AAH33827.1; -; mRNA.
DR   EMBL; BC108922; AAI08923.1; -; mRNA.
DR   EMBL; M28584; AAA59681.1; -; mRNA.
DR   EMBL; M16957; AAA36279.1; -; mRNA.
DR   EMBL; M17378; AAA59801.1; -; mRNA.
DR   CCDS; CCDS47409.1; -.
DR   PIR; I68734; HLHUWB.
DR   RefSeq; NP_002115.2; NM_002124.3.
DR   UniGene; Hs.534322; -.
DR   UniGene; Hs.696211; -.
DR   UniGene; Hs.736560; -.
DR   PDB; 1BX2; X-ray; 2.60 A; B/E=32-222.
DR   PDB; 1YMM; X-ray; 3.50 A; B=30-227.
DR   PDB; 2WBJ; X-ray; 3.00 A; B/F=30-227.
DR   PDBsum; 1BX2; -.
DR   PDBsum; 1YMM; -.
DR   PDBsum; 2WBJ; -.
DR   ProteinModelPortal; P01911; -.
DR   SMR; P01911; 32-222.
DR   BioGrid; 109368; 15.
DR   IntAct; P01911; 1.
DR   DMDM; 166214928; -.
DR   MaxQB; P01911; -.
DR   PRIDE; P01911; -.
DR   DNASU; 3123; -.
DR   Ensembl; ENST00000360004; ENSP00000353099; ENSG00000196126.
DR   GeneID; 3123; -.
DR   KEGG; hsa:3123; -.
DR   UCSC; uc003obp.4; human.
DR   CTD; 3123; -.
DR   GeneCards; GC06M032546; -.
DR   HGNC; HGNC:4948; HLA-DRB1.
DR   HPA; CAB015400; -.
DR   HPA; CAB034021; -.
DR   MIM; 142857; gene.
DR   neXtProt; NX_P01911; -.
DR   PharmGKB; PA35072; -.
DR   HOVERGEN; HBG012730; -.
DR   InParanoid; P01911; -.
DR   KO; K06752; -.
DR   OMA; ERISCGI; -.
DR   PhylomeDB; P01911; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-DRB1; human.
DR   EvolutionaryTrace; P01911; -.
DR   GeneWiki; HLA-DRB1; -.
DR   GenomeRNAi; 3123; -.
DR   NextBio; 12394; -.
DR   PRO; PR:P01911; -.
DR   ArrayExpress; P01911; -.
DR   Bgee; P01911; -.
DR   CleanEx; HS_HLA-DRB1; -.
DR   Genevestigator; P01911; -.
DR   GO; GO:0009986; C:cell surface; IDA:UniProt.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031902; C:late endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0042613; C:MHC class II protein complex; IDA:UniProt.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0030658; C:transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0023026; F:MHC class II protein complex binding; IDA:UniProt.
DR   GO; GO:0042605; F:peptide antigen binding; IDA:UniProt.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0002506; P:polysaccharide assembly with MHC class II protein complex; IDA:UniProt.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.320.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR014745; MHC_II_a/b_N.
DR   InterPro; IPR000353; MHC_II_b_N.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00969; MHC_II_beta; 1.
DR   ProDom; PD000328; MHC_II_b_N; 1.
DR   SMART; SM00407; IGc1; 1.
DR   SMART; SM00921; MHC_II_beta; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Endoplasmic reticulum;
KW   Endosome; Glycoprotein; Golgi apparatus; Immunity; Isopeptide bond;
KW   Lysosome; Membrane; MHC II; Polymorphism; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     29
FT   CHAIN        30    266       HLA class II histocompatibility antigen,
FT                                DRB1-15 beta chain.
FT                                /FTId=PRO_0000080744.
FT   TOPO_DOM     30    227       Extracellular (Potential).
FT   TRANSMEM    228    248       Helical; (Potential).
FT   TOPO_DOM    249    266       Cytoplasmic (Potential).
FT   DOMAIN      126    214       Ig-like C1-type.
FT   REGION       30    124       Beta-1.
FT   REGION      125    227       Beta-2.
FT   CARBOHYD     48     48       N-linked (GlcNAc...).
FT   DISULFID     44    108
FT   DISULFID    146    202
FT   CROSSLNK    254    254       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VARIANT       5      5       K -> R (in dbSNP:rs9270305).
FT                                /FTId=VAR_050364.
FT   VARIANT      55     55       F -> Y (in dbSNP:rs16822516).
FT                                /FTId=VAR_050365.
FT   VARIANT      59     59       Y -> H (in allele DRB1*15:03).
FT                                /FTId=VAR_038162.
FT   VARIANT      96     96       I -> F (in allele DRB1*15:04;
FT                                dbSNP:rs17886918).
FT                                /FTId=VAR_038163.
FT   VARIANT     106    106       T -> N (in dbSNP:rs9269941).
FT                                /FTId=VAR_050366.
FT   VARIANT     115    115       V -> G (in allele DRB1*15:02;
FT                                dbSNP:rs17885482).
FT                                /FTId=VAR_038164.
FT   VARIANT     164    164       G -> S (in dbSNP:rs1059633).
FT                                /FTId=VAR_050367.
FT   VARIANT     169    169       A -> T (in dbSNP:rs2308768).
FT                                /FTId=VAR_050368.
FT   VARIANT     236    236       V -> M (in dbSNP:rs2230816).
FT                                /FTId=VAR_050369.
FT   VARIANT     262    262       T -> R (in dbSNP:rs9269744).
FT                                /FTId=VAR_050370.
FT   CONFLICT    119    119       T -> A (in Ref. 5; AAI08923).
FT   CONFLICT    154    154       G -> A (in Ref. 8; AAA59801).
FT   CONFLICT    171    171       M -> G (in Ref. 9; AA sequence).
FT   CONFLICT    179    180       NG -> D (in Ref. 9; AA sequence).
FT   STRAND       36     47
FT   TURN         48     51
FT   STRAND       52     61
FT   STRAND       64     70
FT   TURN         71     73
FT   STRAND       75     80
FT   HELIX        81     83
FT   HELIX        84     92
FT   HELIX        94    106
FT   HELIX       108    115
FT   TURN        116    121
FT   STRAND      127    134
FT   STRAND      142    154
FT   STRAND      157    162
FT   STRAND      165    167
FT   STRAND      169    173
FT   STRAND      180    182
FT   STRAND      184    192
FT   STRAND      199    205
FT   STRAND      209    211
FT   STRAND      213    218
SQ   SEQUENCE   266 AA;  29966 MW;  3B5912820A4654BE CRC64;
     MVCLKLPGGS CMTALTVTLM VLSSPLALSG DTRPRFLWQP KRECHFFNGT ERVRFLDRYF
     YNQEESVRFD SDVGEFRAVT ELGRPDAEYW NSQKDILEQA RAAVDTYCRH NYGVVESFTV
     QRRVQPKVTV YPSKTQPLQH HNLLVCSVSG FYPGSIEVRW FLNGQEEKAG MVSTGLIQNG
     DWTFQTLVML ETVPRSGEVY TCQVEHPSVT SPLTVEWRAR SESAQSKMLS GVGGFVLGLL
     FLGAGLFIYF RNQKGHSGLQ PTGFLS
//
ID   2B1G_HUMAN              Reviewed;         266 AA.
AC   Q29974; A7X5J4; O98212; Q0PGR5; Q29792; Q30120; Q30159; Q30200;
AC   Q3HUP9; Q3KTM1; Q3LA84; Q6T865; Q95383;
DT   02-MAR-2010, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   16-APR-2014, entry version 107.
DE   RecName: Full=HLA class II histocompatibility antigen, DRB1-16 beta chain;
DE   AltName: Full=MHC class II antigen DRB1*16;
DE            Short=DR-16;
DE            Short=DR16;
DE   Flags: Precursor;
GN   Name=HLA-DRB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*16:01).
RX   PubMed=3571980;
RA   Wu S.K., Yabe T., Madden M., Saunders T.L., Bach F.H.;
RT   "cDNA cloning and sequencing reveals that the electrophoretically
RT   constant DR beta 2 molecules, as well as the variable DR beta 1
RT   molecules, from HLA-DR2 subtypes have different amino acid sequences
RT   including a hypervariable region for a functionally important
RT   epitope.";
RL   J. Immunol. 138:2953-2959(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*16:02).
RX   PubMed=3129499;
RA   Liu C.P., Bach F.H., Wu S.K.;
RT   "Molecular studies of a rare DR2/LD-5a/DQw3 HLA class II haplotype.
RT   Multiple genetic mechanisms in the generation of polymorphic HLA class
RT   II genes.";
RL   J. Immunol. 140:3631-3639(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB1*16:03).
RC   TISSUE=Blood;
RX   PubMed=8436426; DOI=10.1007/BF00222476;
RA   Rosenlicht J.W., Hartung K., Deicher H., Frey J.;
RT   "A novel HLA-DRB1-DR2 allele associated with HLA mistyping.";
RL   Immunogenetics 37:479-479(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE DRB1*16:01).
RC   TISSUE=Small intestine;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELE DRB1*16:01).
RX   PubMed=2885840; DOI=10.1073/pnas.84.13.4591;
RA   Lee B.S.M., Rust N.A., McMichael A.J., McDevitt H.O.;
RT   "HLA-DR2 subtypes form an additional supertypic family of DR beta
RT   alleles.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4591-4595(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-216 (ALLELE DRB1*16:04).
RC   TISSUE=Peripheral blood;
RX   PubMed=17767557; DOI=10.1111/j.1399-0039.2007.00918.x;
RA   Horn P.A., Albis-Camps M., Verboom M., Bunce M., Yousaf K.,
RA   Williams S., Blasczyk R.;
RT   "The nature of diversity of HLA-DRB1 exon 3.";
RL   Tissue Antigens 70:335-337(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*16:08).
RX   PubMed=9271639; DOI=10.1007/s002510050303;
RA   Reviron D., Dormoy A., Andre M., Froelich N., Roudier J., Tongio M.M.,
RA   Mercier P.;
RT   "HLA-DRB1*1608: a new HLA-DRB1*16 allele with a short DRB1*03
RT   sequence.";
RL   Immunogenetics 46:444-445(1997).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*16:09).
RX   PubMed=16101839; DOI=10.1111/j.1399-0039.2005.00443.x;
RA   Miao K.R., Pan Q.Q., Xue M., Zhou X.Y., Fei X.M., Tang Y.H., Xu R.,
RA   Zhang J.W., Zhao X., Osowski L., Shi W.X., Xu A.L., Wang C.Y.,
RA   Kukuruga D.;
RT   "A novel HLA allele, DRB1*1609, identified in the Chinese Han
RT   population*.";
RL   Tissue Antigens 66:248-250(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*16:11).
RX   PubMed=19500310; DOI=10.1111/j.1399-0039.2009.01260.x;
RA   Chu C.-C., Lee H.-L., Lin M.;
RT   "A novel HLA-DRB1 allele, DRB*1611, is identified in two Taiwanese
RT   individuals.";
RL   Tissue Antigens 74:175-176(2009).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*16:05).
RA   Gedil M.A., Steiner N.K., Hurley C.K.;
RT   "Novel HLA-DRB1 allele.";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*16:10).
RA   Yan L., Zhu F., He J.;
RT   "Identification a novel HLA-DRB1*16 allele by sequence based typing in
RT   Chinese.";
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB1*16:12).
RA   Lazaro A.M., Xiao Y., Hurley C.K.;
RT   "Novel HLA class II allele.";
RL   Submitted (JUL-2007) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-119 (ALLELE DRB1*16:01).
RC   TISSUE=Blood;
RX   PubMed=10551425; DOI=10.1034/j.1399-0039.1999.540411.x;
RA   Lin Y.S., Tang T.F., Ng J., Hartzman R., Hurley C.K.;
RT   "Two DR2-associated novel alleles arose from the silent mutation of
RT   codon 72: DRB1*16012, DRB5*01012.";
RL   Tissue Antigens 54:405-408(1999).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 39-120 (ALLELE DRB1*16:07).
RA   Brautbar C., Israel S., Safirman C., Smith A.G.;
RL   Submitted (MAY-1995) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   REVIEW.
RX   PubMed=8598037; DOI=10.1016/S0092-8674(00)81025-9;
RA   Cresswell P.;
RT   "Invariant chain structure and MHC class II function.";
RL   Cell 84:505-507(1996).
RN   [16]
RP   REVIEW.
RX   PubMed=11684289; DOI=10.1016/S0161-5890(01)00069-4;
RA   Villadangos J.A.;
RT   "Presentation of antigens by MHC class II molecules: getting the most
RT   out of them.";
RL   Mol. Immunol. 38:329-346(2001).
RN   [17]
RP   REVIEW.
RX   PubMed=17241953; DOI=10.1016/j.immuni.2007.01.005;
RA   Menendez-Benito V., Neefjes J.;
RT   "Autophagy in MHC class II presentation: sampling from within.";
RL   Immunity 26:1-3(2007).
RN   [18]
RP   REVIEW.
RX   PubMed=18046453; DOI=10.1038/sj.emboj.7601945;
RA   Rocha N., Neefjes J.;
RT   "MHC class II molecules on the move for successful antigen
RT   presentation.";
RL   EMBO J. 27:1-5(2008).
RN   [19]
RP   UBIQUITINATION BY MARCH1, AND SUBCELLULAR LOCATION.
RX   PubMed=18305173; DOI=10.1073/pnas.0708874105;
RA   De Gassart A., Camosseto V., Thibodeau J., Ceppi M., Catalan N.,
RA   Pierre P., Gatti E.;
RT   "MHC class II stabilization at the surface of human dendritic cells is
RT   the result of maturation-dependent MARCH I down-regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3491-3496(2008).
RN   [20]
RP   REVIEW.
RX   PubMed=19092054; DOI=10.1242/jcs.035089;
RA   Berger A.C., Roche P.A.;
RT   "MHC class II transport at a glance.";
RL   J. Cell Sci. 122:1-4(2009).
RN   [21]
RP   REVIEW.
RX   PubMed=19533806; DOI=10.3748/wjg.15.2855;
RA   Beswick E.J., Reyes V.E.;
RT   "CD74 in antigen presentation, inflammation, and cancers of the
RT   gastrointestinal tract.";
RL   World J. Gastroenterol. 15:2855-2861(2009).
CC   -!- FUNCTION: Binds peptides derived from antigens that access the
CC       endocytic route of antigen presenting cells (APC) and presents
CC       them on the cell surface for recognition by the CD4 T-cells. The
CC       peptide binding cleft accommodates peptides of 10-30 residues. The
CC       peptides presented by MHC class II molecules are generated mostly
CC       by degradation of proteins that access the endocytic route, where
CC       they are processed by lysosomal proteases and other hydrolases.
CC       Exogenous antigens that have been endocytosed by the APC are thus
CC       readily available for presentation via MHC II molecules, and for
CC       this reason this antigen presentation pathway is usually referred
CC       to as exogenous. As membrane proteins on their way to degradation
CC       in lysosomes as part of their normal turn-over are also contained
CC       in the endosomal/lysosomal compartments, exogenous antigens must
CC       compete with those derived from endogenous components. Autophagy
CC       is also a source of endogenous peptides, autophagosomes
CC       constitutively fuse with MHC class II loading compartments. In
CC       addition to APCs, other cells of the gastrointestinal tract, such
CC       as epithelial cells, express MHC class II molecules and CD74 and
CC       act as APCs, which is an unusual trait of the GI tract. To produce
CC       a MHC class II molecule that presents an antigen, three MHC class
CC       II molecules (heterodimers of an alpha and a beta chain) associate
CC       with a CD74 trimer in the ER to form a heterononamer. Soon after
CC       the entry of this complex into the endosomal/lysosomal system
CC       where antigen processing occurs, CD74 undergoes a sequential
CC       degradation by various proteases, including CTSS and CTSL, leaving
CC       a small fragment termed CLIP (class-II-associated invariant chain
CC       peptide). The removal of CLIP is facilitated by HLA-DM via direct
CC       binding to the alpha-beta-CLIP complex so that CLIP is released.
CC       HLA-DM stabilizes MHC class II molecules until primary high
CC       affinity antigenic peptides are bound. The MHC II molecule bound
CC       to a peptide is then transported to the cell membrane surface. In
CC       B-cells, the interaction between HLA-DM and MHC class II molecules
CC       is regulated by HLA-DO. Primary dendritic cells (DCs) also to
CC       express HLA-DO. Lysosomal microenvironment has been implicated in
CC       the regulation of antigen loading into MHC II molecules, increased
CC       acidification produces increased proteolysis and efficient peptide
CC       loading.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit; also referred
CC       as MHC class II molecule. In the endoplasmic reticulum (ER) it
CC       forms a heterononamer; 3 MHC class II molecules bind to a CD74
CC       homotrimer (also known as invariant chain or HLA class II
CC       histocompatibility antigen gamma chain). In the
CC       endosomal/lysosomal system; CD74 undergoes sequential degradation
CC       by various proteases; leaving a small fragment termed CLIP on each
CC       MHC class II molecule. MHC class II molecule interacts with
CC       HLA_DM, and HLA_DO in B-cells, in order to release CLIP and
CC       facilitate the binding of antigenic peptides.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane; Single-pass type I
CC       membrane protein. Golgi apparatus, trans-Golgi network membrane;
CC       Single-pass type I membrane protein. Endosome membrane; Single-
CC       pass type I membrane protein. Lysosome membrane; Single-pass type
CC       I membrane protein. Late endosome membrane; Single-pass type I
CC       membrane protein. Note=The MHC class II complex transits through a
CC       number of intracellular compartments in the endocytic pathway
CC       until it reaches the cell membrane for antigen presentation.
CC   -!- PTM: Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to
CC       sorting into the endosome system and down-regulation of MHC class
CC       II (Probable).
CC   -!- POLYMORPHISM: The following alleles of DRB1-16 are known:
CC       DRB1*16:01; DRB1*16:02; DRB1*16:03; DRB1*16:04; DRB1*16:05;
CC       DRB1*16:07; DRB1*16:08; DRB1*16:09; DRB1*16:10; DRB1*16:11 and
CC       DRB1*16:12. The sequence shown is that of DRB1*16:02.
CC   -!- SIMILARITY: Belongs to the MHC class II family.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M28583; AAA59680.1; -; mRNA.
DR   EMBL; M20504; AAA59827.1; -; mRNA.
DR   EMBL; L02545; AAA59777.1; -; mRNA.
DR   EMBL; AK291987; BAF84676.1; -; mRNA.
DR   EMBL; M16959; AAA36281.1; -; mRNA.
DR   EMBL; AM110006; CAJ33613.1; -; Genomic_DNA.
DR   EMBL; Z72424; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AY912074; AAY17287.1; -; Genomic_DNA.
DR   EMBL; DQ837166; ABH05946.1; -; Genomic_DNA.
DR   EMBL; AY428805; AAR07616.1; -; Genomic_DNA.
DR   EMBL; DQ192647; ABA39176.1; -; Genomic_DNA.
DR   EMBL; EU029801; ABU86860.1; -; Genomic_DNA.
DR   EMBL; U59686; AAB52230.1; -; Genomic_DNA.
DR   EMBL; U26659; AAD09441.1; -; Genomic_DNA.
DR   PIR; B27618; B27618.
DR   PIR; D25239; D25239.
DR   PIR; F27060; F27060.
DR   PIR; I54509; I54509.
DR   RefSeq; NP_002115.2; NM_002124.3.
DR   UniGene; Hs.485130; -.
DR   UniGene; Hs.534322; -.
DR   UniGene; Hs.696211; -.
DR   UniGene; Hs.716081; -.
DR   UniGene; Hs.723344; -.
DR   UniGene; Hs.736560; -.
DR   ProteinModelPortal; Q29974; -.
DR   SMR; Q29974; 32-222.
DR   BioGrid; 109368; 15.
DR   DMDM; 74762149; -.
DR   PRIDE; Q29974; -.
DR   DNASU; 3123; -.
DR   Ensembl; ENST00000360004; ENSP00000353099; ENSG00000196126.
DR   GeneID; 3123; -.
DR   KEGG; hsa:3123; -.
DR   CTD; 3123; -.
DR   GeneCards; GC06M032546; -.
DR   HGNC; HGNC:4948; HLA-DRB1.
DR   HPA; CAB015400; -.
DR   HPA; CAB034021; -.
DR   MIM; 142857; gene.
DR   neXtProt; NX_Q29974; -.
DR   HOVERGEN; HBG012730; -.
DR   KO; K06752; -.
DR   TreeFam; TF336626; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; HLA-DRB1; human.
DR   GenomeRNAi; 3123; -.
DR   NextBio; 12394; -.
DR   ArrayExpress; Q29974; -.
DR   Bgee; Q29974; -.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031902; C:late endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0042613; C:MHC class II protein complex; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0030658; C:transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0032395; F:MHC class II receptor activity; NAS:UniProtKB.
DR   GO; GO:0042605; F:peptide antigen binding; ISS:UniProtKB.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0016045; P:detection of bacterium; ISS:UniProtKB.
DR   GO; GO:0002455; P:humoral immune response mediated by circulating immunoglobulin; ISS:UniProtKB.
DR   GO; GO:0006955; P:immune response; ISS:UniProtKB.
DR   GO; GO:0002381; P:immunoglobulin production involved in immunoglobulin mediated immune response; ISS:UniProtKB.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; ISS:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; ISS:UniProtKB.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; ISS:UniProtKB.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; ISS:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; ISS:UniProtKB.
DR   GO; GO:2001179; P:regulation of interleukin-10 secretion; ISS:UniProtKB.
DR   GO; GO:0032673; P:regulation of interleukin-4 production; ISS:UniProtKB.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042088; P:T-helper 1 type immune response; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.320.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR014745; MHC_II_a/b_N.
DR   InterPro; IPR000353; MHC_II_b_N.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00969; MHC_II_beta; 1.
DR   ProDom; PD000328; MHC_II_b_N; 1.
DR   SMART; SM00407; IGc1; 1.
DR   SMART; SM00921; MHC_II_beta; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Golgi apparatus;
KW   Immunity; Isopeptide bond; Lysosome; Membrane; MHC II; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     29       Potential.
FT   CHAIN        30    266       HLA class II histocompatibility antigen,
FT                                DRB1-16 beta chain.
FT                                /FTId=PRO_0000391833.
FT   TRANSMEM    228    248       Helical; (Potential).
FT   DOMAIN      126    214       Ig-like C1-type.
FT   CARBOHYD     48     48       N-linked (GlcNAc...) (Potential).
FT   DISULFID    146    202       By similarity.
FT   CROSSLNK    254    254       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VARIANT      42     42       R -> K (in allele DRB1*16:12).
FT                                /FTId=VAR_062840.
FT   VARIANT      43     43       E -> K (in allele DRB1*16:11).
FT                                /FTId=VAR_062841.
FT   VARIANT      56     56       L -> P (in allele DRB1*16:07).
FT                                /FTId=VAR_062842.
FT   VARIANT      66     66       S -> N (in allele DRB1*16:08).
FT                                /FTId=VAR_062843.
FT   VARIANT      76     76       Y -> F (in allele DRB1*16:09 and allele
FT                                DRB1*16:10).
FT                                /FTId=VAR_062844.
FT   VARIANT      96     96       F -> I (in allele DRB1*16:05 and allele
FT                                DRB1*16:07).
FT                                /FTId=VAR_062845.
FT   VARIANT      96     96       F -> L (in allele DRB1*16:02, allele
FT                                DRB1*16:10, allele DRB1*16:11 and allele
FT                                DRB1*16:12).
FT                                /FTId=VAR_062846.
FT   VARIANT     101    101       R -> A (in allele DRB1*16:03; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_062847.
FT   VARIANT     103    103       A -> L (in allele DRB1*16:04; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_062848.
FT   VARIANT     262    262       T -> R (in dbSNP:rs9269744).
FT                                /FTId=VAR_062849.
SQ   SEQUENCE   266 AA;  30030 MW;  871CC341692ECA4D CRC64;
     MVCLKLPGGS CMTALTVTLM VLSSPLALAG DTRPRFLWQP KRECHFFNGT ERVRFLDRYF
     YNQEESVRFD SDVGEYRAVT ELGRPDAEYW NSQKDFLEDR RAAVDTYCRH NYGVGESFTV
     QRRVQPKVTV YPSKTQPLQH HNLLVCSVSG FYPGSIEVRW FLNGQEEKAG MVSTGLIQNG
     DWTFQTLVML ETVPRSGEVY TCQVEHPSVT SPLTVEWRAR SESAQSKMLS GVGGFVLGLL
     FLGAGLFIYF RNQKGHSGLQ PTGFLS
//
ID   3BHS2_HUMAN             Reviewed;         372 AA.
AC   P26439; A2RRA5; Q16010; Q53GD4; Q6AI10; Q6LDB9; Q99890; Q9UD08;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   09-JUL-2014, entry version 154.
DE   RecName: Full=3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;
DE   AltName: Full=3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type II;
DE            Short=3-beta-HSD II;
DE   AltName: Full=3-beta-HSD adrenal and gonadal type;
DE   Includes:
DE     RecName: Full=3-beta-hydroxy-Delta(5)-steroid dehydrogenase;
DE              EC=1.1.1.145;
DE     AltName: Full=3-beta-hydroxy-5-ene steroid dehydrogenase;
DE     AltName: Full=Progesterone reductase;
DE   Includes:
DE     RecName: Full=Steroid Delta-isomerase;
DE              EC=5.3.3.1;
DE     AltName: Full=Delta-5-3-ketosteroid isomerase;
GN   Name=HSD3B2; Synonyms=HSDB3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1741954; DOI=10.1089/dna.1991.10.701;
RA   Lachance Y., Luu-The V., Verreault H., Dumont M., Rheaume E.,
RA   Leblanc G., Labrie F.;
RT   "Structure of the human type II 3 beta-hydroxysteroid
RT   dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) gene: adrenal and
RT   gonadal specificity.";
RL   DNA Cell Biol. 10:701-711(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Adrenal gland;
RX   PubMed=1944309; DOI=10.1210/mend-5-8-1147;
RA   Rheaume E., Lachance Y., Zhao H.-F., Breton N., Dumont M.,
RA   de Launoit Y., Trudel C., Luu-The V., Simard J., Labrie F.;
RT   "Structure and expression of a new complementary DNA encoding the
RT   almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-
RT   isomerase in human adrenals and gonads.";
RL   Mol. Endocrinol. 5:1147-1157(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   GLN-94.
RC   TISSUE=Adrenal gland;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Small intestine;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 49-102.
RX   PubMed=7588414;
RA   Russell A.J., McCartin S., Corcao G., Burridge S.M., McBride M.W.,
RA   McNicol A.M., Hawes C.S., Mason J.I., Sutcliffe R.G.;
RT   "Variation in the expression of human 3 beta-hydroxysteroid
RT   dehydrogenase.";
RL   Endocr. Res. 21:485-494(1995).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 167-205.
RX   PubMed=1363812; DOI=10.1038/ng0792-239;
RA   Rheaume E., Simard J., Morel Y., Mebarki F., Zachmann M., Forest M.G.,
RA   New M.I., Labrie F.;
RT   "Congenital adrenal hyperplasia due to point mutations in the type II
RT   3 beta-hydroxysteroid dehydrogenase gene.";
RL   Nat. Genet. 1:239-245(1992).
RN   [10]
RP   POSSIBLE INVOLVEMENT IN INSULIN-RESISTANT POLYCYSTIC OVARY SYNDROME.
RX   PubMed=14764797; DOI=10.1210/jc.2003-030934;
RA   Carbunaru G., Prasad P., Scoccia B., Shea P., Hopwood N., Ziai F.,
RA   Chang Y.T., Myers S.E., Mason J.I., Pang S.;
RT   "The hormonal phenotype of nonclassic 3 beta-hydroxysteroid
RT   dehydrogenase (HSD3B) deficiency in hyperandrogenic females is
RT   associated with insulin-resistant polycystic ovary syndrome and is not
RT   a variant of inherited HSD3B2 deficiency.";
RL   J. Clin. Endocrinol. Metab. 89:783-794(2004).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [12]
RP   VARIANTS AH2 LYS-142; PRO-245 AND ASN-253.
RX   PubMed=8316254; DOI=10.1210/me.7.5.716;
RA   Simard J., Rheaume E., Sanchez R., Laflamme N., de Launoit Y.,
RA   Luu-The V., van Seters A.P., Gordon R.D., Bettendorf M., Heinrich U.,
RA   Moshang T., New M.I., Labrie F.;
RT   "Molecular basis of congenital adrenal hyperplasia due to 3 beta-
RT   hydroxysteroid dehydrogenase deficiency.";
RL   Mol. Endocrinol. 7:716-728(1993).
RN   [13]
RP   VARIANTS AH2 TRP-108 AND LEU-186.
RX   PubMed=7833923; DOI=10.1093/hmg/3.9.1639;
RA   Sanchez R., Mebarki F., Rheaume E., Laflamme N., Forest M.G.,
RA   Bey-Omar F., David M., Morel Y., Labrie F., Simard J.;
RT   "Functional characterization of the novel L108W and P186L mutations
RT   detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a
RT   male pseudohermaphrodite with congenital adrenal hyperplasia.";
RL   Hum. Mol. Genet. 3:1639-1645(1994).
RN   [14]
RP   VARIANT AH2 ASP-254.
RX   PubMed=8126127; DOI=10.1210/jc.78.3.561;
RA   Sanchez R., Rheaume E., Laflamme N., Rosenfield R.L., Labrie F.,
RA   Simard J.;
RT   "Detection and functional characterization of the novel missense
RT   mutation Y254D in type II 3 beta-hydroxysteroid dehydrogenase (3 beta
RT   HSD) gene of a female patient with nonsalt-losing 3 beta HSD
RT   deficiency.";
RL   J. Clin. Endocrinol. Metab. 78:561-567(1994).
RN   [15]
RP   VARIANT AH2 ARG-129.
RX   PubMed=7962268; DOI=10.1210/jc.79.4.1012;
RA   Rheaume E., Sanchez R., Simard J., Chang Y.T., Wang J., Pang S.,
RA   Labrie F.;
RT   "Molecular basis of congenital adrenal hyperplasia in two siblings
RT   with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase
RT   deficiency.";
RL   J. Clin. Endocrinol. Metab. 79:1012-1018(1994).
RN   [16]
RP   VARIANT AH2 THR-82.
RX   PubMed=8185809; DOI=10.1677/jme.0.0120119;
RA   Mendonca B.B., Russell A.J., Vasconcelos-Leite M., Arnhold I.J.,
RA   Bloise W., Wajchenberg B.L., Nicolau W., Sutcliffe R.G., Wallace A.M.;
RT   "Mutation in 3 beta-hydroxysteroid dehydrogenase type II associated
RT   with pseudohermaphroditism in males and premature pubarche or cryptic
RT   expression in females.";
RL   J. Mol. Endocrinol. 12:119-122(1994).
RN   [17]
RP   VARIANT AH2 ARG-173.
RX   PubMed=8060486; DOI=10.1677/jme.0.0120225;
RA   Russell A.J., Wallace A.M., Forest M.G., Donaldson M.D., Edwards C.R.,
RA   Sutcliffe R.G.;
RT   "Mutation in the human gene for 3 beta-hydroxysteroid dehydrogenase
RT   type II leading to male pseudohermaphroditism without salt loss.";
RL   J. Mol. Endocrinol. 12:225-237(1994).
RN   [18]
RP   VARIANT AH2 ASP-15.
RX   PubMed=7893703; DOI=10.1021/bi00009a020;
RA   Rheaume E., Sanchez R., Mebarki F., Gagnon E., Carel J.-C.,
RA   Chaussain J.-L., Morel Y., Labrie F., Simard J.;
RT   "Identification and characterization of the G15D mutation found in a
RT   male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD)
RT   deficiency: alteration of the putative NAD-binding domain of type II 3
RT   beta-HSD.";
RL   Biochemistry 34:2893-2900(1995).
RN   [19]
RP   VARIANT AH2 PRO-205.
RX   PubMed=7633426; DOI=10.1093/hmg/4.4.745;
RA   Katsumata N., Tanae A., Yasunaga T., Horikawa R., Tanaka T., Hibi I.;
RT   "A novel missense mutation in the type II 3 beta-hydroxysteroid
RT   dehydrogenase gene in a family with classical salt-wasting congenital
RT   adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase
RT   deficiency.";
RL   Hum. Mol. Genet. 4:745-746(1995).
RN   [20]
RP   VARIANT AH2 ARG-259.
RX   PubMed=7633460; DOI=10.1093/hmg/4.5.969;
RA   Tajima T., Fujieda K., Nakae J., Shinohara N., Yoshimoto M., Baba T.,
RA   Kinoshita E., Igarashi Y., Oomura T.;
RT   "Molecular analysis of type II 3 beta-hydroxysteroid dehydrogenase
RT   gene in Japanese patients with classical 3 beta-hydroxysteroid
RT   dehydrogenase deficiency.";
RL   Hum. Mol. Genet. 4:969-971(1995).
RN   [21]
RP   VARIANT AH2 SER-100.
RX   PubMed=7608265; DOI=10.1210/jc.80.7.2127;
RA   Mebarki F., Sanchez R., Rheaume E., Laflamme N., Simard J.,
RA   Forest M.G., Bey-Omar F., David M., Labrie F., Morel Y.;
RT   "Nonsalt-losing male pseudohermaphroditism due to the novel homozygous
RT   N100S mutation in the type II 3 beta-hydroxysteroid dehydrogenase
RT   gene.";
RL   J. Clin. Endocrinol. Metab. 80:2127-2134(1995).
RN   [22]
RP   VARIANT AH2 SER-236.
RX   PubMed=9719627; DOI=10.1006/mgme.1998.2715;
RA   Nayak S., Lee P.A., Witchel S.F.;
RT   "Variants of the type II 3beta-hydroxysteroid dehydrogenase gene in
RT   children with premature pubic hair and hyperandrogenic adolescents.";
RL   Mol. Genet. Metab. 64:184-192(1998).
RN   [23]
RP   VARIANTS AH2 GLU-10; VAL-10; ASP-15; THR-82; SER-100; TRP-108;
RP   ARG-129; LYS-142; LEU-155; VAL-167; ARG-173; LEU-186; PRO-205;
RP   GLY-213; GLU-216; GLN-222; HIS-222; SER-236; PRO-245; ASN-253;
RP   ASP-254; ARG-259; MET-259 AND VAL-294.
RX   PubMed=10599696; DOI=10.1210/jc.84.12.4410;
RA   Moisan A.M., Ricketts M.L., Tardy V., Desrochers M., Mebarki F.,
RA   Chaussain J.-L., Cabrol S., Raux-Demay M.C., Forest M.G.,
RA   Sippell W.G., Peter M., Morel Y., Simard J.;
RT   "New insight into the molecular basis of 3beta-hydroxysteroid
RT   dehydrogenase deficiency: identification of eight mutations in the
RT   HSD3B2 gene in eleven patients from seven new families and comparison
RT   of the functional properties of twenty-five mutant enzymes.";
RL   J. Clin. Endocrinol. Metab. 84:4410-4425(1999).
RN   [24]
RP   VARIANTS AH2 ARG-129; GLN-222 AND MET-259.
RX   PubMed=10651755; DOI=10.1046/j.1365-2265.2000.00873.x;
RA   Marui S., Castro M., Latronico A.C., Elias L.L., Arnhold I.J.,
RA   Moreira A.C., Mendonca B.B.;
RT   "Mutations in the type II 3beta-hydroxysteroid dehydrogenase (HSD3B2)
RT   gene can cause premature pubarche in girls.";
RL   Clin. Endocrinol. (Oxf.) 52:67-75(2000).
RN   [25]
RP   VARIANT AH2 GLU-10.
RX   PubMed=10843183; DOI=10.1210/jc.85.5.1968;
RA   Alos N., Moisan A.M., Ward L., Desrochers M., Legault L., Leboeuf G.,
RA   van Vliet G., Simard J.;
RT   "A novel A10E homozygous mutation in the HSD3B2 gene causing severe
RT   salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX
RT   and 46,XY French-Canadians: evaluation of gonadal function after
RT   puberty.";
RL   J. Clin. Endocrinol. Metab. 85:1968-1974(2000).
RN   [26]
RP   VARIANTS AH2 LYS-142 AND THR-222.
RX   PubMed=12050213; DOI=10.1210/jc.87.6.2556;
RA   Pang S., Wang W., Rich B., David R., Chang Y.T., Carbunaru G.,
RA   Myers S.E., Howie A.F., Smillie K.J., Mason J.I.;
RT   "A novel nonstop mutation in the stop codon and a novel missense
RT   mutation in the type II 3-beta-hydroxysteroid dehydrogenase (3-beta-
RT   HSD) gene causing, respectively, nonclassic and classic 3-beta-HSD
RT   deficiency congenital adrenal hyperplasia.";
RL   J. Clin. Endocrinol. Metab. 87:2556-2563(2002).
RN   [27]
RP   VARIANT AH2 LEU-341, AND CHARACTERIZATION OF VARIANT AH2 LEU-341.
RX   PubMed=18252794; DOI=10.1210/jc.2007-1874;
RA   Welzel M., Wustemann N., Simic-Schleicher G., Dorr H.G., Schulze E.,
RA   Shaikh G., Clayton P., Grotzinger J., Holterhus P.M., Riepe F.G.;
RT   "Carboxyl-terminal mutations in 3beta-hydroxysteroid dehydrogenase
RT   type II cause severe salt-wasting congenital adrenal hyperplasia.";
RL   J. Clin. Endocrinol. Metab. 93:1418-1425(2008).
RN   [28]
RP   VARIANT AH2 PRO-82.
RX   PubMed=22579964; DOI=10.1016/j.gene.2012.04.080;
RA   Rabbani B., Mahdieh N., Haghi Ashtiani M.T., Setoodeh A., Rabbani A.;
RT   "In silico structural, functional and pathogenicity evaluation of a
RT   novel mutation: an overview of HSD3B2 gene mutations.";
RL   Gene 503:215-221(2012).
CC   -!- FUNCTION: 3-beta-HSD is a bifunctional enzyme, that catalyzes the
CC       oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and
CC       the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic
CC       system plays a crucial role in the biosynthesis of all classes of
CC       hormonal steroids.
CC   -!- CATALYTIC ACTIVITY: A 3-beta-hydroxy-Delta(5)-steroid + NAD(+) = a
CC       3-oxo-Delta(5)-steroid + NADH.
CC   -!- CATALYTIC ACTIVITY: A 3-oxo-Delta(5)-steroid = a 3-oxo-Delta(4)-
CC       steroid.
CC   -!- PATHWAY: Lipid metabolism; steroid biosynthesis.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Single-pass
CC       membrane protein. Mitochondrion membrane; Single-pass membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P26439-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P26439-2; Sequence=VSP_037399, VSP_037400;
CC   -!- TISSUE SPECIFICITY: Expressed in adrenal gland, testis and ovary.
CC   -!- DISEASE: Adrenal hyperplasia 2 (AH2) [MIM:201810]: A form of
CC       congenital adrenal hyperplasia, a common recessive disease due to
CC       defective synthesis of cortisol. Congenital adrenal hyperplasia is
CC       characterized by androgen excess leading to ambiguous genitalia in
CC       affected females, rapid somatic growth during childhood in both
CC       sexes with premature closure of the epiphyses and short adult
CC       stature. Four clinical types: 'salt wasting' (SW, the most severe
CC       type), 'simple virilizing' (SV, less severely affected patients),
CC       with normal aldosterone biosynthesis, 'non-classic form' or late-
CC       onset (NC or LOAH)and 'cryptic' (asymptomatic). In AH2,
CC       virilization is much less marked or does not occur. AH2 is
CC       frequently lethal in early life. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Mild HSD3B2 deficiency in hyperandrogenic females is
CC       associated with characteristic traits of polycystic ovary
CC       syndrome, such as insulin resistance and luteinizing hormone
CC       hypersecretion.
CC   -!- SIMILARITY: Belongs to the 3-beta-HSD family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC60600.1; Type=Frameshift; Positions=186; Note=The frameshift is caused by a single nucleotide insertion which is found in AH2;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M77144; AAA36014.1; -; Genomic_DNA.
DR   EMBL; M67466; AAA36016.1; -; mRNA.
DR   EMBL; CR627415; CAH10504.1; -; mRNA.
DR   EMBL; AK222997; BAD96717.1; -; mRNA.
DR   EMBL; AL359553; CAC19799.1; -; Genomic_DNA.
DR   EMBL; CH471122; EAW56700.1; -; Genomic_DNA.
DR   EMBL; BC038419; AAH38419.1; -; mRNA.
DR   EMBL; BC131488; AAI31489.1; -; mRNA.
DR   EMBL; S80140; AAD14329.1; -; Genomic_DNA.
DR   EMBL; S60309; AAC60599.1; -; Genomic_DNA.
DR   EMBL; S60310; AAC60600.1; ALT_FRAME; Genomic_DNA.
DR   CCDS; CCDS902.1; -. [P26439-1]
DR   PIR; A39488; DEHUH2.
DR   RefSeq; NP_000189.1; NM_000198.3. [P26439-1]
DR   RefSeq; NP_001159592.1; NM_001166120.1. [P26439-1]
DR   UniGene; Hs.654399; -.
DR   ProteinModelPortal; P26439; -.
DR   SMR; P26439; 6-158.
DR   BioGrid; 109517; 1.
DR   STRING; 9606.ENSP00000358424; -.
DR   BindingDB; P26439; -.
DR   ChEMBL; CHEMBL3670; -.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB01108; Trilostane.
DR   PhosphoSite; P26439; -.
DR   DMDM; 112770; -.
DR   PaxDb; P26439; -.
DR   PRIDE; P26439; -.
DR   DNASU; 3284; -.
DR   Ensembl; ENST00000369416; ENSP00000358424; ENSG00000203859. [P26439-1]
DR   Ensembl; ENST00000543831; ENSP00000445122; ENSG00000203859. [P26439-1]
DR   GeneID; 3284; -.
DR   KEGG; hsa:3284; -.
DR   UCSC; uc001ehs.3; human. [P26439-1]
DR   UCSC; uc001ehu.3; human. [P26439-2]
DR   CTD; 3284; -.
DR   GeneCards; GC01P119957; -.
DR   HGNC; HGNC:5218; HSD3B2.
DR   MIM; 201810; phenotype.
DR   MIM; 613890; gene.
DR   neXtProt; NX_P26439; -.
DR   Orphanet; 90791; Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency.
DR   Orphanet; 3185; Polycystic ovary syndrome.
DR   PharmGKB; PA29487; -.
DR   eggNOG; COG0451; -.
DR   HOVERGEN; HBG000014; -.
DR   InParanoid; P26439; -.
DR   KO; K00070; -.
DR   OMA; TTEWLAS; -.
DR   PhylomeDB; P26439; -.
DR   TreeFam; TF343138; -.
DR   BioCyc; MetaCyc:HS10943-MONOMER; -.
DR   BRENDA; 1.1.1.145; 2681.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_15493; Steroid hormones.
DR   UniPathway; UPA00062; -.
DR   GeneWiki; HSD3B2; -.
DR   GenomeRNAi; 3284; -.
DR   NextBio; 13035; -.
DR   PRO; PR:P26439; -.
DR   ArrayExpress; P26439; -.
DR   Bgee; P26439; -.
DR   CleanEx; HS_HSD3B2; -.
DR   Genevestigator; P26439; -.
DR   GO; GO:0005783; C:endoplasmic reticulum; NAS:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; ISS:UniProtKB.
DR   GO; GO:0005758; C:mitochondrial intermembrane space; ISS:UniProtKB.
DR   GO; GO:0031966; C:mitochondrial membrane; NAS:UniProtKB.
DR   GO; GO:0030868; C:smooth endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0003854; F:3-beta-hydroxy-delta5-steroid dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0004769; F:steroid delta-isomerase activity; IDA:UniProtKB.
DR   GO; GO:0006702; P:androgen biosynthetic process; TAS:Reactome.
DR   GO; GO:0006704; P:glucocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0006705; P:mineralocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0006694; P:steroid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0008202; P:steroid metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.50.720; -; 2.
DR   InterPro; IPR002225; 3Beta_OHSteriod_DH/Estase.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   Pfam; PF01073; 3Beta_HSD; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome;
KW   Congenital adrenal hyperplasia; Disease mutation;
KW   Endoplasmic reticulum; Isomerase; Membrane; Mitochondrion;
KW   Multifunctional enzyme; NAD; Oxidoreductase; Polymorphism;
KW   Reference proteome; Steroidogenesis; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    372       3 beta-hydroxysteroid dehydrogenase/Delta
FT                                5-->4-isomerase type 2.
FT                                /FTId=PRO_0000087775.
FT   TRANSMEM    287    307       Helical; (Potential).
FT   ACT_SITE    154    154       Proton acceptor (By similarity).
FT   BINDING     158    158       NAD (By similarity).
FT   VAR_SEQ     103    222       GTQLLLEACVQASVPVFIYTSSIEVAGPNSYKEIIQNGHEE
FT                                EPLENTWPTPYPYSKKLAEKAVLAANGWNLKNGDTLYTCAL
FT                                RPTYIYGEGGPFLSASINEALNNNGILSSVGKFSTVNP ->
FT                                ELQNKIKLTVLEGDILDEPFLKRACQDVSVVIHTACIIDVF
FT                                GVTHRQSIMNVNVKGRVAWGGDKARWGNEDQKEGQEGKRSL
FT                                SIEHLLCSGPSDFADHYQLGELKAAIFSFIDEKTRTEQ
FT                                (in isoform 2).
FT                                /FTId=VSP_037399.
FT   VAR_SEQ     223    372       Missing (in isoform 2).
FT                                /FTId=VSP_037400.
FT   VARIANT      10     10       A -> E (in AH2; activity abolished;
FT                                dbSNP:rs28934880).
FT                                /FTId=VAR_010517.
FT   VARIANT      10     10       A -> V (in AH2; nonsalt-wasting form).
FT                                /FTId=VAR_010518.
FT   VARIANT      15     15       G -> D (in AH2; activity abolished).
FT                                /FTId=VAR_010519.
FT   VARIANT      74     74       D -> N (in dbSNP:rs4986954).
FT                                /FTId=VAR_048099.
FT   VARIANT      82     82       A -> P (in AH2).
FT                                /FTId=VAR_070028.
FT   VARIANT      82     82       A -> T (in AH2).
FT                                /FTId=VAR_010520.
FT   VARIANT      94     94       E -> Q (in dbSNP:rs6211).
FT                                /FTId=VAR_014818.
FT   VARIANT     100    100       N -> S (in AH2; nonsalt-wasting form).
FT                                /FTId=VAR_010521.
FT   VARIANT     108    108       L -> W (in AH2; activity abolished).
FT                                /FTId=VAR_010522.
FT   VARIANT     129    129       G -> R (in AH2; nonsalt-wasting form).
FT                                /FTId=VAR_010523.
FT   VARIANT     142    142       E -> K (in AH2; activity abolished).
FT                                /FTId=VAR_000006.
FT   VARIANT     155    155       P -> L (in AH2; nonsalt-wasting form).
FT                                /FTId=VAR_010524.
FT   VARIANT     167    167       A -> V (in AH2; late onset; almost normal
FT                                activity; dbSNP:rs35486059).
FT                                /FTId=VAR_010525.
FT   VARIANT     173    173       L -> R (in AH2; nonsalt-wasting form).
FT                                /FTId=VAR_010526.
FT   VARIANT     186    186       P -> L (in AH2; activity abolished).
FT                                /FTId=VAR_010527.
FT   VARIANT     205    205       L -> P (in AH2).
FT                                /FTId=VAR_000007.
FT   VARIANT     213    213       S -> G (in AH2; late onset; partial loss
FT                                of activity).
FT                                /FTId=VAR_010528.
FT   VARIANT     216    216       K -> E (in AH2; late onset; partial loss
FT                                of activity).
FT                                /FTId=VAR_010529.
FT   VARIANT     222    222       P -> H (in AH2; nonsalt-wasting form;
FT                                activity abolished).
FT                                /FTId=VAR_010530.
FT   VARIANT     222    222       P -> Q (in AH2; activity abolished).
FT                                /FTId=VAR_010531.
FT   VARIANT     222    222       P -> T (in AH2).
FT                                /FTId=VAR_015411.
FT   VARIANT     231    238       Missing (in AH2; activity abolished).
FT                                /FTId=VAR_010532.
FT   VARIANT     236    236       L -> S (in AH2; mild; 100% of activity;
FT                                dbSNP:rs35887327).
FT                                /FTId=VAR_010533.
FT   VARIANT     245    245       A -> P (in AH2; loss of 88% of activity).
FT                                /FTId=VAR_000008.
FT   VARIANT     253    253       Y -> N (in AH2; activity abolished).
FT                                /FTId=VAR_000009.
FT   VARIANT     254    254       Y -> D (in AH2; activity abolished).
FT                                /FTId=VAR_000010.
FT   VARIANT     259    259       T -> M (in AH2; activity abolished).
FT                                /FTId=VAR_010534.
FT   VARIANT     259    259       T -> R (in AH2; activity abolished).
FT                                /FTId=VAR_000011.
FT   VARIANT     294    294       G -> V (in AH2; nonsalt-wasting form;
FT                                activity abolished).
FT                                /FTId=VAR_010535.
FT   VARIANT     341    341       P -> L (in AH2; strongly reduced
FT                                activity).
FT                                /FTId=VAR_065665.
FT   CONFLICT     52     53       RT -> KI (in Ref. 8; AAD14329).
FT   CONFLICT     92     94       HRE -> RRQ (in Ref. 8; AAD14329).
FT   CONFLICT    232    232       H -> L (in Ref. 4; BAD96717).
SQ   SEQUENCE   372 AA;  42052 MW;  8E0D933488988451 CRC64;
     MGWSCLVTGA GGLLGQRIVR LLVEEKELKE IRALDKAFRP ELREEFSKLQ NRTKLTVLEG
     DILDEPFLKR ACQDVSVVIH TACIIDVFGV THRESIMNVN VKGTQLLLEA CVQASVPVFI
     YTSSIEVAGP NSYKEIIQNG HEEEPLENTW PTPYPYSKKL AEKAVLAANG WNLKNGDTLY
     TCALRPTYIY GEGGPFLSAS INEALNNNGI LSSVGKFSTV NPVYVGNVAW AHILALRALR
     DPKKAPSVRG QFYYISDDTP HQSYDNLNYI LSKEFGLRLD SRWSLPLTLM YWIGFLLEVV
     SFLLSPIYSY QPPFNRHTVT LSNSVFTFSY KKAQRDLAYK PLYSWEEAKQ KTVEWVGSLV
     DRHKETLKSK TQ
//
ID   3BP2_HUMAN              Reviewed;         561 AA.
AC   P78314; A6NNC2; B2R5R6; B4DT04; D3DVR0; D6R919; O00500; O15373;
AC   P78315;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   09-JUL-2014, entry version 131.
DE   RecName: Full=SH3 domain-binding protein 2;
DE            Short=3BP-2;
GN   Name=SH3BP2; Synonyms=3BP2; ORFNames=RES4-23;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Tonsil;
RA   Gokemeijer J., Deligiannidis K.E., Ligris K., Ernst T.J.;
RT   "3BP2 binds to phosphatidylinositols; linking the hemopoietic tyrosine
RT   kinase c-FES to the cytoplasmic membrane in a phosphorylation
RT   dependent mechanism.";
RL   Blood 88:473A-473A(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9299232; DOI=10.1006/geno.1997.4849;
RA   Bell S.M., Shaw M., Jou Y.-S., Myers R.M., Knowles M.A.;
RT   "Identification and characterization of the human homologue of SH3BP2,
RT   an SH3 binding domain protein within a common region of deletion at
RT   4p16.3 involved in bladder cancer.";
RL   Genomics 44:163-170(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=9734812; DOI=10.1093/dnares/5.3.177;
RA   Hadano S., Ishida Y., Ikeda J.-E.;
RT   "The primary structure and genomic organization of five novel
RT   transcripts located close to the Huntington's disease gene on human
RT   chromosome 4p16.3.";
RL   DNA Res. 5:177-186(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cervix;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-278, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   STRUCTURE BY NMR OF 444-558.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the SH2 domain of human SH3BP2 protein.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [11]
RP   VARIANTS CRBM GLN-415; PRO-415; ARG-418; HIS-418; LEU-418; ARG-420 AND
RP   GLU-420.
RX   PubMed=11381256; DOI=10.1038/88832;
RA   Ueki Y., Tiziani V., Santanna C., Fukai N., Maulik C., Garfinkle J.,
RA   Ninomiya C., doAmaral C., Peters H., Habal M., Rhee-Morris L.,
RA   Doss J.B., Kreiborg S., Olsen B.R., Reichenberger E.;
RT   "Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause
RT   cherubism.";
RL   Nat. Genet. 28:125-126(2001).
RN   [12]
RP   VARIANT CRBM ARG-420.
RX   PubMed=12900899; DOI=10.1002/ajmg.a.20226;
RA   Lo B., Faiyaz-Ul-Haque M., Kennedy S., Aviv R., Tsui L.-C.,
RA   Teebi A.S.;
RT   "Novel mutation in the gene encoding c-Abl-binding protein SH3BP2
RT   causes cherubism.";
RL   Am. J. Med. Genet. A 121:37-40(2003).
RN   [13]
RP   VARIANT CRBM ARG-418.
RX   PubMed=14577811; DOI=10.1597/1545-1569(2003)040<0632:AMMITS>2.0.CO;2;
RA   Imai Y., Kanno K., Moriya T., Kayano S., Seino H., Matsubara Y.,
RA   Yamada A.;
RT   "A missense mutation in the SH3BP2 gene on chromosome 4p16.3 found in
RT   a case of nonfamilial cherubism.";
RL   Cleft Palate Craniofac. J. 40:632-638(2003).
CC   -!- FUNCTION: Binds differentially to the SH3 domains of certain
CC       proteins of signal transduction pathways. Binds to
CC       phosphatidylinositols; linking the hemopoietic tyrosine kinase fes
CC       to the cytoplasmic membrane in a phosphorylation dependent
CC       mechanism.
CC   -!- INTERACTION:
CC       Q9UJU6:DBNL; NbExp=7; IntAct=EBI-727062, EBI-751783;
CC       P10721:KIT; NbExp=3; IntAct=EBI-727062, EBI-1379503;
CC       Q96B97:SH3KBP1; NbExp=8; IntAct=EBI-727062, EBI-346595;
CC       Q9H2K2:TNKS2; NbExp=5; IntAct=EBI-727062, EBI-4398527;
CC       P15498:VAV1; NbExp=8; IntAct=EBI-727062, EBI-625518;
CC       P52735:VAV2; NbExp=4; IntAct=EBI-727062, EBI-297549;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long;
CC         IsoId=P78314-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P78314-2; Sequence=VSP_004085, VSP_004086;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay;
CC       Name=3;
CC         IsoId=P78314-3; Sequence=VSP_043636;
CC         Note=No experimental confirmation available;
CC       Name=4;
CC         IsoId=P78314-4; Sequence=VSP_055046;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Expressed in a variety of tissues including
CC       lung, liver, skeletal muscle, kidney and pancreas.
CC   -!- PTM: Phosphorylated. Phosphorylation at Tyr-448 may stimulate the
CC       activity of the LYN kinase (By similarity).
CC   -!- DISEASE: Cherubism (CRBM) [MIM:118400]: An autosomal dominant
CC       syndrome characterized by excessive bone degradation of the upper
CC       and lower jaws, which often begins around three years of age. It
CC       is followed by development of fibrous tissue masses, which causes
CC       a characteristic facial swelling. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 1 PH domain.
CC   -!- SIMILARITY: Contains 1 SH2 domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF000936; AAB59973.1; -; mRNA.
DR   EMBL; U56386; AAB72034.1; -; mRNA.
DR   EMBL; AB000462; BAA19119.1; -; mRNA.
DR   EMBL; AB000463; BAA19120.1; -; mRNA.
DR   EMBL; AK299996; BAG61816.1; -; mRNA.
DR   EMBL; AK312286; BAG35213.1; -; mRNA.
DR   EMBL; AL121750; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471131; EAW82509.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82510.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82511.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82512.1; -; Genomic_DNA.
DR   EMBL; BC022996; AAH22996.1; -; mRNA.
DR   CCDS; CCDS33944.1; -. [P78314-1]
DR   CCDS; CCDS54715.1; -. [P78314-3]
DR   RefSeq; NP_001116153.1; NM_001122681.1. [P78314-1]
DR   RefSeq; NP_001139327.1; NM_001145855.1. [P78314-3]
DR   RefSeq; NP_001139328.1; NM_001145856.1.
DR   RefSeq; NP_003014.3; NM_003023.4. [P78314-1]
DR   RefSeq; XP_005248056.1; XM_005247999.2. [P78314-1]
DR   UniGene; Hs.167679; -.
DR   PDB; 2CR4; NMR; -; A=446-558.
DR   PDB; 3TWR; X-ray; 1.55 A; E/F/G/H=410-425.
DR   PDBsum; 2CR4; -.
DR   PDBsum; 3TWR; -.
DR   ProteinModelPortal; P78314; -.
DR   SMR; P78314; 27-122, 444-560.
DR   BioGrid; 112350; 17.
DR   IntAct; P78314; 19.
DR   MINT; MINT-254189; -.
DR   STRING; 9606.ENSP00000348685; -.
DR   PhosphoSite; P78314; -.
DR   DMDM; 3023207; -.
DR   MaxQB; P78314; -.
DR   PaxDb; P78314; -.
DR   PRIDE; P78314; -.
DR   Ensembl; ENST00000356331; ENSP00000348685; ENSG00000087266. [P78314-1]
DR   Ensembl; ENST00000389838; ENSP00000374488; ENSG00000087266. [P78314-2]
DR   Ensembl; ENST00000435136; ENSP00000403231; ENSG00000087266. [P78314-1]
DR   Ensembl; ENST00000442312; ENSP00000388152; ENSG00000087266. [P78314-3]
DR   Ensembl; ENST00000452765; ENSP00000409746; ENSG00000087266. [P78314-1]
DR   Ensembl; ENST00000503393; ENSP00000422168; ENSG00000087266.
DR   Ensembl; ENST00000511747; ENSP00000424846; ENSG00000087266. [P78314-1]
DR   Ensembl; ENST00000513020; ENSP00000424072; ENSG00000087266. [P78314-2]
DR   Ensembl; ENST00000515737; ENSP00000422605; ENSG00000087266. [P78314-2]
DR   GeneID; 6452; -.
DR   KEGG; hsa:6452; -.
DR   UCSC; uc003gfi.4; human. [P78314-1]
DR   UCSC; uc011bvp.2; human. [P78314-3]
DR   CTD; 6452; -.
DR   GeneCards; GC04P002831; -.
DR   GeneReviews; SH3BP2; -.
DR   HGNC; HGNC:10825; SH3BP2.
DR   HPA; HPA036790; -.
DR   MIM; 118400; phenotype.
DR   MIM; 602104; gene.
DR   neXtProt; NX_P78314; -.
DR   Orphanet; 184; Cherubism.
DR   PharmGKB; PA35733; -.
DR   eggNOG; NOG42035; -.
DR   HOVERGEN; HBG000016; -.
DR   InParanoid; P78314; -.
DR   KO; K07984; -.
DR   OMA; DFPRRER; -.
DR   OrthoDB; EOG7DRJ2X; -.
DR   PhylomeDB; P78314; -.
DR   SignaLink; P78314; -.
DR   ChiTaRS; SH3BP2; human.
DR   EvolutionaryTrace; P78314; -.
DR   GenomeRNAi; 6452; -.
DR   NextBio; 25079; -.
DR   PRO; PR:P78314; -.
DR   ArrayExpress; P78314; -.
DR   Bgee; P78314; -.
DR   CleanEx; HS_SH3BP2; -.
DR   Genevestigator; P78314; -.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0005070; F:SH3/SH2 adaptor activity; TAS:ProtInc.
DR   GO; GO:0009967; P:positive regulation of signal transduction; TAS:GOC.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011993; PH_like_dom.
DR   InterPro; IPR001849; Pleckstrin_homology.
DR   InterPro; IPR000980; SH2.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00017; SH2; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Disease mutation; Phosphoprotein; Reference proteome; SH2 domain;
KW   SH3-binding.
FT   CHAIN         1    561       SH3 domain-binding protein 2.
FT                                /FTId=PRO_0000064365.
FT   DOMAIN       26    130       PH.
FT   DOMAIN      457    555       SH2.
FT   MOTIF       201    210       SH3-binding.
FT   COMPBIAS    205    212       Poly-Pro.
FT   COMPBIAS    236    240       Poly-Pro.
FT   MOD_RES     174    174       Phosphotyrosine; by SYK (By similarity).
FT   MOD_RES     183    183       Phosphotyrosine; by SYK (By similarity).
FT   MOD_RES     278    278       Phosphoserine.
FT   MOD_RES     448    448       Phosphotyrosine; by SYK (By similarity).
FT   VAR_SEQ       1      1       M -> MASLGPRTPAPSRSRGRRAMCWVSTISFM (in
FT                                isoform 3).
FT                                /FTId=VSP_043636.
FT   VAR_SEQ       1      1       M -> MAGSGPRPRSWGRREAGARDEAAAAGGRGPGPCRCS
FT                                QGRRAWIAPGKPAMPAAWTPFM (in isoform 4).
FT                                /FTId=VSP_055046.
FT   VAR_SEQ      81     97       VMRAAEETTSNNVFPFK -> QPRPQPAQALSQTEAGP
FT                                (in isoform 2).
FT                                /FTId=VSP_004085.
FT   VAR_SEQ      98    561       Missing (in isoform 2).
FT                                /FTId=VSP_004086.
FT   VARIANT     415    415       R -> P (in CRBM).
FT                                /FTId=VAR_013257.
FT   VARIANT     415    415       R -> Q (in CRBM).
FT                                /FTId=VAR_013258.
FT   VARIANT     418    418       P -> H (in CRBM).
FT                                /FTId=VAR_013259.
FT   VARIANT     418    418       P -> L (in CRBM).
FT                                /FTId=VAR_013260.
FT   VARIANT     418    418       P -> R (in CRBM).
FT                                /FTId=VAR_013261.
FT   VARIANT     420    420       G -> E (in CRBM; dbSNP:rs28938171).
FT                                /FTId=VAR_013262.
FT   VARIANT     420    420       G -> R (in CRBM; dbSNP:rs28938170).
FT                                /FTId=VAR_013263.
FT   CONFLICT     27     27       V -> L (in Ref. 3; AAB59973).
FT   CONFLICT    224    224       H -> N (in Ref. 3; AAB59973).
FT   CONFLICT    249    249       L -> R (in Ref. 3; AAB59973).
FT   CONFLICT    251    251       A -> P (in Ref. 3; AAB59973).
FT   TURN        455    457
FT   HELIX       464    474
FT   STRAND      485    489
FT   STRAND      496    501
FT   TURN        503    505
FT   STRAND      506    508
FT   STRAND      514    516
FT   STRAND      519    525
FT   STRAND      527    530
FT   HELIX       531    538
FT   STRAND      544    548
FT   STRAND      553    556
SQ   SEQUENCE   561 AA;  62244 MW;  69E6846A4F6D8F15 CRC64;
     MAAEEMHWPV PMKAIGAQNL LTMPGGVAKA GYLHKKGGTQ LQLLKWPLRF VIIHKRCVYY
     FKSSTSASPQ GAFSLSGYNR VMRAAEETTS NNVFPFKIIH ISKKHRTWFF SASSEEERKS
     WMALLRREIG HFHEKKDLPL DTSDSSSDTD SFYGAVERPV DISLSPYPTD NEDYEHDDED
     DSYLEPDSPE PGRLEDALMH PPAYPPPPVP TPRKPAFSDM PRAHSFTSKG PGPLLPPPPP
     KHGLPDVGLA AEDSKRDPLC PRRAEPCPRV PATPRRMSDP PLSTMPTAPG LRKPPCFRES
     ASPSPEPWTP GHGACSTSSA AIMATATSRN CDKLKSFHLS PRGPPTSEPP PVPANKPKFL
     KIAEEDPPRE AAMPGLFVPP VAPRPPALKL PVPEAMARPA VLPRPEKPQL PHLQRSPPDG
     QSFRSFSFEK PRQPSQADTG GDDSDEDYEK VPLPNSVFVN TTESCEVERL FKATSPRGEP
     QDGLYCIRNS STKSGKVLVV WDETSNKVRN YRIFEKDSKF YLEGEVLFVS VGSMVEHYHT
     HVLPSHQSLL LRHPYGYTGP R
//
ID   3MG_HUMAN               Reviewed;         298 AA.
AC   P29372; G5E9E2; Q13770; Q15275; Q15961; Q5J9I4; Q96BZ6; Q96S33;
AC   Q9NNX5;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 3.
DT   09-JUL-2014, entry version 159.
DE   RecName: Full=DNA-3-methyladenine glycosylase;
DE            EC=3.2.2.21;
DE   AltName: Full=3-alkyladenine DNA glycosylase;
DE   AltName: Full=3-methyladenine DNA glycosidase;
DE   AltName: Full=ADPG;
DE   AltName: Full=N-methylpurine-DNA glycosylase;
DE   Flags: Precursor;
GN   Name=MPG; Synonyms=AAG, ANPG, MID1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=1924375; DOI=10.1073/pnas.88.20.9127;
RA   Samson L., Derfler B., Boosalis M., Call K.;
RT   "Cloning and characterization of a 3-methyladenine DNA glycosylase
RT   cDNA from human cells whose gene maps to chromosome 16.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9127-9131(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=8475094; DOI=10.1073/pnas.90.8.3437;
RA   Vickers M.A., Vyas P., Harris P.C., Simmons D.L., Higgs D.R.;
RT   "Structure of the human 3-methyladenine DNA glycosylase gene and
RT   localization close to the 16p telomere.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:3437-3441(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Kim J.W.;
RT   "Identification of a human cell proliferation gene 11.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-22; HIS-71;
RP   VAL-258 AND SER-298.
RG   NIEHS SNPs program;
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11157797; DOI=10.1093/hmg/10.4.339;
RA   Daniels R.J., Peden J.F., Lloyd C., Horsley S.W., Clark K.,
RA   Tufarelli C., Kearney L., Buckle V.J., Doggett N.A., Flint J.,
RA   Higgs D.R.;
RT   "Sequence, structure and pathology of the fully annotated terminal 2
RT   Mb of the short arm of human chromosome 16.";
RL   Hum. Mol. Genet. 10:339-352(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 28-298 (ISOFORMS 1/2).
RX   PubMed=1874728;
RA   Chakravarti D., Ibeanu G.C., Tano K., Mitra S.;
RT   "Cloning and expression in Escherichia coli of a human cDNA encoding
RT   the DNA repair protein N-methylpurine-DNA glycosylase.";
RL   J. Biol. Chem. 266:15710-15715(1991).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 69-298 (ISOFORMS 1/2).
RX   PubMed=1645538; DOI=10.1016/0006-291X(91)90408-Y;
RA   O'Connor T.R., Laval J.;
RT   "Human cDNA expressing a functional DNA glycosylase excising 3-
RT   methyladenine and 7-methylguanine.";
RL   Biochem. Biophys. Res. Commun. 176:1170-1177(1991).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 230-298 (ISOFORMS 1/2).
RX   PubMed=8318735; DOI=10.1007/BF00357090;
RA   Kielman M.F., Smits R., Devi T.S., Fodde R., Bernini L.F.;
RT   "Homology of a 130-kb region enclosing the alpha-globin gene cluster,
RT   the alpha-locus controlling region, and two non-globin genes in human
RT   and mouse.";
RL   Mamm. Genome 4:314-323(1993).
RN   [12]
RP   INTERACTION WITH MBD1.
RX   PubMed=14555760; DOI=10.1073/pnas.2131819100;
RA   Watanabe S., Ichimura T., Fujita N., Tsuruzoe S., Ohki I.,
RA   Shirakawa M., Kawasuji M., Nakao M.;
RT   "Methylated DNA-binding domain 1 and methylpurine-DNA glycosylase link
RT   transcriptional repression and DNA repair in chromatin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:12859-12864(2003).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-78, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   SUBCELLULAR LOCATION, INTERACTION WITH SSBP1, AND ENZYME REGULATION.
RX   PubMed=23290262; DOI=10.1016/j.dnarep.2012.11.009;
RA   van Loon B., Samson L.D.;
RT   "Alkyladenine DNA glycosylase (AAG) localizes to mitochondria and
RT   interacts with mitochondrial single-stranded binding protein
RT   (mtSSB).";
RL   DNA Repair 12:177-187(2013).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 80-199.
RX   PubMed=9790531; DOI=10.1016/S0092-8674(00)81755-9;
RA   Lau A.Y., Scharer O.D., Samson L., Verdine G.L., Ellenberger T.;
RT   "Crystal structure of a human alkylbase-DNA repair enzyme complexed to
RT   DNA: mechanisms for nucleotide flipping and base excision.";
RL   Cell 95:249-258(1998).
CC   -!- FUNCTION: Hydrolysis of the deoxyribose N-glycosidic bond to
CC       excise 3-methyladenine, and 7-methylguanine from the damaged DNA
CC       polymer formed by alkylation lesions.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of alkylated DNA, releasing 3-
CC       methyladenine, 3-methylguanine, 7-methylguanine and 7-
CC       methyladenine.
CC   -!- ENZYME REGULATION: Binding to SSBP1 in mitochondria inhibits
CC       glycosylase activity in the context of a single-stranded DNA
CC       (ssDNA), but not a double-stranded DNA (dsDNA) substrates.
CC   -!- SUBUNIT: Binds MBD1. Binds SSBP1.
CC   -!- INTERACTION:
CC       P04156:PRNP; NbExp=4; IntAct=EBI-1043398, EBI-977302;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Mitochondrion matrix,
CC       mitochondrion nucleoid. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=Experimental confirmation may be lacking for some
CC         isoforms;
CC       Name=1;
CC         IsoId=P29372-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P29372-2; Sequence=VSP_003249, VSP_035485;
CC       Name=3;
CC         IsoId=P29372-4; Sequence=VSP_003249;
CC       Name=4;
CC         IsoId=P29372-5; Sequence=VSP_046678;
CC         Note=Gene prediction based on EST data;
CC   -!- SIMILARITY: Belongs to the DNA glycosylase MPG family.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/mpg/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M74905; AAA58627.1; -; mRNA.
DR   EMBL; L10752; AAF77073.1; -; mRNA.
DR   EMBL; AY258284; AAP82229.1; -; mRNA.
DR   EMBL; AY305873; AAQ95215.1; -; mRNA.
DR   EMBL; AF499437; AAM14628.1; -; Genomic_DNA.
DR   EMBL; AE006462; AAK61213.1; -; Genomic_DNA.
DR   EMBL; Z69720; CAA93540.1; -; Genomic_DNA.
DR   EMBL; Z69720; CAI95610.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85871.1; -; Genomic_DNA.
DR   EMBL; BC014991; AAH14991.1; -; mRNA.
DR   EMBL; S51033; AAB19537.1; -; mRNA.
DR   EMBL; X56528; CAA39875.1; -; mRNA.
DR   EMBL; M71215; AAA58369.1; -; mRNA.
DR   EMBL; M99626; AAB46421.1; -; mRNA.
DR   CCDS; CCDS32345.1; -. [P29372-4]
DR   CCDS; CCDS32346.1; -. [P29372-1]
DR   CCDS; CCDS42087.1; -. [P29372-5]
DR   PIR; A40798; A40798.
DR   PIR; A41230; A41230.
DR   PIR; A47471; A47471.
DR   PIR; JN0062; JN0062.
DR   RefSeq; NP_001015052.1; NM_001015052.2. [P29372-4]
DR   RefSeq; NP_001015054.1; NM_001015054.2. [P29372-5]
DR   RefSeq; NP_002425.2; NM_002434.3. [P29372-1]
DR   UniGene; Hs.459596; -.
DR   PDB; 1BNK; X-ray; 2.70 A; A=80-295.
DR   PDB; 1EWN; X-ray; 2.10 A; A=80-298.
DR   PDB; 1F4R; X-ray; 2.40 A; A=80-298.
DR   PDB; 1F6O; X-ray; 2.40 A; A=80-298.
DR   PDB; 3QI5; X-ray; 2.20 A; A/B=84-298.
DR   PDB; 3UBY; X-ray; 2.00 A; A/B=84-298.
DR   PDBsum; 1BNK; -.
DR   PDBsum; 1EWN; -.
DR   PDBsum; 1F4R; -.
DR   PDBsum; 1F6O; -.
DR   PDBsum; 3QI5; -.
DR   PDBsum; 3UBY; -.
DR   ProteinModelPortal; P29372; -.
DR   SMR; P29372; 82-293.
DR   BioGrid; 110490; 56.
DR   IntAct; P29372; 3.
DR   MINT; MINT-135511; -.
DR   STRING; 9606.ENSP00000219431; -.
DR   PhosphoSite; P29372; -.
DR   MaxQB; P29372; -.
DR   PaxDb; P29372; -.
DR   PRIDE; P29372; -.
DR   DNASU; 4350; -.
DR   Ensembl; ENST00000219431; ENSP00000219431; ENSG00000103152. [P29372-1]
DR   Ensembl; ENST00000356432; ENSP00000348809; ENSG00000103152. [P29372-4]
DR   Ensembl; ENST00000397817; ENSP00000380918; ENSG00000103152. [P29372-5]
DR   GeneID; 4350; -.
DR   KEGG; hsa:4350; -.
DR   UCSC; uc002cfm.4; human. [P29372-1]
DR   UCSC; uc002cfo.4; human.
DR   CTD; 4350; -.
DR   GeneCards; GC16P000127; -.
DR   HGNC; HGNC:7211; MPG.
DR   HPA; HPA006531; -.
DR   MIM; 156565; gene.
DR   neXtProt; NX_P29372; -.
DR   PharmGKB; PA30917; -.
DR   eggNOG; COG2094; -.
DR   HOGENOM; HOG000224224; -.
DR   HOVERGEN; HBG000019; -.
DR   InParanoid; P29372; -.
DR   KO; K03652; -.
DR   OMA; TIYVYPI; -.
DR   PhylomeDB; P29372; -.
DR   TreeFam; TF331768; -.
DR   Reactome; REACT_216; DNA Repair.
DR   ChiTaRS; MPG; human.
DR   EvolutionaryTrace; P29372; -.
DR   GeneWiki; MPG_(gene); -.
DR   GenomeRNAi; 4350; -.
DR   NextBio; 17110; -.
DR   PRO; PR:P29372; -.
DR   ArrayExpress; P29372; -.
DR   Bgee; P29372; -.
DR   CleanEx; HS_MID1; -.
DR   CleanEx; HS_MPG; -.
DR   Genevestigator; P29372; -.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0003684; F:damaged DNA binding; TAS:ProtInc.
DR   GO; GO:0008725; F:DNA-3-methyladenine glycosylase activity; IEA:UniProtKB-EC.
DR   GO; GO:0052822; F:DNA-3-methylguanine glycosylase activity; IEA:UniProtKB-EC.
DR   GO; GO:0052821; F:DNA-7-methyladenine glycosylase activity; IEA:UniProtKB-EC.
DR   GO; GO:0043916; F:DNA-7-methylguanine glycosylase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0006284; P:base-excision repair; TAS:Reactome.
DR   GO; GO:0006285; P:base-excision repair, AP site formation; TAS:Reactome.
DR   GO; GO:0045007; P:depurination; TAS:Reactome.
DR   GO; GO:0006307; P:DNA dealkylation involved in DNA repair; TAS:ProtInc.
DR   GO; GO:0006281; P:DNA repair; TAS:Reactome.
DR   Gene3D; 3.10.300.10; -; 1.
DR   HAMAP; MF_00527; 3MGH; 1.
DR   InterPro; IPR011034; Formyl_transferase_C-like.
DR   InterPro; IPR003180; PurDNA_glycsylse.
DR   PANTHER; PTHR10429; PTHR10429; 1.
DR   Pfam; PF02245; Pur_DNA_glyco; 1.
DR   SUPFAM; SSF50486; SSF50486; 1.
DR   TIGRFAMs; TIGR00567; 3mg; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   DNA damage; DNA repair; Hydrolase; Mitochondrion;
KW   Mitochondrion nucleoid; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transit peptide.
FT   TRANSIT       1     17       Mitochondrion (Potential).
FT   CHAIN        18    298       DNA-3-methyladenine glycosylase.
FT                                /FTId=PRO_0000100065.
FT   MOD_RES      78     78       Phosphoserine.
FT   VAR_SEQ       1     17       Missing (in isoform 4).
FT                                /FTId=VSP_046678.
FT   VAR_SEQ       1     12       MVTPALQMKKPK -> MPARSGA (in isoform 2 and
FT                                isoform 3).
FT                                /FTId=VSP_003249.
FT   VAR_SEQ     195    196       QL -> HV (in isoform 2).
FT                                /FTId=VSP_035485.
FT   VARIANT      22     22       K -> Q (in dbSNP:rs3176383).
FT                                /FTId=VAR_019138.
FT   VARIANT      64     64       P -> L (in dbSNP:rs2308315).
FT                                /FTId=VAR_014831.
FT   VARIANT      71     71       Y -> H (in dbSNP:rs2266607).
FT                                /FTId=VAR_014832.
FT   VARIANT      93     93       Q -> R (in dbSNP:rs25671).
FT                                /FTId=VAR_050096.
FT   VARIANT     120    120       R -> C (in dbSNP:rs2308313).
FT                                /FTId=VAR_014833.
FT   VARIANT     141    141       R -> Q (in dbSNP:rs2308312).
FT                                /FTId=VAR_014834.
FT   VARIANT     258    258       A -> V (in dbSNP:rs769193).
FT                                /FTId=VAR_014835.
FT   VARIANT     298    298       A -> S (in dbSNP:rs2234949).
FT                                /FTId=VAR_014836.
FT   CONFLICT     13     13       Q -> QV (in Ref. 5; AAK61213).
FT   CONFLICT     29     31       GQP -> ARA (in Ref. 9; AAB19537).
FT   CONFLICT     44     44       Q -> R (in Ref. 9; AAB19537).
FT   CONFLICT     69     71       GPY -> SKD (in Ref. 10; AAA58369/
FT                                CAA39875).
FT   CONFLICT     82     82       H -> L (in Ref. 10; AAA58369/CAA39875).
FT   CONFLICT    134    134       A -> P (in Ref. 1; AAA58627).
FT   CONFLICT    287    287       V -> E (in Ref. 10; AAA58369).
FT   HELIX        82     84
FT   HELIX        88     91
FT   HELIX        95    101
FT   TURN        102    104
FT   STRAND      106    110
FT   STRAND      116    127
FT   STRAND      129    131
FT   HELIX       138    140
FT   HELIX       145    150
FT   STRAND      155    161
FT   TURN        162    164
FT   STRAND      165    171
FT   STRAND      178    188
FT   HELIX       190    199
FT   HELIX       211    213
FT   STRAND      214    217
FT   HELIX       218    224
FT   HELIX       229    231
FT   TURN        236    238
FT   STRAND      240    245
FT   HELIX       253    255
FT   STRAND      256    259
FT   TURN        268    272
FT   STRAND      276    279
FT   TURN        290    292
SQ   SEQUENCE   298 AA;  32869 MW;  BEA8C4CB250D572B CRC64;
     MVTPALQMKK PKQFCRRMGQ KKQRPARAGQ PHSSSDAAQA PAEQPHSSSD AAQAPCPRER
     CLGPPTTPGP YRSIYFSSPK GHLTRLGLEF FDQPAVPLAR AFLGQVLVRR LPNGTELRGR
     IVETEAYLGP EDEAAHSRGG RQTPRNRGMF MKPGTLYVYI IYGMYFCMNI SSQGDGACVL
     LRALEPLEGL ETMRQLRSTL RKGTASRVLK DRELCSGPSK LCQALAINKS FDQRDLAQDE
     AVWLERGPLE PSEPAVVAAA RVGVGHAGEW ARKPLRFYVR GSPWVSVVDR VAEQDTQA
//
ID   41_HUMAN                Reviewed;         864 AA.
AC   P11171; B1ALH8; B1ALH9; D3DPM9; D3DPN0; P11176; Q14245; Q5TB35;
AC   Q5VXN8; Q8IXV9; Q9Y578; Q9Y579;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 4.
DT   09-JUL-2014, entry version 172.
DE   RecName: Full=Protein 4.1;
DE            Short=P4.1;
DE   AltName: Full=4.1R;
DE   AltName: Full=Band 4.1;
DE   AltName: Full=EPB4.1;
GN   Name=EPB41; Synonyms=E41P;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND PROTEIN SEQUENCE OF
RP   378-393.
RC   TISSUE=Reticulocyte;
RX   PubMed=3467321; DOI=10.1073/pnas.83.24.9512;
RA   Conboy J.G., Kan Y.W., Shohet S.B., Mohandas N.;
RT   "Molecular cloning of protein 4.1, a major structural element of the
RT   human erythrocyte membrane skeleton.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:9512-9516(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6).
RX   PubMed=3223413;
RA   Tang T.K., Leto T.L., Marchesi V.T., Benz E.J. Jr.;
RT   "Expression of specific isoforms of protein 4.1 in erythroid and non-
RT   erythroid tissues.";
RL   Adv. Exp. Med. Biol. 241:81-95(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6).
RX   PubMed=3375238; DOI=10.1073/pnas.85.11.3713;
RA   Tang T.K., Leto T.L., Correas I., Alonso M.A., Marchesi V.T.,
RA   Benz E.J. Jr.;
RT   "Selective expression of an erythroid-specific isoform of protein
RT   4.1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3713-3717(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=2022644;
RA   Conboy J.G., Chan J.Y.C., Chasis J.A., Kan Y.W., Mohandas N.;
RT   "Tissue- and development-specific alternative RNA splicing regulates
RT   expression of multiple isoforms of erythroid membrane protein 4.1.";
RL   J. Biol. Chem. 266:8273-8280(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Huang S.C., Wang C., Lichtenauer U., Vortmeyer A., Zhuang Z.;
RT   "Sequence of protein 4.1 from a human neuroblastoma cell line: LAN5.";
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 157-227, AND VARIANT ILE-214.
RA   Lichtenauer U., Huang S.C., Vortmeyer A., Zhuang Z.;
RT   "Valine to isoleucine polymorphism in exon 4 of human protein 4.1.";
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE OF 669-864 (ISOFORM 4), AND ALTERNATIVE SPLICING.
RX   PubMed=3194408; DOI=10.1073/pnas.85.23.9062;
RA   Conboy J.G., Chan J., Mohandas N., Kan Y.W.;
RT   "Multiple protein 4.1 isoforms produced by alternative splicing in
RT   human erythroid cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:9062-9065(1988).
RN   [11]
RP   PROTEIN SEQUENCE OF 534-541; 693-701 AND 793-794, AND PHOSPHORYLATION
RP   AT SER-540 AND SER-709.
RX   PubMed=2171679; DOI=10.1016/0167-4889(90)90095-U;
RA   Horne W.C., Prinz W.C., Tang E.K.;
RT   "Identification of two cAMP-dependent phosphorylation sites on
RT   erythrocyte protein 4.1.";
RL   Biochim. Biophys. Acta 1055:87-92(1990).
RN   [12]
RP   PROTEIN SEQUENCE OF 648-714.
RX   PubMed=3531202;
RA   Correas I., Speicher D.W., Marchesi V.T.;
RT   "Structure of the spectrin-actin binding site of erythrocyte protein
RT   4.1.";
RL   J. Biol. Chem. 261:13362-13366(1986).
RN   [13]
RP   STRUCTURE OF CARBOHYDRATES.
RX   PubMed=2808371;
RA   Inaba M., Maede Y.;
RT   "O-N-acetyl-D-glucosamine moiety on discrete peptide of multiple
RT   protein 4.1 isoforms regulated by alternative pathways.";
RL   J. Biol. Chem. 264:18149-18155(1989).
RN   [14]
RP   PHOSPHORYLATION AT TYR-660 BY EGFR.
RX   PubMed=1647028; DOI=10.1073/pnas.88.12.5222;
RA   Subrahmanyan G., Bertics P.J., Anderson R.A.;
RT   "Phosphorylation of protein 4.1 on tyrosine-418 modulates its function
RT   in vitro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5222-5226(1991).
RN   [15]
RP   INTERACTION WITH DLG1.
RX   PubMed=7937897; DOI=10.1073/pnas.91.21.9818;
RA   Lue R.A., Marfatia S.M., Branton D., Chishti A.H.;
RT   "Cloning and characterization of hdlg: the human homologue of the
RT   Drosophila discs large tumor suppressor binds to protein 4.1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:9818-9822(1994).
RN   [16]
RP   INTERACTION WITH CALMODULIN.
RX   PubMed=10692436; DOI=10.1074/jbc.275.9.6360;
RA   Nunomura W., Takakuwa Y., Parra M., Conboy J.G., Mohandas N.;
RT   "Ca(2+)-dependent and Ca(2+)-independent calmodulin binding sites in
RT   erythrocyte protein 4.1. Implications for regulation of protein 4.1
RT   interactions with transmembrane proteins.";
RL   J. Biol. Chem. 275:6360-6367(2000).
RN   [17]
RP   INTERACTION WITH CENPJ.
RX   PubMed=11003675; DOI=10.1128/MCB.20.20.7813-7825.2000;
RA   Hung L.-Y., Tang C.J., Tang T.K.;
RT   "Protein 4.1 R-135 interacts with a novel centrosomal protein (CPAP)
RT   which is associated with the gamma-tubulin complex.";
RL   Mol. Cell. Biol. 20:7813-7825(2000).
RN   [18]
RP   CHARACTERIZATION OF C-TERMINAL DOMAIN.
RX   PubMed=11432737; DOI=10.1046/j.1432-1327.2001.02276.x;
RA   Scott C., Phillips G.W., Baines A.J.;
RT   "Properties of the C-terminal domain of 4.1 proteins.";
RL   Eur. J. Biochem. 268:3709-3717(2001).
RN   [19]
RP   SUBCELLULAR LOCATION, AND ALTERNATIVE SPLICING.
RX   PubMed=12427749; DOI=10.1074/jbc.M201521200;
RA   Luque C.M., Perez-Ferreiro C.M., Perez-Gonzalez A., Englmeier L.,
RA   Koffa M.D., Correas I.;
RT   "An alternative domain containing a leucine-rich sequence regulates
RT   nuclear cytoplasmic localization of protein 4.1R.";
RL   J. Biol. Chem. 278:2686-2691(2003).
RN   [20]
RP   MUTAGENESIS OF THR-60 AND SER-712, AND PHOSPHORYLATION AT THR-60 AND
RP   SER-712.
RX   PubMed=15525677; DOI=10.1091/mbc.E04-05-0426;
RA   Huang S.-C., Liu E.S., Chan S.-H., Munagala I.D., Cho H.T.,
RA   Jagadeeswaran R., Benz E.J. Jr.;
RT   "Mitotic regulation of protein 4.1R involves phosphorylation by cdc2
RT   kinase.";
RL   Mol. Biol. Cell 16:117-127(2005).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-188; SER-191; SER-555
RP   AND SER-712, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-84; SER-85; SER-188 AND
RP   SER-712, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-149; SER-151 AND
RP   SER-152, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 210-488.
RX   PubMed=11017195; DOI=10.1038/82819;
RA   Han B.-G., Nunomura W., Takakuwa Y., Mohandas N., Jap B.K.;
RT   "Protein 4.1R core domain structure and insights into regulation of
RT   cytoskeletal organization.";
RL   Nat. Struct. Biol. 7:871-875(2000).
CC   -!- FUNCTION: Protein 4.1 is a major structural element of the
CC       erythrocyte membrane skeleton. It plays a key role in regulating
CC       membrane physical properties of mechanical stability and
CC       deformability by stabilizing spectrin-actin interaction. Recruits
CC       DLG1 to membranes.
CC   -!- SUBUNIT: Binds with a high affinity to glycophorin and with lower
CC       affinity to band III protein. Associates with the nuclear mitotic
CC       apparatus. Binds calmodulin, CENPJ and DLG1. Also found to
CC       associate with contractile apparatus and tight junctions.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton. Cytoplasm, cell
CC       cortex. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1;
CC         IsoId=P11171-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P11171-2; Sequence=VSP_000470;
CC       Name=3;
CC         IsoId=P11171-3; Sequence=VSP_000468, VSP_000471;
CC       Name=4; Synonyms=Erythroid;
CC         IsoId=P11171-4; Sequence=VSP_000468, VSP_000470, VSP_000473;
CC       Name=5; Synonyms=Non-erythroid A;
CC         IsoId=P11171-5; Sequence=VSP_000469, VSP_000470, VSP_000472;
CC       Name=6; Synonyms=Non-erythroid B;
CC         IsoId=P11171-6; Sequence=VSP_000468, VSP_000469, VSP_000470,
CC                                  VSP_000472;
CC       Name=7;
CC         IsoId=P11171-7; Sequence=VSP_000471, VSP_012872, VSP_012873;
CC   -!- PTM: Phosphorylated at multiple sites by different protein kinases
CC       and each phosphorylation event selectively modulates the protein's
CC       functions.
CC   -!- PTM: Phosphorylation on Tyr-660 reduces the ability of 4.1 to
CC       promote the assembly of the spectrin/actin/4.1 ternary complex.
CC   -!- PTM: O-glycosylated; contains N-acetylglucosamine side chains in
CC       the C-terminal domain.
CC   -!- DISEASE: Elliptocytosis 1 (EL1) [MIM:611804]: A Rhesus-linked form
CC       of hereditary elliptocytosis, a genetically heterogeneous,
CC       autosomal dominant hematologic disorder. It is characterized by
CC       variable hemolytic anemia and elliptical or oval red cell shape.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Hereditary pyropoikilocytosis (HPP) [MIM:266140]:
CC       Autosomal recessive hematologic disorder characterized by
CC       hemolytic anemia, microspherocytosis, poikilocytosis, and an
CC       unusual thermal sensitivity of red cells. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 1 FERM domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14993; AAA35795.1; -; mRNA.
DR   EMBL; J03796; AAA35793.1; -; mRNA.
DR   EMBL; J03796; AAA35794.1; -; mRNA.
DR   EMBL; M61733; AAA35797.1; -; mRNA.
DR   EMBL; AF156225; AAD42222.1; -; mRNA.
DR   EMBL; AL138785; CAI21967.1; -; Genomic_DNA.
DR   EMBL; AL357500; CAI21967.1; JOINED; Genomic_DNA.
DR   EMBL; AL138785; CAI21966.1; -; Genomic_DNA.
DR   EMBL; AL357500; CAI21966.1; JOINED; Genomic_DNA.
DR   EMBL; AL138785; CAI21968.1; -; Genomic_DNA.
DR   EMBL; AL138785; CAI21969.1; -; Genomic_DNA.
DR   EMBL; AL357500; CAI21969.1; JOINED; Genomic_DNA.
DR   EMBL; AL138785; CAI21970.1; -; Genomic_DNA.
DR   EMBL; AL357500; CAI21970.1; JOINED; Genomic_DNA.
DR   EMBL; AL357500; CAH71636.1; -; Genomic_DNA.
DR   EMBL; AL138785; CAH71636.1; JOINED; Genomic_DNA.
DR   EMBL; AL357500; CAH71637.1; -; Genomic_DNA.
DR   EMBL; AL138785; CAH71637.1; JOINED; Genomic_DNA.
DR   EMBL; AL357500; CAH71638.1; -; Genomic_DNA.
DR   EMBL; AL138785; CAH71638.1; JOINED; Genomic_DNA.
DR   EMBL; AL357500; CAH71639.1; -; Genomic_DNA.
DR   EMBL; AL138785; CAH71639.1; JOINED; Genomic_DNA.
DR   EMBL; CH471059; EAX07663.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07665.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07667.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07668.1; -; Genomic_DNA.
DR   EMBL; BC039079; AAH39079.1; -; mRNA.
DR   EMBL; AF156226; AAD42223.1; -; Genomic_DNA.
DR   CCDS; CCDS330.1; -. [P11171-5]
DR   CCDS; CCDS331.1; -. [P11171-4]
DR   CCDS; CCDS332.1; -. [P11171-3]
DR   CCDS; CCDS53288.1; -. [P11171-1]
DR   CCDS; CCDS53289.1; -. [P11171-7]
DR   PIR; A39810; MMHUE4.
DR   RefSeq; NP_001159477.1; NM_001166005.1. [P11171-1]
DR   RefSeq; NP_001159478.1; NM_001166006.1. [P11171-7]
DR   RefSeq; NP_004428.1; NM_004437.3. [P11171-4]
DR   RefSeq; NP_976217.1; NM_203342.2. [P11171-3]
DR   RefSeq; XP_005245818.1; XM_005245761.1. [P11171-1]
DR   RefSeq; XP_005245821.1; XM_005245764.1. [P11171-2]
DR   UniGene; Hs.175437; -.
DR   UniGene; Hs.708933; -.
DR   UniGene; Hs.712722; -.
DR   PDB; 1GG3; X-ray; 2.80 A; A/B/C=210-488.
DR   PDB; 2RQ1; NMR; -; A=292-396.
DR   PDB; 3QIJ; X-ray; 1.80 A; A/B=211-488.
DR   PDBsum; 1GG3; -.
DR   PDBsum; 2RQ1; -.
DR   PDBsum; 3QIJ; -.
DR   DisProt; DP00678; -.
DR   ProteinModelPortal; P11171; -.
DR   SMR; P11171; 208-519.
DR   BioGrid; 108349; 24.
DR   DIP; DIP-17032N; -.
DR   IntAct; P11171; 5.
DR   MINT; MINT-1208648; -.
DR   TCDB; 8.A.25.1.2; the ezrin/radixin/moesin (ezrin) family.
DR   PhosphoSite; P11171; -.
DR   UniCarbKB; P11171; -.
DR   DMDM; 90101808; -.
DR   MaxQB; P11171; -.
DR   PaxDb; P11171; -.
DR   PRIDE; P11171; -.
DR   DNASU; 2035; -.
DR   Ensembl; ENST00000343067; ENSP00000345259; ENSG00000159023. [P11171-1]
DR   Ensembl; ENST00000347529; ENSP00000290100; ENSG00000159023. [P11171-5]
DR   Ensembl; ENST00000349460; ENSP00000317597; ENSG00000159023. [P11171-3]
DR   Ensembl; ENST00000356093; ENSP00000348397; ENSG00000159023. [P11171-2]
DR   Ensembl; ENST00000373797; ENSP00000362903; ENSG00000159023. [P11171-7]
DR   Ensembl; ENST00000373798; ENSP00000362904; ENSG00000159023. [P11171-1]
DR   Ensembl; ENST00000373800; ENSP00000362906; ENSG00000159023. [P11171-4]
DR   GeneID; 2035; -.
DR   KEGG; hsa:2035; -.
DR   UCSC; uc001brg.2; human. [P11171-3]
DR   UCSC; uc001brh.2; human. [P11171-4]
DR   UCSC; uc001bri.2; human. [P11171-5]
DR   UCSC; uc001brk.3; human. [P11171-7]
DR   UCSC; uc001brl.2; human. [P11171-2]
DR   UCSC; uc001brm.2; human. [P11171-1]
DR   UCSC; uc009vtm.2; human. [P11171-6]
DR   CTD; 2035; -.
DR   GeneCards; GC01P029213; -.
DR   HGNC; HGNC:3377; EPB41.
DR   HPA; HPA028414; -.
DR   MIM; 130500; gene.
DR   MIM; 266140; phenotype.
DR   MIM; 611804; phenotype.
DR   neXtProt; NX_P11171; -.
DR   Orphanet; 98864; Common hereditary elliptocytosis.
DR   Orphanet; 98865; Homozygous hereditary elliptocytosis.
DR   PharmGKB; PA27810; -.
DR   eggNOG; NOG242913; -.
DR   HOVERGEN; HBG007777; -.
DR   InParanoid; P11171; -.
DR   KO; K06107; -.
DR   OMA; HEDLTKN; -.
DR   OrthoDB; EOG7Z69BP; -.
DR   PhylomeDB; P11171; -.
DR   TreeFam; TF351626; -.
DR   ChiTaRS; EPB41; human.
DR   EvolutionaryTrace; P11171; -.
DR   GeneWiki; EPB41; -.
DR   GenomeRNAi; 2035; -.
DR   NextBio; 8259; -.
DR   PMAP-CutDB; B1ALH9; -.
DR   PRO; PR:P11171; -.
DR   ArrayExpress; P11171; -.
DR   Bgee; P11171; -.
DR   CleanEx; HS_EPB41; -.
DR   Genevestigator; P11171; -.
DR   GO; GO:0030863; C:cortical cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0019898; C:extrinsic component of membrane; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:ProtInc.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0008091; C:spectrin; TAS:ProtInc.
DR   GO; GO:0014731; C:spectrin-associated cytoskeleton; TAS:BHF-UCL.
DR   GO; GO:0005545; F:1-phosphatidylinositol binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0030507; F:spectrin binding; TAS:BHF-UCL.
DR   GO; GO:0005200; F:structural constituent of cytoskeleton; TAS:ProtInc.
DR   GO; GO:0030036; P:actin cytoskeleton organization; NAS:UniProtKB.
DR   GO; GO:0008015; P:blood circulation; TAS:ProtInc.
DR   GO; GO:0030866; P:cortical actin cytoskeleton organization; IEA:InterPro.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:BHF-UCL.
DR   Gene3D; 1.20.80.10; -; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR008379; Band_4.1_C.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR019750; Band_41_fam.
DR   InterPro; IPR021187; Band_41_protein.
DR   InterPro; IPR000798; Ez/rad/moesin_like.
DR   InterPro; IPR014847; FERM-adjacent.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_3-hlx.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR019747; FERM_CS.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR018979; FERM_N.
DR   InterPro; IPR018980; FERM_PH-like_C.
DR   InterPro; IPR011993; PH_like_dom.
DR   InterPro; IPR007477; SAB_dom.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   Pfam; PF05902; 4_1_CTD; 1.
DR   Pfam; PF08736; FA; 1.
DR   Pfam; PF09380; FERM_C; 1.
DR   Pfam; PF00373; FERM_M; 1.
DR   Pfam; PF09379; FERM_N; 1.
DR   Pfam; PF04382; SAB; 1.
DR   PIRSF; PIRSF002304; Membrane_skeletal_4_1; 1.
DR   PRINTS; PR00935; BAND41.
DR   PRINTS; PR00661; ERMFAMILY.
DR   SMART; SM00295; B41; 1.
DR   SUPFAM; SSF47031; SSF47031; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   PROSITE; PS00660; FERM_1; 1.
DR   PROSITE; PS00661; FERM_2; 1.
DR   PROSITE; PS50057; FERM_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Actin-binding; Alternative splicing; Calmodulin-binding;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Direct protein sequencing;
KW   Elliptocytosis; Glycoprotein; Hereditary hemolytic anemia; Nucleus;
KW   Phosphoprotein; Polymorphism; Pyropoikilocytosis; Reference proteome.
FT   CHAIN         1    864       Protein 4.1.
FT                                /FTId=PRO_0000219390.
FT   DOMAIN      210    491       FERM.
FT   REGION      494    614       Hydrophilic.
FT   REGION      615    713       Spectrin--actin-binding.
FT   REGION      714    864       C-terminal (CTD).
FT   MOD_RES      14     14       Phosphoserine.
FT   MOD_RES      60     60       Phosphothreonine; by CDK1.
FT   MOD_RES      84     84       Phosphoserine.
FT   MOD_RES      85     85       Phosphoserine.
FT   MOD_RES     149    149       Phosphoserine.
FT   MOD_RES     151    151       Phosphoserine.
FT   MOD_RES     152    152       Phosphoserine.
FT   MOD_RES     188    188       Phosphoserine.
FT   MOD_RES     191    191       Phosphoserine.
FT   MOD_RES     222    222       Phosphotyrosine (By similarity).
FT   MOD_RES     540    540       Phosphoserine.
FT   MOD_RES     542    542       Phosphoserine (By similarity).
FT   MOD_RES     555    555       Phosphoserine.
FT   MOD_RES     660    660       Phosphotyrosine; by EGFR.
FT   MOD_RES     709    709       Phosphoserine.
FT   MOD_RES     712    712       Phosphoserine; by CDK1.
FT   VAR_SEQ       1    209       Missing (in isoform 3, isoform 4 and
FT                                isoform 6).
FT                                /FTId=VSP_000468.
FT   VAR_SEQ     228    262       Missing (in isoform 5 and isoform 6).
FT                                /FTId=VSP_000469.
FT   VAR_SEQ     616    648       Missing (in isoform 2, isoform 4, isoform
FT                                5 and isoform 6).
FT                                /FTId=VSP_000470.
FT   VAR_SEQ     635    648       Missing (in isoform 3 and isoform 7).
FT                                /FTId=VSP_000471.
FT   VAR_SEQ     649    669       Missing (in isoform 5 and isoform 6).
FT                                /FTId=VSP_000472.
FT   VAR_SEQ     729    734       PPLVKT -> VSTLST (in isoform 7).
FT                                /FTId=VSP_012872.
FT   VAR_SEQ     735    864       Missing (in isoform 7).
FT                                /FTId=VSP_012873.
FT   VAR_SEQ     772    805       Missing (in isoform 4).
FT                                /FTId=VSP_000473.
FT   VARIANT     214    214       V -> I (in dbSNP:rs111642750).
FT                                /FTId=VAR_009122.
FT   MUTAGEN      60     60       T->A: Loss of CDK1-mediated
FT                                phosphorylation. Abolishes targeting onto
FT                                the mitotic spindle; when associated with
FT                                A-712.
FT   MUTAGEN     712    712       S->A: Loss of CDK1-mediated
FT                                phosphorylation. Abolishes targeting onto
FT                                the mitotic spindle; when associated with
FT                                A-60.
FT   CONFLICT     51     51       Q -> H (in Ref. 5; AAD42222).
FT   CONFLICT     76     76       S -> N (in Ref. 5; AAD42222).
FT   CONFLICT    168    168       F -> S (in Ref. 9; AAD42223).
FT   CONFLICT    259    259       A -> T (in Ref. 5; AAD42222).
FT   CONFLICT    665    665       N -> S (in Ref. 5; AAD42222).
FT   CONFLICT    669    669       E -> K (in Ref. 10; no nucleotide entry).
FT   CONFLICT    679    679       K -> E (in Ref. 5; AAD42222).
FT   CONFLICT    802    802       Q -> K (in Ref. 2; no nucleotide entry
FT                                and 3; AAA35793/AAA35794).
FT   CONFLICT    852    852       K -> L (in Ref. 10; no nucleotide entry).
FT   CONFLICT    863    863       D -> E (in Ref. 10; no nucleotide entry).
FT   STRAND      211    215
FT   STRAND      221    225
FT   HELIX       232    243
FT   HELIX       248    250
FT   STRAND      251    258
FT   STRAND      261    264
FT   HELIX       271    274
FT   TURN        275    277
FT   STRAND      281    288
FT   HELIX       293    295
FT   HELIX       299    314
FT   HELIX       322    337
FT   HELIX       342    345
FT   HELIX       350    352
FT   STRAND      356    358
FT   HELIX       361    372
FT   HELIX       379    390
FT   TURN        394    397
FT   STRAND      399    404
FT   STRAND      410    415
FT   STRAND      417    424
FT   STRAND      427    433
FT   HELIX       434    436
FT   STRAND      437    443
FT   STRAND      446    451
FT   STRAND      454    458
FT   STRAND      461    466
FT   HELIX       470    486
SQ   SEQUENCE   864 AA;  97017 MW;  B466E7A9D7FBF12B CRC64;
     MTTEKSLVTE AENSQHQQKE EGEEAINSGQ QEPQQEESCQ TAAEGDNWCE QKLKASNGDT
     PTHEDLTKNK ERTSESRGLS RLFSSFLKRP KSQVSEEEGK EVESDKEKGE GGQKEIEFGT
     SLDEEIILKA PIAAPEPELK TDPSLDLHSL SSAETQPAQE ELREDPDFEI KEGEGLEECS
     KIEVKEESPQ SKAETELKAS QKPIRKHRNM HCKVSLLDDT VYECVVEKHA KGQDLLKRVC
     EHLNLLEEDY FGLAIWDNAT SKTWLDSAKE IKKQVRGVPW NFTFNVKFYP PDPAQLTEDI
     TRYYLCLQLR QDIVAGRLPC SFATLALLGS YTIQSELGDY DPELHGVDYV SDFKLAPNQT
     KELEEKVMEL HKSYRSMTPA QADLEFLENA KKLSMYGVDL HKAKDLEGVD IILGVCSSGL
     LVYKDKLRIN RFPWPKVLKI SYKRSSFFIK IRPGEQEQYE STIGFKLPSY RAAKKLWKVC
     VEHHTFFRLT STDTIPKSKF LALGSKFRYS GRTQAQTRQA SALIDRPAPH FERTASKRAS
     RSLDGAAAVD SADRSPRPTS APAITQGQVA EGGVLDASAK KTVVPKAQKE TVKAEVKKED
     EPPEQAEPEP TEAWKVEKTH IEVTVPTSNG DQTQKLAEKT EDLIRMRKKK RERLDGENIY
     IRHSNLMLED LDKSQEEIKK HHASISELKK NFMESVPEPR PSEWDKRLST HSPFRTLNIN
     GQIPTGEGPP LVKTQTVTIS DNANAVKSEI PTKDVPIVHT ETKTITYEAA QTDDNSGDLD
     PGVLLTAQTI TSETPSSTTT TQITKTVKGG ISETRIEKRI VITGDADIDH DQVLVQAIKE
     AKEQHPDMSV TKVVVHQETE IADE
//
ID   4EBP1_HUMAN             Reviewed;         118 AA.
AC   Q13541; B2R502; D3DSW8; Q6IBN3;
DT   19-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   09-JUL-2014, entry version 136.
DE   RecName: Full=Eukaryotic translation initiation factor 4E-binding protein 1;
DE            Short=4E-BP1;
DE            Short=eIF4E-binding protein 1;
DE   AltName: Full=Phosphorylated heat- and acid-stable protein regulated by insulin 1;
DE            Short=PHAS-I;
GN   Name=EIF4EBP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH EIF4E, AND
RP   PHOSPHORYLATION.
RC   TISSUE=Placenta;
RX   PubMed=7935836; DOI=10.1038/371762a0;
RA   Pause A., Belsham G.J., Gingras A.-C., Donze O., Lin T.-A.,
RA   Lawrence J.C. Jr., Sonenberg N.;
RT   "Insulin-dependent stimulation of protein synthesis by phosphorylation
RT   of a regulator of 5'-cap function.";
RL   Nature 371:762-767(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Ito M., Shichijo S., Tsuda N., Ochi M., Harashima N., Saito N.,
RA   Itoh K.;
RT   "Identification of multiple genes and immunogenic epitopes of
RT   pancreatic cancer cells.";
RL   Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-13, AND ACETYLATION AT SER-2.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [9]
RP   INTERACTION WITH EIF4E AND EIF4G.
RX   PubMed=8521827;
RA   Haghighat A., Mader S., Pause A., Sonenberg N.;
RT   "Repression of cap-dependent translation by 4E-binding protein 1:
RT   competition with p220 for binding to eukaryotic initiation factor-
RT   4E.";
RL   EMBO J. 14:5701-5709(1995).
RN   [10]
RP   PHOSPHORYLATION BY MTOR.
RX   PubMed=9465032; DOI=10.1073/pnas.95.4.1432;
RA   Burnett P.E., Barrow R.K., Cohen N.A., Snyder S.H., Sabatini D.M.;
RT   "RAFT1 phosphorylation of the translational regulators p70 S6 kinase
RT   and 4E-BP1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:1432-1437(1998).
RN   [11]
RP   INTERACTION WITH RPTOR.
RX   PubMed=12150926; DOI=10.1016/S0092-8674(02)00833-4;
RA   Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S.,
RA   Tokunaga C., Avruch J., Yonezawa K.;
RT   "Raptor, a binding partner of target of rapamycin (TOR), mediates TOR
RT   action.";
RL   Cell 110:177-189(2002).
RN   [12]
RP   INTERACTION WITH RPTOR, AND PHOSPHORYLATION AT THR-37; THR-46; SER-65
RP   AND THR-70 BY MTOR.
RX   PubMed=12747827; DOI=10.1016/S0960-9822(03)00329-4;
RA   Schalm S.S., Fingar D.C., Sabatini D.M., Blenis J.;
RT   "TOS motif-mediated raptor binding regulates 4E-BP1 multisite
RT   phosphorylation and function.";
RL   Curr. Biol. 13:797-806(2003).
RN   [13]
RP   PHOSPHORYLATION AT SER-65; SER-101 AND SER-112, PROTEIN SEQUENCE, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12588975; DOI=10.1128/MCB.23.5.1546-1557.2003;
RA   Wang X., Li W., Parra J.L., Beugnet A., Proud C.G.;
RT   "The C terminus of initiation factor 4E-binding protein 1 contains
RT   multiple regulatory features that influence its function and
RT   phosphorylation.";
RL   Mol. Cell. Biol. 23:1546-1557(2003).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-65, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Prostate cancer;
RX   PubMed=17487921; DOI=10.1002/elps.200600782;
RA   Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.;
RT   "Toward a global characterization of the phosphoproteome in prostate
RT   cancer cells: identification of phosphoproteins in the LNCaP cell
RT   line.";
RL   Electrophoresis 28:2027-2034(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-112, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-50; THR-70 AND SER-101,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-37; THR-41; THR-46;
RP   THR-50; TYR-54; SER-65; THR-70 AND SER-83, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-37 AND THR-46, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-37 AND THR-70, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-70 AND SER-112, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [24]
RP   FUNCTION, INTERACTION WITH EIF4E, UBIQUITINATION AT LYS-57,
RP   PHOSPHORYLATION AT THR-37; THR-46; SER-65 AND THR-70, AND MUTAGENESIS
RP   OF THR-37; THR-46; LYS-57; 59-LEU-MET-60; SER-65; LYS-69; THR-70 AND
RP   LYS-105.
RX   PubMed=22578813; DOI=10.1016/j.molcel.2012.04.004;
RA   Yanagiya A., Suyama E., Adachi H., Svitkin Y.V., Aza-Blanc P.,
RA   Imataka H., Mikami S., Martineau Y., Ronai Z.A., Sonenberg N.;
RT   "Translational homeostasis via the mRNA cap-binding protein, eIF4E.";
RL   Mol. Cell 46:847-858(2012).
RN   [25]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [26]
RP   STRUCTURE BY NMR OF 4-118.
RX   PubMed=9684899; DOI=10.1002/pro.5560070720;
RA   Fletcher C.M., Wagner G.;
RT   "The interaction of eIF4E with 4E-BP1 is an induced fit to a
RT   completely disordered protein.";
RL   Protein Sci. 7:1639-1642(1998).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 36-70 IN COMPLEX WITH EIF4E
RP   AND MRNA CAP ANALOG.
RX   PubMed=16271312; DOI=10.1016/j.bbapap.2005.07.023;
RA   Tomoo K., Matsushita Y., Fujisaki H., Abiko F., Shen X., Taniguchi T.,
RA   Miyagawa H., Kitamura K., Miura K., Ishida T.;
RT   "Structural basis for mRNA cap-binding regulation of eukaryotic
RT   initiation factor 4E by 4E-binding protein, studied by spectroscopic,
RT   X-ray crystal structural, and molecular dynamics simulation methods.";
RL   Biochim. Biophys. Acta 1753:191-208(2005).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 51-67 IN COMPLEX WITH EIF4E2
RP   AND MRNA CAP ANALOG.
RX   PubMed=17368478; DOI=10.1016/j.jmb.2007.02.019;
RA   Rosettani P., Knapp S., Vismara M.-G., Rusconi L., Cameron A.D.;
RT   "Structures of the human eIF4E homologous protein, h4EHP, in its
RT   m7GTP-bound and unliganded forms.";
RL   J. Mol. Biol. 368:691-705(2007).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 51-64 IN COMPLEX WITH EIF4E
RP   AND MRNA CAP ANALOG.
RX   PubMed=17631896; DOI=10.1016/j.jmb.2007.06.033;
RA   Brown C.J., McNae I., Fischer P.M., Walkinshaw M.D.;
RT   "Crystallographic and mass spectrometric characterisation of eIF4E
RT   with N7-alkylated cap derivatives.";
RL   J. Mol. Biol. 372:7-15(2007).
CC   -!- FUNCTION: Regulates eIF4E activity by preventing its assembly into
CC       the eIF4F complex: hypophosphorylated form competes with
CC       EIF4G1/EIF4G3 and strongly binds to EIF4E, leading to repress
CC       translation. Mediates the regulation of protein translation by
CC       hormones, growth factors and other stimuli that signal through the
CC       MAP kinase and mTORC1 pathways.
CC   -!- SUBUNIT: Hypophosphorylated EIF4EBP1 competes with EIF4G1/EIF4G3
CC       to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and
CC       MAPK3) or mTORC1 phosphorylation of EIF4EBP1 causes dissociation
CC       of the complex allowing EIF4G1/EIF4G3 to bind and consequent
CC       initiation of translation. Interacts with RPTOR.
CC   -!- INTERACTION:
CC       Q9UKV8:AGO2; NbExp=2; IntAct=EBI-74090, EBI-528269;
CC       P06730:EIF4E; NbExp=8; IntAct=EBI-74090, EBI-73440;
CC       P42345:MTOR; NbExp=2; IntAct=EBI-74090, EBI-359260;
CC       Q9JLN9:Mtor (xeno); NbExp=2; IntAct=EBI-74090, EBI-1571628;
CC       Q8N122:RPTOR; NbExp=5; IntAct=EBI-74090, EBI-1567928;
CC   -!- PTM: Phosphorylated on serine and threonine residues in response
CC       to insulin, EGF and PDGF. Phosphorylation at Thr-37, Thr-46, Ser-
CC       65 and Thr-70, corresponding to the hyperphosphorylated form, is
CC       regulated by mTORC1 and abolishes binding to EIF4E.
CC   -!- PTM: Ubiquitinated: when eIF4E levels are low, hypophosphorylated
CC       form is ubiquitinated by the BCR(KLHL25) complex, leading to its
CC       degradation and serving as a homeostatic mechanism to maintain
CC       translation and prevent eIF4E inhibition when eIF4E levels are
CC       low. Not ubiquitinated when hyperphosphorylated (at Thr-37, Thr-
CC       46, Ser-65 and Thr-70) or associated with eIF4E.
CC   -!- SIMILARITY: Belongs to the eIF4E-binding protein family.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EIF4EBP1ID40432ch8p12.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L36055; AAA62269.1; -; mRNA.
DR   EMBL; AB044548; BAB18650.1; -; mRNA.
DR   EMBL; BT007162; AAP35826.1; -; mRNA.
DR   EMBL; CR456769; CAG33050.1; -; mRNA.
DR   EMBL; AK312011; BAG34949.1; -; mRNA.
DR   EMBL; CH471080; EAW63341.1; -; Genomic_DNA.
DR   EMBL; CH471080; EAW63342.1; -; Genomic_DNA.
DR   EMBL; BC004459; AAH04459.1; -; mRNA.
DR   EMBL; BC058073; AAH58073.1; -; mRNA.
DR   CCDS; CCDS6100.1; -.
DR   PIR; S50866; S50866.
DR   RefSeq; NP_004086.1; NM_004095.3.
DR   UniGene; Hs.411641; -.
DR   PDB; 1EJ4; X-ray; 2.25 A; B=51-64.
DR   PDB; 1WKW; X-ray; 2.10 A; B=47-66.
DR   PDB; 2JGB; X-ray; 1.70 A; B=51-67.
DR   PDB; 2JGC; X-ray; 2.40 A; B=51-67.
DR   PDB; 2V8W; X-ray; 2.30 A; B/F=51-64.
DR   PDB; 2V8X; X-ray; 2.30 A; B/F=51-64.
DR   PDB; 2V8Y; X-ray; 2.10 A; B/F=51-64.
DR   PDB; 3HXG; X-ray; 2.10 A; C=51-67.
DR   PDB; 3HXI; X-ray; 1.80 A; C=51-67.
DR   PDB; 3M93; X-ray; 2.90 A; C=51-67.
DR   PDB; 3M94; X-ray; 2.05 A; C=51-67.
DR   PDB; 3U7X; X-ray; 2.10 A; C/D=47-66.
DR   PDBsum; 1EJ4; -.
DR   PDBsum; 1WKW; -.
DR   PDBsum; 2JGB; -.
DR   PDBsum; 2JGC; -.
DR   PDBsum; 2V8W; -.
DR   PDBsum; 2V8X; -.
DR   PDBsum; 2V8Y; -.
DR   PDBsum; 3HXG; -.
DR   PDBsum; 3HXI; -.
DR   PDBsum; 3M93; -.
DR   PDBsum; 3M94; -.
DR   PDBsum; 3U7X; -.
DR   DisProt; DP00028; -.
DR   ProteinModelPortal; Q13541; -.
DR   BioGrid; 108293; 25.
DR   DIP; DIP-30944N; -.
DR   IntAct; Q13541; 14.
DR   MINT; MINT-210160; -.
DR   STRING; 9606.ENSP00000340691; -.
DR   PhosphoSite; Q13541; -.
DR   DMDM; 34921508; -.
DR   MaxQB; Q13541; -.
DR   PaxDb; Q13541; -.
DR   PeptideAtlas; Q13541; -.
DR   PRIDE; Q13541; -.
DR   DNASU; 1978; -.
DR   Ensembl; ENST00000338825; ENSP00000340691; ENSG00000187840.
DR   GeneID; 1978; -.
DR   KEGG; hsa:1978; -.
DR   UCSC; uc003xks.3; human.
DR   CTD; 1978; -.
DR   GeneCards; GC08P037888; -.
DR   HGNC; HGNC:3288; EIF4EBP1.
DR   HPA; CAB005032; -.
DR   HPA; CAB005039; -.
DR   HPA; HPA023501; -.
DR   MIM; 602223; gene.
DR   neXtProt; NX_Q13541; -.
DR   PharmGKB; PA27715; -.
DR   eggNOG; NOG78084; -.
DR   HOGENOM; HOG000231190; -.
DR   HOVERGEN; HBG050425; -.
DR   InParanoid; Q13541; -.
DR   KO; K07205; -.
DR   OMA; NHLRNSP; -.
DR   OrthoDB; EOG7B31Q1; -.
DR   PhylomeDB; Q13541; -.
DR   TreeFam; TF101530; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_17015; Metabolism of proteins.
DR   Reactome; REACT_71; Gene Expression.
DR   SignaLink; Q13541; -.
DR   EvolutionaryTrace; Q13541; -.
DR   GeneWiki; EIF4EBP1; -.
DR   GenomeRNAi; 1978; -.
DR   NextBio; 8003; -.
DR   PMAP-CutDB; Q13541; -.
DR   PRO; PR:Q13541; -.
DR   Bgee; Q13541; -.
DR   CleanEx; HS_EIF4EBP1; -.
DR   Genevestigator; Q13541; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0030371; F:translation repressor activity; IDA:UniProtKB.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0031333; P:negative regulation of protein complex assembly; IEA:Ensembl.
DR   GO; GO:0045947; P:negative regulation of translational initiation; IDA:UniProtKB.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0031929; P:TOR signaling; IDA:UniProtKB.
DR   GO; GO:0006412; P:translation; TAS:Reactome.
DR   GO; GO:0006413; P:translational initiation; TAS:Reactome.
DR   InterPro; IPR008606; EIF4EBP.
DR   Pfam; PF05456; eIF_4EBP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome;
KW   Direct protein sequencing; Isopeptide bond; Phosphoprotein;
KW   Protein synthesis inhibitor; Reference proteome;
KW   Translation regulation; Ubl conjugation.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    118       Eukaryotic translation initiation factor
FT                                4E-binding protein 1.
FT                                /FTId=PRO_0000190513.
FT   MOD_RES       2      2       N-acetylserine.
FT   MOD_RES      37     37       Phosphothreonine; by MTOR.
FT   MOD_RES      41     41       Phosphothreonine.
FT   MOD_RES      46     46       Phosphothreonine; by MTOR.
FT   MOD_RES      50     50       Phosphothreonine.
FT   MOD_RES      54     54       Phosphotyrosine.
FT   MOD_RES      65     65       Phosphoserine; by DYRK2, MAPK1, MAPK3 and
FT                                MTOR.
FT   MOD_RES      70     70       Phosphothreonine; by MTOR.
FT   MOD_RES      83     83       Phosphoserine.
FT   MOD_RES     101    101       Phosphoserine; by DYRK2.
FT   MOD_RES     112    112       Phosphoserine.
FT   CROSSLNK     57     57       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin)
FT                                (Probable).
FT   MUTAGEN      37     37       T->A: Abolishes phosphorylation by MTOR
FT                                and increased ubiquitination by the
FT                                BCR(KLHL25) complex; when associated with
FT                                A-46; A-65 and A-70.
FT   MUTAGEN      46     46       T->A: Abolishes phosphorylation by MTOR
FT                                and increased ubiquitination by the
FT                                BCR(KLHL25) complex; when associated with
FT                                A-37; A-65 and A-70.
FT   MUTAGEN      57     57       K->R: Impaired ubiquitination by the
FT                                BCR(KLHL25) complex.
FT   MUTAGEN      59     60       LM->AA: Abolishes eIF4E-binding.
FT                                Increased ubiquitination by the
FT                                BCR(KLHL25) complex.
FT   MUTAGEN      65     65       S->A: Abolishes phosphorylation by MTOR
FT                                and increased ubiquitination by the
FT                                BCR(KLHL25) complex; when associated with
FT                                A-37; A-46 and A-70.
FT   MUTAGEN      69     69       K->R: Does not affect ubiquitination by
FT                                the BCR(KLHL25) complex.
FT   MUTAGEN      70     70       T->A: Abolishes phosphorylation by MTOR
FT                                and increased ubiquitination by the
FT                                BCR(KLHL25) complex; when associated with
FT                                A-37; A-46 and A-65.
FT   MUTAGEN     105    105       K->R: Does not affect ubiquitination by
FT                                the BCR(KLHL25) complex.
FT   HELIX        56     61
FT   HELIX        62     64
SQ   SEQUENCE   118 AA;  12580 MW;  1682A6BA74132966 CRC64;
     MSGGSSCSQT PSRAIPATRR VVLGDGVQLP PGDYSTTPGG TLFSTTPGGT RIIYDRKFLM
     ECRNSPVTKT PPRDLPTIPG VTSPSSDEPP MEASQSHLRN SPEDKRAGGE ESQFEMDI
//
ID   4ET_HUMAN               Reviewed;         985 AA.
AC   Q9NRA8; B1AKL2; B1AKL3; B2RBF1; Q8NCF2; Q9H708;
DT   02-AUG-2002, integrated into UniProtKB/Swiss-Prot.
DT   02-AUG-2002, sequence version 2.
DT   09-JUL-2014, entry version 121.
DE   RecName: Full=Eukaryotic translation initiation factor 4E transporter;
DE            Short=4E-T;
DE            Short=eIF4E transporter;
DE   AltName: Full=Eukaryotic translation initiation factor 4E nuclear import factor 1;
GN   Name=EIF4ENIF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CHARACTERIZATION,
RP   PHOSPHORYLATION, AND MUTAGENESIS OF TYR-30 AND 195-ARG-ARG-196.
RC   TISSUE=Fetal brain;
RX   PubMed=10856257; DOI=10.1093/emboj/19.12.3142;
RA   Dostie J., Ferraiuolo M., Pause A., Adam S.A., Sonenberg N.;
RT   "A novel shuttling protein, 4E-T, mediates the nuclear import of the
RT   mRNA 5' cap-binding protein, eIF4E.";
RL   EMBO J. 19:3142-3156(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Colon, Placenta, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH APOBEC3G.
RX   PubMed=16699599; DOI=10.1371/journal.ppat.0020041;
RA   Wichroski M.J., Robb G.B., Rana T.M.;
RT   "Human retroviral host restriction factors APOBEC3G and APOBEC3F
RT   localize to mRNA processing bodies.";
RL   PLoS Pathog. 2:E41-E41(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-920, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-120; SER-136; SER-138;
RP   SER-345; SER-564 AND SER-951, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5; SER-564; SER-587 AND
RP   SER-693, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-486, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5; SER-301; SER-513;
RP   SER-564 AND SER-951, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-951, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22090346; DOI=10.1091/mbc.E11-05-0415;
RA   Marnef A., Weil D., Standart N.;
RT   "RNA-related nuclear functions of human Pat1b, the P-body mRNA decay
RT   factor.";
RL   Mol. Biol. Cell 23:213-224(2012).
CC   -!- FUNCTION: Nucleoplasmic shuttling protein. Mediates the nuclear
CC       import of EIF4E by a piggy-back mechanism.
CC   -!- SUBUNIT: Interacts with EIF4E. Interacts with importin beta only
CC       in the presence of importin alpha, suggesting a direct interaction
CC       with importin alpha. Interacts with APOBEC3G in an RNA-dependent
CC       manner.
CC   -!- INTERACTION:
CC       Q9WMX2:- (xeno); NbExp=3; IntAct=EBI-301024, EBI-6863741;
CC       P06730:EIF4E; NbExp=6; IntAct=EBI-301024, EBI-73440;
CC       O60573:EIF4E2; NbExp=3; IntAct=EBI-301024, EBI-398610;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Nucleus, PML body.
CC       Nucleus speckle. Note=Predominantly cytoplasmic. Shuttles between
CC       the nucleus and the cytoplasm in a CRM1-dependent manner.
CC       Localization to nuclear foci and speckles requires active
CC       transcription.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9NRA8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NRA8-2; Sequence=VSP_003783, VSP_003784, VSP_047042;
CC         Note=No experimental confirmation available;
CC       Name=3;
CC         IsoId=Q9NRA8-3; Sequence=VSP_047042;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15092.1; Type=Erroneous initiation;
CC       Sequence=BAC11194.1; Type=Erroneous initiation;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF240775; AAF81693.1; -; mRNA.
DR   EMBL; CR456386; CAG30272.1; -; mRNA.
DR   EMBL; AK025254; BAB15092.1; ALT_INIT; mRNA.
DR   EMBL; AK074768; BAC11194.1; ALT_INIT; mRNA.
DR   EMBL; AK314636; BAG37198.1; -; mRNA.
DR   EMBL; AL096701; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471095; EAW59977.1; -; Genomic_DNA.
DR   EMBL; BC032941; AAH32941.1; -; mRNA.
DR   EMBL; BC033028; AAH33028.1; -; mRNA.
DR   CCDS; CCDS13898.1; -. [Q9NRA8-1]
DR   CCDS; CCDS54520.1; -. [Q9NRA8-2]
DR   RefSeq; NP_001157973.1; NM_001164501.1. [Q9NRA8-1]
DR   RefSeq; NP_001157974.1; NM_001164502.1. [Q9NRA8-2]
DR   RefSeq; NP_062817.2; NM_019843.3. [Q9NRA8-1]
DR   RefSeq; XP_005261743.1; XM_005261686.1. [Q9NRA8-3]
DR   RefSeq; XP_005261744.1; XM_005261687.1. [Q9NRA8-3]
DR   RefSeq; XP_005261745.1; XM_005261688.1. [Q9NRA8-3]
DR   UniGene; Hs.517559; -.
DR   ProteinModelPortal; Q9NRA8; -.
DR   BioGrid; 121148; 10.
DR   IntAct; Q9NRA8; 15.
DR   MINT; MINT-1956064; -.
DR   STRING; 9606.ENSP00000328103; -.
DR   PhosphoSite; Q9NRA8; -.
DR   DMDM; 22095430; -.
DR   MaxQB; Q9NRA8; -.
DR   PaxDb; Q9NRA8; -.
DR   PRIDE; Q9NRA8; -.
DR   DNASU; 56478; -.
DR   Ensembl; ENST00000330125; ENSP00000328103; ENSG00000184708. [Q9NRA8-1]
DR   Ensembl; ENST00000344710; ENSP00000342927; ENSG00000184708. [Q9NRA8-2]
DR   Ensembl; ENST00000397525; ENSP00000380659; ENSG00000184708. [Q9NRA8-1]
DR   GeneID; 56478; -.
DR   KEGG; hsa:56478; -.
DR   UCSC; uc003aky.2; human. [Q9NRA8-1]
DR   CTD; 56478; -.
DR   GeneCards; GC22M031835; -.
DR   H-InvDB; HIX0016395; -.
DR   HGNC; HGNC:16687; EIF4ENIF1.
DR   HPA; HPA001619; -.
DR   HPA; HPA002078; -.
DR   MIM; 607445; gene.
DR   neXtProt; NX_Q9NRA8; -.
DR   Orphanet; 619; Primary ovarian failure.
DR   PharmGKB; PA38410; -.
DR   eggNOG; NOG43453; -.
DR   HOGENOM; HOG000232370; -.
DR   HOVERGEN; HBG023298; -.
DR   InParanoid; Q9NRA8; -.
DR   OMA; HQVPLVP; -.
DR   OrthoDB; EOG7GFB42; -.
DR   PhylomeDB; Q9NRA8; -.
DR   TreeFam; TF101531; -.
DR   ChiTaRS; EIF4ENIF1; human.
DR   GeneWiki; EIF4ENIF1; -.
DR   GenomeRNAi; 56478; -.
DR   NextBio; 62017; -.
DR   PRO; PR:Q9NRA8; -.
DR   ArrayExpress; Q9NRA8; -.
DR   Bgee; Q9NRA8; -.
DR   CleanEx; HS_EIF4ENIF1; -.
DR   Genevestigator; Q9NRA8; -.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0008565; F:protein transporter activity; TAS:ProtInc.
DR   InterPro; IPR018862; eIF4E_transporter.
DR   Pfam; PF10477; EIF4E-T; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Complete proteome; Cytoplasm;
KW   Nucleus; Phosphoprotein; Protein transport; Reference proteome;
KW   Transport.
FT   CHAIN         1    985       Eukaryotic translation initiation factor
FT                                4E transporter.
FT                                /FTId=PRO_0000064381.
FT   REGION       30     36       EIF4E-binding.
FT   MOTIF       195    211       Nuclear localization signal.
FT   MOTIF       438    447       Nuclear export signal.
FT   MOTIF       613    638       Nuclear export signal.
FT   COMPBIAS    148    210       Arg-rich.
FT   MOD_RES       5      5       Phosphoserine.
FT   MOD_RES     120    120       Phosphoserine.
FT   MOD_RES     136    136       Phosphoserine.
FT   MOD_RES     138    138       Phosphoserine.
FT   MOD_RES     301    301       Phosphoserine.
FT   MOD_RES     345    345       Phosphoserine.
FT   MOD_RES     486    486       N6-acetyllysine.
FT   MOD_RES     513    513       Phosphoserine.
FT   MOD_RES     564    564       Phosphoserine.
FT   MOD_RES     587    587       Phosphoserine.
FT   MOD_RES     693    693       Phosphoserine.
FT   MOD_RES     920    920       Phosphoserine.
FT   MOD_RES     951    951       Phosphoserine.
FT   VAR_SEQ     100    262       Missing (in isoform 2).
FT                                /FTId=VSP_003783.
FT   VAR_SEQ     493    504       Missing (in isoform 2).
FT                                /FTId=VSP_003784.
FT   VAR_SEQ     616    616       Q -> QQ (in isoform 2 and isoform 3).
FT                                /FTId=VSP_047042.
FT   MUTAGEN      30     30       Y->A: Abolishes interaction with EIF4E.
FT   MUTAGEN     195    196       RR->NS: Abolishes the nuclear
FT                                localization.
FT   CONFLICT    114    114       L -> F (in Ref. 1; AAF81693).
FT   CONFLICT    825    825       Q -> R (in Ref. 6; AAH33028).
SQ   SEQUENCE   985 AA;  108201 MW;  4C898E0488903C04 CRC64;
     MDRRSMGETE SGDAFLDLKK PPASKCPHRY TKEELLDIKE LPHSKQRPSC LSEKYDSDGV
     WDPEKWHASL YPASGRSSPV ESLKKELDTD RPSLVRRIVD PRERVKEDDL DVVLSPQRRS
     FGGGCHVTAA VSSRRSGSPL EKDSDGLRLL GGRRIGSGRI ISARTFEKDH RLSDKDLRDL
     RDRDRERDFK DKRFRREFGD SKRVFGERRR NDSYTEEEPE WFSAGPTSQS ETIELTGFDD
     KILEEDHKGR KRTRRRTASV KEGIVECNGG VAEEDEVEVI LAQEPAADQE VPRDAVLPEQ
     SPGDFDFNEF FNLDKVPCLA SMIEDVLGEG SVSASRFSRW FSNPSRSGSR SSSLGSTPHE
     ELERLAGLEQ AILSPGQNSG NYFAPIPLED HAENKVDILE MLQKAKVDLK PLLSSLSANK
     EKLKESSHSG VVLSVEEVEA GLKGLKVDQQ VKNSTPFMAE HLEETLSAVT NNRQLKKDGD
     MTAFNKLVST MKASGTLPSQ PKVSRNLESH LMSPAEIPGQ PVPKNILQEL LGQPVQRPAS
     SNLLSGLMGS LEPTTSLLGQ RAPSPPLSQV FQTRAASADY LRPRIPSPIG FTPGPQQLLG
     DPFQGMRKPM SPITAQMSQL ELQQAALEGL ALPHDLAVQA ANFYQPGFGK PQVDRTRDGF
     RNRQQRVTKS PAPVHRGNSS SPAPAASITS MLSPSFTPTS VIRKMYESKE KSKEEPASGK
     AALGDSKEDT QKASEENLLS SSSVPSADRD SSPTTNSKLS ALQRSSCSTP LSQANRYTKE
     QDYRPKATGR KTPTLASPVP TTPFLRPVHQ VPLVPHVPMV RPAHQLHPGL VQRMLAQGVH
     PQHLPSLLQT GVLPPGMDLS HLQGISGPIL GQPFYPLPAA SHPLLNPRPG TPLHLAMVQQ
     QLQRSVLHPP GSGSHAAAVS VQTTPQNVPS RSGLPHMHSQ LEHRPSQRSS SPVGLAKWFG
     SDVLQQPLPS MPAKVISVDE LEYRQ
//
ID   4F2_HUMAN               Reviewed;         630 AA.
AC   P08195; Q13543;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-SEP-2009, sequence version 3.
DT   09-JUL-2014, entry version 168.
DE   RecName: Full=4F2 cell-surface antigen heavy chain;
DE            Short=4F2hc;
DE   AltName: Full=4F2 heavy chain antigen;
DE   AltName: Full=Lymphocyte activation antigen 4F2 large subunit;
DE   AltName: Full=Solute carrier family 3 member 2;
DE   AltName: CD_antigen=CD98;
GN   Name=SLC3A2; Synonyms=MDU1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=3476959; DOI=10.1073/pnas.84.18.6526;
RA   Quackenbush E., Clabby M., Gottesdiener K.M., Barbosa J., Jones N.H.,
RA   Strominger J.L., Speck S., Leiden J.M.;
RT   "Molecular cloning of complementary DNAs encoding the heavy chain of
RT   the human 4F2 cell-surface antigen: a type II membrane glycoprotein
RT   involved in normal and neoplastic cell growth.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6526-6530(1987).
RN   [2]
RP   ERRATUM, AND SEQUENCE REVISION.
RA   Quackenbush E., Clabby M., Gottesdiener K.M., Barbosa J., Jones N.H.,
RA   Strominger J.L., Speck S., Leiden J.M.;
RL   Proc. Natl. Acad. Sci. U.S.A. 84:8618-8618(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=3036867;
RA   Teixeira S., di Grandi S., Kuehn L.C.;
RT   "Primary structure of the human 4F2 antigen heavy chain predicts a
RT   transmembrane protein with a cytoplasmic NH2 terminus.";
RL   J. Biol. Chem. 262:9574-9580(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND
RP   INDUCTION.
RC   TISSUE=Fibroblast;
RX   PubMed=3480538; DOI=10.1073/pnas.84.24.9204;
RA   Lumadue J.A., Glick A.B., Ruddle F.H.;
RT   "Cloning, sequence analysis, and expression of the large subunit of
RT   the human lymphocyte activation antigen 4F2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:9204-9208(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 2),
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=3265470;
RA   Gottesdiener K.M., Karpinski B.A., Lindsten T., Strominger J.L.,
RA   Jones N.H., Thompson C.B., Leiden J.M.;
RT   "Isolation and structural characterization of the human 4F2 heavy-
RT   chain gene, an inducible gene involved in T-lymphocyte activation.";
RL   Mol. Cell. Biol. 8:3809-3819(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBUNIT, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=11557028; DOI=10.1016/S0005-2736(01)00384-4;
RA   Yanagida O., Kanai Y., Chairoungdua A., Kim D.K., Segawa H., Nii T.,
RA   Cha S.H., Matsuo H., Fukushima J., Fukasawa Y., Tani Y., Taketani Y.,
RA   Uchino H., Kim J.Y., Inatomi J., Okayasu I., Miyamoto K., Takeda E.,
RA   Goya T., Endou H.;
RT   "Human L-type amino acid transporter 1 (LAT1): characterization of
RT   function and expression in tumor cell lines.";
RL   Biochim. Biophys. Acta 1514:291-302(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE
RP   SPLICING (ISOFORM 4).
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 1-17; 146-171; 227-245; 304-313; 440-451; 511-525
RP   AND 593-630, ACETYLATION AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Lao L., Ryan K.L.;
RL   Submitted (OCT-2009) to UniProtKB.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 83-209 (ISOFORM 4).
RC   TISSUE=Lung carcinoma;
RA   Strausberg R.L.;
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   PROTEIN SEQUENCE OF 112-122; 148-160; 227-245; 248-255; 288-298;
RP   304-313; 440-451; 511-524 AND 593-625, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (MAR-2005) to UniProtKB.
RN   [12]
RP   FUNCTION, SUBUNIT, INHIBITION, AND MUTAGENESIS OF CYS-210 AND CYS-431.
RX   PubMed=9829974; DOI=10.1074/jbc.273.49.32437;
RA   Torrents D., Estevez R., Pineda M., Fernandez E., Lloberas J.,
RA   Shi Y.-B., Zorzano A., Palacin M.;
RT   "Identification and characterization of a membrane protein (y+L amino
RT   acid transporter-1) that associates with 4F2hc to encode the amino
RT   acid transport activity y+L. A candidate gene for lysinuric protein
RT   intolerance.";
RL   J. Biol. Chem. 273:32437-32445(1998).
RN   [13]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=9751058; DOI=10.1038/26246;
RA   Mastroberardino L., Spindler B., Pfeiffer R., Skelly P.J., Loffing J.,
RA   Shoemaker C.B., Verrey F.;
RT   "Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a
RT   permease family.";
RL   Nature 395:288-291(1998).
RN   [14]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=9878049; DOI=10.1093/emboj/18.1.49;
RA   Pfeiffer R., Rossier G., Spindler B., Meier C., Kuehn L.C., Verrey F.;
RT   "Amino acid transport of y+L-type by heterodimers of 4F2hc/CD98 and
RT   members of the glycoprotein-associated amino acid transporter
RT   family.";
RL   EMBO J. 18:49-57(1999).
RN   [15]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10903140;
RA   Broeer A., Wagner C.A., Lang F., Broeer S.;
RT   "The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates
RT   arginine efflux in exchange with glutamine.";
RL   Biochem. J. 349:787-795(2000).
RN   [16]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=11311135;
RA   Broeer A., Friedrich B., Wagner C.A., Fillon S., Ganapathy V.,
RA   Lang F., Broeer S.;
RT   "Association of 4F2hc with light chains LAT1, LAT2 or y+LAT2 requires
RT   different domains.";
RL   Biochem. J. 355:725-731(2001).
RN   [17]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11389679; DOI=10.1042/0264-6021:3560719;
RA   Ritchie J.W.A., Taylor P.M.;
RT   "Role of the System L permease LAT1 in amino acid and iodothyronine
RT   transport in placenta.";
RL   Biochem. J. 356:719-725(2001).
RN   [18]
RP   SUBUNIT, INTERACTION WITH BETA-1 INTEGRINS, AND MUTAGENESIS OF CYS-210
RP   AND CYS-431.
RX   PubMed=11696247; DOI=10.1186/1472-2091-2-10;
RA   Kolesnikova T.V., Mannion B.A., Berditchevski F., Hemler M.E.;
RT   "Beta1 integrins show specific association with CD98 protein in low
RT   density membranes.";
RL   BMC Biochem. 2:10-10(2001).
RN   [19]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=11564694; DOI=10.1210/en.142.10.4339;
RA   Friesema E.C.H., Docter R., Moerings E.P.C.M., Verrey F.,
RA   Krenning E.P., Hennemann G., Visser T.J.;
RT   "Thyroid hormone transport by the heterodimeric human system L amino
RT   acid transporter.";
RL   Endocrinology 142:4339-4348(2001).
RN   [20]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=11742812;
RA   Okamoto Y., Sakata M., Ogura K., Yamamoto T., Yamaguchi M., Tasaka K.,
RA   Kurachi H., Tsurudome M., Murata Y.;
RT   "Expression and regulation of 4F2hc and hLAT1 in human trophoblasts.";
RL   Am. J. Physiol. 282:C196-C204(2002).
RN   [21]
RP   INTERACTION WITH FAM57A/CT120.
RX   PubMed=12270127; DOI=10.1016/S0006-291X(02)02227-1;
RA   He X.H., Di Y., Li J., Xie Y., Tang Y., Zhang F., Wei L., Zhang Y.,
RA   Qin W.X., Huo K., Li Y., Wan D.F., Gu J.R.;
RT   "Molecular cloning and characterization of CT120, a novel membrane-
RT   associated gene involved in amino acid transport and glutathione
RT   metabolism.";
RL   Biochem. Biophys. Res. Commun. 297:528-536(2002).
RN   [22]
RP   FUNCTION.
RX   PubMed=12117417; DOI=10.1042/BJ20020841;
RA   Simmons-Willis T.A., Koh A.S., Clarkson T.W., Ballatori N.;
RT   "Transport of a neurotoxicant by molecular mimicry: the methylmercury-
RT   L-cysteine complex is a substrate for human L-type large neutral amino
RT   acid transporter (LAT) 1 and LAT2.";
RL   Biochem. J. 367:239-246(2002).
RN   [23]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=12225859; DOI=10.1016/S0005-2736(02)00516-3;
RA   Kim D.K., Kanai Y., Choi H.W., Tangtrongsup S., Chairoungdua A.,
RA   Babu E., Tachampa K., Anzai N., Iribe Y., Endou H.;
RT   "Characterization of the system L amino acid transporter in T24 human
RT   bladder carcinoma cells.";
RL   Biochim. Biophys. Acta 1565:112-121(2002).
RN   [24]
RP   MASS SPECTROMETRY.
RC   TISSUE=Mammary cancer;
RX   PubMed=11840567;
RX   DOI=10.1002/1615-9861(200202)2:2<212::AID-PROT212>3.0.CO;2-H;
RA   Harris R.A., Yang A., Stein R.C., Lucy K., Brusten L., Herath A.,
RA   Parekh R., Waterfield M.D., O'Hare M.J., Neville M.A., Page M.J.,
RA   Zvelebil M.J.;
RT   "Cluster analysis of an extensive human breast cancer cell line
RT   protein expression map database.";
RL   Proteomics 2:212-223(2002).
RN   [25]
RP   FUNCTION, SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=14603368; DOI=10.1113/eph8802647;
RA   Arancibia-Garavilla Y., Toledo F., Casanello P., Sobrevia L.;
RT   "Nitric oxide synthesis requires activity of the cationic and neutral
RT   amino acid transport system y+L in human umbilical vein endothelium.";
RL   Exp. Physiol. 88:699-710(2003).
RN   [26]
RP   FUNCTION, SUBUNIT, INTERACTION WITH ICAM1, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=12716892; DOI=10.1074/jbc.M302777200;
RA   Liu X., Charrier L., Gewirtz A., Sitaraman S., Merlin D.;
RT   "CD98 and intracellular adhesion molecule I regulate the activity of
RT   amino acid transporter LAT-2 in polarized intestinal epithelia.";
RL   J. Biol. Chem. 278:23672-23677(2003).
RN   [27]
RP   GLYCOSYLATION AT ASN-365; ASN-381 AND ASN-424.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [28]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15980244; DOI=10.1167/iovs.04-1175;
RA   Tomi M., Mori M., Tachikawa M., Katayama K., Terasaki T., Hosoya K.;
RT   "L-type amino acid transporter 1-mediated L-leucine transport at the
RT   inner blood-retinal barrier.";
RL   Invest. Ophthalmol. Vis. Sci. 46:2522-2530(2005).
RN   [29]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=15769744; DOI=10.1074/jbc.M413164200;
RA   Li S., Whorton A.R.;
RT   "Identification of stereoselective transporters for S-nitroso-L-
RT   cysteine: role of LAT1 and LAT2 in biological activity of S-
RT   nitrosothiols.";
RL   J. Biol. Chem. 280:20102-20110(2005).
RN   [30]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-381 AND ASN-424.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [32]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16496379; DOI=10.1002/ijc.21866;
RA   Nawashiro H., Otani N., Shinomiya N., Fukui S., Ooigawa H., Shima K.,
RA   Matsuo H., Kanai Y., Endou H.;
RT   "L-type amino acid transporter 1 as a potential molecular target in
RT   human astrocytic tumors.";
RL   Int. J. Cancer 119:484-492(2006).
RN   [33]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [34]
RP   PHOSPHORYLATION AT SER-406; SER-408; SER-410; SER-527 AND SER-531.
RX   PubMed=19065266; DOI=10.1371/journal.pone.0003895;
RA   Nguyen H.T.T., Dalmasso G., Yan Y., Obertone T.S., Sitaraman S.V.,
RA   Merlin D.;
RT   "Ecto-phosphorylation of CD98 regulates cell-cell interactions.";
RL   PLoS ONE 3:E3895-E3895(2008).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [36]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-365; ASN-381 AND ASN-506.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [37]
RP   GLYCOSYLATION AT ASN-424.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [38]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-365; ASN-381; ASN-424 AND
RP   ASN-506.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-103 AND SER-134, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [42]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [43]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 212-630, SUBUNIT, MUTAGENESIS
RP   OF CYS-210, SUBCELLULAR LOCATION, AND DISULFIDE BOND.
RX   PubMed=17724034; DOI=10.1074/jbc.M704524200;
RA   Fort J., de la Ballina L.R., Burghardt H.E., Ferrer-Costa C.,
RA   Turnay J., Ferrer-Orta C., Uson I., Zorzano A., Fernandez-Recio J.,
RA   Orozco M., Lizarbe M.A., Fita I., Palacin M.;
RT   "The structure of human 4F2hc ectodomain provides a model for
RT   homodimerization and electrostatic interaction with plasma membrane.";
RL   J. Biol. Chem. 282:31444-31452(2007).
CC   -!- FUNCTION: Required for the function of light chain amino-acid
CC       transporters. Involved in sodium-independent, high-affinity
CC       transport of large neutral amino acids such as phenylalanine,
CC       tyrosine, leucine, arginine and tryptophan. Involved in guiding
CC       and targeting of LAT1 and LAT2 to the plasma membrane. When
CC       associated with SLC7A6 or SLC7A7 acts as an arginine/glutamine
CC       exchanger, following an antiport mechanism for amino acid
CC       transport, influencing arginine release in exchange for
CC       extracellular amino acids. Plays a role in nitric oxide synthesis
CC       in human umbilical vein endothelial cells (HUVECs) via transport
CC       of L-arginine. Required for normal and neoplastic cell growth.
CC       When associated with SLC7A5/LAT1, is also involved in the
CC       transport of L-DOPA across the blood-brain barrier, and that of
CC       thyroid hormones triiodothyronine (T3) and thyroxine (T4) across
CC       the cell membrane in tissues such as placenta. Involved in the
CC       uptake of methylmercury (MeHg) when administered as the L-cysteine
CC       or D,L-homocysteine complexes, and hence plays a role in metal ion
CC       homeostasis and toxicity. When associated with SLC7A5 or SLC7A8,
CC       involved in the cellular activity of small molecular weight
CC       nitrosothiols, via the stereoselective transport of L-
CC       nitrosocysteine (L-CNSO) across the transmembrane. Together with
CC       ICAM1, regulates the transport activity LAT2 in polarized
CC       intestinal cells, by generating and delivering intracellular
CC       signals. When associated with SLC7A5, plays an important role in
CC       transporting L-leucine from the circulating blood to the retina
CC       across the inner blood-retinal barrier.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=295 uM for glutamine (in the presence of NaCl);
CC         KM=236 uM for leucine (in the presence of NaCl);
CC         KM=120 uM for arginine (in the presence of NaCl);
CC         KM=138 uM for arginine (in the absence of NaCl);
CC   -!- SUBUNIT: Disulfide-linked heterodimer of a glycosylated heavy
CC       chain and a non-glycosylated light chain (SLC7A5, SLC7A6, SLCA7A7,
CC       SLC7A8, SLC7A10 or SLCA7A11). Colocalizes with cadherins (By
CC       similarity). Interacts with FAM57A/CT120 and ICAM1. Constitutively
CC       and specifically associates with beta-1 integrins (alpha-2/beta-1,
CC       alpha-3/beta-1, alpha-5/beta-1 and alpha-6/beta-1), but minimally
CC       with alpha-4/beta-1.
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane; Single-pass type II
CC       membrane protein. Melanosome. Note=Identified by mass spectrometry
CC       in melanosome fractions from stage I to stage IV. Localized to the
CC       plasma membrane when associated with SLC7A5 or SLC7A8. Localized
CC       to the placental apical membrane. Located selectively at cell-cell
CC       adhesion sites (By similarity). Colocalized with SLC7A8/LAT2 at
CC       the basolateral membrane of kidney proximal tubules and small
CC       intestine epithelia. Expressed in both luminal and abluminal
CC       membranes of brain capillary endothelial cells (By similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P08195-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08195-2; Sequence=VSP_037907;
CC       Name=3;
CC         IsoId=P08195-3; Sequence=VSP_037908;
CC       Name=4;
CC         IsoId=P08195-4; Sequence=VSP_037909;
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously in all tissues tested
CC       with highest levels detected in kidney, placenta and testis and
CC       weakest level in thymus. During gestation, expression in the
CC       placenta was significantly stronger at full-term than at the mid-
CC       trimester stage. Expressed in HUVECS and at low levels in resting
CC       peripheral blood T-lymphocytes and quiescent fibroblasts. Also
CC       expressed in fetal liver and in the astrocytic process of primary
CC       astrocytic gliomas. Expressed in retinal endothelial cells and in
CC       the intestinal epithelial cell line C2BBe1.
CC   -!- INDUCTION: Expression is induced in resting peripheral blood T-
CC       lymphocytes following PHA stimulation. Expression increases at the
CC       time of maximal DNA synthesis, in fibroblasts stimulated to
CC       divide. Expression and the uptake of leucine is stimulated in
CC       mononuclear, cytotrophoblast-like choriocarcinoma cells by
CC       combined treatment with PMA and calcium ionophore.
CC   -!- PTM: Phosphorylation on Ser-406; Ser-408 or Ser-410 and on Ser-527
CC       or Ser-531 by ecto-protein kinases favors heterotypic cell-cell
CC       interactions.
CC   -!- MASS SPECTROMETRY: Mass=57944.93; Method=MALDI; Range=1-529;
CC       Source=PubMed:11840567;
CC   -!- MISCELLANEOUS: Arginine uptake is inhibited by increasing
CC       concentrations of leucine in the presence of Na(+).
CC   -!- SIMILARITY: Belongs to the SLC3A transporter family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J02939; AAA52497.1; -; mRNA.
DR   EMBL; J02769; AAA51540.1; -; mRNA.
DR   EMBL; J03569; AAA35536.1; -; mRNA.
DR   EMBL; M21904; AAA35489.1; -; Genomic_DNA.
DR   EMBL; M21898; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21899; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21900; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21901; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21902; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21903; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; AB018010; BAA84649.1; -; mRNA.
DR   EMBL; AP001160; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001061; AAH01061.2; -; mRNA.
DR   EMBL; BC003000; AAH03000.2; -; mRNA.
DR   EMBL; BE794697; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS31589.1; -. [P08195-3]
DR   CCDS; CCDS31590.1; -. [P08195-2]
DR   CCDS; CCDS8039.2; -. [P08195-1]
DR   PIR; A28455; SAHU4F.
DR   RefSeq; NP_001012680.1; NM_001012662.2.
DR   RefSeq; NP_001012682.1; NM_001012664.2. [P08195-3]
DR   RefSeq; NP_001013269.1; NM_001013251.2. [P08195-2]
DR   RefSeq; NP_002385.3; NM_002394.5. [P08195-1]
DR   UniGene; Hs.502769; -.
DR   PDB; 2DH2; X-ray; 2.10 A; A=212-630.
DR   PDB; 2DH3; X-ray; 2.80 A; A/B=212-630.
DR   PDBsum; 2DH2; -.
DR   PDBsum; 2DH3; -.
DR   ProteinModelPortal; P08195; -.
DR   SMR; P08195; 212-630.
DR   BioGrid; 112411; 29.
DR   IntAct; P08195; 11.
DR   MINT; MINT-4999018; -.
DR   STRING; 9606.ENSP00000367124; -.
DR   CAZy; GH13; Glycoside Hydrolase Family 13.
DR   TCDB; 8.A.9.2.2; the rbat transport accessory protein (rbat) family.
DR   PhosphoSite; P08195; -.
DR   DMDM; 257051063; -.
DR   MaxQB; P08195; -.
DR   PaxDb; P08195; -.
DR   PRIDE; P08195; -.
DR   DNASU; 6520; -.
DR   Ensembl; ENST00000338663; ENSP00000340815; ENSG00000168003. [P08195-2]
DR   Ensembl; ENST00000377889; ENSP00000367121; ENSG00000168003. [P08195-3]
DR   Ensembl; ENST00000377890; ENSP00000367122; ENSG00000168003. [P08195-1]
DR   Ensembl; ENST00000377892; ENSP00000367124; ENSG00000168003. [P08195-4]
DR   GeneID; 6520; -.
DR   KEGG; hsa:6520; -.
DR   UCSC; uc001nwd.3; human. [P08195-1]
DR   UCSC; uc001nwf.3; human. [P08195-3]
DR   CTD; 6520; -.
DR   GeneCards; GC11P062623; -.
DR   HGNC; HGNC:11026; SLC3A2.
DR   HPA; CAB010455; -.
DR   HPA; HPA017980; -.
DR   MIM; 158070; gene.
DR   neXtProt; NX_P08195; -.
DR   PharmGKB; PA35894; -.
DR   eggNOG; COG0366; -.
DR   HOGENOM; HOG000233529; -.
DR   HOVERGEN; HBG000023; -.
DR   InParanoid; P08195; -.
DR   KO; K06519; -.
DR   OMA; NMTVKGQ; -.
DR   OrthoDB; EOG7ZSHSV; -.
DR   PhylomeDB; P08195; -.
DR   BioCyc; MetaCyc:ENSG00000168003-MONOMER; -.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   Reactome; REACT_19419; Amino acid and oligopeptide SLC transporters.
DR   Reactome; REACT_604; Hemostasis.
DR   SABIO-RK; P08195; -.
DR   ChiTaRS; SLC3A2; human.
DR   EvolutionaryTrace; P08195; -.
DR   GeneWiki; SLC3A2; -.
DR   GenomeRNAi; 6520; -.
DR   NextBio; 25353; -.
DR   PRO; PR:P08195; -.
DR   ArrayExpress; P08195; -.
DR   Bgee; P08195; -.
DR   CleanEx; HS_SLC3A2; -.
DR   Genevestigator; P08195; -.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005432; F:calcium:sodium antiporter activity; TAS:UniProtKB.
DR   GO; GO:0003824; F:catalytic activity; IEA:InterPro.
DR   GO; GO:0043169; F:cation binding; IEA:InterPro.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI.
DR   GO; GO:0015175; F:neutral amino acid transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0006865; P:amino acid transport; TAS:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0006816; P:calcium ion transport; NAS:UniProtKB.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:InterPro.
DR   GO; GO:0016049; P:cell growth; NAS:UniProtKB.
DR   GO; GO:0006811; P:ion transport; TAS:Reactome.
DR   GO; GO:0060356; P:leucine import; ISS:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IMP:MGI.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; TAS:GOC.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0015827; P:tryptophan transport; ISS:UniProtKB.
DR   Gene3D; 2.60.40.1180; -; 1.
DR   Gene3D; 3.20.20.80; -; 1.
DR   InterPro; IPR015902; Glyco_hydro_13.
DR   InterPro; IPR013780; Glyco_hydro_13_b.
DR   InterPro; IPR006047; Glyco_hydro_13_cat_dom.
DR   InterPro; IPR013781; Glyco_hydro_catalytic_dom.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   PANTHER; PTHR10357; PTHR10357; 1.
DR   Pfam; PF00128; Alpha-amylase; 2.
DR   SUPFAM; SSF51445; SSF51445; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Amino-acid transport;
KW   Cell membrane; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Isopeptide bond; Membrane;
KW   Phosphoprotein; Reference proteome; Signal-anchor; Transmembrane;
KW   Transmembrane helix; Transport; Ubl conjugation.
FT   CHAIN         1    630       4F2 cell-surface antigen heavy chain.
FT                                /FTId=PRO_0000064383.
FT   TOPO_DOM    102    184       Cytoplasmic (Potential).
FT   TRANSMEM    185    205       Helical; Signal-anchor for type II
FT                                membrane protein; (Potential).
FT   TOPO_DOM    206    630       Extracellular (Potential).
FT   MOD_RES       1      1       N-acetylmethionine.
FT   MOD_RES     103    103       Phosphoserine.
FT   MOD_RES     134    134       Phosphoserine.
FT   MOD_RES     165    165       Phosphoserine.
FT   MOD_RES     406    406       Phosphoserine (Probable).
FT   MOD_RES     408    408       Phosphoserine (Probable).
FT   MOD_RES     410    410       Phosphoserine (Probable).
FT   MOD_RES     527    527       Phosphoserine (Probable).
FT   MOD_RES     531    531       Phosphoserine (Probable).
FT   CARBOHYD    365    365       N-linked (GlcNAc...).
FT   CARBOHYD    381    381       N-linked (GlcNAc...).
FT   CARBOHYD    424    424       N-linked (GlcNAc...) (complex).
FT   CARBOHYD    506    506       N-linked (GlcNAc...).
FT   DISULFID    210    210       Interchain (with light chain).
FT   CROSSLNK    147    147       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   VAR_SEQ       1    101       Missing (in isoform 2).
FT                                /FTId=VSP_037907.
FT   VAR_SEQ      38     99       Missing (in isoform 3).
FT                                /FTId=VSP_037908.
FT   VAR_SEQ      98     98       V -> VTETGFHHVSQADIEFLTSIDPTASASGSAGI (in
FT                                isoform 4).
FT                                /FTId=VSP_037909.
FT   MUTAGEN     210    210       C->S: Abolishes dimerization, leucine
FT                                uptake and interaction with beta-1
FT                                integrins.
FT   MUTAGEN     431    431       C->S: No effect on dimerization, leucine
FT                                uptake or interaction with beta-1
FT                                integrins.
FT   CONFLICT    137    137       G -> E (in Ref. 4; AAA35536).
FT   CONFLICT    158    158       A -> P (in Ref. 3; AAA51540).
FT   CONFLICT    223    223       A -> P (in Ref. 4; AAA35536).
FT   CONFLICT    315    315       E -> D (in Ref. 4; AAA35536).
FT   CONFLICT    320    320       S -> F (in Ref. 5; AAA35489).
FT   CONFLICT    372    372       E -> G (in Ref. 4; AAA35536).
FT   CONFLICT    412    413       GE -> PQ (in Ref. 4; AAA35536).
FT   CONFLICT    465    465       V -> L (in Ref. 4; AAA35536).
FT   CONFLICT    481    481       G -> P (in Ref. 4; AAA35536).
FT   CONFLICT    549    549       G -> E (in Ref. 5; AAA35489).
FT   CONFLICT    609    609       L -> P (in Ref. 4; AAA35536).
FT   CONFLICT    612    612       E -> G (in Ref. 4; AAA35536).
FT   HELIX       218    220
FT   STRAND      224    227
FT   HELIX       230    234
FT   HELIX       241    245
FT   HELIX       248    253
FT   STRAND      257    261
FT   STRAND      265    267
FT   STRAND      275    280
FT   HELIX       282    284
FT   HELIX       287    299
FT   STRAND      303    307
FT   TURN        310    313
FT   STRAND      314    316
FT   STRAND      319    321
FT   HELIX       323    340
FT   STRAND      344    347
FT   HELIX       350    352
FT   HELIX       356    370
FT   STRAND      375    379
FT   HELIX       385    391
FT   TURN        392    394
FT   STRAND      399    401
FT   TURN        404    407
FT   HELIX       412    426
FT   STRAND      437    439
FT   HELIX       441    443
FT   HELIX       447    449
FT   HELIX       450    457
FT   STRAND      460    467
FT   HELIX       470    472
FT   HELIX       476    478
FT   STRAND      479    481
FT   STRAND      484    486
FT   HELIX       493    495
FT   HELIX       500    502
FT   HELIX       505    507
FT   HELIX       509    513
FT   HELIX       519    532
FT   HELIX       534    538
FT   STRAND      540    545
FT   STRAND      550    556
FT   STRAND      562    568
FT   STRAND      570    572
FT   STRAND      581    583
FT   HELIX       585    587
FT   STRAND      591    603
FT   STRAND      607    610
FT   HELIX       611    613
FT   STRAND      621    626
SQ   SEQUENCE   630 AA;  67994 MW;  AE427F8204CC10B0 CRC64;
     MELQPPEASI AVVSIPRQLP GSHSEAGVQG LSAGDDSELG SHCVAQTGLE LLASGDPLPS
     ASQNAEMIET GSDCVTQAGL QLLASSDPPA LASKNAEVTG TMSQDTEVDM KEVELNELEP
     EKQPMNAASG AAMSLAGAEK NGLVKIKVAE DEAEAAAAAK FTGLSKEELL KVAGSPGWVR
     TRWALLLLFW LGWLGMLAGA VVIIVRAPRC RELPAQKWWH TGALYRIGDL QAFQGHGAGN
     LAGLKGRLDY LSSLKVKGLV LGPIHKNQKD DVAQTDLLQI DPNFGSKEDF DSLLQSAKKK
     SIRVILDLTP NYRGENSWFS TQVDTVATKV KDALEFWLQA GVDGFQVRDI ENLKDASSFL
     AEWQNITKGF SEDRLLIAGT NSSDLQQILS LLESNKDLLL TSSYLSDSGS TGEHTKSLVT
     QYLNATGNRW CSWSLSQARL LTSFLPAQLL RLYQLMLFTL PGTPVFSYGD EIGLDAAALP
     GQPMEAPVML WDESSFPDIP GAVSANMTVK GQSEDPGSLL SLFRRLSDQR SKERSLLHGD
     FHAFSAGPGL FSYIRHWDQN ERFLVVLNFG DVGLSAGLQA SDLPASASLP AKADLLLSTQ
     PGREEGSPLE LERLKLEPHE GLLLRFPYAA
//
ID   5HT1A_HUMAN             Reviewed;         422 AA.
AC   P08908; Q6LAE7;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 3.
DT   09-JUL-2014, entry version 146.
DE   RecName: Full=5-hydroxytryptamine receptor 1A;
DE            Short=5-HT-1A;
DE            Short=5-HT1A;
DE   AltName: Full=G-21;
DE   AltName: Full=Serotonin receptor 1A;
GN   Name=HTR1A; Synonyms=ADRB2RL1, ADRBRL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=3041227; DOI=10.1038/329075a0;
RA   Kobilka B.K., Frielle T., Collins S., Yang-Feng T.L., Kobilka T.S.,
RA   Francke U., Lefkowitz R.J., Caron M.G.;
RT   "An intronless gene encoding a potential member of the family of
RT   receptors coupled to guanine nucleotide regulatory proteins.";
RL   Nature 329:75-79(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Saltzman A.G., Morse B., Felder S.;
RT   "Nucleotide and deduced amino acid sequence of the human serotonin 5-
RT   HT1a receptor gene.";
RL   Submitted (FEB-1991) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Levy F.O., Gudermann T., Birnbaumer M., Kaumann A.J., Birnbaumer L.;
RL   Submitted (MAY-1992) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=15014171; DOI=10.1093/molbev/msh100;
RA   Kitano T., Liu Y.-H., Ueda S., Saitou N.;
RT   "Human-specific amino acid changes found in 103 protein-coding
RT   genes.";
RL   Mol. Biol. Evol. 21:936-944(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-9.
RX   PubMed=1766875; DOI=10.1093/nar/19.25.7155;
RA   Parks C.L., Chang L.S., Shenk T.;
RT   "A polymerase chain reaction mediated by a single primer: cloning of
RT   genomic sequences adjacent to a serotonin receptor protein coding
RT   region.";
RL   Nucleic Acids Res. 19:7155-7160(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 200-365, FUNCTION, SUBCELLULAR LOCATION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=8393041;
RA   Aune T.M., McGrath K.M., Sarr T., Bombara M.P., Kelley K.A.;
RT   "Expression of 5HT1a receptors on activated human T cells. Regulation
RT   of cyclic AMP levels and T cell proliferation by 5-
RT   hydroxytryptamine.";
RL   J. Immunol. 151:1175-1183(1993).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=3138543; DOI=10.1038/335358a0;
RA   Fargin A., Raymond J.R., Lohse M.L., Kobilka B.K., Caron M.G.,
RA   Lefkowitz R.J.;
RT   "The genomic clone G-21 which resembles a beta-adrenergic receptor
RT   sequence encodes the 5-HT1A receptor.";
RL   Nature 335:358-360(1988).
RN   [10]
RP   FUNCTION.
RX   PubMed=8138923;
RA   Harrington M.A., Shaw K., Zhong P., Ciaranello R.D.;
RT   "Agonist-induced desensitization and loss of high-affinity binding
RT   sites of stably expressed human 5-HT1A receptors.";
RL   J. Pharmacol. Exp. Ther. 268:1098-1106(1994).
RN   [11]
RP   UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-334.
RC   TISSUE=Lung adenocarcinoma;
RX   PubMed=17203973; DOI=10.1021/pr060438j;
RA   Vasilescu J., Zweitzig D.R., Denis N.J., Smith J.C., Ethier M.,
RA   Haines D.S., Figeys D.;
RT   "The proteomic reactor facilitates the analysis of affinity-purified
RT   proteins by mass spectrometry: application for identifying
RT   ubiquitinated proteins in human cells.";
RL   J. Proteome Res. 6:298-305(2007).
RN   [12]
RP   REVIEW.
RX   PubMed=18476671; DOI=10.1021/cr078224o;
RA   Nichols D.E., Nichols C.D.;
RT   "Serotonin receptors.";
RL   Chem. Rev. 108:1614-1641(2008).
RN   [13]
RP   REVIEW.
RX   PubMed=20363322; DOI=10.1016/j.cellsig.2010.03.019;
RA   Polter A.M., Li X.;
RT   "5-HT1A receptor-regulated signal transduction pathways in brain.";
RL   Cell. Signal. 22:1406-1412(2010).
RN   [14]
RP   REVIEW.
RX   PubMed=20945968;
RA   Pytliak M., Vargova V., Mechirova V., Felsoci M.;
RT   "Serotonin receptors - from molecular biology to clinical
RT   applications.";
RL   Physiol. Res. 60:15-25(2011).
RN   [15]
RP   INVOLVEMENT IN PFMC.
RX   PubMed=21990073; DOI=10.1002/humu.21622;
RA   Jiang Y.C., Wu H.M., Cheng K.H., Sunny Sun H.;
RT   "Menstrual cycle-dependent febrile episode mediated by sequence-
RT   specific repression of poly(ADP-ribose) polymerase-1 on the
RT   transcription of the human serotonin receptor 1A gene.";
RL   Hum. Mutat. 33:209-217(2012).
RN   [16]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22957663; DOI=10.1111/jnc.12008;
RA   Singh P., Paila Y.D., Chattopadhyay A.;
RT   "Role of glycosphingolipids in the function of human serotonin(1)A
RT   receptors.";
RL   J. Neurochem. 123:716-724(2012).
RN   [17]
RP   SUBUNIT.
RX   PubMed=23300088; DOI=10.1074/jbc.M112.412478;
RA   Akama K.T., Thompson L.I., Milner T.A., McEwen B.S.;
RT   "Post-synaptic density-95 (PSD-95) binding capacity of G-protein-
RT   coupled receptor 30 (GPR30), an estrogen receptor that can be
RT   identified in hippocampal dendritic spines.";
RL   J. Biol. Chem. 288:6438-6450(2013).
RN   [18]
RP   VARIANTS SER-22 AND VAL-28.
RX   PubMed=7755630; DOI=10.1006/bbrc.1995.1692;
RA   Nakhai B., Nielsen D.A., Linnoila M., Goldman D.;
RT   "Two naturally occurring amino acid substitutions in the human 5-HT1A
RT   receptor: glycine 22 to serine 22 and isoleucine 28 to valine 28.";
RL   Biochem. Biophys. Res. Commun. 210:530-536(1995).
RN   [19]
RP   VARIANTS LEU-16 AND ASP-273.
RX   PubMed=9754630;
RX   DOI=10.1002/(SICI)1096-8628(19980907)81:5<434::AID-AJMG13>3.0.CO;2-D;
RA   Kawanishi Y., Harada S., Tachikawa H., Okubo T., Shiraishi H.;
RT   "Novel mutations in the promoter and coding region of the human 5-HT1A
RT   receptor gene and association analysis in schizophrenia.";
RL   Am. J. Med. Genet. 81:434-439(1998).
CC   -!- FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine
CC       (serotonin). Also functions as a receptor for various drugs and
CC       psychoactive substances. Ligand binding causes a conformation
CC       change that triggers signaling via guanine nucleotide-binding
CC       proteins (G proteins) and modulates the activity of down-stream
CC       effectors, such as adenylate cyclase. Beta-arrestin family members
CC       inhibit signaling via G proteins and mediate activation of
CC       alternative signaling pathways. Signaling inhibits adenylate
CC       cyclase activity and activates a phosphatidylinositol-calcium
CC       second messenger system that regulates the release of Ca(2+) ions
CC       from intracellular stores. Plays a role in the regulation of 5-
CC       hydroxytryptamine release and in the regulation of dopamine and 5-
CC       hydroxytryptamine metabolism. Plays a role in the regulation of
CC       dopamine and 5-hydroxytryptamine levels in the brain, and thereby
CC       affects neural activity, mood and behavior. Plays a role in the
CC       response to anxiogenic stimuli.
CC   -!- SUBUNIT: Heterodimer; heterodimerizes with GPER1.
CC   -!- INTERACTION:
CC       P11362:FGFR1; NbExp=11; IntAct=EBI-6570214, EBI-1028277;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Detected in lymph nodes, thymus and spleen.
CC       Detected in activated T-cells, but not in resting T-cells.
CC   -!- DISEASE: Periodic fever, menstrual cycle-dependent (PFMC)
CC       [MIM:614674]: A condition characterized by recurrent fevers up to
CC       40 degrees Celsius associated with the luteal phase of the
CC       menstrual cycle. Women show menstrual cycle-dependent physiologic
CC       changes in relation to sex hormone levels. Because ovulation
CC       triggers a significant change in the hormonal milieu that is
CC       similar to local inflammation, a 0.5 to 1.0 degree Celsius
CC       increase in basal body temperature after ovulation is commonly
CC       associated with progesterone secretion and is believed to be
CC       triggered by the induction of several inflammatory cytokines.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family. 5-
CC       hydroxytryptamine receptor subfamily. HTR1A sub-subfamily.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M28269; AAA36440.1; -; Genomic_DNA.
DR   EMBL; X13556; CAA31908.1; -; Genomic_DNA.
DR   EMBL; X57829; CAA40962.1; -; Genomic_DNA.
DR   EMBL; M83181; AAA66493.1; -; Genomic_DNA.
DR   EMBL; AB041403; BAA94488.1; -; Genomic_DNA.
DR   EMBL; AF498978; AAM21125.1; -; mRNA.
DR   EMBL; BC069159; AAH69159.1; -; mRNA.
DR   EMBL; Z11168; CAA77560.1; -; Genomic_DNA.
DR   CCDS; CCDS34168.1; -.
DR   PIR; I38209; I38209.
DR   RefSeq; NP_000515.2; NM_000524.3.
DR   UniGene; Hs.247940; -.
DR   ProteinModelPortal; P08908; -.
DR   SMR; P08908; 31-418.
DR   BioGrid; 109582; 6.
DR   IntAct; P08908; 4.
DR   STRING; 9606.ENSP00000316244; -.
DR   BindingDB; P08908; -.
DR   ChEMBL; CHEMBL2096904; -.
DR   DrugBank; DB00866; Alprenolol.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB00490; Buspirone.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00216; Eletriptan.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00176; Fluvoxamine.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB00247; Methysergide.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB00960; Pindolol.
DR   DrugBank; DB00571; Propranolol.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB01104; Sertraline.
DR   DrugBank; DB01079; Tegaserod.
DR   DrugBank; DB00656; Trazodone.
DR   DrugBank; DB00285; Venlafaxine.
DR   DrugBank; DB00246; Ziprasidone.
DR   GuidetoPHARMACOLOGY; 1; -.
DR   PhosphoSite; P08908; -.
DR   DMDM; 231454; -.
DR   PaxDb; P08908; -.
DR   PRIDE; P08908; -.
DR   DNASU; 3350; -.
DR   Ensembl; ENST00000323865; ENSP00000316244; ENSG00000178394.
DR   GeneID; 3350; -.
DR   KEGG; hsa:3350; -.
DR   UCSC; uc011cqt.3; human.
DR   CTD; 3350; -.
DR   GeneCards; GC05M063292; -.
DR   HGNC; HGNC:5286; HTR1A.
DR   HPA; HPA018073; -.
DR   MIM; 109760; gene.
DR   MIM; 614674; phenotype.
DR   neXtProt; NX_P08908; -.
DR   PharmGKB; PA192; -.
DR   eggNOG; NOG249628; -.
DR   HOGENOM; HOG000239242; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P08908; -.
DR   KO; K04153; -.
DR   OMA; TGAPCAN; -.
DR   PhylomeDB; P08908; -.
DR   TreeFam; TF316350; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   GenomeRNAi; 3350; -.
DR   NextBio; 13248; -.
DR   PRO; PR:P08908; -.
DR   ArrayExpress; P08908; -.
DR   Bgee; P08908; -.
DR   CleanEx; HS_HTR1A; -.
DR   Genevestigator; P08908; -.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0004993; F:serotonin receptor activity; IDA:UniProtKB.
DR   GO; GO:0007198; P:adenylate cyclase-inhibiting serotonin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0001662; P:behavioral fear response; ISS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; IEA:InterPro.
DR   GO; GO:0035640; P:exploration behavior; ISS:UniProtKB.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0050795; P:regulation of behavior; IEA:InterPro.
DR   GO; GO:0042053; P:regulation of dopamine metabolic process; ISS:UniProtKB.
DR   GO; GO:0046883; P:regulation of hormone secretion; IEA:InterPro.
DR   GO; GO:0014062; P:regulation of serotonin secretion; ISS:UniProtKB.
DR   GO; GO:0042428; P:serotonin metabolic process; ISS:UniProtKB.
DR   GO; GO:0007210; P:serotonin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0042310; P:vasoconstriction; IEA:InterPro.
DR   Gene3D; 1.20.1070.10; -; 2.
DR   InterPro; IPR000610; 5HT1A_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24247:SF20; PTHR24247:SF20; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00512; 5HT1ARECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Behavior; Cell membrane; Complete proteome; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Isopeptide bond; Membrane;
KW   Polymorphism; Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   CHAIN         1    422       5-hydroxytryptamine receptor 1A.
FT                                /FTId=PRO_0000068903.
FT   TOPO_DOM      1     36       Extracellular (By similarity).
FT   TRANSMEM     37     62       Helical; Name=1; (By similarity).
FT   TOPO_DOM     63     73       Cytoplasmic (By similarity).
FT   TRANSMEM     74     98       Helical; Name=2; (By similarity).
FT   TOPO_DOM     99    110       Extracellular (By similarity).
FT   TRANSMEM    111    132       Helical; Name=3; (By similarity).
FT   TOPO_DOM    133    152       Cytoplasmic (By similarity).
FT   TRANSMEM    153    178       Helical; Name=4; (By similarity).
FT   TOPO_DOM    179    191       Extracellular (By similarity).
FT   TRANSMEM    192    217       Helical; Name=5; (By similarity).
FT   TOPO_DOM    218    345       Cytoplasmic (By similarity).
FT   TRANSMEM    346    367       Helical; Name=6; (By similarity).
FT   TOPO_DOM    368    378       Extracellular (By similarity).
FT   TRANSMEM    379    403       Helical; Name=7; (By similarity).
FT   TOPO_DOM    404    422       Cytoplasmic (By similarity).
FT   REGION      112    121       Agonist binding (By similarity).
FT   REGION      358    362       Agonist binding (By similarity).
FT   MOTIF       133    135       DRY motif; important for ligand-induced
FT                                conformation changes (By similarity).
FT   MOTIF       396    400       NPxxY motif; important for ligand-induced
FT                                conformation changes and signaling (By
FT                                similarity).
FT   CARBOHYD     10     10       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     11     11       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     24     24       N-linked (GlcNAc...) (Potential).
FT   DISULFID    109    187       By similarity.
FT   CROSSLNK    334    334       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   VARIANT      16     16       P -> L (in dbSNP:rs1800041).
FT                                /FTId=VAR_003446.
FT   VARIANT      22     22       G -> S (in dbSNP:rs1799920).
FT                                /FTId=VAR_011826.
FT   VARIANT      28     28       I -> V (in dbSNP:rs1799921).
FT                                /FTId=VAR_011827.
FT   VARIANT     184    184       P -> L (in dbSNP:rs1800043).
FT                                /FTId=VAR_011828.
FT   VARIANT     220    220       R -> L (in dbSNP:rs1800044).
FT                                /FTId=VAR_011829.
FT   VARIANT     273    273       G -> D (in dbSNP:rs1800042).
FT                                /FTId=VAR_011830.
FT   CONFLICT    152    154       RAA -> PR (in Ref. 1; AAA36440/CAA31908).
FT   CONFLICT    172    172       M -> I (in Ref. 1; AAA36440/CAA31908).
FT   CONFLICT    200    202       TFG -> RPR (in Ref. 8; no nucleotide
FT                                entry).
FT   CONFLICT    228    228       K -> R (in Ref. 8; no nucleotide entry).
FT   CONFLICT    244    244       A -> AA (in Ref. 8; no nucleotide entry).
FT   CONFLICT    355    355       I -> T (in Ref. 8; no nucleotide entry).
FT   CONFLICT    363    365       IVA -> MRP (in Ref. 8; no nucleotide
FT                                entry).
FT   CONFLICT    418    418       K -> N (in Ref. 1; AAA36440/CAA31908).
SQ   SEQUENCE   422 AA;  46107 MW;  762664FCF62CFD8F CRC64;
     MDVLSPGQGN NTTSPPAPFE TGGNTTGISD VTVSYQVITS LLLGTLIFCA VLGNACVVAA
     IALERSLQNV ANYLIGSLAV TDLMVSVLVL PMAALYQVLN KWTLGQVTCD LFIALDVLCC
     TSSILHLCAI ALDRYWAITD PIDYVNKRTP RRAAALISLT WLIGFLISIP PMLGWRTPED
     RSDPDACTIS KDHGYTIYST FGAFYIPLLL MLVLYGRIFR AARFRIRKTV KKVEKTGADT
     RHGASPAPQP KKSVNGESGS RNWRLGVESK AGGALCANGA VRQGDDGAAL EVIEVHRVGN
     SKEHLPLPSE AGPTPCAPAS FERKNERNAE AKRKMALARE RKTVKTLGII MGTFILCWLP
     FFIVALVLPF CESSCHMPTL LGAIINWLGY SNSLLNPVIY AYFNKDFQNA FKKIIKCKFC
     RQ
//
ID   5HT1B_HUMAN             Reviewed;         390 AA.
AC   P28222; Q4VAY7;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   09-JUL-2014, entry version 137.
DE   RecName: Full=5-hydroxytryptamine receptor 1B;
DE            Short=5-HT-1B;
DE            Short=5-HT1B;
DE   AltName: Full=S12;
DE   AltName: Full=Serotonin 1D beta receptor;
DE            Short=5-HT-1D-beta;
DE   AltName: Full=Serotonin receptor 1B;
GN   Name=HTR1B; Synonyms=HTR1DB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=1315531; DOI=10.1016/0006-291X(92)90654-4;
RA   Hamblin M.W., Metcalf M.A., McGuffin R.W., Karpells S.;
RT   "Molecular cloning and functional characterization of a human 5-HT1B
RT   serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-
RT   HT1D-like pharmacological specificity.";
RL   Biochem. Biophys. Res. Commun. 184:752-759(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=1610347; DOI=10.1016/0006-291X(92)91655-A;
RA   Mochizuki D., Yuyama Y., Tsujita R., Komaki H., Sagai H.;
RT   "Cloning and expression of the human 5-HT1B-type receptor gene.";
RL   Biochem. Biophys. Res. Commun. 185:517-523(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=1348246;
RA   Jin H., Oksenberg D., Ashkenazi A., Peroutka S.J., Duncan A.M.V.,
RA   Rozmahel R., Yang Y., Mengod G., Palacios J.M., O'Dowd B.F.;
RT   "Characterization of the human 5-hydroxytryptamine1B receptor.";
RL   J. Biol. Chem. 267:5735-5738(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=1559993;
RA   Levy F.O., Gudermann T., Perez-Reyes E., Birnbaumer M., Kaumann A.J.,
RA   Birnbaumer L.;
RT   "Molecular cloning of a human serotonin receptor (S12) with a
RT   pharmacological profile resembling that of the 5-HT1D subtype.";
RL   J. Biol. Chem. 267:7553-7562(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=1565658; DOI=10.1073/pnas.89.8.3630;
RA   Weinshank R.L., Zgombick J.M., Macchi M.J., Branchek T.A.,
RA   Hartig P.R.;
RT   "Human serotonin 1D receptor is encoded by a subfamily of two distinct
RT   genes: 5-HT1D alpha and 5-HT1D beta.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3630-3634(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=1351684; DOI=10.1073/pnas.89.12.5522;
RA   Demchyshyn L., Sunahara R.K., Miller K., Teitler M., Hoffman B.J.,
RA   Kennedy J.L., Seeman P., van Tol H.H.M., Niznik H.B.;
RT   "A human serotonin 1D receptor variant (5HT1D beta) encoded by an
RT   intronless gene on chromosome 6.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:5522-5526(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=1328844;
RA   Veldman S.A., Bienkowski M.J.;
RT   "Cloning and pharmacological characterization of a novel human 5-
RT   hydroxytryptamine1D receptor subtype.";
RL   Mol. Pharmacol. 42:439-444(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=15014171; DOI=10.1093/molbev/msh100;
RA   Kitano T., Liu Y.-H., Ueda S., Saitou N.;
RT   "Human-specific amino acid changes found in 103 protein-coding
RT   genes.";
RL   Mol. Biol. Evol. 21:936-944(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "Isolation of complete coding sequence for 5-hydroxytryptamine
RT   (serotonin) receptor 1B (HTR1B).";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   PALMITOYLATION, PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=8218242; DOI=10.1021/bi00094a032;
RA   Ng G.Y.K., George S.R., Zastawny R.L., Caron M., Bouvier M.,
RA   Dennis M., O'Dowd B.F.;
RT   "Human serotonin1B receptor expression in Sf9 cells: phosphorylation,
RT   palmitoylation, and adenylyl cyclase inhibition.";
RL   Biochemistry 32:11727-11733(1993).
RN   [13]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=10452531; DOI=10.1016/S0014-5793(99)00918-7;
RA   Xie Z., Lee S.P., O'Dowd B.F., George S.R.;
RT   "Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed
RT   alone and heterodimers when co-expressed.";
RL   FEBS Lett. 456:63-67(1999).
RN   [14]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15853772; DOI=10.1042/CS20050016;
RA   Edvinsson L., Uddman E., Wackenfors A., Davenport A., Longmore J.,
RA   Malmsjo M.;
RT   "Triptan-induced contractile (5-HT1B receptor) responses in human
RT   cerebral and coronary arteries: relationship to clinical effect.";
RL   Clin. Sci. 109:335-342(2005).
RN   [15]
RP   REVIEW.
RX   PubMed=18476671; DOI=10.1021/cr078224o;
RA   Nichols D.E., Nichols C.D.;
RT   "Serotonin receptors.";
RL   Chem. Rev. 108:1614-1641(2008).
RN   [16]
RP   REVIEW.
RX   PubMed=20945968;
RA   Pytliak M., Vargova V., Mechirova V., Felsoci M.;
RT   "Serotonin receptors - from molecular biology to clinical
RT   applications.";
RL   Physiol. Res. 60:15-25(2011).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=23519215; DOI=10.1126/science.1232808;
RA   Wacker D., Wang C., Katritch V., Han G.W., Huang X.P., Vardy E.,
RA   McCorvy J.D., Jiang Y., Chu M., Siu F.Y., Liu W., Xu H.E.,
RA   Cherezov V., Roth B.L., Stevens R.C.;
RT   "Structural features for functional selectivity at serotonin
RT   receptors.";
RL   Science 340:615-619(2013).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 33-390 IN COMPLEXES WITH
RP   ERGOTAMINE AND DIHYDROERGOTAMINE, FUNCTION, SUBCELLULAR LOCATION,
RP   MEMBRANE TOPOLOGY, DOMAIN, DISULFIDE BOND, AND MUTAGENESIS OF LEU-126;
RP   ASP-129; ILE-130; CYS-133; THR-134; VAL-200; VAL-201; THR-203;
RP   THR-209; SER-212; ALA-216; TRP-327; PHE-330; PHE-331; SER-334;
RP   MET-337; PHE-351; ASP-352; THR-355 AND TYR-359.
RX   PubMed=23519210; DOI=10.1126/science.1232807;
RA   Wang C., Jiang Y., Ma J., Wu H., Wacker D., Katritch V., Han G.W.,
RA   Liu W., Huang X.P., Vardy E., McCorvy J.D., Gao X., Zhou X.E.,
RA   Melcher K., Zhang C., Bai F., Yang H., Yang L., Jiang H., Roth B.L.,
RA   Cherezov V., Stevens R.C., Xu H.E.;
RT   "Structural basis for molecular recognition at serotonin receptors.";
RL   Science 340:610-614(2013).
RN   [19]
RP   VARIANT CYS-124.
RX   PubMed=7802650; DOI=10.1006/bbrc.1994.2792;
RA   Nothen M.M., Erdmann J., Shimron-Abarbanell D., Propping P.;
RT   "Identification of genetic variation in the human serotonin 1D beta
RT   receptor gene.";
RL   Biochem. Biophys. Res. Commun. 205:1194-1200(1994).
CC   -!- FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine
CC       (serotonin). Also functions as a receptor for ergot alkaloid
CC       derivatives, various anxiolytic and antidepressant drugs and other
CC       psychoactive substances, such as lysergic acid diethylamide (LSD).
CC       Ligand binding causes a conformation change that triggers
CC       signaling via guanine nucleotide-binding proteins (G proteins) and
CC       modulates the activity of down-stream effectors, such as adenylate
CC       cyclase. Signaling inhibits adenylate cyclase activity. Arrestin
CC       family members inhibit signaling via G proteins and mediate
CC       activation of alternative signaling pathways. Regulates the
CC       release of 5-hydroxytryptamine, dopamine and acetylcholine in the
CC       brain, and thereby affects neural activity, nociceptive
CC       processing, pain perception, mood and behavior. Besides, plays a
CC       role in vasoconstriction of cerebral arteries.
CC   -!- SUBUNIT: Homodimer. Heterodimer with HTR1D.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Detected in cerebral artery smooth muscle
CC       cells (at protein level). Detected in brain cortex, striatum,
CC       amygdala, medulla, hippocampus, caudate nucleus and putamen.
CC   -!- DOMAIN: Ligands are bound in a hydrophobic pocket formed by the
CC       transmembrane helices.
CC   -!- PTM: Phosphorylated. Desensitization of the receptor may be
CC       mediated by its phosphorylation.
CC   -!- PTM: Palmitoylated.
CC   -!- MISCELLANEOUS: A residue in the 7th transmembrane region (Thr-355
CC       in human, 'Asn-351' in mouse and rat) is important for species-
CC       specific sensitivity to various agonists.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M89478; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; D10995; BAA01763.1; -; Genomic_DNA.
DR   EMBL; M83180; AAA36029.1; -; Genomic_DNA.
DR   EMBL; L09732; AAA36030.1; -; Genomic_DNA.
DR   EMBL; M81590; AAA60316.1; -; mRNA.
DR   EMBL; M75128; AAA58675.1; -; Genomic_DNA.
DR   EMBL; AB041370; BAA94455.1; -; Genomic_DNA.
DR   EMBL; AY225227; AAO67712.1; -; Genomic_DNA.
DR   EMBL; AL049595; CAB51537.1; -; Genomic_DNA.
DR   EMBL; BC069065; AAH69065.1; -; mRNA.
DR   EMBL; BC096206; AAH96206.1; -; mRNA.
DR   EMBL; BC096207; AAH96207.1; -; mRNA.
DR   EMBL; BC096208; AAH96208.1; -; mRNA.
DR   CCDS; CCDS4986.1; -.
DR   PIR; JN0268; JN0268.
DR   RefSeq; NP_000854.1; NM_000863.1.
DR   UniGene; Hs.123016; -.
DR   PDB; 2G1X; Model; -; A=1-390.
DR   PDB; 4IAQ; X-ray; 2.80 A; A=33-239, A=304-390.
DR   PDB; 4IAR; X-ray; 2.70 A; A=33-239, A=306-390.
DR   PDBsum; 2G1X; -.
DR   PDBsum; 4IAQ; -.
DR   PDBsum; 4IAR; -.
DR   ProteinModelPortal; P28222; -.
DR   SMR; P28222; 38-387.
DR   BioGrid; 109583; 3.
DR   IntAct; P28222; 1.
DR   STRING; 9606.ENSP00000358963; -.
DR   BindingDB; P28222; -.
DR   ChEMBL; CHEMBL2095230; -.
DR   DrugBank; DB00918; Almotriptan.
DR   DrugBank; DB01191; Dexfenfluramine.
DR   DrugBank; DB00320; Dihydroergotamine.
DR   DrugBank; DB00216; Eletriptan.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB00998; Frovatriptan.
DR   DrugBank; DB00952; Naratriptan.
DR   DrugBank; DB00960; Pindolol.
DR   DrugBank; DB00571; Propranolol.
DR   DrugBank; DB00953; Rizatriptan.
DR   DrugBank; DB00669; Sumatriptan.
DR   DrugBank; DB00285; Venlafaxine.
DR   DrugBank; DB00315; Zolmitriptan.
DR   GuidetoPHARMACOLOGY; 2; -.
DR   TCDB; 9.A.14.3.6; the g-protein-coupled receptor (gpcr) family.
DR   PhosphoSite; P28222; -.
DR   DMDM; 112821; -.
DR   PaxDb; P28222; -.
DR   PRIDE; P28222; -.
DR   DNASU; 3351; -.
DR   Ensembl; ENST00000369947; ENSP00000358963; ENSG00000135312.
DR   GeneID; 3351; -.
DR   KEGG; hsa:3351; -.
DR   UCSC; uc003pil.1; human.
DR   CTD; 3351; -.
DR   GeneCards; GC06M078171; -.
DR   HGNC; HGNC:5287; HTR1B.
DR   HPA; HPA049046; -.
DR   MIM; 182131; gene.
DR   neXtProt; NX_P28222; -.
DR   PharmGKB; PA29549; -.
DR   eggNOG; NOG249628; -.
DR   HOGENOM; HOG000239242; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P28222; -.
DR   KO; K04153; -.
DR   OMA; IALPWKV; -.
DR   OrthoDB; EOG7NCV3Q; -.
DR   PhylomeDB; P28222; -.
DR   TreeFam; TF316350; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   GeneWiki; 5-HT1B_receptor; -.
DR   GenomeRNAi; 3351; -.
DR   NextBio; 13252; -.
DR   PRO; PR:P28222; -.
DR   Bgee; P28222; -.
DR   CleanEx; HS_HTR1B; -.
DR   Genevestigator; P28222; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0008144; F:drug binding; IEA:Ensembl.
DR   GO; GO:0051378; F:serotonin binding; IEA:Ensembl.
DR   GO; GO:0004993; F:serotonin receptor activity; IDA:UniProtKB.
DR   GO; GO:0007198; P:adenylate cyclase-inhibiting serotonin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0046849; P:bone remodeling; IEA:Ensembl.
DR   GO; GO:0071312; P:cellular response to alkaloid; IDA:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; IDA:UniProtKB.
DR   GO; GO:0071502; P:cellular response to temperature stimulus; IEA:Ensembl.
DR   GO; GO:0042756; P:drinking behavior; IEA:Ensembl.
DR   GO; GO:0002031; P:G-protein coupled receptor internalization; IEA:Ensembl.
DR   GO; GO:0007187; P:G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0030818; P:negative regulation of cAMP biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0014063; P:negative regulation of serotonin secretion; ISS:UniProtKB.
DR   GO; GO:0032229; P:negative regulation of synaptic transmission, GABAergic; IEA:Ensembl.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0007205; P:protein kinase C-activating G-protein coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0050795; P:regulation of behavior; IEA:InterPro.
DR   GO; GO:0014059; P:regulation of dopamine secretion; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051385; P:response to mineralocorticoid; IEA:Ensembl.
DR   GO; GO:0007268; P:synaptic transmission; TAS:ProtInc.
DR   GO; GO:0042310; P:vasoconstriction; IEA:InterPro.
DR   Gene3D; 1.20.1070.10; -; 2.
DR   InterPro; IPR002147; 5HT1B_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24247:SF16; PTHR24247:SF16; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00513; 5HT1BRECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Behavior; Cell membrane; Complete proteome;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Lipoprotein;
KW   Membrane; Palmitate; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN         1    390       5-hydroxytryptamine receptor 1B.
FT                                /FTId=PRO_0000068916.
FT   TOPO_DOM      1     49       Extracellular.
FT   TRANSMEM     50     75       Helical; Name=1.
FT   TOPO_DOM     76     84       Cytoplasmic.
FT   TRANSMEM     85    110       Helical; Name=2.
FT   TOPO_DOM    111    123       Extracellular.
FT   TRANSMEM    124    145       Helical; Name=3.
FT   TOPO_DOM    146    165       Cytoplasmic.
FT   TRANSMEM    166    187       Helical; Name=4.
FT   TOPO_DOM    188    205       Extracellular.
FT   TRANSMEM    206    228       Helical; Name=5.
FT   TOPO_DOM    229    315       Cytoplasmic.
FT   TRANSMEM    316    336       Helical; Name=6.
FT   TOPO_DOM    337    349       Extracellular.
FT   TRANSMEM    350    371       Helical; Name=7.
FT   TOPO_DOM    372    390       Cytoplasmic.
FT   REGION      125    134       Agonist binding.
FT   REGION      327    331       Agonist binding.
FT   MOTIF       146    148       DRY motif; important for ligand-induced
FT                                conformation changes and signaling.
FT   MOTIF       365    369       NPxxY motif; important for ligand-induced
FT                                conformation changes and signaling.
FT   SITE        355    355       Important for species-specific agonist
FT                                sensitivity.
FT   LIPID       388    388       S-palmitoyl cysteine (Potential).
FT   CARBOHYD     24     24       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     32     32       N-linked (GlcNAc...) (Potential).
FT   DISULFID    122    199
FT   VARIANT     124    124       F -> C (in dbSNP:rs130060).
FT                                /FTId=VAR_011715.
FT   VARIANT     219    219       F -> L (in dbSNP:rs130061).
FT                                /FTId=VAR_011831.
FT   VARIANT     367    367       I -> V (in dbSNP:rs130063).
FT                                /FTId=VAR_011832.
FT   VARIANT     374    374       E -> K (in dbSNP:rs130064).
FT                                /FTId=VAR_011833.
FT   MUTAGEN     126    126       L->A: No effect on agonist binding.
FT   MUTAGEN     129    129       D->A: Abolishes agonist binding.
FT   MUTAGEN     130    130       I->A: Abolishes agonist binding.
FT   MUTAGEN     133    133       C->A: Abolishes agonist binding.
FT   MUTAGEN     134    134       T->A: Slightly decreases agonist binding.
FT   MUTAGEN     200    200       V->A: No effect on agonist binding.
FT   MUTAGEN     201    201       V->A: No effect on agonist binding.
FT   MUTAGEN     203    203       T->A: No effect on agonist binding.
FT   MUTAGEN     209    209       T->A: No effect on agonist binding.
FT   MUTAGEN     212    212       S->A: No effect on agonist binding.
FT   MUTAGEN     216    216       A->S: No effect on agonist binding.
FT   MUTAGEN     327    327       W->A: Abolishes agonist binding.
FT   MUTAGEN     330    330       F->A: Abolishes agonist binding.
FT   MUTAGEN     331    331       F->A: No effect on agonist binding.
FT   MUTAGEN     334    334       S->A: No effect on agonist binding.
FT   MUTAGEN     337    337       M->A: No effect on agonist binding.
FT   MUTAGEN     351    351       F->A: No effect on agonist binding.
FT   MUTAGEN     352    352       D->A: No effect on agonist binding.
FT   MUTAGEN     355    355       T->A: No effect on agonist binding.
FT   MUTAGEN     359    359       Y->A: No effect on agonist binding.
FT   HELIX        40     43
FT   HELIX        46     76
FT   HELIX        78     80
FT   HELIX        83    101
FT   HELIX       104    112
FT   HELIX       118    152
FT   HELIX       154    158
FT   HELIX       163    181
FT   HELIX       206    216
FT   HELIX       218    239
FT   HELIX       311    336
FT   HELIX       349    372
FT   HELIX       374    383
SQ   SEQUENCE   390 AA;  43568 MW;  CD874DC7EB44CF12 CRC64;
     MEEPGAQCAP PPPAGSETWV PQANLSSAPS QNCSAKDYIY QDSISLPWKV LLVMLLALIT
     LATTLSNAFV IATVYRTRKL HTPANYLIAS LAVTDLLVSI LVMPISTMYT VTGRWTLGQV
     VCDFWLSSDI TCCTASILHL CVIALDRYWA ITDAVEYSAK RTPKRAAVMI ALVWVFSISI
     SLPPFFWRQA KAEEEVSECV VNTDHILYTV YSTVGAFYFP TLLLIALYGR IYVEARSRIL
     KQTPNRTGKR LTRAQLITDS PGSTSSVTSI NSRVPDVPSE SGSPVYVNQV KVRVSDALLE
     KKKLMAARER KATKTLGIIL GAFIVCWLPF FIISLVMPIC KDACWFHLAI FDFFTWLGYL
     NSLINPIIYT MSNEDFKQAF HKLIRFKCTS
//
ID   5HT2A_HUMAN             Reviewed;         471 AA.
AC   P28223; B2RAC5; B4DZ79; F5GWE8; Q5T8C0;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   09-JUL-2014, entry version 148.
DE   RecName: Full=5-hydroxytryptamine receptor 2A;
DE            Short=5-HT-2;
DE            Short=5-HT-2A;
DE   AltName: Full=Serotonin receptor 2A;
GN   Name=HTR2A; Synonyms=HTR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain stem;
RX   PubMed=1722404; DOI=10.1016/0006-291X(91)92105-S;
RA   Saltzman A.G., Morse B., Whitman M.M., Ivanshchenko Y., Jaye M.,
RA   Felder S.;
RT   "Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes.";
RL   Biochem. Biophys. Res. Commun. 181:1469-1478(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1323014; DOI=10.1016/0169-328X(92)90005-V;
RA   Chen K., Yang W., Grimsby J., Shih J.C.;
RT   "The human 5-HT2 receptor is encoded by a multiple intron-exon gene.";
RL   Brain Res. Mol. Brain Res. 14:20-26(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Platelet;
RX   PubMed=8035173;
RA   Cook E.H. Jr., Fletcher K.E., Wainwright M., Marks N., Yan S.Y.,
RA   Leventhal B.L.;
RT   "Primary structure of the human platelet serotonin 5-HT2A receptor:
RT   identify with frontal cortex serotonin 5-HT2A receptor.";
RL   J. Neurochem. 63:465-469(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Testis, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9-464 (ISOFORM 1).
RC   TISSUE=Brain;
RA   Tritch R.J., Robinson D.L., Sahagan B.G., Horlick R.A.;
RT   "Cloning and nucleotide sequence of the human(5HT) type 2 receptor.";
RL   Submitted (MAY-1992) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 105-218, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=1330647; DOI=10.1016/0922-4106(92)90123-D;
RA   Stam N.J., van Huizen F., van Alebeek C., Brands J., Dijkema R.,
RA   Tonnaer J.A., Olijve W.;
RT   "Genomic organization, coding sequence and functional expression of
RT   human 5-HT2 and 5-HT1A receptor genes.";
RL   Eur. J. Pharmacol. 227:153-162(1992).
RN   [11]
RP   INTERACTION WITH MPDZ.
RX   PubMed=11150294; DOI=10.1074/jbc.M008089200;
RA   Becamel C., Figge A., Poliak S., Dumuis A., Peles E., Bockaert J.,
RA   Luebbert H., Ullmer C.;
RT   "Interaction of serotonin 5-hydroxytryptamine type 2C receptors with
RT   PDZ10 of the multi-PDZ domain protein MUPP1.";
RL   J. Biol. Chem. 276:12974-12982(2001).
RN   [12]
RP   INTERACTION WITH INADL; MPP3; PRDX6; DLG4; DLG1; CASK; APBA1 AND
RP   MAGI2, AND MUTAGENESIS OF GLY-463; ASN-465; CYS-470 AND VAL-471.
RX   PubMed=14988405; DOI=10.1074/jbc.M312106200;
RA   Becamel C., Gavarini S., Chanrion B., Alonso G., Galeotti N.,
RA   Dumuis A., Bockaert J., Marin P.;
RT   "The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets
RT   of PDZ proteins.";
RL   J. Biol. Chem. 279:20257-20266(2004).
RN   [13]
RP   REVIEW.
RX   PubMed=18476671; DOI=10.1021/cr078224o;
RA   Nichols D.E., Nichols C.D.;
RT   "Serotonin receptors.";
RL   Chem. Rev. 108:1614-1641(2008).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18703043; DOI=10.1016/j.ejphar.2008.07.040;
RA   Cussac D., Boutet-Robinet E., Ailhaud M.C., Newman-Tancredi A.,
RA   Martel J.C., Danty N., Rauly-Lestienne I.;
RT   "Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-
RT   HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium
RT   mobilisation in CHO cells.";
RL   Eur. J. Pharmacol. 594:32-38(2008).
RN   [15]
RP   INTERACTION WITH GRM2, FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=18297054; DOI=10.1038/nature06612;
RA   Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V.,
RA   Lopez-Gimenez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G.,
RA   Gingrich J.A., Filizola M., Meana J.J., Sealfon S.C.;
RT   "Identification of a serotonin/glutamate receptor complex implicated
RT   in psychosis.";
RL   Nature 452:93-97(2008).
RN   [16]
RP   FUNCTION.
RX   PubMed=19057895; DOI=10.1007/s00210-008-0378-4;
RA   Knauer C.S., Campbell J.E., Chio C.L., Fitzgerald L.W.;
RT   "Pharmacological characterization of mitogen-activated protein kinase
RT   activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B
RT   receptors.";
RL   Naunyn Schmiedebergs Arch. Pharmacol. 379:461-471(2009).
RN   [17]
RP   INTERACTION WITH DRD2, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21645528; DOI=10.1016/j.neuropharm.2011.05.023;
RA   Albizu L., Holloway T., Gonzalez-Maeso J., Sealfon S.C.;
RT   "Functional crosstalk and heteromerization of serotonin 5-HT2A and
RT   dopamine D2 receptors.";
RL   Neuropharmacology 61:770-777(2011).
RN   [18]
RP   REVIEW.
RX   PubMed=20945968;
RA   Pytliak M., Vargova V., Mechirova V., Felsoci M.;
RT   "Serotonin receptors - from molecular biology to clinical
RT   applications.";
RL   Physiol. Res. 60:15-25(2011).
RN   [19]
RP   INTERACTION WITH GRM2, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22300836; DOI=10.1016/j.neuropharm.2012.01.010;
RA   Delille H.K., Becker J.M., Burkhardt S., Bleher B., Terstappen G.C.,
RA   Schmidt M., Meyer A.H., Unger L., Marek G.J., Mezler M.;
RT   "Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for
RT   cellular signaling cascades.";
RL   Neuropharmacology 62:2184-2191(2012).
RN   [20]
RP   VARIANTS ASN-25 AND TYR-452.
RX   PubMed=8655141; DOI=10.1007/BF02281871;
RA   Erdmann J., Shimron-Abarbanell D., Rietschel M., Albus M., Maier W.,
RA   Koerner J., Bondy B., Chen K., Shih J.C., Knapp M., Propping P.,
RA   Noethen M.M.;
RT   "Systematic screening for mutations in the human serotonin-2A (5-HT2A)
RT   receptor gene: identification of two naturally occurring receptor
RT   variants and association analysis in schizophrenia.";
RL   Hum. Genet. 97:614-619(1996).
RN   [21]
RP   VARIANTS ASN-25 AND TYR-452.
RX   PubMed=10581480;
RX   DOI=10.1002/(SICI)1096-8628(19991215)88:6<621::AID-AJMG9>3.0.CO;2-H;
RA   Marshall S.E., Bird T.G., Hart K., Welsh K.I.;
RT   "Unified approach to the analysis of genetic variation in serotonergic
RT   pathways.";
RL   Am. J. Med. Genet. 88:621-627(1999).
RN   [22]
RP   VARIANTS VAL-197; VAL-447 AND TYR-452.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [23]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine
CC       (serotonin). Also functions as a receptor for various drugs and
CC       psychoactive substances, including mescaline, psilocybin, 1-(2,5-
CC       dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid
CC       diethylamide (LSD). Ligand binding causes a conformation change
CC       that triggers signaling via guanine nucleotide-binding proteins (G
CC       proteins) and modulates the activity of down-stream effectors.
CC       Beta-arrestin family members inhibit signaling via G proteins and
CC       mediate activation of alternative signaling pathways. Signaling
CC       activates phospholipase C and a phosphatidylinositol-calcium
CC       second messenger system that modulates the activity of
CC       phosphatidylinositol 3-kinase and promotes the release of Ca(2+)
CC       ions from intracellular stores. Affects neural activity,
CC       perception, cognition and mood. Plays a role in the regulation of
CC       behavior, including responses to anxiogenic situations and
CC       psychoactive substances. Plays a role in intestinal smooth muscle
CC       contraction, and may play a role in arterial vasoconstriction.
CC   -!- SUBUNIT: Interacts with MPDZ and INADL. May interact with MPP3,
CC       PRDX6, DLG4, DLG1, CASK, APBA1 and MAGI2. Interacts with GRM2 and
CC       DRD2; this may affect signaling.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cell projection, dendrite (By similarity). Cell projection, axon
CC       (By similarity). Cytoplasmic vesicle (By similarity). Membrane,
CC       caveola (By similarity). Note=Localizes to the postsynaptic
CC       thickening of axo-dendritic synapses (By similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P28223-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P28223-2; Sequence=VSP_046663;
CC         Note=Ref.5 (BAG63991) sequence is in conflict in position:
CC         49:D->N;
CC   -!- TISSUE SPECIFICITY: Detected in brain cortex (at protein level).
CC       Detected in blood platelets.
CC   -!- DOMAIN: The PDZ domain-binding motif is involved in the
CC       interaction with INADL, CASK, APBA1, DLG1 and DLG4.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=HTR2A";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X57830; CAA40963.1; -; mRNA.
DR   EMBL; S42168; AAB22791.2; -; Genomic_DNA.
DR   EMBL; S42165; AAB22791.2; JOINED; Genomic_DNA.
DR   EMBL; S42167; AAB22791.2; JOINED; Genomic_DNA.
DR   EMBL; S71229; AAB31320.1; -; mRNA.
DR   EMBL; AF498982; AAM21129.1; -; mRNA.
DR   EMBL; AK302787; BAG63991.1; -; mRNA.
DR   EMBL; AK314132; BAG36822.1; -; mRNA.
DR   EMBL; AL160397; CAI16877.1; -; Genomic_DNA.
DR   EMBL; AL136958; CAI16877.1; JOINED; Genomic_DNA.
DR   EMBL; AL136958; CAI12227.1; -; Genomic_DNA.
DR   EMBL; AL160397; CAI12227.1; JOINED; Genomic_DNA.
DR   EMBL; CH471075; EAX08770.1; -; Genomic_DNA.
DR   EMBL; BC069356; AAH69356.1; -; mRNA.
DR   EMBL; BC069576; AAH69576.1; -; mRNA.
DR   EMBL; BC074848; AAH74848.1; -; mRNA.
DR   EMBL; BC074849; AAH74849.1; -; mRNA.
DR   EMBL; BC096839; AAH96839.1; -; mRNA.
DR   EMBL; M86841; AAA58354.1; -; mRNA.
DR   EMBL; S50130; AAB24166.2; -; Genomic_DNA.
DR   EMBL; S49737; AAB24166.2; JOINED; Genomic_DNA.
DR   EMBL; S50113; AAB24166.2; JOINED; Genomic_DNA.
DR   CCDS; CCDS53867.1; -. [P28223-2]
DR   CCDS; CCDS9405.1; -. [P28223-1]
DR   PIR; A43956; A43956.
DR   RefSeq; NP_000612.1; NM_000621.4. [P28223-1]
DR   RefSeq; NP_001159419.1; NM_001165947.2. [P28223-2]
DR   UniGene; Hs.72630; -.
DR   ProteinModelPortal; P28223; -.
DR   SMR; P28223; 38-406.
DR   BioGrid; 109588; 4.
DR   DIP; DIP-41844N; -.
DR   MINT; MINT-443877; -.
DR   STRING; 9606.ENSP00000367959; -.
DR   BindingDB; P28223; -.
DR   ChEMBL; CHEMBL2096662; -.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00604; Cisapride.
DR   DrugBank; DB01242; Clomipramine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00924; Cyclobenzaprine.
DR   DrugBank; DB00434; Cyproheptadine.
DR   DrugBank; DB00320; Dihydroergotamine.
DR   DrugBank; DB00843; Donepezil.
DR   DrugBank; DB00751; Epinastine.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB00176; Fluvoxamine.
DR   DrugBank; DB00933; Mesoridazine.
DR   DrugBank; DB00247; Methysergide.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB01149; Nefazodone.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB00433; Prochlorperazine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00734; Risperidone.
DR   DrugBank; DB06144; Sertindole.
DR   DrugBank; DB00372; Thiethylperazine.
DR   DrugBank; DB00679; Thioridazine.
DR   DrugBank; DB00752; Tranylcypromine.
DR   DrugBank; DB00656; Trazodone.
DR   DrugBank; DB00285; Venlafaxine.
DR   DrugBank; DB00246; Ziprasidone.
DR   GuidetoPHARMACOLOGY; 6; -.
DR   PhosphoSite; P28223; -.
DR   DMDM; 543727; -.
DR   PaxDb; P28223; -.
DR   PRIDE; P28223; -.
DR   Ensembl; ENST00000378688; ENSP00000367959; ENSG00000102468. [P28223-1]
DR   Ensembl; ENST00000542664; ENSP00000437737; ENSG00000102468. [P28223-1]
DR   Ensembl; ENST00000543956; ENSP00000441861; ENSG00000102468. [P28223-2]
DR   GeneID; 3356; -.
DR   KEGG; hsa:3356; -.
DR   UCSC; uc010acr.4; human. [P28223-1]
DR   CTD; 3356; -.
DR   GeneCards; GC13M047407; -.
DR   HGNC; HGNC:5293; HTR2A.
DR   HPA; HPA014011; -.
DR   MIM; 182135; gene.
DR   neXtProt; NX_P28223; -.
DR   PharmGKB; PA193; -.
DR   eggNOG; NOG247243; -.
DR   HOGENOM; HOG000240378; -.
DR   HOVERGEN; HBG107487; -.
DR   InParanoid; P28223; -.
DR   KO; K04157; -.
DR   OMA; CTMVALG; -.
DR   OrthoDB; EOG70ZZN5; -.
DR   PhylomeDB; P28223; -.
DR   TreeFam; TF316350; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   SignaLink; P28223; -.
DR   GeneWiki; 5-HT2A_receptor; -.
DR   GenomeRNAi; 3356; -.
DR   NextBio; 13270; -.
DR   PRO; PR:P28223; -.
DR   ArrayExpress; P28223; -.
DR   Bgee; P28223; -.
DR   CleanEx; HS_HTR2A; -.
DR   Genevestigator; P28223; -.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005901; C:caveola; IEA:UniProtKB-SubCell.
DR   GO; GO:0070852; C:cell body fiber; IEA:Ensembl.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0043198; C:dendritic shaft; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0071886; F:1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding; IDA:UniProtKB.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0051378; F:serotonin binding; IDA:UniProtKB.
DR   GO; GO:0004993; F:serotonin receptor activity; IDA:UniProtKB.
DR   GO; GO:0007202; P:activation of phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0014824; P:artery smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0048148; P:behavioral response to cocaine; IEA:Ensembl.
DR   GO; GO:0008219; P:cell death; IEA:Ensembl.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0043267; P:negative regulation of potassium ion transport; IEA:Ensembl.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0007208; P:phospholipase C-activating serotonin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IEA:Ensembl.
DR   GO; GO:0010513; P:positive regulation of phosphatidylinositol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0050795; P:regulation of behavior; IEA:InterPro.
DR   GO; GO:0014059; P:regulation of dopamine secretion; IEA:Ensembl.
DR   GO; GO:0046883; P:regulation of hormone secretion; IEA:InterPro.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IDA:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   GO; GO:0007210; P:serotonin receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030431; P:sleep; IEA:Ensembl.
DR   GO; GO:0007268; P:synaptic transmission; TAS:ProtInc.
DR   GO; GO:0001659; P:temperature homeostasis; IEA:Ensembl.
DR   GO; GO:0014832; P:urinary bladder smooth muscle contraction; IEA:Ensembl.
DR   Gene3D; 1.20.1070.10; -; 1.
DR   InterPro; IPR000455; 5HT2A_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24247:SF30; PTHR24247:SF30; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00516; 5HT2ARECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Behavior; Cell membrane; Cell projection;
KW   Complete proteome; Cytoplasmic vesicle; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism;
KW   Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    471       5-hydroxytryptamine receptor 2A.
FT                                /FTId=PRO_0000068946.
FT   TOPO_DOM      1     75       Extracellular (By similarity).
FT   TRANSMEM     76     99       Helical; Name=1; (By similarity).
FT   TOPO_DOM    100    110       Cytoplasmic (By similarity).
FT   TRANSMEM    111    132       Helical; Name=2; (By similarity).
FT   TOPO_DOM    133    148       Extracellular (By similarity).
FT   TRANSMEM    149    171       Helical; Name=3; (By similarity).
FT   TOPO_DOM    172    191       Cytoplasmic (By similarity).
FT   TRANSMEM    192    215       Helical; Name=4; (By similarity).
FT   TOPO_DOM    216    233       Extracellular (By similarity).
FT   TRANSMEM    234    254       Helical; Name=5; (By similarity).
FT   TOPO_DOM    255    324       Cytoplasmic (By similarity).
FT   TRANSMEM    325    346       Helical; Name=6; (By similarity).
FT   TOPO_DOM    347    362       Extracellular (By similarity).
FT   TRANSMEM    363    384       Helical; Name=7; (By similarity).
FT   TOPO_DOM    385    471       Cytoplasmic (By similarity).
FT   REGION      155    160       Agonist binding (By similarity).
FT   REGION      336    340       Agonist binding (By similarity).
FT   MOTIF       172    174       DRY motif; important for ligand-induced
FT                                conformation changes (By similarity).
FT   MOTIF       376    380       NPxxY motif; important for ligand-induced
FT                                conformation changes and signaling (By
FT                                similarity).
FT   MOTIF       469    471       PDZ-binding.
FT   CARBOHYD      8      8       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     38     38       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     44     44       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     51     51       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     54     54       N-linked (GlcNAc...) (Potential).
FT   DISULFID    148    227       By similarity.
FT   DISULFID    349    353       By similarity.
FT   VAR_SEQ       1    138       MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSD
FT                                AFNWTVDSENRTNLSCEGCLSPSCLSLLHLQEKNWSALLTA
FT                                VVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIADMLL
FT                                GFLVMPVSMLTILYG -> MQFLKSAKQKPNYYHIMLVEDQ
FT                                EEGTLHQFNYCERCSESQNNKCISCVDPEDKW (in
FT                                isoform 2).
FT                                /FTId=VSP_046663.
FT   VARIANT      25     25       T -> N (in dbSNP:rs1805055).
FT                                /FTId=VAR_003448.
FT   VARIANT     197    197       I -> V (in dbSNP:rs6304).
FT                                /FTId=VAR_013901.
FT   VARIANT     447    447       A -> V (in dbSNP:rs6308).
FT                                /FTId=VAR_013902.
FT   VARIANT     452    452       H -> Y (in dbSNP:rs6314).
FT                                /FTId=VAR_003449.
FT   MUTAGEN     463    463       G->V: Loss of interaction with INADL.
FT   MUTAGEN     465    465       N->S: No effect on interaction with
FT                                INADL. Acquires the binding properties of
FT                                HTR2C; when associated with S-470.
FT   MUTAGEN     470    470       C->S: No effect on interaction with
FT                                INADL. Acquires the binding properties of
FT                                HTR2C; when associated with S-465.
FT   MUTAGEN     471    471       V->A: Loss of interaction with INADL,
FT                                CASK, APBA1, DLG1 and DLG4.
SQ   SEQUENCE   471 AA;  52603 MW;  EF8AAC0BC5379DA2 CRC64;
     MDILCEENTS LSSTTNSLMQ LNDDTRLYSN DFNSGEANTS DAFNWTVDSE NRTNLSCEGC
     LSPSCLSLLH LQEKNWSALL TAVVIILTIA GNILVIMAVS LEKKLQNATN YFLMSLAIAD
     MLLGFLVMPV SMLTILYGYR WPLPSKLCAV WIYLDVLFST ASIMHLCAIS LDRYVAIQNP
     IHHSRFNSRT KAFLKIIAVW TISVGISMPI PVFGLQDDSK VFKEGSCLLA DDNFVLIGSF
     VSFFIPLTIM VITYFLTIKS LQKEATLCVS DLGTRAKLAS FSFLPQSSLS SEKLFQRSIH
     REPGSYTGRR TMQSISNEQK ACKVLGIVFF LFVVMWCPFF ITNIMAVICK ESCNEDVIGA
     LLNVFVWIGY LSSAVNPLVY TLFNKTYRSA FSRYIQCQYK ENKKPLQLIL VNTIPALAYK
     SSQLQMGQKK NSKQDAKTTD NDCSMVALGK QHSEEASKDN SDGVNEKVSC V
//
ID   5HT2B_HUMAN             Reviewed;         481 AA.
AC   P41595; B2R9D5; Q53TI1; Q62221; Q6P523;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   09-JUL-2014, entry version 139.
DE   RecName: Full=5-hydroxytryptamine receptor 2B;
DE            Short=5-HT-2B;
DE            Short=5-HT2B;
DE   AltName: Full=Serotonin receptor 2B;
GN   Name=HTR2B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=8143856; DOI=10.1016/0014-5793(94)80590-3;
RA   Schmuck K., Ullmer C., Engels P., Luebbert H.;
RT   "Cloning and functional characterization of the human 5-HT2B serotonin
RT   receptor.";
RL   FEBS Lett. 342:85-90(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=7926008; DOI=10.1016/0014-5793(94)00968-6;
RA   Choi D.S., Birraux G., Launay J.-M., Maroteaux L.;
RT   "The human serotonin 5-HT2B receptor: pharmacological link between 5-
RT   HT2 and 5-HT1D receptors.";
RL   FEBS Lett. 352:393-399(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Uterus;
RX   PubMed=8078486;
RA   Kursar J.D., Nelson D.L., Wainscott D.B., Baez M.;
RT   "Molecular cloning, functional expression, and mRNA tissue
RT   distribution of the human 5-hydroxytryptamine2B receptor.";
RL   Mol. Pharmacol. 46:227-234(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10722792; DOI=10.1006/mcpr.1999.0281;
RA   Kim S.J., Veenstra-VanderWeele J., Hanna G.L., Gonen D.,
RA   Leventhal B.L., Cook E.H. Jr.;
RT   "Mutation screening of human 5-HT(2B) receptor gene in early-onset
RT   obsessive-compulsive disorder.";
RL   Mol. Cell. Probes 14:47-52(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=8882600; DOI=10.1111/j.1476-5381.1996.tb16700.x;
RA   Ullmer C., Boddeke H.G., Schmuck K., Lubbert H.;
RT   "5-HT2B receptor-mediated calcium release from ryanodine-sensitive
RT   intracellular stores in human pulmonary artery endothelial cells.";
RL   Br. J. Pharmacol. 117:1081-1088(1996).
RN   [11]
RP   INTERACTION WITH MPDZ.
RX   PubMed=11150294; DOI=10.1074/jbc.M008089200;
RA   Becamel C., Figge A., Poliak S., Dumuis A., Peles E., Bockaert J.,
RA   Luebbert H., Ullmer C.;
RT   "Interaction of serotonin 5-hydroxytryptamine type 2C receptors with
RT   PDZ10 of the multi-PDZ domain protein MUPP1.";
RL   J. Biol. Chem. 276:12974-12982(2001).
RN   [12]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12970106; DOI=10.1038/sj.bjp.0705437;
RA   Schaerlinger B., Hickel P., Etienne N., Guesnier L., Maroteaux L.;
RT   "Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors
RT   and their possible relevance to antimigraine efficacy.";
RL   Br. J. Pharmacol. 140:277-284(2003).
RN   [13]
RP   REVIEW.
RX   PubMed=18476671; DOI=10.1021/cr078224o;
RA   Nichols D.E., Nichols C.D.;
RT   "Serotonin receptors.";
RL   Chem. Rev. 108:1614-1641(2008).
RN   [14]
RP   FUNCTION.
RX   PubMed=18703043; DOI=10.1016/j.ejphar.2008.07.040;
RA   Cussac D., Boutet-Robinet E., Ailhaud M.C., Newman-Tancredi A.,
RA   Martel J.C., Danty N., Rauly-Lestienne I.;
RT   "Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-
RT   HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium
RT   mobilisation in CHO cells.";
RL   Eur. J. Pharmacol. 594:32-38(2008).
RN   [15]
RP   INVOLVEMENT IN IMPULSIVE BEHAVIOR, TISSUE SPECIFICITY, POLYMORPHISM,
RP   AND VARIANTS GLU-45; LEU-173 AND TRP-388.
RX   PubMed=21179162; DOI=10.1038/nature09629;
RA   Bevilacqua L., Doly S., Kaprio J., Yuan Q., Tikkanen R., Paunio T.,
RA   Zhou Z., Wedenoja J., Maroteaux L., Diaz S., Belmer A.,
RA   Hodgkinson C.A., Dell'osso L., Suvisaari J., Coccaro E., Rose R.J.,
RA   Peltonen L., Virkkunen M., Goldman D.;
RT   "A population-specific HTR2B stop codon predisposes to severe
RT   impulsivity.";
RL   Nature 468:1061-1066(2010).
RN   [16]
RP   REVIEW.
RX   PubMed=20945968;
RA   Pytliak M., Vargova V., Mechirova V., Felsoci M.;
RT   "Serotonin receptors - from molecular biology to clinical
RT   applications.";
RL   Physiol. Res. 60:15-25(2011).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-132; ASP-135;
RP   VAL-136; SER-139; THR-140; VAL-208; LEU-209; LYS-211; PHE-217;
RP   MET-218; ALA-225; TRP-337; PHE-340; ASN-344; LEU-347; VAL-348;
RP   LEU-362; GLU-363; VAL-366 AND TYR-370.
RX   PubMed=23519210; DOI=10.1126/science.1232807;
RA   Wang C., Jiang Y., Ma J., Wu H., Wacker D., Katritch V., Han G.W.,
RA   Liu W., Huang X.P., Vardy E., McCorvy J.D., Gao X., Zhou X.E.,
RA   Melcher K., Zhang C., Bai F., Yang H., Yang L., Jiang H., Roth B.L.,
RA   Cherezov V., Stevens R.C., Xu H.E.;
RT   "Structural basis for molecular recognition at serotonin receptors.";
RL   Science 340:610-614(2013).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 36-405 IN COMPLEX WITH THE
RP   AGONIST ERGOTAMINE, FUNCTION, ROLE IN ARRESTIN-MEDIATED SIGNALING AND
RP   CALCIUM RELEASE, SUBCELLULAR LOCATION, MEMBRANE TOPOLOGY, AND
RP   DISULFIDE BONDS.
RX   PubMed=23519215; DOI=10.1126/science.1232808;
RA   Wacker D., Wang C., Katritch V., Han G.W., Huang X.P., Vardy E.,
RA   McCorvy J.D., Jiang Y., Chu M., Siu F.Y., Liu W., Xu H.E.,
RA   Cherezov V., Roth B.L., Stevens R.C.;
RT   "Structural features for functional selectivity at serotonin
RT   receptors.";
RL   Science 340:615-619(2013).
CC   -!- FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine
CC       (serotonin). Also functions as a receptor for various ergot
CC       alkaloid derivatives and psychoactive substances. Ligand binding
CC       causes a conformation change that triggers signaling via guanine
CC       nucleotide-binding proteins (G proteins) and modulates the
CC       activity of down-stream effectors. Beta-arrestin family members
CC       inhibit signaling via G proteins and mediate activation of
CC       alternative signaling pathways. Signaling activates a
CC       phosphatidylinositol-calcium second messenger system that
CC       modulates the activity of phosphatidylinositol 3-kinase and down-
CC       stream signaling cascades and promotes the release of Ca(2+) ions
CC       from intracellular stores. Plays a role in the regulation of
CC       dopamine and 5-hydroxytryptamine release, 5-hydroxytryptamine
CC       uptake and in the regulation of extracellular dopamine and 5-
CC       hydroxytryptamine levels, and thereby affects neural activity. May
CC       play a role in the perception of pain. Plays a role in the
CC       regulation of behavior, including impulsive behavior. Required for
CC       normal proliferation of embryonic cardiac myocytes and normal
CC       heart development. Protects cardiomyocytes against apoptosis.
CC       Plays a role in the adaptation of pulmonary arteries to chronic
CC       hypoxia. Plays a role in vasoconstriction. Required for normal
CC       osteoblast function and proliferation, and for maintaining normal
CC       bone density. Required for normal proliferation of the
CC       interstitial cells of Cajal in the intestine.
CC   -!- SUBUNIT: Interacts with MPDZ.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cell junction, synapse, synaptosome (By similarity).
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Detected in liver, kidney, heart,
CC       pulmonary artery, and intestine. Detected at lower levels in
CC       blood, placenta and brain, especially in cerebellum, occipital
CC       cortex and frontal cortex.
CC   -!- DOMAIN: Ligands are bound in a hydrophobic pocket formed by the
CC       transmembrane helices.
CC   -!- POLYMORPHISM: A variation at a single nucleotide base, which
CC       results in an erroneous stop codon and affects Gln-20, triggers
CC       non-sense mediated RNA decay, such that no HTR2B-receptor protein
CC       is expressed. It is associated with impulsive behavior and co-
CC       segregates with disorders characterized by impulsivity. However,
CC       the presence of this variant is not in itself sufficient to cause
CC       impulsive behavior: male sex, testosterone level, alcohol and
CC       stress exposure are other factors playing important roles.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=On the spur of a whim -
CC       Issue 127 of March 2011;
CC       URL="http://web.expasy.org/spotlight/back_issues/127";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X77307; CAA54513.1; -; mRNA.
DR   EMBL; Z36748; CAA85319.1; -; mRNA.
DR   EMBL; AF156160; AAD39259.1; -; Genomic_DNA.
DR   EMBL; AF156158; AAD39259.1; JOINED; Genomic_DNA.
DR   EMBL; AF156159; AAD39259.1; JOINED; Genomic_DNA.
DR   EMBL; AY136751; AAN01277.1; -; mRNA.
DR   EMBL; AC009407; AAX93128.1; -; Genomic_DNA.
DR   EMBL; AK313741; BAG36482.1; -; mRNA.
DR   EMBL; CH471063; EAW70949.1; -; Genomic_DNA.
DR   EMBL; BC063123; AAH63123.1; -; mRNA.
DR   CCDS; CCDS2483.1; -.
DR   PIR; S43687; S43687.
DR   PIR; S49442; S49442.
DR   RefSeq; NP_000858.3; NM_000867.4.
DR   UniGene; Hs.421649; -.
DR   PDB; 4IB4; X-ray; 2.70 A; A=36-248, A=314-405.
DR   PDB; 4NC3; X-ray; 2.80 A; A=36-248, A=314-405.
DR   PDBsum; 4IB4; -.
DR   PDBsum; 4NC3; -.
DR   ProteinModelPortal; P41595; -.
DR   SMR; P41595; 48-400.
DR   BioGrid; 109589; 3.
DR   MINT; MINT-444010; -.
DR   STRING; 9606.ENSP00000258400; -.
DR   BindingDB; P41595; -.
DR   ChEMBL; CHEMBL2111466; -.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00216; Eletriptan.
DR   DrugBank; DB00574; Fenfluramine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00669; Sumatriptan.
DR   DrugBank; DB01079; Tegaserod.
DR   DrugBank; DB00508; Triflupromazine.
DR   GuidetoPHARMACOLOGY; 7; -.
DR   TCDB; 9.A.14.3.7; the g-protein-coupled receptor (gpcr) family.
DR   PhosphoSite; P41595; -.
DR   DMDM; 1168220; -.
DR   PaxDb; P41595; -.
DR   PRIDE; P41595; -.
DR   DNASU; 3357; -.
DR   Ensembl; ENST00000258400; ENSP00000258400; ENSG00000135914.
DR   GeneID; 3357; -.
DR   KEGG; hsa:3357; -.
DR   UCSC; uc002vro.3; human.
DR   CTD; 3357; -.
DR   GeneCards; GC02M231936; -.
DR   HGNC; HGNC:5294; HTR2B.
DR   HPA; CAB011448; -.
DR   HPA; HPA012867; -.
DR   MIM; 601122; gene.
DR   neXtProt; NX_P41595; -.
DR   PharmGKB; PA29554; -.
DR   eggNOG; NOG247243; -.
DR   HOGENOM; HOG000240378; -.
DR   HOVERGEN; HBG107487; -.
DR   InParanoid; P41595; -.
DR   KO; K04157; -.
DR   OMA; CDSCNQT; -.
DR   OrthoDB; EOG70ZZN5; -.
DR   PhylomeDB; P41595; -.
DR   TreeFam; TF316350; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   GeneWiki; 5-HT2B_receptor; -.
DR   GenomeRNAi; 3357; -.
DR   NextBio; 13274; -.
DR   PRO; PR:P41595; -.
DR   ArrayExpress; P41595; -.
DR   Bgee; P41595; -.
DR   CleanEx; HS_HTR2B; -.
DR   Genevestigator; P41595; -.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:InterPro.
DR   GO; GO:0043005; C:neuron projection; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; IEA:UniProtKB-KW.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; IMP:UniProtKB.
DR   GO; GO:0005099; F:Ras GTPase activator activity; ISS:UniProtKB.
DR   GO; GO:0051378; F:serotonin binding; IDA:UniProtKB.
DR   GO; GO:0004993; F:serotonin receptor activity; IDA:UniProtKB.
DR   GO; GO:0007202; P:activation of phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0007610; P:behavior; IEA:UniProtKB-KW.
DR   GO; GO:0019722; P:calcium-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0003300; P:cardiac muscle hypertrophy; ISS:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0071502; P:cellular response to temperature stimulus; ISS:UniProtKB.
DR   GO; GO:0006182; P:cGMP biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0048598; P:embryonic morphogenesis; ISS:UniProtKB.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0002031; P:G-protein coupled receptor internalization; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0003007; P:heart morphogenesis; ISS:UniProtKB.
DR   GO; GO:0014827; P:intestine smooth muscle contraction; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0060548; P:negative regulation of cell death; IMP:UniProtKB.
DR   GO; GO:0014033; P:neural crest cell differentiation; ISS:UniProtKB.
DR   GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0016310; P:phosphorylation; IMP:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0001819; P:positive regulation of cytokine production; IDA:UniProtKB.
DR   GO; GO:0050715; P:positive regulation of cytokine secretion; ISS:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEP:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IDA:UniProtKB.
DR   GO; GO:0010513; P:positive regulation of phosphatidylinositol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0070528; P:protein kinase C signaling; IMP:UniProtKB.
DR   GO; GO:0007205; P:protein kinase C-activating G-protein coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0050795; P:regulation of behavior; IMP:UniProtKB.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IDA:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   GO; GO:0007210; P:serotonin receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0042310; P:vasoconstriction; IMP:UniProtKB.
DR   Gene3D; 1.20.1070.10; -; 2.
DR   InterPro; IPR000482; 5HT2B_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24247:SF31; PTHR24247:SF31; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00651; 5HT2BRECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Behavior; Cell junction; Cell membrane;
KW   Complete proteome; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Polymorphism;
KW   Receptor; Reference proteome; Synapse; Synaptosome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN         1    481       5-hydroxytryptamine receptor 2B.
FT                                /FTId=PRO_0000068953.
FT   TOPO_DOM      1     56       Extracellular.
FT   TRANSMEM     57     79       Helical; Name=1.
FT   TOPO_DOM     80     90       Cytoplasmic.
FT   TRANSMEM     91    113       Helical; Name=2.
FT   TOPO_DOM    114    129       Extracellular.
FT   TRANSMEM    130    151       Helical; Name=3.
FT   TOPO_DOM    152    171       Cytoplasmic.
FT   TRANSMEM    172    192       Helical; Name=4.
FT   TOPO_DOM    193    216       Extracellular.
FT   TRANSMEM    217    239       Helical; Name=5.
FT   TOPO_DOM    240    324       Cytoplasmic.
FT   TRANSMEM    325    345       Helical; Name=6.
FT   TOPO_DOM    346    360       Extracellular.
FT   TRANSMEM    361    382       Helical; Name=7.
FT   TOPO_DOM    383    481       Cytoplasmic.
FT   REGION      135    140       Agonist binding.
FT   REGION      337    341       Agonist binding.
FT   MOTIF       152    154       DRY motif; important for ligand-induced
FT                                conformation changes.
FT   MOTIF       212    215       [DE]RFG motif; may stabilize a
FT                                conformation that preferentially
FT                                activates signaling via beta-arrestin
FT                                family members.
FT   MOTIF       376    380       NPxxY motif; important for ligand-induced
FT                                conformation changes and signaling.
FT   MOTIF       479    481       PDZ-binding.
FT   LIPID       397    397       S-palmitoyl cysteine (Potential).
FT   CARBOHYD     30     30       N-linked (GlcNAc...) (Potential).
FT   DISULFID    128    207
FT   DISULFID    350    353
FT   VARIANT      45     45       Q -> E (in dbSNP:rs78484969).
FT                                /FTId=VAR_064574.
FT   VARIANT     173    173       F -> L (in dbSNP:rs77570025).
FT                                /FTId=VAR_064575.
FT   VARIANT     388    388       R -> W (in dbSNP:rs77982984).
FT                                /FTId=VAR_064576.
FT   VARIANT     421    421       M -> V (in dbSNP:rs6736017).
FT                                /FTId=VAR_055907.
FT   MUTAGEN     132    132       L->A: No effect on agonist binding.
FT   MUTAGEN     135    135       D->A: Abolishes agonist binding.
FT   MUTAGEN     136    136       V->A: Slightly decreases agonist binding.
FT   MUTAGEN     139    139       S->A: Slightly decreases agonist binding.
FT   MUTAGEN     140    140       T->A: Slightly decreases agonist binding.
FT   MUTAGEN     208    208       V->A: No effect on agonist binding.
FT   MUTAGEN     209    209       L->A: No effect on agonist binding.
FT   MUTAGEN     211    211       K->A: Impairs protein folding and
FT                                stability. Strongly reduced cell surface
FT                                expression.
FT   MUTAGEN     217    217       F->A: Slightly decreases agonist binding.
FT   MUTAGEN     218    218       M->A: No effect on agonist binding.
FT   MUTAGEN     225    225       A->S: No effect on agonist binding.
FT   MUTAGEN     337    337       W->A: Slightly decreases agonist binding.
FT   MUTAGEN     340    340       F->A: Slightly decreases agonist binding.
FT   MUTAGEN     344    344       N->A: Slightly decreases agonist binding.
FT   MUTAGEN     347    347       L->A: No effect on agonist binding.
FT   MUTAGEN     348    348       V->A: No effect on agonist binding.
FT   MUTAGEN     362    362       L->A: No effect on agonist binding.
FT   MUTAGEN     363    363       E->A: No effect on agonist binding.
FT   MUTAGEN     366    366       V->A: No effect on agonist binding.
FT   MUTAGEN     370    370       Y->A: Slightly decreases agonist binding.
FT   CONFLICT    452    452       T -> P (in Ref. 2; CAA85319).
FT   CONFLICT    477    477       Q -> R (in Ref. 9; AAH63123).
FT   HELIX        54     63
FT   HELIX        65     81
FT   HELIX        83     85
FT   HELIX        88    106
FT   HELIX       108    111
FT   HELIX       113    116
FT   HELIX       127    158
FT   HELIX       165    187
FT   HELIX       189    193
FT   HELIX       211    225
FT   HELIX       227    248
FT   HELIX       314    349
FT   STRAND      351    353
FT   HELIX       355    381
FT   HELIX       385    394
FT   TURN        395    397
SQ   SEQUENCE   481 AA;  54298 MW;  CDA4447ECDBA3B46 CRC64;
     MALSYRVSEL QSTIPEHILQ STFVHVISSN WSGLQTESIP EEMKQIVEEQ GNKLHWAALL
     ILMVIIPTIG GNTLVILAVS LEKKLQYATN YFLMSLAVAD LLVGLFVMPI ALLTIMFEAM
     WPLPLVLCPA WLFLDVLFST ASIMHLCAIS VDRYIAIKKP IQANQYNSRA TAFIKITVVW
     LISIGIAIPV PIKGIETDVD NPNNITCVLT KERFGDFMLF GSLAAFFTPL AIMIVTYFLT
     IHALQKKAYL VKNKPPQRLT WLTVSTVFQR DETPCSSPEK VAMLDGSRKD KALPNSGDET
     LMRRTSTIGK KSVQTISNEQ RASKVLGIVF FLFLLMWCPF FITNITLVLC DSCNQTTLQM
     LLEIFVWIGY VSSGVNPLVY TLFNKTFRDA FGRYITCNYR ATKSVKTLRK RSSKIYFRNP
     MAENSKFFKK HGIRNGINPA MYQSPMRLRS STIQSSSIIL LDTLLLTENE GDKTEEQVSY
     V
//
ID   5HT2C_HUMAN             Reviewed;         458 AA.
AC   P28335; B1AMW4; Q5VUF8; Q9NP28;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   09-JUL-2014, entry version 152.
DE   RecName: Full=5-hydroxytryptamine receptor 2C;
DE            Short=5-HT-2C;
DE            Short=5-HT2C;
DE            Short=5-HTR2C;
DE   AltName: Full=5-hydroxytryptamine receptor 1C;
DE            Short=5-HT-1C;
DE            Short=5-HT1C;
DE   AltName: Full=Serotonin receptor 2C;
DE   Flags: Precursor;
GN   Name=HTR2C; Synonyms=HTR1C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=1722404; DOI=10.1016/0006-291X(91)92105-S;
RA   Saltzman A.G., Morse B., Whitman M.M., Ivanshchenko Y., Jaye M.,
RA   Felder S.;
RT   "Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes.";
RL   Biochem. Biophys. Res. Commun. 181:1469-1478(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Hippocampus, and Placenta;
RX   PubMed=7895773; DOI=10.1016/0922-4106(94)90042-6;
RA   Stam N.J., Vanderheyden P., Van Alebeek C., Klomp J., De Boer T.,
RA   Van Delft A.M.L., Olijve W.;
RT   "Genomic organisation and functional expression of the gene encoding
RT   the human serotonin 5-HT2C receptor.";
RL   Eur. J. Pharmacol. 269:339-348(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=8812491; DOI=10.1006/geno.1996.0397;
RA   Xie E., Zhao L., Levine A.J., Shenk T., Chang L.-S.;
RT   "The human serotonin 5-HT2C receptor: complete cDNA, genomic
RT   structure, and alternatively spliced variant.";
RL   Genomics 35:551-561(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND RNA EDITING OF POSITIONS
RP   156; 158 AND 160.
RC   TISSUE=Brain;
RX   PubMed=9928237; DOI=10.1111/j.1749-6632.1998.tb10171.x;
RA   Niswender C.M., Sanders-Bush E., Emeson R.B.;
RT   "Identification and characterization of RNA editing events within the
RT   5-HT2C receptor.";
RL   Ann. N. Y. Acad. Sci. 861:38-48(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH MPDZ, DOMAIN, MUTAGENESIS OF SER-456; SER-457 AND
RP   VAL-458, AND GLYCOSYLATION.
RX   PubMed=11150294; DOI=10.1074/jbc.M008089200;
RA   Becamel C., Figge A., Poliak S., Dumuis A., Peles E., Bockaert J.,
RA   Luebbert H., Ullmer C.;
RT   "Interaction of serotonin 5-hydroxytryptamine type 2C receptors with
RT   PDZ10 of the multi-PDZ domain protein MUPP1.";
RL   J. Biol. Chem. 276:12974-12982(2001).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12970106; DOI=10.1038/sj.bjp.0705437;
RA   Schaerlinger B., Hickel P., Etienne N., Guesnier L., Maroteaux L.;
RT   "Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors
RT   and their possible relevance to antimigraine efficacy.";
RL   Br. J. Pharmacol. 140:277-284(2003).
RN   [11]
RP   INTERACTION WITH ARRB2, AND MUTAGENESIS OF PRO-159.
RX   PubMed=16319069; DOI=10.1074/jbc.M508074200;
RA   Marion S., Oakley R.H., Kim K.-M., Caron M.G., Barak L.S.;
RT   "A beta-arrestin binding determinant common to the second
RT   intracellular loops of rhodopsin family G protein-coupled receptors.";
RL   J. Biol. Chem. 281:2932-2938(2006).
RN   [12]
RP   REVIEW.
RX   PubMed=18476671; DOI=10.1021/cr078224o;
RA   Nichols D.E., Nichols C.D.;
RT   "Serotonin receptors.";
RL   Chem. Rev. 108:1614-1641(2008).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18703043; DOI=10.1016/j.ejphar.2008.07.040;
RA   Cussac D., Boutet-Robinet E., Ailhaud M.C., Newman-Tancredi A.,
RA   Martel J.C., Danty N., Rauly-Lestienne I.;
RT   "Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-
RT   HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium
RT   mobilisation in CHO cells.";
RL   Eur. J. Pharmacol. 594:32-38(2008).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19057895; DOI=10.1007/s00210-008-0378-4;
RA   Knauer C.S., Campbell J.E., Chio C.L., Fitzgerald L.W.;
RT   "Pharmacological characterization of mitogen-activated protein kinase
RT   activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B
RT   receptors.";
RL   Naunyn Schmiedebergs Arch. Pharmacol. 379:461-471(2009).
RN   [15]
RP   REVIEW.
RX   PubMed=20945968;
RA   Pytliak M., Vargova V., Mechirova V., Felsoci M.;
RT   "Serotonin receptors - from molecular biology to clinical
RT   applications.";
RL   Physiol. Res. 60:15-25(2011).
RN   [16]
RP   SIGNAL SEQUENCE CLEAVAGE SITE, AND VARIANT SER-23.
RX   PubMed=22497996; DOI=10.1016/j.ejphar.2012.03.043;
RA   Jahnsen J.A., Uhlen S.;
RT   "The N-terminal region of the human 5-HT(2)C receptor has as a
RT   cleavable signal peptide.";
RL   Eur. J. Pharmacol. 684:44-50(2012).
RN   [17]
RP   VARIANT SER-23.
RX   PubMed=7557992; DOI=10.1006/geno.1995.1042;
RA   Lappalainen J., Zhang L., Dean M., Oz M., Ozaki N., Yu D.,
RA   Virkkunen M., Weight F., Linnoila M., Goldman D.;
RT   "Identification, expression, and pharmacology of a Cys23-Ser23
RT   substitution in the human 5-HT2c receptor gene (HTR2C).";
RL   Genomics 27:274-279(1995).
RN   [18]
RP   VARIANT SER-23.
RX   PubMed=10206230;
RX   DOI=10.1002/(SICI)1096-8628(19990416)88:2<126::AID-AJMG6>3.3.CO;2-D;
RA   Samochowiec J., Smolka M., Winterer G., Rommelspacher H.,
RA   Schmidt L.G., Sander T.;
RT   "Association analysis between a Cys23Ser substitution polymorphism of
RT   the human 5-HT2c receptor gene and neuronal hyperexcitability.";
RL   Am. J. Med. Genet. 88:126-130(1999).
RN   [19]
RP   VARIANT SER-23.
RX   PubMed=10581480;
RX   DOI=10.1002/(SICI)1096-8628(19991215)88:6<621::AID-AJMG9>3.0.CO;2-H;
RA   Marshall S.E., Bird T.G., Hart K., Welsh K.I.;
RT   "Unified approach to the analysis of genetic variation in serotonergic
RT   pathways.";
RL   Am. J. Med. Genet. 88:621-627(1999).
RN   [20]
RP   VARIANT SER-23.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [21]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine
CC       (serotonin). Also functions as a receptor for various drugs and
CC       psychoactive substances, including ergot alkaloid derivatives, 1-
CC       2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid
CC       diethylamide (LSD). Ligand binding causes a conformation change
CC       that triggers signaling via guanine nucleotide-binding proteins (G
CC       proteins) and modulates the activity of down-stream effectors.
CC       Beta-arrestin family members inhibit signaling via G proteins and
CC       mediate activation of alternative signaling pathways. Signaling
CC       activates a phosphatidylinositol-calcium second messenger system
CC       that modulates the activity of phosphatidylinositol 3-kinase and
CC       down-stream signaling cascades and promotes the release of Ca(2+)
CC       ions from intracellular stores. Regulates neuronal activity via
CC       the activation of short transient receptor potential calcium
CC       channels in the brain, and thereby modulates the activation of
CC       pro-opiomelacortin neurons and the release of CRH that then
CC       regulates the release of corticosterone. Plays a role in the
CC       regulation of appetite and eating behavior, responses to
CC       anxiogenic stimuli and stress. Plays a role in insulin sensitivity
CC       and glucose homeostasis.
CC   -!- SUBUNIT: Interacts with MPDZ. Interacts with ARRB2.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P28335-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P28335-2; Sequence=VSP_045171;
CC   -!- TISSUE SPECIFICITY: Detected in brain.
CC   -!- DOMAIN: The PDZ domain-binding motif is involved in the
CC       interaction with MPDZ.
CC   -!- PTM: N-glycosylated.
CC   -!- RNA EDITING: Modified_positions=156, 158, 160; Note=Partially
CC       edited. RNA editing generates receptor isoforms that differ in
CC       their ability to interact with the phospholipase C signaling
CC       cascade in a transfected cell line, suggesting that this RNA
CC       processing event may contribute to the modulation of serotonergic
CC       neurotransmission in the central nervous system.
CC   -!- POLYMORPHISM: Position 23 is polymorphic; the frequencies in
CC       unrelated Caucasians are 0.87 for Cys and 0.13 for Ser.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M81778; AAA60317.1; -; mRNA.
DR   EMBL; X80763; CAB59978.1; -; Genomic_DNA.
DR   EMBL; U49516; AAB40898.1; -; mRNA.
DR   EMBL; AF208053; AAF35842.1; -; mRNA.
DR   EMBL; AF498983; AAM21130.1; -; mRNA.
DR   EMBL; AK295753; BAG58583.1; -; mRNA.
DR   EMBL; AC007022; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC007025; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591402; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL355812; CAI41334.1; -; Genomic_DNA.
DR   EMBL; AC004822; CAI41334.1; JOINED; Genomic_DNA.
DR   EMBL; AL590097; CAI41334.1; JOINED; Genomic_DNA.
DR   EMBL; AC004822; AAC71658.1; -; Genomic_DNA.
DR   EMBL; AL355812; CAI41335.1; -; Genomic_DNA.
DR   EMBL; AL590097; CAI41335.1; JOINED; Genomic_DNA.
DR   EMBL; AC004822; CAI41335.1; JOINED; Genomic_DNA.
DR   EMBL; AL590097; CAH70193.1; -; Genomic_DNA.
DR   EMBL; AC004822; CAH70193.1; JOINED; Genomic_DNA.
DR   EMBL; AL355812; CAH70193.1; JOINED; Genomic_DNA.
DR   EMBL; BC095543; AAH95543.1; -; mRNA.
DR   CCDS; CCDS14564.1; -. [P28335-1]
DR   CCDS; CCDS59174.1; -. [P28335-2]
DR   PIR; JS0616; JS0616.
DR   RefSeq; NP_000859.1; NM_000868.2. [P28335-1]
DR   RefSeq; NP_001243689.1; NM_001256760.1. [P28335-1]
DR   RefSeq; NP_001243690.1; NM_001256761.1. [P28335-2]
DR   UniGene; Hs.149037; -.
DR   ProteinModelPortal; P28335; -.
DR   SMR; P28335; 54-388.
DR   BioGrid; 109590; 7.
DR   IntAct; P28335; 1.
DR   MINT; MINT-443944; -.
DR   STRING; 9606.ENSP00000276198; -.
DR   BindingDB; P28335; -.
DR   ChEMBL; CHEMBL2111466; -.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB01191; Dexfenfluramine.
DR   DrugBank; DB00574; Fenfluramine.
DR   DrugBank; DB00247; Methysergide.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB06144; Sertindole.
DR   DrugBank; DB00372; Thiethylperazine.
DR   DrugBank; DB00193; Tramadol.
DR   DrugBank; DB00246; Ziprasidone.
DR   GuidetoPHARMACOLOGY; 8; -.
DR   PhosphoSite; P28335; -.
DR   DMDM; 112816; -.
DR   PaxDb; P28335; -.
DR   PRIDE; P28335; -.
DR   Ensembl; ENST00000276198; ENSP00000276198; ENSG00000147246. [P28335-1]
DR   Ensembl; ENST00000371950; ENSP00000361018; ENSG00000147246. [P28335-2]
DR   Ensembl; ENST00000371951; ENSP00000361019; ENSG00000147246. [P28335-1]
DR   GeneID; 3358; -.
DR   KEGG; hsa:3358; -.
DR   UCSC; uc004epu.1; human. [P28335-1]
DR   UCSC; uc004epv.1; human.
DR   CTD; 3358; -.
DR   GeneCards; GC0XP113818; -.
DR   HGNC; HGNC:5295; HTR2C.
DR   HPA; CAB006857; -.
DR   HPA; HPA003133; -.
DR   MIM; 312861; gene.
DR   neXtProt; NX_P28335; -.
DR   PharmGKB; PA194; -.
DR   eggNOG; NOG247243; -.
DR   HOGENOM; HOG000240378; -.
DR   HOVERGEN; HBG107487; -.
DR   InParanoid; P28335; -.
DR   KO; K04157; -.
DR   OMA; CCKRNTD; -.
DR   OrthoDB; EOG70ZZN5; -.
DR   PhylomeDB; P28335; -.
DR   TreeFam; TF316350; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   SignaLink; P28335; -.
DR   GeneWiki; 5-HT2C_receptor; -.
DR   GenomeRNAi; 3358; -.
DR   NextBio; 13278; -.
DR   PRO; PR:P28335; -.
DR   ArrayExpress; P28335; -.
DR   Bgee; P28335; -.
DR   CleanEx; HS_HTR2C; -.
DR   Genevestigator; P28335; -.
DR   GO; GO:0005887; C:integral component of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0071886; F:1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding; IDA:UniProtKB.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0001587; F:Gq/11-coupled serotonin receptor activity; IDA:UniProtKB.
DR   GO; GO:0051378; F:serotonin binding; IDA:UniProtKB.
DR   GO; GO:0004993; F:serotonin receptor activity; IDA:MGI.
DR   GO; GO:0001662; P:behavioral fear response; ISS:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0006182; P:cGMP biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0007631; P:feeding behavior; ISS:UniProtKB.
DR   GO; GO:0007626; P:locomotory behavior; IEA:InterPro.
DR   GO; GO:0007200; P:phospholipase C-activating G-protein coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007208; P:phospholipase C-activating serotonin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0010513; P:positive regulation of phosphatidylinositol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0032098; P:regulation of appetite; ISS:UniProtKB.
DR   GO; GO:0043397; P:regulation of corticotropin-releasing hormone secretion; ISS:UniProtKB.
DR   GO; GO:0031644; P:regulation of neurological system process; ISS:UniProtKB.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IMP:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   GO; GO:0007210; P:serotonin receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007268; P:synaptic transmission; TAS:ProtInc.
DR   Gene3D; 1.20.1070.10; -; 2.
DR   InterPro; IPR000377; 5HT2C_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24247:SF32; PTHR24247:SF32; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00517; 5HT2CRECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Behavior; Cell membrane; Complete proteome;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Polymorphism; Receptor; Reference proteome; RNA editing; Signal;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     32
FT   CHAIN        33    458       5-hydroxytryptamine receptor 2C.
FT                                /FTId=PRO_0000068958.
FT   TOPO_DOM     33     52       Extracellular (By similarity).
FT   TRANSMEM     53     78       Helical; Name=1; (By similarity).
FT   TOPO_DOM     79     89       Cytoplasmic (By similarity).
FT   TRANSMEM     90    110       Helical; Name=2; (By similarity).
FT   TOPO_DOM    111    127       Extracellular (By similarity).
FT   TRANSMEM    128    150       Helical; Name=3; (By similarity).
FT   TOPO_DOM    151    170       Cytoplasmic (By similarity).
FT   TRANSMEM    171    193       Helical; Name=4; (By similarity).
FT   TOPO_DOM    194    213       Extracellular (By similarity).
FT   TRANSMEM    214    235       Helical; Name=5; (By similarity).
FT   TOPO_DOM    236    311       Cytoplasmic (By similarity).
FT   TRANSMEM    312    333       Helical; Name=6; (By similarity).
FT   TOPO_DOM    334    348       Extracellular (By similarity).
FT   TRANSMEM    349    371       Helical; Name=7; (By similarity).
FT   TOPO_DOM    372    458       Cytoplasmic (By similarity).
FT   REGION      134    139       Agonist binding (By similarity).
FT   REGION      324    328       Agonist binding (By similarity).
FT   MOTIF       151    153       DRY motif; important for ligand-induced
FT                                conformation changes (By similarity).
FT   MOTIF       364    368       NPxxY motif; important for ligand-induced
FT                                conformation changes and signaling (By
FT                                similarity).
FT   MOTIF       456    458       PDZ-binding.
FT   CARBOHYD     39     39       N-linked (GlcNAc...) (Probable).
FT   DISULFID    127    207       By similarity.
FT   DISULFID    337    341       By similarity.
FT   VAR_SEQ     153    458       YVAIRNPIEHSRFNSRTKAIMKIAIVWAISIGVSVPIPVIG
FT                                LRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITY
FT                                CLTIYVLRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEE
FT                                NSANPNQDQNARRRKKKERRPRGTMQAINNERKASKVLGIV
FT                                FFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIG
FT                                YVCSGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQI
FT                                PRVAATALSGRELNVNIYRHTNEPVIEKASDNEPGIEMQVE
FT                                NLELPVNPSSVVSERISSV -> CISSYPCDWTEGRRKGVR
FT                                EQHDVRAQRPKFRSYWVLRSFLHTADDYGDYVLPDHLRSAP
FT                                TSFDVTARPHRGTAWTKSGFPEVLQEEYGRGRELCKP (in
FT                                isoform 2).
FT                                /FTId=VSP_045171.
FT   VARIANT      23     23       C -> S (in dbSNP:rs6318).
FT                                /FTId=VAR_003450.
FT   VARIANT     156    156       I -> V (in RNA edited version).
FT                                /FTId=VAR_010166.
FT   VARIANT     158    158       N -> S (in RNA edited version).
FT                                /FTId=VAR_010167.
FT   VARIANT     160    160       I -> V (in RNA edited version).
FT                                /FTId=VAR_010168.
FT   MUTAGEN     159    159       P->A: Decreases interaction with ARRB2.
FT   MUTAGEN     456    456       S->A: Loss of interaction with MPDZ.
FT   MUTAGEN     456    456       S->T: No effect on interaction with MPDZ.
FT   MUTAGEN     457    457       S->A: No effect on interaction with MPDZ.
FT   MUTAGEN     458    458       V->A: Loss of interaction with MPDZ.
SQ   SEQUENCE   458 AA;  51821 MW;  9E76B3FFD3E09C93 CRC64;
     MVNLRNAVHS FLVHLIGLLV WQCDISVSPV AAIVTDIFNT SDGGRFKFPD GVQNWPALSI
     VIIIIMTIGG NILVIMAVSM EKKLHNATNY FLMSLAIADM LVGLLVMPLS LLAILYDYVW
     PLPRYLCPVW ISLDVLFSTA SIMHLCAISL DRYVAIRNPI EHSRFNSRTK AIMKIAIVWA
     ISIGVSVPIP VIGLRDEEKV FVNNTTCVLN DPNFVLIGSF VAFFIPLTIM VITYCLTIYV
     LRRQALMLLH GHTEEPPGLS LDFLKCCKRN TAEEENSANP NQDQNARRRK KKERRPRGTM
     QAINNERKAS KVLGIVFFVF LIMWCPFFIT NILSVLCEKS CNQKLMEKLL NVFVWIGYVC
     SGINPLVYTL FNKIYRRAFS NYLRCNYKVE KKPPVRQIPR VAATALSGRE LNVNIYRHTN
     EPVIEKASDN EPGIEMQVEN LELPVNPSSV VSERISSV
//
ID   5HT3A_HUMAN             Reviewed;         478 AA.
AC   P46098; B4DSY6; G5E986; O60854; Q7KZM7; Q99918; Q9BSZ9;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   09-JUL-2014, entry version 148.
DE   RecName: Full=5-hydroxytryptamine receptor 3A;
DE            Short=5-HT3-A;
DE            Short=5-HT3A;
DE   AltName: Full=5-hydroxytryptamine receptor 3;
DE            Short=5-HT-3;
DE            Short=5-HT3R;
DE   AltName: Full=Serotonin receptor 3A;
DE   AltName: Full=Serotonin-gated ion channel receptor;
DE   Flags: Precursor;
GN   Name=HTR3A; Synonyms=5HT3R, HTR3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=7565620;
RA   Miyake A., Mochizuki S., Takemoto Y., Akuzawa S.;
RT   "Molecular cloning of human 5-hydroxytryptamine3 receptor:
RT   heterogeneity in distribution and function among species.";
RL   Mol. Pharmacol. 48:407-416(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Amygdala;
RX   PubMed=8848005;
RA   Belelli D., Balcarek J.M., Hope A.G., Peters J.A., Lambert J.J.,
RA   Blackburn T.P.;
RT   "Cloning and functional expression of a human 5-hydroxytryptamine type
RT   3AS receptor subunit.";
RL   Mol. Pharmacol. 48:1054-1062(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Amygdala, and Hippocampus;
RX   PubMed=9928262; DOI=10.1111/j.1749-6632.1998.tb10196.x;
RA   Bruess M., Goethert M., Hayer M., Bonisch H.;
RT   "Molecular cloning of alternatively spliced human 5HT3 receptor
RT   cDNAs.";
RL   Ann. N. Y. Acad. Sci. 861:234-235(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=10670426; DOI=10.1016/S0028-3908(99)00116-1;
RA   Bruess M., Eucker T., Goethert M., Bonisch H.;
RT   "Exon-intron organization of the human 5-HT3A receptor gene.";
RL   Neuropharmacology 39:308-315(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RX   PubMed=15028279; DOI=10.1016/j.ygeno.2003.09.023;
RA   Jin P., Fu G.K., Wilson A.D., Yang J., Chien D., Hawkins P.R.,
RA   Au-Young J., Stuve L.L.;
RT   "PCR isolation and cloning of novel splice variant mRNAs from known
RT   drug target genes.";
RL   Genomics 83:566-571(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=9950429; DOI=10.1038/16941;
RA   Davies P.A., Pistis M., Hanna M.C., Peters J.A., Lambert J.J.,
RA   Hales T.G., Kirkness E.F.;
RT   "The 5-HT3B subunit is a major determinant of serotonin-receptor
RT   function.";
RL   Nature 397:359-363(1999).
RN   [13]
RP   SUBUNIT, AND TISSUE SPECIFICITY.
RC   TISSUE=Small intestine;
RX   PubMed=10521471; DOI=10.1074/jbc.274.43.30799;
RA   Dubin A.E., Huvar R., D'Andrea M.R., Pyati J., Zhu J.Y., Joy K.C.,
RA   Wilson S.J., Galindo J.E., Glass C.A., Luo L., Jackson M.R.,
RA   Lovenberg T.W., Erlander M.G.;
RT   "The pharmacological and functional characteristics of the serotonin
RT   5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor
RT   subunit.";
RL   J. Biol. Chem. 274:30799-30810(1999).
RN   [14]
RP   FUNCTION, REGION, AND MUTAGENESIS OF ARG-432; ARG-436 AND ARG-440.
RX   PubMed=12867984; DOI=10.1038/nature01788;
RA   Kelley S.P., Dunlop J.I., Kirkness E.F., Lambert J.J., Peters J.A.;
RT   "A cytoplasmic region determines single-channel conductance in 5-HT3
RT   receptors.";
RL   Nature 424:321-324(2003).
RN   [15]
RP   INTERACTION WITH RIC3.
RX   PubMed=15809299; DOI=10.1074/jbc.M414341200;
RA   Cheng A., McDonald N.A., Connolly C.N.;
RT   "Cell surface expression of 5-hydroxytryptamine type 3 receptors is
RT   promoted by RIC-3.";
RL   J. Biol. Chem. 280:22502-22507(2005).
RN   [16]
RP   SUBUNIT, AND MUTAGENESIS OF TRP-178.
RX   PubMed=17392525; DOI=10.1124/mol.106.032144;
RA   Niesler B., Walstab J., Combrink S., Moeller D., Kapeller J.,
RA   Rietdorf J., Boenisch H., Goethert M., Rappold G., Bruess M.;
RT   "Characterization of the novel human serotonin receptor subunits 5-
RT   HT3C, 5-HT3D, and 5-HT3E.";
RL   Mol. Pharmacol. 72:8-17(2007).
RN   [17]
RP   VARIANT THR-33.
RX   PubMed=15293096; DOI=10.1007/s10067-004-0927-2;
RA   Frank B., Niesler B., Bondy B., Spaeth M., Pongratz D.E.,
RA   Ackenheil M., Fischer C., Rappold G.;
RT   "Mutational analysis of serotonin receptor genes: HTR3A and HTR3B in
RT   fibromyalgia patients.";
RL   Clin. Rheumatol. 23:338-344(2004).
RN   [18]
RP   VARIANTS HIS-344; ARG-391 AND GLN-409.
RX   PubMed=16487942; DOI=10.1016/j.biopsych.2005.11.008;
RA   Yamada K., Hattori E., Iwayama Y., Ohnishi T., Ohba H., Toyota T.,
RA   Takao H., Minabe Y., Nakatani N., Higuchi T., Detera-Wadleigh S.D.,
RA   Yoshikawa T.;
RT   "Distinguishable haplotype blocks in the HTR3A and HTR3B region in the
RT   Japanese reveal evidence of association of HTR3B with female major
RT   depression.";
RL   Biol. Psychiatry 60:192-201(2006).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. This receptor is
CC       a ligand-gated ion channel, which when activated causes fast,
CC       depolarizing responses in neurons. It is a cation-specific, but
CC       otherwise relatively nonselective, ion channel.
CC   -!- SUBUNIT: Forms pentahomomeric complex as well as pentaheteromeric
CC       complex with HTR3B or HTR3C or HTR3D or HTR3E; homomeric complex
CC       is functional but exhibits low conductance with modified voltage
CC       dependence, and decreased agonist and antagonist affinity.
CC       Interacts with RIC3.
CC   -!- SUBCELLULAR LOCATION: Cell junction, synapse, postsynaptic cell
CC       membrane; Multi-pass membrane protein. Cell membrane; Multi-pass
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=5-HT3R-AS;
CC         IsoId=P46098-1; Sequence=Displayed;
CC       Name=2; Synonyms=5-HT3R-AL;
CC         IsoId=P46098-2; Sequence=VSP_000078;
CC       Name=3;
CC         IsoId=P46098-3; Sequence=VSP_042214;
CC       Name=4;
CC         IsoId=P46098-4; Sequence=VSP_043484;
CC         Note=No experimental confirmation available;
CC       Name=5;
CC         IsoId=P46098-5; Sequence=VSP_043484, VSP_000078;
CC         Note=No experimental confirmation available. Ref.7 (CD014118)
CC         sequence is in conflict in position: 342:C->W;
CC   -!- TISSUE SPECIFICITY: Expressed in cerebral cortex, amygdala,
CC       hippocampus, and testis. Detected in monocytes of the spleen and
CC       tonsil, in small and large intestine, uterus, prostate, ovary and
CC       placenta.
CC   -!- MISCELLANEOUS: The HA-stretch region of HTR3A seems to be
CC       responsible for the low conductance of HTR3A homomers compared to
CC       that of HTR3A/HTR3B heteromers.
CC   -!- SIMILARITY: Belongs to the ligand-gated ion channel (TC 1.A.9)
CC       family. 5-hydroxytryptamine receptor (TC 1.A.9.2) subfamily. HTR3A
CC       sub-subfamily.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D49394; BAA08387.1; -; mRNA.
DR   EMBL; S82612; AAB37533.2; -; mRNA.
DR   EMBL; AJ003078; CAA05851.1; -; mRNA.
DR   EMBL; AJ003079; CAA05852.1; -; mRNA.
DR   EMBL; AJ005205; CAA06442.3; -; Genomic_DNA.
DR   EMBL; AF498984; AAM21131.1; -; mRNA.
DR   EMBL; BT007204; AAP35868.1; -; mRNA.
DR   EMBL; CD014118; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK299973; BAG61798.1; -; mRNA.
DR   EMBL; AP000908; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471065; EAW67238.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67240.1; -; Genomic_DNA.
DR   EMBL; BC002354; AAH02354.1; -; mRNA.
DR   EMBL; BC004453; AAH04453.2; -; mRNA.
DR   CCDS; CCDS53710.1; -. [P46098-3]
DR   CCDS; CCDS8365.2; -. [P46098-4]
DR   CCDS; CCDS8366.2; -. [P46098-5]
DR   RefSeq; NP_000860.2; NM_000869.5. [P46098-4]
DR   RefSeq; NP_001155244.1; NM_001161772.2. [P46098-3]
DR   RefSeq; NP_998786.2; NM_213621.3. [P46098-5]
DR   UniGene; Hs.413899; -.
DR   ProteinModelPortal; P46098; -.
DR   SMR; P46098; 37-316.
DR   STRING; 9606.ENSP00000347754; -.
DR   BindingDB; P46098; -.
DR   ChEMBL; CHEMBL2094132; -.
DR   DrugBank; DB00969; Alosetron.
DR   DrugBank; DB01161; Chloroprocaine.
DR   DrugBank; DB00604; Cisapride.
DR   DrugBank; DB00757; Dolasetron.
DR   DrugBank; DB00889; Granisetron.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB00904; Ondansetron.
DR   DrugBank; DB00377; Palonosetron.
DR   DrugBank; DB00721; Procaine.
DR   DrugBank; DB01199; Tubocurarine.
DR   GuidetoPHARMACOLOGY; 373; -.
DR   TCDB; 1.A.9.2.1; the neurotransmitter receptor, cys loop, ligand-gated ion channel (lic) family.
DR   PhosphoSite; P46098; -.
DR   DMDM; 1168222; -.
DR   PaxDb; P46098; -.
DR   PRIDE; P46098; -.
DR   DNASU; 3359; -.
DR   Ensembl; ENST00000299961; ENSP00000299961; ENSG00000166736. [P46098-3]
DR   Ensembl; ENST00000355556; ENSP00000347754; ENSG00000166736. [P46098-5]
DR   Ensembl; ENST00000375498; ENSP00000364648; ENSG00000166736. [P46098-4]
DR   Ensembl; ENST00000504030; ENSP00000424189; ENSG00000166736. [P46098-1]
DR   Ensembl; ENST00000506841; ENSP00000424776; ENSG00000166736. [P46098-2]
DR   GeneID; 3359; -.
DR   KEGG; hsa:3359; -.
DR   UCSC; uc010rxa.2; human. [P46098-4]
DR   UCSC; uc010rxb.2; human.
DR   UCSC; uc010rxc.2; human. [P46098-3]
DR   CTD; 3359; -.
DR   GeneCards; GC11P113879; -.
DR   HGNC; HGNC:5297; HTR3A.
DR   MIM; 182139; gene.
DR   neXtProt; NX_P46098; -.
DR   PharmGKB; PA29555; -.
DR   eggNOG; NOG302526; -.
DR   HOGENOM; HOG000241519; -.
DR   HOVERGEN; HBG106638; -.
DR   KO; K04819; -.
DR   OMA; FIVRLVH; -.
DR   OrthoDB; EOG7KDF9H; -.
DR   PhylomeDB; P46098; -.
DR   TreeFam; TF315605; -.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   GeneWiki; HTR3A; -.
DR   GenomeRNAi; 3359; -.
DR   NextBio; 13282; -.
DR   PRO; PR:P46098; -.
DR   ArrayExpress; P46098; -.
DR   Bgee; P46098; -.
DR   CleanEx; HS_HTR3A; -.
DR   Genevestigator; P46098; -.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0051378; F:serotonin binding; IDA:MGI.
DR   GO; GO:0004993; F:serotonin receptor activity; IDA:MGI.
DR   GO; GO:0005232; F:serotonin-activated cation-selective channel activity; TAS:ProtInc.
DR   GO; GO:0005249; F:voltage-gated potassium channel activity; IEA:Ensembl.
DR   GO; GO:0006812; P:cation transport; TAS:GOC.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0007586; P:digestion; TAS:ProtInc.
DR   GO; GO:0034220; P:ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0007210; P:serotonin receptor signaling pathway; IDA:GOC.
DR   GO; GO:0007268; P:synaptic transmission; TAS:ProtInc.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   Gene3D; 1.20.120.370; -; 2.
DR   Gene3D; 2.70.170.10; -; 1.
DR   InterPro; IPR008132; 5HT3_rcpt.
DR   InterPro; IPR008133; 5HT3_rcpt_A.
DR   InterPro; IPR027361; Acetylcholine_rcpt_TM.
DR   InterPro; IPR006202; Neur_chan_lig-bd.
DR   InterPro; IPR006201; Neur_channel.
DR   InterPro; IPR006029; Neurotrans-gated_channel_TM.
DR   InterPro; IPR018000; Neurotransmitter_ion_chnl_CS.
DR   PANTHER; PTHR18945; PTHR18945; 1.
DR   Pfam; PF02931; Neur_chan_LBD; 1.
DR   Pfam; PF02932; Neur_chan_memb; 1.
DR   PRINTS; PR01709; 5HT3ARECEPTR.
DR   PRINTS; PR01708; 5HT3RECEPTOR.
DR   PRINTS; PR00252; NRIONCHANNEL.
DR   SUPFAM; SSF63712; SSF63712; 1.
DR   SUPFAM; SSF90112; SSF90112; 1.
DR   TIGRFAMs; TIGR00860; LIC; 1.
DR   PROSITE; PS00236; NEUROTR_ION_CHANNEL; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell junction; Cell membrane; Complete proteome;
KW   Disulfide bond; Glycoprotein; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Membrane; Polymorphism;
KW   Postsynaptic cell membrane; Receptor; Reference proteome; Signal;
KW   Synapse; Transmembrane; Transmembrane helix; Transport.
FT   SIGNAL        1     23       Potential.
FT   CHAIN        24    478       5-hydroxytryptamine receptor 3A.
FT                                /FTId=PRO_0000000408.
FT   TOPO_DOM     24    241       Extracellular (Potential).
FT   TRANSMEM    242    268       Helical; Name=1; (Potential).
FT   TOPO_DOM    269    273       Cytoplasmic (Potential).
FT   TRANSMEM    274    292       Helical; Name=2; (Potential).
FT   TOPO_DOM    293    302       Extracellular (Potential).
FT   TRANSMEM    303    321       Helical; Name=3; (Potential).
FT   TOPO_DOM    322    455       Cytoplasmic (Potential).
FT   TRANSMEM    456    475       Helical; Name=4; (Potential).
FT   TOPO_DOM    476    478       Extracellular (Potential).
FT   REGION      414    450       HA-stretch.
FT   CARBOHYD     28     28       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    104    104       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    170    170       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    186    186       N-linked (GlcNAc...) (Potential).
FT   DISULFID    157    171       By similarity.
FT   VAR_SEQ       1     22       MLLWVQQALLALLLPTLLAQGE -> MHRSFLQ (in
FT                                isoform 3).
FT                                /FTId=VSP_042214.
FT   VAR_SEQ       1      1       M -> MLGKLAM (in isoform 4 and isoform
FT                                5).
FT                                /FTId=VSP_043484.
FT   VAR_SEQ     306    306       G -> GKAPPGSRAQSGEKPAPSHLLHVSLASALGCTG
FT                                (in isoform 2 and isoform 5).
FT                                /FTId=VSP_000078.
FT   VARIANT      33     33       A -> T (in dbSNP:rs117793058).
FT                                /FTId=VAR_037398.
FT   VARIANT     253    253       S -> N (in dbSNP:rs4938063).
FT                                /FTId=VAR_037399.
FT   VARIANT     344    344       R -> H (in dbSNP:rs35815285).
FT                                /FTId=VAR_037400.
FT   VARIANT     391    391       P -> R.
FT                                /FTId=VAR_037401.
FT   VARIANT     409    409       R -> Q.
FT                                /FTId=VAR_037402.
FT   MUTAGEN     178    178       W->S: Abolished ligand binding to the
FT                                heteromeric receptor.
FT   MUTAGEN     432    432       R->Q: Little effect on conductance.
FT                                Massive increase of conductance; when
FT                                associated with D-436 and A-440.
FT   MUTAGEN     436    436       R->D: Increased conductance. Massive
FT                                increase of conductance; when associated
FT                                with Q-432 and A-440.
FT   MUTAGEN     440    440       R->A: Increased conductance. Massive
FT                                increase of conductance; when associated
FT                                with Q-432 and D-436.
FT   CONFLICT     46     46       R -> T (in Ref. 2; AAB37533).
FT   CONFLICT    125    125       F -> L (in Ref. 2; AAB37533).
FT   CONFLICT    321    321       A -> T (in Ref. 2; AAB37533).
FT   CONFLICT    386    386       S -> T (in Ref. 2; AAB37533).
SQ   SEQUENCE   478 AA;  55280 MW;  24CA9A232286FBC9 CRC64;
     MLLWVQQALL ALLLPTLLAQ GEARRSRNTT RPALLRLSDY LLTNYRKGVR PVRDWRKPTT
     VSIDVIVYAI LNVDEKNQVL TTYIWYRQYW TDEFLQWNPE DFDNITKLSI PTDSIWVPDI
     LINEFVDVGK SPNIPYVYIR HQGEVQNYKP LQVVTACSLD IYNFPFDVQN CSLTFTSWLH
     TIQDINISLW RLPEKVKSDR SVFMNQGEWE LLGVLPYFRE FSMESSNYYA EMKFYVVIRR
     RPLFYVVSLL LPSIFLMVMD IVGFYLPPNS GERVSFKITL LLGYSVFLII VSDTLPATAI
     GTPLIGVYFV VCMALLVISL AETIFIVRLV HKQDLQQPVP AWLRHLVLER IAWLLCLREQ
     STSQRPPATS QATKTDDCSA MGNHCSHMGG PQDFEKSPRD RCSPPPPPRE ASLAVCGLLQ
     ELSSIRQFLE KRDEIREVAR DWLRVGSVLD KLLFHIYLLA VLAYSITLVM LWSIWQYA
//
ID   5NT3A_HUMAN             Reviewed;         336 AA.
AC   Q9H0P0; A8K253; B2RAA5; B8ZZC4; Q6IPZ1; Q6NXS6; Q7L3G6; Q9P0P5;
AC   Q9UC42; Q9UC43; Q9UC44; Q9UC45;
DT   13-SEP-2005, integrated into UniProtKB/Swiss-Prot.
DT   14-NOV-2006, sequence version 3.
DT   09-JUL-2014, entry version 123.
DE   RecName: Full=Cytosolic 5'-nucleotidase 3A;
DE            EC=3.1.3.5;
DE   AltName: Full=Cytosolic 5'-nucleotidase 3;
DE   AltName: Full=Cytosolic 5'-nucleotidase III;
DE            Short=cN-III;
DE   AltName: Full=Pyrimidine 5'-nucleotidase 1;
DE            Short=P5'N-1;
DE            Short=P5N-1;
DE            Short=PN-I;
DE   AltName: Full=Uridine 5'-monophosphate hydrolase 1;
DE   AltName: Full=p36;
GN   Name=NT5C3A; Synonyms=NT5C3, P5N1, UMPH1; ORFNames=HSPC233;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Placenta;
RX   PubMed=10942414;
RA   Amici A., Emanuelli M., Raffaelli N., Ruggieri S., Saccucci F.,
RA   Magni G.;
RT   "Human erythrocyte pyrimidine 5'-nucleotidase, PN-I, is identical to
RT   p36, a protein associated to lupus inclusion formation in response to
RT   alpha-interferon.";
RL   Blood 96:1596-1598(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), TISSUE SPECIFICITY, AND
RP   VARIANT P5N DEFICIENCY VAL-137.
RX   PubMed=11369620; DOI=10.1182/blood.V97.11.3327;
RA   Marinaki A.M., Escuredo E., Duley J.A., Simmonds H.A., Amici A.,
RA   Naponelli V., Magni G., Seip M., Ben-Bassat I., Harley E.H.,
RA   Thein S.L., Rees D.C.;
RT   "Genetic basis of hemolytic anemia caused by pyrimidine 5'
RT   nucleotidase deficiency.";
RL   Blood 97:3327-3332(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), TISSUE SPECIFICITY, VARIANTS
RP   P5N DEFICIENCY PRO-181 AND ARG-280, AND CHARACTERIZATION OF VARIANTS
RP   P5N DEFICIENCY PRO-181 AND ARG-280.
RX   PubMed=15238149; DOI=10.1111/j.1365-2141.2004.05029.x;
RA   Kanno H., Takizawa T., Miwa S., Fujii H.;
RT   "Molecular basis of Japanese variants of pyrimidine 5'-nucleotidase
RT   deficiency.";
RL   Br. J. Haematol. 126:265-271(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Kidney;
RX   PubMed=11230166; DOI=10.1101/gr.GR1547R;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H.,
RA   Lauber J., Duesterhoeft A., Beyer A., Koehrer K., Strack N.,
RA   Mewes H.-W., Ottenwaelder B., Obermaier B., Tampe J., Heubner D.,
RA   Wambutt R., Korn B., Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and
RT   analysis of 500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Brain cortex, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, Lung, Muscle, and Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 29-336 (ISOFORM 2).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for
RT   300 previously undefined genes expressed in CD34+ hematopoietic
RT   stem/progenitor cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [11]
RP   PROTEIN SEQUENCE OF 83-95; 131-147; 226-240; 268-296 AND 311-329,
RP   INDUCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=8557639; DOI=10.1074/jbc.271.20.11595;
RA   Rich S.A., Bose M., Tempst P., Rudofsky U.H.;
RT   "Purification, microsequencing, and immunolocalization of p36, a new
RT   interferon-alpha-induced protein that is associated with human lupus
RT   inclusions.";
RL   J. Biol. Chem. 271:1118-1126(1996).
RN   [12]
RP   PROTEIN SEQUENCE OF 1-11, SUBUNIT, BIOPHYSICOCHEMICAL PROPERTIES,
RP   CHARACTERIZATION OF VARIANTS P5N DEFICIENCY VAL-137; PRO-181; SER-229
RP   AND ARG-280, AND MUTAGENESIS OF ASP-88; PHE-89; ASP-90; GLU-135 AND
RP   PHE-233.
RX   PubMed=15968458; DOI=10.1007/s00018-005-5135-y;
RA   Amici A., Ciccioli K., Naponelli V., Raffaelli N., Magni G.;
RT   "Evidence for essential catalytic determinants for human erythrocyte
RT   pyrimidine 5'-nucleotidase.";
RL   Cell. Mol. Life Sci. 62:1613-1620(2005).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.67 ANGSTROMS) OF 64-336 IN COMPLEX WITH
RP   PHOSPHATE AND MAGNESIUM IONS.
RX   PubMed=17405878; DOI=10.1074/jbc.M700917200;
RA   Wallden K., Stenmark P., Nyman T., Flodin S., Graeslund S.,
RA   Loppnau P., Bianchi V., Nordlund P.;
RT   "Crystal structure of human cytosolic 5'-nucleotidase II: insights
RT   into allosteric regulation and substrate recognition.";
RL   J. Biol. Chem. 282:17828-17836(2007).
RN   [16]
RP   VARIANT P5N DEFICIENCY SER-229.
RX   PubMed=12930399; DOI=10.1046/j.1365-2141.2003.04532.x;
RA   Bianchi P., Fermo E., Alfinito F., Vercellati C., Baserga M.,
RA   Ferraro F., Guzzo I., Rotoli B., Zanella A.;
RT   "Molecular characterization of six unrelated Italian patients affected
RT   by pyrimidine 5'-nucleotidase deficiency.";
RL   Br. J. Haematol. 122:847-851(2003).
CC   -!- FUNCTION: Can act both as nucleotidase and as phosphotransferase.
CC   -!- CATALYTIC ACTIVITY: A 5'-ribonucleotide + H(2)O = a ribonucleoside
CC       + phosphate.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=66 uM for CMP;
CC   -!- SUBUNIT: Monomer.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (Potential).
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Endoplasmic reticulum.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=2;
CC         IsoId=Q9H0P0-4; Sequence=Displayed;
CC       Name=1;
CC         IsoId=Q9H0P0-1; Sequence=VSP_021565;
CC       Name=3;
CC         IsoId=Q9H0P0-2; Sequence=VSP_015623;
CC       Name=4; Synonyms=P5N-R;
CC         IsoId=Q9H0P0-3; Sequence=VSP_015624;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 3 are expressed in
CC       reticulocytes and lymphocytes. Isoform 4 is expressed only in
CC       reticulocytes.
CC   -!- INDUCTION: Isoform 2 is induced by interferon alpha in Raji cells
CC       in association with lupus inclusions.
CC   -!- DISEASE: P5N deficiency (P5ND) [MIM:266120]: Autosomal recessive
CC       condition causing hemolytic anemia characterized by marked
CC       basophilic stippling and the accumulation of high concentrations
CC       of pyrimidine nucleotides within the erythrocyte. It is implicated
CC       in the anemia of lead poisoning and is possibly associated with
CC       learning difficulties. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the pyrimidine 5'-nucleotidase family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF36153.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=AAG33630.1; Type=Frameshift; Positions=Several;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF312735; AAG33630.1; ALT_SEQ; mRNA.
DR   EMBL; AL136716; CAB66650.1; -; mRNA.
DR   EMBL; AK290118; BAF82807.1; -; mRNA.
DR   EMBL; AK314109; BAG36802.1; -; mRNA.
DR   EMBL; CR533518; CAG38549.1; -; mRNA.
DR   EMBL; AC074338; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC083863; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471073; EAW94007.1; -; Genomic_DNA.
DR   EMBL; CH471073; EAW94008.1; -; Genomic_DNA.
DR   EMBL; BC013292; AAH13292.2; -; mRNA.
DR   EMBL; BC015856; AAH15856.2; -; mRNA.
DR   EMBL; BC066914; AAH66914.1; -; mRNA.
DR   EMBL; BC071652; AAH71652.2; -; mRNA.
DR   EMBL; AF151067; AAF36153.1; ALT_INIT; mRNA.
DR   CCDS; CCDS34616.1; -. [Q9H0P0-4]
DR   CCDS; CCDS34617.1; -. [Q9H0P0-1]
DR   CCDS; CCDS55101.1; -. [Q9H0P0-3]
DR   RefSeq; NP_001002009.1; NM_001002009.2. [Q9H0P0-1]
DR   RefSeq; NP_001002010.1; NM_001002010.2. [Q9H0P0-4]
DR   RefSeq; NP_001159590.1; NM_001166118.2. [Q9H0P0-3]
DR   RefSeq; NP_057573.2; NM_016489.12. [Q9H0P0-1]
DR   UniGene; Hs.487933; -.
DR   PDB; 2CN1; X-ray; 2.67 A; A=64-336.
DR   PDB; 2JGA; X-ray; 3.01 A; A=64-336.
DR   PDB; 2VKQ; X-ray; 2.50 A; A=64-336.
DR   PDBsum; 2CN1; -.
DR   PDBsum; 2JGA; -.
DR   PDBsum; 2VKQ; -.
DR   ProteinModelPortal; Q9H0P0; -.
DR   SMR; Q9H0P0; 64-336.
DR   BioGrid; 119408; 6.
DR   IntAct; Q9H0P0; 3.
DR   MINT; MINT-3065844; -.
DR   PhosphoSite; Q9H0P0; -.
DR   DMDM; 117949804; -.
DR   MaxQB; Q9H0P0; -.
DR   PaxDb; Q9H0P0; -.
DR   PRIDE; Q9H0P0; -.
DR   DNASU; 51251; -.
DR   Ensembl; ENST00000242210; ENSP00000242210; ENSG00000122643. [Q9H0P0-4]
DR   Ensembl; ENST00000381626; ENSP00000371039; ENSG00000122643. [Q9H0P0-3]
DR   Ensembl; ENST00000396152; ENSP00000379456; ENSG00000122643. [Q9H0P0-1]
DR   Ensembl; ENST00000405342; ENSP00000385261; ENSG00000122643. [Q9H0P0-1]
DR   Ensembl; ENST00000409467; ENSP00000387166; ENSG00000122643. [Q9H0P0-3]
DR   GeneID; 51251; -.
DR   KEGG; hsa:51251; -.
DR   UCSC; uc003tdi.4; human. [Q9H0P0-1]
DR   UCSC; uc003tdk.4; human. [Q9H0P0-4]
DR   CTD; 51251; -.
DR   GeneCards; GC07M033056; -.
DR   HGNC; HGNC:17820; NT5C3A.
DR   HPA; HPA029058; -.
DR   MIM; 266120; phenotype.
DR   MIM; 606224; gene.
DR   neXtProt; NX_Q9H0P0; -.
DR   Orphanet; 35120; Hemolytic anemia due to pyrimidine 5' nucleotidase deficiency.
DR   PharmGKB; PA31802; -.
DR   eggNOG; NOG266578; -.
DR   HOVERGEN; HBG059750; -.
DR   InParanoid; Q9H0P0; -.
DR   KO; K01081; -.
DR   OMA; NTEYFKQ; -.
DR   PhylomeDB; Q9H0P0; -.
DR   TreeFam; TF314663; -.
DR   Reactome; REACT_111217; Metabolism.
DR   SABIO-RK; Q9H0P0; -.
DR   EvolutionaryTrace; Q9H0P0; -.
DR   GeneWiki; NT5C3; -.
DR   GenomeRNAi; 51251; -.
DR   NextBio; 54391; -.
DR   PRO; PR:Q9H0P0; -.
DR   Bgee; Q9H0P0; -.
DR   Genevestigator; Q9H0P0; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0008665; F:2'-phosphotransferase activity; NAS:UniProtKB.
DR   GO; GO:0008253; F:5'-nucleotidase activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; NAS:UniProtKB.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0046085; P:adenosine metabolic process; IEA:Ensembl.
DR   GO; GO:0016311; P:dephosphorylation; IDA:GOC.
DR   GO; GO:0055086; P:nucleobase-containing small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0009117; P:nucleotide metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0006206; P:pyrimidine nucleobase metabolic process; TAS:Reactome.
DR   GO; GO:0046135; P:pyrimidine nucleoside catabolic process; TAS:Reactome.
DR   GO; GO:0006213; P:pyrimidine nucleoside metabolic process; NAS:UniProtKB.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.50.1000; -; 2.
DR   InterPro; IPR023214; HAD-like_dom.
DR   InterPro; IPR006434; Pyrimidine_nucleotidase_eu.
DR   PANTHER; PTHR13045; PTHR13045; 1.
DR   Pfam; PF05822; UMPH-1; 1.
DR   SUPFAM; SSF56784; SSF56784; 1.
DR   TIGRFAMs; TIGR01544; HAD-SF-IE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Endoplasmic reticulum;
KW   Hydrolase; Magnesium; Metal-binding; Nucleotide metabolism;
KW   Nucleotide-binding; Reference proteome; Transferase.
FT   CHAIN         1    336       Cytosolic 5'-nucleotidase 3A.
FT                                /FTId=PRO_0000064387.
FT   REGION      203    204       Substrate binding.
FT   ACT_SITE     88     88       Nucleophile.
FT   ACT_SITE     90     90       Proton donor.
FT   METAL        88     88       Magnesium.
FT   METAL        90     90       Magnesium; via carbonyl oxygen.
FT   METAL       277    277       Magnesium.
FT   BINDING     252    252       Substrate.
FT   VAR_SEQ       1     51       Missing (in isoform 4).
FT                                /FTId=VSP_015624.
FT   VAR_SEQ       1     50       MRAPSMDRAAVARVGAVASASVCALVAGVVLAQYIFTLKRK
FT                                TGRKTKIIE -> MTNQESAVHVK (in isoform 1).
FT                                /FTId=VSP_021565.
FT   VAR_SEQ       1     50       Missing (in isoform 3).
FT                                /FTId=VSP_015623.
FT   VARIANT     137    137       D -> V (in P5N deficiency; may alter
FT                                protein structure).
FT                                /FTId=VAR_023511.
FT   VARIANT     181    181       L -> P (in P5N deficiency; may alter
FT                                protein structure and markedly decreases
FT                                activity).
FT                                /FTId=VAR_023512.
FT   VARIANT     229    229       N -> S (in P5N deficiency; markedly
FT                                decreases activity).
FT                                /FTId=VAR_023513.
FT   VARIANT     280    280       G -> R (in P5N deficiency; markedly
FT                                decreases activity).
FT                                /FTId=VAR_023514.
FT   MUTAGEN      88     88       D->N: Loss of nucleotidase and
FT                                phosphotransferase activity.
FT   MUTAGEN      89     89       F->A: Increases Km for CMP 45-fold.
FT                                Reduces nucleotidase and
FT                                phosphotransferase activity by 99%.
FT   MUTAGEN      90     90       D->N: Loss of nucleotidase and
FT                                phosphotransferase activity.
FT   MUTAGEN     135    135       E->D: No effect on nucleotidase activity.
FT                                Reduces phosphotransferase activity by
FT                                99%.
FT   MUTAGEN     233    233       F->A: Reduces nucleotidase and
FT                                phosphotransferase activity by 97%.
FT   CONFLICT     95     95       R -> K (in Ref. 11; AA sequence).
FT   CONFLICT    144    144       E -> Q (in Ref. 11; AA sequence).
FT   CONFLICT    329    329       N -> R (in Ref. 11; AA sequence).
FT   HELIX        65     78
FT   HELIX        80     82
FT   STRAND       83     87
FT   TURN         90     92
FT   STRAND       96     98
FT   HELIX       106    111
FT   HELIX       118    135
FT   STRAND      138    140
FT   HELIX       142    163
FT   HELIX       167    169
FT   HELIX       170    175
FT   HELIX       185    194
FT   STRAND      199    206
FT   HELIX       207    216
FT   STRAND      224    229
FT   STRAND      231    233
FT   STRAND      237    242
FT   HELIX       252    258
FT   HELIX       260    264
FT   TURN        265    268
FT   STRAND      271    279
FT   HELIX       280    283
FT   TURN        284    287
FT   STRAND      292    300
FT   HELIX       304    312
FT   STRAND      315    320
FT   HELIX       326    335
SQ   SEQUENCE   336 AA;  37948 MW;  C5D75CCF1BB61021 CRC64;
     MRAPSMDRAA VARVGAVASA SVCALVAGVV LAQYIFTLKR KTGRKTKIIE MMPEFQKSSV
     RIKNPTRVEE IICGLIKGGA AKLQIITDFD MTLSRFSYKG KRCPTCHNII DNCKLVTDEC
     RKKLLQLKEK YYAIEVDPVL TVEEKYPYMV EWYTKSHGLL VQQALPKAKL KEIVAESDVM
     LKEGYENFFD KLQQHSIPVF IFSAGIGDVL EEVIRQAGVY HPNVKVVSNF MDFDETGVLK
     GFKGELIHVF NKHDGALRNT EYFNQLKDNS NIILLGDSQG DLRMADGVAN VEHILKIGYL
     NDRVDELLEK YMDSYDIVLV QDESLEVANS ILQKIL
//
ID   8ODP_HUMAN              Reviewed;         197 AA.
AC   P36639; A4D205; Q6LES7; Q6P0Y6; Q7Z7N6; Q8IV95; Q9UBM0; Q9UBM9;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   28-JUL-2009, sequence version 3.
DT   09-JUL-2014, entry version 139.
DE   RecName: Full=7,8-dihydro-8-oxoguanine triphosphatase;
DE            EC=3.6.1.55;
DE   AltName: Full=2-hydroxy-dATP diphosphatase;
DE            EC=3.6.1.56;
DE   AltName: Full=8-oxo-dGTPase;
DE   AltName: Full=Nucleoside diphosphate-linked moiety X motif 1;
DE            Short=Nudix motif 1;
DE   Flags: Precursor;
GN   Name=NUDT1; Synonyms=MTH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM P18), PARTIAL PROTEIN SEQUENCE,
RP   AND CATALYTIC ACTIVITY.
RX   PubMed=8226881;
RA   Sakumi K., Furuichi M., Tsuzuki T., Kakuma T., Kawabata S., Maki H.,
RA   Sekiguchi M.;
RT   "Cloning and expression of cDNA for a human enzyme that hydrolyzes 8-
RT   oxo-dGTP, a mutagenic substrate for DNA synthesis.";
RL   J. Biol. Chem. 268:23524-23530(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7713500; DOI=10.1006/geno.1994.1657;
RA   Furuichi M., Yoshida M.C., Oda H., Tajiri T., Nakabeppu Y.,
RA   Tsuzuki T., Sekiguchi M.;
RT   "Genomic structure and chromosome location of the human mutT homologue
RT   gene MTH1 encoding 8-oxo-dGTPase for prevention of A:T to C:G
RT   transversion.";
RL   Genomics 24:485-490(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM P18), TISSUE SPECIFICITY,
RP   DEVELOPMENTAL STAGE, AND VARIANT MET-124.
RX   PubMed=9211940; DOI=10.1074/jbc.272.28.17843;
RA   Oda H., Nakabeppu Y., Furuichi M., Sekiguchi M.;
RT   "Regulation of expression of the human MTH1 gene encoding 8-oxo-
RT   dGTPase. Alternative splicing of transcription products.";
RL   J. Biol. Chem. 272:17843-17850(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS P18/P21/P22/P26), AND ALTERNATIVE
RP   INITIATION.
RX   PubMed=10536140; DOI=10.1093/nar/27.22.4335;
RA   Oda H., Taketomi A., Maruyama R., Itoh R., Nishioka K., Yakushiji H.,
RA   Suzuki T., Sekiguchi M., Nakabeppu Y.;
RT   "Multi-forms of human MTH1 polypeptides produced by alternative
RT   translation initiation and single nucleotide polymorphism.";
RL   Nucleic Acids Res. 27:4335-4343(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM P18).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS P18 AND P22), AND
RP   VARIANT MET-124.
RC   TISSUE=Bone, Lymph, Mammary gland, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=7782328; DOI=10.1074/jbc.270.24.14659;
RA   Kang D., Nishida J., Iyama A., Nakabeppu Y., Furuichi M., Fujiwara T.,
RA   Sekiguchi M., Takeshige K.;
RT   "Intracellular localization of 8-oxo-dGTPase in human cells, with
RT   special reference to the role of the enzyme in mitochondria.";
RL   J. Biol. Chem. 270:14659-14665(1995).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10373420; DOI=10.1074/jbc.274.26.18201;
RA   Fujikawa K., Kamiya H., Yakushiji H., Fujii Y., Nakabeppu Y.,
RA   Kasai H.;
RT   "The oxidized forms of dATP are substrates for the human MutT
RT   homologue, the hMTH1 protein.";
RL   J. Biol. Chem. 274:18201-18205(1999).
RN   [13]
RP   MUTAGENESIS OF GLY-77; GLY-78; VAL-80; GLN-81; GLY-83; ILE-86; ASP-88;
RP   GLY-89; ALA-90; LEU-94; GLN-95; GLU-96; GLU-97 AND SER-98, FUNCTION,
RP   AND CATALYTIC ACTIVITY.
RX   PubMed=10608900; DOI=10.1074/jbc.274.53.38251;
RA   Fujii Y., Shimokawa H., Sekiguchi M., Nakabeppu Y.;
RT   "Functional significance of the conserved residues for the 23-residue
RT   module among MTH1 and MutT family proteins.";
RL   J. Biol. Chem. 274:38251-38259(1999).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11139615; DOI=10.1093/nar/29.2.449;
RA   Fujikawa K., Kamiya H., Yakushiji H., Nakabeppu Y., Kasai H.;
RT   "Human MTH1 protein hydrolyzes the oxidized ribonucleotide, 2-hydroxy-
RT   ATP.";
RL   Nucleic Acids Res. 29:449-454(2001).
RN   [15]
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF PHE-68; TRP-158; ASP-160;
RP   LEU-191; ARG-192; GLU-193; VAL-194; ASP-195; THR-196; VAL-197;
RP   192-ARG--VAL-197; 193-GLU--VAL-197; 194-VAL-VAL-197 AND
RP   195-ASP--VAL-197.
RX   PubMed=11756418; DOI=10.1074/jbc.M110566200;
RA   Sakai Y., Furuichi M., Takahashi M., Mishima M., Iwai S.,
RA   Shirakawa M., Nakabeppu Y.;
RT   "A molecular basis for the selective recognition of 2-hydroxy-dATP and
RT   8-oxo-dGTP by human MTH1.";
RL   J. Biol. Chem. 277:8579-8587(2002).
RN   [16]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12857738; DOI=10.1074/jbc.M306201200;
RA   Yoshimura D., Sakumi K., Ohno M., Sakai Y., Furuichi M., Iwai S.,
RA   Nakabeppu Y.;
RT   "An oxidized purine nucleoside triphosphatase, MTH1, suppresses cell
RT   death caused by oxidative stress.";
RL   J. Biol. Chem. 278:37965-37973(2003).
RN   [17]
RP   CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=16607562; DOI=10.1007/s00109-006-0053-5;
RA   Sakai Y., Oda H., Yoshimura D., Furuichi M., Kang D., Iwai S.,
RA   Hara T., Nakabeppu Y.;
RT   "The GT to GC single nucleotide polymorphism at the beginning of an
RT   alternative exon 2C of human MTH1 gene confers an amino terminal
RT   extension that functions as a mitochondrial targeting signal.";
RL   J. Mol. Med. 84:660-670(2006).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22556419; DOI=10.1074/jbc.M112.363010;
RA   Takagi Y., Setoyama D., Ito R., Kamiya H., Yamagata Y., Sekiguchi M.;
RT   "Human MTH3 (NUDT18) protein hydrolyzes oxidized forms of guanosine
RT   and deoxyguanosine diphosphates: comparison with MTH1 and MTH2.";
RL   J. Biol. Chem. 287:21541-21549(2012).
RN   [20]
RP   STRUCTURE BY NMR OF 42-197, SUBUNIT, COFACTOR, AND SUBSTRATE BINDING
RP   SITE.
RX   PubMed=15133035; DOI=10.1074/jbc.M402393200;
RA   Mishima M., Sakai Y., Itoh N., Kamiya H., Furuichi M., Takahashi M.,
RA   Yamagata Y., Iwai S., Nakabeppu Y., Shirakawa M.;
RT   "Structure of human MTH1, a Nudix family hydrolase that selectively
RT   degrades oxidized purine nucleoside triphosphates.";
RL   J. Biol. Chem. 279:33806-33815(2004).
RN   [21]
RP   CRYSTALLIZATION, AND PRELIMINARY X-RAY CRYSTALLOGRAPHY (1.95
RP   ANGSTROMS).
RX   PubMed=17142918; DOI=10.1107/S1744309106049529;
RA   Nakamura T., Kitaguchi Y., Miyazawa M., Kamiya H., Toma S.,
RA   Ikemizu S., Shirakawa M., Nakabeppu Y., Yamagata Y.;
RT   "Crystallization and preliminary X-ray analysis of human MTH1
RT   complexed with two oxidized nucleotides, 8-oxo-dGMP and 2-oxo-dATP.";
RL   Acta Crystallogr. F 62:1283-1285(2006).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 42-197 IN COMPLEX WITH
RP   8-OXO-DGMP, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=21787772; DOI=10.1016/j.febslet.2011.07.017;
RA   Svensson L.M., Jemth A.S., Desroses M., Loseva O., Helleday T.,
RA   Hogbom M., Stenmark P.;
RT   "Crystal structure of human MTH1 and the 8-oxo-dGMP product complex.";
RL   FEBS Lett. 585:2617-2621(2011).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 42-197.
RG   Structural genomics consortium (SGC);
RA   Tresaugues L., Siponen M.I., Arrowsmith C.H., Berglund H., Bountra C.,
RA   Collins R., Edwards A.M., Ekblad T., Flodin S., Flores A.,
RA   Graslund S., Hammarstrom M., Johansson I., Karlberg T., Kol S.,
RA   Kotenyova T., Kouznetsova E., Moche M., Nyman T., Persson C.,
RA   Schuler H., Schutz P., Thorsell A.G., Van Der Berg S., Wahlberg E.,
RA   Weigelt J., Welin M., Nordlund P.;
RT   "Crystal Structure of Human 8-oxo-dGTPase (MTH1).";
RL   Submitted (JAN-2011) to the PDB data bank.
RN   [24]
RP   VARIANT MET-124.
RX   PubMed=15516784; DOI=10.1507/endocrj.51.493;
RA   Miyako K., Kohno H., Ihara K., Kuromaru R., Matsuura N., Hara T.;
RT   "Association study of human MTH1 gene polymorphisms with type 1
RT   diabetes mellitus.";
RL   Endocr. J. 51:493-498(2004).
RN   [25]
RP   VARIANT MET-124.
RX   PubMed=16774934; DOI=10.1093/carcin/bgl095;
RA   Kohno T., Sakiyama T., Kunitoh H., Goto K., Nishiwaki Y., Saito D.,
RA   Hirose H., Eguchi T., Yanagitani N., Saito R., Sasaki-Matsumura R.,
RA   Mimaki S., Toyama K., Yamamoto S., Kuchiba A., Sobue T., Ohta T.,
RA   Ohki M., Yokota J.;
RT   "Association of polymorphisms in the MTH1 gene with small cell lung
RT   carcinoma risk.";
RL   Carcinogenesis 27:2448-2454(2006).
CC   -!- FUNCTION: Antimutagenic. Acts as a sanitizing enzyme for oxidized
CC       nucleotide pools, thus suppressing cell dysfunction and death
CC       induced by oxidative stress. Hydrolyzes 8-oxo-dGTP, 8-oxo-dATP and
CC       2-OH-dATP, thus preventing misincorporation of oxidized purine
CC       nucleoside triphosphates into DNA and subsequently preventing A:T
CC       to C:G and G:C to T:A transversions. Able to hydrolyze also the
CC       corresponding ribonucleotides, 2-OH-ATP, 8-oxo-GTP and 8-oxo-ATP.
CC       Does not play a role in U8 snoRNA decapping activity. Binds U8
CC       snoRNA.
CC   -!- CATALYTIC ACTIVITY: 8-oxo-dGTP + H(2)O = 8-oxo-dGMP + diphosphate.
CC   -!- CATALYTIC ACTIVITY: 2-hydroxy-dATP + H(2)O = 2-hydroxy-dAMP +
CC       diphosphate.
CC   -!- COFACTOR: Binds 1 magnesium ion per subunit (Probable).
CC   -!- ENZYME REGULATION: 2-hydroxy-dATPase activity is inhibited by 2-
CC       OH-dADP, 8-OH-dGDP and 8-OH-dGTP. 8-OH-dGTPase activity is
CC       inhibited by 8-OH-dGDP, 2-OH-dADP and 2-OH-dATP.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=8.3 uM for 2-hydroxy-dATP (at 30 degrees Celsius and pH 8.0,
CC         PubMed:11139615);
CC         KM=5.7 uM for 2-hydroxy-dATP (at 30 degrees Celsius and pH 7.2,
CC         PubMed:11139615);
CC         KM=4.3 uM for 2-hydroxy-rATP (at 30 degrees Celsius and pH 8.0,
CC         PubMed:11139615);
CC         KM=13.9 uM for 8-hydroxy-dATP (at 30 degrees Celsius and pH 8.0,
CC         PubMed:11139615);
CC         KM=51.0 uM for 8-hydroxy-rATP (at 30 degrees Celsius and pH 8.0,
CC         PubMed:11139615);
CC         KM=15.2 uM for 8-hydroxy-dGTP (at 30 degrees Celsius and pH 8.0,
CC         PubMed:11139615);
CC         KM=12.8 uM for 8-hydroxy-dGTP (at 30 degrees Celsius and pH 7.2,
CC         PubMed:11139615);
CC         KM=13.2 uM for 8-hydroxy-dGTP (at 22 degrees Celsius and pH 7.5,
CC         PubMed:21787772);
CC         KM=55.0 uM for 8-hydroxy-rGTP (at 30 degrees Celsius and pH 8.0,
CC         PubMed:11139615);
CC         KM=258 uM for dGTP (at 30 degrees Celsius and pH 8.0,
CC         PubMed:11139615);
CC         Note=The kinetic constants are determined for the recombinant
CC         enzyme expressed in E.coli. 2-hydroxy-rATP shows the best
CC         catalytic efficiency;
CC       pH dependence:
CC         Optimum pH is 7.8-8.2 with 8-hydroxy-dGTP as substrate, and 8.0-
CC         8.5 with 2-hydroxy-dATP as substrate;
CC   -!- SUBUNIT: Monomer.
CC   -!- SUBCELLULAR LOCATION: Isoform p18: Cytoplasm. Mitochondrion
CC       matrix. Nucleus. Note=Mostly present in cytoplasm. Variant Met-124
CC       has decreased efficiency in translocation to mitochondria.
CC   -!- SUBCELLULAR LOCATION: Isoform p26: Cytoplasm. Mitochondrion
CC       matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=4;
CC       Name=p26;
CC         IsoId=P36639-1; Sequence=Displayed;
CC         Note=Derived from a B-type mRNA with a polymorphic alteration
CC         (GU-->GC) at the beginning of exon 2c that converts an in-frame
CC         UGA to CGA yielding another in-frame AUG further upstream;
CC       Name=p22;
CC         IsoId=P36639-2; Sequence=VSP_018812;
CC       Name=p21;
CC         IsoId=P36639-3; Sequence=VSP_018813;
CC       Name=p18;
CC         IsoId=P36639-4; Sequence=VSP_018814;
CC   -!- TISSUE SPECIFICITY: Widely expressed with highest expression in
CC       thymus, testis, embryo and proliferating blood lymphocytes.
CC   -!- DEVELOPMENTAL STAGE: In peripheral blood lymphocytes, expressed at
CC       much higher levels in proliferating cells than in resting cells.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- POLYMORPHISM: A polymorphism between Met-1 and Met-19 removes a
CC       stop codon before the initiation codon for isoform p22 and gives
CC       rise to the production of isoform p26. The allele frequency of
CC       isoform p26 is about 20%. The allele may be associated with an
CC       increased risk for small cell lung carcinoma (SCLC).
CC   -!- SIMILARITY: Belongs to the Nudix hydrolase family.
CC   -!- SIMILARITY: Contains 1 nudix hydrolase domain.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/nudt1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D16581; BAA04013.1; -; mRNA.
DR   EMBL; D38594; BAA07601.1; -; Genomic_DNA.
DR   EMBL; AB025233; BAA83791.1; -; mRNA.
DR   EMBL; AB025234; BAA83792.1; -; mRNA.
DR   EMBL; AB025235; BAA83793.1; -; mRNA.
DR   EMBL; AB025236; BAA83794.1; -; mRNA.
DR   EMBL; AB025237; BAA83795.1; -; mRNA.
DR   EMBL; AB025238; BAA83796.1; -; mRNA.
DR   EMBL; AB025239; BAA83797.1; -; mRNA.
DR   EMBL; AB025240; BAA83798.1; -; mRNA.
DR   EMBL; AB025241; BAA83799.1; -; mRNA.
DR   EMBL; AB025242; BAA83800.1; -; mRNA.
DR   EMBL; DQ230907; ABB02181.1; -; Genomic_DNA.
DR   EMBL; CH236953; EAL23948.1; -; Genomic_DNA.
DR   EMBL; CH236953; EAL23949.1; -; Genomic_DNA.
DR   EMBL; CR407655; CAG28583.1; -; mRNA.
DR   EMBL; CH471144; EAW87225.1; -; Genomic_DNA.
DR   EMBL; CH471144; EAW87227.1; -; Genomic_DNA.
DR   EMBL; AC004971; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC014618; AAH14618.1; -; mRNA.
DR   EMBL; BC040144; AAH40144.2; -; mRNA.
DR   EMBL; BC051375; AAH51375.2; -; mRNA.
DR   EMBL; BC065367; AAH65367.1; -; mRNA.
DR   CCDS; CCDS5329.1; -. [P36639-2]
DR   CCDS; CCDS5330.1; -. [P36639-4]
DR   RefSeq; NP_002443.3; NM_002452.3. [P36639-4]
DR   RefSeq; NP_945186.1; NM_198948.1. [P36639-4]
DR   RefSeq; NP_945187.1; NM_198949.1. [P36639-2]
DR   RefSeq; NP_945188.1; NM_198950.1. [P36639-4]
DR   RefSeq; NP_945190.1; NM_198952.1. [P36639-2]
DR   RefSeq; NP_945191.1; NM_198953.1. [P36639-4]
DR   RefSeq; NP_945192.1; NM_198954.1. [P36639-2]
DR   UniGene; Hs.534331; -.
DR   PDB; 1IRY; NMR; -; A=42-197.
DR   PDB; 3Q93; X-ray; 1.80 A; A/B=42-197.
DR   PDB; 3WHW; X-ray; 2.70 A; A/B=42-197.
DR   PDB; 3ZR0; X-ray; 1.80 A; A/B=42-197.
DR   PDB; 3ZR1; X-ray; 1.90 A; A/B=42-197.
DR   PDB; 4C9W; X-ray; 1.65 A; A=42-197.
DR   PDB; 4C9X; X-ray; 1.20 A; A=42-197.
DR   PDB; 4N1T; X-ray; 1.60 A; A=42-197.
DR   PDB; 4N1U; X-ray; 1.60 A; A/B=42-196.
DR   PDBsum; 1IRY; -.
DR   PDBsum; 3Q93; -.
DR   PDBsum; 3WHW; -.
DR   PDBsum; 3ZR0; -.
DR   PDBsum; 3ZR1; -.
DR   PDBsum; 4C9W; -.
DR   PDBsum; 4C9X; -.
DR   PDBsum; 4N1T; -.
DR   PDBsum; 4N1U; -.
DR   ProteinModelPortal; P36639; -.
DR   SMR; P36639; 44-197.
DR   BioGrid; 110621; 11.
DR   IntAct; P36639; 4.
DR   STRING; 9606.ENSP00000339503; -.
DR   PhosphoSite; P36639; -.
DR   DMDM; 254763430; -.
DR   MaxQB; P36639; -.
DR   PaxDb; P36639; -.
DR   PRIDE; P36639; -.
DR   DNASU; 4521; -.
DR   Ensembl; ENST00000339737; ENSP00000343439; ENSG00000106268. [P36639-4]
DR   Ensembl; ENST00000343985; ENSP00000339503; ENSG00000106268. [P36639-2]
DR   Ensembl; ENST00000356714; ENSP00000349148; ENSG00000106268. [P36639-4]
DR   Ensembl; ENST00000397046; ENSP00000380239; ENSG00000106268. [P36639-4]
DR   Ensembl; ENST00000397048; ENSP00000380241; ENSG00000106268. [P36639-2]
DR   Ensembl; ENST00000397049; ENSP00000380242; ENSG00000106268. [P36639-2]
DR   GeneID; 4521; -.
DR   KEGG; hsa:4521; -.
DR   UCSC; uc003slp.1; human. [P36639-1]
DR   CTD; 4521; -.
DR   GeneCards; GC07P002248; -.
DR   HGNC; HGNC:8048; NUDT1.
DR   HPA; HPA012636; -.
DR   MIM; 600312; gene.
DR   neXtProt; NX_P36639; -.
DR   PharmGKB; PA31830; -.
DR   eggNOG; COG0494; -.
DR   HOGENOM; HOG000261970; -.
DR   HOVERGEN; HBG000032; -.
DR   InParanoid; P36639; -.
DR   KO; K17816; -.
DR   OMA; WFPLMLQ; -.
DR   OrthoDB; EOG7BS4BT; -.
DR   PhylomeDB; P36639; -.
DR   TreeFam; TF106348; -.
DR   BioCyc; MetaCyc:HS02879-MONOMER; -.
DR   Reactome; REACT_111217; Metabolism.
DR   EvolutionaryTrace; P36639; -.
DR   GeneWiki; NUDT1; -.
DR   GenomeRNAi; 4521; -.
DR   NextBio; 17452; -.
DR   PRO; PR:P36639; -.
DR   ArrayExpress; P36639; -.
DR   Bgee; P36639; -.
DR   CleanEx; HS_NUDT1; -.
DR   Genevestigator; P36639; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005759; C:mitochondrial matrix; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0035539; F:8-oxo-7,8-dihydrodeoxyguanosine triphosphate pyrophosphatase activity; IDA:UniProtKB.
DR   GO; GO:0008413; F:8-oxo-7,8-dihydroguanosine triphosphate pyrophosphatase activity; IDA:UniProtKB.
DR   GO; GO:0047693; F:ATP diphosphatase activity; IDA:UniProtKB.
DR   GO; GO:0003924; F:GTPase activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0030515; F:snoRNA binding; ISS:UniProtKB.
DR   GO; GO:0006200; P:ATP catabolic process; IDA:UniProtKB.
DR   GO; GO:0046061; P:dATP catabolic process; IDA:UniProtKB.
DR   GO; GO:0006203; P:dGTP catabolic process; IDA:UniProtKB.
DR   GO; GO:0042262; P:DNA protection; IDA:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IC:UniProtKB.
DR   GO; GO:0006184; P:GTP catabolic process; IDA:UniProtKB.
DR   GO; GO:0034656; P:nucleobase-containing small molecule catabolic process; TAS:Reactome.
DR   GO; GO:0055086; P:nucleobase-containing small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0006195; P:purine nucleotide catabolic process; IDA:UniProtKB.
DR   GO; GO:0006979; P:response to oxidative stress; TAS:ProtInc.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   Gene3D; 3.90.79.10; -; 1.
DR   InterPro; IPR020476; Nudix_hydrolase.
DR   InterPro; IPR020084; NUDIX_hydrolase_CS.
DR   InterPro; IPR000086; NUDIX_hydrolase_dom.
DR   InterPro; IPR015797; NUDIX_hydrolase_dom-like.
DR   InterPro; IPR003563; OxG-triPHTase.
DR   Pfam; PF00293; NUDIX; 1.
DR   PRINTS; PR01403; 8OXTPHPHTASE.
DR   PRINTS; PR00502; NUDIXFAMILY.
DR   SUPFAM; SSF55811; SSF55811; 1.
DR   PROSITE; PS51462; NUDIX; 1.
DR   PROSITE; PS00893; NUDIX_BOX; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Hydrolase; Magnesium; Metal-binding;
KW   Mitochondrion; Nucleus; Polymorphism; Reference proteome; RNA-binding;
KW   Transit peptide.
FT   TRANSIT       1     18       Mitochondrion (Potential).
FT   CHAIN        19    197       7,8-dihydro-8-oxoguanine triphosphatase.
FT                                /FTId=PRO_0000019944.
FT   DOMAIN       44    173       Nudix hydrolase.
FT   REGION       76     79       Substrate binding (Probable).
FT   REGION      158    161       Substrate binding.
FT   MOTIF        78     99       Nudix box.
FT   METAL        78     78       Magnesium; via carbonyl oxygen (By
FT                                similarity).
FT   METAL        93     93       Magnesium (By similarity).
FT   METAL        96     96       Magnesium (By similarity).
FT   METAL        97     97       Magnesium (By similarity).
FT   BINDING      49     49       Substrate; via carbonyl oxygen.
FT   BINDING      68     68       Substrate.
FT   BINDING      74     74       Substrate.
FT   SITE         68     68       Important for 2-OH-dATPase and 8-oxo-
FT                                dGTPase activities.
FT   SITE        158    158       Essential for 2-OH-dATPase and 8-oxo-
FT                                dGTPase activities.
FT   SITE        160    160       Essential for 2-OH-dATPase activity and
FT                                important for 8-oxo-dGTPase activity.
FT   VAR_SEQ       1     41       Missing (in isoform p18).
FT                                /FTId=VSP_018814.
FT   VAR_SEQ       1     26       Missing (in isoform p21).
FT                                /FTId=VSP_018813.
FT   VAR_SEQ       1     18       Missing (in isoform p22).
FT                                /FTId=VSP_018812.
FT   VARIANT      77     77       G -> W (in dbSNP:rs11547459).
FT                                /FTId=VAR_068715.
FT   VARIANT     124    124       V -> M (associated with type I diabetes
FT                                in Japanese female population; may be
FT                                associated with an increased risk for
FT                                small cell lung carcinoma (SCLC);
FT                                dbSNP:rs4866).
FT                                /FTId=VAR_013757.
FT   MUTAGEN      68     68       F->A: Reduces 2-OH-dATPase and 8-oxo-
FT                                dGTPase activities.
FT   MUTAGEN      77     77       G->R: Reduces activity by 97%.
FT   MUTAGEN      78     78       G->F: Loss of activity.
FT   MUTAGEN      80     80       V->E: Loss of activity.
FT   MUTAGEN      81     81       Q->P: Reduces activity by 97%.
FT   MUTAGEN      83     83       G->I: Reduces activity by 60%.
FT   MUTAGEN      86     86       I->K: Loss of activity.
FT   MUTAGEN      88     88       D->P: Loss of activity.
FT   MUTAGEN      89     89       G->M: Loss of activity.
FT   MUTAGEN      90     90       A->P: Loss of activity.
FT   MUTAGEN      94     94       L->P: Loss of activity.
FT   MUTAGEN      95     95       Q->P: Loss of activity.
FT   MUTAGEN      96     96       E->G: Loss of activity.
FT   MUTAGEN      97     97       E->Y: Loss of activity.
FT   MUTAGEN      98     98       S->R: Loss of activity.
FT   MUTAGEN     158    158       W->A: Greatly reduces or abolishes 2-OH-
FT                                dATPase and 8-oxo-dGTPase activities.
FT   MUTAGEN     158    158       W->Y: Enhances 2-OH-dATPase activity and
FT                                greatly reduces 8-oxo-dGTPase activity.
FT   MUTAGEN     160    160       D->A,N: Loss of 2-OH-dATPase activity,
FT                                reduces 8-oxo-dGTPase activity.
FT   MUTAGEN     191    191       L->A: Reduces 2-OH-dATPase and 8-oxo-
FT                                dGTPase activities and increases
FT                                thermolability.
FT   MUTAGEN     192    197       Missing: Almost abolishes 2-OH-dATPase
FT                                and 8-oxo-dGTPase activities and
FT                                increases thermolability.
FT   MUTAGEN     192    192       R->A: Reduces 2-OH-dATPase and 8-oxo-
FT                                dGTPase activities and increases
FT                                thermolability.
FT   MUTAGEN     193    197       Missing: Greatly reduces 2-OH-dATPase and
FT                                8-oxo-dGTPase activities and increases
FT                                thermolability.
FT   MUTAGEN     193    193       E->A: Reduces 2-OH-dATPase and 8-oxo-
FT                                dGTPase activities and increases
FT                                thermolability.
FT   MUTAGEN     194    197       Missing: Reduces 2-OH-dATPase and 8-oxo-
FT                                dGTPase activities and increases
FT                                thermolability.
FT   MUTAGEN     194    194       V->A: Reduces 2-OH-dATPase and 8-oxo-
FT                                dGTPase activities and increases
FT                                thermolability.
FT   MUTAGEN     195    197       Missing: Slightly enhances 2-OH-dATPase
FT                                and 8-oxo-dGTPase activities and
FT                                increases thermolability.
FT   MUTAGEN     195    195       D->A: Enhances 2-OH-dATPase and 8-oxo-
FT                                dGTPase activities and increases
FT                                thermolability.
FT   MUTAGEN     196    196       T->A: Reduces 2-OH-dATPase and 8-oxo-
FT                                dGTPase activities and increases
FT                                thermolability.
FT   MUTAGEN     197    197       V->A: Slightly reduces 2-OH-dATPase and
FT                                8-oxo-dGTPase activities and increases
FT                                thermolability.
FT   STRAND       45     54
FT   STRAND       56     64
FT   TURN         68     71
FT   STRAND       72     74
FT   STRAND       76     79
FT   HELIX        86     98
FT   STRAND      101    103
FT   STRAND      106    115
FT   STRAND      121    130
FT   STRAND      132    134
FT   STRAND      140    148
FT   HELIX       149    151
FT   HELIX       154    156
FT   HELIX       161    169
FT   STRAND      173    181
FT   TURN        182    184
FT   STRAND      185    195
SQ   SEQUENCE   197 AA;  22520 MW;  82AFF5E1CE287957 CRC64;
     MYWSNQITRR LGERVQGFMS GISPQQMGEP EGSWSGKNPG TMGASRLYTL VLVLQPQRVL
     LGMKKRGFGA GRWNGFGGKV QEGETIEDGA RRELQEESGL TVDALHKVGQ IVFEFVGEPE
     LMDVHVFCTD SIQGTPVESD EMRPCWFQLD QIPFKDMWPD DSYWFPLLLQ KKKFHGYFKF
     QGQDTILDYT LREVDTV
//
ID   A16L1_HUMAN             Reviewed;         607 AA.
AC   Q676U5; A3EXK9; A3EXL0; B6ZDH0; Q6IPN1; Q6UXW4; Q6ZVZ5; Q8NCY2;
AC   Q96JV5; Q9H619;
DT   12-APR-2005, integrated into UniProtKB/Swiss-Prot.
DT   12-APR-2005, sequence version 2.
DT   09-JUL-2014, entry version 111.
DE   RecName: Full=Autophagy-related protein 16-1;
DE   AltName: Full=APG16-like 1;
GN   Name=ATG16L1; Synonyms=APG16L; ORFNames=UNQ9393/PRO34307;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-300.
RC   TISSUE=Fetal brain;
RX   PubMed=15620219; DOI=10.1080/10425170400004104;
RA   Zheng H., Ji C., Li J., Jiang H., Ren M., Lu Q., Gu S., Mao Y.,
RA   Xie Y.;
RT   "Cloning and analysis of human Apg16L.";
RL   DNA Seq. 15:303-305(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 5), AND ASSOCIATION OF
RP   VARIANT ALA-300 WITH SUSCEPTIBILITY TO IBD10.
RX   PubMed=17200669; DOI=10.1038/ng1954;
RA   Hampe J., Franke A., Rosenstiel P., Till A., Teuber M., Huse K.,
RA   Albrecht M., Mayr G., De La Vega F.M., Briggs J., Guenther S.,
RA   Prescott N.J., Onnie C.M., Haesler R., Sipos B., Foelsch U.R.,
RA   Lengauer T., Platzer M., Mathew C.G., Krawczak M., Schreiber S.;
RT   "A genome-wide association scan of nonsynonymous SNPs identifies a
RT   susceptibility variant for Crohn disease in ATG16L1.";
RL   Nat. Genet. 39:207-211(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 55-607 (ISOFORM 2).
RC   TISSUE=Brain, Placenta, and Small intestine;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 114-607 (ISOFORM 2).
RC   TISSUE=Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 513-607.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-269 AND SER-287, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH TMEM59; TLR2 AND NOD2.
RX   PubMed=23376921; DOI=10.1038/emboj.2013.8;
RA   Boada-Romero E., Letek M., Fleischer A., Pallauf K., Ramon-Barros C.,
RA   Pimentel-Muinos F.X.;
RT   "TMEM59 defines a novel ATG16L1-binding motif that promotes local
RT   activation of LC3.";
RL   EMBO J. 32:566-582(2013).
RN   [12]
RP   ASSOCIATION OF VARIANT ALA-300 WITH SUSCEPTIBILITY TO IBD10.
RX   PubMed=17435756; DOI=10.1038/ng2032;
RA   Rioux J.D., Xavier R.J., Taylor K.D., Silverberg M.S., Goyette P.,
RA   Huett A., Green T., Kuballa P., Barmada M.M., Datta L.W.,
RA   Shugart Y.Y., Griffiths A.M., Targan S.R., Ippoliti A.F.,
RA   Bernard E.-J., Mei L., Nicolae D.L., Regueiro M., Schumm L.P.,
RA   Steinhart A.H., Rotter J.I., Duerr R.H., Cho J.H., Daly M.J.,
RA   Brant S.R.;
RT   "Genome-wide association study identifies new susceptibility loci for
RT   Crohn disease and implicates autophagy in disease pathogenesis.";
RL   Nat. Genet. 39:596-604(2007).
RN   [13]
RP   FUNCTION IN AUTOPHAGY, CLEAVAGE BY CASP3, CHARACTERIZATION OF VARIANT
RP   ALA-300, AND MUTAGENESIS OF ASP-299.
RX   PubMed=24553140; DOI=10.1038/nature13044;
RA   Murthy A., Li Y., Peng I., Reichelt M., Katakam A.K., Noubade R.,
RA   Roose-Girma M., Devoss J., Diehl L., Graham R.R.,
RA   van Lookeren Campagne M.;
RT   "A Crohn's disease variant in Atg16l1 enhances its degradation by
RT   caspase 3.";
RL   Nature 506:456-462(2014).
CC   -!- FUNCTION: Plays an essential role in autophagy: interacts with
CC       ATG12-ATG5 to mediate the conjugation of phosphatidylethanolamine
CC       (PE) to LC3 (MAP1LC3A, MAP1LC3B or MAP1LC3C), to produce a
CC       membrane-bound activated form of LC3 named LC3-II. Thereby,
CC       controls the elongation of the nascent autophagosomal membrane.
CC   -!- SUBUNIT: Homooligomer. Interacts with ATG5. Part of either the
CC       minor and major complexes respectively composed of 4 sets of
CC       ATG12-ATG5 and ATG16L1 (400 kDa) or 8 sets of ATG12-ATG5 and
CC       ATG16L1 (800 kDa) (By similarity). Interacts with RAB33B (By
CC       similarity). Interacts with TMEM59, TLR2 and NOD2.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-535909, EBI-535909;
CC       P60520:GABARAPL2; NbExp=2; IntAct=EBI-535909, EBI-720116;
CC       Q9GZQ8:MAP1LC3B; NbExp=2; IntAct=EBI-535909, EBI-373144;
CC       Q9BXW4:MAP1LC3C; NbExp=4; IntAct=EBI-535909, EBI-2603996;
CC       Q8TDY2:RB1CC1; NbExp=5; IntAct=EBI-535909, EBI-1047793;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Preautophagosomal
CC       structure membrane; Peripheral membrane protein (By similarity).
CC       Note=Localized to preautophagosomal structure (PAS) where it is
CC       involved in the membrane targeting of ATG5 (By similarity).
CC       Localizes also to discrete punctae along the ciliary axoneme (By
CC       similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=APG16L beta;
CC         IsoId=Q676U5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q676U5-2; Sequence=VSP_013386;
CC       Name=3;
CC         IsoId=Q676U5-3; Sequence=VSP_013387, VSP_013388;
CC         Note=No experimental confirmation available. May be produced at
CC         very low levels due to a premature stop codon in the mRNA,
CC         leading to nonsense-mediated mRNA decay;
CC       Name=4;
CC         IsoId=Q676U5-4; Sequence=VSP_013389, VSP_013390;
CC         Note=No experimental confirmation available;
CC       Name=5;
CC         IsoId=Q676U5-5; Sequence=VSP_013389, VSP_013386;
CC         Note=No experimental confirmation available;
CC   -!- PTM: Proteolytic cleavage by activated CASP3 leads to degradation
CC       and may regulate autophagy upon cellular stress and apoptotic
CC       stimuli.
CC   -!- DISEASE: Inflammatory bowel disease 10 (IBD10) [MIM:611081]: A
CC       chronic, relapsing inflammation of the gastrointestinal tract with
CC       a complex etiology. It is subdivided into Crohn disease and
CC       ulcerative colitis phenotypes. Crohn disease may affect any part
CC       of the gastrointestinal tract from the mouth to the anus, but most
CC       frequently it involves the terminal ileum and colon. Bowel
CC       inflammation is transmural and discontinuous; it may contain
CC       granulomas or be associated with intestinal or perianal fistulas.
CC       In contrast, in ulcerative colitis, the inflammation is continuous
CC       and limited to rectal and colonic mucosal layers; fistulas and
CC       granulomas are not observed. Both diseases include extraintestinal
CC       inflammation of the skin, eyes, or joints. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the WD repeat ATG16 family.
CC   -!- SIMILARITY: Contains 7 WD repeats.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15448.1; Type=Erroneous translation; Note=Wrong choice of CDS;
CC       Sequence=BAB55412.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY398617; AAR32130.1; -; mRNA.
DR   EMBL; EF079889; ABN48554.1; -; mRNA.
DR   EMBL; EF079890; ABN48555.1; -; mRNA.
DR   EMBL; AY358182; AAQ88549.1; -; mRNA.
DR   EMBL; AK026330; BAB15448.1; ALT_SEQ; mRNA.
DR   EMBL; AK027854; BAB55412.1; ALT_INIT; mRNA.
DR   EMBL; AK123876; BAC85713.1; -; mRNA.
DR   EMBL; AC013726; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471063; EAW71034.1; -; Genomic_DNA.
DR   EMBL; BC071846; AAH71846.1; -; mRNA.
DR   EMBL; AL834526; CAD39182.1; -; mRNA.
DR   CCDS; CCDS2502.2; -. [Q676U5-2]
DR   CCDS; CCDS2503.2; -. [Q676U5-1]
DR   CCDS; CCDS54438.1; -. [Q676U5-5]
DR   RefSeq; NP_001177195.1; NM_001190266.1.
DR   RefSeq; NP_001177196.1; NM_001190267.1.
DR   RefSeq; NP_060444.3; NM_017974.3. [Q676U5-2]
DR   RefSeq; NP_110430.5; NM_030803.6. [Q676U5-1]
DR   RefSeq; NP_942593.2; NM_198890.2. [Q676U5-5]
DR   UniGene; Hs.529322; -.
DR   PDB; 4GDK; X-ray; 2.70 A; C/F=11-43.
DR   PDB; 4GDL; X-ray; 2.88 A; C=11-43.
DR   PDB; 4NAW; X-ray; 2.20 A; C/G/K/O=11-43.
DR   PDBsum; 4GDK; -.
DR   PDBsum; 4GDL; -.
DR   PDBsum; 4NAW; -.
DR   ProteinModelPortal; Q676U5; -.
DR   SMR; Q676U5; 11-43, 312-604.
DR   BioGrid; 120375; 28.
DR   DIP; DIP-27552N; -.
DR   DIP; DIP-50290N; -.
DR   IntAct; Q676U5; 25.
DR   MINT; MINT-1141152; -.
DR   STRING; 9606.ENSP00000375872; -.
DR   PhosphoSite; Q676U5; -.
DR   DMDM; 62510482; -.
DR   MaxQB; Q676U5; -.
DR   PaxDb; Q676U5; -.
DR   PRIDE; Q676U5; -.
DR   DNASU; 55054; -.
DR   Ensembl; ENST00000347464; ENSP00000318259; ENSG00000085978. [Q676U5-5]
DR   Ensembl; ENST00000373525; ENSP00000362625; ENSG00000085978. [Q676U5-4]
DR   Ensembl; ENST00000392017; ENSP00000375872; ENSG00000085978. [Q676U5-1]
DR   Ensembl; ENST00000392020; ENSP00000375875; ENSG00000085978. [Q676U5-2]
DR   GeneID; 55054; -.
DR   KEGG; hsa:55054; -.
DR   UCSC; uc002vtx.2; human. [Q676U5-5]
DR   UCSC; uc002vty.3; human. [Q676U5-1]
DR   UCSC; uc002vtz.3; human. [Q676U5-4]
DR   UCSC; uc002vua.3; human. [Q676U5-2]
DR   CTD; 55054; -.
DR   GeneCards; GC02P234118; -.
DR   HGNC; HGNC:21498; ATG16L1.
DR   HPA; HPA012577; -.
DR   MIM; 610767; gene.
DR   MIM; 611081; phenotype.
DR   neXtProt; NX_Q676U5; -.
DR   Orphanet; 206; Crohn disease.
DR   PharmGKB; PA134902949; -.
DR   eggNOG; COG2319; -.
DR   HOGENOM; HOG000112569; -.
DR   HOVERGEN; HBG050534; -.
DR   KO; K17890; -.
DR   OrthoDB; EOG70CR6M; -.
DR   PhylomeDB; Q676U5; -.
DR   TreeFam; TF315541; -.
DR   SignaLink; Q676U5; -.
DR   GeneWiki; ATG16L1; -.
DR   GenomeRNAi; 55054; -.
DR   NextBio; 58531; -.
DR   PRO; PR:Q676U5; -.
DR   ArrayExpress; Q676U5; -.
DR   Bgee; Q676U5; -.
DR   CleanEx; HS_ATG16L1; -.
DR   Genevestigator; Q676U5; -.
DR   GO; GO:0005776; C:autophagic vacuole; ISS:UniProtKB.
DR   GO; GO:0000421; C:autophagic vacuole membrane; IEA:Ensembl.
DR   GO; GO:0005930; C:axoneme; ISS:UniProtKB.
DR   GO; GO:0034045; C:pre-autophagosomal structure membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0000045; P:autophagic vacuole assembly; NAS:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; NAS:UniProtKB.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR013923; Autophagy-rel_prot_16.
DR   InterPro; IPR020472; G-protein_beta_WD-40_rep.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR019775; WD40_repeat_CS.
DR   InterPro; IPR017986; WD40_repeat_dom.
DR   Pfam; PF08614; ATG16; 1.
DR   Pfam; PF00400; WD40; 5.
DR   PRINTS; PR00320; GPROTEINBRPT.
DR   SMART; SM00320; WD40; 7.
DR   SUPFAM; SSF50978; SSF50978; 1.
DR   PROSITE; PS00678; WD_REPEATS_1; 3.
DR   PROSITE; PS50082; WD_REPEATS_2; 6.
DR   PROSITE; PS50294; WD_REPEATS_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autophagy; Coiled coil;
KW   Complete proteome; Cytoplasm; Membrane; Phosphoprotein; Polymorphism;
KW   Protein transport; Reference proteome; Repeat; Transport; WD repeat.
FT   CHAIN         1    607       Autophagy-related protein 16-1.
FT                                /FTId=PRO_0000050848.
FT   REPEAT      320    359       WD 1.
FT   REPEAT      364    403       WD 2.
FT   REPEAT      406    445       WD 3.
FT   REPEAT      447    484       WD 4.
FT   REPEAT      486    525       WD 5.
FT   REPEAT      532    573       WD 6.
FT   REPEAT      575    607       WD 7.
FT   COILED       78    230       Potential.
FT   MOTIF       296    299       Caspase cleavage.
FT   MOD_RES     269    269       Phosphoserine.
FT   MOD_RES     287    287       Phosphoserine.
FT   VAR_SEQ      70    213       Missing (in isoform 4 and isoform 5).
FT                                /FTId=VSP_013389.
FT   VAR_SEQ     266    284       Missing (in isoform 2 and isoform 5).
FT                                /FTId=VSP_013386.
FT   VAR_SEQ     334    368       Missing (in isoform 4).
FT                                /FTId=VSP_013390.
FT   VAR_SEQ     443    470       IKTVFAGSSCNDIVCTEQCVMSGHFDKK -> EEIQSLCLC
FT                                ICLDVSVEVCVCTSEPAFM (in isoform 3).
FT                                /FTId=VSP_013387.
FT   VAR_SEQ     471    607       Missing (in isoform 3).
FT                                /FTId=VSP_013388.
FT   VARIANT     300    300       T -> A (associated with susceptibility to
FT                                IBD10; has no effect on the stability of
FT                                the protein; enhances the cleavage and
FT                                the degradation mediated by activated
FT                                CASP3; results in reduced autophagy and
FT                                defective clearance of intestinal
FT                                pathogens; dbSNP:rs2241880).
FT                                /FTId=VAR_021834.
FT   VARIANT     307    307       E -> K (in dbSNP:rs1866878).
FT                                /FTId=VAR_053386.
FT   MUTAGEN     299    299       D->E: Prevents cleavage by activated
FT                                CASP3.
FT   CONFLICT    151    151       K -> R (in Ref. 6; BAB55412).
FT   CONFLICT    328    328       V -> A (in Ref. 6; BAB55412).
FT   CONFLICT    529    529       P -> T (in Ref. 6; BAB55412).
FT   HELIX        12     28
FT   HELIX        30     42
SQ   SEQUENCE   607 AA;  68265 MW;  5A5816AE2CF03CA0 CRC64;
     MSSGLRAADF PRWKRHISEQ LRRRDRLQRQ AFEEIILQYN KLLEKSDLHS VLAQKLQAEK
     HDVPNRHEIS PGHDGTWNDN QLQEMAQLRI KHQEELTELH KKRGELAQLV IDLNNQMQRK
     DREMQMNEAK IAECLQTISD LETECLDLRT KLCDLERANQ TLKDEYDALQ ITFTALEGKL
     RKTTEENQEL VTRWMAEKAQ EANRLNAENE KDSRRRQARL QKELAEAAKE PLPVEQDDDI
     EVIVDETSDH TEETSPVRAI SRAATKRLSQ PAGGLLDSIT NIFGRRSVSS FPVPQDNVDT
     HPGSGKEVRV PATALCVFDA HDGEVNAVQF SPGSRLLATG GMDRRVKLWE VFGEKCEFKG
     SLSGSNAGIT SIEFDSAGSY LLAASNDFAS RIWTVDDYRL RHTLTGHSGK VLSAKFLLDN
     ARIVSGSHDR TLKLWDLRSK VCIKTVFAGS SCNDIVCTEQ CVMSGHFDKK IRFWDIRSES
     IVREMELLGK ITALDLNPER TELLSCSRDD LLKVIDLRTN AIKQTFSAPG FKCGSDWTRV
     VFSPDGSYVA AGSAEGSLYI WSVLTGKVEK VLSKQHSSSI NAVAWSPSGS HVVSVDKGCK
     AVLWAQY
//
ID   A1AG1_HUMAN             Reviewed;         201 AA.
AC   P02763; B7ZKQ5; Q5T539; Q5U067; Q8TC16;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   09-JUL-2014, entry version 162.
DE   RecName: Full=Alpha-1-acid glycoprotein 1;
DE            Short=AGP 1;
DE   AltName: Full=Orosomucoid-1;
DE            Short=OMD 1;
DE   Flags: Precursor;
GN   Name=ORM1; Synonyms=AGP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2822385;
RA   Dente L., Pizza M.G., Metspalu A., Cortese R.;
RT   "Structure and expression of the genes coding for human alpha 1-acid
RT   glycoprotein.";
RL   EMBO J. 6:2289-2296(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3770479; DOI=10.1016/0378-1119(86)90051-X;
RA   Board P.G., Jones I.M., Bentley A.K.;
RT   "Molecular cloning and nucleotide sequence of human alpha 1 acid
RT   glycoprotein cDNA.";
RL   Gene 44:127-131(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2409529; DOI=10.1093/nar/13.11.3941;
RA   Dente L., Ciliberto G., Cortese R.;
RT   "Structure of the human alpha 1-acid glycoprotein gene: sequence
RT   homology with other human acute phase protein genes.";
RL   Nucleic Acids Res. 13:3941-3952(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-38.
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-38.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-38; CYS-167
RP   AND MET-174.
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 19-129, AND PYROGLUTAMATE FORMATION AT GLN-19.
RX   PubMed=4711474; DOI=10.1021/bi00738a026;
RA   Schmid K., Kaufmann H., Isemura S., Bauer F., Emura J., Motoyama T.,
RA   Ishiguro M., Nanno S.;
RT   "Structure of alpha 1-acid glycoprotein. The complete amino acid
RT   sequence, multiple amino acid substitutions, and homology with the
RT   immunoglobulins.";
RL   Biochemistry 12:2711-2724(1973).
RN   [10]
RP   PROTEIN SEQUENCE OF 129-201.
RX   PubMed=4561179; DOI=10.1021/bi00770a022;
RA   Ikenaka T., Ishiguro M., Emura J., Kaufmann H., Isemura S., Bauer W.,
RA   Schmid K.;
RT   "Isolation and partial characterization of the cyanogen bromide
RT   fragments of alpha 1-acid glycoprotein and the elucidation of the
RT   amino acid sequence of the carboxyl-terminal cyanogen bromide
RT   fragment.";
RL   Biochemistry 11:3817-3829(1972).
RN   [11]
RP   DISULFIDE BONDS.
RX   PubMed=4603214; DOI=10.1021/bi00710a006;
RA   Schmid K., Buergi W., Collins J.H., Nanno S.;
RT   "The disulfide bonds of alpha1-acid glycoprotein.";
RL   Biochemistry 13:2694-2697(1974).
RN   [12]
RP   GLYCOSYLATION AT ASN-33; ASN-56; ASN-72; ASN-93 AND ASN-103.
RX   PubMed=1567356;
RA   Treuheit M.J., Costello C.E., Halsall H.B.;
RT   "Analysis of the five glycosylation sites of human alpha 1-acid
RT   glycoprotein.";
RL   Biochem. J. 283:105-112(1992).
RN   [13]
RP   GLYCOSYLATION AT ASN-33.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [14]
RP   GLYCOSYLATION AT ASN-33; ASN-72 AND ASN-93, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=15253437; DOI=10.1021/pr034112b;
RA   Hagglund P., Bunkenborg J., Elortza F., Jensen O.N., Roepstorff P.;
RT   "A new strategy for identification of N-glycosylated proteins and
RT   unambiguous assignment of their glycosylation sites using HILIC
RT   enrichment and partial deglycosylation.";
RL   J. Proteome Res. 3:556-566(2004).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33 AND ASN-93.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.M400015-MCP200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H.,
RA   Thuluvath P.J., Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-56; ASN-72; ASN-93
RP   AND ASN-103.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-56; ASN-72; ASN-93
RP   AND ASN-103.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [18]
RP   FUNCTION.
RX   PubMed=17008009; DOI=10.1016/j.bbagen.2006.08.015;
RA   Fitos I., Visy J., Zsila F., Mady G., Simonyi M.;
RT   "Selective binding of imatinib to the genetic variants of human
RT   alpha1-acid glycoprotein.";
RL   Biochim. Biophys. Acta 1760:1704-1712(2006).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93.
RC   TISSUE=Saliva;
RX   PubMed=16740002; DOI=10.1021/pr050492k;
RA   Ramachandran P., Boontheung P., Xie Y., Sondej M., Wong D.T.,
RA   Loo J.A.;
RT   "Identification of N-linked glycoproteins in human saliva by
RT   glycoprotein capture and mass spectrometry.";
RL   J. Proteome Res. 5:1493-1503(2006).
RN   [20]
RP   FUNCTION.
RX   PubMed=17321687; DOI=10.1016/j.bbagen.2007.01.009;
RA   Zsila F., Iwao Y.;
RT   "The drug binding site of human alpha1-acid glycoprotein: insight from
RT   induced circular dichroism and electronic absorption spectra.";
RL   Biochim. Biophys. Acta 1770:797-809(2007).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93 AND ASN-103.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33 AND ASN-72, AND
RP   STRUCTURE OF CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [23]
RP   GLYCOSYLATION AT ASN-33, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 20-201, DOMAIN, AND DISULFIDE
RP   BONDS.
RX   PubMed=18823996; DOI=10.1016/j.jmb.2008.09.020;
RA   Schonfeld D.L., Ravelli R.B., Mueller U., Skerra A.;
RT   "The 1.8-A crystal structure of alpha1-acid glycoprotein (Orosomucoid)
RT   solved by UV RIP reveals the broad drug-binding activity of this human
RT   plasma lipocalin.";
RL   J. Mol. Biol. 384:393-405(2008).
RN   [25]
RP   VARIANTS ARG-38 AND MET-174.
RX   PubMed=9050929; DOI=10.1007/s004390050378;
RA   Yuasa I., Umetsu K., Vogt U., Nakamura H., Nanba E., Tamaki N.,
RA   Irizawa Y.;
RT   "Human orosomucoid polymorphism: molecular basis of the three common
RT   ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S.";
RL   Hum. Genet. 99:393-398(1997).
CC   -!- FUNCTION: Functions as transport protein in the blood stream.
CC       Binds various ligands in the interior of its beta-barrel domain.
CC       Also binds synthetic drugs and influences their distribution and
CC       availability in the body. Appears to function in modulating the
CC       activity of the immune system during the acute-phase reaction.
CC   -!- INTERACTION:
CC       P05121:SERPINE1; NbExp=4; IntAct=EBI-976767, EBI-953978;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Expressed by the liver and secreted in plasma.
CC   -!- INDUCTION: Synthesis is controlled by glucocorticoids,
CC       interleukin-1 and interleukin-6, It increases 5- to 50-fold upon
CC       inflammation.
CC   -!- DOMAIN: Contains a beta-barrel that binds various ligands in its
CC       interior.
CC   -!- PTM: N-glycosylated. N-glycan heterogeneity at Asn-33: Hex5HexNAc4
CC       (minor), Hex6HexNAc5 (major) and dHex1Hex6HexNAc5 (minor).
CC   -!- POLYMORPHISM: Three common alleles of ORM1 are known. ORM1*F1 has
CC       Gln-38/Val-174; ORM1*F2 has Gln-38/Met-174 and ORM1*S has Arg-
CC       38/Val-174. The sequence shown is that of allele ORM1*F1.
CC   -!- SIMILARITY: Belongs to the calycin superfamily. Lipocalin family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA29229.1; Type=Erroneous gene model prediction;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X02544; CAA26397.1; -; mRNA.
DR   EMBL; M13692; AAA35515.1; -; mRNA.
DR   EMBL; X05779; CAA29229.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; X05780; CAA29229.1; JOINED; Genomic_DNA.
DR   EMBL; X05781; CAA29229.1; JOINED; Genomic_DNA.
DR   EMBL; X05782; CAA29229.1; JOINED; Genomic_DNA.
DR   EMBL; X05783; CAA29229.1; JOINED; Genomic_DNA.
DR   EMBL; X05784; CAA29229.1; JOINED; Genomic_DNA.
DR   EMBL; X06676; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X06680; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BT019790; AAV38593.1; -; mRNA.
DR   EMBL; AK312035; BAG34972.1; -; mRNA.
DR   EMBL; AL356796; CAI16859.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW87416.1; -; Genomic_DNA.
DR   EMBL; BC104818; AAI04819.1; -; mRNA.
DR   EMBL; BC104820; AAI04821.1; -; mRNA.
DR   EMBL; BC143313; AAI43314.1; -; mRNA.
DR   EMBL; BC143314; AAI43315.1; -; mRNA.
DR   EMBL; BC026238; AAH26238.1; -; mRNA.
DR   CCDS; CCDS6803.1; -.
DR   PIR; A28346; OMHU1.
DR   RefSeq; NP_000598.2; NM_000607.2.
DR   UniGene; Hs.522356; -.
DR   PDB; 3KQ0; X-ray; 1.80 A; A=19-201.
DR   PDBsum; 3KQ0; -.
DR   ProteinModelPortal; P02763; -.
DR   SMR; P02763; 19-193.
DR   BioGrid; 111046; 7.
DR   IntAct; P02763; 7.
DR   MINT; MINT-202382; -.
DR   STRING; 9606.ENSP00000259396; -.
DR   BindingDB; P02763; -.
DR   ChEMBL; CHEMBL4285; -.
DR   DrugBank; DB01418; Acenocoumarol.
DR   DrugBank; DB00802; Alfentanil.
DR   DrugBank; DB01429; Aprindine.
DR   DrugBank; DB00280; Disopyramide.
DR   DrugBank; DB01359; Penbutolol.
DR   DrugBank; DB00946; Phenprocoumon.
DR   DrugBank; DB00908; Quinidine.
DR   DrugBank; DB00706; Tamsulosin.
DR   PhosphoSite; P02763; -.
DR   UniCarbKB; P02763; -.
DR   DMDM; 112877; -.
DR   SWISS-2DPAGE; P02763; -.
DR   MaxQB; P02763; -.
DR   PaxDb; P02763; -.
DR   PeptideAtlas; P02763; -.
DR   PRIDE; P02763; -.
DR   DNASU; 5004; -.
DR   Ensembl; ENST00000259396; ENSP00000259396; ENSG00000229314.
DR   GeneID; 5004; -.
DR   KEGG; hsa:5004; -.
DR   UCSC; uc004bik.4; human.
DR   CTD; 5004; -.
DR   GeneCards; GC09P117085; -.
DR   HGNC; HGNC:8498; ORM1.
DR   HPA; CAB006265; -.
DR   HPA; HPA046438; -.
DR   MIM; 138600; gene.
DR   neXtProt; NX_P02763; -.
DR   PharmGKB; PA260; -.
DR   eggNOG; NOG41523; -.
DR   HOGENOM; HOG000125170; -.
DR   HOVERGEN; HBG000035; -.
DR   InParanoid; P02763; -.
DR   KO; K17308; -.
DR   OrthoDB; EOG7B5WXT; -.
DR   PhylomeDB; P02763; -.
DR   TreeFam; TF343791; -.
DR   ChiTaRS; ORM1; human.
DR   EvolutionaryTrace; P02763; -.
DR   GeneWiki; ORM1; -.
DR   GenomeRNAi; 5004; -.
DR   NextBio; 19272; -.
DR   PRO; PR:P02763; -.
DR   ArrayExpress; P02763; -.
DR   Bgee; P02763; -.
DR   CleanEx; HS_ORM1; -.
DR   Genevestigator; P02763; -.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0006953; P:acute-phase response; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0002682; P:regulation of immune system process; IEA:InterPro.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   Gene3D; 2.40.128.20; -; 1.
DR   InterPro; IPR001500; A1A_glycop.
DR   InterPro; IPR012674; Calycin.
DR   InterPro; IPR011038; Calycin-like.
DR   InterPro; IPR000566; Lipocln_cytosolic_FA-bd_dom.
DR   PANTHER; PTHR11967; PTHR11967; 1.
DR   Pfam; PF00061; Lipocalin; 1.
DR   PIRSF; PIRSF036899; AGP; 1.
DR   PRINTS; PR00708; A1AGLPROTEIN.
DR   SUPFAM; SSF50814; SSF50814; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Polymorphism;
KW   Pyrrolidone carboxylic acid; Reference proteome; Secreted; Signal;
KW   Transport.
FT   SIGNAL        1     18
FT   CHAIN        19    201       Alpha-1-acid glycoprotein 1.
FT                                /FTId=PRO_0000017860.
FT   MOD_RES      19     19       Pyrrolidone carboxylic acid.
FT   CARBOHYD     33     33       N-linked (GlcNAc...) (complex).
FT   CARBOHYD     56     56       N-linked (GlcNAc...).
FT   CARBOHYD     72     72       N-linked (GlcNAc...) (complex).
FT   CARBOHYD     93     93       N-linked (GlcNAc...).
FT   CARBOHYD    103    103       N-linked (GlcNAc...).
FT                                /FTId=CAR_000170.
FT   DISULFID     23    165
FT   DISULFID     90    183
FT   VARIANT      38     38       Q -> R (in allele ORM1*S).
FT                                /FTId=VAR_013840.
FT   VARIANT     167    167       R -> C (in dbSNP:rs3182034).
FT                                /FTId=VAR_056166.
FT   VARIANT     174    174       V -> M (in allele ORM1*F2;
FT                                dbSNP:rs1126801).
FT                                /FTId=VAR_013841.
FT   CONFLICT    170    170       K -> R (in Ref. 8; AAI43315).
FT   CONFLICT    182    182       Missing (in Ref. 10; AA sequence).
FT   CONFLICT    193    193       Missing (in Ref. 10; AA sequence).
FT   HELIX        24     26
FT   HELIX        33     39
FT   STRAND       41     52
FT   HELIX        53     59
FT   STRAND       62     72
FT   TURN         73     76
FT   STRAND       77     86
FT   STRAND       89    100
FT   TURN        101    104
FT   STRAND      105    110
FT   STRAND      113    121
FT   STRAND      127    132
FT   HELIX       137    139
FT   STRAND      141    149
FT   TURN        153    156
FT   HELIX       157    166
FT   HELIX       170    172
FT   HELIX       178    180
FT   HELIX       184    192
SQ   SEQUENCE   201 AA;  23512 MW;  63292233AD6EAD8B CRC64;
     MALSWVLTVL SLLPLLEAQI PLCANLVPVP ITNATLDQIT GKWFYIASAF RNEEYNKSVQ
     EIQATFFYFT PNKTEDTIFL REYQTRQDQC IYNTTYLNVQ RENGTISRYV GGQEHFAHLL
     ILRDTKTYML AFDVNDEKNW GLSVYADKPE TTKEQLGEFY EALDCLRIPK SDVVYTDWKK
     DKCEPLEKQH EKERKQEEGE S
//
ID   A1AG2_HUMAN             Reviewed;         201 AA.
AC   P19652; B2R5L2; Q16571; Q5T538; Q6IB74;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 2.
DT   09-JUL-2014, entry version 151.
DE   RecName: Full=Alpha-1-acid glycoprotein 2;
DE            Short=AGP 2;
DE   AltName: Full=Orosomucoid-2;
DE            Short=OMD 2;
DE   Flags: Precursor;
GN   Name=ORM2; Synonyms=AGP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2822385;
RA   Dente L., Pizza M.G., Metspalu A., Cortese R.;
RT   "Structure and expression of the genes coding for human alpha 1-acid
RT   glycoprotein.";
RL   EMBO J. 6:2289-2296(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2970990; DOI=10.1016/0378-1119(88)90228-4;
RA   Merritt C.M., Board P.G.;
RT   "Structure and characterisation of a duplicated human alpha 1 acid
RT   glycoprotein gene.";
RL   Gene 66:97-106(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   DISULFIDE BONDS.
RX   PubMed=4603214; DOI=10.1021/bi00710a006;
RA   Schmid K., Buergi W., Collins J.H., Nanno S.;
RT   "The disulfide bonds of alpha1-acid glycoprotein.";
RL   Biochemistry 13:2694-2697(1974).
RN   [9]
RP   GLYCOSYLATION AT ASN-33; ASN-56; ASN-72; ASN-93 AND ASN-103.
RX   PubMed=1567356;
RA   Treuheit M.J., Costello C.E., Halsall H.B.;
RT   "Analysis of the five glycosylation sites of human alpha 1-acid
RT   glycoprotein.";
RL   Biochem. J. 283:105-112(1992).
RN   [10]
RP   PYROGLUTAMATE FORMATION AT GLN-19, GLYCOSYLATION AT ASN-33 AND ASN-93,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15253437; DOI=10.1021/pr034112b;
RA   Hagglund P., Bunkenborg J., Elortza F., Jensen O.N., Roepstorff P.;
RT   "A new strategy for identification of N-glycosylated proteins and
RT   unambiguous assignment of their glycosylation sites using HILIC
RT   enrichment and partial deglycosylation.";
RL   J. Proteome Res. 3:556-566(2004).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.M400015-MCP200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H.,
RA   Thuluvath P.J., Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-56; ASN-72 AND
RP   ASN-93.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-56; ASN-72; ASN-93
RP   AND ASN-103.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-56; ASN-93 AND
RP   ASN-103.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33, AND STRUCTURE OF
RP   CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [16]
RP   GLYCOSYLATION AT ASN-33, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 19-201 OF VARIANT ARG-167 IN
RP   COMPLEXES WITH DISOPYRAMIDE; AMITRIPTYLINE AND CHLORPROMAZINE,
RP   FUNCTION, DISULFIDE BONDS, AND DOMAIN.
RX   PubMed=21349832; DOI=10.1074/jbc.M110.208926;
RA   Nishi K., Ono T., Nakamura T., Fukunaga N., Izumi M., Watanabe H.,
RA   Suenaga A., Maruyama T., Yamagata Y., Curry S., Otagiri M.;
RT   "Structural insights into differences in drug-binding selectivity
RT   between two forms of human {alpha}1-acid glycoprotein genetic
RT   variants, the A and F1*S forms.";
RL   J. Biol. Chem. 286:14427-14434(2011).
CC   -!- FUNCTION: Functions as transport protein in the blood stream.
CC       Binds various hydrophobic ligands in the interior of its beta-
CC       barrel domain. Also binds synthetic drugs and influences their
CC       distribution and availability. Appears to function in modulating
CC       the activity of the immune system during the acute-phase reaction.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Expressed by the liver and secreted in plasma.
CC   -!- INDUCTION: Synthesis is controlled by glucocorticoids,
CC       interleukin-1 and interleukin-6, It increases 5- to 50-fold upon
CC       inflammation.
CC   -!- DOMAIN: Contains a beta-barrel that binds various ligands in its
CC       interior.
CC   -!- PTM: N-glycosylated. N-glycan heterogeneity at Asn-33: Hex5HexNAc4
CC       (minor), Hex6HexNAc5 (major) and dHex1Hex6HexNAc5 (minor).
CC   -!- POLYMORPHISM: Many different variants of ORM2 are known.
CC   -!- SIMILARITY: Belongs to the calycin superfamily. Lipocalin family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA29873.2; Type=Erroneous gene model prediction;
CC       Sequence=CAA29874.1; Type=Erroneous gene model prediction;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X06675; CAA29874.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; X05780; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X06674; CAA29873.2; ALT_SEQ; Genomic_DNA.
DR   EMBL; X06676; CAA29873.2; JOINED; Genomic_DNA.
DR   EMBL; X06677; CAA29873.2; JOINED; Genomic_DNA.
DR   EMBL; X06678; CAA29873.2; JOINED; Genomic_DNA.
DR   EMBL; X06679; CAA29873.2; JOINED; Genomic_DNA.
DR   EMBL; X06680; CAA29873.2; JOINED; Genomic_DNA.
DR   EMBL; X05784; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M21540; AAA51549.1; -; Genomic_DNA.
DR   EMBL; AK312226; BAG35159.1; -; mRNA.
DR   EMBL; CR456930; CAG33211.1; -; mRNA.
DR   EMBL; AL356796; CAI16860.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW87417.1; -; Genomic_DNA.
DR   EMBL; BC015964; AAH15964.1; -; mRNA.
DR   EMBL; BC056239; AAH56239.1; -; mRNA.
DR   CCDS; CCDS6804.1; -.
DR   PIR; JT0326; OMHU2.
DR   RefSeq; NP_000599.1; NM_000608.2.
DR   UniGene; Hs.719954; -.
DR   PDB; 3APU; X-ray; 2.10 A; A/B=19-201.
DR   PDB; 3APV; X-ray; 2.15 A; A/B=19-201.
DR   PDB; 3APW; X-ray; 2.20 A; A/B=19-201.
DR   PDB; 3APX; X-ray; 2.20 A; A=19-201.
DR   PDBsum; 3APU; -.
DR   PDBsum; 3APV; -.
DR   PDBsum; 3APW; -.
DR   PDBsum; 3APX; -.
DR   ProteinModelPortal; P19652; -.
DR   SMR; P19652; 19-196.
DR   BioGrid; 111047; 3.
DR   IntAct; P19652; 3.
DR   STRING; 9606.ENSP00000394936; -.
DR   ChEMBL; CHEMBL5958; -.
DR   PhosphoSite; P19652; -.
DR   UniCarbKB; P19652; -.
DR   DMDM; 231458; -.
DR   DOSAC-COBS-2DPAGE; P19652; -.
DR   SWISS-2DPAGE; P19652; -.
DR   MaxQB; P19652; -.
DR   PeptideAtlas; P19652; -.
DR   PRIDE; P19652; -.
DR   DNASU; 5005; -.
DR   Ensembl; ENST00000431067; ENSP00000394936; ENSG00000228278.
DR   GeneID; 5005; -.
DR   KEGG; hsa:5005; -.
DR   UCSC; uc004bil.3; human.
DR   CTD; 5005; -.
DR   GeneCards; GC09P117092; -.
DR   HGNC; HGNC:8499; ORM2.
DR   HPA; HPA046438; -.
DR   MIM; 138610; gene.
DR   neXtProt; NX_P19652; -.
DR   PharmGKB; PA32818; -.
DR   HOGENOM; HOG000125170; -.
DR   HOVERGEN; HBG000035; -.
DR   InParanoid; P19652; -.
DR   KO; K17308; -.
DR   OMA; SKEHMEE; -.
DR   OrthoDB; EOG7B5WXT; -.
DR   PhylomeDB; P19652; -.
DR   TreeFam; TF343791; -.
DR   EvolutionaryTrace; P19652; -.
DR   GenomeRNAi; 5005; -.
DR   NextBio; 19276; -.
DR   PRO; PR:P19652; -.
DR   ArrayExpress; P19652; -.
DR   Bgee; P19652; -.
DR   Genevestigator; P19652; -.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProt.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0006953; P:acute-phase response; TAS:ProtInc.
DR   GO; GO:0002682; P:regulation of immune system process; IEA:InterPro.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   Gene3D; 2.40.128.20; -; 1.
DR   InterPro; IPR001500; A1A_glycop.
DR   InterPro; IPR012674; Calycin.
DR   InterPro; IPR011038; Calycin-like.
DR   InterPro; IPR000566; Lipocln_cytosolic_FA-bd_dom.
DR   PANTHER; PTHR11967; PTHR11967; 1.
DR   Pfam; PF00061; Lipocalin; 1.
DR   PIRSF; PIRSF036899; AGP; 1.
DR   PRINTS; PR00708; A1AGLPROTEIN.
DR   SUPFAM; SSF50814; SSF50814; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Complete proteome; Disulfide bond;
KW   Glycoprotein; Polymorphism; Pyrrolidone carboxylic acid;
KW   Reference proteome; Secreted; Signal; Transport.
FT   SIGNAL        1     18
FT   CHAIN        19    201       Alpha-1-acid glycoprotein 2.
FT                                /FTId=PRO_0000017861.
FT   MOD_RES      19     19       Pyrrolidone carboxylic acid.
FT   CARBOHYD     33     33       N-linked (GlcNAc...) (complex).
FT   CARBOHYD     56     56       N-linked (GlcNAc...).
FT   CARBOHYD     72     72       N-linked (GlcNAc...).
FT   CARBOHYD     93     93       N-linked (GlcNAc...).
FT   CARBOHYD    103    103       N-linked (GlcNAc...).
FT                                /FTId=CAR_000171.
FT   DISULFID     23    165
FT   DISULFID     90    183
FT   VARIANT      38     38       R -> Q (in dbSNP:rs17650).
FT                                /FTId=VAR_014667.
FT   VARIANT      99     99       V -> A (in dbSNP:rs2636889).
FT                                /FTId=VAR_050172.
FT   VARIANT     141    141       G -> R (in dbSNP:rs12685968).
FT                                /FTId=VAR_050173.
FT   VARIANT     167    167       C -> R (in dbSNP:rs1126777).
FT                                /FTId=VAR_050174.
FT   VARIANT     174    174       M -> V (in dbSNP:rs2636890).
FT                                /FTId=VAR_050175.
FT   CONFLICT     32     32       T -> I (in Ref. 4; CAG33211).
FT   CONFLICT    102    102       E -> D (in Ref. 3; BAG35159).
FT   CONFLICT    125    125       T -> I (in Ref. 3; BAG35159).
FT   CONFLICT    162    162       A -> V (in Ref. 3; BAG35159).
FT   CONFLICT    189    189       Q -> H (in Ref. 3; BAG35159).
FT   TURN         20     23
FT   HELIX        24     26
FT   HELIX        33     39
FT   STRAND       41     51
FT   HELIX        53     60
FT   STRAND       62     72
FT   TURN         73     76
FT   STRAND       77     86
FT   STRAND       89    100
FT   TURN        101    104
FT   STRAND      105    110
FT   STRAND      113    120
FT   STRAND      127    133
FT   TURN        137    139
FT   STRAND      141    150
FT   HELIX       153    165
FT   HELIX       170    172
FT   HELIX       178    180
FT   HELIX       184    191
SQ   SEQUENCE   201 AA;  23603 MW;  49167ABCC22933B9 CRC64;
     MALSWVLTVL SLLPLLEAQI PLCANLVPVP ITNATLDRIT GKWFYIASAF RNEEYNKSVQ
     EIQATFFYFT PNKTEDTIFL REYQTRQNQC FYNSSYLNVQ RENGTVSRYE GGREHVAHLL
     FLRDTKTLMF GSYLDDEKNW GLSFYADKPE TTKEQLGEFY EALDCLCIPR SDVMYTDWKK
     DKCEPLEKQH EKERKQEEGE S
//
ID   A1AT_HUMAN              Reviewed;         418 AA.
AC   P01009; A6PX14; B2RDQ8; Q0PVP5; Q13672; Q53XB8; Q5U0M1; Q7M4R2;
AC   Q86U18; Q86U19; Q96BF9; Q96ES1; Q9P1P0; Q9UCE6; Q9UCM3;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 3.
DT   09-JUL-2014, entry version 207.
DE   RecName: Full=Alpha-1-antitrypsin;
DE   AltName: Full=Alpha-1 protease inhibitor;
DE   AltName: Full=Alpha-1-antiproteinase;
DE   AltName: Full=Serpin A1;
DE   Contains:
DE     RecName: Full=Short peptide from AAT;
DE              Short=SPAAT;
DE   Flags: Precursor;
GN   Name=SERPINA1; Synonyms=AAT, PI; ORFNames=PRO0684, PRO2209;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=6319097; DOI=10.1089/dna.1983.2.255;
RA   Bollen A., Herzog A., Cravador A., Herion P., Chuchana P.,
RA   van der Straten A., Loriau R., Jacobs P., van Elsen A.;
RT   "Cloning and expression in Escherichia coli of full-length
RT   complementary DNA coding for human alpha 1-antitrypsin.";
RL   DNA 2:255-264(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6093867; DOI=10.1021/bi00316a003;
RA   Long G.L., Chandra T., Woo S.L.C., Davie E.W., Kurachi K.;
RT   "Complete sequence of the cDNA for human alpha 1-antitrypsin and the
RT   gene for the S variant.";
RL   Biochemistry 23:4828-4837(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF MET-382.
RX   PubMed=6387509; DOI=10.1038/312077a0;
RA   Rosenberg S., Barr P.J., Najarian R.C., Hallewell R.A.;
RT   "Synthesis in yeast of a functional oxidation-resistant mutant of
RT   human alpha-antitrypsin.";
RL   Nature 312:77-80(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2985281; DOI=10.1016/S0092-8674(85)80026-X;
RA   Ciliberto G., Dente L., Cortese R.;
RT   "Cell-specific expression of a transfected human alpha 1-antitrypsin
RT   gene.";
RL   Cell 41:531-540(1985).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND CHARACTERIZATION OF VARIANT Z.
RX   PubMed=3491072;
RA   Nukiwa T., Satoh K., Brantly M.L., Ogushi F., Fells G.A., Courtney M.,
RA   Crystal R.G.;
RT   "Identification of a second mutation in the protein-coding sequence of
RT   the Z type alpha 1-antitrypsin gene.";
RL   J. Biol. Chem. 261:15989-15994(1986).
RN   [6]
RP   ERRATUM.
RA   Nukiwa T., Satoh K., Brantly M.L., Ogushi F., Fells G.A., Courtney M.,
RA   Crystal R.G.;
RL   J. Biol. Chem. 262:10412-10412(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ALA-237 AND
RP   ASP-400.
RC   TISSUE=Liver;
RX   PubMed=17650587;
RA   Shasany A.K., Shukla A.K., Darokar M.P., Saraiya M., Chaturvedi N.,
RA   Tewari L., Khanuja S.P.;
RT   "An alpha-1 antitrypsin genetic variant from India.";
RL   Indian J. Biochem. Biophys. 44:176-178(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TRP-172; ALA-237 AND
RP   LYS-366.
RC   TISSUE=Lymphocyte;
RA   Balduyck M., Porchet N., Aubert J.-P., Zerimech F., Douchain F.,
RA   Verchain S.;
RT   "Characterization of a new variant of alpha1 antitrypsin M Lille
RT   (p.Gly148Trp).";
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Fetal liver;
RA   Zhang C., Yu Y., Zhang S., Ouyang S., Luo L., Wei H., Zhou G.,
RA   Zhou W., Bi J., Zhang Y., Liu M., He F.;
RT   "Functional prediction of the coding sequences of 32 new genes deduced
RT   by analysis of cDNA clones from human fetal liver.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Fetal liver, and Placenta;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-237.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon, and Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-67; 196-255 AND 387-418.
RX   PubMed=6979715; DOI=10.1038/297655a0;
RA   Leicht M., Long G.L., Chandra T., Kurachi K., Kidd V.J., Mace M. Jr.,
RA   Davie E.W., Woo S.L.C.;
RT   "Sequence homology and structural comparison between the chromosomal
RT   human alpha 1-antitrypsin and chicken ovalbumin genes.";
RL   Nature 297:655-659(1982).
RN   [15]
RP   PRELIMINARY PROTEIN SEQUENCE OF 25-418 (ISOFORM 1).
RA   Chan S.K.;
RT   "The covalent structure of human alpha1-protease inhibitor.";
RL   Fed. Proc. 41:1016-1016(1982).
RN   [16]
RP   PROTEIN SEQUENCE OF 25-418 (ISOFORM 1).
RX   PubMed=7045697; DOI=10.1038/298329a0;
RA   Carrell R.W., Jeppsson J.-O., Laurell C.-B., Brennan S.O., Owen M.C.,
RA   Vaughan L., Boswell D.R.;
RT   "Structure and variation of human alpha 1-antitrypsin.";
RL   Nature 298:329-334(1982).
RN   [17]
RP   PROTEIN SEQUENCE OF 25-418 (ISOFORM 1), VARIANTS ABERRANT FORM
RP   190-GLY--ARG-198 AND VAL-288, AND FUNCTION.
RC   TISSUE=Blood;
RA   Sinha A.K., Girish G.V.;
RT   "Appearance of an aberrant form of alpha-antitrypsin in the
RT   circulation of chronic cigarette smokers and its effect on the insulin
RT   induced NO synthesis in blood platelets.";
RL   Submitted (AUG-2007) to UniProtKB.
RN   [18]
RP   PROTEIN SEQUENCE OF 25-39, AND FUNCTION.
RC   TISSUE=Ascites;
RX   PubMed=1906855;
RA   Tanaka N., Sekiya S., Takamizawa H., Kato N., Moriyama Y.,
RA   Fujimura S.;
RT   "Characterization of a 54 kDa, alpha 1-antitrypsin-like protein
RT   isolated from ascitic fluid of an endometrial cancer patient.";
RL   Jpn. J. Cancer Res. 82:693-700(1991).
RN   [19]
RP   PROTEIN SEQUENCE OF 30-48 AND 248-257 (ISOFORMS 1/2/3), GLYCOSYLATION
RP   AT ASN-70; ASN-107 AND ASN-271, STRUCTURE OF CARBOHYDRATES,
RP   CYSTEINE-BINDING, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16622833; DOI=10.1002/pmic.200500751;
RA   Kolarich D., Weber A., Turecek P.L., Schwarz H.P., Altmann F.;
RT   "Comprehensive glyco-proteomic analysis of human alpha1-antitrypsin
RT   and its charge isoforms.";
RL   Proteomics 6:3369-3380(2006).
RN   [20]
RP   PROTEIN SEQUENCE OF 47-66.
RC   TISSUE=Urine;
RX   PubMed=8323530; DOI=10.1006/bbrc.1993.1731;
RA   Umekawa T., Kohri K., Amasaki N., Yamate T., Yoshida K., Yamamoto K.,
RA   Suzuki Y., Sinohara H., Kurita T.;
RT   "Sequencing of a urinary stone protein, identical to alpha-one
RT   antitrypsin, which lacks 22 amino acids.";
RL   Biochem. Biophys. Res. Commun. 193:1049-1053(1993).
RN   [21]
RP   PROTEIN SEQUENCE OF 50-63 AND 161-178 (ISOFORMS 1/2/3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Afjehi-Sadat L.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [22]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 292-418 (ISOFORM 1).
RX   PubMed=3876243; DOI=10.1016/0014-5793(85)81056-5;
RA   Riley J.H., Bathurst I.C., Edbrooke M.R., Carrell R.W., Craig R.K.;
RT   "Alpha 1-antitrypsin and serum albumin mRNA accumulation in normal,
RT   acute phase and ZZ human liver.";
RL   FEBS Lett. 189:361-366(1985).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 350-418 (ISOFORM 1).
RX   PubMed=7031661; DOI=10.1073/pnas.78.11.6826;
RA   Kurachi K., Chandra T., Friezner Degen S.J., White T.T.,
RA   Marchioro T.L., Woo S.L.C., Davie E.W.;
RT   "Cloning and sequence of cDNA coding for alpha 1-antitrypsin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:6826-6830(1981).
RN   [24]
RP   PROTEIN SEQUENCE OF 375-414, IDENTIFICATION OF SPAAT, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=1406456;
RA   Niemann M.A., Narkates A.J., Miller E.J.;
RT   "Isolation and serine protease inhibitory activity of the 44-residue,
RT   C-terminal fragment of alpha 1-antitrypsin from human placenta.";
RL   Matrix 12:233-241(1992).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 387-418 (ISOFORM 1).
RX   PubMed=3873938;
RA   Coutelle C., Speer A., Rogers J., Kalsheker N., Humphries S.,
RA   Williamson R.;
RT   "Construction and partial characterization of a human liver cDNA
RT   library.";
RL   Biomed. Biochim. Acta 44:421-431(1985).
RN   [26]
RP   GLYCOSYLATION AT ASN-70 AND ASN-271.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [27]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70 AND ASN-271.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.M400015-MCP200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H.,
RA   Thuluvath P.J., Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [28]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70 AND ASN-271.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [29]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [30]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [31]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [32]
RP   GLYCOSYLATION AT ASN-107 AND ASN-271.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [33]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271,
RP   AND STRUCTURE OF CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [35]
RP   GLYCOSYLATION AT ASN-70 AND ASN-271, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   PubMed=6332197; DOI=10.1016/0022-2836(84)90298-5;
RA   Loebermann H., Tokuoka R., Deisenhofer J., Huber R.;
RT   "Human alpha 1-proteinase inhibitor. Crystal structure analysis of two
RT   crystal modifications, molecular model and preliminary analysis of the
RT   implications for function.";
RL   J. Mol. Biol. 177:531-556(1984).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   PubMed=2785270; DOI=10.1093/protein/2.6.407;
RA   Engh R., Loebermann H., Schneider M., Wiegand G., Huber R.,
RA   Laurell C.-B.;
RT   "The S variant of human alpha 1-antitrypsin, structure and
RT   implications for function and metabolism.";
RL   Protein Eng. 2:407-415(1989).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (3.46 ANGSTROMS) OF 25-418.
RX   PubMed=8543039; DOI=10.1016/0014-5793(95)01331-8;
RA   Song H.K., Lee K.N., Kwon K.-S., Yu M.-H., Suh S.W.;
RT   "Crystal structure of an uncleaved alpha 1-antitrypsin reveals the
RT   conformation of its inhibitory reactive loop.";
RL   FEBS Lett. 377:150-154(1995).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 26-418.
RX   PubMed=8756325; DOI=10.1038/nsb0896-676;
RA   Elliott P.R., Lomas D.A., Carrell R.W., Abrahams J.P.;
RT   "Inhibitory conformation of the reactive loop of alpha 1-
RT   antitrypsin.";
RL   Nat. Struct. Biol. 3:676-681(1996).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 45-418.
RX   PubMed=8939743; DOI=10.1016/S0969-2126(96)00126-8;
RA   Ryu S.-E., Choi H.-J., Kwon K.-S., Lee K.N., Yu M.-H.;
RT   "The native strains in the hydrophobic core and flexible reactive loop
RT   of a serine protease inhibitor: crystal structure of an uncleaved
RT   alpha1-antitrypsin at 2.7 A.";
RL   Structure 4:1181-1192(1996).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 26-418.
RX   PubMed=9466920; DOI=10.1006/jmbi.1997.1458;
RA   Elliott P.R., Abrahams J.P., Lomas D.A.;
RT   "Wild-type alpha 1-antitrypsin is in the canonical inhibitory
RT   conformation.";
RL   J. Mol. Biol. 275:419-425(1998).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 48-418 IN COMPLEX WITH BOVINE
RP   TRYPSIN.
RX   PubMed=11057674; DOI=10.1038/35038119;
RA   Huntington J.A., Read R.J., Carrell R.W.;
RT   "Structure of a serpin-protease complex shows inhibition by
RT   deformation.";
RL   Nature 407:923-926(2000).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 44-418.
RX   PubMed=10716194; DOI=10.1110/ps.9.2.417;
RA   Dunstone M.A., Dai W., Whisstock J.C., Rossjohn J., Pike R.N.,
RA   Feil S.C., Le Bonniec B.F., Parker M.W., Bottomley S.P.;
RT   "Cleaved antitrypsin polymers at atomic resolution.";
RL   Protein Sci. 9:417-420(2000).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=10933492; DOI=10.1110/ps.9.7.1274;
RA   Elliott P.R., Pei X.Y., Dafforn T.R., Lomas D.A.;
RT   "Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets
RT   for rational drug design to prevent conformational disease.";
RL   Protein Sci. 9:1274-1281(2000).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 25-418.
RX   PubMed=11178897; DOI=10.1006/jmbi.2000.4357;
RA   Kim S.-J., Woo J.-R., Seo E.J., Yu M.-H., Ryu S.-E.;
RT   "A 2.1 A resolution structure of an uncleaved alpha(1)-antitrypsin
RT   shows variability of the reactive center and other loops.";
RL   J. Mol. Biol. 306:109-119(2001).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 25-418.
RX   PubMed=12244055; DOI=10.1074/jbc.M207682200;
RA   Im H., Woo M.-S., Hwang K.Y., Yu M.-H.;
RT   "Interactions causing the kinetic trap in serpin protein folding.";
RL   J. Biol. Chem. 277:46347-46354(2002).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-418 OF VARIANT PITTSBURGH
RP   ARG-382.
RX   PubMed=12860985; DOI=10.1074/jbc.M305195200;
RA   Dementiev A., Simonovic M., Volz K., Gettins P.G.;
RT   "Canonical inhibitor-like interactions explain reactivity of alpha1-
RT   proteinase inhibitor Pittsburgh and antithrombin with proteinases.";
RL   J. Biol. Chem. 278:37881-37887(2003).
RN   [48]
RP   REVIEW.
RX   PubMed=2669992; DOI=10.1007/BF01115992;
RA   Kalsheker N.;
RT   "Alpha 1-antitrypsin: structure, function and molecular biology of the
RT   gene.";
RL   Biosci. Rep. 9:129-138(1989).
RN   [49]
RP   REVIEW.
RX   PubMed=1859394; DOI=10.1002/bies.950130404;
RA   Wu Y., Foreman R.C.;
RT   "The molecular genetics of alpha 1 antitrypsin deficiency.";
RL   Bioessays 13:163-169(1991).
RN   [50]
RP   CHARACTERIZATION OF VARIANT M2.
RX   PubMed=2901226;
RA   Nukiwa T., Brantly M.L., Ogushi F., Fells G.A., Crystal R.G.;
RT   "Characterization of the gene and protein of the common alpha 1-
RT   antitrypsin normal M2 allele.";
RL   Am. J. Hum. Genet. 43:322-330(1988).
RN   [51]
RP   VARIANT M3 ASP-400.
RX   PubMed=2394452; DOI=10.1007/BF00206766;
RA   Graham A., Hayes K., Weidinger S., Newton C.R., Markham A.F.,
RA   Kalsheker N.A.;
RT   "Characterisation of the alpha-1-antitrypsin M3 gene, a normal
RT   variant.";
RL   Hum. Genet. 85:381-382(1990).
RN   [52]
RP   VARIANT F CYS-247.
RX   PubMed=2035534;
RA   Okayama H., Brantly M., Holmes M., Crystal R.G.;
RT   "Characterization of the molecular basis of the alpha 1-antitrypsin F
RT   allele.";
RL   Am. J. Hum. Genet. 48:1154-1158(1991).
RN   [53]
RP   VARIANT M-HEERLEN LEU-393.
RX   PubMed=2784123; DOI=10.1007/BF00279001;
RA   Hofker M.H., Nukiwa T., van Paassen H.M.B., Nelen M., Kramps J.A.,
RA   Klasen E.C., Frants R.R., Crystal R.G.;
RT   "A Pro-->Leu substitution in codon 369 of the alpha-1-antitrypsin
RT   deficiency variant PI M-Heerlen.";
RL   Hum. Genet. 81:264-268(1989).
RN   [54]
RP   VARIANT M-MALTON PHE-75 DEL.
RX   PubMed=2786335;
RA   Fraizer G.C., Harrold T.R., Hofker M.H., Cox D.W.;
RT   "In-frame single codon deletion in the M-Malton deficiency allele of
RT   alpha 1-antitrypsin.";
RL   Am. J. Hum. Genet. 44:894-902(1989).
RN   [55]
RP   VARIANT M-MINERAL SPRINGS GLU-91.
RX   PubMed=1967187;
RA   Curiel D.T., Vogelmeier C., Hubbard R.C., Stier L.E., Crystal R.G.;
RT   "Molecular basis of alpha 1-antitrypsin deficiency and emphysema
RT   associated with the alpha 1-antitrypsin M-Mineral springs allele.";
RL   Mol. Cell. Biol. 10:47-56(1990).
RN   [56]
RP   VARIANT M-NICHINAN PHE-75 DEL.
RX   PubMed=2309708;
RA   Matsunaga E., Shiokawa S., Nakamura H., Maruyama T., Tsuda K.,
RA   Fukumaki Y.;
RT   "Molecular analysis of the gene of the alpha 1-antitrypsin deficiency
RT   variant, M-Nichinan.";
RL   Am. J. Hum. Genet. 46:602-612(1990).
RN   [57]
RP   VARIANT M-PROCIDA PRO-65.
RX   PubMed=3262617;
RA   Takahashi H., Nukiwa T., Satoh K., Ogushi F., Brantly M., Fells G.,
RA   Stier L., Courtney M., Crystal R.G.;
RT   "Characterization of the gene and protein of the alpha 1-antitrypsin
RT   'deficiency' allele M-Procida.";
RL   J. Biol. Chem. 263:15528-15534(1988).
RN   [58]
RP   VARIANT P-DUARTE VAL-280.
RX   PubMed=8364590; DOI=10.1002/humu.1380020311;
RA   Hildesheim J., Kinsley G., Bissell M., Pierce J., Brantly M.;
RT   "Genetic diversity from a limited repertoire of mutations on different
RT   common allelic backgrounds: alpha 1-antitrypsin deficiency variant P-
RT   Duarte.";
RL   Hum. Mutat. 2:221-228(1993).
RN   [59]
RP   INVOLVEMENT OF VARIANT PITTSBURGH ARG-382 IN BLEEDING DIATHESIS.
RX   PubMed=6604220; DOI=10.1056/NEJM198309223091203;
RA   Owen M.C., Brennan S.O., Lewis J.H., Carrell R.W.;
RT   "Mutation of antitrypsin to antithrombin. Alpha 1-antitrypsin
RT   Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder.";
RL   N. Engl. J. Med. 309:694-698(1983).
RN   [60]
RP   INVOLVEMENT IN A1ATD, AND VARIANT S-IIYAMA PHE-77.
RX   PubMed=1905728;
RA   Seyama K., Nukiwa T., Takabe K., Takahashi H., Miyake K., Kira S.;
RT   "Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-
RT   antitrypsin-deficient variant with mutation on a predicted conserved
RT   residue of the serpin backbone.";
RL   J. Biol. Chem. 266:12627-12632(1991).
RN   [61]
RP   VARIANT V-MUNICH ALA-26.
RX   PubMed=2316526;
RA   Holmes M.D., Brantly M.L., Curiel D.T., Weidinger S., Crystal R.G.;
RT   "Characterization of the normal alpha 1-antitrypsin allele V-Munich: a
RT   variant associated with a unique protein isoelectric focusing
RT   pattern.";
RL   Am. J. Hum. Genet. 46:810-816(1990).
RN   [62]
RP   INVOLVEMENT IN A1ATD, AND VARIANT W-BETHESDA THR-360.
RX   PubMed=2390072; DOI=10.1016/0006-291X(90)90493-7;
RA   Holmes M.D., Brantly M.L., Fells G.A., Crystal R.G.;
RT   "Alpha 1-antitrypsin W-Bethesda: molecular basis of an unusual alpha
RT   1-antitrypsin deficiency variant.";
RL   Biochem. Biophys. Res. Commun. 170:1013-1020(1990).
RN   [63]
RP   VARIANT Z-AUGSBURG LYS-366.
RX   PubMed=2339709;
RA   Faber J.-P., Weidinger S., Olek K.;
RT   "Sequence data of the rare deficient alpha 1-antitrypsin variant PI
RT   Zaugsburg.";
RL   Am. J. Hum. Genet. 46:1158-1162(1990).
RN   [64]
RP   INVOLVEMENT IN A1ATD, AND VARIANTS Z-WREXHAM LEU-4 AND Q0-NEWPORT
RP   SER-139.
RX   PubMed=2227940; DOI=10.1007/BF00194233;
RA   Graham A., Kalsheker N.A., Bamforth F.J., Newton C.R., Markham A.F.;
RT   "Molecular characterisation of two alpha-1-antitrypsin deficiency
RT   variants: proteinase inhibitor (Pi) Null(Newport) (Gly115-->Ser) and
RT   (Pi) Z Wrexham (Ser-19-->Leu).";
RL   Hum. Genet. 85:537-540(1990).
RN   [65]
RP   VARIANTS P-CARDIFF VAL-280; I CYS-63 AND M-MALTON PHE-75 DEL.
RX   PubMed=2606478; DOI=10.1007/BF00210671;
RA   Graham A., Kalsheker N.A., Newton C.R., Bamforth F.J., Powell S.J.,
RA   Markham A.F.;
RT   "Molecular characterisation of three alpha-1-antitrypsin deficiency
RT   variants: proteinase inhibitor (Pi) nullcardiff (Asp256-->Val); PiM-
RT   Malton (Phe51-->deletion) and PiI (Arg39-->Cys).";
RL   Hum. Genet. 84:55-58(1989).
RN   [66]
RP   VARIANT QO-LUDWIGSHAFEN ASN-116.
RX   PubMed=2254451; DOI=10.1172/JCI114919;
RA   Fraizer G.C., Siewertsen M.A., Hofker M.H., Brubacher M.G., Cox D.W.;
RT   "A null deficiency allele of alpha 1-antitrypsin, QO-Ludwigshafen,
RT   with altered tertiary structure.";
RL   J. Clin. Invest. 86:1878-1884(1990).
RN   [67]
RP   VARIANTS.
RX   PubMed=7977369;
RA   Faber J.-P., Poller W., Weidinger S., Kirchgesser M., Schwaab R.,
RA   Bidlingmaier F., Olek K.;
RT   "Identification and DNA sequence analysis of 15 new alpha 1-
RT   antitrypsin variants, including two PI*Q0 alleles and one deficient
RT   PI*M allele.";
RL   Am. J. Hum. Genet. 55:1113-1121(1994).
RN   [68]
RP   VARIANT Z-BRISTOL MET-109.
RX   PubMed=9459000; DOI=10.1017/S0003480097006404;
RA   Lovegrove J.U., Jeremiah S., Gillett G.T., Temple I.K., Povey S.,
RA   Whitehouse D.B.;
RT   "A new alpha 1-antitrypsin mutation, Thr-Met 85, (PI ZBristol)
RT   associated with novel electrophoretic properties.";
RL   Ann. Hum. Genet. 61:385-391(1997).
RN   [69]
RP   VARIANTS Y-BARCELONA VAL-280 AND HIS-415.
RX   PubMed=10651487;
RA   Jardi R., Rodriguez F., Miravitlles M., Vidal R., Cotrina M., Quer J.,
RA   Pascual C., Weidinger S.;
RT   "Identification and molecular characterization of the new alpha-1-
RT   antitrypsin deficient allele PI YBarcelona (Asp256Val and
RT   Pro391His).";
RL   Hum. Mutat. 12:213-213(1998).
RN   [70]
RP   VARIANT SAO TOME HIS-386.
RA   Seixas S., Trovoada M.J., Santos M.T., Rocha J.;
RT   "A novel alpha-1-antitrypsin P362H variant found in a population
RT   sample from Sao Tome e Principe (Gulf of Guinea, West Africa).";
RL   Hum. Mutat. 13:414-414(1999).
RN   [71]
RP   VARIANT BASQUE ARG-305 DEL.
RX   PubMed=10612848;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<121::AID-HUMU37>3.0.CO;2-U;
RA   Seixas S., Garcia O., Amorim A., Rocha J.;
RT   "A novel alpha-1-antitrypsin r281del variant found in a population
RT   sample from the Basque country.";
RL   Hum. Mutat. 15:121-122(2000).
RN   [72]
RP   VARIANTS Z ALA-237 AND LYS-366, VARIANT S VAL-288, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, GLYCOSYLATION, AND INTERACTION WITH CANX
RP   AND PDIA3.
RX   PubMed=23826168; DOI=10.1371/journal.pone.0066889;
RA   Marques P.I., Ferreira Z., Martins M., Figueiredo J., Silva D.I.,
RA   Castro P., Morales-Hojas R., Simoes-Correia J., Seixas S.;
RT   "SERPINA2 is a novel gene with a divergent function from SERPINA1.";
RL   PLoS ONE 8:E66889-E66889(2013).
CC   -!- FUNCTION: Inhibitor of serine proteases. Its primary target is
CC       elastase, but it also has a moderate affinity for plasmin and
CC       thrombin. Irreversibly inhibits trypsin, chymotrypsin and
CC       plasminogen activator. The aberrant form inhibits insulin-induced
CC       NO synthesis in platelets, decreases coagulation time and has
CC       proteolytic activity against insulin and plasmin.
CC   -!- FUNCTION: Short peptide from AAT: reversible chymotrypsin
CC       inhibitor. It also inhibits elastase, but not trypsin. Its major
CC       physiological function is the protection of the lower respiratory
CC       tract against proteolytic destruction by human leukocyte elastase
CC       (HLE).
CC   -!- SUBUNIT: The variants S and Z interact with CANX AND PDIA3.
CC   -!- INTERACTION:
CC       Self; NbExp=5; IntAct=EBI-986224, EBI-986224;
CC       P00760:- (xeno); NbExp=5; IntAct=EBI-986224, EBI-986385;
CC       P00772:CELA1 (xeno); NbExp=2; IntAct=EBI-986224, EBI-986248;
CC       P71213:espB (xeno); NbExp=3; IntAct=EBI-986224, EBI-2615322;
CC       P43307:SSR1; NbExp=4; IntAct=EBI-986224, EBI-714168;
CC   -!- SUBCELLULAR LOCATION: Secreted. Endoplasmic reticulum. Note=The S
CC       and Z allele are not secreted effectively and accumulate
CC       intracellularly in the endoplasmic reticulum.
CC   -!- SUBCELLULAR LOCATION: Short peptide from AAT: Secreted,
CC       extracellular space, extracellular matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P01009-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P01009-2; Sequence=VSP_028889;
CC         Note=No experimental confirmation available;
CC       Name=3;
CC         IsoId=P01009-3; Sequence=VSP_028890;
CC         Note=No experimental confirmation available. May be produced at
CC         very low levels due to a premature stop codon in the mRNA,
CC         leading to nonsense-mediated mRNA decay;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Expressed in leukocytes and
CC       plasma.
CC   -!- DOMAIN: The reactive center loop (RCL) extends out from the body
CC       of the protein and directs binding to the target protease. The
CC       protease cleaves the serpin at the reactive site within the RCL,
CC       establishing a covalent linkage between the carboxyl group of the
CC       serpin reactive site and the serine hydroxyl of the protease. The
CC       resulting inactive serpin-protease complex is highly stable.
CC   -!- PTM: N-glycosylated. Differential glycosylation produces a number
CC       of isoforms. N-linked glycan at Asn-107 is alternatively di-
CC       antennary, tri-antennary or tetra-antennary. The glycan at Asn-70
CC       is di-antennary with trace amounts of tri-antennary. Glycan at
CC       Asn-271 is exclusively di-antennary. Structure of glycans at Asn-
CC       70 and Asn-271 is Hex5HexNAc4. The structure of the antennae is
CC       Neu5Ac(alpha1-6)Gal(beta1-4)GlcNAc attached to the core structure
CC       Man(alpha1-6)[Man(alpha1-3)]Man(beta1-4)GlcNAc(beta1-4)GlcNAc.
CC       Some antennae are fucosylated, which forms a Lewis-X determinant.
CC   -!- PTM: Proteolytic processing may yield the truncated form that
CC       ranges from Asp-30 to Lys-418.
CC   -!- POLYMORPHISM: The sequence shown is that of the M1V allele which
CC       is the most common form of PI (44 to 49%). Other frequent alleles
CC       are: M1A 20 to 23%; M2 10 to 11%; M3 14 to 19%.
CC   -!- DISEASE: Alpha-1-antitrypsin deficiency (A1ATD) [MIM:613490]: A
CC       disorder whose most common manifestation is emphysema, which
CC       becomes evident by the third to fourth decade. A less common
CC       manifestation of the deficiency is liver disease, which occurs in
CC       children and adults, and may result in cirrhosis and liver
CC       failure. Environmental factors, particularly cigarette smoking,
CC       greatly increase the risk of emphysema at an earlier age. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: The aberrant form is found in the plasma of chronic
CC       smokers, and persists after smoking is ceased. It can still be
CC       found ten years after smoking has ceased.
CC   -!- SIMILARITY: Belongs to the serpin family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD62334.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC       Sequence=CAD62585.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alpha-1 antitrypsin entry;
CC       URL="http://en.wikipedia.org/wiki/Alpha_1-antitrypsin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K01396; AAB59375.1; -; mRNA.
DR   EMBL; K02212; AAB59495.1; -; Genomic_DNA.
DR   EMBL; X01683; CAA25838.1; -; mRNA.
DR   EMBL; M11465; AAA51546.1; -; mRNA.
DR   EMBL; J02619; AAA51547.1; -; Genomic_DNA.
DR   EMBL; DQ682455; ABG73380.1; -; mRNA.
DR   EMBL; AM048838; CAJ15161.1; -; Genomic_DNA.
DR   EMBL; AF113676; AAF29581.1; -; mRNA.
DR   EMBL; AF130068; AAG35496.1; -; mRNA.
DR   EMBL; BX161449; CAD61914.1; -; mRNA.
DR   EMBL; BX247968; CAD62306.1; -; mRNA.
DR   EMBL; BX248002; CAD62334.1; ALT_INIT; mRNA.
DR   EMBL; BX248257; CAD62585.1; ALT_INIT; mRNA.
DR   EMBL; AK315637; BAG38005.1; -; mRNA.
DR   EMBL; BT019455; AAV38262.1; -; mRNA.
DR   EMBL; BC011991; AAH11991.1; -; mRNA.
DR   EMBL; BC015642; AAH15642.1; -; mRNA.
DR   EMBL; J00064; AAB59369.1; -; Genomic_DNA.
DR   EMBL; J00066; AAB59370.1; -; Genomic_DNA.
DR   EMBL; J00065; AAB59370.1; JOINED; Genomic_DNA.
DR   EMBL; J00067; AAB59371.1; -; Genomic_DNA.
DR   EMBL; X02920; CAA26677.1; -; mRNA.
DR   EMBL; V00496; CAA23755.1; -; mRNA.
DR   EMBL; M26123; AAA51545.1; -; mRNA.
DR   CCDS; CCDS9925.1; -. [P01009-1]
DR   PIR; A21853; ITHU.
DR   PIR; A61391; A61391.
DR   RefSeq; NP_000286.3; NM_000295.4. [P01009-1]
DR   RefSeq; NP_001002235.1; NM_001002235.2. [P01009-1]
DR   RefSeq; NP_001002236.1; NM_001002236.2. [P01009-1]
DR   RefSeq; NP_001121172.1; NM_001127700.1. [P01009-1]
DR   RefSeq; NP_001121173.1; NM_001127701.1. [P01009-1]
DR   RefSeq; NP_001121174.1; NM_001127702.1. [P01009-1]
DR   RefSeq; NP_001121175.1; NM_001127703.1. [P01009-1]
DR   RefSeq; NP_001121176.1; NM_001127704.1. [P01009-1]
DR   RefSeq; NP_001121177.1; NM_001127705.1. [P01009-1]
DR   RefSeq; NP_001121178.1; NM_001127706.1. [P01009-1]
DR   RefSeq; NP_001121179.1; NM_001127707.1. [P01009-1]
DR   UniGene; Hs.525557; -.
DR   PDB; 1ATU; X-ray; 2.70 A; A=45-418.
DR   PDB; 1D5S; X-ray; 3.00 A; A=44-377, B=378-418.
DR   PDB; 1EZX; X-ray; 2.60 A; A=48-382, B=383-418.
DR   PDB; 1HP7; X-ray; 2.10 A; A=25-418.
DR   PDB; 1IZ2; X-ray; 2.20 A; A=25-418.
DR   PDB; 1KCT; X-ray; 3.46 A; A=25-418.
DR   PDB; 1OO8; X-ray; 2.65 A; A=26-418.
DR   PDB; 1OPH; X-ray; 2.30 A; A=26-418.
DR   PDB; 1PSI; X-ray; 2.92 A; A=26-418.
DR   PDB; 1QLP; X-ray; 2.00 A; A=26-418.
DR   PDB; 1QMB; X-ray; 2.60 A; A=49-376, B=377-418.
DR   PDB; 2D26; X-ray; 3.30 A; A=25-382, B=383-418.
DR   PDB; 2QUG; X-ray; 2.00 A; A=25-418.
DR   PDB; 3CWL; X-ray; 2.44 A; A=25-418.
DR   PDB; 3CWM; X-ray; 2.51 A; A=25-418.
DR   PDB; 3DRM; X-ray; 2.20 A; A=26-418.
DR   PDB; 3DRU; X-ray; 3.20 A; A/B/C=26-418.
DR   PDB; 3NDD; X-ray; 1.50 A; A=46-382, B=383-418.
DR   PDB; 3NDF; X-ray; 2.70 A; A=46-382, B=383-418.
DR   PDB; 3NE4; X-ray; 1.81 A; A=48-418.
DR   PDB; 3T1P; X-ray; 3.90 A; A=48-418.
DR   PDB; 7API; X-ray; 3.00 A; A=36-382, B=383-418.
DR   PDB; 8API; X-ray; 3.10 A; A=36-382, B=383-418.
DR   PDB; 9API; X-ray; 3.00 A; A=36-382, B=383-418.
DR   PDBsum; 1ATU; -.
DR   PDBsum; 1D5S; -.
DR   PDBsum; 1EZX; -.
DR   PDBsum; 1HP7; -.
DR   PDBsum; 1IZ2; -.
DR   PDBsum; 1KCT; -.
DR   PDBsum; 1OO8; -.
DR   PDBsum; 1OPH; -.
DR   PDBsum; 1PSI; -.
DR   PDBsum; 1QLP; -.
DR   PDBsum; 1QMB; -.
DR   PDBsum; 2D26; -.
DR   PDBsum; 2QUG; -.
DR   PDBsum; 3CWL; -.
DR   PDBsum; 3CWM; -.
DR   PDBsum; 3DRM; -.
DR   PDBsum; 3DRU; -.
DR   PDBsum; 3NDD; -.
DR   PDBsum; 3NDF; -.
DR   PDBsum; 3NE4; -.
DR   PDBsum; 3T1P; -.
DR   PDBsum; 7API; -.
DR   PDBsum; 8API; -.
DR   PDBsum; 9API; -.
DR   ProteinModelPortal; P01009; -.
DR   SMR; P01009; 48-417.
DR   BioGrid; 111283; 22.
DR   DIP; DIP-35493N; -.
DR   IntAct; P01009; 19.
DR   MINT; MINT-365327; -.
DR   DrugBank; DB00058; Alpha-1-proteinase inhibitor.
DR   MEROPS; I04.001; -.
DR   PhosphoSite; P01009; -.
DR   UniCarbKB; P01009; -.
DR   DMDM; 1703025; -.
DR   DOSAC-COBS-2DPAGE; P01009; -.
DR   OGP; P01009; -.
DR   REPRODUCTION-2DPAGE; IPI00553177; -.
DR   REPRODUCTION-2DPAGE; P01009; -.
DR   SWISS-2DPAGE; P01009; -.
DR   UCD-2DPAGE; P01009; -.
DR   MaxQB; P01009; -.
DR   PaxDb; P01009; -.
DR   PRIDE; P01009; -.
DR   DNASU; 5265; -.
DR   Ensembl; ENST00000355814; ENSP00000348068; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000393087; ENSP00000376802; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000393088; ENSP00000376803; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000402629; ENSP00000386094; ENSG00000197249. [P01009-2]
DR   Ensembl; ENST00000404814; ENSP00000385960; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000437397; ENSP00000408474; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000440909; ENSP00000390299; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000448921; ENSP00000416066; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000449399; ENSP00000416354; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000489769; ENSP00000451525; ENSG00000197249. [P01009-3]
DR   GeneID; 5265; -.
DR   KEGG; hsa:5265; -.
DR   UCSC; uc001ycx.4; human. [P01009-1]
DR   UCSC; uc001yda.1; human. [P01009-2]
DR   CTD; 5265; -.
DR   GeneCards; GC14M094843; -.
DR   GeneReviews; SERPINA1; -.
DR   HGNC; HGNC:8941; SERPINA1.
DR   HPA; CAB013211; -.
DR   HPA; CAB016648; -.
DR   HPA; HPA000927; -.
DR   HPA; HPA001292; -.
DR   MIM; 107400; gene.
DR   MIM; 613490; phenotype.
DR   neXtProt; NX_P01009; -.
DR   Orphanet; 60; Alpha-1-antitrypsin deficiency.
DR   Orphanet; 178396; Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation.
DR   PharmGKB; PA35509; -.
DR   eggNOG; COG4826; -.
DR   HOVERGEN; HBG005957; -.
DR   InParanoid; P01009; -.
DR   KO; K03984; -.
DR   OMA; VVNPTQK; -.
DR   OrthoDB; EOG7QC7W9; -.
DR   PhylomeDB; P01009; -.
DR   TreeFam; TF343201; -.
DR   Reactome; REACT_604; Hemostasis.
DR   ChiTaRS; SERPINA1; human.
DR   EvolutionaryTrace; P01009; -.
DR   GeneWiki; Alpha_1-antitrypsin; -.
DR   GenomeRNAi; 5265; -.
DR   NextBio; 20336; -.
DR   PMAP-CutDB; P01009; -.
DR   PRO; PR:P01009; -.
DR   ArrayExpress; P01009; -.
DR   Bgee; P01009; -.
DR   Genevestigator; P01009; -.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IMP:UniProtKB.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; NAS:UniProtKB.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IBA:RefGenome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0030162; P:regulation of proteolysis; IBA:RefGenome.
DR   GO; GO:0046687; P:response to chromate; IEA:Ensembl.
DR   GO; GO:0034097; P:response to cytokine; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0010288; P:response to lead ion; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0033986; P:response to methanol; IEA:Ensembl.
DR   GO; GO:0034014; P:response to triglyceride; IEA:Ensembl.
DR   InterPro; IPR023795; Serpin_CS.
DR   InterPro; IPR023796; Serpin_dom.
DR   InterPro; IPR000215; Serpin_fam.
DR   PANTHER; PTHR11461; PTHR11461; 1.
DR   Pfam; PF00079; Serpin; 1.
DR   SMART; SM00093; SERPIN; 1.
DR   SUPFAM; SSF56574; SSF56574; 1.
DR   PROSITE; PS00284; SERPIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Alternative splicing; Blood coagulation;
KW   Complete proteome; Direct protein sequencing; Endoplasmic reticulum;
KW   Extracellular matrix; Glycoprotein; Hemostasis; Polymorphism;
KW   Protease inhibitor; Reference proteome; Secreted;
KW   Serine protease inhibitor; Signal.
FT   SIGNAL        1     24
FT   CHAIN        25    418       Alpha-1-antitrypsin.
FT                                /FTId=PRO_0000032377.
FT   PEPTIDE     375    418       Short peptide from AAT.
FT                                /FTId=PRO_0000364030.
FT   REGION      368    392       RCL.
FT   SITE        382    383       Reactive bond.
FT   MOD_RES     256    256       S-cysteinyl cysteine.
FT   CARBOHYD     70     70       N-linked (GlcNAc...) (complex).
FT   CARBOHYD    107    107       N-linked (GlcNAc...) (complex).
FT   CARBOHYD    271    271       N-linked (GlcNAc...) (complex).
FT   VAR_SEQ     307    418       Missing (in isoform 3).
FT                                /FTId=VSP_028890.
FT   VAR_SEQ     356    418       AVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVF
FT                                LMIEQNTKSPLFMGKVVNPTQK -> VRSP (in
FT                                isoform 2).
FT                                /FTId=VSP_028889.
FT   VARIANT       4      4       S -> L (in Z-Wrexham).
FT                                /FTId=VAR_006978.
FT   VARIANT      26     26       D -> A (in V-Munich).
FT                                /FTId=VAR_006979.
FT   VARIANT      37     37       T -> A (in dbSNP:rs11558262).
FT                                /FTId=VAR_051938.
FT   VARIANT      58     58       A -> T (in M5-Karlsruhe).
FT                                /FTId=VAR_006980.
FT   VARIANT      63     63       R -> C (in I; dbSNP:rs28931570).
FT                                /FTId=VAR_006981.
FT   VARIANT      65     65       L -> P (in M-Procida; dbSNP:rs28931569).
FT                                /FTId=VAR_006982.
FT   VARIANT      69     69       S -> F (in M6-Bonn).
FT                                /FTId=VAR_006983.
FT   VARIANT      75     75       Missing (in M-Malton, M-Nichinan and M-
FT                                Palermo; associated with very low serum
FT                                levels of AAT; homozygosity for allele M-
FT                                Malton may be associated with a risk for
FT                                chronic emphysema or infantile liver
FT                                cirrhosis).
FT                                /FTId=VAR_006984.
FT   VARIANT      77     77       S -> F (in S-Iiyama; dbSNP:rs55819880).
FT                                /FTId=VAR_006985.
FT   VARIANT      84     84       A -> T (in M6-Passau).
FT                                /FTId=VAR_006986.
FT   VARIANT      91     91       G -> E (in M-Mineral springs; causes
FT                                reduced AAT secretion; dbSNP:rs28931568).
FT                                /FTId=VAR_006987.
FT   VARIANT      92     92       T -> I (in QO-Lisbon; deficient AAT with
FT                                very low serum levels).
FT                                /FTId=VAR_006988.
FT   VARIANT     109    109       T -> M (in Z-Bristol; deficient AA;
FT                                disrupts the N-glycosylation site N-107).
FT                                /FTId=VAR_011620.
FT   VARIANT     112    112       P -> T (in M5-Berlin).
FT                                /FTId=VAR_006989.
FT   VARIANT     116    116       I -> N (in QO-Ludwigshafen;
FT                                dbSNP:rs28931572).
FT                                /FTId=VAR_006990.
FT   VARIANT     125    125       R -> H (in M2; associated with D-400;
FT                                dbSNP:rs709932).
FT                                /FTId=VAR_006991.
FT   VARIANT     139    139       G -> S (in QO-Newport; dbSNP:rs11558261).
FT                                /FTId=VAR_006992.
FT   VARIANT     172    172       G -> R (in V and M-Nichinan).
FT                                /FTId=VAR_006993.
FT   VARIANT     172    172       G -> W (in M2-Obernburg).
FT                                /FTId=VAR_006994.
FT   VARIANT     180    180       Q -> E (in L-Frankfurt).
FT                                /FTId=VAR_006995.
FT   VARIANT     190    198       QGKIVDLVK -> GFQNAILVR (in Aberrant
FT                                form).
FT                                /FTId=VAR_036746.
FT   VARIANT     228    228       E -> K (in X).
FT                                /FTId=VAR_006996.
FT   VARIANT     237    237       V -> A (in M1A and Z; associated with K-
FT                                366 in Z; dbSNP:rs6647).
FT                                /FTId=VAR_006997.
FT   VARIANT     247    247       R -> C (in F; dbSNP:rs28929470).
FT                                /FTId=VAR_006998.
FT   VARIANT     280    280       D -> V (in P-Duarte/P-Cardiff/P-Lowell;
FT                                associated with H-415 in Y-Barcelona;
FT                                dbSNP:rs28929472).
FT                                /FTId=VAR_006999.
FT   VARIANT     288    288       E -> V (in S and T; dbSNP:rs17580).
FT                                /FTId=VAR_007000.
FT   VARIANT     305    305       Missing (in Basque).
FT                                /FTId=VAR_009216.
FT   VARIANT     354    354       S -> F (in S-Munich).
FT                                /FTId=VAR_007001.
FT   VARIANT     360    360       A -> T (in W-Bethesda; dbSNP:rs1802959).
FT                                /FTId=VAR_007002.
FT   VARIANT     365    365       D -> N (in P-St.Albans/P-Donauwoerth).
FT                                /FTId=VAR_007003.
FT   VARIANT     366    366       E -> K (in Z/Z-Augsburg/Z-Tun; associated
FT                                with A-237 in Z; dbSNP:rs28929474).
FT                                /FTId=VAR_007004.
FT   VARIANT     382    382       M -> R (in Pittsburgh; has antithrombin
FT                                activity; causes fatal bleeding
FT                                diathesis).
FT                                /FTId=VAR_007005.
FT   VARIANT     386    386       P -> H (in Sao Tome).
FT                                /FTId=VAR_007006.
FT   VARIANT     386    386       P -> T (in L-Offenbach).
FT                                /FTId=VAR_007007.
FT   VARIANT     387    387       E -> K (in Christchurch;
FT                                dbSNP:rs121912712).
FT                                /FTId=VAR_007008.
FT   VARIANT     393    393       P -> L (in M-Heerlen).
FT                                /FTId=VAR_007009.
FT   VARIANT     400    400       E -> D (in M2 and M3; associated with H-
FT                                125 in M2; dbSNP:rs1303).
FT                                /FTId=VAR_007010.
FT   VARIANT     415    415       P -> H (in Y-Barcelona; associated with
FT                                V-280).
FT                                /FTId=VAR_007011.
FT   MUTAGEN     382    382       M->V: Oxidation-resistant inhibitor of
FT                                therapeutic importance.
FT   CONFLICT     12     12       Missing (in Ref. 4; AAA51546).
FT   CONFLICT     23     23       L -> P (in Ref. 11; BAG38005).
FT   CONFLICT     26     26       D -> H (in Ref. 18; AA sequence).
FT   CONFLICT     39     39       H -> L (in Ref. 18; AA sequence).
FT   CONFLICT     61     61       L -> P (in Ref. 9; AAF29581).
FT   CONFLICT     96     96       T -> A (in Ref. 7; ABG73380).
FT   CONFLICT    139    140       GN -> DG (in Ref. 1; AAB59375).
FT   CONFLICT    174    174       T -> H (in Ref. 4; AAA51546).
FT   CONFLICT    229    229       E -> D (in Ref. 4; AAA51546).
FT   CONFLICT    273    273       T -> N (in Ref. 1; AAB59375).
FT   CONFLICT    280    280       D -> G (in Ref. 7; ABG73380).
FT   CONFLICT    326    326       V -> I (in Ref. 3; CAA25838).
FT   CONFLICT    410    410       G -> L (in Ref. 24; AA sequence).
FT   CONFLICT    414    414       N -> S (in Ref. 24; AA sequence).
FT   TURN         48     50
FT   HELIX        51     68
FT   STRAND       70     72
FT   STRAND       74     76
FT   HELIX        78     89
FT   HELIX        94    103
FT   TURN        108    110
FT   HELIX       113    127
FT   STRAND      135    145
FT   STRAND      146    148
FT   HELIX       152    162
FT   STRAND      164    169
FT   STRAND      171    173
FT   HELIX       174    188
FT   TURN        189    191
FT   STRAND      206    220
FT   HELIX       224    226
FT   STRAND      228    235
FT   STRAND      238    256
FT   TURN        257    260
FT   STRAND      261    279
FT   STRAND      280    282
FT   HELIX       284    290
FT   HELIX       293    301
FT   STRAND      306    313
FT   STRAND      315    322
FT   HELIX       324    329
FT   HELIX       334    336
FT   TURN        337    339
FT   TURN        343    345
FT   STRAND      347    349
FT   STRAND      351    364
FT   STRAND      366    381
FT   STRAND      387    389
FT   STRAND      394    400
FT   TURN        401    403
FT   STRAND      406    414
SQ   SEQUENCE   418 AA;  46737 MW;  7016555F273B7F16 CRC64;
     MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS
     LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF
     QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ
     INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV
     KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL
     ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA
     VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK
//
ID   A2AP_HUMAN              Reviewed;         491 AA.
AC   P08697; B4E1B7; Q8N5U7; Q9UCG2; Q9UCG3;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 3.
DT   09-JUL-2014, entry version 161.
DE   RecName: Full=Alpha-2-antiplasmin;
DE            Short=Alpha-2-AP;
DE   AltName: Full=Alpha-2-plasmin inhibitor;
DE            Short=Alpha-2-PI;
DE   AltName: Full=Serpin F2;
DE   Flags: Precursor;
GN   Name=SERPINF2; Synonyms=AAP, PLI;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=2830248;
RA   Tone M., Kikuno R., Kume-Iwaki A., Hashimoto-Gotoh T.;
RT   "Structure of human alpha 2-plasmin inhibitor deduced from the cDNA
RT   sequence.";
RL   J. Biochem. 102:1033-1041(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM
RP   1).
RX   PubMed=3166140; DOI=10.1073/pnas.85.18.6836;
RA   Hirosawa S., Nakamura Y., Miura O., Sumi Y., Aoki N.;
RT   "Organization of the human alpha 2-plasmin inhibitor gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6836-6840(1988).
RN   [3]
RP   ERRATUM.
RA   Hirosawa S., Nakamura Y., Miura O., Sumi Y., Aoki N.;
RL   Proc. Natl. Acad. Sci. U.S.A. 86:1612-1613(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-2.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4-491 (ISOFORM 1).
RX   PubMed=2433286;
RA   Holmes W.E., Nelles L., Lijnen H.R., Collen D.;
RT   "Primary structure of human alpha 2-antiplasmin, a serine protease
RT   inhibitor (serpin).";
RL   J. Biol. Chem. 262:1659-1664(1987).
RN   [8]
RP   PROTEIN SEQUENCE OF 28-58.
RC   TISSUE=Plasma;
RX   PubMed=8484741;
RA   Bangert K., Johnsen A.H., Christensen U., Thorsen S.;
RT   "Different N-terminal forms of alpha 2-plasmin inhibitor in human
RT   plasma.";
RL   Biochem. J. 291:623-625(1993).
RN   [9]
RP   PROTEIN SEQUENCE OF 28-52.
RC   TISSUE=Plasma;
RX   PubMed=1385210; DOI=10.1016/0014-5793(92)81419-M;
RA   Christensen S., Sottrup-Jensen L.;
RT   "Bovine alpha 2-antiplasmin. N-terminal and reactive site sequence.";
RL   FEBS Lett. 312:100-104(1992).
RN   [10]
RP   PROTEIN SEQUENCE OF 40-491.
RX   PubMed=2440681; DOI=10.1111/j.1432-1033.1987.tb13551.x;
RA   Lijnen H.R., Holmes W.E., van Hoef B., Wiman B., Rodriguez H.,
RA   Collen D.;
RT   "Amino-acid sequence of human alpha 2-antiplasmin.";
RL   Eur. J. Biochem. 166:565-574(1987).
RN   [11]
RP   PROTEIN SEQUENCE OF 40-43.
RX   PubMed=21075; DOI=10.1111/j.1432-1033.1977.tb11709.x;
RA   Wiman B., Collen D.;
RT   "Purification and characterization of human antiplasmin, the fast-
RT   acting plasmin inhibitor in plasma.";
RL   Eur. J. Biochem. 78:19-26(1977).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 218-491.
RX   PubMed=3818581;
RA   Sumi Y., Nakamura Y., Aoki N., Sakai M., Muramatsu M.;
RT   "Structure of the carboxyl-terminal half of human alpha 2-plasmin
RT   inhibitor deduced from that of cDNA.";
RL   J. Biochem. 100:1399-1402(1986).
RN   [13]
RP   PROTEIN SEQUENCE OF 481-491, AND SULFATION AT TYR-484.
RX   PubMed=2434496;
RA   Hortin G., Fok K.F., Toren P.C., Strauss A.W.;
RT   "Sulfation of a tyrosine residue in the plasmin-binding domain of
RT   alpha 2-antiplasmin.";
RL   J. Biol. Chem. 262:3082-3085(1987).
RN   [14]
RP   REACTIVE SITES.
RX   PubMed=2456616; DOI=10.1126/science.2456616;
RA   Potempa J., Shieh B.-H., Travis J.;
RT   "Alpha-2-antiplasmin: a serpin with two separate but overlapping
RT   reactive sites.";
RL   Science 241:699-700(1988).
RN   [15]
RP   DISULFIDE BOND.
RX   PubMed=9169621;
RA   Christensen S., Valnickova Z., Thogersen I.B., Olsen E.H.,
RA   Enghild J.J.;
RT   "Assignment of a single disulphide bridge in human alpha2-antiplasmin:
RT   implications for the structural and functional properties.";
RL   Biochem. J. 323:847-852(1997).
RN   [16]
RP   FUNCTION IN MEMBRANE-ANCHORED SERINE PROTEASE TMPRSS7 INHIBITION, AND
RP   HETERODIMER WITH TMPRSS7.
RX   PubMed=15853774; DOI=10.1042/BJ20050299;
RA   Szabo R., Netzel-Arnett S., Hobson J.P., Antalis T.M., Bugge T.H.;
RT   "Matriptase-3 is a novel phylogenetically preserved membrane-anchored
RT   serine protease with broad serpin reactivity.";
RL   Biochem. J. 390:231-242(2005).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-126; ASN-295 AND ASN-309.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [18]
RP   VARIANT APLID GLU-176 DEL.
RX   PubMed=2572590;
RA   Miura O., Sugahara Y., Aoki N.;
RT   "Hereditary alpha 2-plasmin inhibitor deficiency caused by a
RT   transport-deficient mutation (alpha 2-PI-Okinawa). Deletion of Glu137
RT   by a trinucleotide deletion blocks intracellular transport.";
RL   J. Biol. Chem. 264:18213-18219(1989).
RN   [19]
RP   VARIANT APLID MET-411, AND VARIANTS VAL-27; TRP-33 AND LYS-434.
RX   PubMed=10583218; DOI=10.1046/j.1365-2141.1999.01708.x;
RA   Lind B., Thorsen S.;
RT   "A novel missense mutation in the human plasmin inhibitor (alpha2-
RT   antiplasmin) gene associated with a bleeding tendency.";
RL   Br. J. Haematol. 107:317-322(1999).
CC   -!- FUNCTION: Serine protease inhibitor. The major targets of this
CC       inhibitor are plasmin and trypsin, but it also inactivates
CC       matriptase-3/TMPRSS7 and chymotrypsin.
CC   -!- SUBUNIT: Forms protease inhibiting heterodimer with TMPRSS7.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P08697-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08697-2; Sequence=VSP_043833, VSP_043834;
CC   -!- TISSUE SPECIFICITY: Expressed by the liver and secreted in plasma.
CC   -!- DISEASE: Alpha-2-plasmin inhibitor deficiency (APLID)
CC       [MIM:262850]: An autosomal recessive disorder resulting in severe
CC       hemorrhagic diathesis. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the serpin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D00174; BAA00124.1; -; mRNA.
DR   EMBL; M20786; AAA51554.1; -; Genomic_DNA.
DR   EMBL; M20782; AAA51554.1; JOINED; Genomic_DNA.
DR   EMBL; M20783; AAA51554.1; JOINED; Genomic_DNA.
DR   EMBL; M20784; AAA51554.1; JOINED; Genomic_DNA.
DR   EMBL; M20785; AAA51554.1; JOINED; Genomic_DNA.
DR   EMBL; AK303763; BAG64729.1; -; mRNA.
DR   EMBL; AC130343; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC031592; AAH31592.1; -; mRNA.
DR   EMBL; J02654; AAA35543.1; -; mRNA.
DR   EMBL; D00116; BAA00070.1; -; mRNA.
DR   CCDS; CCDS11011.1; -. [P08697-1]
DR   CCDS; CCDS54064.1; -. [P08697-2]
DR   PIR; A31402; ITHUA2.
DR   RefSeq; NP_000925.2; NM_000934.3. [P08697-1]
DR   RefSeq; NP_001159392.1; NM_001165920.1. [P08697-1]
DR   RefSeq; NP_001159393.1; NM_001165921.1. [P08697-2]
DR   RefSeq; XP_005256758.1; XM_005256701.2. [P08697-1]
DR   UniGene; Hs.159509; -.
DR   ProteinModelPortal; P08697; -.
DR   SMR; P08697; 74-446.
DR   BioGrid; 111360; 10.
DR   IntAct; P08697; 2.
DR   STRING; 9606.ENSP00000321853; -.
DR   DrugBank; DB00086; Streptokinase.
DR   MEROPS; I04.023; -.
DR   PhosphoSite; P08697; -.
DR   DMDM; 112907; -.
DR   SWISS-2DPAGE; P08697; -.
DR   MaxQB; P08697; -.
DR   PaxDb; P08697; -.
DR   PRIDE; P08697; -.
DR   DNASU; 5345; -.
DR   Ensembl; ENST00000324015; ENSP00000321853; ENSG00000167711. [P08697-1]
DR   Ensembl; ENST00000382061; ENSP00000371493; ENSG00000167711. [P08697-1]
DR   Ensembl; ENST00000450523; ENSP00000403877; ENSG00000167711. [P08697-2]
DR   GeneID; 5345; -.
DR   KEGG; hsa:5345; -.
DR   UCSC; uc002ftk.1; human. [P08697-1]
DR   UCSC; uc010vqr.1; human. [P08697-2]
DR   CTD; 5345; -.
DR   GeneCards; GC17P001593; -.
DR   H-InvDB; HIX0013407; -.
DR   HGNC; HGNC:9075; SERPINF2.
DR   HPA; CAB024863; -.
DR   HPA; HPA001885; -.
DR   MIM; 262850; phenotype.
DR   MIM; 613168; gene.
DR   neXtProt; NX_P08697; -.
DR   Orphanet; 79; Congenital alpha2 antiplasmin deficiency.
DR   PharmGKB; PA35522; -.
DR   eggNOG; COG4826; -.
DR   HOGENOM; HOG000231761; -.
DR   HOVERGEN; HBG000043; -.
DR   InParanoid; P08697; -.
DR   KO; K03983; -.
DR   OMA; RWFLLEQ; -.
DR   PhylomeDB; P08697; -.
DR   TreeFam; TF317350; -.
DR   Reactome; REACT_604; Hemostasis.
DR   ChiTaRS; SERPINF2; human.
DR   GeneWiki; Alpha_2-antiplasmin; -.
DR   GenomeRNAi; 5345; -.
DR   NextBio; 20714; -.
DR   PMAP-CutDB; P08697; -.
DR   PRO; PR:P08697; -.
DR   ArrayExpress; P08697; -.
DR   Bgee; P08697; -.
DR   CleanEx; HS_SERPINF2; -.
DR   Genevestigator; P08697; -.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProt.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005577; C:fibrinogen complex; IDA:BHF-UCL.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0004866; F:endopeptidase inhibitor activity; TAS:ProtInc.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; NAS:UniProtKB.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0048514; P:blood vessel morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0030199; P:collagen fibril organization; ISS:BHF-UCL.
DR   GO; GO:0042730; P:fibrinolysis; TAS:Reactome.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IBA:RefGenome.
DR   GO; GO:0051918; P:negative regulation of fibrinolysis; IDA:BHF-UCL.
DR   GO; GO:0010757; P:negative regulation of plasminogen activation; IDA:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IDA:BHF-UCL.
DR   GO; GO:2000049; P:positive regulation of cell-cell adhesion mediated by cadherin; TAS:BHF-UCL.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:BHF-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0071636; P:positive regulation of transforming growth factor beta production; IDA:BHF-UCL.
DR   GO; GO:0002034; P:regulation of blood vessel size by renin-angiotensin; ISS:BHF-UCL.
DR   GO; GO:0030162; P:regulation of proteolysis; IBA:RefGenome.
DR   GO; GO:0010033; P:response to organic substance; IEA:Ensembl.
DR   InterPro; IPR023795; Serpin_CS.
DR   InterPro; IPR023796; Serpin_dom.
DR   InterPro; IPR000215; Serpin_fam.
DR   PANTHER; PTHR11461; PTHR11461; 1.
DR   Pfam; PF00079; Serpin; 1.
DR   SMART; SM00093; SERPIN; 1.
DR   SUPFAM; SSF56574; SSF56574; 1.
DR   PROSITE; PS00284; SERPIN; 1.
PE   1: Evidence at protein level;
KW   Acute phase; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Isopeptide bond; Polymorphism; Protease inhibitor;
KW   Reference proteome; Secreted; Serine protease inhibitor; Signal;
KW   Sulfation.
FT   SIGNAL        1     27
FT   PROPEP       28     39
FT                                /FTId=PRO_0000032511.
FT   CHAIN        40    491       Alpha-2-antiplasmin.
FT                                /FTId=PRO_0000032512.
FT   SITE        403    404       Reactive bond for plasmin.
FT   SITE        404    405       Reactive bond for chymotrypsin.
FT   MOD_RES     484    484       Sulfotyrosine.
FT   CARBOHYD    126    126       N-linked (GlcNAc...).
FT   CARBOHYD    295    295       N-linked (GlcNAc...).
FT   CARBOHYD    309    309       N-linked (GlcNAc...).
FT   CARBOHYD    316    316       N-linked (GlcNAc...) (Potential).
FT   DISULFID     70    143
FT   CROSSLNK     41     41       Isoglutamyl lysine isopeptide (Gln-Lys)
FT                                (interchain with K-322 in alpha-
FT                                fibrinogen).
FT   VAR_SEQ      56    119       Missing (in isoform 2).
FT                                /FTId=VSP_043833.
FT   VAR_SEQ     120    122       LAL -> VQP (in isoform 2).
FT                                /FTId=VSP_043834.
FT   VARIANT       2      2       A -> V (in dbSNP:rs2070862).
FT                                /FTId=VAR_047951.
FT   VARIANT      27     27       A -> V.
FT                                /FTId=VAR_013252.
FT   VARIANT      33     33       R -> W (in dbSNP:rs2070863).
FT                                /FTId=VAR_013253.
FT   VARIANT      98     98       A -> G (in dbSNP:rs36021516).
FT                                /FTId=VAR_051956.
FT   VARIANT     176    176       Missing (in APLID; variant Okinawa;
FT                                probably blocks intracellular transport
FT                                of alpha-2-plasmin inhibitor).
FT                                /FTId=VAR_013254.
FT   VARIANT     411    411       V -> M (in APLID).
FT                                /FTId=VAR_013255.
FT   VARIANT     434    434       R -> K (in dbSNP:rs1057335).
FT                                /FTId=VAR_013256.
FT   VARIANT     451    451       P -> S (in dbSNP:rs57360598).
FT                                /FTId=VAR_061792.
FT   CONFLICT     49     49       L -> G (in Ref. 10; AA sequence).
FT   CONFLICT    105    105       N -> D (in Ref. 10; AA sequence).
FT   CONFLICT    289    289       H -> D (in Ref. 7; AAA35543).
FT   CONFLICT    408    408       S -> G (in Ref. 10; AA sequence).
FT   CONFLICT    455    455       D -> N (in Ref. 10; AA sequence).
SQ   SEQUENCE   491 AA;  54566 MW;  385A1C90E91A63CB CRC64;
     MALLWGLLVL SWSCLQGPCS VFSPVSAMEP LGRQLTSGPN QEQVSPLTLL KLGNQEPGGQ
     TALKSPPGVC SRDPTPEQTH RLARAMMAFT ADLFSLVAQT STCPNLILSP LSVALALSHL
     ALGAQNHTLQ RLQQVLHAGS GPCLPHLLSR LCQDLGPGAF RLAARMYLQK GFPIKEDFLE
     QSEQLFGAKP VSLTGKQEDD LANINQWVKE ATEGKIQEFL SGLPEDTVLL LLNAIHFQGF
     WRNKFDPSLT QRDSFHLDEQ FTVPVEMMQA RTYPLRWFLL EQPEIQVAHF PFKNNMSFVV
     LVPTHFEWNV SQVLANLSWD TLHPPLVWER PTKVRLPKLY LKHQMDLVAT LSQLGLQELF
     QAPDLRGISE QSLVVSGVQH QSTLELSEVG VEAAAATSIA MSRMSLSSFS VNRPFLFFIF
     EDTTGLPLFV GSVRNPNPSA PRELKEQQDS PGNKDFLQSL KGFPRGDKLF GPDLKLVPPM
     EEDYPQFGSP K
//
ID   A2MG_HUMAN              Reviewed;        1474 AA.
AC   P01023; Q13677; Q59F47; Q5QTS0; Q68DN2; Q6PIY3; Q6PN97;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 3.
DT   09-JUL-2014, entry version 172.
DE   RecName: Full=Alpha-2-macroglobulin;
DE            Short=Alpha-2-M;
DE   AltName: Full=C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5;
DE   Flags: Precursor;
GN   Name=A2M; Synonyms=CPAMD5; ORFNames=FWP007;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASP-639 AND VAL-1000.
RX   PubMed=2581245; DOI=10.1073/pnas.82.8.2282;
RA   Kan C.-C., Solomon E., Belt K.T., Chain A.C., Hiorns L.R., Fey G.H.;
RT   "Nucleotide sequence of cDNA encoding human alpha 2-macroglobulin and
RT   assignment of the chromosomal locus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:2282-2286(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASP-639 AND VAL-1000.
RC   TISSUE=Prostate;
RX   PubMed=15611997; DOI=10.1002/pros.20183;
RA   Lin V.K., Wang S.-Y., Boetticher N.C., Vazquez D.V., Saboorian H.,
RA   McConnell J.D., Roehrborn C.G.;
RT   "Alpha(2) macroglobulin, a PSA-binding protein, is expressed in human
RT   prostate stroma.";
RL   Prostate 63:299-308(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-639.
RC   TISSUE=Spleen;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASP-639 AND
RP   VAL-1000.
RC   TISSUE=Liver;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASP-639 AND
RP   VAL-1000.
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29.
RC   TISSUE=Placenta;
RX   PubMed=1374237; DOI=10.1016/0006-291X(92)90631-T;
RA   Matthijs G., Devriendt K., Cassiman J.-J., van den Berghe H.,
RA   Marynen P.;
RT   "Structure of the human alpha-2 macroglobulin gene and its promotor.";
RL   Biochem. Biophys. Res. Commun. 184:596-603(1992).
RN   [8]
RP   PROTEIN SEQUENCE OF 24-1474, SUBUNIT, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND DISULFIDE BONDS.
RX   PubMed=6203908;
RA   Sottrup-Jensen L., Stepanik T.M., Kristensen T., Wierzbicki D.M.,
RA   Jones C.M., Loenblad P.B., Magnusson S., Petersen T.E.;
RT   "Primary structure of human alpha 2-macroglobulin. V. The complete
RT   structure.";
RL   J. Biol. Chem. 259:8318-8327(1984).
RN   [9]
RP   ERRATUM.
RA   Sottrup-Jensen L., Stepanik T.M., Kristensen T., Wierzbicki D.M.,
RA   Jones C.M., Loenblad P.B., Magnusson S., Petersen T.E.;
RL   J. Biol. Chem. 260:6500-6500(1985).
RN   [10]
RP   PROTEIN SEQUENCE OF 273-286 AND 426-436, AND DISULFIDE BONDS.
RX   PubMed=2430963;
RA   Jensen P.E.H., Sottrup-Jensen L.;
RT   "Primary structure of human alpha 2-macroglobulin. Complete disulfide
RT   bridge assignment and localization of two interchain bridges in the
RT   dimeric proteinase binding unit.";
RL   J. Biol. Chem. 261:15863-15869(1986).
RN   [11]
RP   PROTEIN SEQUENCE OF 672-747.
RX   PubMed=1692292; DOI=10.1016/0014-5793(90)80226-9;
RA   Marynen P., Devriendt K., van den Berghe H., Cassiman J.-J.;
RT   "A genetic polymorphism in a functional domain of human pregnancy zone
RT   protein: the bait region. Genomic structure of the bait domains of
RT   human pregnancy zone protein and alpha 2 macroglobulin.";
RL   FEBS Lett. 262:349-352(1990).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 672-746, AND VARIANT TYR-972.
RX   PubMed=1370808; DOI=10.1007/BF00197266;
RA   Poller W., Faber J.-P., Klobeck G., Olek K.;
RT   "Cloning of the human alpha 2-macroglobulin gene and detection of
RT   mutations in two functional domains: the bait region and the
RT   thiolester site.";
RL   Hum. Genet. 88:313-319(1992).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 832-1474.
RC   TISSUE=Liver;
RX   PubMed=2408344; DOI=10.1007/BF01534685;
RA   Bell G.I., Rall L.B., Sanchez-Pescador R., Merryweather J.P.,
RA   Scott J., Eddy R.L., Shows T.B.;
RT   "Human alpha 2-macroglobulin gene is located on chromosome 12.";
RL   Somat. Cell Mol. Genet. 11:285-289(1985).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1208-1474.
RC   TISSUE=Aorta;
RA   Liu B., Zhao B., Wang X.Y., Xu Y.Y., Liu Y.Q., Song L., Ye J.,
RA   Sheng H., Gao Y., Zhang C.L., Wei Y.J., Zhang J., Song L., Jiang Y.X.,
RA   Zhao Z.W., Ding J.F., Liu L.S., Gao R.L., Wu Q.Y., Qiang B.Q.,
RA   Yuan J.G., Liew C.C., Zhao M.S., Hui R.T.;
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   INHIBITORY SITE.
RX   PubMed=6167263; DOI=10.1016/S0006-291X(81)80055-1;
RA   Hall P.K., Nelles L.P., Travis J., Roberts R.C.;
RT   "Proteolytic cleavage sites on alpha 2-macroglobulin resulting in
RT   proteinase binding are different for trypsin and Staphylococcus aureus
RT   V-8 proteinase.";
RL   Biochem. Biophys. Res. Commun. 100:8-16(1981).
RN   [16]
RP   INHIBITORY SITE.
RX   PubMed=6165619; DOI=10.1016/0014-5793(81)80197-4;
RA   Sottrup-Jensen L., Loenblad P.B., Stepanik T.M., Petersen T.E.,
RA   Magnusson S., Joernvall H.;
RT   "Primary structure of the 'bait' region for proteinases in alpha 2-
RT   macroglobulin. Nature of the complex.";
RL   FEBS Lett. 127:167-173(1981).
RN   [17]
RP   INHIBITORY SITE.
RX   PubMed=6172288; DOI=10.1016/0014-5793(81)80804-6;
RA   Mortensen S.B., Sottrup-Jensen L., Hansen H.F., Petersen T.E.,
RA   Magnusson S.;
RT   "Primary and secondary cleavage sites in the bait region of alpha 2-
RT   macroglobulin.";
RL   FEBS Lett. 135:295-300(1981).
RN   [18]
RP   INHIBITORY SITE.
RX   PubMed=6195065;
RA   Virca G.D., Salvesen G.S., Travis J.;
RT   "Human neutrophil elastase and cathepsin G cleavage sites in the bait
RT   region of alpha 2-macroglobulin. Proposed structural limits of the
RT   bait region.";
RL   Hoppe-Seyler's Z. Physiol. Chem. 364:1297-1302(1983).
RN   [19]
RP   GLYCOSYLATION AT ASN-991.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-869 AND ASN-1424.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-55; ASN-247; ASN-396;
RP   ASN-410; ASN-869; ASN-991 AND ASN-1424.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-396; ASN-991 AND ASN-1424.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [23]
RP   GLYCOSYLATION AT ASN-55 AND ASN-1424.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   STRUCTURE BY NMR OF 1337-1474.
RX   PubMed=9865955; DOI=10.1002/pro.5560071214;
RA   Huang W., Dolmer K., Liao X., Gettins P.G.W.;
RT   "Localization of basic residues required for receptor binding to the
RT   single alpha-helix of the receptor binding domain of human alpha2-
RT   macroglobulin.";
RL   Protein Sci. 7:2602-2612(1998).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 126-227, AND DOMAIN
RP   STRUCTURE.
RX   PubMed=17608619; DOI=10.1042/BJ20070764;
RA   Doan N., Gettins P.G.W.;
RT   "Human alpha2-macroglobulin is composed of multiple domains, as
RT   predicted by homology with complement component C3.";
RL   Biochem. J. 407:23-30(2007).
RN   [27]
RP   VARIANT VAL-1000.
RX   PubMed=1707161; DOI=10.1093/nar/19.1.198-a;
RA   Poller W., Faber J.-P., Olek K.;
RT   "Sequence polymorphism in the human alpha2-macroglobulin (A2M) gene.";
RL   Nucleic Acids Res. 19:198-198(1991).
CC   -!- FUNCTION: Is able to inhibit all four classes of proteinases by a
CC       unique 'trapping' mechanism. This protein has a peptide stretch,
CC       called the 'bait region' which contains specific cleavage sites
CC       for different proteinases. When a proteinase cleaves the bait
CC       region, a conformational change is induced in the protein which
CC       traps the proteinase. The entrapped enzyme remains active against
CC       low molecular weight substrates (activity against high molecular
CC       weight substrates is greatly reduced). Following cleavage in the
CC       bait region a thioester bond is hydrolyzed and mediates the
CC       covalent binding of the protein to the proteinase.
CC   -!- SUBUNIT: Homotetramer; disulfide-linked.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Secreted in plasma.
CC   -!- DEVELOPMENTAL STAGE: Contrary to the rat protein, which is an
CC       acute phase protein, this protein is always present at high levels
CC       in circulation.
CC   -!- SIMILARITY: Belongs to the protease inhibitor I39 (alpha-2-
CC       macroglobulin) family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAT02228.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC       Sequence=BAD92851.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alpha-2 macroglobulin entry;
CC       URL="http://en.wikipedia.org/wiki/Alpha_2-macroglobulin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M11313; AAA51551.1; -; mRNA.
DR   EMBL; AY591530; AAT02228.1; ALT_INIT; mRNA.
DR   EMBL; AB209614; BAD92851.1; ALT_INIT; mRNA.
DR   EMBL; CR749334; CAH18188.1; -; mRNA.
DR   EMBL; AC007436; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC026246; AAH26246.1; -; mRNA.
DR   EMBL; BC040071; AAH40071.1; -; mRNA.
DR   EMBL; Z11711; CAA77774.1; -; Genomic_DNA.
DR   EMBL; X68728; CAA48670.1; -; Genomic_DNA.
DR   EMBL; X68729; CAA48670.1; JOINED; Genomic_DNA.
DR   EMBL; M36501; AAA51552.1; -; mRNA.
DR   EMBL; AF109189; AAQ13498.1; -; mRNA.
DR   CCDS; CCDS44827.1; -.
DR   PIR; A94033; MAHU.
DR   RefSeq; NP_000005.2; NM_000014.4.
DR   UniGene; Hs.212838; -.
DR   PDB; 1BV8; NMR; -; A=1337-1474.
DR   PDB; 2P9R; X-ray; 2.30 A; A/B=126-227.
DR   PDB; 4ACQ; X-ray; 4.30 A; A/B/C/D=24-1474.
DR   PDBsum; 1BV8; -.
DR   PDBsum; 2P9R; -.
DR   PDBsum; 4ACQ; -.
DR   ProteinModelPortal; P01023; -.
DR   SMR; P01023; 126-227, 1338-1474.
DR   BioGrid; 106524; 89.
DR   DIP; DIP-1118N; -.
DR   IntAct; P01023; 95.
DR   MINT; MINT-122288; -.
DR   STRING; 9606.ENSP00000323929; -.
DR   DrugBank; DB00626; Bacitracin.
DR   DrugBank; DB00102; Becaplermin.
DR   MEROPS; I39.001; -.
DR   PhosphoSite; P01023; -.
DR   DMDM; 308153640; -.
DR   DOSAC-COBS-2DPAGE; P01023; -.
DR   SWISS-2DPAGE; P01023; -.
DR   MaxQB; P01023; -.
DR   PaxDb; P01023; -.
DR   PeptideAtlas; P01023; -.
DR   PRIDE; P01023; -.
DR   Ensembl; ENST00000318602; ENSP00000323929; ENSG00000175899.
DR   GeneID; 2; -.
DR   KEGG; hsa:2; -.
DR   UCSC; uc001qvk.1; human.
DR   CTD; 2; -.
DR   GeneCards; GC12M009220; -.
DR   H-InvDB; HIX0026392; -.
DR   HGNC; HGNC:7; A2M.
DR   HPA; CAB017621; -.
DR   HPA; HPA002265; -.
DR   MIM; 103950; gene.
DR   neXtProt; NX_P01023; -.
DR   PharmGKB; PA24357; -.
DR   eggNOG; COG2373; -.
DR   HOVERGEN; HBG000039; -.
DR   KO; K03910; -.
DR   OMA; QTVQAHY; -.
DR   OrthoDB; EOG7DJSKB; -.
DR   PhylomeDB; P01023; -.
DR   TreeFam; TF313285; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_118779; Extracellular matrix organization.
DR   Reactome; REACT_604; Hemostasis.
DR   ChiTaRS; A2M; human.
DR   EvolutionaryTrace; P01023; -.
DR   GenomeRNAi; 2; -.
DR   NextBio; 5; -.
DR   PRO; PR:P01023; -.
DR   ArrayExpress; P01023; -.
DR   Bgee; P01023; -.
DR   CleanEx; HS_A2M; -.
DR   Genevestigator; P01023; -.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProt.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0048306; F:calcium-dependent protein binding; IPI:AgBase.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0019838; F:growth factor binding; IDA:UniProtKB.
DR   GO; GO:0019966; F:interleukin-1 binding; IDA:UniProtKB.
DR   GO; GO:0019959; F:interleukin-8 binding; IPI:UniProtKB.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IMP:AgBase.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0043120; F:tumor necrosis factor binding; IDA:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007597; P:blood coagulation, intrinsic pathway; TAS:Reactome.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0001869; P:negative regulation of complement activation, lectin pathway; IDA:UniProtKB.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IDA:GOC.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0048863; P:stem cell differentiation; IEA:Ensembl.
DR   Gene3D; 1.50.10.20; -; 1.
DR   Gene3D; 2.60.40.690; -; 1.
DR   InterPro; IPR009048; A-macroglobulin_rcpt-bd.
DR   InterPro; IPR011626; A2M_comp.
DR   InterPro; IPR002890; A2M_N.
DR   InterPro; IPR011625; A2M_N_2.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR001599; Macroglobln_a2.
DR   InterPro; IPR019742; MacrogloblnA2_CS.
DR   InterPro; IPR019565; MacrogloblnA2_thiol-ester-bond.
DR   InterPro; IPR008930; Terpenoid_cyclase/PrenylTrfase.
DR   InterPro; IPR010916; TonB_box_CS.
DR   Pfam; PF00207; A2M; 1.
DR   Pfam; PF07678; A2M_comp; 1.
DR   Pfam; PF01835; A2M_N; 1.
DR   Pfam; PF07703; A2M_N_2; 1.
DR   Pfam; PF07677; A2M_recep; 1.
DR   Pfam; PF10569; Thiol-ester_cl; 1.
DR   SUPFAM; SSF48239; SSF48239; 1.
DR   SUPFAM; SSF49410; SSF49410; 1.
DR   SUPFAM; SSF81296; SSF81296; 1.
DR   PROSITE; PS00477; ALPHA_2_MACROGLOBULIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Bait region; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Isopeptide bond; Polymorphism; Protease inhibitor; Reference proteome;
KW   Secreted; Serine protease inhibitor; Signal; Thioester bond.
FT   SIGNAL        1     23
FT   CHAIN        24   1474       Alpha-2-macroglobulin.
FT                                /FTId=PRO_0000000055.
FT   REGION      690    728       Bait region.
FT   REGION      704    709       Inhibitory.
FT   REGION      719    723       Inhibitory.
FT   REGION      730    735       Inhibitory.
FT   CARBOHYD     55     55       N-linked (GlcNAc...) (complex).
FT   CARBOHYD     70     70       N-linked (GlcNAc...).
FT   CARBOHYD    247    247       N-linked (GlcNAc...).
FT   CARBOHYD    396    396       N-linked (GlcNAc...).
FT   CARBOHYD    410    410       N-linked (GlcNAc...).
FT   CARBOHYD    869    869       N-linked (GlcNAc...).
FT   CARBOHYD    991    991       N-linked (GlcNAc...).
FT   CARBOHYD   1424   1424       N-linked (GlcNAc...) (complex).
FT   DISULFID     48     86
FT   DISULFID    251    299
FT   DISULFID    269    287
FT   DISULFID    278    278       Interchain (with C-431).
FT   DISULFID    431    431       Interchain (with C-278).
FT   DISULFID    470    563
FT   DISULFID    595    771
FT   DISULFID    642    689
FT   DISULFID    821    849
FT   DISULFID    847    883
FT   DISULFID    921   1321
FT   DISULFID   1079   1127
FT   DISULFID   1352   1467
FT   CROSSLNK    693    693       Isoglutamyl lysine isopeptide (Gln-Lys)
FT                                (interchain with K-? in other proteins)
FT                                (Potential).
FT   CROSSLNK    694    694       Isoglutamyl lysine isopeptide (Gln-Lys)
FT                                (interchain with K-? in other proteins)
FT                                (Potential).
FT   CROSSLNK    972    975       Isoglutamyl cysteine thioester (Cys-Gln).
FT   VARIANT     639    639       N -> D (in dbSNP:rs226405).
FT                                /FTId=VAR_026820.
FT   VARIANT     704    704       R -> H (in dbSNP:rs1800434).
FT                                /FTId=VAR_000012.
FT   VARIANT     815    815       L -> Q (in dbSNP:rs3180392).
FT                                /FTId=VAR_026821.
FT   VARIANT     972    972       C -> Y (probably interferes with the
FT                                activity; dbSNP:rs1800433).
FT                                /FTId=VAR_000013.
FT   VARIANT    1000   1000       I -> V (in dbSNP:rs669).
FT                                /FTId=VAR_000014.
FT   CONFLICT     63     63       Missing (in Ref. 8; AA sequence).
FT   CONFLICT     82     82       D -> V (in Ref. 3; AAT02228).
FT   CONFLICT    350    353       LSFV -> ACCS (in Ref. 6; AAH26246).
FT   CONFLICT    563    563       C -> E (in Ref. 8; AA sequence).
FT   CONFLICT    844    844       A -> V (in Ref. 4; BAD92851).
FT   CONFLICT    872    872       V -> M (in Ref. 5; CAH18188).
FT   CONFLICT   1148   1148       A -> D (in Ref. 13; AAA51552).
FT   CONFLICT   1195   1195       H -> D (in Ref. 13; AAA51552).
FT   STRAND      128    134
FT   STRAND      136    138
FT   STRAND      143    151
FT   HELIX       153    155
FT   STRAND      161    168
FT   STRAND      174    182
FT   STRAND      187    193
FT   STRAND      201    208
FT   STRAND      214    221
FT   STRAND     1341   1347
FT   HELIX      1355   1359
FT   STRAND     1360   1369
FT   STRAND     1379   1384
FT   STRAND     1389   1391
FT   HELIX      1393   1400
FT   TURN       1401   1403
FT   STRAND     1407   1410
FT   STRAND     1412   1419
FT   STRAND     1427   1434
FT   STRAND     1445   1450
FT   STRAND     1454   1456
FT   STRAND     1459   1463
SQ   SEQUENCE   1474 AA;  163291 MW;  0A46DF09EFD3CF40 CRC64;
     MGKNKLLHPS LVLLLLVLLP TDASVSGKPQ YMVLVPSLLH TETTEKGCVL LSYLNETVTV
     SASLESVRGN RSLFTDLEAE NDVLHCVAFA VPKSSSNEEV MFLTVQVKGP TQEFKKRTTV
     MVKNEDSLVF VQTDKSIYKP GQTVKFRVVS MDENFHPLNE LIPLVYIQDP KGNRIAQWQS
     FQLEGGLKQF SFPLSSEPFQ GSYKVVVQKK SGGRTEHPFT VEEFVLPKFE VQVTVPKIIT
     ILEEEMNVSV CGLYTYGKPV PGHVTVSICR KYSDASDCHG EDSQAFCEKF SGQLNSHGCF
     YQQVKTKVFQ LKRKEYEMKL HTEAQIQEEG TVVELTGRQS SEITRTITKL SFVKVDSHFR
     QGIPFFGQVR LVDGKGVPIP NKVIFIRGNE ANYYSNATTD EHGLVQFSIN TTNVMGTSLT
     VRVNYKDRSP CYGYQWVSEE HEEAHHTAYL VFSPSKSFVH LEPMSHELPC GHTQTVQAHY
     ILNGGTLLGL KKLSFYYLIM AKGGIVRTGT HGLLVKQEDM KGHFSISIPV KSDIAPVARL
     LIYAVLPTGD VIGDSAKYDV ENCLANKVDL SFSPSQSLPA SHAHLRVTAA PQSVCALRAV
     DQSVLLMKPD AELSASSVYN LLPEKDLTGF PGPLNDQDNE DCINRHNVYI NGITYTPVSS
     TNEKDMYSFL EDMGLKAFTN SKIRKPKMCP QLQQYEMHGP EGLRVGFYES DVMGRGHARL
     VHVEEPHTET VRKYFPETWI WDLVVVNSAG VAEVGVTVPD TITEWKAGAF CLSEDAGLGI
     SSTASLRAFQ PFFVELTMPY SVIRGEAFTL KATVLNYLPK CIRVSVQLEA SPAFLAVPVE
     KEQAPHCICA NGRQTVSWAV TPKSLGNVNF TVSAEALESQ ELCGTEVPSV PEHGRKDTVI
     KPLLVEPEGL EKETTFNSLL CPSGGEVSEE LSLKLPPNVV EESARASVSV LGDILGSAMQ
     NTQNLLQMPY GCGEQNMVLF APNIYVLDYL NETQQLTPEI KSKAIGYLNT GYQRQLNYKH
     YDGSYSTFGE RYGRNQGNTW LTAFVLKTFA QARAYIFIDE AHITQALIWL SQRQKDNGCF
     RSSGSLLNNA IKGGVEDEVT LSAYITIALL EIPLTVTHPV VRNALFCLES AWKTAQEGDH
     GSHVYTKALL AYAFALAGNQ DKRKEVLKSL NEEAVKKDNS VHWERPQKPK APVGHFYEPQ
     APSAEVEMTS YVLLAYLTAQ PAPTSEDLTS ATNIVKWITK QQNAQGGFSS TQDTVVALHA
     LSKYGAATFT RTGKAAQVTI QSSGTFSSKF QVDNNNRLLL QQVSLPELPG EYSMKVTGEG
     CVYLQTSLKY NILPEKEEFP FALGVQTLPQ TCDEPKAHTS FQISLSVSYT GSRSASNMAI
     VDVKMVSGFI PLKPTVKMLE RSNHVSRTEV SSNHVLIYLD KVSNQTLSLF FTVLQDVPVR
     DLKPAIVKVY DYYETDEFAI AEYNAPCSKD LGNA
//
ID   A4_HUMAN                Reviewed;         770 AA.
AC   P05067; B2R5V1; B4DII8; D3DSD1; D3DSD2; D3DSD3; P09000; P78438;
AC   Q13764; Q13778; Q13793; Q16011; Q16014; Q16019; Q16020; Q6GSC0;
AC   Q8WZ99; Q9BT38; Q9UC33; Q9UCA9; Q9UCB6; Q9UCC8; Q9UCD1; Q9UQ58;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 3.
DT   09-JUL-2014, entry version 229.
DE   RecName: Full=Amyloid beta A4 protein;
DE   AltName: Full=ABPP;
DE   AltName: Full=APPI;
DE            Short=APP;
DE   AltName: Full=Alzheimer disease amyloid protein;
DE   AltName: Full=Cerebral vascular amyloid peptide;
DE            Short=CVAP;
DE   AltName: Full=PreA4;
DE   AltName: Full=Protease nexin-II;
DE            Short=PN-II;
DE   Contains:
DE     RecName: Full=N-APP;
DE   Contains:
DE     RecName: Full=Soluble APP-alpha;
DE              Short=S-APP-alpha;
DE   Contains:
DE     RecName: Full=Soluble APP-beta;
DE              Short=S-APP-beta;
DE   Contains:
DE     RecName: Full=C99;
DE   Contains:
DE     RecName: Full=Beta-amyloid protein 42;
DE     AltName: Full=Beta-APP42;
DE   Contains:
DE     RecName: Full=Beta-amyloid protein 40;
DE     AltName: Full=Beta-APP40;
DE   Contains:
DE     RecName: Full=C83;
DE   Contains:
DE     RecName: Full=P3(42);
DE   Contains:
DE     RecName: Full=P3(40);
DE   Contains:
DE     RecName: Full=C80;
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 59;
DE     AltName: Full=Amyloid intracellular domain 59;
DE              Short=AICD-59;
DE              Short=AID(59);
DE     AltName: Full=Gamma-CTF(59);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 57;
DE     AltName: Full=Amyloid intracellular domain 57;
DE              Short=AICD-57;
DE              Short=AID(57);
DE     AltName: Full=Gamma-CTF(57);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 50;
DE     AltName: Full=Amyloid intracellular domain 50;
DE              Short=AICD-50;
DE              Short=AID(50);
DE     AltName: Full=Gamma-CTF(50);
DE   Contains:
DE     RecName: Full=C31;
DE   Flags: Precursor;
GN   Name=APP; Synonyms=A4, AD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   TISSUE=Brain;
RX   PubMed=2881207; DOI=10.1038/325733a0;
RA   Kang J., Lemaire H.-G., Unterbeck A., Salbaum J.M., Masters C.L.,
RA   Grzeschik K.-H., Multhaup G., Beyreuther K., Mueller-Hill B.;
RT   "The precursor of Alzheimer's disease amyloid A4 protein resembles a
RT   cell-surface receptor.";
RL   Nature 325:733-736(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP751).
RC   TISSUE=Brain;
RX   PubMed=2893289; DOI=10.1038/331525a0;
RA   Ponte P., Gonzalez-Dewhitt P., Schilling J., Miller J., Hsu D.,
RA   Greenberg B., Davis K., Wallace W., Lieberburg I., Fuller F.,
RA   Cordell B.;
RT   "A new A4 amyloid mRNA contains a domain homologous to serine
RT   proteinase inhibitors.";
RL   Nature 331:525-527(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM APP695).
RX   PubMed=2783775; DOI=10.1093/nar/17.2.517;
RA   Lemaire H.-G., Salbaum J.M., Multhaup G., Kang J., Bayney R.M.,
RA   Unterbeck A., Beyreuther K., Mueller-Hill B.;
RT   "The PreA4(695) precursor protein of Alzheimer's disease A4 amyloid is
RT   encoded by 16 exons.";
RL   Nucleic Acids Res. 17:517-522(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM APP770).
RX   PubMed=2110105; DOI=10.1016/0378-1119(90)90310-N;
RA   Yoshikai S., Sasaki H., Doh-ura K., Furuya H., Sakaki Y.;
RT   "Genomic organization of the human amyloid beta-protein precursor
RT   gene.";
RL   Gene 87:257-263(1990).
RN   [5]
RP   ERRATUM.
RX   PubMed=1908403; DOI=10.1016/0378-1119(91)90093-Q;
RA   Yoshikai S., Sasaki H., Doh-ura K., Furuya H., Sakaki Y.;
RL   Gene 102:291-292(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM L-APP733).
RC   TISSUE=Leukocyte;
RX   PubMed=1587857;
RA   Koenig G., Moenning U., Czech C., Prior R., Banati R.,
RA   Schreiter-Gasser U., Bauer J., Masters C.L., Beyreuther K.;
RT   "Identification and differential expression of a novel alternative
RT   splice isoform of the beta A4 amyloid precursor protein (APP) mRNA in
RT   leukocytes and brain microglial cells.";
RL   J. Biol. Chem. 267:10804-10809(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM APP770).
RX   PubMed=9108164; DOI=10.1093/nar/25.9.1802;
RA   Hattori M., Tsukahara F., Furuhata Y., Tanahashi H., Hirose M.,
RA   Saito M., Tsukuni S., Sakaki Y.;
RT   "A novel method for making nested deletions and its application for
RT   sequencing of a 300 kb region of human APP locus.";
RL   Nucleic Acids Res. 25:1802-1808(1997).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP639), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=12859342; DOI=10.1046/j.1460-9568.2003.02731.x;
RA   Tang K., Wang C., Shen C., Sheng S., Ravid R., Jing N.;
RT   "Identification of a novel alternative splicing isoform of human
RT   amyloid precursor protein gene, APP639.";
RL   Eur. J. Neurosci. 18:102-108(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS APP770 AND 11).
RC   TISSUE=Cerebellum, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-501.
RG   NIEHS SNPs program;
RL   Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA   Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
RA   Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
RA   Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA   Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA   Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA   Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA   Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
RA   Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA   Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA   Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA   Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS APP305 AND APP751).
RC   TISSUE=Eye, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-10.
RC   TISSUE=Liver;
RX   PubMed=3140222; DOI=10.1093/nar/16.19.9351;
RA   Schon E.A., Mita S., Sadlock J., Herbert J.;
RT   "A cDNA specifying the human amyloid beta precursor protein (ABPP)
RT   encodes a 95-kDa polypeptide.";
RL   Nucleic Acids Res. 16:9351-9351(1988).
RN   [15]
RP   ERRATUM, AND SEQUENCE REVISION.
RA   Schon E.A., Mita S., Sadlock J., Herbert J.;
RL   Nucleic Acids Res. 16:11402-11402(1988).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-75.
RX   PubMed=2538123; DOI=10.1016/0006-291X(89)92437-6;
RA   La Fauci G., Lahiri D.K., Salton S.R., Robakis N.K.;
RT   "Characterization of the 5'-end region and the first two exons of the
RT   beta-protein precursor gene.";
RL   Biochem. Biophys. Res. Commun. 159:297-304(1989).
RN   [17]
RP   PROTEIN SEQUENCE OF 18-50.
RC   TISSUE=Fibroblast;
RX   PubMed=3597385;
RA   van Nostrand W.E., Cunningham D.D.;
RT   "Purification of protease nexin II from human fibroblasts.";
RL   J. Biol. Chem. 262:8508-8514(1987).
RN   [18]
RP   PROTEIN SEQUENCE OF 18-40.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 286-366.
RX   PubMed=2893290; DOI=10.1038/331528a0;
RA   Tanzi R.E., McClatchey A.I., Lamperti E.D., Villa-Komaroff L.,
RA   Gusella J.F., Neve R.L.;
RT   "Protease inhibitor domain encoded by an amyloid protein precursor
RT   mRNA associated with Alzheimer's disease.";
RL   Nature 331:528-530(1988).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 287-367.
RX   PubMed=2893291; DOI=10.1038/331530a0;
RA   Kitaguchi N., Takahashi Y., Tokushima Y., Shiojiri S., Ito H.;
RT   "Novel precursor of Alzheimer's disease amyloid protein shows protease
RT   inhibitory activity.";
RL   Nature 331:530-532(1988).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 507-770.
RC   TISSUE=Brain cortex;
RX   PubMed=2893379; DOI=10.1073/pnas.85.3.929;
RA   Zain S.B., Salim M., Chou W.G., Sajdel-Sulkowska E.M., Majocha R.E.,
RA   Marotta C.A.;
RT   "Molecular cloning of amyloid cDNA derived from mRNA of the Alzheimer
RT   disease brain: coding and noncoding regions of the fetal precursor
RT   mRNA are expressed in the cortex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:929-933(1988).
RN   [22]
RP   PROTEIN SEQUENCE OF 523-555, AND DOMAIN COLLAGEN-BINDING.
RX   PubMed=8576160; DOI=10.1074/jbc.271.3.1613;
RA   Beher D., Hesse L., Masters C.L., Multhaup G.;
RT   "Regulation of amyloid protein precursor (APP) binding to collagen and
RT   mapping of the binding sites on APP and collagen type I.";
RL   J. Biol. Chem. 271:1613-1620(1996).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 655-737, AND VARIANTS AD1 GLY-717;
RP   ILE-717 AND PHE-717.
RX   PubMed=8476439; DOI=10.1006/bbrc.1993.1386;
RA   Denman R.B., Rosenzcwaig R., Miller D.L.;
RT   "A system for studying the effect(s) of familial Alzheimer disease
RT   mutations on the processing of the beta-amyloid peptide precursor.";
RL   Biochem. Biophys. Res. Commun. 192:96-103(1993).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 656-737.
RX   PubMed=2675837; DOI=10.1016/0006-291X(89)91112-1;
RA   Johnstone E.M., Chaney M.O., Moore R.E., Ward K.E., Norris F.H.,
RA   Little S.P.;
RT   "Alzheimer's disease amyloid peptide is encoded by two exons and shows
RT   similarity to soybean trypsin inhibitor.";
RL   Biochem. Biophys. Res. Commun. 163:1248-1255(1989).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 672-723, AND VARIANT AD1 ASN-678.
RX   PubMed=15201367; DOI=10.1136/jnnp.2003.010611;
RA   Wakutani Y., Watanabe K., Adachi Y., Wada-Isoe K., Urakami K.,
RA   Ninomiya H., Saido T.C., Hashimoto T., Iwatsubo T., Nakashima K.;
RT   "Novel amyloid precursor protein gene missense mutation (D678N) in
RT   probable familial Alzheimer's disease.";
RL   J. Neurol. Neurosurg. Psych. 75:1039-1042(2004).
RN   [26]
RP   PROTEIN SEQUENCE OF 672-713.
RC   TISSUE=Blood vessel;
RX   PubMed=8248178; DOI=10.1073/pnas.90.22.10836;
RA   Roher A.E., Lowenson J.D., Clarke S., Woods A.S., Cotter R.J.,
RA   Gowing E., Ball M.J.;
RT   "Beta-amyloid-(1-42) is a major component of cerebrovascular amyloid
RT   deposits: implications for the pathology of Alzheimer disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10836-10840(1993).
RN   [27]
RP   PROTEIN SEQUENCE OF 672-704, AND TISSUE SPECIFICITY.
RX   PubMed=1406936; DOI=10.1038/359325a0;
RA   Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D.,
RA   Sinha S., Schlossmacher M., Whaley J., Swindlehurst C.;
RT   "Isolation and quantification of soluble Alzheimer's beta-peptide from
RT   biological fluids.";
RL   Nature 359:325-327(1992).
RN   [28]
RP   PROTEIN SEQUENCE OF 672-701 AND 707-713.
RX   PubMed=8109908; DOI=10.1002/ana.410350223;
RA   Wisniewski T., Lalowski M., Levy E., Marques M.R.F., Frangione B.;
RT   "The amino acid sequence of neuritic plaque amyloid from a familial
RT   Alzheimer's disease patient.";
RL   Ann. Neurol. 35:245-246(1994).
RN   [29]
RP   PROTEIN SEQUENCE OF 672-701.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=8229004; DOI=10.1111/j.1471-4159.1993.tb09841.x;
RA   Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., Schenk D.B.;
RT   "Characterization of beta-amyloid peptide from human cerebrospinal
RT   fluid.";
RL   J. Neurochem. 61:1965-1968(1993).
RN   [30]
RP   PROTEIN SEQUENCE OF 672-681.
RC   TISSUE=Brain cortex;
RX   PubMed=3312495; DOI=10.1111/j.1471-4159.1987.tb01005.x;
RA   Pardridge W.M., Vinters H.V., Yang J., Eisenberg J., Choi T.B.,
RA   Tourtellotte W.W., Huebner V., Shively J.E.;
RT   "Amyloid angiopathy of Alzheimer's disease: amino acid composition and
RT   partial sequence of a 4,200-dalton peptide isolated from cortical
RT   microvessels.";
RL   J. Neurochem. 49:1394-1401(1987).
RN   [31]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 674-770.
RC   TISSUE=Brain;
RX   PubMed=3810169; DOI=10.1126/science.3810169;
RA   Goldgaber D., Lerman M.I., McBride O.W., Saffiotti U., Gajdusek D.C.;
RT   "Characterization and chromosomal localization of a cDNA encoding
RT   brain amyloid of Alzheimer's disease.";
RL   Science 235:877-880(1987).
RN   [32]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 674-703.
RC   TISSUE=Fetal brain;
RX   PubMed=2949367; DOI=10.1126/science.2949367;
RA   Tanzi R.E., Gusella J.F., Watkins P.C., Bruns G.A.,
RA   St George-Hyslop P.H., Van Keuren M.L., Patterson D., Pagan S.,
RA   Kurnit D.M., Neve R.L.;
RT   "Amyloid beta protein gene: cDNA, mRNA distribution, and genetic
RT   linkage near the Alzheimer locus.";
RL   Science 235:880-884(1987).
RN   [33]
RP   PROTEIN SEQUENCE OF 609-713, AND GLYCOSYLATION AT SER-614; SER-623;
RP   SER-628; SER-679 AND SER-697.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=22576872; DOI=10.1002/jms.2987;
RA   Brinkmalm G., Portelius E., Ohrfelt A., Mattsson N., Persson R.,
RA   Gustavsson M.K., Vite C.H., Gobom J., Mansson J.E., Nilsson J.,
RA   Halim A., Larson G., Ruetschi U., Zetterberg H., Blennow K.,
RA   Brinkmalm A.;
RT   "An online nano-LC-ESI-FTICR-MS method for comprehensive
RT   characterization of endogenous fragments from amyloid beta and amyloid
RT   precursor protein in human and cat cerebrospinal fluid.";
RL   J. Mass Spectrom. 47:591-603(2012).
RN   [34]
RP   PROTEIN SEQUENCE OF 691-698, AND CLEAVAGE BY THETA-SECRETASE.
RX   PubMed=16816112; DOI=10.1096/fj.05-5632com;
RA   Sun X., He G., Song W.;
RT   "BACE2, as a novel APP theta-secretase, is not responsible for the
RT   pathogenesis of Alzheimer's disease in Down syndrome.";
RL   FASEB J. 20:1369-1376(2006).
RN   [35]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP751).
RC   TISSUE=Brain;
RX   PubMed=2569763; DOI=10.1126/science.2569763;
RA   de Sauvage F., Octave J.-N.;
RT   "A novel mRNA of the A4 amyloid precursor gene coding for a possibly
RT   secreted protein.";
RL   Science 245:651-653(1989).
RN   [36]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   TISSUE=Brain;
RX   PubMed=3035574; DOI=10.1073/pnas.84.12.4190;
RA   Robakis N.K., Ramakrishna N., Wolfe G., Wisniewski H.M.;
RT   "Molecular cloning and characterization of a cDNA encoding the
RT   cerebrovascular and the neuritic plaque amyloid peptides.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4190-4194(1987).
RN   [37]
RP   CHARACTERIZATION OF L-APP733, AND MUTAGENESIS OF SER-656.
RX   PubMed=7737970; DOI=10.1074/jbc.270.18.10388;
RA   Pangalos M.N., Efthimiopoulos S., Shioi J., Robakis N.K.;
RT   "The chondroitin sulfate attachment site of appican is formed by
RT   splicing out exon 15 of the amyloid precursor gene.";
RL   J. Biol. Chem. 270:10388-10391(1995).
RN   [38]
RP   FUNCTION OF BETA-AMYLOID PEPTIDE AS LIPID PEROXIDATION INHIBITOR, AND
RP   MUTAGENESIS OF MET-706.
RX   PubMed=9168929; DOI=10.1006/bbrc.1997.6547;
RA   Walter M.F., Mason P.E., Mason R.P.;
RT   "Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid
RT   peroxidation as a result of its membrane interactions.";
RL   Biochem. Biophys. Res. Commun. 233:760-764(1997).
RN   [39]
RP   REVIEW ON FUNCTION OF BETA-AMYLOID AS ANTIOXIDANT.
RX   PubMed=11775062; DOI=10.1023/A:1012629603390;
RA   Kontush A.;
RT   "Alzheimer's amyloid-beta as a preventive antioxidant for brain
RT   lipoproteins.";
RL   Cell. Mol. Neurobiol. 21:299-315(2001).
RN   [40]
RP   IDENTITY OF APP WITH NEXIN-II.
RX   PubMed=2506449; DOI=10.1038/341144a0;
RA   Oltersdorf T., Fritz L.C., Schenk D.B., Lieberburg I.,
RA   Johnson-Wood K.L., Beattie E.C., Ward P.J., Blacher R.W., Dovey H.F.,
RA   Sinha S.;
RT   "The secreted form of the Alzheimer's amyloid precursor protein with
RT   the Kunitz domain is protease nexin-II.";
RL   Nature 341:144-147(1989).
RN   [41]
RP   PROTEASE-SPECIFICITY OF INHIBITOR DOMAIN.
RX   PubMed=1969731; DOI=10.1016/0006-291X(90)92084-D;
RA   Kido H., Fukutomi A., Schilling J., Wang Y., Cordell B., Katunuma N.;
RT   "Protease-specificity of Kunitz inhibitor domain of Alzheimer's
RT   disease amyloid protein precursor.";
RL   Biochem. Biophys. Res. Commun. 167:716-721(1990).
RN   [42]
RP   EXTRACELLULAR ZINC-BINDING DOMAIN.
RX   PubMed=8344894;
RA   Bush A.I., Multhaup G., Moir R.D., Williamson T.G., Small D.H.,
RA   Rumble B., Pollwein P., Beyreuther K., Masters C.L.;
RT   "A novel zinc(II) binding site modulates the function of the beta A4
RT   amyloid protein precursor of Alzheimer's disease.";
RL   J. Biol. Chem. 268:16109-16112(1993).
RN   [43]
RP   INTERACTION WITH G(O).
RX   PubMed=8446172; DOI=10.1038/362075a0;
RA   Nishimoto I., Okamoto T., Matsuura Y., Takahashi S., Okamoto T.,
RA   Murayama Y., Ogata E.;
RT   "Alzheimer amyloid protein precursor complexes with brain GTP-binding
RT   protein G(o).";
RL   Nature 362:75-79(1993).
RN   [44]
RP   EXTRACELLULAR COPPER-BINDING DOMAIN, AND MUTAGENESIS OF HIS-137;
RP   MET-141; CYS-144; HIS-147 AND HIS-151.
RX   PubMed=7913895; DOI=10.1016/0014-5793(94)00658-X;
RA   Hesse L., Beher D., Masters C.L., Multhaup G.;
RT   "The beta A4 amyloid precursor protein binding to copper.";
RL   FEBS Lett. 349:109-116(1994).
RN   [45]
RP   N-TERMINAL HEPARIN-BINDING DOMAIN, AND MUTAGENESIS OF 99-LYS--ARG-102.
RX   PubMed=8158260;
RA   Small D.H., Nurcombe V., Reed G., Clarris H., Moir R., Beyreuther K.,
RA   Masters C.L.;
RT   "A heparin-binding domain in the amyloid protein precursor of
RT   Alzheimer's disease is involved in the regulation of neurite
RT   outgrowth.";
RL   J. Neurosci. 14:2117-2127(1994).
RN   [46]
RP   MUTAGENESIS OF VAL-717.
RX   PubMed=8886002; DOI=10.1006/bbrc.1996.1577;
RA   Maruyama K., Tomita T., Shinozaki K., Kume H., Asada H., Saido T.C.,
RA   Ishiura S., Iwatsubo T., Obata K.;
RT   "Familial Alzheimer's disease-linked mutations at Val717 of amyloid
RT   precursor protein are specific for the increased secretion of A beta
RT   42(43).";
RL   Biochem. Biophys. Res. Commun. 227:730-735(1996).
RN   [47]
RP   INTERACTION WITH APP-BP1.
RX   PubMed=8626687; DOI=10.1074/jbc.271.19.11339;
RA   Chow N., Korenberg J.R., Chen X.-N., Neve R.L.;
RT   "APP-BP1, a novel protein that binds to the carboxyl-terminal region
RT   of the amyloid precursor protein.";
RL   J. Biol. Chem. 271:11339-11346(1996).
RN   [48]
RP   INTERACTION WITH APBA1 AND APBB1, AND MUTAGENESIS OF TYR-728; TYR-757;
RP   ASN-759 AND TYR-762.
RX   PubMed=8887653;
RA   Borg J.-P., Ooi J., Levy E., Margolis B.;
RT   "The phosphotyrosine interaction domains of X11 and FE65 bind to
RT   distinct sites on the YENPTY motif of amyloid precursor protein.";
RL   Mol. Cell. Biol. 16:6229-6241(1996).
RN   [49]
RP   INTERACTION WITH APBB2.
RX   PubMed=8855266; DOI=10.1073/pnas.93.20.10832;
RA   Guenette S.Y., Chen J., Jondro P.D., Tanzi R.E.;
RT   "Association of a novel human FE65-like protein with the cytoplasmic
RT   domain of the beta-amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:10832-10837(1996).
RN   [50]
RP   HEPARIN-BINDING DOMAINS.
RX   PubMed=9357988; DOI=10.1016/S0014-5793(97)01146-0;
RA   Mok S.S., Sberna G., Heffernan D., Cappai R., Galatis D.,
RA   Clarris H.J., Sawyer W.H., Beyreuther K., Masters C.L., Small D.H.;
RT   "Expression and analysis of heparin-binding regions of the amyloid
RT   precursor protein of Alzheimer's disease.";
RL   FEBS Lett. 415:303-307(1997).
RN   [51]
RP   INTERACTION OF BETA-AMYLOID PEPTIDE WITH HADH2.
RC   TISSUE=Brain;
RX   PubMed=9338779; DOI=10.1038/39522;
RA   Yan S.D., Fu J., Soto C., Chen X., Zhu H., Al-Mohanna F.,
RA   Collinson K., Zhu A., Stern E., Saido T., Tohyama M., Ogawa S.,
RA   Roher A., Stern D.;
RT   "An intracellular protein that binds amyloid-beta peptide and mediates
RT   neurotoxicity in Alzheimer's disease.";
RL   Nature 389:689-695(1997).
RN   [52]
RP   INTERACTION WITH APPBP2, AND MUTAGENESIS OF TYR-728.
RX   PubMed=9843960; DOI=10.1073/pnas.95.25.14745;
RA   Zheng P., Eastman J., Vande Pol S., Pimplikar S.W.;
RT   "PAT1, a microtubule-interacting protein, recognizes the basolateral
RT   sorting signal of amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:14745-14750(1998).
RN   [53]
RP   BETA-AMYLOID ZINC-BINDING, AND MUTAGENESIS OF ARG-676; TYR-681 AND
RP   HIS-684.
RX   PubMed=10413512; DOI=10.1021/bi990205o;
RA   Liu S.T., Howlett G., Barrow C.J.;
RT   "Histidine-13 is a crucial residue in the zinc ion-induced aggregation
RT   of the A beta peptide of Alzheimer's disease.";
RL   Biochemistry 38:9373-9378(1999).
RN   [54]
RP   IMPORTANCE OF MET-706 IN FREE RADICAL OXIDATIVE STRESS, AND
RP   MUTAGENESIS OF MET-706.
RX   PubMed=10535332; DOI=10.1016/S0361-9230(99)00093-3;
RA   Varadarajan S., Yatin S., Kanski J., Jahanshahi F., Butterfield D.A.;
RT   "Methionine residue 35 is important in amyloid beta-peptide-associated
RT   free radical oxidative stress.";
RL   Brain Res. Bull. 50:133-141(1999).
RN   [55]
RP   INTERACTION WITH APBA2.
RX   PubMed=9890987; DOI=10.1074/jbc.274.4.2243;
RA   Tomita S., Ozaki T., Taru H., Oguchi S., Takeda S., Yagi Y.,
RA   Sakiyama S., Kirino Y., Suzuki T.;
RT   "Interaction of a neuron-specific protein containing PDZ domains with
RT   Alzheimer's amyloid precursor protein.";
RL   J. Biol. Chem. 274:2243-2254(1999).
RN   [56]
RP   ENDOCYTOSIS SIGNAL, AND MUTAGENESIS OF TYR-728; GLY-756; TYR-757;
RP   ASN-759; PRO-760 AND TYR-762.
RX   PubMed=10383380; DOI=10.1074/jbc.274.27.18851;
RA   Perez R.G., Soriano S., Hayes J.D., Ostaszewski B., Xia W.,
RA   Selkoe D.J., Chen X., Stokin G.B., Koo E.H.;
RT   "Mutagenesis identifies new signals for beta-amyloid precursor protein
RT   endocytosis, turnover, and the generation of secreted fragments,
RT   including Abeta42.";
RL   J. Biol. Chem. 274:18851-18856(1999).
RN   [57]
RP   IMPORTANCE OF CYS-144 IN COPPER REDUCTION, AND MUTAGENESIS OF CYS-144
RP   AND 147-HIS--HIS-149.
RX   PubMed=10461923; DOI=10.1046/j.1471-4159.1999.0731288.x;
RA   Ruiz F.H., Gonzalez M., Bodini M., Opazo C., Inestrosa N.C.;
RT   "Cysteine 144 is a key residue in the copper reduction by the beta-
RT   amyloid precursor protein.";
RL   J. Neurochem. 73:1288-1292(1999).
RN   [58]
RP   INTERACTION OF BETA-AMYLOID WITH APOE.
RX   PubMed=10816430; DOI=10.1042/0264-6021:3480359;
RA   Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B.,
RA   Zlokovic B., Smith J.D., Ladu M.J., Rostagno A., Frangione B.,
RA   Ghiso J.;
RT   "Lipidation of apolipoprotein E influences its isoform-specific
RT   interaction with Alzheimer's amyloid beta peptides.";
RL   Biochem. J. 348:359-365(2000).
RN   [59]
RP   INTERACTION OF BETA-APP42 WITH CHRNA7.
RX   PubMed=10681545; DOI=10.1074/jbc.275.8.5626;
RA   Wang H.-Y., Lee D.H.S., D'Andrea M.R., Peterson P.A., Shank R.P.,
RA   Reitz A.B.;
RT   "Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor
RT   with high affinity. Implications for Alzheimer's disease pathology.";
RL   J. Biol. Chem. 275:5626-5632(2000).
RN   [60]
RP   IDENTIFICATION OF GAMMA-CTFS BY MASS SPECTROMETRY, AND MUTAGENESIS OF
RP   ASP-739.
RX   PubMed=12214090;
RA   Passer B., Pellegrini L., Russo C., Siegel R.M., Lenardo M.J.,
RA   Schettini G., Bachmann M., Tabaton M., D'Adamio L.;
RT   "Generation of an apoptotic intracellular peptide by gamma-secretase
RT   cleavage of Alzheimer's amyloid beta protein precursor.";
RL   J. Alzheimers Dis. 2:289-301(2000).
RN   [61]
RP   INTERACTION WITH FPRL1.
RX   PubMed=11689470; DOI=10.1096/fj.01-0251com;
RA   Yazawa H., Yu Z.-X., Takeda K., Le Y., Gong W., Ferrans V.J.,
RA   Oppenheim J.J., Li C.C.H., Wang J.M.;
RT   "Beta amyloid peptide (Abeta42) is internalized via the G-protein-
RT   coupled receptor FPRL1 and forms fibrillar aggregates in
RT   macrophages.";
RL   FASEB J. 15:2454-2462(2001).
RN   [62]
RP   INTERACTION WITH BBP.
RX   PubMed=11278849; DOI=10.1074/jbc.M011161200;
RA   Kajkowski E.M., Lo C.F., Ning X., Walker S., Sofia H.J., Wang W.,
RA   Edris W., Chanda P., Wagner E., Vile S., Ryan K., McHendry-Rinde B.,
RA   Smith S.C., Wood A., Rhodes K.J., Kennedy J.D., Bard J.,
RA   Jacobsen J.S., Ozenberger B.A.;
RT   "Beta-amyloid peptide-induced apoptosis regulated by a novel protein
RT   containing a G protein activation module.";
RL   J. Biol. Chem. 276:18748-18756(2001).
RN   [63]
RP   BETA-AMYLOID COPPER AND ZINC-BINDING.
RX   PubMed=11274207; DOI=10.1074/jbc.M100175200;
RA   Curtain C.C., Ali F., Volitakis I., Cherny R.A., Norton R.S.,
RA   Beyreuther K., Barrow C.J., Masters C.L., Bush A.I., Barnham K.J.;
RT   "Alzheimer's disease amyloid-beta binds copper and zinc to generate an
RT   allosterically ordered structure containing superoxide dismutase-like
RT   subunits.";
RL   J. Biol. Chem. 276:20466-20473(2001).
RN   [64]
RP   SUBUNIT.
RX   PubMed=11438549; DOI=10.1074/jbc.M105410200;
RA   Scheuermann S., Hambsch B., Hesse L., Stumm J., Schmidt C., Beher D.,
RA   Bayer T.A., Beyreuther K., Multhaup G.;
RT   "Homodimerization of amyloid precursor protein and its implication in
RT   the amyloidogenic pathway of Alzheimer's disease.";
RL   J. Biol. Chem. 276:33923-33929(2001).
RN   [65]
RP   INTERACTION WITH APBB1, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11544248; DOI=10.1074/jbc.C100447200;
RA   Kimberly W.T., Zheng J.B., Guenette S.Y., Selkoe D.J.;
RT   "The intracellular domain of the beta-amyloid precursor protein is
RT   stabilized by Fe65 and translocates to the nucleus in a notch-like
RT   manner.";
RL   J. Biol. Chem. 276:40288-40292(2001).
RN   [66]
RP   INTERACTION WITH FBLN1.
RX   PubMed=11238726; DOI=10.1046/j.1471-4159.2001.00144.x;
RA   Ohsawa I., Takamura C., Kohsaka S.;
RT   "Fibulin-1 binds the amino-terminal head of beta-amyloid precursor
RT   protein and modulates its physiological function.";
RL   J. Neurochem. 76:1411-1420(2001).
RN   [67]
RP   INTERACTION WITH MAPT, AND FUNCTION.
RX   PubMed=11943163; DOI=10.1016/S0014-5793(02)02376-1;
RA   Rank K.B., Pauley A.M., Bhattacharya K., Wang Z., Evans D.B.,
RA   Fleck T.J., Johnston J.A., Sharma S.K.;
RT   "Direct interaction of soluble human recombinant tau protein with
RT   Abeta 1-42 results in tau aggregation and hyperphosphorylation by tau
RT   protein kinase II.";
RL   FEBS Lett. 514:263-268(2002).
RN   [68]
RP   INTERACTION WITH MAPK8IP1, AND MUTAGENESIS OF TYR-757.
RX   PubMed=11724784; DOI=10.1074/jbc.M108357200;
RA   Scheinfeld M.H., Roncarati R., Vito P., Lopez P.A., Abdallah M.,
RA   D'Adamio L.;
RT   "Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the
RT   cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein
RT   (APP).";
RL   J. Biol. Chem. 277:3767-3775(2002).
RN   [69]
RP   COPPER-MEDIATED LIPID PEROXIDATION, AND MUTAGENESIS OF HIS-147 AND
RP   HIS-151.
RX   PubMed=11784781;
RA   White A.R., Multhaup G., Galatis D., McKinstry W.J., Parker M.W.,
RA   Pipkorn R., Beyreuther K., Masters C.L., Cappai R.;
RT   "Contrasting species-dependent modulation of copper-mediated
RT   neurotoxicity by the Alzheimer's disease amyloid precursor protein.";
RL   J. Neurosci. 22:365-376(2002).
RN   [70]
RP   REVIEW ON ZINC-BINDING.
RX   PubMed=12032279; DOI=10.1073/pnas.122249699;
RA   Bush A.I., Tanzi R.E.;
RT   "The galvanization of beta-amyloid in Alzheimer's disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:7317-7319(2002).
RN   [71]
RP   SUBCELLULAR LOCATION, AND ASSOCIATION OF AMYLOID FIBRILS WITH GCP1.
RX   PubMed=15084524; DOI=10.1096/fj.03-1040fje;
RA   Watanabe N., Araki W., Chui D.H., Makifuchi T., Ihara Y., Tabira T.;
RT   "Glypican-1 as an Abeta binding HSPG in the human brain: its
RT   localization in DIG domains and possible roles in the pathogenesis of
RT   Alzheimer's disease.";
RL   FASEB J. 18:1013-1015(2004).
RN   [72]
RP   INTERACTION WITH ANKS1B.
RX   PubMed=15347684; DOI=10.1074/jbc.M405329200;
RA   Ghersi E., Noviello C., D'Adamio L.;
RT   "Amyloid-beta protein precursor (AbetaPP) intracellular domain-
RT   associated protein-1 proteins bind to AbetaPP and modulate its
RT   processing in an isoform-specific manner.";
RL   J. Biol. Chem. 279:49105-49112(2004).
RN   [73]
RP   PHOSPHORYLATION AT THR-743.
RX   PubMed=8131745;
RA   Suzuki T., Oishi M., Marshak D.R., Czernik A.J., Nairn A.C.,
RA   Greengard P.;
RT   "Cell cycle-dependent regulation of the phosphorylation and metabolism
RT   of the Alzheimer amyloid precursor protein.";
RL   EMBO J. 13:1114-1122(1994).
RN   [74]
RP   PHOSPHORYLATION AT SER-198 AND SER-206 BY CASEIN KINASES, AND
RP   MUTAGENESIS OF SER-198 AND SER-206.
RX   PubMed=8999878; DOI=10.1074/jbc.272.3.1896;
RA   Walter J., Capell A., Hung A.Y., Langen H., Schnoelzer M.,
RA   Thinakaran G., Sisodia S.S., Selkoe D.J., Haass C.;
RT   "Ectodomain phosphorylation of beta-amyloid precursor protein at two
RT   distinct cellular locations.";
RL   J. Biol. Chem. 272:1896-1903(1997).
RN   [75]
RP   COPPER-BINDING, AND DISULFIDE BOND FORMATION.
RX   PubMed=9585534; DOI=10.1021/bi980022m;
RA   Multhaup G., Ruppert T., Schlicksupp A., Hesse L., Bill E.,
RA   Pipkorn R., Masters C.L., Beyreuther K.;
RT   "Copper-binding amyloid precursor protein undergoes a site-specific
RT   fragmentation in the reduction of hydrogen peroxide.";
RL   Biochemistry 37:7224-7230(1998).
RN   [76]
RP   CLEAVAGE BY CASPASES, AND MUTAGENESIS OF ASP-739.
RX   PubMed=10319819; DOI=10.1016/S0092-8674(00)80748-5;
RA   Gervais F.G., Xu D., Robertson G.S., Vaillancourt J.P., Zhu Y.,
RA   Huang J., LeBlanc A., Smith D., Rigby M., Shearman M.S., Clarke E.E.,
RA   Zheng H., van der Ploeg L.H.T., Ruffolo S.C., Thornberry N.A.,
RA   Xanthoudakis S., Zamboni R.J., Roy S., Nicholson D.W.;
RT   "Involvement of caspases in proteolytic cleavage of Alzheimer's
RT   amyloid-beta precursor protein and amyloidogenic A beta peptide
RT   formation.";
RL   Cell 97:395-406(1999).
RN   [77]
RP   PHOSPHORYLATION, AND MUTAGENESIS OF THR-743.
RX   PubMed=10341243;
RA   Ando K., Oishi M., Takeda S., Iijima K., Isohara T., Nairn A.C.,
RA   Kirino Y., Greengard P., Suzuki T.;
RT   "Role of phosphorylation of Alzheimer's amyloid precursor protein
RT   during neuronal differentiation.";
RL   J. Neurosci. 19:4421-4427(1999).
RN   [78]
RP   CHARACTERIZATION OF CASEIN KINASE PHOSPHORYLATION, AND MUTAGENESIS OF
RP   SER-198 AND SER-206.
RX   PubMed=10806211; DOI=10.1074/jbc.M002850200;
RA   Walter J., Schindzielorz A., Hartung B., Haass C.;
RT   "Phosphorylation of the beta-amyloid precursor protein at the cell
RT   surface by ectocasein kinases 1 and 2.";
RL   J. Biol. Chem. 275:23523-23529(2000).
RN   [79]
RP   CLEAVAGE BY CASPASES, AND MUTAGENESIS OF ASP-739.
RX   PubMed=10742146; DOI=10.1038/74656;
RA   Lu D.C., Rabizadeh S., Chandra S., Shayya R.F., Ellerby L.M., Ye X.,
RA   Salvesen G.S., Koo E.H., Bredesen D.E.;
RT   "A second cytotoxic proteolytic peptide derived from amyloid beta-
RT   protein precursor.";
RL   Nat. Med. 6:397-404(2000).
RN   [80]
RP   PHOSPHORYLATION, INTERACTION WITH APBB1, AND MUTAGENESIS OF THR-743.
RX   PubMed=11517218; DOI=10.1074/jbc.M104059200;
RA   Ando K., Iijima K., Elliott J.I., Kirino Y., Suzuki T.;
RT   "Phosphorylation-dependent regulation of the interaction of amyloid
RT   precursor protein with Fe65 affects the production of beta-amyloid.";
RL   J. Biol. Chem. 276:40353-40361(2001).
RN   [81]
RP   PHOSPHORYLATION BY MAPK10, AND MUTAGENESIS OF THR-743.
RX   PubMed=11146006; DOI=10.1046/j.1471-4159.2001.00102.x;
RA   Standen C.L., Brownlees J., Grierson A.J., Kesavapany S., Lau K.-F.,
RA   McLoughlin D.M., Miller C.C.J.;
RT   "Phosphorylation of thr(668) in the cytoplasmic domain of the
RT   Alzheimer's disease amyloid precursor protein by stress-activated
RT   protein kinase 1b (Jun N-terminal kinase-3).";
RL   J. Neurochem. 76:316-320(2001).
RN   [82]
RP   CLEAVAGE AT LEU-720.
RX   PubMed=11851430; DOI=10.1021/bi015794o;
RA   Weidemann A., Eggert S., Reinhard F.B.M., Vogel M., Paliga K.,
RA   Baier G., Masters C.L., Beyreuther K., Evin G.;
RT   "A novel epsilon-cleavage within the transmembrane domain of the
RT   Alzheimer amyloid precursor protein demonstrates homology with Notch
RT   processing.";
RL   Biochemistry 41:2825-2835(2002).
RN   [83]
RP   PHOSPHORYLATION AT TYR-757, INTERACTION WITH SHC1, AND MUTAGENESIS OF
RP   THR-743 AND TYR-757.
RX   PubMed=11877420; DOI=10.1074/jbc.M110286200;
RA   Tarr P.E., Roncarati R., Pelicci G., Pelicci P.G., D'Adamio L.;
RT   "Tyrosine phosphorylation of the beta-amyloid precursor protein
RT   cytoplasmic tail promotes interaction with Shc.";
RL   J. Biol. Chem. 277:16798-16804(2002).
RN   [84]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-542.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [85]
RP   SIGNAL SEQUENCE CLEAVAGE SITE, AND TOPOLOGY.
RX   PubMed=2900137;
RA   Dyrks T., Weidemann A., Multhaup G., Salbaum J.M., Lemaire H.-G.,
RA   Kang J., Mueller-Hill B., Masters C.L., Beyreuther K.;
RT   "Identification, transmembrane orientation and biogenesis of the
RT   amyloid A4 precursor of Alzheimer's disease.";
RL   EMBO J. 7:949-957(1988).
RN   [86]
RP   REVIEW.
RX   PubMed=12142279; DOI=10.1146/annurev.cellbio.18.020402.142302;
RA   Annaert W., De Strooper B.;
RT   "A cell biological perspective on Alzheimer's disease.";
RL   Annu. Rev. Cell Dev. Biol. 18:25-51(2002).
RN   [87]
RP   INTERACTION WITH SORL1, AND SUBCELLULAR LOCATION.
RX   PubMed=16174740; DOI=10.1073/pnas.0503689102;
RA   Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R.,
RA   Behlke J., von Arnim C.A., Breiderhoff T., Jansen P., Wu X.,
RA   Bales K.R., Cappai R., Masters C.L., Gliemann J., Mufson E.J.,
RA   Hyman B.T., Paul S.M., Nykjaer A., Willnow T.E.;
RT   "Neuronal sorting protein-related receptor sorLA/LR11 regulates
RT   processing of the amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:13461-13466(2005).
RN   [88]
RP   INTERACTION WITH APBB1.
RX   PubMed=18468999; DOI=10.1074/jbc.M801827200;
RA   Nakaya T., Kawai T., Suzuki T.;
RT   "Regulation of FE65 nuclear translocation and function by amyloid
RT   beta-protein precursor in osmotically stressed cells.";
RL   J. Biol. Chem. 283:19119-19131(2008).
RN   [89]
RP   INTERACTION WITH ITM2C.
RX   PubMed=19366692; DOI=10.1074/jbc.M109.006403;
RA   Matsuda S., Matsuda Y., D'Adamio L.;
RT   "BRI3 inhibits amyloid precursor protein processing in a
RT   mechanistically distinct manner from its homologue dementia gene
RT   BRI2.";
RL   J. Biol. Chem. 284:15815-15825(2009).
RN   [90]
RP   FUNCTION, CLEAVAGE, AND INTERACTION WITH TNFRSF21.
RX   PubMed=19225519; DOI=10.1038/nature07767;
RA   Nikolaev A., McLaughlin T., O'Leary D.D.M., Tessier-Lavigne M.;
RT   "APP binds DR6 to trigger axon pruning and neuron death via distinct
RT   caspases.";
RL   Nature 457:981-989(2009).
RN   [91]
RP   FUNCTION, AND INTERACTION WITH AGER.
RX   PubMed=19901339; DOI=10.1073/pnas.0905686106;
RA   Takuma K., Fang F., Zhang W., Yan S., Fukuzaki E., Du H., Sosunov A.,
RA   McKhann G., Funatsu Y., Nakamichi N., Nagai T., Mizoguchi H., Ibi D.,
RA   Hori O., Ogawa S., Stern D.M., Yamada K., Yan S.S.;
RT   "RAGE-mediated signaling contributes to intraneuronal transport of
RT   amyloid-{beta} and neuronal dysfunction.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:20021-20026(2009).
RN   [92]
RP   INTERACTION WITH GSAP.
RX   PubMed=20811458; DOI=10.1038/nature09325;
RA   He G., Luo W., Li P., Remmers C., Netzer W.J., Hendrick J.,
RA   Bettayeb K., Flajolet M., Gorelick F., Wennogle L.P., Greengard P.;
RT   "Gamma-secretase activating protein is a therapeutic target for
RT   Alzheimer's disease.";
RL   Nature 467:95-98(2010).
RN   [93]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [94]
RP   GLYCOSYLATION AT THR-633; THR-651; THR-652; SER-656; THR-663 AND
RP   SER-667 PROTEOLYTIC PROCESSING, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=21712440; DOI=10.1073/pnas.1102664108;
RA   Halim A., Brinkmalm G., Ruetschi U., Westman-Brinkmalm A.,
RA   Portelius E., Zetterberg H., Blennow K., Larson G., Nilsson J.;
RT   "Site-specific characterization of threonine, serine, and tyrosine
RT   glycosylations of amyloid precursor protein/amyloid beta-peptides in
RT   human cerebrospinal fluid.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:11848-11853(2011).
RN   [95]
RP   INTERACTION WITH S100A9.
RX   PubMed=22457725; DOI=10.1371/journal.pone.0032953;
RA   Zhang C., Liu Y., Gilthorpe J., van der Maarel J.R.;
RT   "MRP14 (S100A9) protein interacts with Alzheimer beta-amyloid peptide
RT   and induces its fibrillization.";
RL   PLoS ONE 7:E32953-E32953(2012).
RN   [96]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 287-344.
RX   PubMed=2125487; DOI=10.1021/bi00495a002;
RA   Hynes T.R., Randal M., Kennedy L.A., Eigenbrot C., Kossiakof A.A.;
RT   "X-ray crystal structure of the protease inhibitor domain of
RT   Alzheimer's amyloid beta-protein precursor.";
RL   Biochemistry 29:10018-10022(1990).
RN   [97]
RP   STRUCTURE BY NMR OF 289-344.
RX   PubMed=1718421; DOI=10.1021/bi00107a015;
RA   Heald S.L., Tilton R.F. Jr., Hammond L.S., Lee A., Bayney R.M.,
RA   Kamarck M.E., Ramabhadran T.V., Dreyer R.N., Davis G., Unterbeck A.,
RA   Tamburini P.P.;
RT   "Sequential NMR resonance assignment and structure determination of
RT   the Kunitz-type inhibitor domain of the Alzheimer's beta-amyloid
RT   precursor protein.";
RL   Biochemistry 30:10467-10478(1991).
RN   [98]
RP   STRUCTURE BY NMR OF 672-699.
RX   PubMed=7516706; DOI=10.1021/bi00191a006;
RA   Talafous J., Marcinowski K.J., Klopman G., Zagorski M.G.;
RT   "Solution structure of residues 1-28 of the amyloid beta-peptide.";
RL   Biochemistry 33:7788-7796(1994).
RN   [99]
RP   STRUCTURE BY NMR OF 672-711.
RX   PubMed=7588758; DOI=10.1111/j.1432-1033.1995.293_1.x;
RA   Sticht H., Bayer P., Willbold D., Dames S., Hilbich C., Beyreuther K.,
RA   Frank R.W., Rosch P.;
RT   "Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease.";
RL   Eur. J. Biochem. 233:293-298(1995).
RN   [100]
RP   STRUCTURE BY NMR OF 696-706.
RX   PubMed=8973180; DOI=10.1021/bi961598j;
RA   Kohno T., Kobayashi K., Maeda T., Sato K., Takashima A.;
RT   "Three-dimensional structures of the amyloid beta peptide (25-35) in
RT   membrane-mimicking environment.";
RL   Biochemistry 35:16094-16104(1996).
RN   [101]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF KUNITZ DOMAIN IN COMPLEX WITH
RP   CHYMOTRYPSIN; TRYPSIN AND BASIC PANCREATIC TRYPSIN INHIBITOR.
RX   PubMed=9300481; DOI=10.1002/pro.5560060902;
RA   Scheidig A.J., Hynes T.R., Pelletier L.A., Wells J.A.,
RA   Kossiakoff A.A.;
RT   "Crystal structures of bovine chymotrypsin and trypsin complexed to
RT   the inhibitor domain of Alzheimer's amyloid beta-protein precursor
RT   (APPI) and basic pancreatic trypsin inhibitor (BPTI): engineering of
RT   inhibitors with altered specificities.";
RL   Protein Sci. 6:1806-1824(1997).
RN   [102]
RP   STRUCTURE BY NMR OF 672-711.
RX   PubMed=9693002; DOI=10.1021/bi972979f;
RA   Coles M., Bicknell W., Watson A.A., Fairlie D.P., Craik D.J.;
RT   "Solution structure of amyloid beta-peptide(1-40) in a water-micelle
RT   environment. Is the membrane-spanning domain where we think it is?";
RL   Biochemistry 37:11064-11077(1998).
RN   [103]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 28-123.
RX   PubMed=10201399; DOI=10.1038/7562;
RA   Rossjohn J., Cappai R., Feil S.C., Henry A., McKinstry W.J.,
RA   Galatis D., Hesse L., Multhaup G., Beyreuther K., Masters C.L.,
RA   Parker M.W.;
RT   "Crystal structure of the N-terminal, growth factor-like domain of
RT   Alzheimer amyloid precursor protein.";
RL   Nat. Struct. Biol. 6:327-331(1999).
RN   [104]
RP   STRUCTURE OF CAA-APP VARIANTS.
RX   PubMed=10821838; DOI=10.1074/jbc.M003154200;
RA   Miravalle L., Tokuda T., Chiarle R., Giaccone G., Bugiani O.,
RA   Tagliavini F., Frangione B., Ghiso J.;
RT   "Substitutions at codon 22 of Alzheimer's Abeta peptide induce diverse
RT   conformational changes and apoptotic effects in human cerebral
RT   endothelial cells.";
RL   J. Biol. Chem. 275:27110-27116(2000).
RN   [105]
RP   STRUCTURE BY NMR OF 681-706.
RX   PubMed=10940221; DOI=10.1006/jsbi.2000.4288;
RA   Zhang S., Iwata K., Lachenmann M.J., Peng J.W., Li S., Stimson E.R.,
RA   Lu Y., Felix A.M., Maggio J.E., Lee J.P.;
RT   "The Alzheimer's peptide a beta adopts a collapsed coil structure in
RT   water.";
RL   J. Struct. Biol. 130:130-141(2000).
RN   [106]
RP   STRUCTURE BY NMR OF 672-699.
RX   PubMed=10940222; DOI=10.1006/jsbi.2000.4267;
RA   Poulsen S.-A., Watson A.A., Craik D.J.;
RT   "Solution structures in aqueous SDS micelles of two amyloid beta
RT   peptides of Abeta(1-28) mutated at the alpha-secretase cleavage
RT   site.";
RL   J. Struct. Biol. 130:142-152(2000).
RN   [107]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 346-551, PARTIAL PROTEIN
RP   SEQUENCE, MUTAGENESIS OF ARG-499 AND LYS-503, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=15304215; DOI=10.1016/j.molcel.2004.06.037;
RA   Wang Y., Ha Y.;
RT   "The X-ray structure of an antiparallel dimer of the human amyloid
RT   precursor protein E2 domain.";
RL   Mol. Cell 15:343-353(2004).
RN   [108]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 672-711 IN COMPLEX WITH IDE.
RX   PubMed=17051221; DOI=10.1038/nature05143;
RA   Shen Y., Joachimiak A., Rosner M.R., Tang W.-J.;
RT   "Structures of human insulin-degrading enzyme reveal a new substrate
RT   recognition mechanism.";
RL   Nature 443:870-874(2006).
RN   [109]
RP   X-RAY CRYSTALLOGRAPHY (0.85 ANGSTROMS) OF 133-189, AND DISULFIDE
RP   BONDS.
RX   PubMed=17909280; DOI=10.1107/S1744309107041139;
RA   Kong G.K., Adams J.J., Cappai R., Parker M.W.;
RT   "Structure of Alzheimer's disease amyloid precursor protein copper-
RT   binding domain at atomic resolution.";
RL   Acta Crystallogr. F 63:819-824(2007).
RN   [110]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 133-189 IN COMPLEXES WITH
RP   COPPER IONS, AND DISULFIDE BONDS.
RX   PubMed=17239395; DOI=10.1016/j.jmb.2006.12.041;
RA   Kong G.K., Adams J.J., Harris H.H., Boas J.F., Curtain C.C.,
RA   Galatis D., Masters C.L., Barnham K.J., McKinstry W.J., Cappai R.,
RA   Parker M.W.;
RT   "Structural studies of the Alzheimer's amyloid precursor protein
RT   copper-binding domain reveal how it binds copper ions.";
RL   J. Mol. Biol. 367:148-161(2007).
RN   [111]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 672-679 IN COMPLEX WITH IGG.
RX   PubMed=17895381; DOI=10.1073/pnas.0705888104;
RA   Gardberg A.S., Dice L.T., Ou S., Rich R.L., Helmbrecht E., Ko J.,
RA   Wetzel R., Myszka D.G., Patterson P.H., Dealwis C.;
RT   "Molecular basis for passive immunotherapy of Alzheimer's disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:15659-15664(2007).
RN   [112]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 672-678 IN COMPLEXES WITH
RP   ANTIBODY FAB FRAGMENTS.
RX   PubMed=19923222; DOI=10.1074/jbc.M109.045187;
RA   Basi G.S., Feinberg H., Oshidari F., Anderson J., Barbour R.,
RA   Baker J., Comery T.A., Diep L., Gill D., Johnson-Wood K., Goel A.,
RA   Grantcharova K., Lee M., Li J., Partridge A., Griswold-Prenner I.,
RA   Piot N., Walker D., Widom A., Pangalos M.N., Seubert P.,
RA   Jacobsen J.S., Schenk D., Weis W.I.;
RT   "Structural correlates of antibodies associated with acute reversal of
RT   amyloid beta-related behavioral deficits in a mouse model of Alzheimer
RT   disease.";
RL   J. Biol. Chem. 285:3417-3427(2010).
RN   [113]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 18-190, PARTIAL PROTEIN
RP   SEQUENCE, SUBUNIT, DISULFIDE BONDS, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=20212142; DOI=10.1073/pnas.0911326107;
RA   Dahms S.O., Hoefgen S., Roeser D., Schlott B., Guhrs K.H., Than M.E.;
RT   "Structure and biochemical analysis of the heparin-induced E1 dimer of
RT   the amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:5381-5386(2010).
RN   [114]
RP   REVIEW ON VARIANTS.
RX   PubMed=1363811; DOI=10.1038/ng0792-233;
RA   Hardy J.;
RT   "Framing beta-amyloid.";
RL   Nat. Genet. 1:233-234(1992).
RN   [115]
RP   VARIANT CAA-APP GLN-693.
RX   PubMed=2111584; DOI=10.1126/science.2111584;
RA   Levy E., Carman M.D., Fernandez-Madrid I.J., Power M.D.,
RA   Lieberburg I., van Duinen S.G., Bots G.T.A.M., Luyendijk W.,
RA   Frangione B.;
RT   "Mutation of the Alzheimer's disease amyloid gene in hereditary
RT   cerebral hemorrhage, Dutch type.";
RL   Science 248:1124-1126(1990).
RN   [116]
RP   VARIANT AD1 ILE-717.
RX   PubMed=1671712; DOI=10.1038/349704a0;
RA   Goate A., Chartier-Harlin M.-C., Mullan M., Brown J., Crawford F.,
RA   Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R.,
RA   Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M.,
RA   Roses A.D., Williamson R., Rossor M., Owen M., Hardy J.;
RT   "Segregation of a missense mutation in the amyloid precursor protein
RT   gene with familial Alzheimer's disease.";
RL   Nature 349:704-706(1991).
RN   [117]
RP   VARIANT AD1 ILE-717.
RX   PubMed=1908231; DOI=10.1016/0006-291X(91)91011-Z;
RA   Yoshioka K., Miki T., Katsuya T., Ogihara T., Sakaki Y.;
RT   "The 717Val-->Ile substitution in amyloid precursor protein is
RT   associated with familial Alzheimer's disease regardless of ethnic
RT   groups.";
RL   Biochem. Biophys. Res. Commun. 178:1141-1146(1991).
RN   [118]
RP   VARIANT AD1 ILE-717.
RX   PubMed=1678058; DOI=10.1016/0140-6736(91)91612-X;
RA   Naruse S., Igarashi S., Kobayashi H., Aoki K., Inuzuka T., Kaneko K.,
RA   Shimizu T., Iihara K., Kojima T., Miyatake T., Tsuji S.;
RT   "Mis-sense mutation Val->Ile in exon 17 of amyloid precursor protein
RT   gene in Japanese familial Alzheimer's disease.";
RL   Lancet 337:978-979(1991).
RN   [119]
RP   VARIANT AD1 GLY-717.
RX   PubMed=1944558; DOI=10.1038/353844a0;
RA   Chartier-Harlin M.-C., Crawford F., Houlden H., Warren A., Hughes D.,
RA   Fidani L., Goate A., Rossor M., Roques P., Hardy J., Mullan M.;
RT   "Early-onset Alzheimer's disease caused by mutations at codon 717 of
RT   the beta-amyloid precursor protein gene.";
RL   Nature 353:844-846(1991).
RN   [120]
RP   VARIANT AD1 PHE-717.
RX   PubMed=1925564; DOI=10.1126/science.1925564;
RA   Murrell J.R., Farlow M., Ghetti B., Benson M.D.;
RT   "A mutation in the amyloid precursor protein associated with
RT   hereditary Alzheimer's disease.";
RL   Science 254:97-99(1991).
RN   [121]
RP   VARIANT AD1 GLY-693.
RX   PubMed=1415269;
RA   Kamino K., Orr H.T., Payami H., Wijsman E.M., Alonso M.E., Pulst S.M.,
RA   Anderson L., O'Dahl S., Nemens E., White J.A., Sadovnick A.D.,
RA   Ball M.J., Kaye J., Warren A., McInnis M.G., Antonarakis S.E.,
RA   Korenberg J.R., Sharma V., Kukull W., Larson E., Heston L.L.,
RA   Martin G.M., Bird T.D., Schellenberg G.D.;
RT   "Linkage and mutational analysis of familial Alzheimer disease
RT   kindreds for the APP gene region.";
RL   Am. J. Hum. Genet. 51:998-1014(1992).
RN   [122]
RP   VARIANT AD1 GLY-692.
RX   PubMed=1303239; DOI=10.1038/ng0692-218;
RA   Hendriks L., van Duijn C.M., Cras P., Cruts M., Van Hul W.,
RA   van Harskamp F., Warren A., McInnis M.G., Antonarakis S.E.,
RA   Martin J.J., Hofman A., Van Broeckhoven C.;
RT   "Presenile dementia and cerebral haemorrhage linked to a mutation at
RT   codon 692 of the beta-amyloid precursor protein gene.";
RL   Nat. Genet. 1:218-221(1992).
RN   [123]
RP   VARIANT AD1 670-ASN-LEU-671.
RX   PubMed=1302033; DOI=10.1038/ng0892-345;
RA   Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B.,
RA   Lannfelt L.;
RT   "A pathogenic mutation for probable Alzheimer's disease in the APP
RT   gene at the N-terminus of beta-amyloid.";
RL   Nat. Genet. 1:345-347(1992).
RN   [124]
RP   VARIANT VAL-713.
RX   PubMed=1307241; DOI=10.1038/ng0792-306;
RA   Jones C.T., Morris S., Yates C.M., Moffoot A., Sharpe C.,
RA   Brock D.J.H., St Clair D.;
RT   "Mutation in codon 713 of the beta amyloid precursor protein gene
RT   presenting with schizophrenia.";
RL   Nat. Genet. 1:306-309(1992).
RN   [125]
RP   VARIANT AD1 THR-713.
RX   PubMed=1303275; DOI=10.1038/ng1292-255;
RA   Carter D.A., Desmarais E., Bellis M., Campion D., Clerget-Darpoux F.,
RA   Brice A., Agid Y., Jaillard-Serradt A., Mallet J.;
RT   "More missense in amyloid gene.";
RL   Nat. Genet. 2:255-256(1992).
RN   [126]
RP   VARIANTS AD1 ILE-717 AND PHE-717.
RX   PubMed=8267572; DOI=10.1006/bbrc.1993.2491;
RA   Liepnieks J.J., Ghetti B., Farlow M., Roses A.D., Benson M.D.;
RT   "Characterization of amyloid fibril beta-peptide in familial
RT   Alzheimer's disease with APP717 mutations.";
RL   Biochem. Biophys. Res. Commun. 197:386-392(1993).
RN   [127]
RP   VARIANT ASP-665.
RX   PubMed=8154870; DOI=10.1002/ana.410350410;
RA   Peacock M.L., Murman D.L., Sima A.A.F., Warren J.T. Jr., Roses A.D.,
RA   Fink J.K.;
RT   "Novel amyloid precursor protein gene mutation (codon 665Asp) in a
RT   patient with late-onset Alzheimer's disease.";
RL   Ann. Neurol. 35:432-438(1994).
RN   [128]
RP   VARIANT AD1 PHE-717.
RX   PubMed=8290042; DOI=10.1212/WNL.44.1.105;
RA   Farlow M., Murrell J., Ghetti B., Unverzagt F., Zeldenrust S.,
RA   Benson M.D.;
RT   "Clinical characteristics in a kindred with early-onset Alzheimer's
RT   disease and their linkage to a G-->T change at position 2149 of the
RT   amyloid precursor protein gene.";
RL   Neurology 44:105-111(1994).
RN   [129]
RP   VARIANT AD1 ILE-717.
RX   PubMed=8577393; DOI=10.1016/0304-3940(95)12046-7;
RA   Brooks W.S., Martins R.N., De Voecht J., Nicholson G.A.,
RA   Schofield P.R., Kwok J.B.J., Fisher C., Yeung L.U.,
RA   Van Broeckhoven C.;
RT   "A mutation in codon 717 of the amyloid precursor protein gene in an
RT   Australian family with Alzheimer's disease.";
RL   Neurosci. Lett. 199:183-186(1995).
RN   [130]
RP   VARIANT AD1 VAL-716.
RX   PubMed=9328472; DOI=10.1093/hmg/6.12.2087;
RA   Eckman C.B., Mehta N.D., Crook R., Perez-Tur J., Prihar G.,
RA   Pfeiffer E., Graff-Radford N., Hinder P., Yager D., Zenk B.,
RA   Refolo L.M., Prada C.M., Younkin S.G., Hutton M., Hardy J.;
RT   "A new pathogenic mutation in the APP gene (I716V) increases the
RT   relative proportion of A beta 42(43).";
RL   Hum. Mol. Genet. 6:2087-2089(1997).
RN   [131]
RP   VARIANT AD1 GLY-692, AND CHARACTERIZATION OF PHENOTYPE.
RX   PubMed=9754958; DOI=10.1007/s004010050892;
RA   Cras P., van Harskamp F., Hendriks L., Ceuterick C., van Duijn C.M.,
RA   Stefanko S.Z., Hofman A., Kros J.M., Van Broeckhoven C., Martin J.J.;
RT   "Presenile Alzheimer dementia characterized by amyloid angiopathy and
RT   large amyloid core type senile plaques in the APP 692Ala-->Gly
RT   mutation.";
RL   Acta Neuropathol. 96:253-260(1998).
RN   [132]
RP   VARIANT AD1 MET-715, AND CHARACTERIZATION OF VARIANT AD1 MET-715.
RX   PubMed=10097173; DOI=10.1073/pnas.96.7.4119;
RA   Ancolio K., Dumanchin C., Barelli H., Warter J.-M., Brice A.,
RA   Campion D., Frebourg T., Checler F.;
RT   "Unusual phenotypic alteration of beta amyloid precursor protein
RT   (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation
RT   responsible for probable early-onset Alzheimer's disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:4119-4124(1999).
RN   [133]
RP   VARIANT AD1 ILE-717.
RX   PubMed=10631141; DOI=10.1086/302702;
RA   Finckh U., Mueller-Thomsen T., Mann U., Eggers C., Marksteiner J.,
RA   Meins W., Binetti G., Alberici A., Hock C., Nitsch R.M., Gal A.;
RT   "High prevalence of pathogenic mutations in patients with early-onset
RT   dementia detected by sequence analyses of four different genes.";
RL   Am. J. Hum. Genet. 66:110-117(2000).
RN   [134]
RP   VARIANT AD1 PRO-723.
RX   PubMed=10665499;
RX   DOI=10.1002/1531-8249(200002)47:2<249::AID-ANA18>3.0.CO;2-8;
RA   Kwok J.B.J., Li Q.X., Hallupp M., Whyte S., Ames D., Beyreuther K.,
RA   Masters C.L., Schofield P.R.;
RT   "Novel Leu723Pro amyloid precursor protein mutation increases amyloid
RT   beta42(43) peptide levels and induces apoptosis.";
RL   Ann. Neurol. 47:249-253(2000).
RN   [135]
RP   VARIANT AD1 LEU-717.
RX   PubMed=10867787; DOI=10.1001/archneur.57.6.885;
RA   Murrell J.R., Hake A.M., Quaid K.A., Farlow M.R., Ghetti B.;
RT   "Early-onset Alzheimer disease caused by a new mutation (V717L) in the
RT   amyloid precursor protein gene.";
RL   Arch. Neurol. 57:885-887(2000).
RN   [136]
RP   VARIANT AD1 ILE-714, CHARACTERIZATION OF VARIANT AD1 ILE-714, AND
RP   MUTAGENESIS OF VAL-717.
RX   PubMed=11063718; DOI=10.1093/hmg/9.18.2589;
RA   Kumar-Singh S., De Jonghe C., Cruts M., Kleinert R., Wang R.,
RA   Mercken M., De Strooper B., Vanderstichele H., Loefgren A.,
RA   Vanderhoeven I., Backhovens H., Vanmechelen E., Kroisel P.M.,
RA   Van Broeckhoven C.;
RT   "Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase
RT   site mutation points to an essential role for N-truncated A beta(42)
RT   in Alzheimer's disease.";
RL   Hum. Mol. Genet. 9:2589-2598(2000).
RN   [137]
RP   VARIANT CAA-APP ASN-694.
RX   PubMed=11409420; DOI=10.1002/ana.1009;
RA   Grabowski T.J., Cho H.S., Vonsattel J.P.G., Rebeck G.W.,
RA   Greenberg S.M.;
RT   "Novel amyloid precursor protein mutation in an Iowa family with
RT   dementia and severe cerebral amyloid angiopathy.";
RL   Ann. Neurol. 49:697-705(2001).
RN   [138]
RP   CHARACTERIZATION OF VARIANT AD1 GLY-692.
RX   PubMed=11311152;
RA   Walsh D.M., Hartley D.M., Condron M.M., Selkoe D.J., Teplow D.B.;
RT   "In vitro studies of amyloid beta-protein fibril assembly and toxicity
RT   provide clues to the aetiology of Flemish variant (Ala692-->Gly)
RT   Alzheimer's disease.";
RL   Biochem. J. 355:869-877(2001).
RN   [139]
RP   VARIANT AD1 GLY-693.
RX   PubMed=11528419; DOI=10.1038/nn0901-887;
RA   Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M.,
RA   Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B.,
RA   Younkin S.G., Naeslund J., Lannfelt L.;
RT   "The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by
RT   enhanced Abeta protofibril formation.";
RL   Nat. Neurosci. 4:887-893(2001).
RN   [140]
RP   VARIANT AD1 ALA-714.
RX   PubMed=12034808; DOI=10.1212/WNL.58.10.1574;
RA   Pasalar P., Najmabadi H., Noorian A.R., Moghimi B., Jannati A.,
RA   Soltanzadeh A., Krefft T., Crook R., Hardy J.;
RT   "An Iranian family with Alzheimer's disease caused by a novel APP
RT   mutation (Thr714Ala).";
RL   Neurology 58:1574-1575(2002).
RN   [141]
RP   VARIANT CAA-APP ASN-694.
RX   PubMed=12654973; DOI=10.1212/01.WNL.0000050140.10044.A8;
RA   Greenberg S.M., Shin Y., Grabowski T.J., Cooper G.E., Rebeck G.W.,
RA   Iglesias S., Chapon F., Tournier-Lasserve E., Baron J.-C.;
RT   "Hemorrhagic stroke associated with the Iowa amyloid precursor protein
RT   mutation.";
RL   Neurology 60:1020-1022(2003).
RN   [142]
RP   VARIANT AD1 THR-713.
RX   PubMed=15365148; DOI=10.1212/01.WNL.0000137048.80666.86;
RA   Rossi G., Giaccone G., Maletta R., Morbin M., Capobianco R.,
RA   Mangieri M., Giovagnoli A.R., Bizzi A., Tomaino C., Perri M.,
RA   Di Natale M., Tagliavini F., Bugiani O., Bruni A.C.;
RT   "A family with Alzheimer disease and strokes associated with A713T
RT   mutation of the APP gene.";
RL   Neurology 63:910-912(2004).
RN   [143]
RP   VARIANT CAA-APP VAL-705.
RX   PubMed=16178030; DOI=10.1002/ana.20571;
RA   Obici L., Demarchi A., de Rosa G., Bellotti V., Marciano S.,
RA   Donadei S., Arbustini E., Palladini G., Diegoli M., Genovese E.,
RA   Ferrari G., Coverlizza S., Merlini G.;
RT   "A novel AbetaPP mutation exclusively associated with cerebral amyloid
RT   angiopathy.";
RL   Ann. Neurol. 58:639-644(2005).
RN   [144]
RP   VARIANT AD1 ILE-714.
RX   PubMed=15668448; DOI=10.1212/01.WNL.0000149761.70566.3E;
RA   Edwards-Lee T., Ringman J.M., Chung J., Werner J., Morgan A.,
RA   St George-Hyslop P.H., Thompson P., Dutton R., Mlikotic A.,
RA   Rogaeva E., Hardy J.;
RT   "An African American family with early-onset Alzheimer disease and an
RT   APP (T714I) mutation.";
RL   Neurology 64:377-379(2005).
CC   -!- FUNCTION: Functions as a cell surface receptor and performs
CC       physiological functions on the surface of neurons relevant to
CC       neurite growth, neuronal adhesion and axonogenesis. Involved in
CC       cell mobility and transcription regulation through protein-protein
CC       interactions. Can promote transcription activation through binding
CC       to APBB1-KAT5 and inhibits Notch signaling through interaction
CC       with Numb. Couples to apoptosis-inducing pathways such as those
CC       mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By
CC       similarity). Acts as a kinesin I membrane receptor, mediating the
CC       axonal transport of beta-secretase and presenilin 1. Involved in
CC       copper homeostasis/oxidative stress through copper ion reduction.
CC       In vitro, copper-metallated APP induces neuronal death directly or
CC       is potentiated through Cu(2+)-mediated low-density lipoprotein
CC       oxidation. Can regulate neurite outgrowth through binding to
CC       components of the extracellular matrix such as heparin and
CC       collagen I and IV. The splice isoforms that contain the BPTI
CC       domain possess protease inhibitor activity. Induces a AGER-
CC       dependent pathway that involves activation of p38 MAPK, resulting
CC       in internalization of amyloid-beta peptide and leading to
CC       mitochondrial dysfunction in cultured cortical neurons. Provides
CC       Cu(2+) ions for GPC1 which are required for release of nitric
CC       oxide (NO) and subsequent degradation of the heparan sulfate
CC       chains on GPC1.
CC   -!- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators
CC       with metal-reducing activity. Bind transient metals such as
CC       copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to
CC       Cu(+) and Fe(2+), respectively. Beta-amyloid 42 is a more
CC       effective reductant than beta-amyloid 40. Beta-amyloid peptides
CC       bind to lipoproteins and apolipoproteins E and J in the CSF and to
CC       HDL particles in plasma, inhibiting metal-catalyzed oxidation of
CC       lipoproteins. Beta-APP42 may activate mononuclear phagocytes in
CC       the brain and elicit inflammatory responses. Promotes both tau
CC       aggregation and TPK II-mediated phosphorylation. Interaction with
CC       Also bind GPC1 in lipid rafts.
CC   -!- FUNCTION: Appicans elicit adhesion of neural cells to the
CC       extracellular matrix and may regulate neurite outgrowth in the
CC       brain (By similarity).
CC   -!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved
CC       peptides, including C31, are potent enhancers of neuronal
CC       apoptosis.
CC   -!- FUNCTION: N-APP binds TNFRSF21 triggering caspase activation and
CC       degeneration of both neuronal cell bodies (via caspase-3) and
CC       axons (via caspase-6).
CC   -!- SUBUNIT: Binds, via its C-terminus, to the PID domain of several
CC       cytoplasmic proteins, including APBB family members, the APBA
CC       family, MAPK8IP1, SHC1 and, NUMB and DAB1 (By similarity). Binding
CC       to DAB1 inhibits its serine phosphorylation (By similarity).
CC       Interacts (via NPXY motif) with DAB2 (via PID domain); the
CC       interaction is impaired by tyrosine phosphorylation of the NPXY
CC       motif. Also interacts with GPCR-like protein BPP, FPRL1, APPBP1,
CC       IB1, KNS2 (via its TPR domains) (By similarity), APPBP2 (via BaSS)
CC       and DDB1. In vitro, it binds MAPT via the MT-binding domains (By
CC       similarity). Associates with microtubules in the presence of ATP
CC       and in a kinesin-dependent manner (By similarity). Interacts,
CC       through a C-terminal domain, with GNAO1. Amyloid beta-42 binds
CC       CHRNA7 in hippocampal neurons. Beta-amyloid associates with HADH2.
CC       Soluble APP binds, via its N-terminal head, to FBLN1. Interacts
CC       with CPEB1 and AGER (By similarity). Interacts with ANKS1B and
CC       TNFRSF21. Interacts with ITM2B. Interacts with ITM2C. Interacts
CC       with IDE. Can form homodimers; this is promoted by heparin
CC       binding. Beta-amyloid protein 40 interacts with S100A9. CTF-alpha
CC       product of APP interacts with GSAP. Interacts with SORL1.
CC   -!- INTERACTION:
CC       Self; NbExp=79; IntAct=EBI-77613, EBI-77613;
CC       Q306T3:- (xeno); NbExp=3; IntAct=EBI-77613, EBI-8294101;
CC       P31696:AGRN (xeno); NbExp=3; IntAct=EBI-2431589, EBI-457650;
CC       Q02410:APBA1; NbExp=3; IntAct=EBI-77613, EBI-368690;
CC       O00213:APBB1; NbExp=5; IntAct=EBI-77613, EBI-81694;
CC       Q92870:APBB2; NbExp=2; IntAct=EBI-77613, EBI-79277;
CC       P51693:APLP1; NbExp=2; IntAct=EBI-302641, EBI-74648;
CC       Q06481:APLP2; NbExp=2; IntAct=EBI-302641, EBI-79306;
CC       P02647:APOA1; NbExp=5; IntAct=EBI-77613, EBI-701692;
CC       Q13867:BLMH; NbExp=2; IntAct=EBI-302641, EBI-718504;
CC       P15253:CALR (xeno); NbExp=3; IntAct=EBI-77613, EBI-9005200;
CC       Q8K3H7:CALR (xeno); NbExp=2; IntAct=EBI-3894543, EBI-9005068;
CC       P39060:COL18A1; NbExp=2; IntAct=EBI-821758, EBI-2566375;
CC       P07339:CTSD; NbExp=2; IntAct=EBI-77613, EBI-2115097;
CC       O75955:FLOT1; NbExp=5; IntAct=EBI-77613, EBI-603643;
CC       P01100:FOS; NbExp=3; IntAct=EBI-77613, EBI-852851;
CC       P46089:GPR3; NbExp=2; IntAct=EBI-302641, EBI-3909653;
CC       Q9NSC5:HOMER3; NbExp=3; IntAct=EBI-302661, EBI-748420;
CC       Q99714:HSD17B10; NbExp=4; IntAct=EBI-77613, EBI-79964;
CC       O43736:ITM2A; NbExp=3; IntAct=EBI-302641, EBI-2431769;
CC       P05412:JUN; NbExp=2; IntAct=EBI-77613, EBI-852823;
CC       P10636:MAPT; NbExp=9; IntAct=EBI-77613, EBI-366182;
CC       Q93074:MED12; NbExp=2; IntAct=EBI-77613, EBI-394357;
CC       P03897:MT-ND3; NbExp=2; IntAct=EBI-821758, EBI-1246249;
CC       P21359:NF1; NbExp=3; IntAct=EBI-77613, EBI-1172917;
CC       P08138:NGFR; NbExp=2; IntAct=EBI-77613, EBI-1387782;
CC       P07174:Ngfr (xeno); NbExp=2; IntAct=EBI-2431589, EBI-1038810;
CC       P61457:PCBD1; NbExp=2; IntAct=EBI-77613, EBI-740475;
CC       Q15113:PCOLCE; NbExp=3; IntAct=EBI-821758, EBI-8869614;
CC       P30101:PDIA3; NbExp=3; IntAct=EBI-77613, EBI-979862;
CC       Q13526:PIN1; NbExp=2; IntAct=EBI-302641, EBI-714158;
CC       P04156:PRNP; NbExp=3; IntAct=EBI-77613, EBI-977302;
CC       P49768:PSEN1; NbExp=6; IntAct=EBI-77613, EBI-297277;
CC       P29353:SHC1; NbExp=5; IntAct=EBI-77613, EBI-78835;
CC       Q92529:SHC3; NbExp=2; IntAct=EBI-77613, EBI-79084;
CC       Q9NP59:SLC40A1; NbExp=4; IntAct=EBI-77613, EBI-725153;
CC       Q8BGY9:Slc5a7 (xeno); NbExp=2; IntAct=EBI-77613, EBI-2010752;
CC       Q9HCB6:SPON1; NbExp=3; IntAct=EBI-302641, EBI-2431846;
CC       P01137:TGFB1; NbExp=2; IntAct=EBI-77613, EBI-779636;
CC       P61812:TGFB2; NbExp=6; IntAct=EBI-77613, EBI-779581;
CC       O75509:TNFRSF21; NbExp=3; IntAct=EBI-77613, EBI-2313231;
CC       Q13625:TP53BP2; NbExp=3; IntAct=EBI-77613, EBI-77642;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein. Membrane, clathrin-coated pit. Note=Cell surface protein
CC       that rapidly becomes internalized via clathrin-coated pits. During
CC       maturation, the immature APP (N-glycosylated in the endoplasmic
CC       reticulum) moves to the Golgi complex where complete maturation
CC       occurs (O-glycosylated and sulfated). After alpha-secretase
CC       cleavage, soluble APP is released into the extracellular space and
CC       the C-terminal is internalized to endosomes and lysosomes. Some
CC       APP accumulates in secretory transport vesicles leaving the late
CC       Golgi compartment and returns to the cell surface. Gamma-CTF(59)
CC       peptide is located to both the cytoplasm and nuclei of neurons. It
CC       can be translocated to the nucleus through association with APBB1
CC       (Fe65). Beta-APP42 associates with FRPL1 at the cell surface and
CC       the complex is then rapidly internalized. APP sorts to the
CC       basolateral surface in epithelial cells. During neuronal
CC       differentiation, the Thr-743 phosphorylated form is located mainly
CC       in growth cones, moderately in neurites and sparingly in the cell
CC       body. Casein kinase phosphorylation can occur either at the cell
CC       surface or within a post-Golgi compartment. Associates with GPC1
CC       in perinuclear compartments. Colocalizes with SORL1 in a vesicular
CC       pattern in cytoplasm and perinuclear regions.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist. Experimental
CC         confirmation may be lacking for some isoforms;
CC       Name=APP770; Synonyms=PreA4 770;
CC         IsoId=P05067-1; Sequence=Displayed;
CC         Note=A major isoform;
CC       Name=APP305;
CC         IsoId=P05067-2; Sequence=VSP_000005, VSP_000006;
CC       Name=L-APP677;
CC         IsoId=P05067-3; Sequence=VSP_000002, VSP_000004, VSP_000009;
CC         Note=The L-isoforms are referred to as appicans;
CC       Name=APP695; Synonyms=PreA4 695;
CC         IsoId=P05067-4; Sequence=VSP_000002, VSP_000004;
CC         Note=A major isoform;
CC       Name=L-APP696;
CC         IsoId=P05067-5; Sequence=VSP_000002, VSP_000003, VSP_000009;
CC         Note=The L-isoforms are referred to as appicans;
CC       Name=APP714;
CC         IsoId=P05067-6; Sequence=VSP_000002, VSP_000003;
CC       Name=L-APP733;
CC         IsoId=P05067-7; Sequence=VSP_000007, VSP_000008, VSP_000009;
CC         Note=The L-isoforms are referred to as appicans;
CC       Name=APP751; Synonyms=PreA4 751;
CC         IsoId=P05067-8; Sequence=VSP_000007, VSP_000008;
CC         Note=A major isoform;
CC       Name=L-APP752;
CC         IsoId=P05067-9; Sequence=VSP_000009;
CC       Name=APP639;
CC         IsoId=P05067-10; Sequence=VSP_009116, VSP_009117, VSP_009118;
CC       Name=11;
CC         IsoId=P05067-11; Sequence=VSP_045446, VSP_045447;
CC   -!- TISSUE SPECIFICITY: Expressed in all fetal tissues examined with
CC       highest levels in brain, kidney, heart and spleen. Weak expression
CC       in liver. In adult brain, highest expression found in the frontal
CC       lobe of the cortex and in the anterior perisylvian cortex-
CC       opercular gyri. Moderate expression in the cerebellar cortex, the
CC       posterior perisylvian cortex-opercular gyri and the temporal
CC       associated cortex. Weak expression found in the striate, extra-
CC       striate and motor cortices. Expressed in cerebrospinal fluid, and
CC       plasma. Isoform APP695 is the predominant form in neuronal tissue,
CC       isoform APP751 and isoform APP770 are widely expressed in non-
CC       neuronal cells. Isoform APP751 is the most abundant form in T-
CC       lymphocytes. Appican is expressed in astrocytes.
CC   -!- INDUCTION: Increased levels during neuronal differentiation.
CC   -!- DOMAIN: The basolateral sorting signal (BaSS) is required for
CC       sorting of membrane proteins to the basolateral surface of
CC       epithelial cells.
CC   -!- DOMAIN: The NPXY sequence motif found in many tyrosine-
CC       phosphorylated proteins is required for the specific binding of
CC       the PID domain. However, additional amino acids either N- or C-
CC       terminal to the NPXY motif are often required for complete
CC       interaction. The PID domain-containing proteins which bind APP
CC       require the YENPTY motif for full interaction. These interactions
CC       are independent of phosphorylation on the terminal tyrosine
CC       residue. The NPXY site is also involved in clathrin-mediated
CC       endocytosis.
CC   -!- PTM: Proteolytically processed under normal cellular conditions.
CC       Cleavage either by alpha-secretase, beta-secretase or theta-
CC       secretase leads to generation and extracellular release of soluble
CC       APP peptides, S-APP-alpha and S-APP-beta, and the retention of
CC       corresponding membrane-anchored C-terminal fragments, C80, C83 and
CC       C99. Subsequent processing of C80 and C83 by gamma-secretase
CC       yields P3 peptides. This is the major secretory pathway and is
CC       non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated
CC       gamma-secretase processing of C99 releases the amyloid beta
CC       proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42),
CC       major components of amyloid plaques, and the cytotoxic C-terminal
CC       fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59). Many
CC       other minor beta-amyloid peptides, beta-amyloid 1-X peptides, are
CC       found in cerebral spinal fluid (CSF) including the beta-amyloid X-
CC       15 peptides, produced from the cleavage by alpha-secretase and all
CC       terminatiing at Gln-686.
CC   -!- PTM: Proteolytically cleaved by caspases during neuronal
CC       apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9
CC       results in the production of the neurotoxic C31 peptide and the
CC       increased production of beta-amyloid peptides.
CC   -!- PTM: N- and O-glycosylated. O-glycosylation on Ser and Thr
CC       residues with core 1 or possibly core 8 glycans. Partial tyrosine
CC       glycosylation (Tyr-681) is found on some minor, short beta-amyloid
CC       peptides (beta-amyloid 1-15, 1-16, 1-17, 1-18, 1-19 and 1-20) but
CC       not found on beta-amyloid 38, beta-amyloid 40 nor on beta-amyloid
CC       42. Modification on a tyrosine is unusual and is more prevelant in
CC       AD patients. Glycans had Neu5AcHex(Neu5Ac)HexNAc-O-Tyr,
CC       Neu5AcNeu5AcHex(Neu5Ac)HexNAc-O-Tyr and O-
CC       AcNeu5AcNeu5AcHex(Neu5Ac)HexNAc-O-Tyr structures, where O-Ac is O-
CC       acetylation of Neu5Ac. Neu5AcNeu5Ac is most likely Neu5Ac
CC       2,8Neu5Ac linked. O-glycosylations in the vicinity of the cleavage
CC       sites may influence the proteolytic processing. Appicans are L-APP
CC       isoforms with O-linked chondroitin sulfate.
CC   -!- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and
CC       serine residues is neuron-specific. Phosphorylation can affect APP
CC       processing, neuronal differentiation and interaction with other
CC       proteins. Phosphorylated on Thr-743 in neuronal cells by Cdc5
CC       kinase and Mapk10, in dividing cells by Cdc2 kinase in a cell-
CC       cycle dependent manner with maximal levels at the G2/M phase and,
CC       in vitro, by GSK-3-beta. The Thr-743 phosphorylated form causes a
CC       conformational change which reduces binding of Fe65 family
CC       members. Phosphorylation on Tyr-757 is required for SHC binding.
CC       Phosphorylated in the extracellular domain by casein kinases on
CC       both soluble and membrane-bound APP. This phosphorylation is
CC       inhibited by heparin.
CC   -!- PTM: Extracellular binding and reduction of copper, results in a
CC       corresponding oxidation of Cys-144 and Cys-158, and the formation
CC       of a disulfide bond. In vitro, the APP-Cu(+) complex in the
CC       presence of hydrogen peroxide results in an increased production
CC       of beta-amyloid-containing peptides.
CC   -!- PTM: Trophic-factor deprivation triggers the cleavage of surface
CC       APP by beta-secretase to release sAPP-beta which is further
CC       cleaved to release an N-terminal fragment of APP (N-APP).
CC   -!- PTM: Beta-amyloid peptides are degraded by IDE.
CC   -!- MASS SPECTROMETRY: Mass=6461.6; Method=MALDI; Range=712-767;
CC       Source=PubMed:12214090;
CC   -!- MASS SPECTROMETRY: Mass=6451.6; Method=MALDI; Range=714-770;
CC       Source=PubMed:12214090;
CC   -!- MASS SPECTROMETRY: Mass=6436.8; Method=MALDI; Range=715-769;
CC       Source=PubMed:12214090;
CC   -!- MASS SPECTROMETRY: Mass=5752.5; Method=MALDI; Range=719-767;
CC       Source=PubMed:12214090;
CC   -!- DISEASE: Alzheimer disease 1 (AD1) [MIM:104300]: A familial early-
CC       onset form of Alzheimer disease. It can be associated with
CC       cerebral amyloid angiopathy. Alzheimer disease is a
CC       neurodegenerative disorder characterized by progressive dementia,
CC       loss of cognitive abilities, and deposition of fibrillar amyloid
CC       proteins as intraneuronal neurofibrillary tangles, extracellular
CC       amyloid plaques and vascular amyloid deposits. The major
CC       constituent of these plaques is the neurotoxic amyloid-beta-APP
CC       40-42 peptide (s), derived proteolytically from the transmembrane
CC       precursor protein APP by sequential secretase processing. The
CC       cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved
CC       products such as C31 derived from APP, are also implicated in
CC       neuronal death. Note=The disease is caused by mutations affecting
CC       the gene represented in this entry.
CC   -!- DISEASE: Cerebral amyloid angiopathy, APP-related (CAA-APP)
CC       [MIM:605714]: A hereditary localized amyloidosis due to amyloid-
CC       beta A4 peptide(s) deposition in the cerebral vessels. The
CC       principal clinical characteristics are recurrent cerebral and
CC       cerebellar hemorrhages, recurrent strokes, cerebral ischemia,
CC       cerebral infarction, and progressive mental deterioration.
CC       Patients develop cerebral hemorrhage because of the severe
CC       cerebral amyloid angiopathy. Parenchymal amyloid deposits are rare
CC       and largely in the form of pre-amyloid lesions or diffuse plaque-
CC       like structures. They are Congo red negative and lack the dense
CC       amyloid cores commonly present in Alzheimer disease. Some affected
CC       individuals manifest progressive aphasic dementia,
CC       leukoencephalopathy, and occipital calcifications. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and
CC       zinc, can induce histidine-bridging between beta-amyloid molecules
CC       resulting in beta-amyloid-metal aggregates. The affinity for
CC       copper is much higher than for other transient metals and is
CC       increased under acidic conditions. Extracellular zinc-binding
CC       increases binding of heparin to APP and inhibits collagen-binding.
CC   -!- SIMILARITY: Belongs to the APP family.
CC   -!- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA58727.1; Type=Miscellaneous discrepancy; Note=Contamination by an Alu repeat;
CC   -!- WEB RESOURCE: Name=Alzheimer Research Forum; Note=APP mutations;
CC       URL="http://www.alzforum.org/res/com/mut/app/default.asp";
CC   -!- WEB RESOURCE: Name=AD mutations;
CC       URL="http://www.molgen.ua.ac.be/ADmutations/";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/app/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Amyloid beta entry;
CC       URL="http://en.wikipedia.org/wiki/Amyloid_beta";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00264; CAA68374.1; -; mRNA.
DR   EMBL; X13466; CAA31830.1; -; Genomic_DNA.
DR   EMBL; X13467; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13468; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13469; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13470; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13471; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13472; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13473; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13474; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13475; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13476; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13477; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13478; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13479; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13487; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13488; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X06989; CAA30050.1; -; mRNA.
DR   EMBL; M33112; AAB59502.1; -; Genomic_DNA.
DR   EMBL; M34862; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34863; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34864; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34865; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34866; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34867; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34868; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34869; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34870; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34871; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34872; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34873; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34874; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34876; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34877; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34878; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34879; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34875; AAB59501.1; ALT_TERM; Genomic_DNA.
DR   EMBL; M34862; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34863; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34864; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34865; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34866; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34867; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34868; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34869; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34870; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34871; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34872; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34873; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; D87675; BAA22264.1; -; Genomic_DNA.
DR   EMBL; AK312326; BAG35248.1; -; mRNA.
DR   EMBL; AK295621; BAG58500.1; -; mRNA.
DR   EMBL; AY919674; AAW82435.1; -; Genomic_DNA.
DR   EMBL; AP001439; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001440; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001441; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001442; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001443; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471079; EAX09958.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09959.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09960.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09961.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09963.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09965.1; -; Genomic_DNA.
DR   EMBL; BC004369; AAH04369.1; -; mRNA.
DR   EMBL; BC065529; AAH65529.1; -; mRNA.
DR   EMBL; M35675; AAA60163.1; ALT_SEQ; mRNA.
DR   EMBL; M24547; AAC13654.1; -; Genomic_DNA.
DR   EMBL; M24546; AAC13654.1; JOINED; Genomic_DNA.
DR   EMBL; M28373; AAA58727.1; ALT_SEQ; mRNA.
DR   EMBL; X06982; CAA30042.1; -; mRNA.
DR   EMBL; X06981; CAA30041.1; -; mRNA.
DR   EMBL; M18734; AAA51726.1; -; mRNA.
DR   EMBL; M29270; AAA51768.1; -; Genomic_DNA.
DR   EMBL; M29269; AAA51768.1; JOINED; Genomic_DNA.
DR   EMBL; AB066441; BAB71958.2; -; mRNA.
DR   EMBL; M15533; AAA35540.1; -; mRNA.
DR   EMBL; M15532; AAA51564.1; -; mRNA.
DR   EMBL; M37896; AAA51727.1; -; Genomic_DNA.
DR   EMBL; M37895; AAA51727.1; JOINED; Genomic_DNA.
DR   EMBL; S45136; AAB23646.1; -; Genomic_DNA.
DR   EMBL; S60317; AAC60601.2; -; Genomic_DNA.
DR   EMBL; AF282245; AAQ14327.1; -; mRNA.
DR   EMBL; S60721; AAB26263.2; -; mRNA.
DR   EMBL; S61380; AAB26264.2; -; mRNA.
DR   EMBL; S61383; AAB26265.2; -; mRNA.
DR   EMBL; M16765; AAA51722.1; -; mRNA.
DR   CCDS; CCDS13576.1; -. [P05067-1]
DR   CCDS; CCDS13577.1; -. [P05067-4]
DR   CCDS; CCDS33523.1; -. [P05067-8]
DR   CCDS; CCDS46638.1; -. [P05067-10]
DR   CCDS; CCDS56212.1; -. [P05067-11]
DR   CCDS; CCDS56213.1; -. [P05067-9]
DR   PIR; S01442; S01442.
DR   PIR; S02260; QRHUA4.
DR   RefSeq; NP_000475.1; NM_000484.3. [P05067-1]
DR   RefSeq; NP_001129488.1; NM_001136016.3. [P05067-11]
DR   RefSeq; NP_001129601.1; NM_001136129.2. [P05067-10]
DR   RefSeq; NP_001129602.1; NM_001136130.2.
DR   RefSeq; NP_001129603.1; NM_001136131.2.
DR   RefSeq; NP_001191230.1; NM_001204301.1. [P05067-9]
DR   RefSeq; NP_001191231.1; NM_001204302.1. [P05067-7]
DR   RefSeq; NP_001191232.1; NM_001204303.1. [P05067-3]
DR   RefSeq; NP_958816.1; NM_201413.2. [P05067-8]
DR   RefSeq; NP_958817.1; NM_201414.2. [P05067-4]
DR   UniGene; Hs.434980; -.
DR   PDB; 1AAP; X-ray; 1.50 A; A/B=287-344.
DR   PDB; 1AMB; NMR; -; A=672-699.
DR   PDB; 1AMC; NMR; -; A=672-699.
DR   PDB; 1AML; NMR; -; A=672-711.
DR   PDB; 1BA4; NMR; -; A=672-711.
DR   PDB; 1BA6; NMR; -; A=672-711.
DR   PDB; 1BJB; NMR; -; A=672-699.
DR   PDB; 1BJC; NMR; -; A=672-699.
DR   PDB; 1BRC; X-ray; 2.50 A; I=287-342.
DR   PDB; 1CA0; X-ray; 2.10 A; D/I=289-342.
DR   PDB; 1HZ3; NMR; -; A=681-706.
DR   PDB; 1IYT; NMR; -; A=672-713.
DR   PDB; 1MWP; X-ray; 1.80 A; A=28-123.
DR   PDB; 1OWT; NMR; -; A=124-189.
DR   PDB; 1QCM; NMR; -; A=696-706.
DR   PDB; 1QWP; NMR; -; A=696-706.
DR   PDB; 1QXC; NMR; -; A=696-706.
DR   PDB; 1QYT; NMR; -; A=696-706.
DR   PDB; 1TAW; X-ray; 1.80 A; B=287-344.
DR   PDB; 1TKN; NMR; -; A=460-569.
DR   PDB; 1UO7; Model; -; A=672-713.
DR   PDB; 1UO8; Model; -; A=672-713.
DR   PDB; 1UOA; Model; -; A=672-713.
DR   PDB; 1UOI; Model; -; A=672-713.
DR   PDB; 1X11; X-ray; 2.50 A; C/D=754-766.
DR   PDB; 1Z0Q; NMR; -; A=672-713.
DR   PDB; 1ZE7; NMR; -; A=672-687.
DR   PDB; 1ZE9; NMR; -; A=672-687.
DR   PDB; 1ZJD; X-ray; 2.60 A; B=289-344.
DR   PDB; 2BEG; NMR; -; A/B/C/D/E=672-713.
DR   PDB; 2BOM; Model; -; A/B=681-713.
DR   PDB; 2BP4; NMR; -; A=672-687.
DR   PDB; 2FJZ; X-ray; 1.61 A; A=133-189.
DR   PDB; 2FK1; X-ray; 1.60 A; A=133-189.
DR   PDB; 2FK2; X-ray; 1.65 A; A=133-189.
DR   PDB; 2FK3; X-ray; 2.40 A; A/B/C/D/E/F/G/H=133-189.
DR   PDB; 2FKL; X-ray; 2.50 A; A/B=124-189.
DR   PDB; 2FMA; X-ray; 0.85 A; A=133-189.
DR   PDB; 2G47; X-ray; 2.10 A; C/D=672-711.
DR   PDB; 2IPU; X-ray; 1.65 A; P/Q=672-679.
DR   PDB; 2LFM; NMR; -; A=672-711.
DR   PDB; 2LLM; NMR; -; A=686-726.
DR   PDB; 2LMN; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L=672-711.
DR   PDB; 2LMO; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L=672-711.
DR   PDB; 2LMP; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=672-711.
DR   PDB; 2LMQ; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=672-711.
DR   PDB; 2LNQ; NMR; -; A/B/C/D/E/F/G/H=672-711.
DR   PDB; 2LOH; NMR; -; A/B=686-726.
DR   PDB; 2LP1; NMR; -; A=671-770.
DR   PDB; 2LZ3; NMR; -; A/B=699-726.
DR   PDB; 2LZ4; NMR; -; A/B=699-726.
DR   PDB; 2M4J; NMR; -; A/B/C/D/E/F/G/H/I=672-711.
DR   PDB; 2M9R; NMR; -; A=672-711.
DR   PDB; 2M9S; NMR; -; A=672-711.
DR   PDB; 2OTK; NMR; -; C=672-711.
DR   PDB; 2R0W; X-ray; 2.50 A; Q=672-679.
DR   PDB; 2WK3; X-ray; 2.59 A; C/D=672-713.
DR   PDB; 2Y29; X-ray; 2.30 A; A=687-692.
DR   PDB; 2Y2A; X-ray; 1.91 A; A=687-692.
DR   PDB; 2Y3J; X-ray; 1.99 A; A/B/C/D/E/F/G/H=701-706.
DR   PDB; 2Y3K; X-ray; 1.90 A; A/B/C/D/E/F/G/H=706-713.
DR   PDB; 2Y3L; X-ray; 2.10 A; A/B/C/G=706-713.
DR   PDB; 3AYU; X-ray; 2.00 A; B=586-595.
DR   PDB; 3BAE; X-ray; 1.59 A; A=672-699.
DR   PDB; 3BKJ; X-ray; 1.59 A; A=672-687.
DR   PDB; 3DXC; X-ray; 2.10 A; B/D=739-770.
DR   PDB; 3DXD; X-ray; 2.20 A; B/D=739-770.
DR   PDB; 3DXE; X-ray; 2.00 A; B/D=739-770.
DR   PDB; 3GCI; X-ray; 2.04 A; P=707-713.
DR   PDB; 3IFL; X-ray; 1.50 A; P=672-678.
DR   PDB; 3IFN; X-ray; 1.50 A; P=672-711.
DR   PDB; 3IFO; X-ray; 2.15 A; P/Q=672-678.
DR   PDB; 3IFP; X-ray; 2.95 A; P/Q/R/S=672-678.
DR   PDB; 3JQ5; X-ray; 2.03 A; B=672-679.
DR   PDB; 3JQL; X-ray; 1.20 A; B=687-692.
DR   PDB; 3JTI; X-ray; 1.80 A; B=699-706.
DR   PDB; 3KTM; X-ray; 2.70 A; A/B/C/D/E/F/G/H=18-190.
DR   PDB; 3L33; X-ray; 2.48 A; E/F/G/H=290-341.
DR   PDB; 3L81; X-ray; 1.60 A; B=761-767.
DR   PDB; 3MOQ; X-ray; 2.05 A; A/B/C/D=689-712.
DR   PDB; 3MXC; X-ray; 2.00 A; L=754-762.
DR   PDB; 3MXY; X-ray; 2.30 A; L=754-762.
DR   PDB; 3NYJ; X-ray; 3.20 A; A=365-567.
DR   PDB; 3NYL; X-ray; 2.80 A; A=365-570.
DR   PDB; 3OVJ; X-ray; 1.80 A; A/B/C/D=687-692.
DR   PDB; 3OW9; X-ray; 1.80 A; A/B=687-692.
DR   PDB; 3SV1; X-ray; 3.30 A; D/E/F=754-767.
DR   PDB; 3U0T; X-ray; 2.50 A; E/F=701-711.
DR   PDB; 3UMH; X-ray; 2.00 A; A=370-575.
DR   PDB; 3UMI; X-ray; 2.40 A; A=370-575.
DR   PDB; 3UMK; X-ray; 2.60 A; A=370-575.
DR   PDB; 4HIX; X-ray; 2.20 A; A=672-699.
DR   PDB; 4MDR; X-ray; 1.85 A; B=758-767.
DR   PDB; 4NGE; X-ray; 2.70 A; B/E=672-711.
DR   PDBsum; 1AAP; -.
DR   PDBsum; 1AMB; -.
DR   PDBsum; 1AMC; -.
DR   PDBsum; 1AML; -.
DR   PDBsum; 1BA4; -.
DR   PDBsum; 1BA6; -.
DR   PDBsum; 1BJB; -.
DR   PDBsum; 1BJC; -.
DR   PDBsum; 1BRC; -.
DR   PDBsum; 1CA0; -.
DR   PDBsum; 1HZ3; -.
DR   PDBsum; 1IYT; -.
DR   PDBsum; 1MWP; -.
DR   PDBsum; 1OWT; -.
DR   PDBsum; 1QCM; -.
DR   PDBsum; 1QWP; -.
DR   PDBsum; 1QXC; -.
DR   PDBsum; 1QYT; -.
DR   PDBsum; 1TAW; -.
DR   PDBsum; 1TKN; -.
DR   PDBsum; 1UO7; -.
DR   PDBsum; 1UO8; -.
DR   PDBsum; 1UOA; -.
DR   PDBsum; 1UOI; -.
DR   PDBsum; 1X11; -.
DR   PDBsum; 1Z0Q; -.
DR   PDBsum; 1ZE7; -.
DR   PDBsum; 1ZE9; -.
DR   PDBsum; 1ZJD; -.
DR   PDBsum; 2BEG; -.
DR   PDBsum; 2BOM; -.
DR   PDBsum; 2BP4; -.
DR   PDBsum; 2FJZ; -.
DR   PDBsum; 2FK1; -.
DR   PDBsum; 2FK2; -.
DR   PDBsum; 2FK3; -.
DR   PDBsum; 2FKL; -.
DR   PDBsum; 2FMA; -.
DR   PDBsum; 2G47; -.
DR   PDBsum; 2IPU; -.
DR   PDBsum; 2LFM; -.
DR   PDBsum; 2LLM; -.
DR   PDBsum; 2LMN; -.
DR   PDBsum; 2LMO; -.
DR   PDBsum; 2LMP; -.
DR   PDBsum; 2LMQ; -.
DR   PDBsum; 2LNQ; -.
DR   PDBsum; 2LOH; -.
DR   PDBsum; 2LP1; -.
DR   PDBsum; 2LZ3; -.
DR   PDBsum; 2LZ4; -.
DR   PDBsum; 2M4J; -.
DR   PDBsum; 2M9R; -.
DR   PDBsum; 2M9S; -.
DR   PDBsum; 2OTK; -.
DR   PDBsum; 2R0W; -.
DR   PDBsum; 2WK3; -.
DR   PDBsum; 2Y29; -.
DR   PDBsum; 2Y2A; -.
DR   PDBsum; 2Y3J; -.
DR   PDBsum; 2Y3K; -.
DR   PDBsum; 2Y3L; -.
DR   PDBsum; 3AYU; -.
DR   PDBsum; 3BAE; -.
DR   PDBsum; 3BKJ; -.
DR   PDBsum; 3DXC; -.
DR   PDBsum; 3DXD; -.
DR   PDBsum; 3DXE; -.
DR   PDBsum; 3GCI; -.
DR   PDBsum; 3IFL; -.
DR   PDBsum; 3IFN; -.
DR   PDBsum; 3IFO; -.
DR   PDBsum; 3IFP; -.
DR   PDBsum; 3JQ5; -.
DR   PDBsum; 3JQL; -.
DR   PDBsum; 3JTI; -.
DR   PDBsum; 3KTM; -.
DR   PDBsum; 3L33; -.
DR   PDBsum; 3L81; -.
DR   PDBsum; 3MOQ; -.
DR   PDBsum; 3MXC; -.
DR   PDBsum; 3MXY; -.
DR   PDBsum; 3NYJ; -.
DR   PDBsum; 3NYL; -.
DR   PDBsum; 3OVJ; -.
DR   PDBsum; 3OW9; -.
DR   PDBsum; 3SV1; -.
DR   PDBsum; 3U0T; -.
DR   PDBsum; 3UMH; -.
DR   PDBsum; 3UMI; -.
DR   PDBsum; 3UMK; -.
DR   PDBsum; 4HIX; -.
DR   PDBsum; 4MDR; -.
DR   PDBsum; 4NGE; -.
DR   ProteinModelPortal; P05067; -.
DR   SMR; P05067; 26-192, 287-342, 385-567, 683-728, 741-768.
DR   BioGrid; 106848; 1971.
DR   DIP; DIP-574N; -.
DR   IntAct; P05067; 113.
DR   MINT; MINT-150767; -.
DR   BindingDB; P05067; -.
DR   ChEMBL; CHEMBL2487; -.
DR   MEROPS; I02.015; -.
DR   TCDB; 1.C.50.1.2; the amyloid -protein peptide (app) family.
DR   PhosphoSite; P05067; -.
DR   UniCarbKB; P05067; -.
DR   DMDM; 112927; -.
DR   SWISS-2DPAGE; P05067; -.
DR   MaxQB; P05067; -.
DR   PaxDb; P05067; -.
DR   PRIDE; P05067; -.
DR   DNASU; 351; -.
DR   Ensembl; ENST00000346798; ENSP00000284981; ENSG00000142192. [P05067-1]
DR   Ensembl; ENST00000348990; ENSP00000345463; ENSG00000142192. [P05067-4]
DR   Ensembl; ENST00000354192; ENSP00000346129; ENSG00000142192. [P05067-10]
DR   Ensembl; ENST00000357903; ENSP00000350578; ENSG00000142192. [P05067-8]
DR   Ensembl; ENST00000358918; ENSP00000351796; ENSG00000142192. [P05067-9]
DR   Ensembl; ENST00000359726; ENSP00000352760; ENSG00000142192. [P05067-6]
DR   Ensembl; ENST00000440126; ENSP00000387483; ENSG00000142192. [P05067-11]
DR   GeneID; 351; -.
DR   KEGG; hsa:351; -.
DR   UCSC; uc002ylz.3; human. [P05067-1]
DR   UCSC; uc002yma.3; human. [P05067-8]
DR   UCSC; uc002ymb.3; human. [P05067-4]
DR   UCSC; uc010glj.3; human. [P05067-10]
DR   UCSC; uc010glk.3; human.
DR   UCSC; uc011acj.2; human. [P05067-2]
DR   UCSC; uc021whz.1; human. [P05067-9]
DR   UCSC; uc021wia.1; human. [P05067-7]
DR   UCSC; uc021wib.1; human. [P05067-3]
DR   CTD; 351; -.
DR   GeneCards; GC21M027252; -.
DR   GeneReviews; APP; -.
DR   HGNC; HGNC:620; APP.
DR   HPA; CAB000157; -.
DR   HPA; HPA001462; -.
DR   MIM; 104300; phenotype.
DR   MIM; 104760; gene.
DR   MIM; 605714; phenotype.
DR   neXtProt; NX_P05067; -.
DR   Orphanet; 1020; Early-onset autosomal dominant Alzheimer disease.
DR   Orphanet; 324723; Hereditary cerebral hemorrhage with amyloidosis, Arctic type.
DR   Orphanet; 100006; Hereditary cerebral hemorrhage with amyloidosis, Dutch type.
DR   Orphanet; 324718; Hereditary cerebral hemorrhage with amyloidosis, Flemish type.
DR   Orphanet; 324708; Hereditary cerebral hemorrhage with amyloidosis, Iowa type.
DR   Orphanet; 324713; Hereditary cerebral hemorrhage with amyloidosis, Italian type.
DR   Orphanet; 324703; Hereditary cerebral hemorrhage with amyloidosis, Piedmont type.
DR   PharmGKB; PA24910; -.
DR   eggNOG; NOG289770; -.
DR   HOVERGEN; HBG000051; -.
DR   InParanoid; P05067; -.
DR   KO; K04520; -.
DR   OMA; THAHIVI; -.
DR   OrthoDB; EOG7RNJZP; -.
DR   PhylomeDB; P05067; -.
DR   TreeFam; TF317274; -.
DR   BioCyc; MetaCyc:ENSG00000142192-MONOMER; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_116125; Disease.
DR   Reactome; REACT_118779; Extracellular matrix organization.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6900; Immune System.
DR   SABIO-RK; P05067; -.
DR   ChiTaRS; app; human.
DR   EvolutionaryTrace; P05067; -.
DR   GeneWiki; Amyloid_precursor_protein; -.
DR   GenomeRNAi; 351; -.
DR   NextBio; 1445; -.
DR   PMAP-CutDB; P05067; -.
DR   PRO; PR:P05067; -.
DR   ArrayExpress; P05067; -.
DR   Bgee; P05067; -.
DR   Genevestigator; P05067; -.
DR   GO; GO:0045177; C:apical part of cell; IEA:Ensembl.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0035253; C:ciliary rootlet; IEA:Ensembl.
DR   GO; GO:0005905; C:coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043198; C:dendritic shaft; IDA:MGI.
DR   GO; GO:0043197; C:dendritic spine; IDA:MGI.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0045121; C:membrane raft; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0005641; C:nuclear envelope lumen; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProt.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0051233; C:spindle midzone; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IDA:MGI.
DR   GO; GO:0033130; F:acetylcholine receptor binding; IPI:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016504; F:peptidase activator activity; IEA:Ensembl.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0051425; F:PTB domain binding; IPI:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; IPI:BHF-UCL.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0046914; F:transition metal ion binding; IEA:InterPro.
DR   GO; GO:0008344; P:adult locomotory behavior; ISS:UniProtKB.
DR   GO; GO:0008088; P:axon cargo transport; ISS:UniProtKB.
DR   GO; GO:0016199; P:axon midline choice point recognition; ISS:UniProtKB.
DR   GO; GO:0007409; P:axonogenesis; ISS:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0006878; P:cellular copper ion homeostasis; ISS:UniProtKB.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:Ensembl.
DR   GO; GO:0048669; P:collateral sprouting in absence of injury; ISS:UniProtKB.
DR   GO; GO:0016358; P:dendrite development; ISS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; ISS:UniProtKB.
DR   GO; GO:0030198; P:extracellular matrix organization; ISS:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007626; P:locomotory behavior; ISS:UniProtKB.
DR   GO; GO:0007617; P:mating behavior; ISS:UniProtKB.
DR   GO; GO:0000085; P:mitotic G2 phase; ISS:UniProtKB.
DR   GO; GO:0006378; P:mRNA polyadenylation; ISS:UniProtKB.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IDA:GOC.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IMP:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; ISS:UniProtKB.
DR   GO; GO:0016322; P:neuron remodeling; ISS:UniProtKB.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0035872; P:nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0007176; P:regulation of epidermal growth factor-activated receptor activity; ISS:UniProtKB.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; ISS:UniProtKB.
DR   GO; GO:0043393; P:regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0050803; P:regulation of synapse structure and activity; ISS:UniProtKB.
DR   GO; GO:0006417; P:regulation of translation; ISS:UniProtKB.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0051563; P:smooth endoplasmic reticulum calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0001967; P:suckling behavior; IEA:Ensembl.
DR   GO; GO:0051124; P:synaptic growth at neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0008542; P:visual learning; ISS:UniProtKB.
DR   Gene3D; 3.30.1490.140; -; 1.
DR   Gene3D; 3.90.570.10; -; 1.
DR   Gene3D; 4.10.230.10; -; 1.
DR   Gene3D; 4.10.410.10; -; 1.
DR   InterPro; IPR008155; Amyloid_glyco.
DR   InterPro; IPR013803; Amyloid_glyco_Abeta.
DR   InterPro; IPR011178; Amyloid_glyco_Cu-bd.
DR   InterPro; IPR024329; Amyloid_glyco_E2_domain.
DR   InterPro; IPR008154; Amyloid_glyco_extra.
DR   InterPro; IPR019744; Amyloid_glyco_extracell_CS.
DR   InterPro; IPR015849; Amyloid_glyco_heparin-bd.
DR   InterPro; IPR019745; Amyloid_glyco_intracell_CS.
DR   InterPro; IPR028866; APP.
DR   InterPro; IPR019543; APP_amyloid_C.
DR   InterPro; IPR002223; Prot_inh_Kunz-m.
DR   InterPro; IPR020901; Prtase_inh_Kunz-CS.
DR   PANTHER; PTHR23103:SF7; PTHR23103:SF7; 1.
DR   Pfam; PF10515; APP_amyloid; 1.
DR   Pfam; PF12924; APP_Cu_bd; 1.
DR   Pfam; PF12925; APP_E2; 1.
DR   Pfam; PF02177; APP_N; 1.
DR   Pfam; PF03494; Beta-APP; 1.
DR   Pfam; PF00014; Kunitz_BPTI; 1.
DR   PRINTS; PR00203; AMYLOIDA4.
DR   PRINTS; PR00759; BASICPTASE.
DR   PRINTS; PR00204; BETAAMYLOID.
DR   SMART; SM00006; A4_EXTRA; 1.
DR   SMART; SM00131; KU; 1.
DR   SUPFAM; SSF109843; SSF109843; 1.
DR   SUPFAM; SSF56491; SSF56491; 1.
DR   SUPFAM; SSF57362; SSF57362; 1.
DR   SUPFAM; SSF89811; SSF89811; 1.
DR   PROSITE; PS00319; A4_EXTRA; 1.
DR   PROSITE; PS00320; A4_INTRA; 1.
DR   PROSITE; PS00280; BPTI_KUNITZ_1; 1.
DR   PROSITE; PS50279; BPTI_KUNITZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Alzheimer disease; Amyloid;
KW   Amyloidosis; Apoptosis; Cell adhesion; Coated pit; Complete proteome;
KW   Copper; Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Endocytosis; Glycoprotein; Heparin-binding; Iron; Membrane;
KW   Metal-binding; Neurodegeneration; Notch signaling pathway;
KW   Phosphoprotein; Polymorphism; Protease inhibitor; Proteoglycan;
KW   Reference proteome; Serine protease inhibitor; Signal; Transmembrane;
KW   Transmembrane helix; Zinc.
FT   SIGNAL        1     17
FT   CHAIN        18    770       Amyloid beta A4 protein.
FT                                /FTId=PRO_0000000088.
FT   CHAIN        18    687       Soluble APP-alpha.
FT                                /FTId=PRO_0000000089.
FT   CHAIN        18    671       Soluble APP-beta.
FT                                /FTId=PRO_0000000090.
FT   CHAIN        18    286       N-APP.
FT                                /FTId=PRO_0000381966.
FT   CHAIN       672    770       C99.
FT                                /FTId=PRO_0000000091.
FT   CHAIN       672    713       Beta-amyloid protein 42.
FT                                /FTId=PRO_0000000092.
FT   CHAIN       672    711       Beta-amyloid protein 40.
FT                                /FTId=PRO_0000000093.
FT   CHAIN       688    770       C83.
FT                                /FTId=PRO_0000000094.
FT   PEPTIDE     688    713       P3(42).
FT                                /FTId=PRO_0000000095.
FT   PEPTIDE     688    711       P3(40).
FT                                /FTId=PRO_0000000096.
FT   CHAIN       691    770       C80.
FT                                /FTId=PRO_0000384574.
FT   CHAIN       712    770       Gamma-secretase C-terminal fragment 59.
FT                                /FTId=PRO_0000000097.
FT   CHAIN       714    770       Gamma-secretase C-terminal fragment 57.
FT                                /FTId=PRO_0000000098.
FT   CHAIN       721    770       Gamma-secretase C-terminal fragment 50
FT                                (By similarity).
FT                                /FTId=PRO_0000000099.
FT   CHAIN       740    770       C31.
FT                                /FTId=PRO_0000000100.
FT   TOPO_DOM     18    699       Extracellular (Potential).
FT   TRANSMEM    700    723       Helical; (Potential).
FT   TOPO_DOM    724    770       Cytoplasmic (Potential).
FT   DOMAIN      291    341       BPTI/Kunitz inhibitor.
FT   REGION       96    110       Heparin-binding.
FT   REGION      181    188       Zinc-binding.
FT   REGION      391    423       Heparin-binding.
FT   REGION      491    522       Heparin-binding.
FT   REGION      523    540       Collagen-binding.
FT   REGION      732    751       Interaction with G(o)-alpha.
FT   MOTIF       724    734       Basolateral sorting signal.
FT   MOTIF       759    762       NPXY motif; contains endocytosis signal.
FT   COMPBIAS    230    260       Asp/Glu-rich (acidic).
FT   COMPBIAS    274    280       Poly-Thr.
FT   METAL       147    147       Copper 1.
FT   METAL       151    151       Copper 1.
FT   METAL       168    168       Copper 1.
FT   METAL       677    677       Copper or zinc 2.
FT   METAL       681    681       Copper or zinc 2 (Probable).
FT   METAL       684    684       Copper or zinc 2.
FT   METAL       685    685       Copper or zinc 2.
FT   SITE        144    144       Required for Cu(2+) reduction.
FT   SITE        301    302       Reactive bond.
FT   SITE        671    672       Cleavage; by beta-secretase.
FT   SITE        672    673       Cleavage; by caspase-6; when associated
FT                                with variant 670-N-L-671.
FT   SITE        687    688       Cleavage; by alpha-secretase.
FT   SITE        690    691       Cleavage; by theta-secretase.
FT   SITE        704    704       Implicated in free radical propagation
FT                                (By similarity).
FT   SITE        706    706       Susceptible to oxidation.
FT   SITE        711    712       Cleavage; by gamma-secretase; site 1.
FT   SITE        713    714       Cleavage; by gamma-secretase; site 2.
FT   SITE        720    721       Cleavage; by gamma-secretase; site 3.
FT   SITE        739    740       Cleavage; by caspase-6, caspase-8 or
FT                                caspase-9.
FT   MOD_RES     198    198       Phosphoserine; by CK2.
FT   MOD_RES     206    206       Phosphoserine; by CK1.
FT   MOD_RES     729    729       Phosphothreonine (By similarity).
FT   MOD_RES     730    730       Phosphoserine; by APP-kinase I (By
FT                                similarity).
FT   MOD_RES     743    743       Phosphothreonine; by CDK5 and MAPK10.
FT   MOD_RES     757    757       Phosphotyrosine.
FT   CARBOHYD    542    542       N-linked (GlcNAc...).
FT   CARBOHYD    571    571       N-linked (GlcNAc...) (Probable).
FT   CARBOHYD    614    614       O-linked (GalNAc...).
FT   CARBOHYD    623    623       O-linked (GalNAc...).
FT   CARBOHYD    628    628       O-linked (GalNAc...).
FT   CARBOHYD    633    633       O-linked (GalNAc...).
FT   CARBOHYD    651    651       O-linked (GalNAc...).
FT   CARBOHYD    652    652       O-linked (GalNAc...).
FT   CARBOHYD    656    656       O-linked (Xyl...) (chondroitin sulfate);
FT                                in L-APP isoforms.
FT   CARBOHYD    659    659       O-linked (GalNAc...).
FT   CARBOHYD    663    663       O-linked (GalNAc...) (Probable).
FT   CARBOHYD    667    667       O-linked (GalNAc...) (Probable).
FT   CARBOHYD    679    679       O-linked (GalNAc...).
FT   CARBOHYD    697    697       O-linked (GalNAc...).
FT   DISULFID     38     62
FT   DISULFID     73    117
FT   DISULFID     98    105
FT   DISULFID    133    187
FT   DISULFID    144    174
FT   DISULFID    158    186
FT   DISULFID    291    341
FT   DISULFID    300    324
FT   DISULFID    316    337
FT   VAR_SEQ       1     19       MLPGLALLLLAAWTARALE -> MDQLEDLLVLFINY (in
FT                                isoform 11).
FT                                /FTId=VSP_045446.
FT   VAR_SEQ      19     74       Missing (in isoform APP639).
FT                                /FTId=VSP_009116.
FT   VAR_SEQ     289    363       Missing (in isoform APP639).
FT                                /FTId=VSP_009117.
FT   VAR_SEQ     289    289       E -> V (in isoform APP695, isoform L-
FT                                APP696, isoform L-APP677 and isoform
FT                                APP714).
FT                                /FTId=VSP_000002.
FT   VAR_SEQ     290    364       Missing (in isoform APP695 and isoform L-
FT                                APP677).
FT                                /FTId=VSP_000004.
FT   VAR_SEQ     290    345       Missing (in isoform L-APP696 and isoform
FT                                APP714).
FT                                /FTId=VSP_000003.
FT   VAR_SEQ     290    305       VCSEQAETGPCRAMIS -> KWYKEVHSGQARWLML (in
FT                                isoform APP305).
FT                                /FTId=VSP_000005.
FT   VAR_SEQ     306    770       Missing (in isoform APP305).
FT                                /FTId=VSP_000006.
FT   VAR_SEQ     345    364       MSQSLLKTTQEPLARDPVKL -> I (in isoform
FT                                11).
FT                                /FTId=VSP_045447.
FT   VAR_SEQ     345    345       M -> I (in isoform L-APP733 and isoform
FT                                APP751).
FT                                /FTId=VSP_000007.
FT   VAR_SEQ     346    364       Missing (in isoform L-APP733 and isoform
FT                                APP751).
FT                                /FTId=VSP_000008.
FT   VAR_SEQ     364    364       L -> V (in isoform APP639).
FT                                /FTId=VSP_009118.
FT   VAR_SEQ     637    654       Missing (in isoform L-APP677, isoform L-
FT                                APP696, isoform L-APP733 and isoform L-
FT                                APP752).
FT                                /FTId=VSP_000009.
FT   VARIANT     501    501       E -> K (in dbSNP:rs45588932).
FT                                /FTId=VAR_022315.
FT   VARIANT     665    665       E -> D (in a patient with late onset
FT                                Alzheimer disease).
FT                                /FTId=VAR_010107.
FT   VARIANT     670    671       KM -> NL (in AD1).
FT                                /FTId=VAR_000015.
FT   VARIANT     678    678       D -> N (in AD1).
FT                                /FTId=VAR_044424.
FT   VARIANT     692    692       A -> G (in AD1; Flemish mutation;
FT                                increases the solubility of processed
FT                                beta-amyloid peptides and increases the
FT                                stability of peptide oligomers).
FT                                /FTId=VAR_000016.
FT   VARIANT     693    693       E -> G (in AD1).
FT                                /FTId=VAR_014215.
FT   VARIANT     693    693       E -> K (in CAA-APP; Italian type).
FT                                /FTId=VAR_014216.
FT   VARIANT     693    693       E -> Q (in CAA-APP; Dutch type).
FT                                /FTId=VAR_000017.
FT   VARIANT     694    694       D -> N (in CAA-APP; Iowa type).
FT                                /FTId=VAR_014217.
FT   VARIANT     705    705       L -> V (in CAA-APP; Italian type).
FT                                /FTId=VAR_032276.
FT   VARIANT     713    713       A -> T (in AD1).
FT                                /FTId=VAR_000019.
FT   VARIANT     713    713       A -> V (in one chronic schizophrenia
FT                                patient; unknown pathological
FT                                significance; dbSNP:rs1800557).
FT                                /FTId=VAR_000018.
FT   VARIANT     714    714       T -> A (in AD1).
FT                                /FTId=VAR_032277.
FT   VARIANT     714    714       T -> I (in AD1; increased beta-APP42/
FT                                beta-APP40 ratio).
FT                                /FTId=VAR_014218.
FT   VARIANT     715    715       V -> M (in AD1; decreased beta-APP40/
FT                                total APP-beta).
FT                                /FTId=VAR_010108.
FT   VARIANT     716    716       I -> V (in AD1).
FT                                /FTId=VAR_000020.
FT   VARIANT     717    717       V -> F (in AD1).
FT                                /FTId=VAR_000023.
FT   VARIANT     717    717       V -> G (in AD1).
FT                                /FTId=VAR_000022.
FT   VARIANT     717    717       V -> I (in AD1).
FT                                /FTId=VAR_000021.
FT   VARIANT     717    717       V -> L (in AD1).
FT                                /FTId=VAR_014219.
FT   VARIANT     723    723       L -> P (in AD1).
FT                                /FTId=VAR_010109.
FT   MUTAGEN      99    102       KRGR->NQGG: Reduced heparin-binding.
FT   MUTAGEN     137    137       H->N: Binds copper. Forms dimer.
FT   MUTAGEN     141    141       M->T: Binds copper. Forms dimer.
FT   MUTAGEN     144    144       C->S: Binds copper. No dimer formation.
FT                                No copper reducing activity.
FT   MUTAGEN     147    149       HLH->ALA: 50% decrease in copper reducing
FT                                activity.
FT   MUTAGEN     147    147       H->A: Some decrease in copper reducing
FT                                activity.
FT   MUTAGEN     147    147       H->N: Binds copper. Forms dimer.
FT   MUTAGEN     147    147       H->Y: Greatly reduced copper-mediated
FT                                low-density lipoprotein oxidation.
FT   MUTAGEN     151    151       H->K: Greatly reduced copper-mediated
FT                                low-density lipoprotein oxidation.
FT   MUTAGEN     151    151       H->N: Binds copper. Forms dimer.
FT   MUTAGEN     198    198       S->A: Greatly reduced casein kinase
FT                                phosphorylation.
FT   MUTAGEN     206    206       S->A: Reduced casein kinase
FT                                phosphorylation.
FT   MUTAGEN     499    499       R->A: Reduced affinity for heparin; when
FT                                associated with A-503.
FT   MUTAGEN     503    503       K->A: Reduced affinity for heparin; when
FT                                associated with A-499.
FT   MUTAGEN     656    656       S->A: Abolishes chondroitin sulfate
FT                                binding in L-APP733 isoform.
FT   MUTAGEN     676    676       R->G: 60-70% zinc-induced beta-APP (28)
FT                                peptide aggregation.
FT   MUTAGEN     681    681       Y->F: 60-70% zinc-induced beta-APP (28)
FT                                peptide aggregation.
FT   MUTAGEN     684    684       H->R: Only 23% zinc-induced beta-APP (28)
FT                                peptide aggregation.
FT   MUTAGEN     704    704       G->V: Reduced protein oxidation. No
FT                                hippocampal neuron toxicity.
FT   MUTAGEN     706    706       M->L: Reduced lipid peroxidation
FT                                inhibition.
FT   MUTAGEN     706    706       M->V: No free radical production. No
FT                                hippocampal neuron toxicity.
FT   MUTAGEN     717    717       V->C,S: Unchanged beta-APP42/total APP-
FT                                beta ratio.
FT   MUTAGEN     717    717       V->F,G,I: Increased beta-APP42/beta-APP40
FT                                ratio.
FT   MUTAGEN     717    717       V->K: Decreased beta-APP42/total APP-beta
FT                                ratio.
FT   MUTAGEN     717    717       V->M: Increased beta-APP42/beta-APP40
FT                                ratio. No change in apoptosis after
FT                                caspase cleavage.
FT   MUTAGEN     728    728       Y->A: No effect on APBA1 nor APBB1
FT                                binding. Greatly reduces the binding to
FT                                APPBP2. APP internalization unchanged. No
FT                                change in beta-APP42 secretion.
FT   MUTAGEN     739    739       D->A: No cleavage by caspases during
FT                                apoptosis.
FT   MUTAGEN     739    739       D->N: No effect on FADD-induced
FT                                apoptosis.
FT   MUTAGEN     743    743       T->A: Greatly reduces the binding to SHC1
FT                                and APBB family members; no effect on
FT                                NGF-stimulated neurite extension.
FT   MUTAGEN     743    743       T->E: Reduced NGF-stimulated neurite
FT                                extension. No effect on APP maturation.
FT   MUTAGEN     756    756       G->A: APP internalization unchanged. No
FT                                change in beta-APP42 secretion.
FT   MUTAGEN     757    757       Y->A: Little APP internalization. Reduced
FT                                beta-APP42 secretion.
FT   MUTAGEN     757    757       Y->G: Loss of binding to MAPK8IP1, APBA1,
FT                                APBB1, APPBP2 and SHC1.
FT   MUTAGEN     759    759       N->A: No binding to APBA1, no effect on
FT                                APBB1 binding. Little APP
FT                                internalization. Reduced beta-APP42
FT                                secretion.
FT   MUTAGEN     760    760       P->A: Little APP internalization. Reduced
FT                                beta-APP42 secretion.
FT   MUTAGEN     762    762       Y->A: Loss of binding to APBA1 and APBB1.
FT                                APP internalization unchanged. No change
FT                                in beta-APP42 secretion.
FT   CONFLICT     15     16       AR -> VW (in Ref. 3; CAA31830).
FT   CONFLICT    647    647       D -> E (in Ref. 36; AAA51722).
FT   CONFLICT    724    724       Missing (in Ref. 23; AAB26263/AAB26264).
FT   CONFLICT    731    731       I -> N (in Ref. 23; AAB26263/AAB26264/
FT                                AAB26265).
FT   CONFLICT    757    757       Y -> S (in Ref. 31; AAA35540).
FT   STRAND       33     35
FT   STRAND       43     45
FT   TURN         47     49
FT   STRAND       52     54
FT   HELIX        66     76
FT   STRAND       82     87
FT   STRAND       92     94
FT   STRAND       97     99
FT   HELIX       100    102
FT   STRAND      103    106
FT   STRAND      110    112
FT   STRAND      115    119
FT   STRAND      134    139
FT   HELIX       147    160
FT   STRAND      163    174
FT   TURN        175    177
FT   STRAND      178    188
FT   HELIX       288    292
FT   STRAND      299    301
FT   STRAND      304    310
FT   TURN        311    314
FT   STRAND      315    321
FT   STRAND      323    325
FT   STRAND      331    333
FT   HELIX       334    341
FT   HELIX       374    380
FT   HELIX       389    418
FT   STRAND      421    423
FT   HELIX       425    480
FT   STRAND      482    484
FT   HELIX       487    518
FT   HELIX       520    546
FT   HELIX       547    550
FT   HELIX       552    566
FT   HELIX       673    675
FT   STRAND      679    682
FT   STRAND      683    685
FT   STRAND      688    691
FT   HELIX       695    697
FT   STRAND      698    700
FT   STRAND      702    705
FT   STRAND      707    712
FT   HELIX       744    754
FT   STRAND      755    758
FT   STRAND      763    765
SQ   SEQUENCE   770 AA;  86943 MW;  A12EE761403740F5 CRC64;
     MLPGLALLLL AAWTARALEV PTDGNAGLLA EPQIAMFCGR LNMHMNVQNG KWDSDPSGTK
     TCIDTKEGIL QYCQEVYPEL QITNVVEANQ PVTIQNWCKR GRKQCKTHPH FVIPYRCLVG
     EFVSDALLVP DKCKFLHQER MDVCETHLHW HTVAKETCSE KSTNLHDYGM LLPCGIDKFR
     GVEFVCCPLA EESDNVDSAD AEEDDSDVWW GGADTDYADG SEDKVVEVAE EEEVAEVEEE
     EADDDEDDED GDEVEEEAEE PYEEATERTT SIATTTTTTT ESVEEVVREV CSEQAETGPC
     RAMISRWYFD VTEGKCAPFF YGGCGGNRNN FDTEEYCMAV CGSAMSQSLL KTTQEPLARD
     PVKLPTTAAS TPDAVDKYLE TPGDENEHAH FQKAKERLEA KHRERMSQVM REWEEAERQA
     KNLPKADKKA VIQHFQEKVE SLEQEAANER QQLVETHMAR VEAMLNDRRR LALENYITAL
     QAVPPRPRHV FNMLKKYVRA EQKDRQHTLK HFEHVRMVDP KKAAQIRSQV MTHLRVIYER
     MNQSLSLLYN VPAVAEEIQD EVDELLQKEQ NYSDDVLANM ISEPRISYGN DALMPSLTET
     KTTVELLPVN GEFSLDDLQP WHSFGADSVP ANTENEVEPV DARPAADRGL TTRPGSGLTN
     IKTEEISEVK MDAEFRHDSG YEVHHQKLVF FAEDVGSNKG AIIGLMVGGV VIATVIVITL
     VMLKKKQYTS IHHGVVEVDA AVTPEERHLS KMQQNGYENP TYKFFEQMQN
//
ID   AAAD_HUMAN              Reviewed;         399 AA.
AC   P22760; A8K3L3; D3DNJ6; Q8N1A9;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 5.
DT   09-JUL-2014, entry version 133.
DE   RecName: Full=Arylacetamide deacetylase;
DE            EC=3.1.1.3;
GN   Name=AADAC; Synonyms=DAC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND VARIANT
RP   ILE-281.
RC   TISSUE=Liver;
RX   PubMed=8063807;
RA   Probst M.R., Beer M., Beer D., Jenoe P., Meyer U.A., Gasser R.;
RT   "Human liver arylacetamide deacetylase. Molecular cloning of a novel
RT   esterase involved in the metabolic activation of arylamine carcinogens
RT   with high sequence similarity to hormone-sensitive lipase.";
RL   J. Biol. Chem. 269:21650-21656(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-281.
RC   TISSUE=Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-281.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PARTIAL PROTEIN SEQUENCE, AND CHARACTERIZATION.
RC   TISSUE=Liver;
RX   PubMed=2043131; DOI=10.1016/0006-291X(91)92005-5;
RA   Probst M.R., Jenoe P., Meyer U.A.;
RT   "Purification and characterization of a human liver arylacetamide
RT   deacetylase.";
RL   Biochem. Biophys. Res. Commun. 177:453-459(1991).
RN   [7]
RP   FUNCTION.
RX   PubMed=17936933; DOI=10.1002/jbt.20178;
RA   Ross M.K., Crow J.A.;
RT   "Human carboxylesterases and their role in xenobiotic and endobiotic
RT   metabolism.";
RL   J. Biochem. Mol. Toxicol. 21:187-196(2007).
RN   [8]
RP   FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=19339378; DOI=10.1124/dmd.109.026567;
RA   Watanabe A., Fukami T., Nakajima M., Takamiya M., Aoki Y., Yokoi T.;
RT   "Human arylacetamide deacetylase is a principal enzyme in flutamide
RT   hydrolysis.";
RL   Drug Metab. Dispos. 37:1513-1520(2009).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-78 AND ASN-282.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [10]
RP   BIOPHYSICOCHEMICAL PROPERTIES, FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=22207054; DOI=10.1124/dmd.111.043067;
RA   Kobayashi Y., Fukami T., Nakajima A., Watanabe A., Nakajima M.,
RA   Yokoi T.;
RT   "Species differences in tissue distribution and enzyme activities of
RT   arylacetamide deacetylase in human, rat, and mouse.";
RL   Drug Metab. Dispos. 40:671-679(2012).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, VARIANTS ILE-281 AND GLN-399 EXT, AND CHARACTERIZATION OF
RP   VARIANTS ILE-281 AND GLN-399 EXT.
RX   PubMed=22415931; DOI=10.1124/dmd.112.044883;
RA   Shimizu M., Fukami T., Kobayashi Y., Takamiya M., Aoki Y.,
RA   Nakajima M., Yokoi T.;
RT   "A novel polymorphic allele of human arylacetamide deacetylase leads
RT   to decreased enzyme activity.";
RL   Drug Metab. Dispos. 40:1183-1190(2012).
RN   [12]
RP   BIOPHYSICOCHEMICAL PROPERTIES, GLYCOSYLATION AT ASN-78 AND ASN-282,
RP   AND MUTAGENESIS OF ASN-78 AND ASN-282.
RX   PubMed=24125761; DOI=10.1016/j.bcp.2013.10.001;
RA   Muta K., Fukami T., Nakajima M., Yokoi T.;
RT   "N-Glycosylation during translation is essential for human
RT   arylacetamide deacetylase enzyme activity.";
RL   Biochem. Pharmacol. 87:352-359(2014).
RN   [13]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=23542347; DOI=10.1016/j.jhep.2013.03.022;
RA   Nourbakhsh M., Douglas D.N., Pu C.H., Lewis J.T., Kawahara T.,
RA   Lisboa L.F., Wei E., Asthana S., Quiroga A.D., Law L.M., Chen C.,
RA   Addison W.R., Nelson R., Houghton M., Lehner R., Kneteman N.M.;
RT   "Arylacetamide deacetylase: a novel host factor with important roles
RT   in the lipolysis of cellular triacylglycerol stores, VLDL assembly and
RT   HCV production.";
RL   J. Hepatol. 59:336-343(2013).
RN   [14]
RP   VARIANT ILE-281.
RX   PubMed=12721789; DOI=10.1007/s10038-003-0021-7;
RA   Saito S., Iida A., Sekine A., Kawauchi S., Higuchi S., Ogawa C.,
RA   Nakamura Y.;
RT   "Catalog of 680 variations among eight cytochrome p450 (CYP) genes,
RT   nine esterase genes, and two other genes in the Japanese population.";
RL   J. Hum. Genet. 48:249-270(2003).
CC   -!- FUNCTION: Displays cellular triglyceride lipase activity in liver,
CC       increases the levels of intracellular fatty acids derived from the
CC       hydrolysis of newly formed triglyceride stores and plays a role in
CC       very low-density lipoprotein assembly. Displays serine esterase
CC       activity in liver. Deacetylates a variety of arylacetamide
CC       substrates, including xenobiotic compounds and procarcinogens,
CC       converting them to the primary arylamide compounds and increasing
CC       their toxicity.
CC   -!- CATALYTIC ACTIVITY: Triacylglycerol + H(2)O = diacylglycerol + a
CC       carboxylate.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.8 mM for flutamide (PubMed:19339378);
CC         KM=0.6 mM for flutamide (PubMed:22207054);
CC         KM=0.472 mM for flutamide (PubMed:22415931);
CC         KM=3.05 mM for phenacetin (PubMed:24125761);
CC         KM=1.8 mM for phenacetin (PubMed:22207054);
CC         KM=1.42 mM for phenacetin (PubMed:22415931);
CC         KM=0.2 mM for rifampicin (PubMed:22207054);
CC         KM=0.154 mM for rifampicin (PubMed:22415931);
CC         Vmax=1.1 nmol/min/mg enzyme toward flutamide (PubMed:19339378);
CC         Vmax=1.1 nmol/min/mg enzyme toward flutamide (PubMed:22207054);
CC         Vmax=0.617 nmol/min/mg enzyme toward flutamide
CC         (PubMed:22415931);
CC         Vmax=1.34 nmol/min/mg enzyme toward phenacetin
CC         (PubMed:24125761);
CC         Vmax=6.4 nmol/min/mg enzyme toward phenacetin (PubMed:22207054);
CC         Vmax=1.42 nmol/min/mg enzyme toward phenacetin
CC         (PubMed:22415931);
CC         Vmax=0.149 nmol/min/mg enzyme toward rifampicin
CC         (PubMed:22207054);
CC         Vmax=0.060 nmol/min/mg enzyme toward rifampicin
CC         (PubMed:22415931);
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Single-pass
CC       type II membrane protein. Microsome membrane; Single-pass type II
CC       membrane protein.
CC   -!- TISSUE SPECIFICITY: Detected in liver (at protein level). Mainly
CC       expressed in liver, small intestine, colon, adrenal gland and
CC       bladder.
CC   -!- INDUCTION: Down-regulated following infection with hepatis C virus
CC       which results in impaired triacylglycerol lipolysis and impaired
CC       assembly of very low density lipoproteins. This may represent a
CC       cellular adaptation to infection that is aimed at limiting viral
CC       production.
CC   -!- PTM: Glycosylation is required for enzyme activity.
CC   -!- POLYMORPHISM: Three alleles are known: AADAC*1, AADAC*2 and
CC       AADAC*3. The sequence shown is that of AADAC*1 which is found in
CC       European American, African American, Japanese and Korean
CC       populations at allelic frequencies of 39.3 to 47.4%. The AADAC*2
CC       allele is found in European American, African American, Korean,
CC       and Japanese populations at allelic frequencies of 52.6 to 63.5%
CC       whereas the AADAC*3 allele is found in European American (1.3%)
CC       and African American (2.0%) samples but not in Japanese or Korean
CC       samples.
CC   -!- MISCELLANEOUS: Can hydrolyze a number of clinical drugs such as
CC       flutamide, an antiandrogen drug used for the treatment of prostate
CC       cancer; phenacetin, an analgesic antipyretic which has been
CC       withdrawn from the market due to its links with renal failure; and
CC       rifamycins which have been used as antituberculosis drugs.
CC   -!- SIMILARITY: Belongs to the 'GDXG' lipolytic enzyme family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35551.1; Type=Frameshift; Positions=53, 56;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L32179; AAA35551.1; ALT_FRAME; mRNA.
DR   EMBL; AK290628; BAF83317.1; -; mRNA.
DR   EMBL; AC068647; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW78791.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78792.1; -; Genomic_DNA.
DR   EMBL; BC032309; AAH32309.1; -; mRNA.
DR   CCDS; CCDS33877.1; -.
DR   PIR; A53856; A53856.
DR   RefSeq; NP_001077.2; NM_001086.2.
DR   RefSeq; XP_005247160.1; XM_005247103.2.
DR   UniGene; Hs.506908; -.
DR   ProteinModelPortal; P22760; -.
DR   SMR; P22760; 69-379.
DR   BioGrid; 106531; 1.
DR   STRING; 9606.ENSP00000232892; -.
DR   MEROPS; S09.991; -.
DR   PhosphoSite; P22760; -.
DR   DMDM; 317373587; -.
DR   PaxDb; P22760; -.
DR   PRIDE; P22760; -.
DR   Ensembl; ENST00000232892; ENSP00000232892; ENSG00000114771.
DR   GeneID; 13; -.
DR   KEGG; hsa:13; -.
DR   UCSC; uc003eze.3; human.
DR   CTD; 13; -.
DR   GeneCards; GC03P151531; -.
DR   HGNC; HGNC:17; AADAC.
DR   HPA; HPA002911; -.
DR   MIM; 600338; gene.
DR   neXtProt; NX_P22760; -.
DR   PharmGKB; PA24363; -.
DR   eggNOG; COG0657; -.
DR   HOGENOM; HOG000033738; -.
DR   HOVERGEN; HBG058974; -.
DR   InParanoid; P22760; -.
DR   KO; K13616; -.
DR   OMA; YVYEPIP; -.
DR   OrthoDB; EOG7HB599; -.
DR   PhylomeDB; P22760; -.
DR   TreeFam; TF314978; -.
DR   SABIO-RK; P22760; -.
DR   GeneWiki; AADAC; -.
DR   GenomeRNAi; 13; -.
DR   NextBio; 27; -.
DR   PRO; PR:P22760; -.
DR   ArrayExpress; P22760; -.
DR   Bgee; P22760; -.
DR   CleanEx; HS_AADAC; -.
DR   Genevestigator; P22760; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0003824; F:catalytic activity; TAS:ProtInc.
DR   GO; GO:0019213; F:deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0016298; F:lipase activity; TAS:UniProtKB.
DR   GO; GO:0017171; F:serine hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0004806; F:triglyceride lipase activity; ISS:UniProtKB.
DR   GO; GO:0010898; P:positive regulation of triglyceride catabolic process; ISS:UniProtKB.
DR   Gene3D; 3.40.50.1820; -; 2.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR013094; AB_hydrolase_3.
DR   InterPro; IPR017157; Arylacetamide_deacetylase.
DR   InterPro; IPR002168; Lipase_GDXG_AS.
DR   Pfam; PF07859; Abhydrolase_3; 2.
DR   PIRSF; PIRSF037251; Arylacetamide_deacetylase; 1.
DR   SUPFAM; SSF53474; SSF53474; 1.
DR   PROSITE; PS01174; LIPASE_GDXG_SER; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Direct protein sequencing; Disulfide bond;
KW   Endoplasmic reticulum; Glycoprotein; Hydrolase; Membrane; Microsome;
KW   Polymorphism; Reference proteome; Signal-anchor; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    399       Arylacetamide deacetylase.
FT                                /FTId=PRO_0000071542.
FT   TOPO_DOM      1      5       Cytoplasmic (Potential).
FT   TRANSMEM      6     23       Helical; Signal-anchor for type II
FT                                membrane protein; (Potential).
FT   TOPO_DOM     24    399       Lumenal (Potential).
FT   MOTIF       111    113       Involved in the stabilization of the
FT                                negatively charged intermediate by the
FT                                formation of the oxyanion hole (By
FT                                similarity).
FT   ACT_SITE    111    111       Potential.
FT   ACT_SITE    189    189       Potential.
FT   CARBOHYD     78     78       N-linked (GlcNAc...).
FT   CARBOHYD    282    282       N-linked (GlcNAc...).
FT   DISULFID    116    340       By similarity.
FT   VARIANT     281    281       V -> I (in alleles AADAC*2 and AADAC*3;
FT                                mildly decreased enzyme activity;
FT                                dbSNP:rs1803155).
FT                                /FTId=VAR_014798.
FT   VARIANT     399    399       L -> LQ (in allele AADAC*3; decreased
FT                                enzyme activity).
FT                                /FTId=VAR_070543.
FT   MUTAGEN      78     78       N->Q: Abolishes glycosylation at this
FT                                site and causes moderate decrease in
FT                                activity.
FT   MUTAGEN     282    282       N->Q: Abolishes glycosylation at this
FT                                site and causes substantial decrease in
FT                                activity and reduced substrate affinity.
FT   CONFLICT      3      3       R -> M (in Ref. 6; AA sequence).
FT   CONFLICT     55     57       LHH -> VHI (in Ref. 1; AAA35551).
SQ   SEQUENCE   399 AA;  45734 MW;  34F9CB717DD7417A CRC64;
     MGRKSLYLLI VGILIAYYIY TPLPDNVEEP WRMMWINAHL KTIQNLATFV ELLGLHHFMD
     SFKVVGSFDE VPPTSDENVT VTETKFNNIL VRVYVPKRKS EALRRGLFYI HGGGWCVGSA
     ALSGYDLLSR WTADRLDAVV VSTNYRLAPK YHFPIQFEDV YNALRWFLRK KVLAKYGVNP
     ERIGISGDSA GGNLAAAVTQ QLLDDPDVKI KLKIQSLIYP ALQPLDVDLP SYQENSNFLF
     LSKSLMVRFW SEYFTTDRSL EKAMLSRQHV PVESSHLFKF VNWSSLLPER FIKGHVYNNP
     NYGSSELAKK YPGFLDVRAA PLLADDNKLR GLPLTYVITC QYDLLRDDGL MYVTRLRNTG
     VQVTHNHVED GFHGAFSFLG LKISHRLINQ YIEWLKENL
//
ID   AAAS_HUMAN              Reviewed;         546 AA.
AC   Q9NRG9; Q5JB47; Q9NWI6; Q9UG19;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   09-JUL-2014, entry version 132.
DE   RecName: Full=Aladin;
DE   AltName: Full=Adracalin;
GN   Name=AAAS; Synonyms=ADRACALA; ORFNames=GL003;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=11062474; DOI=10.1038/81642;
RA   Tullio-Pelet A., Salomon R., Hadj-Rabia S., Mugnier C., de Laet M.-H.,
RA   Chaouachi B., Bakiri F., Brottier P., Cattolico L., Penet C.,
RA   Begeot M., Naville D., Nicolino M., Chaussain J.-L., Weissenbach J.,
RA   Munnich A., Lyonnet S.;
RT   "Mutant WD-repeat protein in triple-A syndrome.";
RL   Nat. Genet. 26:332-335(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS AAAS LYS-15; ARG-160
RP   AND PRO-263.
RX   PubMed=11159947; DOI=10.1093/hmg/10.3.283;
RA   Handschug K., Sperling S., Yoon S.-J.K., Hennig S., Clark A.J.L.,
RA   Huebner A.;
RT   "Triple A syndrome is caused by mutations in AAAS, a new WD-repeat
RT   protein gene.";
RL   Hum. Mol. Genet. 10:283-290(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=16022285; DOI=10.1007/s11033-004-6939-9;
RA   Li X., Ji C., Gu J., Xu J., Jin Z., Sun L., Zou X., Lin Y., Sun R.,
RA   Wang P., Gu S., Mao Y.;
RT   "Molecular cloning and characterization of AAAS-V2, a novel splice
RT   variant of human AAAS.";
RL   Mol. Biol. Rep. 32:127-131(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Li Y., Wu T., Xu S., Ren S., Chen Z., Han Z.;
RT   "A novel gene expressed in human liver non-tumor tissues.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Adipose tissue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 210-546 (ISOFORM 1).
RC   TISSUE=Uterus;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-33, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH NDC1.
RX   PubMed=19782045; DOI=10.1016/j.bbrc.2009.09.080;
RA   Kind B., Koehler K., Lorenz M., Huebner A.;
RT   "The nuclear pore complex protein ALADIN is anchored via NDC1 but not
RT   via POM121 and GP210 in the nuclear envelope.";
RL   Biochem. Biophys. Res. Commun. 390:205-210(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-33 AND SER-495, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT CYS-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT CYS-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
CC   -!- FUNCTION: Plays a role in the normal development of the peripheral
CC       and central nervous system.
CC   -!- SUBUNIT: Interacts with NDC1, the interaction is required for
CC       nuclear pore localization.
CC   -!- SUBCELLULAR LOCATION: Nucleus, nuclear pore complex.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=AAAS-v1;
CC         IsoId=Q9NRG9-1; Sequence=Displayed;
CC       Name=2; Synonyms=AAAS-v2;
CC         IsoId=Q9NRG9-2; Sequence=VSP_043014;
CC         Note=Ubiquitously expressed;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Particularly abundant
CC       expression is found in cerebellum, corpus callosum, adrenal gland,
CC       pituitary gland, gastrointestinal structures and fetal lung.
CC   -!- DISEASE: Achalasia-addisonianism-alacrima syndrome (AAAS)
CC       [MIM:231550]: An autosomal recessive disorder characterized by
CC       adreno-corticotropic hormone (ACTH)-resistant adrenal failure,
CC       achalasia of the esophageal cardia and alacrima. The syndrome is
CC       associated with variable and progressive neurological impairment
CC       involving the central, peripheral, and autonomic nervous system.
CC       Other features such as palmoplantar hyperkeratosis, short stature,
CC       facial dysmorphy and osteoporosis may also be present. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Contains 4 WD repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ289857; CAC19017.1; -; mRNA.
DR   EMBL; AJ289841; CAC19038.1; -; Genomic_DNA.
DR   EMBL; AJ289842; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289843; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289844; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289845; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289846; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289847; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289848; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289849; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289850; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289851; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289852; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289853; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289854; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289855; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289856; CAC19038.1; JOINED; Genomic_DNA.
DR   EMBL; AJ297977; CAC17465.1; -; Genomic_DNA.
DR   EMBL; AY237818; AAP69911.1; -; mRNA.
DR   EMBL; AF226048; AAF86948.1; -; mRNA.
DR   EMBL; AK000833; BAA91394.1; -; mRNA.
DR   EMBL; BT006912; AAP35558.1; -; mRNA.
DR   EMBL; AC073611; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000659; AAH00659.1; -; mRNA.
DR   EMBL; AL110160; CAB53665.2; -; mRNA.
DR   CCDS; CCDS53797.1; -. [Q9NRG9-2]
DR   CCDS; CCDS8856.1; -. [Q9NRG9-1]
DR   RefSeq; NP_001166937.1; NM_001173466.1. [Q9NRG9-2]
DR   RefSeq; NP_056480.1; NM_015665.5. [Q9NRG9-1]
DR   UniGene; Hs.369144; -.
DR   ProteinModelPortal; Q9NRG9; -.
DR   SMR; Q9NRG9; 154-179, 247-273.
DR   BioGrid; 113759; 3.
DR   IntAct; Q9NRG9; 1.
DR   MINT; MINT-3073010; -.
DR   STRING; 9606.ENSP00000209873; -.
DR   PhosphoSite; Q9NRG9; -.
DR   DMDM; 20137527; -.
DR   MaxQB; Q9NRG9; -.
DR   PaxDb; Q9NRG9; -.
DR   PRIDE; Q9NRG9; -.
DR   DNASU; 8086; -.
DR   Ensembl; ENST00000209873; ENSP00000209873; ENSG00000094914. [Q9NRG9-1]
DR   Ensembl; ENST00000394384; ENSP00000377908; ENSG00000094914. [Q9NRG9-2]
DR   GeneID; 8086; -.
DR   KEGG; hsa:8086; -.
DR   UCSC; uc001scr.4; human. [Q9NRG9-1]
DR   UCSC; uc001scs.4; human. [Q9NRG9-2]
DR   CTD; 8086; -.
DR   GeneCards; GC12M053701; -.
DR   HGNC; HGNC:13666; AAAS.
DR   HPA; HPA040086; -.
DR   MIM; 231550; phenotype.
DR   MIM; 605378; gene.
DR   neXtProt; NX_Q9NRG9; -.
DR   Orphanet; 869; Triple A syndrome.
DR   PharmGKB; PA24361; -.
DR   eggNOG; NOG314927; -.
DR   HOGENOM; HOG000033741; -.
DR   HOVERGEN; HBG026353; -.
DR   InParanoid; Q9NRG9; -.
DR   KO; K14320; -.
DR   OMA; GEGKGCV; -.
DR   OrthoDB; EOG7JQBN1; -.
DR   PhylomeDB; Q9NRG9; -.
DR   TreeFam; TF324412; -.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_115566; Cell Cycle.
DR   Reactome; REACT_116125; Disease.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   Reactome; REACT_21300; Mitotic M-M/G1 phases.
DR   Reactome; REACT_6900; Immune System.
DR   SignaLink; Q9NRG9; -.
DR   ChiTaRS; AAAS; human.
DR   GeneWiki; AAAS_(gene); -.
DR   GenomeRNAi; 8086; -.
DR   NextBio; 30710; -.
DR   PRO; PR:Q9NRG9; -.
DR   ArrayExpress; Q9NRG9; -.
DR   Bgee; Q9NRG9; -.
DR   CleanEx; HS_AAAS; -.
DR   Genevestigator; Q9NRG9; -.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005635; C:nuclear envelope; TAS:Reactome.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0005643; C:nuclear pore; IDA:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:UniProt.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0009566; P:fertilization; IEA:Ensembl.
DR   GO; GO:0015758; P:glucose transport; TAS:Reactome.
DR   GO; GO:0008645; P:hexose transport; TAS:Reactome.
DR   GO; GO:0007612; P:learning; IEA:Ensembl.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0007077; P:mitotic nuclear envelope disassembly; TAS:Reactome.
DR   GO; GO:0006913; P:nucleocytoplasmic transport; IDA:MGI.
DR   GO; GO:0010827; P:regulation of glucose transport; TAS:Reactome.
DR   GO; GO:0046822; P:regulation of nucleocytoplasmic transport; NAS:UniProtKB.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; TAS:Reactome.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR019775; WD40_repeat_CS.
DR   InterPro; IPR017986; WD40_repeat_dom.
DR   Pfam; PF00400; WD40; 1.
DR   SMART; SM00320; WD40; 4.
DR   PROSITE; PS00678; WD_REPEATS_1; 1.
DR   PROSITE; PS50082; WD_REPEATS_2; 1.
DR   PROSITE; PS50294; WD_REPEATS_REGION; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Complete proteome;
KW   Disease mutation; mRNA transport; Nuclear pore complex; Nucleus;
KW   Phosphoprotein; Protein transport; Reference proteome; Repeat;
KW   Translocation; Transport; WD repeat.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    546       Aladin.
FT                                /FTId=PRO_0000050828.
FT   REPEAT      149    188       WD 1.
FT   REPEAT      191    230       WD 2.
FT   REPEAT      243    282       WD 3.
FT   REPEAT      285    324       WD 4.
FT   MOTIF       544    546       Microbody targeting signal (Potential).
FT   MOD_RES       2      2       N-acetylcysteine.
FT   MOD_RES      33     33       Phosphoserine.
FT   MOD_RES     495    495       Phosphoserine.
FT   VAR_SEQ     149    182       WSSCCLRVFAWHPHTNKFAVALLDDSVRVYNASS -> C
FT                                (in isoform 2).
FT                                /FTId=VSP_043014.
FT   VARIANT      15     15       Q -> K (in AAAS).
FT                                /FTId=VAR_012804.
FT   VARIANT     108    108       K -> M (in dbSNP:rs13330).
FT                                /FTId=VAR_037060.
FT   VARIANT     160    160       H -> R (in AAAS).
FT                                /FTId=VAR_012805.
FT   VARIANT     263    263       S -> P (in AAAS; dbSNP:rs121918550).
FT                                /FTId=VAR_012806.
FT   CONFLICT    122    122       S -> P (in Ref. 5; BAA91394).
FT   CONFLICT    135    135       R -> K (in Ref. 5; BAA91394).
FT   CONFLICT    479    479       I -> V (in Ref. 5; BAA91394).
SQ   SEQUENCE   546 AA;  59574 MW;  E0F4E7145D8C192E CRC64;
     MCSLGLFPPP PPRGQVTLYE HNNELVTGSS YESPPPDFRG QWINLPVLQL TKDPLKTPGR
     LDHGTRTAFI HHREQVWKRC INIWRDVGLF GVLNEIANSE EEVFEWVKTA SGWALALCRW
     ASSLHGSLFP HLSLRSEDLI AEFAQVTNWS SCCLRVFAWH PHTNKFAVAL LDDSVRVYNA
     SSTIVPSLKH RLQRNVASLA WKPLSASVLA VACQSCILIW TLDPTSLSTR PSSGCAQVLS
     HPGHTPVTSL AWAPSGGRLL SASPVDAAIR VWDVSTETCV PLPWFRGGGV TNLLWSPDGS
     KILATTPSAV FRVWEAQMWT CERWPTLSGR CQTGCWSPDG SRLLFTVLGE PLIYSLSFPE
     RCGEGKGCVG GAKSATIVAD LSETTIQTPD GEERLGGEAH SMVWDPSGER LAVLMKGKPR
     VQDGKPVILL FRTRNSPVFE LLPCGIIQGE PGAQPQLITF HPSFNKGALL SVGWSTGRIA
     HIPLYFVNAQ FPRFSPVLGR AQEPPAGGGG SIHDLPLFTE TSPTSAPWDP LPGPPPVLPH
     SPHSHL
//
ID   AAAT_HUMAN              Reviewed;         541 AA.
AC   Q15758; A8K9H5; B4DR77; B4DWS4; B7ZB81; D0EYG6; E9PC01; O95720;
AC   Q96RL9; Q9BWQ3; Q9UNP2;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   20-JUN-2002, sequence version 2.
DT   09-JUL-2014, entry version 140.
DE   RecName: Full=Neutral amino acid transporter B(0);
DE            Short=ATB(0);
DE   AltName: Full=Baboon M7 virus receptor;
DE   AltName: Full=RD114/simian type D retrovirus receptor;
DE   AltName: Full=Sodium-dependent neutral amino acid transporter type 2;
DE   AltName: Full=Solute carrier family 1 member 5;
GN   Name=SLC1A5; Synonyms=ASCT2, M7V1, RDR, RDRC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Choriocarcinoma;
RX   PubMed=8702519; DOI=10.1074/jbc.271.31.18657;
RA   Kekuda R., Prasad P.D., Fei Y.-J., Torres-Zamorano V., Sinha S.,
RA   Yang-Feng T.L., Leibach F.H., Ganapathy V.;
RT   "Cloning of the sodium-dependent, broad-scope, neutral amino acid
RT   transporter Bo from a human placental choriocarcinoma cell line.";
RL   J. Biol. Chem. 271:18657-18661(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION AS A VIRAL
RP   RECEPTOR.
RX   PubMed=10051606; DOI=10.1073/pnas.96.5.2129;
RA   Rasko J.E.J., Battini J.L., Gottschalk R.J., Mazo I., Miller A.D.;
RT   "The RD114/simian type D retrovirus receptor is a neutral amino acid
RT   transporter.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2129-2134(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION AS A VIRAL
RP   RECEPTOR.
RX   PubMed=10196349;
RA   Tailor C.S., Nouri A., Zhao Y., Takeuchi Y., Kabat D.;
RT   "A sodium-dependent neutral-amino-acid transporter mediates infections
RT   of feline and baboon endogenous retroviruses and simian type D
RT   retroviruses.";
RL   J. Virol. 73:4470-4474(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Ouyang D.-Y., Xu L.-H., He X.-H., Zha Q.-B., Guo H., Gao Q.,
RA   Zhang Y.-T.;
RT   "Cloning of ASCT2 cDNA from MCF-7 cells and its expression in B16
RT   cells.";
RL   Submitted (SEP-2009) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND
RP   VARIANT LEU-512.
RC   TISSUE=Esophagus, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 14-541 (ISOFORM 1), AND ALTERNATIVE
RP   INITIATION.
RX   PubMed=11350958; DOI=10.1074/jbc.M100737200;
RA   Tailor C.S., Marin M., Nouri A., Kavanaugh M.P., Kabat D.;
RT   "Truncated forms of the dual function human ASCT2 neutral amino acid
RT   transporter/retroviral receptor are translationally initiated at
RT   multiple alternative CUG and GUG codons.";
RL   J. Biol. Chem. 276:27221-27230(2001).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-535, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-535, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-212.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-503 AND SER-535, VARIANT
RP   [LARGE SCALE ANALYSIS] LEU-512, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-535, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-493, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
CC   -!- FUNCTION: Has a broad substrate specificity, a preference for
CC       zwitterionic amino acids, and a sodium-dependence. It accepts as
CC       substrates all neutral amino acids, including glutamine,
CC       asparagine, and branched-chain and aromatic amino acids, and
CC       excludes methylated amino acids, anionic amino acids, and cationic
CC       amino acids. Acts as a cell surface receptor for feline endogenous
CC       virus RD114, baboon M7 endogenous virus and type D simian
CC       retroviruses.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein
CC       (Probable). Melanosome. Note=Identified by mass spectrometry in
CC       melanosome fractions from stage I to stage IV.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=3;
CC         Comment=A number of isoforms are produced by alternative
CC         initiation. Isoforms start at multiple alternative CUG and GUG
CC         codons;
CC       Name=1;
CC         IsoId=Q15758-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15758-2; Sequence=VSP_046354;
CC         Note=No experimental confirmation available;
CC       Name=3;
CC         IsoId=Q15758-3; Sequence=VSP_046851;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Placenta, lung, skeletal muscle, kidney,
CC       pancreas, and intestine.
CC   -!- SIMILARITY: Belongs to the sodium:dicarboxylate (SDF) symporter
CC       (TC 2.A.23) family. SLC1A5 subfamily.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U53347; AAC50629.1; -; mRNA.
DR   EMBL; AF102826; AAD09812.1; -; mRNA.
DR   EMBL; AF105423; AAD27806.1; -; mRNA.
DR   EMBL; GQ919058; ACX53626.1; -; mRNA.
DR   EMBL; AK292690; BAF85379.1; -; mRNA.
DR   EMBL; AK299137; BAG61189.1; -; mRNA.
DR   EMBL; AK301661; BAG63136.1; -; mRNA.
DR   EMBL; AK316546; BAH14917.1; -; mRNA.
DR   EMBL; AC008622; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471126; EAW57446.1; -; Genomic_DNA.
DR   EMBL; BC000062; AAH00062.1; -; mRNA.
DR   EMBL; AF334818; AAK77026.1; -; mRNA.
DR   CCDS; CCDS12692.1; -. [Q15758-1]
DR   CCDS; CCDS46125.1; -. [Q15758-2]
DR   CCDS; CCDS46126.1; -. [Q15758-3]
DR   RefSeq; NP_001138616.1; NM_001145144.1. [Q15758-3]
DR   RefSeq; NP_001138617.1; NM_001145145.1. [Q15758-2]
DR   RefSeq; NP_005619.1; NM_005628.2. [Q15758-1]
DR   UniGene; Hs.631582; -.
DR   ProteinModelPortal; Q15758; -.
DR   SMR; Q15758; 59-482.
DR   BioGrid; 112401; 15.
DR   IntAct; Q15758; 6.
DR   MINT; MINT-5001314; -.
DR   STRING; 9606.ENSP00000303623; -.
DR   DrugBank; DB00174; L-Asparagine.
DR   DrugBank; DB00130; L-Glutamine.
DR   GuidetoPHARMACOLOGY; 874; -.
DR   TCDB; 2.A.23.3.3; the dicarboxylate/amino acid:cation (na(+) or h(+)) symporter (daacs) family.
DR   PhosphoSite; Q15758; -.
DR   DMDM; 21542389; -.
DR   MaxQB; Q15758; -.
DR   PaxDb; Q15758; -.
DR   PeptideAtlas; Q15758; -.
DR   PRIDE; Q15758; -.
DR   DNASU; 6510; -.
DR   Ensembl; ENST00000412532; ENSP00000397924; ENSG00000105281. [Q15758-3]
DR   Ensembl; ENST00000434726; ENSP00000406532; ENSG00000105281. [Q15758-2]
DR   Ensembl; ENST00000542575; ENSP00000444408; ENSG00000105281. [Q15758-1]
DR   GeneID; 6510; -.
DR   KEGG; hsa:6510; -.
DR   UCSC; uc002pfr.3; human. [Q15758-1]
DR   CTD; 6510; -.
DR   GeneCards; GC19M047278; -.
DR   H-InvDB; HIX0015262; -.
DR   HGNC; HGNC:10943; SLC1A5.
DR   HPA; HPA035239; -.
DR   HPA; HPA035240; -.
DR   MIM; 109190; gene.
DR   neXtProt; NX_Q15758; -.
DR   PharmGKB; PA35830; -.
DR   eggNOG; COG1301; -.
DR   HOVERGEN; HBG000080; -.
DR   InParanoid; Q15758; -.
DR   KO; K05616; -.
DR   OMA; LVRNIFP; -.
DR   OrthoDB; EOG7RV9G2; -.
DR   PhylomeDB; Q15758; -.
DR   TreeFam; TF315206; -.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   Reactome; REACT_19419; Amino acid and oligopeptide SLC transporters.
DR   ChiTaRS; SLC1A5; human.
DR   GeneWiki; SLC1A5; -.
DR   GenomeRNAi; 6510; -.
DR   NextBio; 25315; -.
DR   PRO; PR:Q15758; -.
DR   ArrayExpress; Q15758; -.
DR   Bgee; Q15758; -.
DR   CleanEx; HS_SLC1A5; -.
DR   Genevestigator; Q15758; -.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0015186; F:L-glutamine transmembrane transporter activity; TAS:BHF-UCL.
DR   GO; GO:0015194; F:L-serine transmembrane transporter activity; IEA:Ensembl.
DR   GO; GO:0015175; F:neutral amino acid transmembrane transporter activity; TAS:ProtInc.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0017153; F:sodium:dicarboxylate symporter activity; IEA:InterPro.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0006865; P:amino acid transport; TAS:Reactome.
DR   GO; GO:0006860; P:extracellular amino acid transport; IEA:Ensembl.
DR   GO; GO:0006868; P:glutamine transport; TAS:BHF-UCL.
DR   GO; GO:0006811; P:ion transport; TAS:Reactome.
DR   GO; GO:0015804; P:neutral amino acid transport; TAS:ProtInc.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   Gene3D; 1.10.3860.10; -; 1.
DR   InterPro; IPR001991; Na-dicarboxylate_symporter.
DR   InterPro; IPR018107; Na-dicarboxylate_symporter_CS.
DR   PANTHER; PTHR11958; PTHR11958; 1.
DR   Pfam; PF00375; SDF; 1.
DR   PRINTS; PR00173; EDTRNSPORT.
DR   SUPFAM; SSF118215; SSF118215; 1.
DR   PROSITE; PS00713; NA_DICARBOXYL_SYMP_1; 1.
DR   PROSITE; PS00714; NA_DICARBOXYL_SYMP_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative initiation; Alternative splicing;
KW   Complete proteome; Glycoprotein; Host cell receptor for virus entry;
KW   Membrane; Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Symport; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1    541       Neutral amino acid transporter B(0).
FT                                /FTId=PRO_0000202082.
FT   TOPO_DOM      1     52       Cytoplasmic (Potential).
FT   TRANSMEM     53     73       Helical; (Potential).
FT   TRANSMEM     99    119       Helical; (Potential).
FT   TRANSMEM    133    153       Helical; (Potential).
FT   TOPO_DOM    154    224       Extracellular (Potential).
FT   TRANSMEM    225    245       Helical; (Potential).
FT   TRANSMEM    266    286       Helical; (Potential).
FT   TRANSMEM    306    326       Helical; (Potential).
FT   TRANSMEM    336    356       Helical; (Potential).
FT   TRANSMEM    377    397       Helical; (Potential).
FT   TRANSMEM    399    419       Helical; (Potential).
FT   TRANSMEM    426    446       Helical; (Potential).
FT   MOD_RES       1      1       N-acetylmethionine.
FT   MOD_RES     493    493       Phosphoserine.
FT   MOD_RES     503    503       Phosphoserine.
FT   MOD_RES     535    535       Phosphoserine.
FT   CARBOHYD    163    163       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    212    212       N-linked (GlcNAc...).
FT   VAR_SEQ       1    228       Missing (in isoform 3).
FT                                /FTId=VSP_046851.
FT   VAR_SEQ       1    203       MVADPPRDSKGLAAAEPTANGGLALASIEDQGAAAGGYCGS
FT                                RDQVRRCLRANLLVLLTVVAVVAGVALGLGVSGAGGALALG
FT                                PERLSAFVFPGELLLRLLRMIILPLVVCSLIGGAASLDPGA
FT                                LGRLGAWALLFFLVTTLLASALGVGLALALQPGAASAAINA
FT                                SVGAAGSAENAPSKEVLDSFLDLARNIFPSNLVSAAFRS
FT                                -> M (in isoform 2).
FT                                /FTId=VSP_046354.
FT   VARIANT      17     17       P -> A (in dbSNP:rs3027956).
FT                                /FTId=VAR_020439.
FT   VARIANT     512    512       V -> L (in dbSNP:rs3027961).
FT                                /FTId=VAR_013517.
FT   CONFLICT     18     24       TANGGLA -> PPTGAWQ (in Ref. 1; AAC50629).
FT   CONFLICT     44     44       Q -> L (in Ref. 1; AAC50629).
FT   CONFLICT     84     87       ERLS -> GALE (in Ref. 1; AAC50629).
FT   CONFLICT    341    341       V -> A (in Ref. 5; BAH14917).
FT   CONFLICT    453    453       I -> V (in Ref. 2; AAD09812).
FT   CONFLICT    460    460       D -> G (in Ref. 2; AAD09812).
FT   CONFLICT    463    463       V -> A (in Ref. 2; AAD09812).
FT   CONFLICT    508    508       D -> G (in Ref. 2; AAD09812).
SQ   SEQUENCE   541 AA;  56598 MW;  AD61C789CCFFE934 CRC64;
     MVADPPRDSK GLAAAEPTAN GGLALASIED QGAAAGGYCG SRDQVRRCLR ANLLVLLTVV
     AVVAGVALGL GVSGAGGALA LGPERLSAFV FPGELLLRLL RMIILPLVVC SLIGGAASLD
     PGALGRLGAW ALLFFLVTTL LASALGVGLA LALQPGAASA AINASVGAAG SAENAPSKEV
     LDSFLDLARN IFPSNLVSAA FRSYSTTYEE RNITGTRVKV PVGQEVEGMN ILGLVVFAIV
     FGVALRKLGP EGELLIRFFN SFNEATMVLV SWIMWYAPVG IMFLVAGKIV EMEDVGLLFA
     RLGKYILCCL LGHAIHGLLV LPLIYFLFTR KNPYRFLWGI VTPLATAFGT SSSSATLPLM
     MKCVEENNGV AKHISRFILP IGATVNMDGA ALFQCVAAVF IAQLSQQSLD FVKIITILVT
     ATASSVGAAG IPAGGVLTLA IILEAVNLPV DHISLILAVD WLVDRSCTVL NVEGDALGAG
     LLQNYVDRTE SRSTEPELIQ VKSELPLDPL PVPTEEGNPL LKHYRGPAGD ATVASEKESV
     M
//
ID   AACT_HUMAN              Reviewed;         423 AA.
AC   P01011; B3KVQ7; Q13703; Q2TU87; Q2TU88; Q59GP9; Q6LBY8; Q6LDT7;
AC   Q6NSC9; Q8N177; Q96DW8; Q9UC47; Q9UNU9;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 2.
DT   09-JUL-2014, entry version 180.
DE   RecName: Full=Alpha-1-antichymotrypsin;
DE            Short=ACT;
DE   AltName: Full=Cell growth-inhibiting gene 24/25 protein;
DE   AltName: Full=Serpin A3;
DE   Contains:
DE     RecName: Full=Alpha-1-antichymotrypsin His-Pro-less;
DE   Flags: Precursor;
GN   Name=SERPINA3; Synonyms=AACT; ORFNames=GIG24, GIG25;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=6606438; DOI=10.1021/bi00291a001;
RA   Chandra T., Stackhouse R., Kidd V.J., Robson K.J.H., Woo S.L.C.;
RT   "Sequence homology between human alpha 1-antichymotrypsin, alpha 1-
RT   antitrypsin, and antithrombin III.";
RL   Biochemistry 22:5055-5061(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS BOCHUM-1 PRO-78 AND
RP   BONN-1 ALA-252.
RX   PubMed=8244391; DOI=10.1006/geno.1993.1396;
RA   Poller W., Faber J.-P., Weidinger S., Tief K., Scholz S., Fischer M.,
RA   Olek K., Kirchgesser M., Heidtmann H.-H.;
RT   "A leucine-to-proline substitution causes a defective alpha 1-
RT   antichymotrypsin allele associated with familial obstructive lung
RT   disease.";
RL   Genomics 17:740-743(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-9.
RA   Kim J.W.;
RT   "Identification of a human cell growth inhibiting gene.";
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-9.
RC   TISSUE=Urinary bladder;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT THR-9.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND
RP   VARIANTS THR-9 AND ARG-267.
RC   TISSUE=Brain, Liver, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-46, AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=3257719; DOI=10.1016/0092-8674(88)90462-X;
RA   Abraham C.R., Selkoe D.J., Potter H.;
RT   "Immunochemical identification of the serine protease inhibitor alpha
RT   1-antichymotrypsin in the brain amyloid deposits of Alzheimer's
RT   disease.";
RL   Cell 52:487-501(1988).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 17-423 (ISOFORM 1), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Hippocampus;
RX   PubMed=9880565; DOI=10.1074/jbc.274.3.1821;
RA   Hwang S.-R., Steineckert B., Kohn A., Palkovits M., Hook V.Y.H.;
RT   "Molecular studies define the primary structure of alpha1-
RT   antichymotrypsin (ACT) protease inhibitor in Alzheimer's disease
RT   brains. Comparison of act in hippocampus and liver.";
RL   J. Biol. Chem. 274:1821-1827(1999).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 22-86 AND 130-423 (ISOFORM 1).
RA   Rubin H.;
RL   Submitted (OCT-1989) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   PROTEIN SEQUENCE OF 24-34.
RX   PubMed=2787670; DOI=10.1016/0167-4838(89)90139-8;
RA   Lindmark B., Hilja H., Alan R., Eriksson S.;
RT   "The microheterogeneity of desialylated alpha 1-antichymotrypsin: the
RT   occurrence of two amino-terminal isoforms, one lacking a His-Pro
RT   dipeptide.";
RL   Biochim. Biophys. Acta 997:90-95(1989).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 36-45.
RX   PubMed=7521171; DOI=10.1515/bchm3.1994.375.5.335;
RA   Korzus E., Luisetti M., Travis J.;
RT   "Interactions of alpha-1-antichymotrypsin, alpha-1-proteinase
RT   inhibitor, and alpha-2-macroglobulin with the fungal enzyme,
RT   seaprose.";
RL   Biol. Chem. Hoppe-Seyler 375:335-341(1994).
RN   [12]
RP   PROTEIN SEQUENCE OF 41-60.
RX   PubMed=6687683; DOI=10.1016/0006-291X(83)90325-X;
RA   Morii M., Travis J.;
RT   "Structural alterations in alpha 1-antichymotrypsin from normal and
RT   acute phase human plasma.";
RL   Biochem. Biophys. Res. Commun. 111:438-443(1983).
RN   [13]
RP   PROTEIN SEQUENCE OF 48-68 (ISOFORMS 1/2).
RX   PubMed=8647626;
RX   DOI=10.1002/(SICI)1097-0215(19960529)66:5<636::AID-IJC10>3.0.CO;2-2;
RA   Pinczower G.D., Williams R.P.W., Gianello R.D., Robinson H.C.,
RA   Preston B.N., Linnane A.W.;
RT   "Characterisation of the tumour-associated carbohydrate epitope
RT   recognised by monoclonal antibody 4D3.";
RL   Int. J. Cancer 66:636-644(1996).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 87-129 (ISOFORMS 1/2), AND FUNCTION.
RC   TISSUE=Liver;
RX   PubMed=2404007;
RA   Rubin H., Wang Z., Nickbarg E.B., McLarney S., Naidoo N.,
RA   Schoenberger O.L., Johnson J.L., Cooperman B.S.;
RT   "Cloning, expression, purification, and biological activity of
RT   recombinant native and variant human alpha 1-antichymotrypsins.";
RL   J. Biol. Chem. 265:1199-1207(1990).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 205-423.
RX   PubMed=6547997; DOI=10.1038/311175a0;
RA   Hill R.E., Shaw P.H., Boyd P.A., Baumann H., Hastie N.D.;
RT   "Plasma protease inhibitors in mouse and man: divergence within the
RT   reactive centre regions.";
RL   Nature 311:175-177(1984).
RN   [16]
RP   REACTIVE SITE.
RX   PubMed=6556193;
RA   Morii M., Travis J.;
RT   "Amino acid sequence at the reactive site of human alpha 1-
RT   antichymotrypsin.";
RL   J. Biol. Chem. 258:12749-12752(1983).
RN   [17]
RP   GLYCOSYLATION AT ASN-93 AND ASN-106.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [18]
RP   INTERACTION WITH DNAJC1.
RX   PubMed=14668352; DOI=10.1074/jbc.M310903200;
RA   Kroczynska B., Evangelista C.M., Samant S.S., Elguindi E.C.,
RA   Blond S.Y.;
RT   "The SANT2 domain of the murine tumor cell DnaJ-like protein 1 human
RT   homologue interacts with alpha1-antichymotrypsin and kinetically
RT   interferes with its serpin inhibitory activity.";
RL   J. Biol. Chem. 279:11432-11443(2004).
RN   [19]
RP   REGION RCL.
RX   PubMed=15638460; DOI=10.1007/s00239-004-2640-9;
RA   Horvath A.J., Forsyth S.L., Coughlin P.B.;
RT   "Expression patterns of murine antichymotrypsin-like genes reflect
RT   evolutionary divergence at the Serpina3 locus.";
RL   J. Mol. Evol. 59:488-497(2004).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-93; ASN-106;
RP   ASN-127; ASN-186 AND ASN-271.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93; ASN-106; ASN-127 AND
RP   ASN-271.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [23]
RP   GLYCOSYLATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23234360; DOI=10.1021/pr300963h;
RA   Halim A., Ruetschi U., Larson G., Nilsson J.;
RT   "LC-MS/MS characterization of O-glycosylation sites and glycan
RT   structures of human cerebrospinal fluid glycoproteins.";
RL   J. Proteome Res. 12:573-584(2013).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 24-423.
RX   PubMed=2016749; DOI=10.1016/0022-2836(91)90704-A;
RA   Baumann U., Huber R., Bode W., Grosse D., Lesjak M., Laurell C.-B.;
RT   "Crystal structure of cleaved human alpha 1-antichymotrypsin at 2.7-A
RT   resolution and its comparison with other serpins.";
RL   J. Mol. Biol. 218:595-606(1991).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 43-423 OF MUTANTS ARG-370
RP   AND ARG-372.
RX   PubMed=8836107; DOI=10.1038/nsb1096-888;
RA   Lukacs C.M., Zhong J.Q., Plotnick M.I., Rubin H., Cooperman B.S.,
RA   Christianson D.W.;
RT   "Arginine substitutions in the hinge region of antichymotrypsin affect
RT   serpin beta-sheet rearrangement.";
RL   Nat. Struct. Biol. 3:888-893(1996).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 43-423 OF MUTANTS ARG-370;
RP   ARG-372 AND ARG-374.
RX   PubMed=9521649; DOI=10.1021/bi972359e;
RA   Lukacs C.M., Rubin H., Christianson D.W.;
RT   "Engineering an anion-binding cavity in antichymotrypsin modulates the
RT   'spring-loaded' serpin-protease interaction.";
RL   Biochemistry 37:3297-3304(1998).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 26-423.
RX   PubMed=10618372; DOI=10.1073/pnas.97.1.67;
RA   Gooptu B., Hazes B., Chang W.-S.W., Dafforn T.R., Carrell R.W.,
RA   Read R.J., Lomas D.A.;
RT   "Inactive conformation of the serpin alpha(1)-antichymotrypsin
RT   indicates two-stage insertion of the reactive loop: implications for
RT   inhibitory function and conformational disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:67-72(2000).
RN   [28]
RP   VARIANT ISEHARA-1 VAL-401.
RX   PubMed=1618300; DOI=10.1016/0014-5793(92)80590-D;
RA   Tsuda M., Sei Y., Yamamura M., Yamamoto M., Shinohara Y.;
RT   "Detection of a new mutant alpha-1-antichymotrypsin in patients with
RT   occlusive-cerebrovascular disease.";
RL   FEBS Lett. 304:66-68(1992).
RN   [29]
RP   VARIANT BONN-1 ALA-252.
RX   PubMed=1351206; DOI=10.1016/0140-6736(92)91301-N;
RA   Poller W., Faber J.-P., Scholz S., Weindinger S., Bartholome K.,
RA   Olek K., Eriksson S.;
RT   "Mis-sense mutation of alpha 1-antichymotrypsin gene associated with
RT   chronic lung disease.";
RL   Lancet 339:1538-1538(1992).
RN   [30]
RP   VARIANT VAL-401.
RX   PubMed=11289720; DOI=10.1007/s100380170125;
RA   Tachikawa H., Tsuda M., Onoe K., Ueno M., Takagi S., Shinohara Y.;
RT   "Alpha-1-antichymotrypsin gene A1252G variant (ACT Isehara-1) is
RT   associated with a lacunar type of ischemic cerebrovascular disease.";
RL   J. Hum. Genet. 46:45-47(2001).
CC   -!- FUNCTION: Although its physiological function is unclear, it can
CC       inhibit neutrophil cathepsin G and mast cell chymase, both of
CC       which can convert angiotensin-1 to the active angiotensin-2.
CC   -!- SUBUNIT: Interacts with DNAJC1.
CC   -!- INTERACTION:
CC       Q96KC8:DNAJC1; NbExp=3; IntAct=EBI-296557, EBI-296550;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P01011-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P01011-2; Sequence=VSP_014227, VSP_014228;
CC         Note=No experimental confirmation available;
CC       Name=3;
CC         IsoId=P01011-3; Sequence=VSP_014225, VSP_014226;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Plasma. Synthesized in the liver. Like the
CC       related alpha-1-antitrypsin, its concentration increases in the
CC       acute phase of inflammation or infection. Found in the amyloid
CC       plaques from the hippocampus of Alzheimer disease brains.
CC   -!- DOMAIN: The reactive center loop (RCL) extends out from the body
CC       of the protein and directs binding to the target protease. The
CC       protease cleaves the serpin at the reactive site within the RCL,
CC       establishing a covalent linkage between the carboxyl group of the
CC       serpin reactive site and the serine hydroxyl of the protease. The
CC       resulting inactive serpin-protease complex is highly stable.
CC   -!- PTM: N- and O-glycosylated.
CC   -!- MISCELLANEOUS: Alpha-1-antichymotrypsin can bind DNA.
CC   -!- SIMILARITY: Belongs to the serpin family.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-4 is the initiator.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA51543.1; Type=Frameshift; Positions=101, 106, 111, 117, 123, 129, 421;
CC       Sequence=AAT08029.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC       Sequence=AAT08029.1; Type=Frameshift; Positions=4;
CC       Sequence=BAD92297.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC       Sequence=CAA48671.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alpha-1 antichymotrypsin entry;
CC       URL="http://en.wikipedia.org/wiki/Alpha_1-antichymotrypsin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K01500; AAA51543.1; ALT_FRAME; mRNA.
DR   EMBL; X68733; CAA48671.1; ALT_INIT; Genomic_DNA.
DR   EMBL; X68734; CAA48671.1; JOINED; Genomic_DNA.
DR   EMBL; X68735; CAA48671.1; JOINED; Genomic_DNA.
DR   EMBL; X68736; CAA48671.1; JOINED; Genomic_DNA.
DR   EMBL; X68737; CAA48671.1; JOINED; Genomic_DNA.
DR   EMBL; AY513275; AAT08028.1; -; mRNA.
DR   EMBL; AY513276; AAT08029.1; ALT_SEQ; mRNA.
DR   EMBL; AK123091; BAG53869.1; -; mRNA.
DR   EMBL; AB209060; BAD92297.1; ALT_INIT; mRNA.
DR   EMBL; BC003559; AAH03559.3; -; mRNA.
DR   EMBL; BC010530; AAH10530.1; -; mRNA.
DR   EMBL; BC013189; AAH13189.1; -; mRNA.
DR   EMBL; BC034554; AAH34554.1; -; mRNA.
DR   EMBL; BC070265; AAH70265.1; -; mRNA.
DR   EMBL; M18906; AAA51559.1; -; mRNA.
DR   EMBL; AF089747; AAD08810.1; -; mRNA.
DR   EMBL; J05176; AAA51560.1; -; mRNA.
DR   EMBL; X00947; CAA25459.1; -; Genomic_DNA.
DR   CCDS; CCDS32150.1; -. [P01011-1]
DR   PIR; A90475; ITHUC.
DR   PIR; S62374; S62374.
DR   RefSeq; NP_001076.2; NM_001085.4. [P01011-1]
DR   UniGene; Hs.534293; -.
DR   UniGene; Hs.710488; -.
DR   PDB; 1AS4; X-ray; 2.10 A; A=43-383, B=387-423.
DR   PDB; 1QMN; X-ray; 2.27 A; A=26-423.
DR   PDB; 2ACH; X-ray; 2.70 A; A=24-383, B=384-423.
DR   PDB; 3CAA; X-ray; 2.40 A; A=43-383, B=387-423.
DR   PDB; 3DLW; X-ray; 2.70 A; A=25-423.
DR   PDB; 4CAA; X-ray; 2.90 A; A=43-383, B=387-423.
DR   PDBsum; 1AS4; -.
DR   PDBsum; 1QMN; -.
DR   PDBsum; 2ACH; -.
DR   PDBsum; 3CAA; -.
DR   PDBsum; 3DLW; -.
DR   PDBsum; 4CAA; -.
DR   ProteinModelPortal; P01011; -.
DR   SMR; P01011; 48-422.
DR   BioGrid; 106530; 11.
DR   IntAct; P01011; 10.
DR   ChEMBL; CHEMBL5960; -.
DR   MEROPS; I04.002; -.
DR   PhosphoSite; P01011; -.
DR   UniCarbKB; P01011; -.
DR   DMDM; 112874; -.
DR   DOSAC-COBS-2DPAGE; P01011; -.
DR   SWISS-2DPAGE; P01011; -.
DR   MaxQB; P01011; -.
DR   PaxDb; P01011; -.
DR   PRIDE; P01011; -.
DR   DNASU; 12; -.
DR   Ensembl; ENST00000393078; ENSP00000376793; ENSG00000196136. [P01011-1]
DR   Ensembl; ENST00000393080; ENSP00000376795; ENSG00000196136. [P01011-1]
DR   Ensembl; ENST00000467132; ENSP00000450540; ENSG00000196136. [P01011-1]
DR   Ensembl; ENST00000556968; ENSP00000452476; ENSG00000196136. [P01011-2]
DR   GeneID; 12; -.
DR   KEGG; hsa:12; -.
DR   UCSC; uc001ydp.3; human. [P01011-1]
DR   UCSC; uc021sbb.2; human. [P01011-3]
DR   CTD; 12; -.
DR   GeneCards; GC14P095078; -.
DR   H-InvDB; HIX0079611; -.
DR   HGNC; HGNC:16; SERPINA3.
DR   HPA; CAB016647; -.
DR   HPA; HPA000893; -.
DR   HPA; HPA002560; -.
DR   MIM; 107280; gene.
DR   neXtProt; NX_P01011; -.
DR   Orphanet; 93594; Alpha-1-antichymotrypsin deficiency.
DR   PharmGKB; PA35020; -.
DR   eggNOG; COG4826; -.
DR   HOVERGEN; HBG005957; -.
DR   InParanoid; P01011; -.
DR   KO; K04525; -.
DR   PhylomeDB; P01011; -.
DR   TreeFam; TF343201; -.
DR   ChiTaRS; SERPINA3; human.
DR   EvolutionaryTrace; P01011; -.
DR   GeneWiki; Alpha_1-antichymotrypsin; -.
DR   GenomeRNAi; 12; -.
DR   NextBio; 23; -.
DR   PMAP-CutDB; P01011; -.
DR   PRO; PR:P01011; -.
DR   ArrayExpress; P01011; -.
DR   Bgee; P01011; -.
DR   Genevestigator; P01011; -.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005622; C:intracellular; NAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; TAS:UniProtKB.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0006954; P:inflammatory response; NAS:UniProtKB.
DR   GO; GO:0030277; P:maintenance of gastrointestinal epithelium; NAS:UniProtKB.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IBA:RefGenome.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; NAS:UniProtKB.
DR   GO; GO:0030162; P:regulation of proteolysis; IBA:RefGenome.
DR   InterPro; IPR023795; Serpin_CS.
DR   InterPro; IPR023796; Serpin_dom.
DR   InterPro; IPR000215; Serpin_fam.
DR   PANTHER; PTHR11461; PTHR11461; 1.
DR   Pfam; PF00079; Serpin; 1.
DR   SMART; SM00093; SERPIN; 1.
DR   SUPFAM; SSF56574; SSF56574; 1.
DR   PROSITE; PS00284; SERPIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Glycoprotein;
KW   Polymorphism; Protease inhibitor; Reference proteome; Secreted;
KW   Serine protease inhibitor; Signal.
FT   SIGNAL        1     23
FT   CHAIN        24    423       Alpha-1-antichymotrypsin.
FT                                /FTId=PRO_0000032411.
FT   CHAIN        26    423       Alpha-1-antichymotrypsin His-Pro-less.
FT                                /FTId=PRO_0000032412.
FT   DNA_BIND    235    237
FT   REGION      369    394       RCL.
FT   REGION      381    389       O-glycosylated at one site.
FT   SITE        383    384       Reactive bond.
FT   CARBOHYD     33     33       N-linked (GlcNAc...).
FT   CARBOHYD     93     93       N-linked (GlcNAc...).
FT   CARBOHYD    106    106       N-linked (GlcNAc...).
FT   CARBOHYD    127    127       N-linked (GlcNAc...).
FT   CARBOHYD    186    186       N-linked (GlcNAc...).
FT   CARBOHYD    271    271       N-linked (GlcNAc...).
FT   VAR_SEQ      64     95       LVLKAPDKNVIFSPLSISTALAFLSLGAHNTT -> SPRWS
FT                                IRLCLMYLRRAQKHLLPQQSKSPSFLH (in isoform
FT                                3).
FT                                /FTId=VSP_014225.
FT   VAR_SEQ      96    423       Missing (in isoform 3).
FT                                /FTId=VSP_014226.
FT   VAR_SEQ     215    216       AK -> ER (in isoform 2).
FT                                /FTId=VSP_014227.
FT   VAR_SEQ     217    423       Missing (in isoform 2).
FT                                /FTId=VSP_014228.
FT   VARIANT       9      9       A -> T (in dbSNP:rs4934).
FT                                /FTId=VAR_006973.
FT   VARIANT      78     78       L -> P (in Bochum-1; dbSNP:rs1800463).
FT                                /FTId=VAR_006974.
FT   VARIANT     167    167       A -> G.
FT                                /FTId=VAR_006975.
FT   VARIANT     252    252       P -> A (in Bonn-1; dbSNP:rs17473).
FT                                /FTId=VAR_006976.
FT   VARIANT     267    267       K -> R (in dbSNP:rs17853314).
FT                                /FTId=VAR_037902.
FT   VARIANT     401    401       M -> V (associated with occlusive-
FT                                cerebrovascular disease; Isehara-1).
FT                                /FTId=VAR_006977.
FT   VARIANT     407    407       D -> G (in dbSNP:rs10956).
FT                                /FTId=VAR_011742.
FT   CONFLICT     55     55       D -> S (in Ref. 12; AA sequence).
FT   CONFLICT     69     69       P -> L (in Ref. 1; AAA51543).
FT   CONFLICT    101    101       K -> R (in Ref. 5; BAD92297).
FT   CONFLICT    106    106       N -> Y (in Ref. 3; AAT08028).
FT   CONFLICT    198    198       D -> N (in Ref. 3; AAT08029).
FT   CONFLICT    199    199       L -> P (in Ref. 1; AAA51543).
FT   CONFLICT    234    234       S -> N (in Ref. 3; AAT08029).
FT   CONFLICT    339    339       S -> G (in Ref. 3; AAT08028).
FT   CONFLICT    346    346       I -> S (in Ref. 3; AAT08028).
FT   CONFLICT    361    363       AVL -> VVS (in Ref. 1; AAA51543).
FT   HELIX        49     67
FT   STRAND       69     71
FT   STRAND       73     75
FT   HELIX        77     88
FT   HELIX        93    102
FT   TURN        107    109
FT   HELIX       112    126
FT   STRAND      130    132
FT   STRAND      134    144
FT   HELIX       151    161
FT   STRAND      164    168
FT   HELIX       170    172
FT   HELIX       173    187
FT   TURN        188    190
FT   STRAND      203    219
FT   HELIX       223    225
FT   STRAND      227    234
FT   STRAND      237    256
FT   TURN        257    260
FT   STRAND      261    279
FT   TURN        281    283
FT   HELIX       284    289
FT   HELIX       293    302
FT   STRAND      304    314
FT   STRAND      316    323
FT   HELIX       325    330
FT   HELIX       335    337
FT   HELIX       344    347
FT   STRAND      348    350
FT   STRAND      352    365
FT   STRAND      367    382
FT   STRAND      391    394
FT   STRAND      399    405
FT   STRAND      412    418
SQ   SEQUENCE   423 AA;  47651 MW;  B002F946C86A8951 CRC64;
     MERMLPLLAL GLLAAGFCPA VLCHPNSPLD EENLTQENQD RGTHVDLGLA SANVDFAFSL
     YKQLVLKAPD KNVIFSPLSI STALAFLSLG AHNTTLTEIL KGLKFNLTET SEAEIHQSFQ
     HLLRTLNQSS DELQLSMGNA MFVKEQLSLL DRFTEDAKRL YGSEAFATDF QDSAAAKKLI
     NDYVKNGTRG KITDLIKDLD SQTMMVLVNY IFFKAKWEMP FDPQDTHQSR FYLSKKKWVM
     VPMMSLHHLT IPYFRDEELS CTVVELKYTG NASALFILPD QDKMEEVEAM LLPETLKRWR
     DSLEFREIGE LYLPKFSISR DYNLNDILLQ LGIEEAFTSK ADLSGITGAR NLAVSQVVHK
     AVLDVFEEGT EASAATAVKI TLLSALVETR TIVRFNRPFL MIIVPTDTQN IFFMSKVTNP
     KQA
//
ID   AAK1_HUMAN              Reviewed;         961 AA.
AC   Q2M2I8; Q4ZFZ3; Q53RX6; Q9UPV4;
DT   03-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 3.
DT   09-JUL-2014, entry version 91.
DE   RecName: Full=AP2-associated protein kinase 1;
DE            EC=2.7.11.1;
DE   AltName: Full=Adaptor-associated kinase 1;
GN   Name=AAK1; Synonyms=KIAA1048;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH
RP   CLATHRIN, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=17494869; DOI=10.1091/mbc.E06-09-0831;
RA   Henderson D.M., Conner S.D.;
RT   "A novel AAK1 splice variant functions at multiple steps of the
RT   endocytic pathway.";
RL   Mol. Biol. Cell 18:2698-2706(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   GLN-509.
RC   TISSUE=Brain;
RX   PubMed=10470851; DOI=10.1093/dnares/6.3.197;
RA   Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIV.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 6:197-205(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   GLN-509.
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, AND MUTAGENESIS OF LYS-74 AND ASP-176.
RX   PubMed=12952931; DOI=10.1083/jcb.200304069;
RA   Conner S.D., Schmid S.L.;
RT   "Differential requirements for AP-2 in clathrin-mediated
RT   endocytosis.";
RL   J. Cell Biol. 162:773-779(2003).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-389 AND THR-606, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-389, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-637, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using
RT   sequential IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-389; THR-441; SER-637
RP   AND SER-731, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-234; SER-235; THR-389;
RP   THR-606; THR-620; SER-623; SER-624 AND SER-637, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   FUNCTION, INTERACTION WITH NUMB, AND MUTAGENESIS OF LYS-74 AND
RP   ASP-176.
RX   PubMed=18657069; DOI=10.1111/j.1600-0854.2008.00790.x;
RA   Sorensen E.B., Conner S.D.;
RT   "AAK1 regulates Numb function at an early step in clathrin-mediated
RT   endocytosis.";
RL   Traffic 9:1791-1800(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; THR-354; THR-389;
RP   SER-637; SER-650; TYR-687 AND SER-731, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-389; THR-606; SER-637
RP   AND THR-653, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-620; SER-623; SER-624
RP   AND SER-637, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   FUNCTION, INTERACTION WITH EPS15 AND NOTCH1, AND MUTAGENESIS OF LYS-74
RP   AND 777-ASP--PHE-779.
RX   PubMed=21464124; DOI=10.1074/jbc.M110.190769;
RA   Gupta-Rossi N., Ortica S., Meas-Yedid V., Heuss S., Moretti J.,
RA   Olivo-Marin J.C., Israel A.;
RT   "The adaptor-associated kinase 1, AAK1, is a positive regulator of the
RT   Notch pathway.";
RL   J. Biol. Chem. 286:18720-18730(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-606; THR-620; SER-624
RP   AND SER-637, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-59; HIS-533; ALA-603; MET-694;
RP   THR-725; ARG-771 AND ASP-835.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Regulates clathrin-mediated endocytosis by
CC       phosphorylating the AP2M1/mu2 subunit of the adaptor protein
CC       complex 2 (AP-2) which ensures high affinity binding of AP-2 to
CC       cargo membrane proteins during the initial stages of endocytosis.
CC       Isoform 1 and isoform 2 display similar levels of kinase activity
CC       towards AP2M1. Regulates phosphorylation of other AP-2 subunits as
CC       well as AP-2 localization and AP-2-mediated internalization of
CC       ligand complexes. Phosphorylates NUMB and regulates its cellular
CC       localization, promoting NUMB localization to endosomes. Binds to
CC       and stabilizes the activated form of NOTCH1, increases its
CC       localization in endosomes and regulates its transcriptional
CC       activity.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Stimulated by clathrin (By similarity).
CC   -!- SUBUNIT: Interacts with alpha-adaptin, AP-2, clathrin, NUMB and
CC       EPS15 isoform 2. Interacts with membrane-bound activated NOTCH1
CC       but not with the inactive full-length form of NOTCH1.
CC       Preferentially interacts with monoubiquitinated activated NOTCH1
CC       compared to the non-ubiquitinated form.
CC   -!- INTERACTION:
CC       Q9NQ11:ATP13A2; NbExp=2; IntAct=EBI-1383433, EBI-6308763;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Peripheral membrane protein
CC       (By similarity). Membrane, clathrin-coated pit (By similarity).
CC       Note=Active when found in clathrin-coated pits at the plasma
CC       membrane. In neuronal cells, enriched at presynaptic terminals. In
CC       non-neuronal cells, enriched at leading edge of migrating cells
CC       (By similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=AAK1L;
CC         IsoId=Q2M2I8-1; Sequence=Displayed;
CC       Name=2; Synonyms=AAK1S;
CC         IsoId=Q2M2I8-2; Sequence=VSP_039459;
CC   -!- TISSUE SPECIFICITY: Detected in brain, heart and liver. Isoform 1
CC       is the predominant isoform in brain.
CC   -!- PTM: Autophosphorylated (By similarity).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA83000.2; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB028971; BAA83000.2; ALT_INIT; mRNA.
DR   EMBL; AC092431; AAX88861.1; -; Genomic_DNA.
DR   EMBL; AC079121; AAY14931.1; -; Genomic_DNA.
DR   EMBL; AC136007; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC104842; AAI04843.1; -; mRNA.
DR   EMBL; BC111965; AAI11966.1; -; mRNA.
DR   CCDS; CCDS1893.2; -. [Q2M2I8-1]
DR   RefSeq; NP_055726.3; NM_014911.3.
DR   UniGene; Hs.468878; -.
DR   ProteinModelPortal; Q2M2I8; -.
DR   SMR; Q2M2I8; 32-356.
DR   BioGrid; 116520; 3.
DR   IntAct; Q2M2I8; 3.
DR   STRING; 9606.ENSP00000386456; -.
DR   BindingDB; Q2M2I8; -.
DR   ChEMBL; CHEMBL3830; -.
DR   GuidetoPHARMACOLOGY; 1921; -.
DR   PhosphoSite; Q2M2I8; -.
DR   DMDM; 300669613; -.
DR   MaxQB; Q2M2I8; -.
DR   PaxDb; Q2M2I8; -.
DR   PRIDE; Q2M2I8; -.
DR   Ensembl; ENST00000406297; ENSP00000385181; ENSG00000115977. [Q2M2I8-2]
DR   Ensembl; ENST00000409085; ENSP00000386456; ENSG00000115977. [Q2M2I8-1]
DR   GeneID; 22848; -.
DR   KEGG; hsa:22848; -.
DR   UCSC; uc002sfp.2; human. [Q2M2I8-1]
DR   UCSC; uc010fdk.2; human. [Q2M2I8-2]
DR   CTD; 22848; -.
DR   GeneCards; GC02M069685; -.
DR   H-InvDB; HIX0161871; -.
DR   HGNC; HGNC:19679; AAK1.
DR   HPA; HPA017931; -.
DR   HPA; HPA020289; -.
DR   neXtProt; NX_Q2M2I8; -.
DR   PharmGKB; PA134990616; -.
DR   eggNOG; COG0515; -.
DR   HOGENOM; HOG000232173; -.
DR   HOVERGEN; HBG080803; -.
DR   KO; K08853; -.
DR   OMA; QLIQNFY; -.
DR   PhylomeDB; Q2M2I8; -.
DR   TreeFam; TF317300; -.
DR   SignaLink; Q2M2I8; -.
DR   ChiTaRS; AAK1; human.
DR   GeneWiki; AAK1; -.
DR   GenomeRNAi; 22848; -.
DR   NextBio; 43313; -.
DR   PRO; PR:Q2M2I8; -.
DR   ArrayExpress; Q2M2I8; -.
DR   Bgee; Q2M2I8; -.
DR   CleanEx; HS_AAK1; -.
DR   Genevestigator; Q2M2I8; -.
DR   GO; GO:0031252; C:cell leading edge; ISS:UniProtKB.
DR   GO; GO:0030136; C:clathrin-coated vesicle; ISS:UniProtKB.
DR   GO; GO:0005905; C:coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0019897; C:extrinsic component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043195; C:terminal bouton; ISS:UniProtKB.
DR   GO; GO:0035612; F:AP-2 adaptor complex binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005112; F:Notch binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:UniProtKB.
DR   GO; GO:2000369; P:regulation of clathrin-mediated endocytosis; IDA:UniProtKB.
DR   GO; GO:0032880; P:regulation of protein localization; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Cell membrane;
KW   Coated pit; Complete proteome; Endocytosis; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    961       AP2-associated protein kinase 1.
FT                                /FTId=PRO_0000250578.
FT   DOMAIN       46    315       Protein kinase.
FT   NP_BIND      52     60       ATP (By similarity).
FT   COMPBIAS     12     42       Gly-rich.
FT   COMPBIAS    397    614       Gln-rich.
FT   COMPBIAS    658    663       Poly-Ala.
FT   ACT_SITE    176    176       Proton acceptor (By similarity).
FT   BINDING      74     74       ATP (By similarity).
FT   MOD_RES       1      1       N-acetylmethionine.
FT   MOD_RES      14     14       Phosphoserine.
FT   MOD_RES     234    234       Phosphotyrosine.
FT   MOD_RES     235    235       Phosphoserine.
FT   MOD_RES     354    354       Phosphothreonine.
FT   MOD_RES     389    389       Phosphothreonine.
FT   MOD_RES     441    441       Phosphothreonine.
FT   MOD_RES     606    606       Phosphothreonine.
FT   MOD_RES     620    620       Phosphothreonine.
FT   MOD_RES     623    623       Phosphoserine.
FT   MOD_RES     624    624       Phosphoserine.
FT   MOD_RES     637    637       Phosphoserine.
FT   MOD_RES     650    650       Phosphoserine.
FT   MOD_RES     653    653       Phosphothreonine.
FT   MOD_RES     687    687       Phosphotyrosine.
FT   MOD_RES     731    731       Phosphoserine.
FT   VAR_SEQ     823    961       EKADVAVESLIPGLEPPVPQRLPSQTESVTSNRTDSLTGED
FT                                SLLDCSLLSNPTTDLLEEFAPTAISAPVHKAAEDSNLISGF
FT                                DVPEGSDKVAEDEFDPIPVLITKNPQGGHSRNSSGSSESSL
FT                                PNLARSLLLVDQLIDL -> GKVIISVSSVMHDMCACFKND
FT                                KYLVNQSLGNSPATPEAKAI (in isoform 2).
FT                                /FTId=VSP_039459.
FT   VARIANT      59     59       I -> V (in dbSNP:rs34535244).
FT                                /FTId=VAR_040348.
FT   VARIANT     509    509       K -> Q (in dbSNP:rs6715776).
FT                                /FTId=VAR_031129.
FT   VARIANT     533    533       Q -> H.
FT                                /FTId=VAR_040349.
FT   VARIANT     603    603       V -> A (in dbSNP:rs56038532).
FT                                /FTId=VAR_040350.
FT   VARIANT     694    694       T -> M (in dbSNP:rs55889248).
FT                                /FTId=VAR_040351.
FT   VARIANT     725    725       P -> T (in dbSNP:rs35285785).
FT                                /FTId=VAR_040352.
FT   VARIANT     771    771       P -> R (in dbSNP:rs34422616).
FT                                /FTId=VAR_040353.
FT   VARIANT     835    835       G -> D.
FT                                /FTId=VAR_040354.
FT   MUTAGEN      74     74       K->A: Inhibits autophosphorylation and
FT                                phosphorylation of AP2M1. Does not affect
FT                                NUMB localization. Does not interact with
FT                                monoubiquitinated NOTCH1.
FT   MUTAGEN     176    176       D->A: Inhibits autophosphorylation and
FT                                phosphorylation of AP2M1. Does not affect
FT                                NUMB localization.
FT   MUTAGEN     777    779       DPF->AAA: Does not affect interaction
FT                                with NOTCH1 but abolishes interaction
FT                                with ESP15.
SQ   SEQUENCE   961 AA;  103885 MW;  1FB44D0FDEF6CAD0 CRC64;
     MKKFFDSRRE QGGSGLGSGS SGGGGSTSGL GSGYIGRVFG IGRQQVTVDE VLAEGGFAIV
     FLVRTSNGMK CALKRMFVNN EHDLQVCKRE IQIMRDLSGH KNIVGYIDSS INNVSSGDVW
     EVLILMDFCR GGQVVNLMNQ RLQTGFTENE VLQIFCDTCE AVARLHQCKT PIIHRDLKVE
     NILLHDRGHY VLCDFGSATN KFQNPQTEGV NAVEDEIKKY TTLSYRAPEM VNLYSGKIIT
     TKADIWALGC LLYKLCYFTL PFGESQVAIC DGNFTIPDNS RYSQDMHCLI RYMLEPDPDK
     RPDIYQVSYF SFKLLKKECP IPNVQNSPIP AKLPEPVKAS EAAAKKTQPK ARLTDPIPTT
     ETSIAPRQRP KAGQTQPNPG ILPIQPALTP RKRATVQPPP QAAGSSNQPG LLASVPQPKP
     QAPPSQPLPQ TQAKQPQAPP TPQQTPSTQA QGLPAQAQAT PQHQQQLFLK QQQQQQQPPP
     AQQQPAGTFY QQQQAQTQQF QAVHPATQKP AIAQFPVVSQ GGSQQQLMQN FYQQQQQQQQ
     QQQQQQLATA LHQQQLMTQQ AALQQKPTMA AGQQPQPQPA AAPQPAPAQE PAIQAPVRQQ
     PKVQTTPPPA VQGQKVGSLT PPSSPKTQRA GHRRILSDVT HSAVFGVPAS KSTQLLQAAA
     AEASLNKSKS ATTTPSGSPR TSQQNVYNPS EGSTWNPFDD DNFSKLTAEE LLNKDFAKLG
     EGKHPEKLGG SAESLIPGFQ STQGDAFATT SFSAGTAEKR KGGQTVDSGL PLLSVSDPFI
     PLQVPDAPEK LIEGLKSPDT SLLLPDLLPM TDPFGSTSDA VIEKADVAVE SLIPGLEPPV
     PQRLPSQTES VTSNRTDSLT GEDSLLDCSL LSNPTTDLLE EFAPTAISAP VHKAAEDSNL
     ISGFDVPEGS DKVAEDEFDP IPVLITKNPQ GGHSRNSSGS SESSLPNLAR SLLLVDQLID
     L
//
ID   AAKB1_HUMAN             Reviewed;         270 AA.
AC   Q9Y478; Q9UBV0; Q9UE20; Q9UEX2; Q9Y6V8;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   09-JUL-2014, entry version 140.
DE   RecName: Full=5'-AMP-activated protein kinase subunit beta-1;
DE            Short=AMPK subunit beta-1;
DE            Short=AMPKb;
GN   Name=PRKAB1; Synonyms=AMPK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Carling D.;
RT   "Non-catalytic beta and gamma subunits isoforms of the AMP-activated
RT   protein kinase.";
RL   Submitted (FEB-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=9224708; DOI=10.1016/S0014-5793(97)00569-3;
RA   Stapleton D., Woollatt E., Mitchelhill K., Nicholl J.K.,
RA   Fernandez C.S., Michell B.J., Witters L.A., Power D.A.,
RA   Sutherland G.R., Kemp B.E.;
RT   "AMP-activated protein kinase isoenzyme family: subunit structure and
RT   chromosomal location.";
RL   FEBS Lett. 409:452-456(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RA   Yamagata K., Oda N., Furuta H., Vaxillaire M., Southam L., Boriraj V.,
RA   Chen X., Oda Y., Takeda J., Yamada S., Nishigori H., Lebeau M.M.,
RA   Lathrop M., Cox R.D., Bell G.I.;
RT   "Transcription map of the 5cM region surrounding the hepatocyte
RT   nuclear factor-1a/MODY3 gene on chromosome 12.";
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Wang X., Yu L., Tu Q.;
RT   "Cloning and expression of the complete mRNA coding human AMP-
RT   activated protein kinase.";
RL   Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH FNIP1.
RX   PubMed=17028174; DOI=10.1073/pnas.0603781103;
RA   Baba M., Hong S.-B., Sharma N., Warren M.B., Nickerson M.L.,
RA   Iwamatsu A., Esposito D., Gillette W.K., Hopkins R.F. III,
RA   Hartley J.L., Furihata M., Oishi S., Zhen W., Burke T.R. Jr.,
RA   Linehan W.M., Schmidt L.S., Zbar B.;
RT   "Folliculin encoded by the BHD gene interacts with a binding protein,
RT   FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15552-15557(2006).
RN   [8]
RP   INTERACTION WITH FNIP2.
RX   PubMed=18403135; DOI=10.1016/j.gene.2008.02.022;
RA   Hasumi H., Baba M., Hong S.-B., Hasumi Y., Huang Y., Yao M.,
RA   Valera V.A., Linehan W.M., Schmidt L.S.;
RT   "Identification and characterization of a novel folliculin-interacting
RT   protein FNIP2.";
RL   Gene 415:60-67(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-4; SER-5; SER-6 AND
RP   SER-108, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-19; SER-40 AND SER-108,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-19; SER-40; SER-108 AND
RP   THR-148, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-96 AND SER-108, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-40 AND SER-108, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   PHOSPHORYLATION BY ULK1.
RX   PubMed=21460634; DOI=10.4161/auto.7.7.15451;
RA   Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M.,
RA   Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.;
RT   "Ulk1-mediated phosphorylation of AMPK constitutes a negative
RT   regulatory feedback loop.";
RL   Autophagy 7:696-706(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   INTERACTION WITH PRKAA1 AND PRKAG1, MUTAGENESIS OF GLY-2, AND
RP   MYRISTOYLATION AT GLY-2.
RX   PubMed=21680840; DOI=10.1126/science.1200094;
RA   Oakhill J.S., Steel R., Chen Z.P., Scott J.W., Ling N., Tam S.,
RA   Kemp B.E.;
RT   "AMPK is a direct adenylate charge-regulated protein kinase.";
RL   Science 332:1433-1435(2011).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=17307971; DOI=10.1161/01.RES.0000256090.42690.05;
RA   Towler M.C., Hardie D.G.;
RT   "AMP-activated protein kinase in metabolic control and insulin
RT   signaling.";
RL   Circ. Res. 100:328-341(2007).
RN   [20]
RP   REVIEW ON FUNCTION.
RX   PubMed=17712357; DOI=10.1038/nrm2249;
RA   Hardie D.G.;
RT   "AMP-activated/SNF1 protein kinases: conserved guardians of cellular
RT   energy.";
RL   Nat. Rev. Mol. Cell Biol. 8:774-785(2007).
CC   -!- FUNCTION: Non-catalytic subunit of AMP-activated protein kinase
CC       (AMPK), an energy sensor protein kinase that plays a key role in
CC       regulating cellular energy metabolism. In response to reduction of
CC       intracellular ATP levels, AMPK activates energy-producing pathways
CC       and inhibits energy-consuming processes: inhibits protein,
CC       carbohydrate and lipid biosynthesis, as well as cell growth and
CC       proliferation. AMPK acts via direct phosphorylation of metabolic
CC       enzymes, and by longer-term effects via phosphorylation of
CC       transcription regulators. Also acts as a regulator of cellular
CC       polarity by remodeling the actin cytoskeleton; probably by
CC       indirectly activating myosin. Beta non-catalytic subunit acts as a
CC       scaffold on which the AMPK complex assembles, via its C-terminus
CC       that bridges alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1,
CC       PRKAG2 or PRKAG3).
CC   -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit
CC       (PRKAA1 or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-
CC       catalytic subunits (PRKAG1, PRKAG2 or PRKAG3). Interacts with
CC       FNIP1 and FNIP2.
CC   -!- INTERACTION:
CC       O70302:Cidea (xeno); NbExp=4; IntAct=EBI-719769, EBI-7927848;
CC       P62993:GRB2; NbExp=2; IntAct=EBI-719769, EBI-401755;
CC       Q13131:PRKAA1; NbExp=5; IntAct=EBI-719769, EBI-1181405;
CC       P54619:PRKAG1; NbExp=4; IntAct=EBI-719769, EBI-1181439;
CC   -!- DOMAIN: The glycogen-binding domain may target AMPK to glycogen so
CC       that other factors like glycogen-bound debranching enzyme or
CC       protein phosphatases can directly affect AMPK activity (By
CC       similarity).
CC   -!- PTM: Phosphorylated when associated with the catalytic subunit
CC       (PRKAA1 or PRKAA2). Phosphorylated by ULK1; leading to negatively
CC       regulate AMPK activity and suggesting the existence of a
CC       regulatory feedback loop between ULK1 and AMPK.
CC   -!- SIMILARITY: Belongs to the 5'-AMP-activated protein kinase beta
CC       subunit family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB71326.1; Type=Erroneous gene model prediction;
CC       Sequence=AAC98897.1; Type=Frameshift; Positions=245;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PRKAB1ID44100ch12q24.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ224515; CAA12024.1; -; mRNA.
DR   EMBL; Y12556; CAA73146.1; -; mRNA.
DR   EMBL; U83994; AAD09237.1; -; mRNA.
DR   EMBL; U87276; AAD00625.1; -; Genomic_DNA.
DR   EMBL; U87271; AAD00625.1; JOINED; Genomic_DNA.
DR   EMBL; U87272; AAD00625.1; JOINED; Genomic_DNA.
DR   EMBL; U87273; AAD00625.1; JOINED; Genomic_DNA.
DR   EMBL; U87274; AAD00625.1; JOINED; Genomic_DNA.
DR   EMBL; U87275; AAD00625.1; JOINED; Genomic_DNA.
DR   EMBL; AF022116; AAC98897.1; ALT_FRAME; mRNA.
DR   EMBL; AC002563; AAB71326.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; BC001007; AAH01007.1; -; mRNA.
DR   EMBL; BC001056; AAH01056.1; -; mRNA.
DR   EMBL; BC001823; AAH01823.1; -; mRNA.
DR   EMBL; BC017671; AAH17671.1; -; mRNA.
DR   CCDS; CCDS9191.1; -.
DR   PIR; T09514; T09514.
DR   RefSeq; NP_006244.2; NM_006253.4.
DR   RefSeq; XP_005253966.1; XM_005253909.1.
DR   UniGene; Hs.741184; -.
DR   PDB; 4CFE; X-ray; 3.02 A; B/D=1-270.
DR   PDB; 4CFF; X-ray; 3.92 A; B/D=1-270.
DR   PDBsum; 4CFE; -.
DR   PDBsum; 4CFF; -.
DR   ProteinModelPortal; Q9Y478; -.
DR   SMR; Q9Y478; 77-270.
DR   BioGrid; 111551; 28.
DR   IntAct; Q9Y478; 16.
DR   MINT; MINT-1400840; -.
DR   STRING; 9606.ENSP00000229328; -.
DR   BindingDB; Q9Y478; -.
DR   ChEMBL; CHEMBL2111345; -.
DR   DrugBank; DB00131; Adenosine monophosphate.
DR   DrugBank; DB00331; Metformin.
DR   CAZy; CBM48; Carbohydrate-Binding Module Family 48.
DR   PhosphoSite; Q9Y478; -.
DR   DMDM; 14194425; -.
DR   MaxQB; Q9Y478; -.
DR   PaxDb; Q9Y478; -.
DR   PRIDE; Q9Y478; -.
DR   Ensembl; ENST00000229328; ENSP00000229328; ENSG00000111725.
DR   Ensembl; ENST00000541640; ENSP00000441369; ENSG00000111725.
DR   GeneID; 5564; -.
DR   KEGG; hsa:5564; -.
DR   UCSC; uc001txg.3; human.
DR   CTD; 5564; -.
DR   GeneCards; GC12P120105; -.
DR   HGNC; HGNC:9378; PRKAB1.
DR   HPA; CAB005058; -.
DR   HPA; HPA004247; -.
DR   MIM; 602740; gene.
DR   neXtProt; NX_Q9Y478; -.
DR   PharmGKB; PA33746; -.
DR   eggNOG; NOG238368; -.
DR   HOGENOM; HOG000230597; -.
DR   HOVERGEN; HBG050430; -.
DR   InParanoid; Q9Y478; -.
DR   KO; K07199; -.
DR   OMA; CKAEERF; -.
DR   OrthoDB; EOG7SXW3Z; -.
DR   PhylomeDB; Q9Y478; -.
DR   TreeFam; TF313827; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_200751; Organelle biogenesis and maintenance.
DR   SignaLink; Q9Y478; -.
DR   GeneWiki; PRKAB1; -.
DR   GenomeRNAi; 5564; -.
DR   NextBio; 21556; -.
DR   PRO; PR:Q9Y478; -.
DR   ArrayExpress; Q9Y478; -.
DR   Bgee; Q9Y478; -.
DR   CleanEx; HS_PRKAB1; -.
DR   Genevestigator; Q9Y478; -.
DR   GO; GO:0031588; C:AMP-activated protein kinase complex; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:Reactome.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0051291; P:protein heterooligomerization; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050790; P:regulation of catalytic activity; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR006828; AMP_prot_kin_bsu_interact-dom.
DR   InterPro; IPR014756; Ig_E-set.
DR   Pfam; PF04739; AMPKBI; 1.
DR   SMART; SM01010; AMPKBI; 1.
DR   SUPFAM; SSF81296; SSF81296; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Lipid biosynthesis; Lipid metabolism;
KW   Lipoprotein; Myristate; Phosphoprotein; Reference proteome.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    270       5'-AMP-activated protein kinase subunit
FT                                beta-1.
FT                                /FTId=PRO_0000204363.
FT   REGION       68    163       Glycogen-binding domain (By similarity).
FT   MOD_RES       4      4       Phosphothreonine.
FT   MOD_RES       5      5       Phosphoserine.
FT   MOD_RES       6      6       Phosphoserine.
FT   MOD_RES      19     19       Phosphothreonine.
FT   MOD_RES      24     24       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES      25     25       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES      40     40       Phosphoserine.
FT   MOD_RES      96     96       Phosphoserine.
FT   MOD_RES     101    101       Phosphoserine (By similarity).
FT   MOD_RES     108    108       Phosphoserine.
FT   MOD_RES     148    148       Phosphothreonine.
FT   MOD_RES     182    182       Phosphoserine (By similarity).
FT   LIPID         2      2       N-myristoyl glycine.
FT   MUTAGEN       2      2       G->A: Abolishes myristoylation and AMP-
FT                                enhanced phosphorylation of PRKAA1 or
FT                                PRKAA2.
FT   CONFLICT     10     10       A -> G (in Ref. 2; CAA73146 and 4;
FT                                AAC98897).
FT   CONFLICT     15     15       G -> A (in Ref. 1; CAA12024).
FT   CONFLICT     20     20       P -> A (in Ref. 2; CAA73146 and 4;
FT                                AAC98897).
FT   CONFLICT     22     22       R -> K (in Ref. 3; AAD09237/AAD00625).
FT   CONFLICT     56     56       E -> Y (in Ref. 3; AAD09237/AAD00625).
FT   STRAND       79     84
FT   STRAND       91     95
FT   TURN         96    100
FT   STRAND      112    117
FT   STRAND      120    129
FT   STRAND      132    134
FT   STRAND      141    143
FT   STRAND      145    147
FT   STRAND      149    155
FT   HELIX       157    160
FT   HELIX       162    171
FT   HELIX       208    211
FT   HELIX       214    216
FT   STRAND      238    241
FT   STRAND      248    257
FT   STRAND      260    269
SQ   SEQUENCE   270 AA;  30382 MW;  F0BCAA94D5BC15FC CRC64;
     MGNTSSERAA LERHGGHKTP RRDSSGGTKD GDRPKILMDS PEDADLFHSE EIKAPEKEEF
     LAWQHDLEVN DKAPAQARPT VFRWTGGGKE VYLSGSFNNW SKLPLTRSHN NFVAILDLPE
     GEHQYKFFVD GQWTHDPSEP IVTSQLGTVN NIIQVKKTDF EVFDALMVDS QKCSDVSELS
     SSPPGPYHQE PYVCKPEERF RAPPILPPHL LQVILNKDTG ISCDPALLPE PNHVMLNHLY
     ALSIKDGVMV LSATHRYKKK YVTTLLYKPI
//
ID   AAKB2_HUMAN             Reviewed;         272 AA.
AC   O43741; A8K9V5; Q5VXY0;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   09-JUL-2014, entry version 133.
DE   RecName: Full=5'-AMP-activated protein kinase subunit beta-2;
DE            Short=AMPK subunit beta-2;
GN   Name=PRKAB2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9575201; DOI=10.1074/jbc.273.20.12443;
RA   Thornton C., Snowden M.A., Carling D.;
RT   "Identification of a novel AMP-activated protein kinase beta subunit
RT   isoform that is highly expressed in skeletal muscle.";
RL   J. Biol. Chem. 273:12443-12450(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=12490143; DOI=10.1006/mcpr.2002.0439;
RA   Prochazka M., Farook V.S., Ossowski V., Wolford J.K., Bogardus C.;
RT   "Variant screening of PRKAB2, a type 2 diabetes mellitus
RT   susceptibility candidate gene on 1q in Pima Indians.";
RL   Mol. Cell. Probes 16:421-427(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108 AND SER-184, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-184, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   PHOSPHORYLATION BY ULK1 AND ULK2.
RX   PubMed=21460634; DOI=10.4161/auto.7.7.15451;
RA   Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M.,
RA   Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.;
RT   "Ulk1-mediated phosphorylation of AMPK constitutes a negative
RT   regulatory feedback loop.";
RL   Autophagy 7:696-706(2011).
RN   [15]
RP   REVIEW ON FUNCTION.
RX   PubMed=17307971; DOI=10.1161/01.RES.0000256090.42690.05;
RA   Towler M.C., Hardie D.G.;
RT   "AMP-activated protein kinase in metabolic control and insulin
RT   signaling.";
RL   Circ. Res. 100:328-341(2007).
RN   [16]
RP   REVIEW ON FUNCTION.
RX   PubMed=17712357; DOI=10.1038/nrm2249;
RA   Hardie D.G.;
RT   "AMP-activated/SNF1 protein kinases: conserved guardians of cellular
RT   energy.";
RL   Nat. Rev. Mol. Cell Biol. 8:774-785(2007).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 187-272 IN COMPLEX WITH
RP   PRKAA1 AND PRKAG1.
RX   PubMed=17851531; DOI=10.1038/nature06161;
RA   Xiao B., Heath R., Saiu P., Leiper F.C., Leone P., Jing C.,
RA   Walker P.A., Haire L., Eccleston J.F., Davis C.T., Martin S.R.,
RA   Carling D., Gamblin S.J.;
RT   "Structural basis for AMP binding to mammalian AMP-activated protein
RT   kinase.";
RL   Nature 449:496-500(2007).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.51 ANGSTROMS) OF 187-272 IN COMPLEX WITH
RP   PRKAA1 AND PRKAG1, AND MUTAGENESIS OF HIS-235.
RX   PubMed=21399626; DOI=10.1038/nature09932;
RA   Xiao B., Sanders M.J., Underwood E., Heath R., Mayer F.V., Carmena D.,
RA   Jing C., Walker P.A., Eccleston J.F., Haire L.F., Saiu P.,
RA   Howell S.A., Aasland R., Martin S.R., Carling D., Gamblin S.J.;
RT   "Structure of mammalian AMPK and its regulation by ADP.";
RL   Nature 472:230-233(2011).
CC   -!- FUNCTION: Non-catalytic subunit of AMP-activated protein kinase
CC       (AMPK), an energy sensor protein kinase that plays a key role in
CC       regulating cellular energy metabolism. In response to reduction of
CC       intracellular ATP levels, AMPK activates energy-producing pathways
CC       and inhibits energy-consuming processes: inhibits protein,
CC       carbohydrate and lipid biosynthesis, as well as cell growth and
CC       proliferation. AMPK acts via direct phosphorylation of metabolic
CC       enzymes, and by longer-term effects via phosphorylation of
CC       transcription regulators. Also acts as a regulator of cellular
CC       polarity by remodeling the actin cytoskeleton; probably by
CC       indirectly activating myosin. Beta non-catalytic subunit acts as a
CC       scaffold on which the AMPK complex assembles, via its C-terminus
CC       that bridges alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1,
CC       PRKAG2 or PRKAG3).
CC   -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit
CC       (PRKAA1 or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-
CC       catalytic subunits (PRKAG1, PRKAG2 or PRKAG3).
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-1053424, EBI-1053424;
CC       Q13131:PRKAA1; NbExp=6; IntAct=EBI-1053424, EBI-1181405;
CC       P54619:PRKAG1; NbExp=3; IntAct=EBI-1053424, EBI-1181439;
CC   -!- PTM: Phosphorylated when associated with the catalytic subunit
CC       (PRKAA1 or PRKAA2). Phosphorylated by ULK1 and ULK2; leading to
CC       negatively regulate AMPK activity and suggesting the existence of
CC       a regulatory feedback loop between ULK1, ULK2 and AMPK.
CC   -!- SIMILARITY: Belongs to the 5'-AMP-activated protein kinase beta
CC       subunit family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ224538; CAA12030.1; -; mRNA.
DR   EMBL; AF504543; AAM74153.1; -; Genomic_DNA.
DR   EMBL; AF504538; AAM74153.1; JOINED; Genomic_DNA.
DR   EMBL; AF504539; AAM74153.1; JOINED; Genomic_DNA.
DR   EMBL; AF504540; AAM74153.1; JOINED; Genomic_DNA.
DR   EMBL; AF504541; AAM74153.1; JOINED; Genomic_DNA.
DR   EMBL; AF504542; AAM74153.1; JOINED; Genomic_DNA.
DR   EMBL; AK292820; BAF85509.1; -; mRNA.
DR   EMBL; AL356378; CAH72644.1; -; Genomic_DNA.
DR   EMBL; CH471223; EAW50945.1; -; Genomic_DNA.
DR   EMBL; BC053610; AAH53610.1; -; mRNA.
DR   CCDS; CCDS925.1; -.
DR   RefSeq; NP_005390.1; NM_005399.4.
DR   UniGene; Hs.50732; -.
DR   PDB; 2F15; X-ray; 2.00 A; A=69-163.
DR   PDB; 2V8Q; X-ray; 2.10 A; B=187-272.
DR   PDB; 2V92; X-ray; 2.40 A; B=187-272.
DR   PDB; 2V9J; X-ray; 2.53 A; B=187-272.
DR   PDB; 2Y8L; X-ray; 2.50 A; B=187-272.
DR   PDB; 2Y8Q; X-ray; 2.80 A; B=187-270.
DR   PDB; 2YA3; X-ray; 2.51 A; B=187-272.
DR   PDB; 4CFH; X-ray; 3.24 A; B=187-272.
DR   PDB; 4EAI; X-ray; 2.28 A; B=189-272.
DR   PDB; 4EAJ; X-ray; 2.61 A; B=189-272.
DR   PDBsum; 2F15; -.
DR   PDBsum; 2V8Q; -.
DR   PDBsum; 2V92; -.
DR   PDBsum; 2V9J; -.
DR   PDBsum; 2Y8L; -.
DR   PDBsum; 2Y8Q; -.
DR   PDBsum; 2YA3; -.
DR   PDBsum; 4CFH; -.
DR   PDBsum; 4EAI; -.
DR   PDBsum; 4EAJ; -.
DR   ProteinModelPortal; O43741; -.
DR   SMR; O43741; 68-272.
DR   BioGrid; 111552; 40.
DR   DIP; DIP-39763N; -.
DR   IntAct; O43741; 32.
DR   STRING; 9606.ENSP00000254101; -.
DR   BindingDB; O43741; -.
DR   ChEMBL; CHEMBL3038453; -.
DR   DrugBank; DB00131; Adenosine monophosphate.
DR   CAZy; CBM48; Carbohydrate-Binding Module Family 48.
DR   PhosphoSite; O43741; -.
DR   MaxQB; O43741; -.
DR   PaxDb; O43741; -.
DR   PeptideAtlas; O43741; -.
DR   PRIDE; O43741; -.
DR   DNASU; 5565; -.
DR   Ensembl; ENST00000254101; ENSP00000254101; ENSG00000131791.
DR   Ensembl; ENST00000584647; ENSP00000463518; ENSG00000266198.
DR   GeneID; 5565; -.
DR   KEGG; hsa:5565; -.
DR   UCSC; uc001epe.3; human.
DR   CTD; 5565; -.
DR   GeneCards; GC01M146627; -.
DR   HGNC; HGNC:9379; PRKAB2.
DR   HPA; HPA044342; -.
DR   MIM; 602741; gene.
DR   neXtProt; NX_O43741; -.
DR   PharmGKB; PA33747; -.
DR   eggNOG; NOG238368; -.
DR   HOGENOM; HOG000230597; -.
DR   HOVERGEN; HBG050430; -.
DR   InParanoid; O43741; -.
DR   KO; K07199; -.
DR   OMA; ESKYITV; -.
DR   PhylomeDB; O43741; -.
DR   TreeFam; TF313827; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_200751; Organelle biogenesis and maintenance.
DR   SignaLink; O43741; -.
DR   ChiTaRS; PRKAB2; human.
DR   EvolutionaryTrace; O43741; -.
DR   GeneWiki; PRKAB2; -.
DR   GenomeRNAi; 5565; -.
DR   NextBio; 21560; -.
DR   PRO; PR:O43741; -.
DR   ArrayExpress; O43741; -.
DR   Bgee; O43741; -.
DR   CleanEx; HS_PRKAB2; -.
DR   Genevestigator; O43741; -.
DR   GO; GO:0031588; C:AMP-activated protein kinase complex; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0006853; P:carnitine shuttle; TAS:Reactome.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:Reactome.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0006112; P:energy reserve metabolic process; TAS:Reactome.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:GOC.
DR   GO; GO:0042304; P:regulation of fatty acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   InterPro; IPR006828; AMP_prot_kin_bsu_interact-dom.
DR   InterPro; IPR014756; Ig_E-set.
DR   Pfam; PF04739; AMPKBI; 1.
DR   SMART; SM01010; AMPKBI; 1.
DR   SUPFAM; SSF81296; SSF81296; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Lipid biosynthesis; Lipid metabolism;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN         1    272       5'-AMP-activated protein kinase subunit
FT                                beta-2.
FT                                /FTId=PRO_0000204368.
FT   MOD_RES      39     39       Phosphoserine; by ULK1 (Probable).
FT   MOD_RES      40     40       Phosphothreonine; by ULK1 (Probable).
FT   MOD_RES      69     69       Phosphoserine; by ULK1 (By similarity).
FT   MOD_RES     108    108       Phosphoserine.
FT   MOD_RES     174    174       Phosphoserine (By similarity).
FT   MOD_RES     184    184       Phosphoserine.
FT   MUTAGEN     235    235       H->A: Results in an AMPK enzyme that is
FT                                activable by phosphorylation but has
FT                                significantly increased rate of
FT                                dephosphorylation in phosphatase assays.
FT   STRAND       76     83
FT   STRAND       90     94
FT   HELIX        95     97
FT   STRAND      112    129
FT   STRAND      132    134
FT   STRAND      141    143
FT   STRAND      149    155
FT   TURN        159    162
FT   STRAND      201    204
FT   HELIX       210    213
FT   STRAND      214    217
FT   TURN        236    239
FT   STRAND      242    244
FT   STRAND      250    259
FT   STRAND      262    271
SQ   SEQUENCE   272 AA;  30302 MW;  42B23BD70B92519C CRC64;
     MGNTTSDRVS GERHGAKAAR SEGAGGHAPG KEHKIMVGST DDPSVFSLPD SKLPGDKEFV
     SWQQDLEDSV KPTQQARPTV IRWSEGGKEV FISGSFNNWS TKIPLIKSHN DFVAILDLPE
     GEHQYKFFVD GQWVHDPSEP VVTSQLGTIN NLIHVKKSDF EVFDALKLDS MESSETSCRD
     LSSSPPGPYG QEMYAFRSEE RFKSPPILPP HLLQVILNKD TNISCDPALL PEPNHVMLNH
     LYALSIKDSV MVLSATHRYK KKYVTTLLYK PI
//
ID   AAKG1_HUMAN             Reviewed;         331 AA.
AC   P54619; B4DDT7; Q8N7V9;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   09-JUL-2014, entry version 130.
DE   RecName: Full=5'-AMP-activated protein kinase subunit gamma-1;
DE            Short=AMPK gamma1;
DE            Short=AMPK subunit gamma-1;
DE            Short=AMPKg;
GN   Name=PRKAG1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Fetal liver;
RX   PubMed=8621499; DOI=10.1074/jbc.271.15.8675;
RA   Gao G., Fernandez C.S., Stapleton D., Auster A.S., Widmer J.,
RA   Dyck J.R.B., Kemp B.E., Witters L.A.;
RT   "Non-catalytic beta- and gamma-subunit isoforms of the 5'-AMP-
RT   activated protein kinase.";
RL   J. Biol. Chem. 271:8675-8681(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Glial tumor, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   DOMAIN CBS, AMP-BINDING, AND ATP-BINDING.
RX   PubMed=14722619; DOI=10.1172/JCI19874;
RA   Scott J.W., Hawley S.A., Green K.A., Anis M., Stewart G.,
RA   Scullion G.A., Norman D.G., Hardie D.G.;
RT   "CBS domains form energy-sensing modules whose binding of adenosine
RT   ligands is disrupted by disease mutations.";
RL   J. Clin. Invest. 113:274-284(2004).
RN   [7]
RP   INTERACTION WITH FNIP1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17028174; DOI=10.1073/pnas.0603781103;
RA   Baba M., Hong S.-B., Sharma N., Warren M.B., Nickerson M.L.,
RA   Iwamatsu A., Esposito D., Gillette W.K., Hopkins R.F. III,
RA   Hartley J.L., Furihata M., Oishi S., Zhen W., Burke T.R. Jr.,
RA   Linehan W.M., Schmidt L.S., Zbar B.;
RT   "Folliculin encoded by the BHD gene interacts with a binding protein,
RT   FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15552-15557(2006).
RN   [8]
RP   DOMAIN AMPK PSEUDOSUBSTRATE.
RX   PubMed=17255938; DOI=10.1038/sj.emboj.7601542;
RA   Scott J.W., Ross F.A., Liu J.K., Hardie D.G.;
RT   "Regulation of AMP-activated protein kinase by a pseudosubstrate
RT   sequence on the gamma subunit.";
RL   EMBO J. 26:806-815(2007).
RN   [9]
RP   INTERACTION WITH FNIP2.
RX   PubMed=18403135; DOI=10.1016/j.gene.2008.02.022;
RA   Hasumi H., Baba M., Hong S.-B., Hasumi Y., Huang Y., Yao M.,
RA   Valera V.A., Linehan W.M., Schmidt L.S.;
RT   "Identification and characterization of a novel folliculin-interacting
RT   protein FNIP2.";
RL   Gene 415:60-67(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION BY ULK1 AND ULK2.
RX   PubMed=21460634; DOI=10.4161/auto.7.7.15451;
RA   Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M.,
RA   Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.;
RT   "Ulk1-mediated phosphorylation of AMPK constitutes a negative
RT   regulatory feedback loop.";
RL   Autophagy 7:696-706(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   INTERACTION WITH PRKAA1 AND PRKAB1, DOMAIN CBS, ADP-BINDING,
RP   MUTAGENESIS OF ASP-90; ASP-245 AND ASP-317, AND FUNCTION.
RX   PubMed=21680840; DOI=10.1126/science.1200094;
RA   Oakhill J.S., Steel R., Chen Z.P., Scott J.W., Ling N., Tam S.,
RA   Kemp B.E.;
RT   "AMPK is a direct adenylate charge-regulated protein kinase.";
RL   Science 332:1433-1435(2011).
RN   [14]
RP   REVIEW ON FUNCTION.
RX   PubMed=17307971; DOI=10.1161/01.RES.0000256090.42690.05;
RA   Towler M.C., Hardie D.G.;
RT   "AMP-activated protein kinase in metabolic control and insulin
RT   signaling.";
RL   Circ. Res. 100:328-341(2007).
RN   [15]
RP   REVIEW ON FUNCTION.
RX   PubMed=17712357; DOI=10.1038/nrm2249;
RA   Hardie D.G.;
RT   "AMP-activated/SNF1 protein kinases: conserved guardians of cellular
RT   energy.";
RL   Nat. Rev. Mol. Cell Biol. 8:774-785(2007).
CC   -!- FUNCTION: AMP/ATP-binding subunit of AMP-activated protein kinase
CC       (AMPK), an energy sensor protein kinase that plays a key role in
CC       regulating cellular energy metabolism. In response to reduction of
CC       intracellular ATP levels, AMPK activates energy-producing pathways
CC       and inhibits energy-consuming processes: inhibits protein,
CC       carbohydrate and lipid biosynthesis, as well as cell growth and
CC       proliferation. AMPK acts via direct phosphorylation of metabolic
CC       enzymes, and by longer-term effects via phosphorylation of
CC       transcription regulators. Also acts as a regulator of cellular
CC       polarity by remodeling the actin cytoskeleton; probably by
CC       indirectly activating myosin. Gamma non-catalytic subunit mediates
CC       binding to AMP, ADP and ATP, leading to activate or inhibit AMPK:
CC       AMP-binding results in allosteric activation of alpha catalytic
CC       subunit (PRKAA1 or PRKAA2) both by inducing phosphorylation and
CC       preventing dephosphorylation of catalytic subunits. ADP also
CC       stimulates phosphorylation, without stimulating already
CC       phosphorylated catalytic subunit. ATP promotes dephosphorylation
CC       of catalytic subunit, rendering the AMPK enzyme inactive.
CC   -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit
CC       (PRKAA1 or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-
CC       catalytic subunits (PRKAG1, PRKAG2 or PRKAG3). Interacts with
CC       FNIP1 and FNIP2.
CC   -!- INTERACTION:
CC       Q9Y478:PRKAB1; NbExp=4; IntAct=EBI-1181439, EBI-719769;
CC       O43741:PRKAB2; NbExp=3; IntAct=EBI-1181439, EBI-1053424;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P54619-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P54619-2; Sequence=VSP_046711;
CC         Note=No experimental confirmation available;
CC       Name=3;
CC         IsoId=P54619-3; Sequence=VSP_046712;
CC         Note=No experimental confirmation available. May be due to
CC         competing acceptor splice site;
CC   -!- DOMAIN: The AMPK pseudosubstrate motif resembles the sequence
CC       around sites phosphorylated on target proteins of AMPK, except the
CC       presence of a non-phosphorylatable residue in place of Ser. In the
CC       absence of AMP this pseudosubstrate sequence may bind to the
CC       active site groove on the alpha subunit (PRKAA1 or PRKAA2),
CC       preventing phosphorylation by the upstream activating kinase
CC       STK11/LKB1.
CC   -!- DOMAIN: The CBS domains mediate binding to AMP, ADP and ATP. 2
CC       sites bind either AMP or ATP, whereas a third site contains a
CC       tightly bound AMP that does not exchange. Under physiological
CC       conditions AMPK mainly exists in its inactive form in complex with
CC       ATP, which is much more abundant than AMP.
CC   -!- PTM: Phosphorylated by ULK1 and ULK2; leading to negatively
CC       regulate AMPK activity and suggesting the existence of a
CC       regulatory feedback loop between ULK1, ULK2 and AMPK.
CC   -!- SIMILARITY: Belongs to the 5'-AMP-activated protein kinase gamma
CC       subunit family.
CC   -!- SIMILARITY: Contains 4 CBS domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U42412; AAC50495.1; -; mRNA.
DR   EMBL; BT007345; AAP36009.1; -; mRNA.
DR   EMBL; AK097606; BAC05117.1; -; mRNA.
DR   EMBL; AK293332; BAG56848.1; -; mRNA.
DR   EMBL; AC011603; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000358; AAH00358.1; -; mRNA.
DR   CCDS; CCDS55824.1; -. [P54619-2]
DR   CCDS; CCDS55825.1; -. [P54619-3]
DR   CCDS; CCDS8777.1; -. [P54619-1]
DR   RefSeq; NP_001193638.1; NM_001206709.1. [P54619-3]
DR   RefSeq; NP_001193639.1; NM_001206710.1. [P54619-2]
DR   RefSeq; NP_002724.1; NM_002733.4. [P54619-1]
DR   RefSeq; XP_006719562.1; XM_006719499.1. [P54619-2]
DR   UniGene; Hs.530862; -.
DR   PDB; 2UV4; X-ray; 1.33 A; A=182-325.
DR   PDB; 2UV5; X-ray; 1.69 A; A=182-325.
DR   PDB; 2UV6; X-ray; 2.00 A; A=182-325.
DR   PDB; 2UV7; X-ray; 2.00 A; A=182-325.
DR   PDB; 4CFE; X-ray; 3.02 A; E/F=1-331.
DR   PDB; 4CFF; X-ray; 3.92 A; E/F=1-331.
DR   PDBsum; 2UV4; -.
DR   PDBsum; 2UV5; -.
DR   PDBsum; 2UV6; -.
DR   PDBsum; 2UV7; -.
DR   PDBsum; 4CFE; -.
DR   PDBsum; 4CFF; -.
DR   ProteinModelPortal; P54619; -.
DR   SMR; P54619; 27-325.
DR   BioGrid; 111558; 19.
DR   IntAct; P54619; 19.
DR   MINT; MINT-4649712; -.
DR   STRING; 9606.ENSP00000323867; -.
DR   BindingDB; P54619; -.
DR   ChEMBL; CHEMBL2096907; -.
DR   PhosphoSite; P54619; -.
DR   DMDM; 1703037; -.
DR   MaxQB; P54619; -.
DR   PaxDb; P54619; -.
DR   PRIDE; P54619; -.
DR   DNASU; 5571; -.
DR   Ensembl; ENST00000316299; ENSP00000323867; ENSG00000181929. [P54619-3]
DR   Ensembl; ENST00000548065; ENSP00000447433; ENSG00000181929. [P54619-1]
DR   Ensembl; ENST00000552212; ENSP00000448972; ENSG00000181929. [P54619-2]
DR   GeneID; 5571; -.
DR   KEGG; hsa:5571; -.
DR   UCSC; uc001rsy.3; human. [P54619-1]
DR   UCSC; uc001rsz.3; human.
DR   CTD; 5571; -.
DR   GeneCards; GC12M049396; -.
DR   HGNC; HGNC:9385; PRKAG1.
DR   MIM; 602742; gene.
DR   neXtProt; NX_P54619; -.
DR   PharmGKB; PA33751; -.
DR   eggNOG; COG0517; -.
DR   HOVERGEN; HBG050431; -.
DR   InParanoid; P54619; -.
DR   KO; K07200; -.
DR   OMA; KGGAYDE; -.
DR   PhylomeDB; P54619; -.
DR   TreeFam; TF313247; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_200751; Organelle biogenesis and maintenance.
DR   SignaLink; P54619; -.
DR   ChiTaRS; PRKAG1; human.
DR   EvolutionaryTrace; P54619; -.
DR   GeneWiki; PRKAG1; -.
DR   GenomeRNAi; 5571; -.
DR   NextBio; 21596; -.
DR   PRO; PR:P54619; -.
DR   ArrayExpress; P54619; -.
DR   Bgee; P54619; -.
DR   CleanEx; HS_PRKAG1; -.
DR   Genevestigator; P54619; -.
DR   GO; GO:0031588; C:AMP-activated protein kinase complex; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0043531; F:ADP binding; ISS:UniProtKB.
DR   GO; GO:0016208; F:AMP binding; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0004691; F:cAMP-dependent protein kinase activity; TAS:ProtInc.
DR   GO; GO:0008603; F:cAMP-dependent protein kinase regulator activity; TAS:BHF-UCL.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IDA:BHF-UCL.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:Reactome.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; TAS:BHF-UCL.
DR   GO; GO:0051291; P:protein heterooligomerization; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006110; P:regulation of glycolytic process; TAS:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007283; P:spermatogenesis; TAS:ProtInc.
DR   InterPro; IPR000644; CBS_dom.
DR   Pfam; PF00571; CBS; 4.
DR   SMART; SM00116; CBS; 4.
DR   PROSITE; PS51371; CBS; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; CBS domain;
KW   Complete proteome; Direct protein sequencing; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Lipid biosynthesis; Lipid metabolism;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat.
FT   CHAIN         1    331       5'-AMP-activated protein kinase subunit
FT                                gamma-1.
FT                                /FTId=PRO_0000204377.
FT   DOMAIN       43    103       CBS 1.
FT   DOMAIN      125    187       CBS 2.
FT   DOMAIN      198    260       CBS 3.
FT   DOMAIN      272    329       CBS 4.
FT   MOTIF       138    159       AMPK pseudosubstrate.
FT   BINDING      70     70       AMP 1 (By similarity).
FT   BINDING      70     70       ATP 1 (By similarity).
FT   BINDING     151    151       AMP 2 (By similarity).
FT   BINDING     151    151       AMP 3 (By similarity).
FT   BINDING     151    151       ATP 2 (By similarity).
FT   BINDING     152    152       ATP 1 (By similarity).
FT   BINDING     152    152       ATP 2 (By similarity).
FT   BINDING     170    170       AMP 1 (By similarity).
FT   BINDING     170    170       ATP 1 (By similarity).
FT   BINDING     298    298       AMP 3 (By similarity).
FT   BINDING     299    299       AMP 1 (By similarity).
FT   BINDING     299    299       ATP 1 (By similarity).
FT   MOD_RES     261    261       Phosphoserine; by ULK1 (By similarity).
FT   MOD_RES     263    263       Phosphothreonine; by ULK1 (By
FT                                similarity).
FT   MOD_RES     270    270       Phosphoserine; by ULK1 (By similarity).
FT   VAR_SEQ       1     32       Missing (in isoform 2).
FT                                /FTId=VSP_046711.
FT   VAR_SEQ      83     83       V -> VVLRALSCPL (in isoform 3).
FT                                /FTId=VSP_046712.
FT   VARIANT      89     89       T -> S (in dbSNP:rs1126930).
FT                                /FTId=VAR_033453.
FT   VARIANT     329    329       K -> N (in dbSNP:rs34210356).
FT                                /FTId=VAR_033454.
FT   MUTAGEN      90     90       D->A: Reduced AMP-activation of
FT                                phosphorylation of PRKAA1 or PRKAA2.
FT                                Reduced ADP activation of phosphorylation
FT                                of PRKAA1 or PRKAA2.
FT   MUTAGEN     245    245       D->A: Reduced AMP-activation of
FT                                phosphorylation of PRKAA1 or PRKAA2.
FT                                Reduced ADP activation of phosphorylation
FT                                of PRKAA1 or PRKAA2.
FT   MUTAGEN     317    317       D->A: Reduced AMP-activation of
FT                                phosphorylation of PRKAA1 or PRKAA2. Does
FT                                not affect ADP activation of
FT                                phosphorylation of PRKAA1 or PRKAA2.
FT   HELIX        28     33
FT   HELIX        38     41
FT   STRAND       44     52
FT   HELIX        57     66
FT   STRAND       72     76
FT   TURN         77     80
FT   STRAND       81     86
FT   HELIX        88     97
FT   STRAND      102    104
FT   HELIX       107    111
FT   HELIX       114    120
FT   HELIX       138    147
FT   STRAND      151    156
FT   TURN        158    160
FT   STRAND      163    168
FT   HELIX       169    177
FT   TURN        178    182
FT   HELIX       186    189
FT   HELIX       193    196
FT   HELIX       213    223
FT   STRAND      226    231
FT   STRAND      235    242
FT   HELIX       243    251
FT   HELIX       262    267
FT   HELIX       271    274
FT   STRAND      277    279
FT   HELIX       285    295
FT   STRAND      298    303
FT   STRAND      307    314
FT   HELIX       315    322
SQ   SEQUENCE   331 AA;  37579 MW;  0F22B9CA1DBD87AE CRC64;
     METVISSDSS PAVENEHPQE TPESNNSVYT SFMKSHRCYD LIPTSSKLVV FDTSLQVKKA
     FFALVTNGVR AAPLWDSKKQ SFVGMLTITD FINILHRYYK SALVQIYELE EHKIETWREV
     YLQDSFKPLV CISPNASLFD AVSSLIRNKI HRLPVIDPES GNTLYILTHK RILKFLKLFI
     TEFPKPEFMS KSLEELQIGT YANIAMVRTT TPVYVALGIF VQHRVSALPV VDEKGRVVDI
     YSKFDVINLA AEKTYNNLDV SVTKALQHRS HYFEGVLKCY LHETLETIIN RLVEAEVHRL
     VVVDENDVVK GIVSLSDILQ ALVLTGGEKK P
//
ID   AAKG2_HUMAN             Reviewed;         569 AA.
AC   Q9UGJ0; Q53Y07; Q6NUI0; Q75MP4; Q9NUZ9; Q9UDN8; Q9ULX8;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   09-JUL-2014, entry version 133.
DE   RecName: Full=5'-AMP-activated protein kinase subunit gamma-2;
DE            Short=AMPK gamma2;
DE            Short=AMPK subunit gamma-2;
DE   AltName: Full=H91620p;
GN   Name=PRKAG2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RA   Hattori A., Seki N., Hayashi A., Kozuma S., Muramatsu M., Saito T.;
RT   "Human homolog of AMPK gamma-1 chain.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=10698692; DOI=10.1042/0264-6021:3460659;
RA   Cheung P.C.F., Salt I.P., Davies S.P., Hardie D.G., Carling D.;
RT   "Characterization of AMP-activated protein kinase gamma-subunit
RT   isoforms and their role in AMP binding.";
RL   Biochem. J. 346:659-669(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RX   PubMed=11112354; DOI=10.1006/geno.2000.6376;
RA   Lang T.M., Yu L., Qiang T., Jiang J.M., Chen Z., Xin Y.R., Liu G.Y.,
RA   Zhao S.;
RT   "Molecular cloning, genomic organization, and mapping of PRKAG2, a
RT   heart abundant gamma-2 subunit of 5'-AMP-activated protein kinase, to
RT   human chromosome 7q36.";
RL   Genomics 70:258-263(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS B AND C).
RC   TISSUE=Brain, and Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   DOMAIN CBS, AMP-BINDING, ATP-BINDING, CHARACTERIZATION OF VARIANTS
RP   WPWS GLN-302; ARG-383 AND ASN-400, CHARACTERIZATION OF VARIANT WPWS
RP   GLY-531, AND FUNCTION.
RX   PubMed=14722619; DOI=10.1172/JCI19874;
RA   Scott J.W., Hawley S.A., Green K.A., Anis M., Stewart G.,
RA   Scullion G.A., Norman D.G., Hardie D.G.;
RT   "CBS domains form energy-sensing modules whose binding of adenosine
RT   ligands is disrupted by disease mutations.";
RL   J. Clin. Invest. 113:274-284(2004).
RN   [9]
RP   DOMAIN AMPK PSEUDOSUBSTRATE, AND MUTAGENESIS OF VAL-387.
RX   PubMed=17255938; DOI=10.1038/sj.emboj.7601542;
RA   Scott J.W., Ross F.A., Liu J.K., Hardie D.G.;
RT   "Regulation of AMP-activated protein kinase by a pseudosubstrate
RT   sequence on the gamma subunit.";
RL   EMBO J. 26:806-815(2007).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   PHOSPHORYLATION BY ULK1.
RX   PubMed=21460634; DOI=10.4161/auto.7.7.15451;
RA   Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M.,
RA   Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.;
RT   "Ulk1-mediated phosphorylation of AMPK constitutes a negative
RT   regulatory feedback loop.";
RL   Autophagy 7:696-706(2011).
RN   [14]
RP   REVIEW ON FUNCTION.
RX   PubMed=17307971; DOI=10.1161/01.RES.0000256090.42690.05;
RA   Towler M.C., Hardie D.G.;
RT   "AMP-activated protein kinase in metabolic control and insulin
RT   signaling.";
RL   Circ. Res. 100:328-341(2007).
RN   [15]
RP   REVIEW ON FUNCTION.
RX   PubMed=17712357; DOI=10.1038/nrm2249;
RA   Hardie D.G.;
RT   "AMP-activated/SNF1 protein kinases: conserved guardians of cellular
RT   energy.";
RL   Nat. Rev. Mol. Cell Biol. 8:774-785(2007).
RN   [16]
RP   VARIANT WPWS GLY-531.
RX   PubMed=11748095; DOI=10.1161/hc5001.102111;
RA   Gollob M.H., Seger J.J., Gollob T.N., Tapscott T., Gonzales O.,
RA   Bachinski L., Roberts R.;
RT   "Novel PRKAG2 mutation responsible for the genetic syndrome of
RT   ventricular preexcitation and conduction system disease with childhood
RT   onset and absence of cardiac hypertrophy.";
RL   Circulation 104:3030-3033(2001).
RN   [17]
RP   VARIANTS CMH6 LEU-350 INS AND ARG-383.
RX   PubMed=11371514; DOI=10.1093/hmg/10.11.1215;
RA   Blair E., Redwood C., Ashrafian H., Oliveira M., Broxholme J.,
RA   Kerr B., Salmon A., Oestman-Smith I., Watkins H.;
RT   "Mutations in the gamma(2) subunit of AMP-activated protein kinase
RT   cause familial hypertrophic cardiomyopathy: evidence for the central
RT   role of energy compromise in disease pathogenesis.";
RL   Hum. Mol. Genet. 10:1215-1220(2001).
RN   [18]
RP   VARIANT WPWS GLN-302.
RX   PubMed=11407343; DOI=10.1056/NEJM200106143442403;
RA   Gollob M.H., Green M.S., Tang A.S.-L., Gollob T., Karibe A.,
RA   Al Sayegh A.H., Ahmad F., Lozado R., Shah G., Fananapazir L.,
RA   Bachinski L.L., Roberts R.;
RT   "Identification of a gene responsible for familial Wolff-Parkinson-
RT   White syndrome.";
RL   N. Engl. J. Med. 344:1823-1831(2001).
RN   [19]
RP   ERRATUM.
RA   Gollob M.H., Green M.S., Tang A.S.-L., Gollob T., Karibe A.,
RA   Al Sayegh A.H., Ahmad F., Lozado R., Shah G., Fananapazir L.,
RA   Bachinski L.L., Roberts R.;
RL   N. Engl. J. Med. 345:552-552(2001).
RN   [20]
RP   ERRATUM.
RA   Gollob M.H., Green M.S., Tang A.S.-L., Gollob T., Karibe A.,
RA   Al Sayegh A.H., Ahmad F., Lozado R., Shah G., Fananapazir L.,
RA   Bachinski L.L., Roberts R.;
RL   N. Engl. J. Med. 346:300-300(2002).
RN   [21]
RP   VARIANTS CMH6 GLN-302; ASN-400 AND ILE-488.
RX   PubMed=11827995; DOI=10.1172/JCI0214571;
RA   Arad M., Benson D.W., Perez-Atayde A.R., McKenna W.J., Sparks E.A.,
RA   Kanter R.J., McGarry K., Seidman J.G., Seidman C.E.;
RT   "Constitutively active AMP kinase mutations cause glycogen storage
RT   disease mimicking hypertrophic cardiomyopathy.";
RL   J. Clin. Invest. 109:357-362(2002).
RN   [22]
RP   VARIANT GSDH GLN-531, AND CHARACTERIZATION OF VARIANT GSDH GLN-531.
RX   PubMed=15877279; DOI=10.1086/430840;
RA   Burwinkel B., Scott J.W., Buehrer C., van Landeghem F.K.H., Cox G.F.,
RA   Wilson C.J., Grahame Hardie D., Kilimann M.W.;
RT   "Fatal congenital heart glycogenosis caused by a recurrent activating
RT   R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase
RT   (PRKAG2), not by phosphorylase kinase deficiency.";
RL   Am. J. Hum. Genet. 76:1034-1049(2005).
CC   -!- FUNCTION: AMP/ATP-binding subunit of AMP-activated protein kinase
CC       (AMPK), an energy sensor protein kinase that plays a key role in
CC       regulating cellular energy metabolism. In response to reduction of
CC       intracellular ATP levels, AMPK activates energy-producing pathways
CC       and inhibits energy-consuming processes: inhibits protein,
CC       carbohydrate and lipid biosynthesis, as well as cell growth and
CC       proliferation. AMPK acts via direct phosphorylation of metabolic
CC       enzymes, and by longer-term effects via phosphorylation of
CC       transcription regulators. Also acts as a regulator of cellular
CC       polarity by remodeling the actin cytoskeleton; probably by
CC       indirectly activating myosin. Gamma non-catalytic subunit mediates
CC       binding to AMP, ADP and ATP, leading to activate or inhibit AMPK:
CC       AMP-binding results in allosteric activation of alpha catalytic
CC       subunit (PRKAA1 or PRKAA2) both by inducing phosphorylation and
CC       preventing dephosphorylation of catalytic subunits. ADP also
CC       stimulates phosphorylation, without stimulating already
CC       phosphorylated catalytic subunit. ATP promotes dephosphorylation
CC       of catalytic subunit, rendering the AMPK enzyme inactive.
CC   -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit
CC       (PRKAA1 or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-
CC       catalytic subunits (PRKAG1, PRKAG2 or PRKAG3). Interacts with
CC       FNIP1 and FNIP2.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=A;
CC         IsoId=Q9UGJ0-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=Q9UGJ0-2; Sequence=VSP_000261;
CC       Name=C;
CC         IsoId=Q9UGJ0-3; Sequence=VSP_015589;
CC   -!- TISSUE SPECIFICITY: Isoform B is ubiquitously expressed except in
CC       liver and thymus. The highest level is detected in heart with
CC       abundant expression in placenta and testis.
CC   -!- DOMAIN: The AMPK pseudosubstrate motif resembles the sequence
CC       around sites phosphorylated on target proteins of AMPK, except the
CC       presence of a non-phosphorylatable residue in place of Ser. In the
CC       absence of AMP this pseudosubstrate sequence may bind to the
CC       active site groove on the alpha subunit (PRKAA1 or PRKAA2),
CC       preventing phosphorylation by the upstream activating kinase
CC       STK11/LKB1.
CC   -!- DOMAIN: The CBS domains mediate binding to AMP, ADP and ATP. 2
CC       sites bind either AMP or ATP, whereas a third site contains a
CC       tightly bound AMP that does not exchange. Under physiological
CC       conditions AMPK mainly exists in its inactive form in complex with
CC       ATP, which is much more abundant than AMP.
CC   -!- PTM: Phosphorylated by ULK1; leading to negatively regulate AMPK
CC       activity and suggesting the existence of a regulatory feedback
CC       loop between ULK1 and AMPK.
CC   -!- DISEASE: Wolff-Parkinson-White syndrome (WPWS) [MIM:194200]: A
CC       supernormal conduction disorder characterized by the presence of
CC       one or several accessory atrioventricular connections, which can
CC       lead to episodes of sporadic tachycardia. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Cardiomyopathy, familial hypertrophic 6 (CMH6)
CC       [MIM:600858]: A hereditary heart disorder characterized by
CC       ventricular hypertrophy, which is usually asymmetric and often
CC       involves the interventricular septum. The symptoms include
CC       dyspnea, syncope, collapse, palpitations, and chest pain. They can
CC       be readily provoked by exercise. The disorder has inter- and
CC       intrafamilial variability ranging from benign to malignant forms
CC       with high risk of cardiac failure and sudden cardiac death. CMH6
CC       patients present Wolff-Parkinson-White ventricular preexcitation,
CC       enlarged myocytes without myofiber disarray, and glycogen-
CC       containing cytosolic vacuoles within cardiomyocytes. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Glycogen storage disease of heart lethal congenital
CC       (GSDH) [MIM:261740]: Rare disease which leads to death within a
CC       few weeks to a few months after birth, through heart failure and
CC       respiratory compromise. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the 5'-AMP-activated protein kinase gamma
CC       subunit family.
CC   -!- SIMILARITY: Contains 4 CBS domains.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH20540.2; Type=Erroneous initiation;
CC       Sequence=AAS02032.1; Type=Erroneous gene model prediction;
CC       Sequence=BAA84695.1; Type=Frameshift; Positions=228, 233; Note=Frameshifts are upstream of the initiating Met of isoform B;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB025580; BAA84695.1; ALT_FRAME; mRNA.
DR   EMBL; AJ249976; CAB65116.1; -; mRNA.
DR   EMBL; AF087875; AAK00413.1; -; mRNA.
DR   EMBL; AK001887; BAA91962.1; -; mRNA.
DR   EMBL; BT007127; AAP35791.1; -; mRNA.
DR   EMBL; AC006358; AAS02032.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC006966; AAF03528.2; -; Genomic_DNA.
DR   EMBL; AC093583; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC020540; AAH20540.2; ALT_INIT; mRNA.
DR   EMBL; BC068598; AAH68598.1; -; mRNA.
DR   CCDS; CCDS43683.1; -. [Q9UGJ0-3]
DR   CCDS; CCDS47752.1; -. [Q9UGJ0-2]
DR   CCDS; CCDS5928.1; -. [Q9UGJ0-1]
DR   RefSeq; NP_001035723.1; NM_001040633.1. [Q9UGJ0-3]
DR   RefSeq; NP_057287.2; NM_016203.3. [Q9UGJ0-1]
DR   RefSeq; NP_077747.1; NM_024429.1. [Q9UGJ0-2]
DR   UniGene; Hs.647072; -.
DR   ProteinModelPortal; Q9UGJ0; -.
DR   SMR; Q9UGJ0; 260-557.
DR   BioGrid; 119531; 19.
DR   IntAct; Q9UGJ0; 15.
DR   MINT; MINT-4831646; -.
DR   STRING; 9606.ENSP00000287878; -.
DR   BindingDB; Q9UGJ0; -.
DR   ChEMBL; CHEMBL2096907; -.
DR   PhosphoSite; Q9UGJ0; -.
DR   DMDM; 14285344; -.
DR   MaxQB; Q9UGJ0; -.
DR   PaxDb; Q9UGJ0; -.
DR   PRIDE; Q9UGJ0; -.
DR   DNASU; 51422; -.
DR   Ensembl; ENST00000287878; ENSP00000287878; ENSG00000106617. [Q9UGJ0-1]
DR   Ensembl; ENST00000392801; ENSP00000376549; ENSG00000106617. [Q9UGJ0-3]
DR   Ensembl; ENST00000418337; ENSP00000387386; ENSG00000106617. [Q9UGJ0-2]
DR   GeneID; 51422; -.
DR   KEGG; hsa:51422; -.
DR   UCSC; uc003wki.3; human. [Q9UGJ0-1]
DR   CTD; 51422; -.
DR   GeneCards; GC07M151253; -.
DR   GeneReviews; PRKAG2; -.
DR   HGNC; HGNC:9386; PRKAG2.
DR   HPA; CAB018641; -.
DR   HPA; HPA004246; -.
DR   MIM; 194200; phenotype.
DR   MIM; 261740; phenotype.
DR   MIM; 600858; phenotype.
DR   MIM; 602743; gene.
DR   neXtProt; NX_Q9UGJ0; -.
DR   Orphanet; 155; Familial isolated hypertrophic cardiomyopathy.
DR   Orphanet; 907; Wolff-Parkinson-White syndrome.
DR   PharmGKB; PA33752; -.
DR   eggNOG; COG0517; -.
DR   HOVERGEN; HBG050431; -.
DR   InParanoid; Q9UGJ0; -.
DR   KO; K07200; -.
DR   OMA; GAKQKEN; -.
DR   OrthoDB; EOG74FF0W; -.
DR   PhylomeDB; Q9UGJ0; -.
DR   TreeFam; TF313247; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_200751; Organelle biogenesis and maintenance.
DR   SignaLink; Q9UGJ0; -.
DR   ChiTaRS; PRKAG2; human.
DR   GeneWiki; PRKAG2; -.
DR   GenomeRNAi; 51422; -.
DR   NextBio; 54969; -.
DR   PRO; PR:Q9UGJ0; -.
DR   ArrayExpress; Q9UGJ0; -.
DR   Bgee; Q9UGJ0; -.
DR   CleanEx; HS_PRKAG2; -.
DR   Genevestigator; Q9UGJ0; -.
DR   GO; GO:0031588; C:AMP-activated protein kinase complex; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProt.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0043531; F:ADP binding; IDA:BHF-UCL.
DR   GO; GO:0016208; F:AMP binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:BHF-UCL.
DR   GO; GO:0004862; F:cAMP-dependent protein kinase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0008603; F:cAMP-dependent protein kinase regulator activity; IMP:BHF-UCL.
DR   GO; GO:0008607; F:phosphorylase kinase regulator activity; IMP:BHF-UCL.
DR   GO; GO:0030295; F:protein kinase activator activity; IMP:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IDA:BHF-UCL.
DR   GO; GO:0006754; P:ATP biosynthetic process; TAS:BHF-UCL.
DR   GO; GO:0006853; P:carnitine shuttle; TAS:Reactome.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:Reactome.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0006112; P:energy reserve metabolic process; TAS:Reactome.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0005977; P:glycogen metabolic process; IMP:BHF-UCL.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0035556; P:intracellular signal transduction; IMP:BHF-UCL.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0071901; P:negative regulation of protein serine/threonine kinase activity; IDA:GOC.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IMP:BHF-UCL.
DR   GO; GO:0042304; P:regulation of fatty acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0019217; P:regulation of fatty acid metabolic process; IMP:BHF-UCL.
DR   GO; GO:0046320; P:regulation of fatty acid oxidation; TAS:BHF-UCL.
DR   GO; GO:0046324; P:regulation of glucose import; TAS:BHF-UCL.
DR   GO; GO:0006110; P:regulation of glycolytic process; IMP:BHF-UCL.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0016126; P:sterol biosynthetic process; TAS:BHF-UCL.
DR   InterPro; IPR000644; CBS_dom.
DR   Pfam; PF00571; CBS; 3.
DR   SMART; SM00116; CBS; 4.
DR   PROSITE; PS51371; CBS; 4.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cardiomyopathy; CBS domain;
KW   Complete proteome; Disease mutation; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Glycogen storage disease; Lipid biosynthesis;
KW   Lipid metabolism; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat.
FT   CHAIN         1    569       5'-AMP-activated protein kinase subunit
FT                                gamma-2.
FT                                /FTId=PRO_0000204381.
FT   DOMAIN      275    335       CBS 1.
FT   DOMAIN      357    415       CBS 2.
FT   DOMAIN      430    492       CBS 3.
FT   DOMAIN      504    562       CBS 4.
FT   MOTIF       370    391       AMPK pseudosubstrate.
FT   BINDING     302    302       AMP 1 (By similarity).
FT   BINDING     302    302       ATP 1 (By similarity).
FT   BINDING     383    383       AMP 2 (By similarity).
FT   BINDING     383    383       AMP 3 (By similarity).
FT   BINDING     383    383       ATP 2 (By similarity).
FT   BINDING     384    384       ATP 1 (By similarity).
FT   BINDING     384    384       ATP 2 (By similarity).
FT   BINDING     402    402       AMP 1 (By similarity).
FT   BINDING     402    402       ATP 1 (By similarity).
FT   BINDING     530    530       AMP 3 (By similarity).
FT   BINDING     531    531       AMP 1 (By similarity).
FT   BINDING     531    531       ATP 1 (By similarity).
FT   MOD_RES      65     65       Phosphoserine (By similarity).
FT   MOD_RES      71     71       Phosphoserine (By similarity).
FT   MOD_RES      73     73       Phosphoserine (By similarity).
FT   MOD_RES      90     90       Phosphoserine (By similarity).
FT   MOD_RES     138    138       Phosphoserine (By similarity).
FT   MOD_RES     143    143       Phosphoserine (By similarity).
FT   MOD_RES     161    161       Phosphoserine (By similarity).
FT   MOD_RES     196    196       Phosphoserine (By similarity).
FT   VAR_SEQ       1    241       Missing (in isoform B).
FT                                /FTId=VSP_000261.
FT   VAR_SEQ       1     44       Missing (in isoform C).
FT                                /FTId=VSP_015589.
FT   VARIANT       6      6       M -> L (in dbSNP:rs3207363).
FT                                /FTId=VAR_048250.
FT   VARIANT     302    302       R -> Q (in WPWS and CMH6; impaired AMP-
FT                                and ATP-binding).
FT                                /FTId=VAR_013264.
FT   VARIANT     350    350       R -> RL (in CMH6; severe).
FT                                /FTId=VAR_013265.
FT   VARIANT     383    383       H -> R (in CMH6; severe; impaired AMP-
FT                                and ATP-binding).
FT                                /FTId=VAR_013266.
FT   VARIANT     400    400       T -> N (in CMH6; severe; impaired AMP-
FT                                and ATP-binding; dbSNP:rs28938173).
FT                                /FTId=VAR_013267.
FT   VARIANT     488    488       N -> I (in CMH6; severe).
FT                                /FTId=VAR_013268.
FT   VARIANT     531    531       R -> G (in WPWS; absence of cardiac
FT                                hypertrophy; onset in childhood; impaired
FT                                AMP- and ATP-binding).
FT                                /FTId=VAR_032909.
FT   VARIANT     531    531       R -> Q (in GSDH; reduction of binding
FT                                affinities for AMP and ATP; loss of
FT                                cooperative binding; enhanced basal
FT                                activity; increased phosphorylation of
FT                                the alpha-subunit).
FT                                /FTId=VAR_013269.
FT   MUTAGEN     387    387       V->S: Induces phosphorylation by AMPK.
SQ   SEQUENCE   569 AA;  63066 MW;  F51C30668C294089 CRC64;
     MGSAVMDTKK KKDVSSPGGS GGKKNASQKR RSLRVHIPDL SSFAMPLLDG DLEGSGKHSS
     RKVDSPFGPG SPSKGFFSRG PQPRPSSPMS APVRPKTSPG SPKTVFPFSY QESPPRSPRR
     MSFSGIFRSS SKESSPNSNP ATSPGGIRFF SRSRKTSGLS SSPSTPTQVT KQHTFPLESY
     KHEPERLENR IYASSSPPDT GQRFCPSSFQ SPTRPPLASP THYAPSKAAA LAAALGPAEA
     GMLEKLEFED EAVEDSESGV YMRFMRSHKC YDIVPTSSKL VVFDTTLQVK KAFFALVANG
     VRAAPLWESK KQSFVGMLTI TDFINILHRY YKSPMVQIYE LEEHKIETWR ELYLQETFKP
     LVNISPDASL FDAVYSLIKN KIHRLPVIDP ISGNALYILT HKRILKFLQL FMSDMPKPAF
     MKQNLDELGI GTYHNIAFIH PDTPIIKALN IFVERRISAL PVVDESGKVV DIYSKFDVIN
     LAAEKTYNNL DITVTQALQH RSQYFEGVVK CNKLEILETI VDRIVRAEVH RLVVVNEADS
     IVGIISLSDI LQALILTPAG AKQKETETE
//
ID   AAPK1_HUMAN             Reviewed;         559 AA.
AC   Q13131; A8MTQ6; B2R7E1; O00286; Q5D0E1; Q86VS1; Q9UNQ4;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   28-JUL-2009, sequence version 4.
DT   09-JUL-2014, entry version 158.
DE   RecName: Full=5'-AMP-activated protein kinase catalytic subunit alpha-1;
DE            Short=AMPK subunit alpha-1;
DE            EC=2.7.11.1;
DE   AltName: Full=Acetyl-CoA carboxylase kinase;
DE            Short=ACACA kinase;
DE            EC=2.7.11.27;
DE   AltName: Full=Hydroxymethylglutaryl-CoA reductase kinase;
DE            Short=HMGCR kinase;
DE            EC=2.7.11.31;
DE   AltName: Full=Tau-protein kinase PRKAA1;
DE            EC=2.7.11.26;
GN   Name=PRKAA1; Synonyms=AMPK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   LEU-10.
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3-559 (ISOFORM 1).
RC   TISSUE=Mammary gland;
RA   Yano K.;
RT   "Nucleotide sequence of cDNA for human AMP-activated protein kinase
RT   alpha-1.";
RL   Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 5-559 (ISOFORM 1).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 9-559 (ISOFORM 1).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for
RT   300 previously undefined genes expressed in CD34+ hematopoietic
RT   stem/progenitor cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 36-209 (ISOFORM 1).
RC   TISSUE=Intestine;
RA   Taboada E.N., Hickey D.A.;
RL   Submitted (APR-1995) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 303-559 (ISOFORMS 1/2).
RC   TISSUE=Liver;
RX   PubMed=8557660; DOI=10.1074/jbc.271.2.611;
RA   Stapleton D., Mitchelhill K.I., Gao G., Widmer J., Michell B.J.,
RA   Teh T., House C.M., Fernandez C.S., Cox T., Witters L.A., Kemp B.E.;
RT   "Mammalian AMP-activated protein kinase subfamily.";
RL   J. Biol. Chem. 271:611-614(1996).
RN   [8]
RP   DOMAIN AIS.
RX   PubMed=9857077; DOI=10.1074/jbc.273.52.35347;
RA   Crute B.E., Seefeld K., Gamble J., Kemp B.E., Witters L.A.;
RT   "Functional domains of the alpha1 catalytic subunit of the AMP-
RT   activated protein kinase.";
RL   J. Biol. Chem. 273:35347-35354(1998).
RN   [9]
RP   FUNCTION.
RX   PubMed=11554766; DOI=10.1006/bbrc.2001.5627;
RA   Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.;
RT   "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated
RT   protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-
RT   ribofuranoside, in a human hepatocellular carcinoma cell line.";
RL   Biochem. Biophys. Res. Commun. 287:562-567(2001).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF EP300.
RX   PubMed=11518699; DOI=10.1074/jbc.C100316200;
RA   Yang W., Hong Y.H., Shen X.Q., Frankowski C., Camp H.S., Leff T.;
RT   "Regulation of transcription by AMP-activated protein kinase:
RT   phosphorylation of p300 blocks its interaction with nuclear
RT   receptors.";
RL   J. Biol. Chem. 276:38341-38344(2001).
RN   [11]
RP   ENZYME REGULATION.
RX   PubMed=11602624; DOI=10.1172/JCI13505;
RA   Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M.,
RA   Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F.,
RA   Goodyear L.J., Moller D.E.;
RT   "Role of AMP-activated protein kinase in mechanism of metformin
RT   action.";
RL   J. Clin. Invest. 108:1167-1174(2001).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF CFTR.
RX   PubMed=12519745; DOI=10.1152/ajpcell.00227.2002;
RA   Hallows K.R., Kobinger G.P., Wilson J.M., Witters L.A., Foskett J.K.;
RT   "Physiological modulation of CFTR activity by AMP-activated protein
RT   kinase in polarized T84 cells.";
RL   Am. J. Physiol. 284:C1297-C1308(2003).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF TSC2.
RX   PubMed=14651849; DOI=10.1016/S0092-8674(03)00929-2;
RA   Inoki K., Zhu T., Guan K.L.;
RT   "TSC2 mediates cellular energy response to control cell growth and
RT   survival.";
RL   Cell 115:577-590(2003).
RN   [14]
RP   PHOSPHORYLATION AT THR-183, AND ENZYME REGULATION.
RX   PubMed=14976552; DOI=10.1038/sj.emboj.7600110;
RA   Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A.,
RA   Boudeau J., Hawley S.A., Udd L., Maekelae T.P., Hardie D.G.,
RA   Alessi D.R.;
RT   "LKB1 is a master kinase that activates 13 kinases of the AMPK
RT   subfamily, including MARK/PAR-1.";
RL   EMBO J. 23:833-843(2004).
RN   [15]
RP   PHOSPHORYLATION AT THR-183, AND ENZYME REGULATION.
RX   PubMed=16054095; DOI=10.1016/j.cmet.2005.05.009;
RA   Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M.,
RA   Frenguelli B.G., Hardie D.G.;
RT   "Calmodulin-dependent protein kinase kinase-beta is an alternative
RT   upstream kinase for AMP-activated protein kinase.";
RL   Cell Metab. 2:9-19(2005).
RN   [16]
RP   PHOSPHORYLATION AT THR-183, AND ENZYME REGULATION.
RX   PubMed=15980064; DOI=10.1074/jbc.M503824200;
RA   Hurley R.L., Anderson K.A., Franzone J.M., Kemp B.E., Means A.R.,
RA   Witters L.A.;
RT   "The Ca2+/calmodulin-dependent protein kinase kinases are AMP-
RT   activated protein kinase kinases.";
RL   J. Biol. Chem. 280:29060-29066(2005).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027;
RA   Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y.,
RA   Birnbaum M.J., Thompson C.B.;
RT   "AMP-activated protein kinase induces a p53-dependent metabolic
RT   checkpoint.";
RL   Mol. Cell 18:283-293(2005).
RN   [18]
RP   INTERACTION WITH FNIP1.
RX   PubMed=17028174; DOI=10.1073/pnas.0603781103;
RA   Baba M., Hong S.-B., Sharma N., Warren M.B., Nickerson M.L.,
RA   Iwamatsu A., Esposito D., Gillette W.K., Hopkins R.F. III,
RA   Hartley J.L., Furihata M., Oishi S., Zhen W., Burke T.R. Jr.,
RA   Linehan W.M., Schmidt L.S., Zbar B.;
RT   "Folliculin encoded by the BHD gene interacts with a binding protein,
RT   FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15552-15557(2006).
RN   [19]
RP   DOMAIN AIS, AND MUTAGENESIS OF VAL-307.
RX   PubMed=17088252; DOI=10.1074/jbc.M605790200;
RA   Pang T., Xiong B., Li J.Y., Qiu B.Y., Jin G.Z., Shen J.K., Li J.;
RT   "Conserved alpha-helix acts as autoinhibitory sequence in AMP-
RT   activated protein kinase alpha subunits.";
RL   J. Biol. Chem. 282:495-506(2007).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF FOXO3.
RX   PubMed=17711846; DOI=10.1074/jbc.M705325200;
RA   Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P.,
RA   Gygi S.P., Brunet A.;
RT   "The energy sensor AMP-activated protein kinase directly regulates the
RT   mammalian FOXO3 transcription factor.";
RL   J. Biol. Chem. 282:30107-30119(2007).
RN   [21]
RP   FUNCTION IN CELL POLARITY.
RX   PubMed=17486097; DOI=10.1038/nature05828;
RA   Lee J.H., Koh H., Kim M., Kim Y., Lee S.Y., Karess R.E., Lee S.H.,
RA   Shong M., Kim J.M., Kim J., Chung J.;
RT   "Energy-dependent regulation of cell structure by AMP-activated
RT   protein kinase.";
RL   Nature 447:1017-1020(2007).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF HDAC5.
RX   PubMed=18184930; DOI=10.2337/db07-0843;
RA   McGee S.L., van Denderen B.J., Howlett K.F., Mollica J.,
RA   Schertzer J.D., Kemp B.E., Hargreaves M.;
RT   "AMP-activated protein kinase regulates GLUT4 transcription by
RT   phosphorylating histone deacetylase 5.";
RL   Diabetes 57:860-867(2008).
RN   [23]
RP   INTERACTION WITH FNIP2.
RX   PubMed=18403135; DOI=10.1016/j.gene.2008.02.022;
RA   Hasumi H., Baba M., Hong S.-B., Hasumi Y., Huang Y., Yao M.,
RA   Valera V.A., Linehan W.M., Schmidt L.S.;
RT   "Identification and characterization of a novel folliculin-interacting
RT   protein FNIP2.";
RL   Gene 415:60-67(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-382, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF RPTOR.
RX   PubMed=18439900; DOI=10.1016/j.molcel.2008.03.003;
RA   Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A.,
RA   Vasquez D.S., Turk B.E., Shaw R.J.;
RT   "AMPK phosphorylation of raptor mediates a metabolic checkpoint.";
RL   Mol. Cell 30:214-226(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [28]
RP   INTERACTION WITH FNIP2.
RX   PubMed=18663353; DOI=10.1038/onc.2008.261;
RA   Takagi Y., Kobayashi T., Shiono M., Wang L., Piao X., Sun G.,
RA   Zhang D., Abe M., Hagiwara Y., Takahashi K., Hino O.;
RT   "Interaction of folliculin (Birt-Hogg-Dube gene product) with a novel
RT   Fnip1-like (FnipL/Fnip2) protein.";
RL   Oncogene 27:5339-5347(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-356; SER-486; THR-490
RP   AND SER-496, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-32 AND SER-467, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-382, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF KLC1.
RX   PubMed=20074060; DOI=10.1042/BST0380205;
RA   McDonald A., Fogarty S., Leclerc I., Hill E.V., Hardie D.G.,
RA   Rutter G.A.;
RT   "Cell-wide analysis of secretory granule dynamics in three dimensions
RT   in living pancreatic beta-cells: evidence against a role for AMPK-
RT   dependent phosphorylation of KLC1 at Ser517/Ser520 in glucose-
RT   stimulated insulin granule movement.";
RL   Biochem. Soc. Trans. 38:205-208(2010).
RN   [33]
RP   FUNCTION.
RX   PubMed=20160076; DOI=10.1073/pnas.0913860107;
RA   Alexander A., Cai S.L., Kim J., Nanez A., Sahin M., MacLean K.H.,
RA   Inoki K., Guan K.L., Shen J., Person M.D., Kusewitt D., Mills G.B.,
RA   Kastan M.B., Walker C.L.;
RT   "ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response
RT   to ROS.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4153-4158(2010).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [35]
RP   PHOSPHORYLATION BY ULK1 AND ULK2.
RX   PubMed=21460634; DOI=10.4161/auto.7.7.15451;
RA   Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M.,
RA   Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.;
RT   "Ulk1-mediated phosphorylation of AMPK constitutes a negative
RT   regulatory feedback loop.";
RL   Autophagy 7:696-706(2011).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   FUNCTION IN PHOSPHORYLATION OF ULK1.
RX   PubMed=21205641; DOI=10.1126/science.1196371;
RA   Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A.,
RA   Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M.,
RA   Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J.;
RT   "Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase
RT   connects energy sensing to mitophagy.";
RL   Science 331:456-461(2011).
RN   [38]
RP   INTERACTION WITH PRKAB1 AND PRKAG1, AND ENZYME REGULATION.
RX   PubMed=21680840; DOI=10.1126/science.1200094;
RA   Oakhill J.S., Steel R., Chen Z.P., Scott J.W., Ling N., Tam S.,
RA   Kemp B.E.;
RT   "AMPK is a direct adenylate charge-regulated protein kinase.";
RL   Science 332:1433-1435(2011).
RN   [39]
RP   REVIEW ON FUNCTION.
RX   PubMed=17307971; DOI=10.1161/01.RES.0000256090.42690.05;
RA   Towler M.C., Hardie D.G.;
RT   "AMP-activated protein kinase in metabolic control and insulin
RT   signaling.";
RL   Circ. Res. 100:328-341(2007).
RN   [40]
RP   REVIEW ON FUNCTION.
RX   PubMed=17712357; DOI=10.1038/nrm2249;
RA   Hardie D.G.;
RT   "AMP-activated/SNF1 protein kinases: conserved guardians of cellular
RT   energy.";
RL   Nat. Rev. Mol. Cell Biol. 8:774-785(2007).
RN   [41]
RP   DEPHOSPHORYLATION.
RX   PubMed=23088624; DOI=10.1042/BJ20121201;
RA   Chida T., Ando M., Matsuki T., Masu Y., Nagaura Y.,
RA   Takano-Yamamoto T., Tamura S., Kobayashi T.;
RT   "N-Myristoylation is essential for protein phosphatases PPM1A and
RT   PPM1B to dephosphorylate their physiological substrates in cells.";
RL   Biochem. J. 449:741-749(2013).
RN   [42]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-16.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Catalytic subunit of AMP-activated protein kinase
CC       (AMPK), an energy sensor protein kinase that plays a key role in
CC       regulating cellular energy metabolism. In response to reduction of
CC       intracellular ATP levels, AMPK activates energy-producing pathways
CC       and inhibits energy-consuming processes: inhibits protein,
CC       carbohydrate and lipid biosynthesis, as well as cell growth and
CC       proliferation. AMPK acts via direct phosphorylation of metabolic
CC       enzymes, and by longer-term effects via phosphorylation of
CC       transcription regulators. Also acts as a regulator of cellular
CC       polarity by remodeling the actin cytoskeleton; probably by
CC       indirectly activating myosin. Regulates lipid synthesis by
CC       phosphorylating and inactivating lipid metabolic enzymes such as
CC       ACACA, ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and
CC       cholesterol synthesis by phosphorylating acetyl-CoA carboxylase
CC       (ACACA and ACACB) and hormone-sensitive lipase (LIPE) enzymes,
CC       respectively. Regulates insulin-signaling and glycolysis by
CC       phosphorylating IRS1, PFKFB2 and PFKFB3. AMPK stimulates glucose
CC       uptake in muscle by increasing the translocation of the glucose
CC       transporter SLC2A4/GLUT4 to the plasma membrane, possibly by
CC       mediating phosphorylation of TBC1D4/AS160. Regulates transcription
CC       and chromatin structure by phosphorylating transcription
CC       regulators involved in energy metabolism such as CRTC2/TORC2,
CC       FOXO3, histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A,
CC       p53/TP53, SREBF1, SREBF2 and PPARGC1A. Acts as a key regulator of
CC       glucose homeostasis in liver by phosphorylating CRTC2/TORC2,
CC       leading to CRTC2/TORC2 sequestration in the cytoplasm. In response
CC       to stress, phosphorylates 'Ser-36' of histone H2B (H2BS36ph),
CC       leading to promote transcription. Acts as a key regulator of cell
CC       growth and proliferation by phosphorylating TSC2, RPTOR and
CC       ATG1/ULK1: in response to nutrient limitation, negatively
CC       regulates the mTORC1 complex by phosphorylating RPTOR component of
CC       the mTORC1 complex and by phosphorylating and activating TSC2. In
CC       response to nutrient limitation, promotes autophagy by
CC       phosphorylating and activating ATG1/ULK1. AMPK also acts as a
CC       regulator of circadian rhythm by mediating phosphorylation of
CC       CRY1, leading to destabilize it. May regulate the Wnt signaling
CC       pathway by phosphorylating CTNNB1, leading to stabilize it. Also
CC       has tau-protein kinase activity: in response to amyloid beta A4
CC       protein (APP) exposure, activated by CAMKK2, leading to
CC       phosphorylation of MAPT/TAU; however the relevance of such data
CC       remains unclear in vivo. Also phosphorylates CFTR, EEF2K, KLC1,
CC       NOS3 and SLC12A1.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- CATALYTIC ACTIVITY: ATP + [tau protein] = ADP + [tau protein]
CC       phosphate.
CC   -!- CATALYTIC ACTIVITY: ATP + [hydroxymethylglutaryl-CoA reductase
CC       (NADPH)] = ADP + [hydroxymethylglutaryl-CoA reductase (NADPH)]
CC       phosphate.
CC   -!- CATALYTIC ACTIVITY: ATP + [acetyl-CoA carboxylase] = ADP +
CC       [acetyl-CoA carboxylase] phosphate.
CC   -!- COFACTOR: Magnesium.
CC   -!- ENZYME REGULATION: Activated by phosphorylation on Thr-183.
CC       Binding of AMP to non-catalytic gamma subunit (PRKAG1, PRKAG2 or
CC       PRKAG3) results in allosteric activation, inducing phosphorylation
CC       on Thr-183. AMP-binding to gamma subunit also sustains activity by
CC       preventing dephosphorylation of Thr-183. ADP also stimulates Thr-
CC       183 phosphorylation, without stimulating already phosphorylated
CC       AMPK. ATP promotes dephosphorylation of Thr-183, rendering the
CC       enzyme inactive. Under physiological conditions AMPK mainly exists
CC       in its inactive form in complex with ATP, which is much more
CC       abundant than AMP. AMPK is activated by antihyperglycemic drug
CC       metformin, a drug prescribed to patients with type 2 diabetes: in
CC       vivo, metformin seems to mainly inhibit liver gluconeogenesis.
CC       However, metformin can be used to activate AMPK in muscle and
CC       other cells in culture or ex vivo (PubMed:11602624). Selectively
CC       inhibited by compound C (6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-
CC       3-pyridin-4-yl-pyyrazolo[1,5-a] pyrimidine. Activated by
CC       resveratrol, a natural polyphenol present in red wine, and S17834,
CC       a synthetic polyphenol.
CC   -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit
CC       (PRKAA1 or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-
CC       catalytic subunits (PRKAG1, PRKAG2 or PRKAG3). Interacts with
CC       FNIP1 and FNIP2.
CC   -!- INTERACTION:
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-1181405, EBI-352572;
CC       Q9Y478:PRKAB1; NbExp=5; IntAct=EBI-1181405, EBI-719769;
CC       O43741:PRKAB2; NbExp=6; IntAct=EBI-1181405, EBI-1053424;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=In response to
CC       stress, recruited by p53/TP53 to specific promoters.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13131-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13131-2; Sequence=VSP_035431;
CC   -!- DOMAIN: The AIS (autoinhibitory sequence) region shows some
CC       sequence similarity with the ubiquitin-associated domains and
CC       represses kinase activity.
CC   -!- PTM: Ubiquitinated (By similarity).
CC   -!- PTM: Phosphorylated at Thr-183 by STK11/LKB1 in complex with
CC       STE20-related adapter-alpha (STRADA) pseudo kinase and CAB39. Also
CC       phosphorylated at Thr-183 by CAMKK2; triggered by a rise in
CC       intracellular calcium ions, without detectable changes in the
CC       AMP/ATP ratio. CAMKK1 can also phosphorylate Thr-183, but at a
CC       much lower level. Dephosphorylated by protein phosphatase 2A and
CC       2C (PP2A and PP2C). Phosphorylated by ULK1 and ULK2; leading to
CC       negatively regulate AMPK activity and suggesting the existence of
CC       a regulatory feedback loop between ULK1, ULK2 and AMPK.
CC       Dephosphorylated by PPM1A and PPM1B.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. SNF1 subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA64850.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=AAD43027.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=AAH37303.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=BAA36547.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=BAG35788.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC008810; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC048980; AAH48980.1; -; mRNA.
DR   EMBL; AB022017; BAA36547.1; ALT_INIT; mRNA.
DR   EMBL; AK312947; BAG35788.1; ALT_INIT; mRNA.
DR   EMBL; BC037303; AAH37303.1; ALT_INIT; mRNA.
DR   EMBL; AF100763; AAD43027.1; ALT_INIT; mRNA.
DR   EMBL; U22456; AAA64850.1; ALT_INIT; mRNA.
DR   EMBL; Y12856; CAA73361.1; -; mRNA.
DR   CCDS; CCDS3932.2; -. [Q13131-1]
DR   CCDS; CCDS3933.2; -. [Q13131-2]
DR   PIR; G01743; G01743.
DR   RefSeq; NP_006242.5; NM_006251.5. [Q13131-1]
DR   RefSeq; NP_996790.3; NM_206907.3. [Q13131-2]
DR   UniGene; Hs.43322; -.
DR   ProteinModelPortal; Q13131; -.
DR   SMR; Q13131; 18-559.
DR   BioGrid; 111549; 253.
DR   DIP; DIP-39973N; -.
DR   IntAct; Q13131; 62.
DR   MINT; MINT-6771251; -.
DR   STRING; 9606.ENSP00000346148; -.
DR   BindingDB; Q13131; -.
DR   ChEMBL; CHEMBL3038451; -.
DR   DrugBank; DB00131; Adenosine monophosphate.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB00914; Phenformin.
DR   GuidetoPHARMACOLOGY; 1541; -.
DR   PhosphoSite; Q13131; -.
DR   DMDM; 254763436; -.
DR   MaxQB; Q13131; -.
DR   PaxDb; Q13131; -.
DR   PRIDE; Q13131; -.
DR   DNASU; 5562; -.
DR   Ensembl; ENST00000354209; ENSP00000346148; ENSG00000132356. [Q13131-2]
DR   Ensembl; ENST00000397128; ENSP00000380317; ENSG00000132356. [Q13131-1]
DR   GeneID; 5562; -.
DR   KEGG; hsa:5562; -.
DR   UCSC; uc003jmb.3; human. [Q13131-2]
DR   UCSC; uc003jmc.3; human. [Q13131-1]
DR   CTD; 5562; -.
DR   GeneCards; GC05M040759; -.
DR   H-InvDB; HIX0004832; -.
DR   HGNC; HGNC:9376; PRKAA1.
DR   HPA; CAB005050; -.
DR   HPA; HPA035409; -.
DR   MIM; 602739; gene.
DR   neXtProt; NX_Q13131; -.
DR   PharmGKB; PA33744; -.
DR   eggNOG; COG0515; -.
DR   HOGENOM; HOG000233016; -.
DR   HOVERGEN; HBG050432; -.
DR   KO; K07198; -.
DR   OMA; MKRATIR; -.
DR   OrthoDB; EOG7RRF6K; -.
DR   PhylomeDB; Q13131; -.
DR   TreeFam; TF314032; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; REACT_111102; Signal Transduction.
DR   SignaLink; Q13131; -.
DR   ChiTaRS; PRKAA1; human.
DR   GeneWiki; Protein_kinase,_AMP-activated,_alpha_1; -.
DR   GenomeRNAi; 5562; -.
DR   NextBio; 21546; -.
DR   PRO; PR:Q13131; -.
DR   ArrayExpress; Q13131; -.
DR   Bgee; Q13131; -.
DR   CleanEx; HS_PRKAA1; -.
DR   Genevestigator; Q13131; -.
DR   GO; GO:0031588; C:AMP-activated protein kinase complex; ISS:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005622; C:intracellular; IC:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0050405; F:[acetyl-CoA carboxylase] kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047322; F:[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004679; F:AMP-activated protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004691; F:cAMP-dependent protein kinase activity; NAS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0035174; F:histone serine kinase activity; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0050321; F:tau-protein kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0000187; P:activation of MAPK activity; NAS:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:Reactome.
DR   GO; GO:0071361; P:cellular response to ethanol; IEA:Ensembl.
DR   GO; GO:0042149; P:cellular response to glucose starvation; ISS:UniProtKB.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0031669; P:cellular response to nutrient levels; ISS:UniProtKB.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0009631; P:cold acclimation; IEA:Ensembl.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB.
DR   GO; GO:0019395; P:fatty acid oxidation; IEA:Ensembl.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008610; P:lipid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:2001274; P:negative regulation of glucose import in response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:0046318; P:negative regulation of glucosylceramide biosynthetic process; NAS:UniProtKB.
DR   GO; GO:0050995; P:negative regulation of lipid catabolic process; ISS:UniProtKB.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; ISS:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0045542; P:positive regulation of cholesterol biosynthetic process; NAS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; ISS:UniProtKB.
DR   GO; GO:0051291; P:protein heterooligomerization; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:2000505; P:regulation of energy homeostasis; ISS:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0060627; P:regulation of vesicle-mediated transport; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; ISS:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; NAS:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR028375; KA1/Ssp2_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR028797; PRKAA1.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24343:SF81; PTHR24343:SF81; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF103243; SSF103243; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Autophagy; Biological rhythms;
KW   Cholesterol biosynthesis; Cholesterol metabolism; Chromatin regulator;
KW   Complete proteome; Cytoplasm; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Kinase; Lipid biosynthesis; Lipid metabolism;
KW   Magnesium; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Steroid biosynthesis; Steroid metabolism; Sterol biosynthesis;
KW   Sterol metabolism; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation; Wnt signaling pathway.
FT   CHAIN         1    559       5'-AMP-activated protein kinase catalytic
FT                                subunit alpha-1.
FT                                /FTId=PRO_0000085589.
FT   DOMAIN       27    279       Protein kinase.
FT   NP_BIND      33     41       ATP (By similarity).
FT   REGION      302    381       AIS.
FT   ACT_SITE    150    150       Proton acceptor (By similarity).
FT   BINDING      56     56       ATP (By similarity).
FT   MOD_RES      32     32       Phosphothreonine.
FT   MOD_RES     183    183       Phosphothreonine; by LKB1 and CaMKK2 (By
FT                                similarity).
FT   MOD_RES     269    269       Phosphothreonine (By similarity).
FT   MOD_RES     356    356       Phosphoserine.
FT   MOD_RES     360    360       Phosphoserine; by ULK1 (By similarity).
FT   MOD_RES     368    368       Phosphothreonine; by ULK1 (By
FT                                similarity).
FT   MOD_RES     382    382       Phosphothreonine.
FT   MOD_RES     397    397       Phosphoserine; by ULK1 (Probable).
FT   MOD_RES     467    467       Phosphoserine.
FT   MOD_RES     486    486       Phosphoserine.
FT   MOD_RES     488    488       Phosphothreonine; by ULK1 (Probable).
FT   MOD_RES     490    490       Phosphothreonine.
FT   MOD_RES     496    496       Phosphoserine.
FT   VAR_SEQ     121    121       R -> RKSDVPGVVKTGSTKE (in isoform 2).
FT                                /FTId=VSP_035431.
FT   VARIANT      10     10       M -> L (in dbSNP:rs17855679).
FT                                /FTId=VAR_058401.
FT   VARIANT      16     16       Q -> R (in a breast cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035622.
FT   MUTAGEN     307    307       V->G,Q: Activates the kinase activity.
FT   CONFLICT      5      5       S -> C (in Ref. 4; BAG35788).
FT   CONFLICT      9      9       K -> S (in Ref. 5; AAD43027).
FT   CONFLICT     37     37       T -> A (in Ref. 6; AAA64850).
FT   CONFLICT    202    202       A -> V (in Ref. 6; AAA64850).
FT   CONFLICT    208    208       I -> L (in Ref. 6; AAA64850).
FT   CONFLICT    269    269       T -> S (in Ref. 3; BAA36547).
SQ   SEQUENCE   559 AA;  64009 MW;  ABAE71FBF912947A CRC64;
     MRRLSSWRKM ATAEKQKHDG RVKIGHYILG DTLGVGTFGK VKVGKHELTG HKVAVKILNR
     QKIRSLDVVG KIRREIQNLK LFRHPHIIKL YQVISTPSDI FMVMEYVSGG ELFDYICKNG
     RLDEKESRRL FQQILSGVDY CHRHMVVHRD LKPENVLLDA HMNAKIADFG LSNMMSDGEF
     LRTSCGSPNY AAPEVISGRL YAGPEVDIWS SGVILYALLC GTLPFDDDHV PTLFKKICDG
     IFYTPQYLNP SVISLLKHML QVDPMKRATI KDIREHEWFK QDLPKYLFPE DPSYSSTMID
     DEALKEVCEK FECSEEEVLS CLYNRNHQDP LAVAYHLIID NRRIMNEAKD FYLATSPPDS
     FLDDHHLTRP HPERVPFLVA ETPRARHTLD ELNPQKSKHQ GVRKAKWHLG IRSQSRPNDI
     MAEVCRAIKQ LDYEWKVVNP YYLRVRRKNP VTSTYSKMSL QLYQVDSRTY LLDFRSIDDE
     ITEAKSGTAT PQRSGSVSNY RSCQRSDSDA EAQGKSSEVS LTSSVTSLDS SPVDLTPRPG
     SHTIEFFEMC ANLIKILAQ
//
ID   AAPK2_HUMAN             Reviewed;         552 AA.
AC   P54646; Q9H1E8; Q9UD43;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2002, sequence version 2.
DT   09-JUL-2014, entry version 148.
DE   RecName: Full=5'-AMP-activated protein kinase catalytic subunit alpha-2;
DE            Short=AMPK subunit alpha-2;
DE            EC=2.7.11.1;
DE   AltName: Full=Acetyl-CoA carboxylase kinase;
DE            Short=ACACA kinase;
DE            EC=2.7.11.27;
DE   AltName: Full=Hydroxymethylglutaryl-CoA reductase kinase;
DE            Short=HMGCR kinase;
DE            EC=2.7.11.31;
GN   Name=PRKAA2; Synonyms=AMPK, AMPK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   TISSUE=Heart;
RX   PubMed=7959015; DOI=10.1016/0378-1119(94)90174-0;
RA   Aguan K., Scott J., See C.G., Sarkar N.H.;
RT   "Characterization and chromosomal localization of the human homologue
RT   of a rat AMP-activated protein kinase-encoding gene: a major regulator
RT   of lipid metabolism in mammals.";
RL   Gene 149:345-350(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skeletal muscle;
RX   PubMed=7988703; DOI=10.1016/0014-5793(94)01247-4;
RA   Beri R.K., Marley A.E., See C.G., Sopwith W.F., Aguan K., Carling D.,
RA   Scott J., Carey F.;
RT   "Molecular cloning, expression and chromosomal localisation of human
RT   AMP-activated protein kinase.";
RL   FEBS Lett. 356:117-121(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION.
RX   PubMed=11554766; DOI=10.1006/bbrc.2001.5627;
RA   Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.;
RT   "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated
RT   protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-
RT   ribofuranoside, in a human hepatocellular carcinoma cell line.";
RL   Biochem. Biophys. Res. Commun. 287:562-567(2001).
RN   [6]
RP   FUNCTION IN PHOSPHORYLATION OF EP300.
RX   PubMed=11518699; DOI=10.1074/jbc.C100316200;
RA   Yang W., Hong Y.H., Shen X.Q., Frankowski C., Camp H.S., Leff T.;
RT   "Regulation of transcription by AMP-activated protein kinase:
RT   phosphorylation of p300 blocks its interaction with nuclear
RT   receptors.";
RL   J. Biol. Chem. 276:38341-38344(2001).
RN   [7]
RP   ENZYME REGULATION.
RX   PubMed=11602624; DOI=10.1172/JCI13505;
RA   Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M.,
RA   Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F.,
RA   Goodyear L.J., Moller D.E.;
RT   "Role of AMP-activated protein kinase in mechanism of metformin
RT   action.";
RL   J. Clin. Invest. 108:1167-1174(2001).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF CFTR.
RX   PubMed=12519745; DOI=10.1152/ajpcell.00227.2002;
RA   Hallows K.R., Kobinger G.P., Wilson J.M., Witters L.A., Foskett J.K.;
RT   "Physiological modulation of CFTR activity by AMP-activated protein
RT   kinase in polarized T84 cells.";
RL   Am. J. Physiol. 284:C1297-C1308(2003).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF TSC2.
RX   PubMed=14651849; DOI=10.1016/S0092-8674(03)00929-2;
RA   Inoki K., Zhu T., Guan K.L.;
RT   "TSC2 mediates cellular energy response to control cell growth and
RT   survival.";
RL   Cell 115:577-590(2003).
RN   [10]
RP   PHOSPHORYLATION AT THR-172, AND ENZYME REGULATION.
RX   PubMed=15980064; DOI=10.1074/jbc.M503824200;
RA   Hurley R.L., Anderson K.A., Franzone J.M., Kemp B.E., Means A.R.,
RA   Witters L.A.;
RT   "The Ca2+/calmodulin-dependent protein kinase kinases are AMP-
RT   activated protein kinase kinases.";
RL   J. Biol. Chem. 280:29060-29066(2005).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027;
RA   Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y.,
RA   Birnbaum M.J., Thompson C.B.;
RT   "AMP-activated protein kinase induces a p53-dependent metabolic
RT   checkpoint.";
RL   Mol. Cell 18:283-293(2005).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF FOXO3.
RX   PubMed=17711846; DOI=10.1074/jbc.M705325200;
RA   Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P.,
RA   Gygi S.P., Brunet A.;
RT   "The energy sensor AMP-activated protein kinase directly regulates the
RT   mammalian FOXO3 transcription factor.";
RL   J. Biol. Chem. 282:30107-30119(2007).
RN   [13]
RP   FUNCTION IN CELL POLARITY.
RX   PubMed=17486097; DOI=10.1038/nature05828;
RA   Lee J.H., Koh H., Kim M., Kim Y., Lee S.Y., Karess R.E., Lee S.H.,
RA   Shong M., Kim J.M., Kim J., Chung J.;
RT   "Energy-dependent regulation of cell structure by AMP-activated
RT   protein kinase.";
RL   Nature 447:1017-1020(2007).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF HDAC5.
RX   PubMed=18184930; DOI=10.2337/db07-0843;
RA   McGee S.L., van Denderen B.J., Howlett K.F., Mollica J.,
RA   Schertzer J.D., Kemp B.E., Hargreaves M.;
RT   "AMP-activated protein kinase regulates GLUT4 transcription by
RT   phosphorylating histone deacetylase 5.";
RL   Diabetes 57:860-867(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF KLC1.
RX   PubMed=20074060; DOI=10.1042/BST0380205;
RA   McDonald A., Fogarty S., Leclerc I., Hill E.V., Hardie D.G.,
RA   Rutter G.A.;
RT   "Cell-wide analysis of secretory granule dynamics in three dimensions
RT   in living pancreatic beta-cells: evidence against a role for AMPK-
RT   dependent phosphorylation of KLC1 at Ser517/Ser520 in glucose-
RT   stimulated insulin granule movement.";
RL   Biochem. Soc. Trans. 38:205-208(2010).
RN   [19]
RP   FUNCTION.
RX   PubMed=20160076; DOI=10.1073/pnas.0913860107;
RA   Alexander A., Cai S.L., Kim J., Nanez A., Sahin M., MacLean K.H.,
RA   Inoki K., Guan K.L., Shen J., Person M.D., Kusewitt D., Mills G.B.,
RA   Kastan M.B., Walker C.L.;
RT   "ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response
RT   to ROS.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4153-4158(2010).
RN   [20]
RP   PHOSPHORYLATION BY ULK1.
RX   PubMed=21460634; DOI=10.4161/auto.7.7.15451;
RA   Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M.,
RA   Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.;
RT   "Ulk1-mediated phosphorylation of AMPK constitutes a negative
RT   regulatory feedback loop.";
RL   Autophagy 7:696-706(2011).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF ULK1.
RX   PubMed=21205641; DOI=10.1126/science.1196371;
RA   Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A.,
RA   Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M.,
RA   Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J.;
RT   "Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase
RT   connects energy sensing to mitophagy.";
RL   Science 331:456-461(2011).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=17307971; DOI=10.1161/01.RES.0000256090.42690.05;
RA   Towler M.C., Hardie D.G.;
RT   "AMP-activated protein kinase in metabolic control and insulin
RT   signaling.";
RL   Circ. Res. 100:328-341(2007).
RN   [24]
RP   REVIEW ON FUNCTION.
RX   PubMed=17712357; DOI=10.1038/nrm2249;
RA   Hardie D.G.;
RT   "AMP-activated/SNF1 protein kinases: conserved guardians of cellular
RT   energy.";
RL   Nat. Rev. Mol. Cell Biol. 8:774-785(2007).
RN   [25]
RP   ENZYME REGULATION BY SALICYLATE.
RX   PubMed=22517326; DOI=10.1126/science.1215327;
RA   Hawley S.A., Fullerton M.D., Ross F.A., Schertzer J.D., Chevtzoff C.,
RA   Walker K.J., Peggie M.W., Zibrova D., Green K.A., Mustard K.J.,
RA   Kemp B.E., Sakamoto K., Steinberg G.R., Hardie D.G.;
RT   "The ancient drug salicylate directly activates AMP-activated protein
RT   kinase.";
RL   Science 336:918-922(2012).
RN   [26]
RP   DEPHOSPHORYLATION AT THR-172.
RX   PubMed=23088624; DOI=10.1042/BJ20121201;
RA   Chida T., Ando M., Matsuki T., Masu Y., Nagaura Y.,
RA   Takano-Yamamoto T., Tamura S., Kobayashi T.;
RT   "N-Myristoylation is essential for protein phosphatases PPM1A and
RT   PPM1B to dephosphorylate their physiological substrates in cells.";
RL   Biochem. J. 449:741-749(2013).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 6-279.
RX   PubMed=20124709; DOI=10.1107/S1744309109052543;
RA   Littler D.R., Walker J.R., Davis T., Wybenga-Groot L.E.,
RA   Finerty P.J. Jr., Newman E., Mackenzie F., Dhe-Paganon S.;
RT   "A conserved mechanism of autoinhibition for the AMPK kinase domain:
RT   ATP-binding site and catalytic loop refolding as a means of
RT   regulation.";
RL   Acta Crystallogr. F 66:143-151(2010).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 6-279 OF MUTANT THR-172 IN
RP   COMPLEX WITH COMPOUND C, AND ENZYME REGULATION.
RX   PubMed=21543851; DOI=10.1107/S0907444911010201;
RA   Handa N., Takagi T., Saijo S., Kishishita S., Takaya D., Toyama M.,
RA   Terada T., Shirouzu M., Suzuki A., Lee S., Yamauchi T.,
RA   Okada-Iwabu M., Iwabu M., Kadowaki T., Minokoshi Y., Yokoyama S.;
RT   "Structural basis for compound C inhibition of the human AMP-activated
RT   protein kinase alpha2 subunit kinase domain.";
RL   Acta Crystallogr. D 67:480-487(2011).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLY-523.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [30]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLN-407.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Catalytic subunit of AMP-activated protein kinase
CC       (AMPK), an energy sensor protein kinase that plays a key role in
CC       regulating cellular energy metabolism. In response to reduction of
CC       intracellular ATP levels, AMPK activates energy-producing pathways
CC       and inhibits energy-consuming processes: inhibits protein,
CC       carbohydrate and lipid biosynthesis, as well as cell growth and
CC       proliferation. AMPK acts via direct phosphorylation of metabolic
CC       enzymes, and by longer-term effects via phosphorylation of
CC       transcription regulators. Also acts as a regulator of cellular
CC       polarity by remodeling the actin cytoskeleton; probably by
CC       indirectly activating myosin. Regulates lipid synthesis by
CC       phosphorylating and inactivating lipid metabolic enzymes such as
CC       ACACA, ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and
CC       cholesterol synthesis by phosphorylating acetyl-CoA carboxylase
CC       (ACACA and ACACB) and hormone-sensitive lipase (LIPE) enzymes,
CC       respectively. Regulates insulin-signaling and glycolysis by
CC       phosphorylating IRS1, PFKFB2 and PFKFB3. AMPK stimulates glucose
CC       uptake in muscle by increasing the translocation of the glucose
CC       transporter SLC2A4/GLUT4 to the plasma membrane, possibly by
CC       mediating phosphorylation of TBC1D4/AS160. Regulates transcription
CC       and chromatin structure by phosphorylating transcription
CC       regulators involved in energy metabolism such as CRTC2/TORC2,
CC       FOXO3, histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A,
CC       p53/TP53, SREBF1, SREBF2 and PPARGC1A. Acts as a key regulator of
CC       glucose homeostasis in liver by phosphorylating CRTC2/TORC2,
CC       leading to CRTC2/TORC2 sequestration in the cytoplasm. In response
CC       to stress, phosphorylates 'Ser-36' of histone H2B (H2BS36ph),
CC       leading to promote transcription. Acts as a key regulator of cell
CC       growth and proliferation by phosphorylating TSC2, RPTOR and
CC       ATG1/ULK1: in response to nutrient limitation, negatively
CC       regulates the mTORC1 complex by phosphorylating RPTOR component of
CC       the mTORC1 complex and by phosphorylating and activating TSC2. In
CC       response to nutrient limitation, promotes autophagy by
CC       phosphorylating and activating ATG1/ULK1. AMPK also acts as a
CC       regulator of circadian rhythm by mediating phosphorylation of
CC       CRY1, leading to destabilize it. May regulate the Wnt signaling
CC       pathway by phosphorylating CTNNB1, leading to stabilize it. Also
CC       phosphorylates CFTR, EEF2K, KLC1, NOS3 and SLC12A1.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- CATALYTIC ACTIVITY: ATP + [hydroxymethylglutaryl-CoA reductase
CC       (NADPH)] = ADP + [hydroxymethylglutaryl-CoA reductase (NADPH)]
CC       phosphate.
CC   -!- CATALYTIC ACTIVITY: ATP + [acetyl-CoA carboxylase] = ADP +
CC       [acetyl-CoA carboxylase] phosphate.
CC   -!- COFACTOR: Magnesium (By similarity).
CC   -!- ENZYME REGULATION: Activated by phosphorylation on Thr-172.
CC       Binding of AMP to non-catalytic gamma subunit (PRKAG1, PRKAG2 or
CC       PRKAG3) results in allosteric activation, inducing phosphorylation
CC       on Thr-172. AMP-binding to gamma subunit also sustains activity by
CC       preventing dephosphorylation of Thr-172. ADP also stimulates Thr-
CC       172 phosphorylation, without stimulating already phosphorylated
CC       AMPK. ATP promotes dephosphorylation of Thr-172, rendering the
CC       enzyme inactive. Under physiological conditions AMPK mainly exists
CC       in its inactive form in complex with ATP, which is much more
CC       abundant than AMP. AMPK is activated by antihyperglycemic drug
CC       metformin, a drug prescribed to patients with type 2 diabetes: in
CC       vivo, metformin seems to mainly inhibit liver gluconeogenesis.
CC       However, metformin can be used to activate AMPK in muscle and
CC       other cells in culture or ex vivo (PubMed:11602624). Selectively
CC       inhibited by compound C (6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-
CC       3-pyridin-4-yl-pyyrazolo[1,5-a] pyrimidine. Activated by
CC       resveratrol, a natural polyphenol present in red wine, and S17834,
CC       a synthetic polyphenol. Salicylate/aspirin directly activates
CC       kinase activity, primarily by inhibiting Thr-172
CC       dephosphorylation.
CC   -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit
CC       (PRKAA1 or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-
CC       catalytic subunits (PRKAG1, PRKAG2 or PRKAG3). Interacts with
CC       FNIP1 and FNIP2.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Nucleus. Note=In
CC       response to stress, recruited by p53/TP53 to specific promoters.
CC   -!- DOMAIN: The AIS (autoinhibitory sequence) region shows some
CC       sequence similarity with the ubiquitin-associated domains and
CC       represses kinase activity.
CC   -!- PTM: Ubiquitinated (By similarity).
CC   -!- PTM: Phosphorylated at Thr-172 by STK11/LKB1 in complex with
CC       STE20-related adapter-alpha (STRADA) pseudo kinase and CAB39. Also
CC       phosphorylated at Thr-172 by CAMKK2; triggered by a rise in
CC       intracellular calcium ions, without detectable changes in the
CC       AMP/ATP ratio. CAMKK1 can also phosphorylate Thr-172, but at much
CC       lower level. Dephosphorylated by protein phosphatase 2A and 2C
CC       (PP2A and PP2C). Phosphorylated by ULK1; leading to negatively
CC       regulate AMPK activity and suggesting the existence of a
CC       regulatory feedback loop between ULK1 and AMPK. Dephosphorylated
CC       by PPM1A and PPM1B at Thr-172 (mediated by STK11/LKB1).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. SNF1 subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U06454; AAA64745.1; -; mRNA.
DR   EMBL; AL035705; CAC17574.2; -; Genomic_DNA.
DR   EMBL; BC069680; AAH69680.1; -; mRNA.
DR   EMBL; BC069740; AAH69740.1; -; mRNA.
DR   EMBL; BC069823; AAH69823.1; -; mRNA.
DR   CCDS; CCDS605.1; -.
DR   PIR; S51025; S51025.
DR   RefSeq; NP_006243.2; NM_006252.3.
DR   UniGene; Hs.437039; -.
DR   PDB; 2H6D; X-ray; 1.85 A; A=6-279.
DR   PDB; 2LTU; NMR; -; A=282-339.
DR   PDB; 2YZA; X-ray; 3.02 A; A=6-279.
DR   PDB; 3AQV; X-ray; 2.08 A; A=6-279.
DR   PDB; 4CFE; X-ray; 3.02 A; A/C=1-552.
DR   PDB; 4CFF; X-ray; 3.92 A; A/C=1-552.
DR   PDBsum; 2H6D; -.
DR   PDBsum; 2LTU; -.
DR   PDBsum; 2YZA; -.
DR   PDBsum; 3AQV; -.
DR   PDBsum; 4CFE; -.
DR   PDBsum; 4CFF; -.
DR   ProteinModelPortal; P54646; -.
DR   SMR; P54646; 7-551.
DR   BioGrid; 111550; 45.
DR   IntAct; P54646; 34.
DR   MINT; MINT-2804161; -.
DR   STRING; 9606.ENSP00000360290; -.
DR   BindingDB; P54646; -.
DR   ChEMBL; CHEMBL3038455; -.
DR   GuidetoPHARMACOLOGY; 1542; -.
DR   PhosphoSite; P54646; -.
DR   DMDM; 20178276; -.
DR   MaxQB; P54646; -.
DR   PaxDb; P54646; -.
DR   PRIDE; P54646; -.
DR   DNASU; 5563; -.
DR   Ensembl; ENST00000371244; ENSP00000360290; ENSG00000162409.
DR   GeneID; 5563; -.
DR   KEGG; hsa:5563; -.
DR   UCSC; uc001cyk.4; human.
DR   CTD; 5563; -.
DR   GeneCards; GC01P057027; -.
DR   HGNC; HGNC:9377; PRKAA2.
DR   HPA; CAB013043; -.
DR   MIM; 600497; gene.
DR   neXtProt; NX_P54646; -.
DR   PharmGKB; PA33745; -.
DR   eggNOG; COG0515; -.
DR   HOGENOM; HOG000233016; -.
DR   HOVERGEN; HBG050432; -.
DR   InParanoid; P54646; -.
DR   KO; K07198; -.
DR   OMA; TMHIPPG; -.
DR   OrthoDB; EOG7RRF6K; -.
DR   PhylomeDB; P54646; -.
DR   TreeFam; TF314032; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_11123; Membrane Trafficking.
DR   Reactome; REACT_200751; Organelle biogenesis and maintenance.
DR   SignaLink; P54646; -.
DR   EvolutionaryTrace; P54646; -.
DR   GeneWiki; PRKAA2; -.
DR   GenomeRNAi; 5563; -.
DR   NextBio; 21552; -.
DR   PRO; PR:P54646; -.
DR   Bgee; P54646; -.
DR   CleanEx; HS_PRKAA2; -.
DR   Genevestigator; P54646; -.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0050405; F:[acetyl-CoA carboxylase] kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047322; F:[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004679; F:AMP-activated protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0035174; F:histone serine kinase activity; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0006853; P:carnitine shuttle; TAS:Reactome.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:Reactome.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0042149; P:cellular response to glucose starvation; ISS:UniProtKB.
DR   GO; GO:0031669; P:cellular response to nutrient levels; ISS:UniProtKB.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0006112; P:energy reserve metabolic process; TAS:Reactome.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008610; P:lipid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; ISS:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:2000505; P:regulation of energy homeostasis; ISS:UniProtKB.
DR   GO; GO:0042304; P:regulation of fatty acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0006950; P:response to stress; ISS:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR028375; KA1/Ssp2_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR028783; PRKAA2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24343:SF82; PTHR24343:SF82; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF103243; SSF103243; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Autophagy; Biological rhythms;
KW   Cholesterol biosynthesis; Cholesterol metabolism; Chromatin regulator;
KW   Complete proteome; Cytoplasm; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Kinase; Lipid biosynthesis; Lipid metabolism;
KW   Magnesium; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Steroid biosynthesis; Steroid metabolism; Sterol biosynthesis;
KW   Sterol metabolism; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation; Wnt signaling pathway.
FT   CHAIN         1    552       5'-AMP-activated protein kinase catalytic
FT                                subunit alpha-2.
FT                                /FTId=PRO_0000085594.
FT   DOMAIN       16    268       Protein kinase.
FT   NP_BIND      22     30       ATP (By similarity).
FT   REGION      291    376       AIS (By similarity).
FT   ACT_SITE    139    139       Proton acceptor (By similarity).
FT   BINDING      45     45       ATP (By similarity).
FT   MOD_RES     172    172       Phosphothreonine; by LKB1 and CaMKK2.
FT   MOD_RES     258    258       Phosphothreonine (By similarity).
FT   MOD_RES     377    377       Phosphoserine.
FT   MOD_RES     491    491       Phosphoserine (By similarity).
FT   VARIANT     371    371       P -> T (in breast cancer samples;
FT                                infiltrating ductal carcinoma; somatic
FT                                mutation).
FT                                /FTId=VAR_035623.
FT   VARIANT     407    407       R -> Q (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040355.
FT   VARIANT     523    523       S -> G (in a breast cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035624.
FT   MUTAGEN     172    172       T->D: Phosphomimetic mutant.
FT   CONFLICT    180    180       A -> T (in Ref. 1; AAA64745).
FT   CONFLICT    271    271       D -> G (in Ref. 1; AAA64745).
FT   CONFLICT    403    404       HL -> RQ (in Ref. 1; AAA64745).
FT   STRAND       16     24
FT   STRAND       26     35
FT   TURN         36     38
FT   STRAND       41     48
FT   HELIX        49     54
FT   HELIX        58     69
FT   STRAND       79     84
FT   STRAND       86     94
FT   HELIX       101    108
FT   HELIX       113    133
FT   HELIX       142    144
FT   STRAND      145    147
FT   STRAND      153    155
FT   HELIX       160    162
FT   HELIX       183    185
FT   HELIX       192    209
FT   HELIX       219    228
FT   HELIX       239    248
FT   HELIX       253    255
FT   HELIX       259    264
FT   HELIX       266    269
FT   HELIX       274    276
FT   TURN        284    286
FT   HELIX       291    294
FT   HELIX       304    312
FT   HELIX       322    335
FT   HELIX       338    341
FT   STRAND      403    408
FT   HELIX       412    424
FT   TURN        425    427
FT   STRAND      429    434
FT   STRAND      437    443
FT   TURN        445    447
FT   STRAND      450    460
FT   TURN        461    463
FT   STRAND      464    471
FT   HELIX       535    548
SQ   SEQUENCE   552 AA;  62320 MW;  C46AAFC1D5104975 CRC64;
     MAEKQKHDGR VKIGHYVLGD TLGVGTFGKV KIGEHQLTGH KVAVKILNRQ KIRSLDVVGK
     IKREIQNLKL FRHPHIIKLY QVISTPTDFF MVMEYVSGGE LFDYICKHGR VEEMEARRLF
     QQILSAVDYC HRHMVVHRDL KPENVLLDAH MNAKIADFGL SNMMSDGEFL RTSCGSPNYA
     APEVISGRLY AGPEVDIWSC GVILYALLCG TLPFDDEHVP TLFKKIRGGV FYIPEYLNRS
     VATLLMHMLQ VDPLKRATIK DIREHEWFKQ DLPSYLFPED PSYDANVIDD EAVKEVCEKF
     ECTESEVMNS LYSGDPQDQL AVAYHLIIDN RRIMNQASEF YLASSPPSGS FMDDSAMHIP
     PGLKPHPERM PPLIADSPKA RCPLDALNTT KPKSLAVKKA KWHLGIRSQS KPYDIMAEVY
     RAMKQLDFEW KVVNAYHLRV RRKNPVTGNY VKMSLQLYLV DNRSYLLDFK SIDDEVVEQR
     SGSSTPQRSC SAAGLHRPRS SFDSTTAESH SLSGSLTGSL TGSTLSSVSP RLGSHTMDFF
     EMCASLITTL AR
//
ID   AATF_HUMAN              Reviewed;         560 AA.
AC   Q9NY61; A6NCJ6; B3KQ26; Q9P0A4; Q9UNX5;
DT   19-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   09-JUL-2014, entry version 110.
DE   RecName: Full=Protein AATF;
DE   AltName: Full=Apoptosis-antagonizing transcription factor;
DE   AltName: Full=Rb-binding protein Che-1;
GN   Name=AATF; Synonyms=CHE1, DED; ORFNames=HSPC277;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=11027528; DOI=10.1006/bbrc.2000.3480;
RA   Lindfors K., Halttunen T., Huotari P., Nupponen N., Vihinen M.,
RA   Visakorpi T., Maki M., Kainulainen H.;
RT   "Identification of novel transcription factor-like gene from human
RT   intestinal cells.";
RL   Biochem. Biophys. Res. Commun. 276:660-666(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH POLR2J AND RB1, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Skeletal muscle;
RX   PubMed=10783144;
RA   Fanciulli M., Bruno T., Di Padova M., De Angelis R., Iezzi S.,
RA   Iacobini C., Floridi A., Passananti C.;
RT   "Identification of a novel partner of RNA polymerase II subunit 11,
RT   Che-1, which interacts with and affects the growth suppression
RT   function of Rb.";
RL   FASEB J. 14:904-912(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 361-560.
RC   TISSUE=Umbilical cord blood;
RA   Ye M., Zhang Q.-H., Zhou J., Shen Y., Wu X.-Y., Guan Z.Q., Wang L.,
RA   Fan H.-Y., Mao Y.-F., Dai M., Huang Q.-H., Chen S.-J., Chen Z.;
RT   "Human partial CDS from CD34+ stem cells.";
RL   Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   FUNCTION, PHOSPHORYLATION AT THE G1/S TRANSITION, AND INTERACTION WITH
RP   RB1; RBL1 AND RBL2.
RX   PubMed=12450794; DOI=10.1016/S1535-6108(02)00182-4;
RA   Bruno T., De Angelis R., De Nicola F., Barbato C., Di Padova M.,
RA   Corbi N., Libri V., Benassi B., Mattei E., Chersi A., Soddu S.,
RA   Floridi A., Passananti C., Fanciulli M.;
RT   "Che-1 affects cell growth by interfering with the recruitment of
RT   HDAC1 by Rb.";
RL   Cancer Cell 2:387-399(2002).
RN   [9]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12429849; DOI=10.1091/mbc.E02-05-0271;
RA   Scherl A., Coute Y., Deon C., Calle A., Kindbeiter K., Sanchez J.-C.,
RA   Greco A., Hochstrasser D.F., Diaz J.-J.;
RT   "Functional proteomic analysis of human nucleolus.";
RL   Mol. Biol. Cell 13:4100-4109(2002).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH SP1.
RX   PubMed=12847090; DOI=10.1074/jbc.M306694200;
RA   Di Padova M., Bruno T., De Nicola F., Iezzi S., D'Angelo C., Gallo R.,
RA   Nicosia D., Corbi N., Biroccio A., Floridi A., Passananti C.,
RA   Fanciulli M.;
RT   "Che-1 arrests human colon carcinoma cell proliferation by displacing
RT   HDAC1 from the p21WAF1/CIP1 promoter.";
RL   J. Biol. Chem. 278:36496-36504(2003).
RN   [11]
RP   INTERACTION WITH MAPT.
RX   PubMed=14697667; DOI=10.1016/j.mcn.2003.08.002;
RA   Barbato C., Corbi N., Canu N., Fanciulli M., Serafino A., Ciotti M.,
RA   Libri V., Bruno T., Amadoro G., De Angelis R., Calissano P.,
RA   Passananti C.;
RT   "Rb binding protein Che-1 interacts with Tau in cerebellar granule
RT   neurons. Modulation during neuronal apoptosis.";
RL   Mol. Cell. Neurosci. 24:1038-1050(2003).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH PAWR.
RX   PubMed=14627703; DOI=10.1074/jbc.M309811200;
RA   Guo Q., Xie J.;
RT   "AATF inhibits aberrant production of amyloid beta peptide 1-42 by
RT   interacting directly with Par-4.";
RL   J. Biol. Chem. 279:4596-4603(2004).
RN   [13]
RP   FUNCTION.
RX   PubMed=15207272; DOI=10.1016/j.nbd.2004.02.003;
RA   Xie J., Guo Q.;
RT   "AATF protects neural cells against oxidative damage induced by
RT   amyloid beta-peptide.";
RL   Neurobiol. Dis. 16:150-157(2004).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-316; SER-320 AND
RP   SER-321, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-316; SER-320 AND
RP   SER-321, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203; SER-316; SER-320
RP   AND SER-321, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203; SER-316; SER-320
RP   AND SER-321, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
CC   -!- FUNCTION: May function as a general inhibitor of the histone
CC       deacetylase HDAC1. Binding to the pocket region of RB1 may
CC       displace HDAC1 from RB1/E2F complexes, leading to activation of
CC       E2F target genes and cell cycle progression. Conversely,
CC       displacement of HDAC1 from SP1 bound to the CDKN1A promoter leads
CC       to increased expression of this CDK inhibitor and blocks cell
CC       cycle progression. Also antagonizes PAWR mediated induction of
CC       aberrant amyloid peptide production in Alzheimer disease
CC       (presenile and senile dementia), although the molecular basis for
CC       this phenomenon has not been described to date.
CC   -!- SUBUNIT: Binds PAWR, POLR2J, RB1/RB, RBL1/P107, RBL2/P130, and
CC       SP1. May also bind MAPT.
CC   -!- INTERACTION:
CC       Q13315:ATM; NbExp=3; IntAct=EBI-372428, EBI-495465;
CC       O96017:CHEK2; NbExp=4; IntAct=EBI-372428, EBI-1180783;
CC       Q6ZWQ9:Myl12a (xeno); NbExp=3; IntAct=EBI-372428, EBI-8034418;
CC       Q04206:RELA; NbExp=3; IntAct=EBI-372428, EBI-73886;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Expressed at high
CC       levels in brain, heart, kidney, placenta and thymus.
CC   -!- PTM: Hyperphosphorylated during the G1/S phase transition.
CC   -!- SIMILARITY: Belongs to the AATF family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD52016.1; Type=Frameshift; Positions=355, 365, 487, 498, 503;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AATFID534ch17q11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ249940; CAB57451.2; -; mRNA.
DR   EMBL; AF083208; AAD52016.1; ALT_FRAME; mRNA.
DR   EMBL; AK057229; BAG51888.1; -; mRNA.
DR   EMBL; AC003103; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471199; EAW57575.1; -; Genomic_DNA.
DR   EMBL; BC000591; AAH00591.1; -; mRNA.
DR   EMBL; AF161395; AAF28955.1; -; mRNA.
DR   CCDS; CCDS32632.1; -.
DR   RefSeq; NP_036270.1; NM_012138.3.
DR   UniGene; Hs.195740; -.
DR   ProteinModelPortal; Q9NY61; -.
DR   BioGrid; 117743; 33.
DR   IntAct; Q9NY61; 16.
DR   MINT; MINT-131397; -.
DR   STRING; 9606.ENSP00000225402; -.
DR   PhosphoSite; Q9NY61; -.
DR   DMDM; 71152211; -.
DR   SWISS-2DPAGE; Q9NY61; -.
DR   MaxQB; Q9NY61; -.
DR   PaxDb; Q9NY61; -.
DR   PRIDE; Q9NY61; -.
DR   DNASU; 26574; -.
DR   Ensembl; ENST00000225402; ENSP00000225402; ENSG00000108270.
DR   GeneID; 26574; -.
DR   KEGG; hsa:26574; -.
DR   UCSC; uc002hni.3; human.
DR   CTD; 26574; -.
DR   GeneCards; GC17P035306; -.
DR   HGNC; HGNC:19235; AATF.
DR   HPA; HPA004940; -.
DR   MIM; 608463; gene.
DR   neXtProt; NX_Q9NY61; -.
DR   PharmGKB; PA128395780; -.
DR   eggNOG; NOG270454; -.
DR   HOGENOM; HOG000007555; -.
DR   HOVERGEN; HBG080805; -.
DR   InParanoid; Q9NY61; -.
DR   KO; K14782; -.
DR   OMA; QLHPPDE; -.
DR   OrthoDB; EOG7VDXQ2; -.
DR   PhylomeDB; Q9NY61; -.
DR   TreeFam; TF324341; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   ChiTaRS; AATF; human.
DR   GeneWiki; Apoptosis-antagonizing_transcription_factor; -.
DR   GenomeRNAi; 26574; -.
DR   NextBio; 48910; -.
DR   PRO; PR:Q9NY61; -.
DR   ArrayExpress; Q9NY61; -.
DR   Bgee; Q9NY61; -.
DR   CleanEx; HS_AATF; -.
DR   Genevestigator; Q9NY61; -.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:HPA.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043522; F:leucine zipper domain binding; IPI:UniProtKB.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0003700; F:sequence-specific DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0007155; P:cell adhesion; IEA:Ensembl.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IEP:UniProtKB.
DR   GO; GO:0040016; P:embryonic cleavage; IEA:Ensembl.
DR   GO; GO:0042985; P:negative regulation of amyloid precursor protein biosynthetic process; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IDA:UniProtKB.
DR   GO; GO:0032929; P:negative regulation of superoxide anion generation; IDA:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0042254; P:ribosome biogenesis; IEA:Ensembl.
DR   InterPro; IPR025160; AATF.
DR   InterPro; IPR012617; AATF_C.
DR   Pfam; PF13339; AATF-Che1; 1.
DR   Pfam; PF08164; TRAUB; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Complete proteome; Nucleus; Phosphoprotein;
KW   Reference proteome.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    560       Protein AATF.
FT                                /FTId=PRO_0000056616.
FT   REGION      273    315       POLR2J binding.
FT   REGION      316    372       RB1 binding.
FT   REGION      373    472       RB1 and SP1 binding.
FT   COMPBIAS     96    195       Glu-rich.
FT   MOD_RES       2      2       N-acetylalanine.
FT   MOD_RES     203    203       Phosphoserine.
FT   MOD_RES     316    316       Phosphoserine.
FT   MOD_RES     320    320       Phosphoserine.
FT   MOD_RES     321    321       Phosphoserine.
FT   CONFLICT      2      3       AG -> GR (in Ref. 2; AAD52016).
FT   CONFLICT      4      5       Missing (in Ref. 2; AAD52016).
FT   CONFLICT    139    139       S -> T (in Ref. 2; AAD52016).
FT   CONFLICT    262    262       L -> V (in Ref. 2; AAD52016).
FT   CONFLICT    272    272       S -> A (in Ref. 2; AAD52016).
FT   CONFLICT    306    306       L -> V (in Ref. 2; AAD52016).
FT   CONFLICT    402    402       D -> C (in Ref. 2; AAD52016).
SQ   SEQUENCE   560 AA;  63133 MW;  EC493EF3B4C3A199 CRC64;
     MAGPQPLALQ LEQLLNPRPS EADPEADPEE ATAARVIDRF DEGEDGEGDF LVVGSIRKLA
     SASLLDTDKR YCGKTTSRKA WNEDHWEQTL PGSSDEEISD EEGSGDEDSE GLGLEEYDED
     DLGAAEEQEC GDHRESKKSR SHSAKTPGFS VQSISDFEKF TKGMDDLGSS EEEEDEESGM
     EEGDDAEDSQ GESEEDRAGD RNSEDDGVVM TFSSVKVSEE VEKGRAVKNQ IALWDQLLEG
     RIKLQKALLT TNQLPQPDVF PLFKDKGGPE FSSALKNSHK ALKALLRSLV GLQEELLFQY
     PDTRYLVDGT KPNAGSEEIS SEDDELVEEK KQQRRRVPAK RKLEMEDYPS FMAKRFADFT
     VYRNRTLQKW HDKTKLASGK LGKGFGAFER SILTQIDHIL MDKERLLRRT QTKRSVYRVL
     GKPEPAAQPV PESLPGEPEI LPQAPANAHL KDLDEEIFDD DDFYHQLLRE LIERKTSSLD
     PNDQVAMGRQ WLAIQKLRSK IHKKVDRKAS KGRKLRFHVL SKLLSFMAPI DHTTMNDDAR
     TELYRSLFGQ LHPPDEGHGD
//
ID   ABC3A_HUMAN             Reviewed;         199 AA.
AC   P31941; A0AVM1; Q12807; Q5JZ93; Q9UH18;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2001, sequence version 3.
DT   09-JUL-2014, entry version 128.
DE   RecName: Full=DNA dC->dU-editing enzyme APOBEC-3A;
DE            Short=A3A;
DE            EC=3.5.4.-;
DE   AltName: Full=Phorbolin-1;
GN   Name=APOBEC3A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 19-27; 31-35; 53-60;
RP   112-123; 129-137 AND 192-198, AND FUNCTION.
RC   TISSUE=Keratinocyte;
RX   PubMed=10469298; DOI=10.1046/j.1523-1747.1999.00682.x;
RA   Madsen P.P., Anant S., Rasmussen H.H., Gromov P., Vorum H.,
RA   Dumanski J.P., Tommerup N., Collins J.E., Wright C.L., Dunham I.,
RA   Macginnitie A.J., Davidson N.O., Celis J.E.;
RT   "Psoriasis upregulated phorbolin-1 shares structural but not
RT   functional similarity to the mRNA-editing protein apobec-1.";
RL   J. Invest. Dermatol. 113:162-169(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 53-60; 112-121 AND 129-137.
RC   TISSUE=Keratinocyte;
RX   PubMed=1286667; DOI=10.1002/elps.11501301199;
RA   Rasmussen H.H., van Damme J., Puype M., Gesser B., Celis J.E.,
RA   Vandekerckhove J.;
RT   "Microsequences of 145 proteins recorded in the two-dimensional gel
RT   protein database of normal human epidermal keratinocytes.";
RL   Electrophoresis 13:960-969(1992).
RN   [6]
RP   GENE FAMILY ORGANIZATION, AND TISSUE SPECIFICITY.
RX   PubMed=11863358; DOI=10.1006/geno.2002.6718;
RA   Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J.,
RA   Navaratnam N.;
RT   "An anthropoid-specific locus of orphan C to U RNA-editing enzymes on
RT   chromosome 22.";
RL   Genomics 79:285-296(2002).
RN   [7]
RP   REVIEW ON APOBEC FAMILIES.
RX   PubMed=12683974; DOI=10.1016/S0168-9525(03)00054-4;
RA   Wedekind J.E., Dance G.S.C., Sowden M.P., Smith H.C.;
RT   "Messenger RNA editing in mammals: new members of the APOBEC family
RT   seeking roles in the family business.";
RL   Trends Genet. 19:207-216(2003).
RN   [8]
RP   FUNCTION IN HOST DEFENSE.
RX   PubMed=12859895; DOI=10.1016/S0092-8674(03)00515-4;
RA   Mariani R., Chen D., Schroefelbauer B., Navarro F., Koenig R.,
RA   Bollman B., Muenk C., Nymark-McMahon H., Landau N.R.;
RT   "Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.";
RL   Cell 114:21-31(2003).
RN   [9]
RP   FUNCTION IN HOST DEFENSE, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION,
RP   MUTAGENESIS OF HIS-70; GLU-72 AND CYS-106, AND TISSUE SPECIFICITY.
RX   PubMed=16527742; DOI=10.1016/j.cub.2006.01.031;
RA   Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I.,
RA   Landau N.R., Weitzman M.D.;
RT   "APOBEC3A is a potent inhibitor of adeno-associated virus and
RT   retrotransposons.";
RL   Curr. Biol. 16:480-485(2006).
RN   [10]
RP   REVIEW.
RX   PubMed=18304004; DOI=10.1146/annurev.immunol.26.021607.090350;
RA   Chiu Y.L., Greene W.C.;
RT   "The APOBEC3 cytidine deaminases: an innate defensive network opposing
RT   exogenous retroviruses and endogenous retroelements.";
RL   Annu. Rev. Immunol. 26:317-353(2008).
RN   [11]
RP   FUNCTION IN AAV INHIBITION, AND SUBCELLULAR LOCATION.
RX   PubMed=19461882; DOI=10.1371/journal.ppat.1000439;
RA   Narvaiza I., Linfesty D.C., Greener B.N., Hakata Y., Pintel D.J.,
RA   Logue E., Landau N.R., Weitzman M.D.;
RT   "Deaminase-independent inhibition of parvoviruses by the APOBEC3A
RT   cytidine deaminase.";
RL   PLoS Pathog. 5:E1000439-E1000439(2009).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, INDUCTION, AND ALTERNATIVE SPLICING
RP   (ISOFORMS 1 AND 2).
RX   PubMed=20615867; DOI=10.1074/jbc.M110.102822;
RA   Thielen B.K., McNevin J.P., McElrath M.J., Hunt B.V., Klein K.C.,
RA   Lingappa J.R.;
RT   "Innate immune signaling induces high levels of TC-specific deaminase
RT   activity in primary monocyte-derived cells through expression of
RT   APOBEC3A isoforms.";
RL   J. Biol. Chem. 285:27753-27766(2010).
RN   [13]
RP   FUNCTION IN FOREIGN DNA CLEARANCE, CATALYTIC ACTIVITY, TISSUE
RP   SPECIFICITY, AND INDUCTION.
RX   PubMed=20062055; DOI=10.1038/nsmb.1744;
RA   Stenglein M.D., Burns M.B., Li M., Lengyel J., Harris R.S.;
RT   "APOBEC3 proteins mediate the clearance of foreign DNA from human
RT   cells.";
RL   Nat. Struct. Mol. Biol. 17:222-229(2010).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=20308164; DOI=10.1093/nar/gkq174;
RA   Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L.,
RA   Harris R.S.;
RT   "Quantitative profiling of the full APOBEC3 mRNA repertoire in
RT   lymphocytes and tissues: implications for HIV-1 restriction.";
RL   Nucleic Acids Res. 38:4274-4284(2010).
RN   [15]
RP   FUNCTION IN DNA DEMETHYLATION.
RX   PubMed=21496894; DOI=10.1016/j.cell.2011.03.022;
RA   Guo J.U., Su Y., Zhong C., Ming G.L., Song H.;
RT   "Hydroxylation of 5-methylcytosine by TET1 promotes active DNA
RT   demethylation in the adult brain.";
RL   Cell 145:423-434(2011).
RN   [16]
RP   FUNCTION.
RX   PubMed=21460793; DOI=10.1038/embor.2011.46;
RA   Landry S., Narvaiza I., Linfesty D.C., Weitzman M.D.;
RT   "APOBEC3A can activate the DNA damage response and cause cell-cycle
RT   arrest.";
RL   EMBO Rep. 12:444-450(2011).
RN   [17]
RP   FUNCTION IN HOST DEFENSE, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF ARG-28; HIS-29; LYS-30; ASN-57; LYS-60; ARG-69;
RP   GLU-72; TRP-98; ARG-128; TYR-130; ASP-131; ASP-133 AND TYR-136.
RX   PubMed=21123384; DOI=10.1128/JVI.01651-10;
RA   Bulliard Y., Narvaiza I., Bertero A., Peddi S., Roehrig U.F.,
RA   Ortiz M., Zoete V., Castro-Diaz N., Turelli P., Telenti A.,
RA   Michielin O., Weitzman M.D., Trono D.;
RT   "Structure-function analyses point to a polynucleotide-accommodating
RT   groove essential for APOBEC3A restriction activities.";
RL   J. Virol. 85:1765-1776(2011).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21835787; DOI=10.1128/JVI.05238-11;
RA   Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L.,
RA   Brown W.L., Harris R.S.;
RT   "Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H
RT   demonstrate a conserved capacity to restrict Vif-deficient HIV-1.";
RL   J. Virol. 85:11220-11234(2011).
RN   [19]
RP   FUNCTION.
RX   PubMed=21368204; DOI=10.1073/pnas.1009687108;
RA   Suspene R., Aynaud M.M., Guetard D., Henry M., Eckhoff G., Marchio A.,
RA   Pineau P., Dejean A., Vartanian J.P., Wain-Hobson S.;
RT   "Somatic hypermutation of human mitochondrial and nuclear DNA by
RT   APOBEC3 cytidine deaminases, a pathway for DNA catabolism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:4858-4863(2011).
RN   [20]
RP   REVIEW.
RA   Love R.;
RT   "Cytosine deaminases APOBEC3A, APOBEC3C, and APOBEC3H: Current
RT   understanding of their functional roles.";
RL   Student Perspec. Contemp. Virol. 0:0-0(2011).
RN   [21]
RP   REVIEW.
RX   PubMed=22912627; DOI=10.3389/fmicb.2012.00275;
RA   Arias J.F., Koyama T., Kinomoto M., Tokunaga K.;
RT   "Retroelements versus APOBEC3 family members: No great escape from the
RT   magnificent seven.";
RL   Front. Microbiol. 3:275-275(2012).
RN   [22]
RP   FUNCTION.
RX   PubMed=22896697; DOI=10.1074/jbc.M112.385161;
RA   Carpenter M.A., Li M., Rathore A., Lackey L., Law E.K., Land A.M.,
RA   Leonard B., Shandilya S.M., Bohn M.F., Schiffer C.A., Brown W.L.,
RA   Harris R.S.;
RT   "Methylcytosine and normal cytosine deamination by the foreign DNA
RT   restriction enzyme APOBEC3A.";
RL   J. Biol. Chem. 287:34801-34808(2012).
RN   [23]
RP   INTERACTION WITH TRIB3, AND SUBCELLULAR LOCATION.
RX   PubMed=22977230; DOI=10.1074/jbc.M112.372722;
RA   Aynaud M.M., Suspene R., Vidalain P.O., Mussil B., Guetard D.,
RA   Tangy F., Wain-Hobson S., Vartanian J.P.;
RT   "Human Tribbles 3 protects nuclear DNA from cytidine deamination by
RT   APOBEC3A.";
RL   J. Biol. Chem. 287:39182-39192(2012).
RN   [24]
RP   FUNCTION IN HTLV-1 RESTRICTION.
RX   PubMed=22457529; DOI=10.1128/JVI.06570-11;
RA   Ooms M., Krikoni A., Kress A.K., Simon V., Muenk C.;
RT   "APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-
RT   lymphotropic virus type 1.";
RL   J. Virol. 86:6097-6108(2012).
RN   [25]
RP   INTERACTION WITH AGO2.
RX   PubMed=22915799; DOI=10.1128/JVI.00595-12;
RA   Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H.;
RT   "HIV-1 replication and APOBEC3 antiviral activity are not regulated by
RT   P bodies.";
RL   J. Virol. 86:11712-11724(2012).
RN   [26]
RP   REVIEW.
RX   PubMed=22001110; DOI=10.1016/j.semcdb.2011.10.004;
RA   Smith H.C., Bennett R.P., Kizilyer A., McDougall W.M., Prohaska K.M.;
RT   "Functions and regulation of the APOBEC family of proteins.";
RL   Semin. Cell Dev. Biol. 23:258-268(2012).
CC   -!- FUNCTION: DNA deaminase (cytidine deaminase) with restriction
CC       activity against viruses, foreign DNA and mobility of
CC       retrotransposons. Exhibits antiviral activity against adeno-
CC       associated virus (AAV) and human T-cell leukemia virus type 1
CC       (HTLV-1) and may inhibit the mobility of LTR and non-LTR
CC       retrotransposons. Selectively targets single-stranded DNA and can
CC       deaminate both methylcytosine and cytosine in foreign DNA. Can
CC       induce somatic hypermutation in the nuclear and mitochondrial DNA.
CC       May also play a role in the epigenetic regulation of gene
CC       expression through the process of active DNA demethylation.
CC   -!- CATALYTIC ACTIVITY: Cytidine + H(2)O = uridine + NH(3).
CC   -!- COFACTOR: Zinc (By similarity).
CC   -!- SUBUNIT: Interacts with AGO2. Interacts with TRIB3 (via N-
CC       terminus).
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1; Synonyms=Phorbolin-1;
CC         IsoId=P31941-1; Sequence=Displayed;
CC         Note=Enzymatically active;
CC       Name=2;
CC         IsoId=P31941-2; Sequence=VSP_041723;
CC         Note=Enzymatically active;
CC   -!- TISSUE SPECIFICITY: Expressed in peripheral leukocytes with higher
CC       expression in CD14-positive phagocytic cells. Highly expressed in
CC       keratinocytes and in periphery blood monocytes. Also detected in
CC       non-lymphoid tissues including lung and adipose tissues. Found at
CC       high levels in colorectal adenocarcinoma, Burkitt's lymphoma and
CC       chronic myelogenous leukemia.
CC   -!- INDUCTION: Up-regulated by interferon and CpG single-stranded DNA
CC       (at protein level).
CC   -!- MISCELLANEOUS: It is one of seven related genes or pseudogenes
CC       found in a cluster, thought to result from gene duplication, on
CC       chromosome 22.
CC   -!- SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase
CC       family.
CC   -!- SIMILARITY: Contains 1 CMP/dCMP deaminase zinc-binding domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U03891; AAA03706.2; -; mRNA.
DR   EMBL; CR456393; CAG30279.1; -; mRNA.
DR   EMBL; AL022318; CAI17897.1; -; Genomic_DNA.
DR   EMBL; BC126416; AAI26417.1; -; mRNA.
DR   CCDS; CCDS13981.1; -. [P31941-1]
DR   PIR; G01233; G01233.
DR   RefSeq; NP_001180218.1; NM_001193289.1. [P31941-1]
DR   RefSeq; NP_663745.1; NM_145699.3. [P31941-1]
DR   RefSeq; XP_005277016.1; XM_005276959.1. [P31941-1]
DR   RefSeq; XP_005277017.1; XM_005276960.1. [P31941-1]
DR   UniGene; Hs.226307; -.
DR   PDB; 2M65; NMR; -; A=1-199.
DR   PDBsum; 2M65; -.
DR   ProteinModelPortal; P31941; -.
DR   SMR; P31941; 1-199.
DR   BioGrid; 128318; 1.
DR   STRING; 9606.ENSP00000249116; -.
DR   BindingDB; P31941; -.
DR   ChEMBL; CHEMBL1741179; -.
DR   PhosphoSite; P31941; -.
DR   DMDM; 12644206; -.
DR   PaxDb; P31941; -.
DR   PRIDE; P31941; -.
DR   DNASU; 200315; -.
DR   Ensembl; ENST00000249116; ENSP00000249116; ENSG00000128383. [P31941-1]
DR   Ensembl; ENST00000402255; ENSP00000384359; ENSG00000128383. [P31941-1]
DR   Ensembl; ENST00000570508; ENSP00000461288; ENSG00000262156. [P31941-1]
DR   GeneID; 100913187; -.
DR   GeneID; 200315; -.
DR   KEGG; hsa:100913187; -.
DR   KEGG; hsa:200315; -.
DR   UCSC; uc003awn.2; human. [P31941-1]
DR   CTD; 100913187; -.
DR   CTD; 200315; -.
DR   GeneCards; GC22P039348; -.
DR   HGNC; HGNC:17343; APOBEC3A.
DR   HPA; HPA043237; -.
DR   MIM; 607109; gene.
DR   neXtProt; NX_P31941; -.
DR   PharmGKB; PA24891; -.
DR   eggNOG; NOG293254; -.
DR   HOGENOM; HOG000033754; -.
DR   HOVERGEN; HBG050434; -.
DR   InParanoid; P31941; -.
DR   KO; K01500; -.
DR   OMA; LHNQAKN; -.
DR   OrthoDB; EOG71CFNW; -.
DR   PhylomeDB; P31941; -.
DR   TreeFam; TF331356; -.
DR   NextBio; 89887; -.
DR   PRO; PR:P31941; -.
DR   Bgee; P31941; -.
DR   CleanEx; HS_APOBEC3A; -.
DR   Genevestigator; P31941; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0004126; F:cytidine deaminase activity; IDA:UniProtKB.
DR   GO; GO:0047844; F:deoxycytidine deaminase activity; IMP:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IDA:UniProtKB.
DR   GO; GO:0044356; P:clearance of foreign intracellular DNA by conversion of DNA cytidine to uridine; IDA:UniProtKB.
DR   GO; GO:0009972; P:cytidine deamination; IDA:GOC.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0070383; P:DNA cytosine deamination; IDA:UniProtKB.
DR   GO; GO:0080111; P:DNA demethylation; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0010529; P:negative regulation of transposition; IDA:UniProtKB.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB.
DR   InterPro; IPR016192; APOBEC/CMP_deaminase_Zn-bd.
DR   InterPro; IPR007904; APOBEC_C.
DR   InterPro; IPR016193; Cytidine_deaminase-like.
DR   Pfam; PF05240; APOBEC_C; 1.
DR   SUPFAM; SSF53927; SSF53927; 1.
DR   PROSITE; PS00903; CYT_DCMP_DEAMINASES; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Antiviral defense;
KW   Complete proteome; Cytoplasm; Direct protein sequencing; Hydrolase;
KW   Immunity; Innate immunity; Metal-binding; Nucleus; Polymorphism;
KW   Reference proteome; Zinc.
FT   CHAIN         1    199       DNA dC->dU-editing enzyme APOBEC-3A.
FT                                /FTId=PRO_0000171752.
FT   DOMAIN       70    106       CMP/dCMP deaminase zinc-binding.
FT   ACT_SITE     72     72       Proton donor (By similarity).
FT   METAL        70     70       Zinc; catalytic (By similarity).
FT   METAL       101    101       Zinc; catalytic (By similarity).
FT   METAL       106    106       Zinc; catalytic (By similarity).
FT   VAR_SEQ       1     12       Missing (in isoform 2).
FT                                /FTId=VSP_041723.
FT   VARIANT      19     19       T -> A (in dbSNP:rs17000556).
FT                                /FTId=VAR_048721.
FT   MUTAGEN      28     28       R->E: No effect on deaminase activity
FT                                despite an altered restriction activity
FT                                towards genetic invaders.
FT   MUTAGEN      29     29       H->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders.
FT   MUTAGEN      30     30       K->F: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders.
FT   MUTAGEN      57     57       N->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders.
FT   MUTAGEN      60     60       K->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders.
FT   MUTAGEN      69     69       R->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders.
FT   MUTAGEN      70     70       H->R: Altered deaminase activity.
FT   MUTAGEN      72     72       E->Q: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders.
FT   MUTAGEN      98     98       W->L: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders.
FT   MUTAGEN     106    106       C->S: Altered deaminase activity.
FT   MUTAGEN     128    128       R->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders.
FT   MUTAGEN     130    130       Y->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders.
FT   MUTAGEN     131    131       D->N: No effect on deaminase activity
FT                                despite an altered restriction activity
FT                                towards genetic invaders.
FT   MUTAGEN     133    133       D->N: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders.
FT   MUTAGEN     136    136       Y->A: Altered deaminase activity and
FT                                restriction activity towards genetic
FT                                invaders.
FT   HELIX        15     21
FT   STRAND       27     29
FT   STRAND       32     41
FT   STRAND       44     47
FT   STRAND       53     56
FT   TURN         62     65
FT   HELIX        71     76
FT   HELIX        79     82
FT   STRAND       88     98
FT   TURN        103    105
FT   HELIX       106    117
FT   STRAND      120    128
FT   HELIX       136    144
FT   STRAND      149    152
FT   HELIX       155    165
FT   HELIX       179    194
SQ   SEQUENCE   199 AA;  23012 MW;  42E99E0D7DF7AA14 CRC64;
     MEASPASGPR HLMDPHIFTS NFNNGIGRHK TYLCYEVERL DNGTSVKMDQ HRGFLHNQAK
     NLLCGFYGRH AELRFLDLVP SLQLDPAQIY RVTWFISWSP CFSWGCAGEV RAFLQENTHV
     RLRIFAARIY DYDPLYKEAL QMLRDAGAQV SIMTYDEFKH CWDTFVDHQG CPFQPWDGLD
     EHSQALSGRL RAILQNQGN
//
ID   ABC3B_HUMAN             Reviewed;         382 AA.
AC   Q9UH17; B0QYD2; O95618; Q20WL1; Q5IFJ4; Q7Z2N3; Q7Z6D6; Q9UE74;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   09-JUL-2014, entry version 118.
DE   RecName: Full=DNA dC->dU-editing enzyme APOBEC-3B;
DE            Short=A3B;
DE            EC=3.5.4.-;
DE   AltName: Full=Phorbolin-1-related protein;
DE   AltName: Full=Phorbolin-2/3;
GN   Name=APOBEC3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT LYS-146, AND
RP   INDUCTION.
RC   TISSUE=Keratinocyte;
RX   PubMed=10469298; DOI=10.1046/j.1523-1747.1999.00682.x;
RA   Madsen P.P., Anant S., Rasmussen H.H., Gromov P., Vorum H.,
RA   Dumanski J.P., Tommerup N., Collins J.E., Wright C.L., Dunham I.,
RA   Macginnitie A.J., Davidson N.O., Celis J.E.;
RT   "Psoriasis upregulated phorbolin-1 shares structural but not
RT   functional similarity to the mRNA-editing protein apobec-1.";
RL   J. Invest. Dermatol. 113:162-169(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=16060832; DOI=10.1089/aid.2005.21.611;
RA   Rose K.M., Marin M., Kozak S.L., Kabat D.;
RT   "Regulated production and anti-HIV type 1 activities of cytidine
RT   deaminases APOBEC3B, 3F, and 3G.";
RL   AIDS Res. Hum. Retroviruses 21:611-619(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANTS
RP   GLU-62 AND LYS-146.
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   LYS-146.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   GENE FAMILY ORGANIZATION, TISSUE SPECIFICITY, RNA-BINDING,
RP   ZINC-BINDING, AND INTERACTION WITH APOBEC3G.
RX   PubMed=11863358; DOI=10.1006/geno.2002.6718;
RA   Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J.,
RA   Navaratnam N.;
RT   "An anthropoid-specific locus of orphan C to U RNA-editing enzymes on
RT   chromosome 22.";
RL   Genomics 79:285-296(2002).
RN   [7]
RP   REVIEW ON APOBEC FAMILIES.
RX   PubMed=12683974; DOI=10.1016/S0168-9525(03)00054-4;
RA   Wedekind J.E., Dance G.S.C., Sowden M.P., Smith H.C.;
RT   "Messenger RNA editing in mammals: new members of the APOBEC family
RT   seeking roles in the family business.";
RL   Trends Genet. 19:207-216(2003).
RN   [8]
RP   FUNCTION IN HIV-1 INFECTIVITY.
RX   PubMed=12859895; DOI=10.1016/S0092-8674(03)00515-4;
RA   Mariani R., Chen D., Schroefelbauer B., Navarro F., Koenig R.,
RA   Bollman B., Muenk C., Nymark-McMahon H., Landau N.R.;
RT   "Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.";
RL   Cell 114:21-31(2003).
RN   [9]
RP   FUNCTION IN SIV RESTRICTION.
RX   PubMed=15466872; DOI=10.1074/jbc.M408802200;
RA   Yu Q., Chen D., Koenig R., Mariani R., Unutmaz D., Landau N.R.;
RT   "APOBEC3B and APOBEC3C are potent inhibitors of simian
RT   immunodeficiency virus replication.";
RL   J. Biol. Chem. 279:53379-53386(2004).
RN   [10]
RP   FUNCTION IN RETROTRANSPOSITION.
RX   PubMed=16527742; DOI=10.1016/j.cub.2006.01.031;
RA   Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I.,
RA   Landau N.R., Weitzman M.D.;
RT   "APOBEC3A is a potent inhibitor of adeno-associated virus and
RT   retrotransposons.";
RL   Curr. Biol. 16:480-485(2006).
RN   [11]
RP   DOMAIN CMP/DCMP DEAMINASE ZINC-BINDING.
RX   PubMed=17020885; DOI=10.1074/jbc.M604980200;
RA   Hakata Y., Landau N.R.;
RT   "Reversed functional organization of mouse and human APOBEC3 cytidine
RT   deaminase domains.";
RL   J. Biol. Chem. 281:36624-36631(2006).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16699599; DOI=10.1371/journal.ppat.0020041;
RA   Wichroski M.J., Robb G.B., Rana T.M.;
RT   "Human retroviral host restriction factors APOBEC3G and APOBEC3F
RT   localize to mRNA processing bodies.";
RL   PLoS Pathog. 2:E41-E41(2006).
RN   [13]
RP   REVIEW.
RX   PubMed=18304004; DOI=10.1146/annurev.immunol.26.021607.090350;
RA   Chiu Y.L., Greene W.C.;
RT   "The APOBEC3 cytidine deaminases: an innate defensive network opposing
RT   exogenous retroviruses and endogenous retroelements.";
RL   Annu. Rev. Immunol. 26:317-353(2008).
RN   [14]
RP   REVIEW ON FUNCTION IN HBV RESTRICTION.
RX   PubMed=18448976; DOI=10.1097/QCO.0b013e3282fe1bb2;
RA   Bonvin M., Greeve J.;
RT   "Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine
RT   deaminases as effectors in innate immunity against the hepatitis B
RT   virus.";
RL   Curr. Opin. Infect. Dis. 21:298-303(2008).
RN   [15]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18667511; DOI=10.1128/JVI.02471-07;
RA   Stenglein M.D., Matsuo H., Harris R.S.;
RT   "Two regions within the amino-terminal half of APOBEC3G cooperate to
RT   determine cytoplasmic localization.";
RL   J. Virol. 82:9591-9599(2008).
RN   [16]
RP   TISSUE SPECIFICITY.
RX   PubMed=20308164; DOI=10.1093/nar/gkq174;
RA   Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L.,
RA   Harris R.S.;
RT   "Quantitative profiling of the full APOBEC3 mRNA repertoire in
RT   lymphocytes and tissues: implications for HIV-1 restriction.";
RL   Nucleic Acids Res. 38:4274-4284(2010).
RN   [17]
RP   FUNCTION IN RETROTRANSPOSITION.
RX   PubMed=20062055; DOI=10.1038/nsmb.1744;
RA   Stenglein M.D., Burns M.B., Li M., Lengyel J., Harris R.S.;
RT   "APOBEC3 proteins mediate the clearance of foreign DNA from human
RT   cells.";
RL   Nat. Struct. Mol. Biol. 17:222-229(2010).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21835787; DOI=10.1128/JVI.05238-11;
RA   Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L.,
RA   Brown W.L., Harris R.S.;
RT   "Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H
RT   demonstrate a conserved capacity to restrict Vif-deficient HIV-1.";
RL   J. Virol. 85:11220-11234(2011).
RN   [19]
RP   REVIEW.
RX   PubMed=22912627; DOI=10.3389/fmicb.2012.00275;
RA   Arias J.F., Koyama T., Kinomoto M., Tokunaga K.;
RT   "Retroelements versus APOBEC3 family members: No great escape from the
RT   magnificent seven.";
RL   Front. Microbiol. 3:275-275(2012).
RN   [20]
RP   FUNCTION IN HTLV-1 RESTRICTION.
RX   PubMed=22457529; DOI=10.1128/JVI.06570-11;
RA   Ooms M., Krikoni A., Kress A.K., Simon V., Muenk C.;
RT   "APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-
RT   lymphotropic virus type 1.";
RL   J. Virol. 86:6097-6108(2012).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22915799; DOI=10.1128/JVI.00595-12;
RA   Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H.;
RT   "HIV-1 replication and APOBEC3 antiviral activity are not regulated by
RT   P bodies.";
RL   J. Virol. 86:11712-11724(2012).
RN   [22]
RP   REVIEW.
RX   PubMed=22001110; DOI=10.1016/j.semcdb.2011.10.004;
RA   Smith H.C., Bennett R.P., Kizilyer A., McDougall W.M., Prohaska K.M.;
RT   "Functions and regulation of the APOBEC family of proteins.";
RL   Semin. Cell Dev. Biol. 23:258-268(2012).
CC   -!- FUNCTION: DNA deaminase (cytidine deaminase) which acts as an
CC       inhibitor of retrovirus replication and retrotransposon mobility
CC       via deaminase-dependent and -independent mechanisms. After the
CC       penetration of retroviral nucleocapsids into target cells of
CC       infection and the initiation of reverse transcription, it can
CC       induce the conversion of cytosine to uracil in the minus-sense
CC       single-strand viral DNA, leading to G-to-A hypermutations in the
CC       subsequent plus-strand viral DNA. The resultant detrimental levels
CC       of mutations in the proviral genome, along with a deamination-
CC       independent mechanism that works prior to the proviral
CC       integration, together exert efficient antiretroviral effects in
CC       infected target cells. Selectively targets single-stranded DNA and
CC       does not deaminate double-stranded DNA or single-or double-
CC       stranded RNA. Exhibits antiviral activity against simian
CC       immunodeficiency virus (SIV), hepatitis B virus (HBV) and human T-
CC       cell leukemia virus type 1 (HTLV-1) and may inhibit the mobility
CC       of LTR and non-LTR retrotransposons.
CC   -!- CATALYTIC ACTIVITY: Cytidine + H(2)O = uridine + NH(3).
CC   -!- COFACTOR: Zinc.
CC   -!- SUBUNIT: Homodimer. Interacts with APOBEC3G. Does not interact
CC       with APOBEC1.
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9UH17-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UH17-2; Sequence=VSP_009802;
CC         Note=May be due to a competing donor splice site;
CC       Name=3;
CC         IsoId=Q9UH17-3; Sequence=VSP_044900;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Expressed at high and moderate levels in
CC       peripheral blood leukocytes, spleen, testes, heart, thymus,
CC       prostate and ovary. Also expressed at low levels in several other
CC       tissues.
CC   -!- INDUCTION: Phorbol 12-myristate 13-acetate (PMA) induces
CC       overexpression in keratinocytes. Up-regulated by IFN-alpha.
CC   -!- DOMAIN: The CMP/dCMP deaminase zinc-binding 1 domain mediates RNA
CC       binding, RNA-dependent oligomerization and virion incorporation
CC       whereas the CMP/dCMP deaminase zinc-binding 2 domain confers
CC       deoxycytidine deaminase activity and substrate sequence
CC       specificity (PubMed:17020885).
CC   -!- MISCELLANEOUS: It is one of seven related genes or pseudogenes
CC       found in a cluster, thought to result from gene duplication, on
CC       chromosome 22.
CC   -!- SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase
CC       family.
CC   -!- SIMILARITY: Contains 2 CMP/dCMP deaminase zinc-binding domains.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD00089.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=AAD00090.1; Type=Frameshift; Positions=59, 134; Note=Frameshifts result in two separate ORFs termed phorbolins 2 and 3;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U61083; AAD00089.1; ALT_INIT; mRNA.
DR   EMBL; U61084; AAD00090.1; ALT_FRAME; mRNA.
DR   EMBL; AY743217; AAW31743.1; -; mRNA.
DR   EMBL; CT841510; CAJ86440.1; -; mRNA.
DR   EMBL; AL022318; CAB45270.1; -; Genomic_DNA.
DR   EMBL; AL022318; CAQ09851.1; -; Genomic_DNA.
DR   EMBL; BC053859; AAH53859.1; -; mRNA.
DR   CCDS; CCDS13982.1; -. [Q9UH17-1]
DR   CCDS; CCDS58807.1; -. [Q9UH17-3]
DR   RefSeq; NP_001257340.1; NM_001270411.1.
DR   RefSeq; NP_004891.4; NM_004900.4.
DR   UniGene; Hs.226307; -.
DR   UniGene; Hs.658626; -.
DR   ProteinModelPortal; Q9UH17; -.
DR   SMR; Q9UH17; 4-382.
DR   BioGrid; 114950; 2.
DR   IntAct; Q9UH17; 3.
DR   MINT; MINT-4992727; -.
DR   STRING; 9606.ENSP00000327459; -.
DR   PhosphoSite; Q9UH17; -.
DR   DMDM; 12643884; -.
DR   MaxQB; Q9UH17; -.
DR   PaxDb; Q9UH17; -.
DR   PRIDE; Q9UH17; -.
DR   DNASU; 9582; -.
DR   Ensembl; ENST00000333467; ENSP00000327459; ENSG00000179750. [Q9UH17-1]
DR   Ensembl; ENST00000335760; ENSP00000338897; ENSG00000179750. [Q9UH17-2]
DR   Ensembl; ENST00000407298; ENSP00000385068; ENSG00000179750. [Q9UH17-3]
DR   GeneID; 9582; -.
DR   KEGG; hsa:9582; -.
DR   UCSC; uc003awo.2; human. [Q9UH17-1]
DR   UCSC; uc003awp.2; human.
DR   CTD; 9582; -.
DR   GeneCards; GC22P039378; -.
DR   HGNC; HGNC:17352; APOBEC3B.
DR   MIM; 607110; gene.
DR   neXtProt; NX_Q9UH17; -.
DR   PharmGKB; PA24892; -.
DR   eggNOG; NOG135704; -.
DR   HOGENOM; HOG000033755; -.
DR   HOVERGEN; HBG050434; -.
DR   KO; K01500; -.
DR   OrthoDB; EOG75QR3Z; -.
DR   PhylomeDB; Q9UH17; -.
DR   TreeFam; TF331356; -.
DR   GeneWiki; APOBEC3B; -.
DR   GenomeRNAi; 9582; -.
DR   NextBio; 35465727; -.
DR   PRO; PR:Q9UH17; -.
DR   ArrayExpress; Q9UH17; -.
DR   Bgee; Q9UH17; -.
DR   CleanEx; HS_APOBEC3B; -.
DR   Genevestigator; Q9UH17; -.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0047844; F:deoxycytidine deaminase activity; IMP:UniProtKB.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0008152; P:metabolic process; IMP:GOC.
DR   GO; GO:0010529; P:negative regulation of transposition; IDA:UniProtKB.
DR   InterPro; IPR016192; APOBEC/CMP_deaminase_Zn-bd.
DR   InterPro; IPR007904; APOBEC_C.
DR   InterPro; IPR013158; APOBEC_N.
DR   InterPro; IPR016193; Cytidine_deaminase-like.
DR   Pfam; PF05240; APOBEC_C; 1.
DR   Pfam; PF08210; APOBEC_N; 1.
DR   SUPFAM; SSF53927; SSF53927; 2.
DR   PROSITE; PS00903; CYT_DCMP_DEAMINASES; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Antiviral defense; Complete proteome; Hydrolase;
KW   Immunity; Innate immunity; Metal-binding; Nucleus; Polymorphism;
KW   Reference proteome; Repeat; RNA-binding; Zinc.
FT   CHAIN         1    382       DNA dC->dU-editing enzyme APOBEC-3B.
FT                                /FTId=PRO_0000171753.
FT   DOMAIN       66    100       CMP/dCMP deaminase zinc-binding 1.
FT   DOMAIN      253    289       CMP/dCMP deaminase zinc-binding 2.
FT   ACT_SITE    255    255       Proton donor (Potential).
FT   METAL        66     66       Zinc (By similarity).
FT   METAL        97     97       Zinc (By similarity).
FT   METAL       100    100       Zinc (By similarity).
FT   METAL       253    253       Zinc (By similarity).
FT   METAL       284    284       Zinc (By similarity).
FT   METAL       289    289       Zinc (By similarity).
FT   VAR_SEQ     191    382       YLMDPDTFTFNFNNDPLVLRRRQTYLCYEVERLDNGTWVLM
FT                                DQHMGFLCNEAKNLLCGFYGRHAELRFLDLVPSLQLDPAQI
FT                                YRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIY
FT                                DYDPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGC
FT                                PFQPWDGLEEHSQALSGRLRAILQNQGN -> LRIFSVAFT
FT                                AAMRSCASWTWFLLCSWTRPRSTGSLGSSPGAPASPGAVPG
FT                                KCVRSFRRTHT (in isoform 2).
FT                                /FTId=VSP_009802.
FT   VAR_SEQ     242    266       Missing (in isoform 3).
FT                                /FTId=VSP_044900.
FT   VARIANT      62     62       K -> E (in dbSNP:rs2076109).
FT                                /FTId=VAR_018142.
FT   VARIANT      98     98       P -> L (in dbSNP:rs2076110).
FT                                /FTId=VAR_018143.
FT   VARIANT     109    109       S -> A (in dbSNP:rs17000697).
FT                                /FTId=VAR_033455.
FT   VARIANT     146    146       T -> K (in dbSNP:rs5995649).
FT                                /FTId=VAR_018144.
FT   VARIANT     351    351       R -> H (in dbSNP:rs1053813).
FT                                /FTId=VAR_048722.
FT   CONFLICT    103    104       KL -> NV (in Ref. 1; AAD00090).
FT   CONFLICT    227    228       TW -> WM (in Ref. 1; AAD00089).
FT   CONFLICT    255    256       EL -> DW (in Ref. 1; AAD00089).
FT   CONFLICT    306    306       R -> P (in Ref. 1; AAD00089).
FT   CONFLICT    356    356       F -> S (in Ref. 2; AAW31743).
SQ   SEQUENCE   382 AA;  45924 MW;  DA6EDD23E8856240 CRC64;
     MNPQIRNPME RMYRDTFYDN FENEPILYGR SYTWLCYEVK IKRGRSNLLW DTGVFRGQVY
     FKPQYHAEMC FLSWFCGNQL PAYKCFQITW FVSWTPCPDC VAKLAEFLSE HPNVTLTISA
     ARLYYYWERD YRRALCRLSQ AGARVTIMDY EEFAYCWENF VYNEGQQFMP WYKFDENYAF
     LHRTLKEILR YLMDPDTFTF NFNNDPLVLR RRQTYLCYEV ERLDNGTWVL MDQHMGFLCN
     EAKNLLCGFY GRHAELRFLD LVPSLQLDPA QIYRVTWFIS WSPCFSWGCA GEVRAFLQEN
     THVRLRIFAA RIYDYDPLYK EALQMLRDAG AQVSIMTYDE FEYCWDTFVY RQGCPFQPWD
     GLEEHSQALS GRLRAILQNQ GN
//
ID   ABC3C_HUMAN             Reviewed;         190 AA.
AC   Q9NRW3; B2R884; Q5JZ92; Q7Z2N7; Q96F12;
DT   29-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   29-MAR-2004, sequence version 2.
DT   09-JUL-2014, entry version 111.
DE   RecName: Full=DNA dC->dU-editing enzyme APOBEC-3C;
DE            Short=A3C;
DE            EC=3.5.4.-;
DE   AltName: Full=APOBEC1-like;
DE   AltName: Full=Phorbolin I;
GN   Name=APOBEC3C; Synonyms=APOBEC1L, PBI;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Hematopoietic stem cell;
RA   Gu J., Huang Q., Yu Y., Xu S., Wang Y., Han Z., Chen Z., Zhou J.,
RA   Tu Y., Gu W., Fu G., Huang C.;
RT   "Novel genes expressed in hematopoietic stem/progenitor cells from
RT   myelodysplastic syndrome patients.";
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   GENE FAMILY ORGANIZATION, AND TISSUE SPECIFICITY.
RX   PubMed=11863358; DOI=10.1006/geno.2002.6718;
RA   Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J.,
RA   Navaratnam N.;
RT   "An anthropoid-specific locus of orphan C to U RNA-editing enzymes on
RT   chromosome 22.";
RL   Genomics 79:285-296(2002).
RN   [8]
RP   FUNCTION IN HIV-1 INFECTIVITY.
RX   PubMed=12859895; DOI=10.1016/S0092-8674(03)00515-4;
RA   Mariani R., Chen D., Schroefelbauer B., Navarro F., Koenig R.,
RA   Bollman B., Muenk C., Nymark-McMahon H., Landau N.R.;
RT   "Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.";
RL   Cell 114:21-31(2003).
RN   [9]
RP   FUNCTION IN SIV RESTRICTION.
RX   PubMed=15466872; DOI=10.1074/jbc.M408802200;
RA   Yu Q., Chen D., Koenig R., Mariani R., Unutmaz D., Landau N.R.;
RT   "APOBEC3B and APOBEC3C are potent inhibitors of simian
RT   immunodeficiency virus replication.";
RL   J. Biol. Chem. 279:53379-53386(2004).
RN   [10]
RP   FUNCTION IN RETROTRANSPOSITION.
RX   PubMed=16527742; DOI=10.1016/j.cub.2006.01.031;
RA   Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I.,
RA   Landau N.R., Weitzman M.D.;
RT   "APOBEC3A is a potent inhibitor of adeno-associated virus and
RT   retrotransposons.";
RL   Curr. Biol. 16:480-485(2006).
RN   [11]
RP   REVIEW.
RX   PubMed=18304004; DOI=10.1146/annurev.immunol.26.021607.090350;
RA   Chiu Y.L., Greene W.C.;
RT   "The APOBEC3 cytidine deaminases: an innate defensive network opposing
RT   exogenous retroviruses and endogenous retroelements.";
RL   Annu. Rev. Immunol. 26:317-353(2008).
RN   [12]
RP   REVIEW ON FUNCTION IN HBV RESTRICTION.
RX   PubMed=18448976; DOI=10.1097/QCO.0b013e3282fe1bb2;
RA   Bonvin M., Greeve J.;
RT   "Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine
RT   deaminases as effectors in innate immunity against the hepatitis B
RT   virus.";
RL   Curr. Opin. Infect. Dis. 21:298-303(2008).
RN   [13]
RP   INTERACTION WITH HUMAN FOAMY VIRUS PROTEIN BET.
RX   PubMed=19074429; DOI=10.1074/jbc.M808853200;
RA   Perkovic M., Schmidt S., Marino D., Russell R.A., Stauch B.,
RA   Hofmann H., Kopietz F., Kloke B.-P., Zielonka J., Stroever H.,
RA   Hermle J., Lindemann D., Pathak V.K., Schneider G., Loechelt M.,
RA   Cichutek K., Muenk C.;
RT   "Species-specific inhibition of APOBEC3C by the prototype foamy virus
RT   protein bet.";
RL   J. Biol. Chem. 284:5819-5826(2009).
RN   [14]
RP   FUNCTION IN RETROTRANSPOSITION.
RX   PubMed=20062055; DOI=10.1038/nsmb.1744;
RA   Stenglein M.D., Burns M.B., Li M., Lengyel J., Harris R.S.;
RT   "APOBEC3 proteins mediate the clearance of foreign DNA from human
RT   cells.";
RL   Nat. Struct. Mol. Biol. 17:222-229(2010).
RN   [15]
RP   TISSUE SPECIFICITY.
RX   PubMed=20308164; DOI=10.1093/nar/gkq174;
RA   Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L.,
RA   Harris R.S.;
RT   "Quantitative profiling of the full APOBEC3 mRNA repertoire in
RT   lymphocytes and tissues: implications for HIV-1 restriction.";
RL   Nucleic Acids Res. 38:4274-4284(2010).
RN   [16]
RP   FUNCTION IN DNA DEMETHYLATION.
RX   PubMed=21496894; DOI=10.1016/j.cell.2011.03.022;
RA   Guo J.U., Su Y., Zhong C., Ming G.L., Song H.;
RT   "Hydroxylation of 5-methylcytosine by TET1 promotes active DNA
RT   demethylation in the adult brain.";
RL   Cell 145:423-434(2011).
RN   [17]
RP   FUNCTION IN EBV AND HHV-1 INHIBITION.
RX   PubMed=21632763; DOI=10.1128/JVI.00290-11;
RA   Suspene R., Aynaud M.M., Koch S., Pasdeloup D., Labetoulle M.,
RA   Gaertner B., Vartanian J.P., Meyerhans A., Wain-Hobson S.;
RT   "Genetic editing of herpes simplex virus 1 and Epstein-Barr
RT   herpesvirus genomes by human APOBEC3 cytidine deaminases in culture
RT   and in vivo.";
RL   J. Virol. 85:7594-7602(2011).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21835787; DOI=10.1128/JVI.05238-11;
RA   Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L.,
RA   Brown W.L., Harris R.S.;
RT   "Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H
RT   demonstrate a conserved capacity to restrict Vif-deficient HIV-1.";
RL   J. Virol. 85:11220-11234(2011).
RN   [19]
RP   REVIEW.
RA   Love R.;
RT   "Cytosine deaminases APOBEC3A, APOBEC3C, and APOBEC3H: Current
RT   understanding of their functional roles.";
RL   Student Perspec. Contemp. Virol. 0:0-0(2011).
RN   [20]
RP   REVIEW.
RX   PubMed=22912627; DOI=10.3389/fmicb.2012.00275;
RA   Arias J.F., Koyama T., Kinomoto M., Tokunaga K.;
RT   "Retroelements versus APOBEC3 family members: No great escape from the
RT   magnificent seven.";
RL   Front. Microbiol. 3:275-275(2012).
RN   [21]
RP   INTERACTION WITH TRIB3, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=22977230; DOI=10.1074/jbc.M112.372722;
RA   Aynaud M.M., Suspene R., Vidalain P.O., Mussil B., Guetard D.,
RA   Tangy F., Wain-Hobson S., Vartanian J.P.;
RT   "Human Tribbles 3 protects nuclear DNA from cytidine deamination by
RT   APOBEC3A.";
RL   J. Biol. Chem. 287:39182-39192(2012).
RN   [22]
RP   INTERACTION WITH AGO2.
RX   PubMed=22915799; DOI=10.1128/JVI.00595-12;
RA   Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H.;
RT   "HIV-1 replication and APOBEC3 antiviral activity are not regulated by
RT   P bodies.";
RL   J. Virol. 86:11712-11724(2012).
RN   [23]
RP   REVIEW.
RX   PubMed=22001110; DOI=10.1016/j.semcdb.2011.10.004;
RA   Smith H.C., Bennett R.P., Kizilyer A., McDougall W.M., Prohaska K.M.;
RT   "Functions and regulation of the APOBEC family of proteins.";
RL   Semin. Cell Dev. Biol. 23:258-268(2012).
CC   -!- FUNCTION: DNA deaminase (cytidine deaminase) which acts as an
CC       inhibitor of retrovirus replication and retrotransposon mobility
CC       via deaminase-dependent and -independent mechanisms. After the
CC       penetration of retroviral nucleocapsids into target cells of
CC       infection and the initiation of reverse transcription, it can
CC       induce the conversion of cytosine to uracil in the minus-sense
CC       single-strand viral DNA, leading to G-to-A hypermutations in the
CC       subsequent plus-strand viral DNA. The resultant detrimental levels
CC       of mutations in the proviral genome, along with a deamination-
CC       independent mechanism that works prior to the proviral
CC       integration, together exert efficient antiretroviral effects in
CC       infected target cells. Selectively targets single-stranded DNA and
CC       does not deaminate double-stranded DNA or single-or double-
CC       stranded RNA. Exhibits antiviral activity against simian
CC       immunodeficiency virus (SIV), hepatitis B virus (HBV), herpes
CC       simplex virus 1 (HHV-1) and Epstein-Barr virus (EBV) and may
CC       inhibit the mobility of LTR and non-LTR retrotransposons. May also
CC       play a role in the epigenetic regulation of gene expression
CC       through the process of active DNA demethylation.
CC   -!- CATALYTIC ACTIVITY: Cytidine + H(2)O = uridine + NH(3).
CC   -!- COFACTOR: Zinc (By similarity).
CC   -!- SUBUNIT: Homodimer. Interacts with human foamy virus protein Bet;
CC       this interaction does not induce APOBEC3C degradation, but
CC       prevents dimerization and incorporation into virion of the latter.
CC       Interacts with TRIB3 and AGO2.
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm.
CC   -!- TISSUE SPECIFICITY: Expressed in spleen, testes, peripherical
CC       blood lymphocytes, heart, thymus, prostate and ovary.
CC   -!- INDUCTION: Up-regulated by IFN-alpha.
CC   -!- MISCELLANEOUS: It is one of seven related genes or pseudogenes
CC       found in a cluster, thought to result from gene duplication, on
CC       chromosome 22.
CC   -!- SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase
CC       family.
CC   -!- SIMILARITY: Contains 1 CMP/dCMP deaminase zinc-binding domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF86650.1; Type=Frameshift; Positions=172;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF165520; AAF86650.1; ALT_FRAME; mRNA.
DR   EMBL; CR456394; CAG30280.1; -; mRNA.
DR   EMBL; AK313272; BAG36081.1; -; mRNA.
DR   EMBL; AL022318; CAI17898.1; -; Genomic_DNA.
DR   EMBL; CH471095; EAW60284.1; -; Genomic_DNA.
DR   EMBL; BC011739; AAH11739.1; -; mRNA.
DR   EMBL; BC021080; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS13983.1; -.
DR   RefSeq; NP_055323.2; NM_014508.2.
DR   UniGene; Hs.441124; -.
DR   PDB; 3VM8; X-ray; 3.00 A; A/B=1-190.
DR   PDB; 3VOW; X-ray; 2.15 A; A/B=1-190.
DR   PDBsum; 3VM8; -.
DR   PDBsum; 3VOW; -.
DR   ProteinModelPortal; Q9NRW3; -.
DR   SMR; Q9NRW3; 5-190.
DR   BioGrid; 118162; 9.
DR   DIP; DIP-48919N; -.
DR   IntAct; Q9NRW3; 4.
DR   MINT; MINT-6631470; -.
DR   STRING; 9606.ENSP00000355340; -.
DR   PhosphoSite; Q9NRW3; -.
DR   DMDM; 48474983; -.
DR   MaxQB; Q9NRW3; -.
DR   PaxDb; Q9NRW3; -.
DR   PRIDE; Q9NRW3; -.
DR   DNASU; 27350; -.
DR   Ensembl; ENST00000361441; ENSP00000355340; ENSG00000244509.
DR   GeneID; 27350; -.
DR   KEGG; hsa:27350; -.
DR   UCSC; uc003awr.3; human.
DR   CTD; 27350; -.
DR   GeneCards; GC22P039410; -.
DR   HGNC; HGNC:17353; APOBEC3C.
DR   HPA; CAB033048; -.
DR   MIM; 607750; gene.
DR   neXtProt; NX_Q9NRW3; -.
DR   PharmGKB; PA24893; -.
DR   eggNOG; NOG289247; -.
DR   HOGENOM; HOG000033754; -.
DR   HOVERGEN; HBG050434; -.
DR   InParanoid; Q9NRW3; -.
DR   KO; K01500; -.
DR   OMA; SETHCHA; -.
DR   PhylomeDB; Q9NRW3; -.
DR   TreeFam; TF331356; -.
DR   ChiTaRS; APOBEC3C; human.
DR   GeneWiki; APOBEC3C; -.
DR   GenomeRNAi; 27350; -.
DR   NextBio; 50452; -.
DR   PRO; PR:Q9NRW3; -.
DR   ArrayExpress; Q9NRW3; -.
DR   Bgee; Q9NRW3; -.
DR   CleanEx; HS_APOBEC3C; -.
DR   Genevestigator; Q9NRW3; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016814; F:hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines; IEA:InterPro.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0009972; P:cytidine deamination; IDA:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0080111; P:DNA demethylation; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0010529; P:negative regulation of transposition; IDA:UniProtKB.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR016192; APOBEC/CMP_deaminase_Zn-bd.
DR   InterPro; IPR007904; APOBEC_C.
DR   InterPro; IPR016193; Cytidine_deaminase-like.
DR   Pfam; PF05240; APOBEC_C; 1.
DR   SUPFAM; SSF53927; SSF53927; 1.
DR   PROSITE; PS00903; CYT_DCMP_DEAMINASES; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antiviral defense; Complete proteome; Cytoplasm;
KW   Host-virus interaction; Hydrolase; Immunity; Innate immunity;
KW   Metal-binding; Nucleus; Reference proteome; Zinc.
FT   CHAIN         1    190       DNA dC->dU-editing enzyme APOBEC-3C.
FT                                /FTId=PRO_0000171755.
FT   DOMAIN       66    100       CMP/dCMP deaminase zinc-binding.
FT   ACT_SITE     68     68       Proton donor (By similarity).
FT   METAL        66     66       Zinc; catalytic (By similarity).
FT   METAL        97     97       Zinc; catalytic (By similarity).
FT   METAL       100    100       Zinc; catalytic (By similarity).
FT   CONFLICT     31     31       N -> D (in Ref. 6; AAH11739).
FT   HELIX        14     20
FT   TURN         27     29
FT   STRAND       32     43
FT   STRAND       46     58
FT   HELIX        63     65
FT   HELIX        67     75
FT   STRAND       84     94
FT   HELIX        98    110
FT   STRAND      114    122
FT   TURN        124    127
FT   HELIX       129    141
FT   STRAND      144    147
FT   HELIX       150    160
FT   HELIX       174    189
SQ   SEQUENCE   190 AA;  22826 MW;  BE49E80F95C71214 CRC64;
     MNPQIRNPMK AMYPGTFYFQ FKNLWEANDR NETWLCFTVE GIKRRSVVSW KTGVFRNQVD
     SETHCHAERC FLSWFCDDIL SPNTKYQVTW YTSWSPCPDC AGEVAEFLAR HSNVNLTIFT
     ARLYYFQYPC YQEGLRSLSQ EGVAVEIMDY EDFKYCWENF VYNDNEPFKP WKGLKTNFRL
     LKRRLRESLQ
//
ID   ABC3F_HUMAN             Reviewed;         373 AA.
AC   Q8IUX4; B0QYD4; Q45F03; Q6ICH3; Q7Z2N2; Q7Z2N5;
DT   29-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-OCT-2007, sequence version 3.
DT   09-JUL-2014, entry version 110.
DE   RecName: Full=DNA dC->dU-editing enzyme APOBEC-3F;
DE            EC=3.5.4.-;
DE   AltName: Full=Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3F;
DE            Short=A3F;
GN   Name=APOBEC3F;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANTS THR-178;
RP   ILE-231 AND CYS-307.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND
RP   VARIANTS PRO-48 AND SER-108.
RC   TISSUE=Pancreas, Spleen, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   GENE FAMILY ORGANIZATION, AND TISSUE SPECIFICITY.
RX   PubMed=11863358; DOI=10.1006/geno.2002.6718;
RA   Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J.,
RA   Navaratnam N.;
RT   "An anthropoid-specific locus of orphan C to U RNA-editing enzymes on
RT   chromosome 22.";
RL   Genomics 79:285-296(2002).
RN   [7]
RP   REVIEW ON APOBEC FAMILIES.
RX   PubMed=12683974; DOI=10.1016/S0168-9525(03)00054-4;
RA   Wedekind J.E., Dance G.S.C., Sowden M.P., Smith H.C.;
RT   "Messenger RNA editing in mammals: new members of the APOBEC family
RT   seeking roles in the family business.";
RL   Trends Genet. 19:207-216(2003).
RN   [8]
RP   FUNCTION IN HIV-1 INFECTIVITY, AND TISSUE SPECIFICITY.
RX   PubMed=15152192; DOI=10.1038/sj.emboj.7600246;
RA   Wiegand H.L., Doehle B.P., Bogerd H.P., Cullen B.R.;
RT   "A second human antiretroviral factor, APOBEC3F, is suppressed by the
RT   HIV-1 and HIV-2 Vif proteins.";
RL   EMBO J. 23:2451-2458(2004).
RN   [9]
RP   FUNCTION IN RETROTRANSPOSITION, AND SUBCELLULAR LOCATION.
RX   PubMed=16527742; DOI=10.1016/j.cub.2006.01.031;
RA   Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I.,
RA   Landau N.R., Weitzman M.D.;
RT   "APOBEC3A is a potent inhibitor of adeno-associated virus and
RT   retrotransposons.";
RL   Curr. Biol. 16:480-485(2006).
RN   [10]
RP   DOMAIN CMP/DCMP DEAMINASE ZINC-BINDING, AND MUTAGENESIS OF GLU-67 AND
RP   GLU-251.
RX   PubMed=17020885; DOI=10.1074/jbc.M604980200;
RA   Hakata Y., Landau N.R.;
RT   "Reversed functional organization of mouse and human APOBEC3 cytidine
RT   deaminase domains.";
RL   J. Biol. Chem. 281:36624-36631(2006).
RN   [11]
RP   FUNCTION IN SFV RESTRICTION.
RX   PubMed=16378963; DOI=10.1128/JVI.80.2.605-614.2006;
RA   Delebecque F., Suspene R., Calattini S., Casartelli N., Saib A.,
RA   Froment A., Wain-Hobson S., Gessain A., Vartanian J.P., Schwartz O.;
RT   "Restriction of foamy viruses by APOBEC cytidine deaminases.";
RL   J. Virol. 80:605-614(2006).
RN   [12]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH APOBEC3G.
RX   PubMed=16699599; DOI=10.1371/journal.ppat.0020041;
RA   Wichroski M.J., Robb G.B., Rana T.M.;
RT   "Human retroviral host restriction factors APOBEC3G and APOBEC3F
RT   localize to mRNA processing bodies.";
RL   PLoS Pathog. 2:E41-E41(2006).
RN   [13]
RP   REVIEW.
RX   PubMed=18304004; DOI=10.1146/annurev.immunol.26.021607.090350;
RA   Chiu Y.L., Greene W.C.;
RT   "The APOBEC3 cytidine deaminases: an innate defensive network opposing
RT   exogenous retroviruses and endogenous retroelements.";
RL   Annu. Rev. Immunol. 26:317-353(2008).
RN   [14]
RP   REVIEW ON FUNCTION IN HBV RESTRICTION.
RX   PubMed=18448976; DOI=10.1097/QCO.0b013e3282fe1bb2;
RA   Bonvin M., Greeve J.;
RT   "Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine
RT   deaminases as effectors in innate immunity against the hepatitis B
RT   virus.";
RL   Curr. Opin. Infect. Dis. 21:298-303(2008).
RN   [15]
RP   FUNCTION IN EIAV RESTRICTION.
RX   PubMed=19458006; DOI=10.1128/JVI.00015-09;
RA   Zielonka J., Bravo I.G., Marino D., Conrad E., Perkovic M.,
RA   Battenberg M., Cichutek K., Muenk C.;
RT   "Restriction of equine infectious anemia virus by equine APOBEC3
RT   cytidine deaminases.";
RL   J. Virol. 83:7547-7559(2009).
RN   [16]
RP   FUNCTION IN HIV-1 RESTRICTION.
RX   PubMed=20219927; DOI=10.1128/JVI.02358-09;
RA   Mbisa J.L., Bu W., Pathak V.K.;
RT   "APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different
RT   mechanisms.";
RL   J. Virol. 84:5250-5259(2010).
RN   [17]
RP   FUNCTION IN XMRV RESTRICTION.
RX   PubMed=20335265; DOI=10.1128/JVI.00134-10;
RA   Paprotka T., Venkatachari N.J., Chaipan C., Burdick R.,
RA   Delviks-Frankenberry K.A., Hu W.S., Pathak V.K.;
RT   "Inhibition of xenotropic murine leukemia virus-related virus by
RT   APOBEC3 proteins and antiviral drugs.";
RL   J. Virol. 84:5719-5729(2010).
RN   [18]
RP   FUNCTION IN RETROTRANSPOSITION.
RX   PubMed=20062055; DOI=10.1038/nsmb.1744;
RA   Stenglein M.D., Burns M.B., Li M., Lengyel J., Harris R.S.;
RT   "APOBEC3 proteins mediate the clearance of foreign DNA from human
RT   cells.";
RL   Nat. Struct. Mol. Biol. 17:222-229(2010).
RN   [19]
RP   TISSUE SPECIFICITY.
RX   PubMed=20308164; DOI=10.1093/nar/gkq174;
RA   Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L.,
RA   Harris R.S.;
RT   "Quantitative profiling of the full APOBEC3 mRNA repertoire in
RT   lymphocytes and tissues: implications for HIV-1 restriction.";
RL   Nucleic Acids Res. 38:4274-4284(2010).
RN   [20]
RP   FUNCTION IN DNA DEMETHYLATION.
RX   PubMed=21496894; DOI=10.1016/j.cell.2011.03.022;
RA   Guo J.U., Su Y., Zhong C., Ming G.L., Song H.;
RT   "Hydroxylation of 5-methylcytosine by TET1 promotes active DNA
RT   demethylation in the adult brain.";
RL   Cell 145:423-434(2011).
RN   [21]
RP   FUNCTION IN HIV-1 RESTRICTION, SUBCELLULAR LOCATION, AND ENZYME
RP   REGULATION.
RX   PubMed=21835787; DOI=10.1128/JVI.05238-11;
RA   Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L.,
RA   Brown W.L., Harris R.S.;
RT   "Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H
RT   demonstrate a conserved capacity to restrict Vif-deficient HIV-1.";
RL   J. Virol. 85:11220-11234(2011).
RN   [22]
RP   REVIEW.
RX   PubMed=22912627; DOI=10.3389/fmicb.2012.00275;
RA   Arias J.F., Koyama T., Kinomoto M., Tokunaga K.;
RT   "Retroelements versus APOBEC3 family members: No great escape from the
RT   magnificent seven.";
RL   Front. Microbiol. 3:275-275(2012).
RN   [23]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AGO1; AGO2 AND
RP   AGO3.
RX   PubMed=22915799; DOI=10.1128/JVI.00595-12;
RA   Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H.;
RT   "HIV-1 replication and APOBEC3 antiviral activity are not regulated by
RT   P bodies.";
RL   J. Virol. 86:11712-11724(2012).
RN   [24]
RP   FUNCTION IN HIV-1 RESTRICTION.
RX   PubMed=22807680; DOI=10.1371/journal.ppat.1002800;
RA   Refsland E.W., Hultquist J.F., Harris R.S.;
RT   "Endogenous origins of HIV-1 G-to-A hypermutation and restriction in
RT   the nonpermissive T cell line CEM2n.";
RL   PLoS Pathog. 8:E1002800-E1002800(2012).
RN   [25]
RP   REVIEW.
RX   PubMed=22001110; DOI=10.1016/j.semcdb.2011.10.004;
RA   Smith H.C., Bennett R.P., Kizilyer A., McDougall W.M., Prohaska K.M.;
RT   "Functions and regulation of the APOBEC family of proteins.";
RL   Semin. Cell Dev. Biol. 23:258-268(2012).
RN   [26]
RP   FUNCTION IN HIV-1 RESTRICTION.
RX   PubMed=23097438; DOI=10.1128/JVI.00676-12;
RA   Chaipan C., Smith J.L., Hu W.S., Pathak V.K.;
RT   "APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and
RT   APOBEC3DE in human primary CD4+ t cells and macrophages.";
RL   J. Virol. 87:444-453(2013).
RN   [27]
RP   FUNCTION IN HIV-1 RESTRICTION.
RX   PubMed=23152537; DOI=10.1128/JVI.02587-12;
RA   Gillick K., Pollpeter D., Phalora P., Kim E.Y., Wolinsky S.M.,
RA   Malim M.H.;
RT   "The suppression of HIV-1 infection by APOBEC3 proteins in primary
RT   human CD4+ T cells is associated with the inhibition of processive
RT   reverse transcription as well as excessive cytidine deamination.";
RL   J. Virol. 87:1508-1517(2013).
CC   -!- FUNCTION: DNA deaminase (cytidine deaminase) which acts as an
CC       inhibitor of retrovirus replication and retrotransposon mobility
CC       via deaminase-dependent and -independent mechanisms. Exhibits
CC       antiviral activity against vif-deficient HIV-1. After the
CC       penetration of retroviral nucleocapsids into target cells of
CC       infection and the initiation of reverse transcription, it can
CC       induce the conversion of cytosine to uracil in the minus-sense
CC       single-strand viral DNA, leading to G-to-A hypermutations in the
CC       subsequent plus-strand viral DNA. The resultant detrimental levels
CC       of mutations in the proviral genome, along with a deamination-
CC       independent mechanism that works prior to the proviral
CC       integration, together exert efficient antiretroviral effects in
CC       infected target cells. Selectively targets single-stranded DNA and
CC       does not deaminate double-stranded DNA or single- or double-
CC       stranded RNA. Exhibits antiviral activity also against hepatitis B
CC       virus (HBV), equine infectious anemia virus (EIAV), xenotropic
CC       MuLV-related virus (XMRV) and simian foamy virus (SFV) and may
CC       inhibit the mobility of LTR and non-LTR retrotransposons. May also
CC       play a role in the epigenetic regulation of gene expression
CC       through the process of active DNA demethylation.
CC   -!- CATALYTIC ACTIVITY: Cytidine + H(2)O = uridine + NH(3).
CC   -!- COFACTOR: Zinc (By similarity).
CC   -!- ENZYME REGULATION: Antiviral activity is neutralized by the HIV-1
CC       virion infectivity factor (VIF), that prevents its incorporation
CC       into progeny virions by both inhibiting its translation and/or by
CC       inducing its ubiquitination and subsequent degradation by the 26S
CC       proteasome.
CC   -!- SUBUNIT: Binds HIV-1 Vif. In the absence of Vif protein,
CC       specifically packaged into HIV-1 virions. Interacts with APOBEC3G
CC       in an RNA-dependent manner. Interacts with AGO1, AGO2 and AGO3.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, P-body.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8IUX4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IUX4-2; Sequence=VSP_009803, VSP_009804;
CC         Note=May be due to a competing donor splice site. No
CC         experimental confirmation available;
CC       Name=3;
CC         IsoId=Q8IUX4-3; Sequence=VSP_042754, VSP_042755;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highly expressed in ovary.
CC   -!- INDUCTION: Up-regulated by IFN-alpha.
CC   -!- DOMAIN: The CMP/dCMP deaminase zinc-binding 1 domain mediates RNA
CC       binding, RNA-dependent oligomerization and virion incorporation
CC       whereas the CMP/dCMP deaminase zinc-binding 2 domain confers
CC       deoxycytidine deaminase activity and substrate sequence
CC       specificity (PubMed:17020885).
CC   -!- MISCELLANEOUS: It is one of seven related genes or pseudogenes
CC       found in a cluster, thought to result from gene duplication, on
CC       chromosome 22.
CC   -!- SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase
CC       family.
CC   -!- SIMILARITY: Contains 2 CMP/dCMP deaminase zinc-binding domains.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/apobec3f/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CR456395; CAG30281.1; -; mRNA.
DR   EMBL; DQ146365; AAZ38720.1; -; Genomic_DNA.
DR   EMBL; AL022318; CAQ09853.1; -; Genomic_DNA.
DR   EMBL; CH471095; EAW60288.1; -; Genomic_DNA.
DR   EMBL; CH471095; EAW60289.1; -; Genomic_DNA.
DR   EMBL; BC038808; AAH38808.1; -; mRNA.
DR   EMBL; BC061914; AAH61914.1; -; mRNA.
DR   CCDS; CCDS33648.1; -. [Q8IUX4-1]
DR   CCDS; CCDS33649.1; -. [Q8IUX4-3]
DR   RefSeq; NP_001006667.1; NM_001006666.1. [Q8IUX4-3]
DR   RefSeq; NP_660341.2; NM_145298.5. [Q8IUX4-1]
DR   UniGene; Hs.659809; -.
DR   UniGene; Hs.660143; -.
DR   PDB; 4IOU; X-ray; 2.75 A; A/B/C/D=185-373.
DR   PDB; 4J4J; X-ray; 3.10 A; A/B=218-373.
DR   PDBsum; 4IOU; -.
DR   PDBsum; 4J4J; -.
DR   ProteinModelPortal; Q8IUX4; -.
DR   SMR; Q8IUX4; 6-189, 194-373.
DR   BioGrid; 128319; 5.
DR   DIP; DIP-59966N; -.
DR   MINT; MINT-6631309; -.
DR   STRING; 9606.ENSP00000309749; -.
DR   ChEMBL; CHEMBL2007626; -.
DR   PhosphoSite; Q8IUX4; -.
DR   DMDM; 161784334; -.
DR   MaxQB; Q8IUX4; -.
DR   PaxDb; Q8IUX4; -.
DR   PRIDE; Q8IUX4; -.
DR   DNASU; 200316; -.
DR   Ensembl; ENST00000308521; ENSP00000309749; ENSG00000128394. [Q8IUX4-1]
DR   Ensembl; ENST00000381565; ENSP00000370977; ENSG00000128394. [Q8IUX4-3]
DR   GeneID; 200316; -.
DR   KEGG; hsa:200316; -.
DR   UCSC; uc003awv.3; human. [Q8IUX4-3]
DR   UCSC; uc003aww.3; human. [Q8IUX4-1]
DR   CTD; 200316; -.
DR   GeneCards; GC22P039436; -.
DR   H-InvDB; HIX0213264; -.
DR   HGNC; HGNC:17356; APOBEC3F.
DR   MIM; 608993; gene.
DR   neXtProt; NX_Q8IUX4; -.
DR   PharmGKB; PA24896; -.
DR   eggNOG; NOG135704; -.
DR   HOGENOM; HOG000142455; -.
DR   HOVERGEN; HBG050434; -.
DR   InParanoid; Q8IUX4; -.
DR   KO; K01500; -.
DR   OMA; SHARRCP; -.
DR   OrthoDB; EOG7GXPJ6; -.
DR   PhylomeDB; Q8IUX4; -.
DR   TreeFam; TF331356; -.
DR   BRENDA; 3.5.4.5; 2681.
DR   GeneWiki; APOBEC3F; -.
DR   GenomeRNAi; 200316; -.
DR   NextBio; 89891; -.
DR   PRO; PR:Q8IUX4; -.
DR   ArrayExpress; Q8IUX4; -.
DR   Bgee; Q8IUX4; -.
DR   CleanEx; HS_APOBEC3F; -.
DR   Genevestigator; Q8IUX4; -.
DR   GO; GO:0030895; C:apolipoprotein B mRNA editing enzyme complex; TAS:HGNC.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0000932; C:cytoplasmic mRNA processing body; IDA:UniProtKB.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IDA:UniProtKB.
DR   GO; GO:0004126; F:cytidine deaminase activity; IDA:HGNC.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:HGNC.
DR   GO; GO:0008270; F:zinc ion binding; IDA:HGNC.
DR   GO; GO:0016553; P:base conversion or substitution editing; IDA:HGNC.
DR   GO; GO:0009972; P:cytidine deamination; IDA:GOC.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0070383; P:DNA cytosine deamination; IDA:UniProtKB.
DR   GO; GO:0080111; P:DNA demethylation; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IDA:HGNC.
DR   GO; GO:0045869; P:negative regulation of single stranded viral RNA replication via double stranded DNA intermediate; IDA:UniProtKB.
DR   GO; GO:0010529; P:negative regulation of transposition; IDA:UniProtKB.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB.
DR   GO; GO:0048525; P:negative regulation of viral process; IDA:HGNC.
DR   GO; GO:0002230; P:positive regulation of defense response to virus by host; IDA:HGNC.
DR   InterPro; IPR016192; APOBEC/CMP_deaminase_Zn-bd.
DR   InterPro; IPR013158; APOBEC_N.
DR   InterPro; IPR016193; Cytidine_deaminase-like.
DR   Pfam; PF08210; APOBEC_N; 2.
DR   SUPFAM; SSF53927; SSF53927; 2.
DR   PROSITE; PS00903; CYT_DCMP_DEAMINASES; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Antiviral defense;
KW   Complete proteome; Cytoplasm; Hydrolase; Immunity; Innate immunity;
KW   Metal-binding; Polymorphism; Reference proteome; Repeat; Zinc.
FT   CHAIN         1    373       DNA dC->dU-editing enzyme APOBEC-3F.
FT                                /FTId=PRO_0000171757.
FT   DOMAIN       65     99       CMP/dCMP deaminase zinc-binding 1.
FT   DOMAIN      249    283       CMP/dCMP deaminase zinc-binding 2.
FT   ACT_SITE    251    251       Proton donor (By similarity).
FT   METAL        65     65       Zinc (By similarity).
FT   METAL        96     96       Zinc (By similarity).
FT   METAL        99     99       Zinc (By similarity).
FT   VAR_SEQ      58     79       VYSQPEHHAEMCFLSWFCGNQL -> VPPGLQSLCRQELSQ
FT                                LGKQTTH (in isoform 2).
FT                                /FTId=VSP_009803.
FT   VAR_SEQ      59    113       YSQPEHHAEMCFLSWFCGNQLPAYKCFQITWFVSWTPCPDC
FT                                VAKLAEFLAEHPNV -> PRSFIRAPFQVLSSPFGQCAPPH
FT                                GTAQVQWPPQLTAGREQGRP (in isoform 3).
FT                                /FTId=VSP_042754.
FT   VAR_SEQ      80    373       Missing (in isoform 2).
FT                                /FTId=VSP_009804.
FT   VAR_SEQ     114    373       Missing (in isoform 3).
FT                                /FTId=VSP_042755.
FT   VARIANT      48     48       R -> P (in dbSNP:rs35053197).
FT                                /FTId=VAR_038355.
FT   VARIANT      61     61       Q -> L (in dbSNP:rs2076109).
FT                                /FTId=VAR_018145.
FT   VARIANT      97     97       P -> L (in dbSNP:rs2076110).
FT                                /FTId=VAR_018146.
FT   VARIANT     108    108       A -> S (in dbSNP:rs2020390).
FT                                /FTId=VAR_018147.
FT   VARIANT     178    178       A -> T (in dbSNP:rs34182094).
FT                                /FTId=VAR_025058.
FT   VARIANT     231    231       V -> I (in dbSNP:rs2076101).
FT                                /FTId=VAR_018148.
FT   VARIANT     307    307       Y -> C (in dbSNP:rs12157816).
FT                                /FTId=VAR_025059.
FT   MUTAGEN      67     67       E->A: Decrease in cytidine deaminase and
FT                                antiviral activity; when associated with
FT                                A-251.
FT   MUTAGEN      67     67       E->A: No effect on cytidine deaminase and
FT                                antiviral activity.
FT   MUTAGEN     251    251       E->A: Decrease in cytidine deaminase and
FT                                antiviral activity.
FT   MUTAGEN     251    251       E->A: Decrease in cytidine deaminase and
FT                                antiviral activity; when associated with
FT                                A-67.
FT   HELIX       197    203
FT   STRAND      218    229
FT   STRAND      232    238
FT   STRAND      243    245
FT   HELIX       250    261
FT   STRAND      267    277
FT   HELIX       281    293
FT   STRAND      297    304
FT   TURN        307    310
FT   HELIX       312    323
FT   STRAND      327    330
FT   HELIX       333    342
FT   HELIX       357    372
SQ   SEQUENCE   373 AA;  45020 MW;  AF1A0E13830695F4 CRC64;
     MKPHFRNTVE RMYRDTFSYN FYNRPILSRR NTVWLCYEVK TKGPSRPRLD AKIFRGQVYS
     QPEHHAEMCF LSWFCGNQLP AYKCFQITWF VSWTPCPDCV AKLAEFLAEH PNVTLTISAA
     RLYYYWERDY RRALCRLSQA GARVKIMDDE EFAYCWENFV YSEGQPFMPW YKFDDNYAFL
     HRTLKEILRN PMEAMYPHIF YFHFKNLRKA YGRNESWLCF TMEVVKHHSP VSWKRGVFRN
     QVDPETHCHA ERCFLSWFCD DILSPNTNYE VTWYTSWSPC PECAGEVAEF LARHSNVNLT
     IFTARLYYFW DTDYQEGLRS LSQEGASVEI MGYKDFKYCW ENFVYNDDEP FKPWKGLKYN
     FLFLDSKLQE ILE
//
ID   ABC3G_HUMAN             Reviewed;         384 AA.
AC   Q9HC16; B2RDR9; Q45F02; Q5TF77; Q7Z2N1; Q7Z2N4; Q9H9H8;
DT   01-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   09-JUL-2014, entry version 130.
DE   RecName: Full=DNA dC->dU-editing enzyme APOBEC-3G;
DE            EC=3.5.4.-;
DE   AltName: Full=APOBEC-related cytidine deaminase;
DE            Short=APOBEC-related protein;
DE            Short=ARCD;
DE   AltName: Full=APOBEC-related protein 9;
DE            Short=ARP-9;
DE   AltName: Full=CEM-15;
DE            Short=CEM15;
DE   AltName: Full=Deoxycytidine deaminase;
DE            Short=A3G;
GN   Name=APOBEC3G; ORFNames=MDS019;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN HIV-1
RP   INFECTION INHIBITION.
RC   TISSUE=Kidney;
RX   PubMed=14557625; DOI=10.1128/JVI.77.21.11398-11407.2003;
RA   Kao S., Khan M.A., Miyagi E., Plishka R., Buckler-White A.,
RA   Strebel K.;
RT   "The human immunodeficiency virus type 1 Vif protein reduces
RT   intracellular expression and inhibits packaging of APOBEC3G (CEM15), a
RT   cellular inhibitor of virus infectivity.";
RL   J. Virol. 77:11398-11407(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Synovium, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Hematopoietic stem cell;
RA   Huang C., Qian B., Tu Y., Gu W., Wang Y., Han Z., Chen Z.;
RT   "Novel genes expressed in hematopoietic stem/progenitor cells from
RT   myelodysplastic syndrome patients.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-186 AND GLU-275.
RG   SeattleSNPs program for genomic applications;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   GENE FAMILY ORGANIZATION, TISSUE SPECIFICITY, SUBUNIT, RNA-BINDING,
RP   AND ZINC-BINDING.
RX   PubMed=11863358; DOI=10.1006/geno.2002.6718;
RA   Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J.,
RA   Navaratnam N.;
RT   "An anthropoid-specific locus of orphan C to U RNA-editing enzymes on
RT   chromosome 22.";
RL   Genomics 79:285-296(2002).
RN   [10]
RP   TISSUE SPECIFICITY, AND FUNCTION IN HIV-1 INFECTION INHIBITION.
RC   TISSUE=T-cell lymphoma;
RX   PubMed=12167863; DOI=10.1038/nature00939;
RA   Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H.;
RT   "Isolation of a human gene that inhibits HIV-1 infection and is
RT   suppressed by the viral Vif protein.";
RL   Nature 418:646-650(2002).
RN   [11]
RP   SUBCELLULAR LOCATION, FUNCTION IN DNA C TO U EDITING, AND MUTAGENESIS
RP   OF GLU-67; HIS-81; GLU-85; CYS-97; CYS-100; CYS-221; HIS-257; GLU-259;
RP   CYS-288; CYS-291 AND GLU-323.
RX   PubMed=12808466; DOI=10.1038/nature01709;
RA   Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., Trono D.;
RT   "Broad antiretroviral defence by human APOBEC3G through lethal editing
RT   of nascent reverse transcripts.";
RL   Nature 424:99-103(2003).
RN   [12]
RP   FUNCTION IN DNA C TO U EDITING, AND MLV INFECTION INHIBITION.
RX   PubMed=12809610; DOI=10.1016/S0092-8674(03)00423-9;
RA   Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M.,
RA   Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., Malim M.H.;
RT   "DNA deamination mediates innate immunity to retroviral infection.";
RL   Cell 113:803-809(2003).
RN   [13]
RP   CATALYTIC ACTIVITY, FUNCTION IN DNA C TO U EDITING, AND MUTAGENESIS OF
RP   HIS-81; CYS-97; CYS-100; HIS-257; CYS-288 AND CYS-291.
RX   PubMed=12808465; DOI=10.1038/nature01707;
RA   Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., Gao L.;
RT   "The cytidine deaminase CEM15 induces hypermutation in newly
RT   synthesized HIV-1 DNA.";
RL   Nature 424:94-98(2003).
RN   [14]
RP   FUNCTION IN DNA C TO U EDITING, AND INTERACTION WITH VIF.
RX   PubMed=12859895; DOI=10.1016/S0092-8674(03)00515-4;
RA   Mariani R., Chen D., Schroefelbauer B., Navarro F., Koenig R.,
RA   Bollman B., Muenk C., Nymark-McMahon H., Landau N.R.;
RT   "Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.";
RL   Cell 114:21-31(2003).
RN   [15]
RP   FUNCTION IN DNA C TO U EDITING, INFECTION REGULATION OF HIV-1, AND
RP   MUTAGENESIS OF GLU-67; CYS-100; GLU-259 AND CYS-291.
RC   TISSUE=T-cell lymphoma;
RX   PubMed=12970355; DOI=10.1074/jbc.C300376200;
RA   Shindo K., Takaori-Kondo A., Kobayashi M., Abudu A., Fukunaga K.,
RA   Uchiyama T.;
RT   "The enzymatic activity of CEM15/Apobec-3G is essential for the
RT   regulation of the infectivity of HIV-1 virion but not a sole
RT   determinant of its antiviral activity.";
RL   J. Biol. Chem. 278:44412-44416(2003).
RN   [16]
RP   INTERACTION WITH VIF, PROTEASOME MEDIATED DEGRADATION, AND TRANSLATION
RP   INHIBITION.
RX   PubMed=14527406; DOI=10.1016/S1097-2765(03)00353-8;
RA   Stopak K., de Noronha C., Yonemoto W., Greene W.C.;
RT   "HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both
RT   its translation and intracellular stability.";
RL   Mol. Cell 12:591-601(2003).
RN   [17]
RP   INTERACTION WITH VIF, AND UBIQUITINATION.
RX   PubMed=14528301; DOI=10.1038/nm946;
RA   Marin M., Rose K.M., Kozak S.L., Kabat D.;
RT   "HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its
RT   degradation.";
RL   Nat. Med. 9:1398-1403(2003).
RN   [18]
RP   FUNCTION IN DNA C TO U EDITING, AND UBIQUITINATION.
RX   PubMed=14528300; DOI=10.1038/nm945;
RA   Sheehy A.M., Gaddis N.C., Malim M.H.;
RT   "The antiretroviral enzyme APOBEC3G is degraded by the proteasome in
RT   response to HIV-1 Vif.";
RL   Nat. Med. 9:1404-1407(2003).
RN   [19]
RP   REVIEW ON APOBEC FAMILY.
RX   PubMed=12683974; DOI=10.1016/S0168-9525(03)00054-4;
RA   Wedekind J.E., Dance G.S.C., Sowden M.P., Smith H.C.;
RT   "Messenger RNA editing in mammals: new members of the APOBEC family
RT   seeking roles in the family business.";
RL   Trends Genet. 19:207-216(2003).
RN   [20]
RP   REVIEW.
RX   PubMed=14557052; DOI=10.1016/j.molmed.2003.08.008;
RA   Vartanian J.P., Sommer P., Wain-Hobson S.;
RT   "Death and the retrovirus.";
RL   Trends Mol. Med. 9:409-413(2003).
RN   [21]
RP   REVIEW.
RX   PubMed=14565218; DOI=10.1016/j.ymthe.2003.08.010;
RA   Cullen B.R.;
RT   "HIV-1 Vif: counteracting innate antiretroviral defenses.";
RL   Mol. Ther. 8:525-527(2003).
RN   [22]
RP   MUTAGENESIS OF ASP-128.
RX   PubMed=15054139; DOI=10.1073/pnas.0400830101;
RA   Xu H., Svarovskaia E.S., Barr R., Zhang Y., Khan M.A., Strebel K.,
RA   Pathak V.K.;
RT   "A single amino acid substitution in human APOBEC3G antiretroviral
RT   enzyme confers resistance to HIV-1 virion infectivity factor-induced
RT   depletion.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:5652-5657(2004).
RN   [23]
RP   FUNCTION IN HBV INHIBITION.
RX   PubMed=15031497; DOI=10.1126/science.1092066;
RA   Turelli P., Mangeat B., Jost S., Vianin S., Trono D.;
RT   "Inhibition of hepatitis B virus replication by APOBEC3G.";
RL   Science 303:1829-1829(2004).
RN   [24]
RP   FUNCTION IN RETROTRANSPOSITION, AND SUBCELLULAR LOCATION.
RX   PubMed=16527742; DOI=10.1016/j.cub.2006.01.031;
RA   Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I.,
RA   Landau N.R., Weitzman M.D.;
RT   "APOBEC3A is a potent inhibitor of adeno-associated virus and
RT   retrotransposons.";
RL   Curr. Biol. 16:480-485(2006).
RN   [25]
RP   DOMAIN CMP/DCMP DEAMINASE ZINC-BINDING, SUBUNIT, AND MUTAGENESIS OF
RP   GLU-67 AND GLU-259.
RX   PubMed=17020885; DOI=10.1074/jbc.M604980200;
RA   Hakata Y., Landau N.R.;
RT   "Reversed functional organization of mouse and human APOBEC3 cytidine
RT   deaminase domains.";
RL   J. Biol. Chem. 281:36624-36631(2006).
RN   [26]
RP   FUNCTION IN SFV RESTRICTION.
RX   PubMed=16378963; DOI=10.1128/JVI.80.2.605-614.2006;
RA   Delebecque F., Suspene R., Calattini S., Casartelli N., Saib A.,
RA   Froment A., Wain-Hobson S., Gessain A., Vartanian J.P., Schwartz O.;
RT   "Restriction of foamy viruses by APOBEC cytidine deaminases.";
RL   J. Virol. 80:605-614(2006).
RN   [27]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH APOBEC3F; AGO2; EIF4E;
RP   EIF4ENIF1; DCP2 AND DDX6.
RX   PubMed=16699599; DOI=10.1371/journal.ppat.0020041;
RA   Wichroski M.J., Robb G.B., Rana T.M.;
RT   "Human retroviral host restriction factors APOBEC3G and APOBEC3F
RT   localize to mRNA processing bodies.";
RL   PLoS Pathog. 2:E41-E41(2006).
RN   [28]
RP   REVIEW.
RX   PubMed=18304004; DOI=10.1146/annurev.immunol.26.021607.090350;
RA   Chiu Y.L., Greene W.C.;
RT   "The APOBEC3 cytidine deaminases: an innate defensive network opposing
RT   exogenous retroviruses and endogenous retroelements.";
RL   Annu. Rev. Immunol. 26:317-353(2008).
RN   [29]
RP   REVIEW ON FUNCTION IN HBV RESTRICTION.
RX   PubMed=18448976; DOI=10.1097/QCO.0b013e3282fe1bb2;
RA   Bonvin M., Greeve J.;
RT   "Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine
RT   deaminases as effectors in innate immunity against the hepatitis B
RT   virus.";
RL   Curr. Opin. Infect. Dis. 21:298-303(2008).
RN   [30]
RP   SUBUNIT.
RX   PubMed=18842592; DOI=10.1074/jbc.M803726200;
RA   Bennett R.P., Salter J.D., Liu X., Wedekind J.E., Smith H.C.;
RT   "APOBEC3G subunits self-associate via the C-terminal deaminase
RT   domain.";
RL   J. Biol. Chem. 283:33329-33336(2008).
RN   [31]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18667511; DOI=10.1128/JVI.02471-07;
RA   Stenglein M.D., Matsuo H., Harris R.S.;
RT   "Two regions within the amino-terminal half of APOBEC3G cooperate to
RT   determine cytoplasmic localization.";
RL   J. Virol. 82:9591-9599(2008).
RN   [32]
RP   PHOSPHORYLATION AT THR-32, AND INTERACTION WITH PRKACA.
RX   PubMed=18836454; DOI=10.1038/nsmb.1497;
RA   Shirakawa K., Takaori-Kondo A., Yokoyama M., Izumi T., Matsui M.,
RA   Io K., Sato T., Sato H., Uchiyama T.;
RT   "Phosphorylation of APOBEC3G by protein kinase A regulates its
RT   interaction with HIV-1 Vif.";
RL   Nat. Struct. Mol. Biol. 15:1184-1191(2008).
RN   [33]
RP   FUNCTION IN EIAV RESTRICTION.
RX   PubMed=19458006; DOI=10.1128/JVI.00015-09;
RA   Zielonka J., Bravo I.G., Marino D., Conrad E., Perkovic M.,
RA   Battenberg M., Cichutek K., Muenk C.;
RT   "Restriction of equine infectious anemia virus by equine APOBEC3
RT   cytidine deaminases.";
RL   J. Virol. 83:7547-7559(2009).
RN   [34]
RP   REVIEW.
RX   PubMed=19008196; DOI=10.1098/rstb.2008.0193;
RA   Chiu Y.L., Greene W.C.;
RT   "APOBEC3G: an intracellular centurion.";
RL   Philos. Trans. R. Soc. Lond., B, Biol. Sci. 364:689-703(2009).
RN   [35]
RP   FUNCTION IN HIV-1 RESTRICTION.
RX   PubMed=20219927; DOI=10.1128/JVI.02358-09;
RA   Mbisa J.L., Bu W., Pathak V.K.;
RT   "APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different
RT   mechanisms.";
RL   J. Virol. 84:5250-5259(2010).
RN   [36]
RP   FUNCTION IN XMRV RESTRICTION.
RX   PubMed=20335265; DOI=10.1128/JVI.00134-10;
RA   Paprotka T., Venkatachari N.J., Chaipan C., Burdick R.,
RA   Delviks-Frankenberry K.A., Hu W.S., Pathak V.K.;
RT   "Inhibition of xenotropic murine leukemia virus-related virus by
RT   APOBEC3 proteins and antiviral drugs.";
RL   J. Virol. 84:5719-5729(2010).
RN   [37]
RP   TISSUE SPECIFICITY.
RX   PubMed=20308164; DOI=10.1093/nar/gkq174;
RA   Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L.,
RA   Harris R.S.;
RT   "Quantitative profiling of the full APOBEC3 mRNA repertoire in
RT   lymphocytes and tissues: implications for HIV-1 restriction.";
RL   Nucleic Acids Res. 38:4274-4284(2010).
RN   [38]
RP   INTERACTION WITH HEPATITIS B VIRUS CAPSID PROTEIN.
RX   PubMed=20510315; DOI=10.1016/j.virusres.2010.05.009;
RA   Zhao D., Wang X., Lou G., Peng G., Li J., Zhu H., Chen F., Li S.,
RA   Liu D., Chen Z., Yang Z.;
RT   "APOBEC3G directly binds Hepatitis B virus core protein in cell and
RT   cell free systems.";
RL   Virus Res. 151:213-219(2010).
RN   [39]
RP   PHOSPHORYLATION AT THR-32 AND THR-218, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF THR-218.
RX   PubMed=21659520; DOI=10.1074/jbc.M111.235721;
RA   Demorest Z.L., Li M., Harris R.S.;
RT   "Phosphorylation directly regulates the intrinsic DNA cytidine
RT   deaminase activity of activation-induced deaminase and APOBEC3G
RT   protein.";
RL   J. Biol. Chem. 286:26568-26575(2011).
RN   [40]
RP   FUNCTION IN HOST DEFENSE, AND MUTAGENESIS OF GLU-217 AND PRO-247.
RX   PubMed=21123384; DOI=10.1128/JVI.01651-10;
RA   Bulliard Y., Narvaiza I., Bertero A., Peddi S., Roehrig U.F.,
RA   Ortiz M., Zoete V., Castro-Diaz N., Turelli P., Telenti A.,
RA   Michielin O., Weitzman M.D., Trono D.;
RT   "Structure-function analyses point to a polynucleotide-accommodating
RT   groove essential for APOBEC3A restriction activities.";
RL   J. Virol. 85:1765-1776(2011).
RN   [41]
RP   FUNCTION IN HIV-1 RESTRICTION, SUBCELLULAR LOCATION, AND ENZYME
RP   REGULATION.
RX   PubMed=21835787; DOI=10.1128/JVI.05238-11;
RA   Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L.,
RA   Brown W.L., Harris R.S.;
RT   "Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H
RT   demonstrate a conserved capacity to restrict Vif-deficient HIV-1.";
RL   J. Virol. 85:11220-11234(2011).
RN   [42]
RP   REVIEW.
RX   PubMed=21239176; DOI=10.1016/j.tibs.2010.12.003;
RA   Smith H.C.;
RT   "APOBEC3G: a double agent in defense.";
RL   Trends Biochem. Sci. 36:239-244(2011).
RN   [43]
RP   DOMAIN CMP/DCMP DEAMINASE ZINC-BINDING.
RX   PubMed=21489586; DOI=10.1016/j.virol.2011.03.014;
RA   Li X., Ma J., Zhang Q., Zhou J., Yin X., Zhai C., You X., Yu L.,
RA   Guo F., Zhao L., Li Z., Zeng Y., Cen S.;
RT   "Functional analysis of the two cytidine deaminase domains in
RT   APOBEC3G.";
RL   Virology 414:130-136(2011).
RN   [44]
RP   REVIEW.
RX   PubMed=22787460; DOI=10.3389/fmicb.2012.00250;
RA   Imahashi M., Nakashima M., Iwatani Y.;
RT   "Antiviral mechanism and biochemical basis of the human APOBEC3
RT   family.";
RL   Front. Microbiol. 3:250-250(2012).
RN   [45]
RP   REVIEW.
RX   PubMed=22912627; DOI=10.3389/fmicb.2012.00275;
RA   Arias J.F., Koyama T., Kinomoto M., Tokunaga K.;
RT   "Retroelements versus APOBEC3 family members: No great escape from the
RT   magnificent seven.";
RL   Front. Microbiol. 3:275-275(2012).
RN   [46]
RP   FUNCTION, AND INTERACTION WITH MOV10.
RX   PubMed=22791714; DOI=10.1074/jbc.M112.354001;
RA   Liu C., Zhang X., Huang F., Yang B., Li J., Liu B., Luo H., Zhang P.,
RA   Zhang H.;
RT   "APOBEC3G inhibits microRNA-mediated repression of translation by
RT   interfering with the interaction between Argonaute-2 and MOV10.";
RL   J. Biol. Chem. 287:29373-29383(2012).
RN   [47]
RP   INTERACTION WITH HIV-1 REVERSE TRANSCRIPTASE/RIBONUCLEASE H.
RX   PubMed=22301159; DOI=10.1128/JVI.06594-11;
RA   Wang X., Ao Z., Chen L., Kobinger G., Peng J., Yao X.;
RT   "The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse
RT   transcriptase and inhibits its function during viral replication.";
RL   J. Virol. 86:3777-3786(2012).
RN   [48]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AGO1; AGO2 AND
RP   AGO3.
RX   PubMed=22915799; DOI=10.1128/JVI.00595-12;
RA   Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H.;
RT   "HIV-1 replication and APOBEC3 antiviral activity are not regulated by
RT   P bodies.";
RL   J. Virol. 86:11712-11724(2012).
RN   [49]
RP   FUNCTION IN HIV-1 RESTRICTION.
RX   PubMed=22807680; DOI=10.1371/journal.ppat.1002800;
RA   Refsland E.W., Hultquist J.F., Harris R.S.;
RT   "Endogenous origins of HIV-1 G-to-A hypermutation and restriction in
RT   the nonpermissive T cell line CEM2n.";
RL   PLoS Pathog. 8:E1002800-E1002800(2012).
RN   [50]
RP   REVIEW.
RX   PubMed=22546055; DOI=10.1186/1742-4690-9-35;
RA   Monajemi M., Woodworth C.F., Benkaroun J., Grant M., Larijani M.;
RT   "Emerging complexities of APOBEC3G action on immunity and viral
RT   fitness during HIV infection and treatment.";
RL   Retrovirology 9:35-35(2012).
RN   [51]
RP   REVIEW.
RX   PubMed=22001110; DOI=10.1016/j.semcdb.2011.10.004;
RA   Smith H.C., Bennett R.P., Kizilyer A., McDougall W.M., Prohaska K.M.;
RT   "Functions and regulation of the APOBEC family of proteins.";
RL   Semin. Cell Dev. Biol. 23:258-268(2012).
RN   [52]
RP   FUNCTION IN HIV-1 RESTRICTION.
RX   PubMed=23097438; DOI=10.1128/JVI.00676-12;
RA   Chaipan C., Smith J.L., Hu W.S., Pathak V.K.;
RT   "APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and
RT   APOBEC3DE in human primary CD4+ t cells and macrophages.";
RL   J. Virol. 87:444-453(2013).
RN   [53]
RP   FUNCTION IN HIV-1 RESTRICTION.
RX   PubMed=23152537; DOI=10.1128/JVI.02587-12;
RA   Gillick K., Pollpeter D., Phalora P., Kim E.Y., Wolinsky S.M.,
RA   Malim M.H.;
RT   "The suppression of HIV-1 infection by APOBEC3 proteins in primary
RT   human CD4+ T cells is associated with the inhibition of processive
RT   reverse transcription as well as excessive cytidine deamination.";
RL   J. Virol. 87:1508-1517(2013).
RN   [54]
RP   STRUCTURE BY NMR OF 198-384 IN COMPLEX WITH ZINC, CATALYTIC ACTIVITY,
RP   FUNCTION, AND MUTAGENESIS OF ARG-213; ARG-215; GLU-259; TRP-285;
RP   ARG-313 AND ARG-320.
RX   PubMed=18288108; DOI=10.1038/nature06638;
RA   Chen K.M., Harjes E., Gross P.J., Fahmy A., Lu Y., Shindo K.,
RA   Harris R.S., Matsuo H.;
RT   "Structure of the DNA deaminase domain of the HIV-1 restriction factor
RT   APOBEC3G.";
RL   Nature 452:116-119(2008).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 197-380 IN COMPLEX WITH
RP   ZINC, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ARG-213; ARG-215;
RP   ASN-244; TRP-285 AND TYR-315.
RX   PubMed=18849968; DOI=10.1038/nature07357;
RA   Holden L.G., Prochnow C., Chang Y.P., Bransteitter R., Chelico L.,
RA   Sen U., Stevens R.C., Goodman M.F., Chen X.S.;
RT   "Crystal structure of the anti-viral APOBEC3G catalytic domain and
RT   functional implications.";
RL   Nature 456:121-124(2008).
RN   [56]
RP   STRUCTURE BY NMR OF 193-384 IN COMPLEX WITH ZINC, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=19153609; DOI=10.1038/emboj.2008.290;
RA   Furukawa A., Nagata T., Matsugami A., Habu Y., Sugiyama R.,
RA   Hayashi F., Kobayashi N., Yokoyama S., Takaku H., Katahira M.;
RT   "Structure, interaction and real-time monitoring of the enzymatic
RT   reaction of wild-type APOBEC3G.";
RL   EMBO J. 28:440-451(2009).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (1.38 ANGSTROMS) OF 191-380.
RX   PubMed=22181350; DOI=10.1021/cb200440y;
RA   Li M., Shandilya S.M., Carpenter M.A., Rathore A., Brown W.L.,
RA   Perkins A.L., Harki D.A., Solberg J., Hook D.J., Pandey K.K.,
RA   Parniak M.A., Johnson J.R., Krogan N.J., Somasundaran M., Ali A.,
RA   Schiffer C.A., Harris R.S.;
RT   "First-in-class small molecule inhibitors of the single-strand DNA
RT   cytosine deaminase APOBEC3G.";
RL   ACS Chem. Biol. 7:506-517(2012).
CC   -!- FUNCTION: DNA deaminase (cytidine deaminase) which acts as an
CC       inhibitor of retrovirus replication and retrotransposon mobility
CC       via deaminase-dependent and -independent mechanisms. Exhibits
CC       potent antiviral activity against vif-deficient HIV-1. After the
CC       penetration of retroviral nucleocapsids into target cells of
CC       infection and the initiation of reverse transcription, it can
CC       induce the conversion of cytosine to uracil in the minus-sense
CC       single-strand viral DNA, leading to G-to-A hypermutations in the
CC       subsequent plus-strand viral DNA. The resultant detrimental levels
CC       of mutations in the proviral genome, along with a deamination-
CC       independent mechanism that works prior to the proviral
CC       integration, together exert efficient antiretroviral effects in
CC       infected target cells. Selectively targets single-stranded DNA and
CC       does not deaminate double-stranded DNA or single-or double-
CC       stranded RNA. Exhibits antiviral activity also against simian
CC       immunodeficiency viruses (SIVs), hepatitis B virus (HBV), equine
CC       infectious anemia virus (EIAV), xenotropic MuLV-related virus
CC       (XMRV) and simian foamy virus (SFV). May inhibit the mobility of
CC       LTR and non-LTR retrotransposons.
CC   -!- CATALYTIC ACTIVITY: Deoxycytidine + H(2)O = deoxyuridine + NH(3).
CC   -!- COFACTOR: Zinc.
CC   -!- ENZYME REGULATION: Assembly into ribonucleoprotein complexes of
CC       high-molecular-mass (HMM) inhibits its enzymatic activity.
CC       Antiviral activity is neutralized by the HIV-1 virion infectivity
CC       factor (VIF), that prevents its incorporation into progeny HIV-1
CC       virions by both inhibiting its translation and/or by inducing its
CC       ubiquitination and subsequent degradation by the 26S proteasome.
CC       Can also be neutralized by simian immunodeficiency virus sooty
CC       mangabey monkey virus (SIV-sm) and chimpanzee immunodeficiency
CC       virus (SIV-cpz) VIF.
CC   -!- SUBUNIT: Homodimer. Homooligomer. Can bind RNA to form
CC       ribonucleoprotein complexes of high-molecular-mass (HMM) or low-
CC       molecular-mass (LMM). HMM is inactive and heterogeneous in protein
CC       composition because of binding nonselectively to cellular RNAs,
CC       which in turn are associated with variety of cellular proteins.
CC       The LMM form which is enzymatically active has few or no RNAs
CC       associated. Its ability to form homooligomer is distinct from its
CC       ability to assemble into HMM. Interacts with APOBEC3B, APOBEC3F,
CC       MOV10, AGO2, EIF4E, EIF4ENIF1, DCP2 and DDX6 in an RNA-dependent
CC       manner. Interacts with AGO1, AGO3 and PKA/PRKACA. Interacts with
CC       HIV-1 VIF and reverse transcriptase/ribonuclease H. Interacts with
CC       hepatitis B virus capsid protein.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, P-body.
CC       Note=Mainly cytoplasmic. Small amount are found in the nucleus.
CC       During HIV-1 infection, virion-encapsidated in absence of HIV-1
CC       VIF.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9HC16-1; Sequence=Displayed;
CC       Name=3;
CC         IsoId=Q9HC16-3; Sequence=VSP_009588, VSP_009589;
CC         Note=May be due to a competing donor splice site;
CC   -!- TISSUE SPECIFICITY: Expressed in spleen, testes, ovary and
CC       peripheral blood leukocytes and CD4+ lymphocytes. Also expressed
CC       in non-permissive peripheral blood mononuclear cells, and several
CC       tumor cell lines; no expression detected in permissive lymphoid
CC       and non-lymphoid cell lines. Exists only in the LMM form in
CC       peripheral blood-derived resting CD4 T-cells and monocytes, both
CC       of which are refractory to HIV-1 infection. LMM is converted to a
CC       HMM complex when resting CD4 T-cells are activated or when
CC       monocytes are induced to differentiate into macrophages. This
CC       change correlates with increased susceptibility of these cells to
CC       HIV-1 infection.
CC   -!- INDUCTION: Up-regulated by IFN-alpha.
CC   -!- DOMAIN: The CMP/dCMP deaminase zinc-binding 1 domain mediates RNA
CC       binding, RNA-dependent oligomerization and virion incorporation
CC       whereas the CMP/dCMP deaminase zinc-binding 2 domain confers
CC       deoxycytidine deaminase activity and substrate sequence
CC       specificity (PubMed:17020885).
CC   -!- PTM: Ubiquitinated in the presence of HIV-1 VIF. Association with
CC       VIF targets the protein for proteolysis by the ubiquitin-dependent
CC       proteasome pathway.
CC   -!- PTM: Phosphorylation at Thr-32 reduces its binding to HIV-1 VIF
CC       and subsequent ubiquitination and degradation thus promoting its
CC       antiviral activity.
CC   -!- MISCELLANEOUS: Accumulation of APOBEC3G induced non-lethal
CC       hypermutation could contribute to the genetic variation of primate
CC       lentiviral populations.
CC   -!- MISCELLANEOUS: It is one of seven related genes or pseudogenes
CC       found in a cluster, thought to result from gene duplication, on
CC       chromosome 22.
CC   -!- SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase
CC       family.
CC   -!- SIMILARITY: Contains 2 CMP/dCMP deaminase zinc-binding domains.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAB45274.1; Type=Erroneous gene model prediction;
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/apobec3g/";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Protein wars - Issue 45
CC       of April 2004;
CC       URL="http://web.expasy.org/spotlight/back_issues/045";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK022802; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK315650; BAG38016.1; -; mRNA.
DR   EMBL; AF182420; AAG14956.1; -; mRNA.
DR   EMBL; CR456472; CAG30358.1; -; mRNA.
DR   EMBL; DQ147772; AAZ38722.1; -; Genomic_DNA.
DR   EMBL; AL022318; CAB45274.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL078641; CAI21556.1; -; Genomic_DNA.
DR   EMBL; AL022318; CAI21556.1; JOINED; Genomic_DNA.
DR   EMBL; AL022318; CAI17900.1; -; Genomic_DNA.
DR   EMBL; AL078641; CAI17900.1; JOINED; Genomic_DNA.
DR   EMBL; CH471095; EAW60292.1; -; Genomic_DNA.
DR   EMBL; BC024268; AAH24268.1; -; mRNA.
DR   EMBL; BC061914; AAH61914.1; -; mRNA.
DR   CCDS; CCDS13984.1; -. [Q9HC16-1]
DR   RefSeq; NP_068594.1; NM_021822.3. [Q9HC16-1]
DR   UniGene; Hs.660143; -.
DR   PDB; 2JYW; NMR; -; A=198-384.
DR   PDB; 2KBO; NMR; -; A=193-384.
DR   PDB; 2KEM; NMR; -; A=191-384.
DR   PDB; 3E1U; X-ray; 2.30 A; A=197-380.
DR   PDB; 3IQS; X-ray; 2.30 A; A=197-380.
DR   PDB; 3IR2; X-ray; 2.25 A; A/B=191-384.
DR   PDB; 3V4J; X-ray; 2.04 A; A/B=191-384.
DR   PDB; 3V4K; X-ray; 1.38 A; A/B=191-380.
DR   PDBsum; 2JYW; -.
DR   PDBsum; 2KBO; -.
DR   PDBsum; 2KEM; -.
DR   PDBsum; 3E1U; -.
DR   PDBsum; 3IQS; -.
DR   PDBsum; 3IR2; -.
DR   PDBsum; 3V4J; -.
DR   PDBsum; 3V4K; -.
DR   ProteinModelPortal; Q9HC16; -.
DR   SMR; Q9HC16; 16-193, 197-380.
DR   BioGrid; 121920; 11.
DR   BioGrid; 128319; 5.
DR   DIP; DIP-37519N; -.
DR   IntAct; Q9HC16; 2.
DR   MINT; MINT-1428867; -.
DR   STRING; 9606.ENSP00000385057; -.
DR   BindingDB; Q9HC16; -.
DR   ChEMBL; CHEMBL1741217; -.
DR   PhosphoSite; Q9HC16; -.
DR   DMDM; 44887683; -.
DR   MaxQB; Q9HC16; -.
DR   PaxDb; Q9HC16; -.
DR   PRIDE; Q9HC16; -.
DR   DNASU; 200316; -.
DR   DNASU; 60489; -.
DR   Ensembl; ENST00000407997; ENSP00000385057; ENSG00000239713. [Q9HC16-1]
DR   Ensembl; ENST00000452957; ENSP00000413376; ENSG00000239713. [Q9HC16-1]
DR   GeneID; 60489; -.
DR   KEGG; hsa:60489; -.
DR   UCSC; uc003awx.3; human. [Q9HC16-1]
DR   CTD; 60489; -.
DR   GeneCards; GC22P039437; -.
DR   HGNC; HGNC:17357; APOBEC3G.
DR   HPA; HPA001812; -.
DR   MIM; 607113; gene.
DR   neXtProt; NX_Q9HC16; -.
DR   PharmGKB; PA24897; -.
DR   eggNOG; NOG135704; -.
DR   HOVERGEN; HBG050434; -.
DR   InParanoid; Q9HC16; -.
DR   KO; K01500; -.
DR   OMA; WDPDYQE; -.
DR   OrthoDB; EOG75QR3Z; -.
DR   PhylomeDB; Q9HC16; -.
DR   TreeFam; TF331356; -.
DR   BRENDA; 3.5.4.5; 2681.
DR   Reactome; REACT_116125; Disease.
DR   ChiTaRS; APOBEC3G; human.
DR   EvolutionaryTrace; Q9HC16; -.
DR   GeneWiki; APOBEC3G; -.
DR   GenomeRNAi; 60489; -.
DR   NextBio; 65375; -.
DR   PRO; PR:Q9HC16; -.
DR   ArrayExpress; Q9HC16; -.
DR   Bgee; Q9HC16; -.
DR   CleanEx; HS_APOBEC3G; -.
DR   Genevestigator; Q9HC16; -.
DR   GO; GO:0030895; C:apolipoprotein B mRNA editing enzyme complex; TAS:HGNC.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0000932; C:cytoplasmic mRNA processing body; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IDA:UniProtKB.
DR   GO; GO:0004126; F:cytidine deaminase activity; TAS:HGNC.
DR   GO; GO:0047844; F:deoxycytidine deaminase activity; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; NAS:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0016553; P:base conversion or substitution editing; TAS:HGNC.
DR   GO; GO:0009972; P:cytidine deamination; IDA:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0070383; P:DNA cytosine deamination; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IDA:HGNC.
DR   GO; GO:0045869; P:negative regulation of single stranded viral RNA replication via double stranded DNA intermediate; IDA:UniProtKB.
DR   GO; GO:0010529; P:negative regulation of transposition; IDA:UniProtKB.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB.
DR   GO; GO:0048525; P:negative regulation of viral process; IDA:HGNC.
DR   GO; GO:0002230; P:positive regulation of defense response to virus by host; IDA:HGNC.
DR   GO; GO:0016032; P:viral process; TAS:Reactome.
DR   InterPro; IPR016192; APOBEC/CMP_deaminase_Zn-bd.
DR   InterPro; IPR013158; APOBEC_N.
DR   InterPro; IPR016193; Cytidine_deaminase-like.
DR   Pfam; PF08210; APOBEC_N; 2.
DR   SUPFAM; SSF53927; SSF53927; 1.
DR   PROSITE; PS00903; CYT_DCMP_DEAMINASES; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Antiviral defense;
KW   Complete proteome; Cytoplasm; Host-virus interaction; Hydrolase;
KW   Immunity; Innate immunity; Metal-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Ubl conjugation; Zinc.
FT   CHAIN         1    384       DNA dC->dU-editing enzyme APOBEC-3G.
FT                                /FTId=PRO_0000171761.
FT   DOMAIN       65    100       CMP/dCMP deaminase zinc-binding 1.
FT   DOMAIN      257    291       CMP/dCMP deaminase zinc-binding 2.
FT   REGION        1     60       Essential for cytoplasmic localization.
FT   REGION      209    336       Necessary for homooligomerization.
FT   REGION      213    215       Interaction with DNA (Probable).
FT   REGION      313    320       Interaction with DNA (Probable).
FT   ACT_SITE    259    259       Proton donor (Probable).
FT   METAL        65     65       Zinc (By similarity).
FT   METAL        97     97       Zinc (By similarity).
FT   METAL       100    100       Zinc (By similarity).
FT   METAL       257    257       Zinc; catalytic.
FT   METAL       288    288       Zinc; catalytic.
FT   METAL       291    291       Zinc; catalytic.
FT   SITE        244    244       Interaction with DNA (Probable).
FT   MOD_RES      32     32       Phosphothreonine; by PKA.
FT   MOD_RES     218    218       Phosphothreonine; by PKA and CAMK2.
FT   VAR_SEQ      58     79       VYSELKYHPEMRFFHWFSKWRK -> VPPGLQSLCRQELSQ
FT                                LGKQTTH (in isoform 3).
FT                                /FTId=VSP_009588.
FT   VAR_SEQ      80    384       Missing (in isoform 3).
FT                                /FTId=VSP_009589.
FT   VARIANT     186    186       H -> R (in dbSNP:rs8177832).
FT                                /FTId=VAR_017837.
FT   VARIANT     256    256       R -> H (in dbSNP:rs17000736).
FT                                /FTId=VAR_048723.
FT   VARIANT     275    275       Q -> E (in dbSNP:rs17496046).
FT                                /FTId=VAR_025060.
FT   MUTAGEN      67     67       E->A: Loss of cytidine deaminase activity
FT                                and significant decrease in antiviral
FT                                activity; when associated with A-259.
FT   MUTAGEN      67     67       E->A: No effect on cytidine deaminase and
FT                                antiviral activity.
FT   MUTAGEN      67     67       E->Q: Decreases cytidine deaminase
FT                                activity.
FT   MUTAGEN      81     81       H->A: Decreases cytidine deaminase
FT                                activity.
FT   MUTAGEN      85     85       E->Q: Does not decrease cytidine
FT                                deaminase activity.
FT   MUTAGEN      97     97       C->A: Decreases cytidine deaminase
FT                                activity.
FT   MUTAGEN     100    100       C->A,S: Decreases cytidine deaminase
FT                                activity.
FT   MUTAGEN     128    128       D->K: Complete loss of VIF-induced
FT                                degradation.
FT   MUTAGEN     213    213       R->A: Slightly reduces enzyme activity.
FT   MUTAGEN     213    213       R->E: Reduces enzyme activity.
FT   MUTAGEN     215    215       R->A,E: Abolishes enzyme activity.
FT   MUTAGEN     217    217       E->K: Modifies the spectrum of action
FT                                against mobile genetic elements; when
FT                                associated with K-247.
FT   MUTAGEN     218    218       T->A: Loss of phosphorylation. No effect
FT                                on cytidine deaminase activity or HIV-1
FT                                restriction activity.
FT   MUTAGEN     218    218       T->E: Phosphomimetic mutant which shows
FT                                loss of cytidine deaminase activity and
FT                                HIV-1 restriction activity.
FT   MUTAGEN     221    221       C->S: Does not decrease cytidine
FT                                deaminase activity.
FT   MUTAGEN     244    244       N->A: Abolishes enzyme activity.
FT   MUTAGEN     247    247       P->K: Modifies the spectrum of action
FT                                against mobile genetic elements; when
FT                                associated with K-217.
FT   MUTAGEN     256    256       R->E: Strongly reduces enzyme activity.
FT   MUTAGEN     257    257       H->A: Decreases cytidine deaminase
FT                                activity.
FT   MUTAGEN     259    259       E->A: Loss of cytidine deaminase activity
FT                                and significant decrease in antiviral
FT                                activity.
FT   MUTAGEN     259    259       E->A: Loss of cytidine deaminase activity
FT                                and significant decrease in antiviral
FT                                activity; when associated with A-67.
FT   MUTAGEN     259    259       E->Q: Decreases cytidine deaminase
FT                                activity and antiviral activity.
FT   MUTAGEN     285    285       W->A: Abolishes enzyme activity.
FT   MUTAGEN     288    288       C->A: Decreases cytidine deaminase
FT                                activity.
FT   MUTAGEN     291    291       C->A,S: Decreases cytidine deaminase
FT                                activity.
FT   MUTAGEN     313    313       R->A,E: Abolishes enzyme activity.
FT   MUTAGEN     315    315       Y->A: Abolishes enzyme activity.
FT   MUTAGEN     320    320       R->A: Slightly reduces enzyme activity.
FT   MUTAGEN     320    320       R->E: Reduces enzyme activity.
FT   MUTAGEN     323    323       E->Q: Does not decrease cytidine
FT                                deaminase activity.
FT   CONFLICT    162    162       S -> N (in Ref. 1; no nucleotide entry).
FT   CONFLICT    370    370       D -> Y (in Ref. 1; no nucleotide entry).
FT   STRAND      195    197
FT   HELIX       199    206
FT   STRAND      213    217
FT   STRAND      219    228
FT   STRAND      231    234
FT   HELIX       236    238
FT   STRAND      240    243
FT   STRAND      247    250
FT   HELIX       258    265
FT   HELIX       266    269
FT   STRAND      273    275
FT   STRAND      277    285
FT   HELIX       289    301
FT   STRAND      305    313
FT   STRAND      318    320
FT   HELIX       321    330
FT   STRAND      334    337
FT   HELIX       340    350
FT   HELIX       364    379
SQ   SEQUENCE   384 AA;  46408 MW;  60525DC3B7D903D6 CRC64;
     MKPHFRNTVE RMYRDTFSYN FYNRPILSRR NTVWLCYEVK TKGPSRPPLD AKIFRGQVYS
     ELKYHPEMRF FHWFSKWRKL HRDQEYEVTW YISWSPCTKC TRDMATFLAE DPKVTLTIFV
     ARLYYFWDPD YQEALRSLCQ KRDGPRATMK IMNYDEFQHC WSKFVYSQRE LFEPWNNLPK
     YYILLHIMLG EILRHSMDPP TFTFNFNNEP WVRGRHETYL CYEVERMHND TWVLLNQRRG
     FLCNQAPHKH GFLEGRHAEL CFLDVIPFWK LDLDQDYRVT CFTSWSPCFS CAQEMAKFIS
     KNKHVSLCIF TARIYDDQGR CQEGLRTLAE AGAKISIMTY SEFKHCWDTF VDHQGCPFQP
     WDGLDEHSQD LSGRLRAILQ NQEN
//
ID   ABC3H_HUMAN             Reviewed;         200 AA.
AC   Q6NTF7; B0QYP0; B0QYP1; B7TQM5; E9PF38; Q5JYL9; Q6IC87;
DT   26-JUN-2007, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 3.
DT   09-JUL-2014, entry version 83.
DE   RecName: Full=DNA dC->dU-editing enzyme APOBEC-3H;
DE            EC=3.5.4.-;
DE   AltName: Full=APOBEC-related protein 10;
DE            Short=ARP-10;
DE   AltName: Full=Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3H;
DE            Short=A3H;
GN   Name=APOBEC3H;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLU-140, AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=18945781; DOI=10.1128/JVI.01665-08;
RA   Harari A., Ooms M., Mulder L.C., Simon V.;
RT   "Polymorphisms and splice variants influence the antiretroviral
RT   activity of human APOBEC3H.";
RL   J. Virol. 83:295-303(2009).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS
RP   ASN-15 DEL; LEU-18; ARG-105; GLU-140 AND ASP-178.
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), AND VARIANT
RP   GLU-140.
RC   TISSUE=Astrocyte;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   REVIEW ON APOBEC FAMILY.
RX   PubMed=12683974; DOI=10.1016/S0168-9525(03)00054-4;
RA   Wedekind J.E., Dance G.S.C., Sowden M.P., Smith H.C.;
RT   "Messenger RNA editing in mammals: new members of the APOBEC family
RT   seeking roles in the family business.";
RL   Trends Genet. 19:207-216(2003).
RN   [6]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16571802; DOI=10.1128/JVI.80.8.3853-3862.2006;
RA   OhAinle M., Kerns J.A., Malik H.S., Emerman M.;
RT   "Adaptive evolution and antiviral activity of the conserved mammalian
RT   cytidine deaminase APOBEC3H.";
RL   J. Virol. 80:3853-3862(2006).
RN   [7]
RP   FUNCTION.
RX   PubMed=16920826; DOI=10.1128/JVI.01123-06;
RA   Dang Y., Wang X., Esselman W.J., Zheng Y.-H.;
RT   "Identification of APOBEC3DE as another antiretroviral factor from the
RT   human APOBEC family.";
RL   J. Virol. 80:10522-10533(2006).
RN   [8]
RP   REVIEW.
RX   PubMed=18304004; DOI=10.1146/annurev.immunol.26.021607.090350;
RA   Chiu Y.L., Greene W.C.;
RT   "The APOBEC3 cytidine deaminases: an innate defensive network opposing
RT   exogenous retroviruses and endogenous retroelements.";
RL   Annu. Rev. Immunol. 26:317-353(2008).
RN   [9]
RP   FUNCTION, AND CHARACTERIZATION OF VARIANTS ASN-15 DEL AND ARG-105.
RX   PubMed=18779051; DOI=10.1016/j.chom.2008.07.005;
RA   OhAinle M., Kerns J.A., Li M.M., Malik H.S., Emerman M.;
RT   "Antiretroelement activity of APOBEC3H was lost twice in recent human
RT   evolution.";
RL   Cell Host Microbe 4:249-259(2008).
RN   [10]
RP   FUNCTION IN HIV-1 RESTRICTION.
RX   PubMed=18299330; DOI=10.1074/jbc.M707586200;
RA   Dang Y., Siew L.M., Wang X., Han Y., Lampen R., Zheng Y.H.;
RT   "Human cytidine deaminase APOBEC3H restricts HIV-1 replication.";
RL   J. Biol. Chem. 283:11606-11614(2008).
RN   [11]
RP   FUNCTION, CHARACTERIZATION OF ALLELE A3H-VAR, AND MUTAGENESIS OF
RP   GLU-56.
RX   PubMed=18827027; DOI=10.1096/fj.07-088781;
RA   Tan L., Sarkis P.T., Wang T., Tian C., Yu X.F.;
RT   "Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory
RT   activity against retrotransposons and HIV-1.";
RL   FASEB J. 23:279-287(2009).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=20308164; DOI=10.1093/nar/gkq174;
RA   Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L.,
RA   Harris R.S.;
RT   "Quantitative profiling of the full APOBEC3 mRNA repertoire in
RT   lymphocytes and tissues: implications for HIV-1 restriction.";
RL   Nucleic Acids Res. 38:4274-4284(2010).
RN   [13]
RP   FUNCTION IN RETROTRANSPOSITION.
RX   PubMed=20062055; DOI=10.1038/nsmb.1744;
RA   Stenglein M.D., Burns M.B., Li M., Lengyel J., Harris R.S.;
RT   "APOBEC3 proteins mediate the clearance of foreign DNA from human
RT   cells.";
RL   Nat. Struct. Mol. Biol. 17:222-229(2010).
RN   [14]
RP   CHARACTERIZATION OF ALLELE A3H-VAR, AND SUBCELLULAR LOCATION.
RX   PubMed=21653666; DOI=10.1128/JVI.00624-11;
RA   Li M.M., Emerman M.;
RT   "Polymorphism in human APOBEC3H affects a phenotype dominant for
RT   subcellular localization and antiviral activity.";
RL   J. Virol. 85:8197-8207(2011).
RN   [15]
RP   FUNCTION IN HIV-1 RESTRICTION, SUBCELLULAR LOCATION, AND ENZYME
RP   REGULATION.
RX   PubMed=21835787; DOI=10.1128/JVI.05238-11;
RA   Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L.,
RA   Brown W.L., Harris R.S.;
RT   "Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H
RT   demonstrate a conserved capacity to restrict Vif-deficient HIV-1.";
RL   J. Virol. 85:11220-11234(2011).
RN   [16]
RP   REVIEW.
RA   Love R.;
RT   "Cytosine deaminases APOBEC3A, APOBEC3C, and APOBEC3H: Current
RT   understanding of their functional roles.";
RL   Student Perspec. Contemp. Virol. 0:0-0(2011).
RN   [17]
RP   REVIEW.
RX   PubMed=22912627; DOI=10.3389/fmicb.2012.00275;
RA   Arias J.F., Koyama T., Kinomoto M., Tokunaga K.;
RT   "Retroelements versus APOBEC3 family members: No great escape from the
RT   magnificent seven.";
RL   Front. Microbiol. 3:275-275(2012).
RN   [18]
RP   FUNCTION IN HTLV-1 RESTRICTION.
RX   PubMed=22457529; DOI=10.1128/JVI.06570-11;
RA   Ooms M., Krikoni A., Kress A.K., Simon V., Muenk C.;
RT   "APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-
RT   lymphotropic virus type 1.";
RL   J. Virol. 86:6097-6108(2012).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AGO1; AGO2 AND
RP   AGO3.
RX   PubMed=22915799; DOI=10.1128/JVI.00595-12;
RA   Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H.;
RT   "HIV-1 replication and APOBEC3 antiviral activity are not regulated by
RT   P bodies.";
RL   J. Virol. 86:11712-11724(2012).
RN   [20]
RP   REVIEW.
RX   PubMed=22001110; DOI=10.1016/j.semcdb.2011.10.004;
RA   Smith H.C., Bennett R.P., Kizilyer A., McDougall W.M., Prohaska K.M.;
RT   "Functions and regulation of the APOBEC family of proteins.";
RL   Semin. Cell Dev. Biol. 23:258-268(2012).
RN   [21]
RP   FUNCTION IN HIV-1 RESTRICTION.
RX   PubMed=23097438; DOI=10.1128/JVI.00676-12;
RA   Chaipan C., Smith J.L., Hu W.S., Pathak V.K.;
RT   "APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and
RT   APOBEC3DE in human primary CD4+ t cells and macrophages.";
RL   J. Virol. 87:444-453(2013).
CC   -!- FUNCTION: DNA deaminase (cytidine deaminase) which acts as an
CC       inhibitor of retrovirus replication and retrotransposon mobility
CC       via deaminase-dependent and -independent mechanisms. The A3H-
CC       var/haplotype 2 exhibits antiviral activity against vif-deficient
CC       HIV-1. After the penetration of retroviral nucleocapsids into
CC       target cells of infection and the initiation of reverse
CC       transcription, it can induce the conversion of cytosine to uracil
CC       in the minus-sense single-strand viral DNA, leading to G-to-A
CC       hypermutations in the subsequent plus-strand viral DNA. The
CC       resultant detrimental levels of mutations in the proviral genome,
CC       along with a deamination-independent mechanism that works prior to
CC       the proviral integration, together exert efficient antiretroviral
CC       effects in infected target cells. Selectively targets single-
CC       stranded DNA and does not deaminate double-stranded DNA or single-
CC       or double-stranded RNA. Exhibits antiviral activity also against
CC       T-cell leukemia virus type 1 (HTLV-1) and may inhibit the mobility
CC       of LTR and non-LTR retrotransposons.
CC   -!- CATALYTIC ACTIVITY: Cytidine + H(2)O = uridine + NH(3).
CC   -!- COFACTOR: Zinc (By similarity).
CC   -!- ENZYME REGULATION: Antiviral activity is neutralized by the HIV-1
CC       virion infectivity factor (VIF), that prevents its incorporation
CC       into progeny virions by both inhibiting its translation and/or by
CC       inducing its ubiquitination and subsequent degradation by the 26S
CC       proteasome.
CC   -!- SUBUNIT: Interacts with AGO1, AGO2 and AGO3.
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Cytoplasm, P-body.
CC       Note=Haplotype 1 is distributed in both the nucleus and cytoplasm,
CC       whereas haplotype 2 is predominantly cytoplasmic.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q6NTF7-1; Sequence=Displayed;
CC         Note=No experimental confirmation available;
CC       Name=2;
CC         IsoId=Q6NTF7-2; Sequence=VSP_035034;
CC       Name=3;
CC         IsoId=Q6NTF7-3; Sequence=VSP_039975;
CC       Name=4;
CC         IsoId=Q6NTF7-4; Sequence=VSP_047044;
CC         Note=Gene prediction based on EST data;
CC   -!- TISSUE SPECIFICITY: Expressed in lymphoid organs. Also detected in
CC       non-lymphoid tissues including lung, testis, ovary, fetal liver
CC       and skin.
CC   -!- POLYMORPHISM: There are at least 4 different haplotypes in the
CC       human population. The allele A3H-var/haplotype 2 encodes a more
CC       stable protein which is able to block HIV-1 replication. The
CC       displayed allele (haplotype 1) is unstable and inefficient to
CC       block HIV-1 replication.
CC   -!- MISCELLANEOUS: APOBEC3H from old world monkeys has retained its
CC       antiviral activity, while it is lost in other primates.
CC   -!- MISCELLANEOUS: It is one of seven related genes or pseudogenes
CC       found in a cluster, thought to result from gene duplication, on
CC       chromosome 22.
CC   -!- SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase
CC       family.
CC   -!- SIMILARITY: Contains 1 CMP/dCMP deaminase zinc-binding domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; FJ376613; ACK77774.1; -; mRNA.
DR   EMBL; CR456481; CAG30367.3; -; mRNA.
DR   EMBL; AL031846; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC069023; AAH69023.1; -; mRNA.
DR   EMBL; BQ052182; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS13985.1; -. [Q6NTF7-3]
DR   CCDS; CCDS54530.1; -. [Q6NTF7-1]
DR   CCDS; CCDS54531.1; -. [Q6NTF7-2]
DR   CCDS; CCDS54532.1; -. [Q6NTF7-4]
DR   RefSeq; NP_001159474.1; NM_001166002.1. [Q6NTF7-2]
DR   RefSeq; NP_001159475.1; NM_001166003.1. [Q6NTF7-1]
DR   RefSeq; NP_861438.2; NM_181773.3. [Q6NTF7-3]
DR   UniGene; Hs.440515; -.
DR   ProteinModelPortal; Q6NTF7; -.
DR   SMR; Q6NTF7; 8-177.
DR   STRING; 9606.ENSP00000344182; -.
DR   PhosphoSite; Q6NTF7; -.
DR   DMDM; 205371798; -.
DR   PaxDb; Q6NTF7; -.
DR   PRIDE; Q6NTF7; -.
DR   DNASU; 164668; -.
DR   Ensembl; ENST00000348946; ENSP00000216123; ENSG00000100298. [Q6NTF7-2]
DR   Ensembl; ENST00000401756; ENSP00000385741; ENSG00000100298. [Q6NTF7-1]
DR   Ensembl; ENST00000421988; ENSP00000393520; ENSG00000100298. [Q6NTF7-4]
DR   Ensembl; ENST00000442487; ENSP00000411754; ENSG00000100298. [Q6NTF7-3]
DR   GeneID; 164668; -.
DR   KEGG; hsa:164668; -.
DR   UCSC; uc021wpt.1; human. [Q6NTF7-1]
DR   UCSC; uc021wpu.1; human. [Q6NTF7-3]
DR   UCSC; uc021wpv.1; human. [Q6NTF7-2]
DR   CTD; 164668; -.
DR   GeneCards; GC22P039493; -.
DR   HGNC; HGNC:24100; APOBEC3H.
DR   HPA; HPA021492; -.
DR   MIM; 610976; gene.
DR   neXtProt; NX_Q6NTF7; -.
DR   PharmGKB; PA162376694; -.
DR   eggNOG; NOG135704; -.
DR   HOGENOM; HOG000033754; -.
DR   HOVERGEN; HBG050434; -.
DR   InParanoid; Q6NTF7; -.
DR   OMA; DETQCYQ; -.
DR   OrthoDB; EOG7W154V; -.
DR   PhylomeDB; Q6NTF7; -.
DR   TreeFam; TF331356; -.
DR   GeneWiki; APOBEC3H; -.
DR   GenomeRNAi; 164668; -.
DR   NextBio; 33762998; -.
DR   PRO; PR:Q6NTF7; -.
DR   ArrayExpress; Q6NTF7; -.
DR   Bgee; Q6NTF7; -.
DR   CleanEx; HS_APOBEC3H; -.
DR   Genevestigator; Q6NTF7; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0000932; C:cytoplasmic mRNA processing body; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0004126; F:cytidine deaminase activity; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0009972; P:cytidine deamination; IDA:GOC.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0070383; P:DNA cytosine deamination; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0045869; P:negative regulation of single stranded viral RNA replication via double stranded DNA intermediate; IDA:UniProtKB.
DR   GO; GO:0010529; P:negative regulation of transposition; IDA:UniProtKB.
DR   GO; GO:0048525; P:negative regulation of viral process; IMP:UniProtKB.
DR   InterPro; IPR016192; APOBEC/CMP_deaminase_Zn-bd.
DR   InterPro; IPR007904; APOBEC_C.
DR   InterPro; IPR002125; CMP_dCMP_Zn-bd.
DR   InterPro; IPR016193; Cytidine_deaminase-like.
DR   Pfam; PF05240; APOBEC_C; 1.
DR   Pfam; PF00383; dCMP_cyt_deam_1; 1.
DR   SUPFAM; SSF53927; SSF53927; 1.
DR   PROSITE; PS00903; CYT_DCMP_DEAMINASES; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Antiviral defense; Coiled coil;
KW   Complete proteome; Cytoplasm; Hydrolase; Immunity; Innate immunity;
KW   Metal-binding; Nucleus; Polymorphism; Reference proteome; Zinc.
FT   CHAIN         1    200       DNA dC->dU-editing enzyme APOBEC-3H.
FT                                /FTId=PRO_0000291663.
FT   DOMAIN       54     88       CMP/dCMP deaminase zinc-binding.
FT   COILED      160    182       Potential.
FT   ACT_SITE     56     56       Proton donor (By similarity).
FT   METAL        54     54       Zinc (By similarity).
FT   METAL        85     85       Zinc (By similarity).
FT   METAL        88     88       Zinc (By similarity).
FT   VAR_SEQ     140    200       KFADCWENFVDHEKPLSFNPYKMLEELDKNSRAIKRRLERI
FT                                KIPGVRAQGRYMDILCDAEV -> NSRGTCAGSLHGYIV
FT                                (in isoform 4).
FT                                /FTId=VSP_047044.
FT   VAR_SEQ     182    200       IPGVRAQGRYMDILCDAEV -> S (in isoform 2).
FT                                /FTId=VSP_035034.
FT   VAR_SEQ     182    200       IPGVRAQGRYMDILCDAEV -> QS (in isoform 3).
FT                                /FTId=VSP_039975.
FT   VARIANT      15     15       Missing (decreases protein stability).
FT                                /FTId=VAR_065622.
FT   VARIANT      18     18       R -> L (in dbSNP:rs139293).
FT                                /FTId=VAR_032835.
FT   VARIANT     105    105       G -> R (in allele A3H-Var; haplotype 2;
FT                                allele presenting a higher expression and
FT                                which is more effective in
FT                                retrotransposons and HIV-1 restriction;
FT                                increases protein stability and exhibits
FT                                a cytoplasmic localization;
FT                                dbSNP:rs139297).
FT                                /FTId=VAR_032836.
FT   VARIANT     121    121       K -> E (in allele A3H-Var; haplotype 2;
FT                                allele presenting a higher expression and
FT                                more effective in retrotransposons and
FT                                HIV-1 restriction; dbSNP:rs139298).
FT                                /FTId=VAR_032837.
FT   VARIANT     121    121       K -> N (in dbSNP:rs139299).
FT                                /FTId=VAR_032838.
FT   VARIANT     140    140       K -> E (in dbSNP:rs139300).
FT                                /FTId=VAR_067444.
FT   VARIANT     178    178       E -> D (in allele A3H-Var; haplotype 2;
FT                                allele presenting a higher expression and
FT                                more effective in retrotransposons and
FT                                HIV-1 restriction; dbSNP:rs139302).
FT                                /FTId=VAR_032839.
FT   MUTAGEN      56     56       E->Q: Reduces the ability to inhibit the
FT                                retrotransposition of LINE-1 elements.
FT   CONFLICT    121    121       K -> D (in Ref. 2; CAG30367).
SQ   SEQUENCE   200 AA;  23531 MW;  6F89E0138CC29386 CRC64;
     MALLTAETFR LQFNNKRRLR RPYYPRKALL CYQLTPQNGS TPTRGYFENK KKCHAEICFI
     NEIKSMGLDE TQCYQVTCYL TWSPCSSCAW ELVDFIKAHD HLNLGIFASR LYYHWCKPQQ
     KGLRLLCGSQ VPVEVMGFPK FADCWENFVD HEKPLSFNPY KMLEELDKNS RAIKRRLERI
     KIPGVRAQGR YMDILCDAEV
//
ID   ABCA1_HUMAN             Reviewed;        2261 AA.
AC   O95477; Q5VX33; Q96S56; Q96T85; Q9NQV4; Q9UN06; Q9UN07; Q9UN08;
AC   Q9UN09;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 3.
DT   09-JUL-2014, entry version 159.
DE   RecName: Full=ATP-binding cassette sub-family A member 1;
DE   AltName: Full=ATP-binding cassette transporter 1;
DE            Short=ABC-1;
DE            Short=ATP-binding cassette 1;
DE   AltName: Full=Cholesterol efflux regulatory protein;
GN   Name=ABCA1; Synonyms=ABC1, CERP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT ARG-1587.
RX   PubMed=10884428; DOI=10.1073/pnas.97.14.7987;
RA   Santamarina-Fojo S., Peterson K.M., Knapper C.L., Qiu Y.,
RA   Freeman L.A., Cheng J.-F., Osorio J., Remaley A.T., Yang X.-P.,
RA   Haudenschild C.C., Prades C., Chimini G., Blackmon E.E.,
RA   Francois T.L., Duverger N., Rubin E.M., Rosier M., Denefle P.,
RA   Fredrickson D.S., Brewer H.B. Jr.;
RT   "Complete genomic sequence of the human ABCA1 gene: analysis of the
RT   human and mouse ATP-binding cassette A promoter.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:7987-7992(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-1587.
RC   TISSUE=Skin;
RA   Schwartz K., Lawn R.M., Wade D.P.;
RT   "ABCA1 gene expression and apoA-I-mediated cholesterol efflux are
RT   regulated by LXR.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-1587.
RX   PubMed=11352567; DOI=10.1006/geno.2000.6467;
RA   Qiu Y., Cavelier L., Chiu S., Yang X., Rubin E., Cheng J.-F.;
RT   "Human and mouse ABCA1 comparative sequencing and transgenesis studies
RT   revealing novel regulatory sequences.";
RL   Genomics 73:66-76(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Tanaka A.R., Abe-Dohmae S., Arakawa R., Sadanami K., Kidera A.,
RA   Kioka N., Amachi T., Yokoyama S., Ueda K.;
RT   "A new topological model of functional human ABCA1-signal peptide
RT   cleavage and glycosylation of a large extracellular domain.";
RL   Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 21-2261, AND VARIANTS THR-1555;
RP   ARG-1587; PRO-1648 AND PRO-2168.
RX   PubMed=10092505; DOI=10.1006/bbrc.1999.0406;
RA   Langmann T., Klucken J., Reil M., Liebisch G., Luciani M.-F.,
RA   Chimini G., Kaminski W.E., Schmitz G.;
RT   "Molecular cloning of the human ATP-binding cassette transporter 1
RT   (hABC1): evidence for sterol-dependent regulation in macrophages.";
RL   Biochem. Biophys. Res. Commun. 257:29-33(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 21-2261, AND VARIANTS
RP   THR-1555; ARG-1587; PRO-1648 AND PRO-2168.
RX   PubMed=10431238; DOI=10.1038/11921;
RA   Rust S., Rosier M., Funke H., Real J., Amoura Z., Piette J.-C.,
RA   Deleuze J.-F., Brewer H.B. Jr., Duverger N., Denefle P., Assmann G.;
RT   "Tangier disease is caused by mutations in the gene encoding ATP-
RT   binding cassette transporter 1.";
RL   Nat. Genet. 22:352-355(1999).
RN   [8]
RP   PHOSPHORYLATION AT SER-1042 AND SER-2054.
RX   PubMed=12196520; DOI=10.1074/jbc.M204923200;
RA   See R.H., Caday-Malcolm R.A., Singaraja R.R., Zhou S., Silverston A.,
RA   Huber M.T., Moran J., James E.R., Janoo R., Savill J.M., Rigot V.,
RA   Zhang L.H., Wang M., Chimini G., Wellington C.L., Tafuri S.R.,
RA   Hayden M.R.;
RT   "Protein kinase A site-specific phosphorylation regulates ATP-binding
RT   cassette A1 (ABCA1)-mediated phospholipid efflux.";
RL   J. Biol. Chem. 277:41835-41842(2002).
RN   [9]
RP   REPRESSION BY ZNF202.
RX   PubMed=11279031; DOI=10.1074/jbc.M100218200;
RA   Porsch-Oezcueruemez M., Langmann T., Heimerl S., Borsukova H.,
RA   Kaminski W.E., Drobnik W., Honer C., Schumacher C., Schmitz G.;
RT   "The zinc finger protein 202 (ZNF202) is a transcriptional repressor
RT   of ATP binding cassette transporter A1 (ABCA1) and ABCG1 gene
RT   expression and a modulator of cellular lipid efflux.";
RL   J. Biol. Chem. 276:12427-12433(2001).
RN   [10]
RP   INDUCTION BY LPS.
RX   PubMed=12032171;
RA   Kaplan R., Gan X., Menke J.G., Wright S.D., Cai T.-Q.;
RT   "Bacterial lipopolysaccharide induces expression of ABCA1 but not
RT   ABCG1 via an LXR-independent pathway.";
RL   J. Lipid Res. 43:952-959(2002).
RN   [11]
RP   INTERACTION WITH MEGF10.
RX   PubMed=17205124; DOI=10.1371/journal.pone.0000120;
RA   Hamon Y., Trompier D., Ma Z., Venegas V., Pophillat M., Mignotte V.,
RA   Zhou Z., Chimini G.;
RT   "Cooperation between engulfment receptors: the case of ABCA1 and
RT   MEGF10.";
RL   PLoS ONE 1:E120-E120(2006).
RN   [12]
RP   REVIEW ON VARIANTS.
RX   PubMed=12763760; DOI=10.1161/01.ATV.0000078520.89539.77;
RA   Singaraja R.R., Brunham L.R., Visscher H., Kastelein J.J.P.,
RA   Hayden M.R.;
RT   "Efflux and atherosclerosis: the clinical and biochemical impact of
RT   variations in the ABCA1 gene.";
RL   Arterioscler. Thromb. Vasc. Biol. 23:1322-1332(2003).
RN   [13]
RP   PALMITOYLATION AT CYS-3; CYS-23; CYS-1110 AND CYS-1111, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19556522; DOI=10.1161/CIRCRESAHA.108.193011;
RA   Singaraja R.R., Kang M.H., Vaid K., Sanders S.S., Vilas G.L.,
RA   Arstikaitis P., Coutinho J., Drisdel R.C., El-Husseini Ael D.,
RA   Green W.N., Berthiaume L., Hayden M.R.;
RT   "Palmitoylation of ATP-binding cassette transporter A1 is essential
RT   for its trafficking and function.";
RL   Circ. Res. 105:138-147(2009).
RN   [14]
RP   DISULFIDE BONDS, AND SUBCELLULAR LOCATION.
RX   PubMed=19258317; DOI=10.1074/jbc.M900580200;
RA   Hozoji M., Kimura Y., Kioka N., Ueda K.;
RT   "Formation of two intramolecular disulfide bonds is necessary for
RT   ApoA-I-dependent cholesterol efflux mediated by ABCA1.";
RL   J. Biol. Chem. 284:11293-11300(2009).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-98 AND ASN-244.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [16]
RP   VARIANTS HDLD2 THR-1091 AND 1893-GLU-ASP-1894 DEL.
RX   PubMed=10533863; DOI=10.1016/S0140-6736(99)07026-9;
RA   Marcil M., Brooks-Wilson A., Clee S.M., Roomp K., Zhang L.-H., Yu L.,
RA   Collins J.A., van Dam M., Molhuizen H.O.F., Loubser O.,
RA   Ouellette B.F.F., Sensen C.W., Fichter K., Mott S., Denis M.,
RA   Boucher B., Pimstone S., Genest J. Jr., Kastelein J.J.P., Hayden M.R.;
RT   "Mutations in the ABC1 gene in familial HDL deficiency with defective
RT   cholesterol efflux.";
RL   Lancet 354:1341-1346(1999).
RN   [17]
RP   VARIANTS HDLD1 ARG-597 AND ARG-1477, AND VARIANT HDLD2 LEU-693 DEL.
RX   PubMed=10431236; DOI=10.1038/11905;
RA   Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.-H., Roomp K.,
RA   van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O.F.,
RA   Loubser O., Ouelette B.F.F., Fichter K., Ashbourne-Excoffon K.J.D.,
RA   Sensen C.W., Scherer S., Mott S., Denis M., Martindale D.,
RA   Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J.P.,
RA   Hayden M.R.;
RT   "Mutations in ABC1 in Tangier disease and familial high-density
RT   lipoprotein deficiency.";
RL   Nat. Genet. 22:336-345(1999).
RN   [18]
RP   VARIANTS HDLD1 SER-590; SER-935 AND VAL-937, AND VARIANTS ALA-399 AND
RP   MET-883.
RX   PubMed=10431237; DOI=10.1038/11914;
RA   Bodzioch M., Orso E., Klucken J., Langmann T., Boettcher A.,
RA   Diederich W., Drobnik W., Barlage S., Buechler C.,
RA   Porsch-Oezcueruemez M., Kaminski W.E., Hahmann H.W., Oette K.,
RA   Rothe G., Aslanidis C., Lackner K.J., Schmitz G.;
RT   "The gene encoding ATP-binding cassette transporter 1 is mutated in
RT   Tangier disease.";
RL   Nat. Genet. 22:347-351(1999).
RN   [19]
RP   VARIANTS HDLD1 ARG-597; ILE-929 AND ARG-1477, AND VARIANTS HDLD2
RP   LEU-693 DEL; THR-1091; 1893-GLU-ASP-1894 DEL AND LEU-2150.
RX   PubMed=11086027; DOI=10.1172/JCI10727;
RA   Clee S.M., Kastelein J.J.P., van Dam M., Marcil M., Roomp K.,
RA   Zwarts K.Y., Collins J.A., Roelants R., Tamasawa N., Stulc T.,
RA   Suda T., Ceska R., Boucher B., Rondeau C., DeSouich C.,
RA   Brooks-Wilson A., Molhuizen H.O.F., Frohlich J., Genest J. Jr.,
RA   Hayden M.R.;
RT   "Age and residual cholesterol efflux affect HDL cholesterol levels and
RT   coronary artery disease in ABCA1 heterozygotes.";
RL   J. Clin. Invest. 106:1263-1270(2000).
RN   [20]
RP   VARIANTS HDLD1 ASN-1289 AND HIS-1800.
RX   PubMed=10706591;
RA   Brousseau M.E., Schaefer E.J., Dupuis J., Eustace B.,
RA   Van Eerdewegh P., Goldkamp A.L., Thurston L.M., FitzGerald M.G.,
RA   Yasek-McKenna D., O'Neill G., Eberhart G.P., Weiffenbach B.,
RA   Ordovas J.M., Freeman M.W., Brown R.H. Jr., Gu J.Z.;
RT   "Novel mutations in the gene encoding ATP-binding cassette 1 in four
RT   tangier disease kindreds.";
RL   J. Lipid Res. 41:433-441(2000).
RN   [21]
RP   VARIANT HDLD1 ASP-1046, VARIANT HDLD2 CYS-230, AND VARIANTS LYS-219;
RP   ILE-825; MET-883 AND ARG-1587.
RX   PubMed=10938021; DOI=10.1161/01.ATV.20.8.1983;
RA   Wang J., Burnett J.R., Near S., Young K., Zinman B., Hanley A.J.G.,
RA   Connelly P.W., Harris S.B., Hegele R.A.;
RT   "Common and rare ABCA1 variants affecting plasma HDL cholesterol.";
RL   Arterioscler. Thromb. Vasc. Biol. 20:1983-1989(2000).
RN   [22]
RP   VARIANT HDLD1 TRP-587, AND VARIANT PRO-2168.
RX   PubMed=11257260; DOI=10.1016/S0021-9150(00)00587-6;
RA   Bertolini S., Pisciotta L., Seri M., Cusano R., Cantafora A.,
RA   Calabresi L., Franceschini G., Ravazzolo R., Calandra S.;
RT   "A point mutation in ABC1 gene in a patient with severe premature
RT   coronary heart disease and mild clinical phenotype of Tangier
RT   disease.";
RL   Atherosclerosis 154:599-605(2001).
RN   [23]
RP   VARIANTS LYS-219; MET-883 AND ASP-1172.
RX   PubMed=11257261; DOI=10.1016/S0021-9150(00)00722-X;
RA   Brousseau M.E., Bodzioch M., Schaefer E.J., Goldkamp A.L., Kielar D.,
RA   Probst M., Ordovas J.M., Aslanidis C., Lackner K.J.,
RA   Bloomfield Rubins H., Collins D., Robins S.J., Wilson P.W.F.,
RA   Schmitz G.;
RT   "Common variants in the gene encoding ATP-binding cassette transporter
RT   1 in men with low HDL cholesterol levels and coronary heart disease.";
RL   Atherosclerosis 154:607-611(2001).
RN   [24]
RP   VARIANT HDLD1 LEU-1506.
RX   PubMed=11476961; DOI=10.1016/S0925-4439(01)00053-9;
RA   Lapicka-Bodzioch K., Bodzioch M., Kruell M., Kielar D., Probst M.,
RA   Kiec B., Andrikovics H., Boettcher A., Hubacek J., Aslanidis C.,
RA   Suttorp N., Schmitz G.;
RT   "Homogeneous assay based on 52 primer sets to scan for mutations of
RT   the ABCA1 gene and its application in genetic analysis of a new
RT   patient with familial high-density lipoprotein deficiency syndrome.";
RL   Biochim. Biophys. Acta 1537:42-48(2001).
RN   [25]
RP   VARIANTS HDLD1 ASN-1289 AND TRP-2081, AND VARIANT LYS-219.
RX   PubMed=11476965; DOI=10.1016/S0925-4439(01)00058-8;
RA   Huang W., Moriyama K., Koga T., Hua H., Ageta M., Kawabata S.,
RA   Mawatari K., Imamura T., Eto T., Kawamura M., Teramoto T., Sasaki J.;
RT   "Novel mutations in ABCA1 gene in Japanese patients with Tangier
RT   disease and familial high density lipoprotein deficiency with coronary
RT   heart disease.";
RL   Biochim. Biophys. Acta 1537:71-78(2001).
RN   [26]
RP   VARIANTS LYS-219; ALA-399; MET-771; PRO-774; ASN-776; ILE-825;
RP   MET-883; ASP-1172; ARG-1587 AND CYS-1731.
RX   PubMed=11238261; DOI=10.1161/01.CIR.103.9.1198;
RA   Clee S.M., Zwinderman A.H., Engert J.C., Zwarts K.Y.,
RA   Molhuizen H.O.F., Roomp K., Jukema J.W., van Wijland M., van Dam M.,
RA   Hudson T.J., Brooks-Wilson A., Genest J. Jr., Kastelein J.J.P.,
RA   Hayden M.R.;
RT   "Common genetic variation in ABCA1 is associated with altered
RT   lipoprotein levels and a modified risk for coronary artery disease.";
RL   Circulation 103:1198-1205(2001).
RN   [27]
RP   VARIANT HDLD2 LEU-85.
RX   PubMed=12204794; DOI=10.1016/S0021-9150(02)00106-5;
RA   Hong S.H., Rhyne J., Zeller K., Miller M.;
RT   "ABCA1(Alabama): a novel variant associated with HDL deficiency and
RT   premature coronary artery disease.";
RL   Atherosclerosis 164:245-250(2002).
RN   [28]
RP   VARIANTS HDLD2 TYR-1099 AND SER-2009.
RX   PubMed=12009425; DOI=10.1016/S0925-4439(02)00066-2;
RA   Hong S.H., Rhyne J., Zeller K., Miller M.;
RT   "Novel ABCA1 compound variant associated with HDL cholesterol
RT   deficiency.";
RL   Biochim. Biophys. Acta 1587:60-64(2002).
RN   [29]
RP   VARIANT HDLD1 THR-255, AND VARIANT ATHEROSCLEROSIS ASP-1611.
RX   PubMed=11785958; DOI=10.1006/bbrc.2001.6219;
RA   Nishida Y., Hirano K., Tsukamoto K., Nagano M., Ikegami C., Roomp K.,
RA   Ishihara M., Sakane N., Zhang Z., Tsujii K., Matsuyama A., Ohama T.,
RA   Matsuura F., Ishigami M., Sakai N., Hiraoka H., Hattori H.,
RA   Wellington C., Yoshida Y., Misugi S., Hayden M.R., Egashira T.,
RA   Yamashita S., Matsuzawa Y.;
RT   "Expression and functional analyses of novel mutations of ATP-binding
RT   cassette transporter-1 in Japanese patients with high-density
RT   lipoprotein deficiency.";
RL   Biochem. Biophys. Res. Commun. 290:713-721(2002).
RN   [30]
RP   VARIANT HDLD1 LEU-590.
RX   PubMed=12407001;
RA   Hong S.H., Riley W., Rhyne J., Friel G., Miller M.;
RT   "Lack of association between increased carotid intima-media thickening
RT   and decreased HDL-cholesterol in a family with a novel ABCA1 variant,
RT   G2265T.";
RL   Clin. Chem. 48:2066-2070(2002).
RN   [31]
RP   VARIANTS HDLD1 HIS-935 AND SER-935.
RX   PubMed=12111381; DOI=10.1007/s100380200044;
RA   Guo Z., Inazu A., Yu W., Suzumura T., Okamoto M., Nohara A.,
RA   Higashikata T., Sano R., Wakasugi K., Hayakawa T., Yoshida K.,
RA   Suehiro T., Schmitz G., Mabuchi H.;
RT   "Double deletions and missense mutations in the first nucleotide-
RT   binding fold of the ATP-binding cassette transporter A1 (ABCA1) gene
RT   in Japanese patients with Tangier disease.";
RL   J. Hum. Genet. 47:325-329(2002).
RN   [32]
RP   VARIANT HDLD1 TRP-1680.
RX   PubMed=12111371; DOI=10.1007/s100380200051;
RA   Ishii J., Nagano M., Kujiraoka T., Ishihara M., Egashira T.,
RA   Takada D., Tsuji M., Hattori H., Emi M.;
RT   "Clinical variant of Tangier disease in Japan: mutation of the ABCA1
RT   gene in hypoalphalipoproteinemia with corneal lipidosis.";
RL   J. Hum. Genet. 47:366-369(2002).
RN   [33]
RP   VARIANT HDLD1 GLN-1851.
RX   PubMed=14576201; DOI=10.1161/01.RES.0000102957.84247.8F;
RA   Hong S.H., Rhyne J., Miller M.;
RT   "Novel polypyrimidine variation (IVS46: del T -39._.-46) in ABCA1
RT   causes exon skipping and contributes to HDL cholesterol deficiency in
RT   a family with premature coronary disease.";
RL   Circ. Res. 93:1006-1012(2003).
RN   [34]
RP   VARIANTS ILE-825 AND MET-883, AND ASSOCIATION OF VARIANTS ILE-825 AND
RP   MET-883 WITH HIGHER PLASMA HDL CHOLESTEROL.
RX   PubMed=12709788; DOI=10.1007/s00439-003-0943-3;
RA   Tan J.H., Low P.S., Tan Y.S., Tong M.C., Saha N., Yang H., Heng C.K.;
RT   "ABCA1 gene polymorphisms and their associations with coronary artery
RT   disease and plasma lipids in males from three ethnic populations in
RT   Singapore.";
RL   Hum. Genet. 113:106-117(2003).
RN   [35]
RP   VARIANTS LYS-219; MET-771; ILE-825; MET-883; ASP-1172; PHE-1181 AND
RP   ARG-1587.
RX   PubMed=12966036; DOI=10.1093/hmg/ddg314;
RA   Morabia A., Cayanis E., Costanza M.C., Ross B.M., Flaherty M.S.,
RA   Alvin G.B., Das K., Gilliam T.C.;
RT   "Association of extreme blood lipid profile phenotypic variation with
RT   11 reverse cholesterol transport genes and 10 non-genetic
RT   cardiovascular disease risk factors.";
RL   Hum. Mol. Genet. 12:2733-2743(2003).
RN   [36]
RP   VARIANT LYS-219.
RX   PubMed=12624133; DOI=10.1136/jmg.40.3.163;
RA   Cenarro A., Artieda M., Castillo S., Mozas P., Reyes G., Tejedor D.,
RA   Alonso R., Mata P., Pocovi M., Civeira F.;
RT   "A common variant in the ABCA1 gene is associated with a lower risk
RT   for premature coronary heart disease in familial
RT   hypercholesterolaemia.";
RL   J. Med. Genet. 40:163-168(2003).
RN   [37]
RP   VARIANTS HDLD1 LEU-590; ARG-840 AND CYS-1068, AND VARIANTS MET-771;
RP   SER-2163 AND ILE-2244.
RX   PubMed=15262183; DOI=10.1016/j.atherosclerosis.2004.02.019;
RA   Probst M.C., Thumann H., Aslanidis C., Langmann T., Buechler C.,
RA   Patsch W., Baralle F.E., Dallinga-Thie G.M., Geisel J., Keller C.,
RA   Menys V.C., Schmitz G.;
RT   "Screening for functional sequence variations and mutations in
RT   ABCA1.";
RL   Atherosclerosis 175:269-279(2004).
RN   [38]
RP   VARIANTS HDLD1 LYS-284; CYS-482; HIS-1800; SER-1901 AND HIS-2196.
RX   PubMed=15019541; DOI=10.1016/j.atherosclerosis.2003.11.009;
RA   Pisciotta L., Hamilton-Craig I., Tarugi P., Bellocchio A., Fasano T.,
RA   Alessandrini P., Bon G.B., Siepi D., Mannarino E., Cattin L.,
RA   Averna M., Cefalu A.B., Cantafora A., Calandra S., Bertolini S.;
RT   "Familial HDL deficiency due to ABCA1 gene mutations with or without
RT   other genetic lipoprotein disorders.";
RL   Atherosclerosis 172:309-320(2004).
RN   [39]
RP   VARIANTS HDLD1 PHE-1379 AND ASP-1704, AND CHARACTERIZATION OF VARIANTS
RP   HDLD1 PHE-1379 AND ASP-1704.
RX   PubMed=15158913; DOI=10.1016/j.bbadis.2004.01.007;
RA   Albrecht C., Baynes K., Sardini A., Schepelmann S., Eden E.R.,
RA   Davies S.W., Higgins C.F., Feher M.D., Owen J.S., Soutar A.K.;
RT   "Two novel missense mutations in ABCA1 result in altered trafficking
RT   and cause severe autosomal recessive HDL deficiency.";
RL   Biochim. Biophys. Acta 1689:47-57(2004).
RN   [40]
RP   VARIANT HDLD1 HIS-1800, AND VARIANTS LYS-219; CYS-364; MET-771;
RP   PRO-774; ASN-776; ILE-825; MET-883; SER-1065; ASP-1172; VAL-1216 AND
RP   ARG-1587.
RX   PubMed=15520867; DOI=10.1172/JCI20361;
RA   Frikke-Schmidt R., Nordestgaard B.G., Jensen G.B., Tybjaerg-Hansen A.;
RT   "Genetic variation in ABC transporter A1 contributes to HDL
RT   cholesterol in the general population.";
RL   J. Clin. Invest. 114:1343-1353(2004).
RN   [41]
RP   VARIANT HDLD1 HIS-1800, AND VARIANTS ALA-248; GLN-401; TRP-496;
RP   SER-590; GLN-638; SER-774; GLY-815; PHE-1181; THR-1341; GLY-1376;
RP   GLN-1615; THR-1670; GLN-1680 AND GLU-2243.
RX   PubMed=15297675; DOI=10.1126/science.1099870;
RA   Cohen J.C., Kiss R.S., Pertsemlidis A., Marcel Y.L., McPherson R.,
RA   Hobbs H.H.;
RT   "Multiple rare alleles contribute to low plasma levels of HDL
RT   cholesterol.";
RL   Science 305:869-872(2004).
RN   [42]
RP   VARIANT SCOTT SYNDROME GLN-1925, AND CHARACTERIZATION OF VARIANT SCOTT
RP   SYNDROME GLN-1925.
RX   PubMed=15790791; DOI=10.1182/blood-2004-05-2056;
RA   Albrecht C., McVey J.H., Elliott J.I., Sardini A., Kasza I.,
RA   Mumford A.D., Naoumova R.P., Tuddenham E.G., Szabo K., Higgins C.F.;
RT   "A novel missense mutation in ABCA1 results in altered protein
RT   trafficking and reduced phosphatidylserine translocation in a patient
RT   with Scott syndrome.";
RL   Blood 106:542-549(2005).
RN   [43]
RP   VARIANT ASN-776, AND ASSOCIATION OF VARIANT ASN-776 WITH INCREASED
RP   RISK OF ISCHEMIC HEART DISEASE.
RX   PubMed=16226177; DOI=10.1016/j.jacc.2005.06.066;
RA   Frikke-Schmidt R., Nordestgaard B.G., Schnohr P., Steffensen R.,
RA   Tybjaerg-Hansen A.;
RT   "Mutation in ABCA1 predicted risk of ischemic heart disease in the
RT   Copenhagen City Heart Study Population.";
RL   J. Am. Coll. Cardiol. 46:1516-1520(2005).
RN   [44]
RP   VARIANT HDLD2 TRP-1897.
RX   PubMed=15722566; DOI=10.1194/jlr.D400038-JLR200;
RA   Fasano T., Bocchi L., Pisciotta L., Bertolini S., Calandra S.;
RT   "Denaturing high-performance liquid chromatography in the detection of
RT   ABCA1 gene mutations in familial HDL deficiency.";
RL   J. Lipid Res. 46:817-822(2005).
RN   [45]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-210; TYR-917; THR-1407 AND
RP   THR-2109.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: cAMP-dependent and sulfonylurea-sensitive anion
CC       transporter. Key gatekeeper influencing intracellular cholesterol
CC       transport.
CC   -!- SUBUNIT: Interacts with MEGF10.
CC   -!- INTERACTION:
CC       P02647:APOA1; NbExp=4; IntAct=EBI-784112, EBI-701692;
CC       P60953:CDC42; NbExp=2; IntAct=EBI-784112, EBI-81752;
CC       Q13424:SNTA1; NbExp=2; IntAct=EBI-784112, EBI-717191;
CC       Q13884:SNTB1; NbExp=3; IntAct=EBI-784112, EBI-295843;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Widely expressed, but most abundant in
CC       macrophages.
CC   -!- INDUCTION: By bacterial lipopolysaccharides (LPS). LPS regulates
CC       expression through a liver X receptor (LXR) -independent
CC       mechanism. Repressed by ZNF202.
CC   -!- DOMAIN: Multifunctional polypeptide with two homologous halves,
CC       each containing a hydrophobic membrane-anchoring domain and an ATP
CC       binding cassette (ABC) domain.
CC   -!- PTM: Phosphorylation on Ser-2054 regulates phospholipid efflux.
CC   -!- PTM: Palmitoylation by DHHC8 is essential for membrane
CC       localization.
CC   -!- POLYMORPHISM: Genetic variations in ABCA1 define the high density
CC       lipoprotein cholesterol level quantitative trait locus 13
CC       (HDLCQ13) [MIM:600046].
CC   -!- DISEASE: High density lipoprotein deficiency 1 (HDLD1)
CC       [MIM:205400]: Recessive disorder characterized by absence of high
CC       density lipoprotein (HDL) cholesterol from plasma, accumulation of
CC       cholesteryl esters, premature coronary artery disease (CAD),
CC       hepatosplenomegaly, recurrent peripheral neuropathy and
CC       progressive muscle wasting and weakness. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: High density lipoprotein deficiency 2 (HDLD2)
CC       [MIM:604091]: Inherited as autosomal dominant trait. It is
CC       characterized by moderately low HDL cholesterol, predilection
CC       toward premature coronary artery disease (CAD) and a reduction in
CC       cellular cholesterol efflux. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCA
CC       family.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD49849.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=CAA10005.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=ABCA1";
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=O95477";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF275948; AAF86276.1; -; Genomic_DNA.
DR   EMBL; AL353685; CAH72444.1; -; Genomic_DNA.
DR   EMBL; AL359846; CAH72444.1; JOINED; Genomic_DNA.
DR   EMBL; AL359846; CAH73579.1; -; Genomic_DNA.
DR   EMBL; AL353685; CAH73579.1; JOINED; Genomic_DNA.
DR   EMBL; AF285167; AAF98175.1; -; mRNA.
DR   EMBL; AF287262; AAK43526.1; -; Genomic_DNA.
DR   EMBL; AB055982; BAB63210.1; -; mRNA.
DR   EMBL; AJ012376; CAA10005.1; ALT_INIT; mRNA.
DR   EMBL; AF165281; AAD49849.1; ALT_INIT; mRNA.
DR   EMBL; AF165286; AAD49851.1; -; Genomic_DNA.
DR   EMBL; AF165282; AAD49851.1; JOINED; Genomic_DNA.
DR   EMBL; AF165283; AAD49851.1; JOINED; Genomic_DNA.
DR   EMBL; AF165284; AAD49851.1; JOINED; Genomic_DNA.
DR   EMBL; AF165285; AAD49851.1; JOINED; Genomic_DNA.
DR   EMBL; AF165306; AAD49852.1; -; Genomic_DNA.
DR   EMBL; AF165287; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165288; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165289; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165290; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165291; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165292; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165293; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165294; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165295; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165296; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165297; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165298; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165299; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165300; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165301; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165302; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165303; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165304; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165305; AAD49852.1; JOINED; Genomic_DNA.
DR   EMBL; AF165309; AAD49854.1; -; Genomic_DNA.
DR   EMBL; AF165307; AAD49854.1; JOINED; Genomic_DNA.
DR   EMBL; AF165308; AAD49854.1; JOINED; Genomic_DNA.
DR   EMBL; AF165310; AAD49853.1; -; Genomic_DNA.
DR   CCDS; CCDS6762.1; -.
DR   RefSeq; NP_005493.2; NM_005502.3.
DR   UniGene; Hs.659274; -.
DR   ProteinModelPortal; O95477; -.
DR   BioGrid; 106537; 24.
DR   DIP; DIP-29211N; -.
DR   IntAct; O95477; 17.
DR   MINT; MINT-239561; -.
DR   ChEMBL; CHEMBL2362986; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB01016; Glibenclamide.
DR   TCDB; 3.A.1.211.14; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; O95477; -.
DR   MaxQB; O95477; -.
DR   PaxDb; O95477; -.
DR   PRIDE; O95477; -.
DR   Ensembl; ENST00000374736; ENSP00000363868; ENSG00000165029.
DR   GeneID; 19; -.
DR   KEGG; hsa:19; -.
DR   UCSC; uc004bcl.3; human.
DR   CTD; 19; -.
DR   GeneCards; GC09M107543; -.
DR   HGNC; HGNC:29; ABCA1.
DR   MIM; 205400; phenotype.
DR   MIM; 600046; gene+phenotype.
DR   MIM; 604091; phenotype.
DR   neXtProt; NX_O95477; -.
DR   Orphanet; 425; Apolipoprotein A-I deficiency.
DR   Orphanet; 31150; Tangier disease.
DR   PharmGKB; PA24373; -.
DR   eggNOG; COG1131; -.
DR   HOVERGEN; HBG050436; -.
DR   InParanoid; O95477; -.
DR   KO; K05641; -.
DR   OMA; FSMRSWS; -.
DR   OrthoDB; EOG78D7J6; -.
DR   PhylomeDB; O95477; -.
DR   TreeFam; TF105191; -.
DR   Reactome; REACT_111217; Metabolism.
DR   SignaLink; O95477; -.
DR   ChiTaRS; ABCA1; human.
DR   GeneWiki; ABCA1; -.
DR   GenomeRNAi; 19; -.
DR   NextBio; 51; -.
DR   PRO; PR:O95477; -.
DR   ArrayExpress; O95477; -.
DR   Bgee; O95477; -.
DR   Genevestigator; O95477; -.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0045121; C:membrane raft; IDA:BHF-UCL.
DR   GO; GO:0045335; C:phagocytic vesicle; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0008509; F:anion transmembrane transporter activity; ISS:BHF-UCL.
DR   GO; GO:0034186; F:apolipoprotein A-I binding; IPI:BHF-UCL.
DR   GO; GO:0034188; F:apolipoprotein A-I receptor activity; IDA:BHF-UCL.
DR   GO; GO:0034185; F:apolipoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:BHF-UCL.
DR   GO; GO:0016887; F:ATPase activity; IEA:InterPro.
DR   GO; GO:0015485; F:cholesterol binding; IC:BHF-UCL.
DR   GO; GO:0017127; F:cholesterol transporter activity; IDA:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IC:BHF-UCL.
DR   GO; GO:0005548; F:phospholipid transporter activity; IDA:BHF-UCL.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0031267; F:small GTPase binding; IPI:BHF-UCL.
DR   GO; GO:0019905; F:syntaxin binding; IPI:BHF-UCL.
DR   GO; GO:0038027; P:apolipoprotein A-I-mediated signaling pathway; IDA:GOC.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0071397; P:cellular response to cholesterol; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IDA:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IDA:BHF-UCL.
DR   GO; GO:0016197; P:endosomal transport; IDA:BHF-UCL.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; IMP:BHF-UCL.
DR   GO; GO:0050702; P:interleukin-1 beta secretion; IMP:BHF-UCL.
DR   GO; GO:0032367; P:intracellular cholesterol transport; IMP:BHF-UCL.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0007040; P:lysosome organization; IDA:BHF-UCL.
DR   GO; GO:0010887; P:negative regulation of cholesterol storage; TAS:BHF-UCL.
DR   GO; GO:0010745; P:negative regulation of macrophage derived foam cell differentiation; TAS:BHF-UCL.
DR   GO; GO:0002790; P:peptide secretion; IEA:Ensembl.
DR   GO; GO:0006911; P:phagocytosis, engulfment; IEA:Ensembl.
DR   GO; GO:0033700; P:phospholipid efflux; IDA:BHF-UCL.
DR   GO; GO:0055091; P:phospholipid homeostasis; IMP:BHF-UCL.
DR   GO; GO:0045332; P:phospholipid translocation; IEA:Ensembl.
DR   GO; GO:0060155; P:platelet dense granule organization; IMP:BHF-UCL.
DR   GO; GO:0030819; P:positive regulation of cAMP biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; IEA:Ensembl.
DR   GO; GO:0006497; P:protein lipidation; IEA:Ensembl.
DR   GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; IMP:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0034616; P:response to laminar fluid shear stress; IEP:BHF-UCL.
DR   GO; GO:0055098; P:response to low-density lipoprotein particle; IEP:BHF-UCL.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0043691; P:reverse cholesterol transport; IMP:BHF-UCL.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.50.300; -; 2.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR026082; ABC_A.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR19229; PTHR19229; 1.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Atherosclerosis; ATP-binding; Cholesterol metabolism;
KW   Complete proteome; Disease mutation; Disulfide bond; Glycoprotein;
KW   Lipid metabolism; Lipoprotein; Membrane; Nucleotide-binding;
KW   Palmitate; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Steroid metabolism; Sterol metabolism; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN         1   2261       ATP-binding cassette sub-family A member
FT                                1.
FT                                /FTId=PRO_0000093288.
FT   TRANSMEM     22     42       Helical; (Potential).
FT   TOPO_DOM     43    639       Extracellular.
FT   TRANSMEM    640    660       Helical; (Potential).
FT   TRANSMEM    683    703       Helical; (Potential).
FT   TRANSMEM    716    736       Helical; (Potential).
FT   TRANSMEM    745    765       Helical; (Potential).
FT   TRANSMEM    777    797       Helical; (Potential).
FT   TRANSMEM    827    847       Helical; (Potential).
FT   TRANSMEM   1041   1057       Helical; (Potential).
FT   TRANSMEM   1351   1371       Helical; (Potential).
FT   TOPO_DOM   1372   1656       Extracellular.
FT   TRANSMEM   1657   1677       Helical; (Potential).
FT   TRANSMEM   1703   1723       Helical; (Potential).
FT   TRANSMEM   1735   1755       Helical; (Potential).
FT   TRANSMEM   1768   1788       Helical; (Potential).
FT   TRANSMEM   1802   1822       Helical; (Potential).
FT   TRANSMEM   1852   1872       Helical; (Potential).
FT   DOMAIN      899   1131       ABC transporter 1.
FT   DOMAIN     1912   2144       ABC transporter 2.
FT   NP_BIND     933    940       ATP 1 (Potential).
FT   NP_BIND    1946   1953       ATP 2 (Potential).
FT   MOD_RES    1042   1042       Phosphoserine; by PKA.
FT   MOD_RES    1296   1296       Phosphoserine (By similarity).
FT   MOD_RES    2054   2054       Phosphoserine; by PKA.
FT   LIPID         3      3       S-palmitoyl cysteine.
FT   LIPID        23     23       S-palmitoyl cysteine.
FT   LIPID      1110   1110       S-palmitoyl cysteine.
FT   LIPID      1111   1111       S-palmitoyl cysteine.
FT   CARBOHYD     14     14       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     98     98       N-linked (GlcNAc...).
FT   CARBOHYD    151    151       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    161    161       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    196    196       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    244    244       N-linked (GlcNAc...).
FT   CARBOHYD    292    292       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    337    337       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    349    349       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    400    400       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    478    478       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    489    489       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    521    521       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    820    820       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1144   1144       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1294   1294       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1453   1453       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1504   1504       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1637   1637       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   2044   2044       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   2238   2238       N-linked (GlcNAc...) (Potential).
FT   DISULFID     75    309
FT   DISULFID   1463   1477
FT   VARIANT      85     85       P -> L (in HDLD2; Alabama;
FT                                dbSNP:rs145183203).
FT                                /FTId=VAR_017529.
FT   VARIANT     210    210       E -> D (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035724.
FT   VARIANT     219    219       R -> K (common polymorphism; associated
FT                                with a decreased severity of CAD;
FT                                dbSNP:rs2230806).
FT                                /FTId=VAR_012618.
FT   VARIANT     230    230       R -> C (in HDLD2; dbSNP:rs9282541).
FT                                /FTId=VAR_012619.
FT   VARIANT     248    248       P -> A.
FT                                /FTId=VAR_062481.
FT   VARIANT     255    255       A -> T (in HDLD1; deficient cellular
FT                                cholesterol efflux).
FT                                /FTId=VAR_012620.
FT   VARIANT     284    284       E -> K (in HDLD1).
FT                                /FTId=VAR_062482.
FT   VARIANT     364    364       S -> C.
FT                                /FTId=VAR_062483.
FT   VARIANT     399    399       V -> A (in dbSNP:rs9282543).
FT                                /FTId=VAR_009145.
FT   VARIANT     401    401       K -> Q.
FT                                /FTId=VAR_062484.
FT   VARIANT     482    482       Y -> C (in HDLD1).
FT                                /FTId=VAR_062485.
FT   VARIANT     496    496       R -> W (associated with increased plasma
FT                                HDL cholesterol; dbSNP:rs147675550).
FT                                /FTId=VAR_062486.
FT   VARIANT     587    587       R -> W (in HDLD1; dbSNP:rs2853574).
FT                                /FTId=VAR_009146.
FT   VARIANT     590    590       W -> L (in HDLD1).
FT                                /FTId=VAR_062487.
FT   VARIANT     590    590       W -> S (in HDLD1).
FT                                /FTId=VAR_009147.
FT   VARIANT     597    597       Q -> R (in HDLD1; dbSNP:rs2853578).
FT                                /FTId=VAR_009148.
FT   VARIANT     638    638       R -> Q (associated with reduced plasma
FT                                HDL cholesterol).
FT                                /FTId=VAR_062488.
FT   VARIANT     693    693       Missing (in HDLD2).
FT                                /FTId=VAR_009149.
FT   VARIANT     771    771       V -> M (associated with HDL cholesterol;
FT                                dbSNP:rs2066718).
FT                                /FTId=VAR_012621.
FT   VARIANT     774    774       T -> P (in dbSNP:rs35819696).
FT                                /FTId=VAR_012622.
FT   VARIANT     774    774       T -> S.
FT                                /FTId=VAR_062489.
FT   VARIANT     776    776       K -> N (may be associated with increased
FT                                risk of ischemic heart disease;
FT                                dbSNP:rs138880920).
FT                                /FTId=VAR_012623.
FT   VARIANT     815    815       E -> G (associated with reduced plasma
FT                                HDL cholesterol; dbSNP:rs145582736).
FT                                /FTId=VAR_062490.
FT   VARIANT     825    825       V -> I (associated with higher plasma
FT                                cholesterol; dbSNP:rs2066715).
FT                                /FTId=VAR_012624.
FT   VARIANT     840    840       W -> R (in HDLD1).
FT                                /FTId=VAR_062491.
FT   VARIANT     883    883       I -> M (associated with higher plasma
FT                                cholesterol; dbSNP:rs2066714).
FT                                /FTId=VAR_012625.
FT   VARIANT     917    917       D -> Y (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035725.
FT   VARIANT     929    929       T -> I (in HDLD1).
FT                                /FTId=VAR_012626.
FT   VARIANT     935    935       N -> H (in HDLD1; dbSNP:rs28937314).
FT                                /FTId=VAR_037968.
FT   VARIANT     935    935       N -> S (in HDLD1; dbSNP:rs28937313).
FT                                /FTId=VAR_009150.
FT   VARIANT     937    937       A -> V (in HDLD1).
FT                                /FTId=VAR_009151.
FT   VARIANT    1046   1046       A -> D (in HDLD1).
FT                                /FTId=VAR_012627.
FT   VARIANT    1054   1054       V -> I (in dbSNP:rs13306072).
FT                                /FTId=VAR_037969.
FT   VARIANT    1065   1065       P -> S.
FT                                /FTId=VAR_062492.
FT   VARIANT    1068   1068       R -> C (in HDLD1).
FT                                /FTId=VAR_062493.
FT   VARIANT    1091   1091       M -> T (in HDLD2).
FT                                /FTId=VAR_012628.
FT   VARIANT    1099   1099       D -> Y (in HDLD2; dbSNP:rs28933692).
FT                                /FTId=VAR_017530.
FT   VARIANT    1172   1172       E -> D (associated with premature
FT                                coronary heart disease;
FT                                dbSNP:rs33918808).
FT                                /FTId=VAR_012629.
FT   VARIANT    1181   1181       S -> F (associated with reduced plasma
FT                                HDL cholesterol; dbSNP:rs76881554).
FT                                /FTId=VAR_017016.
FT   VARIANT    1216   1216       G -> V.
FT                                /FTId=VAR_062494.
FT   VARIANT    1289   1289       D -> N (in HDLD1).
FT                                /FTId=VAR_009152.
FT   VARIANT    1341   1341       R -> T (associated with reduced plasma
FT                                HDL cholesterol; dbSNP:rs147743782).
FT                                /FTId=VAR_062495.
FT   VARIANT    1376   1376       S -> G.
FT                                /FTId=VAR_062496.
FT   VARIANT    1379   1379       L -> F (in HDLD1; the mutant protein is
FT                                retained in the endoplasmic reticulum
FT                                while the wild-type protein is located at
FT                                the plasma membrane).
FT                                /FTId=VAR_062497.
FT   VARIANT    1407   1407       A -> T (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035726.
FT   VARIANT    1477   1477       C -> R (in HDLD1).
FT                                /FTId=VAR_009153.
FT   VARIANT    1506   1506       S -> L (in HDLD1).
FT                                /FTId=VAR_012630.
FT   VARIANT    1517   1517       I -> R (in HDLD1).
FT                                /FTId=VAR_009154.
FT   VARIANT    1555   1555       I -> T (in dbSNP:rs1997618).
FT                                /FTId=VAR_012638.
FT   VARIANT    1587   1587       K -> R (associated with HDL cholesterol;
FT                                dbSNP:rs2230808).
FT                                /FTId=VAR_012631.
FT   VARIANT    1611   1611       N -> D (probable disease-associated
FT                                mutation; associated with
FT                                atherosclerosis; deficient cellular
FT                                cholesterol efflux).
FT                                /FTId=VAR_012632.
FT   VARIANT    1615   1615       R -> Q (associated with reduced plasma
FT                                HDL cholesterol).
FT                                /FTId=VAR_062498.
FT   VARIANT    1648   1648       L -> P (in dbSNP:rs1883024).
FT                                /FTId=VAR_012639.
FT   VARIANT    1670   1670       A -> T (associated with reduced plasma
FT                                HDL cholesterol).
FT                                /FTId=VAR_062499.
FT   VARIANT    1680   1680       R -> Q (associated with increased plasma
FT                                HDL cholesterol; dbSNP:rs150125857).
FT                                /FTId=VAR_062500.
FT   VARIANT    1680   1680       R -> W (in HDLD1; dbSNP:rs137854498).
FT                                /FTId=VAR_037970.
FT   VARIANT    1704   1704       V -> D (in HDLD1; the mutant protein is
FT                                retained in the endoplasmic reticulum
FT                                while the wild-type protein is located at
FT                                the plasma membrane).
FT                                /FTId=VAR_062501.
FT   VARIANT    1731   1731       S -> C.
FT                                /FTId=VAR_012633.
FT   VARIANT    1800   1800       N -> H (in HDLD1).
FT                                /FTId=VAR_009155.
FT   VARIANT    1851   1851       R -> Q (in HDLD1).
FT                                /FTId=VAR_062502.
FT   VARIANT    1893   1894       Missing (in HDLD2).
FT                                /FTId=VAR_012634.
FT   VARIANT    1897   1897       R -> W (in HDLD2; uncertain pathological
FT                                significance).
FT                                /FTId=VAR_062503.
FT   VARIANT    1901   1901       R -> S (in HDLD1).
FT                                /FTId=VAR_062504.
FT   VARIANT    1925   1925       R -> Q (in Scott syndrome; shows impaired
FT                                trafficking of the mutant protein to the
FT                                plasma membrane; dbSNP:rs142688906).
FT                                /FTId=VAR_062505.
FT   VARIANT    2009   2009       F -> S (in HDLD2).
FT                                /FTId=VAR_037971.
FT   VARIANT    2081   2081       R -> W (in HDLD1).
FT                                /FTId=VAR_012635.
FT   VARIANT    2109   2109       A -> T (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035727.
FT   VARIANT    2150   2150       P -> L (in HDLD2).
FT                                /FTId=VAR_012636.
FT   VARIANT    2163   2163       F -> S (could be associated with reduced
FT                                plasma HDL cholesterol).
FT                                /FTId=VAR_062506.
FT   VARIANT    2168   2168       L -> P (in dbSNP:rs2853577).
FT                                /FTId=VAR_012637.
FT   VARIANT    2196   2196       Q -> H (in HDLD1).
FT                                /FTId=VAR_062507.
FT   VARIANT    2243   2243       D -> E (in dbSNP:rs34879708).
FT                                /FTId=VAR_062508.
FT   VARIANT    2244   2244       V -> I (could be associated with reduced
FT                                plasma HDL cholesterol;
FT                                dbSNP:rs144588452).
FT                                /FTId=VAR_062509.
FT   CONFLICT    793    793       Y -> C (in Ref. 3; AAK43526).
FT   CONFLICT    831    831       D -> N (in Ref. 3; AAK43526).
FT   CONFLICT   1005   1005       E -> K (in Ref. 3; AAK43526).
FT   CONFLICT   1745   1746       Missing (in Ref. 7; AAD49852).
SQ   SEQUENCE   2261 AA;  254302 MW;  21A2CF8F3F518D6D CRC64;
     MACWPQLRLL LWKNLTFRRR QTCQLLLEVA WPLFIFLILI SVRLSYPPYE QHECHFPNKA
     MPSAGTLPWV QGIICNANNP CFRYPTPGEA PGVVGNFNKS IVARLFSDAR RLLLYSQKDT
     SMKDMRKVLR TLQQIKKSSS NLKLQDFLVD NETFSGFLYH NLSLPKSTVD KMLRADVILH
     KVFLQGYQLH LTSLCNGSKS EEMIQLGDQE VSELCGLPRE KLAAAERVLR SNMDILKPIL
     RTLNSTSPFP SKELAEATKT LLHSLGTLAQ ELFSMRSWSD MRQEVMFLTN VNSSSSSTQI
     YQAVSRIVCG HPEGGGLKIK SLNWYEDNNY KALFGGNGTE EDAETFYDNS TTPYCNDLMK
     NLESSPLSRI IWKALKPLLV GKILYTPDTP ATRQVMAEVN KTFQELAVFH DLEGMWEELS
     PKIWTFMENS QEMDLVRMLL DSRDNDHFWE QQLDGLDWTA QDIVAFLAKH PEDVQSSNGS
     VYTWREAFNE TNQAIRTISR FMECVNLNKL EPIATEVWLI NKSMELLDER KFWAGIVFTG
     ITPGSIELPH HVKYKIRMDI DNVERTNKIK DGYWDPGPRA DPFEDMRYVW GGFAYLQDVV
     EQAIIRVLTG TEKKTGVYMQ QMPYPCYVDD IFLRVMSRSM PLFMTLAWIY SVAVIIKGIV
     YEKEARLKET MRIMGLDNSI LWFSWFISSL IPLLVSAGLL VVILKLGNLL PYSDPSVVFV
     FLSVFAVVTI LQCFLISTLF SRANLAAACG GIIYFTLYLP YVLCVAWQDY VGFTLKIFAS
     LLSPVAFGFG CEYFALFEEQ GIGVQWDNLF ESPVEEDGFN LTTSVSMMLF DTFLYGVMTW
     YIEAVFPGQY GIPRPWYFPC TKSYWFGEES DEKSHPGSNQ KRISEICMEE EPTHLKLGVS
     IQNLVKVYRD GMKVAVDGLA LNFYEGQITS FLGHNGAGKT TTMSILTGLF PPTSGTAYIL
     GKDIRSEMST IRQNLGVCPQ HNVLFDMLTV EEHIWFYARL KGLSEKHVKA EMEQMALDVG
     LPSSKLKSKT SQLSGGMQRK LSVALAFVGG SKVVILDEPT AGVDPYSRRG IWELLLKYRQ
     GRTIILSTHH MDEADVLGDR IAIISHGKLC CVGSSLFLKN QLGTGYYLTL VKKDVESSLS
     SCRNSSSTVS YLKKEDSVSQ SSSDAGLGSD HESDTLTIDV SAISNLIRKH VSEARLVEDI
     GHELTYVLPY EAAKEGAFVE LFHEIDDRLS DLGISSYGIS ETTLEEIFLK VAEESGVDAE
     TSDGTLPARR NRRAFGDKQS CLRPFTEDDA ADPNDSDIDP ESRETDLLSG MDGKGSYQVK
     GWKLTQQQFV ALLWKRLLIA RRSRKGFFAQ IVLPAVFVCI ALVFSLIVPP FGKYPSLELQ
     PWMYNEQYTF VSNDAPEDTG TLELLNALTK DPGFGTRCME GNPIPDTPCQ AGEEEWTTAP
     VPQTIMDLFQ NGNWTMQNPS PACQCSSDKI KKMLPVCPPG AGGLPPPQRK QNTADILQDL
     TGRNISDYLV KTYVQIIAKS LKNKIWVNEF RYGGFSLGVS NTQALPPSQE VNDAIKQMKK
     HLKLAKDSSA DRFLNSLGRF MTGLDTKNNV KVWFNNKGWH AISSFLNVIN NAILRANLQK
     GENPSHYGIT AFNHPLNLTK QQLSEVALMT TSVDVLVSIC VIFAMSFVPA SFVVFLIQER
     VSKAKHLQFI SGVKPVIYWL SNFVWDMCNY VVPATLVIII FICFQQKSYV SSTNLPVLAL
     LLLLYGWSIT PLMYPASFVF KIPSTAYVVL TSVNLFIGIN GSVATFVLEL FTDNKLNNIN
     DILKSVFLIF PHFCLGRGLI DMVKNQAMAD ALERFGENRF VSPLSWDLVG RNLFAMAVEG
     VVFFLITVLI QYRFFIRPRP VNAKLSPLND EDEDVRRERQ RILDGGGQND ILEIKELTKI
     YRRKRKPAVD RICVGIPPGE CFGLLGVNGA GKSSTFKMLT GDTTVTRGDA FLNKNSILSN
     IHEVHQNMGY CPQFDAITEL LTGREHVEFF ALLRGVPEKE VGKVGEWAIR KLGLVKYGEK
     YAGNYSGGNK RKLSTAMALI GGPPVVFLDE PTTGMDPKAR RFLWNCALSV VKEGRSVVLT
     SHSMEECEAL CTRMAIMVNG RFRCLGSVQH LKNRFGDGYT IVVRIAGSNP DLKPVQDFFG
     LAFPGSVLKE KHRNMLQYQL PSSLSSLARI FSILSQSKKR LHIEDYSVSQ TTLDQVFVNF
     AKDQSDDDHL KDLSLHKNQT VVDVAVLTSF LQDEKVKESY V
//
ID   ABCA4_HUMAN             Reviewed;        2273 AA.
AC   P78363; O15112; O60438; O60915; Q0QD48; Q4LE31;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 3.
DT   09-JUL-2014, entry version 152.
DE   RecName: Full=Retinal-specific ATP-binding cassette transporter;
DE   AltName: Full=ATP-binding cassette sub-family A member 4;
DE   AltName: Full=RIM ABC transporter;
DE            Short=RIM protein;
DE            Short=RmP;
DE   AltName: Full=Stargardt disease protein;
GN   Name=ABCA4; Synonyms=ABCR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANTS STGD1, AND VARIANTS HIS-846;
RP   GLN-943 AND ASP-1817.
RX   PubMed=9054934; DOI=10.1038/ng0397-236;
RA   Allikmets R., Singh N., Sun H., Shroyer N.F., Hutchinson A.,
RA   Chidambaram A., Gerrard B., Baird L., Stauffer D., Peiffer A.,
RA   Rattner A., Smallwood P.M., Li Y., Anderson K.L., Lewis R.A.,
RA   Nathans J., Leppert M., Dean M., Lupski J.R.;
RT   "A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is
RT   mutated in recessive Stargardt macular dystrophy.";
RL   Nat. Genet. 15:236-246(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9202155; DOI=10.1016/S0014-5793(97)00517-6;
RA   Azarian S.M., Travis G.H.;
RT   "The photoreceptor rim protein is an ABC transporter encoded by the
RT   gene for recessive Stargardt's disease (ABCR).";
RL   FEBS Lett. 409:247-252(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS STGD1 TRP-18 AND CYS-212,
RP   AND VARIANT ASP-1817.
RX   PubMed=9503029; DOI=10.1006/geno.1997.5164;
RA   Gerber S., Rozet J.-M., van de Pol T.J.R., Hoyng C.B., Munnich A.,
RA   Blankenagel A., Kaplan J., Cremers F.P.M.;
RT   "Complete exon-intron structure of the retina-specific ATP binding
RT   transporter gene (ABCR) allows the identification of novel mutations
RT   underlying Stargardt disease.";
RL   Genomics 48:139-142(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS STGD1.
RX   PubMed=9490294; DOI=10.1007/s004390050649;
RA   Nasonkin I., Illing M., Koehler M.R., Schmid M., Molday R.S.,
RA   Weber B.H.F.;
RT   "Mapping of the rod photoreceptor ABC transporter (ABCR) to 1p21-p22.1
RT   and identification of novel mutations in Stargardt's disease.";
RL   Hum. Genet. 102:21-26(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLN-943.
RC   TISSUE=Brain;
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M.,
RA   Ohara R., Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long
RT   cDNAs encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-29.
RC   TISSUE=Retina;
RX   PubMed=17286855; DOI=10.1186/1471-2164-8-42;
RA   Roni V., Carpio R., Wissinger B.;
RT   "Mapping of transcription start sites of human retina expressed
RT   genes.";
RL   BMC Genomics 8:42-42(2007).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=10075733; DOI=10.1074/jbc.274.12.8269;
RA   Sun H., Molday R.S., Nathans J.;
RT   "Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR,
RT   the photoreceptor-specific ATP-binding cassette transporter
RT   responsible for Stargardt disease.";
RL   J. Biol. Chem. 274:8269-8281(1999).
RN   [9]
RP   DISEASE.
RX   PubMed=9466990; DOI=10.1093/hmg/7.3.355;
RA   Cremers F.P.M., van de Pol D.J.R., van Driel M.A., den Hollander A.I.,
RA   van Haren F.J.J., Knoers N.V.A.M., Tijmes N., Bergen A.A.B.,
RA   Rohrschneider K., Blankenagel A., Pinckers A.J.L.G., Deutman A.F.,
RA   Hoyng C.B.;
RT   "Autosomal recessive retinitis pigmentosa and cone-rod dystrophy
RT   caused by splice site mutations in the Stargardt's disease gene
RT   ABCR.";
RL   Hum. Mol. Genet. 7:355-362(1998).
RN   [10]
RP   MEMBRANE TOPOLOGY, AND GLYCOSYLATION AT ASN-98; ASN-415; ASN-444;
RP   ASN-504; ASN-1469; ASN-1529; ASN-1588 AND ASN-1662.
RX   PubMed=11320094; DOI=10.1074/jbc.M101902200;
RA   Bungert S., Molday L.L., Molday R.S.;
RT   "Membrane topology of the ATP binding cassette transporter ABCR and
RT   its relationship to ABC1 and related ABCA transporters: identification
RT   of N-linked glycosylation sites.";
RL   J. Biol. Chem. 276:23539-23546(2001).
RN   [11]
RP   VARIANTS ARMD2, AND VARIANTS.
RX   PubMed=9295268; DOI=10.1126/science.277.5333.1805;
RA   Allikmets R., Shroyer N.F., Singh N., Seddon J.M., Lewis R.A.,
RA   Bernstein P.S., Peiffer A., Zabriskie N.A., Li Y., Hutchinson A.,
RA   Dean M., Lupski J.R., Leppert M.;
RT   "Mutation of the Stargardt disease gene (ABCR) in age-related macular
RT   degeneration.";
RL   Science 277:1805-1807(1997).
RN   [12]
RP   VARIANTS STGD1 TRP-18; CYS-212; HIS-636; MET-1019; VAL-1038; CYS-1108;
RP   TRP-1640; SER-1977 AND HIS-2107, AND VARIANTS FFM PRO-11; PRO-541;
RP   VAL-1038; GLU-1091; CYS-1508; PHE-1970 AND ARG-1971.
RX   PubMed=9781034; DOI=10.1038/sj.ejhg.5200221;
RA   Rozet J.-M., Gerber S., Souied E., Perrault I., Chatelin S., Ghazi I.,
RA   Leowski C., Dufier J.-L., Munnich A., Kaplan J.;
RT   "Spectrum of ABCR gene mutations in autosomal recessive macular
RT   dystrophies.";
RL   Eur. J. Hum. Genet. 6:291-295(1998).
RN   [13]
RP   VARIANTS STGD1.
RX   PubMed=9973280; DOI=10.1086/302251;
RA   Lewis R.A., Shroyer N.F., Singh N., Allikmets R., Hutchinson A.,
RA   Li Y., Lupski J.R., Leppert M., Dean M.;
RT   "Genotype/phenotype analysis of a photoreceptor-specific ATP-binding
RT   cassette transporter gene, ABCR, in Stargardt disease.";
RL   Am. J. Hum. Genet. 64:422-434(1999).
RN   [14]
RP   VARIANTS STGD1, AND VARIANTS.
RX   PubMed=10090887; DOI=10.1086/302323;
RA   Maugeri A., van Driel M.A., van de Pol D.J.R., Klevering B.J.,
RA   van Haren F.J.J., Tijmes N., Bergen A.A.B., Rohrschneider K.,
RA   Blankenagel A., Pinckers A.J.L.G., Dahl N., Brunner H.G.,
RA   Deutman A.F., Hoyng C.B., Cremers F.P.M.;
RT   "The 2588G-->C mutation in the ABCR gene is a mild frequent founder
RT   mutation in the western European population and allows the
RT   classification of ABCR Mutations in patients with Stargardt disease.";
RL   Am. J. Hum. Genet. 64:1024-1035(1999).
RN   [15]
RP   VARIANT STGD1 TYR-54, AND VARIANT ALA-863.
RX   PubMed=10612508; DOI=10.1016/S0002-9394(99)00236-6;
RA   Zhang K., Garibaldi D.C., Kniazeva M., Albini T., Chiang M.F.,
RA   Kerrigan M., Sunness J.S., Han M., Allikmets R.;
RT   "A novel mutation in the ABCR gene in four patients with autosomal
RT   recessive Stargardt disease.";
RL   Am. J. Ophthalmol. 128:720-724(1999).
RN   [16]
RP   VARIANTS STGD1 VAL-60; ARG-206; ASN-300; PRO-541; ALA-849; PRO-974;
RP   VAL-1038; CYS-1108; LEU-1408; ARG-1488; ASP-1652; PRO-1729; GLU-1961;
RP   TRP-2038; TRP-2077; HIS-2107; ARG-2128 AND TYR-2150.
RX   PubMed=10206579; DOI=10.1001/archopht.117.4.504;
RA   Fishman G.A., Stone E.M., Grover S., Derlacki D.J., Haines H.L.,
RA   Hockey R.R.;
RT   "Variation of clinical expression in patients with Stargardt dystrophy
RT   and sequence variations in the ABCR gene.";
RL   Arch. Ophthalmol. 117:504-510(1999).
RN   [17]
RP   VARIANTS GLU-1961 AND ASN-2177.
RX   PubMed=10880298; DOI=10.1086/303018;
RA   Allikmets R., Tammur J., Hutchinson A., Lewis R.A., Shroyer N.F.,
RA   Dalakishvili K., Lupski J.R., Steiner K., Pauleikhoff D., Holz F.G.,
RA   Weber B.H.F., Dean M., Atkinson A., Gail M.H., Bernstein P.S.,
RA   Singh N., Peiffer A., Zabriskie N.A., Leppert M., Seddon J.M.,
RA   Zhang K., Sunness J.S., Udar N.S., Yelchits S., Silva-Garcia R.,
RA   Small K.W., Simonelli F., Testa F., D'Urso M., Brancato R.,
RA   Rinaldi E., Ingvast S., Taube A., Wadelius C., Souied E., Ducroq D.,
RA   Kaplan J., Assink J.J.M., ten Brink J.B., de Jong P.T.V.M.,
RA   Bergen A.A.B., Maugeri A., van Driel M.A., Hoyng C.B., Cremers F.P.M.,
RA   Paloma E., Coco R., Balcells S., Gonzalez-Duarte R., Kermani S.,
RA   Stanga P., Bhattacharya S.S., Bird A.C.;
RT   "Further evidence for an association of ABCR alleles with age-related
RT   macular degeneration.";
RL   Am. J. Hum. Genet. 67:487-491(2000).
RN   [18]
RP   VARIANTS STGD1 GLU-60; THR-60; GLU-65; LEU-68; ARG-72; CYS-212;
RP   SER-230; SER-247; VAL-328; LYS-471; PRO-541; GLN-572; ARG-607;
RP   LYS-635; CYS-653; TYR-764; ARG-765; ALA-901; ILE-959; LYS-1036;
RP   VAL-1038; PRO-1063; ASP-1087; CYS-1097; CYS-1108; LEU-1380; LYS-1399;
RP   PRO-1430; VAL-1440; HIS-1443; LEU-1486; TYR-1488; MET-1537; PRO-1689;
RP   LEU-1705; THR-1733; ARG-1748; PRO-1763; LYS-1885; HIS-1898; GLU-1961;
RP   ARG-1975; SER-1977; GLY-2077; TRP-2077 AND VAL-2241, AND VARIANTS
RP   GLN-152; HIS-212; ARG-423; ILE-552; ARG-914; GLN-943; THR-1562;
RP   ILE-1868; MET-1921; LEU-1948; PHE-1970; ALA-2059; ASN-2177 AND
RP   VAL-2216.
RX   PubMed=10958763; DOI=10.1086/303090;
RA   Rivera A., White K., Stoehr H., Steiner K., Hemmrich N., Grimm T.,
RA   Jurklies B., Lorenz B., Scholl H.P.N., Apfelstedt-Sylla E.,
RA   Weber B.H.F.;
RT   "A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene
RT   in Stargardt disease and age-related macular degeneration.";
RL   Am. J. Hum. Genet. 67:800-813(2000).
RN   [19]
RP   VARIANTS CORD3 GLU-65; CYS-212; PRO-541; ALA-863; GLY-863 DEL;
RP   VAL-1038; LYS-1122; TYR-1490 AND ASP-1598.
RX   PubMed=10958761; DOI=10.1086/303079;
RA   Maugeri A., Klevering B.J., Rohrschneider K., Blankenagel A.,
RA   Brunner H.G., Deutman A.F., Hoyng C.B., Cremers F.P.M.;
RT   "Mutations in the ABCA4 (ABCR) gene are the major cause of autosomal
RT   recessive cone-rod dystrophy.";
RL   Am. J. Hum. Genet. 67:960-966(2000).
RN   [20]
RP   VARIANTS STGD1 ASP-340; GLN-572; ALA-863; SER-965; VAL-1038; ALA-1780
RP   AND HIS-1898, AND VARIANT GLN-943.
RX   PubMed=10746567; DOI=10.1007/s004390051034;
RA   Shroyer N.F., Lewis R.A., Lupski J.R.;
RT   "Complex inheritance of ABCR mutations in Stargardt disease: linkage
RT   disequilibrium, complex alleles, and pseudodominance.";
RL   Hum. Genet. 106:244-248(2000).
RN   [21]
RP   VARIANTS STGD1.
RX   PubMed=10634594;
RA   Papaioannou M., Ocaka L., Bessant D., Lois N., Bird A.C., Payne A.,
RA   Bhattacharya S.S.;
RT   "An analysis of ABCR mutations in British patients with recessive
RT   retinal dystrophies.";
RL   Invest. Ophthalmol. Vis. Sci. 41:16-19(2000).
RN   [22]
RP   VARIANTS STGD1 CYS-212; ASP-767; ILE-897; VAL-1038; LYS-1087;
RP   LYS-1399; GLN-1640 AND GLU-1961, AND VARIANT HIS-212.
RX   PubMed=10711710;
RA   Simonelli F., Testa F., de Crecchio G., Rinaldi E., Hutchinson A.,
RA   Atkinson A., Dean M., D'Urso M., Allikmets R.;
RT   "New ABCR mutations and clinical phenotype in Italian patients with
RT   Stargardt disease.";
RL   Invest. Ophthalmol. Vis. Sci. 41:892-897(2000).
RN   [23]
RP   CHARACTERIZATION OF VARIANTS, AND MUTAGENESIS OF GLY-966; LYS-969;
RP   GLY-1975 AND LYS-1978.
RX   PubMed=11017087; DOI=10.1038/79994;
RA   Sun H., Smallwood P.M., Nathans J.;
RT   "Biochemical defects in ABCR protein variants associated with human
RT   retinopathies.";
RL   Nat. Genet. 26:242-246(2000).
RN   [24]
RP   VARIANT STGD1 ASN-972, AND VARIANTS GLN-943; ILE-1868 AND LEU-1948.
RX   PubMed=11594993; DOI=10.1034/j.1600-0420.2001.790520.x;
RA   Eksandh L., Ekstroem U., Abrahamson M., Bauer B., Andreasson S.;
RT   "Different clinical expressions in two families with Stargardt's
RT   macular dystrophy (STGD1).";
RL   Acta Ophthalmol. Scand. 79:524-530(2001).
RN   [25]
RP   VARIANTS RETINAL TOXICITY CYS-1129; ARG-1201 AND HIS-2107, AND
RP   VARIANTS HIS-212; ARG-423; ILE-1868 AND ILE-2255.
RX   PubMed=11384574; DOI=10.1016/S0002-9394(01)00838-8;
RA   Shroyer N.F., Lewis R.A., Lupski J.R.;
RT   "Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is
RT   retinal toxicity by chloroquine and hydroxychloroquine related to
RT   Stargardt disease?";
RL   Am. J. Ophthalmol. 131:761-766(2001).
RN   [26]
RP   VARIANTS GLU-1961 AND ASN-2177.
RX   PubMed=11346402; DOI=10.1001/archopht.119.5.745;
RA   Guymer R.H., Heon E., Lotery A.J., Munier F.L., Schorderet D.F.,
RA   Baird P.N., McNeil R.J., Haines H.L., Sheffield V.C., Stone E.M.;
RT   "Variation of codons 1961 and 2177 of the Stargardt disease gene is
RT   not associated with age-related macular degeneration.";
RL   Arch. Ophthalmol. 119:745-751(2001).
RN   [27]
RP   VARIANTS FFM GLY-339; ALA-863; TRP-943; ARG-991; VAL-1038; CYS-1108;
RP   ARG-1488; THR-1562; GLN-1640; PHE-2027; GLN-2030 AND CYS-2106, AND
RP   VARIANTS HIS-212; ARG-423; GLN-943; THR-1148; ILE-1868 AND ILE-2255.
RX   PubMed=11379881; DOI=10.1007/s004390100493;
RA   Yatsenko A.N., Shroyer N.F., Lewis R.A., Lupski J.R.;
RT   "Late-onset Stargardt disease is associated with missense mutations
RT   that map outside known functional regions of ABCR (ABCA4).";
RL   Hum. Genet. 108:346-355(2001).
RN   [28]
RP   VARIANTS STGD1 SER-686; TRP-1055; ASP-1799; ASP-1805; PRO-1940 AND
RP   HIS-2107, VARIANTS FFM MET-1253 AND PRO-1940, VARIANTS CORD3 CYS-212
RP   AND ARG-2060, AND VARIANTS GLN-943; LEU-1948 AND ILE-2255.
RX   PubMed=11385708; DOI=10.1002/humu.1133;
RA   Paloma E., Martinez-Mir A., Vilageliu L., Gonzalez-Duarte R.,
RA   Balcells S.;
RT   "Spectrum of ABCA4 (ABCR) gene mutations in Spanish patients with
RT   autosomal recessive macular dystrophies.";
RL   Hum. Mutat. 17:504-510(2001).
RN   [29]
RP   VARIANTS STGD1, AND VARIANTS.
RX   PubMed=11328725;
RA   Webster A.R., Heon E., Lotery A.J., Vandenburgh K., Casavant T.L.,
RA   Oh K.T., Beck G., Fishman G.A., Lam B.L., Levin A., Heckenlively J.R.,
RA   Jacobson S.G., Weleber R.G., Sheffield V.C., Stone E.M.;
RT   "An analysis of allelic variation in the ABCA4 gene.";
RL   Invest. Ophthalmol. Vis. Sci. 42:1179-1189(2001).
RN   [30]
RP   VARIANTS STGD1 13-LYS--TRP-15 DEL; TYR-54; LYS-58; VAL-60; GLU-65;
RP   GLU-77; HIS-190; PRO-244; ARG-309; CYS-525; CYS-537; PRO-541; PRO-549;
RP   ARG-550; GLN-602; ARG-607; MET-643; ASP-767; PRO-797; ARG-821;
RP   THR-824; ALA-863; ALA-935; TRP-943; ALA-989; VAL-1038; CYS-1108;
RP   LEU-1108; LYS-1122; ARG-1201; GLN-1300; LEU-1380; PRO-1388; ARG-1408;
RP   LEU-1486; ARG-1488; TYR-1490; MET-1526; ASN-1532; THR-1562; TRP-1640;
RP   LEU-1776; THR-1846; GLU-1961; SER-1977; PHE-2027; GLN-2030; PRO-2035;
RP   LEU-2050; CYS-2107; HIS-2107; TRP-2139; ARG-2150 AND TYR-2150,
RP   VARIANTS CORD3 GLN-1640 AND ASP-2146, AND VARIANTS HIS-212; ARG-423;
RP   GLN-943; THR-1637; ILE-1868 AND LEU-1948.
RX   PubMed=11527935;
RA   Briggs C.E., Rucinski D., Rosenfeld P.J., Hirose T., Berson E.L.,
RA   Dryja T.P.;
RT   "Mutations in ABCR (ABCA4) in patients with Stargardt macular
RT   degeneration or cone-rod degeneration.";
RL   Invest. Ophthalmol. Vis. Sci. 42:2229-2236(2001).
RN   [31]
RP   VARIANT ARG-423.
RX   PubMed=12111378; DOI=10.1007/s100380200041;
RA   Iida A., Saito S., Sekine A., Mishima C., Kitamura Y., Kondo K.,
RA   Harigae S., Osawa S., Nakamura Y.;
RT   "Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes
RT   encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8,
RT   ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and
RT   ABCG8.";
RL   J. Hum. Genet. 47:285-310(2002).
RN   [32]
RP   VARIANT [LARGE SCALE ANALYSIS] MET-224.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [33]
RP   VARIANTS ARMD2 GLU-762; LEU-1129; CYS-1724; SER-1977; ASN-2047 AND
RP   TYR-2137, AND VARIANT ILE-552.
RX   PubMed=19028736; DOI=10.1136/bjo.2008.145193;
RA   Aguirre-Lamban J., Riveiro-Alvarez R., Maia-Lopes S.,
RA   Cantalapiedra D., Vallespin E., Avila-Fernandez A.,
RA   Villaverde-Montero C., Trujillo-Tiebas M.J., Ramos C., Ayuso C.;
RT   "Molecular analysis of the ABCA4 gene for reliable detection of
RT   allelic variations in Spanish patients: identification of 21 novel
RT   variants.";
RL   Br. J. Ophthalmol. 93:614-621(2009).
RN   [34]
RP   VARIANTS STGD1 VAL-156; CYS-212; LYS-380; ARG-550; PRO-572; TRP-602;
RP   ARG-607; CYS-653; ASP-767; ILE-897; ALA-901; MET-931; SER-965;
RP   MET-1019; HIS-1108; LEU-1129; LEU-1380; ILE-1433; LEU-1486; TYR-1490;
RP   GLN-1640; TRP-1640; ARG-1748; ASP-1799; PRO-1940; GLU-1961; SER-1977;
RP   PHE-2027; ARG-2060; HIS-2107; TYR-2150 AND VAL-2241.
RX   PubMed=18977788; DOI=10.1136/bjo.2008.148155;
RA   Riveiro-Alvarez R., Aguirre-Lamban J., Lopez-Martinez M.A.,
RA   Trujillo-Tiebas M.J., Cantalapiedra D., Vallespin E.,
RA   Avila-Fernandez A., Ramos C., Ayuso C.;
RT   "Frequency of ABCA4 mutations in 278 Spanish controls: an insight into
RT   the prevalence of autosomal recessive Stargardt disease.";
RL   Br. J. Ophthalmol. 93:1359-1364(2009).
CC   -!- FUNCTION: In the visual cycle, acts as an inward-directed retinoid
CC       flipase, retinoid substrates imported by ABCA4 from the
CC       extracellular or intradiscal (rod) membrane surfaces to the
CC       cytoplasmic membrane surface are all-trans-retinaldehyde (ATR) and
CC       N-retinyl-phosphatidyl-ethanolamine (NR-PE). Once transported to
CC       the cytoplasmic surface, ATR is reduced to vitamin A by trans-
CC       retinol dehydrogenase (tRDH) and then transferred to the retinal
CC       pigment epithelium (RPE) where it is converted to 11-cis-retinal.
CC       May play a role in photoresponse, removing ATR/NR-PE from the
CC       extracellular photoreceptor surfaces during bleach recovery.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC       Note=Localized to outer segment disk edges of rods and cones, with
CC       around one million copies/photoreceptor.
CC   -!- TISSUE SPECIFICITY: Retinal-specific. Seems to be exclusively
CC       found in the rims of rod photoreceptor cells.
CC   -!- POLYMORPHISM: The variant Ala-863 is present in the general
CC       population at a frequency of approximately 3% and 1% in Northern
CC       Europe and United States, respectively. It is a mild alteration
CC       probably leading to STGD phenotype only in combination with a more
CC       severe allele. The variant Glu-1961 is found with high frequency
CC       in healthy individuals of Somali ancestry.
CC   -!- DISEASE: Stargardt disease 1 (STGD1) [MIM:248200]: A common
CC       hereditary macular degeneration. It is characterized by decreased
CC       central vision, atrophy of the macula and underlying retinal
CC       pigment epithelium, and frequent presence of prominent flecks in
CC       the posterior pole of the retina. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Fundus flavimaculatus (FFM) [MIM:248200]: Autosomal
CC       recessive retinal disorder very similar to Stargardt disease. In
CC       contrast to Stargardt disease, FFM is characterized by later onset
CC       and slowly progressive course. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Macular degeneration, age-related, 2 (ARMD2)
CC       [MIM:153800]: A form of age-related macular degeneration, a
CC       multifactorial eye disease and the most common cause of
CC       irreversible vision loss in the developed world. In most patients,
CC       the disease is manifest as ophthalmoscopically visible yellowish
CC       accumulations of protein and lipid that lie beneath the retinal
CC       pigment epithelium and within an elastin-containing structure
CC       known as Bruch membrane. Note=Disease susceptibility is associated
CC       with variations affecting the gene represented in this entry.
CC   -!- DISEASE: Cone-rod dystrophy 3 (CORD3) [MIM:604116]: An inherited
CC       retinal dystrophy characterized by retinal pigment deposits
CC       visible on fundus examination, predominantly in the macular
CC       region, and initial loss of cone photoreceptors followed by rod
CC       degeneration. This leads to decreased visual acuity and
CC       sensitivity in the central visual field, followed by loss of
CC       peripheral vision. Severe loss of vision occurs earlier than in
CC       retinitis pigmentosa. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Retinitis pigmentosa 19 (RP19) [MIM:601718]: A retinal
CC       dystrophy belonging to the group of pigmentary retinopathies.
CC       Retinitis pigmentosa is characterized by retinal pigment deposits
CC       visible on fundus examination and primary loss of rod
CC       photoreceptor cells followed by secondary loss of cone
CC       photoreceptors. Patients typically have night vision blindness and
CC       loss of midperipheral visual field. As their condition progresses,
CC       they lose their far peripheral visual field and eventually central
CC       vision as well. RP19 is characterized by choroidal atrophy.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCA
CC       family.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAE06122.1; Type=Erroneous initiation;
CC   -!- WEB RESOURCE: Name=Mutations of the ABCA4 gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="http://www.retina-international.org/files/sci-news/abcrmut.htm";
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=P78363";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U88667; AAC51144.1; -; mRNA.
DR   EMBL; AF000148; AAC23915.1; -; mRNA.
DR   EMBL; Y15635; CAA75729.1; -; Genomic_DNA.
DR   EMBL; Y15636; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15637; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15638; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15639; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15640; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15641; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15642; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15643; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15644; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15645; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15646; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15647; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15648; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15649; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15650; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15651; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15652; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15653; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15654; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15655; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15656; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15657; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15658; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15659; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15660; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15661; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15662; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15663; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15664; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15665; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15666; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15667; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15668; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15669; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15670; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15671; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15672; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15673; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15674; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15675; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15676; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15677; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15678; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15679; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15680; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15681; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15682; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15683; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; Y15684; CAA75729.1; JOINED; Genomic_DNA.
DR   EMBL; AF001945; AAC05632.1; -; mRNA.
DR   EMBL; AB210040; BAE06122.1; ALT_INIT; mRNA.
DR   EMBL; AC093579; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC105278; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; DQ426859; ABD90529.1; -; mRNA.
DR   CCDS; CCDS747.1; -.
DR   RefSeq; NP_000341.2; NM_000350.2.
DR   UniGene; Hs.416707; -.
DR   ProteinModelPortal; P78363; -.
DR   BioGrid; 106542; 1.
DR   STRING; 9606.ENSP00000359245; -.
DR   TCDB; 3.A.1.211.2; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; P78363; -.
DR   DMDM; 6707663; -.
DR   PaxDb; P78363; -.
DR   PRIDE; P78363; -.
DR   DNASU; 24; -.
DR   Ensembl; ENST00000370225; ENSP00000359245; ENSG00000198691.
DR   GeneID; 24; -.
DR   KEGG; hsa:24; -.
DR   UCSC; uc001dqh.3; human.
DR   CTD; 24; -.
DR   GeneCards; GC01M094458; -.
DR   GeneReviews; ABCA4; -.
DR   H-InvDB; HIX0028510; -.
DR   HGNC; HGNC:34; ABCA4.
DR   MIM; 153800; phenotype.
DR   MIM; 248200; phenotype.
DR   MIM; 601691; gene.
DR   MIM; 601718; phenotype.
DR   MIM; 604116; phenotype.
DR   neXtProt; NX_P78363; -.
DR   Orphanet; 279; Age-related macular degeneration.
DR   Orphanet; 1872; Cone rod dystrophy.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   Orphanet; 827; Stargardt disease.
DR   PharmGKB; PA24379; -.
DR   eggNOG; COG1131; -.
DR   HOGENOM; HOG000231547; -.
DR   HOVERGEN; HBG050436; -.
DR   InParanoid; P78363; -.
DR   KO; K05644; -.
DR   OMA; IMVKGAF; -.
DR   OrthoDB; EOG78D7J6; -.
DR   PhylomeDB; P78363; -.
DR   TreeFam; TF105191; -.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_116125; Disease.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   ChiTaRS; ABCA4; human.
DR   GeneWiki; ABCA4; -.
DR   GenomeRNAi; 24; -.
DR   NextBio; 75; -.
DR   PRO; PR:P78363; -.
DR   ArrayExpress; P78363; -.
DR   Bgee; P78363; -.
DR   CleanEx; HS_ABCA4; -.
DR   Genevestigator; P78363; -.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:InterPro.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0097381; C:photoreceptor disc membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; TAS:ProtInc.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; TAS:ProtInc.
DR   GO; GO:0004012; F:phospholipid-translocating ATPase activity; IEA:Ensembl.
DR   GO; GO:0005215; F:transporter activity; TAS:ProtInc.
DR   GO; GO:0006649; P:phospholipid transfer to membrane; IEA:Ensembl.
DR   GO; GO:0045494; P:photoreceptor cell maintenance; IEA:Ensembl.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   GO; GO:0007601; P:visual perception; TAS:ProtInc.
DR   Gene3D; 3.40.50.300; -; 2.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR026082; ABC_A.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005951; Rim_ABC_transpt.
DR   PANTHER; PTHR19229; PTHR19229; 1.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   TIGRFAMs; TIGR01257; rim_protein; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Age-related macular degeneration; ATP-binding; Complete proteome;
KW   Cone-rod dystrophy; Disease mutation; Disulfide bond; Glycoprotein;
KW   Membrane; Nucleotide-binding; Polymorphism; Reference proteome;
KW   Repeat; Retinitis pigmentosa; Sensory transduction; Stargardt disease;
KW   Transmembrane; Transmembrane helix; Transport; Vision.
FT   CHAIN         1   2273       Retinal-specific ATP-binding cassette
FT                                transporter.
FT                                /FTId=PRO_0000093301.
FT   TOPO_DOM      1     21       Cytoplasmic.
FT   TRANSMEM     22     42       Helical; (Potential).
FT   TOPO_DOM     43    646       Extracellular.
FT   TRANSMEM    647    667       Helical; (Potential).
FT   TRANSMEM    700    720       Helical; (Potential).
FT   TRANSMEM    731    751       Helical; (Potential).
FT   TRANSMEM    760    780       Helical; (Potential).
FT   TRANSMEM    836    856       Helical; (Potential).
FT   TOPO_DOM    857   1376       Cytoplasmic.
FT   TRANSMEM   1377   1397       Helical; (Potential).
FT   TOPO_DOM   1398   1727       Extracellular.
FT   TRANSMEM   1728   1748       Helical; (Potential).
FT   TRANSMEM   1760   1780       Helical; (Potential).
FT   TRANSMEM   1793   1813       Helical; (Potential).
FT   TRANSMEM   1832   1852       Helical; (Potential).
FT   TRANSMEM   1874   1894       Helical; (Potential).
FT   TOPO_DOM   1895   2273       Cytoplasmic.
FT   DOMAIN      929   1160       ABC transporter 1.
FT   DOMAIN     1938   2170       ABC transporter 2.
FT   NP_BIND     963    970       ATP 1 (Potential).
FT   NP_BIND    1972   1979       ATP 2 (Potential).
FT   CARBOHYD     98     98       N-linked (GlcNAc...).
FT   CARBOHYD    415    415       N-linked (GlcNAc...).
FT   CARBOHYD    444    444       N-linked (GlcNAc...).
FT   CARBOHYD    504    504       N-linked (GlcNAc...).
FT   CARBOHYD   1469   1469       N-linked (GlcNAc...).
FT   CARBOHYD   1529   1529       N-linked (GlcNAc...).
FT   CARBOHYD   1588   1588       N-linked (GlcNAc...).
FT   CARBOHYD   1662   1662       N-linked (GlcNAc...).
FT   DISULFID     75    324       By similarity.
FT   DISULFID   1488   1502       By similarity.
FT   VARIANT      11     11       L -> P (in FFM).
FT                                /FTId=VAR_012493.
FT   VARIANT      13     15       Missing (in STGD1).
FT                                /FTId=VAR_012494.
FT   VARIANT      18     18       R -> W (in STGD1; dbSNP:rs121909205).
FT                                /FTId=VAR_008398.
FT   VARIANT      24     24       R -> H (in STGD1).
FT                                /FTId=VAR_008399.
FT   VARIANT      54     54       C -> Y (in STGD1).
FT                                /FTId=VAR_008400.
FT   VARIANT      58     58       N -> K (in STGD1).
FT                                /FTId=VAR_012495.
FT   VARIANT      60     60       A -> E (in STGD1).
FT                                /FTId=VAR_012496.
FT   VARIANT      60     60       A -> T (in STGD1).
FT                                /FTId=VAR_012497.
FT   VARIANT      60     60       A -> V (in STGD1).
FT                                /FTId=VAR_008492.
FT   VARIANT      65     65       G -> E (in STGD1 and CORD3).
FT                                /FTId=VAR_008401.
FT   VARIANT      68     68       P -> L (in STGD1).
FT                                /FTId=VAR_012498.
FT   VARIANT      68     68       P -> R (in STGD1).
FT                                /FTId=VAR_012499.
FT   VARIANT      72     72       G -> R (in STGD1).
FT                                /FTId=VAR_012500.
FT   VARIANT      75     75       C -> G (in STGD1).
FT                                /FTId=VAR_008402.
FT   VARIANT      77     77       V -> E (in STGD1).
FT                                /FTId=VAR_012501.
FT   VARIANT      96     96       N -> D (in STGD1).
FT                                /FTId=VAR_008403.
FT   VARIANT      96     96       N -> H (in STGD1).
FT                                /FTId=VAR_008404.
FT   VARIANT     100    100       S -> P (in STGD1).
FT                                /FTId=VAR_012502.
FT   VARIANT     152    152       R -> Q (in dbSNP:rs62646862).
FT                                /FTId=VAR_012503.
FT   VARIANT     156    156       I -> V (in STGD1; dbSNP:rs62646863).
FT                                /FTId=VAR_012504.
FT   VARIANT     190    190       Q -> H (in STGD1).
FT                                /FTId=VAR_012505.
FT   VARIANT     192    192       A -> T (in STGD1).
FT                                /FTId=VAR_008405.
FT   VARIANT     206    206       S -> R (in STGD1; reduced basal and
FT                                retinal-stimulated ATP-hydrolysis;
FT                                dbSNP:rs61748536).
FT                                /FTId=VAR_012506.
FT   VARIANT     212    212       R -> C (in STGD1 and CORD3; common
FT                                mutation in southern Europe; reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008406.
FT   VARIANT     212    212       R -> H (in dbSNP:rs6657239).
FT                                /FTId=VAR_012507.
FT   VARIANT     220    220       R -> C (in STGD1).
FT                                /FTId=VAR_012508.
FT   VARIANT     224    224       T -> M (in a breast cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035736.
FT   VARIANT     230    230       C -> S (in STGD1).
FT                                /FTId=VAR_012509.
FT   VARIANT     244    244       L -> P (in STGD1).
FT                                /FTId=VAR_012510.
FT   VARIANT     247    247       N -> S (in STGD1).
FT                                /FTId=VAR_012511.
FT   VARIANT     249    249       D -> G (in STGD1).
FT                                /FTId=VAR_008407.
FT   VARIANT     300    300       T -> N (in STGD1).
FT                                /FTId=VAR_008408.
FT   VARIANT     309    309       P -> R (in STGD1).
FT                                /FTId=VAR_012512.
FT   VARIANT     328    328       E -> V (in STGD1).
FT                                /FTId=VAR_012513.
FT   VARIANT     333    333       R -> W (in STGD1).
FT                                /FTId=VAR_012514.
FT   VARIANT     336    336       S -> C (in STGD1).
FT                                /FTId=VAR_008409.
FT   VARIANT     339    339       W -> G (in FFM).
FT                                /FTId=VAR_012515.
FT   VARIANT     340    340       Y -> D (in STGD1).
FT                                /FTId=VAR_008410.
FT   VARIANT     380    380       N -> K (in STGD1).
FT                                /FTId=VAR_012516.
FT   VARIANT     407    407       A -> V (in STGD1 and CORD3).
FT                                /FTId=VAR_008411.
FT   VARIANT     423    423       H -> R (in dbSNP:rs3112831).
FT                                /FTId=VAR_012517.
FT   VARIANT     445    445       S -> R (in STGD1).
FT                                /FTId=VAR_008412.
FT   VARIANT     471    471       E -> K (in ARMD2 and STGD1; ATP-binding
FT                                capacity and retinal stimulation as in
FT                                wild-type; dbSNP:rs1800548).
FT                                /FTId=VAR_008413.
FT   VARIANT     523    523       D -> E (in STGD1).
FT                                /FTId=VAR_008414.
FT   VARIANT     525    525       F -> C (in STGD1).
FT                                /FTId=VAR_012518.
FT   VARIANT     537    537       R -> C (in STGD1).
FT                                /FTId=VAR_012519.
FT   VARIANT     541    541       L -> P (in STGD1, FFM and CORD3; reduced
FT                                ATP-binding capacity; abolishes retinal-
FT                                stimulated ATP hydrolysis).
FT                                /FTId=VAR_008415.
FT   VARIANT     549    549       A -> P (in STGD1).
FT                                /FTId=VAR_012520.
FT   VARIANT     550    550       G -> R (in STGD1).
FT                                /FTId=VAR_012521.
FT   VARIANT     552    552       V -> I.
FT                                /FTId=VAR_012522.
FT   VARIANT     572    572       R -> P (in STGD1).
FT                                /FTId=VAR_008416.
FT   VARIANT     572    572       R -> Q (in STGD1).
FT                                /FTId=VAR_008417.
FT   VARIANT     602    602       R -> Q (in STGD1).
FT                                /FTId=VAR_012523.
FT   VARIANT     602    602       R -> W (in STGD1).
FT                                /FTId=VAR_008418.
FT   VARIANT     607    607       G -> R (in STGD1).
FT                                /FTId=VAR_012524.
FT   VARIANT     607    607       G -> W (in STGD1).
FT                                /FTId=VAR_012525.
FT   VARIANT     608    608       F -> I (in STGD1).
FT                                /FTId=VAR_008419.
FT   VARIANT     635    635       Q -> K (in STGD1).
FT                                /FTId=VAR_012526.
FT   VARIANT     636    636       Q -> H (in STGD1).
FT                                /FTId=VAR_012527.
FT   VARIANT     643    643       V -> G (in dbSNP:rs114572202).
FT                                /FTId=VAR_008420.
FT   VARIANT     643    643       V -> M (in STGD1; dbSNP:rs143548435).
FT                                /FTId=VAR_012528.
FT   VARIANT     645    645       D -> N (in STGD1).
FT                                /FTId=VAR_008421.
FT   VARIANT     653    653       R -> C (in STGD1).
FT                                /FTId=VAR_012529.
FT   VARIANT     686    686       L -> S (in STGD1).
FT                                /FTId=VAR_012530.
FT   VARIANT     716    716       T -> M (in STGD1).
FT                                /FTId=VAR_012531.
FT   VARIANT     752    752       S -> I (in dbSNP:rs1801369).
FT                                /FTId=VAR_014703.
FT   VARIANT     762    762       A -> E (in ARMD2).
FT                                /FTId=VAR_067427.
FT   VARIANT     764    764       C -> Y (in STGD1).
FT                                /FTId=VAR_012532.
FT   VARIANT     765    765       S -> N (in STGD1).
FT                                /FTId=VAR_012534.
FT   VARIANT     765    765       S -> R (in STGD1).
FT                                /FTId=VAR_012533.
FT   VARIANT     767    767       V -> D (in STGD1).
FT                                /FTId=VAR_012535.
FT   VARIANT     797    797       L -> P (in STGD1).
FT                                /FTId=VAR_012536.
FT   VARIANT     818    818       G -> E (in ARMD2 and STGD1; reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008422.
FT   VARIANT     821    821       W -> R (in STGD1).
FT                                /FTId=VAR_008423.
FT   VARIANT     824    824       I -> T (in STGD1).
FT                                /FTId=VAR_012537.
FT   VARIANT     846    846       D -> H.
FT                                /FTId=VAR_008493.
FT   VARIANT     849    849       V -> A (in STGD1; dbSNP:rs61749435).
FT                                /FTId=VAR_012538.
FT   VARIANT     851    851       G -> D (in STGD1; highly reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008424.
FT   VARIANT     854    854       A -> T (in STGD1).
FT                                /FTId=VAR_012539.
FT   VARIANT     863    863       G -> A (in STGD1, FFM and CORD3; frequent
FT                                mutation in northern Europe in linkage
FT                                disequilibrium with the polymorphic
FT                                variant Q-943; reduced ATP-binding
FT                                capacity and retinal-stimulated ATP
FT                                hydrolysis; dbSNP:rs76157638).
FT                                /FTId=VAR_008425.
FT   VARIANT     863    863       Missing (in STGD1 and CORD3; reduced ATP-
FT                                binding capacity and retinal-stimulated
FT                                ATP hydrolysis).
FT                                /FTId=VAR_012540.
FT   VARIANT     873    873       F -> L (in STGD1).
FT                                /FTId=VAR_012541.
FT   VARIANT     897    897       T -> I (in STGD1; dbSNP:rs61749440).
FT                                /FTId=VAR_012542.
FT   VARIANT     901    901       T -> A (in dbSNP:rs61754030).
FT                                /FTId=VAR_008426.
FT   VARIANT     914    914       H -> R.
FT                                /FTId=VAR_012543.
FT   VARIANT     931    931       V -> M (in STGD1; dbSNP:rs58331765).
FT                                /FTId=VAR_008427.
FT   VARIANT     935    935       V -> A (in STGD1).
FT                                /FTId=VAR_012544.
FT   VARIANT     943    943       R -> Q (in linkage disequilibrium with A-
FT                                863 in the European population;
FT                                dbSNP:rs1801581).
FT                                /FTId=VAR_008428.
FT   VARIANT     943    943       R -> W (in STGD1 and FFM;
FT                                dbSNP:rs61749446).
FT                                /FTId=VAR_012545.
FT   VARIANT     957    957       Q -> R (in STGD1).
FT                                /FTId=VAR_008429.
FT   VARIANT     959    959       T -> I (in STGD1).
FT                                /FTId=VAR_012546.
FT   VARIANT     965    965       N -> S (in STGD1; reduced retinal-
FT                                stimulated ATP hydrolysis).
FT                                /FTId=VAR_008430.
FT   VARIANT     971    971       T -> N (in STGD1; highly reduced ATP-
FT                                binding capacity; abolishes retinal-
FT                                stimulated ATP hydrolysis).
FT                                /FTId=VAR_012547.
FT   VARIANT     972    972       T -> N (in STGD1; unknown pathological
FT                                significance).
FT                                /FTId=VAR_012548.
FT   VARIANT     974    974       S -> P (in STGD1).
FT                                /FTId=VAR_012549.
FT   VARIANT     978    978       G -> C (in STGD1).
FT                                /FTId=VAR_008431.
FT   VARIANT     989    989       V -> A (in STGD1; dbSNP:rs139296587).
FT                                /FTId=VAR_012550.
FT   VARIANT     991    991       G -> R (in FFM; dbSNP:rs147484266).
FT                                /FTId=VAR_012551.
FT   VARIANT    1014   1014       L -> R (in STGD1).
FT                                /FTId=VAR_012552.
FT   VARIANT    1019   1019       T -> A (in STGD1).
FT                                /FTId=VAR_012553.
FT   VARIANT    1019   1019       T -> M (in STGD1).
FT                                /FTId=VAR_012554.
FT   VARIANT    1022   1022       E -> K (in STGD1).
FT                                /FTId=VAR_012555.
FT   VARIANT    1031   1031       K -> E (in STGD1).
FT                                /FTId=VAR_012556.
FT   VARIANT    1036   1036       E -> K (in STGD1).
FT                                /FTId=VAR_008432.
FT   VARIANT    1038   1038       A -> V (in STGD1, FFM and CORD3; frequent
FT                                mutation; reduced ATP-binding and
FT                                retinal-stimulated ATP hydrolysis;
FT                                dbSNP:rs61751374).
FT                                /FTId=VAR_008433.
FT   VARIANT    1055   1055       R -> W (in STGD1).
FT                                /FTId=VAR_012557.
FT   VARIANT    1063   1063       S -> P (in STGD1).
FT                                /FTId=VAR_012558.
FT   VARIANT    1071   1071       S -> L (in STGD1; reduced ATP-binding
FT                                capacity).
FT                                /FTId=VAR_008434.
FT   VARIANT    1072   1072       V -> A (in STGD1).
FT                                /FTId=VAR_008435.
FT   VARIANT    1087   1087       E -> D (in STGD1).
FT                                /FTId=VAR_012559.
FT   VARIANT    1087   1087       E -> K (in STGD1).
FT                                /FTId=VAR_008436.
FT   VARIANT    1091   1091       G -> E (in FFM).
FT                                /FTId=VAR_012560.
FT   VARIANT    1097   1097       R -> C (in STGD1).
FT                                /FTId=VAR_012561.
FT   VARIANT    1108   1108       R -> C (in STGD1 and FFM; reduced ATP-
FT                                binding capacity; dbSNP:rs61750120).
FT                                /FTId=VAR_012562.
FT   VARIANT    1108   1108       R -> H (in STGD1).
FT                                /FTId=VAR_012563.
FT   VARIANT    1108   1108       R -> L (in STGD1).
FT                                /FTId=VAR_012564.
FT   VARIANT    1112   1112       T -> N (in STGD1).
FT                                /FTId=VAR_008437.
FT   VARIANT    1122   1122       E -> K (in STGD1 and CORD3).
FT                                /FTId=VAR_008438.
FT   VARIANT    1129   1129       R -> C (in STGD1; may predispose to
FT                                develop retinal toxicity after treatment
FT                                with chloroquine and hydroxychloroquine).
FT                                /FTId=VAR_012565.
FT   VARIANT    1129   1129       R -> L (in ARMD2 and STGD1; also found in
FT                                patients with fundus flavimaculatus;
FT                                reduced ATP-binding capacity;
FT                                dbSNP:rs1801269).
FT                                /FTId=VAR_008439.
FT   VARIANT    1148   1148       K -> T.
FT                                /FTId=VAR_012566.
FT   VARIANT    1201   1201       L -> R (in STGD1; may predispose to
FT                                develop retinal toxicity after treatment
FT                                with chloroquine and hydroxychloroquine;
FT                                dbSNP:rs61750126).
FT                                /FTId=VAR_008440.
FT   VARIANT    1204   1204       D -> N (in STGD1).
FT                                /FTId=VAR_008441.
FT   VARIANT    1250   1250       L -> P (in STGD1).
FT                                /FTId=VAR_012567.
FT   VARIANT    1253   1253       T -> M (in FFM; unknown pathological
FT                                significance).
FT                                /FTId=VAR_012568.
FT   VARIANT    1300   1300       R -> Q (in STGD1; dbSNP:rs61750129).
FT                                /FTId=VAR_012569.
FT   VARIANT    1314   1314       P -> T.
FT                                /FTId=VAR_008442.
FT   VARIANT    1380   1380       P -> L (in STGD1; reduced ATP-binding
FT                                capacity).
FT                                /FTId=VAR_008443.
FT   VARIANT    1388   1388       L -> P (in STGD1).
FT                                /FTId=VAR_012570.
FT   VARIANT    1399   1399       E -> K (in STGD1).
FT                                /FTId=VAR_012571.
FT   VARIANT    1406   1406       H -> Y (in STGD1).
FT                                /FTId=VAR_008444.
FT   VARIANT    1408   1408       W -> L (in STGD1).
FT                                /FTId=VAR_008445.
FT   VARIANT    1408   1408       W -> R (in STGD1; reduced retinal-
FT                                stimulated ATP hydrolysis).
FT                                /FTId=VAR_008446.
FT   VARIANT    1428   1428       T -> M (in ARMD2; dbSNP:rs1800549).
FT                                /FTId=VAR_008447.
FT   VARIANT    1429   1429       V -> A (in STGD1).
FT                                /FTId=VAR_008448.
FT   VARIANT    1430   1430       L -> P (in STGD1).
FT                                /FTId=VAR_012572.
FT   VARIANT    1433   1433       V -> I (in STGD1; dbSNP:rs56357060).
FT                                /FTId=VAR_008449.
FT   VARIANT    1439   1439       G -> D (in STGD1).
FT                                /FTId=VAR_008450.
FT   VARIANT    1440   1440       F -> S (in STGD1).
FT                                /FTId=VAR_008451.
FT   VARIANT    1440   1440       F -> V (in STGD1).
FT                                /FTId=VAR_012573.
FT   VARIANT    1443   1443       R -> H (in STGD1).
FT                                /FTId=VAR_012574.
FT   VARIANT    1486   1486       P -> L (in STGD1).
FT                                /FTId=VAR_008452.
FT   VARIANT    1488   1488       C -> F (in STGD1).
FT                                /FTId=VAR_012575.
FT   VARIANT    1488   1488       C -> R (in STGD1 and FFM; reduced
FT                                retinal-stimulated ATP hydrolysis).
FT                                /FTId=VAR_008453.
FT   VARIANT    1488   1488       C -> Y (in STGD1).
FT                                /FTId=VAR_012576.
FT   VARIANT    1490   1490       C -> Y (in STGD1 and CORD3; reduced
FT                                retinal-stimulated ATP hydrolysis).
FT                                /FTId=VAR_008454.
FT   VARIANT    1508   1508       G -> C (in FFM).
FT                                /FTId=VAR_012577.
FT   VARIANT    1513   1513       Q -> R (in STGD1).
FT                                /FTId=VAR_012578.
FT   VARIANT    1517   1517       R -> S (in ARMD2; dbSNP:rs1800550).
FT                                /FTId=VAR_008455.
FT   VARIANT    1525   1525       L -> P (in STGD1).
FT                                /FTId=VAR_012579.
FT   VARIANT    1526   1526       T -> M (in STGD1; reduced retinal-
FT                                stimulated ATP hydrolysis).
FT                                /FTId=VAR_008456.
FT   VARIANT    1532   1532       D -> N (in STGD1).
FT                                /FTId=VAR_008457.
FT   VARIANT    1537   1537       T -> M (in STGD1).
FT                                /FTId=VAR_012580.
FT   VARIANT    1562   1562       I -> T (in STGD1, FFM, ARMD2 and CORD3;
FT                                dbSNP:rs1762111).
FT                                /FTId=VAR_008458.
FT   VARIANT    1578   1578       G -> R (in ARMD2; dbSNP:rs1800551).
FT                                /FTId=VAR_008459.
FT   VARIANT    1598   1598       A -> D (in CORD3).
FT                                /FTId=VAR_012581.
FT   VARIANT    1631   1631       L -> P (in STGD1).
FT                                /FTId=VAR_008460.
FT   VARIANT    1637   1637       A -> T (rare polymorphism).
FT                                /FTId=VAR_012582.
FT   VARIANT    1640   1640       R -> Q (in STGD1, FFM and CORD3).
FT                                /FTId=VAR_012583.
FT   VARIANT    1640   1640       R -> W (in STGD1 and CORD3).
FT                                /FTId=VAR_008461.
FT   VARIANT    1652   1652       Y -> D (in STGD1).
FT                                /FTId=VAR_008462.
FT   VARIANT    1681   1685       Missing (in STGD1; highly reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_012584.
FT   VARIANT    1689   1689       S -> P (in STGD1).
FT                                /FTId=VAR_012585.
FT   VARIANT    1693   1693       V -> I (in STGD1; dbSNP:rs61750563).
FT                                /FTId=VAR_012586.
FT   VARIANT    1696   1696       S -> N (in STGD1).
FT                                /FTId=VAR_008463.
FT   VARIANT    1703   1703       Q -> K (in STGD1).
FT                                /FTId=VAR_008464.
FT   VARIANT    1705   1705       R -> L (in STGD1).
FT                                /FTId=VAR_012587.
FT   VARIANT    1724   1724       W -> C (in ARMD2).
FT                                /FTId=VAR_067428.
FT   VARIANT    1729   1729       L -> P (in STGD1).
FT                                /FTId=VAR_008465.
FT   VARIANT    1733   1733       M -> T (in STGD1).
FT                                /FTId=VAR_012588.
FT   VARIANT    1736   1736       S -> P (in STGD1).
FT                                /FTId=VAR_012589.
FT   VARIANT    1748   1748       G -> R (in STGD1).
FT                                /FTId=VAR_012590.
FT   VARIANT    1761   1763       Missing (in STGD1; highly reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_012591.
FT   VARIANT    1763   1763       L -> P (in STGD1).
FT                                /FTId=VAR_012592.
FT   VARIANT    1776   1776       P -> L (in STGD1).
FT                                /FTId=VAR_012593.
FT   VARIANT    1780   1780       P -> A (in STGD1).
FT                                /FTId=VAR_012594.
FT   VARIANT    1794   1794       A -> D (in STGD1).
FT                                /FTId=VAR_008466.
FT   VARIANT    1799   1799       N -> D (in STGD1).
FT                                /FTId=VAR_012595.
FT   VARIANT    1805   1805       N -> D (in STGD1).
FT                                /FTId=VAR_012596.
FT   VARIANT    1817   1817       E -> D.
FT                                /FTId=VAR_012597.
FT   VARIANT    1820   1820       R -> P (in STGD1).
FT                                /FTId=VAR_008467.
FT   VARIANT    1838   1838       H -> Y (in STGD1).
FT                                /FTId=VAR_008468.
FT   VARIANT    1843   1843       R -> W (in STGD1).
FT                                /FTId=VAR_008469.
FT   VARIANT    1846   1846       I -> T.
FT                                /FTId=VAR_008494.
FT   VARIANT    1868   1868       N -> I (slightly reduced retinal-
FT                                stimulated ATP hydrolysis;
FT                                dbSNP:rs1801466).
FT                                /FTId=VAR_008470.
FT   VARIANT    1884   1884       V -> E (in STGD1).
FT                                /FTId=VAR_012598.
FT   VARIANT    1885   1885       E -> K (in STGD1).
FT                                /FTId=VAR_012599.
FT   VARIANT    1886   1886       G -> E (in STGD1; highly reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008471.
FT   VARIANT    1890   1890       Missing (in STGD1).
FT                                /FTId=VAR_008472.
FT   VARIANT    1896   1896       V -> D (in STGD1).
FT                                /FTId=VAR_012600.
FT   VARIANT    1898   1898       R -> H (in STGD1 and ARMD2;
FT                                dbSNP:rs1800552).
FT                                /FTId=VAR_008473.
FT   VARIANT    1921   1921       V -> M (in dbSNP:rs61753032).
FT                                /FTId=VAR_012601.
FT   VARIANT    1940   1940       L -> P (in STGD1 and FFM).
FT                                /FTId=VAR_012602.
FT   VARIANT    1948   1948       P -> L (in dbSNP:rs56142141).
FT                                /FTId=VAR_008474.
FT   VARIANT    1961   1961       G -> E (in STGD1 and FFM; frequent
FT                                mutation; may be associated with ARMD2;
FT                                inhibition of ATP hydrolysis by retinal;
FT                                dbSNP:rs1800553).
FT                                /FTId=VAR_008475.
FT   VARIANT    1970   1970       L -> F (in ARMD2 and FFM;
FT                                dbSNP:rs1800554).
FT                                /FTId=VAR_008476.
FT   VARIANT    1971   1971       L -> R (in FFM; highly reduced ATP-
FT                                binding capacity; abolishes basal and
FT                                retinal-stimulated ATP hydrolysis).
FT                                /FTId=VAR_012603.
FT   VARIANT    1975   1975       G -> R (in STGD1).
FT                                /FTId=VAR_012604.
FT   VARIANT    1977   1977       G -> S (in STGD1 and ARMD2; highly
FT                                reduced ATP-binding capacity; inhibition
FT                                of ATP hydrolysis by retinal).
FT                                /FTId=VAR_008477.
FT   VARIANT    2027   2027       L -> F (in STGD1 and FFM; highly reduced
FT                                ATP-binding capacity; dbSNP:rs61751408).
FT                                /FTId=VAR_008478.
FT   VARIANT    2030   2030       R -> Q (in STGD1 and FFM;
FT                                dbSNP:rs61750641).
FT                                /FTId=VAR_008480.
FT   VARIANT    2035   2035       L -> P (in STGD1).
FT                                /FTId=VAR_012605.
FT   VARIANT    2038   2038       R -> W (in STGD1; highly reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008495.
FT   VARIANT    2047   2047       I -> N (in ARMD2).
FT                                /FTId=VAR_067429.
FT   VARIANT    2050   2050       V -> L (in STGD1; dbSNP:rs41292677).
FT                                /FTId=VAR_008481.
FT   VARIANT    2059   2059       G -> A.
FT                                /FTId=VAR_012606.
FT   VARIANT    2060   2060       L -> R (in CORD3).
FT                                /FTId=VAR_012607.
FT   VARIANT    2071   2071       Y -> F (in STGD1).
FT                                /FTId=VAR_012608.
FT   VARIANT    2077   2077       R -> G (in STGD1).
FT                                /FTId=VAR_012609.
FT   VARIANT    2077   2077       R -> W (in STGD1; highly reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008482.
FT   VARIANT    2096   2096       E -> K (in STGD1; inhibition of ATP
FT                                hydrolysis by retinal).
FT                                /FTId=VAR_008483.
FT   VARIANT    2106   2106       R -> C (in STGD1 and FFM; reduced ATP-
FT                                binding capacity).
FT                                /FTId=VAR_008484.
FT   VARIANT    2107   2107       R -> C (in STGD1; dbSNP:rs2297669).
FT                                /FTId=VAR_012610.
FT   VARIANT    2107   2107       R -> H (in STGD1; may predispose to
FT                                develop retinal toxicity after treatment
FT                                with chloroquine and hydroxychloroquine;
FT                                dbSNP:rs62642564).
FT                                /FTId=VAR_008485.
FT   VARIANT    2128   2128       H -> R (in STGD1).
FT                                /FTId=VAR_008486.
FT   VARIANT    2131   2131       E -> K (in STGD1).
FT                                /FTId=VAR_008487.
FT   VARIANT    2137   2137       C -> Y (in ARMD2).
FT                                /FTId=VAR_067430.
FT   VARIANT    2139   2139       R -> W (in STGD1).
FT                                /FTId=VAR_008488.
FT   VARIANT    2146   2146       G -> D (in CORD3).
FT                                /FTId=VAR_012611.
FT   VARIANT    2149   2149       R -> L (in STGD1).
FT                                /FTId=VAR_012612.
FT   VARIANT    2150   2150       C -> R (in STGD1).
FT                                /FTId=VAR_012613.
FT   VARIANT    2150   2150       C -> Y (in STGD1 and CORD3).
FT                                /FTId=VAR_008489.
FT   VARIANT    2160   2160       K -> R (in STGD1).
FT                                /FTId=VAR_008490.
FT   VARIANT    2177   2177       D -> N (may be associated with ARMD2;
FT                                increased retinal-stimulated ATP
FT                                hydrolysis; dbSNP:rs1800555).
FT                                /FTId=VAR_008491.
FT   VARIANT    2216   2216       A -> V.
FT                                /FTId=VAR_012614.
FT   VARIANT    2229   2229       L -> P (in STGD1).
FT                                /FTId=VAR_012615.
FT   VARIANT    2241   2241       L -> V (in STGD1; dbSNP:rs61748521).
FT                                /FTId=VAR_012616.
FT   VARIANT    2255   2255       S -> I (in dbSNP:rs6666652).
FT                                /FTId=VAR_009157.
FT   VARIANT    2263   2263       R -> L (in STGD1).
FT                                /FTId=VAR_012617.
FT   MUTAGEN     966    966       G->D: Abolishes basal and retinal-
FT                                stimulated ATP hydrolysis.
FT   MUTAGEN     969    969       K->M: Abolishes basal and retinal-
FT                                stimulated ATP hydrolysis.
FT   MUTAGEN    1975   1975       G->D: Inhibition of retinal-stimulated
FT                                ATP hydrolysis.
FT   MUTAGEN    1978   1978       K->M: Inhibition of retinal-stimulated
FT                                ATP hydrolysis.
FT   CONFLICT    722    722       G -> V (in Ref. 2; AAC23915).
FT   CONFLICT    849    849       V -> C (in Ref. 1; AAC51144).
FT   CONFLICT    882    882       G -> S (in Ref. 1; AAC51144 and 3;
FT                                CAA75729).
FT   CONFLICT    941    941       C -> S (in Ref. 2; AAC23915).
FT   CONFLICT   1116   1116       S -> P (in Ref. 1; AAC51144).
FT   CONFLICT   1125   1126       LL -> HQ (in Ref. 1; AAC51144).
FT   CONFLICT   1395   1395       P -> L (in Ref. 1; AAC51144 and 3;
FT                                CAA75729).
FT   CONFLICT   1465   1465       S -> C (in Ref. 4; AAC05632).
FT   CONFLICT   1518   1518       S -> T (in Ref. 4; AAC05632).
FT   CONFLICT   1733   1733       M -> V (in Ref. 2; AAC23915).
FT   CONFLICT   1989   1989       T -> N (in Ref. 2; AAC23915).
FT   CONFLICT   2119   2119       E -> K (in Ref. 1; AAC51144).
SQ   SEQUENCE   2273 AA;  255944 MW;  6E7012D3041CD043 CRC64;
     MGFVRQIQLL LWKNWTLRKR QKIRFVVELV WPLSLFLVLI WLRNANPLYS HHECHFPNKA
     MPSAGMLPWL QGIFCNVNNP CFQSPTPGES PGIVSNYNNS ILARVYRDFQ ELLMNAPESQ
     HLGRIWTELH ILSQFMDTLR THPERIAGRG IRIRDILKDE ETLTLFLIKN IGLSDSVVYL
     LINSQVRPEQ FAHGVPDLAL KDIACSEALL ERFIIFSQRR GAKTVRYALC SLSQGTLQWI
     EDTLYANVDF FKLFRVLPTL LDSRSQGINL RSWGGILSDM SPRIQEFIHR PSMQDLLWVT
     RPLMQNGGPE TFTKLMGILS DLLCGYPEGG GSRVLSFNWY EDNNYKAFLG IDSTRKDPIY
     SYDRRTTSFC NALIQSLESN PLTKIAWRAA KPLLMGKILY TPDSPAARRI LKNANSTFEE
     LEHVRKLVKA WEEVGPQIWY FFDNSTQMNM IRDTLGNPTV KDFLNRQLGE EGITAEAILN
     FLYKGPRESQ ADDMANFDWR DIFNITDRTL RLVNQYLECL VLDKFESYND ETQLTQRALS
     LLEENMFWAG VVFPDMYPWT SSLPPHVKYK IRMDIDVVEK TNKIKDRYWD SGPRADPVED
     FRYIWGGFAY LQDMVEQGIT RSQVQAEAPV GIYLQQMPYP CFVDDSFMII LNRCFPIFMV
     LAWIYSVSMT VKSIVLEKEL RLKETLKNQG VSNAVIWCTW FLDSFSIMSM SIFLLTIFIM
     HGRILHYSDP FILFLFLLAF STATIMLCFL LSTFFSKASL AAACSGVIYF TLYLPHILCF
     AWQDRMTAEL KKAVSLLSPV AFGFGTEYLV RFEEQGLGLQ WSNIGNSPTE GDEFSFLLSM
     QMMLLDAAVY GLLAWYLDQV FPGDYGTPLP WYFLLQESYW LGGEGCSTRE ERALEKTEPL
     TEETEDPEHP EGIHDSFFER EHPGWVPGVC VKNLVKIFEP CGRPAVDRLN ITFYENQITA
     FLGHNGAGKT TTLSILTGLL PPTSGTVLVG GRDIETSLDA VRQSLGMCPQ HNILFHHLTV
     AEHMLFYAQL KGKSQEEAQL EMEAMLEDTG LHHKRNEEAQ DLSGGMQRKL SVAIAFVGDA
     KVVILDEPTS GVDPYSRRSI WDLLLKYRSG RTIIMSTHHM DEADLLGDRI AIIAQGRLYC
     SGTPLFLKNC FGTGLYLTLV RKMKNIQSQR KGSEGTCSCS SKGFSTTCPA HVDDLTPEQV
     LDGDVNELMD VVLHHVPEAK LVECIGQELI FLLPNKNFKH RAYASLFREL EETLADLGLS
     SFGISDTPLE EIFLKVTEDS DSGPLFAGGA QQKRENVNPR HPCLGPREKA GQTPQDSNVC
     SPGAPAAHPE GQPPPEPECP GPQLNTGTQL VLQHVQALLV KRFQHTIRSH KDFLAQIVLP
     ATFVFLALML SIVIPPFGEY PALTLHPWIY GQQYTFFSMD EPGSEQFTVL ADVLLNKPGF
     GNRCLKEGWL PEYPCGNSTP WKTPSVSPNI TQLFQKQKWT QVNPSPSCRC STREKLTMLP
     ECPEGAGGLP PPQRTQRSTE ILQDLTDRNI SDFLVKTYPA LIRSSLKSKF WVNEQRYGGI
     SIGGKLPVVP ITGEALVGFL SDLGRIMNVS GGPITREASK EIPDFLKHLE TEDNIKVWFN
     NKGWHALVSF LNVAHNAILR ASLPKDRSPE EYGITVISQP LNLTKEQLSE ITVLTTSVDA
     VVAICVIFSM SFVPASFVLY LIQERVNKSK HLQFISGVSP TTYWVTNFLW DIMNYSVSAG
     LVVGIFIGFQ KKAYTSPENL PALVALLLLY GWAVIPMMYP ASFLFDVPST AYVALSCANL
     FIGINSSAIT FILELFENNR TLLRFNAVLR KLLIVFPHFC LGRGLIDLAL SQAVTDVYAR
     FGEEHSANPF HWDLIGKNLF AMVVEGVVYF LLTLLVQRHF FLSQWIAEPT KEPIVDEDDD
     VAEERQRIIT GGNKTDILRL HELTKIYPGT SSPAVDRLCV GVRPGECFGL LGVNGAGKTT
     TFKMLTGDTT VTSGDATVAG KSILTNISEV HQNMGYCPQF DAIDELLTGR EHLYLYARLR
     GVPAEEIEKV ANWSIKSLGL TVYADCLAGT YSGGNKRKLS TAIALIGCPP LVLLDEPTTG
     MDPQARRMLW NVIVSIIREG RAVVLTSHSM EECEALCTRL AIMVKGAFRC MGTIQHLKSK
     FGDGYIVTMK IKSPKDDLLP DLNPVEQFFQ GNFPGSVQRE RHYNMLQFQV SSSSLARIFQ
     LLLSHKDSLL IEEYSVTQTT LDQVFVNFAK QQTESHDLPL HPRAAGASRQ AQD
//
ID   ABCAC_HUMAN             Reviewed;        2595 AA.
AC   Q86UK0; Q53QE2; Q53S55; Q8IZW6; Q96JT3; Q9Y4M5;
DT   16-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 3.
DT   09-JUL-2014, entry version 114.
DE   RecName: Full=ATP-binding cassette sub-family A member 12;
DE   AltName: Full=ATP-binding cassette transporter 12;
DE            Short=ATP-binding cassette 12;
GN   Name=ABCA12; Synonyms=ABC12;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANT THR-777.
RC   TISSUE=Placenta;
RX   PubMed=12697999; DOI=10.1159/000069811;
RA   Annilo T., Shulemin S., Chen Z.Q., Arnould I., Prades C., Lemoine C.,
RA   Maintoux-Larois C., Devaud C., Dean M., Denefle P., Rosier M.;
RT   "Identification and characterization of a novel ABCA subfamily member,
RT   ABCA12, located in the lamellar ichthyosis region on 2q34.";
RL   Cytogenet. Genome Res. 98:169-176(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT THR-777.
RC   TISSUE=Retina;
RA   Bonner T.I., Moses T., Detera-Wadleigh S.;
RT   "A retinal cDNA for the ATP-binding cassette transporter ABCA12.";
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 221-2595, AND VARIANT THR-777.
RA   Schaap F.G., van Wijland M., Groen A.K.;
RT   "Cloning of a novel ABC transporter (ABCA12) tentatively involved in
RT   lipid homeostatis.";
RL   Submitted (SEP-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2400-2595.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   REVIEW ON VARIANTS, AND INVOLVEMENT IN ARCI.
RX   PubMed=20672373; DOI=10.1002/humu.21326;
RA   Akiyama M.;
RT   "ABCA12 mutations and autosomal recessive congenital ichthyosis: a
RT   review of genotype/phenotype correlations and of pathogenetic
RT   concepts.";
RL   Hum. Mutat. 31:1090-1096(2010).
RN   [7]
RP   VARIANTS ARCI4A SER-1380; GLU-1381; HIS-1514; LYS-1539 AND SER-1651.
RX   PubMed=12915478; DOI=10.1093/hmg/ddg235;
RA   Lefevre C., Audebert S., Jobard F., Bouadjar B., Lakhdar H.,
RA   Boughdene-Stambouli O., Blanchet-Bardon C., Heilig R., Foglio M.,
RA   Weissenbach J., Lathrop M., Prud'homme J.F., Fischer J.;
RT   "Mutations in the transporter ABCA12 are associated with lamellar
RT   ichthyosis type 2.";
RL   Hum. Mol. Genet. 12:2369-2378(2003).
RN   [8]
RP   VARIANT ARCI4B ASN-2365.
RX   PubMed=15756637; DOI=10.1086/429844;
RA   Kelsell D.P., Norgett E.E., Unsworth H., Teh M.-T., Cullup T.,
RA   Mein C.A., Dopping-Hepenstal P.J., Dale B.A., Tadini G., Fleckman P.,
RA   Stephens K.G., Sybert V.P., Mallory S.B., North B.V., Witt D.R.,
RA   Sprecher E., Taylor A.E.M., Ilchyshyn A., Kennedy C.T., Goodyear H.,
RA   Moss C., Paige D., Harper J.I., Young B.D., Leigh I.M., Eady R.A.J.,
RA   O'Toole E.A.;
RT   "Mutations in ABCA12 underlie the severe congenital skin disease
RT   harlequin ichthyosis.";
RL   Am. J. Hum. Genet. 76:794-803(2005).
RN   [9]
RP   VARIANT ARCI4B ASN-387.
RX   PubMed=16675967; DOI=10.1038/sj.jid.5700295;
RA   Akiyama M., Sakai K., Sugiyama-Nakagiri Y., Yamanaka Y.,
RA   McMillan J.R., Sawamura D., Niizeki H., Miyagawa S., Shimizu H.;
RT   "Compound heterozygous mutations including a de novo missense mutation
RT   in ABCA12 led to a case of harlequin ichthyosis with moderate clinical
RT   severity.";
RL   J. Invest. Dermatol. 126:1518-1523(2006).
RN   [10]
RP   VARIANT ARCI4B ARG-1179.
RX   PubMed=16902423; DOI=10.1038/sj.jid.5700455;
RA   Thomas A.C., Cullup T., Norgett E.E., Hill T., Barton S., Dale B.A.,
RA   Sprecher E., Sheridan E., Taylor A.E., Wilroy R.S., DeLozier C.,
RA   Burrows N., Goodyear H., Fleckman P., Stephens K.G., Mehta L.,
RA   Watson R.M., Graham R., Wolf R., Slavotinek A., Martin M., Bourn D.,
RA   Mein C.A., O'Toole E.A., Kelsell D.P.;
RT   "ABCA12 is the major harlequin ichthyosis gene.";
RL   J. Invest. Dermatol. 126:2408-2413(2006).
RN   [11]
RP   VARIANTS ARCI4A PRO-345 AND THR-1494.
RX   PubMed=17508018; DOI=10.1038/sj.jid.5700885;
RA   Natsuga K., Akiyama M., Kato N., Sakai K., Sugiyama-Nakagiri Y.,
RA   Nishimura M., Hata H., Abe M., Arita K., Tsuji-Abe Y., Onozuka T.,
RA   Aoyagi S., Kodama K., Ujiie H., Tomita Y., Shimizu H.;
RT   "Novel ABCA12 mutations identified in two cases of non-bullous
RT   congenital ichthyosiform erythroderma associated with multiple skin
RT   malignant neoplasia.";
RL   J. Invest. Dermatol. 127:2669-2673(2007).
RN   [12]
RP   VARIANT ARCI4A ASP-1136.
RX   PubMed=18284401; DOI=10.1111/j.1365-2133.2008.08439.x;
RA   Akiyama M., Sakai K., Hatamochi A., Yamazaki S., McMillan J.R.,
RA   Shimizu H.;
RT   "Novel compound heterozygous nonsense and missense ABCA12 mutations
RT   lead to nonbullous congenital ichthyosiform erythroderma.";
RL   Br. J. Dermatol. 158:864-867(2008).
RN   [13]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-476.
RX   PubMed=18772397; DOI=10.1126/science.1164368;
RA   Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P.,
RA   Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B.,
RA   Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T.,
RA   Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D.,
RA   Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C.,
RA   Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N.,
RA   Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W.;
RT   "Core signaling pathways in human pancreatic cancers revealed by
RT   global genomic analyses.";
RL   Science 321:1801-1806(2008).
RN   [14]
RP   VARIANTS ARCI4A SER-1235; HIS-1514; LEU-1798 AND LYS-1980.
RX   PubMed=19262603; DOI=10.1038/jid.2009.23;
RA   Sakai K., Akiyama M., Yanagi T., McMillan J.R., Suzuki T.,
RA   Tsukamoto K., Sugiyama H., Hatano Y., Hayashitani M., Takamori K.,
RA   Nakashima K., Shimizu H.;
RT   "ABCA12 is a major causative gene for non-bullous congenital
RT   ichthyosiform erythroderma.";
RL   J. Invest. Dermatol. 129:2306-2309(2009).
RN   [15]
RP   VARIANT ARCI4A VAL-1559.
RX   PubMed=22257947; DOI=10.1684/ejd.2011.1638;
RA   Nawaz S., Tariq M., Ahmad I., Malik N.A., Baig S.M., Dahl N., Klar J.;
RT   "Non-bullous congenital ichthyosiform erythroderma associated with
RT   homozygosity for a novel missense mutation in an ATP binding domain of
RT   ABCA12.";
RL   Eur. J. Dermatol. 22:178-181(2012).
CC   -!- FUNCTION: Probable transporter involved in lipid homeostasis.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein
CC       (Potential).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Additional isoforms seem to exist;
CC       Name=1;
CC         IsoId=Q86UK0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q86UK0-2; Sequence=VSP_011283, VSP_011284;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Mainly expressed in the stomach, placenta,
CC       testis and fetal brain.
CC   -!- DOMAIN: Multifunctional polypeptide with two homologous halves,
CC       each containing a hydrophobic membrane-anchoring domain and an ATP
CC       binding cassette (ABC) domain (By similarity).
CC   -!- DISEASE: Ichthyosis, congenital, autosomal recessive 4A (ARCI4A)
CC       [MIM:601277]: A form of autosomal recessive congenital ichthyosis,
CC       a disorder of keratinization with abnormal differentiation and
CC       desquamation of the epidermis, resulting in abnormal skin scaling
CC       over the whole body. The main skin phenotypes are lamellar
CC       ichthyosis (LI) and non-bullous congenital ichthyosiform
CC       erythroderma (NCIE), although phenotypic overlap within the same
CC       patient or among patients from the same family can occur. Lamellar
CC       ichthyosis is a condition often associated with an embedment in a
CC       collodion-like membrane at birth; skin scales later develop,
CC       covering the entire body surface. Non-bullous congenital
CC       ichthyosiform erythroderma characterized by fine whitish scaling
CC       on an erythrodermal background; larger brownish scales are present
CC       on the buttocks, neck and legs. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Ichthyosis, congenital, autosomal recessive 4B (ARCI4B)
CC       [MIM:242500]: A rare, very severe form of congenital ichthyosis,
CC       in which the neonate is born with a thick covering of armor-like
CC       scales. The skin dries out to form hard diamond-shaped plaques
CC       separated by fissures, resembling 'armor plating'. The normal
CC       facial features are severely affected, with distortion of the lips
CC       (eclabion), eyelids (ectropion), ears, and nostrils. Affected
CC       babies are often born prematurely and rarely survive the perinatal
CC       period. Babies who survive into infancy and beyond develop skin
CC       changes resembling severe non-bullous congenital ichthyosiform
CC       erythroderma. Note=The disease is caused by mutations affecting
CC       the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCA
CC       family.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAN40735.1; Type=Erroneous initiation;
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=Q86UK0";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY219711; AAP21093.1; -; mRNA.
DR   EMBL; AY033486; AAK54355.1; -; mRNA.
DR   EMBL; AC072062; AAY24276.1; -; Genomic_DNA.
DR   EMBL; AC114780; AAY24230.1; -; Genomic_DNA.
DR   EMBL; AF418105; AAN40735.1; ALT_INIT; mRNA.
DR   EMBL; AL080207; CAB45776.1; -; mRNA.
DR   CCDS; CCDS33372.1; -. [Q86UK0-1]
DR   CCDS; CCDS33373.1; -. [Q86UK0-2]
DR   PIR; T12512; T12512.
DR   RefSeq; NP_056472.2; NM_015657.3. [Q86UK0-2]
DR   RefSeq; NP_775099.2; NM_173076.2. [Q86UK0-1]
DR   UniGene; Hs.134585; -.
DR   ProteinModelPortal; Q86UK0; -.
DR   BioGrid; 117585; 1.
DR   STRING; 9606.ENSP00000272895; -.
DR   TCDB; 3.A.1.211.13; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; Q86UK0; -.
DR   DMDM; 269849713; -.
DR   MaxQB; Q86UK0; -.
DR   PaxDb; Q86UK0; -.
DR   PRIDE; Q86UK0; -.
DR   Ensembl; ENST00000272895; ENSP00000272895; ENSG00000144452. [Q86UK0-1]
DR   Ensembl; ENST00000389661; ENSP00000374312; ENSG00000144452. [Q86UK0-2]
DR   GeneID; 26154; -.
DR   KEGG; hsa:26154; -.
DR   UCSC; uc002vev.3; human. [Q86UK0-2]
DR   UCSC; uc002vew.3; human. [Q86UK0-1]
DR   CTD; 26154; -.
DR   GeneCards; GC02M215796; -.
DR   GeneReviews; ABCA12; -.
DR   HGNC; HGNC:14637; ABCA12.
DR   HPA; HPA043194; -.
DR   MIM; 242500; phenotype.
DR   MIM; 601277; phenotype.
DR   MIM; 607800; gene.
DR   neXtProt; NX_Q86UK0; -.
DR   Orphanet; 79394; Congenital non-bullous ichthyosiform erythroderma.
DR   Orphanet; 457; Harlequin ichthyosis.
DR   Orphanet; 313; Lamellar ichthyosis.
DR   PharmGKB; PA29604; -.
DR   eggNOG; COG1131; -.
DR   HOGENOM; HOG000168538; -.
DR   HOVERGEN; HBG080807; -.
DR   InParanoid; Q86UK0; -.
DR   KO; K05646; -.
DR   OMA; GMAAPWY; -.
DR   OrthoDB; EOG78D7J6; -.
DR   PhylomeDB; Q86UK0; -.
DR   TreeFam; TF105191; -.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   GeneWiki; ABCA12; -.
DR   GenomeRNAi; 26154; -.
DR   NextBio; 48241; -.
DR   PRO; PR:Q86UK0; -.
DR   ArrayExpress; Q86UK0; -.
DR   Bgee; Q86UK0; -.
DR   CleanEx; HS_ABCA12; -.
DR   Genevestigator; Q86UK0; -.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; NAS:UniProtKB.
DR   GO; GO:0016887; F:ATPase activity; IEA:InterPro.
DR   GO; GO:0019725; P:cellular homeostasis; NAS:UniProtKB.
DR   GO; GO:0035627; P:ceramide transport; IEA:Ensembl.
DR   GO; GO:0061436; P:establishment of skin barrier; IEA:Ensembl.
DR   GO; GO:0031424; P:keratinization; IEA:Ensembl.
DR   GO; GO:0055088; P:lipid homeostasis; IEA:Ensembl.
DR   GO; GO:0006869; P:lipid transport; NAS:UniProtKB.
DR   GO; GO:0048286; P:lung alveolus development; IEA:Ensembl.
DR   GO; GO:0043129; P:surfactant homeostasis; IEA:Ensembl.
DR   Gene3D; 3.40.50.300; -; 2.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR026082; ABC_A.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR19229; PTHR19229; 1.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome;
KW   Disease mutation; Glycoprotein; Ichthyosis; Membrane;
KW   Nucleotide-binding; Polymorphism; Reference proteome; Repeat;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1   2595       ATP-binding cassette sub-family A member
FT                                12.
FT                                /FTId=PRO_0000093300.
FT   TRANSMEM     23     43       Helical; (Potential).
FT   TRANSMEM   1065   1085       Helical; (Potential).
FT   TRANSMEM   1112   1132       Helical; (Potential).
FT   TRANSMEM   1145   1165       Helical; (Potential).
FT   TRANSMEM   1174   1194       Helical; (Potential).
FT   TRANSMEM   1200   1220       Helical; (Potential).
FT   TRANSMEM   1250   1270       Helical; (Potential).
FT   TRANSMEM   1747   1767       Helical; (Potential).
FT   TRANSMEM   1979   1999       Helical; (Potential).
FT   TRANSMEM   2035   2055       Helical; (Potential).
FT   TRANSMEM   2072   2092       Helical; (Potential).
FT   TRANSMEM   2103   2123       Helical; (Potential).
FT   TRANSMEM   2187   2207       Helical; (Potential).
FT   TRANSMEM   2270   2290       Helical; (Potential).
FT   DOMAIN     1346   1577       ABC transporter 1.
FT   DOMAIN     2254   2489       ABC transporter 2.
FT   NP_BIND    1378   1385       ATP 1 (Potential).
FT   NP_BIND    2290   2297       ATP 2 (Potential).
FT   CARBOHYD    156    156       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    174    174       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    214    214       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    275    275       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    333    333       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    367    367       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    383    383       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    412    412       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    435    435       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    528    528       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    543    543       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    577    577       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    608    608       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    648    648       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    752    752       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    826    826       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    920    920       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    963    963       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1170   1170       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1524   1524       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1663   1663       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1704   1704       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1769   1769       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1819   1819       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1835   1835       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1876   1876       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1921   1921       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1952   1952       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   2178   2178       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   2208   2208       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   2223   2223       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   2318   2318       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   2542   2542       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   2547   2547       N-linked (GlcNAc...) (Potential).
FT   VAR_SEQ       1    318       Missing (in isoform 2).
FT                                /FTId=VSP_011283.
FT   VAR_SEQ     319    328       LLYTLDSPAQ -> MFTYIKIITS (in isoform 2).
FT                                /FTId=VSP_011284.
FT   VARIANT     199    199       W -> C (in dbSNP:rs16853238).
FT                                /FTId=VAR_055473.
FT   VARIANT     237    237       N -> H (in dbSNP:rs11890512).
FT                                /FTId=VAR_055474.
FT   VARIANT     274    274       Q -> R (in dbSNP:rs11890468).
FT                                /FTId=VAR_055475.
FT   VARIANT     287    287       R -> G (in dbSNP:rs11891778).
FT                                /FTId=VAR_055476.
FT   VARIANT     345    345       T -> P (in ARCI4A; skin phenotype
FT                                consistent with non-bullous congenital
FT                                ichthyosiform erythroderma).
FT                                /FTId=VAR_067075.
FT   VARIANT     387    387       S -> N (in ARCI4B).
FT                                /FTId=VAR_067076.
FT   VARIANT     459    459       S -> T (in dbSNP:rs7560008).
FT                                /FTId=VAR_019597.
FT   VARIANT     476    476       A -> V (in a pancreatic ductal
FT                                adenocarcinoma sample; somatic mutation).
FT                                /FTId=VAR_062663.
FT   VARIANT     550    550       E -> G (in dbSNP:rs16853149).
FT                                /FTId=VAR_027444.
FT   VARIANT     777    777       S -> T (in dbSNP:rs7560008).
FT                                /FTId=VAR_027445.
FT   VARIANT    1136   1136       G -> D (in ARCI4A; skin phenotype
FT                                consistent with non-bullous congenital
FT                                ichthyosiform erythroderma).
FT                                /FTId=VAR_067077.
FT   VARIANT    1179   1179       G -> R (in ARCI4B).
FT                                /FTId=VAR_067078.
FT   VARIANT    1235   1235       W -> S (in ARCI4A; skin phenotype
FT                                consistent with non-bullous congenital
FT                                ichthyosiform erythroderma).
FT                                /FTId=VAR_067079.
FT   VARIANT    1251   1251       G -> D (in dbSNP:rs13414448).
FT                                /FTId=VAR_027446.
FT   VARIANT    1380   1380       N -> S (in ARCI4A; dbSNP:rs28940269).
FT                                /FTId=VAR_019598.
FT   VARIANT    1381   1381       G -> E (in ARCI4A; dbSNP:rs28940268).
FT                                /FTId=VAR_019599.
FT   VARIANT    1494   1494       I -> T (in ARCI4A; skin phenotype
FT                                consistent with non-bullous congenital
FT                                ichthyosiform erythroderma).
FT                                /FTId=VAR_067080.
FT   VARIANT    1514   1514       R -> H (in ARCI4A; dbSNP:rs28940270).
FT                                /FTId=VAR_019600.
FT   VARIANT    1539   1539       E -> K (in ARCI4A; dbSNP:rs28940271).
FT                                /FTId=VAR_019601.
FT   VARIANT    1546   1546       R -> C (in dbSNP:rs13401480).
FT                                /FTId=VAR_027447.
FT   VARIANT    1559   1559       G -> V (in ARCI4A; skin phenotype
FT                                consistent with non-bullous congenital
FT                                ichthyosiform erythroderma).
FT                                /FTId=VAR_067081.
FT   VARIANT    1651   1651       G -> S (in ARCI4A; dbSNP:rs28940568).
FT                                /FTId=VAR_019602.
FT   VARIANT    1798   1798       P -> L (in ARCI4A; skin phenotype
FT                                consistent with non-bullous congenital
FT                                ichthyosiform erythroderma).
FT                                /FTId=VAR_067082.
FT   VARIANT    1980   1980       T -> K (in ARCI4A; skin phenotype
FT                                consistent with non-bullous congenital
FT                                ichthyosiform erythroderma).
FT                                /FTId=VAR_067083.
FT   VARIANT    2064   2064       E -> K (in dbSNP:rs1213011).
FT                                /FTId=VAR_027448.
FT   VARIANT    2365   2365       D -> N (in ARCI4B; dbSNP:rs726070).
FT                                /FTId=VAR_027449.
FT   CONFLICT    651    651       Y -> D (in Ref. 1; AAP21093).
FT   CONFLICT    811    811       Y -> H (in Ref. 1; AAP21093).
FT   CONFLICT    826    826       N -> D (in Ref. 2; AAK54355).
FT   CONFLICT   2079   2079       Y -> H (in Ref. 1; AAP21093).
SQ   SEQUENCE   2595 AA;  293237 MW;  5B71359B642BBAE6 CRC64;
     MASLFHQLQI LVWKNWLGVK RQPLWTLVLI LWPVIIFIIL AITRTKFPPT AKPTCYLAPR
     NLPSTGFFPF LQTLLCDTDS KCKDTPYGPQ DLLRRKGIDD ALFKDSEILR KSSNLDKDSS
     LSFQSTQVPE RRHASLATVF PSPSSDLEIP GTYTFNGSQV LARILGLEKL LKQNSTSEDI
     RRELCDSYSG YIVDDAFSWT FLGRNVFNKF CLSNMTLLES SLQELNKQFS QLSSDPNNQK
     IVFQEIVRML SFFSQVQEQK AVWQLLSSFP NVFQNDTSLS NLFDVLRKAN SVLLVVQKVY
     PRFATNEGFR TLQKSVKHLL YTLDSPAQGD SDNITHVWNE DDGQTLSPSS LAAQLLILEN
     FEDALLNISA NSPYIPYLAC VRNVTDSLAR GSPENLRLLQ STIRFKKSFL RNGSYEDYFP
     PVPEVLKSKL SQLRNLTELL CESETFSLIE KSCQLSDMSF GSLCEESEFD LQLLEAAELG
     TEIAASLLYH DNVISKKVRD LLTGDPSKIN LNMDQFLEQA LQMNYLENIT QLIPIIEAML
     HVNNSADASE KPGQLLEMFK NVEELKEDLR RTTGMSNRTI DKLLAIPIPD NRAEIISQVF
     WLHSCDTNIT TPKLEDAMKE FCNLSLSERS RQSYLIGLTL LHYLNIYNFT YKVFFPRKDQ
     KPVEKMMELF IRLKEILNQM ASGTHPLLDK MRSLKQMHLP RSVPLTQAMY RSNRMNTPQG
     SFSTISQALC SQGITTEYLT AMLPSSQRPK GNHTKDFLTY KLTKEQIASK YGIPINSTPF
     CFSLYKDIIN MPAGPVIWAF LKPMLLGRIL YAPYNPVTKA IMEKSNVTLR QLAELREKSQ
     EWMDKSPLFM NSFHLLNQAI PMLQNTLRNP FVQVFVKFSV GLDAVELLKQ IDELDILRLK
     LENNIDIIDQ LNTLSSLTVN ISSCVLYDRI QAAKTIDEME REAKRLYKSN ELFGSVIFKL
     PSNRSWHRGY DSGNVFLPPV IKYTIRMSLK TAQTTRSLRT KIWAPGPHNS PSHNQIYGRA
     FIYLQDSIER AIIELQTGRN SQEIAVQVQA IPYPCFMKDN FLTSVSYSLP IVLMVAWVVF
     IAAFVKKLVY EKDLRLHEYM KMMGVNSCSH FFAWLIESVG FLLVTIVILI IILKFGNILP
     KTNGFILFLY FSDYSFSVIA MSYLISVFFN NTNIAALIGS LIYIIAFFPF IVLVTVENEL
     SYVLKVFMSL LSPTAFSYAS QYIARYEEQG IGLQWENMYT SPVQDDTTSF GWLCCLILAD
     SFIYFLIAWY VRNVFPGTYG MAAPWYFPIL PSYWKERFGC AEVKPEKSNG LMFTNIMMQN
     TNPSASPEYM FSSNIEPEPK DLTVGVALHG VTKIYGSKVA VDNLNLNFYE GHITSLLGPN
     GAGKTTTISM LTGLFGASAG TIFVYGKDIK TDLHTVRKNM GVCMQHDVLF SYLTTKEHLL
     LYGSIKVPHW TKKQLHEEVK RTLKDTGLYS HRHKRVGTLS GGMKRKLSIS IALIGGSRVV
     ILDEPSTGVD PCSRRSIWDV ISKNKTARTI ILSTHHLDEA EVLSDRIAFL EQGGLRCCGS
     PFYLKEAFGD GYHLTLTKKK SPNLNANAVC DTMAVTAMIQ SHLPEAYLKE DIGGELVYVL
     PPFSTKVSGA YLSLLRALDN GMGDLNIGCY GISDTTVEEV FLNLTKESQK NSAMSLEHLT
     QKKIGNSNAN GISTPDDLSV SSSNFTDRDD KILTRGERLD GFGLLLKKIM AILIKRFHHT
     RRNWKGLIAQ VILPIVFVTT AMGLGTLRNS SNSYPEIQIS PSLYGTSEQT AFYANYHPST
     EALVSAMWDF PGIDNMCLNT SDLQCLNKDS LEKWNTSGEP ITNFGVCSCS ENVQECPKFN
     YSPPHRRTYS SQVIYNLTGQ RVENYLISTA NEFVQKRYGG WSFGLPLTKD LRFDITGVPA
     NRTLAKVWYD PEGYHSLPAY LNSLNNFLLR VNMSKYDAAR HGIIMYSHPY PGVQDQEQAT
     ISSLIDILVA LSILMGYSVT TASFVTYVVR EHQTKAKQLQ HISGIGVTCY WVTNFIYDMV
     FYLVPVAFSI GIIAIFKLPA FYSENNLGAV SLLLLLFGYA TFSWMYLLAG LFHETGMAFI
     TYVCVNLFFG INSIVSLSVV YFLSKEKPND PTLELISETL KRIFLIFPQF CFGYGLIELS
     QQQSVLDFLK AYGVEYPNET FEMNKLGAMF VALVSQGTMF FSLRLLINES LIKKLRLFFR
     KFNSSHVRET IDEDEDVRAE RLRVESGAAE FDLVQLYCLT KTYQLIHKKI IAVNNISIGI
     PAGECFGLLG VNGAGKTTIF KMLTGDIIPS SGNILIRNKT GSLGHVDSHS SLVGYCPQED
     ALDDLVTVEE HLYFYARVHG IPEKDIKETV HKLLRRLHLM PFKDRATSMC SYGTKRKLST
     ALALIGKPSI LLLDEPSSGM DPKSKRHLWK IISEEVQNKC SVILTSHSME ECEALCTRLA
     IMVNGKFQCI GSLQHIKSRF GRGFTVKVHL KNNKVTMETL TKFMQLHFPK TYLKDQHLSM
     LEYHVPVTAG GVANIFDLLE TNKTALNITN FLVSQTTLEE VFINFAKDQK SYETADTSSQ
     GSTISVDSQD DQMES
//
ID   ABCB5_HUMAN             Reviewed;         812 AA.
AC   Q2M3G0; A4D131; A7BKA4; B5MD19; B7WPL1; F8QQP8; J3KQ04; Q2M3I5;
AC   Q5I5Q7; Q5I5Q8; Q6KG50; Q6XFQ5; Q8IXA1;
DT   17-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 3.
DT   09-JUL-2014, entry version 87.
DE   RecName: Full=ATP-binding cassette sub-family B member 5;
DE   AltName: Full=ABCB5 P-gp;
DE   AltName: Full=P-glycoprotein ABCB5;
GN   Name=ABCB5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR
RP   LOCATION, TOPOLOGY, TISSUE SPECIFICITY, AND VARIANT LYS-525.
RC   TISSUE=Melanocyte, and Melanoma;
RX   PubMed=12960149; DOI=10.1074/jbc.M308700200;
RA   Frank N.Y., Pendse S.S., Lapchak P.H., Margaryan A., Shlain D.,
RA   Doeing C., Sayegh M.H., Frank M.H.;
RT   "Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel
RT   human ATP-binding cassette transporter.";
RL   J. Biol. Chem. 278:47156-47165(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), VARIANTS GLU-115 AND
RP   LYS-525, AND TISSUE SPECIFICITY.
RC   TISSUE=Melanoma;
RX   PubMed=15760339; DOI=10.1111/j.1600-0749.2005.00214.x;
RA   Chen K.G., Szakacs G., Annereau J.-P., Rouzaud F., Liang X.-J.,
RA   Valencia J.C., Nagineni C.N., Hooks J.J., Hearing V.J.,
RA   Gottesman M.M.;
RT   "Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB
RT   5beta) of the ATP-binding cassette transporter gene ABCB 5 in melanoma
RT   cells and melanocytes.";
RL   Pigment Cell Res. 18:102-112(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Colon adenocarcinoma;
RX   PubMed=21652540; DOI=10.1158/0008-5472.CAN-11-0221;
RA   Wilson B.J., Schatton T., Zhan Q., Gasser M., Ma J., Saab K.R.,
RA   Schanche R., Waaga-Gasser A.M., Gold J.S., Huang Q., Murphy G.F.,
RA   Frank M.H., Frank N.Y.;
RT   "ABCB5 identifies a therapy-refractory tumor cell population in
RT   colorectal cancer patients.";
RL   Cancer Res. 71:5307-5316(2011).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION, AND VARIANT LYS-525.
RC   TISSUE=Prostate, and Testis;
RX   PubMed=22306008; DOI=10.1016/j.bbrc.2012.01.090;
RA   Kawanobe T., Kogure S., Nakamura S., Sato M., Katayama K.,
RA   Mitsuhashi J., Noguchi K., Sugimoto Y.;
RT   "Expression of human ABCB5 confers resistance to taxanes and
RT   anthracyclines.";
RL   Biochem. Biophys. Res. Commun. 418:736-741(2012).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND VARIANT LYS-525.
RA   Meij I.C., van Aubel R., Tammur J., Dean M., Russel F.G.,
RA   Allikmets R., Cremers F.P.M.;
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LYS-525.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Melanoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   FUNCTION.
RX   PubMed=15205344; DOI=10.1158/0008-5472.CAN-03-3884;
RA   Huang Y., Anderle P., Bussey K.J., Barbacioru C., Shankavaram U.,
RA   Dai Z., Reinhold W.C., Papp A., Weinstein J.N., Sadee W.;
RT   "Membrane transporters and channels: role of the transportome in
RT   cancer chemosensitivity and chemoresistance.";
RL   Cancer Res. 64:4294-4301(2004).
RN   [11]
RP   FUNCTION.
RX   PubMed=15899824; DOI=10.1158/0008-5472.CAN-04-3327;
RA   Frank N.Y., Margaryan A., Huang Y., Schatton T., Waaga-Gasser A.M.,
RA   Gasser M., Sayegh M.H., Sadee W., Frank M.H.;
RT   "ABCB5-mediated doxorubicin transport and chemoresistance in human
RT   malignant melanoma.";
RL   Cancer Res. 65:4320-4333(2005).
RN   [12]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-230.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [13]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-435.
RX   PubMed=18772397; DOI=10.1126/science.1164368;
RA   Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P.,
RA   Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B.,
RA   Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T.,
RA   Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D.,
RA   Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C.,
RA   Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N.,
RA   Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W.;
RT   "Core signaling pathways in human pancreatic cancers revealed by
RT   global genomic analyses.";
RL   Science 321:1801-1806(2008).
CC   -!- FUNCTION: Plasma membrane transporter able to mediate efflux from
CC       cells of the rhodamine dye and of the therapeutic drug
CC       doxorubicin. Responsible for the resistance to doxorubicin of a
CC       subset of malignant melanomas.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=ABCB5beta;
CC         IsoId=Q2M3G0-1; Sequence=Displayed;
CC       Name=2; Synonyms=ABCB5alpha;
CC         IsoId=Q2M3G0-2; Sequence=VSP_021075, VSP_021076;
CC       Name=3;
CC         IsoId=Q2M3G0-3; Sequence=VSP_045489, VSP_045490;
CC         Note=No experimental confirmation available;
CC       Name=4;
CC         IsoId=Q2M3G0-4; Sequence=VSP_046857;
CC         Note=Contains 1 extra ABC transmembrane type-1 domain;
CC   -!- TISSUE SPECIFICITY: Expressed by CD133-expressing progenitor cells
CC       among epidermal melanocytes (at protein level). Widely expressed
CC       with specific expression in pigment cells. Also expressed in
CC       several malignant tissues.
CC   -!- MISCELLANEOUS: Depletion of ABCB5 by RNAi increases the
CC       sensitivity to several drugs of a subset of melanoma cells.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCB
CC       family. Multidrug resistance exporter (TC 3.A.1.201) subfamily.
CC   -!- SIMILARITY: Contains 1 ABC transmembrane type-1 domain.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -!- CAUTION: Was named ABCB1 by some authors.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAN76500.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=AAQ03033.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ABCB5ID44305ch7p15.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF319622; AAN76500.1; ALT_INIT; mRNA.
DR   EMBL; AF399931; AAQ03033.1; ALT_INIT; mRNA.
DR   EMBL; AY090613; AAM09027.1; -; mRNA.
DR   EMBL; AY234788; AAO73470.1; -; mRNA.
DR   EMBL; AY851364; AAW31629.1; -; mRNA.
DR   EMBL; AY851365; AAW31630.1; -; mRNA.
DR   EMBL; GU437216; ADV32636.1; -; mRNA.
DR   EMBL; AB353947; BAF75364.1; -; mRNA.
DR   EMBL; AY230001; AAP55848.1; -; mRNA.
DR   EMBL; AC002486; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005060; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236948; EAL24273.1; -; Genomic_DNA.
DR   EMBL; CH471073; EAW93726.1; -; Genomic_DNA.
DR   EMBL; BC104894; AAI04895.2; -; mRNA.
DR   EMBL; BC104920; AAI04921.1; -; mRNA.
DR   EMBL; BC110370; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS5371.1; -. [Q2M3G0-1]
DR   CCDS; CCDS55090.1; -. [Q2M3G0-4]
DR   CCDS; CCDS55091.1; -. [Q2M3G0-2]
DR   CCDS; CCDS55092.1; -. [Q2M3G0-3]
DR   RefSeq; NP_001157413.1; NM_001163941.1. [Q2M3G0-4]
DR   RefSeq; NP_001157414.1; NM_001163942.1. [Q2M3G0-2]
DR   RefSeq; NP_001157465.1; NM_001163993.2. [Q2M3G0-3]
DR   RefSeq; NP_848654.3; NM_178559.5. [Q2M3G0-1]
DR   UniGene; Hs.404102; -.
DR   ProteinModelPortal; Q2M3G0; -.
DR   SMR; Q2M3G0; 16-197, 203-811.
DR   IntAct; Q2M3G0; 1.
DR   ChEMBL; CHEMBL1772928; -.
DR   TCDB; 3.A.1.201.13; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; Q2M3G0; -.
DR   DMDM; 308153645; -.
DR   PaxDb; Q2M3G0; -.
DR   PRIDE; Q2M3G0; -.
DR   DNASU; 340273; -.
DR   Ensembl; ENST00000258738; ENSP00000258738; ENSG00000004846. [Q2M3G0-1]
DR   Ensembl; ENST00000404938; ENSP00000384881; ENSG00000004846. [Q2M3G0-4]
DR   Ensembl; ENST00000406935; ENSP00000383899; ENSG00000004846. [Q2M3G0-3]
DR   Ensembl; ENST00000443026; ENSP00000406730; ENSG00000004846. [Q2M3G0-2]
DR   GeneID; 340273; -.
DR   KEGG; hsa:340273; -.
DR   UCSC; uc003suv.4; human. [Q2M3G0-2]
DR   UCSC; uc003suw.4; human. [Q2M3G0-1]
DR   CTD; 340273; -.
DR   GeneCards; GC07P020653; -.
DR   H-InvDB; HIX0025281; -.
DR   HGNC; HGNC:46; ABCB5.
DR   HPA; HPA026975; -.
DR   MIM; 611785; gene.
DR   neXtProt; NX_Q2M3G0; -.
DR   PharmGKB; PA24387; -.
DR   eggNOG; COG1132; -.
DR   HOVERGEN; HBG080809; -.
DR   InParanoid; Q2M3G0; -.
DR   KO; K05660; -.
DR   OMA; YCIGAAV; -.
DR   OrthoDB; EOG7Z3F4H; -.
DR   PhylomeDB; Q2M3G0; -.
DR   TreeFam; TF105193; -.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   GeneWiki; ABCB5; -.
DR   GenomeRNAi; 340273; -.
DR   NextBio; 35535241; -.
DR   PRO; PR:Q2M3G0; -.
DR   ArrayExpress; Q2M3G0; -.
DR   Bgee; Q2M3G0; -.
DR   CleanEx; HS_ABCB5; -.
DR   Genevestigator; Q2M3G0; -.
DR   GO; GO:0016324; C:apical plasma membrane; IBA:RefGenome.
DR   GO; GO:0000139; C:Golgi membrane; IBA:RefGenome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0046581; C:intercellular canaliculus; IBA:RefGenome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; IBA:RefGenome.
DR   GO; GO:0015562; F:efflux transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0042391; P:regulation of membrane potential; IDA:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; IDA:UniProtKB.
DR   Gene3D; 3.40.50.300; -; 2.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00664; ABC_membrane; 1.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   SUPFAM; SSF90123; SSF90123; 1.
DR   PROSITE; PS50929; ABC_TM1F; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Membrane; Nucleotide-binding; Polymorphism; Reference proteome;
KW   Repeat; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1    812       ATP-binding cassette sub-family B member
FT                                5.
FT                                /FTId=PRO_0000253575.
FT   TOPO_DOM      1    247       Extracellular (Potential).
FT   TRANSMEM    248    268       Helical; (Potential).
FT   TOPO_DOM    269    291       Cytoplasmic (Potential).
FT   TRANSMEM    292    312       Helical; (Potential).
FT   TOPO_DOM    313    381       Extracellular (Potential).
FT   TRANSMEM    382    402       Helical; (Potential).
FT   TOPO_DOM    403    471       Cytoplasmic (Potential).
FT   TRANSMEM    472    492       Helical; (Potential).
FT   TOPO_DOM    493    508       Extracellular (Potential).
FT   TRANSMEM    509    529       Helical; (Potential).
FT   TOPO_DOM    530    812       Cytoplasmic (Potential).
FT   DOMAIN        2    177       ABC transporter 1.
FT   DOMAIN      247    535       ABC transmembrane type-1.
FT   DOMAIN      570    808       ABC transporter 2.
FT   NP_BIND     605    612       ATP (Potential).
FT   VAR_SEQ       1      1       M -> MENSERAEEMQENYQRNGTAEEQPKLRKEAVGSIEI
FT                                FRFADGLDITLMILGILASLVNGACLPLMPLVLGEMSDNLI
FT                                SGCLVQTNTTNYQNCTQSQEKLNEDMTLLTLYYVGIGVAAL
FT                                IFGYIQISLWIITAARQTKRIRKQFFHSVLAQDIGWFDSCD
FT                                IGELNTRMTDDIDKISDGIGDKIALLFQNMSTFSIGLAVGL
FT                                VKGWKLTLVTLSTSPLIMASAAACSRMVISLTSKELSAYSK
FT                                AGAVAEEVLSSIRTVIAFRAQEKELQRYTQNLKDAKDFGIK
FT                                RTIASKVSLGAVYFFMNGTYGLAFWYGTSLILNGEPGYTIG
FT                                TVLAVFFSVIHSSYCIGAAVPHFETFAIARGAAFHIFQVID
FT                                KKPSIDNFSTAGYKPESIEGTVEFKNVSFNYPSRPSIKILK
FT                                GLNLRIKSGETVALVGLNGSGKSTVVQLLQRLYDPDDGFIM
FT                                (in isoform 4).
FT                                /FTId=VSP_046857.
FT   VAR_SEQ     125    131       ASKGRTT -> DTPRYSF (in isoform 2).
FT                                /FTId=VSP_021075.
FT   VAR_SEQ     125    126       AS -> KK (in isoform 3).
FT                                /FTId=VSP_045489.
FT   VAR_SEQ     127    812       Missing (in isoform 3).
FT                                /FTId=VSP_045490.
FT   VAR_SEQ     132    812       Missing (in isoform 2).
FT                                /FTId=VSP_021076.
FT   VARIANT     115    115       K -> E (in dbSNP:rs2301641).
FT                                /FTId=VAR_028387.
FT   VARIANT     224    224       K -> R (in dbSNP:rs13222448).
FT                                /FTId=VAR_028388.
FT   VARIANT     230    230       E -> V (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035731.
FT   VARIANT     435    435       A -> T (in a pancreatic ductal
FT                                adenocarcinoma sample; somatic mutation).
FT                                /FTId=VAR_062662.
FT   VARIANT     460    460       Q -> H (in dbSNP:rs35885925).
FT                                /FTId=VAR_033456.
FT   VARIANT     470    470       A -> T (in dbSNP:rs17143304).
FT                                /FTId=VAR_028389.
FT   VARIANT     525    525       E -> K (in dbSNP:rs6461515).
FT                                /FTId=VAR_028390.
FT   CONFLICT    132    132       I -> M (in Ref. 1; AAN76500).
FT   CONFLICT    696    696       L -> P (in Ref. 2; AAW31630).
SQ   SEQUENCE   812 AA;  89832 MW;  588E5F90AE305BE5 CRC64;
     MVDENDIRAL NVRHYRDHIG VVSQEPVLFG TTISNNIKYG RDDVTDEEME RAAREANAYD
     FIMEFPNKFN TLVGEKGAQM SGGQKQRIAI ARALVRNPKI LILDEATSAL DSESKSAVQA
     ALEKASKGRT TIVVAHRLST IRSADLIVTL KDGMLAEKGA HAELMAKRGL YYSLVMSQDI
     KKADEQMESM TYSTERKTNS LPLHSVKSIK SDFIDKAEES TQSKEISLPE VSLLKILKLN
     KPEWPFVVLG TLASVLNGTV HPVFSIIFAK IITMFGNNDK TTLKHDAEIY SMIFVILGVI
     CFVSYFMQGL FYGRAGEILT MRLRHLAFKA MLYQDIAWFD EKENSTGGLT TILAIDIAQI
     QGATGSRIGV LTQNATNMGL SVIISFIYGW EMTFLILSIA PVLAVTGMIE TAAMTGFANK
     DKQELKHAGK IATEALENIR TIVSLTREKA FEQMYEEMLQ TQHRNTSKKA QIIGSCYAFS
     HAFIYFAYAA GFRFGAYLIQ AGRMTPEGMF IVFTAIAYGA MAIGETLVLA PEYSKAKSGA
     AHLFALLEKK PNIDSRSQEG KKPDTCEGNL EFREVSFFYP CRPDVFILRG LSLSIERGKT
     VAFVGSSGCG KSTSVQLLQR LYDPVQGQVL FDGVDAKELN VQWLRSQIAI VPQEPVLFNC
     SIAENIAYGD NSRVVPLDEI KEAANAANIH SFIEGLPEKY NTQVGLKGAQ LSGGQKQRLA
     IARALLQKPK ILLLDEATSA LDNDSEKVVQ HALDKARTGR TCLVVTHRLS AIQNADLIVV
     LHNGKIKEQG THQELLRNRD IYFKLVNAQS VQ
//
ID   ABCB6_HUMAN             Reviewed;         842 AA.
AC   Q9NP58; O75542; Q49A66; Q59GQ5; Q6ZME6; Q96ME8; Q9HAQ6; Q9HAQ7;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   09-JUL-2014, entry version 142.
DE   RecName: Full=ATP-binding cassette sub-family B member 6, mitochondrial;
DE   AltName: Full=Mitochondrial ABC transporter 3;
DE            Short=Mt-ABC transporter 3;
DE   AltName: Full=P-glycoprotein-related protein;
DE   AltName: Full=Ubiquitously-expressed mammalian ABC half transporter;
GN   Name=ABCB6; Synonyms=MTABC3, PRP, UMAT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), FUNCTION, TISSUE
RP   SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=10837493; DOI=10.1074/jbc.275.23.17536;
RA   Mitsuhashi N., Miki T., Senbongi H., Yokoi N., Yano H., Miyazaki M.,
RA   Nakajima N., Iwanaga T., Yokoyama Y., Shibata T., Seino S.;
RT   "MTABC3, a novel mitochondrial ATP-binding cassette protein involved
RT   in iron homeostasis.";
RL   J. Biol. Chem. 275:17536-17540(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE
RP   [GENOMIC DNA] OF 1-229.
RC   TISSUE=Colon, and Liver;
RX   PubMed=11955620; DOI=10.1016/S0167-4781(01)00340-2;
RA   Emadi-Konjin H.-P., Zhang H., Anandan V., Sun D., Schuetz J.D.,
RA   Furuya K.N.;
RT   "Isolation of a genomic clone containing the promoter region of the
RT   human ATP binding cassette (ABC) transporter, ABCB6.";
RL   Biochim. Biophys. Acta 1574:117-130(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Hirsch-Ernst K.I., Schaefer A., Ernst B.-P., Schmitz-Salue C.,
RA   Awuah D., Kahl G.F.;
RT   "Subcellular localization of the ABC transporter umat.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 112-842 (ISOFORM 1).
RC   TISSUE=Hepatoma, and Neuroepithelium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 332-842 (ISOFORM 1).
RC   TISSUE=Brain;
RA   Yu W., Gibbs R.A.;
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   FUNCTION, DEVELOPMENTAL STAGE, INDUCTION BY CELLULAR PORPHYRINS,
RP   SUBUNIT, SUBCELLULAR LOCATION, AND INTERACTION WITH HEMIN.
RX   PubMed=17006453; DOI=10.1038/nature05125;
RA   Krishnamurthy P.C., Du G., Fukuda Y., Sun D., Sampath J., Mercer K.E.,
RA   Wang J., Sosa-Pineda B., Murti K.G., Schuetz J.D.;
RT   "Identification of a mammalian mitochondrial porphyrin transporter.";
RL   Nature 443:586-589(2006).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17661442; DOI=10.1021/bi700015m;
RA   Paterson J.K., Shukla S., Black C.M., Tachiwada T., Garfield S.,
RA   Wincovitch S., Ernst D.N., Agadir A., Li X., Ambudkar S.V.,
RA   Szakacs G., Akiyama S., Gottesman M.M.;
RT   "Human ABCB6 localizes to both the outer mitochondrial membrane and
RT   the plasma membrane.";
RL   Biochemistry 46:9443-9452(2007).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18279659; DOI=10.1016/j.bbrc.2008.02.027;
RA   Tsuchida M., Emi Y., Kida Y., Sakaguchi M.;
RT   "Human ABC transporter isoform B6 (ABCB6) localizes primarily in the
RT   Golgi apparatus.";
RL   Biochem. Biophys. Res. Commun. 369:369-375(2008).
RN   [11]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, VARIANTS MCOPCB7 THR-57 AND
RP   VAL-811, AND CHARACTERIZATION OF VARIANTS MCOPCB7 THR-57 AND VAL-811.
RX   PubMed=22226084; DOI=10.1016/j.ajhg.2011.11.026;
RA   Wang L., He F., Bu J., Liu X., Du W., Dong J., Cooney J.D.,
RA   Dubey S.K., Shi Y., Gong B., Li J., McBride P.F., Jia Y., Lu F.,
RA   Soltis K.A., Lin Y., Namburi P., Liang C., Sundaresan P., Paw B.H.,
RA   Li D.Y., Phillips J.D., Yang Z.;
RT   "ABCB6 mutations cause ocular coloboma.";
RL   Am. J. Hum. Genet. 90:40-48(2012).
RN   [12]
RP   INVOLVEMENT IN LANGEREIS BLOOD GROUP SYSTEM.
RX   PubMed=22246506; DOI=10.1038/ng.1069;
RA   Helias V., Saison C., Ballif B.A., Peyrard T., Takahashi J.,
RA   Takahashi H., Tanaka M., Deybach J.C., Puy H., Le Gall M., Sureau C.,
RA   Pham B.N., Le Pennec P.Y., Tani Y., Cartron J.P., Arnaud L.;
RT   "ABCB6 is dispensable for erythropoiesis and specifies the new blood
RT   group system Langereis.";
RL   Nat. Genet. 44:170-173(2012).
RN   [13]
RP   STRUCTURE BY NMR OF 558-842 IN COMPLEX WITH ADP.
RX   PubMed=16791740; DOI=10.1007/s10858-006-9000-6;
RA   Kurashima-Ito K., Ikeya T., Senbongi H., Tochio H., Mikawa T.,
RA   Shibata T., Ito Y.;
RT   "Heteronuclear multidimensional NMR and homology modelling studies of
RT   the C-terminal nucleotide-binding domain of the human mitochondrial
RT   ABC transporter ABCB6.";
RL   J. Biomol. NMR 35:53-71(2006).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 558-842 IN COMPLEXES WITH
RP   ADP; ATP AND PHOSPHATE.
RX   PubMed=20823549; DOI=10.1107/S0907444910028593;
RA   Haffke M., Menzel A., Carius Y., Jahn D., Heinz D.W.;
RT   "Structures of the nucleotide-binding domain of the human ABCB6
RT   transporter and its complexes with nucleotides.";
RL   Acta Crystallogr. D 66:979-987(2010).
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] GLY-69.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [16]
RP   VARIANTS DUH3 GLY-170; PRO-356 AND GLU-579, AND CHARACTERIZATION OF
RP   VARIANTS DUH3 GLY-170; PRO-356 AND GLU-579.
RX   PubMed=23519333; DOI=10.1038/jid.2013.145;
RA   Zhang C., Li D., Zhang J., Chen X., Huang M., Archacki S., Tian Y.,
RA   Ren W., Mei A., Zhang Q., Fang M., Su Z., Yin Y., Liu D., Chen Y.,
RA   Cui X., Li C., Yang H., Wang Q., Wang J., Liu M., Deng Y.;
RT   "Mutations in ABCB6 cause dyschromatosis universalis hereditaria.";
RL   J. Invest. Dermatol. 133:2221-2228(2013).
CC   -!- FUNCTION: Binds heme and porphyrins and functions in their ATP-
CC       dependent uptake into the mitochondria. Plays a crucial role in
CC       heme synthesis.
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Cell membrane. Mitochondrion outer membrane;
CC       Multi-pass membrane protein. Endoplasmic reticulum. Golgi
CC       apparatus. Endosome (By similarity). Note=localized to the
CC       endosome-like compartement and dendrite tips.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NP58-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NP58-4; Sequence=VSP_021973;
CC         Note=Ref.4 (BAB71347) sequence differs from that shown due to
CC         splicing through aberrant splice sites;
CC   -!- TISSUE SPECIFICITY: Widely expressed. High expression is detected
CC       in the retinal epithelium.
CC   -!- DEVELOPMENTAL STAGE: Highly expressed in fetal liver.
CC   -!- INDUCTION: Up-regulated by cellular porphyrins (at protein level).
CC   -!- POLYMORPHISM: Genetic variations in ABCB6 define the Langereis
CC       blood group system (LAN) [MIM:111600]. Individuals with Lan(-)
CC       blood group lack the Lan antigen on their red blood cells. These
CC       individuals may have anti-Lan antibodies in their serum, which can
CC       cause transfusion reactions or hemolytic disease of the fetus or
CC       newborn. The Lan(-) blood group is only clinically significant in
CC       transfusion settings or during pregnancy; otherwise Lan(-)
CC       individuals have no clinical features.
CC   -!- DISEASE: Microphthalmia, isolated, with coloboma, 7 (MCOPCB7)
CC       [MIM:614497]: A disorder of eye formation, ranging from small size
CC       of a single eye to complete bilateral absence of ocular tissues.
CC       Ocular abnormalities like opacities of the cornea and lens,
CC       scaring of the retina and choroid, and other abnormalities may
CC       also be present. Ocular colobomas are a set of malformations
CC       resulting from abnormal morphogenesis of the optic cup and stalk,
CC       and the fusion of the fetal fissure (optic fissure). Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Dyschromatosis universalis hereditaria 3 (DUH3)
CC       [MIM:615402]: An autosomal dominant pigmentary genodermatosis
CC       characterized by a mixture of hyperpigmented and hypopigmented
CC       macules distributed randomly over the body, that appear in infancy
CC       or early childhood. The trunk and extremities are the dominant
CC       sites of abnormal pigmentation. Facial lesions can be seen in 50%
CC       of affected individuals, but involvement of palms and soles is
CC       unusual. Abnormalities of hair and nails have also been reported.
CC       Dyschromatosis universalis hereditaria may be associated with
CC       abnormalities of dermal connective tissue, nerve tissue, or other
CC       systemic complications. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Depletion of Abcb6 by RNAi abrogates heme
CC       biosynthesis. Overexpression enhances porphyrin biosynthesis.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCB
CC       family. Heavy Metal importer (TC 3.A.1.210) subfamily.
CC   -!- SIMILARITY: Contains 1 ABC transmembrane type-1 domain.
CC   -!- SIMILARITY: Contains 1 ABC transporter domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAG33617.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC       Sequence=AAG33618.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC       Sequence=AAH43423.1; Type=Miscellaneous discrepancy; Note=Intron retention;
CC       Sequence=BAD18782.1; Type=Erroneous termination; Positions=168; Note=Translated as Trp;
CC       Sequence=BAD92291.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA;
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=Q9NP58";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB039371; BAA96733.1; -; Genomic_DNA.
DR   EMBL; AF076775; AAF75107.1; -; mRNA.
DR   EMBL; AF308472; AAG33617.1; ALT_INIT; mRNA.
DR   EMBL; AF308473; AAG33618.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AJ289233; CAB95766.2; -; mRNA.
DR   EMBL; AK057026; BAB71347.1; ALT_SEQ; mRNA.
DR   EMBL; AK172812; BAD18782.1; ALT_SEQ; mRNA.
DR   EMBL; AB209054; BAD92291.1; ALT_SEQ; mRNA.
DR   EMBL; BC000559; AAH00559.1; -; mRNA.
DR   EMBL; BC043423; AAH43423.1; ALT_SEQ; mRNA.
DR   EMBL; AF070598; AAC28653.1; -; mRNA.
DR   CCDS; CCDS2436.1; -. [Q9NP58-1]
DR   RefSeq; NP_005680.1; NM_005689.2. [Q9NP58-1]
DR   UniGene; Hs.107911; -.
DR   PDB; 3NH6; X-ray; 2.00 A; A=558-842.
DR   PDB; 3NH9; X-ray; 2.10 A; A=558-842.
DR   PDB; 3NHA; X-ray; 2.10 A; A=558-842.
DR   PDB; 3NHB; X-ray; 2.15 A; A=558-842.
DR   PDBsum; 3NH6; -.
DR   PDBsum; 3NH9; -.
DR   PDBsum; 3NHA; -.
DR   PDBsum; 3NHB; -.
DR   ProteinModelPortal; Q9NP58; -.
DR   SMR; Q9NP58; 234-833.
DR   BioGrid; 115369; 6.
DR   IntAct; Q9NP58; 3.
DR   MINT; MINT-3071268; -.
DR   STRING; 9606.ENSP00000265316; -.
DR   BindingDB; Q9NP58; -.
DR   ChEMBL; CHEMBL2007630; -.
DR   TCDB; 3.A.1.210.6; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; Q9NP58; -.
DR   DMDM; 13123949; -.
DR   MaxQB; Q9NP58; -.
DR   PaxDb; Q9NP58; -.
DR   PRIDE; Q9NP58; -.
DR   DNASU; 10058; -.
DR   Ensembl; ENST00000265316; ENSP00000265316; ENSG00000115657. [Q9NP58-1]
DR   Ensembl; ENST00000439002; ENSP00000394333; ENSG00000115657. [Q9NP58-4]
DR   GeneID; 10058; -.
DR   KEGG; hsa:10058; -.
DR   UCSC; uc002vkc.2; human. [Q9NP58-1]
DR   UCSC; uc010fwe.2; human. [Q9NP58-4]
DR   CTD; 10058; -.
DR   GeneCards; GC02M220038; -.
DR   HGNC; HGNC:47; ABCB6.
DR   HPA; HPA046723; -.
DR   MIM; 111600; phenotype.
DR   MIM; 605452; gene.
DR   MIM; 614497; phenotype.
DR   MIM; 615402; phenotype.
DR   neXtProt; NX_Q9NP58; -.
DR   Orphanet; 98938; Colobomatous microphthalmia.
DR   Orphanet; 241; Dyschromatosis universalis.
DR   Orphanet; 194; Ocular coloboma.
DR   PharmGKB; PA24388; -.
DR   eggNOG; COG5265; -.
DR   HOVERGEN; HBG080810; -.
DR   InParanoid; Q9NP58; -.
DR   KO; K05661; -.
DR   OMA; KPQTMER; -.
DR   OrthoDB; EOG7Z69BT; -.
DR   PhylomeDB; Q9NP58; -.
DR   TreeFam; TF105194; -.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   ChiTaRS; ABCB6; human.
DR   EvolutionaryTrace; Q9NP58; -.
DR   GeneWiki; ABCB6; -.
DR   GenomeRNAi; 10058; -.
DR   NextBio; 38003; -.
DR   PRO; PR:Q9NP58; -.
DR   Bgee; Q9NP58; -.
DR   CleanEx; HS_ABCB6; -.
DR   Genevestigator; Q9NP58; -.
DR   GO; GO:0043190; C:ATP-binding cassette (ABC) transporter complex; NAS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; ISS:UniProtKB.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0031307; C:integral component of mitochondrial outer membrane; IDA:UniProtKB.
DR   GO; GO:0005740; C:mitochondrial envelope; IDA:MGI.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005774; C:vacuolar membrane; IBA:RefGenome.
DR   GO; GO:0005524; F:ATP binding; IDA:MGI.
DR   GO; GO:0015562; F:efflux transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0015232; F:heme transporter activity; TAS:Reactome.
DR   GO; GO:0015439; F:heme-transporting ATPase activity; IMP:UniProtKB.
DR   GO; GO:0007420; P:brain development; IMP:UniProtKB.
DR   GO; GO:0070574; P:cadmium ion transmembrane transport; IBA:RefGenome.
DR   GO; GO:0006879; P:cellular iron ion homeostasis; NAS:UniProtKB.
DR   GO; GO:0071585; P:detoxification of cadmium ion; IBA:RefGenome.
DR   GO; GO:0015886; P:heme transport; IDA:UniProtKB.
DR   GO; GO:0006779; P:porphyrin-containing compound biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0043588; P:skin development; IMP:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0006810; P:transport; IDA:MGI.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00664; ABC_membrane; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF90123; SSF90123; 1.
DR   PROSITE; PS50929; ABC_TM1F; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Disease mutation; Dyskeratosis congenita;
KW   Endoplasmic reticulum; Endosome; Golgi apparatus; Membrane;
KW   Microphthalmia; Mitochondrion; Mitochondrion outer membrane;
KW   Nucleotide-binding; Polymorphism; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN         1    842       ATP-binding cassette sub-family B member
FT                                6, mitochondrial.
FT                                /FTId=PRO_0000000248.
FT   TRANSMEM     27     47       Helical; (Potential).
FT   TRANSMEM     73     93       Helical; (Potential).
FT   TRANSMEM    107    127       Helical; (Potential).
FT   TRANSMEM    148    168       Helical; (Potential).
FT   TRANSMEM    186    206       Helical; (Potential).
FT   TRANSMEM    265    285       Helical; (Potential).
FT   TRANSMEM    376    396       Helical; (Potential).
FT   TRANSMEM    409    431       Helical; (Potential).
FT   TRANSMEM    502    522       Helical; (Potential).
FT   TRANSMEM    530    550       Helical; (Potential).
FT   DOMAIN      265    556       ABC transmembrane type-1.
FT   DOMAIN      590    824       ABC transporter.
FT   NP_BIND     623    634       ATP.
FT   BINDING     599    599       ATP.
FT   VAR_SEQ     183    228       Missing (in isoform 2).
FT                                /FTId=VSP_021973.
FT   VARIANT      57     57       A -> T (in MCOPCB7; hypomorphic
FT                                mutation).
FT                                /FTId=VAR_067394.
FT   VARIANT      69     69       R -> G (in a breast cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035732.
FT   VARIANT     170    170       S -> G (in DUH3; the protein is retained
FT                                in the Golgi apparatus).
FT                                /FTId=VAR_070602.
FT   VARIANT     293    293       L -> V (in dbSNP:rs13018440).
FT                                /FTId=VAR_047552.
FT   VARIANT     343    343       R -> Q (in dbSNP:rs60322991).
FT                                /FTId=VAR_060986.
FT   VARIANT     356    356       L -> P (in DUH3; the protein is retained
FT                                in the Golgi apparatus).
FT                                /FTId=VAR_070603.
FT   VARIANT     579    579       G -> E (in DUH3; the protein is retained
FT                                in the Golgi apparatus).
FT                                /FTId=VAR_070604.
FT   VARIANT     648    648       R -> Q (in dbSNP:rs13402964).
FT                                /FTId=VAR_029749.
FT   VARIANT     811    811       L -> V (in MCOPCB7; hypomorphic
FT                                mutation).
FT                                /FTId=VAR_067395.
FT   CONFLICT    170    170       S -> N (in Ref. 2; AAG33618).
FT   CONFLICT    320    320       T -> S (in Ref. 4; BAD18782).
FT   CONFLICT    413    413       F -> S (in Ref. 4; BAD18782).
FT   CONFLICT    616    616       G -> E (in Ref. 4; BAD18782).
FT   CONFLICT    638    638       R -> L (in Ref. 4; BAD18782).
FT   HELIX       561    572
FT   STRAND      590    600
FT   STRAND      604    613
FT   STRAND      618    625
FT   HELIX       628    636
FT   STRAND      643    649
FT   HELIX       654    656
FT   HELIX       659    664
FT   STRAND      666    669
FT   STRAND      677    679
FT   HELIX       680    685
FT   HELIX       693    702
FT   HELIX       706    711
FT   HELIX       715    717
FT   STRAND      719    721
FT   HELIX       729    743
FT   STRAND      746    751
FT   HELIX       759    773
FT   STRAND      776    781
FT   HELIX       785    789
FT   STRAND      792    798
FT   STRAND      801    806
FT   HELIX       808    814
FT   HELIX       817    826
SQ   SEQUENCE   842 AA;  93886 MW;  E63A7D59DCE5B9ED CRC64;
     MVTVGNYCEA EGPVGPAWMQ DGLSPCFFFT LVPSTRMALG TLALVLALPC RRRERPAGAD
     SLSWGAGPRI SPYVLQLLLA TLQAALPLAG LAGRVGTARG APLPSYLLLA SVLESLAGAC
     GLWLLVVERS QARQRLAMGI WIKFRHSPGL LLLWTVAFAA ENLALVSWNS PQWWWARADL
     GQQVQFSLWV LRYVVSGGLF VLGLWAPGLR PQSYTLQVHE EDQDVERSQV RSAAQQSTWR
     DFGRKLRLLS GYLWPRGSPA LQLVVLICLG LMGLERALNV LVPIFYRNIV NLLTEKAPWN
     SLAWTVTSYV FLKFLQGGGT GSTGFVSNLR TFLWIRVQQF TSRRVELLIF SHLHELSLRW
     HLGRRTGEVL RIADRGTSSV TGLLSYLVFN VIPTLADIII GIIYFSMFFN AWFGLIVFLC
     MSLYLTLTIV VTEWRTKFRR AMNTQENATR ARAVDSLLNF ETVKYYNAES YEVERYREAI
     IKYQGLEWKS SASLVLLNQT QNLVIGLGLL AGSLLCAYFV TEQKLQVGDY VLFGTYIIQL
     YMPLNWFGTY YRMIQTNFID MENMFDLLKE ETEVKDLPGA GPLRFQKGRI EFENVHFSYA
     DGRETLQDVS FTVMPGQTLA LVGPSGAGKS TILRLLFRFY DISSGCIRID GQDISQVTQA
     SLRSHIGVVP QDTVLFNDTI ADNIRYGRVT AGNDEVEAAA QAAGIHDAIM AFPEGYRTQV
     GERGLKLSGG EKQRVAIART ILKAPGIILL DEATSALDTS NERAIQASLA KVCANRTTIV
     VAHRLSTVVN ADQILVIKDG CIVERGRHEA LLSRGGVYAD MWQLQQGQEE TSEDTKPQTM
     ER
//
ID   ABCB7_HUMAN             Reviewed;         752 AA.
AC   O75027; G3XAC4; O75345; Q5VWY7; Q5VWY8; Q9BRE1; Q9UND1; Q9UP01;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   09-JUL-2014, entry version 141.
DE   RecName: Full=ATP-binding cassette sub-family B member 7, mitochondrial;
DE   AltName: Full=ATP-binding cassette transporter 7;
DE            Short=ABC transporter 7 protein;
DE   Flags: Precursor;
GN   Name=ABCB7; Synonyms=ABC7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS GLY-315 AND
RP   ILE-346.
RC   TISSUE=Placenta;
RX   PubMed=9621516; DOI=10.1007/s100380050051;
RA   Shimada Y., Okuno S., Kawai A., Shinomiya H., Saito A., Suzuki M.,
RA   Omori Y., Nishino N., Kanemoto N., Fujiwara T., Horie M.,
RA   Takahashi E.;
RT   "Cloning and chromosomal mapping of a novel ABC transporter gene
RT   (hABC7), a candidate for X-linked sideroblastic anemia with
RT   spinocerebellar ataxia.";
RL   J. Hum. Genet. 43:115-122(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASAT MET-400.
RX   PubMed=10196363; DOI=10.1093/hmg/8.5.743;
RA   Allikmets R., Raskind W.H., Hutchinson A., Schueck N.D., Dean M.,
RA   Koeller D.M.;
RT   "Mutation of a putative mitochondrial iron transporter gene (ABC7) in
RT   X-linked sideroblastic anemia and ataxia (XLSA/A).";
RL   Hum. Mol. Genet. 8:743-749(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASAT LYS-433.
RX   PubMed=11050011;
RA   Bekri S., Kispal G., Lange H., Fitzsimons E., Tolmie J., Lill R.,
RA   Bishop D.F.;
RT   "Human ABC7 transporter: gene structure and mutation causing X-linked
RT   sideroblastic anemia with ataxia with disruption of cytosolic iron-
RT   sulfur protein maturation.";
RL   Blood 96:3256-3264(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=9653160; DOI=10.1073/pnas.95.14.8175;
RA   Mao M., Fu G., Wu J.-S., Zhang Q.-H., Zhou J., Kan L.-X., Huang Q.-H.,
RA   He K.-L., Gu B.-W., Han Z.-G., Shen Y., Gu J., Yu Y.-P., Xu S.-H.,
RA   Wang Y.-X., Chen S.-J., Chen Z.;
RT   "Identification of genes expressed in human CD34(+) hematopoietic
RT   stem/progenitor cells by expressed sequence tags and efficient full-
RT   length cDNA cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:8175-8180(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 5-752 (ISOFORM 1).
RX   PubMed=9883897; DOI=10.1016/S0014-5793(98)01560-9;
RA   Csere P., Lill R., Kispal G.;
RT   "Identification of a human mitochondrial ABC transporter, the
RT   functional orthologue of yeast Atm1p.";
RL   FEBS Lett. 441:266-270(1998).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-216 AND LYS-251, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   VARIANT ASAT LEU-411, AND VARIANTS GLY-315 AND ILE-346.
RX   PubMed=11843825; DOI=10.1046/j.1365-2141.2001.03015.x;
RA   Maguire A., Hellier K., Hammans S., May A.;
RT   "X-linked cerebellar ataxia and sideroblastic anaemia associated with
RT   a missense mutation in the ABC7 gene predicting V411L.";
RL   Br. J. Haematol. 115:910-917(2001).
RN   [13]
RP   VARIANT ASAT ASP-208.
RX   PubMed=22398176; DOI=10.1016/j.ejpn.2012.02.003;
RA   D'Hooghe M., Selleslag D., Mortier G., Van Coster R., Vermeersch P.,
RA   Billiet J., Bekri S.;
RT   "X-linked sideroblastic anemia and ataxia: A new family with
RT   identification of a fourth ABCB7 gene mutation.";
RL   Eur. J. Paediatr. Neurol. 16:730-735(2012).
CC   -!- FUNCTION: Could be involved in the transport of heme from the
CC       mitochondria to the cytosol. Plays a central role in the
CC       maturation of cytosolic iron-sulfur (Fe/S) cluster-containing
CC       proteins.
CC   -!- SUBUNIT: Homodimer or heterodimer (Potential).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein (Potential).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O75027-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75027-2; Sequence=VSP_014635;
CC       Name=3;
CC         IsoId=O75027-3; Sequence=VSP_054700;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on EST data;
CC   -!- DISEASE: Anemia, sideroblastic, spinocerebellar ataxia (ASAT)
CC       [MIM:301310]: A X-linked recessive disorder characterized by an
CC       infantile to early childhood onset of non-progressive cerebellar
CC       ataxia and mild anemia, with hypochromia and microcytosis.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCB
CC       family. Heavy Metal importer (TC 3.A.1.210) subfamily.
CC   -!- SIMILARITY: Contains 1 ABC transmembrane type-1 domain.
CC   -!- SIMILARITY: Contains 1 ABC transporter domain.
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=O75027";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB005289; BAA28861.1; -; mRNA.
DR   EMBL; AF133659; AAD33045.1; -; mRNA.
DR   EMBL; AF241887; AAK20173.1; -; Genomic_DNA.
DR   EMBL; AF241872; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241873; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241874; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241875; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241876; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241877; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241878; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241879; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241880; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241881; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241882; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241883; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241884; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241885; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF241886; AAK20173.1; JOINED; Genomic_DNA.
DR   EMBL; AF038950; AAC39865.1; -; mRNA.
DR   EMBL; BT009918; AAP88920.1; -; mRNA.
DR   EMBL; AL360179; CAH70564.1; -; Genomic_DNA.
DR   EMBL; AL359545; CAH70564.1; JOINED; Genomic_DNA.
DR   EMBL; AL360179; CAH70565.1; -; Genomic_DNA.
DR   EMBL; AL359545; CAH70565.1; JOINED; Genomic_DNA.
DR   EMBL; AL359545; CAI41573.1; -; Genomic_DNA.
DR   EMBL; AL360179; CAI41573.1; JOINED; Genomic_DNA.
DR   EMBL; AL359545; CAI41574.1; -; Genomic_DNA.
DR   EMBL; AL360179; CAI41574.1; JOINED; Genomic_DNA.
DR   EMBL; CH471104; EAW98635.1; -; Genomic_DNA.
DR   EMBL; BC006323; AAH06323.1; -; mRNA.
DR   EMBL; AF078777; AAD47141.1; -; mRNA.
DR   CCDS; CCDS14428.1; -. [O75027-2]
DR   CCDS; CCDS65291.1; -. [O75027-1]
DR   RefSeq; NP_001258625.1; NM_001271696.1. [O75027-1]
DR   RefSeq; NP_001258626.1; NM_001271697.1. [O75027-3]
DR   RefSeq; NP_001258627.1; NM_001271698.1.
DR   RefSeq; NP_004290.2; NM_004299.4. [O75027-2]
DR   UniGene; Hs.370480; -.
DR   ProteinModelPortal; O75027; -.
DR   SMR; O75027; 127-738.
DR   BioGrid; 106540; 11.
DR   IntAct; O75027; 2.
DR   STRING; 9606.ENSP00000253577; -.
DR   TCDB; 3.A.1.210.4; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; O75027; -.
DR   MaxQB; O75027; -.
DR   PaxDb; O75027; -.
DR   PRIDE; O75027; -.
DR   DNASU; 22; -.
DR   Ensembl; ENST00000253577; ENSP00000253577; ENSG00000131269. [O75027-2]
DR   Ensembl; ENST00000339447; ENSP00000343849; ENSG00000131269.
DR   Ensembl; ENST00000373394; ENSP00000362492; ENSG00000131269. [O75027-1]
DR   GeneID; 22; -.
DR   KEGG; hsa:22; -.
DR   UCSC; uc004ebz.4; human. [O75027-2]
DR   UCSC; uc004eca.4; human. [O75027-1]
DR   CTD; 22; -.
DR   GeneCards; GC0XM074189; -.
DR   GeneReviews; ABCB7; -.
DR   H-InvDB; HIX0028475; -.
DR   HGNC; HGNC:48; ABCB7.
DR   HPA; HPA034982; -.
DR   MIM; 300135; gene.
DR   MIM; 301310; phenotype.
DR   neXtProt; NX_O75027; -.
DR   Orphanet; 2802; X-linked sideroblastic anemia - ataxia.
DR   PharmGKB; PA24389; -.
DR   eggNOG; COG5265; -.
DR   HOVERGEN; HBG080194; -.
DR   KO; K05662; -.
DR   OMA; MHQLSLR; -.
DR   OrthoDB; EOG7Z69BT; -.
DR   PhylomeDB; O75027; -.
DR   TreeFam; TF105195; -.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   GeneWiki; ABCB7; -.
DR   GenomeRNAi; 22; -.
DR   NextBio; 35517837; -.
DR   PRO; PR:O75027; -.
DR   ArrayExpress; O75027; -.
DR   Bgee; O75027; -.
DR   CleanEx; HS_ABCB7; -.
DR   Genevestigator; O75027; -.
DR   GO; GO:0016021; C:integral component of membrane; IBA:RefGenome.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; TAS:ProtInc.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; IBA:RefGenome.
DR   GO; GO:0015232; F:heme transporter activity; TAS:ProtInc.
DR   GO; GO:0006879; P:cellular iron ion homeostasis; IBA:RefGenome.
DR   GO; GO:0015886; P:heme transport; TAS:GOC.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0055085; P:transmembrane transport; IBA:RefGenome.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00664; ABC_membrane; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF90123; SSF90123; 1.
DR   PROSITE; PS50929; ABC_TM1F; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Complete proteome;
KW   Disease mutation; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transit peptide; Transmembrane;
KW   Transmembrane helix; Transport.
FT   TRANSIT       1      ?       Mitochondrion (Potential).
FT   CHAIN         ?    752       ATP-binding cassette sub-family B member
FT                                7, mitochondrial.
FT                                /FTId=PRO_0000000249.
FT   TRANSMEM    141    161       Helical; (Potential).
FT   TRANSMEM    186    206       Helical; (Potential).
FT   TRANSMEM    260    280       Helical; (Potential).
FT   TRANSMEM    291    311       Helical; (Potential).
FT   TRANSMEM    383    403       Helical; (Potential).
FT   TRANSMEM    410    430       Helical; (Potential).
FT   DOMAIN      140    436       ABC transmembrane type-1.
FT   DOMAIN      472    706       ABC transporter.
FT   NP_BIND     505    516       ATP (By similarity).
FT   BINDING     481    481       ATP (By similarity).
FT   MOD_RES     216    216       N6-acetyllysine.
FT   MOD_RES     251    251       N6-acetyllysine.
FT   MOD_RES     336    336       Phosphoserine (By similarity).
FT   MOD_RES     340    340       Phosphotyrosine (By similarity).
FT   MOD_RES     342    342       Phosphothreonine (By similarity).
FT   VAR_SEQ      56     56       Q -> QQ (in isoform 2).
FT                                /FTId=VSP_014635.
FT   VAR_SEQ     112    151       Missing (in isoform 3).
FT                                /FTId=VSP_054700.
FT   VARIANT     208    208       E -> D (in ASAT).
FT                                /FTId=VAR_067354.
FT   VARIANT     315    315       R -> G.
FT                                /FTId=VAR_022872.
FT   VARIANT     346    346       F -> I.
FT                                /FTId=VAR_022873.
FT   VARIANT     400    400       I -> M (in ASAT).
FT                                /FTId=VAR_009156.
FT   VARIANT     411    411       V -> L (in ASAT).
FT                                /FTId=VAR_022874.
FT   VARIANT     433    433       E -> K (in ASAT; impaired maturation of
FT                                cytosolic Fe/S proteins).
FT                                /FTId=VAR_012640.
FT   VARIANT     580    580       A -> V (in dbSNP:rs1340989).
FT                                /FTId=VAR_055471.
FT   VARIANT     581    581       V -> A (in dbSNP:rs1340989).
FT                                /FTId=VAR_037972.
FT   CONFLICT    141    141       A -> P (in Ref. 4; AAC39865).
FT   CONFLICT    258    258       R -> K (in Ref. 1; BAA28861).
FT   CONFLICT    271    276       LLPIMF -> PLPNHV (in Ref. 4; AAC39865).
FT   CONFLICT    280    280       L -> LL (in Ref. 4; AAC39865).
FT   CONFLICT    290    290       G -> C (in Ref. 4; AAC39865).
FT   CONFLICT    293    297       FALVT -> LLGN (in Ref. 4; AAC39865).
FT   CONFLICT    320    324       IEMNK -> LEIDQ (in Ref. 4; AAC39865).
FT   CONFLICT    542    542       E -> V (in Ref. 9; AAD47141).
SQ   SEQUENCE   752 AA;  82641 MW;  B1FFA57ABD24FB90 CRC64;
     MALLAMHSWR WAAAAAAFEK RRHSAILIRP LVSVSGSGPQ WRPHQLGALG TARAYQIPES
     LKSITWQRLG KGNSGQFLDA AKALQVWPLI EKRTCWHGHA GGGLHTDPKE GLKDVDTRKI
     IKAMLSYVWP KDRPDLRARV AISLGFLGGA KAMNIVVPFM FKYAVDSLNQ MSGNMLNLSD
     APNTVATMAT AVLIGYGVSR AGAAFFNEVR NAVFGKVAQN SIRRIAKNVF LHLHNLDLGF
     HLSRQTGALS KAIDRGTRGI SFVLSALVFN LLPIMFEVML VSGVLYYKCG AQFALVTLGT
     LGTYTAFTVA VTRWRTRFRI EMNKADNDAG NAAIDSLLNY ETVKYFNNER YEAQRYDGFL
     KTYETASLKS TSTLAMLNFG QSAIFSVGLT AIMVLASQGI VAGTLTVGDL VMVNGLLFQL
     SLPLNFLGTV YRETRQALID MNTLFTLLKV DTQIKDKVMA SPLQITPQTA TVAFDNVHFE
     YIEGQKVLSG ISFEVPAGKK VAIVGGSGSG KSTIVRLLFR FYEPQKGSIY LAGQNIQDVS
     LESLRRAVGV VPQDAVLFHN TIYYNLLYGN ISASPEEVYA VAKLAGLHDA ILRMPHGYDT
     QVGERGLKLS GGEKQRVAIA RAILKDPPVI LYDEATSSLD SITEETILGA MKDVVKHRTS
     IFIAHRLSTV VDADEIIVLD QGKVAERGTH HGLLANPHSI YSEMWHTQSS RVQNHDNPKW
     EAKKENISKE EERKKLQEEI VNSVKGCGNC SC
//
ID   ABCB9_HUMAN             Reviewed;         766 AA.
AC   Q9NP78; B4E2J0; Q5W9G7; Q769F3; Q769F4; Q96AB1; Q9P208;
DT   02-AUG-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   09-JUL-2014, entry version 139.
DE   RecName: Full=ATP-binding cassette sub-family B member 9;
DE   AltName: Full=ATP-binding cassette transporter 9;
DE            Short=ABC transporter 9 protein;
DE            Short=hABCB9;
DE   AltName: Full=TAP-like protein;
DE            Short=TAPL;
GN   Name=ABCB9; Synonyms=KIAA1520;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INDUCTION.
RC   TISSUE=Embryonic kidney;
RX   PubMed=11011155; DOI=10.1093/oxfordjournals.jbchem.a022805;
RA   Kobayashi A., Kasano M., Maeda T., Hori S., Motojima K., Suzuki M.,
RA   Fujiwara T., Takahashi E., Yabe T., Tanaka K., Kasahara M.,
RA   Yamaguchi Y., Maeda M.;
RT   "A half-type ABC transporter TAPL is highly conserved between rodent
RT   and man, and the human gene is not responsive to interferon-gamma in
RT   contrast to TAP1 and TAP2.";
RL   J. Biochem. 128:711-718(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Lymphoblast;
RX   PubMed=10748049; DOI=10.1074/jbc.M001819200;
RA   Zhang F., Zhang W., Liu L., Fisher C.L., Hui D., Childs S.,
RA   Dorovini-Zis K., Ling V.;
RT   "Characterization of ABCB9, an ATP binding cassette protein associated
RT   with lysosomes.";
RL   J. Biol. Chem. 275:23287-23294(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 5).
RC   TISSUE=Cervix carcinoma, and Embryonic kidney;
RX   PubMed=13679046; DOI=10.1016/j.bbrc.2003.08.081;
RA   Kobayashi A., Hori S., Suita N., Maeda M.;
RT   "Gene organization of human transporter associated with antigen
RT   processing-like (TAPL, ABCB9): analysis of alternative splicing
RT   variants and promoter activity.";
RL   Biochem. Biophys. Res. Commun. 309:815-822(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15491607; DOI=10.1016/j.jmb.2004.09.028;
RA   Homma K., Kikuno R.F., Nagase T., Ohara O., Nishikawa K.;
RT   "Alternative splice variants encoding unstable protein domains exist
RT   in the human brain.";
RL   J. Mol. Biol. 343:1207-1220(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10819331; DOI=10.1093/dnares/7.2.143;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:143-150(2000).
RN   [6]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R.;
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=15577206; DOI=10.1248/bpb.27.1916;
RA   Kobayashi A., Maeda T., Maeda M.;
RT   "Membrane localization of transporter associated with antigen
RT   processing (TAP)-like (ABCB9) visualized in vivo with a fluorescence
RT   protein-fusion technique.";
RL   Biol. Pharm. Bull. 27:1916-1922(2004).
RN   [11]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.
RX   PubMed=15863492; DOI=10.1074/jbc.M503231200;
RA   Wolters J.C., Abele R., Tampe R.;
RT   "Selective and ATP-dependent translocation of peptides by the
RT   homodimeric ATP binding cassette transporter TAP-like (ABCB9).";
RL   J. Biol. Chem. 280:23631-23636(2005).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17977821; DOI=10.1074/jbc.M708139200;
RA   Demirel O., Waibler Z., Kalinke U., Grunebach F., Appel S.,
RA   Brossart P., Hasilik A., Tampe R., Abele R.;
RT   "Identification of a lysosomal peptide transport system induced during
RT   dendritic cell development.";
RL   J. Biol. Chem. 282:37836-37843(2007).
RN   [13]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Placenta;
RX   PubMed=17897319; DOI=10.1111/j.1600-0854.2007.00643.x;
RA   Schroeder B., Wrocklage C., Pan C., Jaeger R., Koesters B.,
RA   Schaefer H., Elsaesser H.-P., Mann M., Hasilik A.;
RT   "Integral and associated lysosomal membrane proteins.";
RL   Traffic 8:1676-1686(2007).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18952056; DOI=10.1016/j.bbrc.2008.10.078;
RA   Kamakura A., Fujimoto Y., Motohashi Y., Ohashi K.,
RA   Ohashi-Kobayashi A., Maeda M.;
RT   "Functional dissection of transmembrane domains of human TAP-like
RT   (ABCB9).";
RL   Biochem. Biophys. Res. Commun. 377:847-851(2008).
RN   [15]
RP   SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=18175933; DOI=10.1248/bpb.31.1;
RA   Ohara T., Ohashi-Kobayashi A., Maeda M.;
RT   "Biochemical characterization of transporter associated with antigen
RT   processing (TAP)-like (ABCB9) expressed in insect cells.";
RL   Biol. Pharm. Bull. 31:1-5(2008).
RN   [16]
RP   FUNCTION.
RX   PubMed=18434309; DOI=10.1074/jbc.M801794200;
RA   Zhao C., Haase W., Tampe R., Abele R.;
RT   "Peptide specificity and lipid activation of the lysosomal transport
RT   complex ABCB9 (TAPL).";
RL   J. Biol. Chem. 283:17083-17091(2008).
RN   [17]
RP   SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF 136-LYS-LYS-137.
RX   PubMed=20377823; DOI=10.1111/j.1600-0854.2009.01021.x;
RA   Demirel O., Bangert I., Tampe R., Abele R.;
RT   "Tuning the cellular trafficking of the lysosomal peptide transporter
RT   TAPL by its N-terminal domain.";
RL   Traffic 11:383-393(2010).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21212514; DOI=10.1248/bpb.34.36;
RA   Fujimoto Y., Kamakura A., Motohashi Y., Ohashi-Kobayashi A., Maeda M.;
RT   "Transporter associated with antigen processing-like (ABCB9) stably
RT   expressed in Chinese hamster ovary-K1 cells is sorted to the
RT   microdomains of lysosomal membranes.";
RL   Biol. Pharm. Bull. 34:36-40(2011).
RN   [19]
RP   VARIANT MET-121.
RX   PubMed=11829140; DOI=10.1007/s10038-002-8653-6;
RA   Saito S., Iida A., Sekine A., Miura Y., Ogawa C., Kawauchi S.,
RA   Higuchi S., Nakamura Y.;
RT   "Three hundred twenty-six genetic variations in genes encoding nine
RT   members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the
RT   Japanese population.";
RL   J. Hum. Genet. 47:38-50(2002).
CC   -!- FUNCTION: ATP-dependent low-affinity peptide transporter which
CC       translocates a broad spectrum of peptides from the cytosol to the
CC       lysosomal lumen. Displays a broad peptide length specificity from
CC       6-mer up to at least 59-mer peptides with an optimum of 23-mers.
CC       Favors positively charged, aromatic or hydrophobic residues in the
CC       N- and C-terminal positions whereas negatively charged residues as
CC       well as asparagine and methionine are not favored.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.8 uM for peptide RRYQNSTCL;
CC       pH dependence:
CC         Optimum pH is 7.0;
CC       Temperature dependence:
CC         Optimum temperature is 37 degrees Celsius;
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Lysosome membrane; Multi-pass membrane
CC       protein. Note=May be located in membrane rafts.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=12A, c1-l;
CC         IsoId=Q9NP78-1; Sequence=Displayed;
CC       Name=2; Synonyms=c1-s;
CC         IsoId=Q9NP78-2; Sequence=VSP_000027;
CC       Name=3;
CC         IsoId=Q9NP78-3; Sequence=VSP_000029, VSP_000030;
CC         Note=No experimental confirmation available;
CC       Name=4; Synonyms=12B;
CC         IsoId=Q9NP78-5; Sequence=VSP_041884, VSP_041886;
CC       Name=5; Synonyms=12C;
CC         IsoId=Q9NP78-6; Sequence=VSP_041885;
CC       Name=6;
CC         IsoId=Q9NP78-7; Sequence=VSP_044884;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Highly expressed in testis, and at moderate
CC       levels in brain, spinal cord, and thyroid. Not expressed in
CC       monocytes but strongly expressed during differentiation of
CC       monocytes to dendritic cells and macrophages.
CC   -!- INDUCTION: Not induced by interferon-gamma.
CC   -!- DOMAIN: The N-terminal region comprising the first four
CC       transmembrane domains is required for lysosomal localization but
CC       not for homodimerization or peptide transport.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCB
CC       family. MHC peptide exporter (TC 3.A.1.209) subfamily.
CC   -!- SIMILARITY: Contains 1 ABC transmembrane type-1 domain.
CC   -!- SIMILARITY: Contains 1 ABC transporter domain.
CC   -!- CAUTION: Has also been detected in the endoplasmic reticulum
CC       (PubMed:11011155) but appears to be a lysosomal protein in vivo.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA96044.2; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC       Sequence=BAD66830.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=Q9NP78";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB045381; BAA97989.2; -; mRNA.
DR   EMBL; AF216494; AAF89993.1; -; mRNA.
DR   EMBL; AB112582; BAC98409.1; -; mRNA.
DR   EMBL; AB112583; BAC98410.1; -; mRNA.
DR   EMBL; AB177852; BAD66830.1; ALT_INIT; mRNA.
DR   EMBL; AB040953; BAA96044.2; ALT_INIT; mRNA.
DR   EMBL; AK304295; BAG65152.1; -; mRNA.
DR   EMBL; AC026362; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC027290; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC017348; AAH17348.1; -; mRNA.
DR   CCDS; CCDS58286.1; -. [Q9NP78-7]
DR   CCDS; CCDS58287.1; -. [Q9NP78-6]
DR   CCDS; CCDS58288.1; -. [Q9NP78-5]
DR   CCDS; CCDS9241.1; -. [Q9NP78-1]
DR   RefSeq; NP_001229942.1; NM_001243013.1. [Q9NP78-7]
DR   RefSeq; NP_001229943.1; NM_001243014.1. [Q9NP78-6]
DR   RefSeq; NP_062570.1; NM_019624.3. [Q9NP78-2]
DR   RefSeq; NP_062571.1; NM_019625.3. [Q9NP78-1]
DR   RefSeq; NP_982269.2; NM_203444.3. [Q9NP78-5]
DR   UniGene; Hs.511951; -.
DR   ProteinModelPortal; Q9NP78; -.
DR   SMR; Q9NP78; 175-739.
DR   BioGrid; 117021; 1.
DR   STRING; 9606.ENSP00000280560; -.
DR   ChEMBL; CHEMBL1293189; -.
DR   TCDB; 3.A.1.209.2; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; Q9NP78; -.
DR   DMDM; 22095458; -.
DR   PaxDb; Q9NP78; -.
DR   PRIDE; Q9NP78; -.
DR   Ensembl; ENST00000280560; ENSP00000280560; ENSG00000150967. [Q9NP78-1]
DR   Ensembl; ENST00000344275; ENSP00000456813; ENSG00000150967. [Q9NP78-6]
DR   Ensembl; ENST00000346530; ENSP00000280559; ENSG00000150967. [Q9NP78-2]
DR   Ensembl; ENST00000392439; ENSP00000376234; ENSG00000150967. [Q9NP78-1]
DR   Ensembl; ENST00000442833; ENSP00000456375; ENSG00000150967. [Q9NP78-5]
DR   Ensembl; ENST00000540285; ENSP00000441734; ENSG00000150967. [Q9NP78-7]
DR   Ensembl; ENST00000542678; ENSP00000440288; ENSG00000150967. [Q9NP78-1]
DR   GeneID; 23457; -.
DR   KEGG; hsa:23457; -.
DR   UCSC; uc001udm.4; human. [Q9NP78-1]
DR   UCSC; uc001udo.4; human. [Q9NP78-2]
DR   UCSC; uc001udr.3; human. [Q9NP78-3]
DR   UCSC; uc010taj.2; human.
DR   UCSC; uc021rfp.1; human. [Q9NP78-5]
DR   CTD; 23457; -.
DR   GeneCards; GC12M123413; -.
DR   HGNC; HGNC:50; ABCB9.
DR   HPA; HPA035114; -.
DR   MIM; 605453; gene.
DR   neXtProt; NX_Q9NP78; -.
DR   PharmGKB; PA24391; -.
DR   eggNOG; COG1132; -.
DR   HOVERGEN; HBG008358; -.
DR   InParanoid; Q9NP78; -.
DR   KO; K05656; -.
DR   OrthoDB; EOG7Z3F4H; -.
DR   PhylomeDB; Q9NP78; -.
DR   TreeFam; TF105197; -.
DR   BRENDA; 3.6.3.43; 2681.
DR   GeneWiki; ABCB9; -.
DR   GenomeRNAi; 23457; -.
DR   NextBio; 45751; -.
DR   PRO; PR:Q9NP78; -.
DR   ArrayExpress; Q9NP78; -.
DR   Bgee; Q9NP78; -.
DR   CleanEx; HS_ABCB9; -.
DR   Genevestigator; Q9NP78; -.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:UniProt.
DR   GO; GO:0005886; C:plasma membrane; IBA:RefGenome.
DR   GO; GO:0042825; C:TAP complex; IBA:RefGenome.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0042288; F:MHC class I protein binding; IBA:RefGenome.
DR   GO; GO:0015421; F:oligopeptide-transporting ATPase activity; IBA:RefGenome.
DR   GO; GO:0042605; F:peptide antigen binding; IBA:RefGenome.
DR   GO; GO:0015440; F:peptide-transporting ATPase activity; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProt.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0022891; F:substrate-specific transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0046978; F:TAP1 binding; IBA:RefGenome.
DR   GO; GO:0046979; F:TAP2 binding; IBA:RefGenome.
DR   GO; GO:0046980; F:tapasin binding; IBA:RefGenome.
DR   GO; GO:0035672; P:oligopeptide transmembrane transport; IBA:GOC.
DR   GO; GO:0015833; P:peptide transport; IDA:UniProtKB.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IBA:RefGenome.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0055085; P:transmembrane transport; IBA:RefGenome.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00664; ABC_membrane; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF90123; SSF90123; 1.
DR   PROSITE; PS50929; ABC_TM1F; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome; Lysosome;
KW   Membrane; Nucleotide-binding; Peptide transport; Polymorphism;
KW   Protein transport; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN         1    766       ATP-binding cassette sub-family B member
FT                                9.
FT                                /FTId=PRO_0000000252.
FT   TRANSMEM      7     27       Helical; (Potential).
FT   TRANSMEM     47     67       Helical; (Potential).
FT   TRANSMEM     84    104       Helical; (Potential).
FT   TRANSMEM    116    136       Helical; (Potential).
FT   TRANSMEM    185    205       Helical; (Potential).
FT   TRANSMEM    225    245       Helical; (Potential).
FT   TRANSMEM    319    339       Helical; (Potential).
FT   TRANSMEM    416    436       Helical; (Potential).
FT   DOMAIN      188    471       ABC transmembrane type-1.
FT   DOMAIN      504    740       ABC transporter.
FT   NP_BIND     539    546       ATP (Potential).
FT   COMPBIAS    384    389       Poly-Glu.
FT   VAR_SEQ     418    460       Missing (in isoform 2).
FT                                /FTId=VSP_000027.
FT   VAR_SEQ     461    523       Missing (in isoform 6).
FT                                /FTId=VSP_044884.
FT   VAR_SEQ     582    596       ISLVSQEPVLFARSI -> VCARAWATLLRPFCI (in
FT                                isoform 3).
FT                                /FTId=VSP_000029.
FT   VAR_SEQ     597    766       Missing (in isoform 3).
FT                                /FTId=VSP_000030.
FT   VAR_SEQ     681    683       IQQ -> CAG (in isoform 4).
FT                                /FTId=VSP_041884.
FT   VAR_SEQ     682    766       Missing (in isoform 5).
FT                                /FTId=VSP_041885.
FT   VAR_SEQ     684    766       Missing (in isoform 4).
FT                                /FTId=VSP_041886.
FT   VARIANT     121    121       V -> M (in dbSNP:rs3803002).
FT                                /FTId=VAR_013701.
FT   MUTAGEN     136    137       LL->AA: No effect on lysosomal
FT                                localization.
SQ   SEQUENCE   766 AA;  84475 MW;  C83FA62C929EC792 CRC64;
     MRLWKAVVVT LAFMSVDICV TTAIYVFSHL DRSLLEDIRH FNIFDSVLDL WAACLYRSCL
     LLGATIGVAK NSALGPRRLR ASWLVITLVC LFVGIYAMVK LLLFSEVRRP IRDPWFWALF
     VWTYISLGAS FLLWWLLSTV RPGTQALEPG AATEAEGFPG SGRPPPEQAS GATLQKLLSY
     TKPDVAFLVA ASFFLIVAAL GETFLPYYTG RAIDGIVIQK SMDQFSTAVV IVCLLAIGSS
     FAAGIRGGIF TLIFARLNIR LRNCLFRSLV SQETSFFDEN RTGDLISRLT SDTTMVSDLV
     SQNINVFLRN TVKVTGVVVF MFSLSWQLSL VTFMGFPIIM MVSNIYGKYY KRLSKEVQNA
     LARASNTAEE TISAMKTVRS FANEEEEAEV YLRKLQQVYK LNRKEAAAYM YYVWGSGLTL
     LVVQVSILYY GGHLVISGQM TSGNLIAFII YEFVLGDCME SVGSVYSGLM QGVGAAEKVF
     EFIDRQPTMV HDGSLAPDHL EGRVDFENVT FTYRTRPHTQ VLQNVSFSLS PGKVTALVGP
     SGSGKSSCVN ILENFYPLEG GRVLLDGKPI SAYDHKYLHR VISLVSQEPV LFARSITDNI
     SYGLPTVPFE MVVEAAQKAN AHGFIMELQD GYSTETGEKG AQLSGGQKQR VAMARALVRN
     PPVLILDEAT SALDAESEYL IQQAIHGNLQ KHTVLIIAHR LSTVEHAHLI VVLDKGRVVQ
     QGTHQQLLAQ GGLYAKLVQR QMLGLQPAAD FTAGHNEPVA NGSHKA
//
ID   ABCBB_HUMAN             Reviewed;        1321 AA.
AC   O95342; Q53TL2; Q9UNB2;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   03-NOV-2009, sequence version 2.
DT   09-JUL-2014, entry version 137.
DE   RecName: Full=Bile salt export pump;
DE   AltName: Full=ATP-binding cassette sub-family B member 11;
GN   Name=ABCB11; Synonyms=BSEP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS PFIC2 GLY-297; GLU-461;
RP   GLY-482; ARG-982; CYS-1153 AND GLN-1268.
RX   PubMed=9806540; DOI=10.1038/3034;
RA   Strautnieks S.S., Bull L.N., Knisely A.S., Kocoshis S.A., Dahl N.,
RA   Arnell H., Sokal E.M., Dahan K., Childs S., Ling V., Tanner M.S.,
RA   Kagalwalla A.F., Nemeth A., Pawlowska J., Baker A., Mieli-Vergani G.,
RA   Freimer N.B., Gardiner R.M., Thompson R.J.;
RT   "A gene encoding a liver-specific ABC transporter is mutated in
RT   progressive familial intrahepatic cholestasis.";
RL   Nat. Genet. 20:233-238(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-444.
RA   Mol O., Hooiveld G.J.E.J., Jansen P.L.M., Muller M.;
RT   "Cellular localization and functional characterization of the human
RT   bile salt export pump (BSEP).";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   GLYCOSYLATION AT ASN-109; ASN-116; ASN-122 AND ASN-125.
RX   PubMed=17082223; DOI=10.1152/ajpgi.00415.2006;
RA   Mochizuki K., Kagawa T., Numari A., Harris M.J., Itoh J., Watanabe N.,
RA   Mine T., Arias I.M.;
RT   "Two N-linked glycans are required to maintain the transport activity
RT   of the bile salt export pump (ABCB11) in MDCK II cells.";
RL   Am. J. Physiol. 292:G818-G828(2007).
RN   [5]
RP   VARIANTS PFIC2 VAL-238 AND SER-336.
RX   PubMed=10579978; DOI=10.1016/S0016-5085(99)70287-8;
RA   Jansen P.L.M., Strautnieks S.S., Jacquemin E., Hadchouel M.,
RA   Sokal E.M., Hooiveld G.J.E.J., Koning J.H., De Jager-Krikken A.,
RA   Kuipers F., Stellaard F., Bijleveld C.M., Gouw A., Van Goor H.,
RA   Thompson R.J., Muller M.;
RT   "Hepatocanalicular bile salt export pump deficiency in patients with
RT   progressive familial intrahepatic cholestasis.";
RL   Gastroenterology 117:1370-1379(1999).
RN   [6]
RP   VARIANT ALA-444.
RX   PubMed=11829140; DOI=10.1007/s10038-002-8653-6;
RA   Saito S., Iida A., Sekine A., Miura Y., Ogawa C., Kawauchi S.,
RA   Higuchi S., Nakamura Y.;
RT   "Three hundred twenty-six genetic variations in genes encoding nine
RT   members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the
RT   Japanese population.";
RL   J. Hum. Genet. 47:38-50(2002).
RN   [7]
RP   VARIANTS PFIC2 LEU-284 AND ASP-1004.
RX   PubMed=11815775; DOI=10.1067/mpd.2002.119993;
RA   Chen H.-L., Chang P.-S., Hsu H.-C., Ni Y.-H., Hsu H.-Y., Lee J.-H.,
RA   Jeng Y.-M., Shau W.-Y., Chang M.-H.;
RT   "FIC1 and BSEP defects in Taiwanese patients with chronic intrahepatic
RT   cholestasis with low gamma-glutamyltranspeptidase levels.";
RL   J. Pediatr. 140:119-124(2002).
RN   [8]
RP   VARIANTS BRIC2 GLY-186; GLY-297; THR-570; PRO-923; PRO-926; CYS-1050
RP   AND HIS-1128.
RX   PubMed=15300568; DOI=10.1053/j.gastro.2004.04.065;
RA   van Mil S.W.C., van der Woerd W.L., van der Brugge G., Sturm E.,
RA   Jansen P.L.M., Bull L.N., van den Berg I.E.T., Berger R.,
RA   Houwen R.H.J., Klomp L.W.J.;
RT   "Benign recurrent intrahepatic cholestasis type 2 is caused by
RT   mutations in ABCB11.";
RL   Gastroenterology 127:379-384(2004).
RN   [9]
RP   VARIANTS GLN-415; ALA-444; SER-591 AND VAL-677.
RX   PubMed=15077010; DOI=10.1097/00008571-200402000-00003;
RA   Pauli-Magnus C., Lang T., Meier Y., Zodan-Marin T., Jung D.,
RA   Breymann C., Zimmermann R., Kenngott S., Beuers U., Reichel C.,
RA   Kerb R., Penger A., Meier P.J., Kullak-Ublick G.A.;
RT   "Sequence analysis of bile salt export pump (ABCB11) and multidrug
RT   resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with
RT   intrahepatic cholestasis of pregnancy.";
RL   Pharmacogenetics 14:91-102(2004).
RN   [10]
RP   VARIANTS BRIC2 GLY-297 AND THR-432, AND CHARACTERIZATION OF VARIANTS
RP   BRIC2 GLY-297 AND THR-432.
RX   PubMed=16039748; DOI=10.1016/j.jhep.2005.05.020;
RA   Noe J., Kullak-Ublick G.A., Jochum W., Stieger B., Kerb R., Haberl M.,
RA   Muellhaupt B., Meier P.J., Pauli-Magnus C.;
RT   "Impaired expression and function of the bile salt export pump due to
RT   three novel ABCB11 mutations in intrahepatic cholestasis.";
RL   J. Hepatol. 43:536-543(2005).
RN   [11]
RP   VARIANTS VAL-206; ALA-284; LYS-299; ALA-444; GLY-616; ALA-619;
RP   VAL-677; HIS-698; VAL-865 AND GLN-958.
RX   PubMed=16763017; DOI=10.1124/dmd.105.008854;
RA   Lang T., Haberl M., Jung D., Drescher A., Schlagenhaufer R., Keil A.,
RA   Mornhinweg E., Stieger B., Kullak-Ublick G.A., Kerb R.;
RT   "Genetic variability, haplotype structures, and ethnic diversity of
RT   hepatic transporters MDR3 (ABCB4) and bile salt export pump
RT   (ABCB11).";
RL   Drug Metab. Dispos. 34:1582-1599(2006).
RN   [12]
RP   VARIANTS ALA-444 AND VAL-677.
RX   PubMed=16799996; DOI=10.1002/hep.21214;
RA   Meier Y., Pauli-Magnus C., Zanger U.M., Klein K., Schaeffeler E.,
RA   Nussler A.K., Nussler N., Eichelbaum M., Meier P.J., Stieger B.;
RT   "Interindividual variability of canalicular ATP-binding-cassette
RT   (ABC)-transporter expression in human liver.";
RL   Hepatology 44:62-74(2006).
RN   [13]
RP   VARIANTS ALA-284; ALA-444; TYR-676; VAL-677; HIS-698 AND ARG-855,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND CHARACTERIZATION OF VARIANTS
RP   ALA-444; TYR-676; VAL-677 AND ARG-855.
RX   PubMed=17264802; DOI=10.1097/01.fpc.0000230418.28091.76;
RA   Lang C., Meier Y., Stieger B., Beuers U., Lang T., Kerb R.,
RA   Kullak-Ublick G.A., Meier P.J., Pauli-Magnus C.;
RT   "Mutations and polymorphisms in the bile salt export pump and the
RT   multidrug resistance protein 3 associated with drug-induced liver
RT   injury.";
RL   Pharmacogenet. Genomics 17:47-60(2007).
CC   -!- FUNCTION: Involved in the ATP-dependent secretion of bile salts
CC       into the canaliculus of hepatocytes.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=30.4 uM for taurocholate;
CC         Vmax=232 pmol/min/mg enzyme for taurocholate transport;
CC   -!- SUBUNIT: Interacts with HAX1 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed predominantly, if not exclusively in
CC       the liver, where it was further localized to the canalicular
CC       microvilli and to subcanalicular vesicles of the hepatocytes by in
CC       situ.
CC   -!- DOMAIN: Multifunctional polypeptide with two homologous halves,
CC       each containing a hydrophobic membrane-anchoring domain and an ATP
CC       binding cassette (ABC) domain.
CC   -!- DISEASE: Cholestasis, progressive familial intrahepatic, 2 (PFIC2)
CC       [MIM:601847]: A disorder characterized by early onset of
CC       cholestasis that progresses to hepatic fibrosis, cirrhosis, and
CC       end-stage liver disease before adulthood. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Cholestasis, benign recurrent intrahepatic, 2 (BRIC2)
CC       [MIM:605479]: A disorder characterized by intermittent episodes of
CC       cholestasis without progression to liver failure. There is initial
CC       elevation of serum bile acids, followed by cholestatic jaundice
CC       which generally spontaneously resolves after periods of weeks to
CC       months. The cholestatic attacks vary in severity and duration.
CC       Patients are asymptomatic between episodes, both clinically and
CC       biochemically. Note=The disease is caused by mutations affecting
CC       the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCB
CC       family. Multidrug resistance exporter (TC 3.A.1.201) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=O95342";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF091582; AAC77455.1; -; mRNA.
DR   EMBL; AF136523; AAD28285.1; -; mRNA.
DR   EMBL; AC008177; AAY24305.1; -; Genomic_DNA.
DR   EMBL; AC093723; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC069137; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS46444.1; -.
DR   RefSeq; NP_003733.2; NM_003742.2.
DR   UniGene; Hs.658439; -.
DR   ProteinModelPortal; O95342; -.
DR   SMR; O95342; 18-1316.
DR   BioGrid; 114199; 6.
DR   IntAct; O95342; 2.
DR   MINT; MINT-5003953; -.
DR   STRING; 9606.ENSP00000263817; -.
DR   BindingDB; O95342; -.
DR   ChEMBL; CHEMBL6020; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB00559; Bosentan.
DR   DrugBank; DB01016; Glibenclamide.
DR   TCDB; 3.A.1.201.2; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; O95342; -.
DR   MaxQB; O95342; -.
DR   PaxDb; O95342; -.
DR   PRIDE; O95342; -.
DR   Ensembl; ENST00000263817; ENSP00000263817; ENSG00000073734.
DR   Ensembl; ENST00000576612; ENSP00000459250; ENSG00000263298.
DR   GeneID; 8647; -.
DR   KEGG; hsa:8647; -.
DR   UCSC; uc002ueo.1; human.
DR   CTD; 8647; -.
DR   GeneCards; GC02M169743; -.
DR   GeneReviews; ABCB11; -.
DR   H-InvDB; HIX0029772; -.
DR   HGNC; HGNC:42; ABCB11.
DR   HPA; HPA019035; -.
DR   MIM; 601847; phenotype.
DR   MIM; 603201; gene.
DR   MIM; 605479; phenotype.
DR   neXtProt; NX_O95342; -.
DR   Orphanet; 99961; Benign recurrent intrahepatic cholestasis type 2.
DR   Orphanet; 69665; Intrahepatic cholestasis of pregnancy.
DR   Orphanet; 79304; Progressive familial intrahepatic cholestasis type 2.
DR   PharmGKB; PA374; -.
DR   eggNOG; COG1132; -.
DR   HOVERGEN; HBG080809; -.
DR   InParanoid; O95342; -.
DR   KO; K05664; -.
DR   OMA; TIVWTNS; -.
DR   PhylomeDB; O95342; -.
DR   TreeFam; TF105193; -.
DR   Reactome; REACT_111217; Metabolism.
DR   ChiTaRS; ABCB11; human.
DR   GeneWiki; ABCB11; -.
DR   GenomeRNAi; 8647; -.
DR   NextBio; 32419; -.
DR   PRO; PR:O95342; -.
DR   ArrayExpress; O95342; -.
DR   Bgee; O95342; -.
DR   CleanEx; HS_ABCB11; -.
DR   Genevestigator; O95342; -.
DR   GO; GO:0016324; C:apical plasma membrane; IBA:RefGenome.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0000139; C:Golgi membrane; IBA:RefGenome.
DR   GO; GO:0016021; C:integral component of membrane; IBA:RefGenome.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0046581; C:intercellular canaliculus; IBA:RefGenome.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; TAS:ProtInc.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; IBA:RefGenome.
DR   GO; GO:0015432; F:bile acid-exporting ATPase activity; TAS:ProtInc.
DR   GO; GO:0015126; F:canalicular bile acid transmembrane transporter activity; IBA:RefGenome.
DR   GO; GO:0008554; F:sodium-exporting ATPase activity, phosphorylative mechanism; TAS:ProtInc.
DR   GO; GO:0005215; F:transporter activity; TAS:ProtInc.
DR   GO; GO:0015721; P:bile acid and bile salt transport; TAS:Reactome.
DR   GO; GO:0006699; P:bile acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0008206; P:bile acid metabolic process; TAS:Reactome.
DR   GO; GO:0015722; P:canalicular bile acid transport; IBA:RefGenome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; TAS:GOC.
DR   GO; GO:0055085; P:transmembrane transport; IBA:RefGenome.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   Gene3D; 3.40.50.300; -; 2.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   SUPFAM; SSF90123; SSF90123; 3.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Disease mutation; Glycoprotein;
KW   Intrahepatic cholestasis; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1   1321       Bile salt export pump.
FT                                /FTId=PRO_0000093296.
FT   TOPO_DOM      1     62       Cytoplasmic (Potential).
FT   TRANSMEM     63     83       Helical; (Potential).
FT   TOPO_DOM     84    147       Extracellular (Potential).
FT   TRANSMEM    148    168       Helical; (Potential).
FT   TOPO_DOM    169    215       Cytoplasmic (Potential).
FT   TRANSMEM    216    236       Helical; (Potential).
FT   TOPO_DOM    237    240       Extracellular (Potential).
FT   TRANSMEM    241    261       Helical; (Potential).
FT   TOPO_DOM    262    319       Cytoplasmic (Potential).
FT   TRANSMEM    320    340       Helical; (Potential).
FT   TOPO_DOM    341    353       Extracellular (Potential).
FT   TRANSMEM    354    374       Helical; (Potential).
FT   TOPO_DOM    375    755       Cytoplasmic (Potential).
FT   TRANSMEM    756    776       Helical; (Potential).
FT   TOPO_DOM    777    794       Extracellular (Potential).
FT   TRANSMEM    795    815       Helical; (Potential).
FT   TOPO_DOM    816    869       Cytoplasmic (Potential).
FT   TRANSMEM    870    890       Helical; (Potential).
FT   TRANSMEM    891    911       Helical; (Potential).
FT   TOPO_DOM    912    979       Cytoplasmic (Potential).
FT   TRANSMEM    980   1000       Helical; (Potential).
FT   TOPO_DOM   1001   1011       Extracellular (Potential).
FT   TRANSMEM   1012   1032       Helical; (Potential).
FT   TOPO_DOM   1033   1321       Cytoplasmic (Potential).
FT   DOMAIN       62    385       ABC transmembrane type-1 1.
FT   DOMAIN      420    656       ABC transporter 1.
FT   DOMAIN      755   1043       ABC transmembrane type-1 2.
FT   DOMAIN     1078   1316       ABC transporter 2.
FT   NP_BIND     455    462       ATP 1 (Potential).
FT   NP_BIND    1113   1120       ATP 2 (Potential).
FT   REGION      651    672       Interaction with HAX1 (By similarity).
FT   MOD_RES     690    690       Phosphoserine (By similarity).
FT   CARBOHYD    109    109       N-linked (GlcNAc...).
FT   CARBOHYD    116    116       N-linked (GlcNAc...).
FT   CARBOHYD    122    122       N-linked (GlcNAc...).
FT   CARBOHYD    125    125       N-linked (GlcNAc...).
FT   VARIANT      56     56       S -> L (in dbSNP:rs11568361).
FT                                /FTId=VAR_055472.
FT   VARIANT     186    186       E -> G (in BRIC2).
FT                                /FTId=VAR_030386.
FT   VARIANT     206    206       I -> V (in dbSNP:rs11568357).
FT                                /FTId=VAR_030387.
FT   VARIANT     238    238       G -> V (in PFIC2).
FT                                /FTId=VAR_030388.
FT   VARIANT     284    284       V -> A.
FT                                /FTId=VAR_035349.
FT   VARIANT     284    284       V -> L (in PFIC2).
FT                                /FTId=VAR_013332.
FT   VARIANT     297    297       E -> G (in PFIC2 and BRIC2; reduced
FT                                transport capacity for taurocholate).
FT                                /FTId=VAR_010271.
FT   VARIANT     299    299       R -> K (in dbSNP:rs2287617).
FT                                /FTId=VAR_030389.
FT   VARIANT     336    336       C -> S (in PFIC2).
FT                                /FTId=VAR_030390.
FT   VARIANT     415    415       R -> Q.
FT                                /FTId=VAR_043074.
FT   VARIANT     432    432       R -> T (in BRIC2; reduced transport
FT                                capacity for taurocholate).
FT                                /FTId=VAR_030391.
FT   VARIANT     444    444       V -> A (more frequent in patients with
FT                                drug-induced cholestasis than healthy
FT                                controls; associated with lower hepatic
FT                                expression; does not affect transport
FT                                capacity for taurocholate;
FT                                dbSNP:rs2287622).
FT                                /FTId=VAR_013333.
FT   VARIANT     444    444       V -> D (in dbSNP:rs2287622).
FT                                /FTId=VAR_059106.
FT   VARIANT     444    444       V -> G (in dbSNP:rs2287622).
FT                                /FTId=VAR_059107.
FT   VARIANT     461    461       K -> E (in PFIC2).
FT                                /FTId=VAR_013334.
FT   VARIANT     482    482       D -> G (in PFIC2).
FT                                /FTId=VAR_013335.
FT   VARIANT     570    570       A -> T (in BRIC2).
FT                                /FTId=VAR_030392.
FT   VARIANT     591    591       N -> S (in a patient with intrahepatic
FT                                cholestasis of pregnancy;
FT                                dbSNP:rs11568367).
FT                                /FTId=VAR_043075.
FT   VARIANT     616    616       R -> G.
FT                                /FTId=VAR_035350.
FT   VARIANT     619    619       T -> A.
FT                                /FTId=VAR_035351.
FT   VARIANT     676    676       D -> Y (in fluvastatin-induced
FT                                cholestasis; does not affect transport
FT                                capacity for taurocholate).
FT                                /FTId=VAR_043076.
FT   VARIANT     677    677       M -> V (does not affect transport
FT                                capacity for taurocholate;
FT                                dbSNP:rs11568364).
FT                                /FTId=VAR_030393.
FT   VARIANT     698    698       R -> H (in dbSNP:rs138642043).
FT                                /FTId=VAR_035352.
FT   VARIANT     855    855       G -> R (in ethinylestradiol/gestodene-
FT                                induced cholestasis; loss of transport
FT                                capacity for taurocholate).
FT                                /FTId=VAR_043077.
FT   VARIANT     865    865       A -> V (in dbSNP:rs118109635).
FT                                /FTId=VAR_035353.
FT   VARIANT     923    923       T -> P (in BRIC2).
FT                                /FTId=VAR_030394.
FT   VARIANT     926    926       A -> P (in BRIC2).
FT                                /FTId=VAR_030395.
FT   VARIANT     958    958       R -> Q.
FT                                /FTId=VAR_035354.
FT   VARIANT     982    982       G -> R (in PFIC2).
FT                                /FTId=VAR_013336.
FT   VARIANT    1004   1004       G -> D (in PFIC2).
FT                                /FTId=VAR_013337.
FT   VARIANT    1050   1050       R -> C (in BRIC2).
FT                                /FTId=VAR_030396.
FT   VARIANT    1128   1128       R -> H (in BRIC2).
FT                                /FTId=VAR_030397.
FT   VARIANT    1153   1153       R -> C (in PFIC2).
FT                                /FTId=VAR_013338.
FT   VARIANT    1186   1186       E -> K (in dbSNP:rs1521808).
FT                                /FTId=VAR_030398.
FT   VARIANT    1268   1268       R -> Q (in PFIC2).
FT                                /FTId=VAR_013339.
FT   CONFLICT    339    339       L -> V (in Ref. 1; AAC77455).
SQ   SEQUENCE   1321 AA;  146407 MW;  61EE2173E2351D80 CRC64;
     MSDSVILRSI KKFGEENDGF ESDKSYNNDK KSRLQDEKKG DGVRVGFFQL FRFSSSTDIW
     LMFVGSLCAF LHGIAQPGVL LIFGTMTDVF IDYDVELQEL QIPGKACVNN TIVWTNSSLN
     QNMTNGTRCG LLNIESEMIK FASYYAGIAV AVLITGYIQI CFWVIAAARQ IQKMRKFYFR
     RIMRMEIGWF DCNSVGELNT RFSDDINKIN DAIADQMALF IQRMTSTICG FLLGFFRGWK
     LTLVIISVSP LIGIGAATIG LSVSKFTDYE LKAYAKAGVV ADEVISSMRT VAAFGGEKRE
     VERYEKNLVF AQRWGIRKGI VMGFFTGFVW CLIFLCYALA FWYGSTLVLD EGEYTPGTLV
     QIFLSVIVGA LNLGNASPCL EAFATGRAAA TSIFETIDRK PIIDCMSEDG YKLDRIKGEI
     EFHNVTFHYP SRPEVKILND LNMVIKPGEM TALVGPSGAG KSTALQLIQR FYDPCEGMVT
     VDGHDIRSLN IQWLRDQIGI VEQEPVLFST TIAENIRYGR EDATMEDIVQ AAKEANAYNF
     IMDLPQQFDT LVGEGGGQMS GGQKQRVAIA RALIRNPKIL LLDMATSALD NESEAMVQEV
     LSKIQHGHTI ISVAHRLSTV RAADTIIGFE HGTAVERGTH EELLERKGVY FTLVTLQSQG
     NQALNEEDIK DATEDDMLAR TFSRGSYQDS LRASIRQRSK SQLSYLVHEP PLAVVDHKST
     YEEDRKDKDI PVQEEVEPAP VRRILKFSAP EWPYMLVGSV GAAVNGTVTP LYAFLFSQIL
     GTFSIPDKEE QRSQINGVCL LFVAMGCVSL FTQFLQGYAF AKSGELLTKR LRKFGFRAML
     GQDIAWFDDL RNSPGALTTR LATDASQVQG AAGSQIGMIV NSFTNVTVAM IIAFSFSWKL
     SLVILCFFPF LALSGATQTR MLTGFASRDK QALEMVGQIT NEALSNIRTV AGIGKERRFI
     EALETELEKP FKTAIQKANI YGFCFAFAQC IMFIANSASY RYGGYLISNE GLHFSYVFRV
     ISAVVLSATA LGRAFSYTPS YAKAKISAAR FFQLLDRQPP ISVYNTAGEK WDNFQGKIDF
     VDCKFTYPSR PDSQVLNGLS VSISPGQTLA FVGSSGCGKS TSIQLLERFY DPDQGKVMID
     GHDSKKVNVQ FLRSNIGIVS QEPVLFACSI MDNIKYGDNT KEIPMERVIA AAKQAQLHDF
     VMSLPEKYET NVGSQGSQLS RGEKQRIAIA RAIVRDPKIL LLDEATSALD TESEKTVQVA
     LDKAREGRTC IVIAHRLSTI QNADIIAVMA QGVVIEKGTH EELMAQKGAY YKLVTTGSPI
     S
//
ID   ABCC8_HUMAN             Reviewed;        1581 AA.
AC   Q09428; A6NMX8; E3UYX6; O75948; Q16583;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 6.
DT   09-JUL-2014, entry version 153.
DE   RecName: Full=ATP-binding cassette sub-family C member 8;
DE   AltName: Full=Sulfonylurea receptor 1;
GN   Name=ABCC8; Synonyms=HRINS, SUR, SUR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Heart;
RX   PubMed=21671119; DOI=10.1007/s00018-011-0739-x;
RA   Schmid D., Stolzlechner M., Sorgner A., Bentele C., Assinger A.,
RA   Chiba P., Moeslinger T.;
RT   "An abundant, truncated human sulfonylurea receptor 1 splice variant
RT   has prodiabetic properties and impairs sulfonylurea action.";
RL   Cell. Mol. Life Sci. 69:129-148(2012).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], ALTERNATIVE SPLICING, AND
RP   VARIANT SER-1369.
RC   TISSUE=Pancreatic islet;
RA   Gonzalez G., Aguilar-Bryan L., Bryan J.;
RT   "Human beta cell sulfonylurea receptor, SUR1, expression.";
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT
RP   SER-1369.
RC   TISSUE=Brain, and Foreskin;
RA   Thomas P.T., Wohllk N., Huang E., Gagel R.F., Cote G.J.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-1369.
RC   TISSUE=Pancreas;
RA   Nishimura M., Miki T., Aizawa T., Seino S.;
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1187-1581, AND VARIANT SER-1369.
RC   TISSUE=Pancreatic islet;
RX   PubMed=7716548; DOI=10.1126/science.7716548;
RA   Thomas P.M., Cote G.J., Wohllk N., Haddad B., Mathew P.M., Rabl W.,
RA   Aguilar-Bryan L., Gagel R.F., Bryan J.;
RT   "Mutations in the sulfonylurea receptor gene in familial persistent
RT   hyperinsulinemic hypoglycemia of infancy.";
RL   Science 268:426-429(1995).
RN   [7]
RP   TOPOLOGY.
RX   PubMed=10506167; DOI=10.1074/jbc.274.41.29122;
RA   Raab-Graham K.F., Cirilo L.J., Boettcher A.A., Radeke C.M.,
RA   Vandenberg C.A.;
RT   "Membrane topology of the amino-terminal region of the sulfonylurea
RT   receptor.";
RL   J. Biol. Chem. 274:29122-29129(1999).
RN   [8]
RP   REVIEW.
RX   PubMed=10204114; DOI=10.1210/er.20.2.101;
RA   Aguilar-Bryan L., Bryan J.;
RT   "Molecular biology of adenosine triphosphate-sensitive potassium
RT   channels.";
RL   Endocr. Rev. 20:101-135(1999).
RN   [9]
RP   REVIEW ON VARIANTS.
RX   PubMed=10338089;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:5<351::AID-HUMU3>3.0.CO;2-R;
RA   Meissner T., Beinbrech B., Mayatepek E.;
RT   "Congenital hyperinsulinism: molecular basis of a heterogeneous
RT   disease.";
RL   Hum. Mutat. 13:351-361(1999).
RN   [10]
RP   VARIANT HHF1 VAL-716.
RX   PubMed=8751851;
RA   Thomas P.M., Wohllk N., Huang E., Kuhnle U., Rabl W., Gagel R.F.,
RA   Cote G.J.;
RT   "Inactivation of the first nucleotide-binding fold of the sulfonylurea
RT   receptor, and familial persistent hyperinsulinemic hypoglycemia of
RT   infancy.";
RL   Am. J. Hum. Genet. 59:510-518(1996).
RN   [11]
RP   VARIANT SER-1369.
RX   PubMed=8635661; DOI=10.2337/diab.45.6.825;
RA   Inoue H., Ferrer J., Welling C.M., Elbein S.C., Hoffman M.,
RA   Mayorga R., Warren-Perry M., Zhang Y., Millns H., Turner R.,
RA   Province M., Bryan J., Permutt M.A., Aguilar-Bryan L.;
RT   "Sequence variants in the sulfonylurea receptor (SUR) gene are
RT   associated with NIDDM in Caucasians.";
RL   Diabetes 45:825-831(1996).
RN   [12]
RP   VARIANT HHF1 PHE-1387 DEL, AND VARIANTS GLY-1360; SER-1369 AND
RP   ILE-1572.
RX   PubMed=8923011; DOI=10.1093/hmg/5.11.1813;
RA   Nestorowicz A., Wilson B.A., Schoor K.P., Inoue H., Glaser B.,
RA   Landau H., Stanley C.A., Thornton P.S., Clement J.P. IV, Bryan J.,
RA   Aguilar-Bryan L., Permutt M.A.;
RT   "Mutations in the sulfonylurea receptor gene are associated with
RT   familial hyperinsulinism in Ashkenazi Jews.";
RL   Hum. Mol. Genet. 5:1813-1822(1996).
RN   [13]
RP   CHARACTERIZATION OF VARIANT HHF1 ARG-1478.
RX   PubMed=8650576; DOI=10.1126/science.272.5269.1785;
RA   Nichols C.G., Shyng S.-L., Nestorowicz A., Glaser B., Clement J.P. IV,
RA   Gonzalez G., Aguilar-Bryan L., Permutt M.A., Bryan J.;
RT   "Adenosine diphosphate as an intracellular regulator of insulin
RT   secretion.";
RL   Science 272:1785-1787(1996).
RN   [14]
RP   VARIANTS GLN-275; MET-560; ASN-810; CYS-834 AND SER-1369.
RX   PubMed=9519757; DOI=10.2337/diabetes.47.3.476;
RA   Ohta Y., Tanizawa Y., Inoue H., Hosaka T., Ueda K., Matsutani A.,
RA   Repunte V.P., Yamada M., Kurachi Y., Bryan J., Aguilar-Bryan L.,
RA   Permutt M.A., Oka Y.;
RT   "Identification and functional analysis of sulfonylurea receptor 1
RT   variants in Japanese patients with NIDDM.";
RL   Diabetes 47:476-481(1998).
RN   [15]
RP   VARIANTS ASN-673 AND SER-1369.
RX   PubMed=9568693; DOI=10.2337/diabetes.47.4.598;
RA   Hansen T., Echwald S.M., Hansen L., Moeller A.M., Almind K.,
RA   Clausen J.O., Urhammer S.A., Inoue H., Ferrer J., Bryan J.,
RA   Aguilar-Bryan L., Permutt M.A., Pedersen O.;
RT   "Decreased tolbutamide-stimulated insulin secretion in healthy
RT   subjects with sequence variants in the high-affinity sulfonylurea
RT   receptor gene.";
RL   Diabetes 47:598-605(1998).
RN   [16]
RP   CHARACTERIZATION OF VARIANTS HHF1 GLN-125; SER-188; LEU-591; MET-1138;
RP   GLN-1214; SER-1381; PHE-1387 DEL AND HIS-1393.
RX   PubMed=9648840; DOI=10.2337/diabetes.47.7.1145;
RA   Shyng S.-L., Ferrigni T., Shepard J.B., Nestorowicz A., Glaser B.,
RA   Permutt M.A., Nichols C.G.;
RT   "Functional analyses of novel mutations in the sulfonylurea receptor 1
RT   associated with persistent hyperinsulinemic hypoglycemia of infancy.";
RL   Diabetes 47:1145-1151(1998).
RN   [17]
RP   VARIANTS HHF1 GLN-74; GLN-125; SER-188; ASP-406; LEU-591; MET-1138;
RP   GLN-1214; ARG-1378; SER-1381; PHE-1387 DEL AND HIS-1393.
RX   PubMed=9618169; DOI=10.1093/hmg/7.7.1119;
RA   Nestorowicz A., Glaser B., Wilson B.A., Shyng S.-L., Nichols C.G.,
RA   Stanley C.A., Thornton P.S., Permutt M.A.;
RT   "Genetic heterogeneity in familial hyperinsulinism.";
RL   Hum. Mol. Genet. 7:1119-1128(1998).
RN   [18]
RP   VARIANTS HHF1 PRO-1352; CYS-1420 AND TRP-1493.
RX   PubMed=9769320; DOI=10.1172/JCI4495;
RA   Verkarre V., Fournet J.-C., de Lonlay P., Gross-Morand M.-S.,
RA   Devillers M., Rahier J., Brunelle F., Robert J.-J., Nihoul-Fekete C.,
RA   Saudubray J.-M., Junien C.;
RT   "Paternal mutation of the sulfonylurea receptor (SUR1) gene and
RT   maternal loss of 11p15 imprinted genes lead to persistent
RT   hyperinsulinism in focal adenomatous hyperplasia.";
RL   J. Clin. Invest. 102:1286-1291(1998).
RN   [19]
RP   VARIANT HHF1 ASP-187.
RX   PubMed=10334322; DOI=10.2337/diabetes.48.2.408;
RA   Otonkoski T., Aemmaelae C., Huopio H., Cote G.J., Chapman J.,
RA   Cosgrove K., Ashfield R., Huang E., Komulainen J., Ashcroft F.M.,
RA   Dunne M.J., Kere J., Thomas P.M.;
RT   "A point mutation inactivating the sulfonylurea receptor causes the
RT   severe form of persistent hyperinsulinemic hypoglycemia of infancy in
RT   Finland.";
RL   Diabetes 48:408-415(1999).
RN   [20]
RP   VARIANTS SER-1369 AND ILE-1572.
RX   PubMed=10447255;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:1<23::AID-HUMU3>3.0.CO;2-#;
RA   Glaser B., Furth J., Stanley C.A., Baker L., Thornton P.S., Landau H.,
RA   Permutt M.A.;
RT   "Intragenic single nucleotide polymorphism haplotype analysis of SUR1
RT   mutations in familial hyperinsulinism.";
RL   Hum. Mutat. 14:23-29(1999).
RN   [21]
RP   VARIANTS HHF1 GLY-841; CYS-1420 AND TRP-1493.
RX   PubMed=10202168; DOI=10.1056/NEJM199904153401505;
RA   de Lonlay-Debeney P., Poggi-Travert F., Fournet J.-C., Sempoux C.,
RA   Vici C.D., Brunelle F., Touati G., Rahier J., Junien C.,
RA   Nihoul-Fekete C., Robert J.-J., Saudubray J.-M.;
RT   "Clinical features of 52 neonates with hyperinsulinism.";
RL   N. Engl. J. Med. 340:1169-1175(1999).
RN   [22]
RP   CHARACTERIZATION OF VARIANTS HHF1 CYS-1420 AND GLN-1436, AND VARIANT
RP   SER-1369.
RX   PubMed=10615958; DOI=10.2337/diabetes.49.1.114;
RA   Tanizawa Y., Matsuda K., Matsuo M., Ohta Y., Ochi N., Adachi M.,
RA   Koga M., Mizuno S., Kajita M., Tanaka Y., Tachibana K., Inoue H.,
RA   Furukawa S., Amachi T., Ueda K., Oka Y.;
RT   "Genetic analysis of Japanese patients with persistent
RT   hyperinsulinemic hypoglycemia of infancy: nucleotide-binding fold-2
RT   mutation impairs cooperative binding of adenine nucleotides to
RT   sulfonylurea receptor 1.";
RL   Diabetes 49:114-120(2000).
RN   [23]
RP   CHARACTERIZATION OF VARIANT HHF1 LYS-1506.
RX   PubMed=11018078; DOI=10.1172/JCI9804;
RA   Huopio H., Reimann F., Ashfield R., Komulainen J., Lenko H.-L.,
RA   Rahier J., Vauhkonen I., Kere J., Laakso M., Ashcroft F.,
RA   Otonkoski T.;
RT   "Dominantly inherited hyperinsulinism caused by a mutation in the
RT   sulfonylurea receptor type 1.";
RL   J. Clin. Invest. 106:897-906(2000).
RN   [24]
RP   CHARACTERIZATION OF VARIANT HHF1 PHE-1387 DEL.
RX   PubMed=11226335; DOI=10.1073/pnas.051499698;
RA   Cartier E.A., Conti L.R., Vandenberg C.A., Shyng S.-L.;
RT   "Defective trafficking and function of KATP channels caused by a
RT   sulfonylurea receptor 1 mutation associated with persistent
RT   hyperinsulinemic hypoglycemia of infancy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:2882-2887(2001).
RN   [25]
RP   CHARACTERIZATION OF VARIANT HHF1 PRO-1543.
RX   PubMed=11867634; DOI=10.1074/jbc.M200363200;
RA   Taschenberger G., Mougey A., Shen S., Lester L.B., LaFranchi S.,
RA   Shyng S.-L.;
RT   "Identification of a familial hyperinsulinism-causing mutation in the
RT   sulfonylurea receptor 1 that prevents normal trafficking and function
RT   of KATP channels.";
RL   J. Biol. Chem. 277:17139-17146(2002).
RN   [26]
RP   VARIANTS HHF1 ASP-187; THR-1457; LYS-1506; ASP-1550 AND VAL-1551.
RX   PubMed=12364426; DOI=10.1210/jc.2002-020378;
RA   Huopio H., Jaeaeskelaeinen J., Komulainen J., Miettinen R.,
RA   Kaerkkaeinen P., Laakso M., Tapanainen P., Voutilainen R.,
RA   Otonkoski T.;
RT   "Acute insulin response tests for the differential diagnosis of
RT   congenital hyperinsulinism.";
RL   J. Clin. Endocrinol. Metab. 87:4502-4507(2002).
RN   [27]
RP   VARIANT HHF1 SER-1385 DEL, AND CHARACTERIZATION OF VARIANT HHF1
RP   SER-1385 DEL.
RX   PubMed=12941782; DOI=10.2337/diabetes.52.9.2403;
RA   Thornton P.S., MacMullen C., Ganguly A., Ruchelli E., Steinkrauss L.,
RA   Crane A., Aguilar-Bryan L., Stanley C.A.;
RT   "Clinical and molecular characterization of a dominant form of
RT   congenital hyperinsulinism caused by a mutation in the high-affinity
RT   sulfonylurea receptor.";
RL   Diabetes 52:2403-2410(2003).
RN   [28]
RP   VARIANT LIH HIS-1352, AND CHARACTERIZATION OF VARIANT LIH HIS-1352.
RX   PubMed=15356046; DOI=10.1210/jc.2004-0441;
RA   Magge S.N., Shyng S.-L., MacMullen C., Steinkrauss L., Ganguly A.,
RA   Katz L.E.L., Stanley C.A.;
RT   "Familial leucine-sensitive hypoglycemia of infancy due to a dominant
RT   mutation of the beta-cell sulfonylurea receptor.";
RL   J. Clin. Endocrinol. Metab. 89:4450-4456(2004).
RN   [29]
RP   VARIANTS HHF1 GLU-70; ARG-111; GLU-1342; HIS-1418 AND TRP-1493, AND
RP   CHARACTERIZATION OF VARIANTS HHF1 GLU-70; ARG-111; GLU-1342; HIS-1418
RP   AND TRP-1493.
RX   PubMed=15579781; DOI=10.1210/jc.2004-1233;
RA   Tornovsky S., Crane A., Cosgrove K.E., Hussain K., Lavie J.,
RA   Heyman M., Nesher Y., Kuchinski N., Ben-Shushan E., Shatz O.,
RA   Nahari E., Potikha T., Zangen D., Tenenbaum-Rakover Y., de Vries L.,
RA   Argente J., Gracia R., Landau H., Eliakim A., Lindley K., Dunne M.J.,
RA   Aguilar-Bryan L., Glaser B.;
RT   "Hyperinsulinism of infancy: novel ABCC8 and KCNJ11 mutations and
RT   evidence for additional locus heterogeneity.";
RL   J. Clin. Endocrinol. Metab. 89:6224-6234(2004).
RN   [30]
RP   VARIANTS HHF1 GLN-1384 AND LYS-1486, AND VARIANT SER-1369.
RX   PubMed=15807877; DOI=10.1111/j.1365-2265.2005.02242.x;
RA   Ohkubo K., Nagashima M., Naito Y., Taguchi T., Suita S., Okamoto N.,
RA   Fujinaga H., Tsumura K., Kikuchi K., Ono J.;
RT   "Genotypes of the pancreatic beta-cell K-ATP channel and clinical
RT   phenotypes of Japanese patients with persistent hyperinsulinaemic
RT   hypoglycaemia of infancy.";
RL   Clin. Endocrinol. (Oxf.) 62:458-465(2005).
RN   [31]
RP   VARIANTS HHF1 SER-27; TRP-74; SER-188; GLN-495; LYS-501; SER-686;
RP   TRP-1214; GLN-1214; ASN-1336; PHE-1387 DEL; HIS-1471 AND ASN-1471.
RX   PubMed=15562009; DOI=10.1210/jc.2004-1604;
RA   Henwood M.J., Kelly A., MacMullen C., Bhatia P., Ganguly A.,
RA   Thornton P.S., Stanley C.A.;
RT   "Genotype-phenotype correlations in children with congenital
RT   hyperinsulinism due to recessive mutations of the adenosine
RT   triphosphate-sensitive potassium channel genes.";
RL   J. Clin. Endocrinol. Metab. 90:789-794(2005).
RN   [32]
RP   VARIANT PNDM LEU-132, AND CHARACTERIZATION OF VARIANT PNDM LEU-132.
RX   PubMed=16613899; DOI=10.1093/hmg/ddl101;
RA   Proks P., Arnold A.L., Bruining J., Girard C., Flanagan S.E.,
RA   Larkin B., Colclough K., Hattersley A.T., Ashcroft F.M., Ellard S.;
RT   "A heterozygous activating mutation in the sulphonylurea receptor SUR1
RT   (ABCC8) causes neonatal diabetes.";
RL   Hum. Mol. Genet. 15:1793-1800(2006).
RN   [33]
RP   VARIANTS HHF1 TRP-74; ARG-111; SER-188; ARG-233; ASN-310; ARG-551;
RP   THR-719; PRO-1130; ARG-1147; LYS-1295 AND PRO-1450, AND VARIANTS
RP   SER-1369 AND ILE-1572.
RX   PubMed=16429405; DOI=10.1002/humu.9401;
RA   Fernandez-Marmiesse A., Salas A., Vega A., Fernandez-Lorenzo J.R.,
RA   Barreiro J., Carracedo A.;
RT   "Mutation spectra of ABCC8 gene in Spanish patients with
RT   Hyperinsulinism of Infancy (HI).";
RL   Hum. Mutat. 27:214-214(2006).
RN   [34]
RP   VARIANTS HHF1 ARG-7; ASP-21; SER-27; TRP-74; LYS-501; PRO-503;
RP   SER-686; TRP-1214; TRP-1214; GLN-1349; ARG-1378; PHE-1387 DEL;
RP   ARG-1400 AND GLN-1493.
RX   PubMed=16357843; DOI=10.1038/modpathol.3800497;
RA   Suchi M., MacMullen C.M., Thornton P.S., Adzick N.S., Ganguly A.,
RA   Ruchelli E.D., Stanley C.A.;
RT   "Molecular and immunohistochemical analyses of the focal form of
RT   congenital hyperinsulinism.";
RL   Mod. Pathol. 19:122-129(2006).
RN   [35]
RP   VARIANTS PNDM ARG-213 AND VAL-1424, VARIANTS TNDM2 ARG-435; VAL-582;
RP   TYR-1023; GLN-1182 AND CYS-1379, CHARACTERIZATION OF VARIANT PNDM
RP   VAL-1424, AND CHARACTERIZATION OF VARIANT TNDM2 TYR-1023.
RX   PubMed=16885549; DOI=10.1056/NEJMoa055068;
RA   Babenko A.P., Polak M., Cave H., Busiah K., Czernichow P.,
RA   Scharfmann R., Bryan J., Aguilar-Bryan L., Vaxillaire M., Froguel P.;
RT   "Activating mutations in the ABCC8 gene in neonatal diabetes
RT   mellitus.";
RL   N. Engl. J. Med. 355:456-466(2006).
RN   [36]
RP   VARIANT PNDM ALA-86.
RX   PubMed=17213273; DOI=10.1210/jc.2006-2490;
RA   Stanik J., Gasperikova D., Paskova M., Barak L., Javorkova J.,
RA   Jancova E., Ciljakova M., Hlava P., Michalek J., Flanagan S.E.,
RA   Pearson E., Hattersley A.T., Ellard S., Klimes I.;
RT   "Prevalence of permanent neonatal diabetes in Slovakia and successful
RT   replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8
RT   mutation carriers.";
RL   J. Clin. Endocrinol. Metab. 92:1276-1282(2007).
CC   -!- FUNCTION: Putative subunit of the beta-cell ATP-sensitive
CC       potassium channel (KATP). Regulator of ATP-sensitive K(+) channels
CC       and insulin release.
CC   -!- SUBUNIT: Interacts with KCNJ11.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q09428-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q09428-2; Sequence=VSP_000055;
CC       Name=3; Synonyms=SUR1Delta2;
CC         IsoId=Q09428-3; Sequence=VSP_044090;
CC         Note=Abundant isoform with prodiabetic properties, predominant
CC         in heart;
CC   -!- DISEASE: Leucine-induced hypoglycemia (LIH) [MIM:240800]: Rare
CC       cause of hypoglycemia and is described as a condition in which
CC       symptomatic hypoglycemia is provoked by high protein feedings.
CC       Hypoglycemia is also elicited by administration of oral or
CC       intravenous infusions of a single amino acid, leucine. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Familial hyperinsulinemic hypoglycemia 1 (HHF1)
CC       [MIM:256450]: Most common cause of persistent hypoglycemia in
CC       infancy. Unless early and aggressive intervention is undertaken,
CC       brain damage from recurrent episodes of hypoglycemia may occur.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Diabetes mellitus, permanent neonatal (PNDM)
CC       [MIM:606176]: A rare form of diabetes distinct from childhood-
CC       onset autoimmune diabetes mellitus type 1. It is characterized by
CC       insulin-requiring hyperglycemia that is diagnosed within the first
CC       months of life. Permanent neonatal diabetes requires lifelong
CC       therapy. Note=The disease is caused by mutations affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Transient neonatal diabetes mellitus 2 (TNDM2)
CC       [MIM:610374]: Neonatal diabetes is a form of diabetes mellitus
CC       defined by the onset of mild-to-severe hyperglycemia within the
CC       first months of life. Transient neonatal diabetes remits early,
CC       with a possible relapse during adolescence. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=Q09428";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; HM635782; ADM67556.1; -; mRNA.
DR   EMBL; L78207; AAB02278.1; -; mRNA.
DR   EMBL; L78243; AAB02417.1; -; Genomic_DNA.
DR   EMBL; L78208; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78209; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78210; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78211; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78212; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78255; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78213; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78214; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78215; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78216; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78217; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78218; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78219; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78220; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78221; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78222; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78223; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78225; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78254; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78226; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78227; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78228; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78229; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78230; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78231; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78232; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78233; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78234; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78235; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78236; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78237; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78238; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78239; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78240; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78241; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78242; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78243; AAB02418.1; -; Genomic_DNA.
DR   EMBL; L78208; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78209; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78210; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78211; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78212; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78255; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78213; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78214; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78215; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78216; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78217; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78218; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78219; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78220; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78221; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78222; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78224; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78225; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78254; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78226; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78227; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78228; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78229; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78230; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78231; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78232; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78233; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78234; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78235; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78236; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78237; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78238; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78239; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78240; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78241; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78242; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; U63421; AAB36699.1; -; mRNA.
DR   EMBL; U63455; AAB36700.1; -; Genomic_DNA.
DR   EMBL; U63422; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63423; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63424; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63425; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63426; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63427; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63428; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63429; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63430; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63431; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63432; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63433; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63434; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63435; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63436; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63437; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63438; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63439; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63441; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63442; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63443; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63444; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63445; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63446; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63447; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63448; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63449; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63450; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63451; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63452; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63453; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63454; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; AF087138; AAC36724.1; -; mRNA.
DR   EMBL; AC124798; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L40625; AAA99227.1; -; mRNA.
DR   CCDS; CCDS31437.1; -. [Q09428-1]
DR   RefSeq; NP_000343.2; NM_000352.4. [Q09428-1]
DR   RefSeq; NP_001274103.1; NM_001287174.1. [Q09428-2]
DR   UniGene; Hs.54470; -.
DR   ProteinModelPortal; Q09428; -.
DR   BioGrid; 112700; 2.
DR   DIP; DIP-58642N; -.
DR   STRING; 9606.ENSP00000374467; -.
DR   BindingDB; Q09428; -.
DR   ChEMBL; CHEMBL2096972; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB01016; Glibenclamide.
DR   DrugBank; DB01120; Gliclazide.
DR   DrugBank; DB01252; Mitiglinide.
DR   DrugBank; DB00731; Nateglinide.
DR   DrugBank; DB00912; Repaglinide.
DR   TCDB; 3.A.1.208.4; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; Q09428; -.
DR   DMDM; 311033501; -.
DR   PaxDb; Q09428; -.
DR   PRIDE; Q09428; -.
DR   DNASU; 6833; -.
DR   Ensembl; ENST00000302539; ENSP00000303960; ENSG00000006071. [Q09428-2]
DR   Ensembl; ENST00000389817; ENSP00000374467; ENSG00000006071. [Q09428-1]
DR   GeneID; 6833; -.
DR   KEGG; hsa:6833; -.
DR   UCSC; uc001mnc.3; human. [Q09428-1]
DR   CTD; 6833; -.
DR   GeneCards; GC11M017414; -.
DR   GeneReviews; ABCC8; -.
DR   H-InvDB; HIX0035864; -.
DR   HGNC; HGNC:59; ABCC8.
DR   HPA; CAB011451; -.
DR   HPA; HPA042318; -.
DR   MIM; 240800; phenotype.
DR   MIM; 256450; phenotype.
DR   MIM; 600509; gene.
DR   MIM; 602485; phenotype.
DR   MIM; 606176; phenotype.
DR   MIM; 610374; phenotype.
DR   neXtProt; NX_Q09428; -.
DR   Orphanet; 276575; Autosomal dominant hyperinsulinism due to SUR1 deficiency.
DR   Orphanet; 79643; Autosomal recessive hyperinsulinism due to SUR1 deficiency.
DR   Orphanet; 276598; Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency.
DR   Orphanet; 552; MODY syndrome.
DR   Orphanet; 99885; Permanent neonatal diabetes mellitus.
DR   Orphanet; 99886; Transient neonatal diabetes mellitus.
DR   PharmGKB; PA24395; -.
DR   eggNOG; COG1132; -.
DR   HOVERGEN; HBG101342; -.
DR   KO; K05032; -.
DR   OMA; RKDSVFA; -.
DR   OrthoDB; EOG7MWGW0; -.
DR   PhylomeDB; Q09428; -.
DR   TreeFam; TF105201; -.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_13685; Neuronal System.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   SignaLink; Q09428; -.
DR   GeneWiki; ABCC8; -.
DR   GenomeRNAi; 6833; -.
DR   NextBio; 26675; -.
DR   PRO; PR:Q09428; -.
DR   ArrayExpress; Q09428; -.
DR   Bgee; Q09428; -.
DR   CleanEx; HS_ABCC8; -.
DR   Genevestigator; Q09428; -.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; TAS:ProtInc.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; IEA:InterPro.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0015079; F:potassium ion transmembrane transporter activity; TAS:ProtInc.
DR   GO; GO:0008281; F:sulfonylurea receptor activity; TAS:ProtInc.
DR   GO; GO:0005975; P:carbohydrate metabolic process; NAS:ProtInc.
DR   GO; GO:0006112; P:energy reserve metabolic process; TAS:Reactome.
DR   GO; GO:0071805; P:potassium ion transmembrane transport; TAS:GOC.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:GOC.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0007268; P:synaptic transmission; TAS:Reactome.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   Gene3D; 3.40.50.300; -; 2.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000388; Sulphorea_rcpt.
DR   InterPro; IPR000844; Surea_rcpt-1.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   PRINTS; PR01093; SULFNYLUR1.
DR   PRINTS; PR01092; SULFNYLUREAR.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   SUPFAM; SSF90123; SSF90123; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome;
KW   Diabetes mellitus; Disease mutation; Glycoprotein; Membrane;
KW   Nucleotide-binding; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1   1581       ATP-binding cassette sub-family C member
FT                                8.
FT                                /FTId=PRO_0000093400.
FT   TOPO_DOM      1     34       Extracellular (By similarity).
FT   TRANSMEM     35     55       Helical; Name=1; (By similarity).
FT   TOPO_DOM     56     75       Cytoplasmic (By similarity).
FT   TRANSMEM     76     96       Helical; Name=2; (By similarity).
FT   TOPO_DOM     97    101       Extracellular (By similarity).
FT   TRANSMEM    102    122       Helical; Name=3; (By similarity).
FT   TOPO_DOM    123    134       Cytoplasmic (By similarity).
FT   TRANSMEM    135    154       Helical; Name=4; (By similarity).
FT   TOPO_DOM    155    167       Extracellular (By similarity).
FT   TRANSMEM    168    194       Helical; Name=5; (By similarity).
FT   TOPO_DOM    195    311       Cytoplasmic (By similarity).
FT   TRANSMEM    312    331       Helical; Name=6; (By similarity).
FT   TOPO_DOM    332    355       Extracellular (By similarity).
FT   TRANSMEM    356    376       Helical; Name=7; (By similarity).
FT   TOPO_DOM    377    434       Cytoplasmic (By similarity).
FT   TRANSMEM    435    455       Helical; Name=8; (By similarity).
FT   TOPO_DOM    456    458       Extracellular (By similarity).
FT   TRANSMEM    459    479       Helical; Name=9; (By similarity).
FT   TOPO_DOM    480    541       Cytoplasmic (By similarity).
FT   TRANSMEM    542    562       Helical; Name=10; (By similarity).
FT   TOPO_DOM    563    584       Extracellular (By similarity).
FT   TRANSMEM    585    605       Helical; Name=11; (By similarity).
FT   TOPO_DOM    606   1004       Cytoplasmic (By similarity).
FT   TRANSMEM   1005   1025       Helical; Name=12; (By similarity).
FT   TOPO_DOM   1026   1072       Extracellular (By similarity).
FT   TRANSMEM   1073   1093       Helical; Name=13; (By similarity).
FT   TOPO_DOM   1094   1137       Cytoplasmic (By similarity).
FT   TRANSMEM   1138   1158       Helical; Name=14; (By similarity).
FT   TOPO_DOM   1159   1159       Extracellular (By similarity).
FT   TRANSMEM   1160   1180       Helical; Name=15; (By similarity).
FT   TOPO_DOM   1181   1251       Cytoplasmic (By similarity).
FT   TRANSMEM   1252   1272       Helical; Name=16; (By similarity).
FT   TOPO_DOM   1273   1276       Extracellular (By similarity).
FT   TRANSMEM   1277   1297       Helical; Name=17; (By similarity).
FT   TOPO_DOM   1298   1581       Cytoplasmic (By similarity).
FT   DOMAIN      299    602       ABC transmembrane type-1 1.
FT   DOMAIN      679    929       ABC transporter 1.
FT   DOMAIN     1012   1306       ABC transmembrane type-1 2.
FT   DOMAIN     1344   1578       ABC transporter 2.
FT   NP_BIND     713    720       ATP 1 (Potential).
FT   NP_BIND    1378   1385       ATP 2 (Potential).
FT   CARBOHYD     10     10       N-linked (GlcNAc...) (By similarity).
FT   CARBOHYD   1049   1049       N-linked (GlcNAc...) (By similarity).
FT   VAR_SEQ      51   1581       Missing (in isoform 3).
FT                                /FTId=VSP_044090.
FT   VAR_SEQ     740    740       S -> SS (in isoform 2).
FT                                /FTId=VSP_000055.
FT   VARIANT       7      7       G -> R (in HHF1).
FT                                /FTId=VAR_031349.
FT   VARIANT      21     21       V -> D (in HHF1).
FT                                /FTId=VAR_031350.
FT   VARIANT      27     27       F -> S (in HHF1).
FT                                /FTId=VAR_031351.
FT   VARIANT      70     70       G -> E (in HHF1; altered intracellular
FT                                trafficking).
FT                                /FTId=VAR_031352.
FT   VARIANT      74     74       R -> Q (in HHF1).
FT                                /FTId=VAR_008639.
FT   VARIANT      74     74       R -> W (in HHF1; dbSNP:rs201682634).
FT                                /FTId=VAR_031353.
FT   VARIANT      86     86       V -> A (in PNDM).
FT                                /FTId=VAR_031354.
FT   VARIANT     104    104       L -> V (in dbSNP:rs10400391).
FT                                /FTId=VAR_029777.
FT   VARIANT     111    111       G -> R (in HHF1; altered intracellular
FT                                trafficking).
FT                                /FTId=VAR_031355.
FT   VARIANT     116    116       A -> P (in HHF1).
FT                                /FTId=VAR_031356.
FT   VARIANT     125    125       H -> Q (in HHF1; mild; dbSNP:rs60637558).
FT                                /FTId=VAR_008640.
FT   VARIANT     132    132       F -> L (in PNDM; with neurologic
FT                                features; reduces the sensitivity of the
FT                                K(ATP) channel to inhibition by MgATP;
FT                                increases whole-cell K(ATP) current).
FT                                /FTId=VAR_029778.
FT   VARIANT     187    187       V -> D (in HHF1; severe; high prevalence
FT                                in Finland; loss of channel activity).
FT                                /FTId=VAR_008641.
FT   VARIANT     188    188       N -> S (in HHF1; severe).
FT                                /FTId=VAR_008642.
FT   VARIANT     213    213       L -> R (in PNDM).
FT                                /FTId=VAR_029779.
FT   VARIANT     233    233       M -> R (in HHF1).
FT                                /FTId=VAR_031357.
FT   VARIANT     275    275       R -> Q.
FT                                /FTId=VAR_008643.
FT   VARIANT     310    310       D -> N (in HHF1).
FT                                /FTId=VAR_031358.
FT   VARIANT     406    406       N -> D (in HHF1).
FT                                /FTId=VAR_008644.
FT   VARIANT     418    418       C -> R (in HHF1; dbSNP:rs67254669).
FT                                /FTId=VAR_031359.
FT   VARIANT     435    435       C -> R (in TNDM2).
FT                                /FTId=VAR_029780.
FT   VARIANT     495    495       R -> Q (in HHF1).
FT                                /FTId=VAR_031360.
FT   VARIANT     501    501       E -> K (in HHF1).
FT                                /FTId=VAR_031361.
FT   VARIANT     503    503       L -> P (in HHF1).
FT                                /FTId=VAR_031362.
FT   VARIANT     508    508       L -> P (in HHF1).
FT                                /FTId=VAR_031363.
FT   VARIANT     551    551       P -> R (in HHF1).
FT                                /FTId=VAR_031364.
FT   VARIANT     560    560       V -> M (in dbSNP:rs4148619).
FT                                /FTId=VAR_008645.
FT   VARIANT     582    582       L -> V (in TNDM2).
FT                                /FTId=VAR_029781.
FT   VARIANT     591    591       F -> L (in HHF1).
FT                                /FTId=VAR_008646.
FT   VARIANT     620    620       R -> C (in HHF1; dbSNP:rs58241708).
FT                                /FTId=VAR_031365.
FT   VARIANT     673    673       D -> N.
FT                                /FTId=VAR_015006.
FT   VARIANT     686    686       F -> S (in HHF1).
FT                                /FTId=VAR_031366.
FT   VARIANT     716    716       G -> V (in HHF1).
FT                                /FTId=VAR_000100.
FT   VARIANT     719    719       K -> T (in HHF1).
FT                                /FTId=VAR_031367.
FT   VARIANT     810    810       D -> N.
FT                                /FTId=VAR_008647.
FT   VARIANT     834    834       R -> C.
FT                                /FTId=VAR_008648.
FT   VARIANT     841    841       R -> G (in HHF1).
FT                                /FTId=VAR_031368.
FT   VARIANT     889    889       K -> T (in HHF1).
FT                                /FTId=VAR_031369.
FT   VARIANT     956    956       S -> F (in HHF1).
FT                                /FTId=VAR_031370.
FT   VARIANT    1023   1023       H -> Y (in TNDM2; overactive channel).
FT                                /FTId=VAR_029782.
FT   VARIANT    1130   1130       T -> P (in HHF1).
FT                                /FTId=VAR_031371.
FT   VARIANT    1138   1138       T -> M (in HHF1).
FT                                /FTId=VAR_008649.
FT   VARIANT    1147   1147       L -> R (in HHF1).
FT                                /FTId=VAR_031372.
FT   VARIANT    1182   1182       R -> Q (in TNDM2).
FT                                /FTId=VAR_029783.
FT   VARIANT    1214   1214       R -> Q (in HHF1; severe).
FT                                /FTId=VAR_008650.
FT   VARIANT    1214   1214       R -> W (in HHF1).
FT                                /FTId=VAR_031373.
FT   VARIANT    1295   1295       N -> K (in HHF1).
FT                                /FTId=VAR_031374.
FT   VARIANT    1336   1336       K -> N (in HHF1).
FT                                /FTId=VAR_031375.
FT   VARIANT    1342   1342       G -> E (in HHF1; altered intracellular
FT                                trafficking).
FT                                /FTId=VAR_031376.
FT   VARIANT    1349   1349       L -> Q (in HHF1).
FT                                /FTId=VAR_031377.
FT   VARIANT    1352   1352       R -> H (in LIH; partially impairs ATP-
FT                                dependent potassium channel function).
FT                                /FTId=VAR_029784.
FT   VARIANT    1352   1352       R -> P (in HHF1; dbSNP:rs28936370).
FT                                /FTId=VAR_008537.
FT   VARIANT    1360   1360       V -> G.
FT                                /FTId=VAR_008651.
FT   VARIANT    1360   1360       V -> M (in HHF1).
FT                                /FTId=VAR_015007.
FT   VARIANT    1369   1369       A -> S (in dbSNP:rs757110).
FT                                /FTId=VAR_008652.
FT   VARIANT    1378   1378       G -> R (in HHF1).
FT                                /FTId=VAR_008653.
FT   VARIANT    1379   1379       R -> C (in TNDM2).
FT                                /FTId=VAR_029785.
FT   VARIANT    1381   1381       G -> S (in HHF1).
FT                                /FTId=VAR_008654.
FT   VARIANT    1384   1384       K -> Q (in HHF1).
FT                                /FTId=VAR_031378.
FT   VARIANT    1385   1385       Missing (in HHF1; does not alter surface
FT                                expression but channels are not
FT                                functional).
FT                                /FTId=VAR_029786.
FT   VARIANT    1386   1386       S -> F (in HHF1).
FT                                /FTId=VAR_031379.
FT   VARIANT    1387   1387       Missing (in HHF1; severe; high frequency
FT                                in Ashkenazi Jewish patients; defective
FT                                trafficking and lack of surface
FT                                expression).
FT                                /FTId=VAR_008538.
FT   VARIANT    1393   1393       R -> H (in HHF1; severe; loss of channel
FT                                activity).
FT                                /FTId=VAR_008655.
FT   VARIANT    1400   1400       G -> R (in HHF1).
FT                                /FTId=VAR_031380.
FT   VARIANT    1418   1418       R -> H (in HHF1; altered intracellular
FT                                trafficking).
FT                                /FTId=VAR_031381.
FT   VARIANT    1420   1420       R -> C (in HHF1; modest impairment of
FT                                channel function; dbSNP:rs28938469).
FT                                /FTId=VAR_008539.
FT   VARIANT    1424   1424       I -> V (in PNDM; overactive channel).
FT                                /FTId=VAR_029787.
FT   VARIANT    1436   1436       R -> Q (in HHF1; cannot form a functional
FT                                channel, due to protein instability or
FT                                defective transport to the membrane).
FT                                /FTId=VAR_015008.
FT   VARIANT    1450   1450       L -> P (in HHF1).
FT                                /FTId=VAR_031382.
FT   VARIANT    1457   1457       A -> T (in HHF1).
FT                                /FTId=VAR_031383.
FT   VARIANT    1471   1471       D -> H (in HHF1).
FT                                /FTId=VAR_031384.
FT   VARIANT    1471   1471       D -> N (in HHF1).
FT                                /FTId=VAR_031385.
FT   VARIANT    1478   1478       G -> R (in HHF1; channels insensitive to
FT                                metabolic inhibition and to activation by
FT                                ADP).
FT                                /FTId=VAR_008656.
FT   VARIANT    1486   1486       R -> K (in HHF1).
FT                                /FTId=VAR_031386.
FT   VARIANT    1493   1493       R -> Q (in HHF1).
FT                                /FTId=VAR_031387.
FT   VARIANT    1493   1493       R -> W (in HHF1; altered intracellular
FT                                trafficking; dbSNP:rs28936371).
FT                                /FTId=VAR_008540.
FT   VARIANT    1506   1506       E -> K (in HHF1; mild; dominantly
FT                                inherited; channels insensitive to
FT                                metabolic inhibition and to activation by
FT                                ADP).
FT                                /FTId=VAR_015009.
FT   VARIANT    1507   1507       A -> AAS (in HHF1).
FT                                /FTId=VAR_008657.
FT   VARIANT    1543   1543       L -> P (in HHF1; reduced channels surface
FT                                expression and response to ADP).
FT                                /FTId=VAR_015010.
FT   VARIANT    1550   1550       V -> D (in HHF1).
FT                                /FTId=VAR_031388.
FT   VARIANT    1551   1551       L -> V (in HHF1).
FT                                /FTId=VAR_031389.
FT   VARIANT    1572   1572       V -> I (in dbSNP:rs8192690).
FT                                /FTId=VAR_008658.
FT   CONFLICT     30     30       A -> V (in Ref. 2; AAB02278/AAB02417/
FT                                AAB02418).
FT   CONFLICT    157    157       F -> L (in Ref. 3; AAB36699/AAB36700).
FT   CONFLICT    163    163       G -> A (in Ref. 2; AAB02278/AAB02417/
FT                                AAB02418).
FT   CONFLICT    167    167       L -> V (in Ref. 2; AAB02278/AAB02417/
FT                                AAB02418).
FT   CONFLICT    225    225       L -> P (in Ref. 3; AAB36699/AAB36700).
FT   CONFLICT    256    256       A -> V (in Ref. 3; AAB36699/AAB36700).
FT   CONFLICT    487    487       S -> T (in Ref. 2; AAB02278/AAB02417/
FT                                AAB02418).
FT   CONFLICT   1069   1070       VL -> AV (in Ref. 2; AAB02278/AAB02417/
FT                                AAB02418).
FT   CONFLICT   1172   1172       I -> V (in Ref. 3; AAB36699/AAB36700).
FT   CONFLICT   1410   1410       A -> R (in Ref. 3; AAB36699/AAB36700).
FT   CONFLICT   1418   1418       R -> P (in Ref. 3; AAB36699/AAB36700).
SQ   SEQUENCE   1581 AA;  176992 MW;  09CF2EC97899D1CE CRC64;
     MPLAFCGSEN HSAAYRVDQG VLNNGCFVDA LNVVPHVFLL FITFPILFIG WGSQSSKVHI
     HHSTWLHFPG HNLRWILTFM LLFVLVCEIA EGILSDGVTE SHHLHLYMPA GMAFMAAVTS
     VVYYHNIETS NFPKLLIALL VYWTLAFITK TIKFVKFLDH AIGFSQLRFC LTGLLVILYG
     MLLLVEVNVI RVRRYIFFKT PREVKPPEDL QDLGVRFLQP FVNLLSKGTY WWMNAFIKTA
     HKKPIDLRAI GKLPIAMRAL TNYQRLCEAF DAQVRKDIQG TQGARAIWQA LSHAFGRRLV
     LSSTFRILAD LLGFAGPLCI FGIVDHLGKE NDVFQPKTQF LGVYFVSSQE FLANAYVLAV
     LLFLALLLQR TFLQASYYVA IETGINLRGA IQTKIYNKIM HLSTSNLSMG EMTAGQICNL
     VAIDTNQLMW FFFLCPNLWA MPVQIIVGVI LLYYILGVSA LIGAAVIILL APVQYFVATK
     LSQAQRSTLE YSNERLKQTN EMLRGIKLLK LYAWENIFRT RVETTRRKEM TSLRAFAIYT
     SISIFMNTAI PIAAVLITFV GHVSFFKEAD FSPSVAFASL SLFHILVTPL FLLSSVVRST
     VKALVSVQKL SEFLSSAEIR EEQCAPHEPT PQGPASKYQA VPLRVVNRKR PAREDCRGLT
     GPLQSLVPSA DGDADNCCVQ IMGGYFTWTP DGIPTLSNIT IRIPRGQLTM IVGQVGCGKS
     SLLLAALGEM QKVSGAVFWS SLPDSEIGED PSPERETATD LDIRKRGPVA YASQKPWLLN
     ATVEENIIFE SPFNKQRYKM VIEACSLQPD IDILPHGDQT QIGERGINLS GGQRQRISVA
     RALYQHANVV FLDDPFSALD IHLSDHLMQA GILELLRDDK RTVVLVTHKL QYLPHADWII
     AMKDGTIQRE GTLKDFQRSE CQLFEHWKTL MNRQDQELEK ETVTERKATE PPQGLSRAMS
     SRDGLLQDEE EEEEEAAESE EDDNLSSMLH QRAEIPWRAC AKYLSSAGIL LLSLLVFSQL
     LKHMVLVAID YWLAKWTDSA LTLTPAARNC SLSQECTLDQ TVYAMVFTVL CSLGIVLCLV
     TSVTVEWTGL KVAKRLHRSL LNRIILAPMR FFETTPLGSI LNRFSSDCNT IDQHIPSTLE
     CLSRSTLLCV SALAVISYVT PVFLVALLPL AIVCYFIQKY FRVASRDLQQ LDDTTQLPLL
     SHFAETVEGL TTIRAFRYEA RFQQKLLEYT DSNNIASLFL TAANRWLEVR MEYIGACVVL
     IAAVTSISNS LHRELSAGLV GLGLTYALMV SNYLNWMVRN LADMELQLGA VKRIHGLLKT
     EAESYEGLLA PSLIPKNWPD QGKIQIQNLS VRYDSSLKPV LKHVNALIAP GQKIGICGRT
     GSGKSSFSLA FFRMVDTFEG HIIIDGIDIA KLPLHTLRSR LSIILQDPVL FSGTIRFNLD
     PERKCSDSTL WEALEIAQLK LVVKALPGGL DAIITEGGEN FSQGQRQLFC LARAFVRKTS
     IFIMDEATAS IDMATENILQ KVVMTAFADR TVVTIAHRVH TILSADLVIV LKRGAILEFD
     KPEKLLSRKD SVFASFVRAD K
//
ID   ABCD1_HUMAN             Reviewed;         745 AA.
AC   P33897; Q6GTZ2;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2005, sequence version 2.
DT   09-JUL-2014, entry version 167.
DE   RecName: Full=ATP-binding cassette sub-family D member 1;
DE   AltName: Full=Adrenoleukodystrophy protein;
DE            Short=ALDP;
GN   Name=ABCD1; Synonyms=ALD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=8441467; DOI=10.1038/361726a0;
RA   Mosser J., Douar A.-M., Sarde C.-O., Kioschis P., Feil R., Moser H.,
RA   Poustka A.-M., Mandel J.-L., Aubourg P.;
RT   "Putative X-linked adrenoleukodystrophy gene shares unexpected
RT   homology with ABC transporters.";
RL   Nature 361:726-730(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   SUBUNIT, AND CHARACTERIZATION OF VARIANTS ALD HIS-389; GLN-401;
RP   ARG-484 AND GLN-591.
RX   PubMed=10551832; DOI=10.1074/jbc.274.46.32738;
RA   Liu L.X., Janvier K., Berteaux-Lecellier V., Cartier N., Benarous R.,
RA   Aubourg P.;
RT   "Homo- and heterodimerization of peroxisomal ATP-binding cassette
RT   half-transporters.";
RL   J. Biol. Chem. 274:32738-32743(1999).
RN   [5]
RP   FUNCTION, AND CHARACTERIZATION OF VARIANTS ALD SER-512 AND LEU-606.
RX   PubMed=11248239; DOI=10.1016/S0014-5793(01)02235-9;
RA   Roerig P., Mayerhofer P., Holzinger A., Gaertner J.;
RT   "Characterization and functional analysis of the nucleotide binding
RT   fold in human peroxisomal ATP binding cassette transporters.";
RL   FEBS Lett. 492:66-72(2001).
RN   [6]
RP   REVIEW.
RX   PubMed=8507690; DOI=10.1016/0300-9084(93)90089-B;
RA   Aubourg P., Mosser J., Douar A.-M., Sarde C.-O., Lopez J.,
RA   Mandel J.-L.;
RT   "Adrenoleukodystrophy gene: unexpected homology to a protein involved
RT   in peroxisome biogenesis.";
RL   Biochimie 75:293-302(1993).
RN   [7]
RP   INTERACTION WITH PEX19.
RC   TISSUE=Brain;
RX   PubMed=10777694; DOI=10.1006/bbrc.2000.2572;
RA   Gloeckner C.J., Mayerhofer P.U., Landgraf P., Muntau A.C.,
RA   Holzinger A., Gerber J.-K., Kammerer S., Adamski J., Roscher A.A.;
RT   "Human adrenoleukodystrophy protein and related peroxisomal ABC
RT   transporters interact with the peroxisomal assembly protein PEX19p.";
RL   Biochem. Biophys. Res. Commun. 271:144-150(2000).
RN   [8]
RP   INTERACTION WITH PEX19.
RX   PubMed=10704444; DOI=10.1083/jcb.148.5.931;
RA   Sacksteder K.A., Jones J.M., South S.T., Li X., Liu Y., Gould S.J.;
RT   "PEX19 binds multiple peroxisomal membrane proteins, is predominantly
RT   cytoplasmic, and is required for peroxisome membrane synthesis.";
RL   J. Cell Biol. 148:931-944(2000).
RN   [9]
RP   REVIEW ON VARIANTS.
RX   PubMed=9195223;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:6<500::AID-HUMU2>3.0.CO;2-5;
RA   Dodd A., Rowland S.A., Hawkes S.L.J., Kennedy M.A., Love D.R.;
RT   "Mutations in the adrenoleukodystrophy gene.";
RL   Hum. Mutat. 9:500-511(1997).
RN   [10]
RP   REVIEW ON VARIANTS.
RX   PubMed=11748843; DOI=10.1002/humu.1227;
RA   Kemp S., Pujol A., Waterham H.R., van Geel B.M., Boehm C.D.,
RA   Raymond G.V., Cutting G.R., Wanders R.J.A., Moser H.W.;
RT   "ABCD1 mutations and the X-linked adrenoleukodystrophy mutation
RT   database: role in diagnosis and clinical correlations.";
RL   Hum. Mutat. 18:499-515(2001).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-733, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-733, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   VARIANT ALD LYS-291.
RX   PubMed=7904210; DOI=10.1093/hmg/2.11.1949;
RA   Cartier N., Sarde C.-O., Douar A.-M., Mosser J., Mandel J.-L.,
RA   Aubourg P.;
RT   "Abnormal messenger RNA expression and a missense mutation in patients
RT   with X-linked adrenoleukodystrophy.";
RL   Hum. Mol. Genet. 2:1949-1951(1993).
RN   [15]
RP   VARIANTS ALD SER-148; ASP-174; ARG-266; GLN-401; TRP-418 AND PHE-515.
RX   PubMed=7849723; DOI=10.1093/hmg/3.10.1903;
RA   Fuchs S., Sarde C.-O., Wedemann H., Schwinger E., Mandel J.-L.,
RA   Gal A.;
RT   "Missense mutations are frequent in the gene for X-chromosomal
RT   adrenoleukodystrophy (ALD).";
RL   Hum. Mol. Genet. 3:1903-1905(1994).
RN   [16]
RP   VARIANTS ALD TRP-518; LEU-606; CYS-617 AND HIS-617.
RX   PubMed=8040304; DOI=10.1172/JCI117363;
RA   Fanen P., Guidoux S., Sarde C.-O., Mandel J.-L., Goossens M.,
RA   Aubourg P.;
RT   "Identification of mutations in the putative ATP-binding domain of the
RT   adrenoleukodystrophy gene.";
RL   J. Clin. Invest. 94:516-520(1994).
RN   [17]
RP   VARIANTS ALD.
RX   PubMed=7825602;
RA   Ligtenberg M.J.L., Kemp S., Sarde C.-O., van Geel B.M., Kleijer W.J.,
RA   Barth P.G., Mandel J.-L., van Oost B.A., Bolhuis P.A.;
RT   "Spectrum of mutations in the gene encoding the adrenoleukodystrophy
RT   protein.";
RL   Am. J. Hum. Genet. 56:44-50(1995).
RN   [18]
RP   VARIANTS ALD HIS-104; GLU-178; GLY-528 DEL AND LEU-560.
RX   PubMed=7717396;
RA   Braun A., Ambach H., Kammerer S., Rolinski B., Stoeckler S., Rabl W.,
RA   Gaertner J., Zierz S., Roscher A.A.;
RT   "Mutations in the gene for X-linked adrenoleukodystrophy in patients
RT   with different clinical phenotypes.";
RL   Am. J. Hum. Genet. 56:854-861(1995).
RN   [19]
RP   VARIANTS ALD.
RX   PubMed=7581394; DOI=10.1002/humu.1380060203;
RA   Kok F., Neumann S., Sarde C.-O., Zheng S., Wu K.-H., Wei H.-M.,
RA   Bergin J., Watkins P.A., Gould S., Sack G., Moser H., Mandel J.-L.,
RA   Smith K.D.;
RT   "Mutational analysis of patients with X-linked adrenoleukodystrophy.";
RL   Hum. Mutat. 6:104-115(1995).
RN   [20]
RP   VARIANTS ALD.
RX   PubMed=8651290;
RA   Feigenbaum V., Lombard-Platet G., Guidoux S., Sarde C.-O.,
RA   Mandel J.-L., Aubourg P.;
RT   "Mutational and protein analysis of patients and heterozygous women
RT   with X-linked adrenoleukodystrophy.";
RL   Am. J. Hum. Genet. 58:1135-1144(1996).
RN   [21]
RP   VARIANTS ALD PRO-107; ASP-174; MET-254; GLY-389; GLN-401; TRP-418;
RP   LYS-609; CYS-617 AND GLY-617.
RX   PubMed=8566952; DOI=10.1007/BF02265264;
RA   Krasemann E.W., Meier V., Korenke G.C., Hunneman D.H., Hanefeld F.;
RT   "Identification of mutations in the ALD-gene of 20 families with
RT   adrenoleukodystrophy/adrenomyeloneuropathy.";
RL   Hum. Genet. 97:194-197(1996).
RN   [22]
RP   VARIANT ALD ARG-679.
RX   PubMed=9452087;
RA   Korenke G.C., Krasemann E., Meier V., Beuche W., Hunneman D.H.,
RA   Hanefeld F.;
RT   "First missense mutation (W679R) in exon 10 of the
RT   adrenoleukodystrophy gene in siblings with adrenomyeloneuropathy.";
RL   Hum. Mutat. Suppl. 1:S204-S206(1998).
RN   [23]
RP   VARIANTS ALD PRO-105; SER-143; SER-148; PRO-190; ASP-298; SER-529 AND
RP   TYR-638.
RX   PubMed=10480364; DOI=10.1007/s004399900090;
RA   Wichers M., Kohler W., Brennemann W., Boese V., Sokolowski P.,
RA   Bidlingmaier F., Ludwig M.;
RT   "X-linked adrenomyeloneuropathy associated with 14 novel ALD-gene
RT   mutations: no correlation between type of mutation and age of onset.";
RL   Hum. Genet. 105:116-119(1999).
RN   [24]
RP   VARIANTS ALD LEU-108 AND SER-143.
RX   PubMed=10369742; DOI=10.1006/mcpr.1999.0232;
RA   Perusi C., Gomez-Lira M., Mottes M., Pignatti P.F., Bertini E.,
RA   Cappa M., Vigliani M.C., Schiffer D., Rizzuto N., Salviati A.;
RT   "Two novel missense mutations causing adrenoleukodystrophy in Italian
RT   patients.";
RL   Mol. Cell. Probes 13:179-182(1999).
RN   [25]
RP   VARIANTS ALD ARG-103; ARG-116; SER-152; CYS-174; TRP-189; THR-218;
RP   PRO-229; ASP-298; GLN-401; TRP-401; TRP-418; LEU-543; HIS-554;
RP   VAL-616; ARG-633 AND PRO-646.
RX   PubMed=10737980;
RX   DOI=10.1002/(SICI)1098-1004(200004)15:4<348::AID-HUMU7>3.0.CO;2-N;
RA   Lachtermacher M.B., Seuanez H.N., Moser A.B., Moser H.W., Smith K.D.;
RT   "Determination of 30 X-linked adrenoleukodystrophy mutations,
RT   including 15 not previously described.";
RL   Hum. Mutat. 15:348-353(2000).
RN   [26]
RP   VARIANTS ALD GLN-401; TRP-418; LEU-543 AND ARG-556.
RX   PubMed=10980539;
RX   DOI=10.1002/1098-1004(200009)16:3<271::AID-HUMU15>3.0.CO;2-D;
RA   Lira M.G., Mottes M., Pignatti P.F., Medica I., Uziel G., Cappa M.,
RA   Bertini E., Rizzuto N., Salviati A.;
RT   "Detection of mutations in the ALD gene (ABCD1) in seven Italian
RT   families: description of four novel mutations.";
RL   Hum. Mutat. 16:271-271(2000).
RN   [27]
RP   VARIANTS ALD LEU-98; ASP-99; GLU-217; GLN-518; ASP-608; ILE-633 AND
RP   PRO-660, AND VARIANT THR-13.
RX   PubMed=11438993; DOI=10.1002/humu.1149;
RA   Dvorakova L., Storkanova G., Unterrainer G., Hujova J., Kmoch S.,
RA   Zeman J., Hrebicek M., Berger J.;
RT   "Eight novel ABCD1 gene mutations and three polymorphisms in patients
RT   with X-linked adrenoleukodystrophy: the first polymorphism causing an
RT   amino acid exchange.";
RL   Hum. Mutat. 18:52-60(2001).
RN   [28]
RP   VARIANT ALD VAL-GLY-GLN-300 INS.
RX   PubMed=11810273; DOI=10.1007/s00439-001-0632-z;
RA   Guimaraes C.P., Lemos M., Menezes I., Coelho T., Sa-Miranda C.,
RA   Azevedo J.E.;
RT   "Characterisation of two mutations in the ABCD1 gene leading to low
RT   levels of normal ALDP.";
RL   Hum. Genet. 109:616-622(2001).
RN   [29]
RP   INVOLVEMENT IN CONTIGUOUS ABCD1/DXS1375E DELETION SYNDROME.
RX   PubMed=11992258; DOI=10.1086/340849;
RA   Corzo D., Gibson W., Johnson K., Mitchell G., LePage G., Cox G.F.,
RA   Casey R., Zeiss C., Tyson H., Cutting G.R., Raymond G.V., Smith K.D.,
RA   Watkins P.A., Moser A.B., Moser H.W., Steinberg S.J.;
RT   "Contiguous deletion of the X-linked adrenoleukodystrophy gene (ABCD1)
RT   and DXS1357E: a novel neonatal phenotype similar to peroxisomal
RT   biogenesis disorders.";
RL   Am. J. Hum. Genet. 70:1520-1531(2002).
RN   [30]
RP   VARIANTS ALD TRP-88; CYS-152; CYS-181; SER-343; PRO-503; ARG-514 AND
RP   HIS-554.
RX   PubMed=15643618; DOI=10.1002/humu.9303;
RA   Montagna G., Di Biase A., Cappa M., Melone M.A.B., Piantadosi C.,
RA   Colabianchi D., Patrono C., Attori L., Cannelli N., Cotrufo R.,
RA   Salvati S., Santorelli F.M.;
RT   "Identification of seven novel mutations in ABCD1 by a DHPLC-based
RT   assay in Italian patients with X-linked adrenoleukodystrophy.";
RL   Hum. Mutat. 25:222-222(2005).
RN   [31]
RP   VARIANTS ALD GLN-401; PRO-516; LEU-560; PRO-606 AND GLN-660.
RX   PubMed=21889498; DOI=10.1016/j.cca.2011.08.026;
RA   Shukla P., Gupta N., Gulati S., Ghosh M., Vasisht S., Sharma R.,
RA   Gupta A.K., Kalra V., Kabra M.;
RT   "Molecular analysis of ABCD1 gene in Indian patients with X-linked
RT   adrenoleukodystrophy.";
RL   Clin. Chim. Acta 412:2289-2295(2011).
RN   [32]
RP   VARIANTS ALD LEU-139 DEL; ARG-198; ARG-266; GLU-266; TRP-401; GLN-518;
RP   PHE-523; CYS-540; LEU-560; PRO-606; HIS-617; THR-626; PRO-632;
RP   ARG-633; LYS-640 AND ASP-677.
RX   PubMed=21700483; DOI=10.1016/j.ymgme.2011.05.016;
RA   Wang Y., Busin R., Reeves C., Bezman L., Raymond G., Toomer C.J.,
RA   Watkins P.A., Snowden A., Moser A., Naidu S., Bibat G., Hewson S.,
RA   Tam K., Clarke J.T., Charnas L., Stetten G., Karczeski B., Cutting G.,
RA   Steinberg S.;
RT   "X-linked adrenoleukodystrophy: ABCD1 de novo mutations and
RT   mosaicism.";
RL   Mol. Genet. Metab. 104:160-166(2011).
CC   -!- FUNCTION: Probable transporter. The nucleotide-binding fold acts
CC       as an ATP-binding subunit with ATPase activity.
CC   -!- SUBUNIT: Can form homodimers and heterodimers with ABCD2/ALDR and
CC       ABCD3/PMP70. Dimerization is necessary to form an active
CC       transporter. Interacts with PEX19.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-81045, EBI-81045;
CC       P48410:Abcd1 (xeno); NbExp=2; IntAct=EBI-81045, EBI-81118;
CC       P28288:ABCD3; NbExp=2; IntAct=EBI-81045, EBI-80992;
CC       P40855:PEX19; NbExp=3; IntAct=EBI-81045, EBI-594747;
CC   -!- SUBCELLULAR LOCATION: Peroxisome membrane; Multi-pass membrane
CC       protein.
CC   -!- DISEASE: Adrenoleukodystrophy (ALD) [MIM:300100]: A peroxisomal
CC       metabolic disorder characterized by progressive multifocal
CC       demyelination of the central nervous system and by peripheral
CC       adrenal insufficiency (Addison disease). It results in mental
CC       deterioration, corticospinal tract dysfunction, and cortical
CC       blindness. Different clinical manifestations exist like: cerebral
CC       childhood ALD (CALD), adult cerebral ALD (ACALD),
CC       adrenomyeloneuropathy (AMN) and 'Addison disease only' (ADO)
CC       phenotype. Note=The disease is caused by mutations affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Note=The promoter region of ABCD1 is deleted in the
CC       chromosome Xq28 deletion syndrome which involves ABCD1 and the
CC       neighboring gene BCAP31.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCD
CC       family. Peroxisomal fatty acyl CoA transporter (TC 3.A.1.203)
CC       subfamily.
CC   -!- SIMILARITY: Contains 1 ABC transmembrane type-1 domain.
CC   -!- SIMILARITY: Contains 1 ABC transporter domain.
CC   -!- WEB RESOURCE: Name=X-ALD gene mutation database;
CC       URL="http://www.x-ald.nl/";
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=P33897";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z21876; CAA79922.1; -; mRNA.
DR   EMBL; Z31348; CAA83230.1; -; Genomic_DNA.
DR   EMBL; Z31006; CAA83230.1; JOINED; Genomic_DNA.
DR   EMBL; Z31007; CAA83230.1; JOINED; Genomic_DNA.
DR   EMBL; Z31008; CAA83230.1; JOINED; Genomic_DNA.
DR   EMBL; Z31009; CAA83230.1; JOINED; Genomic_DNA.
DR   EMBL; Z31010; CAA83230.1; JOINED; Genomic_DNA.
DR   EMBL; U52111; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015541; AAH15541.1; -; mRNA.
DR   EMBL; BC025358; AAH25358.1; -; mRNA.
DR   CCDS; CCDS14728.1; -.
DR   PIR; G02500; G02500.
DR   RefSeq; NP_000024.2; NM_000033.3.
DR   UniGene; Hs.159546; -.
DR   ProteinModelPortal; P33897; -.
DR   SMR; P33897; 466-675.
DR   BioGrid; 106717; 17.
DR   IntAct; P33897; 6.
DR   STRING; 9606.ENSP00000218104; -.
DR   TCDB; 3.A.1.203.3; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; P33897; -.
DR   DMDM; 67476960; -.
DR   MaxQB; P33897; -.
DR   PaxDb; P33897; -.
DR   PeptideAtlas; P33897; -.
DR   PRIDE; P33897; -.
DR   DNASU; 215; -.
DR   Ensembl; ENST00000218104; ENSP00000218104; ENSG00000101986.
DR   Ensembl; ENST00000601366; ENSP00000473207; ENSG00000268757.
DR   GeneID; 215; -.
DR   KEGG; hsa:215; -.
DR   UCSC; uc004fif.2; human.
DR   CTD; 215; -.
DR   GeneCards; GC0XP152990; -.
DR   GeneReviews; ABCD1; -.
DR   HGNC; HGNC:61; ABCD1.
DR   HPA; HPA035214; -.
DR   MIM; 300100; phenotype.
DR   MIM; 300371; gene.
DR   neXtProt; NX_P33897; -.
DR   Orphanet; 139399; Adrenomyeloneuropathy.
DR   Orphanet; 369942; CADDS.
DR   Orphanet; 139396; X-linked cerebral adrenoleukodystrophy.
DR   PharmGKB; PA24396; -.
DR   eggNOG; COG4178; -.
DR   HOGENOM; HOG000206081; -.
DR   HOVERGEN; HBG050438; -.
DR   InParanoid; P33897; -.
DR   KO; K05675; -.
DR   OMA; IPKMQRR; -.
DR   PhylomeDB; P33897; -.
DR   TreeFam; TF105205; -.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   GeneWiki; ABCD1; -.
DR   GenomeRNAi; 215; -.
DR   NextBio; 870; -.
DR   PRO; PR:P33897; -.
DR   ArrayExpress; P33897; -.
DR   Bgee; P33897; -.
DR   CleanEx; HS_ABCD1; -.
DR   Genevestigator; P33897; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005779; C:integral component of peroxisomal membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005778; C:peroxisomal membrane; IDA:UniProtKB.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0016887; F:ATPase activity; IDA:UniProtKB.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; NAS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005325; F:peroxisomal fatty-acyl-CoA transporter activity; IGI:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0005215; F:transporter activity; NAS:UniProtKB.
DR   GO; GO:0036109; P:alpha-linolenic acid metabolic process; TAS:Reactome.
DR   GO; GO:0006200; P:ATP catabolic process; IDA:GOC.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0006635; P:fatty acid beta-oxidation; IDA:UniProtKB.
DR   GO; GO:0033540; P:fatty acid beta-oxidation using acyl-CoA oxidase; TAS:Reactome.
DR   GO; GO:0043651; P:linoleic acid metabolic process; TAS:Reactome.
DR   GO; GO:0042758; P:long-chain fatty acid catabolic process; IGI:UniProtKB.
DR   GO; GO:0015910; P:peroxisomal long-chain fatty acid import; IGI:UniProtKB.
DR   GO; GO:0015919; P:peroxisomal membrane transport; NAS:UniProtKB.
DR   GO; GO:0007031; P:peroxisome organization; IDA:UniProtKB.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0033559; P:unsaturated fatty acid metabolic process; TAS:Reactome.
DR   GO; GO:0042760; P:very long-chain fatty acid catabolic process; IDA:UniProtKB.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR010509; ABC_Peroxi_TM.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR005283; FA_transporter.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF06472; ABC_membrane_2; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF90123; SSF90123; 1.
DR   TIGRFAMs; TIGR00954; 3a01203; 1.
DR   PROSITE; PS50929; ABC_TM1F; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Disease mutation; Glycoprotein;
KW   Membrane; Nucleotide-binding; Peroxisome; Phosphoprotein;
KW   Reference proteome; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1    745       ATP-binding cassette sub-family D member
FT                                1.
FT                                /FTId=PRO_0000093304.
FT   TRANSMEM     92    112       Helical; (Potential).
FT   TRANSMEM    131    151       Helical; (Potential).
FT   TRANSMEM    238    258       Helical; (Potential).
FT   TRANSMEM    333    353       Helical; (Potential).
FT   TRANSMEM    473    493       Helical; (Potential).
FT   DOMAIN       94    386       ABC transmembrane type-1.
FT   DOMAIN      474    700       ABC transporter.
FT   NP_BIND     507    514       ATP (By similarity).
FT   REGION       67    186       Interaction with PEX19.
FT   MOD_RES     733    733       Phosphoserine.
FT   CARBOHYD    214    214       N-linked (GlcNAc...) (Potential).
FT   VARIANT      13     13       N -> T (very rare polymorphism; does not
FT                                affect ALDP function; dbSNP:rs183021839).
FT                                /FTId=VAR_013340.
FT   VARIANT      88     88       C -> W (in ALD).
FT                                /FTId=VAR_023004.
FT   VARIANT      90     90       E -> K (in ALD).
FT                                /FTId=VAR_009349.
FT   VARIANT      98     98       S -> L (in ALD; CALD type).
FT                                /FTId=VAR_000024.
FT   VARIANT      99     99       A -> D (in ALD; AMN-type).
FT                                /FTId=VAR_013341.
FT   VARIANT     103    103       S -> R (in ALD).
FT                                /FTId=VAR_009350.
FT   VARIANT     104    104       R -> C (in ALD).
FT                                /FTId=VAR_000025.
FT   VARIANT     104    104       R -> H (in ALD; ADO-type).
FT                                /FTId=VAR_000026.
FT   VARIANT     105    105       T -> I (in ALD; ADO-type).
FT                                /FTId=VAR_000027.
FT   VARIANT     105    105       T -> P (in ALD).
FT                                /FTId=VAR_009351.
FT   VARIANT     107    107       L -> P (in ALD; ALD/AMN/ADO-types and
FT                                asymptomatic).
FT                                /FTId=VAR_000028.
FT   VARIANT     108    108       S -> L (in ALD).
FT                                /FTId=VAR_009352.
FT   VARIANT     108    108       S -> W (in ALD; CALD and AMN-types).
FT                                /FTId=VAR_000029.
FT   VARIANT     113    113       R -> C (in ALD).
FT                                /FTId=VAR_009353.
FT   VARIANT     113    113       R -> P (in ALD).
FT                                /FTId=VAR_013342.
FT   VARIANT     116    116       G -> R (in ALD; CALD-type).
FT                                /FTId=VAR_000030.
FT   VARIANT     138    141       Missing (in ALD; ALD-type).
FT                                /FTId=VAR_000032.
FT   VARIANT     139    139       Missing (in ALD).
FT                                /FTId=VAR_067239.
FT   VARIANT     141    141       A -> T (in ALD).
FT                                /FTId=VAR_000033.
FT   VARIANT     143    143       P -> S (in ALD).
FT                                /FTId=VAR_009354.
FT   VARIANT     148    148       N -> S (in ALD; ADO-type).
FT                                /FTId=VAR_000034.
FT   VARIANT     149    149       S -> N (in ALD).
FT                                /FTId=VAR_000035.
FT   VARIANT     152    152       R -> C (in ALD; ADO-type).
FT                                /FTId=VAR_000036.
FT   VARIANT     152    152       R -> L (in ALD).
FT                                /FTId=VAR_009355.
FT   VARIANT     152    152       R -> P (in ALD).
FT                                /FTId=VAR_000037.
FT   VARIANT     152    152       R -> S (in ALD).
FT                                /FTId=VAR_009356.
FT   VARIANT     161    161       S -> P (in ALD).
FT                                /FTId=VAR_009357.
FT   VARIANT     163    163       R -> H (in ALD).
FT                                /FTId=VAR_000038.
FT   VARIANT     163    163       R -> P (in ALD).
FT                                /FTId=VAR_009358.
FT   VARIANT     174    174       Y -> C (in ALD).
FT                                /FTId=VAR_009359.
FT   VARIANT     174    174       Y -> D (in ALD; ALD-type).
FT                                /FTId=VAR_000039.
FT   VARIANT     174    174       Y -> S (in ALD; CALD-type).
FT                                /FTId=VAR_000040.
FT   VARIANT     178    178       Q -> E (in ALD; AMN-type).
FT                                /FTId=VAR_000041.
FT   VARIANT     181    181       Y -> C (in ALD; ALMD-type).
FT                                /FTId=VAR_000042.
FT   VARIANT     182    182       R -> P (in ALD).
FT                                /FTId=VAR_000043.
FT   VARIANT     189    189       R -> W (in ALD).
FT                                /FTId=VAR_009360.
FT   VARIANT     190    190       L -> P (in ALD).
FT                                /FTId=VAR_009361.
FT   VARIANT     194    194       D -> H (in ALD).
FT                                /FTId=VAR_000044.
FT   VARIANT     198    198       T -> K (in ALD).
FT                                /FTId=VAR_009362.
FT   VARIANT     198    198       T -> R (in ALD).
FT                                /FTId=VAR_067240.
FT   VARIANT     200    200       D -> N (in ALD).
FT                                /FTId=VAR_009363.
FT   VARIANT     200    200       D -> V (in ALD; CALD-type).
FT                                /FTId=VAR_000045.
FT   VARIANT     207    207       S -> SAAS (in ALD).
FT                                /FTId=VAR_013343.
FT   VARIANT     211    211       L -> P (in ALD).
FT                                /FTId=VAR_000046.
FT   VARIANT     213    213       S -> C (in ALD).
FT                                /FTId=VAR_009364.
FT   VARIANT     214    214       N -> D (in ALD).
FT                                /FTId=VAR_009365.
FT   VARIANT     217    217       K -> E (in ALD).
FT                                /FTId=VAR_013344.
FT   VARIANT     218    218       P -> T (in ALD).
FT                                /FTId=VAR_009366.
FT   VARIANT     220    220       L -> P (in ALD).
FT                                /FTId=VAR_000047.
FT   VARIANT     221    221       D -> G (in ALD; CALD and AMN-types).
FT                                /FTId=VAR_000048.
FT   VARIANT     224    224       V -> E (in ALD).
FT                                /FTId=VAR_013345.
FT   VARIANT     229    229       L -> P (in ALD).
FT                                /FTId=VAR_009367.
FT   VARIANT     254    254       T -> M (in ALD; AMN-type).
FT                                /FTId=VAR_000049.
FT   VARIANT     254    254       T -> P (in ALD; AMN-type).
FT                                /FTId=VAR_000050.
FT   VARIANT     263    263       P -> L (in ALD; CALD, AMN and AD-types).
FT                                /FTId=VAR_000051.
FT   VARIANT     266    266       G -> E (in ALD).
FT                                /FTId=VAR_067241.
FT   VARIANT     266    266       G -> R (in ALD).
FT                                /FTId=VAR_000052.
FT   VARIANT     271    271       E -> K (in ALD).
FT                                /FTId=VAR_009368.
FT   VARIANT     274    274       R -> W (in ALD).
FT                                /FTId=VAR_013346.
FT   VARIANT     276    276       K -> E (in ALD; CALD-type).
FT                                /FTId=VAR_000053.
FT   VARIANT     277    277       G -> GN (in ALD; ADO-type).
FT                                /FTId=VAR_000055.
FT   VARIANT     277    277       G -> R (in ALD; AMN-type).
FT                                /FTId=VAR_000054.
FT   VARIANT     277    277       G -> W (in ALD).
FT                                /FTId=VAR_000056.
FT   VARIANT     280    280       R -> C (in ALD).
FT                                /FTId=VAR_013347.
FT   VARIANT     285    285       R -> P (in ALD).
FT                                /FTId=VAR_009369.
FT   VARIANT     291    291       E -> D (in ALD; ACALD and CALD-types).
FT                                /FTId=VAR_000057.
FT   VARIANT     291    291       E -> K (in ALD).
FT                                /FTId=VAR_000058.
FT   VARIANT     291    291       Missing (in ALD; ALD-type).
FT                                /FTId=VAR_000059.
FT   VARIANT     294    294       A -> T (in ALD; AMN-type).
FT                                /FTId=VAR_000060.
FT   VARIANT     296    296       Y -> C (in ALD).
FT                                /FTId=VAR_009370.
FT   VARIANT     298    298       G -> D (in ALD).
FT                                /FTId=VAR_009371.
FT   VARIANT     300    300       E -> EVGQ (in ALD).
FT                                /FTId=VAR_013348.
FT   VARIANT     302    302       E -> K (in ALD).
FT                                /FTId=VAR_009372.
FT   VARIANT     322    322       L -> P (in ALD).
FT                                /FTId=VAR_009373.
FT   VARIANT     336    336       K -> M (in ALD).
FT                                /FTId=VAR_009374.
FT   VARIANT     339    339       W -> R (in ALD).
FT                                /FTId=VAR_013349.
FT   VARIANT     342    342       S -> P (in ALD; AMN-type).
FT                                /FTId=VAR_000061.
FT   VARIANT     343    343       G -> D (in ALD).
FT                                /FTId=VAR_013350.
FT   VARIANT     343    343       G -> S (in ALD).
FT                                /FTId=VAR_023005.
FT   VARIANT     389    389       R -> G (in ALD; AMN-type).
FT                                /FTId=VAR_000062.
FT   VARIANT     389    389       R -> H (in ALD; does not affect protein
FT                                stability, homo- and heterodimerization
FT                                with ALDR and PMP70).
FT                                /FTId=VAR_000063.
FT   VARIANT     401    401       R -> Q (in ALD; ALD and AMN-types; does
FT                                not affect protein stability, homo- and
FT                                heterodimerization with ALDR and PMP70).
FT                                /FTId=VAR_000064.
FT   VARIANT     401    401       R -> W (in ALD).
FT                                /FTId=VAR_009375.
FT   VARIANT     418    418       R -> W (in ALD; AMN-type).
FT                                /FTId=VAR_000065.
FT   VARIANT     427    427       Missing (in ALD).
FT                                /FTId=VAR_013351.
FT   VARIANT     484    484       P -> R (in ALD; CALD, AMN and ADO-types;
FT                                significantly decreases homodimerization
FT                                and abolishes heterodimerization with
FT                                ALDR and PMP70).
FT                                /FTId=VAR_000066.
FT   VARIANT     503    503       L -> P (in ALD).
FT                                /FTId=VAR_023006.
FT   VARIANT     507    507       G -> V (in ALD; CALD-types).
FT                                /FTId=VAR_000067.
FT   VARIANT     512    512       G -> S (in ALD; CALD and AS-types;
FT                                reduced ATPase activity).
FT                                /FTId=VAR_000068.
FT   VARIANT     514    514       S -> R (in ALD).
FT                                /FTId=VAR_023007.
FT   VARIANT     515    515       S -> F (in ALD).
FT                                /FTId=VAR_000069.
FT   VARIANT     516    516       L -> P (in ALD).
FT                                /FTId=VAR_067328.
FT   VARIANT     518    518       R -> Q (in ALD; CALD-type).
FT                                /FTId=VAR_000070.
FT   VARIANT     518    518       R -> W (in ALD; CALD-type).
FT                                /FTId=VAR_000071.
FT   VARIANT     522    522       G -> W (in ALD; AD-type).
FT                                /FTId=VAR_000072.
FT   VARIANT     523    523       L -> F (in ALD).
FT                                /FTId=VAR_067242.
FT   VARIANT     528    528       Missing (in ALD; CALD-type).
FT                                /FTId=VAR_000073.
FT   VARIANT     529    529       G -> S (in ALD).
FT                                /FTId=VAR_009376.
FT   VARIANT     534    534       P -> L (in ALD; CALD-type).
FT                                /FTId=VAR_000074.
FT   VARIANT     540    540       F -> C (in ALD).
FT                                /FTId=VAR_067243.
FT   VARIANT     540    540       F -> S (in ALD).
FT                                /FTId=VAR_009377.
FT   VARIANT     543    543       P -> L (in ALD).
FT                                /FTId=VAR_009378.
FT   VARIANT     544    544       Q -> R (in ALD).
FT                                /FTId=VAR_009379.
FT   VARIANT     552    552       S -> P (in ALD).
FT                                /FTId=VAR_009380.
FT   VARIANT     554    554       R -> H (in ALD).
FT                                /FTId=VAR_009381.
FT   VARIANT     556    556       Q -> R (in ALD; ACALD type).
FT                                /FTId=VAR_013352.
FT   VARIANT     560    560       P -> L (in ALD; CALD-type).
FT                                /FTId=VAR_000075.
FT   VARIANT     560    560       P -> R (in ALD; AMN and ALMD-types).
FT                                /FTId=VAR_000076.
FT   VARIANT     560    560       P -> S (in ALD).
FT                                /FTId=VAR_013353.
FT   VARIANT     566    566       M -> K (in ALD).
FT                                /FTId=VAR_000077.
FT   VARIANT     591    591       R -> P (in ALD).
FT                                /FTId=VAR_013354.
FT   VARIANT     591    591       R -> Q (in ALD; AMN-type; significantly
FT                                decreases homodimerization and abolishes
FT                                heterodimerization with ALDR and PMP70).
FT                                /FTId=VAR_000078.
FT   VARIANT     591    591       R -> W (in ALD).
FT                                /FTId=VAR_009382.
FT   VARIANT     606    606       S -> L (in ALD; decreased ATP-binding
FT                                affinity).
FT                                /FTId=VAR_000079.
FT   VARIANT     606    606       S -> P (in ALD; CALD, AMN and ALMD-
FT                                types).
FT                                /FTId=VAR_000080.
FT   VARIANT     608    608       G -> D (in ALD; CALD-type).
FT                                /FTId=VAR_013355.
FT   VARIANT     609    609       E -> G (in ALD).
FT                                /FTId=VAR_000081.
FT   VARIANT     609    609       E -> K (in ALD; AMN-type).
FT                                /FTId=VAR_000082.
FT   VARIANT     616    616       A -> V (in ALD).
FT                                /FTId=VAR_009383.
FT   VARIANT     617    617       R -> C (in ALD; ALD-type and
FT                                asymptomatic).
FT                                /FTId=VAR_000083.
FT   VARIANT     617    617       R -> G (in ALD; ADO and AMN-types with
FT                                cerebral involvement).
FT                                /FTId=VAR_000084.
FT   VARIANT     617    617       R -> H (in ALD).
FT                                /FTId=VAR_000085.
FT   VARIANT     626    626       A -> D (in ALD).
FT                                /FTId=VAR_013356.
FT   VARIANT     626    626       A -> T (in ALD; CALD and AMN-types).
FT                                /FTId=VAR_000086.
FT   VARIANT     629    629       D -> H (in ALD).
FT                                /FTId=VAR_000087.
FT   VARIANT     630    630       E -> G (in ALD).
FT                                /FTId=VAR_009384.
FT   VARIANT     631    631       C -> Y (in ALD).
FT                                /FTId=VAR_009385.
FT   VARIANT     632    632       T -> I (in ALD).
FT                                /FTId=VAR_013357.
FT   VARIANT     632    632       T -> P (in ALD).
FT                                /FTId=VAR_067244.
FT   VARIANT     633    633       S -> I (in ALD; asymptomatic).
FT                                /FTId=VAR_013358.
FT   VARIANT     633    633       S -> R (in ALD).
FT                                /FTId=VAR_009386.
FT   VARIANT     635    635       V -> M (in ALD).
FT                                /FTId=VAR_013359.
FT   VARIANT     636    636       S -> I (in ALD).
FT                                /FTId=VAR_009387.
FT   VARIANT     638    638       D -> Y (in ALD).
FT                                /FTId=VAR_009388.
FT   VARIANT     640    640       E -> K (in ALD).
FT                                /FTId=VAR_067245.
FT   VARIANT     646    646       A -> P (in ALD).
FT                                /FTId=VAR_009389.
FT   VARIANT     654    654       L -> P (in ALD).
FT                                /FTId=VAR_009390.
FT   VARIANT     657    657       Missing (in ALD; CALD-type).
FT                                /FTId=VAR_000088.
FT   VARIANT     660    660       R -> P (in ALD; CALD-type).
FT                                /FTId=VAR_013360.
FT   VARIANT     660    660       R -> Q (in ALD).
FT                                /FTId=VAR_067329.
FT   VARIANT     660    660       R -> W (in ALD; CALD, ALMD and AS-types).
FT                                /FTId=VAR_000089.
FT   VARIANT     667    667       H -> D (in ALD).
FT                                /FTId=VAR_009391.
FT   VARIANT     668    668       T -> I (in ALD).
FT                                /FTId=VAR_009392.
FT   VARIANT     677    677       G -> D (in ALD).
FT                                /FTId=VAR_067246.
FT   VARIANT     679    679       W -> R (in ALD; AMN-type).
FT                                /FTId=VAR_000090.
FT   VARIANT     693    693       T -> M (in ALD).
FT                                /FTId=VAR_009393.
FT   CONFLICT    123    123       V -> A (in Ref. 1; CAA79922/CAA83230).
SQ   SEQUENCE   745 AA;  82937 MW;  82F90905F71FFDC8 CRC64;
     MPVLSRPRPW RGNTLKRTAV LLALAAYGAH KVYPLVRQCL APARGLQAPA GEPTQEASGV
     AAAKAGMNRV FLQRLLWLLR LLFPRVLCRE TGLLALHSAA LVSRTFLSVY VARLDGRLAR
     CIVRKDPRAF GWQLLQWLLI ALPATFVNSA IRYLEGQLAL SFRSRLVAHA YRLYFSQQTY
     YRVSNMDGRL RNPDQSLTED VVAFAASVAH LYSNLTKPLL DVAVTSYTLL RAARSRGAGT
     AWPSAIAGLV VFLTANVLRA FSPKFGELVA EEARRKGELR YMHSRVVANS EEIAFYGGHE
     VELALLQRSY QDLASQINLI LLERLWYVML EQFLMKYVWS ASGLLMVAVP IITATGYSES
     DAEAVKKAAL EKKEEELVSE RTEAFTIARN LLTAAADAIE RIMSSYKEVT ELAGYTARVH
     EMFQVFEDVQ RCHFKRPREL EDAQAGSGTI GRSGVRVEGP LKIRGQVVDV EQGIICENIP
     IVTPSGEVVV ASLNIRVEEG MHLLITGPNG CGKSSLFRIL GGLWPTYGGV LYKPPPQRMF
     YIPQRPYMSV GSLRDQVIYP DSVEDMQRKG YSEQDLEAIL DVVHLHHILQ REGGWEAMCD
     WKDVLSGGEK QRIGMARMFY HRPKYALLDE CTSAVSIDVE GKIFQAAKDA GIALLSITHR
     PSLWKYHTHL LQFDGEGGWK FEKLDSAARL SLTEEKQRLE QQLAGIPKMQ RRLQELCQIL
     GEAVAPAHVP APSPQGPGGL QGAST
//
ID   ABCF1_HUMAN             Reviewed;         845 AA.
AC   Q8NE71; A2BF75; O14897; Q69YP6;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   07-DEC-2004, sequence version 2.
DT   09-JUL-2014, entry version 119.
DE   RecName: Full=ATP-binding cassette sub-family F member 1;
DE   AltName: Full=ATP-binding cassette 50;
DE   AltName: Full=TNF-alpha-stimulated ABC protein;
GN   Name=ABCF1; Synonyms=ABC50;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=9790762; DOI=10.1006/geno.1998.5480;
RA   Richard M., Drouin R., Beaulieu A.D.;
RT   "ABC50, a novel human ATP-binding cassette protein found in tumor
RT   necrosis factor-alpha-stimulated synoviocytes.";
RL   Genomics 53:137-145(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Shiina S., Tamiya G., Oka A., Inoko H.;
RT   "Homo sapiens 2,229,817bp genomic DNA of 6p21.3 HLA class I region.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Shiina T., Ota M., Katsuyama Y., Hashimoto N., Inoko H.;
RT   "Genome diversity in HLA: a new strategy for detection of genetic
RT   polymorphisms in expressed genes within the HLA class III and class I
RT   regions.";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Embryonic stem cell, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 160-845 (ISOFORM 1).
RC   TISSUE=Melanoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-105; THR-108; SER-109;
RP   SER-140 AND SER-228, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-228, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [9]
RP   UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-573 AND LYS-582.
RC   TISSUE=Mammary cancer;
RX   PubMed=17370265; DOI=10.1002/pmic.200600410;
RA   Denis N.J., Vasilescu J., Lambert J.-P., Smith J.C., Figeys D.;
RT   "Tryptic digestion of ubiquitin standards reveals an improved strategy
RT   for identifying ubiquitinated proteins by mass spectrometry.";
RL   Proteomics 7:868-874(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-595, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [11]
RP   INTERACTION WITH EIF2S1, ASSOCIATION WITH RIBOSOMES, PHOSPHORYLATION
RP   AT SER-109 AND SER-140, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   MUTAGENESIS OF SER-109 AND SER-140.
RX   PubMed=17894550; DOI=10.1042/BJ20070811;
RA   Paytubi S., Morrice N.A., Boudeau J., Proud C.G.;
RT   "The N-terminal region of ABC50 interacts with eukaryotic initiation
RT   factor eIF2 and is a target for regulatory phosphorylation by CK2.";
RL   Biochem. J. 409:223-231(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24 AND SER-228, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-228, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   FUNCTION, ATP-BINDING, ASSOCIATION WITH RIBOSOMES, MUTAGENESIS OF
RP   LYS-342; GLN-367; GLY-454; GLU-477; HIS-506; LYS-664; GLN-695;
RP   GLY-745; GLU-768 AND HIS-797, AND SUBCELLULAR LOCATION.
RX   PubMed=19570978; DOI=10.1074/jbc.M109.031625;
RA   Paytubi S., Wang X., Lam Y.W., Izquierdo L., Hunter M.J., Jan E.,
RA   Hundal H.S., Proud C.G.;
RT   "ABC50 promotes translation initiation in mammalian cells.";
RL   J. Biol. Chem. 284:24061-24073(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-108; SER-109; SER-140
RP   AND SER-228, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22; SER-105; THR-108;
RP   SER-109; SER-140 AND SER-228, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-108; SER-109; SER-140;
RP   SER-166 AND SER-228, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
CC   -!- FUNCTION: Isoform 2 is required for efficient Cap- and IRES-
CC       mediated mRNA translation initiation. Isoform 2 is not involved in
CC       the ribosome biogenesis.
CC   -!- SUBUNIT: Isoform 2 interacts (via N-terminus) with EIF2S1; the
CC       interaction is independent of its phosphorylated status. Isoform 2
CC       associates (via both ABC transporter domains) with the ribosomes.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Nucleus, nucleoplasm.
CC       Nucleus envelope.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8NE71-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NE71-2; Sequence=VSP_012078;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- INDUCTION: By TNF in cultured synoviocytes.
CC   -!- PTM: Isoform 2 is phosphorylated at phosphoserine and
CC       phosphothreonine. Isoform 2 phosphorylation on Ser-109 and Ser-140
CC       by CK2; inhibits association of EIF2 with ribosomes.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCF
CC       family. EF3 subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=Q8NE71";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF027302; AAC70891.1; -; mRNA.
DR   EMBL; BA000025; BAB63325.1; -; Genomic_DNA.
DR   EMBL; AB088096; BAC54928.1; -; Genomic_DNA.
DR   EMBL; AL662800; CAI18158.1; -; Genomic_DNA.
DR   EMBL; AL662800; CAI18159.1; -; Genomic_DNA.
DR   EMBL; AL662825; CAI17836.1; -; Genomic_DNA.
DR   EMBL; AL662825; CAI17837.1; -; Genomic_DNA.
DR   EMBL; BX000357; CAI18562.1; -; Genomic_DNA.
DR   EMBL; BX000357; CAI18563.1; -; Genomic_DNA.
DR   EMBL; BX119957; CAM25907.1; -; Genomic_DNA.
DR   EMBL; BX248518; CAM25907.1; JOINED; Genomic_DNA.
DR   EMBL; BX248518; CAM26017.1; -; Genomic_DNA.
DR   EMBL; BX119957; CAM26017.1; JOINED; Genomic_DNA.
DR   EMBL; CR753328; CAQ07804.1; -; Genomic_DNA.
DR   EMBL; CR388372; CAQ07804.1; JOINED; Genomic_DNA.
DR   EMBL; CR388372; CAQ07873.1; -; Genomic_DNA.
DR   EMBL; CR753328; CAQ07873.1; JOINED; Genomic_DNA.
DR   EMBL; BX927220; CAQ09058.1; -; Genomic_DNA.
DR   EMBL; CR759778; CAQ09401.1; -; Genomic_DNA.
DR   EMBL; CR847863; CAQ09401.1; JOINED; Genomic_DNA.
DR   EMBL; CR847863; CAQ10059.1; -; Genomic_DNA.
DR   EMBL; CR759778; CAQ10059.1; JOINED; Genomic_DNA.
DR   EMBL; BC034488; AAH34488.1; -; mRNA.
DR   EMBL; BC112923; AAI12924.1; -; mRNA.
DR   EMBL; AL832430; CAH10648.1; -; mRNA.
DR   CCDS; CCDS34380.1; -. [Q8NE71-1]
DR   CCDS; CCDS34381.1; -. [Q8NE71-2]
DR   RefSeq; NP_001020262.1; NM_001025091.1. [Q8NE71-1]
DR   RefSeq; NP_001081.1; NM_001090.2. [Q8NE71-2]
DR   UniGene; Hs.655285; -.
DR   ProteinModelPortal; Q8NE71; -.
DR   SMR; Q8NE71; 301-834.
DR   BioGrid; 106541; 48.
DR   IntAct; Q8NE71; 6.
DR   MINT; MINT-1392646; -.
DR   STRING; 9606.ENSP00000412553; -.
DR   PhosphoSite; Q8NE71; -.
DR   DMDM; 56417894; -.
DR   MaxQB; Q8NE71; -.
DR   PaxDb; Q8NE71; -.
DR   PRIDE; Q8NE71; -.
DR   DNASU; 23; -.
DR   Ensembl; ENST00000326195; ENSP00000313603; ENSG00000204574. [Q8NE71-1]
DR   Ensembl; ENST00000376545; ENSP00000365728; ENSG00000204574. [Q8NE71-2]
DR   Ensembl; ENST00000383587; ENSP00000373081; ENSG00000206490. [Q8NE71-2]
DR   Ensembl; ENST00000383588; ENSP00000373082; ENSG00000206490. [Q8NE71-1]
DR   Ensembl; ENST00000412443; ENSP00000404726; ENSG00000236342. [Q8NE71-2]
DR   Ensembl; ENST00000419893; ENSP00000389065; ENSG00000232169. [Q8NE71-1]
DR   Ensembl; ENST00000420257; ENSP00000391102; ENSG00000225989. [Q8NE71-2]
DR   Ensembl; ENST00000421042; ENSP00000393143; ENSG00000231129. [Q8NE71-2]
DR   Ensembl; ENST00000423247; ENSP00000411327; ENSG00000225989. [Q8NE71-1]
DR   Ensembl; ENST00000426219; ENSP00000414373; ENSG00000231129. [Q8NE71-1]
DR   Ensembl; ENST00000448939; ENSP00000403526; ENSG00000232169. [Q8NE71-2]
DR   Ensembl; ENST00000452530; ENSP00000389472; ENSG00000236149. [Q8NE71-2]
DR   Ensembl; ENST00000457078; ENSP00000412553; ENSG00000236342. [Q8NE71-1]
DR   Ensembl; ENST00000457111; ENSP00000413319; ENSG00000236149. [Q8NE71-1]
DR   GeneID; 23; -.
DR   KEGG; hsa:23; -.
DR   UCSC; uc003nqk.2; human. [Q8NE71-1]
DR   CTD; 23; -.
DR   GeneCards; GC06P030539; -.
DR   GeneCards; GC06Pj30529; -.
DR   GeneCards; GC06Pk30529; -.
DR   GeneCards; GC06Pl30583; -.
DR   GeneCards; GC06Pm30617; -.
DR   GeneCards; GC06Pn30528; -.
DR   GeneCards; GC06Po30530; -.
DR   HGNC; HGNC:70; ABCF1.
DR   HPA; HPA017578; -.
DR   MIM; 603429; gene.
DR   neXtProt; NX_Q8NE71; -.
DR   PharmGKB; PA24405; -.
DR   eggNOG; COG0488; -.
DR   HOGENOM; HOG000271637; -.
DR   HOVERGEN; HBG050440; -.
DR   InParanoid; Q8NE71; -.
DR   KO; K06184; -.
DR   OMA; FNELVIP; -.
DR   PhylomeDB; Q8NE71; -.
DR   TreeFam; TF105207; -.
DR   ChiTaRS; ABCF1; human.
DR   GeneWiki; ABCF1; -.
DR   GenomeRNAi; 23; -.
DR   NextBio; 69; -.
DR   PRO; PR:Q8NE71; -.
DR   ArrayExpress; Q8NE71; -.
DR   Bgee; Q8NE71; -.
DR   CleanEx; HS_ABCF1; -.
DR   Genevestigator; Q8NE71; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0042788; C:polysomal ribosome; IDA:UniProtKB.
DR   GO; GO:0005840; C:ribosome; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0016887; F:ATPase activity; IEA:InterPro.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0043022; F:ribosome binding; IDA:UniProtKB.
DR   GO; GO:0008494; F:translation activator activity; IDA:UniProtKB.
DR   GO; GO:0008135; F:translation factor activity, nucleic acid binding; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB.
DR   GO; GO:0006412; P:translation; TAS:ProtInc.
DR   GO; GO:0006413; P:translational initiation; IMP:UniProtKB.
DR   Gene3D; 3.40.50.300; -; 2.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 3.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Isopeptide bond; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Ubl conjugation.
FT   CHAIN         1    845       ATP-binding cassette sub-family F member
FT                                1.
FT                                /FTId=PRO_0000093318.
FT   DOMAIN      304    548       ABC transporter 1.
FT   DOMAIN      625    840       ABC transporter 2.
FT   NP_BIND     336    343       ATP 1 (By similarity).
FT   NP_BIND     658    665       ATP 2 (By similarity).
FT   COMPBIAS    141    243       Glu-rich.
FT   MOD_RES      22     22       Phosphoserine.
FT   MOD_RES      24     24       Phosphoserine.
FT   MOD_RES     105    105       Phosphoserine.
FT   MOD_RES     108    108       Phosphothreonine.
FT   MOD_RES     109    109       Phosphoserine; by CK2.
FT   MOD_RES     140    140       Phosphoserine; by CK2.
FT   MOD_RES     166    166       Phosphoserine.
FT   MOD_RES     228    228       Phosphoserine.
FT   MOD_RES     595    595       Phosphoserine.
FT   CROSSLNK    573    573       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    582    582       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   VAR_SEQ     226    263       Missing (in isoform 2).
FT                                /FTId=VSP_012078.
FT   VARIANT     198    198       N -> D (in dbSNP:rs6902544).
FT                                /FTId=VAR_048136.
FT   MUTAGEN     109    109       S->A: Reduces phosphorylation. Inhibits
FT                                strongly phosphorylation by CK2; when
FT                                associated with S-140. Does not inhibit
FT                                interaction with EIF2; when associated
FT                                with S-140. Does not inhibit association
FT                                with ribosomes; when associated with S-
FT                                140. Reduces EIF2 interaction with
FT                                ribosomes; when associated with S-140.
FT                                Does not inhibit protein synthesis; when
FT                                associated with A-140.
FT   MUTAGEN     140    140       S->A: Reduces phosphorylation. Inhibits
FT                                strongly phosphorylation by CK2; when
FT                                associated with S-109. Does not inhibits
FT                                interaction with EIF2; when associated
FT                                with S-109. Does not inhibit association
FT                                with ribosomes; when associated with S-
FT                                109. Reduces EIF2 interaction with
FT                                ribosomes; when associated with S-109.
FT                                Does not inhibit protein synthesis; when
FT                                associated with A-109.
FT   MUTAGEN     342    342       K->M: Does not inhibit ribosome binding.
FT                                Reduces ATP-binding. Inhibits ATP-binding
FT                                and reduces protein synthesis; when
FT                                associated with M-664. Shows an enhanced
FT                                association with polyribosomes; when
FT                                associated with M-664. Does not inhibit
FT                                IRES-mediated protein synthesis; when
FT                                associated with M-664.
FT   MUTAGEN     367    367       Q->E: Does not inhibit ribosome binding.
FT   MUTAGEN     454    454       G->D: Does not inhibit ribosome binding.
FT   MUTAGEN     477    477       E->Q: Does not inhibit ribosome binding.
FT                                Reduces protein synthesis; when
FT                                associated with Q-768.
FT   MUTAGEN     506    506       H->L: Does not inhibit ribosome binding.
FT   MUTAGEN     664    664       K->M: Does not inhibit ribosome binding.
FT                                Reduces ATP-binding. Inhibits ATP-binding
FT                                and reduces protein synthesis; when
FT                                associated with M-342. Shows a reduced
FT                                association with polyribosomes; when
FT                                associated with M-664. Does not inhibit
FT                                IRES-mediated protein synthesis; when
FT                                associated with M-664.
FT   MUTAGEN     695    695       Q->E: Does not inhibit ribosome binding.
FT   MUTAGEN     745    745       G->D: Does not inhibit ribosome binding.
FT   MUTAGEN     768    768       E->Q: Does not inhibit ribosome binding.
FT                                Reduces protein synthesis; when
FT                                associated with Q-477.
FT   MUTAGEN     797    797       H->L: Does not inhibit ribosome binding.
FT   CONFLICT    166    166       S -> P (in Ref. 5; AAH34488).
SQ   SEQUENCE   845 AA;  95926 MW;  5C5AA662DF4C99E4 CRC64;
     MPKAPKQQPP EPEWIGDGES TSPSDKVVKK GKKDKKIKKT FFEELAVEDK QAGEEEKVLK
     EKEQQQQQQQ QQQKKKRDTR KGRRKKDVDD DGEEKELMER LKKLSVPTSD EEDEVPAPKP
     RGGKKTKGGN VFAALIQDQS EEEEEEEKHP PKPAKPEKNR INKAVSEEQQ PALKGKKGKE
     EKSKGKAKPQ NKFAALDNEE EDKEEEIIKE KEPPKQGKEK AKKAEQGSEE EGEGEEEEEE
     GGESKADDPY AHLSKKEKKK LKKQMEYERQ VASLKAANAA ENDFSVSQAE MSSRQAMLEN
     ASDIKLEKFS ISAHGKELFV NADLYIVAGR RYGLVGPNGK GKTTLLKHIA NRALSIPPNI
     DVLLCEQEVV ADETPAVQAV LRADTKRLKL LEEERRLQGQ LEQGDDTAAE RLEKVYEELR
     ATGAAAAEAK ARRILAGLGF DPEMQNRPTQ KFSGGWRMRV SLARALFMEP TLLMLDEPTN
     HLDLNAVIWL NNYLQGWRKT LLIVSHDQGF LDDVCTDIIH LDAQRLHYYR GNYMTFKKMY
     QQKQKELLKQ YEKQEKKLKE LKAGGKSTKQ AEKQTKEALT RKQQKCRRKN QDEESQEAPE
     LLKRPKEYTV RFTFPDPPPL SPPVLGLHGV TFGYQGQKPL FKNLDFGIDM DSRICIVGPN
     GVGKSTLLLL LTGKLTPTHG EMRKNHRLKI GFFNQQYAEQ LRMEETPTEY LQRGFNLPYQ
     DARKCLGRFG LESHAHTIQI CKLSGGQKAR VVFAELACRE PDVLILDEPT NNLDIESIDA
     LGEAINEYKG AVIVVSHDAR LITETNCQLW VVEEQSVSQI DGDFEDYKRE VLEALGEVMV
     SRPRE
//
ID   ABCD3_HUMAN             Reviewed;         659 AA.
AC   P28288; D3DT46; Q15271; Q6NUN5; Q96DA3; Q9H529;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   09-JUL-2014, entry version 151.
DE   RecName: Full=ATP-binding cassette sub-family D member 3;
DE   AltName: Full=70 kDa peroxisomal membrane protein;
DE            Short=PMP70;
GN   Name=ABCD3; Synonyms=PMP70, PXMP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-17.
RC   TISSUE=Liver;
RX   PubMed=1301993; DOI=10.1038/ng0492-16;
RA   Gaertner J., Moser H., Valle D.;
RT   "Mutations in the 70K peroxisomal membrane protein gene in Zellweger
RT   syndrome.";
RL   Nat. Genet. 1:16-23(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=1536884; DOI=10.1016/0167-4781(92)90510-7;
RA   Kamijo K., Kamijo T., Ueno I., Osumi T., Hashimoto T.;
RT   "Nucleotide sequence of the human 70 kDa peroxisomal membrane protein:
RT   a member of ATP-binding cassette transporters.";
RL   Biochim. Biophys. Acta 1129:323-327(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9521874; DOI=10.1006/geno.1997.5177;
RA   Gaertner J., Jimenez-Sanchez G., Roerig P., Valle D.;
RT   "Genomic organization of the 70-kDa peroxisomal membrane protein gene
RT   (PXMP1).";
RL   Genomics 48:203-208(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   SUBUNIT.
RX   PubMed=10551832; DOI=10.1074/jbc.274.46.32738;
RA   Liu L.X., Janvier K., Berteaux-Lecellier V., Cartier N., Benarous R.,
RA   Aubourg P.;
RT   "Homo- and heterodimerization of peroxisomal ATP-binding cassette
RT   half-transporters.";
RL   J. Biol. Chem. 274:32738-32743(1999).
RN   [9]
RP   INTERACTION WITH PEX19.
RC   TISSUE=Brain;
RX   PubMed=10777694; DOI=10.1006/bbrc.2000.2572;
RA   Gloeckner C.J., Mayerhofer P.U., Landgraf P., Muntau A.C.,
RA   Holzinger A., Gerber J.-K., Kammerer S., Adamski J., Roscher A.A.;
RT   "Human adrenoleukodystrophy protein and related peroxisomal ABC
RT   transporters interact with the peroxisomal assembly protein PEX19p.";
RL   Biochem. Biophys. Res. Commun. 271:144-150(2000).
RN   [10]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PEX19.
RX   PubMed=10704444; DOI=10.1083/jcb.148.5.931;
RA   Sacksteder K.A., Jones J.M., South S.T., Li X., Liu Y., Gould S.J.;
RT   "PEX19 binds multiple peroxisomal membrane proteins, is predominantly
RT   cytoplasmic, and is required for peroxisome membrane synthesis.";
RL   J. Cell Biol. 148:931-944(2000).
RN   [11]
RP   FUNCTION, AND MUTAGENESIS OF GLY-478 AND SER-572.
RX   PubMed=11248239; DOI=10.1016/S0014-5793(01)02235-9;
RA   Roerig P., Mayerhofer P., Holzinger A., Gaertner J.;
RT   "Characterization and functional analysis of the nucleotide binding
RT   fold in human peroxisomal ATP binding cassette transporters.";
RL   FEBS Lett. 492:66-72(2001).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-260 AND LYS-399, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
CC   -!- FUNCTION: Probable transporter. The nucleotide-binding fold acts
CC       as an ATP-binding subunit with ATPase activity.
CC   -!- SUBUNIT: Can form heterodimers with ABCD1/ALD and ABCD2/ALDR.
CC       Dimerization is necessary to form an active transporter. Interacts
CC       with PEX19.
CC   -!- INTERACTION:
CC       P33897:ABCD1; NbExp=2; IntAct=EBI-80992, EBI-81045;
CC       P40855:PEX19; NbExp=4; IntAct=EBI-80992, EBI-594747;
CC   -!- SUBCELLULAR LOCATION: Peroxisome membrane; Multi-pass membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P28288-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P28288-2; Sequence=VSP_031189;
CC         Note=No experimental confirmation available;
CC       Name=3;
CC         IsoId=P28288-3; Sequence=VSP_031187, VSP_031188;
CC   -!- MISCELLANEOUS: Mutation in ABCD3 have been found in two
CC       individuals affected by Zellweger syndrome. However, the role of
CC       ABCD3 in the causation of Zellweger syndrome remains uncertain.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCD
CC       family. Peroxisomal fatty acyl CoA transporter (TC 3.A.1.203)
CC       subfamily.
CC   -!- SIMILARITY: Contains 1 ABC transmembrane type-1 domain.
CC   -!- SIMILARITY: Contains 1 ABC transporter domain.
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=P28288";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M81182; AAA60128.1; -; mRNA.
DR   EMBL; X58528; CAA41416.1; -; mRNA.
DR   EMBL; X83467; CAA58470.1; -; Genomic_DNA.
DR   EMBL; X83468; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83469; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83470; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83471; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83472; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83473; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83474; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83475; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83476; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83477; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83478; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83479; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83480; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83481; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83482; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83483; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83484; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83485; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83486; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83487; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83488; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; X83489; CAA58470.1; JOINED; Genomic_DNA.
DR   EMBL; BT006644; AAP35290.1; -; mRNA.
DR   EMBL; AL138758; CAC15960.2; -; Genomic_DNA.
DR   EMBL; AC093117; CAC15960.2; JOINED; Genomic_DNA.
DR   EMBL; AC118469; CAC15960.2; JOINED; Genomic_DNA.
DR   EMBL; CH471097; EAW73049.1; -; Genomic_DNA.
DR   EMBL; CH471097; EAW73050.1; -; Genomic_DNA.
DR   EMBL; CH471097; EAW73047.1; -; Genomic_DNA.
DR   EMBL; CH471097; EAW73048.1; -; Genomic_DNA.
DR   EMBL; BC009712; AAH09712.1; -; mRNA.
DR   EMBL; BC068509; AAH68509.1; -; mRNA.
DR   CCDS; CCDS44175.1; -. [P28288-3]
DR   CCDS; CCDS749.1; -. [P28288-1]
DR   PIR; S20313; S20313.
DR   RefSeq; NP_001116146.1; NM_001122674.1. [P28288-3]
DR   RefSeq; NP_002849.1; NM_002858.3. [P28288-1]
DR   UniGene; Hs.700576; -.
DR   ProteinModelPortal; P28288; -.
DR   SMR; P28288; 427-640.
DR   BioGrid; 111783; 41.
DR   IntAct; P28288; 12.
DR   MINT; MINT-3010926; -.
DR   STRING; 9606.ENSP00000359233; -.
DR   TCDB; 3.A.1.203.1; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; P28288; -.
DR   DMDM; 130358; -.
DR   MaxQB; P28288; -.
DR   PaxDb; P28288; -.
DR   PeptideAtlas; P28288; -.
DR   PRIDE; P28288; -.
DR   DNASU; 5825; -.
DR   Ensembl; ENST00000315713; ENSP00000326880; ENSG00000117528. [P28288-3]
DR   Ensembl; ENST00000370214; ENSP00000359233; ENSG00000117528. [P28288-1]
DR   Ensembl; ENST00000394233; ENSP00000377780; ENSG00000117528. [P28288-2]
DR   GeneID; 5825; -.
DR   KEGG; hsa:5825; -.
DR   UCSC; uc001dqm.4; human. [P28288-3]
DR   UCSC; uc001dqn.4; human. [P28288-1]
DR   UCSC; uc009wdr.3; human. [P28288-2]
DR   CTD; 5825; -.
DR   GeneCards; GC01P094883; -.
DR   HGNC; HGNC:67; ABCD3.
DR   HPA; HPA032026; -.
DR   HPA; HPA032027; -.
DR   MIM; 170995; gene.
DR   neXtProt; NX_P28288; -.
DR   PharmGKB; PA24402; -.
DR   eggNOG; COG4178; -.
DR   HOGENOM; HOG000206081; -.
DR   HOVERGEN; HBG050438; -.
DR   InParanoid; P28288; -.
DR   KO; K05677; -.
DR   OrthoDB; EOG70ZZMP; -.
DR   PhylomeDB; P28288; -.
DR   TreeFam; TF105205; -.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   ChiTaRS; ABCD3; human.
DR   GeneWiki; ABCD3; -.
DR   GenomeRNAi; 5825; -.
DR   NextBio; 22689; -.
DR   PRO; PR:P28288; -.
DR   ArrayExpress; P28288; -.
DR   Bgee; P28288; -.
DR   CleanEx; HS_ABCD3; -.
DR   Genevestigator; P28288; -.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:Ensembl.
DR   GO; GO:0005782; C:peroxisomal matrix; IDA:UniProtKB.
DR   GO; GO:0005778; C:peroxisomal membrane; IDA:UniProtKB.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0016887; F:ATPase activity; IDA:UniProtKB.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; IEA:InterPro.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0006200; P:ATP catabolic process; IDA:GOC.
DR   GO; GO:0006635; P:fatty acid beta-oxidation; IGI:UniProtKB.
DR   GO; GO:0007031; P:peroxisome organization; IDA:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0042760; P:very long-chain fatty acid catabolic process; IGI:UniProtKB.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR010509; ABC_Peroxi_TM.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR005283; FA_transporter.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF06472; ABC_membrane_2; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF90123; SSF90123; 1.
DR   TIGRFAMs; TIGR00954; 3a01203; 1.
DR   PROSITE; PS50929; ABC_TM1F; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Complete proteome;
KW   Glycoprotein; Membrane; Nucleotide-binding; Peroxisome;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2    659       ATP-binding cassette sub-family D member
FT                                3.
FT                                /FTId=PRO_0000093309.
FT   TRANSMEM     84    104       Helical; (Potential).
FT   TRANSMEM    126    146       Helical; (Potential).
FT   TRANSMEM    224    244       Helical; (Potential).
FT   TRANSMEM    313    333       Helical; (Potential).
FT   DOMAIN       85    372       ABC transmembrane type-1.
FT   DOMAIN      440    659       ABC transporter.
FT   NP_BIND     473    480       ATP (Potential).
FT   REGION        2    199       Interaction with PEX19.
FT   REGION        2    124       Targeting to peroxisomes.
FT   MOD_RES      61     61       N6-acetyllysine (By similarity).
FT   MOD_RES     260    260       N6-acetyllysine.
FT   MOD_RES     399    399       N6-acetyllysine.
FT   MOD_RES     533    533       N6-acetyllysine (By similarity).
FT   MOD_RES     659    659       Phosphoserine (By similarity).
FT   CARBOHYD     12     12       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    106    106       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    206    206       N-linked (GlcNAc...) (Potential).
FT   VAR_SEQ     229    236       GPASMMAY -> VLGKILWH (in isoform 3).
FT                                /FTId=VSP_031187.
FT   VAR_SEQ     237    659       Missing (in isoform 3).
FT                                /FTId=VSP_031188.
FT   VAR_SEQ     277    386       Missing (in isoform 2).
FT                                /FTId=VSP_031189.
FT   VARIANT      17     17       G -> D (in a patient with Zellweger
FT                                syndrome).
FT                                /FTId=VAR_000091.
FT   MUTAGEN     478    478       G->R: Decreased ATP-binding affinity.
FT   MUTAGEN     572    572       S->I: Decreased ATPase activity.
FT   CONFLICT    175    175       M -> K (in Ref. 2; CAA41416).
FT   CONFLICT    191    192       QD -> LV (in Ref. 3; CAA58470).
FT   CONFLICT    336    336       P -> L (in Ref. 3; CAA58470).
FT   CONFLICT    503    503       G -> R (in Ref. 2; CAA41416).
FT   CONFLICT    542    542       L -> Q (in Ref. 2; CAA41416).
FT   CONFLICT    616    634       VGITLFTVSHRKSLWKHHE -> GWHHSLHLCLIGNLFGNI
FT                                MR (in Ref. 3; CAA58470).
SQ   SEQUENCE   659 AA;  75476 MW;  2CA976FEB6EB6217 CRC64;
     MAAFSKYLTA RNSSLAGAAF LLLCLLHKRR RALGLHGKKS GKPPLQNNEK EGKKERAVVD
     KVFFSRLIQI LKIMVPRTFC KETGYLVLIA VMLVSRTYCD VWMIQNGTLI ESGIIGRSRK
     DFKRYLLNFI AAMPLISLVN NFLKYGLNEL KLCFRVRLTK YLYEEYLQAF TYYKMGNLDN
     RIANPDQLLT QDVEKFCNSV VDLYSNLSKP FLDIVLYIFK LTSAIGAQGP ASMMAYLVVS
     GLFLTRLRRP IGKMTITEQK YEGEYRYVNS RLITNSEEIA FYNGNKREKQ TVHSVFRKLV
     EHLHNFILFR FSMGFIDSII AKYLATVVGY LVVSRPFLDL SHPRHLKSTH SELLEDYYQS
     GRMLLRMSQA LGRIVLAGRE MTRLAGFTAR ITELMQVLKD LNHGKYERTM VSQQEKGIEG
     VQVIPLIPGA GEIIIADNII KFDHVPLATP NGDVLIRDLN FEVRSGANVL ICGPNGCGKS
     SLFRVLGELW PLFGGRLTKP ERGKLFYVPQ RPYMTLGTLR DQVIYPDGRE DQKRKGISDL
     VLKEYLDNVQ LGHILEREGG WDSVQDWMDV LSGGEKQRMA MARLFYHKPQ FAILDECTSA
     VSVDVEGYIY SHCRKVGITL FTVSHRKSLW KHHEYYLHMD GRGNYEFKQI TEDTVEFGS
//
ID   ABCG1_HUMAN             Reviewed;         678 AA.
AC   P45844; Q86SU8; Q96L76; Q9BXK6; Q9BXK7; Q9BXK8; Q9BXK9; Q9BXL0;
AC   Q9BXL1; Q9BXL2; Q9BXL3; Q9BXL4;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   05-DEC-2001, sequence version 3.
DT   09-JUL-2014, entry version 154.
DE   RecName: Full=ATP-binding cassette sub-family G member 1;
DE   AltName: Full=ATP-binding cassette transporter 8;
DE   AltName: Full=White protein homolog;
GN   Name=ABCG1; Synonyms=ABC8, WHT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3-678 (ISOFORMS 1 AND 4).
RC   TISSUE=Retina;
RX   PubMed=8659545;
RA   Chen H.M., Rossier C., Lalioti M.D., Lynn A., Chakravarti A.,
RA   Perrin G., Antonarakis S.E.;
RT   "Cloning of the cDNA for a human homologue of the Drosophila white
RT   gene and mapping to chromosome 21q22.3.";
RL   Am. J. Hum. Genet. 59:66-75(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=10950923; DOI=10.1006/geno.2000.6253;
RA   Berry A., Scott H.S., Kudoh J., Talior I., Korostishevsky M.,
RA   Wattenhofer M., Guipponi M., Barras C., Rossier C., Shibuya K.,
RA   Wang J., Kawasaki K., Asakawa S., Minoshima S., Shimizu N.,
RA   Antonarakis S.E., Bonne-Tamir B.;
RT   "Refined localization of autosomal recessive nonsyndromic deafness
RT   DFNB10 locus using 34 novel microsatellite markers, genomic structure,
RT   and exclusion of six known genes in the region.";
RL   Genomics 68:22-29(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND REPRESSION BY
RP   ZNF202.
RX   PubMed=11279031; DOI=10.1074/jbc.M100218200;
RA   Porsch-Oezcueruemez M., Langmann T., Heimerl S., Borsukova H.,
RA   Kaminski W.E., Drobnik W., Honer C., Schumacher C., Schmitz G.;
RT   "The zinc finger protein 202 (ZNF202) is a transcriptional repressor
RT   of ATP binding cassette transporter A1 (ABCA1) and ABCG1 gene
RT   expression and a modulator of cellular lipid efflux.";
RL   J. Biol. Chem. 276:12427-12433(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 2; 3; 4; 5; 6 AND
RP   7).
RX   PubMed=11162488; DOI=10.1006/bbrc.2000.4089;
RA   Lorkowski S., Rust S., Engel T., Jung E., Tegelkamp K., Galinski E.A.,
RA   Assmann G., Cullen P.;
RT   "Genomic sequence and structure of the human ABCG1 (ABC8) gene.";
RL   Biochem. Biophys. Res. Commun. 280:121-131(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8), AND VARIANT LEU-668.
RX   PubMed=11500512; DOI=10.1074/jbc.M105863200;
RA   Kennedy M.A., Venkateswaran A., Tarr P.T., Xenarios I., Kudoh J.,
RA   Shimizu N., Edwards P.A.;
RT   "Characterization of the human ABCG1 gene: liver X receptor activates
RT   an internal promoter that produces a novel transcript encoding an
RT   alternative form of the protein.";
RL   J. Biol. Chem. 276:39438-39447(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORM 1).
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA   Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
RA   Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
RA   Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA   Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA   Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA   Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA   Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
RA   Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA   Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA   Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA   Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-678.
RC   TISSUE=Fetal brain;
RX   PubMed=9034316; DOI=10.1016/S0378-1119(96)00633-6;
RA   Croop J.M., Tiller G.E., Fletcher J.A., Lux M.L., Raab E.,
RA   Goldenson D., Son D., Arciniegas S., Wu R.;
RT   "Isolation and characterization of a mammalian homolog of the
RT   Drosophila white gene.";
RL   Gene 185:77-85(1997).
RN   [9]
RP   INDUCTION, AND PROBABLE FUNCTION.
RX   PubMed=10799558; DOI=10.1074/jbc.275.19.14700;
RA   Venkateswaran A., Repa J.J., Lobaccaro J.-M.A., Bronson A.,
RA   Mangelsdorf D.J., Edwards P.A.;
RT   "Human white/murine ABC8 mRNA levels are highly induced in lipid-
RT   loaded macrophages. A transcriptional role for specific oxysterols.";
RL   J. Biol. Chem. 275:14700-14707(2000).
RN   [10]
RP   INDUCTION, AND PROBABLE FUNCTION.
RX   PubMed=10639163; DOI=10.1073/pnas.97.2.817;
RA   Klucken J., Buechler C., Orso E., Kaminski W.E.,
RA   Porsch-Oezcueruemez M., Liebisch G., Kapinsky M., Diederich W.,
RA   Drobnik W., Dean M., Allikmets R., Schmitz G.;
RT   "ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a
RT   regulator of macrophage cholesterol and phospholipid transport.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:817-822(2000).
RN   [11]
RP   INDUCTION.
RX   PubMed=12032171;
RA   Kaplan R., Gan X., Menke J.G., Wright S.D., Cai T.-Q.;
RT   "Bacterial lipopolysaccharide induces expression of ABCA1 but not
RT   ABCG1 via an LXR-independent pathway.";
RL   J. Lipid Res. 43:952-959(2002).
RN   [12]
RP   REVIEW.
RX   PubMed=11590207;
RA   Schmitz G., Langmann T., Heimerl S.;
RT   "Role of ABCG1 and other ABCG family members in lipid metabolism.";
RL   J. Lipid Res. 42:1513-1520(2001).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=11350058; DOI=10.1006/bbrc.2001.4863;
RA   Lorkowski S., Kratz M., Wenner C., Schmidt R., Weitkamp B., Fobker M.,
RA   Reinhardt J., Rauterberg J., Galinski E.A., Cullen P.;
RT   "Expression of the ATP-binding cassette transporter gene ABCG1 (ABC8)
RT   in Tangier disease.";
RL   Biochem. Biophys. Res. Commun. 283:821-830(2001).
RN   [14]
RP   SUBCELLULAR LOCATION, AND MISCELLANEOUS.
RX   PubMed=22042635; DOI=10.1074/mcp.M111.013458;
RA   Uhlen M., Oksvold P., Algenas C., Hamsten C., Fagerberg L.,
RA   Klevebring D., Lundberg E., Odeberg J., Ponten F., Kondo T.,
RA   Sivertsson A.;
RT   "Antibody-based protein profiling of the human chromosome 21.";
RL   Mol. Cell. Proteomics 11:0-0(2012).
RN   [15]
RP   PALMITOYLATION AT CYS-30; CYS-154; CYS-315; CYS-394 AND CYS-406, AND
RP   MUTAGENESIS OF CYS-30; CYS-154; CYS-315; CYS-394 AND CYS-406.
RX   PubMed=23388354; DOI=10.1016/j.bbalip.2013.01.019;
RA   Gu H.M., Li G., Gao X., Berthiaume L.G., Zhang D.W.;
RT   "Characterization of palmitoylation of ATP binding cassette
RT   transporter G1: Effect on protein trafficking and function.";
RL   Biochim. Biophys. Acta 1831:1067-1078(2013).
CC   -!- FUNCTION: Transporter involved in macrophage lipid homeostasis. Is
CC       an active component of the macrophage lipid export complex. Could
CC       also be involved in intracellular lipid transport processes. The
CC       role in cellular lipid homeostasis may not be limited to
CC       macrophages.
CC   -!- SUBUNIT: May form heterodimers with several heterologous partners
CC       of the ABCG subfamily.
CC   -!- INTERACTION:
CC       Q9H172:ABCG4; NbExp=2; IntAct=EBI-8584087, EBI-8584118;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion. Endoplasmic reticulum
CC       membrane; Multi-pass membrane protein. Golgi apparatus membrane;
CC       Multi-pass membrane protein. Note=Predominantly localized in the
CC       intracellular compartments mainly associated with the endoplasmic
CC       reticulum (ER) and Golgi membranes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC         Comment=Additional isoforms seem to exist;
CC       Name=1;
CC         IsoId=P45844-1; Sequence=Displayed;
CC       Name=2; Synonyms=J;
CC         IsoId=P45844-2; Sequence=VSP_000047, VSP_000051;
CC       Name=3; Synonyms=ABDE;
CC         IsoId=P45844-3; Sequence=VSP_000048, VSP_000051;
CC       Name=4; Synonyms=G;
CC         IsoId=P45844-4; Sequence=VSP_000051;
CC       Name=5; Synonyms=F;
CC         IsoId=P45844-5; Sequence=VSP_000049, VSP_000051;
CC       Name=6; Synonyms=HI;
CC         IsoId=P45844-6; Sequence=VSP_000046, VSP_000051;
CC       Name=7; Synonyms=C;
CC         IsoId=P45844-7; Sequence=VSP_000050, VSP_000051;
CC       Name=8;
CC         IsoId=P45844-8; Sequence=VSP_010718;
CC   -!- TISSUE SPECIFICITY: Expressed in several tissues. Expressed in
CC       macrophages; expression is increased in macrophages from patients
CC       with Tangier disease.
CC   -!- INDUCTION: Strongly induced in monocyte-derived macrophages during
CC       cholesterol influx. Conversely, mRNA and protein expression are
CC       suppressed by lipid efflux. Induction is mediated by the liver X
CC       receptor/retinoid X receptor (LXR/RXR) pathway. Not induced by
CC       bacterial lipopolysaccharides (LPS). Repressed by ZNF202.
CC   -!- PTM: Palmitoylation at Cys-315 seems important for trafficking
CC       from the endoplasmic reticulum.
CC   -!- MISCELLANEOUS: A protein of the expected size has been detected by
CC       antibody binding and Western blot in at least one of the analyzed
CC       tissues or cells (PubMed:22042635).
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCG
CC       family. Eye pigment precursor importer (TC 3.A.1.204) subfamily.
CC   -!- SIMILARITY: Contains 1 ABC transmembrane type-2 domain.
CC   -!- SIMILARITY: Contains 1 ABC transporter domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC51098.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=AAK28841.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=BAA95530.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=BAB13728.2; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=CAA62631.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=CAC00730.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=P45844";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X91249; CAA62631.1; ALT_INIT; mRNA.
DR   EMBL; AB038161; BAB13728.2; ALT_INIT; Genomic_DNA.
DR   EMBL; AJ289137; CAC00730.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AJ289138; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289139; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289140; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289141; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289142; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289143; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289144; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289145; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289146; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289147; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289148; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289149; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289150; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AJ289151; CAC00730.1; JOINED; Genomic_DNA.
DR   EMBL; AF323658; AAK28836.1; -; Genomic_DNA.
DR   EMBL; AF323644; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323645; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323646; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323647; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323648; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323649; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323650; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323651; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323652; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323653; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323654; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323655; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323656; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323657; AAK28836.1; JOINED; Genomic_DNA.
DR   EMBL; AF323664; AAK28842.1; -; mRNA.
DR   EMBL; AF323658; AAK28833.1; -; Genomic_DNA.
DR   EMBL; AF323640; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323645; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323646; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323647; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323648; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323649; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323650; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323651; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323652; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323653; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323654; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323655; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323656; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323657; AAK28833.1; JOINED; Genomic_DNA.
DR   EMBL; AF323660; AAK28838.1; -; mRNA.
DR   EMBL; AF323663; AAK28841.1; ALT_INIT; mRNA.
DR   EMBL; AF323658; AAK28835.1; -; Genomic_DNA.
DR   EMBL; AF323642; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323645; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323646; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323647; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323648; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323649; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323650; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323651; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323652; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323653; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323654; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323655; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323656; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323657; AAK28835.1; JOINED; Genomic_DNA.
DR   EMBL; AF323662; AAK28840.1; -; mRNA.
DR   EMBL; AF323658; AAK28837.1; -; Genomic_DNA.
DR   EMBL; AF323643; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323645; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323646; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323647; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323648; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323649; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323650; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323651; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323652; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323653; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323654; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323655; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323656; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323657; AAK28837.1; JOINED; Genomic_DNA.
DR   EMBL; AF323658; AAK28834.1; -; Genomic_DNA.
DR   EMBL; AF323645; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323646; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323647; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323648; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323649; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323650; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323651; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323652; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323653; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323654; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323655; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323656; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323657; AAK28834.1; JOINED; Genomic_DNA.
DR   EMBL; AF323661; AAK28839.1; -; mRNA.
DR   EMBL; AY048757; AAL06598.1; -; mRNA.
DR   EMBL; AP001746; BAA95530.1; ALT_INIT; Genomic_DNA.
DR   EMBL; BC029158; AAH29158.2; -; mRNA.
DR   EMBL; U34919; AAC51098.1; ALT_INIT; mRNA.
DR   CCDS; CCDS13681.1; -. [P45844-5]
DR   CCDS; CCDS13682.1; -. [P45844-1]
DR   CCDS; CCDS13683.1; -. [P45844-2]
DR   CCDS; CCDS42937.1; -. [P45844-3]
DR   CCDS; CCDS42938.1; -. [P45844-4]
DR   RefSeq; NP_004906.3; NM_004915.3. [P45844-1]
DR   RefSeq; NP_058198.2; NM_016818.2. [P45844-4]
DR   RefSeq; NP_997057.1; NM_207174.1. [P45844-2]
DR   RefSeq; NP_997510.1; NM_207627.1. [P45844-3]
DR   RefSeq; NP_997511.1; NM_207628.1. [P45844-7]
DR   RefSeq; NP_997512.1; NM_207629.1. [P45844-5]
DR   UniGene; Hs.124649; -.
DR   UniGene; Hs.418279; -.
DR   ProteinModelPortal; P45844; -.
DR   SMR; P45844; 9-323.
DR   BioGrid; 114980; 2.
DR   IntAct; P45844; 2.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   TCDB; 3.A.1.204.12; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; P45844; -.
DR   DMDM; 17433715; -.
DR   MaxQB; P45844; -.
DR   PaxDb; P45844; -.
DR   PRIDE; P45844; -.
DR   DNASU; 9619; -.
DR   Ensembl; ENST00000343687; ENSP00000339744; ENSG00000160179. [P45844-2]
DR   Ensembl; ENST00000347800; ENSP00000291524; ENSG00000160179. [P45844-5]
DR   Ensembl; ENST00000361802; ENSP00000354995; ENSG00000160179. [P45844-1]
DR   Ensembl; ENST00000398449; ENSP00000381467; ENSG00000160179. [P45844-4]
DR   Ensembl; ENST00000398457; ENSP00000381475; ENSG00000160179. [P45844-3]
DR   GeneID; 9619; -.
DR   KEGG; hsa:9619; -.
DR   UCSC; uc002zam.3; human. [P45844-7]
DR   UCSC; uc002zan.3; human. [P45844-3]
DR   UCSC; uc002zao.3; human. [P45844-5]
DR   UCSC; uc002zap.3; human. [P45844-4]
DR   UCSC; uc002zaq.3; human. [P45844-1]
DR   UCSC; uc002zar.3; human. [P45844-2]
DR   CTD; 9619; -.
DR   GeneCards; GC21P043619; -.
DR   HGNC; HGNC:73; ABCG1.
DR   HPA; HPA031470; -.
DR   HPA; HPA031471; -.
DR   MIM; 603076; gene.
DR   neXtProt; NX_P45844; -.
DR   PharmGKB; PA24408; -.
DR   eggNOG; COG1131; -.
DR   HOVERGEN; HBG103052; -.
DR   KO; K05679; -.
DR   OMA; RERICDT; -.
DR   OrthoDB; EOG7KWSGT; -.
DR   PhylomeDB; P45844; -.
DR   TreeFam; TF105210; -.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   ChiTaRS; ABCG1; human.
DR   GeneWiki; ABCG1; -.
DR   GenomeRNAi; 9619; -.
DR   NextBio; 36087; -.
DR   PRO; PR:P45844; -.
DR   ArrayExpress; P45844; -.
DR   Bgee; P45844; -.
DR   Genevestigator; P45844; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; ISS:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IC:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0055037; C:recycling endosome; ISS:BHF-UCL.
DR   GO; GO:0043531; F:ADP binding; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:BHF-UCL.
DR   GO; GO:0015485; F:cholesterol binding; IC:BHF-UCL.
DR   GO; GO:0017127; F:cholesterol transporter activity; IDA:BHF-UCL.
DR   GO; GO:0034437; F:glycoprotein transporter activity; IDA:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IC:BHF-UCL.
DR   GO; GO:0005548; F:phospholipid transporter activity; IDA:BHF-UCL.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0046983; F:protein dimerization activity; NAS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0034041; F:sterol-transporting ATPase activity; IDA:BHF-UCL.
DR   GO; GO:0019534; F:toxin transporter activity; IDA:BHF-UCL.
DR   GO; GO:0042987; P:amyloid precursor protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IDA:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IDA:BHF-UCL.
DR   GO; GO:0009720; P:detection of hormone stimulus; NAS:UniProtKB.
DR   GO; GO:0034436; P:glycoprotein transport; IDA:BHF-UCL.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; ISS:BHF-UCL.
DR   GO; GO:0032367; P:intracellular cholesterol transport; IMP:BHF-UCL.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; ISS:BHF-UCL.
DR   GO; GO:0010887; P:negative regulation of cholesterol storage; TAS:BHF-UCL.
DR   GO; GO:0010745; P:negative regulation of macrophage derived foam cell differentiation; TAS:BHF-UCL.
DR   GO; GO:0033700; P:phospholipid efflux; IMP:BHF-UCL.
DR   GO; GO:0055091; P:phospholipid homeostasis; IMP:BHF-UCL.
DR   GO; GO:0045542; P:positive regulation of cholesterol biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; IEA:Ensembl.
DR   GO; GO:0010872; P:regulation of cholesterol esterification; ISS:BHF-UCL.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; ISS:BHF-UCL.
DR   GO; GO:0055099; P:response to high density lipoprotein particle; IEA:Ensembl.
DR   GO; GO:0033993; P:response to lipid; IDA:BHF-UCL.
DR   GO; GO:0010033; P:response to organic substance; IDA:UniProtKB.
DR   GO; GO:0043691; P:reverse cholesterol transport; ISS:BHF-UCL.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:1901998; P:toxin transport; IDA:GOC.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR013525; ABC_2_trans.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR020064; ABCG1.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005284; Pigment_permease.
DR   PANTHER; PTHR19241:SF177; PTHR19241:SF177; 1.
DR   Pfam; PF01061; ABC2_membrane; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00955; 3a01204; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome;
KW   Endoplasmic reticulum; Golgi apparatus; Lipid transport; Lipoprotein;
KW   Membrane; Mitochondrion; Nucleotide-binding; Palmitate; Polymorphism;
KW   Reference proteome; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1    678       ATP-binding cassette sub-family G member
FT                                1.
FT                                /FTId=PRO_0000093384.
FT   TOPO_DOM      1    426       Cytoplasmic (Potential).
FT   TRANSMEM    427    445       Helical; (Potential).
FT   TOPO_DOM    446    456       Extracellular (Potential).
FT   TRANSMEM    457    477       Helical; (Potential).
FT   TOPO_DOM    478    506       Cytoplasmic (Potential).
FT   TRANSMEM    507    525       Helical; (Potential).
FT   TOPO_DOM    526    533       Extracellular (Potential).
FT   TRANSMEM    534    555       Helical; (Potential).
FT   TOPO_DOM    556    567       Cytoplasmic (Potential).
FT   TRANSMEM    568    586       Helical; (Potential).
FT   TOPO_DOM    587    649       Extracellular (Potential).
FT   TRANSMEM    650    669       Helical; (Potential).
FT   TOPO_DOM    670    678       Cytoplasmic (Potential).
FT   DOMAIN       77    317       ABC transporter.
FT   DOMAIN      415    673       ABC transmembrane type-2.
FT   NP_BIND     118    125       ATP (Potential).
FT   LIPID        30     30       S-palmitoyl cysteine.
FT   LIPID       154    154       S-palmitoyl cysteine.
FT   LIPID       315    315       S-palmitoyl cysteine.
FT   LIPID       394    394       S-palmitoyl cysteine.
FT   LIPID       406    406       S-palmitoyl cysteine.
FT   VAR_SEQ       1     95       MACLMAAFSVGTAMNASSYSAEMTEPKSVCVSVDEVVSSNM
FT                                EATETDLLNGHLKKVDNNLTEAQRFSSLPRRAAVNIEFRDL
FT                                SYSVPEGPWWRKK -> MVRRGWSVCTAILLARLWCLVPTH
FT                                TFLSEYPEAAEYPHPGWVYWLQMAVAPGHLRAWVMRNNVTT
FT                                NIPSAFSGTLTHEEKAVLTVFTGTATAVHVQVAALASAKLE
FT                                SSVFVTDCVSCKIENVCDSALQGKRVPMSGLQGSSIVIMPP
FT                                SNRPLASAASCTWSVQVQGGPHHLGVVAISGKVLSAAHGAG
FT                                RAYGWGFPGDPMEE (in isoform 8).
FT                                /FTId=VSP_010718.
FT   VAR_SEQ       1     22       Missing (in isoform 7).
FT                                /FTId=VSP_000050.
FT   VAR_SEQ       1     14       MACLMAAFSVGTAM -> MRISLPRAPERDGGVSASSLLDT
FT                                VT (in isoform 2).
FT                                /FTId=VSP_000047.
FT   VAR_SEQ       1     14       MACLMAAFSVGTAM -> MLGTQGWTKQRKPCPQ (in
FT                                isoform 3).
FT                                /FTId=VSP_000048.
FT   VAR_SEQ       1     14       MACLMAAFSVGTAM -> MIMRLPQPHGT (in isoform
FT                                5).
FT                                /FTId=VSP_000049.
FT   VAR_SEQ       1      4       Missing (in isoform 6).
FT                                /FTId=VSP_000046.
FT   VAR_SEQ     375    386       Missing (in isoform 2, isoform 3, isoform
FT                                4, isoform 5, isoform 6 and isoform 7).
FT                                /FTId=VSP_000051.
FT   VARIANT     668    668       F -> L.
FT                                /FTId=VAR_012279.
FT   MUTAGEN      30     30       C->A: No significant effect.
FT   MUTAGEN     154    154       C->A: No significant effect.
FT   MUTAGEN     315    315       C->A,S: Significantly decreases ABCG1-
FT                                mediated cholesterol efflux.
FT   MUTAGEN     394    394       C->A: No significant effect.
FT   MUTAGEN     406    406       C->A: No significant effect.
FT   CONFLICT     38     38       S -> T (in Ref. 4; AAK28839/AAK28841).
FT   CONFLICT    448    448       A -> T (in Ref. 1; CAA62631, 4; AAK28838/
FT                                AAK28839/AAK28840/AAK28841/AAK28842 and
FT                                5; AAL06598).
FT   CONFLICT    533    533       R -> A (in Ref. 8; AAC51098).
SQ   SEQUENCE   678 AA;  75592 MW;  B901CABDA6C19E09 CRC64;
     MACLMAAFSV GTAMNASSYS AEMTEPKSVC VSVDEVVSSN MEATETDLLN GHLKKVDNNL
     TEAQRFSSLP RRAAVNIEFR DLSYSVPEGP WWRKKGYKTL LKGISGKFNS GELVAIMGPS
     GAGKSTLMNI LAGYRETGMK GAVLINGLPR DLRCFRKVSC YIMQDDMLLP HLTVQEAMMV
     SAHLKLQEKD EGRREMVKEI LTALGLLSCA NTRTGSLSGG QRKRLAIALE LVNNPPVMFF
     DEPTSGLDSA SCFQVVSLMK GLAQGGRSII CTIHQPSAKL FELFDQLYVL SQGQCVYRGK
     VCNLVPYLRD LGLNCPTYHN PADFVMEVAS GEYGDQNSRL VRAVREGMCD SDHKRDLGGD
     AEVNPFLWHR PSEEVKQTKR LKGLRKDSSS MEGCHSFSAS CLTQFCILFK RTFLSIMRDS
     VLTHLRITSH IGIGLLIGLL YLGIGNEAKK VLSNSGFLFF SMLFLMFAAL MPTVLTFPLE
     MGVFLREHLN YWYSLKAYYL AKTMADVPFQ IMFPVAYCSI VYWMTSQPSD AVRFVLFAAL
     GTMTSLVAQS LGLLIGAAST SLQVATFVGP VTAIPVLLFS GFFVSFDTIP TYLQWMSYIS
     YVRYGFEGVI LSIYGLDRED LHCDIDETCH FQKSEAILRE LDVENAKLYL DFIVLGIFFI
     SLRLIAYFVL RYKIRAER
//
ID   ABCG2_HUMAN             Reviewed;         655 AA.
AC   Q9UNQ0; A0A1W3; A8K1T5; O95374; Q4W5I3; Q53ZQ1; Q569L4; Q5YLG4;
AC   Q86V64; Q8IX16; Q96LD6; Q96TA8; Q9BY73; Q9NUS0;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2005, sequence version 3.
DT   09-JUL-2014, entry version 148.
DE   RecName: Full=ATP-binding cassette sub-family G member 2;
DE   AltName: Full=Breast cancer resistance protein;
DE   AltName: Full=CDw338;
DE   AltName: Full=Mitoxantrone resistance-associated protein;
DE   AltName: Full=Placenta-specific ATP-binding cassette transporter;
DE   AltName: Full=Urate exporter;
DE   AltName: CD_antigen=CD338;
GN   Name=ABCG2; Synonyms=ABCP, BCRP, BCRP1, MXR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS GLU-166 AND SER-208,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=9850061;
RA   Allikmets R., Schriml L.M., Hutchinson A., Romano-Spica V., Dean M.;
RT   "A human placenta-specific ATP-binding cassette gene (ABCP) on
RT   chromosome 4q22 that is involved in multidrug resistance.";
RL   Cancer Res. 58:5337-5339(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Mammary cancer;
RX   PubMed=9861027; DOI=10.1073/pnas.95.26.15665;
RA   Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K.,
RA   Ross D.D.;
RT   "A multidrug resistance transporter from human MCF-7 breast cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:15665-15670(1998).
RN   [3]
RP   ERRATUM.
RA   Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K.,
RA   Ross D.D.;
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2569-2569(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Kage K., Tsukahara S., Sugiyama T., Asada S., Ishikawa E., Tsuruo T.,
RA   Sugimoto Y.;
RT   "Breast cancer resistance protein constitutes a 140-kDa complex as a
RT   homodimer.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11306452;
RA   Komatani H., Kotani H., Hara Y., Nakagawa R., Matsumoto M.,
RA   Arakawa H., Nishimura S.;
RT   "Identification of breast cancer resistant protein/mitoxantrone
RT   resistance/placenta-specific, ATP-binding cassette transporter as a
RT   transporter of NB-506 and J-107088, topoisomerase I inhibitors with an
RT   indolocarbazole structure.";
RL   Cancer Res. 61:2827-2832(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11533706; DOI=10.1038/nm0901-1028;
RA   Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J.,
RA   Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H.,
RA   Sorrentino B.P.;
RT   "The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of
RT   stem cells and is a molecular determinant of the side-population
RT   phenotype.";
RL   Nat. Med. 7:1028-1034(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND VARIANTS GLU-166
RP   AND SER-208.
RC   TISSUE=Brain endothelium;
RX   PubMed=12958161; DOI=10.1096/fj.02-1131fje;
RA   Zhang W., Mojsilovic-Petrovic J., Andrade M.F., Zhang H., Ball M.,
RA   Stanimirovic D.B.;
RT   "The expression and functional characterization of ABCG2 in brain
RT   endothelial cells and vessels.";
RL   FASEB J. 17:2085-2087(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LYS-141.
RA   Yoshikawa M., Yabuuchi H., Ikegami Y., Ishikawa T.;
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT PRO-316.
RA   Sudarikov A., Makarik T., Andreeff M.;
RT   "Cell line K562 resistant to Hoechst 33342.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-12; LYS-141;
RP   HIS-296 AND THR-528.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   LYS-141.
RC   TISSUE=Pancreas, and PNS;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 294-655 (ISOFORM 1).
RX   PubMed=9892175;
RA   Miyake K., Mickley L., Litman T., Zhan Z., Robey R.W., Cristensen B.,
RA   Brangi M., Greenberger L., Dean M., Fojo T., Bates S.E.;
RT   "Molecular cloning of cDNAs which are highly overexpressed in
RT   mitoxantrone-resistant cells: demonstration of homology to ABC
RT   transport genes.";
RL   Cancer Res. 59:8-13(1999).
RN   [15]
RP   REVIEW.
RX   PubMed=11590207;
RA   Schmitz G., Langmann T., Heimerl S.;
RT   "Role of ABCG1 and other ABCG family members in lipid metabolism.";
RL   J. Lipid Res. 42:1513-1520(2001).
RN   [16]
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=15001581; DOI=10.1074/jbc.M310785200;
RA   Xu J., Liu Y., Yang Y., Bates S., Zhang J.T.;
RT   "Characterization of oligomeric human half-ABC transporter ATP-binding
RT   cassette G2.";
RL   J. Biol. Chem. 279:19781-19789(2004).
RN   [17]
RP   SUBCELLULAR LOCATION, GLYCOSYLATION AT ASN-596, AND MUTAGENESIS OF
RP   ASN-418; ASN-557 AND ASN-596.
RX   PubMed=15807535; DOI=10.1021/bi0479858;
RA   Diop N.K., Hrycyna C.A.;
RT   "N-linked glycosylation of the human ABC transporter ABCG2 on
RT   asparagine 596 is not essential for expression, transport activity, or
RT   trafficking to the plasma membrane.";
RL   Biochemistry 44:5420-5429(2005).
RN   [18]
RP   MUTAGENESIS OF ARG-482.
RX   PubMed=15670731; DOI=10.1016/j.bbamem.2004.11.005;
RA   Oezvegy-Laczka C., Koebloes G., Sarkadi B., Varadi A.;
RT   "Single amino acid (482) variants of the ABCG2 multidrug transporter:
RT   major differences in transport capacity and substrate recognition.";
RL   Biochim. Biophys. Acta 1668:53-63(2005).
RN   [19]
RP   MUTAGENESIS OF LYS-86, SUBCELLULAR LOCATION, AND HOMODIMERIZATION.
RX   PubMed=15769853; DOI=10.1242/jcs.01729;
RA   Henriksen U., Gether U., Litman T.;
RT   "Effect of Walker A mutation (K86M) on oligomerization and surface
RT   targeting of the multidrug resistance transporter ABCG2.";
RL   J. Cell Sci. 118:1417-1426(2005).
RN   [20]
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=17686774; DOI=10.1074/jbc.C700133200;
RA   Wakabayashi K., Nakagawa H., Tamura A., Koshiba S., Hoshijima K.,
RA   Komada M., Ishikawa T.;
RT   "Intramolecular disulfide bond is a critical check point determining
RT   degradative fates of ATP-binding cassette (ABC) transporter ABCG2
RT   protein.";
RL   J. Biol. Chem. 282:27841-27846(2007).
RN   [21]
RP   INVOLVEMENT IN UAQTL1 AND GOUT.
RX   PubMed=18834626; DOI=10.1016/S0140-6736(08)61343-4;
RA   Dehghan A., Kottgen A., Yang Q., Hwang S.J., Kao W.L., Rivadeneira F.,
RA   Boerwinkle E., Levy D., Hofman A., Astor B.C., Benjamin E.J.,
RA   van Duijn C.M., Witteman J.C., Coresh J., Fox C.S.;
RT   "Association of three genetic loci with uric acid concentration and
RT   risk of gout: a genome-wide association study.";
RL   Lancet 372:1953-1961(2008).
RN   [22]
RP   INVOLVEMENT IN UAQTL1, ASSOCIATION OF VARIANT LYS-141 WITH GOUT, AND
RP   CHARACTERIZATION OF VARIANT LYS-141.
RX   PubMed=19506252; DOI=10.1073/pnas.0901249106;
RA   Woodward O.M., Kottgen A., Coresh J., Boerwinkle E., Guggino W.B.,
RA   Kottgen M.;
RT   "Identification of a urate transporter, ABCG2, with a common
RT   functional polymorphism causing gout.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:10338-10342(2009).
RN   [23]
RP   INVOLVEMENT IN UAQTL1, AND ASSOCIATION OF VARIANT LYS-141 WITH GOUT.
RX   PubMed=20368174; DOI=10.1126/scitranslmed.3000237;
RA   Matsuo H., Takada T., Ichida K., Nakamura T., Nakayama A.,
RA   Ikebuchi Y., Ito K., Kusanagi Y., Chiba T., Tadokoro S., Takada Y.,
RA   Oikawa Y., Inoue H., Suzuki K., Okada R., Nishiyama J., Domoto H.,
RA   Watanabe S., Fujita M., Morimoto Y., Naito M., Nishio K., Hishida A.,
RA   Wakai K., Asai Y., Niwa K., Kamakura K., Nonoyama S., Sakurai Y.,
RA   Hosoya T., Kanai Y., Suzuki H., Hamajima N., Shinomiya N.;
RT   "Common defects of ABCG2, a high-capacity urate exporter, cause gout:
RT   a function-based genetic analysis in a Japanese population.";
RL   Sci. Transl. Med. 1:5ra11-5ra11(2009).
RN   [24]
RP   FUNCTION, DOMAIN, AND MUTAGENESIS OF HIS-583; CYS-603 AND TYR-605.
RX   PubMed=20705604; DOI=10.1074/jbc.M110.139170;
RA   Desuzinges-Mandon E., Arnaud O., Martinez L., Huche F., Di Pietro A.,
RA   Falson P.;
RT   "ABCG2 transports and transfers heme to albumin through its large
RT   extracellular loop.";
RL   J. Biol. Chem. 285:33123-33133(2010).
RN   [25]
RP   FUNCTION.
RX   PubMed=22132962; DOI=10.1080/15257770.2011.633953;
RA   Nakayama A., Matsuo H., Takada T., Ichida K., Nakamura T.,
RA   Ikebuchi Y., Ito K., Hosoya T., Kanai Y., Suzuki H., Shinomiya N.;
RT   "ABCG2 is a high-capacity urate transporter and its genetic impairment
RT   increases serum uric acid levels in humans.";
RL   Nucleosides Nucleotides Nucleic Acids 30:1091-1097(2011).
RN   [26]
RP   REVIEW.
RX   PubMed=22509477;
RA   Mo W., Zhang J.T.;
RT   "Human ABCG2: structure, function, and its role in multidrug
RT   resistance.";
RL   Int. J. Biochem. Mol. Biol. 3:1-27(2012).
RN   [27]
RP   INVOLVEMENT IN JR, AND VARIANT MET-12.
RX   PubMed=22246507; DOI=10.1038/ng.1075;
RA   Zelinski T., Coghlan G., Liu X.Q., Reid M.E.;
RT   "ABCG2 null alleles define the Jr(a-) blood group phenotype.";
RL   Nat. Genet. 44:131-132(2012).
RN   [28]
RP   INVOLVEMENT IN JR.
RX   PubMed=22246505; DOI=10.1038/ng.1070;
RA   Saison C., Helias V., Ballif B.A., Peyrard T., Puy H., Miyazaki T.,
RA   Perrot S., Vayssier-Taussat M., Waldner M., Le Pennec P.Y.,
RA   Cartron J.P., Arnaud L.;
RT   "Null alleles of ABCG2 encoding the breast cancer resistance protein
RT   define the new blood group system Junior.";
RL   Nat. Genet. 44:174-177(2012).
RN   [29]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=23189181; DOI=10.1371/journal.pone.0050082;
RA   Kobuchi H., Moriya K., Ogino T., Fujita H., Inoue K., Shuin T.,
RA   Yasuda T., Utsumi K., Utsumi T.;
RT   "Mitochondrial localization of ABC transporter ABCG2 and its function
RT   in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation.";
RL   PLoS ONE 7:E50082-E50082(2012).
RN   [30]
RP   VARIANTS MET-12 AND LYS-141.
RX   PubMed=12111378; DOI=10.1007/s100380200041;
RA   Iida A., Saito S., Sekine A., Mishima C., Kitamura Y., Kondo K.,
RA   Harigae S., Osawa S., Nakamura Y.;
RT   "Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes
RT   encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8,
RT   ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and
RT   ABCG8.";
RL   J. Hum. Genet. 47:285-310(2002).
RN   [31]
RP   VARIANTS LEU-431 AND LEU-489.
RX   PubMed=15618737; DOI=10.2133/dmpk.18.212;
RA   Itoda M., Saito Y., Shirao K., Minami H., Ohtsu A., Yoshida T.,
RA   Saijo N., Suzuki H., Sugiyama Y., Ozawa S., Sawada J.;
RT   "Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese
RT   cancer patients administered irinotacan.";
RL   Drug Metab. Pharmacokinet. 18:212-217(2003).
RN   [32]
RP   VARIANTS MET-12; LYS-141; LEU-206 AND TYR-590.
RX   PubMed=12544509; DOI=10.1097/00008571-200301000-00004;
RA   Zamber C.P., Lamba J.K., Yasuda K., Farnum J., Thummel K.,
RA   Schuetz J.D., Schuetz E.G.;
RT   "Natural allelic variants of breast cancer resistance protein (BCRP)
RT   and their relationship to BCRP expression in human intestine.";
RL   Pharmacogenetics 13:19-28(2003).
RN   [33]
RP   CHARACTERIZATION OF VARIANTS MET-12; LYS-141 AND ASN-620.
RX   PubMed=15838659; DOI=10.1007/s00280-004-0931-x;
RA   Morisaki K., Robey R.W., Oezvegy-Laczka C., Honjo Y., Polgar O.,
RA   Steadman K., Sarkadi B., Bates S.E.;
RT   "Single nucleotide polymorphisms modify the transporter activity of
RT   ABCG2.";
RL   Cancer Chemother. Pharmacol. 56:161-172(2005).
RN   [34]
RP   VARIANTS MET-12; LEU-13; LYS-141; GLN-160; ARG-354; LEU-431; ASN-441
RP   AND LEU-489.
RX   PubMed=16702730; DOI=10.2133/dmpk.21.109;
RA   Maekawa K., Itoda M., Sai K., Saito Y., Kaniwa N., Shirao K.,
RA   Hamaguchi T., Kunitoh H., Yamamoto N., Tamura T., Minami H.,
RA   Kubota K., Ohtsu A., Yoshida T., Saijo N., Kamatani N., Ozawa S.,
RA   Sawada J.;
RT   "Genetic variation and haplotype structure of the ABC transporter gene
RT   ABCG2 in a Japanese population.";
RL   Drug Metab. Pharmacokinet. 21:109-121(2006).
CC   -!- FUNCTION: High-capacity urate exporter functioning in both renal
CC       and extrarenal urate excretion. Plays a role in porphyrin
CC       homeostasis as it is able to mediates the export of protoporhyrin
CC       IX (PPIX) both from mitochondria to cytosol and from cytosol to
CC       extracellular space, and cellular export of hemin, and heme.
CC       Xenobiotic transporter that may play an important role in the
CC       exclusion of xenobiotics from the brain. Appears to play a major
CC       role in the multidrug resistance phenotype of several cancer cell
CC       lines. Implicated in the efflux of numerous drugs and xenobiotics:
CC       mitoxantrone, the photosensitizer pheophorbide, camptothecin,
CC       methotrexate, azidothymidine (AZT), and the anthracyclines
CC       daunorubicin and doxorubicin.
CC   -!- SUBUNIT: Monomer under reducing conditions, the minimal functional
CC       units is a homodimer; disulfide-linked, but the major oligomeric
CC       form in plasma membranes is a homotetramer with possibility of
CC       higher order oligomerization up to homododecamers.
CC   -!- INTERACTION:
CC       P11309-1:PIM1; NbExp=9; IntAct=EBI-1569435, EBI-1018629;
CC       P0CG48:UBC; NbExp=2; IntAct=EBI-1569435, EBI-3390054;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Mitochondrion membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9UNQ0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UNQ0-2; Sequence=VSP_014232, VSP_014233;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Highly expressed in placenta. Low expression
CC       in small intestine, liver and colon.
CC   -!- INDUCTION: Up-regulated in brain tumors.
CC   -!- DOMAIN: The extracellular loop 3 (ECL3) is involved in binding
CC       porphyrins and transfer them to other carriers, probably albumin.
CC   -!- PTM: Glycosylation-deficient ABCG2 is normally expressed and
CC       functional.
CC   -!- POLYMORPHISM: Genetic variations in ABCG2 define the blood group
CC       Junior system (JR) [MIM:614490]. Individuals with Jr(a-) blood
CC       group lack the Jr(a) antigen on their red blood cells. These
CC       individuals may have anti-Jr(a) antibodies in their serum, which
CC       can cause transfusion reactions or hemolytic disease of the fetus
CC       or newborn. Although the clinical significance of the Jr(a-) blood
CC       group has been controversial, severe fatal hemolytic disease of
CC       the newborn has been reported. The Jr(a-) phenotype has a higher
CC       frequency in individuals of Asian descent, compared to those of
CC       European descent. The Jr(a-) phenotype is inherited as an
CC       autosomal recessive trait.
CC   -!- POLYMORPHISM: Genetic variations in ABCG2 influence the variance
CC       in serum uric acid concentrations and define the serum uric acid
CC       concentration quantitative trait locus 1 (UAQTL1) [MIM:138900].
CC       Excess serum accumulation of uric acid can lead to the development
CC       of gout, a common disorder characterized by tissue deposition of
CC       monosodium urate crystals as a consequence of hyperuricemia.
CC   -!- MISCELLANEOUS: When overexpressed, the transfected cells become
CC       resistant to mitoxantrone, daunorubicin and doxorubicin.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCG
CC       family. Eye pigment precursor importer (TC 3.A.1.204) subfamily.
CC   -!- SIMILARITY: Contains 1 ABC transmembrane type-2 domain.
CC   -!- SIMILARITY: Contains 1 ABC transporter domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AF093771; Type=Frameshift; Positions=486, 586;
CC       Sequence=AF093772; Type=Frameshift; Positions=386, 502, 586;
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/abcg2/";
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=Q9UNQ0";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF103796; AAD09188.1; -; mRNA.
DR   EMBL; AF098951; AAC97367.1; -; mRNA.
DR   EMBL; AB056867; BAB39212.1; -; mRNA.
DR   EMBL; AB051855; BAB46933.1; -; mRNA.
DR   EMBL; AY017168; AAG52982.1; -; mRNA.
DR   EMBL; AY289766; AAP44087.1; -; mRNA.
DR   EMBL; AY288307; AAP31310.1; -; mRNA.
DR   EMBL; AF463519; AAO14617.1; -; mRNA.
DR   EMBL; AY333755; AAQ92941.1; -; mRNA.
DR   EMBL; AY333756; AAQ92942.1; -; mRNA.
DR   EMBL; AK002040; BAA92050.1; -; mRNA.
DR   EMBL; AK290000; BAF82689.1; -; mRNA.
DR   EMBL; DQ996467; ABI97388.1; -; Genomic_DNA.
DR   EMBL; AC084732; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC097484; AAY40902.1; -; Genomic_DNA.
DR   EMBL; BC021281; AAH21281.1; -; mRNA.
DR   EMBL; BC092408; AAH92408.1; -; mRNA.
DR   EMBL; AF093771; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AF093772; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS3628.1; -. [Q9UNQ0-1]
DR   CCDS; CCDS58910.1; -. [Q9UNQ0-2]
DR   RefSeq; NP_001244315.1; NM_001257386.1. [Q9UNQ0-2]
DR   RefSeq; NP_004818.2; NM_004827.2. [Q9UNQ0-1]
DR   RefSeq; XP_005263411.1; XM_005263354.1. [Q9UNQ0-1]
DR   RefSeq; XP_005263412.1; XM_005263355.1. [Q9UNQ0-1]
DR   UniGene; Hs.480218; -.
DR   ProteinModelPortal; Q9UNQ0; -.
DR   SMR; Q9UNQ0; 37-337.
DR   BioGrid; 114821; 3.
DR   DIP; DIP-29162N; -.
DR   IntAct; Q9UNQ0; 3.
DR   MINT; MINT-2840423; -.
DR   BindingDB; Q9UNQ0; -.
DR   ChEMBL; CHEMBL5393; -.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB01204; Mitoxantrone.
DR   DrugBank; DB00622; Nicardipine.
DR   DrugBank; DB01054; Nitrendipine.
DR   DrugBank; DB01098; Rosuvastatin.
DR   DrugBank; DB01232; Saquinavir.
DR   DrugBank; DB01030; Topotecan.
DR   TCDB; 3.A.1.204.2; the atp-binding cassette (abc) superfamily.
DR   PhosphoSite; Q9UNQ0; -.
DR   DMDM; 67462103; -.
DR   MaxQB; Q9UNQ0; -.
DR   PaxDb; Q9UNQ0; -.
DR   PRIDE; Q9UNQ0; -.
DR   DNASU; 9429; -.
DR   Ensembl; ENST00000237612; ENSP00000237612; ENSG00000118777. [Q9UNQ0-1]
DR   Ensembl; ENST00000515655; ENSP00000426917; ENSG00000118777. [Q9UNQ0-2]
DR   GeneID; 9429; -.
DR   KEGG; hsa:9429; -.
DR   UCSC; uc003hrf.3; human. [Q9UNQ0-1]
DR   UCSC; uc003hrh.3; human. [Q9UNQ0-2]
DR   CTD; 9429; -.
DR   GeneCards; GC04M089011; -.
DR   HGNC; HGNC:74; ABCG2.
DR   HPA; CAB037299; -.
DR   HPA; HPA054719; -.
DR   MIM; 138900; phenotype.
DR   MIM; 603756; gene.
DR   MIM; 614490; phenotype.
DR   neXtProt; NX_Q9UNQ0; -.
DR   PharmGKB; PA390; -.
DR   eggNOG; COG1131; -.
DR   HOVERGEN; HBG050441; -.
DR   InParanoid; Q9UNQ0; -.
DR   KO; K05681; -.
DR   OMA; FYKETKA; -.
DR   OrthoDB; EOG7HXCR2; -.
DR   PhylomeDB; Q9UNQ0; -.
DR   TreeFam; TF105211; -.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_15518; Transmembrane transport of small molecules.
DR   ChiTaRS; ABCG2; human.
DR   GeneWiki; ABCG2; -.
DR   GenomeRNAi; 9429; -.
DR   NextBio; 35322; -.
DR   PRO; PR:Q9UNQ0; -.
DR   ArrayExpress; Q9UNQ0; -.
DR   Bgee; Q9UNQ0; -.
DR   Genevestigator; Q9UNQ0; -.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; TAS:ProtInc.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; TAS:ProtInc.
DR   GO; GO:0015232; F:heme transporter activity; TAS:Reactome.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0005215; F:transporter activity; TAS:ProtInc.
DR   GO; GO:0008559; F:xenobiotic-transporting ATPase activity; TAS:ProtInc.
DR   GO; GO:0006879; P:cellular iron ion homeostasis; TAS:Reactome.
DR   GO; GO:0006855; P:drug transmembrane transport; TAS:Reactome.
DR   GO; GO:0015886; P:heme transport; TAS:GOC.
DR   GO; GO:0042493; P:response to drug; TAS:ProtInc.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   GO; GO:0046415; P:urate metabolic process; IMP:UniProtKB.
DR   GO; GO:0042908; P:xenobiotic transport; TAS:GOC.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR013525; ABC_2_trans.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF01061; ABC2_membrane; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Disulfide bond; Glycoprotein; Membrane; Mitochondrion;
KW   Nucleotide-binding; Polymorphism; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN         1    655       ATP-binding cassette sub-family G member
FT                                2.
FT                                /FTId=PRO_0000093386.
FT   TOPO_DOM      1    395       Cytoplasmic (Potential).
FT   TRANSMEM    396    416       Helical; (Potential).
FT   TOPO_DOM    417    428       Extracellular (Potential).
FT   TRANSMEM    429    449       Helical; (Potential).
FT   TOPO_DOM    450    477       Cytoplasmic (Potential).
FT   TRANSMEM    478    498       Helical; (Potential).
FT   TOPO_DOM    499    506       Extracellular (Potential).
FT   TRANSMEM    507    527       Helical; (Potential).
FT   TOPO_DOM    528    535       Cytoplasmic (Potential).
FT   TRANSMEM    536    556       Helical; (Potential).
FT   TOPO_DOM    557    630       Extracellular (Potential).
FT   TRANSMEM    631    651       Helical; (Potential).
FT   TOPO_DOM    652    655       Cytoplasmic (Potential).
FT   DOMAIN       37    286       ABC transporter.
FT   DOMAIN      389    651       ABC transmembrane type-2.
FT   NP_BIND      80     87       ATP (Potential).
FT   SITE        418    418       Not glycosylated.
FT   SITE        557    557       Not glycosylated.
FT   CARBOHYD    596    596       N-linked (GlcNAc...).
FT   DISULFID    592    608
FT   DISULFID    603    603       Interchain.
FT   VAR_SEQ     550    611       IFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQN
FT                                FCPGLNATGNNPCNYATCTGE -> VCWSISQPLHLGCHGF
FT                                STSAFHDMDLRLCSIMNFWDKTSAQDSMQQETILVTMQHVL
FT                                AKNIW (in isoform 2).
FT                                /FTId=VSP_014232.
FT   VAR_SEQ     612    655       Missing (in isoform 2).
FT                                /FTId=VSP_014233.
FT   VARIANT      12     12       V -> M (found in Jr(a-) blood group
FT                                phenotype; dbSNP:rs2231137).
FT                                /FTId=VAR_020779.
FT   VARIANT      13     13       S -> L.
FT                                /FTId=VAR_067363.
FT   VARIANT     141    141       Q -> K (polymorphism associated with high
FT                                serum levels of uric acid and increased
FT                                risk of gout; results in lower urate
FT                                transport rates compared to wild-type;
FT                                dbSNP:rs2231142).
FT                                /FTId=VAR_020780.
FT   VARIANT     160    160       R -> Q.
FT                                /FTId=VAR_067364.
FT   VARIANT     166    166       Q -> E (in dbSNP:rs1061017).
FT                                /FTId=VAR_022704.
FT   VARIANT     206    206       I -> L.
FT                                /FTId=VAR_022705.
FT   VARIANT     208    208       F -> S (in dbSNP:rs1061018).
FT                                /FTId=VAR_022706.
FT   VARIANT     248    248       S -> P (in dbSNP:rs3116448).
FT                                /FTId=VAR_022707.
FT   VARIANT     296    296       D -> H (in dbSNP:rs41282401).
FT                                /FTId=VAR_030357.
FT   VARIANT     316    316       T -> P.
FT                                /FTId=VAR_022443.
FT   VARIANT     354    354       G -> R (in dbSNP:rs138606116).
FT                                /FTId=VAR_067365.
FT   VARIANT     431    431       F -> L.
FT                                /FTId=VAR_018349.
FT   VARIANT     441    441       S -> N.
FT                                /FTId=VAR_067366.
FT   VARIANT     489    489       F -> L (in dbSNP:rs192169063).
FT                                /FTId=VAR_018350.
FT   VARIANT     528    528       A -> T (in dbSNP:rs45605536).
FT                                /FTId=VAR_030358.
FT   VARIANT     571    571       F -> I (in dbSNP:rs9282571).
FT                                /FTId=VAR_022708.
FT   VARIANT     590    590       N -> Y (in dbSNP:rs34264773).
FT                                /FTId=VAR_035355.
FT   VARIANT     620    620       D -> N (in dbSNP:rs34783571).
FT                                /FTId=VAR_022709.
FT   MUTAGEN      86     86       K->M: Inactive and altered subcellular
FT                                location.
FT   MUTAGEN     418    418       N->Q: No effect.
FT   MUTAGEN     482    482       R->D: Decreases ATPase activity.
FT   MUTAGEN     482    482       R->G,N,S,T: Increases ATPase activity.
FT   MUTAGEN     482    482       R->K,I,M,Y: No change in ATPase activity.
FT   MUTAGEN     482    482       R->T,Y: Decreases transport activity.
FT   MUTAGEN     557    557       N->Q: No effect.
FT   MUTAGEN     583    583       H->A: Strongly reduced binding to hemin
FT                                but not to PPIX.
FT   MUTAGEN     596    596       N->Q: Loss of glycosylation.
FT   MUTAGEN     603    603       C->A: Strongly reduced binding to hemin
FT                                but not to PPIX.
FT   MUTAGEN     605    605       Y->A: No effect on hemin binding.
FT   CONFLICT     24     24       A -> V (in Ref. 1; AAD09188 and 7;
FT                                AAP44087).
FT   CONFLICT    315    316       Missing (in Ref. 10; BAA92050).
FT   CONFLICT    390    390       G -> V (in Ref. 13; AAH92408).
FT   CONFLICT    482    482       R -> G (in Ref. 14; AF093771/AF093772).
FT   CONFLICT    482    482       R -> T (in Ref. 2; AAC97367).
FT   CONFLICT    484    485       LP -> FT (in Ref. 14; AF093772).
FT   CONFLICT    501    501       P -> A (in Ref. 6; AAG52982).
SQ   SEQUENCE   655 AA;  72314 MW;  A8AF66B96034C5A8 CRC64;
     MSSSNVEVFI PVSQGNTNGF PATASNDLKA FTEGAVLSFH NICYRVKLKS GFLPCRKPVE
     KEILSNINGI MKPGLNAILG PTGGGKSSLL DVLAARKDPS GLSGDVLING APRPANFKCN
     SGYVVQDDVV MGTLTVRENL QFSAALRLAT TMTNHEKNER INRVIQELGL DKVADSKVGT
     QFIRGVSGGE RKRTSIGMEL ITDPSILFLD EPTTGLDSST ANAVLLLLKR MSKQGRTIIF
     SIHQPRYSIF KLFDSLTLLA SGRLMFHGPA QEALGYFESA GYHCEAYNNP ADFFLDIING
     DSTAVALNRE EDFKATEIIE PSKQDKPLIE KLAEIYVNSS FYKETKAELH QLSGGEKKKK
     ITVFKEISYT TSFCHQLRWV SKRSFKNLLG NPQASIAQII VTVVLGLVIG AIYFGLKNDS
     TGIQNRAGVL FFLTTNQCFS SVSAVELFVV EKKLFIHEYI SGYYRVSSYF LGKLLSDLLP
     MRMLPSIIFT CIVYFMLGLK PKADAFFVMM FTLMMVAYSA SSMALAIAAG QSVVSVATLL
     MTICFVFMMI FSGLLVNLTT IASWLSWLQY FSIPRYGFTA LQHNEFLGQN FCPGLNATGN
     NPCNYATCTG EEYLVKQGID LSPWGLWKNH VALACMIVIF LTIAYLKLLF LKKYS
//
ID   ABI1_HUMAN              Reviewed;         508 AA.
AC   Q8IZP0; A9Z1Y6; B3KX62; B4DQ58; H7BXI6; O15147; O76049; O95060;
AC   Q5T2R3; Q5T2R4; Q5T2R6; Q5T2R7; Q5T2R9; Q5W070; Q5W072; Q8TB63;
AC   Q96S81; Q9NXZ9; Q9NYB8;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   09-JUL-2014, entry version 128.
DE   RecName: Full=Abl interactor 1;
DE   AltName: Full=Abelson interactor 1;
DE            Short=Abi-1;
DE   AltName: Full=Abl-binding protein 4;
DE            Short=AblBP4;
DE   AltName: Full=Eps8 SH3 domain-binding protein;
DE            Short=Eps8-binding protein;
DE   AltName: Full=Nap1-binding protein;
DE            Short=Nap1BP;
DE   AltName: Full=Spectrin SH3 domain-binding protein 1;
DE   AltName: Full=e3B1;
GN   Name=ABI1; Synonyms=SSH3BP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), PHOSPHORYLATION, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH EPS8 AND ABL1.
RX   PubMed=9010225; DOI=10.1038/sj.onc.1200822;
RA   Biesova Z., Piccoli C., Wong W.T.;
RT   "Isolation and characterization of e3B1, an eps8 binding protein that
RT   regulates cell growth.";
RL   Oncogene 14:233-241(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ALTERNATIVE SPLICING (ISOFORMS
RP   3; 7; 8 AND 9), AND INTERACTION WITH SPTA1.
RX   PubMed=9593709; DOI=10.1074/jbc.273.22.13681;
RA   Ziemnicka-Kotula D., Xu J., Gu H., Potempska A., Kim K.S.,
RA   Jenkins E.C., Trenkner E., Kotula L.;
RT   "Identification of a candidate human spectrin Src homology 3 domain-
RT   binding protein suggests a general mechanism of association of
RT   tyrosine kinases with the spectrin-based membrane skeleton.";
RL   J. Biol. Chem. 273:13681-13692(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, AND
RP   INTERACTION WITH ABL1; NAP1 AND NCK1.
RX   PubMed=11418237; DOI=10.1016/S0378-1119(01)00521-2;
RA   Yamamoto A., Suzuki T., Sakaki Y.;
RT   "Isolation of hNap1BP which interacts with human Nap 1 (NCKAP1) whose
RT   expression is down-regulated in Alzheimer's disease.";
RL   Gene 271:159-169(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND INTERACTION WITH NCF1.
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=12681507; DOI=10.1016/S0014-5793(03)00262-X;
RA   Gu Y., Souza R.F., Wu R.F., Xu Y.C., Terada L.S.;
RT   "Induction of colonic epithelial cell apoptosis by p47-dependent
RT   oxidants(1).";
RL   FEBS Lett. 540:195-200(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=T-cell;
RA   Wilson L.A., Fields D., Cruz L., Friesen J., Siminovitch K.A.;
RT   "A new member of the Abl interactor protein family, AblBP4.";
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Chikri M.M., Boutin M.P., Vaxillaire M.M., Froguel M.P.;
RT   "In silico cloning of the human SSH3BP1/e3B1 gene.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Quackenbush R.C., Pendergast A.M.;
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 11 AND 12).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   PROTEIN SEQUENCE OF 2-17.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-17; 139-154; 229-237 AND 451-477, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Hepatoma;
RA   Bienvenut W.V., Boldt K., von Kriegsheim A.F., Kolch W.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [14]
RP   FUNCTION, AND INTERACTION WITH SOS1; SOS2 AND GRB2.
RX   PubMed=11003655; DOI=10.1128/MCB.20.20.7591-7601.2000;
RA   Fan P.-D., Goff S.P.;
RT   "Abl interactor 1 binds to sos and inhibits epidermal growth factor-
RT   and v-Abl-induced activation of extracellular signal-regulated
RT   kinases.";
RL   Mol. Cell. Biol. 20:7591-7601(2000).
RN   [15]
RP   ALTERNATIVE SPLICING (ISOFORMS 2 AND 10), AND CHROMOSOMAL
RP   TRANSLOCATION WITH KMT2A.
RX   PubMed=9694699;
RA   Taki T., Shibuya N., Taniwaki M., Hanada R., Morishita K., Bessho F.,
RA   Yanagisawa M., Hayashi Y.;
RT   "ABI-1, a human homolog to mouse Abl-interactor 1, fuses the MLL gene
RT   in acute myeloid leukemia with t(10;11)(p11.2;q23).";
RL   Blood 92:1125-1130(1998).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-225, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [17]
RP   FUNCTION, AND PHOSPHORYLATION AT TYR-213.
RX   PubMed=18328268; DOI=10.1016/j.bbamcr.2008.01.028;
RA   Xiong X., Cui P., Hossain S., Xu R., Warner B., Guo X., An X.,
RA   Debnath A.K., Cowburn D., Kotula L.;
RT   "Allosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase
RT   by phosphopeptides derived from Abi1/Hssh3bp1.";
RL   Biochim. Biophys. Acta 1783:737-747(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-225, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-225, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-183 AND SER-216, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-225 AND THR-507, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-222; SER-225 AND
RP   SER-323, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [25]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
CC   -!- FUNCTION: May act in negative regulation of cell growth and
CC       transformation by interacting with nonreceptor tyrosine kinases
CC       ABL1 and/or ABL2. May play a role in regulation of EGF-induced Erk
CC       pathway activation. Involved in cytoskeletal reorganization and
CC       EGFR signaling. Together with EPS8 participates in transduction of
CC       signals from Ras to Rac. In vitro, a trimeric complex of ABI1,
CC       EPS8 and SOS1 exhibits Rac specific guanine nucleotide exchange
CC       factor (GEF) activity and ABI1 seems to act as an adapter in the
CC       complex. Regulates ABL1/c-Abl-mediated phosphorylation of ENAH.
CC       Recruits WASF1 to lamellipodia and there seems to regulate WASF1
CC       protein level. In brain, seems to regulate the dendritic outgrowth
CC       and branching as well as to determine the shape and number of
CC       synaptic contacts of developing neurons.
CC   -!- SUBUNIT: Interacts with ABL1, ENAH, STX1A, SNAP25, VAMP2, EPS8,
CC       and through its N-terminus with WASF1. Part of a complex
CC       consisting of ABI1, STX1A and SNAP25. Part of a complex consisting
CC       of ABI1, EPS8 and SOS1 (By similarity). Interacts with SOS1, SOS2,
CC       GRB2, SPTA1 and the first SH3 domain of NCK1. Isoform 6 does not
CC       interact with NCK1. Component of the WAVE2 complex composed of
CC       ABI1, CYFIP1/SRA1, NCKAP1/NAP1 and WASF2/WAVE2. Interacts (via SH3
CC       domain) with SHANK2 and SHANK3, but not SHANK1; the interaction is
CC       direct. Interacts with the heterodimer MYC:MAX; the interaction
CC       may enhance MYC:MAX transcriptional activity.
CC   -!- INTERACTION:
CC       P00519:ABL1; NbExp=11; IntAct=EBI-375446, EBI-375543;
CC       P00520-4:Abl1 (xeno); NbExp=5; IntAct=EBI-8593095, EBI-8593082;
CC       P42684:ABL2; NbExp=2; IntAct=EBI-375446, EBI-1102694;
CC       O00555:CACNA1A; NbExp=2; IntAct=EBI-375446, EBI-766279;
CC       P22681:CBL; NbExp=3; IntAct=EBI-7358775, EBI-518228;
CC       Q08509:Eps8 (xeno); NbExp=2; IntAct=EBI-375446, EBI-375596;
CC       P14598:NCF1; NbExp=5; IntAct=EBI-375446, EBI-395044;
CC       Q9Y2A7:NCKAP1; NbExp=2; IntAct=EBI-375446, EBI-389845;
CC       P27986:PIK3R1; NbExp=8; IntAct=EBI-375446, EBI-79464;
CC       P26450:Pik3r1 (xeno); NbExp=3; IntAct=EBI-375446, EBI-641764;
CC       Q92569:PIK3R3; NbExp=2; IntAct=EBI-375446, EBI-79893;
CC       P20936:RASA1; NbExp=2; IntAct=EBI-375446, EBI-1026476;
CC       O14512:SOCS7; NbExp=2; IntAct=EBI-375446, EBI-1539606;
CC       P02549:SPTA1; NbExp=2; IntAct=EBI-375446, EBI-375617;
CC       P15498:VAV1; NbExp=2; IntAct=EBI-375446, EBI-625518;
CC       P52735:VAV2; NbExp=2; IntAct=EBI-375446, EBI-297549;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Nucleus (By
CC       similarity). Cell projection, lamellipodium (By similarity). Cell
CC       projection, filopodium (By similarity). Cell projection, growth
CC       cone (By similarity). Cell junction, synapse, postsynaptic cell
CC       membrane, postsynaptic density (By similarity). Cytoplasm,
CC       cytoskeleton (By similarity). Note=Localized to protruding
CC       lamellipodia and filopodia tips. Also localized to neuronal growth
CC       cones and synaptosomes. May shuttle from the postsynaptic
CC       densities to the nucleus (By similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=12;
CC         Comment=Additional isoforms seem to exist;
CC       Name=1;
CC         IsoId=Q8IZP0-1; Sequence=Displayed;
CC       Name=2; Synonyms=long, B48;
CC         IsoId=Q8IZP0-2; Sequence=VSP_010749, VSP_010750, VSP_010751,
CC                                  VSP_010752;
CC       Name=3;
CC         IsoId=Q8IZP0-3; Sequence=VSP_010750, VSP_010752;
CC       Name=4;
CC         IsoId=Q8IZP0-4; Sequence=VSP_010750, VSP_010751, VSP_010752;
CC       Name=5;
CC         IsoId=Q8IZP0-5; Sequence=VSP_010749, VSP_010750;
CC       Name=6;
CC         IsoId=Q8IZP0-6; Sequence=VSP_010750, VSP_010751;
CC       Name=7; Synonyms=4;
CC         IsoId=Q8IZP0-7; Sequence=VSP_010750, VSP_010751, VSP_010754,
CC                                  VSP_010755;
CC       Name=8; Synonyms=5;
CC         IsoId=Q8IZP0-8; Sequence=VSP_010750, VSP_010751, VSP_010754,
CC                                  VSP_010752;
CC       Name=9; Synonyms=2;
CC         IsoId=Q8IZP0-9; Sequence=VSP_010750;
CC       Name=10; Synonyms=B30;
CC         IsoId=Q8IZP0-10; Sequence=VSP_010749, VSP_010750, VSP_010751,
CC                                   VSP_010754, VSP_010752, VSP_010753;
CC       Name=11;
CC         IsoId=Q8IZP0-11; Sequence=VSP_043403, VSP_010750, VSP_010751,
CC                                   VSP_010754, VSP_010752, VSP_010753;
CC         Note=No experimental confirmation available;
CC       Name=12;
CC         IsoId=Q8IZP0-12; Sequence=VSP_044604, VSP_010752;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest expression in
CC       brain.
CC   -!- DOMAIN: The t-SNARE coiled-coil homology domain is necessary and
CC       sufficient for interaction with STX1A (By similarity).
CC   -!- PTM: Phosphorylated on tyrosine residues after serum stimulation
CC       or induction by v-Abl. Seems to be phosphorylated at Tyr-53 by
CC       ABL1, required for nuclear but not for synaptic localization.
CC   -!- DISEASE: Note=A chromosomal aberration involving ABI1 is a cause
CC       of acute leukemias. Translocation t(10;11)(p11.2;q23) with
CC       KMT2A/MLL1. ABI1 isoform 2 was found to be present in acute
CC       leukemia KMT2A/MLL1-ABI1 fusion transcript.
CC   -!- SIMILARITY: Belongs to the ABI family.
CC   -!- SIMILARITY: Contains 1 SH3 domain.
CC   -!- SIMILARITY: Contains 1 t-SNARE coiled-coil homology domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ABI1ID233.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF006516; AAB62569.1; -; mRNA.
DR   EMBL; U87166; AAC39757.1; -; mRNA.
DR   EMBL; AB040151; BAB55675.1; -; mRNA.
DR   EMBL; AF540955; AAN28379.1; -; mRNA.
DR   EMBL; AF001628; AAD00897.1; -; mRNA.
DR   EMBL; AJ277065; CAB88006.1; -; Genomic_DNA.
DR   EMBL; AJ277066; CAB88006.1; JOINED; Genomic_DNA.
DR   EMBL; AJ277067; CAB88006.1; JOINED; Genomic_DNA.
DR   EMBL; AJ277068; CAB88006.1; JOINED; Genomic_DNA.
DR   EMBL; AJ277069; CAB88006.1; JOINED; Genomic_DNA.
DR   EMBL; AJ277070; CAB88006.1; JOINED; Genomic_DNA.
DR   EMBL; AJ277071; CAB88006.1; JOINED; Genomic_DNA.
DR   EMBL; AJ277072; CAB88006.1; JOINED; Genomic_DNA.
DR   EMBL; AJ277073; CAB88006.1; JOINED; Genomic_DNA.
DR   EMBL; AJ277074; CAB88006.1; JOINED; Genomic_DNA.
DR   EMBL; AF260262; AAF70309.1; -; mRNA.
DR   EMBL; AK126803; BAG54374.1; -; mRNA.
DR   EMBL; AK298646; BAG60820.1; -; mRNA.
DR   EMBL; AK291823; BAF84512.1; -; mRNA.
DR   EMBL; AL139404; CAH73112.1; -; Genomic_DNA.
DR   EMBL; AL390961; CAH73112.1; JOINED; Genomic_DNA.
DR   EMBL; AL139404; CAH73113.1; -; Genomic_DNA.
DR   EMBL; AL390961; CAH73113.1; JOINED; Genomic_DNA.
DR   EMBL; AL139404; CAH73114.1; -; Genomic_DNA.
DR   EMBL; AL390961; CAH73114.1; JOINED; Genomic_DNA.
DR   EMBL; AL139404; CAH73115.1; -; Genomic_DNA.
DR   EMBL; AL390961; CAH73115.1; JOINED; Genomic_DNA.
DR   EMBL; AL139404; CAH73116.1; -; Genomic_DNA.
DR   EMBL; AL390961; CAH73116.1; JOINED; Genomic_DNA.
DR   EMBL; AL139404; CAH73117.1; -; Genomic_DNA.
DR   EMBL; AL390961; CAH73117.1; JOINED; Genomic_DNA.
DR   EMBL; AL139404; CAH73118.1; -; Genomic_DNA.
DR   EMBL; AL390961; CAH73118.1; JOINED; Genomic_DNA.
DR   EMBL; AL139404; CAH73119.1; -; Genomic_DNA.
DR   EMBL; AL390961; CAH73119.1; JOINED; Genomic_DNA.
DR   EMBL; AL390961; CAI17272.1; -; Genomic_DNA.
DR   EMBL; AL139404; CAI17272.1; JOINED; Genomic_DNA.
DR   EMBL; AL390961; CAI17273.1; -; Genomic_DNA.
DR   EMBL; AL139404; CAI17273.1; JOINED; Genomic_DNA.
DR   EMBL; AL390961; CAI17274.1; -; Genomic_DNA.
DR   EMBL; AL139404; CAI17274.1; JOINED; Genomic_DNA.
DR   EMBL; AL390961; CAI17275.1; -; Genomic_DNA.
DR   EMBL; AL139404; CAI17275.1; JOINED; Genomic_DNA.
DR   EMBL; AL390961; CAI17276.1; -; Genomic_DNA.
DR   EMBL; AL139404; CAI17276.1; JOINED; Genomic_DNA.
DR   EMBL; AL390961; CAI17277.1; -; Genomic_DNA.
DR   EMBL; AL139404; CAI17277.1; JOINED; Genomic_DNA.
DR   EMBL; AL390961; CAI17278.1; -; Genomic_DNA.
DR   EMBL; AL139404; CAI17278.1; JOINED; Genomic_DNA.
DR   EMBL; AL390961; CAI17279.1; -; Genomic_DNA.
DR   EMBL; AL139404; CAI17279.1; JOINED; Genomic_DNA.
DR   EMBL; CH471072; EAW86079.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86080.1; -; Genomic_DNA.
DR   EMBL; BC024254; AAH24254.1; -; mRNA.
DR   CCDS; CCDS31169.1; -. [Q8IZP0-5]
DR   CCDS; CCDS31170.1; -. [Q8IZP0-3]
DR   CCDS; CCDS31171.1; -. [Q8IZP0-9]
DR   CCDS; CCDS53497.1; -. [Q8IZP0-11]
DR   CCDS; CCDS53498.1; -. [Q8IZP0-2]
DR   CCDS; CCDS53499.1; -. [Q8IZP0-4]
DR   CCDS; CCDS53500.1; -. [Q8IZP0-6]
DR   CCDS; CCDS53501.1; -. [Q8IZP0-12]
DR   CCDS; CCDS7150.1; -. [Q8IZP0-1]
DR   RefSeq; NP_001012768.1; NM_001012750.2. [Q8IZP0-9]
DR   RefSeq; NP_001012769.1; NM_001012751.2. [Q8IZP0-3]
DR   RefSeq; NP_001012770.1; NM_001012752.2. [Q8IZP0-5]
DR   RefSeq; NP_001171587.1; NM_001178116.1. [Q8IZP0-12]
DR   RefSeq; NP_001171590.1; NM_001178119.1. [Q8IZP0-6]
DR   RefSeq; NP_001171591.1; NM_001178120.1. [Q8IZP0-4]
DR   RefSeq; NP_001171592.1; NM_001178121.1. [Q8IZP0-2]
DR   RefSeq; NP_001171593.1; NM_001178122.1. [Q8IZP0-7]
DR   RefSeq; NP_001171594.1; NM_001178123.1.
DR   RefSeq; NP_001171595.1; NM_001178124.1. [Q8IZP0-10]
DR   RefSeq; NP_001171596.1; NM_001178125.1. [Q8IZP0-11]
DR   RefSeq; NP_005461.2; NM_005470.3. [Q8IZP0-1]
DR   UniGene; Hs.508148; -.
DR   ProteinModelPortal; Q8IZP0; -.
DR   SMR; Q8IZP0; 1-154, 436-503.
DR   BioGrid; 115324; 24.
DR   DIP; DIP-31118N; -.
DR   IntAct; Q8IZP0; 61.
DR   MINT; MINT-106609; -.
DR   PhosphoSite; Q8IZP0; -.
DR   DMDM; 50400546; -.
DR   MaxQB; Q8IZP0; -.
DR   PaxDb; Q8IZP0; -.
DR   PRIDE; Q8IZP0; -.
DR   Ensembl; ENST00000346832; ENSP00000279599; ENSG00000136754. [Q8IZP0-12]
DR   Ensembl; ENST00000359188; ENSP00000352114; ENSG00000136754. [Q8IZP0-6]
DR   Ensembl; ENST00000376138; ENSP00000365308; ENSG00000136754. [Q8IZP0-3]
DR   Ensembl; ENST00000376139; ENSP00000365309; ENSG00000136754. [Q8IZP0-5]
DR   Ensembl; ENST00000376140; ENSP00000365310; ENSG00000136754. [Q8IZP0-9]
DR   Ensembl; ENST00000376142; ENSP00000365312; ENSG00000136754. [Q8IZP0-1]
DR   Ensembl; ENST00000376166; ENSP00000365336; ENSG00000136754. [Q8IZP0-2]
DR   Ensembl; ENST00000376170; ENSP00000365340; ENSG00000136754. [Q8IZP0-4]
DR   Ensembl; ENST00000490841; ENSP00000440101; ENSG00000136754. [Q8IZP0-11]
DR   GeneID; 10006; -.
DR   KEGG; hsa:10006; -.
DR   UCSC; uc001isx.3; human. [Q8IZP0-1]
DR   UCSC; uc001isy.3; human. [Q8IZP0-9]
DR   UCSC; uc001isz.3; human. [Q8IZP0-5]
DR   UCSC; uc001ita.3; human. [Q8IZP0-3]
DR   UCSC; uc001itc.3; human. [Q8IZP0-6]
DR   UCSC; uc001itd.3; human. [Q8IZP0-4]
DR   UCSC; uc001ite.3; human. [Q8IZP0-2]
DR   UCSC; uc010qdh.2; human. [Q8IZP0-10]
DR   UCSC; uc010qdi.2; human. [Q8IZP0-11]
DR   CTD; 10006; -.
DR   GeneCards; GC10M027075; -.
DR   HGNC; HGNC:11320; ABI1.
DR   HPA; CAB008375; -.
DR   HPA; HPA029973; -.
DR   MIM; 603050; gene.
DR   neXtProt; NX_Q8IZP0; -.
DR   PharmGKB; PA36144; -.
DR   eggNOG; NOG262939; -.
DR   HOVERGEN; HBG050446; -.
DR   OrthoDB; EOG7J17ZT; -.
DR   PhylomeDB; Q8IZP0; -.
DR   TreeFam; TF314303; -.
DR   Reactome; REACT_6900; Immune System.
DR   SignaLink; Q8IZP0; -.
DR   ChiTaRS; ABI1; human.
DR   GeneWiki; ABI1; -.
DR   GenomeRNAi; 10006; -.
DR   NextBio; 37795; -.
DR   PRO; PR:Q8IZP0; -.
DR   ArrayExpress; Q8IZP0; -.
DR   Bgee; Q8IZP0; -.
DR   Genevestigator; Q8IZP0; -.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; TAS:ProtInc.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0030175; C:filopodium; IDA:UniProtKB.
DR   GO; GO:0030426; C:growth cone; IEA:UniProtKB-SubCell.
DR   GO; GO:0005622; C:intracellular; IDA:MGI.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031209; C:SCAR complex; IDA:UniProt.
DR   GO; GO:0008092; F:cytoskeletal protein binding; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0032403; F:protein complex binding; IDA:UniProt.
DR   GO; GO:0030296; F:protein tyrosine kinase activator activity; IEA:Ensembl.
DR   GO; GO:0008154; P:actin polymerization or depolymerization; NAS:UniProtKB.
DR   GO; GO:0006928; P:cellular component movement; IDA:UniProtKB.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0072673; P:lamellipodium morphogenesis; IEA:Ensembl.
DR   GO; GO:0035855; P:megakaryocyte development; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; TAS:ProtInc.
DR   InterPro; IPR028457; ABI.
DR   InterPro; IPR028456; ABI1.
DR   InterPro; IPR012849; Abl-interactor_HHR_dom.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR000727; T_SNARE_dom.
DR   PANTHER; PTHR10460; PTHR10460; 1.
DR   PANTHER; PTHR10460:SF2; PTHR10460:SF2; 1.
DR   Pfam; PF07815; Abi_HHR; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   PROSITE; PS50002; SH3; 1.
DR   PROSITE; PS50192; T_SNARE; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Cell junction; Cell membrane;
KW   Cell projection; Chromosomal rearrangement; Coiled coil;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Direct protein sequencing;
KW   Membrane; Nucleus; Phosphoprotein; Polymorphism;
KW   Postsynaptic cell membrane; Reference proteome; SH3 domain; Synapse.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    508       Abl interactor 1.
FT                                /FTId=PRO_0000191787.
FT   DOMAIN       45    107       t-SNARE coiled-coil homology.
FT   DOMAIN      446    505       SH3.
FT   REGION       18     79       Required for binding to WASF1 (By
FT                                similarity).
FT   COMPBIAS    260    418       Pro-rich.
FT   SITE         95     96       Breakpoint for translocation to form
FT                                KMT2A/MLL1-ABI1.
FT   MOD_RES       2      2       N-acetylalanine.
FT   MOD_RES      53     53       Phosphotyrosine (By similarity).
FT   MOD_RES     183    183       Phosphoserine.
FT   MOD_RES     213    213       Phosphotyrosine; by ABL1.
FT   MOD_RES     216    216       Phosphoserine.
FT   MOD_RES     222    222       Phosphoserine.
FT   MOD_RES     225    225       Phosphoserine.
FT   MOD_RES     323    323       Phosphoserine.
FT   MOD_RES     455    455       Phosphotyrosine (By similarity).
FT   MOD_RES     507    507       Phosphothreonine.
FT   VAR_SEQ      38     38       I -> IQRHGFAVLLCLLSNSWP (in isoform 12).
FT                                /FTId=VSP_044604.
FT   VAR_SEQ      96    159       Missing (in isoform 11).
FT                                /FTId=VSP_043403.
FT   VAR_SEQ     154    158       Missing (in isoform 2, isoform 5 and
FT                                isoform 10).
FT                                /FTId=VSP_010749.
FT   VAR_SEQ     274    300       Missing (in isoform 2, isoform 3, isoform
FT                                4, isoform 5, isoform 6, isoform 7,
FT                                isoform 8, isoform 9, isoform 10 and
FT                                isoform 11).
FT                                /FTId=VSP_010750.
FT   VAR_SEQ     301    301       Missing (in isoform 2, isoform 4, isoform
FT                                6, isoform 7, isoform 8, isoform 10 and
FT                                isoform 11).
FT                                /FTId=VSP_010751.
FT   VAR_SEQ     302    359       Missing (in isoform 7, isoform 8, isoform
FT                                10 and isoform 11).
FT                                /FTId=VSP_010754.
FT   VAR_SEQ     360    388       Missing (in isoform 2, isoform 3, isoform
FT                                4, isoform 8, isoform 10, isoform 11 and
FT                                isoform 12).
FT                                /FTId=VSP_010752.
FT   VAR_SEQ     360    360       I -> V (in isoform 7).
FT                                /FTId=VSP_010755.
FT   VAR_SEQ     389    389       I -> V (in isoform 10 and isoform 11).
FT                                /FTId=VSP_010753.
FT   VARIANT     331    331       G -> A (in dbSNP:rs2306236).
FT                                /FTId=VAR_048159.
FT   CONFLICT    177    177       P -> L (in Ref. 2; AAC39757).
FT   CONFLICT    410    410       S -> F (in Ref. 2; AAC39757 and 4;
FT                                AAN28379).
FT   CONFLICT    437    437       D -> G (in Ref. 8; BAG54374).
SQ   SEQUENCE   508 AA;  55081 MW;  2D76F305934127CB CRC64;
     MAELQMLLEE EIPSGKRALI ESYQNLTRVA DYCENNYIQA TDKRKALEET KAYTTQSLAS
     VAYQINALAN NVLQLLDIQA SQLRRMESSI NHISQTVDIH KEKVARREIG ILTTNKNTSR
     THKIIAPANM ERPVRYIRKP IDYTVLDDVG HGVKWLKAKH GNNQPARTGT LSRTNPPTQK
     PPSPPMSGRG TLGRNTPYKT LEPVKPPTVP NDYMTSPARL GSQHSPGRTA SLNQRPRTHS
     GSSGGSGSRE NSGSSSIGIP IAVPTPSPPT IGPENISVPP PSGAPPAPPL APLLPVSTVI
     AAPGSAPGSQ YGTMTRQISR HNSTTSSTSS GGYRRTPSVT AQFSAQPHVN GGPLYSQNSI
     SIAPPPPPMP QLTPQIPLTG FVARVQENIA DSPTPPPPPP PDDIPMFDDS PPPPPPPPVD
     YEDEEAAVVQ YNDPYADGDP AWAPKNYIEK VVAIYDYTKD KDDELSFMEG AIIYVIKKND
     DGWYEGVCNR VTGLFPGNYV ESIMHYTD
//
ID   ABI2_HUMAN              Reviewed;         513 AA.
AC   Q9NYB9; B4DSN1; Q13147; Q13249; Q13801; Q9BV70;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   09-JUL-2014, entry version 122.
DE   RecName: Full=Abl interactor 2;
DE   AltName: Full=Abelson interactor 2;
DE            Short=Abi-2;
DE   AltName: Full=Abl-binding protein 3;
DE            Short=AblBP3;
DE   AltName: Full=Arg-binding protein 1;
DE            Short=ArgBP1;
GN   Name=ABI2; Synonyms=ARGBPIA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), FUNCTION,
RP   PHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH ABL1.
RX   PubMed=7590236; DOI=10.1101/gad.9.21.2569;
RA   Dai Z., Pendergast A.M.;
RT   "Abi-2, a novel SH3-containing protein interacts with the c-Abl
RT   tyrosine kinase and modulates c-Abl transforming activity.";
RL   Genes Dev. 9:2569-2582(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Ren R.;
RT   "Cloning of a binding substrate of the Abl protein tyrosine kinase.";
RL   Submitted (JUL-1995) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND INTERACTION WITH
RP   ABL2.
RC   TISSUE=Brain;
RX   PubMed=8649853;
RA   Wang B., Mysliwiec T., Krainc D., Jensen R.A., Sonoda G., Testa J.R.,
RA   Golemis E.A., Kruh G.D.;
RT   "Identification of ArgBP1, an Arg protein tyrosine kinase binding
RT   protein that is the human homologue of a CNS-specific Xenopus gene.";
RL   Oncogene 12:1921-1929(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION.
RX   PubMed=10498863; DOI=10.1038/sj.onc.1202911;
RA   Juang J.L., Hoffmann F.M.;
RT   "Drosophila abelson interacting protein (dAbi) is a positive regulator
RT   of abelson tyrosine kinase activity.";
RL   Oncogene 18:5138-5147(1999).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11516653; DOI=10.1016/S0960-9822(01)00239-1;
RA   Stradal T.E.B., Courtney K.D., Rottner K., Hahne P., Small J.V.,
RA   Pendergast A.M.;
RT   "The Abl interactor proteins localize to sites of actin polymerization
RT   at the tips of lamellipodia and filopodia.";
RL   Curr. Biol. 11:891-895(2001).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-227, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-227 AND SER-368, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-227, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [13]
RP   STRUCTURE BY NMR OF 444-508.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the SH3 domain of Abl interactor 2 (Abelson
RT   interactor 2).";
RL   Submitted (FEB-2008) to the PDB data bank.
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.29 ANGSTROMS) OF 1-164, AND SUBUNIT.
RX   PubMed=21107423; DOI=10.1038/nature09623;
RA   Chen Z., Borek D., Padrick S.B., Gomez T.S., Metlagel Z., Ismail A.M.,
RA   Umetani J., Billadeau D.D., Otwinowski Z., Rosen M.K.;
RT   "Structure and control of the actin regulatory WAVE complex.";
RL   Nature 468:533-538(2010).
CC   -!- FUNCTION: May act in regulation of cell growth and transformation
CC       by interacting with nonreceptor tyrosine kinases ABL1 and/or ABL2.
CC       Part of the WAVE complex that regulates lamellipodia formation.
CC       The WAVE complex regulates actin filament reorganization via its
CC       interaction with the Arp2/3 complex. Regulates ABL1/c-Abl-mediated
CC       phosphorylation of MENA.
CC   -!- SUBUNIT: Component of the WAVE1 complex composed of ABI2, CYFIP1
CC       or CYFIP2, BRK1, NCKAP1 and WASF1/WAVE1. Within the complex, a
CC       heterdimer containing NCKAP1 and CYFIP1 interacts with a
CC       heterotrimer formed by WAVE1, ABI2 and BRK1. CYFIP2 binds to
CC       activated RAC1 which causes the complex to dissociate, releasing
CC       activated WASF1. The complex can also be activated by NCK1 (By
CC       similarity). Interacts with ABL1 and ABL2.
CC   -!- INTERACTION:
CC       P00519:ABL1; NbExp=2; IntAct=EBI-743598, EBI-375543;
CC       Q8VHK2:Caskin1 (xeno); NbExp=3; IntAct=EBI-743598, EBI-7049475;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity).
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell projection, lamellipodium
CC       (By similarity). Cell projection, filopodium (By similarity).
CC       Cytoplasm, cytoskeleton (By similarity). Note=Isoform 1 but not
CC       isoform 3 is localized to protruding lamellipodia and filopodia
CC       tips (By similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Abi-2b;
CC         IsoId=Q9NYB9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NYB9-2; Sequence=VSP_010761, VSP_010762, VSP_010763;
CC       Name=3; Synonyms=Abi-2a;
CC         IsoId=Q9NYB9-3; Sequence=VSP_010759, VSP_010760, VSP_010761,
CC                                  VSP_010762;
CC       Name=4;
CC         IsoId=Q9NYB9-4; Sequence=VSP_010761;
CC   -!- PTM: Is a substrate for ABL1.
CC   -!- SIMILARITY: Belongs to the ABI family.
CC   -!- SIMILARITY: Contains 1 SH3 domain.
CC   -!- SIMILARITY: Contains 1 t-SNARE coiled-coil homology domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U23435; AAA92289.1; -; mRNA.
DR   EMBL; U31089; AAA75446.1; -; mRNA.
DR   EMBL; AF260261; AAF70308.1; -; mRNA.
DR   EMBL; X95632; CAA64885.1; -; mRNA.
DR   EMBL; BT009920; AAP88922.1; -; mRNA.
DR   EMBL; AK299824; BAG61693.1; -; mRNA.
DR   EMBL; BC001439; AAH01439.1; -; mRNA.
DR   CCDS; CCDS2358.1; -. [Q9NYB9-2]
DR   CCDS; CCDS63093.1; -. [Q9NYB9-1]
DR   CCDS; CCDS63094.1; -. [Q9NYB9-4]
DR   CCDS; CCDS63096.1; -. [Q9NYB9-3]
DR   PIR; G01936; G01936.
DR   RefSeq; NP_001269854.1; NM_001282925.1.
DR   RefSeq; NP_001269855.1; NM_001282926.1.
DR   RefSeq; NP_001269856.1; NM_001282927.1. [Q9NYB9-3]
DR   RefSeq; NP_005750.4; NM_005759.5. [Q9NYB9-2]
DR   RefSeq; XP_006712248.1; XM_006712185.1. [Q9NYB9-3]
DR   UniGene; Hs.471156; -.
DR   PDB; 2ED0; NMR; -; A=444-508.
DR   PDB; 3P8C; X-ray; 2.29 A; F=1-164.
DR   PDB; 4N78; X-ray; 2.43 A; F=1-513.
DR   PDBsum; 2ED0; -.
DR   PDBsum; 3P8C; -.
DR   PDBsum; 4N78; -.
DR   ProteinModelPortal; Q9NYB9; -.
DR   SMR; Q9NYB9; 1-154, 444-508.
DR   BioGrid; 115454; 21.
DR   DIP; DIP-37566N; -.
DR   IntAct; Q9NYB9; 23.
DR   MINT; MINT-252647; -.
DR   STRING; 9606.ENSP00000261017; -.
DR   PhosphoSite; Q9NYB9; -.
DR   DMDM; 50400673; -.
DR   MaxQB; Q9NYB9; -.
DR   PaxDb; Q9NYB9; -.
DR   PRIDE; Q9NYB9; -.
DR   DNASU; 10152; -.
DR   Ensembl; ENST00000261016; ENSP00000261016; ENSG00000138443. [Q9NYB9-3]
DR   Ensembl; ENST00000261017; ENSP00000261017; ENSG00000138443. [Q9NYB9-2]
DR   Ensembl; ENST00000424558; ENSP00000391433; ENSG00000138443.
DR   GeneID; 10152; -.
DR   KEGG; hsa:10152; -.
DR   UCSC; uc002uzz.3; human. [Q9NYB9-2]
DR   UCSC; uc002vab.3; human. [Q9NYB9-3]
DR   CTD; 10152; -.
DR   GeneCards; GC02P204192; -.
DR   H-InvDB; HIX0002759; -.
DR   HGNC; HGNC:24011; ABI2.
DR   MIM; 606442; gene.
DR   neXtProt; NX_Q9NYB9; -.
DR   PharmGKB; PA134977642; -.
DR   eggNOG; NOG262939; -.
DR   HOGENOM; HOG000293213; -.
DR   HOVERGEN; HBG050446; -.
DR   InParanoid; Q9NYB9; -.
DR   KO; K05751; -.
DR   PhylomeDB; Q9NYB9; -.
DR   TreeFam; TF314303; -.
DR   Reactome; REACT_6900; Immune System.
DR   ChiTaRS; ABI2; human.
DR   EvolutionaryTrace; Q9NYB9; -.
DR   GeneWiki; ABI2; -.
DR   GenomeRNAi; 10152; -.
DR   NextBio; 38426; -.
DR   PRO; PR:Q9NYB9; -.
DR   ArrayExpress; Q9NYB9; -.
DR   Bgee; Q9NYB9; -.
DR   CleanEx; HS_ABI2; -.
DR   Genevestigator; Q9NYB9; -.
DR   GO; GO:0005913; C:cell-cell adherens junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0030175; C:filopodium; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0031209; C:SCAR complex; IDA:UniProt.
DR   GO; GO:0008093; F:cytoskeletal adaptor activity; TAS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0019900; F:kinase binding; NAS:UniProtKB.
DR   GO; GO:0070064; F:proline-rich region binding; IPI:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0032403; F:protein complex binding; IDA:UniProt.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL.
DR   GO; GO:0008154; P:actin polymerization or depolymerization; NAS:UniProtKB.
DR   GO; GO:0043010; P:camera-type eye development; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; TAS:UniProtKB.
DR   GO; GO:0006928; P:cellular component movement; IDA:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0016358; P:dendrite development; IEA:Ensembl.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:2000601; P:positive regulation of Arp2/3 complex-mediated actin nucleation; IDA:UniProt.
DR   GO; GO:0016601; P:Rac protein signal transduction; IDA:UniProt.
DR   InterPro; IPR028457; ABI.
DR   InterPro; IPR028454; Abi2.
DR   InterPro; IPR012849; Abl-interactor_HHR_dom.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR000727; T_SNARE_dom.
DR   PANTHER; PTHR10460; PTHR10460; 1.
DR   PANTHER; PTHR10460:SF3; PTHR10460:SF3; 1.
DR   Pfam; PF07815; Abi_HHR; 1.
DR   Pfam; PF14604; SH3_9; 1.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   PROSITE; PS50002; SH3; 1.
DR   PROSITE; PS50192; T_SNARE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell projection; Coiled coil;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Phosphoprotein;
KW   Reference proteome; SH3 domain.
FT   CHAIN         1    513       Abl interactor 2.
FT                                /FTId=PRO_0000191790.
FT   DOMAIN       45    107       t-SNARE coiled-coil homology.
FT   DOMAIN      451    510       SH3.
FT   COMPBIAS    172    423       Pro-rich.
FT   MOD_RES     227    227       Phosphoserine.
FT   MOD_RES     368    368       Phosphoserine.
FT   VAR_SEQ       1     45       Missing (in isoform 3).
FT                                /FTId=VSP_010759.
FT   VAR_SEQ      46     95       ALEETKAYTTQSLASVAYLINTLANNVLQMLDIQASQLRRM
FT                                ESSINHISQ -> MSCRCWISRHPSYEGWNLQSIIFHKQIR
FT                                GVDLESTFVTKFGNNCSLRLNE (in isoform 3).
FT                                /FTId=VSP_010760.
FT   VAR_SEQ     154    159       Missing (in isoform 2, isoform 3 and
FT                                isoform 4).
FT                                /FTId=VSP_010761.
FT   VAR_SEQ     284    344       Missing (in isoform 2 and isoform 3).
FT                                /FTId=VSP_010762.
FT   VAR_SEQ     399    399       S -> SLAPPPPSILQVTPQLPLMGFVARVQENIS (in
FT                                isoform 2).
FT                                /FTId=VSP_010763.
FT   CONFLICT     22     22       S -> R (in Ref. 3; CAA64885).
FT   CONFLICT     69     69       A -> D (in Ref. 3; CAA64885).
FT   CONFLICT    243    243       S -> T (in Ref. 2; AAA75446).
FT   CONFLICT    249    249       G -> P (in Ref. 1; AAA92289).
FT   CONFLICT    317    317       N -> D (in Ref. 5; BAG61693).
FT   CONFLICT    324    325       PN -> QT (in Ref. 5; BAG61693).
FT   CONFLICT    432    432       A -> V (in Ref. 2; AAA75446).
FT   CONFLICT    500    500       F -> S (in Ref. 2; AAA75446).
FT   HELIX         1      9
FT   HELIX        11     39
FT   HELIX        43    110
FT   STRAND      123    125
FT   TURN        143    151
FT   STRAND      453    458
FT   STRAND      477    483
FT   STRAND      485    493
FT   STRAND      496    501
FT   STRAND      504    507
SQ   SEQUENCE   513 AA;  55663 MW;  822983A69E5EA512 CRC64;
     MAELQMLLEE EIPGGRRALF DSYTNLERVA DYCENNYIQS ADKQRALEET KAYTTQSLAS
     VAYLINTLAN NVLQMLDIQA SQLRRMESSI NHISQTVDIH KEKVARREIG ILTTNKNTSR
     THKIIAPANL ERPVRYIRKP IDYTILDDIG HGVKWLLRFK VSTQNMKMGG LPRTTPPTQK
     PPSPPMSGKG TLGRHSPYRT LEPVRPPVVP NDYVPSPTRN MAPSQQSPVR TASVNQRNRT
     YSSSGSSGGS HPSSRSSSRE NSGSGSVGVP IAVPTPSPPS VFPAPAGSAG TPPLPATSAS
     APAPLVPATV PSSTAPNAAA GGAPNLADGF TSPTPPVVSS TPPTGHPVQF YSMNRPASRH
     TPPTIGGSLP YRRPPSITSQ TSLQNQMNGG PFYSQNPVSD TPPPPPPVEE PVFDESPPPP
     PPPEDYEEEE AAVVEYSDPY AEEDPPWAPR SYLEKVVAIY DYTKDKEDEL SFQEGAIIYV
     IKKNDDGWYE GVMNGVTGLF PGNYVESIMH YSE
//
ID   ABL1_HUMAN              Reviewed;        1130 AA.
AC   P00519; A3KFJ3; Q13869; Q13870; Q16133; Q17R61; Q45F09;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2006, sequence version 4.
DT   09-JUL-2014, entry version 204.
DE   RecName: Full=Tyrosine-protein kinase ABL1;
DE            EC=2.7.10.2;
DE   AltName: Full=Abelson murine leukemia viral oncogene homolog 1;
DE   AltName: Full=Abelson tyrosine-protein kinase 1;
DE   AltName: Full=Proto-oncogene c-Abl;
DE   AltName: Full=p150;
GN   Name=ABL1; Synonyms=ABL, JTK7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM IA), ALTERNATIVE SPLICING, AND
RP   VARIANT PRO-140.
RX   PubMed=3021337; DOI=10.1016/0092-8674(86)90450-2;
RA   Shtivelman E., Lifshitz B., Gale R.P., Roe B.A., Canaani E.;
RT   "Alternative splicing of RNAs transcribed from the human abl gene and
RT   from the bcr-abl fused gene.";
RL   Cell 47:277-284(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM IA).
RC   TISSUE=Fibroblast;
RX   PubMed=2687768;
RA   Fainstein E., Einat M., Gokkel E., Marcelle C., Croce C.M., Gale R.P.,
RA   Canaani E.;
RT   "Nucleotide sequence analysis of human abl and bcr-abl cDNAs.";
RL   Oncogene 4:1477-1481(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS IA AND IB).
RC   TISSUE=Lung;
RX   PubMed=7665185; DOI=10.1006/geno.1995.1008;
RA   Chissoe S.L., Bodenteich A., Wang Y.-F., Wang Y.-P., Burian D.,
RA   Clifton S.W., Crabtree J., Freeman A., Iyer K., Jian L., Ma Y.,
RA   McLaury H.-J., Pan H.-Q., Sarhan O.H., Toth S., Wang Z., Zhang G.,
RA   Heisterkamp N., Groffen J., Roe B.A.;
RT   "Sequence and analysis of the human ABL gene, the BCR gene, and
RT   regions involved in the Philadelphia chromosomal translocation.";
RL   Genomics 27:67-82(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-706; PRO-852;
RP   SER-900 AND LEU-972.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM IB).
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 27-40, AND SUBCELLULAR COMPONENT.
RX   PubMed=2825022; DOI=10.1038/330386a0;
RA   Fainstein E., Marcelle C., Rosner A., Canaani E., Gale R.P.,
RA   Dreazen O., Smith S.D., Croce C.M.;
RT   "A new fused transcript in Philadelphia chromosome positive acute
RT   lymphocytic leukaemia.";
RL   Nature 330:386-388(1987).
RN   [9]
RP   NUCLEOTIDE SEQUENCE OF 360-426.
RX   PubMed=6191223; DOI=10.1038/304167a0;
RA   Groffen J., Heisterkamp N., Reynolds F.H. Jr., Stephenson J.R.;
RT   "Homology between phosphotyrosine acceptor site of human c-abl and
RT   viral oncogene products.";
RL   Nature 304:167-169(1983).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 825-845.
RX   PubMed=7545908;
RA   Inokuchi K., Futaki M., Dan K., Nomura T.;
RT   "Sequence analysis of the mutation at codon 834 and the sequence
RT   variation of codon 837 of c-abl gene.";
RL   Leukemia 8:343-344(1994).
RN   [11]
RP   MYRISTOYLATION (ISOFORM IB).
RX   PubMed=2542016;
RA   Jackson P., Baltimore D.;
RT   "N-terminal mutations activate the leukemogenic potential of the
RT   myristoylated form of c-abl.";
RL   EMBO J. 8:449-456(1989).
RN   [12]
RP   DOMAIN, AND DNA-BINDING.
RX   PubMed=2183353; DOI=10.1126/science.2183353;
RA   Kipreos E.T., Wang J.Y.;
RT   "Differential phosphorylation of c-Abl in cell cycle determined by
RT   cdc2 kinase and phosphatase activity.";
RL   Science 248:217-220(1990).
RN   [13]
RP   FUNCTION.
RX   PubMed=9037071; DOI=10.1073/pnas.94.4.1437;
RA   Yuan Z.M., Huang Y., Ishiko T., Kharbanda S., Weichselbaum R.,
RA   Kufe D.;
RT   "Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine
RT   kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:1437-1440(1997).
RN   [14]
RP   INTERACTION WITH RIN1, AND FUNCTION.
RX   PubMed=9144171; DOI=10.1073/pnas.94.10.4954;
RA   Han L., Wong D., Dhaka A., Afar D.E.H., White M., Xie W.,
RA   Herschman H., Witte O., Colicelli J.;
RT   "Protein binding and signaling properties of RIN1 suggest a unique
RT   effector function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:4954-4959(1997).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH RAD51.
RX   PubMed=9461559; DOI=10.1074/jbc.273.7.3799;
RA   Yuan Z.M., Huang Y., Ishiko T., Nakada S., Utsugisawa T.,
RA   Kharbanda S., Wang R., Sung P., Shinohara A., Weichselbaum R.,
RA   Kufe D.;
RT   "Regulation of Rad51 function by c-Abl in response to DNA damage.";
RL   J. Biol. Chem. 273:3799-3802(1998).
RN   [16]
RP   INTERACTION WITH INPPL1.
RX   PubMed=10194451;
RA   Wisniewski D., Strife A., Swendeman S., Erdjument-Bromage H.,
RA   Geromanos S., Kavanaugh W.M., Tempst P., Clarkson B.;
RT   "A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-
RT   phosphatase (SHIP2) is constitutively tyrosine phosphorylated and
RT   associated with src homologous and collagen gene (SHC) in chronic
RT   myelogenous leukemia progenitor cells.";
RL   Blood 93:2707-2720(1999).
RN   [17]
RP   FUNCTION, ENZYME REGULATION, AND INTERACTION WITH TP73.
RX   PubMed=10391250; DOI=10.1038/21697;
RA   Agami R., Blandino G., Oren M., Shaul Y.;
RT   "Interaction of c-Abl and p73alpha and their collaboration to induce
RT   apoptosis.";
RL   Nature 399:809-813(1999).
RN   [18]
RP   DNA-BINDING.
RX   PubMed=10325413; DOI=10.1093/nar/27.11.2265;
RA   David-Cordonnier M.H., Payet D., D'Halluin J.C., Waring M.J.,
RA   Travers A.A., Bailly C.;
RT   "The DNA-binding domain of human c-Abl tyrosine kinase promotes the
RT   interaction of a HMG chromosomal protein with DNA.";
RL   Nucleic Acids Res. 27:2265-2270(1999).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=11114745; DOI=10.1038/sj.onc.1203878;
RA   Wang J.Y.;
RT   "Regulation of cell death by the Abl tyrosine kinase.";
RL   Oncogene 19:5643-5650(2000).
RN   [20]
RP   INTERACTION WITH SORBS1.
RX   PubMed=11374898; DOI=10.1006/geno.2001.6541;
RA   Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y.,
RA   Chuang L.-M.;
RT   "Cloning, mapping, and characterization of the human sorbin and SH3
RT   domain containing 1 (SORBS1) gene: a protein associated with c-Abl
RT   during insulin signaling in the hepatoma cell line Hep3B.";
RL   Genomics 74:12-20(2001).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH RAD52.
RX   PubMed=12379650; DOI=10.1074/jbc.M208151200;
RA   Kitao H., Yuan Z.M.;
RT   "Regulation of ionizing radiation-induced Rad52 nuclear foci formation
RT   by c-Abl-mediated phosphorylation.";
RL   J. Biol. Chem. 277:48944-48948(2002).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH RAD9A.
RX   PubMed=11971963; DOI=10.1128/MCB.22.10.3292-3300.2002;
RA   Yoshida K., Komatsu K., Wang H.-G., Kufe D.;
RT   "c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in
RT   response to DNA damage.";
RL   Mol. Cell. Biol. 22:3292-3300(2002).
RN   [23]
RP   UBIQUITINATION.
RX   PubMed=12475393; DOI=10.1042/BJ20021539;
RA   Soubeyran P., Barac A., Szymkiewicz I., Dikic I.;
RT   "Cbl-ArgBP2 complex mediates ubiquitination and degradation of c-
RT   Abl.";
RL   Biochem. J. 370:29-34(2003).
RN   [24]
RP   FUNCTION.
RX   PubMed=12531427; DOI=10.1016/S0898-6568(02)00090-6;
RA   Sanguinetti A.R., Mastick C.C.;
RT   "c-Abl is required for oxidative stress-induced phosphorylation of
RT   caveolin-1 on tyrosine 14.";
RL   Cell. Signal. 15:289-298(2003).
RN   [25]
RP   FUNCTION.
RX   PubMed=12672821; DOI=10.1074/jbc.M301447200;
RA   Tani K., Sato S., Sukezane T., Kojima H., Hirose H., Hanafusa H.,
RA   Shishido T.;
RT   "Abl interactor 1 promotes tyrosine 296 phosphorylation of mammalian
RT   enabled (Mena) by c-Abl kinase.";
RL   J. Biol. Chem. 278:21685-21692(2003).
RN   [26]
RP   REVIEW ON FUNCTION.
RX   PubMed=12775773; DOI=10.1242/jcs.00622;
RA   Woodring P.J., Hunter T., Wang J.Y.;
RT   "Regulation of F-actin-dependent processes by the Abl family of
RT   tyrosine kinases.";
RL   J. Cell Sci. 116:2613-2626(2003).
RN   [27]
RP   INTERACTION WITH BCR.
RX   PubMed=15302586; DOI=10.1016/j.yexcr.2004.05.010;
RA   Laurent C.E., Smithgall T.E.;
RT   "The c-Fes tyrosine kinase cooperates with the breakpoint cluster
RT   region protein (Bcr) to induce neurite extension in a Rac- and Cdc42-
RT   dependent manner.";
RL   Exp. Cell Res. 299:188-198(2004).
RN   [28]
RP   FUNCTION.
RX   PubMed=15556646; DOI=10.1016/j.febslet.2004.10.054;
RA   Grossmann A.H., Kolibaba K.S., Willis S.G., Corbin A.S., Langdon W.S.,
RA   Deininger M.W., Druker B.J.;
RT   "Catalytic domains of tyrosine kinases determine the phosphorylation
RT   sites within c-Cbl.";
RL   FEBS Lett. 577:555-562(2004).
RN   [29]
RP   FUNCTION.
RX   PubMed=15031292; DOI=10.1074/jbc.M311479200;
RA   Perkinton M.S., Standen C.L., Lau K.F., Kesavapany S., Byers H.L.,
RA   Ward M., McLoughlin D.M., Miller C.C.;
RT   "The c-Abl tyrosine kinase phosphorylates the Fe65 adaptor protein to
RT   stimulate Fe65/amyloid precursor protein nuclear signaling.";
RL   J. Biol. Chem. 279:22084-22091(2004).
RN   [30]
RP   REVIEW ON FUNCTION.
RX   PubMed=15686624; DOI=10.1038/sj.cr.7290261;
RA   Shaul Y., Ben-Yehoyada M.;
RT   "Role of c-Abl in the DNA damage stress response.";
RL   Cell Res. 15:33-35(2005).
RN   [31]
RP   FUNCTION.
RX   PubMed=15886098; DOI=10.1016/j.cub.2005.03.049;
RA   Hu H., Bliss J.M., Wang Y., Colicelli J.;
RT   "RIN1 is an ABL tyrosine kinase activator and a regulator of
RT   epithelial-cell adhesion and migration.";
RL   Curr. Biol. 15:815-823(2005).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH CASP9.
RX   PubMed=15657060; DOI=10.1074/jbc.M413787200;
RA   Raina D., Pandey P., Ahmad R., Bharti A., Ren J., Kharbanda S.,
RA   Weichselbaum R., Kufe D.;
RT   "c-Abl tyrosine kinase regulates caspase-9 autocleavage in the
RT   apoptotic response to DNA damage.";
RL   J. Biol. Chem. 280:11147-11151(2005).
RN   [33]
RP   INTERACTION WITH YWHAB; YWHAE; YWHAG; YWHAH; SFN AND YWHAZ,
RP   PHOSPHORYLATION AT THR-735, IDENTIFICATION BY MASS SPECTROMETRY,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-735.
RX   PubMed=15696159; DOI=10.1038/ncb1228;
RA   Yoshida K., Yamaguchi T., Natsume T., Kufe D., Miki Y.;
RT   "JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of
RT   c-Abl in the apoptotic response to DNA damage.";
RL   Nat. Cell Biol. 7:278-285(2005).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [35]
RP   ACETYLATION AT LYS-711, AND SUBCELLULAR LOCATION.
RX   PubMed=16648821; DOI=10.1038/sj.embor.7400700;
RA   di Bari M.G., Ciuffini L., Mingardi M., Testi R., Soddu S., Barila D.;
RT   "c-Abl acetylation by histone acetyltransferases regulates its
RT   nuclear-cytoplasmic localization.";
RL   EMBO Rep. 7:727-733(2006).
RN   [36]
RP   PHOSPHORYLATION AT TYR-70; TYR-115; TYR-128; TYR-139; TYR-172; TYR-185
RP   TYR-215; TYR-226 AND TYR-393, INTERACTION WITH HCK; LYN AND FYN, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16912036; DOI=10.1074/jbc.M605902200;
RA   Meyn M.A. III, Wilson M.B., Abdi F.A., Fahey N., Schiavone A.P.,
RA   Wu J., Hochrein J.M., Engen J.R., Smithgall T.E.;
RT   "Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and
RT   modulate Bcr-Abl transforming activity.";
RL   J. Biol. Chem. 281:30907-30916(2006).
RN   [37]
RP   FUNCTION.
RX   PubMed=16943190; DOI=10.1074/jbc.M603126200;
RA   Tanos B., Pendergast A.M.;
RT   "Abl tyrosine kinase regulates endocytosis of the epidermal growth
RT   factor receptor.";
RL   J. Biol. Chem. 281:32714-32723(2006).
RN   [38]
RP   FUNCTION, AND INTERACTION WITH PSMA7.
RX   PubMed=16678104; DOI=10.1016/j.molcel.2006.04.007;
RA   Liu X., Huang W., Li C., Li P., Yuan J., Li X., Qiu X.B., Ma Q.,
RA   Cao C.;
RT   "Interaction between c-Abl and Arg tyrosine kinases and proteasome
RT   subunit PSMA7 regulates proteasome degradation.";
RL   Mol. Cell 22:317-327(2006).
RN   [39]
RP   FUNCTION.
RX   PubMed=17306540; DOI=10.1016/j.cub.2007.01.057;
RA   Boyle S.N., Michaud G.A., Schweitzer B., Predki P.F., Koleske A.J.;
RT   "A critical role for cortactin phosphorylation by Abl-family kinases
RT   in PDGF-induced dorsal-wave formation.";
RL   Curr. Biol. 17:445-451(2007).
RN   [40]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH WASF3.
RX   PubMed=17623672; DOI=10.1074/jbc.M701484200;
RA   Sossey-Alaoui K., Li X., Cowell J.K.;
RT   "c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia
RT   formation and cell migration.";
RL   J. Biol. Chem. 282:26257-26265(2007).
RN   [41]
RP   PHOSPHORYLATION AT SER-618 AND SER-619, AND INTERACTION WITH ABI2 AND
RP   CRK.
RX   PubMed=18161990; DOI=10.1021/bi701533j;
RA   Jung J.H., Pendergast A.M., Zipfel P.A., Traugh J.A.;
RT   "Phosphorylation of c-Abl by protein kinase Pak2 regulates
RT   differential binding of ABI2 and CRK.";
RL   Biochemistry 47:1094-1104(2008).
RN   [42]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=18328268; DOI=10.1016/j.bbamcr.2008.01.028;
RA   Xiong X., Cui P., Hossain S., Xu R., Warner B., Guo X., An X.,
RA   Debnath A.K., Cowburn D., Kotula L.;
RT   "Allosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase
RT   by phosphopeptides derived from Abi1/Hssh3bp1.";
RL   Biochim. Biophys. Acta 1783:737-747(2008).
RN   [43]
RP   FUNCTION.
RX   PubMed=18945674; DOI=10.1074/jbc.M804543200;
RA   Yogalingam G., Pendergast A.M.;
RT   "Abl kinases regulate autophagy by promoting the trafficking and
RT   function of lysosomal components.";
RL   J. Biol. Chem. 283:35941-35953(2008).
RN   [44]
RP   PHOSPHORYLATION AT TYR-70, AND INTERACTION WITH ABI1.
RX   PubMed=18775435; DOI=10.1016/j.jmb.2008.08.040;
RA   Chen S., O'Reilly L.P., Smithgall T.E., Engen J.R.;
RT   "Tyrosine phosphorylation in the SH3 domain disrupts negative
RT   regulatory interactions within the c-Abl kinase core.";
RL   J. Mol. Biol. 383:414-423(2008).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50; SER-569; SER-659;
RP   THR-814; THR-844 AND SER-977, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569; THR-852 AND
RP   SER-917, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [47]
RP   REVIEW ON FUNCTION.
RX   PubMed=18182299; DOI=10.1016/j.tibs.2007.10.006;
RA   Backert S., Feller S.M., Wessler S.;
RT   "Emerging roles of Abl family tyrosine kinases in microbial
RT   pathogenesis.";
RL   Trends Biochem. Sci. 33:80-90(2008).
RN   [48]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [49]
RP   FUNCTION.
RX   PubMed=19891780; DOI=10.1186/1471-2121-10-80;
RA   Fernow I., Tomasovic A., Siehoff-Icking A., Tikkanen R.;
RT   "Cbl-associated protein is tyrosine phosphorylated by c-Abl and c-Src
RT   kinases.";
RL   BMC Cell Biol. 10:80-80(2009).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50 AND SER-569, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [52]
RP   FUNCTION.
RX   PubMed=20417104; DOI=10.1016/j.cub.2010.03.048;
RA   Michael M., Vehlow A., Navarro C., Krause M.;
RT   "c-Abl, Lamellipodin, and Ena/VASP proteins cooperate in dorsal
RT   ruffling of fibroblasts and axonal morphogenesis.";
RL   Curr. Biol. 20:783-791(2010).
RN   [53]
RP   INTERACTION WITH MYLK AND CTTN.
RX   PubMed=20861316; DOI=10.1091/mbc.E09-10-0876;
RA   Dudek S.M., Chiang E.T., Camp S.M., Guo Y., Zhao J., Brown M.E.,
RA   Singleton P.A., Wang L., Desai A., Arce F.T., Lal R., Van Eyk J.E.,
RA   Imam S.Z., Garcia J.G.N.;
RT   "Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain
RT   kinase to regulate endothelial barrier function.";
RL   Mol. Biol. Cell 21:4042-4056(2010).
RN   [54]
RP   REVIEW ON FUNCTION, AND DOMAIN.
RX   PubMed=20841568; DOI=10.1126/scisignal.3139re6;
RA   Colicelli J.;
RT   "ABL tyrosine kinases: evolution of function, regulation, and
RT   specificity.";
RL   Sci. Signal. 3:RE6-RE6(2010).
RN   [55]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [56]
RP   INTERACTION WITH STX17.
RX   PubMed=23006999; DOI=10.1016/j.bbamcr.2012.09.003;
RA   Muppirala M., Gupta V., Swarup G.;
RT   "Tyrosine phosphorylation of a SNARE protein, Syntaxin 17:
RT   Implications for membrane trafficking in the early secretory
RT   pathway.";
RL   Biochim. Biophys. Acta 1823:2109-2119(2012).
RN   [57]
RP   STRUCTURE BY NMR OF SH2 DOMAIN.
RX   PubMed=1505033; DOI=10.1016/0092-8674(92)90437-H;
RA   Overduin M., Rios C.B., Mayer B.J., Baltimore D., Cowburn D.;
RT   "Three-dimensional solution structure of the src homology 2 domain of
RT   c-abl.";
RL   Cell 70:697-704(1992).
RN   [58]
RP   STRUCTURE BY NMR OF SH2 DOMAIN.
RX   PubMed=1281542; DOI=10.1073/pnas.89.24.11673;
RA   Overduin M., Mayer B.J., Rios C.B., Baltimore D., Cowburn D.;
RT   "Secondary structure of Src homology 2 domain of c-Abl by
RT   heteronuclear NMR spectroscopy in solution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:11673-11677(1992).
RN   [59]
RP   3D-STRUCTURE MODELING OF SH3 DOMAIN.
RX   PubMed=7892170; DOI=10.1002/prot.340200302;
RA   Pisabarro M.T., Ortiz A.R., Serrano L., Wade R.C.;
RT   "Homology modeling of the Abl-SH3 domain.";
RL   Proteins 20:203-215(1994).
RN   [60]
RP   STRUCTURE BY NMR OF SH3 DOMAIN.
RX   PubMed=8590002; DOI=10.1016/S0969-2126(01)00243-X;
RA   Gosser Y.Q., Zheng J., Overduin M., Mayer B.J., Cowburn D.;
RT   "The solution structure of Abl SH3, and its relationship to SH2 in the
RT   SH(32) construct.";
RL   Structure 3:1075-1086(1995).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 64-121.
RX   PubMed=9698566; DOI=10.1006/jmbi.1998.1932;
RA   Pisabarro M.T., Serrano L., Wilmanns M.;
RT   "Crystal structure of the abl-SH3 domain complexed with a designed
RT   high-affinity peptide ligand: implications for SH3-ligand
RT   interactions.";
RL   J. Mol. Biol. 281:513-521(1998).
RN   [62]
RP   STRUCTURE BY NMR OF 62-122 IN COMPLEX WITH CRK.
RX   PubMed=12384576; DOI=10.1073/pnas.212518799;
RA   Donaldson L.W., Gish G., Pawson T., Kay L.E., Forman-Kay J.D.;
RT   "Structure of a regulatory complex involving the Abl SH3 domain, the
RT   Crk SH2 domain, and a Crk-derived phosphopeptide.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14053-14058(2002).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (3.42 ANGSTROMS) OF 27-512, MYRISTOYLATION
RP   (ISOFORM IB), ENZYME REGULATION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=12654251; DOI=10.1016/S0092-8674(03)00194-6;
RA   Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D.,
RA   Bornmann W., Clarkson B., Superti-Furga G., Kuriyan J.;
RT   "Structural basis for the autoinhibition of c-Abl tyrosine kinase.";
RL   Cell 112:859-871(2003).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 229-513 OF MUTANT PRO-396 IN
RP   COMPLEX WITH INHIBITOR VX-680, FUNCTION, AND ENZYME REGULATION.
RX   PubMed=16424036; DOI=10.1158/0008-5472.CAN-05-2788;
RA   Young M.A., Shah N.P., Chao L.H., Seeliger M., Milanov Z.V.,
RA   Biggs W.H. III, Treiber D.K., Patel H.K., Zarrinkar P.P.,
RA   Lockhart D.J., Sawyers C.L., Kuriyan J.;
RT   "Structure of the kinase domain of an imatinib-resistant Abl mutant in
RT   complex with the Aurora kinase inhibitor VX-680.";
RL   Cancer Res. 66:1007-1014(2006).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 38-512, IDENTIFICATION BY
RP   MASS SPECTROMETRY, MYRISTOYLATION OF N-TERMINUS (ISOFORM IB),
RP   PHOSPHORYLATION AT SER-50, AUTOINHIBITORY MECHANISM, AND ENZYME
RP   REGULATION.
RX   PubMed=16543148; DOI=10.1016/j.molcel.2006.01.035;
RA   Nagar B., Hantschel O., Seeliger M., Davies J.M., Weis W.I.,
RA   Superti-Furga G., Kuriyan J.;
RT   "Organization of the SH3-SH2 unit in active and inactive forms of the
RT   c-Abl tyrosine kinase.";
RL   Mol. Cell 21:787-798(2006).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 229-512 IN COMPLEXES WITH
RP   ATP-PEPTIDE CONJUGATE, AND CONFORMATION CHANGES DURING ACTIVATION.
RX   PubMed=16640460; DOI=10.1371/journal.pbio.0040144;
RA   Levinson N.M., Kuchment O., Shen K., Young M.A., Koldobskiy M.,
RA   Karplus M., Cole P.A., Kuriyan J.;
RT   "A Src-like inactive conformation in the abl tyrosine kinase domain.";
RL   PLoS Biol. 4:E144-E144(2006).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 229-500 IN COMPLEXES WITH
RP   IMATINIB AND WITH THE INHIBITORS NVP-AEG082; NVP-AFN941; NVP-AFG210
RP   AND PD180970.
RX   PubMed=17164530; DOI=10.1107/S0907444906047287;
RA   Cowan-Jacob S.W., Fendrich G., Floersheimer A., Furet P.,
RA   Liebetanz J., Rummel G., Rheinberger P., Centeleghe M., Fabbro D.,
RA   Manley P.W.;
RT   "Structural biology contributions to the discovery of drugs to treat
RT   chronic myelogenous leukaemia.";
RL   Acta Crystallogr. D 63:80-93(2007).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 64-121 OF MUTANT ALA-114 IN
RP   COMPLEX WITH PROLINE-RICH PEPTIDE.
RX   PubMed=17452790; DOI=10.1107/S0907444907011109;
RA   Camara-Artigas A., Palencia A., Martinez J.C., Luque I., Gavira J.A.,
RA   Garcia-Ruiz J.M.;
RT   "Crystallization by capillary counter-diffusion and structure
RT   determination of the N114A mutant of the SH3 domain of Abl tyrosine
RT   kinase complexed with a high-affinity peptide ligand.";
RL   Acta Crystallogr. D 63:646-652(2007).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 60-121 IN COMPLEX WITH
RP   PROLINE-RICH PEPTIDE P41.
RX   PubMed=19906645; DOI=10.1074/jbc.M109.048033;
RA   Palencia A., Camara-Artigas A., Pisabarro M.T., Martinez J.C.,
RA   Luque I.;
RT   "Role of interfacial water molecules in proline-rich ligand
RT   recognition by the Src homology 3 domain of Abl.";
RL   J. Biol. Chem. 285:2823-2833(2010).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 121-232 IN COMPLEX WITH
RP   ANTIBODY MIMIC HA4, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20357770; DOI=10.1038/nsmb.1793;
RA   Wojcik J., Hantschel O., Grebien F., Kaupe I., Bennett K.L.,
RA   Barkinge J., Jones R.B., Koide A., Superti-Furga G., Koide S.;
RT   "A potent and highly specific FN3 monobody inhibitor of the Abl SH2
RT   domain.";
RL   Nat. Struct. Mol. Biol. 17:519-527(2010).
RN   [71]
RP   VARIANTS GLY-47; LYS-166; VAL-706; LEU-810 AND LEU-972.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase that plays a role
CC       in many key processes linked to cell growth and survival such as
CC       cytoskeleton remodeling in response to extracellular stimuli, cell
CC       motility and adhesion, receptor endocytosis, autophagy, DNA damage
CC       response and apoptosis. Coordinates actin remodeling through
CC       tyrosine phosphorylation of proteins controlling cytoskeleton
CC       dynamics like WASF3 (involved in branch formation); ANXA1
CC       (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH
CC       (involved in signaling); or MAPT and PXN (microtubule-binding
CC       proteins). Phosphorylation of WASF3 is critical for the
CC       stimulation of lamellipodia formation and cell migration. Involved
CC       in the regulation of cell adhesion and motility through
CC       phosphorylation of key regulators of these processes such as
CC       BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple
CC       receptor tyrosine kinases and more particularly promotes
CC       endocytosis of EGFR, facilitates the formation of neuromuscular
CC       synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and
CC       modulates the endocytosis of activated B-cell receptor complexes.
CC       Other substrates which are involved in endocytosis regulation are
CC       the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL
CC       family of ubiquitin ligases that drive receptor down-regulation
CC       and actin remodeling. Phosphorylation of CBL leads to increased
CC       EGFR stability. Involved in late-stage autophagy by regulating
CC       positively the trafficking and function of lysosomal components.
CC       ABL1 targets to mitochondria in response to oxidative stress and
CC       thereby mediates mitochondrial dysfunction and cell death. ABL1 is
CC       also translocated in the nucleus where it has DNA-binding activity
CC       and is involved in DNA-damage response and apoptosis. Many
CC       substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3,
CC       ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic
CC       pathway when the DNA damage is too severe to be repaired.
CC       Phosphorylates TP73, a primary regulator for this type of damage-
CC       induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153'
CC       and regulates its processing in the apoptotic response to DNA
CC       damage. Phosphorylates PSMA7 that leads to an inhibition of
CC       proteasomal activity and cell cycle transition blocks. ABL1 acts
CC       also as a regulator of multiple pathological signaling cascades
CC       during infection. Several known tyrosine-phosphorylated microbial
CC       proteins have been identified as ABL1 substrates. This is the case
CC       of A36R of Vaccinia virus, Tir (translocated intimin receptor) of
CC       pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin-
CC       associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing
CC       protein A) of A.phagocytophilum. Pathogens can highjack ABL1
CC       kinase signaling to reorganize the host actin cytoskeleton for
CC       multiple purposes, like facilitating intracellular movement and
CC       host cell exit. Finally, functions as its own regulator through
CC       autocatalytic activity as well as through phosphorylation of its
CC       inhibitor, ABI1.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- COFACTOR: Magnesium or manganese.
CC   -!- ENZYME REGULATION: Stabilized in the inactive form by an
CC       association between the SH3 domain and the SH2-TK linker region,
CC       interactions of the N-terminal cap, and contributions from an N-
CC       terminal myristoyl group and phospholipids. Activated by
CC       autophosphorylation as well as by SRC-family kinase-mediated
CC       phosphorylation. Activated by RIN1 binding to the SH2 and SH3
CC       domains. Also stimulated by cell death inducers and DNA-damage.
CC       Phosphatidylinositol 4,5-bisphosphate (PIP2), a highly abundant
CC       phosphoinositide known to regulate cytoskeletal and membrane
CC       proteins, inhibits also the tyrosine kinase activity (By
CC       similarity). Inhibited by ABI1, whose activity is controlled by
CC       ABL1 itself through tyrosine phosphorylation. Also inhibited by
CC       imatinib mesylate (Gleevec) which is used for the treatment of
CC       chronic myeloid leukemia (CML), and by VX-680, an inhibitor that
CC       acts also on imatinib-resistant mutants.
CC   -!- SUBUNIT: Interacts with SORBS1 following insulin stimulation.
CC       Found in a trimolecular complex containing CDK5 and CABLES1.
CC       Interacts with CABLES1 and PSTPIP1. Interacts with ZDHHC16, ITGB1
CC       and HCK (By similarity). Interacts with STX17; probably
CC       phosphorylates STX17. Interacts with INPPL1/SHIP2. Interacts with
CC       the 14-3-3 proteins, YWHAB, YWHAE, YWHAG, YWHAH, SFN AND YWHAZ;
CC       the interaction with 14-3-3 proteins requires phosphorylation on
CC       Thr-735 and, sequesters ABL1 into the cytoplasm. Interacts with
CC       ABI1, ABI2, BCR, CRK, FGR, FYN, HCK, LYN, PSMA7 RAD9A, RAD51,
CC       RAD52, TP73 and WASF3. A complex made of ABL1, CTTN and MYLK
CC       regulates cortical actin-based cytoskeletal rearrangement critical
CC       to sphingosine 1-phosphate (S1P)-mediated endothelial cell (EC)
CC       barrier enhancement. Interacts (via SH3 domain) with CASP9; the
CC       interaction is direct and increases in the response of cells to
CC       genotoxic stress and ABL1/c-Abl activation.
CC   -!- INTERACTION:
CC       Q8IZP0:ABI1; NbExp=11; IntAct=EBI-375543, EBI-375446;
CC       Q9NYB9:ABI2; NbExp=2; IntAct=EBI-375543, EBI-743598;
CC       P10275:AR; NbExp=2; IntAct=EBI-375543, EBI-608057;
CC       Q4KMG0:CDON; NbExp=2; IntAct=EBI-375543, EBI-7016840;
CC       O35158:Cdon (xeno); NbExp=4; IntAct=EBI-375543, EBI-7016767;
CC       P46108:CRK; NbExp=2; IntAct=EBI-375543, EBI-886;
CC       P46109:CRKL; NbExp=2; IntAct=EBI-375543, EBI-910;
CC       P35222:CTNNB1; NbExp=2; IntAct=EBI-375543, EBI-491549;
CC       P04626:ERBB2; NbExp=2; IntAct=EBI-375543, EBI-641062;
CC       Q14315:FLNC; NbExp=2; IntAct=EBI-375543, EBI-489954;
CC       P05107:ITGB2; NbExp=4; IntAct=EBI-375543, EBI-300173;
CC       P10721:KIT; NbExp=2; IntAct=EBI-375543, EBI-1379503;
CC       Q92918:MAP4K1; NbExp=3; IntAct=EBI-375543, EBI-881;
CC       Q7Z434:MAVS; NbExp=6; IntAct=EBI-375543, EBI-995373;
CC       O43196:MSH5; NbExp=10; IntAct=EBI-375543, EBI-6092730;
CC       P15941:MUC1; NbExp=8; IntAct=EBI-375543, EBI-2804728;
CC       P16333:NCK1; NbExp=2; IntAct=EBI-375543, EBI-389883;
CC       O43900:PRICKLE3; NbExp=2; IntAct=EBI-375543, EBI-1751761;
CC       Q13905:RAPGEF1; NbExp=4; IntAct=EBI-375543, EBI-976876;
CC       Q86UR5:RIMS1; NbExp=2; IntAct=EBI-375543, EBI-1043236;
CC       Q13671:RIN1; NbExp=4; IntAct=EBI-375543, EBI-366017;
CC       P31947:SFN; NbExp=2; IntAct=EBI-375543, EBI-476295;
CC       Q15464:SHB; NbExp=5; IntAct=EBI-375543, EBI-4402156;
CC       O75751:SLC22A3; NbExp=2; IntAct=EBI-375543, EBI-1752674;
CC       Q9BX66:SORBS1; NbExp=2; IntAct=EBI-375543, EBI-433642;
CC       O60504-2:SORBS3; NbExp=5; IntAct=EBI-375543, EBI-1222956;
CC       Q07890:SOS2; NbExp=2; IntAct=EBI-375543, EBI-298181;
CC       P12931:SRC; NbExp=2; IntAct=EBI-375543, EBI-621482;
CC       Q9Y4G6:TLN2; NbExp=3; IntAct=EBI-375543, EBI-1220811;
CC       P11387:TOP1; NbExp=7; IntAct=EBI-375543, EBI-876302;
CC       P15498:VAV1; NbExp=5; IntAct=EBI-375543, EBI-625518;
CC       P63104:YWHAZ; NbExp=2; IntAct=EBI-375543, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton. Nucleus.
CC       Mitochondrion (By similarity). Note=Shuttles between the nucleus
CC       and cytoplasm depending on environmental signals. Sequestered into
CC       the cytoplasm through interaction with 14-3-3 proteins. Localizes
CC       to mitochondria in response to oxidative stress (By similarity).
CC   -!- SUBCELLULAR LOCATION: Isoform IB: Nucleus membrane; Lipid-anchor.
CC       Note=The myristoylated c-ABL protein is reported to be nuclear.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=IA;
CC         IsoId=P00519-1; Sequence=Displayed;
CC       Name=IB;
CC         IsoId=P00519-2; Sequence=VSP_004957;
CC         Note=Contains a N-myristoyl glycine at position 2;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- PTM: Acetylated at Lys-711 by EP300 which promotes the cytoplasmic
CC       translocation.
CC   -!- PTM: Phosphorylation at Tyr-70 by members of the SRC family of
CC       kinases disrupts SH3 domain-based autoinhibitory interactions and
CC       intermolecular associations, such as that with ABI1, and also
CC       enhances kinase activity. Phosphorylation at Tyr-226 and Tyr-393
CC       correlate with increased activity. DNA damage-induced activation
CC       of ABL1 requires the function of ATM and Ser-446 phosphorylation
CC       (By similarity). Phosphorylation at Ser-569 has been attributed to
CC       a CDC2-associated kinase and is coupled to cell division (By
CC       similarity). Phosphorylation at Ser-618 and Ser-619 by PAK2
CC       increases binding to CRK and reduces binding to ABI1.
CC       Phosphorylation on Thr-735 is required for binding 14-3-3 proteins
CC       for cytoplasmic translocation. Phosphorylated by PRKDC (By
CC       similarity).
CC   -!- PTM: Polyubiquitinated. Polyubiquitination of ABL1 leads to
CC       degradation.
CC   -!- PTM: Isoform IB is myristoylated on Gly-2.
CC   -!- DISEASE: Leukemia, chronic myeloid (CML) [MIM:608232]: A clonal
CC       myeloproliferative disorder of a pluripotent stem cell with a
CC       specific cytogenetic abnormality, the Philadelphia chromosome
CC       (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid,
CC       and sometimes T-lymphoid cells, but not marrow fibroblasts.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Note=A chromosomal aberration involving ABL1 has been
CC       found in patients with chronic myeloid leukemia. Translocation
CC       t(9;22)(q34;q11) with BCR. The translocation produces a BCR-ABL
CC       found also in acute myeloid leukemia (AML) and acute lymphoblastic
CC       leukemia (ALL).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. ABL subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 SH2 domain.
CC   -!- SIMILARITY: Contains 1 SH3 domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ABL.html";
CC   -!- WEB RESOURCE: Name=CGP resequencing studies;
CC       URL="http://www.sanger.ac.uk/perl/genetics/CGP/cgp_viewer?action=gene&ln=ABL1";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/abl1/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Abl entry;
CC       URL="http://en.wikipedia.org/wiki/Abl_gene";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14752; AAA51561.1; -; mRNA.
DR   EMBL; X16416; CAA34438.1; -; mRNA.
DR   EMBL; U07563; AAB60394.1; -; Genomic_DNA.
DR   EMBL; U07563; AAB60393.1; -; Genomic_DNA.
DR   EMBL; U07561; AAB60393.1; JOINED; Genomic_DNA.
DR   EMBL; DQ145721; AAZ38718.1; -; Genomic_DNA.
DR   EMBL; AL359092; CAM45752.1; -; Genomic_DNA.
DR   EMBL; AL161733; CAM45752.1; JOINED; Genomic_DNA.
DR   EMBL; AL161733; CAM45754.1; -; Genomic_DNA.
DR   EMBL; AL161733; CAM45756.1; -; Genomic_DNA.
DR   EMBL; AL359092; CAM45756.1; JOINED; Genomic_DNA.
DR   EMBL; CH471090; EAW87948.1; -; Genomic_DNA.
DR   EMBL; BC117451; AAI17452.1; -; mRNA.
DR   EMBL; S69223; AAD14034.1; -; Genomic_DNA.
DR   CCDS; CCDS35165.1; -. [P00519-2]
DR   CCDS; CCDS35166.1; -. [P00519-1]
DR   PIR; S08519; TVHUA.
DR   RefSeq; NP_005148.2; NM_005157.4. [P00519-1]
DR   RefSeq; NP_009297.2; NM_007313.2. [P00519-2]
DR   UniGene; Hs.431048; -.
DR   PDB; 1AB2; NMR; -; A=120-220.
DR   PDB; 1ABL; Model; -; A=65-121.
DR   PDB; 1AWO; NMR; -; A=65-119.
DR   PDB; 1BBZ; X-ray; 1.65 A; A/C/E/G=64-121.
DR   PDB; 1JU5; NMR; -; C=62-122.
DR   PDB; 1OPL; X-ray; 3.42 A; A/B=27-512.
DR   PDB; 1ZZP; NMR; -; A=1007-1130.
DR   PDB; 2ABL; X-ray; 2.50 A; A=57-218.
DR   PDB; 2E2B; X-ray; 2.20 A; A/B=229-515.
DR   PDB; 2F4J; X-ray; 1.91 A; A=229-513.
DR   PDB; 2FO0; X-ray; 2.27 A; A=38-512.
DR   PDB; 2G1T; X-ray; 1.80 A; A/B/C/D=229-512.
DR   PDB; 2G2F; X-ray; 2.70 A; A/B=229-512.
DR   PDB; 2G2H; X-ray; 2.00 A; A/B=229-512.
DR   PDB; 2G2I; X-ray; 3.12 A; A/B=229-512.
DR   PDB; 2GQG; X-ray; 2.40 A; A/B=229-500.
DR   PDB; 2HIW; X-ray; 2.20 A; A/B=230-512.
DR   PDB; 2HYY; X-ray; 2.40 A; A/B/C/D=228-500.
DR   PDB; 2HZ0; X-ray; 2.10 A; A/B=228-497.
DR   PDB; 2HZ4; X-ray; 2.80 A; A/B/C=228-500.
DR   PDB; 2HZI; X-ray; 1.70 A; A/B=229-500.
DR   PDB; 2O88; X-ray; 1.75 A; A/B=64-121.
DR   PDB; 2V7A; X-ray; 2.50 A; A/B=229-512.
DR   PDB; 3CS9; X-ray; 2.21 A; A/B/C/D=229-500.
DR   PDB; 3EG0; X-ray; 2.30 A; A=60-121.
DR   PDB; 3EG1; X-ray; 1.85 A; A/B=60-121.
DR   PDB; 3EG2; X-ray; 1.80 A; A=60-121.
DR   PDB; 3EG3; X-ray; 1.40 A; A=60-121.
DR   PDB; 3EGU; X-ray; 2.25 A; A=60-121.
DR   PDB; 3K2M; X-ray; 1.75 A; A/B=121-232.
DR   PDB; 3PYY; X-ray; 1.85 A; A/B=229-512.
DR   PDB; 3QRI; X-ray; 2.10 A; A/B=229-499.
DR   PDB; 3QRJ; X-ray; 1.82 A; A/B=229-499.
DR   PDB; 3QRK; X-ray; 2.30 A; A=229-499.
DR   PDB; 3T04; X-ray; 2.10 A; A=112-232.
DR   PDB; 3UE4; X-ray; 2.42 A; A/B=229-512.
DR   PDB; 3UYO; X-ray; 1.83 A; A=112-232.
DR   PDB; 4J9B; X-ray; 1.70 A; A=60-121.
DR   PDB; 4J9C; X-ray; 1.05 A; A=60-121.
DR   PDB; 4J9D; X-ray; 1.50 A; A/C/E=60-121.
DR   PDB; 4J9E; X-ray; 1.40 A; A/C/E=60-121.
DR   PDB; 4J9F; X-ray; 1.09 A; A/C/E=60-121.
DR   PDB; 4J9G; X-ray; 1.80 A; A/C/E=60-121.
DR   PDB; 4J9H; X-ray; 1.70 A; A/B/C/D/E/F=60-121.
DR   PDB; 4J9I; X-ray; 2.20 A; A/C/E=60-121.
DR   PDB; 4JJB; X-ray; 1.65 A; A=60-121.
DR   PDB; 4JJC; X-ray; 1.60 A; A=60-121.
DR   PDB; 4JJD; X-ray; 1.60 A; A=60-121.
DR   PDBsum; 1AB2; -.
DR   PDBsum; 1ABL; -.
DR   PDBsum; 1AWO; -.
DR   PDBsum; 1BBZ; -.
DR   PDBsum; 1JU5; -.
DR   PDBsum; 1OPL; -.
DR   PDBsum; 1ZZP; -.
DR   PDBsum; 2ABL; -.
DR   PDBsum; 2E2B; -.
DR   PDBsum; 2F4J; -.
DR   PDBsum; 2FO0; -.
DR   PDBsum; 2G1T; -.
DR   PDBsum; 2G2F; -.
DR   PDBsum; 2G2H; -.
DR   PDBsum; 2G2I; -.
DR   PDBsum; 2GQG; -.
DR   PDBsum; 2HIW; -.
DR   PDBsum; 2HYY; -.
DR   PDBsum; 2HZ0; -.
DR   PDBsum; 2HZ4; -.
DR   PDBsum; 2HZI; -.
DR   PDBsum; 2O88; -.
DR   PDBsum; 2V7A; -.
DR   PDBsum; 3CS9; -.
DR   PDBsum; 3EG0; -.
DR   PDBsum; 3EG1; -.
DR   PDBsum; 3EG2; -.
DR   PDBsum; 3EG3; -.
DR   PDBsum; 3EGU; -.
DR   PDBsum; 3K2M; -.
DR   PDBsum; 3PYY; -.
DR   PDBsum; 3QRI; -.
DR   PDBsum; 3QRJ; -.
DR   PDBsum; 3QRK; -.
DR   PDBsum; 3T04; -.
DR   PDBsum; 3UE4; -.
DR   PDBsum; 3UYO; -.
DR   PDBsum; 4J9B; -.
DR   PDBsum; 4J9C; -.
DR   PDBsum; 4J9D; -.
DR   PDBsum; 4J9E; -.
DR   PDBsum; 4J9F; -.
DR   PDBsum; 4J9G; -.
DR   PDBsum; 4J9H; -.
DR   PDBsum; 4J9I; -.
DR   PDBsum; 4JJB; -.
DR   PDBsum; 4JJC; -.
DR   PDBsum; 4JJD; -.
DR   ProteinModelPortal; P00519; -.
DR   SMR; P00519; 46-528, 1024-1130.
DR   BioGrid; 106543; 138.
DR   DIP; DIP-1042N; -.
DR   IntAct; P00519; 198.
DR   MINT; MINT-7236141; -.
DR   STRING; 9606.ENSP00000361423; -.
DR   BindingDB; P00519; -.
DR   ChEMBL; CHEMBL1862; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00619; Imatinib.
DR   GuidetoPHARMACOLOGY; 1923; -.
DR   PhosphoSite; P00519; -.
DR   DMDM; 85681908; -.
DR   MaxQB; P00519; -.
DR   PaxDb; P00519; -.
DR   PRIDE; P00519; -.
DR   DNASU; 25; -.
DR   Ensembl; ENST00000318560; ENSP00000323315; ENSG00000097007. [P00519-1]
DR   Ensembl; ENST00000372348; ENSP00000361423; ENSG00000097007. [P00519-2]
DR   GeneID; 25; -.
DR   KEGG; hsa:25; -.
DR   UCSC; uc004bzv.3; human. [P00519-2]
DR   UCSC; uc004bzw.3; human. [P00519-1]
DR   CTD; 25; -.
DR   GeneCards; GC09P133589; -.
DR   HGNC; HGNC:76; ABL1.
DR   HPA; CAB002686; -.
DR   HPA; HPA027251; -.
DR   HPA; HPA027280; -.
DR   HPA; HPA028409; -.
DR   MIM; 189980; gene.
DR   MIM; 608232; phenotype.
DR   neXtProt; NX_P00519; -.
DR   Orphanet; 521; Chronic myeloid leukemia.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   Orphanet; 99861; Precursor T-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA24413; -.
DR   eggNOG; COG0515; -.
DR   HOVERGEN; HBG004162; -.
DR   KO; K06619; -.
DR   OMA; GAFRESG; -.
DR   OrthoDB; EOG7GTT2V; -.
DR   PhylomeDB; P00519; -.
DR   TreeFam; TF105081; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; REACT_111045; Developmental Biology.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6900; Immune System.
DR   SignaLink; P00519; -.
DR   ChiTaRS; ABL1; human.
DR   EvolutionaryTrace; P00519; -.
DR   GeneWiki; ABL_(gene); -.
DR   GenomeRNAi; 25; -.
DR   NextBio; 79; -.
DR   PMAP-CutDB; P00519; -.
DR   PRO; PR:P00519; -.
DR   ArrayExpress; P00519; -.
DR   Bgee; P00519; -.
DR   CleanEx; HS_ABL1; -.
DR   Genevestigator; P00519; -.
DR   GO; GO:0015629; C:actin cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0031252; C:cell leading edge; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005730; C:nucleolus; IDA:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0003785; F:actin monomer binding; TAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0004515; F:nicotinate-nucleotide adenylyltransferase activity; TAS:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0070064; F:proline-rich region binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:UniProtKB.
DR   GO; GO:0019905; F:syntaxin binding; IPI:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0006464; P:cellular protein modification process; NAS:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; TAS:UniProtKB.
DR   GO; GO:0006298; P:mismatch repair; TAS:ProtInc.
DR   GO; GO:0042692; P:muscle cell differentiation; TAS:Reactome.
DR   GO; GO:0071901; P:negative regulation of protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0051149; P:positive regulation of muscle cell differentiation; TAS:Reactome.
DR   GO; GO:0051353; P:positive regulation of oxidoreductase activity; IDA:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; TAS:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; TAS:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IEA:Ensembl.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:0030100; P:regulation of endocytosis; TAS:UniProtKB.
DR   GO; GO:2001020; P:regulation of response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:ProtInc.
DR   GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:UniProtKB.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR015015; F-actin_binding.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF08919; F_actin_bind; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00808; FABD; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Autophagy; Cell adhesion; Chromosomal rearrangement;
KW   Complete proteome; Cytoplasm; Cytoskeleton; DNA damage; DNA repair;
KW   DNA-binding; Endocytosis; Kinase; Lipoprotein; Magnesium; Manganese;
KW   Membrane; Metal-binding; Mitochondrion; Myristate; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Reference proteome; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   CHAIN         1   1130       Tyrosine-protein kinase ABL1.
FT                                /FTId=PRO_0000088050.
FT   DOMAIN       61    121       SH3.
FT   DOMAIN      127    217       SH2.
FT   DOMAIN      242    493       Protein kinase.
FT   NP_BIND     248    256       ATP.
FT   NP_BIND     316    322       ATP.
FT   REGION        1     60       CAP.
FT   REGION      869    968       DNA-binding (By similarity).
FT   REGION      953   1130       F-actin-binding.
FT   MOTIF       381    405       Kinase activation loop.
FT   MOTIF       605    609       Nuclear localization signal 1
FT                                (Potential).
FT   MOTIF       709    715       Nuclear localization signal 2
FT                                (Potential).
FT   MOTIF       762    769       Nuclear localization signal 3
FT                                (Potential).
FT   MOTIF      1090   1100       Nuclear export signal (By similarity).
FT   COMPBIAS     18     22       Poly-Ser.
FT   COMPBIAS    605    609       Poly-Lys.
FT   COMPBIAS    782   1019       Pro-rich.
FT   COMPBIAS    897    903       Poly-Pro.
FT   ACT_SITE    363    363       Proton acceptor (By similarity).
FT   BINDING     271    271       ATP.
FT   SITE         26     27       Breakpoint for translocation to form BCR-
FT                                ABL oncogene.
FT   MOD_RES      50     50       Phosphoserine.
FT   MOD_RES      70     70       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     115    115       Phosphotyrosine.
FT   MOD_RES     128    128       Phosphotyrosine.
FT   MOD_RES     139    139       Phosphotyrosine.
FT   MOD_RES     172    172       Phosphotyrosine.
FT   MOD_RES     185    185       Phosphotyrosine.
FT   MOD_RES     215    215       Phosphotyrosine.
FT   MOD_RES     226    226       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     253    253       Phosphotyrosine.
FT   MOD_RES     257    257       Phosphotyrosine.
FT   MOD_RES     264    264       Phosphotyrosine.
FT   MOD_RES     392    392       Phosphothreonine.
FT   MOD_RES     393    393       Phosphotyrosine; by autocatalysis and
FT                                SRC-type Tyr-kinases.
FT   MOD_RES     394    394       Phosphothreonine.
FT   MOD_RES     446    446       Phosphoserine (By similarity).
FT   MOD_RES     469    469       Phosphotyrosine.
FT   MOD_RES     569    569       Phosphoserine.
FT   MOD_RES     613    613       Phosphothreonine.
FT   MOD_RES     618    618       Phosphoserine; by PAK2.
FT   MOD_RES     619    619       Phosphoserine; by PAK2.
FT   MOD_RES     620    620       Phosphoserine.
FT   MOD_RES     659    659       Phosphoserine.
FT   MOD_RES     683    683       Phosphoserine.
FT   MOD_RES     711    711       N6-acetyllysine; by EP300.
FT   MOD_RES     718    718       Phosphoserine.
FT   MOD_RES     735    735       Phosphothreonine.
FT   MOD_RES     781    781       Phosphothreonine.
FT   MOD_RES     805    805       Phosphoserine.
FT   MOD_RES     809    809       Phosphoserine.
FT   MOD_RES     814    814       Phosphothreonine.
FT   MOD_RES     844    844       Phosphothreonine.
FT   MOD_RES     852    852       Phosphothreonine.
FT   MOD_RES     855    855       Phosphoserine.
FT   MOD_RES     917    917       Phosphoserine.
FT   MOD_RES     919    919       Phosphoserine.
FT   MOD_RES     936    936       Phosphoserine.
FT   MOD_RES     949    949       Phosphoserine.
FT   MOD_RES     977    977       Phosphoserine.
FT   VAR_SEQ       1     26       MLEICLKLVGCKSKKGLSSSSSCYLE -> MGQQPGKVLGD
FT                                QRRPSLPALHFIKGAGKKESSRHGGPHCNVFVEH (in
FT                                isoform IB).
FT                                /FTId=VSP_004957.
FT   VARIANT      47     47       R -> G (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_032676.
FT   VARIANT     140    140       L -> P (in dbSNP:rs1064152).
FT                                /FTId=VAR_051692.
FT   VARIANT     166    166       R -> K (in a melanoma sample; somatic
FT                                mutation).
FT                                /FTId=VAR_032677.
FT   VARIANT     247    247       K -> R (in dbSNP:rs34549764).
FT                                /FTId=VAR_051693.
FT   VARIANT     706    706       G -> V (in dbSNP:rs34634745).
FT                                /FTId=VAR_025043.
FT   VARIANT     810    810       P -> L (in dbSNP:rs2229071).
FT                                /FTId=VAR_032678.
FT   VARIANT     852    852       T -> P.
FT                                /FTId=VAR_025044.
FT   VARIANT     900    900       P -> S (in dbSNP:rs35266696).
FT                                /FTId=VAR_025045.
FT   VARIANT     968    968       S -> P (in dbSNP:rs1064165).
FT                                /FTId=VAR_051694.
FT   VARIANT     972    972       S -> L (in dbSNP:rs2229067).
FT                                /FTId=VAR_025046.
FT   MUTAGEN     735    735       T->A: Abolishes phosphorylation. Loss of
FT                                binding YWHAS and YWHAZ. Localizes to the
FT                                nucleus. No effect on kinase activity.
FT   CONFLICT    159    159       G -> S (in Ref. 1; AAA51561).
FT   CONFLICT    424    425       AF -> GK (in Ref. 9).
FT   CONFLICT    445    445       L -> R (in Ref. 1; AAA51561).
FT   CONFLICT    459    459       E -> K (in Ref. 1; AAA51561).
FT   CONFLICT    520    520       S -> T (in Ref. 1; AAA51561).
FT   CONFLICT    719    719       A -> V (in Ref. 1; AAA51561).
FT   CONFLICT    837    837       G -> E (in Ref. 2; CAA34438).
FT   CONFLICT    837    837       G -> W (in Ref. 1; AAA51561).
FT   CONFLICT    863    863       G -> R (in Ref. 1; AAA51561).
FT   CONFLICT    894    894       R -> K (in Ref. 1; AAA51561).
FT   CONFLICT    917    919       SPS -> RPG (in Ref. 1; AAA51561).
FT   CONFLICT    952    952       G -> A (in Ref. 1; AAA51561).
FT   CONFLICT    967    968       QS -> HP (in Ref. 1; AAA51561).
FT   CONFLICT    982    982       P -> PL (in Ref. 1; AAA51561).
FT   CONFLICT   1022   1022       Missing (in Ref. 1; AAA51561).
FT   CONFLICT   1045   1045       R -> G (in Ref. 1; AAA51561).
FT   CONFLICT   1103   1103       T -> S (in Ref. 1; AAA51561).
FT   HELIX        49     53
FT   HELIX        58     60
FT   STRAND       65     70
FT   STRAND       76     79
FT   STRAND       87     93
FT   STRAND       97    104
FT   STRAND      107    112
FT   HELIX       113    115
FT   STRAND      116    118
FT   HELIX       122    124
FT   STRAND      128    131
FT   HELIX       134    140
FT   TURN        141    143
FT   STRAND      148    153
FT   STRAND      155    157
FT   STRAND      161    167
FT   STRAND      170    178
FT   STRAND      180    182
FT   STRAND      184    187
FT   STRAND      192    194
FT   HELIX       195    204
FT   STRAND      209    211
FT   STRAND      226    228
FT   STRAND      229    231
FT   TURN        233    235
FT   HELIX       239    241
FT   STRAND      242    248
FT   HELIX       249    251
FT   STRAND      254    261
FT   HELIX       262    264
FT   STRAND      266    272
FT   STRAND      275    278
FT   HELIX       280    290
FT   STRAND      301    305
FT   STRAND      307    310
FT   STRAND      312    316
FT   STRAND      319    322
FT   HELIX       323    329
FT   TURN        332    334
FT   HELIX       337    356
FT   STRAND      359    361
FT   HELIX       366    368
FT   STRAND      369    371
FT   HELIX       373    375
FT   STRAND      377    379
FT   HELIX       381    383
FT   HELIX       384    387
FT   HELIX       390    392
FT   STRAND      395    401
FT   HELIX       403    405
FT   HELIX       408    413
FT   HELIX       418    433
FT   HELIX       445    447
FT   HELIX       448    453
FT   HELIX       466    475
FT   HELIX       480    482
FT   HELIX       486    499
FT   TURN        510    512
FT   HELIX      1029   1045
FT   TURN       1046   1048
FT   HELIX      1053   1070
FT   HELIX      1071   1073
FT   HELIX      1080   1097
FT   STRAND     1101   1104
FT   STRAND     1106   1108
FT   HELIX      1115   1128
SQ   SEQUENCE   1130 AA;  122873 MW;  85FE6C1C0E483EA2 CRC64;
     MLEICLKLVG CKSKKGLSSS SSCYLEEALQ RPVASDFEPQ GLSEAARWNS KENLLAGPSE
     NDPNLFVALY DFVASGDNTL SITKGEKLRV LGYNHNGEWC EAQTKNGQGW VPSNYITPVN
     SLEKHSWYHG PVSRNAAEYL LSSGINGSFL VRESESSPGQ RSISLRYEGR VYHYRINTAS
     DGKLYVSSES RFNTLAELVH HHSTVADGLI TTLHYPAPKR NKPTVYGVSP NYDKWEMERT
     DITMKHKLGG GQYGEVYEGV WKKYSLTVAV KTLKEDTMEV EEFLKEAAVM KEIKHPNLVQ
     LLGVCTREPP FYIITEFMTY GNLLDYLREC NRQEVNAVVL LYMATQISSA MEYLEKKNFI
     HRDLAARNCL VGENHLVKVA DFGLSRLMTG DTYTAHAGAK FPIKWTAPES LAYNKFSIKS
     DVWAFGVLLW EIATYGMSPY PGIDLSQVYE LLEKDYRMER PEGCPEKVYE LMRACWQWNP
     SDRPSFAEIH QAFETMFQES SISDEVEKEL GKQGVRGAVS TLLQAPELPT KTRTSRRAAE
     HRDTTDVPEM PHSKGQGESD PLDHEPAVSP LLPRKERGPP EGGLNEDERL LPKDKKTNLF
     SALIKKKKKT APTPPKRSSS FREMDGQPER RGAGEEEGRD ISNGALAFTP LDTADPAKSP
     KPSNGAGVPN GALRESGGSG FRSPHLWKKS STLTSSRLAT GEEEGGGSSS KRFLRSCSAS
     CVPHGAKDTE WRSVTLPRDL QSTGRQFDSS TFGGHKSEKP ALPRKRAGEN RSDQVTRGTV
     TPPPRLVKKN EEAADEVFKD IMESSPGSSP PNLTPKPLRR QVTVAPASGL PHKEEAGKGS
     ALGTPAAAEP VTPTSKAGSG APGGTSKGPA EESRVRRHKH SSESPGRDKG KLSRLKPAPP
     PPPAASAGKA GGKPSQSPSQ EAAGEAVLGA KTKATSLVDA VNSDAAKPSQ PGEGLKKPVL
     PATPKPQSAK PSGTPISPAP VPSTLPSASS ALAGDQPSST AFIPLISTRV SLRKTRQPPE
     RIASGAITKG VVLDSTEALC LAISRNSEQM ASHSAVLEAG KNLYTFCVSY VDSIQQMRNK
     FAFREAINKL ENNLRELQIC PATAGSGPAA TQDFSKLLSS VKEISDIVQR
//
ID   ABL2_HUMAN              Reviewed;        1182 AA.
AC   P42684; A0M8X0; B7UEF2; B7UEF3; B7UEF4; B7UEF5; Q5T0X6; Q5W0C5;
AC   Q6NZY6; Q7Z301;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   09-JUL-2014, entry version 168.
DE   RecName: Full=Abelson tyrosine-protein kinase 2;
DE            EC=2.7.10.2;
DE   AltName: Full=Abelson murine leukemia viral oncogene homolog 2;
DE   AltName: Full=Abelson-related gene protein;
DE   AltName: Full=Tyrosine-protein kinase ARG;
GN   Name=ABL2; Synonyms=ABLL, ARG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING
RP   (ISOFORM 2).
RX   PubMed=2198571; DOI=10.1073/pnas.87.15.5802;
RA   Kruh G.D., Perego R., Miki T., Aaronson S.A.;
RT   "The complete coding sequence of arg defines the Abelson subfamily of
RT   cytoplasmic tyrosine kinases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5802-5806(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4; 5; 6 AND 7), ALTERNATIVE
RP   SPLICING (ISOFORM 10), AND VARIANT THR-12 (ISOFORM 4).
RX   PubMed=18810762; DOI=10.1002/jcb.21922;
RA   Bianchi C., Torsello B., Angeloni V., Bombelli S., Soldi M.,
RA   Invernizzi L., Brambilla P., Perego R.A.;
RT   "Eight full-length abelson related gene (Arg) isoforms are
RT   constitutively expressed in caki-1 cell line and cell distribution of
RT   two isoforms has been analyzed after transfection.";
RL   J. Cell. Biochem. 105:1219-1227(2008).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 8).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Uterine endothelium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-930; MET-946;
RP   ARG-996; ASN-1085 AND ALA-1101.
RG   NIEHS SNPs program;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 343-469.
RX   PubMed=3787260; DOI=10.1126/science.3787260;
RA   Kruh G.D., King C.R., Kraus M.H., Popescu N.C., Amsbaugh S.C.,
RA   McBride W.O., Aaronson S.A.;
RT   "A novel human gene closely related to the abl proto-oncogene.";
RL   Science 234:1545-1548(1986).
RN   [10]
RP   AUTOPHOSPHORYLATION AT TYR-272; TYR-439; TYR-568 AND TYR-683, AND
RP   ENZYME REGULATION.
RX   PubMed=12748290; DOI=10.1128/MCB.23.11.3884-3896.2003;
RA   Tanis K.Q., Veach D., Duewel H.S., Bornmann W.G., Koleske A.J.;
RT   "Two distinct phosphorylation pathways have additive effects on Abl
RT   family kinase activation.";
RL   Mol. Cell. Biol. 23:3884-3896(2003).
RN   [11]
RP   INTERACTION WITH RIN1, FUNCTION, AND ENZYME REGULATION.
RX   PubMed=15886098; DOI=10.1016/j.cub.2005.03.049;
RA   Hu H., Bliss J.M., Wang Y., Colicelli J.;
RT   "RIN1 is an ABL tyrosine kinase activator and a regulator of
RT   epithelial-cell adhesion and migration.";
RL   Curr. Biol. 15:815-823(2005).
RN   [12]
RP   FUNCTION, PHOSPHORYLATION AT TYR-261, AND UBIQUITINATION.
RX   PubMed=15735735; DOI=10.1038/sj.onc.1208454;
RA   Cao C., Li Y., Leng Y., Li P., Ma Q., Kufe D.;
RT   "Ubiquitination and degradation of the Arg tyrosine kinase is
RT   regulated by oxidative stress.";
RL   Oncogene 24:2433-2440(2005).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH PSMA7.
RX   PubMed=16678104; DOI=10.1016/j.molcel.2006.04.007;
RA   Liu X., Huang W., Li C., Li P., Yuan J., Li X., Qiu X.B., Ma Q.,
RA   Cao C.;
RT   "Interaction between c-Abl and Arg tyrosine kinases and proteasome
RT   subunit PSMA7 regulates proteasome degradation.";
RL   Mol. Cell 22:317-327(2006).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [15]
RP   FUNCTION.
RX   PubMed=17306540; DOI=10.1016/j.cub.2007.01.057;
RA   Boyle S.N., Michaud G.A., Schweitzer B., Predki P.F., Koleske A.J.;
RT   "A critical role for cortactin phosphorylation by Abl-family kinases
RT   in PDGF-induced dorsal-wave formation.";
RL   Curr. Biol. 17:445-451(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-817, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [17]
RP   FUNCTION.
RX   PubMed=18945674; DOI=10.1074/jbc.M804543200;
RA   Yogalingam G., Pendergast A.M.;
RT   "Abl kinases regulate autophagy by promoting the trafficking and
RT   function of lysosomal components.";
RL   J. Biol. Chem. 283:35941-35953(2008).
RN   [18]
RP   REVIEW ON FUNCTION.
RX   PubMed=12775773; DOI=10.1242/jcs.00622;
RA   Woodring P.J., Hunter T., Wang J.Y.;
RT   "Regulation of F-actin-dependent processes by the Abl family of
RT   tyrosine kinases.";
RL   J. Cell Sci. 116:2613-2626(2003).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=14729179; DOI=10.1016/j.tcb.2003.11.003;
RA   Hernandez S.E., Krishnaswami M., Miller A.L., Koleske A.J.;
RT   "How do Abl family kinases regulate cell shape and movement?";
RL   Trends Cell Biol. 14:36-44(2004).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-275 AND SER-915, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-620; SER-631; SER-633;
RP   SER-655; SER-817; SER-820 AND SER-936, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=18182299; DOI=10.1016/j.tibs.2007.10.006;
RA   Backert S., Feller S.M., Wessler S.;
RT   "Emerging roles of Abl family tyrosine kinases in microbial
RT   pathogenesis.";
RL   Trends Biochem. Sci. 33:80-90(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-718, PHOSPHORYLATION
RP   [LARGE SCALE ANALYSIS] AT TYR-668 (ISOFORM 10), PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT TYR-647 (ISOFORM 4), PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT TYR-683 (ISOFORM 5), PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT TYR-662 (ISOFORM 7), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-820 AND SER-936, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631 AND SER-936, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [27]
RP   REVIEW ON FUNCTION, AND DOMAIN.
RX   PubMed=20841568; DOI=10.1126/scisignal.3139re6;
RA   Colicelli J.;
RT   "ABL tyrosine kinases: evolution of function, regulation, and
RT   specificity.";
RL   Sci. Signal. 3:RE6-RE6(2010).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [29]
RP   STRUCTURE BY NMR OF 163-268.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the human ABL2 SH2 domain.";
RL   Submitted (FEB-2008) to the PDB data bank.
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 279-546 IN COMPLEXES WITH
RP   INHIBITORS.
RX   PubMed=21417343; DOI=10.1021/jm101506n;
RA   Salah E., Ugochukwu E., Barr A.J., von Delft F., Knapp S.,
RA   Elkins J.M.;
RT   "Crystal structures of ABL-related gene (ABL2) in complex with
RT   imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole
RT   carbothioamide class.";
RL   J. Med. Chem. 54:2359-2367(2011).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 563-579 IN COMPLEX WITH
RP   CTTN, AND INTERACTION WITH CTTN.
RX   PubMed=22297987; DOI=10.1107/S1744309111056132;
RA   Liu W., MacGrath S.M., Koleske A.J., Boggon T.J.;
RT   "Lysozyme contamination facilitates crystallization of a
RT   heterotrimeric cortactin-Arg-lysozyme complex.";
RL   Acta Crystallogr. F 68:154-158(2012).
RN   [32]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-78; GLN-99; ILE-519; SER-769;
RP   ARG-930 AND ARG-996, AND VARIANT [LARGE SCALE ANALYSIS] THR-12
RP   (ISOFORM 4).
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase that plays an ABL1-
CC       overlapping role in key processes linked to cell growth and
CC       survival such as cytoskeleton remodeling in response to
CC       extracellular stimuli, cell motility and adhesion and receptor
CC       endocytosis. Coordinates actin remodeling through tyrosine
CC       phosphorylation of proteins controlling cytoskeleton dynamics like
CC       MYH10 (involved in movement); CTTN (involved in signaling); or
CC       TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and
CC       regulates actin cytoskeletal structure through its F-actin-
CC       bundling activity. Involved in the regulation of cell adhesion and
CC       motility through phosphorylation of key regulators of these
CC       processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent
CC       phosphorylation of ARHGAP35 promotes its association with RASA1,
CC       resulting in recruitment of ARHGAP35 to the cell periphery where
CC       it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases
CC       like PDGFRB and other substrates which are involved in endocytosis
CC       regulation such as RIN1. In brain, may regulate neurotransmission
CC       by phosphorylating proteins at the synapse. ABL2 acts also as a
CC       regulator of multiple pathological signaling cascades during
CC       infection. Pathogens can highjack ABL2 kinase signaling to
CC       reorganize the host actin cytoskeleton for multiple purposes, like
CC       facilitating intracellular movement and host cell exit. Finally,
CC       functions as its own regulator through autocatalytic activity as
CC       well as through phosphorylation of its inhibitor, ABI1.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- COFACTOR: Magnesium or manganese.
CC   -!- ENZYME REGULATION: Stabilized in the inactive form by an
CC       association between the SH3 domain and the SH2-TK linker region,
CC       interactions of the N-terminal cap, and contributions from an N-
CC       terminal myristoyl group and phospholipids. Activated by
CC       autophosphorylation as well as by SRC-family kinase-mediated
CC       phosphorylation. Activated by RIN1 binding to the SH2 and SH3
CC       domains. Inhibited by imatinib mesylate (Gleevec) which is used
CC       for the treatment of chronic myeloid leukemia (CML).
CC       Phosphatidylinositol 4,5-bisphosphate (PIP2), a highly abundant
CC       phosphoinositide known to regulate cytoskeletal and membrane
CC       proteins, inhibits the tyrosine kinase activity (By similarity).
CC   -!- SUBUNIT: Interacts with PSMA7. Interacts with CTTN.
CC   -!- INTERACTION:
CC       Q8IZP0:ABI1; NbExp=2; IntAct=EBI-1102694, EBI-375446;
CC       P46108:CRK; NbExp=5; IntAct=EBI-1102694, EBI-886;
CC       P00533:EGFR; NbExp=7; IntAct=EBI-1102694, EBI-297353;
CC       P04626:ERBB2; NbExp=6; IntAct=EBI-1102694, EBI-641062;
CC       P21860:ERBB3; NbExp=10; IntAct=EBI-1102694, EBI-720706;
CC       Q15303:ERBB4; NbExp=4; IntAct=EBI-1102694, EBI-80371;
CC       P06241:FYN; NbExp=2; IntAct=EBI-1102694, EBI-515315;
CC       P62993:GRB2; NbExp=2; IntAct=EBI-1102694, EBI-401755;
CC       P10721:KIT; NbExp=2; IntAct=EBI-1102694, EBI-1379503;
CC       P16333:NCK1; NbExp=3; IntAct=EBI-1102694, EBI-389883;
CC       P27986:PIK3R1; NbExp=2; IntAct=EBI-1102694, EBI-79464;
CC       P19174:PLCG1; NbExp=4; IntAct=EBI-1102694, EBI-79387;
CC       Q13671:RIN1; NbExp=4; IntAct=EBI-1102694, EBI-366017;
CC       P12931:SRC; NbExp=2; IntAct=EBI-1102694, EBI-621482;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=9;
CC       Name=1; Synonyms=IB, 1BLCTL;
CC         IsoId=P42684-1; Sequence=Displayed;
CC       Name=2; Synonyms=IA, 1ASCTL;
CC         IsoId=P42684-2; Sequence=VSP_004961;
CC       Name=3; Synonyms=IC, 1ALCTL;
CC         IsoId=P42684-3; Sequence=VSP_017112;
CC       Name=4; Synonyms=1ASCTS;
CC         IsoId=P42684-4; Sequence=VSP_004961, VSP_021308;
CC         Note=Variant in position: 12:N->T (in dbSNP:rs1318056). Contains
CC         a phosphotyrosine at position 647;
CC       Name=5; Synonyms=1BLCTS;
CC         IsoId=P42684-5; Sequence=VSP_021308;
CC         Note=Contains a phosphotyrosine at position 683;
CC       Name=6; Synonyms=1BSCTL;
CC         IsoId=P42684-6; Sequence=VSP_041772;
CC       Name=7; Synonyms=1BSCTS;
CC         IsoId=P42684-7; Sequence=VSP_041772, VSP_021308;
CC         Note=Contains a phosphotyrosine at position 662;
CC       Name=10; Synonyms=1ALCTS;
CC         IsoId=P42684-10; Sequence=VSP_017112, VSP_021308;
CC         Note=Contains a phosphotyrosine at position 668;
CC       Name=8;
CC         IsoId=P42684-8; Sequence=VSP_041772, VSP_041773, VSP_041774;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- DOMAIN: Contains two distinct classes of F-actin-binding domains.
CC       Although both can bind F-actin, the 2 are required to bundle actin
CC       filaments (By similarity).
CC   -!- PTM: Phosphorylated at Tyr-261 by ABL1 in response to oxidative
CC       stress. Phosphorylated by PDGFRB (By similarity).
CC   -!- PTM: Polyubiquitinated. Polyubiquitination of ABL2 leads to
CC       degradation.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. ABL subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 SH2 domain.
CC   -!- SIMILARITY: Contains 1 SH3 domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD98092.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ABL2ID226.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/abl2/";
CC   -!- WEB RESOURCE: Name=CGP resequencing studies;
CC       URL="http://www.sanger.ac.uk/perl/genetics/CGP/cgp_viewer?action=gene&ln=ABL2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M35296; AAA35553.1; -; mRNA.
DR   EMBL; FJ542283; ACK76601.1; -; mRNA.
DR   EMBL; FJ542284; ACK76602.1; -; mRNA.
DR   EMBL; FJ542285; ACK76603.1; -; mRNA.
DR   EMBL; FJ542286; ACK76604.1; -; mRNA.
DR   EMBL; AK311045; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BX538317; CAD98092.1; ALT_INIT; mRNA.
DR   EMBL; DQ009672; AAY16984.1; -; Genomic_DNA.
DR   EMBL; AL139132; CAH70921.1; -; Genomic_DNA.
DR   EMBL; AL359179; CAH70921.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAH70921.1; JOINED; Genomic_DNA.
DR   EMBL; AL139132; CAH70925.1; -; Genomic_DNA.
DR   EMBL; AL359179; CAH70925.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAH70925.1; JOINED; Genomic_DNA.
DR   EMBL; AL359179; CAI15584.1; -; Genomic_DNA.
DR   EMBL; AL139132; CAI15584.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAI15584.1; JOINED; Genomic_DNA.
DR   EMBL; AL359179; CAI15585.1; -; Genomic_DNA.
DR   EMBL; AL139132; CAI15585.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAI15585.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAI13566.1; -; Genomic_DNA.
DR   EMBL; AL359179; CAI13566.1; JOINED; Genomic_DNA.
DR   EMBL; AL139132; CAI13566.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAI13570.1; -; Genomic_DNA.
DR   EMBL; AL359179; CAI13570.1; JOINED; Genomic_DNA.
DR   EMBL; AL139132; CAI13570.1; JOINED; Genomic_DNA.
DR   EMBL; CH471067; EAW91040.1; -; Genomic_DNA.
DR   EMBL; BC065912; AAH65912.1; -; mRNA.
DR   CCDS; CCDS30947.1; -. [P42684-1]
DR   CCDS; CCDS41441.2; -. [P42684-3]
DR   CCDS; CCDS44282.1; -. [P42684-10]
DR   CCDS; CCDS44283.1; -. [P42684-8]
DR   CCDS; CCDS53435.1; -. [P42684-4]
DR   CCDS; CCDS53436.1; -. [P42684-6]
DR   CCDS; CCDS53437.1; -. [P42684-7]
DR   CCDS; CCDS53438.1; -. [P42684-5]
DR   PIR; A35962; A35962.
DR   PIR; B35962; B35962.
DR   RefSeq; NP_001129472.1; NM_001136000.2.
DR   RefSeq; NP_001129473.1; NM_001136001.1. [P42684-8]
DR   RefSeq; NP_001161708.1; NM_001168236.1. [P42684-6]
DR   RefSeq; NP_001161709.1; NM_001168237.1. [P42684-5]
DR   RefSeq; NP_001161710.1; NM_001168238.1. [P42684-7]
DR   RefSeq; NP_001161711.1; NM_001168239.1.
DR   RefSeq; NP_005149.4; NM_005158.4.
DR   RefSeq; NP_009298.1; NM_007314.3. [P42684-1]
DR   UniGene; Hs.159472; -.
DR   PDB; 2ECD; NMR; -; A=163-268.
DR   PDB; 2KK1; NMR; -; A=1058-1182.
DR   PDB; 2XYN; X-ray; 2.81 A; A/B/C=279-546.
DR   PDB; 3GVU; X-ray; 2.05 A; A=279-546.
DR   PDB; 3HMI; X-ray; 1.65 A; A=279-546.
DR   PDB; 3ULR; X-ray; 1.65 A; C=563-579.
DR   PDB; 4EIH; X-ray; 1.20 A; A=165-273.
DR   PDBsum; 2ECD; -.
DR   PDBsum; 2KK1; -.
DR   PDBsum; 2XYN; -.
DR   PDBsum; 3GVU; -.
DR   PDBsum; 3HMI; -.
DR   PDBsum; 3ULR; -.
DR   PDBsum; 4EIH; -.
DR   ProteinModelPortal; P42684; -.
DR   SMR; P42684; 108-558, 1058-1182.
DR   BioGrid; 106545; 25.
DR   DIP; DIP-91N; -.
DR   IntAct; P42684; 34.
DR   MINT; MINT-1347081; -.
DR   STRING; 9606.ENSP00000356595; -.
DR   BindingDB; P42684; -.
DR   ChEMBL; CHEMBL4014; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB01254; Dasatinib.
DR   GuidetoPHARMACOLOGY; 1924; -.
DR   PhosphoSite; P42684; -.
DR   DMDM; 1168268; -.
DR   MaxQB; P42684; -.
DR   PaxDb; P42684; -.
DR   PRIDE; P42684; -.
DR   DNASU; 27; -.
DR   Ensembl; ENST00000344730; ENSP00000339209; ENSG00000143322. [P42684-10]
DR   Ensembl; ENST00000367623; ENSP00000356595; ENSG00000143322. [P42684-6]
DR   Ensembl; ENST00000392043; ENSP00000375897; ENSG00000143322. [P42684-8]
DR   Ensembl; ENST00000408940; ENSP00000386152; ENSG00000143322. [P42684-2]
DR   Ensembl; ENST00000502732; ENSP00000427562; ENSG00000143322. [P42684-1]
DR   Ensembl; ENST00000504405; ENSP00000426831; ENSG00000143322. [P42684-4]
DR   Ensembl; ENST00000507173; ENSP00000423413; ENSG00000143322. [P42684-7]
DR   Ensembl; ENST00000511413; ENSP00000424697; ENSG00000143322. [P42684-5]
DR   Ensembl; ENST00000512653; ENSP00000423578; ENSG00000143322. [P42684-3]
DR   GeneID; 27; -.
DR   KEGG; hsa:27; -.
DR   UCSC; uc001gmg.4; human. [P42684-10]
DR   UCSC; uc001gmi.4; human. [P42684-3]
DR   UCSC; uc001gmj.4; human. [P42684-1]
DR   UCSC; uc001gmk.3; human. [P42684-8]
DR   UCSC; uc010pne.2; human. [P42684-4]
DR   UCSC; uc010pnf.2; human. [P42684-5]
DR   UCSC; uc010png.2; human. [P42684-7]
DR   UCSC; uc010pnh.2; human. [P42684-6]
DR   CTD; 27; -.
DR   GeneCards; GC01M179068; -.
DR   HGNC; HGNC:77; ABL2.
DR   HPA; CAB017106; -.
DR   HPA; HPA001866; -.
DR   MIM; 164690; gene.
DR   neXtProt; NX_P42684; -.
DR   PharmGKB; PA24414; -.
DR   eggNOG; COG0515; -.
DR   HOVERGEN; HBG004162; -.
DR   InParanoid; P42684; -.
DR   KO; K08887; -.
DR   OMA; PPKCYGG; -.
DR   OrthoDB; EOG7GTT2V; -.
DR   PhylomeDB; P42684; -.
DR   TreeFam; TF105081; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; REACT_111045; Developmental Biology.
DR   SignaLink; P42684; -.
DR   ChiTaRS; ABL2; human.
DR   EvolutionaryTrace; P42684; -.
DR   GeneWiki; ABL2; -.
DR   GenomeRNAi; 27; -.
DR   NextBio; 89; -.
DR   PRO; PR:P42684; -.
DR   Bgee; P42684; -.
DR   CleanEx; HS_ABL2; -.
DR   Genevestigator; P42684; -.
DR   GO; GO:0015629; C:actin cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0051015; F:actin filament binding; TAS:UniProtKB.
DR   GO; GO:0003785; F:actin monomer binding; TAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0051017; P:actin filament bundle assembly; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0051353; P:positive regulation of oxidoreductase activity; IDA:BHF-UCL.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; TAS:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; TAS:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:0030100; P:regulation of endocytosis; TAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR015015; F-actin_binding.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF08919; F_actin_bind; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00808; FABD; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Kinase; Lipoprotein;
KW   Magnesium; Manganese; Metal-binding; Myristate; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; SH2 domain;
KW   SH3 domain; Transferase; Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2   1182       Abelson tyrosine-protein kinase 2.
FT                                /FTId=PRO_0000088052.
FT   DOMAIN      107    167       SH3.
FT   DOMAIN      173    263       SH2.
FT   DOMAIN      288    539       Protein kinase.
FT   NP_BIND     294    302       ATP (By similarity).
FT   NP_BIND     362    368       ATP (By similarity).
FT   REGION        2    106       CAP.
FT   REGION      694    930       F-actin-binding (By similarity).
FT   REGION     1020   1182       F-actin-binding (By similarity).
FT   MOTIF       427    451       Kinase activation loop (By similarity).
FT   MOTIF       658    660       Nuclear localization signal (Potential).
FT   COMPBIAS    561    564       Poly-Ser.
FT   COMPBIAS    732    739       Poly-Gly.
FT   COMPBIAS    843   1055       Pro-rich.
FT   COMPBIAS    984    988       Poly-Pro.
FT   ACT_SITE    409    409       Proton acceptor (By similarity).
FT   BINDING     317    317       ATP (By similarity).
FT   MOD_RES     261    261       Phosphotyrosine; by ABL1 and
FT                                autocatalysis.
FT   MOD_RES     272    272       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     275    275       Phosphoserine.
FT   MOD_RES     439    439       Phosphotyrosine; by autocatalysis and
FT                                SRC-type Tyr-kinases.
FT   MOD_RES     568    568       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     620    620       Phosphoserine.
FT   MOD_RES     631    631       Phosphoserine.
FT   MOD_RES     633    633       Phosphoserine.
FT   MOD_RES     655    655       Phosphoserine.
FT   MOD_RES     683    683       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     718    718       Phosphotyrosine.
FT   MOD_RES     817    817       Phosphoserine.
FT   MOD_RES     820    820       Phosphoserine.
FT   MOD_RES     915    915       Phosphoserine.
FT   MOD_RES     936    936       Phosphoserine.
FT   LIPID         2      2       N-myristoyl glycine (By similarity).
FT   VAR_SEQ       2     73       GQQVGRVGEAPGLQQPQPRGIRGSSAARPSGRRRDPAGRTT
FT                                ETGFNIFTQHDHFASCVEDGFEGDKTGGSSP -> MVLGTV
FT                                LLPPNSYGRDQDTSLCCLCTEASESALPDLT (in
FT                                isoform 2 and isoform 4).
FT                                /FTId=VSP_004961.
FT   VAR_SEQ       2     52       GQQVGRVGEAPGLQQPQPRGIRGSSAARPSGRRRDPAGRTT
FT                                ETGFNIFTQH -> MVLGTVLLPPNSYGRDQDTSLCCLCTE
FT                                ASESALPDLT (in isoform 3 and isoform 10).
FT                                /FTId=VSP_017112.
FT   VAR_SEQ      53     73       Missing (in isoform 6, isoform 7 and
FT                                isoform 8).
FT                                /FTId=VSP_041772.
FT   VAR_SEQ     550    564       EEVAEELGRAASSSS -> EVLLHCANQTCITL (in
FT                                isoform 8).
FT                                /FTId=VSP_041773.
FT   VAR_SEQ     565   1182       Missing (in isoform 8).
FT                                /FTId=VSP_041774.
FT   VAR_SEQ     688    790       Missing (in isoform 4, isoform 5, isoform
FT                                7 and isoform 10).
FT                                /FTId=VSP_021308.
FT   VARIANT      78     78       R -> H (in dbSNP:rs55655202).
FT                                /FTId=VAR_055411.
FT   VARIANT      99     99       E -> Q (somatic mutation in a breast
FT                                cancer sample).
FT                                /FTId=VAR_055412.
FT   VARIANT     519    519       R -> I (somatic mutation in a lung
FT                                squamous cell carcinoma).
FT                                /FTId=VAR_055413.
FT   VARIANT     769    769       T -> S (in dbSNP:rs55892721).
FT                                /FTId=VAR_055414.
FT   VARIANT     930    930       K -> R (in dbSNP:rs17277288).
FT                                /FTId=VAR_029232.
FT   VARIANT     946    946       V -> M (in dbSNP:rs28913889).
FT                                /FTId=VAR_029233.
FT   VARIANT     996    996       P -> R (in dbSNP:rs28913890).
FT                                /FTId=VAR_029234.
FT   VARIANT    1085   1085       S -> N (in dbSNP:rs28913891).
FT                                /FTId=VAR_029235.
FT   VARIANT    1101   1101       T -> A (in dbSNP:rs28913892).
FT                                /FTId=VAR_029236.
FT   CONFLICT    343    344       NL -> TI (in Ref. 9; no nucleotide
FT                                entry).
FT   CONFLICT    435    435       T -> I (in Ref. 3; AK311045).
FT   CONFLICT    981    981       K -> R (in Ref. 4; CAD98092).
FT   HELIX       168    170
FT   STRAND      174    177
FT   HELIX       180    187
FT   STRAND      194    199
FT   STRAND      207    213
FT   STRAND      216    221
FT   STRAND      226    228
FT   STRAND      230    233
FT   STRAND      236    240
FT   HELIX       241    248
FT   STRAND      255    257
FT   STRAND      280    282
FT   HELIX       285    287
FT   STRAND      288    293
FT   HELIX       294    297
FT   STRAND      300    307
FT   HELIX       308    310
FT   STRAND      312    318
FT   HELIX       326    337
FT   STRAND      347    351
FT   STRAND      353    356
FT   STRAND      358    362
FT   HELIX       369    375
FT   TURN        378    380
FT   HELIX       383    402
FT   HELIX       412    414
FT   STRAND      415    417
FT   HELIX       419    421
FT   STRAND      423    425
FT   STRAND      435    437
FT   STRAND      438    440
FT   HELIX       449    451
FT   HELIX       454    459
FT   HELIX       464    479
FT   HELIX       491    493
FT   HELIX       494    499
FT   HELIX       512    521
FT   HELIX       526    528
FT   HELIX       532    545
FT   HELIX      1069   1071
FT   TURN       1076   1078
FT   HELIX      1080   1083
FT   HELIX      1086   1099
FT   HELIX      1106   1123
FT   HELIX      1124   1126
FT   HELIX      1130   1152
FT   STRAND     1155   1158
FT   HELIX      1165   1181
SQ   SEQUENCE   1182 AA;  128343 MW;  ED93869BC2B14FAA CRC64;
     MGQQVGRVGE APGLQQPQPR GIRGSSAARP SGRRRDPAGR TTETGFNIFT QHDHFASCVE
     DGFEGDKTGG SSPEALHRPY GCDVEPQALN EAIRWSSKEN LLGATESDPN LFVALYDFVA
     SGDNTLSITK GEKLRVLGYN QNGEWSEVRS KNGQGWVPSN YITPVNSLEK HSWYHGPVSR
     SAAEYLLSSL INGSFLVRES ESSPGQLSIS LRYEGRVYHY RINTTADGKV YVTAESRFST
     LAELVHHHST VADGLVTTLH YPAPKCNKPT VYGVSPIHDK WEMERTDITM KHKLGGGQYG
     EVYVGVWKKY SLTVAVKTLK EDTMEVEEFL KEAAVMKEIK HPNLVQLLGV CTLEPPFYIV
     TEYMPYGNLL DYLRECNREE VTAVVLLYMA TQISSAMEYL EKKNFIHRDL AARNCLVGEN
     HVVKVADFGL SRLMTGDTYT AHAGAKFPIK WTAPESLAYN TFSIKSDVWA FGVLLWEIAT
     YGMSPYPGID LSQVYDLLEK GYRMEQPEGC PPKVYELMRA CWKWSPADRP SFAETHQAFE
     TMFHDSSISE EVAEELGRAA SSSSVVPYLP RLPILPSKTR TLKKQVENKE NIEGAQDATE
     NSASSLAPGF IRGAQASSGS PALPRKQRDK SPSSLLEDAK ETCFTRDRKG GFFSSFMKKR
     NAPTPPKRSS SFREMENQPH KKYELTGNFS SVASLQHADG FSFTPAQQEA NLVPPKCYGG
     SFAQRNLCND DGGGGGGSGT AGGGWSGITG FFTPRLIKKT LGLRAGKPTA SDDTSKPFPR
     SNSTSSMSSG LPEQDRMAMT LPRNCQRSKL QLERTVSTSS QPEENVDRAN DMLPKKSEES
     AAPSRERPKA KLLPRGATAL PLRTPSGDLA ITEKDPPGVG VAGVAAAPKG KEKNGGARLG
     MAGVPEDGEQ PGWPSPAKAA PVLPTTHNHK VPVLISPTLK HTPADVQLIG TDSQGNKFKL
     LSEHQVTSSG DKDRPRRVKP KCAPPPPPVM RLLQHPSICS DPTEEPTALT AGQSTSETQE
     GGKKAALGAV PISGKAGRPV MPPPQVPLPT SSISPAKMAN GTAGTKVALR KTKQAAEKIS
     ADKISKEALL ECADLLSSAL TEPVPNSQLV DTGHQLLDYC SGYVDCIPQT RNKFAFREAV
     SKLELSLQEL QVSSAAAGVP GTNPVLNNLL SCVQEISDVV QR
//
ID   ABLM1_HUMAN             Reviewed;         778 AA.
AC   O14639; A6NI16; A6NJ06; A8MXA9; Q15039; Q5JVV1; Q5JVV2; Q5T6N3;
AC   Q5T6N5; Q68CQ9; Q9BUP1;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 3.
DT   09-JUL-2014, entry version 136.
DE   RecName: Full=Actin-binding LIM protein 1;
DE            Short=abLIM-1;
DE   AltName: Full=Actin-binding LIM protein family member 1;
DE   AltName: Full=Actin-binding double zinc finger protein;
DE   AltName: Full=LIMAB1;
DE   AltName: Full=Limatin;
GN   Name=ABLIM1; Synonyms=ABLIM, KIAA0059, LIMAB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ALTERNATIVE
RP   SPLICING, AND TISSUE SPECIFICITY.
RC   TISSUE=Retina;
RX   PubMed=9245787; DOI=10.1083/jcb.138.3.575;
RA   Roof D.J., Hayes A., Adamian M., Chishti A.H., Li T.;
RT   "Molecular characterization of abLIM, a novel actin-binding and double
RT   zinc finger protein.";
RL   J. Cell Biol. 138:575-588(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Bone marrow;
RX   PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S.,
RA   Seki N., Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II.
RT   The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [3]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Retina;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-439, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-396, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [10]
RP   INTERACTION WITH ABRA.
RX   PubMed=17194709; DOI=10.1074/jbc.M607549200;
RA   Barrientos T., Frank D., Kuwahara K., Bezprozvannaya S., Pipes G.C.T.,
RA   Bassel-Duby R., Richardson J.A., Katus H.A., Olson E.N., Frey N.;
RT   "Two novel members of the ABLIM protein family, ABLIM-2 and -3,
RT   associate with STARS and directly bind F-actin.";
RL   J. Biol. Chem. 282:8393-8403(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-431; SER-435; SER-455;
RP   SER-458; SER-587; SER-640 AND SER-655, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-367; TYR-373; SER-426;
RP   SER-431; THR-433 AND SER-435, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-435 AND SER-640, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-435, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
CC   -!- FUNCTION: May act as scaffold protein (By similarity). May play a
CC       role in the development of the retina. Has been suggested to play
CC       a role in axon guidance.
CC   -!- SUBUNIT: Binds F-actin. Interacts with ABRA.
CC   -!- INTERACTION:
CC       O95751:LDOC1; NbExp=2; IntAct=EBI-487024, EBI-740738;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Cytoplasm,
CC       cytoskeleton (By similarity). Note=Associated with the
CC       cytoskeleton (By similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=O14639-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O14639-2; Sequence=VSP_012100;
CC       Name=3;
CC         IsoId=O14639-3; Sequence=VSP_012099, VSP_012102;
CC       Name=4;
CC         IsoId=O14639-4; Sequence=VSP_012099, VSP_012101, VSP_012102;
CC       Name=5;
CC         IsoId=O14639-5; Sequence=VSP_012099, VSP_041185, VSP_012102;
CC   -!- TISSUE SPECIFICITY: Detected in liver, heart, skeletal muscle,
CC       brain and retina, where it is concentrated in the inner segment
CC       and in the outer plexiform layers.
CC   -!- SIMILARITY: Contains 1 HP (headpiece) domain.
CC   -!- SIMILARITY: Contains 4 LIM zinc-binding domains.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA06681.2; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF005654; AAC51676.1; -; mRNA.
DR   EMBL; D31883; BAA06681.2; ALT_INIT; mRNA.
DR   EMBL; AK098277; BAG53605.1; -; mRNA.
DR   EMBL; CR749819; CAH18679.1; -; mRNA.
DR   EMBL; AL133384; CAI40135.1; -; Genomic_DNA.
DR   EMBL; AL133384; CAI40136.1; -; Genomic_DNA.
DR   EMBL; AL133384; CAI40140.1; -; Genomic_DNA.
DR   EMBL; AL354873; CAI40140.1; JOINED; Genomic_DNA.
DR   EMBL; AL133384; CAI40141.1; -; Genomic_DNA.
DR   EMBL; AL354873; CAI40141.1; JOINED; Genomic_DNA.
DR   EMBL; AL354873; CAI10908.1; -; Genomic_DNA.
DR   EMBL; AL133384; CAI10908.1; JOINED; Genomic_DNA.
DR   EMBL; AL354873; CAI10910.1; -; Genomic_DNA.
DR   EMBL; AL133384; CAI10910.1; JOINED; Genomic_DNA.
DR   EMBL; AL590109; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC002448; AAH02448.1; -; mRNA.
DR   CCDS; CCDS31288.1; -. [O14639-2]
DR   CCDS; CCDS31289.1; -. [O14639-5]
DR   CCDS; CCDS7590.1; -. [O14639-1]
DR   RefSeq; NP_001003407.1; NM_001003407.1. [O14639-2]
DR   RefSeq; NP_001003408.1; NM_001003408.1.
DR   RefSeq; NP_002304.3; NM_002313.5. [O14639-1]
DR   RefSeq; NP_006711.3; NM_006720.3. [O14639-5]
DR   RefSeq; XP_005269885.1; XM_005269828.2. [O14639-3]
DR   UniGene; Hs.438236; -.
DR   UniGene; Hs.538331; -.
DR   UniGene; Hs.593868; -.
DR   ProteinModelPortal; O14639; -.
DR   SMR; O14639; 89-344, 714-778.
DR   BioGrid; 110171; 21.
DR   IntAct; O14639; 17.
DR   MINT; MINT-1447354; -.
DR   STRING; 9606.ENSP00000338190; -.
DR   PhosphoSite; O14639; -.
DR   MaxQB; O14639; -.
DR   PaxDb; O14639; -.
DR   PRIDE; O14639; -.
DR   Ensembl; ENST00000277895; ENSP00000277895; ENSG00000099204. [O14639-1]
DR   Ensembl; ENST00000369252; ENSP00000358256; ENSG00000099204. [O14639-2]
DR   Ensembl; ENST00000369253; ENSP00000358257; ENSG00000099204. [O14639-4]
DR   Ensembl; ENST00000392952; ENSP00000376679; ENSG00000099204. [O14639-5]
DR   GeneID; 3983; -.
DR   KEGG; hsa:3983; -.
DR   UCSC; uc021pyu.1; human. [O14639-5]
DR   UCSC; uc021pyw.1; human. [O14639-1]
DR   UCSC; uc021pyz.1; human. [O14639-2]
DR   UCSC; uc021pzc.1; human. [O14639-4]
DR   CTD; 3983; -.
DR   GeneCards; GC10M116190; -.
DR   HGNC; HGNC:78; ABLIM1.
DR   HPA; HPA038951; -.
DR   HPA; HPA038952; -.
DR   MIM; 602330; gene.
DR   neXtProt; NX_O14639; -.
DR   PharmGKB; PA35023; -.
DR   eggNOG; NOG302299; -.
DR   HOVERGEN; HBG031499; -.
DR   KO; K07520; -.
DR   OMA; HHPSEKP; -.
DR   PhylomeDB; O14639; -.
DR   TreeFam; TF318042; -.
DR   Reactome; REACT_111045; Developmental Biology.
DR   ChiTaRS; ABLIM1; human.
DR   GeneWiki; ABLIM1; -.
DR   GenomeRNAi; 3983; -.
DR   NextBio; 15616; -.
DR   PRO; PR:O14639; -.
DR   ArrayExpress; O14639; -.
DR   Bgee; O14639; -.
DR   CleanEx; HS_ABLIM1; -.
DR   Genevestigator; O14639; -.
DR   GO; GO:0015629; C:actin cytoskeleton; TAS:ProtInc.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0003779; F:actin binding; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007010; P:cytoskeleton organization; IEA:InterPro.
DR   GO; GO:0009887; P:organ morphogenesis; TAS:ProtInc.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0007601; P:visual perception; TAS:ProtInc.
DR   Gene3D; 1.10.950.10; -; 1.
DR   Gene3D; 2.10.110.10; -; 4.
DR   InterPro; IPR028448; ABLIM1.
DR   InterPro; IPR003128; Villin_headpiece.
DR   InterPro; IPR001781; Znf_LIM.
DR   PANTHER; PTHR24213:SF18; PTHR24213:SF18; 1.
DR   Pfam; PF00412; LIM; 4.
DR   Pfam; PF02209; VHP; 1.
DR   SMART; SM00132; LIM; 4.
DR   SMART; SM00153; VHP; 1.
DR   SUPFAM; SSF47050; SSF47050; 1.
DR   PROSITE; PS51089; HP; 1.
DR   PROSITE; PS00478; LIM_DOMAIN_1; 4.
DR   PROSITE; PS50023; LIM_DOMAIN_2; 4.
PE   1: Evidence at protein level;
KW   Actin-binding; Alternative splicing; Coiled coil; Complete proteome;
KW   Cytoplasm; Cytoskeleton; LIM domain; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Zinc.
FT   CHAIN         1    778       Actin-binding LIM protein 1.
FT                                /FTId=PRO_0000075697.
FT   DOMAIN       97    156       LIM zinc-binding 1.
FT   DOMAIN      156    216       LIM zinc-binding 2.
FT   DOMAIN      224    283       LIM zinc-binding 3.
FT   DOMAIN      283    343       LIM zinc-binding 4.
FT   DOMAIN      710    778       HP.
FT   COILED      590    614       Potential.
FT   MOD_RES     367    367       Phosphoserine.
FT   MOD_RES     373    373       Phosphotyrosine.
FT   MOD_RES     396    396       Phosphotyrosine.
FT   MOD_RES     426    426       Phosphoserine.
FT   MOD_RES     431    431       Phosphoserine.
FT   MOD_RES     433    433       Phosphothreonine.
FT   MOD_RES     435    435       Phosphoserine.
FT   MOD_RES     439    439       Phosphotyrosine.
FT   MOD_RES     455    455       Phosphoserine.
FT   MOD_RES     458    458       Phosphoserine.
FT   MOD_RES     587    587       Phosphoserine.
FT   MOD_RES     640    640       Phosphoserine.
FT   MOD_RES     655    655       Phosphoserine.
FT   VAR_SEQ       1    316       Missing (in isoform 3, isoform 4 and
FT                                isoform 5).
FT                                /FTId=VSP_012099.
FT   VAR_SEQ       1     81       MPAFLGLKCLGKLCSSEKSKVTSSERTSARGSNRKRLIVED
FT                                RRVSGTSFTAHRRATITHLLYLCPKDYCPRGRVCNSVDPF
FT                                -> MLMTLEMTELTDPHHTMGDYK (in isoform 2).
FT                                /FTId=VSP_012100.
FT   VAR_SEQ     347    347       R -> RLPNIRRSSSDFFYSKSLIRRTGRSPSLQ (in
FT                                isoform 5).
FT                                /FTId=VSP_041185.
FT   VAR_SEQ     348    373       Missing (in isoform 4).
FT                                /FTId=VSP_012101.
FT   VAR_SEQ     480    514       Missing (in isoform 3, isoform 4 and
FT                                isoform 5).
FT                                /FTId=VSP_012102.
FT   VARIANT     434    434       P -> T (in dbSNP:rs11593544).
FT                                /FTId=VAR_050141.
FT   VARIANT     637    637       R -> G (in dbSNP:rs7091419).
FT                                /FTId=VAR_050142.
FT   CONFLICT    499    499       R -> L (in Ref. 1; AAC51676).
FT   CONFLICT    532    532       A -> R (in Ref. 1; AAC51676).
FT   CONFLICT    563    563       K -> E (in Ref. 2; BAA06681).
FT   CONFLICT    578    578       V -> I (in Ref. 2; BAA06681).
SQ   SEQUENCE   778 AA;  87688 MW;  EBC2F14BE558752B CRC64;
     MPAFLGLKCL GKLCSSEKSK VTSSERTSAR GSNRKRLIVE DRRVSGTSFT AHRRATITHL
     LYLCPKDYCP RGRVCNSVDP FVAHPQDPHH PSEKPVIHCH KCGEPCKGEV LRVQTKHFHI
     KCFTCKVCGC DLAQGGFFIK NGEYLCTLDY QRMYGTRCHG CGEFVEGEVV TALGKTYHPN
     CFACTICKRP FPPGDRVTFN GRDCLCQLCA QPMSSSPKET TFSSNCAGCG RDIKNGQALL
     ALDKQWHLGC FKCKSCGKVL TGEYISKDGA PYCEKDYQGL FGVKCEACHQ FITGKVLEAG
     DKHYHPSCAR CSRCNQMFTE GEEMYLQGST VWHPDCKQST KTEEKLRPTR TSSESIYSRP
     GSSIPGSPGH TIYAKVDNEI LDYKDLAAIP KVKAIYDIER PDLITYEPFY TSGYDDKQER
     QSLGESPRTL SPTPSAEGYQ DVRDRMIHRS TSQGSINSPV YSRHSYTPTT SRSPQHFHRP
     GNEPSSGRNS PLPYRPDSRP LTPTYAQAPK HFHVPDQGIN IYRKPPIYKQ HAALAAQSKS
     SEDIIKFSKF PAAQAPDPSE TPKIETDHWP GPPSFAVVGP DMKRRSSGRE EDDEELLRRR
     QLQEEQLMKL NSGLGQLILK EEMEKESRER SSLLASRYDS PINSASHIPS SKTASLPGYG
     RNGLHRPVST DFAQYNSYGD VSGGVRDYQT LPDGHMPAMR MDRGVSMPNM LEPKIFPYEM
     LMVTNRGRNK ILREVDRTRL ERHLAPEVFR EIFGMSIQEF DRLPLWRRND MKKKAKLF
//
ID   ACACA_HUMAN             Reviewed;        2346 AA.
AC   Q13085; B2RP68; Q6KEV6; Q6XDA8; Q7Z2G8; Q7Z561; Q7Z563; Q7Z564;
AC   Q86WB2; Q86WB3;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2006, sequence version 2.
DT   09-JUL-2014, entry version 146.
DE   RecName: Full=Acetyl-CoA carboxylase 1;
DE            Short=ACC1;
DE            EC=6.4.1.2;
DE   AltName: Full=ACC-alpha;
DE   Includes:
DE     RecName: Full=Biotin carboxylase;
DE              EC=6.3.4.14;
GN   Name=ACACA; Synonyms=ACAC, ACC1, ACCA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=7732023; DOI=10.1073/pnas.92.9.4011;
RA   Abu-Elheiga L., Jayakumar A., Baldini A., Chirala S.S., Wakil S.J.;
RT   "Human acetyl-CoA carboxylase: characterization, molecular cloning,
RT   and evidence for two isoforms.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:4011-4015(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   1-366 (ISOFORMS 2 AND 3), AND NUCLEOTIDE SEQUENCE [MRNA] OF 1-120
RP   (ISOFORM 4).
RC   TISSUE=Adipocyte;
RX   PubMed=12810950; DOI=10.1073/pnas.1332670100;
RA   Mao J., Chirala S.S., Wakil S.J.;
RT   "Human acetyl-CoA carboxylase 1 gene: presence of three promoters and
RT   heterogeneity at the 5'-untranslated mRNA region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:7515-7520(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-2271.
RX   PubMed=15333468; DOI=10.1093/carcin/bgh273;
RA   Sinilnikova O.M., Ginolhac S.M., Magnard C., Leone M., Anczukow O.,
RA   Hughes D., Moreau K., Thompson D., Coutanson C., Hall J.,
RA   Romestaing P., Gerard J.-P., Bonadona V., Lasset C., Goldgar D.E.,
RA   Joulin V., Venezia N.D., Lenoir G.M.;
RT   "Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility.";
RL   Carcinogenesis 25:2417-2424(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-113 (ISOFORM 2), AND NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 1-93 (ISOFORM 3).
RC   TISSUE=Mammary gland, and Testis;
RX   PubMed=14643797; DOI=10.1016/j.bbalip.2003.09.005;
RA   Travers M.T., Vallance A.J., Clegg R.A., Thomson R., Price N.T.,
RA   Barber M.C.;
RT   "Characterisation of an N-terminal variant of acetyl-CoA carboxylase-
RT   alpha: expression in human tissues and evolutionary aspects.";
RL   Biochim. Biophys. Acta 1634:97-106(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-47 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15607423; DOI=10.1016/j.ygeno.2004.10.001;
RA   Travers M.T., Cambot M., Kennedy H.T., Lenoir G.M., Barber M.C.,
RA   Joulin V.;
RT   "Asymmetric expression of transcripts derived from the shared promoter
RT   between the divergently oriented ACACA and TADA2L genes.";
RL   Genomics 85:71-84(2005).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-18; 39-45; 77-86; 99-111; 121-132; 153-170;
RP   218-224; 267-276; 278-288; 323-335; 568-579; 589-615; 646-657;
RP   748-755; 818-838; 985-992; 997-1008; 1083-1096; 1147-1169; 1192-1199;
RP   1233-1247; 1283-1294; 1317-1325; 1327-1334; 1372-1385; 1401-1420;
RP   1508-1514; 1553-1564; 1668-1687; 1714-1731; 1750-1759; 1782-1798;
RP   1824-1833; 1838-1856; 1905-1916; 1922-1929; 1978-2009; 2063-2072;
RP   2104-2111; 2115-2127; 2139-2161; 2200-2209; 2213-2218; 2221-2229 AND
RP   2261-2293, ACETYLATION AT MET-1, PHOSPHORYLATION AT SER-80, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Hepatoma;
RA   Bienvenut W.V., Boldt K., von Kriegsheim A.F., Kolch W.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [8]
RP   INTERACTION WITH BRCA1.
RX   PubMed=12360400; DOI=10.1038/sj.onc.1205915;
RA   Magnard C., Bachelier R., Vincent A., Jaquinod M., Kieffer S.,
RA   Lenoir G.M., Venezia N.D.;
RT   "BRCA1 interacts with acetyl-CoA carboxylase through its tandem of
RT   BRCT domains.";
RL   Oncogene 21:6729-6739(2002).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-29 AND SER-53, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   INTERACTION WITH BRCA1.
RX   PubMed=16326698; DOI=10.1074/jbc.M504652200;
RA   Moreau K., Dizin E., Ray H., Luquain C., Lefai E., Foufelle F.,
RA   Billaud M., Lenoir G.M., Venezia N.D.;
RT   "BRCA1 affects lipid synthesis through its interaction with acetyl-CoA
RT   carboxylase.";
RL   J. Biol. Chem. 281:3172-3181(2006).
RN   [11]
RP   PHOSPHORYLATION AT SER-1263, AND MUTAGENESIS OF SER-78; SER-344;
RP   SER-432; SER-1201; SER-1263; SER-1585; SER-1952 AND SER-2211.
RX   PubMed=16698035; DOI=10.1016/j.jmb.2006.04.010;
RA   Ray H., Moreau K., Dizin E., Callebaut I., Venezia N.D.;
RT   "ACCA phosphopeptide recognition by the BRCT repeats of BRCA1.";
RL   J. Mol. Biol. 359:973-982(2006).
RN   [12]
RP   INVOLVEMENT IN ACACAD.
RX   PubMed=6114432;
RA   Blom W., de Muinck Keizer S.M.P.F., Scholte H.R.;
RT   "Acetyl-CoA carboxylase deficiency: an inborn error of de novo fatty
RT   acid synthesis.";
RL   N. Engl. J. Med. 305:465-466(1981).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-488, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-29, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-25; SER-29 AND
RP   SER-80, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-5 AND SER-29, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-25 AND SER-29,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1334, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [20]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, ENZYME REGULATION, AND
RP   INTERACTION WITH MID1IP1.
RX   PubMed=20952656; DOI=10.1073/pnas.1012736107;
RA   Colbert C.L., Kim C.W., Moon Y.A., Henry L., Palnitkar M.,
RA   McKean W.B., Fitzgerald K., Deisenhofer J., Horton J.D., Kwon H.J.;
RT   "Crystal structure of Spot 14, a modulator of fatty acid synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:18820-18825(2010).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-5; SER-23; SER-29 AND SER-80, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-29 AND SER-80, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [24]
RP   VARIANT [LARGE SCALE ANALYSIS] GLN-1687.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Catalyzes the rate-limiting reaction in the biogenesis
CC       of long-chain fatty acids. Carries out three functions: biotin
CC       carboxyl carrier protein, biotin carboxylase and
CC       carboxyltransferase.
CC   -!- CATALYTIC ACTIVITY: ATP + acetyl-CoA + HCO(3)(-) = ADP + phosphate
CC       + malonyl-CoA.
CC   -!- CATALYTIC ACTIVITY: ATP + biotin-[carboxyl-carrier-protein] +
CC       CO(2) = ADP + phosphate + carboxy-biotin-[carboxyl-carrier-
CC       protein].
CC   -!- COFACTOR: Biotin.
CC   -!- COFACTOR: Binds 2 manganese ions per subunit.
CC   -!- ENZYME REGULATION: By phosphorylation (By similarity). Activity is
CC       increased by oligomerization. Citrate and MID1IP1 promote
CC       oligomerization.
CC   -!- PATHWAY: Lipid metabolism; malonyl-CoA biosynthesis; malonyl-CoA
CC       from acetyl-CoA: step 1/1.
CC   -!- SUBUNIT: Monomer, homodimer, and homotetramer. Can form
CC       filamentous polymers. Interacts in its inactive phosphorylated
CC       form with the BRCT domains of BRCA1 which prevents ACACA
CC       dephosphorylation and inhibits lipid synthesis. Interacts with
CC       MID1IP1; interaction with MID1IP1 promotes oligomerization and
CC       increases its activity.
CC   -!- INTERACTION:
CC       O60218:AKR1B10; NbExp=4; IntAct=EBI-717681, EBI-1572139;
CC       P38398:BRCA1; NbExp=2; IntAct=EBI-717681, EBI-349905;
CC       Q96EB6:SIRT1; NbExp=3; IntAct=EBI-717681, EBI-1802965;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q13085-1; Sequence=Displayed;
CC       Name=2; Synonyms=E5A;
CC         IsoId=Q13085-2; Sequence=VSP_026099;
CC       Name=3; Synonyms=E5B;
CC         IsoId=Q13085-3; Sequence=VSP_026098;
CC       Name=4;
CC         IsoId=Q13085-4; Sequence=VSP_026100;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, placental, skeletal
CC       muscle, renal, pancreatic and adipose tissues; expressed at low
CC       level in pulmonary tissue; not detected in the liver.
CC   -!- PTM: Phosphorylation on Ser-1263 is required for interaction with
CC       BRCA1.
CC   -!- DISEASE: Acetyl-CoA carboxylase 1 deficiency (ACACAD)
CC       [MIM:613933]: An inborn error of de novo fatty acid synthesis
CC       associated with severe brain damage, persistent myopathy and poor
CC       growth. Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Contains 1 ATP-grasp domain.
CC   -!- SIMILARITY: Contains 1 biotin carboxylation domain.
CC   -!- SIMILARITY: Contains 1 biotinyl-binding domain.
CC   -!- SIMILARITY: Contains 1 carboxyltransferase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAP94120.1; Type=Erroneous initiation;
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Acetyl-CoA carboxylase entry;
CC       URL="http://en.wikipedia.org/wiki/Acetyl-CoA_carboxylase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U19822; AAC50139.1; -; mRNA.
DR   EMBL; AY315619; AAP94114.1; -; mRNA.
DR   EMBL; AY315620; AAP94115.1; -; mRNA.
DR   EMBL; AY315621; AAP94116.1; -; mRNA.
DR   EMBL; AY315623; AAP94118.1; -; mRNA.
DR   EMBL; AY315625; AAP94120.1; ALT_INIT; mRNA.
DR   EMBL; AY315627; AAP94122.1; -; mRNA.
DR   EMBL; AY237919; AAP69841.1; -; mRNA.
DR   EMBL; BC137287; AAI37288.1; -; mRNA.
DR   EMBL; AJ534888; CAD59556.1; -; mRNA.
DR   EMBL; AJ534889; CAD59557.1; -; mRNA.
DR   EMBL; AJ564444; CAD92089.1; -; mRNA.
DR   CCDS; CCDS11317.1; -. [Q13085-1]
DR   CCDS; CCDS11318.1; -. [Q13085-2]
DR   CCDS; CCDS42302.1; -. [Q13085-4]
DR   CCDS; CCDS42303.1; -. [Q13085-3]
DR   PIR; I38928; I38928.
DR   RefSeq; NP_942131.1; NM_198834.2. [Q13085-4]
DR   RefSeq; NP_942133.1; NM_198836.2. [Q13085-1]
DR   RefSeq; NP_942134.1; NM_198837.1. [Q13085-2]
DR   RefSeq; NP_942135.1; NM_198838.1. [Q13085-3]
DR   RefSeq; NP_942136.1; NM_198839.2. [Q13085-1]
DR   RefSeq; XP_005257323.1; XM_005257266.2. [Q13085-3]
DR   RefSeq; XP_005257324.1; XM_005257267.2. [Q13085-3]
DR   RefSeq; XP_006725384.1; XM_006725321.1. [Q13085-3]
DR   UniGene; Hs.160556; -.
DR   PDB; 2YL2; X-ray; 2.30 A; A/B=78-617.
DR   PDB; 3COJ; X-ray; 3.21 A; H/I/J/K/L/M/N/O=1258-1270.
DR   PDB; 4ASI; X-ray; 2.80 A; A/B/C/D/E/F=1571-2338.
DR   PDBsum; 2YL2; -.
DR   PDBsum; 3COJ; -.
DR   PDBsum; 4ASI; -.
DR   ProteinModelPortal; Q13085; -.
DR   SMR; Q13085; 102-817, 1581-2338.
DR   BioGrid; 106549; 65.
DR   DIP; DIP-36122N; -.
DR   IntAct; Q13085; 26.
DR   MINT; MINT-1415014; -.
DR   BindingDB; Q13085; -.
DR   ChEMBL; CHEMBL3351; -.
DR   DrugBank; DB00121; Biotin.
DR   GuidetoPHARMACOLOGY; 1263; -.
DR   PhosphoSite; Q13085; -.
DR   DMDM; 118601083; -.
DR   MaxQB; Q13085; -.
DR   PaxDb; Q13085; -.
DR   PRIDE; Q13085; -.
DR   Ensembl; ENST00000335166; ENSP00000335323; ENSG00000132142. [Q13085-3]
DR   Ensembl; ENST00000353139; ENSP00000344789; ENSG00000132142. [Q13085-4]
DR   Ensembl; ENST00000360679; ENSP00000353898; ENSG00000132142. [Q13085-2]
DR   Ensembl; ENST00000394406; ENSP00000377928; ENSG00000132142. [Q13085-1]
DR   Ensembl; ENST00000451642; ENSP00000397282; ENSG00000132142.
DR   GeneID; 31; -.
DR   KEGG; hsa:31; -.
DR   UCSC; uc002hnk.3; human. [Q13085-1]
DR   UCSC; uc002hnl.3; human. [Q13085-2]
DR   UCSC; uc002hno.3; human. [Q13085-4]
DR   CTD; 31; -.
DR   GeneCards; GC17M035441; -.
DR   HGNC; HGNC:84; ACACA.
DR   HPA; CAB013715; -.
DR   MIM; 200350; gene.
DR   MIM; 613933; phenotype.
DR   neXtProt; NX_Q13085; -.
DR   PharmGKB; PA24421; -.
DR   eggNOG; COG0511; -.
DR   HOVERGEN; HBG005371; -.
DR   InParanoid; Q13085; -.
DR   KO; K11262; -.
DR   OMA; HVFSGQC; -.
DR   OrthoDB; EOG7HXCPW; -.
DR   PhylomeDB; Q13085; -.
DR   TreeFam; TF300061; -.
DR   BRENDA; 6.4.1.2; 2681.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_116125; Disease.
DR   SABIO-RK; Q13085; -.
DR   UniPathway; UPA00655; UER00711.
DR   ChiTaRS; ACACA; human.
DR   EvolutionaryTrace; Q13085; -.
DR   GeneWiki; ACACA; -.
DR   GenomeRNAi; 31; -.
DR   NextBio; 111; -.
DR   PRO; PR:Q13085; -.
DR   ArrayExpress; Q13085; -.
DR   Bgee; Q13085; -.
DR   Genevestigator; Q13085; -.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0003989; F:acetyl-CoA carboxylase activity; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004075; F:biotin carboxylase activity; IEA:UniProtKB-EC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0006084; P:acetyl-CoA metabolic process; ISS:UniProtKB.
DR   GO; GO:0006768; P:biotin metabolic process; TAS:Reactome.
DR   GO; GO:0006853; P:carnitine shuttle; TAS:Reactome.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0006112; P:energy reserve metabolic process; TAS:Reactome.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0055088; P:lipid homeostasis; IEA:Ensembl.
DR   GO; GO:0035338; P:long-chain fatty-acyl-CoA biosynthetic process; TAS:Reactome.
DR   GO; GO:2001295; P:malonyl-CoA biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0044268; P:multicellular organismal protein metabolic process; IEA:Ensembl.
DR   GO; GO:0031325; P:positive regulation of cellular metabolic process; TAS:Reactome.
DR   GO; GO:0051289; P:protein homotetramerization; ISS:UniProtKB.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl.
DR   GO; GO:0019432; P:triglyceride biosynthetic process; TAS:Reactome.
DR   GO; GO:0006766; P:vitamin metabolic process; TAS:Reactome.
DR   GO; GO:0006767; P:water-soluble vitamin metabolic process; TAS:Reactome.
DR   Gene3D; 3.30.1490.20; -; 1.
DR   Gene3D; 3.30.470.20; -; 1.
DR   Gene3D; 3.40.50.20; -; 1.
DR   Gene3D; 3.90.226.10; -; 3.
DR   InterPro; IPR013537; AcCoA_COase_cen.
DR   InterPro; IPR011761; ATP-grasp.
DR   InterPro; IPR013815; ATP_grasp_subdomain_1.
DR   InterPro; IPR013816; ATP_grasp_subdomain_2.
DR   InterPro; IPR001882; Biotin_BS.
DR   InterPro; IPR011764; Biotin_carboxylation_dom.
DR   InterPro; IPR005482; Biotin_COase_C.
DR   InterPro; IPR000089; Biotin_lipoyl.
DR   InterPro; IPR005481; CarbamoylP_synth_lsu_N.
DR   InterPro; IPR000022; Carboxyl_trans.
DR   InterPro; IPR005479; CbamoylP_synth_lsu-like_ATP-bd.
DR   InterPro; IPR029045; ClpP/crotonase-like_dom.
DR   InterPro; IPR011763; COA_CT_C.
DR   InterPro; IPR011762; COA_CT_N.
DR   InterPro; IPR016185; PreATP-grasp_dom.
DR   InterPro; IPR011054; Rudment_hybrid_motif.
DR   InterPro; IPR011053; Single_hybrid_motif.
DR   Pfam; PF08326; ACC_central; 1.
DR   Pfam; PF02785; Biotin_carb_C; 1.
DR   Pfam; PF00364; Biotin_lipoyl; 1.
DR   Pfam; PF01039; Carboxyl_trans; 1.
DR   Pfam; PF00289; CPSase_L_chain; 1.
DR   Pfam; PF02786; CPSase_L_D2; 1.
DR   SMART; SM00878; Biotin_carb_C; 1.
DR   SUPFAM; SSF51230; SSF51230; 1.
DR   SUPFAM; SSF51246; SSF51246; 1.
DR   SUPFAM; SSF52096; SSF52096; 2.
DR   SUPFAM; SSF52440; SSF52440; 1.
DR   PROSITE; PS50975; ATP_GRASP; 1.
DR   PROSITE; PS50979; BC; 1.
DR   PROSITE; PS00188; BIOTIN; 1.
DR   PROSITE; PS50968; BIOTINYL_LIPOYL; 1.
DR   PROSITE; PS50989; COA_CT_CTER; 1.
DR   PROSITE; PS50980; COA_CT_NTER; 1.
DR   PROSITE; PS00866; CPSASE_1; 1.
DR   PROSITE; PS00867; CPSASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme;
KW   Alternative promoter usage; ATP-binding; Biotin; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Ligase; Lipid biosynthesis; Lipid metabolism;
KW   Manganese; Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN         1   2346       Acetyl-CoA carboxylase 1.
FT                                /FTId=PRO_0000146764.
FT   DOMAIN      117    618       Biotin carboxylation.
FT   DOMAIN      275    466       ATP-grasp.
FT   DOMAIN      752    818       Biotinyl-binding.
FT   DOMAIN     1698   2194       Carboxyltransferase.
FT   NP_BIND     315    320       ATP (Potential).
FT   ACT_SITE    441    441       By similarity.
FT   METAL       424    424       Manganese 1 (By similarity).
FT   METAL       437    437       Manganese 1 (By similarity).
FT   METAL       437    437       Manganese 2 (By similarity).
FT   METAL       439    439       Manganese 2 (By similarity).
FT   BINDING    1823   1823       Coenzyme A (By similarity).
FT   BINDING    2127   2127       Coenzyme A (By similarity).
FT   BINDING    2129   2129       Coenzyme A (By similarity).
FT   MOD_RES       1      1       N-acetylmethionine.
FT   MOD_RES       5      5       Phosphoserine.
FT   MOD_RES      23     23       Phosphoserine.
FT   MOD_RES      25     25       Phosphoserine.
FT   MOD_RES      29     29       Phosphoserine.
FT   MOD_RES      53     53       Phosphoserine.
FT   MOD_RES      78     78       Phosphoserine (By similarity).
FT   MOD_RES      80     80       Phosphoserine.
FT   MOD_RES     488    488       Phosphoserine.
FT   MOD_RES     786    786       N6-biotinyllysine (By similarity).
FT   MOD_RES    1201   1201       Phosphoserine (By similarity).
FT   MOD_RES    1216   1216       Phosphoserine (By similarity).
FT   MOD_RES    1263   1263       Phosphoserine.
FT   MOD_RES    1334   1334       N6-acetyllysine.
FT   VAR_SEQ       1     78       Missing (in isoform 3).
FT                                /FTId=VSP_026098.
FT   VAR_SEQ       1     75       MDEPSPLAQPLELNQHSRFIIGSVSEDNSEDEISNLVKLDL
FT                                LEEKEGSLSPASVGSDTLSDLGISSLQDGLALHI -> MEG
FT                                SPEENKEMRYYMLQ (in isoform 2).
FT                                /FTId=VSP_026099.
FT   VAR_SEQ       1      1       M -> MWWSTLMSILRARSFWKWISTQTVRIIRAVRAHFGG
FT                                IM (in isoform 4).
FT                                /FTId=VSP_026100.
FT   VARIANT     838    838       R -> W (in dbSNP:rs2287351).
FT                                /FTId=VAR_042941.
FT   VARIANT    1687   1687       R -> Q (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_036514.
FT   VARIANT    2271   2271       A -> V (rare polymorphism; frequency
FT                                <0.004; may play a role in breast cancer
FT                                susceptibility).
FT                                /FTId=VAR_028929.
FT   MUTAGEN      78     78       S->A: No effect on interaction with
FT                                BRCA1.
FT   MUTAGEN     344    344       S->A: No effect on interaction with
FT                                BRCA1.
FT   MUTAGEN     432    432       S->A: No effect on interaction with
FT                                BRCA1.
FT   MUTAGEN    1201   1201       S->A: No effect on interaction with
FT                                BRCA1.
FT   MUTAGEN    1263   1263       S->A: Abolishes interaction with BRCA1.
FT   MUTAGEN    1585   1585       S->A: No effect on interaction with
FT                                BRCA1.
FT   MUTAGEN    1952   1952       S->A: No effect on interaction with
FT                                BRCA1.
FT   MUTAGEN    2211   2211       S->A: No effect on interaction with
FT                                BRCA1.
FT   CONFLICT     66     66       S -> A (in Ref. 1; AAC50139).
FT   CONFLICT     79     79       M -> W (in Ref. 1; AAC50139).
FT   CONFLICT     89     89       R -> G (in Ref. 1; AAC50139).
FT   CONFLICT    182    182       P -> A (in Ref. 1; AAC50139).
FT   CONFLICT    234    234       S -> N (in Ref. 1; AAC50139).
FT   CONFLICT    299    299       Q -> K (in Ref. 1; AAC50139).
FT   CONFLICT    303    303       E -> K (in Ref. 1; AAC50139).
FT   CONFLICT    364    364       A -> V (in Ref. 2; AAP94122).
FT   CONFLICT    446    446       H -> Q (in Ref. 1; AAC50139).
FT   CONFLICT    494    494       D -> N (in Ref. 1; AAC50139).
FT   CONFLICT    554    554       D -> G (in Ref. 1; AAC50139).
FT   CONFLICT    622    622       Q -> R (in Ref. 1; AAC50139).
FT   CONFLICT    640    640       A -> G (in Ref. 1; AAC50139).
FT   CONFLICT    814    814       V -> I (in Ref. 2; AAP94122).
FT   CONFLICT   1061   1061       N -> S (in Ref. 1; AAC50139).
FT   CONFLICT   1094   1095       EL -> DV (in Ref. 1; AAC50139).
FT   CONFLICT   1225   1225       S -> A (in Ref. 1; AAC50139).
FT   CONFLICT   1257   1257       S -> C (in Ref. 1; AAC50139).
FT   CONFLICT   1297   1297       C -> G (in Ref. 1; AAC50139).
FT   CONFLICT   1320   1320       V -> A (in Ref. 1; AAC50139).
FT   CONFLICT   1444   1444       N -> S (in Ref. 1; AAC50139).
FT   CONFLICT   1474   1474       F -> L (in Ref. 1; AAC50139).
FT   CONFLICT   1665   1666       TF -> SL (in Ref. 1; AAC50139).
FT   CONFLICT   1677   1677       I -> V (in Ref. 1; AAC50139).
FT   CONFLICT   1741   1741       P -> S (in Ref. 1; AAC50139).
FT   CONFLICT   1762   1762       S -> G (in Ref. 1; AAC50139).
FT   CONFLICT   1822   1822       C -> S (in Ref. 1; AAC50139).
FT   CONFLICT   1875   1875       M -> T (in Ref. 1; AAC50139).
FT   CONFLICT   1888   1888       D -> G (in Ref. 1; AAC50139).
FT   CONFLICT   1997   1997       I -> V (in Ref. 1; AAC50139).
FT   CONFLICT   2013   2013       Q -> H (in Ref. 1; AAC50139).
FT   CONFLICT   2058   2058       D -> H (in Ref. 1; AAC50139).
FT   CONFLICT   2075   2075       C -> S (in Ref. 1; AAC50139).
FT   CONFLICT   2098   2099       SS -> PT (in Ref. 1; AAC50139).
FT   CONFLICT   2158   2159       TA -> PT (in Ref. 1; AAC50139).
FT   CONFLICT   2166   2166       N -> S (in Ref. 1; AAC50139).
FT   CONFLICT   2234   2234       N -> S (in Ref. 1; AAC50139).
FT   CONFLICT   2321   2321       H -> R (in Ref. 2; AAP94122).
FT   HELIX       105    111
FT   STRAND      120    123
FT   HELIX       127    145
FT   STRAND      150    157
FT   HELIX       159    163
FT   HELIX       168    171
FT   STRAND      172    177
FT   HELIX       183    185
FT   TURN        186    188
FT   HELIX       190    199
FT   STRAND      203    206
FT   TURN        211    214
FT   HELIX       217    224
FT   STRAND      228    231
FT   HELIX       234    241
FT   HELIX       243    252
FT   TURN        261    264
FT   HELIX       283    289
FT   HELIX       294    304
FT   STRAND      306    312
FT   STRAND      320    324
FT   TURN        327    329
FT   HELIX       330    340
FT   STRAND      346    350
FT   STRAND      356    364
FT   STRAND      370    382
FT   STRAND      385    392
FT   HELIX       398    415
FT   STRAND      419    427
FT   STRAND      433    439
FT   TURN        444    446
FT   HELIX       447    453
FT   HELIX       457    465
FT   HELIX       470    472
FT   HELIX       474    479
FT   TURN        492    495
FT   STRAND      496    498
FT   STRAND      503    510
FT   STRAND      526    530
FT   STRAND      537    542
FT   STRAND      557    566
FT   HELIX       567    582
FT   HELIX       589    599
FT   HELIX       601    604
FT   HELIX       612    616
FT   HELIX      1582   1592
FT   HELIX      1598   1600
FT   HELIX      1601   1619
FT   HELIX      1628   1631
FT   STRAND     1632   1639
FT   STRAND     1645   1648
FT   STRAND     1656   1666
FT   STRAND     1675   1682
FT   HELIX      1687   1689
FT   HELIX      1693   1709
FT   STRAND     1713   1717
FT   HELIX      1728   1731
FT   STRAND     1735   1739
FT   HELIX      1744   1746
FT   STRAND     1748   1753
FT   HELIX      1755   1761
FT   HELIX      1762   1764
FT   STRAND     1767   1774
FT   STRAND     1777   1785
FT   HELIX      1795   1813
FT   STRAND     1816   1820
FT   STRAND     1822   1825
FT   HELIX      1827   1834
FT   STRAND     1837   1841
FT   STRAND     1845   1849
FT   HELIX      1851   1858
FT   HELIX      1866   1870
FT   HELIX      1872   1875
FT   TURN       1876   1879
FT   STRAND     1882   1887
FT   HELIX      1888   1899
FT   STRAND     1914   1917
FT   HELIX      1934   1939
FT   STRAND     1944   1946
FT   STRAND     1961   1964
FT   STRAND     1971   1978
FT   STRAND     1981   1988
FT   STRAND     1993   1996
FT   STRAND     2010   2013
FT   HELIX      2020   2036
FT   STRAND     2040   2043
FT   HELIX      2053   2057
FT   HELIX      2060   2072
FT   STRAND     2078   2082
FT   STRAND     2087   2089
FT   HELIX      2090   2094
FT   HELIX      2098   2100
FT   TURN       2102   2104
FT   STRAND     2105   2110
FT   STRAND     2114   2118
FT   HELIX      2120   2127
FT   HELIX      2130   2140
FT   HELIX      2142   2150
FT   HELIX      2158   2188
FT   HELIX      2193   2198
FT   STRAND     2201   2206
FT   HELIX      2208   2210
FT   HELIX      2211   2235
FT   HELIX      2241   2256
FT   HELIX      2258   2265
FT   HELIX      2267   2278
FT   HELIX      2289   2310
FT   HELIX      2312   2314
FT   HELIX      2315   2322
FT   HELIX      2323   2325
FT   HELIX      2328   2337
SQ   SEQUENCE   2346 AA;  265554 MW;  F1F0A518F8824FFC CRC64;
     MDEPSPLAQP LELNQHSRFI IGSVSEDNSE DEISNLVKLD LLEEKEGSLS PASVGSDTLS
     DLGISSLQDG LALHIRSSMS GLHLVKQGRD RKKIDSQRDF TVASPAEFVT RFGGNKVIEK
     VLIANNGIAA VKCMRSIRRW SYEMFRNERA IRFVVMVTPE DLKANAEYIK MADHYVPVPG
     GPNNNNYANV ELILDIAKRI PVQAVWAGWG HASENPKLPE LLLKNGIAFM GPPSQAMWAL
     GDKIASSIVA QTAGIPTLPW SGSGLRVDWQ ENDFSKRILN VPQELYEKGY VKDVDDGLQA
     AEEVGYPVMI KASEGGGGKG IRKVNNADDF PNLFRQVQAE VPGSPIFVMR LAKQSRHLEV
     QILADQYGNA ISLFGRDCSV QRRHQKIIEE APATIATPAV FEHMEQCAVK LAKMVGYVSA
     GTVEYLYSQD GSFYFLELNP RLQVEHPCTE MVADVNLPAA QLQIAMGIPL YRIKDIRMMY
     GVSPWGDSPI DFEDSAHVPC PRGHVIAARI TSENPDEGFK PSSGTVQELN FRSNKNVWGY
     FSVAAAGGLH EFADSQFGHC FSWGENREEA ISNMVVALKE LSIRGDFRTT VEYLIKLLET
     ESFQMNRIDT GWLDRLIAEK VQAERPDTML GVVCGALHVA DVSLRNSVSN FLHSLERGQV
     LPAHTLLNTV DVELIYEGVK YVLKVTRQSP NSYVVIMNGS CVEVDVHRLS DGGLLLSYDG
     SSYTTYMKEE VDRYRITIGN KTCVFEKEND PSVMRSPSAG KLIQYIVEDG GHVFAGQCYA
     EIEVMKMVMT LTAVESGCIH YVKRPGAALD PGCVLAKMQL DNPSKVQQAE LHTGSLPRIQ
     STALRGEKLH RVFHYVLDNL VNVMNGYCLP DPFFSSKVKD WVERLMKTLR DPSLPLLELQ
     DIMTSVSGRI PPNVEKSIKK EMAQYASNIT SVLCQFPSQQ IANILDSHAA TLNRKSEREV
     FFMNTQSIVQ LVQRYRSGIR GHMKAVVMDL LRQYLRVETQ FQNGHYDKCV FALREENKSD
     MNTVLNYIFS HAQVTKKNLL VTMLIDQLCG RDPTLTDELL NILTELTQLS KTTNAKVALR
     ARQVLIASHL PSYELRHNQV ESIFLSAIDM YGHQFCIENL QKLILSETSI FDVLPNFFYH
     SNQVVRMAAL EVYVRRAYIA YELNSVQHRQ LKDNTCVVEF QFMLPTSHPN RGNIPTLNRM
     SFSSNLNHYG MTHVASVSDV LLDNSFTPPC QRMGGMVSFR TFEDFVRIFD EVMGCFSDSP
     PQSPTFPEAG HTSLYDEDKV PRDEPIHILN VAIKTDCDIE DDRLAAMFRE FTQQNKATLV
     DHGIRRLTFL VAQKDFRKQV NYEVDRRFHR EFPKFFTFRA RDKFEEDRIY RHLEPALAFQ
     LELNRMRNFD LTAIPCANHK MHLYLGAAKV EVGTEVTDYR FFVRAIIRHS DLVTKEASFE
     YLQNEGERLL LEAMDELEVA FNNTNVRTDC NHIFLNFVPT VIMDPSKIEE SVRSMVMRYG
     SRLWKLRVLQ AELKINIRLT PTGKAIPIRL FLTNESGYYL DISLYKEVTD SRTAQIMFQA
     YGDKQGPLHG MLINTPYVTK DLLQSKRFQA QSLGTTYIYD IPEMFRQSLI KLWESMSTQA
     FLPSPPLPSD MLTYTELVLD DQGQLVHMNR LPGGNEIGMV AWKMTFKSPE YPEGRDIIVI
     GNDITYRIGS FGPQEDLLFL RASELARAEG IPRIYVSANS GARIGLAEEI RHMFHVAWVD
     PEDPYKGYRY LYLTPQDYKR VSALNSVHCE HVEDEGESRY KITDIIGKEE GIGPENLRGS
     GMIAGESSLA YNEIITISLV TCRAIGIGAY LVRLGQRTIQ VENSHLILTG AGALNKVLGR
     EVYTSNNQLG GIQIMHNNGV THCTVCDDFE GVFTVLHWLS YMPKSVHSSV PLLNSKDPID
     RIIEFVPTKT PYDPRWMLAG RPHPTQKGQW LSGFFDYGSF SEIMQPWAQT VVVGRARLGG
     IPVGVVAVET RTVELSIPAD PANLDSEAKI IQQAGQVWFP DSAFKTYQAI KDFNREGLPL
     MVFANWRGFS GGMKDMYDQV LKFGAYIVDG LRECCQPVLV YIPPQAELRG GSWVVIDSSI
     NPRHMEMYAD RESRGSVLEP EGTVEIKFRR KDLVKTMRRV DPVYIHLAER LGTPELSTAE
     RKELENKLKE REEFLIPIYH QVAVQFADLH DTPGRMQEKG VISDILDWKT SRTFFYWRLR
     RLLLEDLVKK KIHNANPELT DGQIQAMLRR WFVEVEGTVK AYVWDNNKDL AEWLEKQLTE
     EDGVHSVIEE NIKCISRDYV LKQIRSLVQA NPEVAMDSII HMTQHISPTQ RAEVIRILST
     MDSPST
//
ID   ACADM_HUMAN             Reviewed;         421 AA.
AC   P11310; Q5T4U4; Q9NYF1;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   09-JUL-2014, entry version 174.
DE   RecName: Full=Medium-chain specific acyl-CoA dehydrogenase, mitochondrial;
DE            Short=MCAD;
DE            EC=1.3.8.7;
DE   Flags: Precursor;
GN   Name=ACADM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3035565; DOI=10.1073/pnas.84.12.4068;
RA   Kelly D.P., Kim J.-J.P., Billadello J.J., Hainline B.E., Chu T.W.,
RA   Strauss A.W.;
RT   "Nucleotide sequence of medium-chain acyl-CoA dehydrogenase mRNA and
RT   its expression in enzyme-deficient human tissue.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4068-4072(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=1731887; DOI=10.1021/bi00116a013;
RA   Zhang Z.F., Kelly D.P., Kim J.-J.P., Zhou Y.Q., Ogden M.L.,
RA   Whelan A.J., Strauss A.W.;
RT   "Structural organization and regulatory regions of the human medium-
RT   chain acyl-CoA dehydrogenase gene.";
RL   Biochemistry 31:81-89(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Colon;
RA   Sun F., Wang Y., Block G.D.;
RT   "Medium-chain acyl-CoA dehydrogenase.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 218-235, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Vishwanath V.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 314-342, AND VARIANT ACADMD
RP   GLU-329.
RX   PubMed=2393404; DOI=10.1016/0006-291X(90)91421-N;
RA   Matsubara Y., Narisawa K., Miyabayashi S., Tada K., Coates P.M.,
RA   Bachmann C., Elsas L.J. II, Pollitt R.J., Rhead W.J., Roe C.R.;
RT   "Identification of a common mutation in patients with medium-chain
RT   acyl-CoA dehydrogenase deficiency.";
RL   Biochem. Biophys. Res. Commun. 171:498-505(1990).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-279 AND LYS-301, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   DEACETYLATION BY SIRT3.
RX   PubMed=24121500; DOI=10.1074/jbc.M113.510354;
RA   Bharathi S.S., Zhang Y., Mohsen A.W., Uppala R., Balasubramani M.,
RA   Schreiber E., Uechi G., Beck M.E., Rardin M.J., Vockley J., Verdin E.,
RA   Gibson B.W., Hirschey M.D., Goetzman E.S.;
RT   "SIRT3 regulates long-chain acyl-coA dehydrogenase by deacetylating
RT   conserved lysines near the active site.";
RL   J. Biol. Chem. 288:33837-33847(2013).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH FAD AND
RP   OCTANOYL-COENZYME A, AND SUBUNIT.
RX   PubMed=8823176; DOI=10.1021/bi9607867;
RA   Lee H.J., Wang M., Paschke R., Nandy A., Ghisla S., Kim J.-J.P.;
RT   "Crystal structures of the wild type and the Glu376Gly/Thr255Glu
RT   mutant of human medium-chain acyl-CoA dehydrogenase: influence of the
RT   location of the catalytic base on substrate specificity.";
RL   Biochemistry 35:12412-12420(1996).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 26-421 IN COMPLEXES WITH FAD
RP   AND THE ETFA-ETFB HETERODIMER, MUTAGENESIS OF LEU-86; LEU-98; LEU-100;
RP   ILE-108; GLU-237 AND GLU-384, AND SUBUNIT.
RX   PubMed=15159392; DOI=10.1074/jbc.M404884200;
RA   Toogood H.S., van Thiel A., Basran J., Sutcliffe M.J., Scrutton N.S.,
RA   Leys D.;
RT   "Extensive domain motion and electron transfer in the human electron
RT   transferring flavoprotein-medium chain acyl-CoA dehydrogenase
RT   complex.";
RL   J. Biol. Chem. 279:32904-32912(2004).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEXES WITH FAD AND THE
RP   ETFA-ETFB HETERODIMER, MUTAGENESIS OF TRP-191; GLU-237 AND GLU-384,
RP   AND SUBUNIT.
RX   PubMed=15975918; DOI=10.1074/jbc.M505562200;
RA   Toogood H.S., van Thiel A., Scrutton N.S., Leys D.;
RT   "Stabilization of non-productive conformations underpins rapid
RT   electron transfer to electron-transferring flavoprotein.";
RL   J. Biol. Chem. 280:30361-30366(2005).
RN   [16]
RP   REVIEW ON VARIANTS ACADMD.
RX   PubMed=1363805; DOI=10.1002/humu.1380010402;
RA   Tanaka K., Yokota I., Coates P.M., Strauss A.W., Kelly D.P.,
RA   Zhang Z.F., Gregersen N., Andresen B.S., Matsubara Y., Curtis D.,
RA   Chen Y.-T.;
RT   "Mutations in the medium chain acyl-CoA dehydrogenase (MCAD) gene.";
RL   Hum. Mutat. 1:271-279(1992).
RN   [17]
RP   VARIANT ACADMD GLU-329.
RX   PubMed=2394825; DOI=10.1172/JCI114761;
RA   Yokota I., Indo Y., Coates P.M., Tanaka K.;
RT   "Molecular basis of medium chain acyl-coenzyme A dehydrogenase
RT   deficiency. An A to G transition at position 985 that causes a lysine-
RT   304 to glutamate substitution in the mature protein is the single
RT   prevalent mutation.";
RL   J. Clin. Invest. 86:1000-1003(1990).
RN   [18]
RP   VARIANT ACADMD GLU-329.
RX   PubMed=2251268; DOI=10.1073/pnas.87.23.9236;
RA   Kelly D.P., Whelan A.J., Ogden M.L., Alpers R., Zhang Z.F., Bellus G.,
RA   Gregersen N., Dorland L., Strauss A.W.;
RT   "Molecular characterization of inherited medium-chain acyl-CoA
RT   dehydrogenase deficiency.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9236-9240(1990).
RN   [19]
RP   VARIANTS ACADMD ILE-149; ARG-244; ARG-267 AND THR-375.
RX   PubMed=1684086;
RA   Yokota I., Coates P.M., Hale D.E., Rinaldo P., Tanaka K.;
RT   "Molecular survey of a prevalent mutation, 985A-to-G transition, and
RT   identification of five infrequent mutations in the medium-chain Acyl-
RT   CoA dehydrogenase (MCAD) gene in 55 patients with MCAD deficiency.";
RL   Am. J. Hum. Genet. 49:1280-1291(1991).
RN   [20]
RP   VARIANT ACADMD GLU-329.
RX   PubMed=1902818; DOI=10.1007/BF00201539;
RA   Gregersen N., Andresen B.S., Bross P., Winter V., Ruediger N.,
RA   Engst S., Christensen E., Kelly D., Strauss A.W., Koelvraa S.,
RA   Bolund L., Ghisla S.;
RT   "Molecular characterization of medium-chain acyl-CoA dehydrogenase
RT   (MCAD) deficiency: identification of a lys329 to glu mutation in the
RT   MCAD gene, and expression of inactive mutant enzyme protein in E.
RT   coli.";
RL   Hum. Genet. 86:545-551(1991).
RN   [21]
RP   VARIANT ACADMD GLU-329 FREQUENCY.
RX   PubMed=1671131; DOI=10.1016/0140-6736(91)90907-7;
RA   Blakemore A.I., Singleton H., Pollitt R.J., Engel P.C., Kolvraa S.,
RA   Gregersen N., Curtis D.;
RT   "Frequency of the G985 MCAD mutation in the general population.";
RL   Lancet 337:298-299(1991).
RN   [22]
RP   VARIANTS ACADMD THR-326 AND ARG-336.
RX   PubMed=8198141;
RA   Andresen B.S., Jensen T.G., Bross P., Knudsen I., Winter V.,
RA   Koelvraa S., Bolund L., Ding J.-H., Chen Y.-T., van Hove J.L.K.,
RA   Curtis D., Yokota I., Tanaka K., Kim J.-J.P., Gregersen N.;
RT   "Disease-causing mutations in exon 11 of the medium-chain acyl-CoA
RT   dehydrogenase gene.";
RL   Am. J. Hum. Genet. 54:975-988(1994).
RN   [23]
RP   VARIANT ACADMD 115-GLY-CYS-116 DEL.
RX   PubMed=7603790; DOI=10.1203/00006450-199505000-00021;
RA   Ziadeh R., Hoffman E.P., Finegold D.N., Hoop R.C., Brackett J.C.,
RA   Strauss A.W., Naylor E.W.;
RT   "Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania:
RT   neonatal screening shows high incidence and unexpected mutation
RT   frequencies.";
RL   Pediatr. Res. 37:675-678(1995).
RN   [24]
RP   VARIANT ACADMD ARG-195.
RX   PubMed=7929823; DOI=10.1172/JCI117486;
RA   Brackett J.C., Sims H.F., Steiner R.D., Nunge M., Zimmerman E.M.,
RA   Demartinville B., Rinaldo P., Slaugh R., Strauss A.W.;
RT   "A novel mutation in medium chain acyl-CoA dehydrogenase causes sudden
RT   neonatal death.";
RL   J. Clin. Invest. 94:1477-1483(1994).
RN   [25]
RP   VARIANTS ACADMD TYR-116; ALA-193 AND CYS-352.
RX   PubMed=9158144; DOI=10.1093/hmg/6.5.695;
RA   Andresen B.S., Bross P., Udvari S., Kirk J., Gray G., Kmoch S.,
RA   Chamoles N., Knudsen I., Winter V., Wilcken B., Yokota I., Hart K.,
RA   Packman S., Harpey J.P., Saudubray J.-M., Hale D.E., Bolund L.,
RA   Koelvraa S., Gregersen N.;
RT   "The molecular basis of medium-chain acyl-CoA dehydrogenase (MCAD)
RT   deficiency in compound heterozygous patients: is there correlation
RT   between genotype and phenotype?";
RL   Hum. Mol. Genet. 6:695-707(1997).
RN   [26]
RP   CHARACTERIZATION OF VARIANT ACADMD ALA-193.
RX   PubMed=9882619; DOI=10.1042/0264-6021:3370225;
RA   Kuchler B., Abdel-Ghany A.G., Bross P., Nandy A., Rasched I.,
RA   Ghisla S.;
RT   "Biochemical characterization of a variant human medium-chain acyl-CoA
RT   dehydrogenase with a disease-associated mutation localized in the
RT   active site.";
RL   Biochem. J. 337:225-230(1999).
RN   [27]
RP   VARIANTS ACADMD LEU-206 AND GLU-329.
RX   PubMed=10767181; DOI=10.1006/mgme.2000.2978;
RA   Yang B.-Z., Ding J.-H., Zhou C., Dimachkie M.M., Sweetman L.,
RA   Dasouki M.J., Wilkinson J., Roe C.R.;
RT   "Identification of a novel mutation in patients with medium-chain
RT   acyl-CoA dehydrogenase deficiency.";
RL   Mol. Genet. Metab. 69:259-262(2000).
RN   [28]
RP   VARIANTS ACADMD HIS-67; THR-78; ILE-121 AND ARG-310.
RX   PubMed=11349232; DOI=10.1086/320602;
RA   Andresen B.S., Dobrowolski S.F., O'Reilly L., Muenzer J.,
RA   McCandless S.E., Frazier D.M., Udvari S., Bross P., Knudsen I.,
RA   Banas R., Chace D.H., Engel P.C., Naylor E.W., Gregersen N.;
RT   "Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by
RT   MS/MS-based prospective screening of newborns differ from those
RT   observed in patients with clinical symptoms: identification and
RT   characterization of a new, prevalent mutation that results in mild
RT   MCAD deficiency.";
RL   Am. J. Hum. Genet. 68:1408-1418(2001).
RN   [29]
RP   VARIANT ACADMD LEU-245.
RX   PubMed=11409868; DOI=10.1007/s004390100501;
RA   Zschocke J., Schulze A., Lindner M., Fiesel S., Olgemoller K.,
RA   Hoffmann G.F., Penzien J., Ruiter J.P.N., Wanders R.J.A.,
RA   Mayatepek E.;
RT   "Molecular and functional characterization of mild MCAD deficiency.";
RL   Hum. Genet. 108:404-408(2001).
RN   [30]
RP   VARIANTS ACADMD THR-281 AND GLU-329.
RX   PubMed=11486912; DOI=10.1023/A:1010533408635;
RA   Albers S., Levy H.L., Irons M., Strauss A.W., Marsden D.;
RT   "Compound heterozygosity in four asymptomatic siblings with medium-
RT   chain acyl-CoA dehydrogenase deficiency.";
RL   J. Inherit. Metab. Dis. 24:417-418(2001).
RN   [31]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-132.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: This enzyme is specific for acyl chain lengths of 4 to
CC       16.
CC   -!- CATALYTIC ACTIVITY: A medium-chain acyl-CoA + electron-transfer
CC       flavoprotein = a medium-chain trans-2,3-dehydroacyl-CoA + reduced
CC       electron-transfer flavoprotein.
CC   -!- COFACTOR: FAD.
CC   -!- PATHWAY: Lipid metabolism; mitochondrial fatty acid beta-
CC       oxidation.
CC   -!- SUBUNIT: Homotetramer. Interacts with the heterodimeric electron
CC       transfer flavoprotein ETF.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P11310-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P11310-2; Sequence=VSP_038420;
CC   -!- PTM: Acetylation at Lys-307 and Lys-311 in proximity of the
CC       cofactor-binding sites reduces catalytic activity (By similarity).
CC       These sites are deacetylated by SIRT3.
CC   -!- DISEASE: Acyl-CoA dehydrogenase medium-chain deficiency (ACADMD)
CC       [MIM:201450]: An inborn error of mitochondrial fatty acid beta-
CC       oxidation which causes fasting hypoglycemia, hepatic dysfunction
CC       and encephalopathy, often resulting in death in infancy. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: A number of straight-chain acyl-CoA dehydrogenases
CC       of different substrate specificities are present in mammalian
CC       tissues.
CC   -!- MISCELLANEOUS: Utilizes the electron transfer flavoprotein (ETF)
CC       as electron acceptor that transfers the electrons to the main
CC       mitochondrial respiratory chain via ETF-ubiquinone oxidoreductase
CC       (ETF dehydrogenase).
CC   -!- SIMILARITY: Belongs to the acyl-CoA dehydrogenase family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M16827; AAA51566.1; -; mRNA.
DR   EMBL; M91432; AAA59567.1; -; Genomic_DNA.
DR   EMBL; M91421; AAA59567.1; JOINED; Genomic_DNA.
DR   EMBL; M91422; AAA59567.1; JOINED; Genomic_DNA.
DR   EMBL; M91423; AAA59567.1; JOINED; Genomic_DNA.
DR   EMBL; M91425; AAA59567.1; JOINED; Genomic_DNA.
DR   EMBL; M91426; AAA59567.1; JOINED; Genomic_DNA.
DR   EMBL; M91427; AAA59567.1; JOINED; Genomic_DNA.
DR   EMBL; M91428; AAA59567.1; JOINED; Genomic_DNA.
DR   EMBL; M91429; AAA59567.1; JOINED; Genomic_DNA.
DR   EMBL; M91430; AAA59567.1; JOINED; Genomic_DNA.
DR   EMBL; M91431; AAA59567.1; JOINED; Genomic_DNA.
DR   EMBL; AF251043; AAF63626.1; -; mRNA.
DR   EMBL; AK312629; BAG35514.1; -; mRNA.
DR   EMBL; AL357314; CAI22390.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06401.1; -; Genomic_DNA.
DR   EMBL; BC005377; AAH05377.1; -; mRNA.
DR   EMBL; M60505; AAB59625.1; -; Genomic_DNA.
DR   CCDS; CCDS44165.1; -. [P11310-2]
DR   CCDS; CCDS668.1; -. [P11310-1]
DR   PIR; A29031; DEHUCM.
DR   RefSeq; NP_000007.1; NM_000016.5. [P11310-1]
DR   RefSeq; NP_001120800.1; NM_001127328.2. [P11310-2]
DR   UniGene; Hs.445040; -.
DR   PDB; 1EGC; X-ray; 2.60 A; A/B/C/D=26-421.
DR   PDB; 1EGD; X-ray; 2.40 A; A/B/C/D=26-421.
DR   PDB; 1EGE; X-ray; 2.75 A; A/B/C/D=26-421.
DR   PDB; 1T9G; X-ray; 2.90 A; A/B/C/D=26-421.
DR   PDB; 2A1T; X-ray; 2.80 A; A/B/C/D=1-421.
DR   PDBsum; 1EGC; -.
DR   PDBsum; 1EGD; -.
DR   PDBsum; 1EGE; -.
DR   PDBsum; 1T9G; -.
DR   PDBsum; 2A1T; -.
DR   ProteinModelPortal; P11310; -.
DR   SMR; P11310; 35-421.
DR   BioGrid; 106552; 10.
DR   DIP; DIP-34281N; -.
DR   IntAct; P11310; 6.
DR   MINT; MINT-3007693; -.
DR   STRING; 9606.ENSP00000409612; -.
DR   PhosphoSite; P11310; -.
DR   DMDM; 113017; -.
DR   REPRODUCTION-2DPAGE; IPI00005040; -.
DR   UCD-2DPAGE; P11310; -.
DR   MaxQB; P11310; -.
DR   PaxDb; P11310; -.
DR   PRIDE; P11310; -.
DR   DNASU; 34; -.
DR   Ensembl; ENST00000370841; ENSP00000359878; ENSG00000117054. [P11310-1]
DR   Ensembl; ENST00000420607; ENSP00000409612; ENSG00000117054. [P11310-2]
DR   GeneID; 34; -.
DR   KEGG; hsa:34; -.
DR   UCSC; uc001dgw.4; human. [P11310-1]
DR   UCSC; uc009wbp.3; human. [P11310-2]
DR   CTD; 34; -.
DR   GeneCards; GC01P076190; -.
DR   GeneReviews; ACADM; -.
DR   HGNC; HGNC:89; ACADM.
DR   HPA; HPA006198; -.
DR   HPA; HPA026542; -.
DR   MIM; 201450; phenotype.
DR   MIM; 607008; gene.
DR   neXtProt; NX_P11310; -.
DR   Orphanet; 42; Medium chain acyl-CoA dehydrogenase deficiency.
DR   PharmGKB; PA24425; -.
DR   eggNOG; COG1960; -.
DR   HOGENOM; HOG000131659; -.
DR   HOVERGEN; HBG000224; -.
DR   KO; K00249; -.
DR   OrthoDB; EOG74FF0S; -.
DR   PhylomeDB; P11310; -.
DR   TreeFam; TF105020; -.
DR   BioCyc; MetaCyc:HS04089-MONOMER; -.
DR   Reactome; REACT_111217; Metabolism.
DR   SABIO-RK; P11310; -.
DR   UniPathway; UPA00660; -.
DR   EvolutionaryTrace; P11310; -.
DR   GenomeRNAi; 34; -.
DR   NextBio; 131; -.
DR   PRO; PR:P11310; -.
DR   ArrayExpress; P11310; -.
DR   Bgee; P11310; -.
DR   CleanEx; HS_ACADM; -.
DR   Genevestigator; P11310; -.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:LIFEdb.
DR   GO; GO:0005634; C:nucleus; IDA:UniProt.
DR   GO; GO:0003995; F:acyl-CoA dehydrogenase activity; IMP:UniProtKB.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IEA:InterPro.
DR   GO; GO:0042802; F:identical protein binding; IDA:BHF-UCL.
DR   GO; GO:0070991; F:medium-chain-acyl-CoA dehydrogenase activity; IDA:BHF-UCL.
DR   GO; GO:0055007; P:cardiac muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0045329; P:carnitine biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0019254; P:carnitine metabolic process, CoA-linked; IMP:BHF-UCL.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0006635; P:fatty acid beta-oxidation; IMP:UniProtKB.
DR   GO; GO:0033539; P:fatty acid beta-oxidation using acyl-CoA dehydrogenase; IDA:BHF-UCL.
DR   GO; GO:0005978; P:glycogen biosynthetic process; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0051793; P:medium-chain fatty acid catabolic process; IDA:BHF-UCL.
DR   GO; GO:0051791; P:medium-chain fatty acid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:BHF-UCL.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0006111; P:regulation of gluconeogenesis; IEA:Ensembl.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   GO; GO:0042594; P:response to starvation; IEA:Ensembl.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   Gene3D; 1.10.540.10; -; 1.
DR   Gene3D; 2.40.110.10; -; 1.
DR   InterPro; IPR006089; Acyl-CoA_DH_CS.
DR   InterPro; IPR006091; Acyl-CoA_Oxase/DH_cen-dom.
DR   InterPro; IPR009075; AcylCo_DH/oxidase_C.
DR   InterPro; IPR013786; AcylCoA_DH/ox_N.
DR   InterPro; IPR009100; AcylCoA_DH/oxidase_NM_dom.
DR   Pfam; PF00441; Acyl-CoA_dh_1; 1.
DR   Pfam; PF02770; Acyl-CoA_dh_M; 1.
DR   Pfam; PF02771; Acyl-CoA_dh_N; 1.
DR   SUPFAM; SSF47203; SSF47203; 1.
DR   SUPFAM; SSF56645; SSF56645; 1.
DR   PROSITE; PS00072; ACYL_COA_DH_1; 1.
DR   PROSITE; PS00073; ACYL_COA_DH_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; FAD;
KW   Fatty acid metabolism; Flavoprotein; Lipid metabolism; Mitochondrion;
KW   Oxidoreductase; Polymorphism; Reference proteome; Transit peptide.
FT   TRANSIT       1     25       Mitochondrion.
FT   CHAIN        26    421       Medium-chain specific acyl-CoA
FT                                dehydrogenase, mitochondrial.
FT                                /FTId=PRO_0000000502.
FT   NP_BIND     158    167       FAD.
FT   NP_BIND     191    193       FAD.
FT   NP_BIND     306    308       FAD.
FT   NP_BIND     316    317       FAD.
FT   NP_BIND     374    378       FAD.
FT   NP_BIND     403    405       FAD.
FT   REGION      278    281       Substrate binding.
FT   ACT_SITE    401    401       Proton acceptor.
FT   BINDING     167    167       Substrate; via carbonyl oxygen.
FT   BINDING     216    216       Substrate.
FT   BINDING     402    402       Substrate; via amide nitrogen.
FT   BINDING     413    413       Substrate.
FT   MOD_RES      69     69       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES      69     69       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     179    179       N6-succinyllysine (By similarity).
FT   MOD_RES     212    212       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     212    212       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     217    217       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     217    217       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     259    259       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     259    259       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     271    271       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     271    271       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     279    279       N6-acetyllysine.
FT   MOD_RES     301    301       N6-acetyllysine.
FT   VAR_SEQ      10     10       R -> RCSLQ (in isoform 2).
FT                                /FTId=VSP_038420.
FT   VARIANT      53     53       R -> C (in ACADMD).
FT                                /FTId=VAR_000317.
FT   VARIANT      67     67       Y -> H (in ACADMD; mild).
FT                                /FTId=VAR_013698.
FT   VARIANT      78     78       I -> T (in ACADMD).
FT                                /FTId=VAR_015954.
FT   VARIANT     115    116       Missing (in ACADMD).
FT                                /FTId=VAR_000318.
FT   VARIANT     116    116       C -> Y (in ACADMD).
FT                                /FTId=VAR_015955.
FT   VARIANT     121    121       T -> I (in ACADMD).
FT                                /FTId=VAR_015956.
FT   VARIANT     132    132       P -> R (in a breast cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035716.
FT   VARIANT     149    149       M -> I (in ACADMD).
FT                                /FTId=VAR_000319.
FT   VARIANT     193    193       T -> A (in ACADMD; the thermostability is
FT                                markedly decreased).
FT                                /FTId=VAR_000320.
FT   VARIANT     195    195       G -> R (in ACADMD).
FT                                /FTId=VAR_000321.
FT   VARIANT     206    206       R -> L (in ACADMD).
FT                                /FTId=VAR_015957.
FT   VARIANT     244    244       C -> R (in ACADMD).
FT                                /FTId=VAR_000322.
FT   VARIANT     245    245       S -> L (in ACADMD).
FT                                /FTId=VAR_013699.
FT   VARIANT     267    267       G -> R (in ACADMD).
FT                                /FTId=VAR_000323.
FT   VARIANT     281    281       R -> T (in ACADMD; mild or benign
FT                                clinical phenotype).
FT                                /FTId=VAR_013700.
FT   VARIANT     310    310       G -> R (in ACADMD).
FT                                /FTId=VAR_015958.
FT   VARIANT     326    326       M -> T (in ACADMD).
FT                                /FTId=VAR_000324.
FT   VARIANT     329    329       K -> E (in ACADMD; most common variant;
FT                                dbSNP:rs77931234).
FT                                /FTId=VAR_000325.
FT   VARIANT     336    336       S -> R (in ACADMD).
FT                                /FTId=VAR_000326.
FT   VARIANT     352    352       Y -> C (in ACADMD).
FT                                /FTId=VAR_015959.
FT   VARIANT     375    375       I -> T (in ACADMD).
FT                                /FTId=VAR_000327.
FT   MUTAGEN      86     86       L->M: Strongly reduced rate of electron
FT                                transfer to ETF.
FT   MUTAGEN      98     98       L->W: Strongly reduced rate of electron
FT                                transfer to ETF.
FT   MUTAGEN     100    100       L->Y: Strongly reduced rate of electron
FT                                transfer to ETF.
FT   MUTAGEN     108    108       I->M: Strongly reduced rate of electron
FT                                transfer to ETF.
FT   MUTAGEN     191    191       W->A: Loss of electron transfer to ETF.
FT   MUTAGEN     191    191       W->F: Reduces rate of electron transfer
FT                                to ETF about six-fold.
FT   MUTAGEN     237    237       E->A: Strongly reduced rate of electron
FT                                transfer to ETF.
FT   MUTAGEN     384    384       E->A: Reduces rate of electron transfer
FT                                to ETF three-fold.
FT   MUTAGEN     384    384       E->Q: Reduces rate of electron transfer
FT                                to ETF two-fold.
FT   CONFLICT    356    356       I -> T (in Ref. 3; AAF63626).
FT   STRAND       36     38
FT   HELIX        43     59
FT   HELIX        61     70
FT   HELIX        75     84
FT   HELIX        93     95
FT   HELIX       102    115
FT   HELIX       117    129
FT   HELIX       131    136
FT   HELIX       139    151
FT   STRAND      156    159
FT   STRAND      165    168
FT   HELIX       169    171
FT   STRAND      175    178
FT   STRAND      180    193
FT   TURN        194    197
FT   STRAND      199    206
FT   HELIX       215    217
FT   STRAND      219    225
FT   STRAND      231    233
FT   STRAND      239    241
FT   STRAND      247    258
FT   HELIX       259    261
FT   STRAND      262    265
FT   TURN        266    268
FT   HELIX       269    303
FT   STRAND      309    312
FT   HELIX       313    315
FT   HELIX       317    345
FT   HELIX       351    376
FT   HELIX       377    379
FT   HELIX       387    394
FT   HELIX       395    398
FT   TURN        399    401
FT   HELIX       404    417
SQ   SEQUENCE   421 AA;  46588 MW;  7CD0B5832410581B CRC64;
     MAAGFGRCCR VLRSISRFHW RSQHTKANRQ REPGLGFSFE FTEQQKEFQA TARKFAREEI
     IPVAAEYDKT GEYPVPLIRR AWELGLMNTH IPENCGGLGL GTFDACLISE ELAYGCTGVQ
     TAIEGNSLGQ MPIIIAGNDQ QKKKYLGRMT EEPLMCAYCV TEPGAGSDVA GIKTKAEKKG
     DEYIINGQKM WITNGGKANW YFLLARSDPD PKAPANKAFT GFIVEADTPG IQIGRKELNM
     GQRCSDTRGI VFEDVKVPKE NVLIGDGAGF KVAMGAFDKT RPVVAAGAVG LAQRALDEAT
     KYALERKTFG KLLVEHQAIS FMLAEMAMKV ELARMSYQRA AWEVDSGRRN TYYASIAKAF
     AGDIANQLAT DAVQILGGNG FNTEYPVEKL MRDAKIYQIY EGTSQIQRLI VAREHIDKYK
     N
//
ID   ACADV_HUMAN             Reviewed;         655 AA.
AC   P49748; B4DEB6; F5H2A9; O76056; Q8WUL0;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   09-JUL-2014, entry version 151.
DE   RecName: Full=Very long-chain specific acyl-CoA dehydrogenase, mitochondrial;
DE            Short=VLCAD;
DE            EC=1.3.8.9;
DE   Flags: Precursor;
GN   Name=ACADVL; Synonyms=VLCAD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7668252;
RA   Aoyama T., Souri M., Ueno I., Kamijo T., Yamaguchi S., Rhead W.J.,
RA   Tanaka K., Hashimoto T.;
RT   "Cloning of human very-long-chain acyl-coenzyme A dehydrogenase and
RT   molecular characterization of its deficiency in two patients.";
RL   Am. J. Hum. Genet. 57:273-283(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANTS.
RC   TISSUE=Placenta;
RX   PubMed=8845838; DOI=10.1093/hmg/5.4.461;
RA   Andresen B.S., Bross P., Vianey-Saban C., Divry P., Zabot M.-T.,
RA   Roe C.R., Nada M.A., Byskov A., Kruse T.A., Neve S., Kristiansen K.,
RA   Knudsen I., Corydon M.J., Gregersen N.;
RT   "Cloning and characterization of human very-long-chain acyl-CoA
RT   dehydrogenase cDNA, chromosomal assignment of the gene and
RT   identification in four patients of nine different mutations within the
RT   VLCAD gene.";
RL   Hum. Mol. Genet. 5:461-472(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RC   TISSUE=Peripheral blood;
RX   PubMed=8554625; DOI=10.1006/bbrc.1995.2867;
RA   Orii K.O., Aoyama T., Souri M., Orii K.E., Kondo N., Orii T.,
RA   Hashimoto T.;
RT   "Genomic DNA organization of human mitochondrial very-long-chain acyl-
RT   CoA dehydrogenase and mutation analysis.";
RL   Biochem. Biophys. Res. Commun. 217:987-992(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Liver, Lung, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CHARACTERIZATION.
RX   PubMed=7769092; DOI=10.1172/JCI117947;
RA   Aoyama T., Souri M., Ushikubo S., Kamijo T., Yamaguchi S.,
RA   Kelley R.I., Rhead W.J., Uetake K., Tanaka K., Hashimoto T.;
RT   "Purification of human very-long-chain acyl-coenzyme A dehydrogenase
RT   and characterization of its deficiency in seven patients.";
RL   J. Clin. Invest. 95:2465-2473(1995).
RN   [8]
RP   REVIEW ON VARIANTS.
RX   PubMed=9973285; DOI=10.1086/302261;
RA   Andresen B.S., Olpin S., Poorthuis B.J.H.M., Scholte H.R.,
RA   Vianey-Saban C., Wanders R., Ijlst L., Morris A., Pourfarzam M.,
RA   Bartlett K., Baumgartner E.R., de Klerk J.B.C., Schroeder L.D.,
RA   Corydon T.J., Lund H., Winter V., Bross P., Bolund L., Gregersen N.;
RT   "Clear correlation of genotype with disease phenotype in very-long-
RT   chain acyl-CoA dehydrogenase deficiency.";
RL   Am. J. Hum. Genet. 64:479-494(1999).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-239 AND LYS-331, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 69-655 IN COMPLEX WITH
RP   MYRISTOYL-COA, FUNCTION, SUBUNIT, COFACTOR, AND ACTIVE SITE.
RX   PubMed=18227065; DOI=10.1074/jbc.M709135200;
RA   McAndrew R.P., Wang Y., Mohsen A.W., He M., Vockley J., Kim J.J.;
RT   "Structural basis for substrate fatty acyl chain specificity: crystal
RT   structure of human very-long-chain acyl-CoA dehydrogenase.";
RL   J. Biol. Chem. 283:9435-9443(2008).
RN   [12]
RP   VARIANTS ACADVLD GLU-130 DEL; LYS-299 DEL; GLN-382 AND TRP-613.
RX   PubMed=8554073;
RA   Souri M., Aoyama T., Orii K., Yamaguchi S., Hashimoto T.;
RT   "Mutation analysis of very-long-chain acyl-coenzyme A dehydrogenase
RT   (VLCAD) deficiency: identification and characterization of mutant
RT   VLCAD cDNAs from four patients.";
RL   Am. J. Hum. Genet. 58:97-106(1996).
RN   [13]
RP   VARIANT ACADVLD HIS-450.
RX   PubMed=9546340; DOI=10.1002/ana.410430422;
RA   Smelt A.H., Poorthuis B.J.H.M., Onkenhout W., Scholte H.R.,
RA   Andresen B.S., van Duinen S.G., Gregersen N., Wintzen A.R.;
RT   "Very long chain acyl-coenzyme A dehydrogenase deficiency with adult
RT   onset.";
RL   Ann. Neurol. 43:540-544(1998).
RN   [14]
RP   VARIANTS ACADVLD.
RX   PubMed=10077518; DOI=10.1161/01.CIR.99.10.1337;
RA   Mathur A., Sims H.F., Gopalakrishnan D., Gibson B., Rinaldo P.,
RA   Vockley J., Hug G., Strauss A.W.;
RT   "Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase
RT   deficiency causing pediatric cardiomyopathy and sudden death.";
RL   Circulation 99:1337-1343(1999).
CC   -!- FUNCTION: Active toward esters of long-chain and very long chain
CC       fatty acids such as palmitoyl-CoA, mysritoyl-CoA and stearoyl-CoA.
CC       Can accommodate substrate acyl chain lengths as long as 24
CC       carbons, but shows little activity for substrates of less than 12
CC       carbons.
CC   -!- CATALYTIC ACTIVITY: A very-long-chain acyl-CoA + electron-transfer
CC       flavoprotein = a very-long-chain trans-2,3-dehydroacyl-CoA +
CC       reduced electron-transfer flavoprotein.
CC   -!- COFACTOR: FAD.
CC   -!- PATHWAY: Lipid metabolism; mitochondrial fatty acid beta-
CC       oxidation.
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P49748-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P49748-2; Sequence=VSP_007734;
CC         Note=No experimental confirmation available;
CC       Name=3;
CC         IsoId=P49748-3; Sequence=VSP_046031;
CC         Note=No experimental confirmation available;
CC   -!- PTM: S-nitrosylation at Cys-237 in liver improves catalytic
CC       efficiency (By similarity).
CC   -!- DISEASE: Acyl-CoA dehydrogenase very long-chain deficiency
CC       (ACADVLD) [MIM:201475]: An inborn error of mitochondrial fatty
CC       acid beta-oxidation which leads to impaired long-chain fatty acid
CC       beta-oxidation. It is clinically heterogeneous, with three major
CC       phenotypes: a severe childhood form characterized by early onset,
CC       high mortality and high incidence of cardiomyopathy; a milder
CC       childhood form with later onset, characterized by hypoketotic
CC       hypoglycemia, low mortality and rare cardiomyopathy; an adult
CC       form, with isolated skeletal muscle involvement, rhabdomyolysis
CC       and myoglobinuria, usually triggered by exercise or fasting.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: A number of straight-chain acyl-CoA dehydrogenases
CC       of different substrate specificities are present in mammalian
CC       tissues.
CC   -!- SIMILARITY: Belongs to the acyl-CoA dehydrogenase family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D43682; BAA07781.1; -; mRNA.
DR   EMBL; L46590; AAA79002.1; -; Genomic_DNA.
DR   EMBL; X86556; CAA60253.1; -; mRNA.
DR   EMBL; D78298; BAA29057.1; -; Genomic_DNA.
DR   EMBL; AK293549; BAG57027.1; -; mRNA.
DR   EMBL; AC120057; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000399; AAH00399.1; -; mRNA.
DR   EMBL; BC012912; AAH12912.1; -; mRNA.
DR   EMBL; BC020218; AAH20218.1; -; mRNA.
DR   CCDS; CCDS11090.1; -. [P49748-1]
DR   CCDS; CCDS42249.1; -. [P49748-2]
DR   CCDS; CCDS58509.1; -. [P49748-3]
DR   PIR; S54183; S54183.
DR   RefSeq; NP_000009.1; NM_000018.3. [P49748-1]
DR   RefSeq; NP_001029031.1; NM_001033859.2. [P49748-2]
DR   RefSeq; NP_001257376.1; NM_001270447.1. [P49748-3]
DR   UniGene; Hs.437178; -.
DR   PDB; 2UXW; X-ray; 1.45 A; A=72-655.
DR   PDB; 3B96; X-ray; 1.91 A; A=69-655.
DR   PDBsum; 2UXW; -.
DR   PDBsum; 3B96; -.
DR   ProteinModelPortal; P49748; -.
DR   SMR; P49748; 69-655.
DR   BioGrid; 106555; 11.
DR   IntAct; P49748; 12.
DR   MINT; MINT-4824254; -.
DR   STRING; 9606.ENSP00000325395; -.
DR   PhosphoSite; P49748; -.
DR   DMDM; 1703068; -.
DR   MaxQB; P49748; -.
DR   PaxDb; P49748; -.
DR   PRIDE; P49748; -.
DR   Ensembl; ENST00000350303; ENSP00000344152; ENSG00000072778. [P49748-2]
DR   Ensembl; ENST00000356839; ENSP00000349297; ENSG00000072778. [P49748-1]
DR   Ensembl; ENST00000543245; ENSP00000438689; ENSG00000072778. [P49748-3]
DR   GeneID; 37; -.
DR   KEGG; hsa:37; -.
DR   UCSC; uc002gev.4; human. [P49748-1]
DR   UCSC; uc002gew.4; human. [P49748-2]
DR   CTD; 37; -.
DR   GeneCards; GC17P007120; -.
DR   GeneReviews; ACADVL; -.
DR   HGNC; HGNC:92; ACADVL.
DR   HPA; HPA019006; -.
DR   HPA; HPA020595; -.
DR   MIM; 201475; phenotype.
DR   MIM; 609575; gene.
DR   neXtProt; NX_P49748; -.
DR   Orphanet; 26793; Very long chain acyl-CoA dehydrogenase deficiency.
DR   PharmGKB; PA24428; -.
DR   eggNOG; COG1960; -.
DR   HOVERGEN; HBG050448; -.
DR   InParanoid; P49748; -.
DR   KO; K09479; -.
DR   OMA; ATNRTQF; -.
DR   OrthoDB; EOG712TVX; -.
DR   PhylomeDB; P49748; -.
DR   TreeFam; TF105053; -.
DR   BioCyc; MetaCyc:ENSG00000072778-MONOMER; -.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_17015; Metabolism of proteins.
DR   UniPathway; UPA00660; -.
DR   ChiTaRS; ACADVL; human.
DR   EvolutionaryTrace; P49748; -.
DR   GenomeRNAi; 37; -.
DR   NextBio; 143; -.
DR   PRO; PR:P49748; -.
DR   ArrayExpress; P49748; -.
DR   Bgee; P49748; -.
DR   CleanEx; HS_ACADVL; -.
DR   Genevestigator; P49748; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IDA:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; ISS:BHF-UCL.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0003995; F:acyl-CoA dehydrogenase activity; TAS:Reactome.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IEA:InterPro.
DR   GO; GO:0004466; F:long-chain-acyl-CoA dehydrogenase activity; TAS:ProtInc.
DR   GO; GO:0006987; P:activation of signaling protein activity involved in unfolded protein response; TAS:Reactome.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; TAS:Reactome.
DR   GO; GO:0015980; P:energy derivation by oxidation of organic compounds; TAS:ProtInc.
DR   GO; GO:0030855; P:epithelial cell differentiation; IEP:UniProt.
DR   GO; GO:0006635; P:fatty acid beta-oxidation; TAS:Reactome.
DR   GO; GO:0033539; P:fatty acid beta-oxidation using acyl-CoA dehydrogenase; ISS:BHF-UCL.
DR   GO; GO:0045717; P:negative regulation of fatty acid biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0046322; P:negative regulation of fatty acid oxidation; ISS:BHF-UCL.
DR   GO; GO:0090181; P:regulation of cholesterol metabolic process; ISS:BHF-UCL.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0001659; P:temperature homeostasis; ISS:BHF-UCL.
DR   Gene3D; 1.10.540.10; -; 1.
DR   Gene3D; 2.40.110.10; -; 1.
DR   InterPro; IPR006089; Acyl-CoA_DH_CS.
DR   InterPro; IPR006091; Acyl-CoA_Oxase/DH_cen-dom.
DR   InterPro; IPR009075; AcylCo_DH/oxidase_C.
DR   InterPro; IPR013786; AcylCoA_DH/ox_N.
DR   InterPro; IPR009100; AcylCoA_DH/oxidase_NM_dom.
DR   Pfam; PF00441; Acyl-CoA_dh_1; 1.
DR   Pfam; PF02770; Acyl-CoA_dh_M; 1.
DR   Pfam; PF02771; Acyl-CoA_dh_N; 1.
DR   SUPFAM; SSF47203; SSF47203; 1.
DR   SUPFAM; SSF56645; SSF56645; 1.
DR   PROSITE; PS00072; ACYL_COA_DH_1; 1.
DR   PROSITE; PS00073; ACYL_COA_DH_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cardiomyopathy;
KW   Complete proteome; Disease mutation; FAD; Fatty acid metabolism;
KW   Flavoprotein; Isopeptide bond; Lipid metabolism; Membrane;
KW   Mitochondrion; Mitochondrion inner membrane; Oxidoreductase;
KW   Polymorphism; Reference proteome; S-nitrosylation; Transit peptide;
KW   Ubl conjugation.
FT   TRANSIT       1     40       Mitochondrion (By similarity).
FT   CHAIN        41    655       Very long-chain specific acyl-CoA
FT                                dehydrogenase, mitochondrial.
FT                                /FTId=PRO_0000000515.
FT   NP_BIND     214    223       FAD.
FT   NP_BIND     249    251       FAD.
FT   NP_BIND     435    439       FAD (By similarity).
FT   NP_BIND     464    466       FAD.
FT   REGION       41    482       Catalytic.
FT   REGION      338    341       Substrate binding (By similarity).
FT   REGION      462    463       Substrate binding.
FT   REGION      483    516       Membrane-anchoring (Probable).
FT   ACT_SITE    462    462       Proton acceptor.
FT   BINDING     223    223       Substrate; via carbonyl oxygen (By
FT                                similarity).
FT   BINDING     366    366       FAD (By similarity).
FT   BINDING     463    463       Substrate; via amide nitrogen (By
FT                                similarity).
FT   MOD_RES      51     51       N6-acetyllysine (By similarity).
FT   MOD_RES      71     71       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES      71     71       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     195    195       N6-succinyllysine (By similarity).
FT   MOD_RES     237    237       S-nitrosocysteine (By similarity).
FT   MOD_RES     239    239       N6-acetyllysine; alternate.
FT   MOD_RES     239    239       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     276    276       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     276    276       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     278    278       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     278    278       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     298    298       N6-acetyllysine (By similarity).
FT   MOD_RES     331    331       N6-acetyllysine; alternate.
FT   MOD_RES     331    331       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     372    372       N6-succinyllysine (By similarity).
FT   MOD_RES     482    482       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     482    482       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     550    550       N6-acetyllysine (By similarity).
FT   MOD_RES     556    556       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     556    556       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     639    639       N6-succinyllysine (By similarity).
FT   CROSSLNK    331    331       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin);
FT                                alternate (By similarity).
FT   VAR_SEQ       1     20       MQAARMAASLGRQLLRLGGG -> MLGGLAAAAGTRIMGKE
FT                                IEAEAQRPLRQTWRPGQPPAMTAKTM (in isoform
FT                                3).
FT                                /FTId=VSP_046031.
FT   VAR_SEQ      47     68       Missing (in isoform 2).
FT                                /FTId=VSP_007734.
FT   VARIANT      17     17       L -> F (in dbSNP:rs2230179).
FT                                /FTId=VAR_029286.
FT   VARIANT      43     43       G -> D (in dbSNP:rs2230178).
FT                                /FTId=VAR_000330.
FT   VARIANT      65     65       P -> L (in dbSNP:rs28934585).
FT                                /FTId=VAR_048176.
FT   VARIANT     130    130       Missing (in ACADVLD).
FT                                /FTId=VAR_000331.
FT   VARIANT     158    158       T -> N (in ACADVLD).
FT                                /FTId=VAR_000332.
FT   VARIANT     159    159       Q -> R (in ACADVLD).
FT                                /FTId=VAR_000333.
FT   VARIANT     174    174       V -> M (in ACADVLD).
FT                                /FTId=VAR_000334.
FT   VARIANT     185    185       G -> S (in ACADVLD).
FT                                /FTId=VAR_000335.
FT   VARIANT     213    213       A -> P (in ACADVLD; dbSNP:rs140629318).
FT                                /FTId=VAR_010101.
FT   VARIANT     218    218       E -> K (in ACADVLD).
FT                                /FTId=VAR_000336.
FT   VARIANT     243    243       L -> R (in ACADVLD).
FT                                /FTId=VAR_000337.
FT   VARIANT     247    247       K -> E (in ACADVLD).
FT                                /FTId=VAR_010102.
FT   VARIANT     247    247       K -> T (in ACADVLD).
FT                                /FTId=VAR_000338.
FT   VARIANT     260    260       T -> M (in ACADVLD; dbSNP:rs113994168).
FT                                /FTId=VAR_000339.
FT   VARIANT     278    278       Missing (in ACADVLD).
FT                                /FTId=VAR_000340.
FT   VARIANT     281    281       A -> D (in ACADVLD).
FT                                /FTId=VAR_000341.
FT   VARIANT     283    283       V -> A (in ACADVLD; dbSNP:rs113994167).
FT                                /FTId=VAR_000342.
FT   VARIANT     290    290       G -> D (in ACADVLD).
FT                                /FTId=VAR_000343.
FT   VARIANT     294    294       G -> E (in ACADVLD; dbSNP:rs200573371).
FT                                /FTId=VAR_000344.
FT   VARIANT     299    299       K -> N (in ACADVLD).
FT                                /FTId=VAR_000345.
FT   VARIANT     299    299       Missing (in ACADVLD).
FT                                /FTId=VAR_000346.
FT   VARIANT     317    317       V -> A (in ACADVLD).
FT                                /FTId=VAR_000347.
FT   VARIANT     352    352       M -> V (in ACADVLD).
FT                                /FTId=VAR_000348.
FT   VARIANT     359    359       A -> S (in dbSNP:rs1051701).
FT                                /FTId=VAR_011990.
FT   VARIANT     366    366       R -> C (in ACADVLD).
FT                                /FTId=VAR_000349.
FT   VARIANT     366    366       R -> H (in ACADVLD; dbSNP:rs112406105).
FT                                /FTId=VAR_000350.
FT   VARIANT     381    381       Missing (in ACADVLD).
FT                                /FTId=VAR_000351.
FT   VARIANT     382    382       K -> Q (in ACADVLD; dbSNP:rs118204015).
FT                                /FTId=VAR_000352.
FT   VARIANT     405    405       D -> H (in ACADVLD).
FT                                /FTId=VAR_000353.
FT   VARIANT     441    441       G -> D (in ACADVLD; dbSNP:rs2309689).
FT                                /FTId=VAR_000354.
FT   VARIANT     450    450       R -> H (in ACADVLD; dbSNP:rs118204016).
FT                                /FTId=VAR_000355.
FT   VARIANT     453    453       R -> Q (in ACADVLD; dbSNP:rs138058572).
FT                                /FTId=VAR_000356.
FT   VARIANT     454    454       D -> N (in ACADVLD).
FT                                /FTId=VAR_000357.
FT   VARIANT     456    456       R -> H (in ACADVLD).
FT                                /FTId=VAR_000358.
FT   VARIANT     458    458       F -> L (in ACADVLD; dbSNP:rs118204017).
FT                                /FTId=VAR_010103.
FT   VARIANT     459    459       R -> W (in ACADVLD).
FT                                /FTId=VAR_000359.
FT   VARIANT     463    463       G -> E (in ACADVLD; dbSNP:rs200366828).
FT                                /FTId=VAR_000360.
FT   VARIANT     469    469       R -> Q (in ACADVLD).
FT                                /FTId=VAR_000361.
FT   VARIANT     469    469       R -> W (in ACADVLD; dbSNP:rs113994170).
FT                                /FTId=VAR_000362.
FT   VARIANT     490    490       A -> P (in ACADVLD).
FT                                /FTId=VAR_010104.
FT   VARIANT     502    502       L -> P (in ACADVLD).
FT                                /FTId=VAR_000363.
FT   VARIANT     534    534       E -> K (in ACADVLD; dbSNP:rs2230180).
FT                                /FTId=VAR_010105.
FT   VARIANT     602    602       L -> I (in ACADVLD).
FT                                /FTId=VAR_000364.
FT   VARIANT     613    613       R -> W (in ACADVLD; dbSNP:rs118204014).
FT                                /FTId=VAR_000365.
FT   VARIANT     615    615       R -> Q (in ACADVLD; dbSNP:rs148584617).
FT                                /FTId=VAR_010106.
FT   VARIANT     623    623       S -> F (in dbSNP:rs13383).
FT                                /FTId=VAR_011991.
FT   CONFLICT    193    193       G -> C (in Ref. 3; BAA29057).
FT   CONFLICT    200    200       K -> E (in Ref. 4; BAG57027).
FT   CONFLICT    541    541       E -> K (in Ref. 4; BAG57027).
FT   HELIX        73     77
FT   TURN         78     80
FT   TURN         85     87
FT   HELIX        96    115
FT   HELIX       119    125
FT   HELIX       130    138
FT   TURN        139    142
FT   HELIX       148    150
FT   HELIX       157    170
FT   HELIX       172    182
FT   TURN        183    186
FT   HELIX       187    192
FT   HELIX       195    206
FT   STRAND      212    215
FT   STRAND      221    223
FT   HELIX       225    227
FT   STRAND      231    234
FT   STRAND      238    251
FT   TURN        252    255
FT   STRAND      257    268
FT   TURN        270    272
FT   STRAND      275    285
FT   HELIX       286    288
FT   STRAND      289    293
FT   STRAND      307    318
FT   HELIX       319    321
FT   STRAND      322    325
FT   HELIX       329    365
FT   HELIX       373    375
FT   HELIX       377    405
FT   HELIX       412    437
FT   HELIX       439    442
FT   HELIX       448    455
FT   HELIX       456    459
FT   STRAND      461    463
FT   HELIX       465    485
FT   HELIX       486    488
FT   TURN        522    524
FT   HELIX       527    529
FT   HELIX       530    554
FT   HELIX       555    560
FT   HELIX       562    591
FT   HELIX       596    622
FT   HELIX       627    644
SQ   SEQUENCE   655 AA;  70390 MW;  A5594D1EA7911D19 CRC64;
     MQAARMAASL GRQLLRLGGG SSRLTALLGQ PRPGPARRPY AGGAAQLALD KSDSHPSDAL
     TRKKPAKAES KSFAVGMFKG QLTTDQVFPY PSVLNEEQTQ FLKELVEPVS RFFEEVNDPA
     KNDALEMVEE TTWQGLKELG AFGLQVPSEL GGVGLCNTQY ARLVEIVGMH DLGVGITLGA
     HQSIGFKGIL LFGTKAQKEK YLPKLASGET VAAFCLTEPS SGSDAASIRT SAVPSPCGKY
     YTLNGSKLWI SNGGLADIFT VFAKTPVTDP ATGAVKEKIT AFVVERGFGG ITHGPPEKKM
     GIKASNTAEV FFDGVRVPSE NVLGEVGSGF KVAMHILNNG RFGMAAALAG TMRGIIAKAV
     DHATNRTQFG EKIHNFGLIQ EKLARMVMLQ YVTESMAYMV SANMDQGATD FQIEAAISKI
     FGSEAAWKVT DECIQIMGGM GFMKEPGVER VLRDLRIFRI FEGTNDILRL FVALQGCMDK
     GKELSGLGSA LKNPFGNAGL LLGEAGKQLR RRAGLGSGLS LSGLVHPELS RSGELAVRAL
     EQFATVVEAK LIKHKKGIVN EQFLLQRLAD GAIDLYAMVV VLSRASRSLS EGHPTAQHEK
     MLCDTWCIEA AARIREGMAA LQSDPWQQEL YRNFKSISKA LVERGGVVTS NPLGF
//
ID   ACAP2_HUMAN             Reviewed;         778 AA.
AC   Q15057; A8K2V4; Q8N5Z8; Q9UQR3;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-2003, sequence version 3.
DT   09-JUL-2014, entry version 144.
DE   RecName: Full=Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2;
DE   AltName: Full=Centaurin-beta-2;
DE            Short=Cnt-b2;
GN   Name=ACAP2; Synonyms=CENTB2, KIAA0041;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ENZYME REGULATION, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF ARG-442.
RC   TISSUE=Leukocyte;
RX   PubMed=11062263; DOI=10.1083/jcb.151.3.627;
RA   Jackson T.R., Brown F.D., Nie Z., Miura K., Foroni L., Sun J.,
RA   Hsu V.W., Donaldson J.G., Randazzo P.A.;
RT   "ACAPs are arf6 GTPase-activating proteins that function in the cell
RT   periphery.";
RL   J. Cell Biol. 151:627-638(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Bone marrow;
RX   PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S.,
RA   Seki N., Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II.
RT   The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [3]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R., Nomura N.;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-742, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-384, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-521, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
CC   -!- FUNCTION: GTPase-activating protein (GAP) for ADP ribosylation
CC       factor 6 (ARF6).
CC   -!- ENZYME REGULATION: GAP activity stimulated by phosphatidylinositol
CC       4,5-bisphosphate (PIP2) and phosphatidic acid.
CC   -!- SUBUNIT: Interacts with RAB35 (GTP-bound form); the interaction is
CC       direct and probably recruits ACAP2 to membranes. Interacts with
CC       MICALL1; the interaction is indirect through RAB35 (By
CC       similarity).
CC   -!- SUBCELLULAR LOCATION: Endosome membrane; Peripheral membrane
CC       protein (By similarity).
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highest level in lung.
CC   -!- SIMILARITY: Contains 3 ANK repeats.
CC   -!- SIMILARITY: Contains 1 Arf-GAP domain.
CC   -!- SIMILARITY: Contains 1 BAR domain.
CC   -!- SIMILARITY: Contains 1 PH domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA05064.2; Type=Erroneous initiation;
CC       Sequence=CAB41450.1; Type=Frameshift; Positions=98, 106, 111;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ238248; CAB41450.1; ALT_FRAME; mRNA.
DR   EMBL; D26069; BAA05064.2; ALT_INIT; mRNA.
DR   EMBL; AK290369; BAF83058.1; -; mRNA.
DR   EMBL; CH471052; EAW78027.1; -; Genomic_DNA.
DR   EMBL; BC031005; AAH31005.1; -; mRNA.
DR   EMBL; BC060767; AAH60767.1; -; mRNA.
DR   CCDS; CCDS33924.1; -.
DR   RefSeq; NP_036419.3; NM_012287.5.
DR   UniGene; Hs.593373; -.
DR   ProteinModelPortal; Q15057; -.
DR   SMR; Q15057; 7-360, 378-758.
DR   BioGrid; 117073; 3.
DR   IntAct; Q15057; 1.
DR   STRING; 9606.ENSP00000324287; -.
DR   PhosphoSite; Q15057; -.
DR   DMDM; 39932727; -.
DR   MaxQB; Q15057; -.
DR   PaxDb; Q15057; -.
DR   PeptideAtlas; Q15057; -.
DR   PRIDE; Q15057; -.
DR   Ensembl; ENST00000326793; ENSP00000324287; ENSG00000114331.
DR   GeneID; 23527; -.
DR   KEGG; hsa:23527; -.
DR   UCSC; uc003fun.4; human.
DR   CTD; 23527; -.
DR   GeneCards; GC03M194995; -.
DR   HGNC; HGNC:16469; ACAP2.
DR   HPA; HPA034807; -.
DR   HPA; HPA034808; -.
DR   MIM; 607766; gene.
DR   neXtProt; NX_Q15057; -.
DR   PharmGKB; PA26407; -.
DR   eggNOG; COG5347; -.
DR   HOGENOM; HOG000220815; -.
DR   HOVERGEN; HBG050889; -.
DR   InParanoid; Q15057; -.
DR   KO; K12489; -.
DR   OMA; QHATDED; -.
DR   OrthoDB; EOG7PVWNT; -.
DR   PhylomeDB; Q15057; -.
DR   TreeFam; TF318315; -.
DR   ChiTaRS; ACAP2; human.
DR   GeneWiki; CENTB2; -.
DR   GenomeRNAi; 23527; -.
DR   NextBio; 45992; -.
DR   PRO; PR:Q15057; -.
DR   ArrayExpress; Q15057; -.
DR   Bgee; Q15057; -.
DR   CleanEx; HS_ACAP2; -.
DR   Genevestigator; Q15057; -.
DR   GO; GO:0010008; C:endosome membrane; ISS:UniProtKB.
DR   GO; GO:0008060; F:ARF GTPase activator activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0036010; P:protein localization to endosome; ISS:UniProtKB.
DR   GO; GO:0032312; P:regulation of ARF GTPase activity; IEA:InterPro.
DR   Gene3D; 1.20.1270.60; -; 1.
DR   Gene3D; 1.25.40.20; -; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR027267; AH/BAR-dom.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR001164; ArfGAP.
DR   InterPro; IPR011993; PH_like_dom.
DR   InterPro; IPR001849; Pleckstrin_homology.
DR   Pfam; PF00023; Ank; 2.
DR   Pfam; PF01412; ArfGap; 1.
DR   Pfam; PF00169; PH; 1.
DR   PRINTS; PR00405; REVINTRACTNG.
DR   SMART; SM00248; ANK; 3.
DR   SMART; SM00105; ArfGap; 1.
DR   SMART; SM00233; PH; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 2.
DR   PROSITE; PS50115; ARFGAP; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   ANK repeat; Coiled coil; Complete proteome; Endosome;
KW   GTPase activation; Membrane; Metal-binding; Phosphoprotein;
KW   Reference proteome; Repeat; Zinc; Zinc-finger.
FT   CHAIN         1    778       Arf-GAP with coiled-coil, ANK repeat and
FT                                PH domain-containing protein 2.
FT                                /FTId=PRO_0000074210.
FT   DOMAIN        1    226       BAR.
FT   DOMAIN      266    361       PH.
FT   DOMAIN      399    520       Arf-GAP.
FT   REPEAT      640    669       ANK 1.
FT   REPEAT      673    702       ANK 2.
FT   REPEAT      706    735       ANK 3.
FT   ZN_FING     414    437       C4-type.
FT   MOD_RES     384    384       Phosphoserine.
FT   MOD_RES     521    521       Phosphoserine.
FT   MOD_RES     742    742       Phosphotyrosine.
FT   MUTAGEN     442    442       R->Q: Loss of GAP activity.
FT   CONFLICT      5      5       V -> G (in Ref. 1; CAB41450).
FT   CONFLICT     42     42       C -> G (in Ref. 1; CAB41450).
FT   CONFLICT    229    229       V -> G (in Ref. 1; CAB41450).
FT   CONFLICT    252    252       S -> R (in Ref. 1; CAB41450).
FT   CONFLICT    258    258       E -> K (in Ref. 1; CAB41450).
FT   CONFLICT    296    296       L -> V (in Ref. 1; CAB41450).
FT   CONFLICT    564    564       G -> E (in Ref. 6; AAH60767).
SQ   SEQUENCE   778 AA;  88029 MW;  64B620957FEE6195 CRC64;
     MKMTVDFEEC LKDSPRFRAA LEEVEGDVAE LELKLDKLVK LCIAMIDTGK AFCVANKQFM
     NGIRDLAQYS SNDAVVETSL TKFSDSLQEM INFHTILFDQ TQRSIKAQLQ NFVKEDLRKF
     KDAKKQFEKV SEEKENALVK NAQVQRNKQH EVEEATNILT ATRKCFRHIA LDYVLQINVL
     QSKRRSEILK SMLSFMYAHL AFFHQGYDLF SELGPYMKDL GAQLDRLVVD AAKEKREMEQ
     KHSTIQQKDF SSDDSKLEYN VDAANGIVME GYLFKRASNA FKTWNRRWFS IQNNQLVYQK
     KFKDNPTVVV EDLRLCTVKH CEDIERRFCF EVVSPTKSCM LQADSEKLRQ AWIKAVQTSI
     ATAYREKGDE SEKLDKKSSP STGSLDSGNE SKEKLLKGES ALQRVQCIPG NASCCDCGLA
     DPRWASINLG ITLCIECSGI HRSLGVHFSK VRSLTLDTWE PELLKLMCEL GNDVINRVYE
     ANVEKMGIKK PQPGQRQEKE AYIRAKYVER KFVDKYSISL SPPEQQKKFV SKSSEEKRLS
     ISKFGPGDQV RASAQSSVRS NDSGIQQSSD DGRESLPSTV SANSLYEPEG ERQDSSMFLD
     SKHLNPGLQL YRASYEKNLP KMAEALAHGA DVNWANSEEN KATPLIQAVL GGSLVTCEFL
     LQNGANVNQR DVQGRGPLHH ATVLGHTGQV CLFLKRGANQ HATDEEGKDP LSIAVEAANA
     DIVTLLRLAR MNEEMRESEG LYGQPGDETY QDIFRDFSQM ASNNPEKLNR FQQDSQKF
//
ID   ACBP_HUMAN              Reviewed;          87 AA.
AC   P07108; B8ZWD2; B8ZWD6; B8ZWD7; P08869; Q4VWZ6; Q53SQ7; Q6IB48;
AC   Q9UCI8;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   09-JUL-2014, entry version 152.
DE   RecName: Full=Acyl-CoA-binding protein;
DE            Short=ACBP;
DE   AltName: Full=Diazepam-binding inhibitor;
DE            Short=DBI;
DE   AltName: Full=Endozepine;
DE            Short=EP;
GN   Name=DBI;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=3020548; DOI=10.1073/pnas.83.19.7547;
RA   Gray P.W., Glaister D., Seeburg P.H., Guidotti A., Costa E.;
RT   "Cloning and expression of cDNA for human diazepam binding inhibitor,
RT   a natural ligand of an allosteric regulatory site of the gamma-
RT   aminobutyric acid type A receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7547-7551(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2881742; DOI=10.1089/dna.1987.6.71;
RA   Webb N.R., Rose T.M., Malik N., Marquardt H., Shoyab M., Todaro G.J.,
RA   Lee D.C.;
RT   "Bovine and human cDNA sequences encoding a putative benzodiazepine
RT   receptor ligand.";
RL   DNA 6:71-79(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND TISSUE SPECIFICITY.
RX   PubMed=16055366; DOI=10.1016/j.biocel.2005.06.008;
RA   Nitz I., Doering F., Schrezenmeir J., Burwinkel B.;
RT   "Identification of new acyl-CoA binding protein transcripts in human
RT   and mouse.";
RL   Int. J. Biochem. Cell Biol. 37:2395-2405(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=21698759; DOI=10.1002/iub.471;
RA   Ludewig A.H., Nitz I., Klapper M., Doring F.;
RT   "Identification of a novel human Acyl-CoA binding protein isoform with
RT   a unique C-terminal domain.";
RL   IUBMB Life 63:547-552(2011).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 4 AND 5), ALTERNATIVE
RP   SPLICING, AND ALTERNATIVE PROMOTER USAGE.
RX   PubMed=20345851; DOI=10.1111/j.1582-4934.2010.01055.x;
RA   Nitz I., Kruse M.L., Klapper M., Doring F.;
RT   "Specific regulation of low-abundance transcript variants encoding
RT   human Acyl-CoA binding protein (ACBP) isoforms.";
RL   J. Cell. Mol. Med. 15:909-927(2011).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-87 (ISOFORM 1), AND ACETYLATION AT SER-2.
RC   TISSUE=Brain;
RX   PubMed=3525533;
RA   Marquardt H., Todaro G.J., Shoyab M.;
RT   "Complete amino acid sequences of bovine and human endozepines.
RT   Homology with rat diazepam binding inhibitor.";
RL   J. Biol. Chem. 261:9727-9731(1986).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-14 (ISOFORM 1).
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [12]
RP   PROTEIN SEQUENCE OF 26-30 AND 72-87.
RX   PubMed=1292782;
RA   Apfel R., Lottspeich F., Hoppe J., Behl C., Duerr G., Bogdahn U.;
RT   "Purification and analysis of growth regulating proteins secreted by a
RT   human melanoma cell line.";
RL   Melanoma Res. 2:327-336(1992).
RN   [13]
RP   ALTERNATIVE SPLICING.
RX   PubMed=7534063;
RA   Kolmer M., Rovio A., Alho H.;
RT   "The characterization of two diazepam binding inhibitor (DBI)
RT   transcripts in humans.";
RL   Biochem. J. 306:327-330(1995).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17953517; DOI=10.1042/BJ20070559;
RA   Hansen J.S., Faergeman N.J., Kragelund B.B., Knudsen J.;
RT   "Acyl-CoA-binding protein (ACBP) localizes to the endoplasmic
RT   reticulum and Golgi in a ligand-dependent manner in mammalian cells.";
RL   Biochem. J. 410:463-472(2008).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2; LYS-8; LYS-19; LYS-55 AND
RP   LYS-77, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-29, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   MALONYLATION AT LYS-55.
RX   PubMed=21908771; DOI=10.1074/mcp.M111.012658;
RA   Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y.,
RA   He W., Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C.,
RA   Dai J., Verdin E., Ye Y., Zhao Y.;
RT   "The first identification of lysine malonylation substrates and its
RT   regulatory enzyme.";
RL   Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) IN COMPLEX WITH ACYL-COENZYME A.
RX   PubMed=17044054; DOI=10.1002/prot.21124;
RA   Taskinen J.P., van Aalten D.M., Knudsen J., Wierenga R.K.;
RT   "High resolution crystal structures of unliganded and liganded human
RT   liver ACBP reveal a new mode of binding for the acyl-CoA ligand.";
RL   Proteins 66:229-238(2007).
CC   -!- FUNCTION: Binds medium- and long-chain acyl-CoA esters with very
CC       high affinity and may function as an intracellular carrier of
CC       acyl-CoA esters. It is also able to displace diazepam from the
CC       benzodiazepine (BZD) recognition site located on the GABA type A
CC       receptor. It is therefore possible that this protein also acts as
CC       a neuropeptide to modulate the action of the GABA receptor.
CC   -!- SUBUNIT: Monomer.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum. Golgi apparatus.
CC       Note=Golgi localization is dependent on ligand binding.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=ACBP-1a, Short;
CC         IsoId=P07108-1; Sequence=Displayed;
CC       Name=2; Synonyms=ACBP-1b, Long;
CC         IsoId=P07108-2; Sequence=VSP_000068;
CC       Name=3; Synonyms=ACBP-1c;
CC         IsoId=P07108-3; Sequence=VSP_038680;
CC       Name=4; Synonyms=ACBP-1a1-g;
CC         IsoId=P07108-4; Sequence=VSP_043437;
CC       Name=5; Synonyms=ACBP-1g;
CC         IsoId=P07108-5; Sequence=VSP_043438;
CC       Name=6; Synonyms=ACBP-1e;
CC         IsoId=P07108-6; Sequence=VSP_044114;
CC         Note=Predominantly expressed in adipose tissue and hippocampus;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is ubiquitous, with a moderate
CC       expression level. Isoform 2 is ubiquitous with high level in liver
CC       and adipose tissue. Isoform 3 is ubiquitous with strong expression
CC       in adipose tissue and heart.
CC   -!- SIMILARITY: Belongs to the ACBP family.
CC   -!- SIMILARITY: Contains 1 ACB (acyl-CoA-binding) domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14200; AAA52171.1; -; mRNA.
DR   EMBL; M15887; AAA35788.1; -; mRNA.
DR   EMBL; FM213123; CAR82405.1; -; mRNA.
DR   EMBL; FM213124; CAR82406.1; -; mRNA.
DR   EMBL; FM213125; CAR82407.1; -; mRNA.
DR   EMBL; FM213126; CAR82408.1; -; mRNA.
DR   EMBL; FM213127; CAR82409.1; -; mRNA.
DR   EMBL; FM213128; CAR82410.1; -; mRNA.
DR   EMBL; FM213131; CAR82414.1; -; mRNA.
DR   EMBL; CR456956; CAG33237.1; -; mRNA.
DR   EMBL; AC016736; AAY14873.1; -; Genomic_DNA.
DR   EMBL; CH471103; EAW95214.1; -; Genomic_DNA.
DR   EMBL; BC006466; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC062996; AAH62996.1; -; mRNA.
DR   EMBL; AM000001; CAJ00736.1; -; mRNA.
DR   CCDS; CCDS2126.1; -. [P07108-2]
DR   CCDS; CCDS42740.1; -. [P07108-1]
DR   CCDS; CCDS42741.1; -. [P07108-3]
DR   CCDS; CCDS54390.1; -. [P07108-4]
DR   CCDS; CCDS54391.1; -. [P07108-5]
DR   PIR; B26448; NZHU.
DR   RefSeq; NP_001073331.1; NM_001079862.2. [P07108-1]
DR   RefSeq; NP_001073332.1; NM_001079863.1. [P07108-3]
DR   RefSeq; NP_001171488.1; NM_001178017.1. [P07108-5]
DR   RefSeq; NP_001171512.1; NM_001178041.2. [P07108-4]
DR   RefSeq; NP_001171513.1; NM_001178042.2. [P07108-2]
DR   RefSeq; NP_001269562.1; NM_001282633.1. [P07108-2]
DR   RefSeq; NP_001269563.1; NM_001282634.1. [P07108-2]
DR   RefSeq; NP_001269564.1; NM_001282635.1. [P07108-2]
DR   RefSeq; NP_065438.1; NM_020548.7. [P07108-2]
DR   UniGene; Hs.78888; -.
DR   PDB; 2CB8; X-ray; 1.40 A; A/B=2-87.
DR   PDB; 2FJ9; X-ray; 1.60 A; A=2-87.
DR   PDBsum; 2CB8; -.
DR   PDBsum; 2FJ9; -.
DR   ProteinModelPortal; P07108; -.
DR   SMR; P07108; 2-87.
DR   BioGrid; 107990; 10.
DR   IntAct; P07108; 9.
DR   MINT; MINT-1394907; -.
DR   STRING; 9606.ENSP00000311117; -.
DR   PhosphoSite; P07108; -.
DR   MaxQB; P07108; -.
DR   PaxDb; P07108; -.
DR   PRIDE; P07108; -.
DR   DNASU; 1622; -.
DR   Ensembl; ENST00000311521; ENSP00000311117; ENSG00000155368. [P07108-2]
DR   Ensembl; ENST00000355857; ENSP00000348116; ENSG00000155368. [P07108-1]
DR   Ensembl; ENST00000393103; ENSP00000376815; ENSG00000155368. [P07108-3]
DR   Ensembl; ENST00000409094; ENSP00000386486; ENSG00000155368. [P07108-2]
DR   Ensembl; ENST00000535617; ENSP00000442917; ENSG00000155368. [P07108-4]
DR   Ensembl; ENST00000535757; ENSP00000439012; ENSG00000155368. [P07108-2]
DR   Ensembl; ENST00000542275; ENSP00000440698; ENSG00000155368. [P07108-5]
DR   GeneID; 1622; -.
DR   KEGG; hsa:1622; -.
DR   UCSC; uc002tlv.3; human. [P07108-1]
DR   UCSC; uc002tlw.3; human. [P07108-2]
DR   UCSC; uc002tlx.3; human. [P07108-3]
DR   UCSC; uc010yyk.2; human. [P07108-4]
DR   UCSC; uc021vnj.1; human. [P07108-5]
DR   CTD; 1622; -.
DR   GeneCards; GC02P120124; -.
DR   HGNC; HGNC:2690; DBI.
DR   HPA; CAB008595; -.
DR   MIM; 125950; gene.
DR   neXtProt; NX_P07108; -.
DR   PharmGKB; PA27158; -.
DR   eggNOG; COG4281; -.
DR   HOVERGEN; HBG000398; -.
DR   KO; K08762; -.
DR   OMA; LTKRPSD; -.
DR   OrthoDB; EOG7SN8G8; -.
DR   PhylomeDB; P07108; -.
DR   TreeFam; TF335802; -.
DR   ChiTaRS; DBI; human.
DR   EvolutionaryTrace; P07108; -.
DR   GeneWiki; Diazepam_binding_inhibitor; -.
DR   GenomeRNAi; 1622; -.
DR   NextBio; 6658; -.
DR   PRO; PR:P07108; -.
DR   ArrayExpress; P07108; -.
DR   Bgee; P07108; -.
DR   CleanEx; HS_DBI; -.
DR   Genevestigator; P07108; -.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProt.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0097038; C:perinuclear endoplasmic reticulum; IDA:UniProt.
DR   GO; GO:0030156; F:benzodiazepine receptor binding; TAS:ProtInc.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0036042; F:long-chain fatty acyl-CoA binding; IDA:UniProt.
DR   GO; GO:0046983; F:protein dimerization activity; IDA:UniProt.
DR   GO; GO:0001942; P:hair follicle development; IEA:Ensembl.
DR   GO; GO:0036151; P:phosphatidylcholine acyl-chain remodeling; IDA:UniProt.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   GO; GO:0006641; P:triglyceride metabolic process; IEA:Ensembl.
DR   Gene3D; 1.20.80.10; -; 1.
DR   InterPro; IPR022408; Acyl-CoA-binding_prot_CS.
DR   InterPro; IPR000582; Acyl-CoA-binding_protein.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_3-hlx.
DR   Pfam; PF00887; ACBP; 1.
DR   PRINTS; PR00689; ACOABINDINGP.
DR   SUPFAM; SSF47027; SSF47027; 1.
DR   PROSITE; PS00880; ACB_1; 1.
DR   PROSITE; PS51228; ACB_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative promoter usage;
KW   Alternative splicing; Complete proteome; Direct protein sequencing;
KW   Endoplasmic reticulum; Golgi apparatus; Lipid-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transport.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2     87       Acyl-CoA-binding protein.
FT                                /FTId=PRO_0000214004.
FT   DOMAIN        2     87       ACB.
FT   REGION       29     33       Acyl-CoA binding.
FT   BINDING      14     14       Acyl-CoA.
FT   BINDING      55     55       Acyl-CoA.
FT   BINDING      74     74       Acyl-CoA.
FT   MOD_RES       2      2       N-acetylserine.
FT   MOD_RES       8      8       N6-acetyllysine; alternate.
FT   MOD_RES       8      8       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES      17     17       N6-succinyllysine (By similarity).
FT   MOD_RES      19     19       N6-acetyllysine.
FT   MOD_RES      29     29       Phosphotyrosine.
FT   MOD_RES      55     55       N6-acetyllysine; alternate.
FT   MOD_RES      55     55       N6-malonyllysine; alternate.
FT   MOD_RES      55     55       N6-succinyllysine; alternate (By
FT                                similarity).
FT   MOD_RES      77     77       N6-acetyllysine; alternate.
FT   MOD_RES      77     77       N6-succinyllysine; alternate (By
FT                                similarity).
FT   VAR_SEQ       1      3       MSQ -> MWGDLWLLPPASANPGTGTE (in isoform
FT                                2).
FT                                /FTId=VSP_000068.
FT   VAR_SEQ       1      3       MSQ -> MPAF (in isoform 3).
FT                                /FTId=VSP_038680.
FT   VAR_SEQ       1      3       MSQ -> MSQHRAGRRGGVGKRGVRGRELGGQGKYGAGCSE
FT                                CGTRRIAARGE (in isoform 4).
FT                                /FTId=VSP_043437.
FT   VAR_SEQ       1      3       MSQ -> MERWGKGLHGLEERGDSVPIPKHRAGRRGGVGKR
FT                                GVRGRELGGQGKYGAGCSECGTRRIAARGE (in
FT                                isoform 5).
FT                                /FTId=VSP_043438.
FT   VAR_SEQ      43     87       ERPGMLDFTGKAKWDAWNELKGTSKEDAMKAYINKVEELKK
FT                                KYGI -> GMQSGGWKGICSSKQAQQLRLEVPGNFTLKLPE
FT                                ALLFRWGMVMVPEVEKTMFRILSVSSSNRIQILVLEGLYWP
FT                                SPAATLY (in isoform 6).
FT                                /FTId=VSP_044114.
FT   VARIANT      39     39       D -> N (in dbSNP:rs8192504).
FT                                /FTId=VAR_048160.
FT   VARIANT      71     71       M -> V (in dbSNP:rs8192506).
FT                                /FTId=VAR_048161.
FT   VARIANT      86     86       G -> R (in dbSNP:rs8192507).
FT                                /FTId=VAR_048162.
FT   HELIX         3     12
FT   HELIX        13     15
FT   HELIX        22     36
FT   HELIX        50     60
FT   TURN         61     64
FT   HELIX        67     85
SQ   SEQUENCE   87 AA;  10044 MW;  B343A309F1B1AE28 CRC64;
     MSQAEFEKAA EEVRHLKTKP SDEEMLFIYG HYKQATVGDI NTERPGMLDF TGKAKWDAWN
     ELKGTSKEDA MKAYINKVEE LKKKYGI
//
ID   ACD_HUMAN               Reviewed;         544 AA.
AC   Q96AP0; Q562H5; Q9H8F9;
DT   30-MAY-2006, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   09-JUL-2014, entry version 101.
DE   RecName: Full=Adrenocortical dysplasia protein homolog;
DE   AltName: Full=POT1 and TIN2-interacting protein;
GN   Name=ACD; Synonyms=PIP1, PTOP, TINT1, TPP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), MOTIF, SUBCELLULAR LOCATION,
RP   INTERACTION WITH POT1 AND TINF2, FUNCTION, AND VARIANT ALA-518.
RX   PubMed=15181449; DOI=10.1038/ncb1142;
RA   Liu D., Safari A., O'Connor M.S., Chan D.W., Laegeler A., Qin J.,
RA   Songyang Z.;
RT   "PTOP interacts with POT1 and regulates its localization to
RT   telomeres.";
RL   Nat. Cell Biol. 6:673-680(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-518.
RC   TISSUE=Duodenum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 65-544, AND ALTERNATIVE SPLICING
RP   (ISOFORM 1).
RX   PubMed=15537664; DOI=10.1093/hmg/ddi011;
RA   Keegan C.E., Hutz J.E., Else T., Adamska M., Shah S.P., Kent A.E.,
RA   Howes J.M., Beamer W.G., Hammer G.D.;
RT   "Urogenital and caudal dysgenesis in adrenocortical dysplasia (acd)
RT   mice is caused by a splicing mutation in a novel telomeric
RT   regulator.";
RL   Hum. Mol. Genet. 14:113-123(2005).
RN   [6]
RP   INTERACTION WITH POT1 AND TINF2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=15231715; DOI=10.1101/gad.1215404;
RA   Ye J.Z.-S., Hockemeyer D., Krutchinsky A.N., Loayza D., Hooper S.M.,
RA   Chait B.T., de Lange T.;
RT   "POT1-interacting protein PIP1: a telomere length regulator that
RT   recruits POT1 to the TIN2/TRF1 complex.";
RL   Genes Dev. 18:1649-1654(2004).
RN   [7]
RP   IDENTIFICATION IN THE SHELTERIN COMPLEX.
RX   PubMed=15316005; DOI=10.1074/jbc.M409047200;
RA   Ye J.Z.-S., Donigian J.R., van Overbeek M., Loayza D., Luo Y.,
RA   Krutchinsky A.N., Chait B.T., de Lange T.;
RT   "TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2
RT   complex on telomeres.";
RL   J. Biol. Chem. 279:47264-47271(2004).
RN   [8]
RP   IDENTIFICATION IN THE SHELTERIN COMPLEX.
RX   PubMed=15383534; DOI=10.1074/jbc.M409293200;
RA   Liu D., O'Connor M.S., Qin J., Songyang Z.;
RT   "Telosome, a mammalian telomere-associated complex formed by multiple
RT   telomeric proteins.";
RL   J. Biol. Chem. 279:51338-51342(2004).
RN   [9]
RP   FUNCTION OF THE SHELTERIN COMPLEX.
RX   PubMed=16166375; DOI=10.1101/gad.1346005;
RA   de Lange T.;
RT   "Shelterin: the protein complex that shapes and safeguards human
RT   telomeres.";
RL   Genes Dev. 19:2100-2110(2005).
RN   [10]
RP   FUNCTION IN SHELTERIN COMPLEX ASSEMBLY.
RX   PubMed=16880378; DOI=10.1073/pnas.0605303103;
RA   O'Connor M.S., Safari A., Xin H., Liu D., Songyang Z.;
RT   "A critical role for TPP1 and TIN2 interaction in high-order telomeric
RT   complex assembly.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:11874-11879(2006).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   INTERACTION WITH OBFC1.
RX   PubMed=19648609; DOI=10.1074/jbc.M109.021105;
RA   Wan M., Qin J., Songyang Z., Liu D.;
RT   "OB fold-containing protein 1 (OBFC1), a human homolog of yeast Stn1,
RT   associates with TPP1 and is implicated in telomere length
RT   regulation.";
RL   J. Biol. Chem. 284:26725-26731(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-111, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   FUNCTION.
RX   PubMed=20231318; DOI=10.1101/gad.1881810;
RA   Zaug A.J., Podell E.R., Nandakumar J., Cech T.R.;
RT   "Functional interaction between telomere protein TPP1 and
RT   telomerase.";
RL   Genes Dev. 24:613-622(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 90-250, FUNCTION, SUBUNIT,
RP   AND IDENTIFICATION IN A COMPLEX WITH POT1 AND SINGLE-STRANDED
RP   TELOMERIC DNA.
RX   PubMed=17237768; DOI=10.1038/nature05454;
RA   Wang F., Podell E.R., Zaug A.J., Yang Y., Baciu P., Cech T.R., Lei M.;
RT   "The POT1-TPP1 telomere complex is a telomerase processivity factor.";
RL   Nature 445:506-510(2007).
CC   -!- FUNCTION: Component of the shelterin complex (telosome) that is
CC       involved in the regulation of telomere length and protection.
CC       Shelterin associates with arrays of double-stranded TTAGGG repeats
CC       added by telomerase and protects chromosome ends; without its
CC       protective activity, telomeres are no longer hidden from the DNA
CC       damage surveillance and chromosome ends are inappropriately
CC       processed by DNA repair pathways. Promotes binding of POT1 to
CC       single-stranded telomeric DNA. Modulates the inhibitory effects of
CC       POT1 on telomere elongation. The ACD-POT1 heterodimer enhances
CC       telomere elongation by increasing telomerase processivity. Plays a
CC       role in shelterin complex assembly. May play a role in
CC       organogenesis.
CC   -!- SUBUNIT: Component of the shelterin complex (telosome) composed of
CC       TERF1, TERF2, TINF2, TERF2IP ACD and POT1. Forms heterodimers with
CC       POT1. Identified in a complex with POT1 and single-stranded
CC       telomeric DNA. Interacts with STN1/OBFC1 and TINF2.
CC   -!- INTERACTION:
CC       Q9H668:OBFC1; NbExp=4; IntAct=EBI-717666, EBI-746930;
CC       Q9NUX5:POT1; NbExp=3; IntAct=EBI-717666, EBI-752420;
CC       Q9NUX5-2:POT1; NbExp=3; IntAct=EBI-717666, EBI-752435;
CC       Q9BSI4-3:TINF2; NbExp=5; IntAct=EBI-717666, EBI-717418;
CC       Q92900:UPF1; NbExp=3; IntAct=EBI-717666, EBI-373471;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome, telomere.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96AP0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96AP0-2; Sequence=VSP_019066;
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAX82621.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY502940; AAS80318.1; -; mRNA.
DR   EMBL; AK023726; BAB14658.1; -; mRNA.
DR   EMBL; AC010530; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC016904; AAH16904.1; -; mRNA.
DR   EMBL; AY971883; AAX82621.1; ALT_INIT; Genomic_DNA.
DR   CCDS; CCDS10842.1; -. [Q96AP0-2]
DR   CCDS; CCDS42181.1; -. [Q96AP0-1]
DR   RefSeq; NP_001075955.1; NM_001082486.1. [Q96AP0-1]
DR   RefSeq; NP_001075956.1; NM_001082487.1.
DR   RefSeq; NP_075065.2; NM_022914.2. [Q96AP0-2]
DR   UniGene; Hs.78019; -.
DR   PDB; 2I46; X-ray; 2.70 A; A/B=90-250.
DR   PDBsum; 2I46; -.
DR   ProteinModelPortal; Q96AP0; -.
DR   SMR; Q96AP0; 90-241.
DR   BioGrid; 122379; 65.
DR   DIP; DIP-29611N; -.
DR   IntAct; Q96AP0; 10.
DR   MINT; MINT-1387856; -.
DR   STRING; 9606.ENSP00000377496; -.
DR   PhosphoSite; Q96AP0; -.
DR   DMDM; 296439451; -.
DR   MaxQB; Q96AP0; -.
DR   PaxDb; Q96AP0; -.
DR   PRIDE; Q96AP0; -.
DR   Ensembl; ENST00000219251; ENSP00000219251; ENSG00000102977. [Q96AP0-2]
DR   Ensembl; ENST00000393919; ENSP00000377496; ENSG00000102977. [Q96AP0-1]
DR   GeneID; 65057; -.
DR   KEGG; hsa:65057; -.
DR   UCSC; uc002etp.4; human. [Q96AP0-2]
DR   UCSC; uc002etq.4; human. [Q96AP0-1]
DR   CTD; 65057; -.
DR   GeneCards; GC16M067691; -.
DR   H-InvDB; HIX0013152; -.
DR   HGNC; HGNC:25070; ACD.
DR   HPA; HPA057660; -.
DR   MIM; 609377; gene.
DR   neXtProt; NX_Q96AP0; -.
DR   PharmGKB; PA134882431; -.
DR   eggNOG; NOG81452; -.
DR   HOGENOM; HOG000033778; -.
DR   HOVERGEN; HBG080817; -.
DR   InParanoid; Q96AP0; -.
DR   KO; K11114; -.
DR   OMA; WEEKEFG; -.
DR   OrthoDB; EOG7HHWSJ; -.
DR   PhylomeDB; Q96AP0; -.
DR   TreeFam; TF338536; -.
DR   Reactome; REACT_115566; Cell Cycle.
DR   Reactome; REACT_120956; Cellular responses to stress.
DR   EvolutionaryTrace; Q96AP0; -.
DR   GeneWiki; ACD_(gene); -.
DR   GenomeRNAi; 65057; -.
DR   NextBio; 67230; -.
DR   PRO; PR:Q96AP0; -.
DR   Bgee; Q96AP0; -.
DR   CleanEx; HS_ACD; -.
DR   CleanEx; HS_TPP1; -.
DR   Genevestigator; Q96AP0; -.
DR   GO; GO:0000781; C:chromosome, telomeric region; IDA:BHF-UCL.
DR   GO; GO:0000783; C:nuclear telomere cap complex; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0070182; F:DNA polymerase binding; IPI:BHF-UCL.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IEA:Ensembl.
DR   GO; GO:0006886; P:intracellular protein transport; IMP:BHF-UCL.
DR   GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0060381; P:positive regulation of single-stranded telomeric DNA binding; IDA:BHF-UCL.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IDA:BHF-UCL.
DR   GO; GO:0031848; P:protection from non-homologous end joining at telomere; ISS:BHF-UCL.
DR   GO; GO:0070198; P:protein localization to chromosome, telomeric region; IMP:BHF-UCL.
DR   GO; GO:0035282; P:segmentation; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR   GO; GO:0032202; P:telomere assembly; IMP:BHF-UCL.
DR   GO; GO:0016233; P:telomere capping; IGI:BHF-UCL.
DR   GO; GO:0000723; P:telomere maintenance; IDA:MGI.
DR   GO; GO:0001655; P:urogenital system development; IEA:Ensembl.
DR   InterPro; IPR028631; ACD.
DR   PANTHER; PTHR14487; PTHR14487; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosome; Complete proteome;
KW   DNA-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Telomere.
FT   CHAIN         1    544       Adrenocortical dysplasia protein homolog.
FT                                /FTId=PRO_0000239019.
FT   REGION      244    337       Interaction with POT1.
FT   MOTIF        97     99       PWI.
FT   COMPBIAS    354    442       Ser-rich.
FT   MOD_RES     111    111       Phosphoserine.
FT   VAR_SEQ     120    122       Missing (in isoform 2).
FT                                /FTId=VSP_019066.
FT   VARIANT     301    301       T -> M (in dbSNP:rs72547495).
FT                                /FTId=VAR_060224.
FT   VARIANT     518    518       V -> A (in dbSNP:rs6979).
FT                                /FTId=VAR_060225.
FT   CONFLICT    224    224       C -> R (in Ref. 2; BAB14658).
FT   HELIX        99    104
FT   STRAND      105    107
FT   STRAND      113    122
FT   STRAND      142    147
FT   STRAND      152    157
FT   HELIX       159    163
FT   STRAND      180    192
FT   STRAND      201    215
FT   HELIX       224    226
FT   HELIX       228    238
SQ   SEQUENCE   544 AA;  57733 MW;  D2FDF242DA98C483 CRC64;
     MPGRCQSDAA MRVNGPASRA PAGWTSGSLH TGPRAGRPRA QARGVRGRGL LLRPRPAKEL
     PLPRKGGAWA PAGNPGPLHP LGVAVGMAGS GRLVLRPWIR ELILGSETPS SPRAGQLLEV
     LQDAEAAVAG PSHAPDTSDV GATLLVSDGT HSVRCLVTRE ALDTSDWEEK EFGFRGTEGR
     LLLLQDCGVH VQVAEGGAPA EFYLQVDRFS LLPTEQPRLR VPGCNQDLDV QKKLYDCLEE
     HLSESTSSNA GLSLSQLLDE MREDQEHQGA LVCLAESCLT LEGPCTAPPV THWAASRCKA
     TGEAVYTVPS SMLCISENDQ LILSSLGPCQ RTQGPELPPP DPALQDLSLT LIASPPSSPS
     SSGTPALPGH MSSEESGTSI SLLPALSLAA PDPGQRSSSQ PSPAICSAPA TLTPRSPHAS
     RTPSSPLQSC TPSLSPRSHV PSPHQALVTR PQKPSLEFKE FVGLPCKNRP PFPRTGATRG
     AQEPCSVWEP PKRHRDGSAF QYEYEPPCTS LCARVQAVRL PPQLMAWALH FLMDAQPGSE
     PTPM
//
ID   ACE2_HUMAN              Reviewed;         805 AA.
AC   Q9BYF1; C7ECU1; Q6UWP0; Q86WT0; Q9NRA7; Q9UFZ6;
DT   02-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   02-AUG-2005, sequence version 2.
DT   09-JUL-2014, entry version 129.
DE   RecName: Full=Angiotensin-converting enzyme 2;
DE            EC=3.4.17.23;
DE   AltName: Full=ACE-related carboxypeptidase;
DE   AltName: Full=Angiotensin-converting enzyme homolog;
DE            Short=ACEH;
DE   AltName: Full=Metalloprotease MPROT15;
DE   Contains:
DE     RecName: Full=Processed angiotensin-converting enzyme 2;
DE   Flags: Precursor;
GN   Name=ACE2; ORFNames=UNQ868/PRO1885;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, FUNCTION,
RP   AND ENZYME REGULATION.
RC   TISSUE=Heart;
RX   PubMed=10969042; DOI=10.1161/01.RES.87.5.e1;
RA   Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M.,
RA   Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R.,
RA   Breitbart R.E., Acton S.;
RT   "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2)
RT   converts angiotensin I to angiotensin 1-9.";
RL   Circ. Res. 87:E1-E9(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   GLYCOSYLATION, FUNCTION, AND ENZYME REGULATION.
RC   TISSUE=Lymphoma;
RX   PubMed=10924499; DOI=10.1074/jbc.M002615200;
RA   Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G.,
RA   Turner A.J.;
RT   "A human homolog of angiotensin-converting enzyme. Cloning and
RT   functional expression as a captopril-insensitive carboxypeptidase.";
RL   J. Biol. Chem. 275:33238-33243(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, AND ENZYME REGULATION.
RC   TISSUE=Testis;
RX   PubMed=15231706; DOI=10.1210/en.2004-0443;
RA   Douglas G.C., O'Bryan M.K., Hedger M.P., Lee D.K.L., Yarski M.A.,
RA   Smith A.I., Lew R.A.;
RT   "The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is
RT   selectively expressed by adult Leydig cells of the testis.";
RL   Endocrinology 145:4703-4711(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-638.
RC   TISSUE=Lung, and Testis;
RX   PubMed=15937940; DOI=10.1002/ajmg.a.30779;
RA   Itoyama S., Keicho N., Hijikata M., Quy T., Phi N.C., Long H.T.,
RA   Ha L.D., Ban V.V., Matsushita I., Yanai H., Kirikae F., Kirikae T.,
RA   Kuratsuji T., Sasazuki T.;
RT   "Identification of an alternative 5'-untranslated exon and new
RT   polymorphisms of angiotensin-converting enzyme 2 gene: lack of
RT   association with SARS in the Vietnamese population.";
RL   Am. J. Med. Genet. A 136:52-57(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Suzuki Y., Watanabe M., Sugano S.;
RT   "Cloning, expression analysis and chromosomal localization of a novel
RT   ACE like enzyme.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Southan C., Burgess N.;
RT   "MPROT15 polypeptide and MPROT15 polynucleotide.";
RL   Patent number JP11318472, 24-NOV-1999.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Li K.K.B., Yip C.W., Hon C.C., Lam C.Y., Leung F.C.C.;
RT   "Comparative susceptibility to SARS-CoV mediated by ACE2 protein of 15
RT   different species.";
RL   Submitted (JUN-2009) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-26.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-805 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [13]
RP   PROTEIN SEQUENCE OF 679-689, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   INTERACTION WITH ITGB1.
RX   PubMed=15276642; DOI=10.1016/j.bbadis.2004.05.005;
RA   Lin Q., Keller R.S., Weaver B., Zisman L.S.;
RT   "Interaction of ACE2 and integrin beta1 in failing human heart.";
RL   Biochim. Biophys. Acta 1689:175-178(2004).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=12459472; DOI=10.1016/S0014-5793(02)03640-2;
RA   Harmer D., Gilbert M., Borman R., Clark K.L.;
RT   "Quantitative mRNA expression profiling of ACE 2, a novel homologue of
RT   angiotensin converting enzyme.";
RL   FEBS Lett. 532:107-110(2002).
RN   [15]
RP   BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, AND COFACTOR.
RX   PubMed=11815627; DOI=10.1074/jbc.M200581200;
RA   Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J.,
RA   Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M.A.,
RA   Nichols A., Tummino P.;
RT   "Hydrolysis of biological peptides by human angiotensin-converting
RT   enzyme-related carboxypeptidase.";
RL   J. Biol. Chem. 277:14838-14843(2002).
RN   [16]
RP   FUNCTION, INTERACTION WITH SARS-COV SPIKE GLYCOPROTEIN, GLYCOSYLATION,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=14647384; DOI=10.1038/nature02145;
RA   Li W., Moore M.J., Vasilieva N., Sui J., Wong S.-K., Berne M.A.,
RA   Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H.,
RA   Farzan M.;
RT   "Angiotensin-converting enzyme 2 is a functional receptor for the SARS
RT   coronavirus.";
RL   Nature 426:450-454(2003).
RN   [17]
RP   INDUCTION.
RX   PubMed=15151696; DOI=10.1186/1741-7015-2-19;
RA   Goulter A.B., Goddard M.J., Allen J.C., Clark K.L.;
RT   "ACE2 gene expression is up-regulated in the human failing heart.";
RL   BMC Med. 2:19-19(2004).
RN   [18]
RP   TISSUE SPECIFICITY.
RX   PubMed=15141377; DOI=10.1002/path.1570;
RA   Hamming I., Timens W., Bulthuis M.L.C., Lely A.T., Navis G.J.,
RA   van Goor H.;
RT   "Tissue distribution of ACE2 protein, the functional receptor for SARS
RT   coronavirus. A first step in understanding SARS pathogenesis.";
RL   J. Pathol. 203:631-637(2004).
RN   [19]
RP   INTERACTION WITH SARS-COV SPIKE GLYCOPROTEIN.
RX   PubMed=15452268; DOI=10.1128/JVI.78.20.11429-11433.2004;
RA   Li W., Greenough T.C., Moore M.J., Vasilieva N., Somasundaran M.,
RA   Sullivan J.L., Farzan M., Choe H.;
RT   "Efficient replication of severe acute respiratory syndrome
RT   coronavirus in mouse cells is limited by murine angiotensin-converting
RT   enzyme 2.";
RL   J. Virol. 78:11429-11433(2004).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-90.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.M400015-MCP200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H.,
RA   Thuluvath P.J., Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [21]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=15671045; DOI=10.1093/eurheartj/ehi114;
RA   Burrell L.M., Risvanis J., Kubota E., Dean R.G., MacDonald P.S.,
RA   Lu S., Tikellis C., Grant S.L., Lew R.A., Smith A.I., Cooper M.E.,
RA   Johnston C.I.;
RT   "Myocardial infarction increases ACE2 expression in rat and humans.";
RL   Eur. Heart J. 26:369-375(2005).
RN   [22]
RP   INTERACTION WITH SARS-COV SPIKE GLYCOPROTEIN, AND MUTAGENESIS.
RX   PubMed=15791205; DOI=10.1038/sj.emboj.7600640;
RA   Li W., Zhang C., Sui J., Kuhn J.H., Moore M.J., Luo S., Wong S.-K.,
RA   Huang I.-C., Xu K., Vasilieva N., Murakami A., He Y., Marasco W.A.,
RA   Guan Y., Choe H., Farzan M.;
RT   "Receptor and viral determinants of SARS-coronavirus adaptation to
RT   human ACE2.";
RL   EMBO J. 24:1634-1643(2005).
RN   [23]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=15983030; DOI=10.1074/jbc.M505111200;
RA   Lambert D.W., Yarski M., Warner F.J., Thornhill P., Parkin E.T.,
RA   Smith A.I., Hooper N.M., Turner A.J.;
RT   "Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated
RT   ectodomain shedding of the severe-acute respiratory syndrome-
RT   coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2
RT   (ACE2).";
RL   J. Biol. Chem. 280:30113-30119(2005).
RN   [24]
RP   INTERACTION WITH HCOV-NL63 SPIKE GLYCOPROTEIN.
RX   PubMed=15897467; DOI=10.1073/pnas.0409465102;
RA   Hofmann H., Pyrc K., van der Hoek L., Geier M., Berkhout B.,
RA   Poehlmann S.;
RT   "Human coronavirus NL63 employs the severe acute respiratory syndrome
RT   coronavirus receptor for cellular entry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:7988-7993(2005).
RN   [25]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-546.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [26]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=21563828; DOI=10.1021/bi200525y;
RA   Lai Z.W., Hanchapola I., Steer D.L., Smith A.I.;
RT   "Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site
RT   identification: determinants and constraints.";
RL   Biochemistry 50:5182-5194(2011).
RN   [27]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC CLEAVAGE, AND INTERACTION WITH
RP   TMPRSS2.
RX   PubMed=21068237; DOI=10.1128/JVI.02062-10;
RA   Shulla A., Heald-Sargent T., Subramanya G., Zhao J., Perlman S.,
RA   Gallagher T.;
RT   "A transmembrane serine protease is linked to the severe acute
RT   respiratory syndrome coronavirus receptor and activates virus entry.";
RL   J. Virol. 85:873-882(2011).
RN   [28]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=24227843; DOI=10.1128/JVI.02202-13;
RA   Heurich A., Hofmann-Winkler H., Gierer S., Liepold T., Jahn O.,
RA   Poehlmann S.;
RT   "TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by
RT   TMPRSS2 augments entry driven by the severe acute respiratory syndrome
RT   coronavirus spike protein.";
RL   J. Virol. 88:1293-1307(2014).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 19-615, X-RAY CRYSTALLOGRAPHY
RP   (3.0 ANGSTROMS) OF 19-615 IN COMPLEX WITH MLN-4760, DISULFIDE BONDS,
RP   AND GLYCOSYLATION AT ASN-53; ASN-90; ASN-103; ASN-322; ASN-432 AND
RP   ASN-546.
RX   PubMed=14754895; DOI=10.1074/jbc.M311191200;
RA   Towler P., Staker B., Prasad S.G., Menon S., Tang J., Parsons T.,
RA   Ryan D., Fisher M., Williams D., Dales N.A., Patane M.A.,
RA   Pantoliano M.W.;
RT   "ACE2 X-ray structures reveal a large hinge-bending motion important
RT   for inhibitor binding and catalysis.";
RL   J. Biol. Chem. 279:17996-18007(2004).
CC   -!- FUNCTION: Carboxypeptidase which converts angiotensin I to
CC       angiotensin 1-9, a peptide of unknown function, and angiotensin II
CC       to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-
CC       13 and dynorphin-13 with high efficiency. May be an important
CC       regulator of heart function. In case of human coronaviruses SARS
CC       and HCoV-NL63 infections, serve as functional receptor for the
CC       spike glycoprotein of both coronaviruses.
CC   -!- CATALYTIC ACTIVITY: Angiotensin II + H(2)O = angiotensin-(1-7) +
CC       L-phenylalanine.
CC   -!- COFACTOR: Binds 1 zinc ion per subunit.
CC   -!- COFACTOR: Binds 1 chloride ion per subunit.
CC   -!- ENZYME REGULATION: Activated by chloride and fluoride, but not
CC       bromide. Inhibited by MLN-4760, cFP_Leu, and EDTA, but not by the
CC       ACE inhibitors linosipril, captopril and enalaprilat.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.9 uM for angiotensin I;
CC         KM=2 uM for angiotensin II;
CC         KM=6.8 uM for apelin-13;
CC         KM=5.5 uM for dynorphin-13;
CC       pH dependence:
CC         Optimum pH is 6.5 in the presence of 1 M NaCl. Active from pH 6
CC         to 9;
CC   -!- SUBUNIT: Interacts with ITGB1. Interacts with SARS-CoV and HCoV-
CC       NL63 spike glycoprotein. Interacts with the catalytically active
CC       form of TMPRSS2.
CC   -!- SUBCELLULAR LOCATION: Processed angiotensin-converting enzyme 2:
CC       Secreted.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BYF1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BYF1-2; Sequence=VSP_014901, VSP_014902;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Expressed in endothelial cells from small and
CC       large arteries, and in arterial smooth muscle cells. Expressed in
CC       lung alveolar epithelial cells, enterocytes of the small
CC       intestine, Leydig cells and Sertoli cells (at protein level).
CC       Expressed in heart, kidney, testis, and gastrointestinal system.
CC   -!- INDUCTION: Up-regulated in failing heart.
CC   -!- PTM: N-glycosylation on Asn-90 may limit SARS infectivity.
CC   -!- PTM: Proteolytic cleavage by ADAM17 generates a secreted form.
CC       Also cleaved by serine proteases: TMPRSS2, TMPRSS11D and
CC       HPN/TMPRSS1.
CC   -!- SIMILARITY: Belongs to the peptidase M2 family.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ace2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF291820; AAF99721.1; -; mRNA.
DR   EMBL; AF241254; AAF78220.1; -; mRNA.
DR   EMBL; AY623811; AAT45083.1; -; mRNA.
DR   EMBL; AB193259; BAD99266.1; -; mRNA.
DR   EMBL; AB193260; BAD99267.1; -; mRNA.
DR   EMBL; AB046569; BAB40370.1; -; mRNA.
DR   EMBL; E39033; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; GQ262784; ACT66268.1; -; mRNA.
DR   EMBL; AY358714; AAQ89076.1; -; mRNA.
DR   EMBL; AY217547; AAO25651.1; -; Genomic_DNA.
DR   EMBL; CH471074; EAW98892.1; -; Genomic_DNA.
DR   EMBL; BC039902; AAH39902.1; -; mRNA.
DR   EMBL; BC048094; AAH48094.2; -; mRNA.
DR   EMBL; AL110224; CAB53682.1; -; mRNA.
DR   CCDS; CCDS14169.1; -. [Q9BYF1-1]
DR   PIR; T14762; T14762.
DR   RefSeq; NP_068576.1; NM_021804.2. [Q9BYF1-1]
DR   UniGene; Hs.178098; -.
DR   PDB; 1R42; X-ray; 2.20 A; A=1-615.
DR   PDB; 1R4L; X-ray; 3.00 A; A=1-615.
DR   PDB; 1XJP; Model; -; B=19-615.
DR   PDB; 2AJF; X-ray; 2.90 A; A/B=19-615.
DR   PDB; 3D0G; X-ray; 2.80 A; A/B=56-615.
DR   PDB; 3D0H; X-ray; 3.10 A; A/B=56-615.
DR   PDB; 3D0I; X-ray; 2.90 A; A/B=56-615.
DR   PDB; 3KBH; X-ray; 3.31 A; A/B/C/D=19-615.
DR   PDB; 3SCI; X-ray; 2.90 A; A/B=19-615.
DR   PDB; 3SCJ; X-ray; 3.00 A; A/B=19-615.
DR   PDB; 3SCK; X-ray; 3.00 A; A/B=83-615.
DR   PDB; 3SCL; X-ray; 3.00 A; A/B=83-615.
DR   PDBsum; 1R42; -.
DR   PDBsum; 1R4L; -.
DR   PDBsum; 1XJP; -.
DR   PDBsum; 2AJF; -.
DR   PDBsum; 3D0G; -.
DR   PDBsum; 3D0H; -.
DR   PDBsum; 3D0I; -.
DR   PDBsum; 3KBH; -.
DR   PDBsum; 3SCI; -.
DR   PDBsum; 3SCJ; -.
DR   PDBsum; 3SCK; -.
DR   PDBsum; 3SCL; -.
DR   ProteinModelPortal; Q9BYF1; -.
DR   SMR; Q9BYF1; 19-615.
DR   BioGrid; 121864; 3.
DR   DIP; DIP-44689N; -.
DR   IntAct; Q9BYF1; 1.
DR   MINT; MINT-4538816; -.
DR   STRING; 9606.ENSP00000252519; -.
DR   BindingDB; Q9BYF1; -.
DR   ChEMBL; CHEMBL2096989; -.
DR   DrugBank; DB00691; Moexipril.
DR   GuidetoPHARMACOLOGY; 1614; -.
DR   MEROPS; M02.006; -.
DR   PhosphoSite; Q9BYF1; -.
DR   DMDM; 71658783; -.
DR   PaxDb; Q9BYF1; -.
DR   PRIDE; Q9BYF1; -.
DR   Ensembl; ENST00000252519; ENSP00000252519; ENSG00000130234. [Q9BYF1-1]
DR   Ensembl; ENST00000427411; ENSP00000389326; ENSG00000130234. [Q9BYF1-1]
DR   GeneID; 59272; -.
DR   KEGG; hsa:59272; -.
DR   UCSC; uc004cxa.1; human. [Q9BYF1-1]
DR   CTD; 59272; -.
DR   GeneCards; GC0XM015489; -.
DR   HGNC; HGNC:13557; ACE2.
DR   HPA; CAB026174; -.
DR   HPA; HPA000288; -.
DR   MIM; 300335; gene.
DR   neXtProt; NX_Q9BYF1; -.
DR   PharmGKB; PA425; -.
DR   eggNOG; NOG71044; -.
DR   HOGENOM; HOG000292210; -.
DR   HOVERGEN; HBG000265; -.
DR   InParanoid; Q9BYF1; -.
DR   KO; K09708; -.
DR   OMA; RDGANEG; -.
DR   OrthoDB; EOG76HQ13; -.
DR   PhylomeDB; Q9BYF1; -.
DR   TreeFam; TF312861; -.
DR   BRENDA; 3.4.15.1; 2681.
DR   Reactome; REACT_17015; Metabolism of proteins.
DR   SABIO-RK; Q9BYF1; -.
DR   ChiTaRS; ACE2; human.
DR   EvolutionaryTrace; Q9BYF1; -.
DR   GeneWiki; Angiotensin-converting_enzyme_2; -.
DR   GenomeRNAi; 59272; -.
DR   NextBio; 65154; -.
DR   PMAP-CutDB; Q9BYF1; -.
DR   PRO; PR:Q9BYF1; -.
DR   Bgee; Q9BYF1; -.
DR   CleanEx; HS_ACE2; -.
DR   Genevestigator; Q9BYF1; -.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProt.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0045121; C:membrane raft; TAS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004180; F:carboxypeptidase activity; IDA:UniProtKB.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0017046; F:peptide hormone binding; IEA:Ensembl.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0001618; F:virus receptor activity; IMP:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; TAS:BHF-UCL.
DR   GO; GO:0002005; P:angiotensin catabolic process in blood; IC:BHF-UCL.
DR   GO; GO:0002003; P:angiotensin maturation; TAS:Reactome.
DR   GO; GO:0003051; P:angiotensin-mediated drinking behavior; IMP:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IC:BHF-UCL.
DR   GO; GO:0032800; P:receptor biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0046813; P:receptor-mediated virion attachment to host cell; IDA:BHF-UCL.
DR   GO; GO:0042127; P:regulation of cell proliferation; TAS:BHF-UCL.
DR   GO; GO:0001817; P:regulation of cytokine production; IC:BHF-UCL.
DR   GO; GO:0050727; P:regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0003081; P:regulation of systemic arterial blood pressure by renin-angiotensin; IMP:BHF-UCL.
DR   GO; GO:0019229; P:regulation of vasoconstriction; IC:BHF-UCL.
DR   GO; GO:0042312; P:regulation of vasodilation; IC:BHF-UCL.
DR   GO; GO:0009615; P:response to virus; IDA:GOC.
DR   GO; GO:0046718; P:viral entry into host cell; TAS:UniProtKB.
DR   InterPro; IPR001548; Peptidase_M2.
DR   PANTHER; PTHR10514; PTHR10514; 1.
DR   Pfam; PF01401; Peptidase_M2; 1.
DR   PRINTS; PR00791; PEPDIPTASEA.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Carboxypeptidase; Cell membrane;
KW   Chloride; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Host-virus interaction; Hydrolase;
KW   Membrane; Metal-binding; Metalloprotease; Polymorphism; Protease;
KW   Reference proteome; Secreted; Signal; Transmembrane;
KW   Transmembrane helix; Zinc.
FT   SIGNAL        1     17       Potential.
FT   CHAIN        18    805       Angiotensin-converting enzyme 2.
FT                                /FTId=PRO_0000028570.
FT   CHAIN        18    708       Processed angiotensin-converting enzyme
FT                                2.
FT                                /FTId=PRO_0000292268.
FT   TOPO_DOM     18    740       Extracellular (Potential).
FT   TRANSMEM    741    761       Helical; (Potential).
FT   TOPO_DOM    762    805       Cytoplasmic (Potential).
FT   REGION       30     41       Interaction with SARS-CoV spike
FT                                glycoprotein.
FT   REGION       82     84       Interaction with SARS-CoV spike
FT                                glycoprotein.
FT   REGION      353    357       Interaction with SARS-CoV spike
FT                                glycoprotein.
FT   REGION      652    659       Essential for cleavage by ADAM17.
FT   REGION      697    716       Essential for cleavage by TMPRSS11D and
FT                                TMPRSS2.
FT   ACT_SITE    375    375
FT   ACT_SITE    505    505
FT   METAL       374    374       Zinc; catalytic.
FT   METAL       378    378       Zinc; catalytic.
FT   METAL       402    402       Zinc; catalytic.
FT   BINDING     169    169       Chloride.
FT   BINDING     273    273       Substrate.
FT   BINDING     345    345       Substrate.
FT   BINDING     346    346       Substrate; via carbonyl oxygen.
FT   BINDING     371    371       Substrate.
FT   BINDING     477    477       Chloride.
FT   BINDING     481    481       Chloride.
FT   BINDING     515    515       Substrate.
FT   CARBOHYD     53     53       N-linked (GlcNAc...) (Probable).
FT   CARBOHYD     90     90       N-linked (GlcNAc...).
FT   CARBOHYD    103    103       N-linked (GlcNAc...).
FT   CARBOHYD    322    322       N-linked (GlcNAc...) (Probable).
FT   CARBOHYD    432    432       N-linked (GlcNAc...).
FT   CARBOHYD    546    546       N-linked (GlcNAc...).
FT   CARBOHYD    690    690       N-linked (GlcNAc...) (Potential).
FT   DISULFID    133    141
FT   DISULFID    344    361
FT   DISULFID    530    542
FT   VAR_SEQ     555    555       F -> L (in isoform 2).
FT                                /FTId=VSP_014901.
FT   VAR_SEQ     556    805       Missing (in isoform 2).
FT                                /FTId=VSP_014902.
FT   VARIANT      26     26       K -> R (in dbSNP:rs4646116).
FT                                /FTId=VAR_023082.
FT   VARIANT     638    638       N -> S (in dbSNP:rs183135788).
FT                                /FTId=VAR_023083.
FT   MUTAGEN      24     26       QAK->KAE: Slightly inhibits interaction
FT                                with SARS-CoV spike glycoprotein.
FT   MUTAGEN      31     31       K->D: Abolishes interaction with SARS-CoV
FT                                spike glycoprotein.
FT   MUTAGEN      37     37       E->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT   MUTAGEN      38     38       D->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT   MUTAGEN      41     41       Y->A: Strongly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN      68     68       K->D: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN      82     84       MYP->NFS: Inhibits interaction with SARS-
FT                                CoV spike glycoprotein.
FT   MUTAGEN     110    110       E->P: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT   MUTAGEN     135    136       PD->SM: No effect on interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN     160    160       E->R: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT   MUTAGEN     192    192       R->D: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT   MUTAGEN     219    219       R->D: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT   MUTAGEN     239    239       H->Q: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT   MUTAGEN     309    309       K->D: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT   MUTAGEN     312    312       E->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT   MUTAGEN     324    324       T->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT   MUTAGEN     338    340       NVQ->DDR: No effect on interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN     350    350       D->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT   MUTAGEN     353    353       K->H,A,D: Abolishes interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN     355    355       D->A: Strongly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN     357    357       R->A: Strongly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN     359    359       L->K,A: No effect on interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN     383    383       M->A: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN     389    389       P->A: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN     393    393       R->A: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN     425    427       SPD->PSN: Slightly inhibits interaction
FT                                with SARS-CoV spike glycoprotein.
FT   MUTAGEN     465    467       KGE->QDK: No effect on interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN     559    559       R->S: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT   MUTAGEN     603    603       F->T: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT   CONFLICT     18     18       Q -> H (in Ref. 12; CAB53682).
FT   CONFLICT    508    508       N -> D (in Ref. 8; AAQ89076).
FT   CONFLICT    631    631       K -> R (in Ref. 5; BAB40370).
FT   HELIX        23     52
FT   HELIX        56     77
FT   TURN         78     82
FT   HELIX        85     87
FT   HELIX        91    100
FT   HELIX       104    107
FT   HELIX       110    129
FT   STRAND      131    134
FT   STRAND      137    143
FT   TURN        144    146
FT   HELIX       148    154
FT   HELIX       158    171
FT   HELIX       173    193
FT   STRAND      196    198
FT   HELIX       199    204
FT   TURN        205    207
FT   TURN        213    215
FT   HELIX       220    251
FT   TURN        253    255
FT   STRAND      258    260
FT   HELIX       264    266
FT   STRAND      267    271
FT   HELIX       276    278
FT   HELIX       279    282
FT   TURN        284    287
FT   TURN        294    297
FT   HELIX       298    300
FT   HELIX       304    316
FT   TURN        317    319
FT   HELIX       327    330
FT   STRAND      338    340
FT   STRAND      347    352
FT   STRAND      355    359
FT   HELIX       366    384
FT   TURN        385    387
FT   HELIX       390    392
FT   HELIX       400    413
FT   HELIX       415    420
FT   TURN        422    426
FT   HELIX       432    446
FT   HELIX       449    465
FT   STRAND      466    468
FT   HELIX       470    472
FT   HELIX       473    483
FT   STRAND      486    488
FT   HELIX       499    502
FT   HELIX       504    507
FT   HELIX       514    531
FT   TURN        532    534
FT   HELIX       539    541
FT   HELIX       548    558
FT   TURN        559    562
FT   HELIX       566    574
FT   STRAND      575    578
FT   HELIX       582    598
FT   STRAND      600    602
FT   STRAND      607    609
SQ   SEQUENCE   805 AA;  92463 MW;  8EE6EB0A931550E8 CRC64;
     MSSSSWLLLS LVAVTAAQST IEEQAKTFLD KFNHEAEDLF YQSSLASWNY NTNITEENVQ
     NMNNAGDKWS AFLKEQSTLA QMYPLQEIQN LTVKLQLQAL QQNGSSVLSE DKSKRLNTIL
     NTMSTIYSTG KVCNPDNPQE CLLLEPGLNE IMANSLDYNE RLWAWESWRS EVGKQLRPLY
     EEYVVLKNEM ARANHYEDYG DYWRGDYEVN GVDGYDYSRG QLIEDVEHTF EEIKPLYEHL
     HAYVRAKLMN AYPSYISPIG CLPAHLLGDM WGRFWTNLYS LTVPFGQKPN IDVTDAMVDQ
     AWDAQRIFKE AEKFFVSVGL PNMTQGFWEN SMLTDPGNVQ KAVCHPTAWD LGKGDFRILM
     CTKVTMDDFL TAHHEMGHIQ YDMAYAAQPF LLRNGANEGF HEAVGEIMSL SAATPKHLKS
     IGLLSPDFQE DNETEINFLL KQALTIVGTL PFTYMLEKWR WMVFKGEIPK DQWMKKWWEM
     KREIVGVVEP VPHDETYCDP ASLFHVSNDY SFIRYYTRTL YQFQFQEALC QAAKHEGPLH
     KCDISNSTEA GQKLFNMLRL GKSEPWTLAL ENVVGAKNMN VRPLLNYFEP LFTWLKDQNK
     NSFVGWSTDW SPYADQSIKV RISLKSALGD KAYEWNDNEM YLFRSSVAYA MRQYFLKVKN
     QMILFGEEDV RVANLKPRIS FNFFVTAPKN VSDIIPRTEV EKAIRMSRSR INDAFRLNDN
     SLEFLGIQPT LGPPNQPPVS IWLIVFGVVM GVIVVGIVIL IFTGIRDRKK KNKARSGENP
     YASIDISKGE NNPGFQNTDD VQTSF
//
